PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bash, RC; Vargason, JM; Cornejo, S; Ho, PS; Lohr, D				Bash, RC; Vargason, JM; Cornejo, S; Ho, PS; Lohr, D			Intrinsically bent DNA in the promoter regions of the yeast GAL1-10 and GAL80 genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN-STRUCTURE; PROTEINS NHP6A/B; TRANSCRIPTION; BINDING; CONSEQUENCES; ACTIVATION; CURVATURE; REPEAT; SITES	Circular permutation analysis has detected fairly strong sites of intrinsic DNA bending on the promoter regions of the yeast GAL1-10 and GAL80 genes. These bends lie in functionally suggestive locations. On the promoter of the GAL1-10 structural genes, strong bends bracket nucleosome B, which lies between the UAS(G) and the GAL1 TATA, These intrinsic bends could help position nucleosome B, Nucleosome B plus two other promoter nucleosomes protect the TATA and start site elements in the inactive state of expression but are completely disrupted (removed) when GAL1-10 expression is induced. The strongest intrinsic bend (similar to 70 degrees) lies at the downstream edge of nucleosome B; this places it approximately 30 base pairs upstream of the GAL1 TATA a position that could allow it to be involved in GAL1 activation in several ways, including the recruitment of a yeast HMG protein that is required for the normally robust level of GAL1 expression in the induced state (Paull, T,, Carey, M,, and Johnson, R, (1996) Genes Dev, 10, 2769-2781), On the regulatory gene GAL80, the single bend lies in the non-nucleosomal hypersensitive region, between a GAL80-specific far upstream promoter element and the more gene-proximal promoter elements. GAL80 promoter region nucleosomes contain no intrinsically bent DNA.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Arizona State Univ, Dept Biochem & Chem, Tempe, AZ 85287 USA	Oregon State University; Arizona State University; Arizona State University-Tempe	Lohr, D (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.	dlohr@asu.edu	Ho, Pui/AAF-8838-2020; Ho, Pui S/F-6186-2014	Ho, Pui/0000-0002-8082-4311; Ho, Pui S/0000-0002-8082-4311	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bash R, 2001, PROG NUCLEIC ACID RE, V65, P197; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; BRUKNER I, 1995, EMBO J, V14, P1812, DOI 10.1002/j.1460-2075.1995.tb07169.x; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Cress WD, 1996, MOL CELL BIOL, V16, P2119; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DIECKMANN S, 1987, NUCL ACIDS MOL BIOL, V1, P138; DIEKMANN S, 1987, NUCLEIC ACIDS RES, V15, P5765, DOI 10.1093/nar/15.14.5765; DIEKMANN S, 1989, ELECTROPHORESIS, V10, P354, DOI 10.1002/elps.1150100513; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FISHERADAMS G, 1995, EMBO J, V14, P1468, DOI 10.1002/j.1460-2075.1995.tb07133.x; FITZGERALD DJ, 1994, J BIOL CHEM, V269, P21303; GOODSELL DS, 1994, NUCLEIC ACIDS RES, V22, P5497, DOI 10.1093/nar/22.24.5497; HAGERMAN PJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P125, DOI 10.1016/0167-4781(92)90066-9; HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.biochem.59.1.755; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; Johnston M., 1992, MOL CELLULAR BIOL YE, P193; KAWAMOTO T, 1989, NUCLEIC ACIDS RES, V17, P523, DOI 10.1093/nar/17.2.523; KIM J, 1995, J BIOL CHEM, V270, P1282, DOI 10.1074/jbc.270.3.1282; Kim J, 1996, BIOCHEM BIOPH RES CO, V226, P638, DOI 10.1006/bbrc.1996.1408; LOHR D, 1993, P NATL ACAD SCI USA, V90, P10628, DOI 10.1073/pnas.90.22.10628; LOHR D, 1995, J BIOL CHEM, V270, P27671, DOI 10.1074/jbc.270.46.27671; Lohr D, 1997, J BIOL CHEM, V272, P26795, DOI 10.1074/jbc.272.43.26795; LOHR D, 1984, NUCLEIC ACIDS RES, V12, P8457, DOI 10.1093/nar/12.22.8457; LOHR D, 1985, NUCLEIC ACIDS RES, V13, P8409, DOI 10.1093/nar/13.23.8409; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Maxam A M, 1980, Methods Enzymol, V65, P499; Nair TM, 1998, FEBS LETT, V422, P94, DOI 10.1016/S0014-5793(97)01607-4; NARDULLI AM, 1992, MOL CELL BIOL, V12, P2037, DOI 10.1128/MCB.12.5.2037; PARVIN JD, 1995, NATURE, V373, P724, DOI 10.1038/373724a0; Paull TT, 1996, GENE DEV, V10, P2769, DOI 10.1101/gad.10.21.2769; PAULL TT, 1995, J BIOL CHEM, V270, P8744, DOI 10.1074/jbc.270.15.8744; PECK LJ, 1981, NATURE, V292, P375, DOI 10.1038/292375a0; PEREZMARTIN J, 1994, MICROBIOL REV, V58, P268; PerezMartin J, 1997, ANNU REV MICROBIOL, V51, P593, DOI 10.1146/annurev.micro.51.1.593; RAINBOW M, 1989, BIOCHEMISTRY-US, V28, P7486, DOI 10.1021/bi00444a048; Reece RJ, 1997, BIOESSAYS, V19, P1001, DOI 10.1002/bies.950191110; SAKURAI H, 1994, MOL CELL BIOL, V14, P6819, DOI 10.1128/MCB.14.10.6819; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHROTH GP, 1992, J BIOL CHEM, V267, P9958; SHIMADA H, 1985, GENE, V39, P1; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; Ulyanov NB, 1995, METHOD ENZYMOL, V261, P90; VANHOLDE K, 1988, CHROMATIN, P247; WADAKIYAMA Y, 1994, J BIOL CHEM, V269, P22238; Widlund HR, 1999, J BIOL CHEM, V274, P31847, DOI 10.1074/jbc.274.45.31847; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; Yen YM, 1998, J BIOL CHEM, V273, P4424, DOI 10.1074/jbc.273.8.4424	51	13	13	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					861	866		10.1074/jbc.M007070200	http://dx.doi.org/10.1074/jbc.M007070200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11013248	Green Submitted, hybrid			2022-12-27	WOS:000166430900002
J	Wielowieyski, PA; Wigle, JT; Salih, M; Hum, P; Tuana, BS				Wielowieyski, PA; Wigle, JT; Salih, M; Hum, P; Tuana, BS			Alternative splicing in intracellular loop connecting domains II and III of the alpha(1) subunit of Ca(v)1.2 Ca2+ channels predicts two-domain polypeptides with unique C-terminal tails	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE DIHYDROPYRIDINE RECEPTOR; PRESYNAPTIC CALCIUM-CHANNELS; PROTEIN-INTERACTION SITE; SKELETAL-MUSCLE; T-TYPE; IMMUNOCHEMICAL IDENTIFICATION; DIFFERENTIAL PHOSPHORYLATION; MOLECULAR CHARACTERIZATION; RELEASE CHANNEL; EXONS 40-42	Novel splice variants of the Lu, subunit of the Ca(v)1.2 voltage-gated Ca2+ channel were identified that predicted two truncated forms of the or, subunit comprising domains I and II generated by alternative splicing in the intracellular loop region linking domains II and III. In rabbit heart splice variant 1 (RH-1), exon 19 was deleted, which resulted in a reading frameshift of exon 20 with a premature termination codon and a novel 19-amino acid carboxyl-terminal tail. In the RH-2 variant, exons 17 and 18 were deleted, leading to a reading frameshift of exons 19 and 20 with a premature stop codon and a novel 62-amino acid carboxyl-terminal tail. RNase protection assays with RH-1 and RH-2 cRNA probes confirmed the expression in cardiac and neuronal tissue but not skeletal muscle. The deduced amino acid sequence from full-length cDNAs encoding the two variants predicted polypeptides of 99.0 and 99.2 kDa, which constituted domains I and II of the alpha (1), subunit of the Ca(v)1.2 channel. Antipeptide antibodies directed to sequences in the second intracellular loop between domains II and III identified the 240-kDa Ca(v)1.2 subunit in sarcolemmal and heavy sarcoplasmic reticulum (HSR) membranes and a 99-kDa polypeptide in the HSR, An antipeptide antibody raised against unique sequences in the RH-2 variant also identified a 99-kDa polypeptide in the HSR. These data reveal the expression of additional Ca2+ channel structural units generated by alternative splicing of the Ca(v)1.2 gene.	Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Tuana, BS (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8H5, Canada.		Wigle, J.t./G-2005-2014	Wigle, J.t./0000-0002-4985-7684				Bahls FH, 1998, J NEUROBIOL, V35, P198, DOI 10.1002/(SICI)1097-4695(199805)35:2<198::AID-NEU6>3.0.CO;2-#; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; Blaine JT, 1998, J NEUROSCI, V18, P9585; Bulman DE, 1997, HUM MOL GENET, V6, P1679, DOI 10.1093/hmg/6.10.1679; Castellano A, 1997, J NEUROSCI, V17, P4652; Catterall WA, 1996, J BIOENERG BIOMEMBR, V28, P219, DOI 10.1007/BF02110697; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; De Waard M, 1996, Ion Channels, V4, P41; DIEBOLD RJ, 1992, P NATL ACAD SCI USA, V89, P1497, DOI 10.1073/pnas.89.4.1497; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FEHER JJ, 1991, J MOL CELL CARDIOL, V23, P249, DOI 10.1016/0022-2828(91)90061-P; FERRIER GR, 1995, J PHYSIOL-LONDON, V484, P107, DOI 10.1113/jphysiol.1995.sp020651; Fisher SE, 1997, GENOMICS, V45, P340, DOI 10.1006/geno.1997.4941; Gurnett CA, 1996, J BIOL CHEM, V271, P27975, DOI 10.1074/jbc.271.45.27975; HELL JW, 1994, ANN NY ACAD SCI, V747, P282; HOFMANN F, 1984, ANNU REV NEUROSCI, V17, P399; Ishibashi K, 2000, BIOCHEM BIOPH RES CO, V270, P370, DOI 10.1006/bbrc.2000.2435; Jones SW, 1998, J BIOENERG BIOMEMBR, V30, P299, DOI 10.1023/A:1021977304001; Klockner U, 1997, AM J PHYSIOL-HEART C, V272, pH1372, DOI 10.1152/ajpheart.1997.272.3.H1372; Lee JH, 1999, J NEUROSCI, V19, P1912; Leong P, 1998, J BIOL CHEM, V273, P29958, DOI 10.1074/jbc.273.45.29958; Lory P, 1997, HUM GENET, V100, P149, DOI 10.1007/s004390050481; LU XY, 1995, J BIOL CHEM, V270, P18459, DOI 10.1074/jbc.270.31.18459; LU XY, 1994, J BIOL CHEM, V269, P6511; MALOUF NN, 1992, NEURON, V8, P899, DOI 10.1016/0896-6273(92)90204-Q; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Mochida S, 1998, P NATL ACAD SCI USA, V95, P14523, DOI 10.1073/pnas.95.24.14523; Mori Y, 1996, JPN J PHARMACOL, V72, P83, DOI 10.1254/jjp.72.83; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; Ophoff RA, 1998, TRENDS PHARMACOL SCI, V19, P121, DOI 10.1016/S0165-6147(98)01182-1; Pereon Y, 1998, PFLUG ARCH EUR J PHY, V436, P309, DOI 10.1007/s004240050637; Perez-Reyes E, 1998, J BIOENERG BIOMEMBR, V30, P313, DOI 10.1023/A:1021981420839; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Plummer NW, 1997, J BIOL CHEM, V272, P24008, DOI 10.1074/jbc.272.38.24008; Puri TS, 1997, BIOCHEMISTRY-US, V36, P9605, DOI 10.1021/bi970500d; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; Reuter H, 1996, CURR OPIN NEUROBIOL, V6, P331, DOI 10.1016/S0959-4388(96)80116-4; SAKURAI T, 1995, J BIOL CHEM, V270, P21234, DOI 10.1074/jbc.270.36.21234; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sather William A., 1994, Current Opinion in Neurobiology, V4, P313, DOI 10.1016/0959-4388(94)90091-4; Scott VES, 1998, J NEUROSCI, V18, P641; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; Sheng ZH, 1998, J BIOENERG BIOMEMBR, V30, P335, DOI 10.1023/A:1021985521748; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; Sobko A, 1998, J NEUROSCI, V18, P10398; SOLDATOV NM, 1992, P NATL ACAD SCI USA, V89, P4628, DOI 10.1073/pnas.89.10.4628; Soldatov NM, 1998, HUM HERED, V48, P241, DOI 10.1159/000022810; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; SOLDATOV NM, 1994, GENOMICS, V22, P77, DOI 10.1006/geno.1994.1347; Soldatov NM, 1998, J BIOL CHEM, V273, P957, DOI 10.1074/jbc.273.2.957; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; Talley EM, 1999, J NEUROSCI, V19, P1895; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TSIEN RW, 1995, TRENDS NEUROSCI, V18, P52; Vajna R, 1998, EUR J BIOCHEM, V257, P274, DOI 10.1046/j.1432-1327.1998.2570274.x; VARADI G, 1995, TRENDS PHARMACOL SCI, V16, P43, DOI 10.1016/S0165-6147(00)88977-4; Welling A, 1997, CIRC RES, V81, P526, DOI 10.1161/01.RES.81.4.526; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; Yokoyama CT, 1997, J NEUROSCI, V17, P6929; Zhou ZF, 1998, BIOPHYS J, V74, P1830, DOI 10.1016/S0006-3495(98)77893-2	70	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1398	1406		10.1074/jbc.M006868200	http://dx.doi.org/10.1074/jbc.M006868200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11010971	hybrid			2022-12-27	WOS:000166430900073
J	Hu, JB; Roy, SK; Shapiro, PS; Rodig, SR; Reddy, SPM; Platanias, LC; Schreiber, RD; Kalvakolanu, DV				Hu, JB; Roy, SK; Shapiro, PS; Rodig, SR; Reddy, SPM; Platanias, LC; Schreiber, RD; Kalvakolanu, DV			ERK1 and ERK2 activate CCAAAT/enhancer-binding protein-dependent gene transcription in response to interferon-gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; MAP KINASE; TARGETED DISRUPTION; REGULATORY FACTOR; DNA-BINDING; TYROSINE-PHOSPHATASE; FEEDBACK-REGULATION; ALPHA-INTERFERON; CELLS; EXPRESSION	Interferons (IFNs) regulate the expression of a number of cellular genes by activating the JAK-STAT pathway, We have recently discovered that CCAAAT/enhancer-binding protein-beta (C/EBP-beta) induces gene transcription through a novel IFN response element called the gamma -IFN-activated transcriptional element (Roy, S. K., Wachira, S. J., Weihua, X., Hu, J., and Kalvakolanu, D. V, (2000) J. Biol. Chem. 275, 12626-12632, Here, we describe a new IFN-gamma -stimulated pathway that operates C/EBP-beta -regulated gene expression independent of JAK1, We show that ERKs are activated by IFN-gamma to stimulate C/EBP-beta -dependent expression. Sustained ERK activation directly correlated with C/EBP-beta dependent gene expression in response to IFN-gamma. Mutant MKK1, its inhibitors, and mutant ERK suppressed IFN-gamma -stimulated gene induction through the gamma -IFN-activated transcriptional element. Ras and Raf activation was not required for this process. Furthermore, Raf-1 phosphorylation negatively correlated with its activity. Interestingly, C/EBP-beta -induced gene expression required STAT1, but not JAK1. A C/EBP-beta mutant lacking the ERK phosphorylation site failed to promote IFN-gamma stimulated gene expression. Thus, our data link C/EBP-beta to IFN-gamma signaling through ERKs.	Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Microbiol & Immunol,Mol & Cellular Biol Prog, Baltimore, MD 21201 USA; Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA; Johns Hopkins Univ, Dept Environm Hlth Sci, Sch Publ Hlth, Baltimore, MD 21205 USA; Univ Illinois, Sect Hematol & Oncol, Chicago, IL 60607 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Washington University (WUSTL)	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Microbiol & Immunol,Mol & Cellular Biol Prog, Baltimore, MD 21201 USA.	dkalvako@umaryland.edu	Schreiber, Robert/Q-7550-2019; Schreiber, Robert D/A-1276-2013	Schreiber, Robert D/0000-0001-6311-0432; Schreiber, Robert/0000-0003-1590-2341	NCI NIH HHS [CA 41401, CA 78282, CA77816] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077816, R01CA078282] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bach EA, 1996, MOL CELL BIOL, V16, P3214; BANDYOPADHYAY SK, 1990, MOL CELL BIOL, V10, P5055, DOI 10.1128/MCB.10.10.5055; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Brickey WJ, 1999, J IMMUNOL, V163, P6622; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUCHMEIER NA, 1985, P NATL ACAD SCI USA, V82, P7404, DOI 10.1073/pnas.82.21.7404; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Contursi C, 2000, P NATL ACAD SCI USA, V97, P91, DOI 10.1073/pnas.97.1.91; CRESPO P, 1994, J BIOL CHEM, V269, P21103; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Kalvakolanu DV, 1999, TRENDS MICROBIOL, V7, P166, DOI 10.1016/S0966-842X(99)01476-6; Kaplan DH, 1996, J BIOL CHEM, V271, P9, DOI 10.1074/jbc.271.1.9; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KIMCHI A, 1992, J CELL BIOCHEM, V50, P1, DOI 10.1002/jcb.240500102; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; PETRICOIN E, 1994, MOL CELL BIOL, V14, P1477, DOI 10.1128/MCB.14.2.1477; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Roy SK, 2000, J BIOL CHEM, V275, P12626, DOI 10.1074/jbc.275.17.12626; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; Shapiro PS, 1998, J BIOL CHEM, V273, P1788, DOI 10.1074/jbc.273.3.1788; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UEKI K, 1994, J BIOL CHEM, V269, P15756; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; Vuong H, 2000, J BIOL CHEM, V275, P32250, DOI 10.1074/jbc.M005227200; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Weihua Xiao, 1997, Journal of Biological Chemistry, V272, P9742; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Xiao WH, 2000, BBA-GENE STRUCT EXPR, V1492, P163, DOI 10.1016/S0167-4781(00)00111-1; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P103, DOI 10.1073/pnas.94.1.103	62	132	133	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					287	297		10.1074/jbc.M004885200	http://dx.doi.org/10.1074/jbc.M004885200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	10995751	hybrid			2022-12-27	WOS:000166280700040
J	Raza, SL; Nehring, LC; Shapiro, SD; Cornelius, LA				Raza, SL; Nehring, LC; Shapiro, SD; Cornelius, LA			Proteinase-activated receptor-1 regulation of macrophage elastase (MMP-12) secretion by serine proteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALVEOLAR MACROPHAGES; NECROSIS-FACTOR-ALPHA; THROMBIN RECEPTOR; MATRIX METALLOPROTEINASES; ANGIOGENESIS INHIBITOR; PLASMINOGEN-ACTIVATOR; ENDOTHELIAL-CELLS; ANGIOSTATIN; EXPRESSION; METALLOELASTASE	The serine proteinases plasmin and thrombin convert proenzyme matrix metalloproteinases (MMPs) into catalytically active forms. In addition, we demonstrate that plasmin(ogen) and thrombin induce a significant increase in secretion of activated murine macrophage elastase (MMP-12) protein. Active serine protease is responsible for induction, as demonstrated by the absence of MMP-12 induction in plasminogen(Plg)-treated urokinase-type plasminogen activator-deficient macrophages, Since increased MMP-12 protein secretion was not accompanied by an increase in MMP-12 mRNA, we examined post-translational mechanisms. Protein synthesis was not required for early release of MMP-12 but was required for later secretion of activated enzyme. Immunofluorescent microscopy demonstrated basal expression in macrophages that increased following serine proteinase exposure. Inhibition of MMP-12 secretion by hirudin and pertussis toxin demonstrated a role for the thrombin G protein-coupled receptor (protease-activated receptor 1 (PAR-1)). PAR-1-activating peptides were able to induce MMP-12 release. Investigation of signal transduction pathways involved in this response demonstrate the requirement for protein kinase C, but not tyrosine kinase, activity. These data demonstrate that plasmin and thrombin regulate MMP-12 activity through distinct mechanisms: post-translational secretion of preformed MMP-12 protein, induction of protein secretion that is protein kinase C-mediated, and extracellular enzyme activation. Most importantly, we show that serine proteinase MMP-12 regulation in macrophages occurs via the protein kinase C-activating G protein-coupled receptor PAR-1.	Washington Univ, Sch Med, Barnes Jewish Hosp, Div Dermatol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Div Resp & Crit Care,Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Div Allergy & Pulm Med,Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	Cornelius, LA (corresponding author), Div Dermatol, 216 S Kingshighway, St Louis, MO 63110 USA.			Cornelius, Lynn A/0000-0002-6329-2819	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001938] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL29594] Funding Source: Medline; NIAMS NIH HHS [K08AR01938] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abraham LA, 1998, J BONE MINER RES, V13, P818, DOI 10.1359/jbmr.1998.13.5.818; Bernatowicz MS, 1996, J MED CHEM, V39, P4879, DOI 10.1021/jm960455s; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu TM, 1998, BIOCHEM BIOPH RES CO, V253, P128, DOI 10.1006/bbrc.1998.9760; Cornelius LA, 1998, J IMMUNOL, V161, P6845; Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671; DeClerck YA, 1997, ADV EXP MED BIOL, V425, P89; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; DUHAMELCLERIN E, 1997, ATHEROSCLER THROMB V, V17, P1555; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; Falcone DJ, 1998, J BIOL CHEM, V273, P31480, DOI 10.1074/jbc.273.47.31480; Gately S, 1996, CANCER RES, V56, P4887; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; Hollenberg MD, 1997, CAN J PHYSIOL PHARM, V75, P832, DOI 10.1139/cjpp-75-7-832; Kumar R, 1996, J IMMUNOL, V157, P5104; Lijnen HR, 1999, THROMB HAEMOSTASIS, V81, P799; MAZZIERI R, 1997, EMBO J, V9, P2319; MOLINO M, 1995, J BIOL CHEM, V270, P11168, DOI 10.1074/jbc.270.19.11168; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; SAARIALHOKERE UK, 1993, J BIOL CHEM, V268, P17354; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SHAPIRO SD, 1992, J BIOL CHEM, V267, P13890; Shen GX, 1998, SEMIN THROMB HEMOST, V24, P151, DOI 10.1055/s-2007-995834; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; Solomon KR, 1998, J CLIN INVEST, V102, P2019, DOI 10.1172/JCI4317; St-Denis A, 1998, J BIOL CHEM, V273, P32787, DOI 10.1074/jbc.273.49.32787; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; Sudbeck BD, 1997, J BIOL CHEM, V272, P22103, DOI 10.1074/jbc.272.35.22103; Xie B, 1998, J BIOL CHEM, V273, P11583, DOI 10.1074/jbc.273.19.11583; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730	36	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41243	41250		10.1074/jbc.M005788200	http://dx.doi.org/10.1074/jbc.M005788200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10993890	hybrid			2022-12-27	WOS:000166114600078
J	Toth, M; Bernardo, MM; Gervasi, DC; Soloway, PD; Wang, ZP; Bigg, HF; Overall, CM; DeClerck, YA; Tschesche, H; Cher, ML; Brown, S; Mobashery, S; Fridman, R				Toth, M; Bernardo, MM; Gervasi, DC; Soloway, PD; Wang, ZP; Bigg, HF; Overall, CM; DeClerck, YA; Tschesche, H; Cher, ML; Brown, S; Mobashery, S; Fridman, R			Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (membrane type 1)-MMP-dependent activation of pro-MMP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUAMOUS-CELL CARCINOMA; MEMBRANE-TYPES 1; GELATINASE-A; 1-MATRIX METALLOPROTEINASE; 72-KDA GELATINASE; CATALYTIC DOMAIN; EFFICIENT ACTIVATION; BREAST CARCINOMAS; HUMAN FIBROBLASTS; TERMINAL DOMAIN	The membrane-type 1 matrix metalloproteinase (MT1-MMP) has been shown to be a key enzyme in tumor angiogenesis and metastasis. MT1-MMP hydrolyzes a variety of extracellular matrix components and is a physiological activator of pro-MMP-2, another MMP involved in malignancy. Pro-MMP-2 activation by MT1-MMP involves the formation of an MT1-MMP tissue inhibitors of metalloproteinases 2 (TIMP-2) pro-MMP-2 complex on the cell surface that promotes the hydrolysis of pro-MMP-2 by a neighboring TIMP-2-free MT1-MMP. The MT1-MMP TIMP-2 complex also serves to reduce the intermolecular autocatalytic turnover of MT1-MMP, resulting in accumulation of active MT1-MMP (57 kDa) on the cell surface. Evidence shown here in Timp2-null cells demonstrates that pro-MMP-2 activation by MT1-MMP requires TIMP-2. In contrast, a C-terminally deleted TIMP-2 (Delta -TIMP-2), unable to form ternary complex, had no effect, However, Delta -TIMP-2 and certain synthetic MMP inhibitors, which inhibit MT1-MMP autocatalysis, can act synergistically with TIMP-2 in the promotion of pro-MMP-2 activation by MT1-MMP. In contrast, TIMP-4, an efficient MT1-MMP inhibitor, had no synergistic effect, These studies suggest that under certain conditions the pericellular activity of MT1-MMP in the presence of TIMP-2 can be modulated by synthetic and natural (TIMP-4) MMP inhibitors.	Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Dept Urol, Detroit, MI 48201 USA; Wayne State Univ, Dept Chem, Detroit, MI 48201 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ So Calif, Childrens Hosp Los Angeles, Div Hematol Oncol, Los Angeles, CA 90027 USA; Univ So Calif, Childrens Hosp Los Angeles, Dept Pediat, Los Angeles, CA 90027 USA; Univ Bielefeld, Dept Biochem, Fac Chem, W-4800 Bielefeld 1, Germany	Wayne State University; Wayne State University; Wayne State University; Roswell Park Cancer Institute; University of British Columbia; Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California; University of Bielefeld	Fridman, R (corresponding author), Wayne State Univ, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.	fridman@med.wayne.edu	Soloway, Paul/T-8243-2019	Soloway, Paul/0000-0003-1967-0437; DeClerck, Yves/0000-0002-3688-0113	NCI NIH HHS [CA61986-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061986] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belotti D, 1999, INT J BIOL MARKER, V14, P232, DOI 10.1177/172460089901400406; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brown PD, 1997, MED ONCOL, V14, P1, DOI 10.1007/BF02990939; Brown PD, 1999, APMIS, V107, P174, DOI 10.1111/j.1699-0463.1999.tb01541.x; Brown S, 2000, J AM CHEM SOC, V122, P6799, DOI 10.1021/ja001461n; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Caterina JJ, 2000, J BIOL CHEM, V275, P26416, DOI 10.1074/jbc.M001271200; d'Ortho MP, 1998, FEBS LETT, V421, P159, DOI 10.1016/S0014-5793(97)01555-X; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Davidson B, 1999, GYNECOL ONCOL, V73, P372, DOI 10.1006/gyno.1999.5381; De B, 1999, ANN NY ACAD SCI, V878, P40, DOI 10.1111/j.1749-6632.1999.tb07673.x; Della Porta P, 1999, ANTICANCER RES, V19, P3809; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; FRIDMAN R, 1993, BIOCHEM J, V289, P411, DOI 10.1042/bj2890411; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; Gervasi DC, 1996, BIOCHEM BIOPH RES CO, V228, P530, DOI 10.1006/bbrc.1996.1694; Harada T, 1998, J HEPATOL, V28, P231, DOI 10.1016/0168-8278(88)80010-2; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; HOYHTYA M, 1994, INT J CANCER, V56, P500, DOI 10.1002/ijc.2910560408; Jo Y, 2000, BIOCHEM J, V345, P511, DOI 10.1042/bj3450511; Jones JL, 1999, J PATHOL, V189, P161, DOI 10.1002/(SICI)1096-9896(199910)189:2<161::AID-PATH406>3.0.CO;2-2; Kadono Y, 1998, CANCER RES, V58, P2240; Kanayama H, 1998, CANCER, V82, P1359, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1359::AID-CNCR20>3.0.CO;2-4; Kitagawa Y, 1998, J UROLOGY, V160, P1540, DOI 10.1016/S0022-5347(01)62609-0; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P18; Ko YC, 1997, BIOCHEM BIOPH RES CO, V236, P100, DOI 10.1006/bbrc.1997.6859; Kurahara S, 1999, HEAD NECK-J SCI SPEC, V21, P627, DOI 10.1002/(SICI)1097-0347(199910)21:7<627::AID-HED7>3.3.CO;2-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li H, 1998, MOL CARCINOGEN, V22, P84; Lichte A, 1996, FEBS LETT, V397, P277, DOI 10.1016/S0014-5793(96)01206-9; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MULLERSTEFFNER HM, 1992, J BIOL CHEM, V267, P9606; Murashige M, 1996, JPN J CLIN ONCOL, V26, P303, DOI 10.1093/oxfordjournals.jjco.a023237; Nabeshima K, 2000, CANCER RES, V60, P3364; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Olson MW, 2000, J BIOL CHEM, V275, P2661, DOI 10.1074/jbc.275.4.2661; Overall CM, 1999, ANN NY ACAD SCI, V878, P747, DOI 10.1111/j.1749-6632.1999.tb07780.x; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Puente XS, 1996, CANCER RES, V56, P944; Rasmussen HS, 1997, PHARMACOL THERAPEUT, V75, P69, DOI 10.1016/S0163-7258(97)00023-5; Ree AH, 1997, CLIN CANCER RES, V3, P1623; Rosenthal EL, 1999, OTOLARYNG HEAD NECK, V121, P337, DOI 10.1016/S0194-5998(99)70217-2; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Segel I. H., 1993, ENZYME KINETICS BEHA, P100; Soloway PD, 1996, ONCOGENE, V13, P2307; Stanton H, 1998, J CELL SCI, V111, P2789; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Steward WP, 1999, CANCER CHEMOTH PHARM, V43, pS56, DOI 10.1007/s002800051099; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Toth M, 1997, CANCER RES, V57, P3159; Tsunezuka Y, 1996, CANCER RES, V56, P5678; Ueno H, 1997, CANCER RES, V57, P2055; Velasco G, 2000, CANCER RES, V60, P877; VISSCHER DW, 1994, INT J CANCER, V59, P339, DOI 10.1002/ijc.2910590308; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Wingfield PT, 1999, J BIOL CHEM, V274, P21362, DOI 10.1074/jbc.274.30.21362; Wojtowicz-Praga S, 1999, Drugs R D, V1, P117, DOI 10.2165/00126839-199901020-00001; Yamamoto M, 1998, J MED CHEM, V41, P1209, DOI 10.1021/jm970404a; Yoshizaki T, 1997, CANCER, V79, P139, DOI 10.1002/(SICI)1097-0142(19970101)79:1<139::AID-CNCR20>3.0.CO;2-4; Yu AE, 1997, DRUG AGING, V11, P229, DOI 10.2165/00002512-199711030-00006; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	80	109	114	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41415	41423		10.1074/jbc.M006871200	http://dx.doi.org/10.1074/jbc.M006871200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10998420	hybrid			2022-12-27	WOS:000166114600099
J	Wei, M; Li, Z; Ye, DM; Herzberg, O; Dunaway-Mariano, D				Wei, M; Li, Z; Ye, DM; Herzberg, O; Dunaway-Mariano, D			Identification of domain-domain docking sites within Clostridium symbiosum pyruvate phosphate dikinase by amino acid replacement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MUTAGENESIS; PHOSPHOENOLPYRUVATE FORMATION; PROTEIN-STRUCTURE; CATALYTIC SITE; BINDING SITE; LOCATION	Potential domain-domain docking residues, identified from the x-ray structure of the Clostridium symbiosum apoPPDK, were replaced by site-directed mutagenesis, The steady-state and transient kinetic properties of the mutant enzymes were determined as a way of evaluating docking efficiency. PPDK mutants, in which one of two stringently conserved docking residues located on the N-terminal domain (Arg(219) and Glu(271)) was substituted, displayed largely unimpeded catalysis of the phosphoenolpyruvate partial reaction at the C-terminal domain, but significantly impaired catalysis (>10(4)) of the ATP pyrophosphorylation of His(455) at the N-terminal domain: In contrast, alanine mutants of two potential docking residues located on the N-terminal domain (Ser(262) and Lys(149)), which are not conserved among the PPDKs, exhibited essentially normal catalytic turnover. Arg(219) and Glu(271) were thus proposed to play an important role in guiding the central domain and, hence, the catalytic His(455) into position for catalysis, Substitution of central domain residues Glu(434)/Glu(437) and Thr(453), th, respective docking partners of Arg(219) and Glu(271) resulted in mutants impaired in catalysis at the ATP active site. The x-ray crystal structure of the apo-T453A PPDK mutant was determined to test for possible misalignment of residues at the N-terminal domain-central domain interface that might result from loss of the Thr(453)-Glu(271) binding interaction. With the exception of the mutation site, the structure of T453A PPDK was found to be identical to that of the wild-type enzyme. It is hypothesized that the two Glu(271) interfacial binding sites that remain in the T453A PPDK mutant, Thr(453) backbone NH and Met(452) backbone NH, are sufficient to stabilize the native conformation as observed in the crystalline state but may be less effective in populating the reactive conformation in solution.	Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA	University of New Mexico	Herzberg, O (corresponding author), Ctr Adv Res Biotechnol, Rockville, MD 20850 USA.	dd39@unm.edu		Herzberg, Osnat/0000-0003-2823-7627; Li, Zhong/0000-0002-1039-7000	NIGMS NIH HHS [GM36260] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036260] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CARROLL LJ, 1989, J AM CHEM SOC, V111, P5965, DOI 10.1021/ja00197a081; Cleland W W, 1979, Methods Enzymol, V63, P500; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Herzberg O, 1996, P NATL ACAD SCI USA, V93, P2652, DOI 10.1073/pnas.93.7.2652; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; McGuire M, 1998, BIOCHEMISTRY-US, V37, P13463, DOI 10.1021/bi980920i; McGuire M, 1996, BIOCHEMISTRY-US, V35, P8544, DOI 10.1021/bi960275k; MEHL A, 1994, BIOCHEMISTRY-US, V33, P1093, DOI 10.1021/bi00171a007; POCALYKO DJ, 1990, BIOCHEMISTRY-US, V29, P10757, DOI 10.1021/bi00500a006; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; ROUSSEL A, 1989, TURBO FRODO SILICON; SPOLAR RS, 1989, P NATL ACAD SCI USA, V86, P8382, DOI 10.1073/pnas.86.21.8382; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; WANG HC, 1988, BIOCHEMISTRY-US, V27, P625, DOI 10.1021/bi00402a020; Wood H G, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P85; XU Y, 1995, BIOCHEMISTRY-US, V34, P2181, DOI 10.1021/bi00007a011; YANKIE L, 1995, BIOCHEMISTRY-US, V34, P2188, DOI 10.1021/bi00007a012	18	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41156	41165		10.1074/jbc.M006149200	http://dx.doi.org/10.1074/jbc.M006149200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10995759	hybrid			2022-12-27	WOS:000166114600068
J	Gerelsaikhan, T; Turner, RJ				Gerelsaikhan, T; Turner, RJ			Transmembrane topology of the secretory Na+-K+-2Cl(-) cotransporter NKCC1 studied by in vitro translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; SHARK RECTAL GLAND; MOLECULAR-CLONING; MEMBRANE-PROTEINS; NA-K-2CL COTRANSPORTER; FUNCTIONAL EXPRESSION; HYPOKALEMIC ALKALOSIS; BARTTERS-SYNDROME; PREDICTION; TRANSPORT	The secretory Na+-K+-2Cl(-) cotransporter NKCC1 is a member of a small gene family of electroneutral salt transporters. Hydropathy analyses indicate that all of these transporters have a similar general structure consisting of large hydrophilic N and C termini on either side of a central, relatively well conserved, hydrophobic domain. Programs that predict the transmembrane topology of polytopic membrane proteins identify 10-12 putative membrane-spanning segments (MSSs) in this hydrophobic domain; but to date, there is little experimental data on the structure of this region for any of these transporters. In this report, we have studied the transmembrane topology of NKCC1 using an in vitro translation system designed to test the membrane insertion properties of putative MSSs (Bamberg, K., and Sachs, G. (1994) J. Biol. Chem. 269, 16909-16919). Fusion proteins consisting of putative NKCC1 MSSs inserted either (i) between an N-terminal cytosolic anchor sequence and a C-terminal reporter sequence containing multiple N-linked glycosidation sites or (ii) between an N-terminal signal anchor sequence and the same glycosidation flag were expressed in the presence of canine pancreatic microsomes. The glycosidation status of the reporter sequence, which indicated its luminal or extraluminal location in the microsomes, was then used to characterize the signal anchor or stop transfer activity of the inserted MSSs. The results of this experimental analysis yielded a topology scheme consisting of 12 membrane-spanning segments, two pairs of which apparently form rather tight hairpin-like structures within the membrane.	NIDCR, Membrane Biol Sect, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Turner, RJ (corresponding author), NIDCR, Membrane Biol Sect, Gene Therapy & Therapeut Branch, NIH, Rm 1A01,Bldg 10, Bethesda, MD 20892 USA.	rjturner@nih.gov			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [ZIADE000415, Z01DE000415] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; Bayle D, 1997, J BIOL CHEM, V272, P19697, DOI 10.1074/jbc.272.32.19697; Behnke RD, 1998, FASEB J, V12, pA1013; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; Bowie JU, 1997, J MOL BIOL, V272, P780, DOI 10.1006/jmbi.1997.1279; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; DELPIRE E, 1994, J BIOL CHEM, V269, P25677; Delpire E, 1999, NAT GENET, V22, P192, DOI 10.1038/9713; Evans RL, 1998, BIOCHEM BIOPH RES CO, V245, P301, DOI 10.1006/bbrc.1998.8428; Flagella M, 1999, J BIOL CHEM, V274, P26946, DOI 10.1074/jbc.274.38.26946; FORBUSH B, 1995, INT SOC NEPHR; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Isenring P, 1998, J GEN PHYSIOL, V112, P549, DOI 10.1085/jgp.112.5.549; Isenring P, 1998, P NATL ACAD SCI USA, V95, P7179, DOI 10.1073/pnas.95.12.7179; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; Kaplan MR, 1996, ANNU REV PHYSIOL, V58, P649, DOI 10.1146/annurev.ph.58.030196.003245; Kurihara K, 1999, AM J PHYSIOL-CELL PH, V277, pC1184, DOI 10.1152/ajpcell.1999.277.6.C1184; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LYTLE C, 1992, J BIOL CHEM, V267, P25428; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Monne M, 1999, J MOL BIOL, V288, P141, DOI 10.1006/jmbi.1999.2657; Moore-Hoon ML, 1998, BBA-BIOMEMBRANES, V1373, P261, DOI 10.1016/S0005-2736(98)00112-6; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; REAGAN JD, 1995, INSECT BIOCHEM MOLEC, V25, P875, DOI 10.1016/0965-1748(95)00049-2; ROST B, 1995, PROTEIN SCI, V4, P521; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201	37	54	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40471	40477		10.1074/jbc.M007751200	http://dx.doi.org/10.1074/jbc.M007751200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11013260	hybrid			2022-12-27	WOS:000166039500090
J	Gorzalczany, Y; Sigal, N; Itan, M; Lotan, O; Pick, E				Gorzalczany, Y; Sigal, N; Itan, M; Lotan, O; Pick, E			Targeting of Rac1 to the phagocyte membrane is sufficient for the induction of NADPH oxidase assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; GTP-BINDING PROTEINS; RESPIRATORY BURST OXIDASE; GDP/GTP EXCHANGE PROTEIN; SUPEROXIDE PRODUCTION; PLASMA-MEMBRANE; IN-VITRO; ACTIVATION; MACROPHAGES; P47(PHOX)	The superoxide (O-2(.-))-generating NADPH oxidase complex of phagocytes consists of a membrane-associated flavocytochrome (cytochrome b559) and four cytosolic proteins, p47(phox) p67(phox), p40(phox), and the small GTPase Rac (Rac1 or -2). NADPH oxidase activation (O-2 production) is elicited as the consequence of assembly of some or all cytosolic components with cytochrome b(559). This process can be reproduced in an in vitro system consisting of phagocyte membranes, p47(phox) p67(phox), and Rac1 activated by an anionic amphiphile. We now show that posttranslationally processed (prenylated) Rad initiates NADPH oxidase assembly, expressed in O-2, production, in a cell-free system containing phagocyte membrane vesicles and p67(phox), in the absence of an activating amphiphile and of p47(phox). Prenylated Cdc42Hs, a GTPase closely related to Rac, is inactive under the same conditions. Results obtained with phagocyte membrane vesicles can be reproduced fully by replacing these with partially purified cytochrome b(559), incorporated in phosphatidylcholine vesicles. Prenylated, but not nonprenylated, Rac1 binds spontaneously to phagocyte membrane vesicles and also to artificial, protein-free, phosphatidylcholine vesicles, a process counteracted by GDP dissociation inhibitor for Rho. Binding of prenylated Rac1 to membrane vesicles is accompanied by the recruitment of p67(phox) to the same location and the formation of an assembled NADPH oxidase complex, producing O-2 upon the addition of NADPH. Amphiphile and p47(phox)-independent NADPH oxidase activation by prenylated Rad is inhibited by Rho GDP dissociation inhibitor and by phosphatidylcholine vesicles, both competing with membrane for prenylated Rac1. We conclude that, in vitro, targeting of Rac to the phagocyte membrane is sufficient for the induction of NADPH oxidase assembly, suggesting that the principal or, possibly, the only role of Rac is to recruit cytosolic p67(phox) to the membrane environment, to be followed by the interaction of p67(phox) with cytochrome b(559).	Tel Aviv Univ, Sackler Sch Med, Julius Friedrich Cohnheim Minerva Ctr Phagocyte R, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Pick, E (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel.		Pick, Edgar/B-1795-2008	Pick, Edgar/0000-0003-4625-3233				ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; Ambruso DR, 2000, P NATL ACAD SCI USA, V97, P4654, DOI 10.1073/pnas.080074897; ANDO S, 1992, J BIOL CHEM, V267, P25709; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1994, J BIOL CHEM, V269, P7055; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; Cross AR, 1999, J BIOL CHEM, V274, P15519, DOI 10.1074/jbc.274.22.15519; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; FUCHS A, 1994, EUR J BIOCHEM, V226, P587, DOI 10.1111/j.1432-1033.1994.tb20084.x; Hata K, 1998, J BIOL CHEM, V273, P4232, DOI 10.1074/jbc.273.7.4232; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Illenberger D, 1998, EMBO J, V17, P6241, DOI 10.1093/emboj/17.21.6241; JOSEPH G, 1995, J BIOL CHEM, V270, P29079, DOI 10.1074/jbc.270.49.29079; JOSEPH G, 1994, J BIOL CHEM, V269, P29024; JOUAN A, 1993, ANAL BIOCHEM, V214, P251; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; Koshkin V, 1997, BBA-BIOENERGETICS, V1319, P139, DOI 10.1016/S0005-2728(96)00154-5; KRECK ML, 1994, J BIOL CHEM, V269, P4161; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; LECABEC V, 1994, BIOCHEM BIOPH RES CO, V198, P1216, DOI 10.1006/bbrc.1994.1172; Leto TL., 1999, INFLAMMATION BASIC P, P769; Lopes LR, 1999, J BIOL CHEM, V274, P15533, DOI 10.1074/jbc.274.22.15533; PHILIPS MR, 1995, J BIOL CHEM, V270, P11514, DOI 10.1074/jbc.270.19.11514; PICK E, 1993, EUR J BIOCHEM, V217, P441, DOI 10.1111/j.1432-1033.1993.tb18264.x; Pugach N., 1998, European Journal of Haematology, V60, P343; QUINN MT, 1993, J BIOL CHEM, V268, P20983; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Toporik A, 1998, BIOCHEMISTRY-US, V37, P7147, DOI 10.1021/bi9800404	40	115	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40073	40081		10.1074/jbc.M006013200	http://dx.doi.org/10.1074/jbc.M006013200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007780	hybrid			2022-12-27	WOS:000166039500039
J	Sakamoto, H; Imai, H; Nakagawa, Y				Sakamoto, H; Imai, H; Nakagawa, Y			Involvement of phospholipid hydroperoxide glutathione peroxidase in the modulation of prostaglandin D-2 synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; BASOPHILIC LEUKEMIA-CELLS; ENDOPEROXIDE-H SYNTHASE-1; MAST-CELLS; RBL-2H3 CELLS; HYDROGEN-PEROXIDE; OXYGEN RADICALS; RAT; 5-LIPOXYGENASE; TRANSLOCATION	Antigenic cross-linking of the high affinity IgE receptors on mast cells induced the synthesis of prostaglandin D-2 (PGD(2)). The production of PGD(2) in L9 cells, which overexpressed non-mitochondrial phospholipid glutathione peroxidase (PHGPx), was only one-third that in the control line of cells (S1 cells). The reduction in the formation of PGD, in L9 cells was reversed upon inhibition of PHGPx activity by buthionine sulfoximine. Experiments with inhibitors demonstrated that prostaglandin H synthase-a (PGHS-2) was the isozyme responsible for the production of PGD, upon cross-linking of IgE receptors. The conversion of radiolabeled arachidonic acid to prostaglandin H, (PGH,) was strongly inhibited in L9 cells, whereas the rate of conversion of PGH, to PGD, was the same in L9 cells and S1 cells, indicating that PGHS was inactivated in L9 cells. The PGHS activity in L9 cells was about half that in S1 cells. However, PGHS activity in L9 cells increased to the level in S1 cells upon the addition of the hydroperoxide 15-hydroperoxyeicosatetraenoic acid or of 3-chloroperoxy-benzoic acid. These results suggest that non-mitochondrial PHGPx might be involved in the inactivation of PGHS-2 in nucleus and endoplasmic reticulum via reductions in levels of the hydroperoxides that are required for full activation of PGHS. Therefore, it appears that PHGPx might function as a modulator of the production of prostanoids, in addition to its role as an antioxidant enzyme.	Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, Tokyo 1088641, Japan	Kitasato University	Nakagawa, Y (corresponding author), Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan.							Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Chen W, 1999, J BIOL CHEM, V274, P20301, DOI 10.1074/jbc.274.29.20301; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Godeas C, 1996, BIOCHEM MOL MED, V59, P118, DOI 10.1006/bmme.1996.0076; GREEN K, 1964, J LIPID RES, V5, P117; GUARNIERI C, 1992, FREE RADICALS AGING, P73; HARLAN JM, 1984, J CLIN INVEST, V74, P442, DOI 10.1172/JCI111440; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HOLGATE ST, 1984, J IMMUNOL, V133, P2138; Imai H, 1996, BIOCHEM BIOPH RES CO, V222, P432, DOI 10.1006/bbrc.1996.0762; Imai H, 1998, J BIOL CHEM, V273, P1990, DOI 10.1074/jbc.273.4.1990; JOLLY SR, 1984, CIRC RES, V54, P277, DOI 10.1161/01.RES.54.3.277; KAWATA R, 1995, J IMMUNOL, V155, P818; Keelan JA, 1999, BIOCHEM BIOPH RES CO, V262, P579, DOI 10.1006/bbrc.1999.1257; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; LEWIS RA, 1982, J IMMUNOL, V129, P1627; Lu GQ, 1999, J BIOL CHEM, V274, P16162, DOI 10.1074/jbc.274.23.16162; MALAVIYA R, 1993, J BIOL CHEM, V268, P4939; Margalit A, 1998, AM J PHYSIOL-REG I, V274, pR294, DOI 10.1152/ajpregu.1998.274.2.R294; MARSHALL PJ, 1986, J LAB CLIN MED, V108, P525; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; PEDEN DB, 1995, AM J PHYSIOL-LUNG C, V268, pL902, DOI 10.1152/ajplung.1995.268.6.L902; PETERS SP, 1984, J IMMUNOL, V132, P1972; ROVERI A, 1994, METHOD ENZYMOL, V143, P307; Sakamoto H, 1999, J BIOCHEM-TOKYO, V125, P90, DOI 10.1093/oxfordjournals.jbchem.a022274; Schnurr K, 1996, J BIOL CHEM, V271, P4653; Shitashige M, 1998, BBA-LIPID LIPID MET, V1389, P57, DOI 10.1016/S0005-2760(97)00129-X; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; SPORN PHS, 1988, AM REV RESPIR DIS, V137, P49, DOI 10.1164/ajrccm/137.1.49; TAYLOR L, 1983, J BIOL CHEM, V258, P6855; THOMAS JP, 1990, J BIOL CHEM, V265, P454; Tsai AL, 1999, J BIOL CHEM, V274, P21695, DOI 10.1074/jbc.274.31.21695; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; WEI CH, 1995, BIOCHEMISTRY-US, V34, P8499, DOI 10.1021/bi00026a034; WENNOGLE LP, 1995, FEBS LETT, V371, P315, DOI 10.1016/0014-5793(95)00930-8; Westcott JY, 1996, BBA-LIPID LIPID MET, V1303, P74, DOI 10.1016/0005-2760(96)00074-4; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u	48	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40028	40035		10.1074/jbc.M003191200	http://dx.doi.org/10.1074/jbc.M003191200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11010961	hybrid			2022-12-27	WOS:000166039500033
J	Temple, CA; Rajagopalan, KV				Temple, CA; Rajagopalan, KV			Mechanism of assembly of the bis(molybdopterin guanine dinucleotide)molybdenum cofactor in Rhodobacter sphaeroides dimethyl sulfoxide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM-COFACTOR; ESCHERICHIA-COLI; NITRATE REDUCTASE; CRYSTAL-STRUCTURE; MOB LOCUS; GENE-PRODUCT; BIOSYNTHESIS; MOLYBDOPTERIN; NARJ; INVOLVEMENT	A fully defined in vitro system has been developed for studying the mechanism of assembly of the bis(molybdopterin guanine dinucleotide)molybdenum cofactor in Rhodobacter sphaeroides dimethyl sulfoxide reductase (DMSOR). R. sphaeroides DMSOR expressed in a mobA(-) Escherichia coli strain lacks molybdopterin and molybdenum but contains a full complement of guanine in the form of GMP and GDP. Escherichia coli MobA, molybdopterin-Mo, GTP, and MgCl2, are required and sufficient for the in vitro activation of purified DMSOR expressed in the absence of MobA High levels of MobA inhibit the in vitro activation. A chaperone is not required for the in vitro activation process. The reconstituted DMSOR can exhibit up to 73% of the activity observed in recombinant DMSOR purified from a wildtype strain. The use of radiolabeled GTP has demonstrated incorporation of the guanine moiety from the GTP into the activated DMSOR. No role was observed for E. coli MobB in the in vitro activation of apo-DMSOR. This work also represents the first time that the MobA-mediated conversion of molybdopterin to molybdopterin guanine dinucleotide has been demonstrated directly without using the activation of a molybdoenzyme as an indicator for cofactor formation.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Rajagopalan, KV (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raj@biochem.duke.edu			NIGMS NIH HHS [GM00091] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blasco F, 1998, MOL MICROBIOL, V28, P435, DOI 10.1046/j.1365-2958.1998.00795.x; BLASCO F, 1992, MOL MICROBIOL, V6, P221, DOI 10.1111/j.1365-2958.1992.tb02003.x; Czjzek M, 1998, J MOL BIOL, V284, P435, DOI 10.1006/jmbi.1998.2156; Dias JM, 1999, STRUCTURE, V7, P65, DOI 10.1016/S0969-2126(99)80010-0; Eaves DJ, 1997, EUR J BIOCHEM, V246, P690, DOI 10.1111/j.1432-1033.1997.t01-1-00690.x; Garton SD, 1997, J AM CHEM SOC, V119, P12906, DOI 10.1021/ja972109l; George GN, 1999, J AM CHEM SOC, V121, P1256, DOI 10.1021/ja982843k; Hanzelmann P, 1998, EUR J BIOCHEM, V255, P755, DOI 10.1046/j.1432-1327.1998.2550755.x; Hilton JC, 1999, J BIOL CHEM, V274, P8428, DOI 10.1074/jbc.274.13.8428; Hilton JC, 1996, ARCH BIOCHEM BIOPHYS, V325, P139, DOI 10.1006/abbi.1996.0017; HUNGKEI L, 2000, J AM CHEM SOC, V122, P7673; IOBBINIVOL C, 1995, MICROBIOL-SGM, V141, P1663; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; Lake MW, 2000, J BIOL CHEM, V275, P40211, DOI 10.1074/jbc.M007406200; McAlpine AS, 1998, J MOL BIOL, V275, P613, DOI 10.1006/jmbi.1997.1513; Mouncey NJ, 1997, J BACTERIOL, V179, P7617, DOI 10.1128/jb.179.24.7617-7624.1997; NGUYEN BT, 1986, BIOCHEM J, V234, P263, DOI 10.1042/bj2340263; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; Palmer T, 1998, BBA-GENE STRUCT EXPR, V1395, P135, DOI 10.1016/S0167-4781(97)00145-0; PALMER T, 1994, EUR J BIOCHEM, V222, P687, DOI 10.1111/j.1432-1033.1994.tb18913.x; PLUNKETT G, 1993, NUCLEIC ACIDS RES, V21, P3391, DOI 10.1093/nar/21.15.3391; Rajagopalan KV, 1996, ESCHERICHIA COLI SAL, P674; ROTHERY RA, 1995, J BACTERIOL, V177, P2057, DOI 10.1128/jb.177.8.2057-2063.1995; Rothery RA, 1998, J BIOL CHEM, V273, P7462, DOI 10.1074/jbc.273.13.7462; SANTINI CL, 1992, J BACTERIOL, V174, P7934, DOI 10.1128/JB.174.24.7934-7940.1992; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; TEMPLE C, 2000, IN PRESS ARCH BIOCH; Temple CA, 2000, BIOCHEMISTRY-US, V39, P4046, DOI 10.1021/bi9921541; Ujiiye T, 1996, BBA-BIOENERGETICS, V1277, P1, DOI 10.1016/S0005-2728(96)00101-6	31	55	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40202	40210		10.1074/jbc.M007407200	http://dx.doi.org/10.1074/jbc.M007407200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10978348	hybrid			2022-12-27	WOS:000166039500057
J	Zhou, JJ; Trueman, LJ; Boorer, KJ; Theodoulou, FL; Forde, BG; Miller, AJ				Zhou, JJ; Trueman, LJ; Boorer, KJ; Theodoulou, FL; Forde, BG; Miller, AJ			A high affinity fungal nitrate carrier with two transport mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-NIDULANS; CHLAMYDOMONAS-REINHARDTII; XENOPUS-OOCYTES; MEMBRANE VOLTAGE; COTRANSPORTER; SYSTEMS; PH; KINETICS; NITRITE; CLONING	We have expressed the CRNA high affinity nitrate transporter from Emericella (Aspergillus) nidulans in Xenopus oocytes and used electrophysiology to study its properties. This method was used because there are no convenient radiolabeled substrates for the transporter. Oocytes injected with crnA mRNA showed nitrate-, nitrite-, and chlorite-dependent currents. Although the gene was originally identified by chlorate selection there was no evidence for transport of this anion, The gene selection is explained by the high affinity of the transporter for chlorite, and the fact that this ion contaminates solutions of chlorate, The pH-dependence of the anion-elicited currents was consistent with H+-coupled mechanism of transport. At any given voltage, currents showed hyperbolic kinetics with respect to extracellular H+, and these data could be fitted with a Michaelis-Menten relationship. But this equation did not adequately describe transport of the anion substrates, At higher concentrations of the anion substrates and more negative membrane voltages, the currents were decreased, but this effect was independent of changes in external pH, These more complicated kinetics could be fit by an equation containing two Michaelis-Menten terms. The substrate inhibition of the currents could be explained by a transport reaction cycle that included two routes for the transfer of nitrate across the membrane, one on the empty carrier and the other proton coupled. The model predicts that the substrate inhibition of transporter current depends on the cytosolic nitrate concentration. This is the first time a high affinity nitrate transport activity has been characterized in a heterologous system and the measurements show how the properties of the CRNA transporter are modified by changes in the membrane potential, external pH, and nitrate concentration. The physiological significance of these observations is discussed.	IACR, Biochem & Physiol Dept, Harpenden AL5 2JQ, Herts, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Miller, AJ (corresponding author), IACR, Biochem & Physiol Dept, Harpenden AL5 2JQ, Herts, England.		Miller, Anthony John/B-5139-2008; Forde, Brian G/C-6554-2009	Miller, Anthony John/0000-0003-0572-7607; Forde, Brian G/0000-0001-7973-7280; Theodoulou, Frederica/0000-0002-8306-0716				Blatt MR, 1997, J MEMBRANE BIOL, V160, P59, DOI 10.1007/s002329900295; BOORER KJ, 1994, J BIOL CHEM, V269, P20417; BROWNLEE AG, 1983, J BACTERIOL, V155, P1138, DOI 10.1128/JB.155.3.1138-1146.1983; Chow CW, 1997, J GEN PHYSIOL, V110, P185, DOI 10.1085/jgp.110.2.185; DOWNEY RJ, 1994, MICROBIOS, V78, P35; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; EDDY AA, 1985, BIOCHEM J, V231, P291, DOI 10.1042/bj2310291; Forde BG, 2000, BBA-BIOMEMBRANES, V1465, P219, DOI 10.1016/S0005-2736(00)00140-1; Galvan A, 1996, J BIOL CHEM, V271, P2088, DOI 10.1074/jbc.271.4.2088; GOLDSMITH J, 1973, PLANT PHYSIOL, V52, P362, DOI 10.1104/pp.52.4.362; MEHARG AA, 1995, J MEMBRANE BIOL, V145, P49; PARENT L, 1992, J MEMBRANE BIOL, V125, P9; PARKER I, 1988, PROC R SOC SER B-BIO, V233, P191, DOI 10.1098/rspb.1988.0018; Perez MD, 1997, BIOCHEM J, V321, P397, DOI 10.1042/bj3210397; POMBEIRO SRC, 1983, GENET RES, V41, P203, DOI 10.1017/S0016672300021224; POMBEIRO SRC, 1992, WORLD J MICROB BIOT, V8, P477, DOI 10.1007/BF01201943; QUESADA A, 1994, PLANT J, V5, P407, DOI 10.1111/j.1365-313X.1994.00407.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANDERS D, 1986, J MEMBRANE BIOL, V90, P67, DOI 10.1007/BF01869687; SCHLOEME.RH, 1974, J BACTERIOL, V118, P259, DOI 10.1128/JB.118.1.259-269.1974; SCHLOEME.RH, 1974, J BACTERIOL, V118, P270, DOI 10.1128/JB.118.1.270-274.1974; SLOAN C. H., 1966, TOBACCO SCI, V10, P121; TOMSETT AB, 1979, GENET RES, V34, P19, DOI 10.1017/S001667230001925X; Trueman LJ, 1996, GENE, V175, P223, DOI 10.1016/0378-1119(96)00154-0; TSAY YF, 1993, CELL, V72, P705, DOI 10.1016/0092-8674(93)90399-B; UNKLES SE, 1991, P NATL ACAD SCI USA, V88, P204, DOI 10.1073/pnas.88.1.204; van der Leij M, 1998, PLANTA, V205, P64, DOI 10.1007/s004250050297; YU L, 1989, J BIOL CHEM, V264, P20847; Zhou JJ, 1998, J BIOL CHEM, V273, P12017, DOI 10.1074/jbc.273.20.12017; Zhou JJ, 1997, J MEMBRANE BIOL, V159, P113, DOI 10.1007/s002329900275; Zhou JJ, 2000, FEBS LETT, V466, P225, DOI 10.1016/S0014-5793(00)01085-1	31	51	56	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39894	39899		10.1074/jbc.M004610200	http://dx.doi.org/10.1074/jbc.M004610200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10984478	hybrid			2022-12-27	WOS:000166039500016
J	Carson, JA; Fillmore, RA; Schwartz, RJ; Zimmer, WE				Carson, JA; Fillmore, RA; Schwartz, RJ; Zimmer, WE			The smooth muscle gamma-actin gene promoter is a molecular target for the mouse bagpipe homologue, mNkx3-1, and serum response factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; BOX TRANSCRIPTION FACTORS; DNA-BINDING SPECIFICITY; GROWTH-FACTOR-BETA; HOMEODOMAIN PROTEINS; TINMAN HOMOLOG; HOMEOBOX GENES; CARDIAC TRANSCRIPTION; TRANSGENIC MICE; SONIC HEDGEHOG	An evolutionarily conserved vertebrate homologue of the Drosophila NK-3 homeodomain gene bagpipe, Nkx3-1, is expressed in vascular and visceral mesoderm-derived muscle tissues and may influence smooth muscle cell differentiation. Nkx3-1 was evaluated for mediating smooth muscle gamma -actin (SMGA) gene activity, a specific marker of smooth muscle differentiation. Expression of mNkx3-1 in heterologous CV-1 fibroblasts was unable to elicit SMGA promoter activity but required the coexpression of serum response factor (SRF) to activate robust SMGA transcription. A novel complex element containing a juxtaposed Nkx-binding site (NKE) and an SRF-binding element (SRE) in the proximal promoter region was found to be necessary for the Nkx3-1/SRF coactivation of SMGA transcription. Furthermore, Nkx3-1 and SRF associate through protein-protein interactions and the homeodomain region of Nkx3-1 facilitated SRF binding to the complex NKE SRE. Mutagenesis of Nkx3-1 revealed an inhibitory domain within its C-terminal segment. In addition, mNkx3-1/SRF cooperative activity required an intact Nkx3-1 homeodomain along with the MADS box of SRF, which contains DNA binding and dimerization structural domains, and the contiguous C-terminal SRF activation domain. Thus, SMGA is a novel target for Nkx3-1, and the activity of Nkx3-1 on the SMGA promoter is dependent upon SRF.	Baylor Coll Med, Dept Cellular & Mol Biol, Houston, TX 77030 USA; Univ S Alabama, Dept Struct & Cellular Biol, Mobile, AL 36688 USA	Baylor College of Medicine; University of South Alabama	Schwartz, RJ (corresponding author), Baylor Coll Med, Dept Cellular & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Carson, James/Q-5693-2019	Carson, James/0000-0003-3733-8796; Zimmer, Warren/0000-0002-0668-6096	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038639, P01HL049953] Funding Source: NIH RePORTER; NHLBI NIH HHS [5P60HL38639, R01HL50422, P01HL49953] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BABIJ P, 1989, J MOL BIOL, V210, P673, DOI 10.1016/0022-2836(89)90142-3; BECKER JC, 1995, P NATL ACAD SCI USA, V92, P9727, DOI 10.1073/pnas.92.21.9727; Belaguli NS, 1999, MOL CELL BIOL, V19, P4582; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; BODMER R, 1993, DEVELOPMENT, V118, P719; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; Browning CL, 1998, DEV BIOL, V194, P18, DOI 10.1006/dbio.1997.8808; CARROLL SL, 1986, J BIOL CHEM, V261, P8965; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Chen CY, 1997, MOL ENDOCRINOL, V11, P812, DOI 10.1210/me.11.6.812; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Chen CY, 1996, MOL CELL BIOL, V16, P6372; COLLINGE M, 1992, MOL CELL BIOL, V12, P2359, DOI 10.1128/MCB.12.5.2359; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Doevendans PA, 1996, INT J BIOCHEM CELL B, V28, P387, DOI 10.1016/1357-2725(95)00145-X; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Durocher D, 1998, DEV GENET, V22, P250, DOI 10.1002/(SICI)1520-6408(1998)22:3<250::AID-DVG7>3.0.CO;2-5; GABBIANI G, 1984, J CLIN INVEST, V73, P148, DOI 10.1172/JCI111185; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; Galvagni F, 1997, MOL CELL BIOL, V17, P1731, DOI 10.1128/MCB.17.3.1731; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Groisman R, 1996, J BIOL CHEM, V271, P5258; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Herring BP, 1996, AM J PHYSIOL-CELL PH, V270, pC1656, DOI 10.1152/ajpcell.1996.270.6.C1656; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; Kallmeier RC, 1995, J BIOL CHEM, V270, P30949, DOI 10.1074/jbc.270.52.30949; Kerppola TK, 1998, STRUCT FOLD DES, V6, P549, DOI 10.1016/S0969-2126(98)00057-4; Khorasanizadeh S, 1999, CURR BIOL, V9, pR456, DOI 10.1016/S0960-9822(99)80281-4; KIM E, 1989, MOL CELL BIOL, V9, P1875, DOI 10.1128/MCB.9.5.1875; KIM JH, 1994, J BIOL CHEM, V269, P13740; KIM YS, 1989, P NATL ACAD SCI USA, V86, P7716, DOI 10.1073/pnas.86.20.7716; Knezevic V, 1997, DEVELOPMENT, V124, P4523; Kos L, 1998, MECH DEVELOP, V70, P25, DOI 10.1016/S0925-4773(97)00168-8; Kovacs AM, 1998, GENE EXPRESSION, V7, P115; KOVACS AM, 1993, CELL MOTIL CYTOSKEL, V24, P67, DOI 10.1002/cm.970240108; Landerholm TE, 1999, DEVELOPMENT, V126, P2053; LEESMILLER JP, 1987, J BIOL CHEM, V262, P2988; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; MACDERMOTT RP, 1988, INFLAMM BOWEL DIS, P21; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; Mannervik M, 1999, BIOESSAYS, V21, P267, DOI 10.1002/(SICI)1521-1878(199904)21:4<267::AID-BIES1>3.3.CO;2-3; MCHUGH KM, 1991, DEV BIOL, V148, P442, DOI 10.1016/0012-1606(91)90263-3; MCHUGH KM, 1995, DEV DYNAM, V204, P278, DOI 10.1002/aja.1002040306; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; MIWA T, 1991, MOL CELL BIOL, V11, P3296, DOI 10.1128/MCB.11.6.3296; MOSSE PRL, 1986, ARTERIOSCLEROSIS, V6, P664, DOI 10.1161/01.ATV.6.6.664; NELSON H B, 1990, New Biologist, V2, P171; NURRISH SJ, 1995, MOL CELL BIOL, V15, P4076; OWENS GK, 1995, PHYSIOL REV, V75, P487; PEREZMARTIN J, 1993, SCIENCE, V260, P805, DOI 10.1126/science.8387228; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; Qian J, 1996, DEV DYNAM, V207, P135; Ray MK, 1996, MOL CELL BIOL, V16, P2056; Reecy JM, 1999, DEVELOPMENT, V126, P839; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Samaha FF, 1996, J BIOL CHEM, V271, P395, DOI 10.1074/jbc.271.1.395; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; Sciavolino PJ, 1997, DEV DYNAM, V209, P127, DOI 10.1002/(SICI)1097-0177(199705)209:1<127::AID-AJA12>3.0.CO;2-Z; SZUCSIK JC, 1995, GENOMICS, V28, P154, DOI 10.1006/geno.1995.1126; Tanaka M, 1998, DEV GENET, V22, P239, DOI 10.1002/(SICI)1520-6408(1998)22:3<239::AID-DVG6>3.3.CO;2-G; Topouzis S, 1996, DEV BIOL, V178, P430, DOI 10.1006/dbio.1996.0229; Tribioli C, 1997, MECH DEVELOP, V65, P145, DOI 10.1016/S0925-4773(97)00067-1; VANDERVLIET PC, 1993, BIOESSAYS, V15, P25, DOI 10.1002/bies.950150105; West AG, 1997, MOL CELL BIOL, V17, P2876, DOI 10.1128/MCB.17.5.2876; Wolberger C, 1999, ANNU REV BIOPH BIOM, V28, P29, DOI 10.1146/annurev.biophys.28.1.29; Yoshiura KI, 1997, GENOMICS, V45, P425, DOI 10.1006/geno.1997.4926; ZIMMER WE, 1996, DEV BIOL, V175, P399	76	72	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39061	39072		10.1074/jbc.M006532200	http://dx.doi.org/10.1074/jbc.M006532200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993896	hybrid			2022-12-27	WOS:000165953100018
J	Fujise, K; Zhang, D; Liu, JL; Yeh, ETH				Fujise, K; Zhang, D; Liu, JL; Yeh, ETH			Regulation of apoptosis and cell cycle progression by MCL1 - Differential role of proliferating cell nuclear antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE PROTEIN-KINASES; DNA POLYMERASE-DELTA; DEPENDENT KINASES; REPLICATION FORK; HUMAN P53; LIGASE-I; PCNA; GENE; EXPRESSION; BINDING	MCL1 (ML1 myeloid cell leukemia 1), a Bcl-2 (B-cell lymphoma-leukemia 2) homologue, is known to function as an anti-apoptotic protein. Here we show in vitro and in vivo that MCL1 interacts with the cell cycle regulator, proliferating cell nuclear antigen (PCNA). This finding prompted us to investigate whether MCL1, in addition to its anti-apoptotic function, has an effect on cell cycle progression. A bromodeoxyuridine uptake assay showed that the overexpression of MCL1 significantly inhibited the cell cycle progression through the S-phase. The S-phase of the cell cycle is also known to be regulated by PCNA. A mutant of MCL1 that lacks PCNA binding (MCL1(Delta 4A)) could not inhibit cell cycle progression as effectively as wild type MCL1. In contrast, MCL1(Delta 4A) retained its anti-apoptotic function in HeLa cells when challenged by Etoposide. In addition, the intracellular localization of MCL1(Delta 4A) was identical to that of wild type MCL1. An in vitro pull-down assay suggested that MCL1 is the only Bcl-2 family protein to interact with PCNA. In fact, MCL1, not other Bcl-2 family proteins, contained the PCNA-binding motif described previously. Taken together, MCL1 is a regulator of both apoptosis and cell cycle progression, and the cell cycle regulatory function of MCL1 is mediated through its interaction with PCNA.	Univ Texas, MD Anderson Canc Ctr, Res Ctr Cardiovasc Dis, Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Internal Med, Div Cardiol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Internal Med, Div Mol Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fujise, K (corresponding author), 6431 Fannin St,Suite 4200, Houston, TX 77030 USA.				NHLBI NIH HHS [1KO8 HL04015-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004015] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BAI C, 1994, EMBO J, V13, P6087, DOI 10.1002/j.1460-2075.1994.tb06955.x; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BRAVO R, 1986, EXP CELL RES, V163, P287, DOI 10.1016/0014-4827(86)90059-5; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; *CLONTECH, 1997, YEAST HDB, P30; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; Eichinger L, 1998, J BIOL CHEM, V273, P12952, DOI 10.1074/jbc.273.21.12952; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; JIANG YQ, 1995, ARCH BIOCHEM BIOPHYS, V320, P297, DOI 10.1016/0003-9861(95)90013-6; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Liu JL, 1999, J VIROL, V73, P4208, DOI 10.1128/JVI.73.5.4208-4219.1999; MIYASHITA T, 1995, CELL, V80, P293; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; MURO Y, 1994, J BIOL CHEM, V269, P18529; NAKAMURA T, 1995, EXP CELL RES, V221, P534, DOI 10.1006/excr.1995.1406; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SALA A, 1994, CANCER RES, V54, P1402; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Zhan QM, 1997, ONCOGENE, V14, P1031, DOI 10.1038/sj.onc.1200927	52	138	149	7	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39458	39465		10.1074/jbc.M006626200	http://dx.doi.org/10.1074/jbc.M006626200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10978339	hybrid			2022-12-27	WOS:000165953100071
J	Leppanen, A; White, SP; Helin, J; McEver, RP; Cummings, RD				Leppanen, A; White, SP; Helin, J; McEver, RP; Cummings, RD			Binding of glycosulfopeptides to P-selectin requires stereospecific contributions of individual tyrosine sulfate and sugar residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-PHASE SYNTHESIS; GLYCOPROTEIN LIGAND-1; CARBOHYDRATE INTERACTIONS; AMINO-TERMINUS; GMP-140 BINDS; ADHESION; PSGL-1; NEUTROPHILS; OLIGOSACCHARIDES; COUNTERRECEPTOR	P-selectin glycoprotein ligand-l (PSGL-1) is a mucin on leukocytes that binds to selectins. P-selectin binds to an N-terminal region of PSGL-1 that requires sulfation of at least one of three clustered tyrosines (TyrSO(3)) and an adjacent core-2-based O-glycan expressing sialyl Lewis x (C2-O-sLe(x)). We synthesized glycosulfopeptides (GSPs) modeled after this region of PSGL-1 to explore the roles of individual TyrSO(3) residues, the placement of C2-O-sLe(x) relative to TyrSO(3), the relative contributions of fucose and sialic acid on C2-O-sLe(x), and the function of the peptide sequence for binding to P-selectin. Binding of GSPs to P-selectin was measured by affinity chromatography and equilibrium gel filtration. 2-GSP-6, which has C2-O-sLe(x) at Thr-57 and TyrSO(3) at residues 46, 48, and 51, bound to P-selectin with high affinity (K-d similar to 650 nm), whereas an isomeric trisulfated GSP containing C2-O-sLe(x) at Thr-44 bound much less well. Non-sulfated glycopeptide (2-GP-6) containing C2-O-sLe(x) at Thr-57 bound to P-selectin with similar to 40-fold lower affinity (K(d)similar to 25 mum). Proteolysis of 2-GP-6 abolished detectable binding of the residual C2-O-sLe(x)-Thr to P-selectin, demonstrating that the peptide backbone contributes to binding. Monosulfated and disulfated GSPs bound significantly better than non-sulfated 2-GP-6, but sulfation of Tyr-48 enhanced affinity (K-d similar to 6 mum) more than sulfation of Tyr-46 or Tyr-51. 2-GSP-6 lacking sialic acid bound to P-selectin at similar to 10% that of the level of the parent 2-GSP-6, whereas 2-GSP-6 lacking fucose did not detectably bind; thus, fucose contributes more than sialic acid to binding. Reducing NaCl from 150 to 50 mm markedly enhanced binding of 2-GSP-6 to P-selectin (K-d similar to 75 nm), demonstrating the charge dependence of the interaction. These results reveal a stereospecific interaction of P-selectin with PSGL-1 that includes distinct contributions of each of the three TyrSO(3) residues, adjacent peptide determinants, and fucose/sialic acid on an optimally positioned core-2 O-glycan.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, WK Warren Med Res Inst, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA; Univ Helsinki, Inst Biotechnol, Helsinki 00014, Finland	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; Oklahoma State University System; Oklahoma State University - Stillwater; University of Helsinki	Cummings, RD (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 975 NE 10th St,BRC417, Oklahoma City, OK 73104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 54804] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ackers G K, 1973, Methods Enzymol, V27, P441; BAJORATH J, 1994, BIOCHEMISTRY-US, V33, P1332, DOI 10.1021/bi00172a007; Borges E, 1997, BLOOD, V90, P1934, DOI 10.1182/blood.V90.5.1934; Cummings RD, 1999, BRAZ J MED BIOL RES, V32, P519, DOI 10.1590/S0100-879X1999000500004; CUMMINGS RD, 1999, ESSENTIALS GLYCOBIOL, P391; Epperson TR, 2000, J BIOL CHEM, V275, P7839, DOI 10.1074/jbc.275.11.7839; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HOLLENBAUGH D, 1995, BIOCHEMISTRY-US, V34, P5678, DOI 10.1021/bi00016a044; HOLLENBAUGH D, 1993, BIOCHEMISTRY-US, V32, P2960, DOI 10.1021/bi00063a006; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; Jain RK, 1998, GLYCOBIOLOGY, V8, P707, DOI 10.1093/glycob/8.7.707; KITAGAWA K, 1994, INT J PEPT PROT RES, V43, P190; Kitagawa K, 1997, TETRAHEDRON LETT, V38, P599, DOI 10.1016/S0040-4039(96)02401-X; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Koenig A, 1997, GLYCOBIOLOGY, V7, P79, DOI 10.1093/glycob/7.1.79; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Liu W, 1998, J BIOL CHEM, V273, P7078, DOI 10.1074/jbc.273.12.7078; Liu Y, 2000, J EXP MED, V191, P1105, DOI 10.1084/jem.191.7.1105; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; McEver RP, 1997, GLYCOCONJUGATE J, V14, P585, DOI 10.1023/A:1018584425879; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; Moore KL, 1998, LEUKEMIA LYMPHOMA, V29, P1, DOI 10.3109/10428199809058377; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; Ng KKS, 1997, BIOCHEMISTRY-US, V36, P979, DOI 10.1021/bi962564e; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Ramachandran V, 1999, P NATL ACAD SCI USA, V96, P13771, DOI 10.1073/pnas.96.24.13771; Romo GM, 1999, J EXP MED, V190, P803, DOI 10.1084/jem.190.6.803; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Torgersen D, 1998, J BIOL CHEM, V273, P6254, DOI 10.1074/jbc.273.11.6254; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; Yang J, 1999, THROMB HAEMOSTASIS, V81, P1; Yang J, 1996, BLOOD, V87, P4176, DOI 10.1182/blood.V87.10.4176.bloodjournal87104176; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	41	172	177	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39569	39578		10.1074/jbc.M005005200	http://dx.doi.org/10.1074/jbc.M005005200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10978329	hybrid			2022-12-27	WOS:000165953100083
J	Gonzalez, A; Schulz, I; Schmid, A				Gonzalez, A; Schulz, I; Schmid, A			Agonist-evoked mitochondrial Ca2+ signals in mouse pancreatic acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; INOSITOL TRISPHOSPHATE; EXOCRINE PANCREAS; CARDIAC MYOCYTES; CALCIUM SIGNALS; SMOOTH-MUSCLE; OSCILLATIONS; RELEASE; WAVES; CONDUCTANCE	In the present study we have investigated cytosolic and mitochondrial Ca2+ signals in isolated mouse pancreatic acinar cells double-loaded with the fluorescent probes fluo-3 and rhod-2. Stimulation of pancreatic acinar cells with 500 nM acetylcholine caused release of Ca2+ from intracellular stores and produced cytosolic Ca2+ signals in form of Ca2+ waves propagating from the luminal to the basal cell pole. The increase in the cytosolic Ca2+ concentration was followed by Ca2+ uptake into mitochondria. Between onset of cytosolic and mitochondriaI Ca2+ signals there was a delay of 10.7 +/- 0.4 s. Ca2+ uptake into mitochondria could be inhibited with Ruthenium Red and carbonyl cyanide m-chlorophenylhydrazone, whereas 2,5-di-tert-butylhydroquinone, which inhibits sarco(endo)plasmic reticulum Ca2+ ATPases, did not prevent Ca2+ accumulation in mitochondria. Carbonyl cyanide m-chlorophenylhydrazone-induced Ca2+ release from mitochondria could only be observed after a preceding stimulation of the cell with a physiological agonist or by treatment with 2,5 di-tertbutylhydroquinone, indicating that under resting conditions mitochondria do not contain releasable Ca2+ ions. Analysis of the propagation rate of acetylcholine-induced Ca2+ waves revealed that inhibition of mitochondrial Ca2+ uptake did not accelerate spreading of cytosolic Ca2+ signals. Our experiments indicate that in the early phase of secretagogue-induced Ca2+ signals, mitochondria behave as passive Ca2+-buffering elements and do not actively suppress spreading of Ca2+ signals in pancreatic acinar cells.	Univ Saarland, Dept Physiol, D-66421 Homburg, Germany	Saarland University	Schmid, A (corresponding author), Univ Saarland, Dept Physiol, D-66421 Homburg, Germany.	andreas.schmid@med-rz.uni-saarland.de	Gonzalez, Antonio/C-5428-2018	Gonzalez, Antonio/0000-0001-8380-0270				Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Belan PV, 1996, J BIOL CHEM, V271, P7615, DOI 10.1074/jbc.271.13.7615; Boitier E, 1999, J CELL BIOL, V145, P795, DOI 10.1083/jcb.145.4.795; Brandenburger Y, 1996, ENDOCRINOLOGY, V137, P5544, DOI 10.1210/en.137.12.5544; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; David G, 1998, J PHYSIOL-LONDON, V509, P59, DOI 10.1111/j.1469-7793.1998.059bo.x; DENTON RM, 1980, FEBS LETT, V119, P1, DOI 10.1016/0014-5793(80)80986-0; Drummond RM, 1999, J PHYSIOL-LONDON, V516, P139, DOI 10.1111/j.1469-7793.1999.139aa.x; Gonzalez A, 1999, BIOCHEM BIOPH RES CO, V261, P726, DOI 10.1006/bbrc.1999.1106; Gonzalez A, 1997, PFLUG ARCH EUR J PHY, V434, P609, DOI 10.1007/s004240050443; Gonzalez A, 1998, AM J PHYSIOL-CELL PH, V275, pC810, DOI 10.1152/ajpcell.1998.275.3.C810; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Haugland RP, 1996, HDB FLUORESCENT PROB, P266; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Jou MJ, 1996, J PHYSIOL-LONDON, V497, P299, DOI 10.1113/jphysiol.1996.sp021769; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; Krause E, 1996, J BIOL CHEM, V271, P32523, DOI 10.1074/jbc.271.51.32523; Lawrie AM, 1996, J BIOL CHEM, V271, P10753, DOI 10.1074/jbc.271.18.10753; McCarron JG, 1999, J PHYSIOL-LONDON, V516, P149, DOI 10.1111/j.1469-7793.1999.149aa.x; MINTA A, 1989, J BIOL CHEM, V264, P8171; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; Monteith GR, 1999, AM J PHYSIOL-CELL PH, V276, pC1193, DOI 10.1152/ajpcell.1999.276.5.C1193; Nitschke R, 1997, PFLUG ARCH EUR J PHY, V433, P653, DOI 10.1007/s004240050327; Pfeiffer F, 1998, AM J PHYSIOL-CELL PH, V274, pC663; Ricken S, 1998, J BIOL CHEM, V273, P34961, DOI 10.1074/jbc.273.52.34961; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; ROHLICEK V, 1994, PFLUG ARCH EUR J PHY, V428, P30, DOI 10.1007/BF00374749; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Schmid A, 1996, PFLUG ARCH EUR J PHY, V432, P876, DOI 10.1007/s004240050211; Schulz I, 1999, BIOL CHEM, V380, P903, DOI 10.1515/BC.1999.111; Simpson PB, 1998, J PHYSIOL-LONDON, V508, P413, DOI 10.1111/j.1469-7793.1998.413bq.x; SMITH JS, 1986, BIOPHYS J, V50, P921, DOI 10.1016/S0006-3495(86)83533-0; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; THEVENOD F, 1989, J MEMBRANE BIOL, V109, P173, DOI 10.1007/BF01870856; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; TOESCU EC, 1993, BIOCHEM BIOPH RES CO, V192, P854, DOI 10.1006/bbrc.1993.1493; Trollinger DR, 1997, BIOCHEM BIOPH RES CO, V236, P738, DOI 10.1006/bbrc.1997.7042; YULE DI, 1994, PHYSL GASTROINTESTIN	43	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38680	38686		10.1074/jbc.M005667200	http://dx.doi.org/10.1074/jbc.M005667200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10995756	hybrid			2022-12-27	WOS:000165739800074
J	Bonham, K; Ritchie, SA; Dehm, SM; Snyder, K; Boyd, FM				Bonham, K; Ritchie, SA; Dehm, SM; Snyder, K; Boyd, FM			An alternative, human SRC promoter and its regulation by hepatic nuclear factor-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; ENRICHED TRANSCRIPTION FACTORS; PP60C-SRC PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; TUMOR-NECROSIS-FACTOR; C-SRC; GENE-EXPRESSION; EARLY EVENT; CELL-LINE; ACTIVATION	The SRC gene encodes the proto-oncogene pp60(c-src), a tyrosine kinase implicated in numerous signal transduction pathways. In addition, the SRC gene is differentially expressed, developmentally regulated, and frequently overexpressed in human neoplasia. However, the mechanisms regulating its expression have not been completely explored. Here we describe the isolation of a new distal SRC promoter and associated exon, designated 1 alpha, which we mapped to a position 1.0 kilobase upstream of the previously described SRC1A housekeeping promoter. Differential use of these promoters and their associated exons coupled with subsequent splicing to a common downstream exon results in c-Src transcripts with different 5' ends but identical coding regions. Promoter analysis following transient transfections into HepG2 cells mapped the minimal 1 alpha promoter to a region 145 bp upstream of the major transcription start site. This region contained a consensus binding site for hepatic nuclear factor-1 (HNF-1), a liver-enriched transcription factor implicated in the regulation of a number of genes in liver, kidney, stomach, intestine, and pancreas. Subsequent mobility shift assays confirmed that HNF-1 alpha isoform was the predominant factor interacting with this region of the promoter. Mutation of the HNF-1 site resulted in a dramatic reduction in SRC promoter activity. Cotransfection studies demonstrated the promoter could be strongly transactivated by the HNF-1 alpha isoform but not by the related HNF-1 beta factor. Consistent with these results, we demonstrated that transcripts originating from the SRC1 alpha promoter display a tissue restricted pattern of expression with highest levels present in stomach, kidney, and pancreas. These results indicate that SRC transcriptional regulation is much more complex than previously realized and implicates HNF-1 in both the tissue-specific regulation of the SRC gene in normal tissues and the overexpression of c-Src in certain human cancers.	Univ Saskatchewan, Hlth Res Div, Canc Res Unit, Saskatchewan Canc Agcy, Saskatoon, SK S7N 4H4, Canada; Univ Saskatchewan, Div Oncol, Saskatoon, SK S7N 4H4, Canada; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan	Bonham, K (corresponding author), Univ Saskatchewan, Hlth Res Div, Canc Res Unit, Saskatchewan Canc Agcy, 20 Campus Dr, Saskatoon, SK S7N 4H4, Canada.	kbonhamA@scf.sk.ca						AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BAUMHUETER S, 1988, EMBO J, V7, P2485, DOI 10.1002/j.1460-2075.1988.tb03095.x; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; BLUMENFELD M, 1991, DEVELOPMENT, V113, P589; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BONHAM K, 1993, ONCOGENE, V8, P1973; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CHAKRABORTY M, 1993, BRAIN RES, V625, P197, DOI 10.1016/0006-8993(93)91059-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coffinier C, 1999, DEVELOPMENT, V126, P4785; Coffinier C, 1999, MECH DEVELOP, V89, P211, DOI 10.1016/S0925-4773(99)00221-X; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; GEE CE, 1986, P NATL ACAD SCI USA, V83, P5131, DOI 10.1073/pnas.83.14.5131; Hayashi Y, 1999, J CLIN PATHOL-MOL PA, V52, P19; Higuchi Y, 1999, BONE, V25, P17, DOI 10.1016/S8756-3282(99)00103-9; Hochman JA, 1997, AM J PHYSIOL-GASTR L, V273, pG833, DOI 10.1152/ajpgi.1997.273.4.G833; Hu CB, 1999, AM J PHYSIOL-GASTR L, V276, pG1181, DOI 10.1152/ajpgi.1999.276.5.G1181; Iravani S, 1998, LAB INVEST, V78, P365; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lin BC, 1997, BIOCHEMISTRY-US, V36, P14096, DOI 10.1021/bi9703249; LIN PH, 1995, ONCOGENE, V10, P401; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Masaki T, 1998, HEPATOLOGY, V27, P1257, DOI 10.1002/hep.510270511; MAZURENKO NN, 1992, EUR J CANCER, V28A, P372, DOI 10.1016/S0959-8049(05)80056-5; MELLSTROM K, 1987, MOL CELL BIOL, V7, P4178, DOI 10.1128/MCB.7.12.4178; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; OTT MO, 1991, MECH DEVELOP, V36, P47, DOI 10.1016/0925-4773(91)90071-D; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PARK JS, 1993, ONCOGENE, V8, P2627; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Ritchie S, 2000, J BIOL CHEM, V275, P847, DOI 10.1074/jbc.275.2.847; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; SERFAS MS, 1993, AM J PHYSIOL, V265, pG506, DOI 10.1152/ajpgi.1993.265.3.G506; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SORIO C, 1993, FEBS LETT, V327, P315, DOI 10.1016/0014-5793(93)81012-O; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; Tsuganezawa H, 1998, KIDNEY INT, V54, P394, DOI 10.1046/j.1523-1755.1998.00029.x; VALLET V, 1995, EXP CELL RES, V216, P363, DOI 10.1006/excr.1995.1046; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; Visser CJT, 1996, LAB INVEST, V74, P2; Wang WP, 1998, J PATHOL, V184, P272, DOI 10.1002/(SICI)1096-9896(199803)184:3<272::AID-PATH4>3.0.CO;2-K; WEBER TK, 1992, J CLIN INVEST, V90, P815, DOI 10.1172/JCI115956; Wiener JR, 1999, CLIN CANCER RES, V5, P2164	54	35	41	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37604	37611		10.1074/jbc.M004882200	http://dx.doi.org/10.1074/jbc.M004882200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978326	hybrid			2022-12-27	WOS:000165618700042
J	Pedersen, PA; Jorgensen, JR; Jorgensen, PL				Pedersen, PA; Jorgensen, JR; Jorgensen, PL			Importance of conserved alpha-subunit segment (709)GDGVND for Mg2+ binding, phosphorylation, and energy transduction in Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA-2+-ATPASE; P-TYPE ATPASE; AMINO-ACIDS; CONFORMATIONAL TRANSITIONS; BETA-UNITS; SITE; (NA,K)-ATPASE; CONSEQUENCES; SUPERFAMILY; PHOSPHATASE	The segment (708)TGDGVNDSPALKK(720) in the cu subunit P domain of Na,K-ATPase is highly conserved among cation pumps, but little is known about its role in binding of Mg2+ or ATP and energy transduction. Here, 11 mutations of polar residues are expressed at reduced temperature in yeast with preserved capacities for high affinity binding of ouabain and ATP, whereas the Thr(708) --> Ser mutation and alterations of Asp(714) abolish all catalytic reactions. In mutations of Asp(710) and Asn(713) ATP affinity is preserved or increased, whereas Na,K-ATPase activity is severely reduced. Assay of phosphorylation from ATP in the presence of oligomycin shows that Asp710 contributes to coordination of Mg2+ during transfer of gamma -phosphate to Asp(369) in the high energy (MgE1P)-E-.[3Na] intermediate and that Asn(713) is involved in these processes. In contrast, Asp(710) and Asp(713) do not contribute to Mg2+ binding in the E(2)P(.)ouabain complex. Transition to E2P thus involves a shift of Mg2+ coordination away from Asp(710) and Asn(713), and the two residues become more important for hydrolysis of the acyl phosphate bond at Asp(369). Th, Asp(710), Ala mutation blocks interaction with vanadate, whereas Asn(713) --> Ala interferes with phosphorylation from Pi of the E(2)(.)ouabain complex, showing that the GDGVND segment is required for stabilization of the transition state and for the phosphorylation reaction. The Asp(710), Ala mutation also interferes with transmission of structural changes to the ouabain site and reduces the affinity for binding of T1(+) 2- to 3-fold, suggesting a role in transmission of KC stimulation of phospho-enzyme hydrolysis from transmembrane segment 5 to the P domain.	Univ Copenhagen, August Krogh Inst, Biomembrane Res Ctr, DK-2100 Copenhagen OE, Denmark	University of Copenhagen	Jorgensen, PL (corresponding author), Univ Copenhagen, August Krogh Inst, Biomembrane Res Ctr, Universitetsparken 13, DK-2100 Copenhagen OE, Denmark.	pljorgensen@aki.ku.dk	Pedersen, Per Amstrup/M-4592-2014	Pedersen, Per Amstrup/0000-0001-8648-9748				ANDERSEN JP, 1982, J BIOL CHEM, V257, P8300; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; Collet JF, 1999, J BIOL CHEM, V274, P33985, DOI 10.1074/jbc.274.48.33985; Farley RA, 1997, BIOCHEMISTRY-US, V36, P941, DOI 10.1021/bi962153y; FERSHT A, 1999, STRUCTURE MECH PROTE, P129; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIRARDET JL, 1993, EUR J BIOCHEM, V217, P225, DOI 10.1111/j.1432-1033.1993.tb18237.x; Goldshleger R, 1999, J BIOL CHEM, V274, P16213, DOI 10.1074/jbc.274.23.16213; Haldane J. B. S., 1965, ENZYMES; HANSEN O, 1984, PHARMACOL REV, V36, P143; HANSEN O, 1973, BIOCHIM BIOPHYS ACTA, V233, P122; HELMICHDEJONG ML, 1985, 4 INT C NA K ATP CO, P379; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jorgensen PL, 1997, ANN NY ACAD SCI, V834, P161, DOI 10.1111/j.1749-6632.1997.tb52248.x; JORGENSEN PL, 1986, BIOCHEMISTRY-US, V25, P2889; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; JORGENSEN PL, 1992, MOL ASPECTS TRANSPOR, P1; LANE LK, 1993, J BIOL CHEM, V268, P17930; LAUGER P, 1991, ELECTROGENIC ION PUM, P177; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MARKS PW, 1991, ANAL BIOCHEM, V193, P61, DOI 10.1016/0003-2697(91)90044-T; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P111, DOI 10.1016/0014-5793(87)81253-X; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; Pedersen PA, 1996, J BIOL CHEM, V271, P2514, DOI 10.1074/jbc.271.5.2514; Pedersen PA, 1996, BIOCHEMISTRY-US, V35, P16085, DOI 10.1021/bi961614c; Pedersen PA, 1998, BIOCHEMISTRY-US, V37, P17818, DOI 10.1021/bi981898w; RICHARDS DE, 1988, J PHYSIOL-LONDON, V404, P497, DOI 10.1113/jphysiol.1988.sp017302; Ridder IS, 1999, BIOCHEM J, V339, P223, DOI 10.1042/0264-6021:3390223; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VILSEN B, 1987, J BIOL CHEM, V262, P10511	34	54	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37588	37595		10.1074/jbc.M005610200	http://dx.doi.org/10.1074/jbc.M005610200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982798	hybrid			2022-12-27	WOS:000165618700040
J	Ratcliffe, MJ; Itoh, K; Sokol, SY				Ratcliffe, MJ; Itoh, K; Sokol, SY			A positive role for the PP2A catalytic subunit in Wnt signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; GLYCOGEN-SYNTHASE KINASE-3; TUMOR-SUPPRESSOR PROTEIN; BETA-CATENIN; XENOPUS-EMBRYOS; AXIS FORMATION; NEGATIVE REGULATOR; PATHWAY; TRANSCRIPTION; SIAMOIS	Protein phosphatase-2A (PP2A) is a multisubunit serine/threonine phosphatase involved in intracellular signaling, gene regulation, and cell cycle progression. Different, subunits of PP2A bind to Axin and Adenomatous Polyposis Coli, components of the Wnt signal transduction pathway. Using early Xenopus embryos, we studied how PP2A functions in Wnt signal transduction. The catalytic subunit of PP2A (PP2A-C) potentiated secondary axis induction and Siamois reporter gene activation by Dishevelled, a component of the Wnt pathway, indicating a: positive regulatory role of this enzyme in Wnt signaling. in contrast, small t antigen, an antagonist of PP2A-C, inhibited Dishevelled-mediated signal transduction, as did the regulatory PP2A-B'epsilon subunit, consistent with the requirement of PP2A function in this pathway. Although Wnt signaling is thought to occur via regulation of beta -catenin degradation, PP2A-C did not significantly affect beta -catenin stability. Moreover, the pathway activated by a stabilized form of beta -catenin was sensitive to PP2A-C and its inhibitors, suggesting that PP2A-C acts downstream of beta -catenin. Because previous work has suggested that PP2A can act upstream of beta -catenin, we propose that PP2A regulates the Wnt pathway at multiple levels.	Harvard Univ, Sch Med,Beth Israel Deaconess Med Ctr, Dept Microbiol & Mol Genet, Mol Med Unit, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Ratcliffe, MJ (corresponding author), Harvard Univ, Sch Med,Beth Israel Deaconess Med Ctr, Dept Microbiol & Mol Genet, Mol Med Unit, RW 663,East Campus,330 Brookline Ave, Boston, MA 02215 USA.	mratclif@caregroup.harvard.edu		Sokol, Sergei/0000-0002-3963-9202				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brannon M, 1999, DEVELOPMENT, V126, P3159; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fan MJ, 1998, P NATL ACAD SCI USA, V95, P5626, DOI 10.1073/pnas.95.10.5626; Fan MJ, 1997, DEVELOPMENT, V124, P2581; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Itoh K, 2000, MOL CELL BIOL, V20, P2228, DOI 10.1128/MCB.20.6.2228-2238.2000; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; Kishida S, 1999, MOL CELL BIOL, V19, P4414; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; LILY W, 1987, NATURE, V326, P512, DOI 10.1038/326512a0; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; ROTHBACHER U, 1995, DEV BIOL, V170, P717, DOI 10.1006/dbio.1995.1249; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SOKOL SY, 1995, DEVELOPMENT, V121, P1637; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Vleminckx K, 1997, J CELL BIOL, V136, P411, DOI 10.1083/jcb.136.2.411; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	50	86	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35680	35683		10.1074/jbc.C000639200	http://dx.doi.org/10.1074/jbc.C000639200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	11007767	hybrid			2022-12-27	WOS:000165382000007
J	Lock, H; Valverde, MA				Lock, H; Valverde, MA			Contribution of the IsK (MinK) potassium channel subunit to regulatory volume decrease in murine tracheal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE P-GLYCOPROTEIN; SMALL-INTESTINAL CRYPTS; AIRWAY SURFACE LIQUID; VESTIBULAR DARK CELLS; CHLORIDE CHANNELS; CYSTIC-FIBROSIS; K+ CONDUCTANCE; SECRETION; CURRENTS; PROTEIN	The cell volume regulatory response following hypotonic shocks is often achieved by the coordinated activation of K+ and Cl- channels. In this study, we investigate the identity of the K+ and Cl- channels that mediate the regulatory volume decrease (RVD) in ciliated epithelial cells from murine trachea. RVD was inhibited by tamoxifen and 1,9-dideoxyforskolin, two agents that block swelling-activated Cl- channels. These data suggest that swelling-activated Cl- channels play an important role in cell volume regulation in murine tracheal epithelial cells. Ba2+ and apamin, inhibitors of K+ channels, were without effect on RVD, while tetraethylammoniun had little effect on RVD. In contrast, clofilium, an inhibitor of the KvLQT/IsK potassium channel complex potently inhibited RVD, suggesting a role for the KvLQT/IsK channel complex in cell volume regulation by tracheal epithelial cells. To investigate further the role of KvLQT/IsK channels in RVD, we used IsK knock-out mice. When exposed to hypotonic solutions, tracheal cells from IsK(+/+) mice underwent RVD, whereas cells from IsK(-/-) failed to recover their normal size. These data suggest that the IsK potassium subunit plays an important role in RVD in murine tracheal epithelial cells.	Univ Pompeu Fabra, Dept Expt Sci, Cell Signalling Unit, Barcelona 08003, Spain	Pompeu Fabra University	Valverde, MA (corresponding author), Univ Pompeu Fabra, Dept Expt Sci, Cell Signalling Unit, C Dr Aiguader 80, Barcelona 08003, Spain.			Valverde, Miguel A./0000-0002-6961-3361				Bleich M, 2000, PFLUG ARCH EUR J PHY, V440, P202, DOI 10.1007/s004240000257; Bond TD, 1998, J PHYSIOL-LONDON, V511, P45, DOI 10.1111/j.1469-7793.1998.045bi.x; Boucher RC, 1999, J PHYSIOL-LONDON, V516, P631, DOI 10.1111/j.1469-7793.1999.0631u.x; BOUCHER RC, 1981, J APPL PHYSIOL, V50, P613, DOI 10.1152/jappl.1981.50.3.613; Busch AE, 1997, TRENDS PHARMACOL SCI, V18, P26, DOI 10.1016/S0165-6147(96)01016-4; BUSCH AE, 1992, BIOCHEM BIOPH RES CO, V184, P804, DOI 10.1016/0006-291X(92)90661-4; CASTLE NA, 1989, TRENDS NEUROSCI, V12, P59, DOI 10.1016/0166-2236(89)90137-9; DIAZ M, 1993, PFLUG ARCH EUR J PHY, V422, P347, DOI 10.1007/BF00374290; Guggino WB, 1999, CELL, V96, P607, DOI 10.1016/S0092-8674(00)80570-X; HOFFMANN EK, 1993, ADV COMP ENV PHYSL, V14, P187; Hwang TH, 1996, J MEMBRANE BIOL, V154, P251, DOI 10.1007/s002329900149; KIM YK, 1993, AM J PHYSIOL, V265, pC1306, DOI 10.1152/ajpcell.1993.265.5.C1306; KROUSE ME, 1994, AM J PHYSIOL, V267, pC642, DOI 10.1152/ajpcell.1994.267.2.C642; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; MacVinish LJ, 1998, J PHYSIOL-LONDON, V510, P237, DOI 10.1111/j.1469-7793.1998.237bz.x; MALAYEV AA, 1995, MOL PHARMACOL, V47, P198; MAN SFP, 1979, J APPL PHYSIOL, V46, P205, DOI 10.1152/jappl.1979.46.2.205; MARCUS DC, 1994, AM J PHYSIOL, V267, pC857, DOI 10.1152/ajpcell.1994.267.3.C857; MCCANN JD, 1989, J GEN PHYSIOL, V94, P1015, DOI 10.1085/jgp.94.6.1015; Niemeyer MI, 2000, J PHYSIOL-LONDON, V524, P757, DOI 10.1111/j.1469-7793.2000.00757.x; OBRIEN JA, 1993, PFLUG ARCH EUR J PHY, V423, P67, DOI 10.1007/BF00374962; Okada Y, 1997, AM J PHYSIOL-CELL PH, V273, pC755, DOI 10.1152/ajpcell.1997.273.3.C755; PRICE AM, 1993, J APPL PHYSIOL, V74, P2788, DOI 10.1152/jappl.1993.74.6.2788; SCHOPPA N, 1989, J MEMBRANE BIOL, V108, P73, DOI 10.1007/BF01870427; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; STRANGE K, 1996, AM J PHYSIOL, V270, P711; Suessbrich H, 1997, FEBS LETT, V414, P435, DOI 10.1016/S0014-5793(97)01030-2; TAKUMI T, 1993, NEWS PHYSIOL SCI, V8, P175; Valverde MA, 1996, EMBO J, V15, P4460, DOI 10.1002/j.1460-2075.1996.tb00823.x; VALVERDE MA, 1993, PFLUG ARCH EUR J PHY, V425, P552, DOI 10.1007/BF00374885; Valverde MA, 1999, CURR OPIN CELL BIOL, V11, P509, DOI 10.1016/S0955-0674(99)80074-X; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WALTERS RJ, 1992, PFLUG ARCH EUR J PHY, V421, P598, DOI 10.1007/BF00375057; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WANGEMANN P, 1995, J MEMBRANE BIOL, V147, P263; WELLS UM, 1994, J APPL PHYSIOL, V77, P2400, DOI 10.1152/jappl.1994.77.5.2400; WILLUMSEN NJ, 1994, J CLIN INVEST, V94, P779, DOI 10.1172/JCI117397; Zabner J, 1998, MOL CELL, V2, P397, DOI 10.1016/S1097-2765(00)80284-1; ZHANG JJ, 1994, J CLIN INVEST, V94, P1690, DOI 10.1172/JCI117514	42	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34849	34852		10.1074/jbc.C000633200	http://dx.doi.org/10.1074/jbc.C000633200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10995738	hybrid			2022-12-27	WOS:000165422800005
J	Solano, RM; Langer, I; Perret, J; Vertongen, P; Juarranz, MG; Robberecht, P; Waelbroeck, M				Solano, RM; Langer, I; Perret, J; Vertongen, P; Juarranz, MG; Robberecht, P; Waelbroeck, M			Two basic residues of the h-VPAC(1) receptor second transmembrane helix are essential for ligand binding and signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; CYCLASE-ACTIVATING POLYPEPTIDE; RAT SECRETIN RECEPTOR; AMINO-TERMINAL TAIL; VIP RECEPTOR; AGONIST BINDING; CHO CELLS; PACAP-I; DOMAINS; PEPTIDE	We mutated the vasoactive intestinal peptide (VIP) Asp(3) residue and two VPAC(1) receptor second transmembrane helix basic residues (Arg(188) and Lys(195)). VIP had a lower affinity for R188Q, R188L, K195Q, and R195I VPAC(1), receptors than for VPAC, receptors, [Asn(3)] VIP and [Gln(3)] VIP had lower affinities than VIP for VPAC, receptors but higher affinities for the mutant receptors; the two basic amino acids facilitated the introduction of the negatively charged aspartate inside the transmembrane domain. The resulting interaction was necessary for receptor activation. 1/[Asn(3)] VIP and [Gln(3)] VIP were partial agonists at VPAC, receptors; 21VIP did not fully activate the K195Q, K195I, R188Q, and R188L VPAC, receptors; a VIP analogue ([Arg(16)] VIP) was more efficient than VIP at the four mutated receptors; and [Asn3] VIP and [Gln(3)] VIP were more efficient than VIP at the R188Q and R188L VPAC, receptors; the [Asp(3)] negative charge did not contribute to the recognition of the VIP1 antagonist, [AcHis(1),D-Phe(2),Lys(15),Arg(16),Leu(27)] VIP (1-7)/growth hormone releasing factor (8-27). This is the first demonstration that, to activate the VPAC, receptor, the Asp(3) side chain of VIP must penetrate within the transmembrane domain, in close proximity to two highly conserved basic amino acids from transmembrane 2.	Free Univ Brussels, Fac Med, Lab Chim Biol & Nutr, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Waelbroeck, M (corresponding author), Free Univ Brussels, Fac Med, Lab Chim Biol & Nutr, 808 Route Lennik,Bldg G-E,CP 611, B-1070 Brussels, Belgium.		Juarranz, Yasmina/H-5545-2019; Juarranz, Yasmina/H-7942-2016	Juarranz, Yasmina/0000-0001-5886-8273; Juarranz, Yasmina/0000-0001-5886-8273				ANDREWS P, 1986, TRENDS PHARMACOL SCI, V7, P148, DOI 10.1016/0165-6147(86)90292-0; CHRISTOPHE J, 1993, BIOCHIM BIOPHYS ACTA, V1154, P183, DOI 10.1016/0304-4157(93)90011-C; CICCARELLI E, 1994, REGUL PEPTIDES, V54, P397, DOI 10.1016/0167-0115(94)90537-1; COUVINEAU A, 1994, BIOCHEM BIOPH RES CO, V200, P769, DOI 10.1006/bbrc.1994.1517; Di Paolo E, 1999, PEPTIDES, V20, P1187, DOI 10.1016/S0196-9781(99)00122-9; DONG M, 2000, J BIOL CHEM; Dong MQ, 1999, J BIOL CHEM, V274, P19161, DOI 10.1074/jbc.274.27.19161; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; Du K, 1997, BIOCHEM BIOPH RES CO, V230, P289, DOI 10.1006/bbrc.1996.5949; Gaudin P, 1999, BIOCHEM BIOPH RES CO, V254, P15, DOI 10.1006/bbrc.1998.9883; Gourlet P, 1996, EUR J BIOCHEM, V239, P349, DOI 10.1111/j.1432-1033.1996.0349u.x; Gourlet P, 1996, BBA-MOL CELL RES, V1314, P267, DOI 10.1016/S0167-4889(96)00106-1; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Gourlet P, 1996, REGUL PEPTIDES, V62, P125, DOI 10.1016/0167-0115(96)00010-9; Gourlet P, 1997, PEPTIDES, V18, P1555, DOI 10.1016/S0196-9781(97)00230-1; Gourlet P, 1996, PEPTIDES, V17, P825, DOI 10.1016/0196-9781(96)00107-6; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Hashimoto H, 1997, MOL PHARMACOL, V52, P128, DOI 10.1124/mol.52.1.128; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; Juarranz MG, 1999, MOL PHARMACOL, V56, P1280, DOI 10.1124/mol.56.6.1280; Juarranz MG, 1999, EUR J BIOCHEM, V265, P449, DOI 10.1046/j.1432-1327.1999.00769.x; Knudsen SM, 1997, FEBS LETT, V412, P141, DOI 10.1016/S0014-5793(97)00714-X; PANDOL SJ, 1986, AM J PHYSIOL, V250, pG553, DOI 10.1152/ajpgi.1986.250.4.G553; Rawlings SR, 1996, ENDOCR REV, V17, P4, DOI 10.1210/er.17.1.4; RAWLINGS SR, 1994, MOL CELL ENDOCRINOL, V101, pC5, DOI 10.1016/0303-7207(94)90212-7; Rekasi Z, 2000, P NATL ACAD SCI USA, V97, P1218, DOI 10.1073/pnas.97.3.1218; Rolz C, 1999, BIOCHEMISTRY-US, V38, P6397, DOI 10.1021/bi9829276; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sambrook J., 2002, MOL CLONING LAB MANU; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; USDIN TB, 1994, ENDOCRINOLOGY, V135, P2662, DOI 10.1210/en.135.6.2662; Van Rampelbergh J, 2000, BRIT J PHARMACOL, V130, P819, DOI 10.1038/sj.bjp.0703384; VanRampelbergh J, 1997, BBA-MOL CELL RES, V1357, P249, DOI 10.1016/S0167-4889(97)00028-1; Vertongen P, 1998, ANN NY ACAD SCI, V865, P412, DOI 10.1111/j.1749-6632.1998.tb11206.x; Vilardaga JP, 1997, EUR J BIOCHEM, V246, P173, DOI 10.1111/j.1432-1033.1997.00173.x; Vilardaga JP, 1996, BIOCHEM BIOPH RES CO, V218, P842, DOI 10.1006/bbrc.1996.0150; VILARDAGA JP, 1995, BIOCHEM BIOPH RES CO, V211, P885, DOI 10.1006/bbrc.1995.1895	39	80	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1084	1088		10.1074/jbc.M007686200	http://dx.doi.org/10.1074/jbc.M007686200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11013258	hybrid			2022-12-27	WOS:000166430900032
J	Bourke, E; Kennedy, EJ; Moynagh, PN				Bourke, E; Kennedy, EJ; Moynagh, PN			Loss of I kappa B-beta is associated with prolonged NF-kappa B activity in human glial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; ACTIVATES TRANSCRIPTION; ENDOTHELIAL-CELLS; VIRUS TYPE-1; PEST DOMAIN; ALPHA; PHOSPHORYLATION; KINASE; PROTEIN; SIGNAL	Nuclear factor-kappaB (NF-kappaB) is an inducible transcription factor central in the regulation of expression of a wide variety of genes and synthesis of several proteins involved in the generation of the immune response and inflammatory processes. In resting cells, NF-kappaB is maintained in an inactive state through cytoplasmic retention by I kappaB inhibitors. Stimulation of cells with a wide variety of inducers results in proteolytic degradation of these I kappaB proteins, leading to activation of NF-kappaB. The present study shows that interleukin-1 (IL-1) causes persistent activation of NF-kappaB in glial cells. Stimulation with IL-1 also causes rapid but transient degradation of I kappaB-alpha and I kappaB-epsilon. However, NF-kappaB remains active even after these I kappaB isoforms have returned to control levels. In contrast, the I kappaB-beta isoform fails to reappear following its initial degradation by IL-1, coincident with sustained activation of NF-kappaB. In addition, in vivo overexpression of the various I kappaB isoforms revealed that I kappaB-beta is the only isoform that has the ability to inhibit IL-1-induced NF-kappaB-driven transcription. The findings also suggest that the inability of I kappaB-alpha and I kappaB-epsilon to modulate NF-kappaB activity is due to their modification in viuo. These findings indicate that I kappaB-beta is the key regulator of the activity of NF-kappaB in human glial cells.	Univ Coll Dublin, Dept Pharmacol, Conway Inst Biomol & Biomed Res, Dublin 2, Ireland	University College Dublin	Moynagh, PN (corresponding author), Univ Coll Dublin, Dept Pharmacol, Conway Inst Biomol & Biomed Res, Fosters Ave, Dublin 2, Ireland.			Bourke, Emer/0000-0002-2218-3114; Moynagh, Paul/0000-0002-4139-3061				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Heilker R, 1999, BIOCHEMISTRY-US, V38, P6231, DOI 10.1021/bi990220t; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; Lin RT, 1996, MOL CELL BIOL, V16, P1401; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; McKinsey TA, 1997, J BIOL CHEM, V272, P22377, DOI 10.1074/jbc.272.36.22377; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MOYNAGH PN, 1994, J IMMUNOL, V153, P2681; MOYNAGH PN, 1993, BIOCHEM J, V294, P343, DOI 10.1042/bj2940343; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Sambrook J., 2002, MOL CLONING LAB MANU; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRIENZENBERG SJ, 1987, CURRENT PROTOCOLS MO; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	37	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39996	40002		10.1074/jbc.M007693200	http://dx.doi.org/10.1074/jbc.M007693200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10998424	hybrid, Green Accepted			2022-12-27	WOS:000166039500029
J	Komori, K; Sakae, S; Daiyasu, H; Toh, H; Morikawa, K; Shinagawa, H; Ishino, Y				Komori, K; Sakae, S; Daiyasu, H; Toh, H; Morikawa, K; Shinagawa, H; Ishino, Y			Mutational analysis of the Pyrococcus furiosus Holliday junction resolvase Hjc revealed functionally important residues for dimer formation, junction DNA binding, and cleavage activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; AMINO-ACID-RESIDUES; ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; CRYSTAL-STRUCTURE; RIBONUCLEASE-H; ACTIVE-SITE; ENDONUCLEASE; RECOGNITION; PROTEIN	The Holliday junction cleavage protein, Hjc resolvase of Pyrococcus furiosus, is the first Holliday junction resolvase to be discovered in Archaea. Although the archaeal resolvase shares certain biochemical properties with other non-archaeal junction resolvases, no amino acid sequence similarity has been identified. To investigate the structure-function relationship of this new Holliday junction resolvase, we constructed a series of mutant hjc genes using site-directed mutagenesis targeted at the residues conserved among the archaeal orthologs. The products of these mutant genes were purified to homogeneity. With analysis of the activity of the mutant proteins to bind and cleave synthetic Holliday junctions, one acidic residue, Glu-9, and two basic residues, Arg-10 and Arg-25, were found to play critical roles in enzyme action. This is in addition to the three conserved residues, Asp-33, Glu-46, and Lys-48, which are also conserved in the motif found in the type II restriction endonuclease family proteins. Two aromatic residues, Phe-68 and Phe-72, are important for the formation of the homodimer probably through hydrophobic interactions. The results of these studies have provided insights into the structure-function relationships of the archaeal Holliday junction resolvase as well as the universality and diversity of the Holliday junction cleavage reaction.	Biomol Engn Res Inst, Dept Mol Biol, Suita, Osaka 5650874, Japan; Biomol Engn Res Inst, Dept Bioinformat, Suita, Osaka 5650874, Japan; Biomol Engn Res Inst, Dept Biol Struct, Suita, Osaka 5650874, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Mol Microbiol, Osaka 5650874, Japan	Osaka University	Ishino, Y (corresponding author), Biomol Engn Res Inst, Dept Mol Biol, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.	ishino@beri.co.jp		Ishino, Yoshizumi/0000-0001-9419-0826				ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; Bianco P R, 1998, Front Biosci, V3, pD570; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Daiyasu H, 2000, NUCLEIC ACIDS RES, V28, P4540, DOI 10.1093/nar/28.22.4540; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; Giraud-Panis MJE, 1998, J MOL BIOL, V278, P117, DOI 10.1006/jmbi.1998.1681; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1993, J BIOL CHEM, V268, P22092; Kawarabayasi Y, 1999, DNA Res, V6, P83, DOI 10.1093/dnares/6.2.83; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Komori K, 1999, P NATL ACAD SCI USA, V96, P8873, DOI 10.1073/pnas.96.16.8873; Komori K, 2000, NUCLEIC ACIDS RES, V28, P4544, DOI 10.1093/nar/28.22.4544; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kvaratskhelia M, 2000, J BIOL CHEM, V275, P25540, DOI 10.1074/jbc.M003420200; Kvaratskhelia M, 2000, J MOL BIOL, V297, P923, DOI 10.1006/jmbi.2000.3624; LILLEY DM, 1995, DNA PROTEIN STRUCTUR, P114; Lilley DMJ, 2000, P NATL ACAD SCI USA, V97, P9351, DOI 10.1073/pnas.97.17.9351; MIZRAHI V, 1990, NUCLEIC ACIDS RES, V18, P5359, DOI 10.1093/nar/18.18.5359; MORIKAWA K, 1998, NUCL ACID M, V12, P275; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; Raaijmakers H, 1999, EMBO J, V18, P1447, DOI 10.1093/emboj/18.6.1447; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SAITO A, 1995, P NATL ACAD SCI USA, V92, P7470, DOI 10.1073/pnas.92.16.7470; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; Shinagawa H, 1996, TRENDS BIOCHEM SCI, V21, P107, DOI 10.1016/0968-0004(96)10014-1; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsutakawa SE, 1999, MOL CELL, V3, P621, DOI 10.1016/S1097-2765(00)80355-X; Tsutakawa SE, 1999, CELL, V99, P615, DOI 10.1016/S0092-8674(00)81550-0; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; White MF, 1997, J MOL BIOL, V269, P647, DOI 10.1006/jmbi.1997.1097	42	27	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40385	40391		10.1074/jbc.M006294200	http://dx.doi.org/10.1074/jbc.M006294200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11005813	hybrid			2022-12-27	WOS:000166039500080
J	Allen, MP; Xu, M; Zeng, C; Tobet, SA; Wierman, ME				Allen, MP; Xu, M; Zeng, C; Tobet, SA; Wierman, ME			Myocyte enhancer factors-2B and-2C are required for adhesion related kinase repression of neuronal gonadotropin releasing hormone gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; CENTRAL-NERVOUS-SYSTEM; TRANSCRIPTION FACTOR; PROMOTER ACTIVITY; SURVIVAL ACTIVITIES; FUNCTIONAL-ANALYSIS; MEF2 GENES; PROTEIN-S; FACTOR 2C; GROWTH	Synthesis of the hypothalamic peptide, gonadotropin releasing hormone (GnRH), is paramount for reproductive function. GnRH neurons originate in the olfactory region and migrate into the forebrain during development. We recently implicated adhesion related kinase (Ark) in GnRH neuron development based on its differential expression in two GnRH producing cell lines, GT1-7 and Gn10. The Ark membrane receptor encodes an extracellular domain resembling cell adhesion molecules and an intracellular tyrosine kinase. Ark is expressed in Gn10 cells derived from migrating GnRH neurons but not GT1-7 cells of the post-migratory phenotype. Here, we show that Ark and GnRH transcripts are colocalized in the cribriform plate at midgestation, suggesting that Ark is expressed in migrating GnRH neurons in vivo. Furthermore, we have identified the GnRH gene as a downstream target of Ark signaling. Ark inhibits GnRH gene expression in GnRH neuronal cells via the coordinated binding of myocyte enhancer factor-2B and -2C (MEF-2B and -2C) and a putative homeoprotein within the proximal rat GnRH: promoter. Given that MEF-2 proteins are widely expressed in the brain, these studies provide further evidence for MEF-2 action during neuronal development. Moreover, our studies elucidate a potential role for Ark in regulating GnRH gene expression during GnRH neuronal migration.	Vet Affairs Med Ctr, Res Serv, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Physiol & Biophys, Denver, CO 80262 USA; Harvard Univ, Sch Med, Shriver Ctr, Program Neurosci, Waltham, MA 02452 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Harvard University	Wierman, ME (corresponding author), Vet Affairs Med Ctr, Res Serv, Box 111H,1055 Clermont St, Denver, CO 80220 USA.	margaret.wierman@uchsc.edu		Tobet, Stuart/0000-0002-1615-7331	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033441] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33441] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Allen MP, 1999, MOL ENDOCRINOL, V13, P191, DOI 10.1210/me.13.2.191; ALLEN MP, 2000, SOC NEUR ABST, V26, P1352; ASTRUC ME, 1995, ENDOCRINOLOGY, V136, P824, DOI 10.1210/en.136.3.824; Bellosta P, 1997, ONCOGENE, V15, P2387, DOI 10.1038/sj.onc.1201419; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; Belsham DD, 2000, MOL ENDOCRINOL, V14, P212, DOI 10.1210/me.14.2.212; Biscardi JS, 1996, J BIOL CHEM, V271, P29049, DOI 10.1074/jbc.271.46.29049; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Black BL, 1996, J BIOL CHEM, V271, P26659, DOI 10.1074/jbc.271.43.26659; Bless EP, 2000, ENDOCRINOLOGY, V141, P1254, DOI 10.1210/en.141.3.1254; Bruder JM, 1996, MOL ENDOCRINOL, V10, P35, DOI 10.1210/me.10.1.35; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; CLARK ME, 1995, MOL CELL BIOL, V15, P6169; Crosier KE, 1997, PATHOLOGY, V29, P131, DOI 10.1080/00313029700169744; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fang ZQ, 1998, ENDOCRINOLOGY, V139, P3654, DOI 10.1210/en.139.8.3654; Firulli AB, 1996, CIRC RES, V78, P196, DOI 10.1161/01.RES.78.2.196; Fridell YWC, 1998, J BIOL CHEM, V273, P7123, DOI 10.1074/jbc.273.12.7123; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; FUJIMOTO J, 1994, ONCOGENE, V9, P693; Goruppi S, 1999, ONCOGENE, V18, P4224, DOI 10.1038/sj.onc.1202788; Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442; Goruppi S, 1996, ONCOGENE, V12, P471; Grayson J, 1998, J CELL BIOCHEM, V70, P366, DOI 10.1002/(SICI)1097-4644(19980901)70:3<366::AID-JCB10>3.3.CO;2-T; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HIATT ES, 1992, ENDOCRINOLOGY, V130, P1030, DOI 10.1210/en.130.2.1030; IKESHIMA H, 1995, NEUROSCI LETT, V200, P117, DOI 10.1016/0304-3940(95)12092-I; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; Kelley CG, 2000, MOL ENDOCRINOL, V14, P1246, DOI 10.1210/me.14.8.1246; KEPA JK, 1992, NUCLEIC ACIDS RES, V20, P1393, DOI 10.1093/nar/20.6.1393; Kepa JK, 1996, NUCLEIC ACIDS RES, V24, P3614, DOI 10.1093/nar/24.18.3614; KEPA JK, 1994, ENDOCRINE, V2, P947; KING JC, 1995, CELL MOL NEUROBIOL, V15, P89, DOI 10.1007/BF02069560; Krainc D, 1998, J BIOL CHEM, V273, P26218, DOI 10.1074/jbc.273.40.26218; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; Lakich MM, 1998, J BIOL CHEM, V273, P15217, DOI 10.1074/jbc.273.24.15217; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LEIFER D, 1994, NEUROSCIENCE, V63, P1067, DOI 10.1016/0306-4522(94)90573-8; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; Lin X, 1996, MOL BRAIN RES, V42, P307, DOI 10.1016/S0169-328X(96)00135-0; Loeser RF, 1997, ARTHRITIS RHEUM, V40, P1455, DOI 10.1002/art.1780400814; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Mao ZX, 1999, J BIOL CHEM, V274, P31102, DOI 10.1074/jbc.274.43.31102; Mao ZX, 1996, J BIOL CHEM, V271, P14371, DOI 10.1074/jbc.271.24.14371; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; MARK MR, 1994, J BIOL CHEM, V269, P10720; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; McCloskey P, 1997, J BIOL CHEM, V272, P23285, DOI 10.1074/jbc.272.37.23285; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; Melaragno MG, 1998, CIRC RES, V83, P697, DOI 10.1161/01.RES.83.7.697; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; Naya FJ, 1999, DEVELOPMENT, V126, P2045; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; Osborn MT, 1999, BIOTECHNIQUES, V27, P887, DOI 10.2144/99275bm02; RADOVICK S, 1991, P NATL ACAD SCI USA, V88, P3402, DOI 10.1073/pnas.88.8.3402; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SCHUG J, 1997, CBILTR19971001V0 U P; SCHULZ NT, 1995, MOL BRAIN RES, V28, P273, DOI 10.1016/0169-328X(94)00216-2; SCHWANZELFUKUDA M, 1989, NATURE, V338, P161, DOI 10.1038/338161a0; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Tobet SA, 1996, DEV BRAIN RES, V97, P287, DOI 10.1016/S0165-3806(96)00151-4; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Wierman ME, 1997, MOL CELL BIOL, V17, P1652, DOI 10.1128/MCB.17.3.1652; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790	76	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39662	39670		10.1074/jbc.M007097200	http://dx.doi.org/10.1074/jbc.M007097200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995769	hybrid			2022-12-27	WOS:000165953100094
J	Chen, G; Hitomi, M; Han, JH; Stacey, DW				Chen, G; Hitomi, M; Han, JH; Stacey, DW			The p38 pathway provides negative feedback for Ras proliferative signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NIH 3T3 CELLS; MAP KINASE; C-JUN; TRANSCRIPTIONAL ACTIVATION; CELLULAR-TRANSFORMATION; INCREASING COMPLEXITY; REGULATED KINASE-1/2; TOPOISOMERASE-II; GENE-EXPRESSION	Ras activates three mitogen-activated protein kinases (MAPKs) including ERK, JNK and p38. Whereas the essential roles of ERK and JNK in Ras signaling has been established, the contribution of p38 remains unclear. Here we demonstrate that the p38 pathway functions as a negative regulator of Pas proliferative signaling via a feedback mechanism. Oncogenic Ras activated p38 and two p38-activated protein kinases, MAPK-activated protein kinase 2 (MK2) and p58-related/activated protein kinase (PRAK). MK2 and PRAK in turn suppressed Pas-induced gene expression and cell proliferation, whereas two mutant PRAKs, unresponsive to has, had little effect. Moreover, the constitutive p38 activator MKK6 also suppressed Pas activity in a p38-dependent manner whereas arsenite, a potent chemical inducer of p38, inhibited proliferation only in a tumor cell line that required Pas activity. MEK was required for Ras stimulation of the p38 pathway. The p38 pathway inhibited Pas activity by blocking activation of JNK, without effect upon ERK, as evidenced by the fact that PRAK-mediated suppression of Pas-induced cell proliferation was reversed by coexpression of JNKK2 or JNK1. These studies thus establish a negative feedback mechanism by which Pas proliferative activity is regulated via signaling integrations of MAPK pathways.	Cleveland Clin Fdn, Dept Mol Biol, Cleveland, OH 44195 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Cleveland Clinic Foundation; Scripps Research Institute	Chen, G (corresponding author), Loyola Univ, Med Ctr, Dept Radiat Oncol, 2160 S 1st Ave,Bldg 1,Mail Rte 114B, Maywood, IL 60153 USA.		Han, J/G-4671-2010		NCI NIH HHS [CA91576] Funding Source: Medline; NIGMS NIH HHS [GM51417, GM52271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA091576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052271] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arata S, 1997, J CELL PHYSIOL, V170, P19, DOI 10.1002/(SICI)1097-4652(199701)170:1<19::AID-JCP3>3.0.CO;2-O; Blackburn RV, 1997, INT J CANCER, V72, P871, DOI 10.1002/(SICI)1097-0215(19970904)72:5<871::AID-IJC26>3.0.CO;2-A; BOS JL, 1989, CANCER RES, V49, P4682; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen G, 1996, J BIOL CHEM, V271, P28259, DOI 10.1074/jbc.271.45.28259; Chen G, 1997, ONCOGENE, V15, P1643, DOI 10.1038/sj.onc.1201347; Chen G, 1999, ONCOGENE, V18, P7149, DOI 10.1038/sj.onc.1203149; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; Foos G, 1998, J BIOL CHEM, V273, P18871, DOI 10.1074/jbc.273.30.18871; GALANG CK, 1994, ONCOGENE, V9, P2913; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; Larsen CM, 1998, J BIOL CHEM, V273, P15294, DOI 10.1074/jbc.273.24.15294; Larsen JK, 1997, AM J PHYSIOL-LUNG C, V273, pL930, DOI 10.1152/ajplung.1997.273.5.L930; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STACEY DW, 1987, EXP CELL RES, V171, P232, DOI 10.1016/0014-4827(87)90266-7; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Verheijen MHG, 1999, ONCOGENE, V18, P4435, DOI 10.1038/sj.onc.1202834; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WOESSNER RD, 1990, CANCER RES, V50, P2901; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232	66	139	145	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					38973	38980		10.1074/jbc.M002856200	http://dx.doi.org/10.1074/jbc.M002856200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10978313	hybrid			2022-12-27	WOS:000165953100006
J	Einsle, O; Stach, P; Messerschmidt, A; Simon, J; Kroger, A; Huber, R; Kroneck, PMH				Einsle, O; Stach, P; Messerschmidt, A; Simon, J; Kroger, A; Huber, R; Kroneck, PMH			Cytochrome c nitrite reductase from Wolinella succinogenes - Structure at 1.6 angstrom resolution, inhibitor binding, and heme-packing motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-DESULFURICANS; CRYSTAL-STRUCTURE; PROTEIN; AMMONIA; C(3); PURIFICATION; HYDROGENASE; BIOGENESIS; MOLSCRIPT; SEQUENCE	Cytochrome c nitrite reductase catalyzes the 6-electron reduction of nitrite to ammonia. This second part of the respiratory pathway of nitrate ammonification is a key step in the biological nitrogen cycle. The x-ray structure of the enzyme from the epsilon -proteobacterium Wolinella succinogenes has been solved to a resolution of 1.6 Angstrom It is a pentaheme c-type cytochrome whose heme groups are packed in characteristic motifs that also occur in other multiheme cytochromes. Structures of W. succinogenes nitrite reductase have been obtained with water bound to the active site heme iron as well as complexes with two inhibitors, sulfate and azide, whose binding modes and inhibitory functions differ significantly. Cytochrome c nitrite reductase is part of a highly optimized respiratory system found in a wide range of Gram-negative bacteria. It reduces both anionic and neutral substrates at the distal side of a lysine-coordinated high-spin heme group, which is accessible through two different channels, allowing for a guided flow of reaction educt and product. Based on sequence comparison and secondary structure prediction, we have demonstrated that cytochrome c nitrite reductases constitute a protein family of high structural similarity.	Univ Konstanz, Math Naturwissensch Sekt, Fachbereich Biol, D-78457 Constance, Germany; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Goethe Univ Frankfurt, Inst Mikrobiol, D-60439 Frankfurt, Germany	University of Konstanz; Max Planck Society; Goethe University Frankfurt	Einsle, O (corresponding author), Univ Konstanz, Math Naturwissensch Sekt, Fachbereich Biol, Fach M665,Univ Str 10, D-78457 Constance, Germany.	einsle@biochem.mpg.de; Peter.Kroneck@uni-konstanz.de	Messerschmidt, Albrecht/A-8337-2008; Simon, Jörg/F-2355-2016	Simon, Jörg/0000-0003-0214-3745; Einsle, Oliver/0000-0001-8722-2893				Bamford V, 1999, NAT STRUCT BIOL, V6, P1104; Banci L, 1996, P NATL ACAD SCI USA, V93, P14396, DOI 10.1073/pnas.93.25.14396; Barker PD, 1999, STRUCTURE, V7, pR281, DOI 10.1016/S0969-2126(00)88334-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COLE JA, 1980, FEMS MICROBIOL LETT, V7, P65, DOI 10.1111/j.1574-6941.1980.tb01578.x; DARWIN A, 1993, MOL MICROBIOL, V9, P1255, DOI 10.1111/j.1365-2958.1993.tb01255.x; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; Eaves DJ, 1998, MOL MICROBIOL, V28, P205, DOI 10.1046/j.1365-2958.1998.00792.x; Einsle O, 1999, NATURE, V400, P476, DOI 10.1038/22802; EINSLE O, 2000, HDB METALLOPROTEINS; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Guex, 1996, PROTEIN DATA BANK Q, V77, P7; HALADJIAN J, 1987, BIOCHEM BIOPH RES CO, V147, P1289, DOI 10.1016/S0006-291X(87)80210-3; HUSSAIN H, 1994, MOL MICROBIOL, V12, P153, DOI 10.1111/j.1365-2958.1994.tb01004.x; Igarashi N, 1997, NAT STRUCT BIOL, V4, P276, DOI 10.1038/nsb0497-276; Iverson TM, 1998, NAT STRUCT BIOL, V5, P1005, DOI 10.1038/2975; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Matias PM, 1997, J BIOL INORG CHEM, V2, P507, DOI 10.1007/s007750050162; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NIVIERE V, 1988, BIOCHIM BIOPHYS ACTA, V935, P34, DOI 10.1016/0005-2728(88)90105-3; Norager S, 1999, J MOL BIOL, V290, P881, DOI 10.1006/jmbi.1999.2917; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; SCHUMACHER W, 1994, BIOCHEM BIOPH RES CO, V205, P911, DOI 10.1006/bbrc.1994.2751; SCHUMACHER W, 1991, ARCH MICROBIOL, V156, P70, DOI 10.1007/BF00418190; Simon J, 2000, MOL MICROBIOL, V35, P686, DOI 10.1046/j.1365-2958.2000.01742.x; Stach P, 2000, J INORG BIOCHEM, V79, P381, DOI 10.1016/S0162-0134(99)00248-2; STEUBER J, 1994, ARCH MICROBIOL, V162, P255, DOI 10.1007/s002030050134; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337	37	158	161	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39608	39616		10.1074/jbc.M006188200	http://dx.doi.org/10.1074/jbc.M006188200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10984487	hybrid			2022-12-27	WOS:000165953100087
J	Lee, YS; Kim, HW; Park, SS				Lee, YS; Kim, HW; Park, SS			The role of alpha-amino group of the N-terminal serine of beta subunit for enzyme catalysis and autoproteolytic activation of glutaryl 7-aminocephalosporanic acid acylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LYSOSOMAL ASPARTYLGLUCOSAMINIDASE; 20S PROTEASOME; PENICILLIN ACYLASE; MECHANISM; ACIDOPHILUM; STRAIN	Glutaryl 7-aminocephalosporanic acid (GL-7-ACA) acylase of Pseudomonas sp. strain GK16 catalyzes the cleavage of the amide bond in the GL-7-ACA side chain to produce glutaric acid and 7-aminocephalosporanic acid (7-ACA). The active enzyme is an (alpha beta)(2) heterotetramer of two non-identical subunits that are cleaved autoproteolytically from an enzymatically inactive precursor polypeptide. In this study, we prepared and characterized a chemically modified enzyme, and also examined an effect of the modification on enzyme catalysis and autocatalytic processing of the enzyme precursor. We found that treatment of the enzyme with cyanate ion led to a significant loss of the enzyme activity. Structural and functional analyses of the modified enzyme showed that carbamylation of the free alpha -amino group of the N-terminal Ser-199 of the beta subunit resulted in the loss of the enzyme activity. The pH dependence of the kinetic parameters indicates that a single ionizing group is involved in enzyme catalysis with pK(a) = 6.0, which could be attributed to the cu-amino group of the N-terminal Ser-199. The carbamylation also inhibited the secondary processing of the enzyme precursor, suggesting a possible role of the ar-amino group for the reaction. Mutagenesis of the invariant N-terminal residue Ser-199 confirmed the key function of its side chain hydroxyl group in both enzyme catalysis and autoproteolytic activation. Partial activity and correct processing of a mutant S199T were in agreement with the general mechanism of N-terminal nucleophile hydrolases. Our results indicate that GL-7-ACA acylase utilizes as a nucleophile Ser-199 in both enzyme activity and autocatalytic processing and most importantly its own alpha -amino group of the Ser-199 as a general base catalyst for the activation of the hydroxyl group both in enzyme catalysis and in the secondary cleavage of the enzyme precursor. All of the data also imply that GL-7-ACA acylase is a member of a novel class of N-terminal nucleophile hydrolases that have a single catalytic center for enzyme catalysis.	Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea	Korea University	Park, SS (corresponding author), Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea.							BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; CLELAND WW, 1982, METHOD ENZYMOL, V87, P309; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Guan C, 1998, J BIOL CHEM, V273, P9695, DOI 10.1074/jbc.273.16.9695; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; HAYASHI N, 1994, BIOTECHNIQUES, V17, P314; ICHIKAWA S, 1981, AGR BIOL CHEM TOKYO, V45, P2225, DOI 10.1080/00021369.1981.10864877; ICHIKAWA S, 1981, AGR BIOL CHEM TOKYO, V45, P2281; Kwon TH, 2000, J STRUCT BIOL, V131, P79, DOI 10.1006/jsbi.2000.4256; Lee YS, 1998, J BACTERIOL, V180, P4576, DOI 10.1128/JB.180.17.4576-4582.1998; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MATSUDA A, 1985, J BACTERIOL, V163, P1222, DOI 10.1128/JB.163.3.1222-1228.1985; Morillas M, 1999, BIOCHEM J, V338, P235, DOI 10.1042/0264-6021:3380235; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; Saarela J, 1998, J BIOL CHEM, V273, P25320, DOI 10.1074/jbc.273.39.25320; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; TANFORD C, 1962, ADV PROTEIN CHEM, V17, P69; Tikkanen R, 1996, EMBO J, V15, P2954, DOI 10.1002/j.1460-2075.1996.tb00658.x; Xu QA, 1999, CELL, V98, P651, DOI 10.1016/S0092-8674(00)80052-5	22	24	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39200	39206		10.1074/jbc.M002504200	http://dx.doi.org/10.1074/jbc.M002504200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10991936	hybrid			2022-12-27	WOS:000165953100036
J	Muller, L; Cameron, A; Fortenberry, Y; Apletalina, EV; Lindberg, I				Muller, L; Cameron, A; Fortenberry, Y; Apletalina, EV; Lindberg, I			Processing and sorting of the prohormone convertase 2 propeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPROTEIN CONVERTASE; POSTTRANSLATIONAL MODIFICATIONS; ENZYMATIC CHARACTERIZATION; INTRAMOLECULAR CHAPERONES; ENDOPLASMIC-RETICULUM; NEUROENDOCRINE CELLS; STRUCTURAL ELEMENTS; TERMINAL SEQUENCES; PROCATHEPSIN-L; PROTEIN 7B2	The prohormone convertases (PCs) are synthesized as zymogens whose propeptides contain several multibasic sites. In this study, we investigated the processing of the PC2 propeptide and its function in the regulation of PC2 activity. By using purified pro-PC2 and directed mutagenesis, we found that the propeptide is first cleaved at the multibasic site separating it from the catalytic domain (primary cleavage site); the intact propeptide thus generated is then sequentially processed at two internal sites. Unlike the mechanism described for furin, our mutagenesis studies show that internal cleavage of the propeptide is not required for activation of pro-PCS, In addition, we identified a point mutation in the primary cleavage site that does not prevent the folding nor the processing of the zymogen but nevertheless results in the generation of an inactive PC2 species. These data suggest that the propeptide cleavage site is directly involved in the folding of the catalytic site. By using synthetic peptides, we found that a PC2 propeptide fragment inhibits PC2 activity, and we identified the inhibitory site as the peptide sequence containing basic residues at the extreme carboxyl terminus of the primary cleavage site. Finally, our study supplies information concerning the intracellular fate of a convertase propeptide by providing evidence that the PC2 propeptide is generated and is internally processed within the secretory granules, In agreement with this localization, an internally cleaved propeptide fragment could be released by stimulated secretion.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Lindberg, I (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St, New Orleans, LA 70112 USA.		muller, laurent/S-1990-2016; Lindberg, Iris/Q-3825-2019	muller, laurent/0000-0001-9634-4323; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R56DA005084, R01DA005084] Funding Source: NIH RePORTER; NIDA NIH HHS [R56 DA005084, DA05084] Funding Source: Medline; NIDDK NIH HHS [R01 DK049703, DK49703, DK49703S2] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; Bhattacharjya S, 2000, BIOCHEMISTRY-US, V39, P2868, DOI 10.1021/bi9923961; Boudreault A, 1998, J BIOL CHEM, V273, P31574, DOI 10.1074/jbc.273.47.31574; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; COLL M, 1991, EMBO J, V10, P1; Creemers JWM, 1998, SEMIN CELL DEV BIOL, V9, P3, DOI 10.1006/scdb.1997.0195; Creemers JWM, 1996, J BIOL CHEM, V271, P25284, DOI 10.1074/jbc.271.41.25284; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; Cygler M, 1996, STRUCTURE, V4, P405, DOI 10.1016/S0969-2126(96)00046-9; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; Elias CF, 1998, J COMP NEUROL, V402, P442, DOI 10.1002/(SICI)1096-9861(19981228)402:4<442::AID-CNE2>3.0.CO;2-R; FRICKER LD, 1986, NATURE, V323, P461, DOI 10.1038/323461a0; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; GALLAGHER T, 1995, STRUCTURE, V3, P907, DOI 10.1016/S0969-2126(01)00225-8; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; GUEST PC, 1992, J BIOL CHEM, V267, P22401; Hu ZX, 1996, J BIOL CHEM, V271, P3375; INOUYE M, 1991, ENZYME, V45, P314, DOI 10.1159/000468904; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; Johanning K, 1998, J BIOL CHEM, V273, P22672, DOI 10.1074/jbc.273.35.22672; Khan AR, 1998, PROTEIN SCI, V7, P815; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; Lamango NS, 1996, ARCH BIOCHEM BIOPHYS, V330, P238, DOI 10.1006/abbi.1996.0249; Lamango NS, 1999, ARCH BIOCHEM BIOPHYS, V362, P275, DOI 10.1006/abbi.1998.1033; LEDUC R, 1992, J BIOL CHEM, V267, P14304; Lesage G, 2000, MOL BIOL CELL, V11, P1947, DOI 10.1091/mbc.11.6.1947; LI YY, 1994, J BIOL CHEM, V269, P4169; Li YY, 1996, J MOL BIOL, V262, P591, DOI 10.1006/jmbi.1996.0537; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P5486, DOI 10.1021/bi00016a020; LINDBERG I, 1986, J BIOL CHEM, V261, P6317; MACH L, 1994, J BIOL CHEM, V269, P13036; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; MCINTYRE GF, 1994, J BIOL CHEM, V269, P567; Menard R, 1998, J BIOL CHEM, V273, P4478, DOI 10.1074/jbc.273.8.4478; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Muller L, 1997, J CELL BIOL, V139, P625, DOI 10.1083/jcb.139.3.625; Muller L, 2000, PROG NUCLEIC ACID RE, V63, P69, DOI 10.1016/S0079-6603(08)60720-5; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; SEVARINO KA, 1989, CELL, V57, P11, DOI 10.1016/0092-8674(89)90167-0; SHEN FS, 1993, J BIOL CHEM, V268, P24910; Shinde U, 1999, J BIOL CHEM, V274, P15615, DOI 10.1074/jbc.274.22.15615; SHINDE U, 1995, J MOL BIOL, V247, P390, DOI 10.1006/jmbi.1994.0147; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; SIEZEN RJ, INTRAMOLECULAR CHAPE, P233; Stack MS, 1996, ARCH BIOCHEM BIOPHYS, V333, P163, DOI 10.1006/abbi.1996.0377; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; SUTER U, 1991, EMBO J, V10, P2395, DOI 10.1002/j.1460-2075.1991.tb07778.x; Taylor NA, 1997, BIOCHEM J, V321, P367, DOI 10.1042/bj3210367; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; Volkov A, 1996, J MOL BIOL, V262, P595, DOI 10.1006/jmbi.1996.0538; Wagner I, 1997, EMBO J, V16, P7317, DOI 10.1093/emboj/16.24.7317; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6; Williams J W, 1979, Methods Enzymol, V63, P437; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745; ZHOU A, 1994, J BIOL CHEM, V269, P17440; Zhou A, 1998, J BIOL CHEM, V273, P11107, DOI 10.1074/jbc.273.18.11107; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509; Zhu X, 1996, P NATL ACAD SCI USA, V93, P4919, DOI 10.1073/pnas.93.10.4919; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641; Zhu XR, 1998, J BIOL CHEM, V273, P1158, DOI 10.1074/jbc.273.2.1158	69	41	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39213	39222		10.1074/jbc.M003547200	http://dx.doi.org/10.1074/jbc.M003547200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995742	hybrid			2022-12-27	WOS:000165953100038
J	Beatrix, B; Sakai, H; Wiedmann, M				Beatrix, B; Sakai, H; Wiedmann, M			The alpha and beta subunit of the nascent polypeptide-associated complex have distinct functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; ENDOPLASMIC-RETICULUM MEMBRANE; BTF3 TRANSCRIPTION FACTOR; MESSENGER-RNA; PROTEIN TRANSLOCATION; MICROSOMAL-MEMBRANES; RIBOSOMES; BINDING; CHAINS; YEAST	Nascent polypeptide-associated complex (NAC) is probably the first cytosolic protein to contact nascent polypeptide chains emerging from ribosomes. In this way NAC prevents inappropriate interactions with other factors. Eventually other factors involved in targeting and folding, like the Signal Recognition Particle or cytosolic chaperones, must gain access to the nascent chain. AU. NAC preparations to date consist of two copurifying polypeptides. Here we rigorously show that these two polypeptides, termed alpha- and beta NAC, form a very stable complex in vivo and in vitro and that a functional complex can be reconstituted from the individual subunits. A dissection of the contributions of the individual subunits to NACs function revealed that both subunits are in direct contact with nascent polypeptide chains on the ribosome and that both contribute to the prevention of inappropriate interactions. However, beta NAC alone directly binds to the ribosome and is sufficient to prevent ribosome binding to the endoplasmic reticulum membrane.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Nagasaki Univ, Sch Dent, Dept Pharmacol, Nagasaki 852, Japan	Memorial Sloan Kettering Cancer Center; Nagasaki University	Wiedmann, M (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.	m-wiedmann@ski.mskcc.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050920] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50920-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELMAN MR, 1973, J CELL BIOL, V56, P191, DOI 10.1083/jcb.56.1.191; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BORGESE N, 1974, J MOL BIOL, V88, P559, DOI 10.1016/0022-2836(74)90408-2; BULL AL, 1966, J EXP ZOOL, V161, P221, DOI 10.1002/jez.1401610207; DENG JM, 1995, TRANSGENIC RES, V4, P264, DOI 10.1007/BF01969120; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; Funfschilling U, 1999, MOL BIOL CELL, V10, P3289, DOI 10.1091/mbc.10.10.3289; George R, 1998, P NATL ACAD SCI USA, V95, P2296, DOI 10.1073/pnas.95.5.2296; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; GORLICH D, 1991, METHOD CELL BIOL, V34, P241; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HAUSER S, 1995, EMBO J, V14, P5485, DOI 10.1002/j.1460-2075.1995.tb00235.x; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; KANNO M, 1992, GENE, V117, P219, DOI 10.1016/0378-1119(92)90732-5; Lauring B, 1995, COLD SPRING HARB SYM, V60, P47, DOI 10.1101/SQB.1995.060.01.008; LAURING B, 1995, P NATL ACAD SCI USA, V92, P5411, DOI 10.1073/pnas.92.12.5411; LAURING B, 1995, P NATL ACAD SCI USA, V92, P9435, DOI 10.1073/pnas.92.21.9435; Markesich DC, 2000, DEVELOPMENT, V127, P559; Moller I, 1998, P NATL ACAD SCI USA, V95, P13425, DOI 10.1073/pnas.95.23.13425; Moller I, 1998, FEBS LETT, V441, P1, DOI 10.1016/S0014-5793(98)01440-9; Moreau A, 1998, MOL CELL BIOL, V18, P1312, DOI 10.1128/MCB.18.3.1312; Munz B, 1999, J BIOL CHEM, V274, P13305, DOI 10.1074/jbc.274.19.13305; Netzer WJ, 1998, TRENDS BIOCHEM SCI, V23, P68, DOI 10.1016/S0968-0004(97)01171-7; Neuhof A, 1998, MOL BIOL CELL, V9, P103, DOI 10.1091/mbc.9.1.103; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Prinz A, 2000, EMBO J, V19, P1900, DOI 10.1093/emboj/19.8.1900; Raden D, 1998, MOL BIOL CELL, V9, P117, DOI 10.1091/mbc.9.1.117; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Reimann B, 1999, YEAST, V15, P397, DOI 10.1002/(SICI)1097-0061(19990330)15:5<397::AID-YEA384>3.3.CO;2-L; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; Yotov WV, 1998, MOL CELL BIOL, V18, P1303, DOI 10.1128/MCB.18.3.1303; Yotov WV, 1996, GENE DEV, V10, P1763, DOI 10.1101/gad.10.14.1763	42	77	87	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37838	37845		10.1074/jbc.M006368200	http://dx.doi.org/10.1074/jbc.M006368200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982809	hybrid			2022-12-27	WOS:000165618700072
J	Gabai, VL; Meriin, AB; Yaglom, JA; Wei, JY; Mosser, DD; Sherman, MY				Gabai, VL; Meriin, AB; Yaglom, JA; Wei, JY; Mosser, DD; Sherman, MY			Suppression of stress kinase JNK is involved in Hsp72-mediated protection of myogenic cells from transient energy deprivation - Hsp72 alleviates the stress-induced inhibition of JNK dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HEAT-SHOCK PROTEINS; MYOCARDIAL-ISCHEMIA; TRANSGENIC MICE; CARDIOVASCULAR BIOLOGY; INDUCED APOPTOSIS; TERMINAL KINASES; GENE-EXPRESSION; CARDIAC-CELLS; INFARCT SIZE	Since protection of cells from stress-induced apoptosis by the heat shock protein Hsp72 involves suppression of stress kinase JNK, we suggested that Hsp72-mediated JNK inhibition might also be critical for myocardial protection from ischemia/reperfusion. Transient energy deprivation of H9c2 myogenic cells, used as an in vitro model of myocardial ischemia, led to cell death that had morphological features of apoptosis and necrosis and was independent of caspases. Surprisingly, this unusual type of cell death was regulated by JNK and ERK kinases, In fact, specific inhibition of JNK increased cell survival; specific inhibition of ERKs enhanced deleterious consequences of energy deprivation, whereas inhibition of p38 kinase had no effect. Hsp72 suppressed activation of JNK and did not increase ERK activity, suggesting that inhibition of JNK is the important component of Hsp72-mediated protection. Upon transient energy deprivation, activation of JNK proceeds via two distinct pathways, stimulation of JNK phosphorylation by a protein kinase SEK1 and inhibition of JNK dephosphorylation. Remarkably, in cells exposed to transient energy deprivation, Hsp72 enhanced the rate of JNK dephosphorylation but did not affect SEK1 activity. Therefore, it appears that Hsp72 specifically down-regulates JNK by accelerating its dephosphorylation, which reduces the susceptibility of cardiac cells to simulated ischemia/reperfusion.	Boston Biomed Res Inst, Watertown, MA 02472 USA; Russian Acad Med Sci, Med Radiol Res Inst, Obninsk 249020, Russia; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	Boston Biomedical Research Institute; Russian Academy of Medical Sciences; Harvard University; Beth Israel Deaconess Medical Center; National Research Council Canada	Sherman, MY (corresponding author), Boston Biomed Res Inst, 64 Grove St, Watertown, MA 02472 USA.		Gabai, Vladimir L/I-1650-2013; Mosser, Dick D/A-7391-2008	Gabai, Vladimir L/0000-0003-4505-4718; Meriin, Anatoli/0000-0003-0087-814X; Yaglom, Julia/0000-0002-8723-3506; Mosser, Richard/0000-0002-9183-2288	NATIONAL CANCER INSTITUTE [R01CA081244] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA81244-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Brar BK, 1999, J MOL CELL CARDIOL, V31, P135, DOI 10.1006/jmcc.1998.0857; Cheng W, 1996, EXP CELL RES, V226, P316, DOI 10.1006/excr.1996.0232; Elsasser A, 2000, J MOL CELL CARDIOL, V32, P711, DOI 10.1006/jmcc.2000.1125; Feige U., 1996, STRESS INDUCIBLE CEL; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; Gabai VL, 1998, FEBS LETT, V438, P1, DOI 10.1016/S0014-5793(98)01242-3; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gottlieb RA, 1999, ANN NY ACAD SCI, V874, P412, DOI 10.1111/j.1749-6632.1999.tb09255.x; HEADS RJ, 1995, J MOL CELL CARDIOL, V27, P1669, DOI 10.1016/S0022-2828(95)90722-X; Hutter JJ, 1996, CIRCULATION, V94, P1408, DOI 10.1161/01.CIR.94.6.1408; Kabakov A. E., 1997, HEAT SHOCK PROTEINS; KABAKOV AE, 1993, EXPERIENTIA, V49, P706, DOI 10.1007/BF01923956; KABAKOV AE, 1994, ARCH BIOCHEM BIOPHYS, V309, P247, DOI 10.1006/abbi.1994.1109; Kajstura J, 1996, LAB INVEST, V74, P86; Karwatowska-Prokopczuk E, 1998, CIRC RES, V82, P1139, DOI 10.1161/01.RES.82.11.1139; Kumar S, 1999, BIOCHEM BIOPH RES CO, V263, P825, DOI 10.1006/bbrc.1999.1454; Ma XL, 1999, CIRCULATION, V99, P1685, DOI 10.1161/01.CIR.99.13.1685; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; MacLellan WR, 1997, CIRC RES, V81, P137, DOI 10.1161/01.RES.81.2.137; Massie B, 1998, CYTOTECHNOLOGY, V28, P53, DOI 10.1023/A:1008013211222; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; MESTRIL R, 1995, J MOL CELL CARDIOL, V27, P45, DOI 10.1016/S0022-2828(08)80006-5; Mestril R, 1996, J MOL CELL CARDIOL, V28, P2351, DOI 10.1006/jmcc.1996.0228; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Mosser DD, 1997, BIOTECHNIQUES, V22, P150, DOI 10.2144/97221rr02; Nayeem MA, 1997, AM J PHYSIOL-HEART C, V273, pH861, DOI 10.1152/ajpheart.1997.273.2.H861; Ovelgonne JH, 1996, J MOL CELL CARDIOL, V28, P1617, DOI 10.1006/jmcc.1996.0152; Piper HM, 1998, CARDIOVASC RES, V38, P291, DOI 10.1016/S0008-6363(98)00033-9; PLUMIER JCL, 1995, J CLIN INVEST, V95, P1854, DOI 10.1172/JCI117865; POMBO CM, 1994, J BIOL CHEM, V269, P26546; Radford NB, 1996, P NATL ACAD SCI USA, V93, P2339, DOI 10.1073/pnas.93.6.2339; Rieger D, 1997, ANAL BIOCHEM, V246, P67, DOI 10.1006/abio.1996.9978; Stephanou A, 1998, J MOL CELL CARDIOL, V30, P849, DOI 10.1006/jmcc.1998.0651; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Turner NA, 1998, J MOL CELL CARDIOL, V30, P1789, DOI 10.1006/jmcc.1998.0743; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang CC, 1998, J ELECTROCERAM, V2, P273, DOI 10.1023/A:1009978607621; Webb S J, 1997, Adv Pharmacol, V41, P1, DOI 10.1016/S1054-3589(08)61052-2; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Yue TL, 2000, CIRC RES, V86, P692, DOI 10.1161/01.RES.86.6.692; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115	46	95	100	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38088	38094		10.1074/jbc.M006632200	http://dx.doi.org/10.1074/jbc.M006632200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978340	hybrid			2022-12-27	WOS:000165618700104
J	Nakatogawa, H; Mori, H; Ito, K				Nakatogawa, H; Mori, H; Ito, K			Two independent mechanisms down-regulate the intrinsic SecA ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; MEMBRANE INSERTION; PREPROTEIN; BINDING; DOMAINS; HYDROLYSIS; MUTANTS; SUBUNIT; SECYEG	SecA initiates protein translocation by interacting with ATP, preprotein, and the SecYEG membrane components. Under such conditions, it undergoes a conformational change characterized as membrane insertion, which is then followed by hydrolysis of ATP, enabling the release of the preprotein and deinsertion of SecA itself for the next cycle of reactions. Without ongoing translocation, the ATPase activity of SecA is kept very low. Previously, it was shown that the C-terminal 34-kDa domain of SecA interacts with the N-terminal 68-kDa ATPase domain to down-regulate the ATPase, Here, we show, using a deregulated SecA mutant, that the intrinsic ATPase activity is subject to dual inhibitory mechanisms. Thus, the proposed second ATP-binding domain down-regulates the ATPase activity executed by the primary ATPase domain. This regulation, within the N-terminal ATPase domain, operates independently of the C-terminal domain-mediated regulation. The absence of both the mechanisms resulted in a 50-fold elevation of translocation-uncoupled ATP hydrolysis.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Ito, K (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.	kito@virus.kyoto-u.ac.jp	Nakatogawa, Hitoshi/D-5155-2015	Nakatogawa, Hitoshi/0000-0002-5828-0741				BABA T, 1990, J BACTERIOL, V172, P7005, DOI 10.1128/jb.172.12.7005-7010.1990; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1997, P NATL ACAD SCI USA, V94, P5574, DOI 10.1073/pnas.94.11.5574; Karamanou S, 1999, MOL MICROBIOL, V34, P1133, DOI 10.1046/j.1365-2958.1999.01686.x; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; KIM YJ, 1994, CELL, V78, P845; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; Matsumoto G, 1997, EMBO J, V16, P6384, DOI 10.1093/emboj/16.21.6384; MATSUMOTO G, 2000, IN PRESS GENES CELLS; MCFARLAND L, 1993, J BACTERIOL, V175, P2255, DOI 10.1128/JB.175.8.2255-2262.1993; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; Nakatogawa H, 2000, J BIOCHEM-TOKYO, V127, P1071, DOI 10.1093/oxfordjournals.jbchem.a022700; OLIVER DB, 1982, J BACTERIOL, V150, P686, DOI 10.1128/JB.150.2.686-691.1982; Price A, 1996, J BIOL CHEM, V271, P31580, DOI 10.1074/jbc.271.49.31580; Ramamurthy V, 1997, J BIOL CHEM, V272, P23239, DOI 10.1074/jbc.272.37.23239; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Song M, 1997, J BIOCHEM-TOKYO, V122, P1010; Taura T, 1997, BIOCHIMIE, V79, P517, DOI 10.1016/S0300-9084(97)82744-7; TOKUDA H, 1993, BIOCHEM BIOPH RES CO, V195, P1415, DOI 10.1006/bbrc.1993.2201	20	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33209	33212		10.1074/jbc.C000550200	http://dx.doi.org/10.1074/jbc.C000550200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10982786	hybrid			2022-12-27	WOS:000090104600007
J	Faulkner, G; Pallavicini, A; Comelli, A; Salamon, M; Bortoletto, G; Ievolella, C; Trevisan, S; Kojic, S; Dalla Vecchia, F; Laveder, P; Valle, G; Lanfranchi, G				Faulkner, G; Pallavicini, A; Comelli, A; Salamon, M; Bortoletto, G; Ievolella, C; Trevisan, S; Kojic, S; Dalla Vecchia, F; Laveder, P; Valle, G; Lanfranchi, G			FATZ, a filamin-, actinin-, and telethonin-binding protein of the Z-disc of skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOMERIC PROTEIN; DOMAIN; TITIN; IDENTIFICATION; REPEAT; PDZ; ACTIVATION; INTERACTS; SEQUENCE; CLONING	We report the identification and characterization of a novel 32-kDa protein expressed in skeletal muscle and located in the Z-disc of the sarcomere. We found that this protein binds to three other Z-disc proteins; therefore, we have-named it FATZ, gamma -filamin/ABP-L, alpha -actinin and telethonin binding protein of the Z-disc. From yeast two-hybrid experiments we are able to show that the SR3-SR4 domains of alpha -actinin 2 are required to bind the COOH-terminal region of the FATZ as does gamma -filamin/ABP-L, Furthermore, by using a glutathione S-transferase overlay assay we find that FATZ also binds telethonin. The level of FATZ protein in muscle cells increases during differentiation, being clearly detectable before the onset of myosin, Although FATZ has no known interaction domains, it would appear to be involved in a complex network of interactions with other Z-band components. On the basis of the information known about its binding partners, we could envisage a central role for FATZ in the: myofibrillogenesis, After screening our muscle expressed sequence tag data base and the public expressed sequence tag data bases, we were able to assemble two other muscle transcripts that show a high level of identity with FATZ in two different domains. Therefore, FATZ may be the first member of a small family of novel muscle proteins.	Univ Padua, CRIBI, Ctr Biotechnol, I-35121 Padua, Italy; Univ Padua, Dipartimento Biol, I-35121 Padua, Italy; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	University of Padua; University of Padua; International Center for Genetic Engineering & Biotechnology (ICGEB)	Lanfranchi, G (corresponding author), Univ Padua, CRIBI, Ctr Biotechnol, Via Ugo Bassi 58B, I-35121 Padua, Italy.	lanfra@eos.bio.unipd.it	Pallavicini, Alberto/J-4158-2012; Kojic, Snezana/AAF-4873-2019; Pallavicini, Alberto/H-9281-2019	Pallavicini, Alberto/0000-0001-7174-4603; Pallavicini, Alberto/0000-0001-7174-4603; VALLE, GIORGIO/0000-0003-4377-5685; Kojic, Snezana/0000-0001-5090-1278	Telethon [1023, B.57] Funding Source: Medline	Telethon(Fondazione Telethon)		Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; BEGGS AH, 1992, J BIOL CHEM, V267, P9281; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; Chan YM, 1998, BIOCHEM BIOPH RES CO, V248, P134, DOI 10.1006/bbrc.1998.8920; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; DIJOVNOVIAECARU.K, 1999, CELL, V98, P537; Faulkner G, 1999, J CELL BIOL, V146, P465, DOI 10.1083/jcb.146.2.465; FLOOD G, 1995, J MOL BIOL, V252, P227, DOI 10.1006/jmbi.1995.0490; Gautel M, 1996, J CELL SCI, V109, P2747; GORLIN JB, 1993, GENOMICS, V17, P496, DOI 10.1006/geno.1993.1354; GREGORIO CC, 1999, CELL BIOL, V11, P8; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Lanfranchi G, 1996, GENOME RES, V6, P35, DOI 10.1101/gr.6.1.35; MAESTRINI E, 1993, HUM MOL GENET, V2, P761, DOI 10.1093/hmg/2.6.761; Mayans O, 1998, NATURE, V395, P863, DOI 10.1038/27603; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; MIMURA N, 1986, J BIOL CHEM, V261, P680; Moreira ES, 2000, NAT GENET, V24, P163, DOI 10.1038/72822; Mues A, 1998, FEBS LETT, V428, P111, DOI 10.1016/S0014-5793(98)00501-8; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Ohtsuka H, 1997, BIOCHEM BIOPH RES CO, V235, P1, DOI 10.1006/bbrc.1997.6534; POLLARD TD, 1981, J CELL BIOL, V91, pS156, DOI 10.1083/jcb.91.3.156s; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Salmikangas P, 1999, HUM MOL GENET, V8, P1329, DOI 10.1093/hmg/8.7.1329; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sorimachi H, 1997, J MOL BIOL, V270, P688, DOI 10.1006/jmbi.1997.1145; Takafuta T, 1998, J BIOL CHEM, V273, P17531, DOI 10.1074/jbc.273.28.17531; Thompson TG, 2000, J CELL BIOL, V148, P115, DOI 10.1083/jcb.148.1.115; Valle G, 1997, FEBS LETT, V415, P163, DOI 10.1016/S0014-5793(97)01108-3; van der Ven PFM, 2000, CELL MOTIL CYTOSKEL, V45, P149, DOI 10.1002/(SICI)1097-0169(200002)45:2<149::AID-CM6>3.0.CO;2-G; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507; Xie ZW, 1998, BIOCHEM BIOPH RES CO, V251, P914, DOI 10.1006/bbrc.1998.9506; Young P, 1998, EMBO J, V17, P1614, DOI 10.1093/emboj/17.6.1614; Zhou Q, 1999, J BIOL CHEM, V274, P19807, DOI 10.1074/jbc.274.28.19807; [No title captured]	42	131	146	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41234	41242		10.1074/jbc.M007493200	http://dx.doi.org/10.1074/jbc.M007493200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10984498	hybrid, Green Published			2022-12-27	WOS:000166114600077
J	Grun, F; Hirose, Y; Kawauchi, S; Ogura, T; Umesono, K				Grun, F; Hirose, Y; Kawauchi, S; Ogura, T; Umesono, K			Aldehyde dehydrogenase 6, a cytosolic retinaldehyde dehydrogenase prominently expressed in sensory neuroepithelia during development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID SYNTHESIS; ABNORMAL-DEVELOPMENT; SYNTHESIZING ENZYME; GENE-EXPRESSION; CHICKEN-EMBRYO; RECEPTORS RARS; VENTRAL RETINA; CLONING; HINDBRAIN; HORMONE	We have isolated the chick and mouse homologs of human aldehyde dehydrogenase 6 (ALDH6) that encode a third cytosolic retinaldehyde-specific aldehyde dehydrogenase, In both chick and mouse embryos, strong expression is observed in the sensory neuroepithelia of the head. In situ hybridization analysis in chick, shows compartmentalized expression primarily in the ventral retina, olfactory epithelium, and otic vesicle; additional sites of expression include the isthmus, Rathke's pouch, posterior spinal cord interneurons, and developing limbs. Recombinant chick ALDH6 has a K-0.5 = 0.26 muM, V-max = 48.4 nmol/min/mg and exhibits strong positive cooperativity (H = 1.9) toward all-trans-retinaldehyde; mouse ALDH6 has similar kinetic parameters. Expression constructs can confer 1000-fold increased sensitivity to retinoic acid receptor-dependent signaling from retinol in transient transfections experiments. The localization of ALDH6 to the developing sensory neuroepithelia of the eye, nose, and ear and discreet sites within the CNS suggests a role for RA signaling during primary neurogenesis at these sites.	Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan; Nara Inst Sci & Technol, Ikoma 6300101, Japan	Kyoto University; University of Tsukuba; Nara Institute of Science & Technology	Grun, F (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, 5207 Biosci 2, Irvine, CA 92697 USA.	fgrun@uci.edu	Grun, Felix/C-8271-2011					Anchan RM, 1997, J COMP NEUROL, V379, P171; BALKAN W, 1992, P NATL ACAD SCI USA, V89, P3347, DOI 10.1073/pnas.89.8.3347; Berggren K, 1999, DEV BIOL, V210, P288, DOI 10.1006/dbio.1999.9286; BLATTER EE, 1992, BIOCHEM J, V282, P353, DOI 10.1042/bj2820353; Blumberg B, 1997, DEVELOPMENT, V124, P373; Burrill JD, 1997, DEVELOPMENT, V124, P4493; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COLBERT MC, 1993, P NATL ACAD SCI USA, V90, P6572, DOI 10.1073/pnas.90.14.6572; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; Dickman ED, 1997, DEVELOPMENT, V124, P3111; Duester G, 1999, ADV EXP MED BIOL, V463, P311; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Frenz DA, 1996, TERATOLOGY, V53, P292; GODBOUT R, 1992, EXP EYE RES, V54, P297, DOI 10.1016/S0014-4835(05)80219-2; Haselbeck RJ, 1999, DEV GENET, V25, P353, DOI 10.1002/(SICI)1520-6408(1999)25:4<353::AID-DVG9>3.0.CO;2-G; HSU LC, 1994, GENOMICS, V24, P333, DOI 10.1006/geno.1994.1624; Hyatt GA, 1996, DEVELOPMENT, V122, P195; Ishii Y, 1997, DEV GROWTH DIFFER, V39, P643; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; Kikonyogo A, 1999, EUR J BIOCHEM, V262, P704, DOI 10.1046/j.1432-1327.1999.00415.x; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; Li HX, 2000, MECH DEVELOP, V95, P283, DOI 10.1016/S0925-4773(00)00352-X; LIRA SA, 1993, MOL ENDOCRINOL, V7, P694, DOI 10.1210/me.7.5.694; LOHNES D, 1994, DEVELOPMENT, V120, P2723; Maden M, 1996, CURR BIOL, V6, P417, DOI 10.1016/S0960-9822(02)00509-2; Maden M, 1998, DEVELOPMENT, V125, P4133; MARSHARMSTRONG N, 1994, P NATL ACAD SCI USA, V91, P7286, DOI 10.1073/pnas.91.15.7286; MCCAFFERY P, 1992, DEVELOPMENT, V115, P371; McCaffery Peter, 1999, Mechanisms of Development, V85, P203; MCCLEAN SW, 1982, CLIN CHEM, V28, P693; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; Mey J, 1997, J NEUROSCI, V17, P7441; Milam AH, 1997, VISUAL NEUROSCI, V14, P601, DOI 10.1017/S0952523800012256; MorrissKay GM, 1996, FASEB J, V10, P961, DOI 10.1096/fasebj.10.9.8801178; Moss JB, 1998, DEV BIOL, V199, P55, DOI 10.1006/dbio.1998.8911; Napoli JL, 2000, PROG NUCLEIC ACID RE, V63, P139, DOI 10.1016/S0079-6603(08)60722-9; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Niederreither K, 1997, MECH DEVELOP, V62, P67, DOI 10.1016/S0925-4773(96)00653-3; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; Penzes P, 1997, GENE, V191, P167, DOI 10.1016/S0378-1119(97)00054-1; Penzes P, 1997, BBA-PROTEIN STRUCT M, V1342, P175, DOI 10.1016/S0167-4838(97)00102-7; Perozich J, 1999, PROTEIN SCI, V8, P137, DOI 10.1110/ps.8.1.137; Pierani A, 1999, CELL, V97, P903, DOI 10.1016/S0092-8674(00)80802-8; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; Sharpe C, 2000, MECH DEVELOP, V91, P69, DOI 10.1016/S0925-4773(99)00273-7; Swindell EC, 1999, DEV BIOL, V216, P282, DOI 10.1006/dbio.1999.9487; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Wagner E, 2000, DEV BIOL, V222, P460, DOI 10.1006/dbio.2000.9719; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; White JC, 2000, DEV BIOL, V220, P263, DOI 10.1006/dbio.2000.9635; WHITESIDES J, 1996, J COMP NEUROL, V53, P292; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202; YOSHIDA A, 1992, ENZYME, V46, P239, DOI 10.1159/000468794; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x	58	104	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41210	41218		10.1074/jbc.M007376200	http://dx.doi.org/10.1074/jbc.M007376200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11013254	hybrid			2022-12-27	WOS:000166114600074
J	Liu, HL; Lo, CR; Jones, BE; Pradhan, Z; Srinivasan, A; Valentino, KL; Stocker, RJ; Czaja, MJ				Liu, HL; Lo, CR; Jones, BE; Pradhan, Z; Srinivasan, A; Valentino, KL; Stocker, RJ; Czaja, MJ			Inhibition of c-Myc expression sensitizes hepatocytes to tumor necrosis factor-induced apoptosis and necrosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LIVER-REGENERATION; FACTOR-ALPHA; GENE-EXPRESSION; RAT HEPATOCYTES; FACTOR RECEPTOR; CELL-DEATH; TNF-ALPHA; ACTIVATION; DIFFERENTIATION	The typical proliferative response of hepatocytes to tumor necrosis factor (TNF) can be converted to a cytotoxic one by transcriptional arrest. Although NF-kappaB activation is critical for hepatocyte resistance to TNF toxicity, the contribution of other TNF-inducible transcription factors remains unknown. To determine the function of c-Myc in hepatocyte sensitivity to TNF, stable transfectants of the rat hepatocyte cell. line RALA255-10G containing sense and antisense c-myc expression vectors were isolated with increased (S-Myc cells) and decreased (AN-Myc cells) c-Myc transcriptional activity. While S-Myc cells proliferated in response to TNF treatment, AN-Myc cells underwent 32% cell death within 6 h. Fluorescent microscopic studies indicated that TNF induced apoptosis and necrosis in AN-Myc cells. Cell death was associated with DNA hypoploidy and poly(ADP-ribose) polymerase cleavage but occurred in the absence of detectable caspase-3, -7, or -8 activation. TNF-induced, AN-Myc cell death was dependent on Fas-associated protein with death domain and partially blocked by caspase inhibitors. AN-Myc cells had decreased levels of NF-kappaB transcriptional activity, but S-Myc cells maintained resistance to TNF despite NF-kappaB inactivation, suggesting that c-Myc and NF-kappaB independently mediate TNF resistance. Thus, in the absence of sufficient c-Myc expression, hepatocytes are sensitized to TNF-induced apoptosis and necrosis, These findings demonstrate that hepatocyte resistance to TNF is regulated by multiple transcriptional activators.	Yeshiva Univ Albert Einstein Coll Med, Liver Res Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; IDUN Pharmaceut Inc, La Jolla, CA 92037 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Czaja, MJ (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Liver Res Ctr, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Stocker, Roland/AAV-4489-2021		NCI NIH HHS [5P30CA13330] Funding Source: Medline; NIDDK NIH HHS [DK44234, DK32972, R01 DK044234] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032972, R01DK044234] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERMAN P, 1992, AM J PHYSIOL, V263, P579; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BLAZKA ME, 1995, TOXICOL APPL PHARM, V133, P43, DOI 10.1006/taap.1995.1125; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Bradham CA, 1998, AM J PHYSIOL-GASTR L, V275, pG387, DOI 10.1152/ajpgi.1998.275.3.G387; CHOU JY, 1983, MOL CELL BIOL, V3, P1013, DOI 10.1128/MCB.3.6.1013; CZAJA MJ, 1991, J CELL PHYSIOL, V147, P434, DOI 10.1002/jcp.1041470308; CZAJA MJ, 1995, GASTROENTEROLOGY, V108, P1849, DOI 10.1016/0016-5085(95)90149-3; Dang CV, 1999, MOL CELL BIOL, V19, P1; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GALANG CK, 1994, ONCOGENE, V9, P2913; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HISHINUMA I, 1990, HEPATOLOGY, V12, P1187, DOI 10.1002/hep.1840120518; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Jones BE, 1999, HEPATOLOGY, V30, P215, DOI 10.1002/hep.510300146; Jones BE, 2000, J BIOL CHEM, V275, P705, DOI 10.1074/jbc.275.1.705; Jones BE, 2000, AM J PHYSIOL-GASTR L, V278, pG693, DOI 10.1152/ajpgi.2000.278.5.G693; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; KULL FC, 1981, CANCER RES, V41, P4885; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MANCHESTER KM, 1993, BIOCHEM J, V290, P185, DOI 10.1042/bj2900185; NINOMIYATSUJI J, 1993, P NATL ACAD SCI USA, V90, P9611, DOI 10.1073/pnas.90.20.9611; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; SCHMIEDEBERG P, 1993, J CELL PHYSIOL, V154, P294, DOI 10.1002/jcp.1041540212; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Soares MP, 1998, J IMMUNOL, V161, P4572; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; Tracey KJ, 1997, CYTOKINES HLTH DIS, P223; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang W, 1999, J IMMUNOL, V162, P314; Wu M, 1996, MOL CELL BIOL, V16, P5015; Xu J, 1996, AM J PHYSIOL-GASTR L, V270, pG60, DOI 10.1152/ajpgi.1996.270.1.G60; Xu Y, 1997, AM J PHYSIOL-GASTR L, V273, pG795, DOI 10.1152/ajpgi.1997.273.4.G795; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441	49	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40155	40162		10.1074/jbc.M001565200	http://dx.doi.org/10.1074/jbc.M001565200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11016920	hybrid			2022-12-27	WOS:000166039500050
J	Yu, R; Chen, C; Mo, YY; Hebbar, V; Owuor, ED; Tann, TH; Kong, ANT				Yu, R; Chen, C; Mo, YY; Hebbar, V; Owuor, ED; Tann, TH; Kong, ANT			Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; YA SUBUNIT GENE; TRANSCRIPTION FACTOR NRF2; BETA SIGNAL-TRANSDUCTION; MAP KINASE; PHENOLIC ANTIOXIDANTS; OXIDOREDUCTASE GENE; CELL-DEATH; INDUCTION; JUN	Antioxidant response element (ARE) regulates the induction of a number of cellular antioxidant and detoxifying enzymes. However, the signaling pathways that lead to ARE activation remain unknown. Here, we report that the expression of mitogen-activated protein (MAP) kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1), transforming growth factor-beta -activated kinase (TAK1), and apoptosis signal-regulating kinase (ASK1) in HepG2 cells activated the ARE reporter gene, whereas the expression of their dominant-negative mutants impaired ARE activation by the chemicals sodium arsenite and mercury chloride. Coexpression of downstream kinases, MAP kinase kinase 4, MAP kinase kinase 6, and c-Jun NH(2)-terminal kinase-1, but not MAP kinase kinase 3 and p38, augmented ARE activation by MEKK1, TAK1, and ASK1. The coexpression of a basic leucine zipper transcription factor Nrf2 but not c-Jun also greatly enhanced the activation of reporter gene by MEKK1, TAK1, and ASK1; however, a dominant-negative mutant of Nrf2 (NF-ES-related factor 2) blocked this event. Furthermore, when overexpressed, MEKK1, TAK1, and ASK1 induced the expression of heme oxygenase-l, a gene regulated by ARE, and the cotransfection with the dominant-negative mutant of Nrf2 abolished the induction. Taken together, these results suggest that MAP kinase pathways that are activated by MEKK1, TAK1, and ASK1 may link chemical signals to Nrf2, leading to the activation of ARE-dependent genes.	Univ Illinois, Coll Pharm, Dept Pharmaceut & Pharmacodynam, Chicago, IL 60612 USA; Univ Illinois, Coll Pharm, Ctr Pharmaceut Biotechnol, Chicago, IL 60612 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Baylor College of Medicine	Kong, ANT (corresponding author), Univ Illinois, Coll Pharm, Ctr Pharmaceut Biotechnol, Dept Pharmaceut & Pharmacodynam, MC870,900 S Ashland Ave,MBRB Rm 3102, Chicago, IL 60607 USA.	KongT@uic.edu	Mo, Yin-Yuan/R-8255-2019; Mo, Yin-Yuan/B-6141-2011; Chen, Chi/AAF-5343-2020; Tan, Tse-Hua/E-3983-2010; Tan, Tse-Hua/ABD-7080-2021; Kong, Ah-Ng Tony/AAX-2828-2020	Chen, Chi/0000-0001-9703-604X; Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; 	NCI NIH HHS [R01CA73647] Funding Source: Medline; NIAID NIH HHS [R01AI42532, R01AI38649] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649, R01AI042532] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hayes JD, 1999, BIOCHEM SOC SYMP, P141; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; JAISWAL AK, 1994, PHARMACOGENETICS, V4, P1, DOI 10.1097/00008571-199402000-00001; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; PEZZUTO JM, 1995, RECENT ADV PHYTOCHEM, V29, P19; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; WANG B, 1994, BBA-GENE STRUCT EXPR, V1219, P645, DOI 10.1016/0167-4781(94)90223-2; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; WATTENBERG LW, 1972, JNCI-J NATL CANCER I, V48, P1425; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545; Yu R, 2000, J BIOL CHEM, V275, P9612, DOI 10.1074/jbc.275.13.9612; Yu R, 2000, J BIOL CHEM, V275, P2322, DOI 10.1074/jbc.275.4.2322	40	299	304	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39907	39913		10.1074/jbc.M004037200	http://dx.doi.org/10.1074/jbc.M004037200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10986282	hybrid			2022-12-27	WOS:000166039500018
J	Du, BH; Fu, CZ; Kent, KC; Bush, H; Schulick, AH; Kreiger, K; Collins, T; McCaffrey, TA				Du, BH; Fu, CZ; Kent, KC; Bush, H; Schulick, AH; Kreiger, K; Collins, T; McCaffrey, TA			Elevated Egr-1 in human atherosclerotic cells transcriptionally represses the transforming growth factor-beta type II receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; TGF-BETA; GENE-EXPRESSION; REGULATORY ELEMENT; IN-VITRO; PROMOTER; SP1; INDUCTION; BINDING; GROWTH-FACTOR-BETA-1	Atherosclerotic lesions may progress due to a "failure to die" by vascular repair cells. Egr-1, a zinc finger transcription factor, is elevated more than 5-fold in human carotid lesions relative to the adjacent tunica media. Lesion cells in vitro also express 2-3-fold higher Egr-1 mRNA and protein levels but express much lower levels of the transforming growth factor-beta (TGF-beta) Type II receptor (T betaR-2) and are functionally resistant to the antiproliferative effects of TGF-beta. Lesion cells fail to express a T betaR-2 promoter/chloramphenicol acetyltransferase (CAT) construct but overexpress an Egr-1-inducible platelet-derived growth factor-A promoter/CAT construct. Transfection of Egr-1 cDNA represses T betaR-2/CAT constructs but induces PDGF-A/CAT, Egr-1 transfection reduces the levels of T betaR-2 and confers resistance to the antiproliferative effect of TGF-beta1, Egr-1 can interact directly with both the -143 Spl site and the positive regulatory element 2 (PRE2) (ERT/ets) region of the T betaR-2 promoter. Thus, although activating a family of stress-responsive genes, Egr-1 also transcriptionally represses one of the major inhibitory pathways that restrains vascular repair.	Cornell Univ, Weill Med Coll, Dept Med, Div Hematol Oncol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Surg, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Div Vasc Surg, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Cardiothorac Surg, New York, NY 10021 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Cornell University; Cornell University; Cornell University; Cornell University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	McCaffrey, TA (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Hematol Oncol, 1300 York Ave,C-608, New York, NY 10021 USA.	tamccaf@med.cornell.edu			NHLBI NIH HHS [HL56987, HL56985] Funding Source: Medline; NIA NIH HHS [AG12712] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056987, P50HL056985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012712, R37AG012712] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; Aicher WK, 1999, RHEUMATOL INT, V18, P207, DOI 10.1007/s002960050086; Akuzawa N, 2000, ARTERIOSCL THROM VAS, V20, P377, DOI 10.1161/01.ATV.20.2.377; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; Bobik A, 1999, CIRCULATION, V99, P2883, DOI 10.1161/01.CIR.99.22.2883; Bray PJ, 1999, ARTERIOSCL THROM VAS, V19, P1180, DOI 10.1161/01.ATV.19.5.1180; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; Cui MZ, 1999, J BIOL CHEM, V274, P32795, DOI 10.1074/jbc.274.46.32795; Day FL, 1999, J BIOL CHEM, V274, P23726, DOI 10.1074/jbc.274.34.23726; Dinkel A, 1997, J IMMUNOL, V159, P2678; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GRAINGER DJ, 1995, NAT MED, V1, P74, DOI 10.1038/nm0195-74; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hougaard S, 1999, BRIT J CANCER, V79, P1005, DOI 10.1038/sj.bjc.6690161; Houston P, 1999, ARTERIOSCL THROM VAS, V19, P281, DOI 10.1161/01.ATV.19.2.281; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; KIM SJ, 1994, J BIOL CHEM, V269, P3739; KIM SK, 1995, J PHARMACOL EXP THER, V273, P509; Li-Weber M, 1999, EUR J IMMUNOL, V29, P3017, DOI 10.1002/(SICI)1521-4141(199909)29:09<3017::AID-IMMU3017>3.0.CO;2-R; Liu CT, 2000, J BIOL CHEM, V275, P20315, DOI 10.1074/jbc.M909046199; Maltzman JS, 1996, J EXP MED, V183, P1747, DOI 10.1084/jem.183.4.1747; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; McCaffrey TA, 2000, CYTOKINE GROWTH F R, V11, P103, DOI 10.1016/S1359-6101(99)00034-9; McCaffrey TA, 1995, J CLIN INVEST, V96, P2667, DOI 10.1172/JCI118333; McCaffrey TA, 1999, J MOL CELL CARDIOL, V31, P1627, DOI 10.1006/jmcc.1999.0999; McCaffrey TA, 1997, J CLIN INVEST, V100, P2182, DOI 10.1172/JCI119754; MCCAFFREY TA, 1993, MOL BIOL CELL, V4, P315, DOI 10.1091/mbc.4.3.315; McCaffrey TA, 2000, J CLIN INVEST, V105, P653, DOI 10.1172/JCI8592; McKay S, 1998, AM J RESP CELL MOL, V18, P823, DOI 10.1165/ajrcmb.18.6.2924; Minc E, 1999, J BIOL CHEM, V274, P503, DOI 10.1074/jbc.274.1.503; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; Rembold C, 1996, PERSPECT BIOL MED, V39, P405; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Santiago FS, 1999, NAT MED, V5, P1264, DOI 10.1038/15215; Santiago FS, 1999, AM J PATHOL, V155, P897, DOI 10.1016/S0002-9440(10)65189-9; Sato K, 1999, MOL BRAIN RES, V74, P182, DOI 10.1016/S0169-328X(99)00279-X; SCHMITTGRAFF A, 1994, VIRCHOWS ARCH, V425, P3, DOI 10.1007/BF00193944; SHIMIZU N, 1992, J BIOCHEM-TOKYO, V111, P272, DOI 10.1093/oxfordjournals.jbchem.a123748; Silverman ES, 1998, AM J RESP CELL MOL, V19, P316, DOI 10.1165/ajrcmb.19.2.3154; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; Thottassery JV, 1999, J BIOL CHEM, V274, P3199, DOI 10.1074/jbc.274.5.3199; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; Yan YX, 1997, J BIOL CHEM, V272, P33181, DOI 10.1074/jbc.272.52.33181; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795	53	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39039	39047		10.1074/jbc.M005159200	http://dx.doi.org/10.1074/jbc.M005159200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10982796	hybrid			2022-12-27	WOS:000165953100015
J	Fraaije, MW; van den Heuvel, RHH; van Berkel, WJH; Mattevi, A				Fraaije, MW; van den Heuvel, RHH; van Berkel, WJH; Mattevi, A			Structural analysis of flavinylation in vanillyl-alcohol oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-HYDROXYBENZOATE HYDROXYLASE; L-ASPARTATE OXIDASE; OXIDOREDUCTASE FAMILY; CRYSTAL-STRUCTURES; PROTEIN MODELS; ACTIVE-SITE; BINDING; FLAVOPROTEIN; FAD; REFINEMENT	Vanillyl-alcohol oxidase (VAO) is member of a newly recognized flavoprotein family of structurally related oxidoreductases. The enzyme contains a covalently linked FAD cofactor. To study the mechanism of flavinylation we have created a design point mutation (His-61 --> Thr). In the mutant enzyme the covalent His-C8 alpha -flavin linkage is not formed, while the enzyme is still able to bind FAD and perform catalysis. The H61T mutant displays a similar affinity for FAD and ADP (K-d = 1.8 and 2.1 muM, respectively) but does not interact with FMN. H61T is about 10-fold less active with 4-(methoxymethyl)phenol) (k(cat) = 0.24 s(-1), K-m = 40 muM) than the wild-type enzyme. The crystal structures of both the hole and apo form of H61T are highly similar to the structure of wild-type VAO, indicating that binding of FAD to the apoprotein does not require major structural rearrangements. These results show that covalent flavinylation is an autocatalytical process in which His-BI plays a crucial role by activating His-422. Furthermore, our studies clearly demonstrate that in VAO, the FAD binds via a typical lock-and-key approach to a preorganized binding site.	Univ Wageningen & Res Ctr, Biochem Lab, Dept Biomol Sci, NL-6703 HA Wageningen, Netherlands; Univ Pavia, Dept Genet & Microbiol, I-27100 Pavia, Italy	Wageningen University & Research; University of Pavia	Fraaije, MW (corresponding author), Univ Groningen, Biochem Lab, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Fraaije, Marco/E-8421-2014; mattevi, andrea/K-5464-2012; Mattevi, Andrea/R-4469-2019; van Berkel, Willem J.H./O-2431-2014	mattevi, andrea/0000-0002-9523-7128; Mattevi, Andrea/0000-0002-9523-7128; van Berkel, Willem J.H./0000-0002-6551-2782; Fraaije, Marco/0000-0001-6346-5014				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; *DINO, 1999, VIS STRUCT BIOL; Dobbek H, 1999, P NATL ACAD SCI USA, V96, P8884, DOI 10.1073/pnas.96.16.8884; Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9; Fraaije MW, 1999, J BIOL CHEM, V274, P35514, DOI 10.1074/jbc.274.50.35514; Fraaije MW, 1997, J BIOL CHEM, V272, P18111, DOI 10.1074/jbc.272.29.18111; Fraaije MW, 1998, TRENDS BIOCHEM SCI, V23, P206, DOI 10.1016/S0968-0004(98)01210-9; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; Guenther BD, 1999, NAT STRUCT BIOL, V6, P359, DOI 10.1038/7594; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Mattevi A, 1997, STRUCTURE, V5, P907, DOI 10.1016/S0969-2126(97)00245-1; Mattevi A, 1997, PROTEINS, V27, P601, DOI 10.1002/(SICI)1097-0134(199704)27:4<601::AID-PROT12>3.0.CO;2-O; Mattevi A, 1999, STRUCTURE, V7, P745, DOI 10.1016/S0969-2126(99)80099-9; Mewies M, 1998, PROTEIN SCI, V7, P7, DOI 10.1002/pro.5560070102; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; MULLER F, 1982, EUR J BIOCHEM, V128, P21; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; SANDALOVA T, 1993, FEBS LETT, V327, P361, DOI 10.1016/0014-5793(93)81021-Q; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; SATO K, 1992, J BIOCHEM-TOKYO, V112, P804, DOI 10.1093/oxfordjournals.jbchem.a123980; SCHREUDER HA, 1994, BIOCHEMISTRY-US, V33, P10161, DOI 10.1021/bi00199a044; Steensma E, 1998, J MOL BIOL, V282, P653, DOI 10.1006/jmbi.1998.2045; Tedeschi G, 1999, EUR J BIOCHEM, V260, P896, DOI 10.1046/j.1432-1327.1999.00234.x; Trickey P, 1999, STRUCTURE, V7, P331, DOI 10.1016/S0969-2126(99)80043-4; Van Berkel WJH, 2000, PROTEIN SCI, V9, P435; VANDERLAAN JM, 1989, BIOCHEMISTRY-US, V28, P7199, DOI 10.1021/bi00444a011	28	52	54	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38654	38658		10.1074/jbc.M004753200	http://dx.doi.org/10.1074/jbc.M004753200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10984479	hybrid, Green Published			2022-12-27	WOS:000165739800070
J	Pandey, A; Fernandez, MM; Steen, H; Blagoev, B; Nielsen, MM; Roche, S; Mann, M; Lodish, HF				Pandey, A; Fernandez, MM; Steen, H; Blagoev, B; Nielsen, MM; Roche, S; Mann, M; Lodish, HF			Identification of a novel immunoreceptor tyrosine-based activation motif-containing molecule, STAM2, by mass spectrometry and its involvement in growth factor and cytokine receptor signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCING ADAPTER MOLECULE; POLYACRYLAMIDE GELS; PROTEINS; KINASE; PEPTIDE; CANCER; DOMAIN; GENE	In an effort to clone novel tyrosine-phosphorylated substrates of the epidermal growth factor receptor, we have initiated an approach coupling affinity purification using anti-phosphotyrosine antibodies to mass spectrometry-based identification, Here, we report the identification of a signaling molecule containing a Src homology 3 domain as well as an immunoreceptor tyrosine-based activation motif (ITAM). This molecule is 55% identical to a previously isolated molecule designated signal transducing adaptor molecule (STAM) that was identified as an interleukin (IL)-2-induced phosphoprotein and is therefore designated STAM2, Tyrosine phosphorylation of STAM2 is induced by growth factors such as epidermal growth factor and platelet-derived growth factor as well as by cytokines like IL-3. Several of the deletion mutants tested except the one containing only the amino-terminal region underwent tyrosine phosphorylation upon growth factor stimulation, implying that STAM2 is phosphorylated on several tyrosine residues, STAM2 is downstream of the Jak family of kinases since coexpression of STAM2 with Jak1 or Jak2 but not an unrelated Tec family kinase, Etk, resulted in its tyrosine phosphorylation, In contrast to epidermal growth factor receptor-induced phosphorylation, this required the ITAM domain since mutants lacking this region did not undergo tyrosine phosphorylation, Finally, overexpression of wild type STAM2 led to an increase in IL-8-mediated induction of c-Myc promoter activation indicating that it potentiates cytokine receptor signaling.	Univ So Denmark, Ctr Expt Bioinformat, Prot Interact Lab, DK-5230 Odense M, Denmark; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Ctr Rech Biochim & Macromol, CNRS UPR 1086, F-34293 Montpellier, France	University of Southern Denmark; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Brigham & Women's Hospital; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Mann, M (corresponding author), Univ So Denmark, Ctr Expt Bioinformat, Prot Interact Lab, DK-5230 Odense M, Denmark.		Pandey, Akhilesh/B-4127-2009; Mann, Matthias/A-3454-2013	Pandey, Akhilesh/0000-0001-9943-6127; Mann, Matthias/0000-0003-1292-4799; Steen, Hanno/0000-0003-0179-6648; roche, serge/0000-0003-3413-3859; Blagoev, Blagoy/0000-0002-3596-0066	NCI NIH HHS [KO1CA75447] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA075447] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Dong ZG, 1999, ANTICANCER RES, V19, P3743; Endo K, 2000, FEBS LETT, V477, P55, DOI 10.1016/S0014-5793(00)01760-9; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; Leonard W.J., 1999, FUNDAMENTAL IMMUNOLO, Vfourth, P741; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Mesilaty-Gross S, 1999, GENE, V231, P173, DOI 10.1016/S0378-1119(99)00053-0; Neubauer G, 1999, ANAL CHEM, V71, P235, DOI 10.1021/ac9804902; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; PANDEY A, 2000, SCI STKE; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; Takeshita T, 1996, BIOCHEM BIOPH RES CO, V225, P1035, DOI 10.1006/bbrc.1996.1290; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vente A, 1999, NAT GENET, V22, P22, DOI 10.1038/8734; Watowich SS, 1996, ANNU REV CELL DEV BI, V12, P91, DOI 10.1146/annurev.cellbio.12.1.91; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Yang WC, 2000, IMMUNITY, V12, P373, DOI 10.1016/S1074-7613(00)80189-2	30	99	108	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38633	38639		10.1074/jbc.M007849200	http://dx.doi.org/10.1074/jbc.M007849200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10993906	hybrid			2022-12-27	WOS:000165739800067
J	Stephenson, K; Yamaguchi, Y; Hoch, JA				Stephenson, K; Yamaguchi, Y; Hoch, JA			The mechanism of action of inhibitors of bacterial two-component signal transduction systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SYSTEMS; BACILLUS-SUBTILIS; SPORULATION; DOMAIN; GENE	Two-component signal transduction systems allow bacteria to sense and respond rapidly to changes in their environment leading to specific gene activation or repression. These two-component systems are integral in the ability of pathogenic bacteria to mount and establish a successful infection within the host and, consequently, have been recognized as targets for new antimicrobial agents. In this paper, we define the site and mechanism of action of several previously identified inhibitors of bacterial two-component systems. We show that the most potent inhibitors target the carboxyl-terminal catalytic domain of the sensor kinase and exert their affect by causing structural alterations of the kinase leading to aggregation. Recognition of this phenomenon has important implications for the development of novel inhibitors of two-component systems and should facilitate the rapid identification and elimination of compounds with nonspecific affects from medicinal chemistry drug discovery programs.	Scripps Res Inst, Dept Mol & Expt Med, Div Cellular Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Hoch, JA (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Cellular Biol, MEM-116,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hoch@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019416, R37GM019416] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19416] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrett J. F., 1995, ANNU REP MED CHEM, P111; Barrett JF, 1998, ANTIMICROB AGENTS CH, V42, P1529, DOI 10.1128/AAC.42.7.1529; Barrett JF, 1998, P NATL ACAD SCI USA, V95, P5317, DOI 10.1073/pnas.95.9.5317; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; Domagala JM, 1998, ADV EXP MED BIOL, V456, P269; Grimshaw CE, 1998, BIOCHEMISTRY-US, V37, P1365, DOI 10.1021/bi971917m; Hilliard JJ, 1995, ADV EXP MED BIOL, V390, P59; Hilliard JJ, 1999, ANTIMICROB AGENTS CH, V43, P1693, DOI 10.1128/AAC.43.7.1693; Hlasta DJ, 1998, BIOORG MED CHEM LETT, V8, P1923, DOI 10.1016/S0960-894X(98)00326-6; Hoch JA, 1995, 2 COMPONENT SIGNAL T; Macielag MJ, 1998, J MED CHEM, V41, P2939, DOI 10.1021/jm9803572; NINFA AJ, 1986, J BACTERIOL, V168, P1002, DOI 10.1128/jb.168.2.1002-1004.1986; Ninfa AJ, 1995, 2 COMPONENT SIGNAL T, P67; ROYCHOUDHURY S, 1993, P NATL ACAD SCI USA, V90, P965, DOI 10.1073/pnas.90.3.965; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sui ZH, 1998, BIOORG MED CHEM LETT, V8, P1929, DOI 10.1016/S0960-894X(98)00325-4; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; Throup JP, 2000, MOL MICROBIOL, V35, P566, DOI 10.1046/j.1365-2958.2000.01725.x; Tomomori C, 1999, NAT STRUCT BIOL, V6, P729; Varughese KI, 1998, MOL CELL, V2, P485, DOI 10.1016/S1097-2765(00)80148-3; Wang L, 1997, GENE DEV, V11, P2569, DOI 10.1101/gad.11.19.2569; Zapf JW, 1996, BIOCHEMISTRY-US, V35, P2926, DOI 10.1021/bi9519361	23	79	93	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38900	38904		10.1074/jbc.M006633200	http://dx.doi.org/10.1074/jbc.M006633200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10978341	hybrid			2022-12-27	WOS:000165739800103
J	Hefner, Y; Borsch-Haubold, AG; Murakami, M; Wilde, JI; Pasquet, S; Schieltz, D; Ghomashchi, F; Yates, JR; Armstrong, CG; Paterson, A; Cohen, P; Fukunaga, R; Hunter, T; Kudo, I; Watson, SP; Gelb, MH				Hefner, Y; Borsch-Haubold, AG; Murakami, M; Wilde, JI; Pasquet, S; Schieltz, D; Ghomashchi, F; Yates, JR; Armstrong, CG; Paterson, A; Cohen, P; Fukunaga, R; Hunter, T; Kudo, I; Watson, SP; Gelb, MH			Serine 727 phosphorylation and activation of cytosolic phospholipase A(2) by MNK1-related protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELAXATION MAGNETIC-RESONANCE; STIMULATED HUMAN PLATELETS; MAP KINASE; ARACHIDONIC-ACID; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURE; NUCLEAR-ENVELOPE; BINDING DOMAIN; IN-VIVO; STRESS	We have previously reported that in thrombin-stimulated human platelets, cytosolic phospholipase A, (cPLA2) is phosphorylated on Ser-505 by p38 protein kinase and on Ser-727 by an unknown kinase. Pharmacological inhibition of p38 leads to inhibition of cPLA2 phosphorylation at both Ser-505 and Ser-727 suggesting that the kinase responsible for phosphorylation on Ser727 is activated in a p38-dependent pathway. By using Chinese hamster ovary, HeLa, and HEK293 cells stably transfected with wild type and phosphorylation site mutant forms of cPLA2, we show that phosphorylation of cPLA2 at both Ser-505 and Ser-727 and elevation of Ca2+ leads to its activation in agonist-stimulated cells. The p38-activated protein kinases MNK1, MSK1, and PRAK1 phosphorylate cPLA2 in vitro uniquely on Ser-727 as shown by mass spectrometry. Furthermore, MNK1 and PRAK1, but not MSK1, is present in platelets and undergo modest activation in response to thrombin. Expression of a dominant negative form of MNK1 in HFK293 cells leads to significant inhibition of cPLA2-mediated arachidonate release. The results suggest that MNK1 or a closely related kinase is responsible for in vivo phosphorylation of cPLA2 on Ser-727.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 142, Japan; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Univ Dundee, Dept Biochem, Div Signal Transduct, Dundee DD1 5EH, Scotland; Osaka Univ, Sch Med, Dept Genet, Suita, Osaka 565, Japan; Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Oxford; Showa University; University of Washington; University of Washington Seattle; University of Dundee; Osaka University; Salk Institute	Gelb, MH (corresponding author), Univ Washington, Dept Chem, Seattle, WA 98195 USA.		Watson, Stephen P/Q-6292-2016; Fukunaga, Rikiro/CAG-2891-2022	Watson, Stephen P/0000-0002-7846-7423; gelb, michael/0000-0001-7000-5219	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050040] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50040] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ball A, 1999, P NATL ACAD SCI USA, V96, P6637, DOI 10.1073/pnas.96.12.6637; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; Borsch-Haubold AG, 1999, EUR J BIOCHEM, V265, P195, DOI 10.1046/j.1432-1327.1999.00722.x; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; BorschHaubold AG, 1996, BIOCHEM J, V318, P207; BorschHaubold AG, 1997, EUR J BIOCHEM, V245, P751, DOI 10.1111/j.1432-1033.1997.t01-1-00751.x; BORSCHHAUBOLD AG, 1995, J BIOL CHEM, V270, P25855; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Flati V, 1996, EMBO J, V15, P1566, DOI 10.1002/j.1460-2075.1996.tb00501.x; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gatlin CL, 1998, ANAL BIOCHEM, V263, P93, DOI 10.1006/abio.1998.2809; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lin Y, 1998, SCIENCE, V279, P1925, DOI 10.1126/science.279.5358.1925; LUDWIG S, 1998, MOL CELL BIOL, V12, P6687; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SHARP JD, 1991, J BIOL CHEM, V266, P14850; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; YATES I, 1994, CELL BIOL LAB HDB, P380	41	186	189	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37542	37551		10.1074/jbc.M003395200	http://dx.doi.org/10.1074/jbc.M003395200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978317	hybrid			2022-12-27	WOS:000165618700034
J	Rangasamy, D; Woytek, K; Khan, SA; Wilson, VG				Rangasamy, D; Woytek, K; Khan, SA; Wilson, VG			SUMO-1 modification of bovine papillomavirus E1 protein is required for intranuclear accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; DNA-POLYMERASE-ALPHA; REPLICATION PROTEIN; E2 PROTEINS; PML; IDENTIFICATION; ACTIVATION; ORIGIN; LOCALIZATION; CONJUGATION	The El protein is a multifunctional, origin-binding helicase that is essential for replication of papillomaviruses. Recently, bovine papillomavirus El was shown to be post-translationally modified by the addition of the SUMO-1 polypeptide, Here we show that the site of sumoylation maps to lysine residue 514. This lysine and the flanking sequences are well conserved in human papillomavirus (HPV) El proteins. Both HPV1a and HPV18 El proteins are substrates for sumoylation in vitro, which is consistent with this modification being a general property of El proteins. Mutations, which impair the sumoylation of bovine papillomavirus El, prevent normal nuclear accumulation of El with a concomitant loss of replication capacity. These results suggest that sumoylation plays a role in nuclear transport and could regulate the El replication function by controlling access to the nuclear replication domains.	Texas A&M Univ, Coll Med, Dept Med Microbiol, Syst Hlth Sci Ctr, College Stn, TX 77843 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wilson, VG (corresponding author), Texas A&M Univ, Coll Med, Dept Med Microbiol, Syst Hlth Sci Ctr, College Stn, TX 77843 USA.	v-wilson@tamu.edu	, Van G Wilson/B-1868-2009					Boddy MN, 1996, ONCOGENE, V13, P971; BONNEANDREA C, 1995, J VIROL, V69, P2341, DOI 10.1128/JVI.69.4.2341-2350.1995; BONNEANDREA C, 1995, J VIROL, V69, P3201, DOI 10.1128/JVI.69.5.3201-3205.1995; Day PM, 1998, J VIROL, V72, P142, DOI 10.1128/JVI.72.1.142-150.1998; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Gonzalez A, 2000, J VIROL, V74, P245, DOI 10.1128/JVI.74.1.245-253.2000; GOPALAKRISHNAN V, 1994, P NATL ACAD SCI USA, V91, P9597, DOI 10.1073/pnas.91.20.9597; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Han YF, 1999, J VIROL, V73, P4899, DOI 10.1128/JVI.73.6.4899-4907.1999; HOLT SE, 1995, J VIROL, V69, P6525, DOI 10.1128/JVI.69.10.6525-6532.1995; Howley Peter M., 1996, P947; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Kawabe Y, 2000, J BIOL CHEM, V275, P20963, DOI 10.1074/jbc.C000273200; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; LENTZ MR, 1993, J VIROL, V67, P1414, DOI 10.1128/JVI.67.3.1414-1423.1993; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELENDY T, 1995, J VIROL, V69, P7857, DOI 10.1128/JVI.69.12.7857-7867.1995; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; PARK P, 1994, P NATL ACAD SCI USA, V91, P8700, DOI 10.1073/pnas.91.18.8700; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sanders CM, 1998, EMBO J, V17, P7044, DOI 10.1093/emboj/17.23.7044; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SVERDRUP F, 1994, J VIROL, V68, P505, DOI 10.1128/JVI.68.1.505-509.1994; Swindle CS, 1998, J VIROL, V72, P1994, DOI 10.1128/JVI.72.3.1994-2001.1998; Swindle CS, 1999, J VIROL, V73, P1001, DOI 10.1128/JVI.73.2.1001-1009.1999; USTAV M, 1991, EMBO J, V10, P4321, DOI 10.1002/j.1460-2075.1991.tb05010.x; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; WILSON VG, 1992, BIOCHIM BIOPHYS ACTA, V1129, P215, DOI 10.1016/0167-4781(92)90490-Q; WILSON VG, 1991, J VIROL, V65, P5314, DOI 10.1128/JVI.65.10.5314-5322.1991; XIAO XL, 1994, J GEN VIROL, V75, P2463, DOI 10.1099/0022-1317-75-9-2463; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; Yasugi T, 1997, J VIROL, V71, P891, DOI 10.1128/JVI.71.2.891-899.1997; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	39	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37999	38004		10.1074/jbc.M007777200	http://dx.doi.org/10.1074/jbc.M007777200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	11005821	hybrid			2022-12-27	WOS:000165618700093
J	Titus, SA; Moran, RG				Titus, SA; Moran, RG			Retrovirally mediated complementation of the glyB phenotype - Cloning of a human gene encoding the carrier for entry of folates into mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMATE SYNTHETASE; ONE-CARBON METABOLISM; RAT-LIVER MITOCHONDRIA; ADP ATP CARRIER; BROWN FAT MITOCHONDRIA; SERINE HYDROXYMETHYLTRANSFERASE; STRUCTURAL RELATIONSHIP; THIAMINE TRANSPORTER; UNCOUPLING PROTEIN; HIGH-TITER	The transduction of a human placental cDNA retroviral library into glyB cells, a Chinese hamster ovary RI subline that is deficient in the transport of folates into mitochondria, resulted in the complementation of glycine auxotrophy of these cells. A 2.6-kilobase pair cDNA insert flanked by retroviral sequences had integrated into genomic DNA in rescued cells. An open reading frame in this cDNA encoded a 35-kDa protein homologous to several inner mitochondrial wall transporters for intermediate metabolites. The subcloned cDNA complemented the glycine auxotrophy of glyB cells and reinstated folate accumulation in the mitochondria of transfected cells, The human origin, chromosomal location, and intron-exon organization of the isolated mitochondrial folate transporter gene were deduced from the expressed sequence tag database and human genome project data.	Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Moran, RG (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, 1101 E Marshall St,Box 980230, Richmond, VA 23298 USA.	rmoran@hsc.vcu.edu			NCI NIH HHS [CA-27605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027605] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; AQUILA H, 1982, H-S Z PHYSIOL CHEM, V363, P345; AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BRIGLE KE, 1994, BIOCHEM PHARMACOL, V47, P337, DOI 10.1016/0006-2952(94)90025-6; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; CHASIN LA, 1974, P NATL ACAD SCI USA, V71, P718, DOI 10.1073/pnas.71.3.718; Chen L, 1996, J BIOL CHEM, V271, P13077, DOI 10.1074/jbc.271.22.13077; COOK RJ, 1979, BIOCHEM J, V178, P651, DOI 10.1042/bj1780651; CYBULSKI RL, 1981, BIOCHIM BIOPHYS ACTA, V646, P329, DOI 10.1016/0005-2736(81)90339-4; Diaz GA, 1999, NAT GENET, V22, P309, DOI 10.1038/10385; DIXON KH, 1994, J BIOL CHEM, V269, P17; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; Fleming JC, 1999, NAT GENET, V22, P305, DOI 10.1038/10379; FREEMANTLE SJ, 1995, J BIOL CHEM, V270, P9579, DOI 10.1074/jbc.270.16.9579; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENDERSON GB, 1990, CANCER RES, V50, P1709; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HORNE DW, 1992, J NUTR, V122, P2204, DOI 10.1093/jn/122.11.2204; JONES C, 1981, SOMAT CELL GENET, V7, P399, DOI 10.1007/BF01542985; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAO FT, 1984, CYTOGENET CELL GENET, V37, P504; KAO FT, 1975, GENETICS, V79, P343; KAO FT, 1969, P NATL ACAD SCI USA, V64, P1284, DOI 10.1073/pnas.64.4.1284; Kastanos EK, 1997, BIOCHEMISTRY-US, V36, P14956, DOI 10.1021/bi971610n; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUAN J, 1993, CRIT REV BIOCHEM MOL, V28, P209, DOI 10.3109/10409239309086795; LIN BF, 1993, J BIOL CHEM, V268, P21674; Nelson DR, 1998, J MOL BIOL, V277, P285, DOI 10.1006/jmbi.1997.1594; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Qi H, 1999, ADV ENZYME REGUL, V39, P263, DOI 10.1016/S0065-2571(98)00023-5; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; Scharfe C, 2000, NUCLEIC ACIDS RES, V28, P155, DOI 10.1093/nar/28.1.155; SCHIRCH L, 1980, J BIOL CHEM, V255, P7801; SHANE B, 1989, VITAM HORM, V45, P263; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; TAYLOR RT, 1982, ARCH BIOCHEM BIOPHYS, V217, P609, DOI 10.1016/0003-9861(82)90543-4; Turner FB, 1999, CANCER RES, V59, P6074; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG FK, 1967, BIOCHEM Z, V346, P458	48	102	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36811	36817		10.1074/jbc.M005163200	http://dx.doi.org/10.1074/jbc.M005163200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10978331	Green Submitted, hybrid			2022-12-27	WOS:000165577700053
J	Chen, Z; Otto, JC; Bergo, MO; Young, SG; Casey, PJ				Chen, Z; Otto, JC; Bergo, MO; Young, SG; Casey, PJ			The C-terminal polylysine region and methylation of K-Ras are critical for the interaction between K-Ras and microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL METHYLTRANSFERASE; ACTIVATE RAF-1; GAMMA-SUBUNIT; CAAX MOTIF; A-FACTOR; PROTEIN; GENE; APOPTOSIS; FARNESYL; P21RAS	After synthesis in the cytosol, Res proteins must be targeted to the inner leaflet of the plasma membrane for biological activity. This targeting requires a series of C-terminal posttranslational modifications initiated by the addition of an isoprenoid lipid in a process termed prenylation. A search for factors involved in the intracellular trafficking of Res has identified a specific and prenylation-dependent interaction between tubulin/microtubules and K-Ras, In this study, we examined the structural requirements for this interaction between K-Ras and microtubules. By using a series of chimeras in which regions of the C terminus of K-Ras were replaced with those of Ha-Ras and vice versa, we found that the polylysine region of K-Ras located immediately upstream of the prenylation site is required for binding of K-Ras to microtubules. Studies in intact cells confirmed the importance of the K-Ras polylysine region for microtubule binding, as deletion or replacement of this region resulted in loss of paclitaxel-induced mislocalization of a fluorescent K-Ras fusion protein. The additional modifications in the prenyl protein processing pathway also affected the interaction of K-Ras with microtubules. Removal of the three C-terminal amino acids of farnesylated K-Ras with the specific endoprotease Rce1p abolished its binding to microtubules. Interestingly, however, methylation of the C-terminal prenylcysteine restored binding. Consistent with these results, localization of the fluorescent K-Ras fusion protein remained paclitaxel-sensitive in cells lacking Reel, whereas no paclitaxel effect was observed in cells lacking the methyltransferase, These studies show that the polylysine region of K-Ras is critical for its interaction with microtubules and provide the first evidence for a functional consequence of Ras C-terminal proteolysis and methylation.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA	Duke University; Duke University; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	casey006@mc.duke.edu		Casey, Patrick/0000-0002-7366-9309; Young, Stephen/0000-0001-7270-3176	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015451] Funding Source: NIH RePORTER; NIA NIH HHS [AG15451] Funding Source: Medline; NIGMS NIH HHS [GM46372] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Ashby MN, 1998, CURR OPIN LIPIDOL, V9, P99, DOI 10.1097/00041433-199804000-00004; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; Blagosklonny MV, 1996, CANCER RES, V56, P1851; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; FISCHER TH, 1994, J BIOL CHEM, V269, P17257; FUKADA Y, 1994, J BIOL CHEM, V269, P5163; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; Moasser MM, 1998, P NATL ACAD SCI USA, V95, P1369, DOI 10.1073/pnas.95.4.1369; Otto JC, 1999, J BIOL CHEM, V274, P8379, DOI 10.1074/jbc.274.13.8379; PARISH CA, 1995, BIOCHEMISTRY-US, V34, P7722, DOI 10.1021/bi00023a019; Rando RR, 1996, BBA-LIPID LIPID MET, V1300, P5, DOI 10.1016/0005-2760(95)00233-2; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Thissen JA, 1996, ANAL BIOCHEM, V243, P80, DOI 10.1006/abio.1996.0484; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; THISSEN JA, 1993, J BIOL CHEM, V268, P13780; TORTI M, 1993, P NATL ACAD SCI USA, V90, P7553, DOI 10.1073/pnas.90.16.7553; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Yu DH, 1996, ONCOGENE, V13, P1359; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	41	73	75	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41251	41257		10.1074/jbc.M006687200	http://dx.doi.org/10.1074/jbc.M006687200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007785	hybrid			2022-12-27	WOS:000166114600079
J	Grimm, C; Maser, E; Mobus, E; Klebe, G; Reuter, K; Ficner, R				Grimm, C; Maser, E; Mobus, E; Klebe, G; Reuter, K; Ficner, R			The crystal structure of 3 alpha-hydroxysteroid dehydrogenase/carbonyl reductase from Comamonas testosteroni shows a novel oligomerization pattern within the short chain dehydrogenase/reductase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA ALCOHOL-DEHYDROGENASE; PROTEIN-STRUCTURE COMPARISONS; LUNG CARBONYL REDUCTASE; 3-ALPHA,20-BETA-HYDROXYSTEROID DEHYDROGENASE; 3-DIMENSIONAL STRUCTURE; COENZYME SPECIFICITY; ANGSTROM RESOLUTION; GENETIC ALGORITHM; CDNA CLONING; MEMBER	The crystal structure of 3 alpha -hydroxysteroid dehydrogenase/carbonyl reductase from Comamonas testosteroni (3 alpha -HSDH) as well as the structure of its binary complex with NAD(+) have been solved at 1.68-Angstrom and com 1.95-Angstrom resolution, respectively. The enzyme is a member of the short chain dehydrogenase/reductase (SDR) family. Accordingly, the active center and the conformation of the bound nucleotide cofactor closely resemble those of other SDRs. The crystal structure reveals one homodimer per asymmetric unit representing the physiologically active unity. Dimerization takes place via an interface essentially built-up by helix alphaG and strand betaG of each subunit. So far this type of intermolecular contact has exclusively been observed in homotetrameric SDRs but never in the structure of a homodimeric SDR. The formation of a tetramer is blocked in 3 alpha -HSDH by the presence of a predominantly alpha -helical subdomain which is missing in all other SDRs of known structure.	Univ Marburg, Inst Molekularbiol & Tumorforsch, D-35037 Marburg, Germany; Univ Marburg, Inst Pharmazeut Chem, D-35032 Marburg, Germany; Univ Marburg, Inst Pharmakol & Toxikol, D-35032 Marburg, Germany	Philipps University Marburg; Philipps University Marburg; Philipps University Marburg	Reuter, K (corresponding author), Univ Marburg, Inst Molekularbiol & Tumorforsch, D-35037 Marburg, Germany.		Maser, Edmund/B-1728-2010	Reuter, Klaus/0000-0003-3673-7971				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Auerbach G, 1997, EMBO J, V16, P7219, DOI 10.1093/emboj/16.24.7219; Benach J, 1998, J MOL BIOL, V282, P383, DOI 10.1006/jmbi.1998.2015; Benach J, 1999, J MOL BIOL, V289, P335, DOI 10.1006/jmbi.1999.2765; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; GHOSH D, 1994, STRUCTURE, V2, P973, DOI 10.1016/S0969-2126(94)00099-9; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; GHOSH D, 1994, STRUCTURE, V2, P629, DOI 10.1016/S0969-2126(00)00064-2; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KROOK M, 1993, FEBS LETT, V322, P139, DOI 10.1016/0014-5793(93)81554-D; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Maser E, 2000, BIOCHEM BIOPH RES CO, V272, P622, DOI 10.1006/bbrc.2000.2813; MAY ACW, 1994, PROTEIN ENG, V7, P475, DOI 10.1093/protein/7.4.475; May ACW, 1995, PROTEIN ENG, V8, P873, DOI 10.1093/protein/8.9.873; Mobus E, 1998, J BIOL CHEM, V273, P30888, DOI 10.1074/jbc.273.47.30888; Mobus E, 1997, J BACTERIOL, V179, P5951; Nakajima K, 1998, P NATL ACAD SCI USA, V95, P4876, DOI 10.1073/pnas.95.9.4876; Nakanishi M, 1997, J BIOL CHEM, V272, P2218, DOI 10.1074/jbc.272.4.2218; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Oppermann UCT, 1996, J STEROID BIOCHEM, V58, P217, DOI 10.1016/0960-0760(96)00021-0; Oppermann UCT, 1996, EUR J BIOCHEM, V241, P744, DOI 10.1111/j.1432-1033.1996.00744.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; Somers WS, 1998, STRUCTURE, V6, P1601, DOI 10.1016/S0969-2126(98)00157-9; Su J, 1998, J BIOL CHEM, V273, P17910, DOI 10.1074/jbc.273.28.17910; TALALAY P, 1952, NATURE, V170, P620, DOI 10.1038/170620a0; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; VARUGHESE KI, 1992, P NATL ACAD SCI USA, V89, P6080, DOI 10.1073/pnas.89.13.6080; WILLEMS A, 1992, PROCARYOTES HDB BIOL, P2583; Winberg JO, 1999, J MOL BIOL, V294, P601, DOI 10.1006/jmbi.1999.3235	35	81	83	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41333	41339		10.1074/jbc.M007559200	http://dx.doi.org/10.1074/jbc.M007559200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007791	hybrid			2022-12-27	WOS:000166114600089
J	Ha, NC; Kim, MS; Lee, WT; Choi, KY; Oh, BH				Ha, NC; Kim, MS; Lee, WT; Choi, KY; Oh, BH			Detection of large pK(alpha) perturbations of an inhibitor and a catalytic group at an enzyme active site, a mechanistic basis for catalytic power of many enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARRIER HYDROGEN-BONDS; DELTA(5)-3-KETOSTEROID ISOMERASE; DELTA-5-3-KETOSTEROID ISOMERASE; CARBON ACIDS; 3-OXO-DELTA(5)-STEROID ISOMERASE; PSEUDOMONAS-TESTOSTERONI; ELECTROPHILIC CATALYSIS; SPECTROSCOPIC EVIDENCE; FRACTIONATION FACTORS; DIRECTED MUTAGENESIS	Delta (5)-3-Ketosteroid isomerase catalyzes cleavage and formation of a C-H bond at a diffusion-controlled limit. By determining the crystal structures of the enzyme in complex with each of three different inhibitors and by nuclear magnetic resonance (NMR) spectroscopic investigation, we evidenced the ionization of a hydroxyl group (pK(a) similar to 16.5) of an inhibitor, which forms a low barrier hydrogen bond (LBHB) with a catalytic residue Tyr(14) (pK(a) similar to 11.5), and the protonation of the catalytic residue Asp(38) With pK(a) of similar to4.5 at pH 6.7 in the interaction with a carboxylate group of an inhibitor. The perturbation of the pK(a) values in both cases arises from the formation of favorable interactions between inhibitors and catalytic residues. The results indicate that the pK(a) difference between catalytic residue and substrate can be significantly:reduced in the active site environment as:a result of the formation of energetically favorable interactions during the course of enzyme reactions. The reduction in the pK(a) difference should facilitate the abstraction of a proton and thereby eliminate a large fraction of activation energy in general acid/base enzyme reactions. The pK(a) perturbation provides a mechanistic ground for the fast reactivity of many enzymes and for the understanding of how some enzymes are able to extract a proton from a C-H group with a pK(a) value as high as similar to 30.	Pohang Univ Sci & Technol, Natl Creat Res Iniat Ctr Biomol Recognit, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, Kyungbuk, South Korea; Yonsei Univ, Dept Biochem, Coll Sci, Seoul 120749, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Yonsei University	Oh, BH (corresponding author), Pohang Univ Sci & Technol, Natl Creat Res Iniat Ctr Biomol Recognit, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea.		Oh, Byung-Ha/C-2061-2011; LEE, WEON TAE/AAQ-9088-2021					Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Cannon WR, 1998, J BIOL CHEM, V273, P26257, DOI 10.1074/jbc.273.41.26257; Cho HS, 1998, BIOCHEMISTRY-US, V37, P8325, DOI 10.1021/bi9801614; Cho HS, 1999, J BIOL CHEM, V274, P32863, DOI 10.1074/jbc.274.46.32863; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; Cleland WW, 1998, J BIOL CHEM, V273, P25529, DOI 10.1074/jbc.273.40.25529; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; GALLO KA, 1993, BIOCHEMISTRY-US, V32, P3991, DOI 10.1021/bi00066a020; GERLT JA, 1991, J AM CHEM SOC, V113, P9667, DOI 10.1021/ja00025a039; GERLT JA, 1993, J AM CHEM SOC, V115, P11552, DOI 10.1021/ja00077a062; GERLT JA, 1992, J AM CHEM SOC, V114, P5928, DOI 10.1021/ja00041a004; HAWKINSON DC, 1994, BIOCHEMISTRY-US, V33, P12172, DOI 10.1021/bi00206a021; HOLMAN CM, 1995, BIOCHEMISTRY-US, V34, P14245, DOI 10.1021/bi00043a032; Hwang KY, 1999, NAT STRUCT BIOL, V6, P422; Kim DH, 2000, BIOCHEMISTRY-US, V39, P4581, DOI 10.1021/bi992119u; KIM SW, 1995, J BACTERIOL, V177, P2602, DOI 10.1128/jb.177.9.2602-2605.1995; Kim SW, 1997, BIOCHEMISTRY-US, V36, P14030, DOI 10.1021/bi971546+; KINTANAR A, 1991, J BIOL CHEM, V266, P17222; LI YK, 1993, BIOCHEMISTRY-US, V32, P1816, DOI 10.1021/bi00058a016; Lin J, 1998, P NATL ACAD SCI USA, V95, P14664, DOI 10.1073/pnas.95.25.14664; LOH SN, 1994, BIOCHEMISTRY-US, V33, P1029, DOI 10.1021/bi00170a023; MAITLAND JJ, 1997, ORGANIC CHEM, P824; MITRA B, 1995, BIOCHEMISTRY-US, V34, P2777, DOI 10.1021/bi00009a006; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; Schiott B, 1998, P NATL ACAD SCI USA, V95, P12799, DOI 10.1073/pnas.95.22.12799; TALALAY P, 1955, BIOCHIM BIOPHYS ACTA, V18, P300, DOI 10.1016/0006-3002(55)90079-2; WALSH C, 1984, ENZYMATIC REACTION M; Wu ZR, 1997, SCIENCE, V276, P415, DOI 10.1126/science.276.5311.415; XUE L, 1991, BIOCHEMISTRY-US, V30, P10858, DOI 10.1021/bi00109a008; XUE L, 1991, BIOCHEMISTRY-US, V30, P4991, DOI 10.1021/bi00234a022; ZHAO QJ, 1995, BIOCHEMISTRY-US, V34, P426, DOI 10.1021/bi00002a006; Zhao QJ, 1996, P NATL ACAD SCI USA, V93, P8220, DOI 10.1073/pnas.93.16.8220; ZHAO QJ, 1995, BIOCHEMISTRY-US, V34, P6562, DOI 10.1021/bi00019a038	34	50	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41100	41106		10.1074/jbc.M007561200	http://dx.doi.org/10.1074/jbc.M007561200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007792	hybrid			2022-12-27	WOS:000166114600060
J	Abdian, PL; Lellouch, AC; Gautier, C; Ielpi, L; Geremia, RA				Abdian, PL; Lellouch, AC; Gautier, C; Ielpi, L; Geremia, RA			Identification of essential amino acids in the bacterial alpha-mannosyltransferase AceA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; XANTHOMONAS-CAMPESTRIS; BETA-GLUCOSYLTRANSFERASE; SEQUENCE SIMILARITIES; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; GLYCOSYLTRANSFERASES; BIOSYNTHESIS; MECHANISM	The alpha -mannosyltransferase AceA from Acetobacter xylinum belongs to the CaZY family 4 of retaining glycosyltransferases. We have identified a series of either highly conserved or invariant residues that are found in all family 4 enzymes as well as other retaining glycosyltransferases. These residues included Glu-287 and Glu-295, which comprise an EX7E motif and have been proposed to be involved in catalysis. Alanine replacements of each conserved residue were constructed by site-directed mutagenesis, The mannosyltransferase activity of each mutant was examined by both an in vitro transferase assay using recombinant mutant AceA expressed in Escherichia coli and by an in vivo rescue assay by expressing the mutant AceA in a Xanthomonas campestris gumH(-) strain. We found that only mutants K211A and E287A lost all detectable activity both in vitro and in vivo, whereas E295A retained residual activity in the more sensitive in vivo assay. H127A and S162A each retained reduced but significant activities both in vitro and in vivo. Secondary structure predictions of AceA and subsequent comparison with the crystal structures of the T4 beta -glucosyltransferase and MurG suggest that AceA Lys-211 and Glu-295 are involved in nucleotide sugar donor binding, leaving Glu-287 of the EX7E as a potential catalytic residue.	Univ Grenoble 1, CNRS, CERMA, Ctr Rech Macromol Vegetales, F-38041 Grenoble 9, France; Fdn Campomar, Inst Invest Bioquim, Fac Ciencias Exactas & Nat, RA-1045 Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, RA-1045 Buenos Aires, DF, Argentina	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Leloir Institute; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Geremia, RA (corresponding author), Univ Grenoble 1, CNRS, CERMA, Ctr Rech Macromol Vegetales, BP 53, F-38041 Grenoble 9, France.	roberto.geremia@cermav.cnrs.fr	Abdian, Patricia/AAW-2420-2020; Geremia, Roberto A/A-7972-2010; Lellouch, Annemarie/E-9905-2014	Abdian, Patricia/0000-0002-8366-8115; 				AMEMURA A, 1986, J GEN MICROBIOL, V132, P2443; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Campbell JA, 1998, BIOCHEM J, V329, P719, DOI 10.1042/bj3290719; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; CAPAGE MA, 1987, Patent No. 8705938; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; Cid E, 2000, J BIOL CHEM, V275, P33614, DOI 10.1074/jbc.M005358200; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; FILISETTICOZZI TMCC, 1991, ANAL BIOCHEM, V197, P157, DOI 10.1016/0003-2697(91)90372-Z; Garinot-Schneider C, 2000, J BIOL CHEM, V275, P31407, DOI 10.1074/jbc.M004524200; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Geremia RA, 1999, MOL GEN GENET, V261, P933, DOI 10.1007/s004380051040; Geremia RA, 1996, BIOCHEM J, V318, P133, DOI 10.1042/bj3180133; Green JA, 1998, METH MOL B, V80, P1; Ha S, 2000, PROTEIN SCI, V9, P1045, DOI 10.1110/ps.9.6.1045; HARDING NE, 1993, J GEN MICROBIOL, V139, P447, DOI 10.1099/00221287-139-3-447; IELPI L, 1993, J BACTERIOL, V175, P2490, DOI 10.1128/JB.175.9.2490-2500.1993; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; Katzen F, 1998, J BACTERIOL, V180, P1607, DOI 10.1128/JB.180.7.1607-1617.1998; LEIGH JA, 1994, TRENDS GENET, V10, P63, DOI 10.1016/0168-9525(94)90151-1; Markwell M A, 1981, Methods Enzymol, V72, P296; Morera S, 1999, J MOL BIOL, V292, P717, DOI 10.1006/jmbi.1999.3094; Nichols DJ, 2000, BIOCHEMISTRY-US, V39, P7820, DOI 10.1021/bi000407g; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Petroni EA, 1996, J BACTERIOL, V178, P4814, DOI 10.1128/jb.178.16.4814-4821.1996; Sambrook J., 2002, MOL CLONING LAB MANU; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Sippl MJ, 1996, FOLD DES, V1, P289, DOI 10.1016/S1359-0278(96)00042-9; TSENG YH, 1992, LETT APPL MICROBIOL, V14, P43, DOI 10.1111/j.1472-765X.1992.tb00643.x; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; WHITFIELD C, 1993, ADV MICROB PHYSIOL, V35, P135, DOI 10.1016/S0065-2911(08)60099-5; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945	33	48	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40568	40575		10.1074/jbc.M007496200	http://dx.doi.org/10.1074/jbc.M007496200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11001941	Green Published, hybrid			2022-12-27	WOS:000166039500103
J	Burmeister, WP; Cottaz, S; Rollin, P; Vasella, A; Henrissat, B				Burmeister, WP; Cottaz, S; Rollin, P; Vasella, A; Henrissat, B			High resolution x-ray crystallography shows that ascorbate is a cofactor for myrosinase and substitutes for the function of the catalytic base	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYL HYDROLASES; GLYCOSIDASE INHIBITORS; CRYSTAL-STRUCTURES; BETA-GLUCOSIDASE; SINAPIS-ALBA; MECHANISM; ACID; COMPARTMENTATION; CLASSIFICATION; INTERMEDIATE	Myrosinase, an S-glycosidase, hydrolyzes plant anionic 1-thio beta -D-glucosides (glucosinolates) considered part of the plant defense system. Although O-glycosidases are ubiquitous, myrosinase is the only known S-glycosidase. Its active site is very similar to that of retaining O-glycosidases, but one of the catalytic residues in O-glycosidases, a carboxylate residue functioning as the general base, is replaced by a glutamine residue. Myrosinase is strongly activated by ascorbic acid. Several binary and ternary complexes of myrosinase with different transition state analogues and ascorbic acid have been analyzed at high resolution by x-ray crystallography along with a 2-deoxy-2-fluoro-glucosyl enzyme intermediate. One of the inhibitors, D-gluconhydroximo-1,5-lactam, binds simultaneously with a sulfate ion to form a mimic of the enzyme-substrate complex, Ascorbate binds to a site distinct from the glucose binding site but overlapping with the aglycon binding site, suggesting that activation occurs at the second step of catalysis, i.e. hydrolysis of the glycosyl enzyme, A water molecule is placed perfectly for activation by ascorbate and for nucleophilic attack on the covalently trapped S-fluoroglucosyl-moiety, Activation of the hydrolysis of the glucosyl enzyme intermediate is further evidenced by the observation that ascorbate enhances the rate of reactivation of the 2-fluoro-glycosyl enzyme, leading to the conclusion that ascorbic acid substitutes for the catalytic base in myrosinase.	European Synchrotron Radiat Facil, F-38043 Grenoble, France; Forschungszentrum Julich, F-38043 Grenoble, France; CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble, France; Univ Orleans, Inst Chim Organ & Analyt, F-45067 Orleans 2, France; ETH Zentrum, Organ Chem Lab, CH-8092 Zurich, Switzerland; CNRS, IFR1, F-13402 Marseille 20, France	European Synchrotron Radiation Facility (ESRF); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Universite de Orleans; Swiss Federal Institutes of Technology Domain; ETH Zurich; Centre National de la Recherche Scientifique (CNRS)	Burmeister, WP (corresponding author), European Mol Biol Lab, BP 156, F-38042 Grenoble, France.		Henrissat, Bernard/J-2475-2012	Henrissat, Bernard/0000-0002-3434-8588; Burmeister, Wim/0000-0003-0876-6118; cottaz, sylvain/0000-0001-8674-0162				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Aucagne V, 2000, TETRAHEDRON, V56, P2647, DOI 10.1016/S0040-4020(00)00153-8; BARRETT T, 1995, STRUCTURE, V3, P951, DOI 10.1016/S0969-2126(01)00229-5; BJORKMAN R, 1973, BIOCHIM BIOPHYS ACTA, V327, P121, DOI 10.1016/0005-2744(73)90109-5; BONES AM, 1996, PHYSIOL PLANTARUM, V97, P1194; BOTTI MG, 1995, J BIOL CHEM, V270, P20530, DOI 10.1074/jbc.270.35.20530; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; Burmeister WP, 1997, STRUCTURE, V5, P663, DOI 10.1016/S0969-2126(97)00221-9; CONCHIE J, 1967, BIOCHEM J, V103, P609, DOI 10.1042/bj1030609; Cottaz S, 1996, BIOCHEMISTRY-US, V35, P15256, DOI 10.1021/bi9622480; Cottaz S, 1997, CARBOHYD RES, V298, P127, DOI 10.1016/S0008-6215(96)00294-7; Cutfield SM, 1999, J MOL BIOL, V294, P771, DOI 10.1006/jmbi.1999.3287; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P11707, DOI 10.1021/bi981315i; Dixon M., 1964, ENZYMES, p[63, 92]; ERMERT P, 1993, CARBOHYD RES, V250, P113, DOI 10.1016/0008-6215(93)84160-8; ERMERT P, 1991, HELV CHIM ACTA, V74, P2043, DOI 10.1002/hlca.19910740839; ETTLINGER MG, 1961, P NATL ACAD SCI USA, V47, P1875, DOI 10.1073/pnas.47.12.1875; FENWICK GR, 1983, CRC CR REV FOOD SCI, V18, P123, DOI 10.1080/10408398209527361; GMELIN R, 1961, ANN ACAD SCI FENN A, V11, P3; GROB K, 1980, Z PFLANZENPHYSIOL, V98, P235, DOI 10.1016/S0044-328X(80)80273-X; Heightman TD, 1999, ANGEW CHEM INT EDIT, V38, P750, DOI 10.1002/(SICI)1521-3773(19990315)38:6<750::AID-ANIE750>3.0.CO;2-6; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HOOS R, 1993, HELV CHIM ACTA, V76, P2666, DOI 10.1002/hlca.19930760723; Iori R, 1996, FEBS LETT, V385, P87, DOI 10.1016/0014-5793(96)00335-3; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISS G, 1966, MITT GEB LEBENSM HYG, V57, P443; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1992, JOINT CCP4 ESF EADBM; LEVVY GA, 1972, ADV ENZYMOL RAMB, V36, P151; MATILE P, 1980, BIOCHEM PHYSIOL PFL, V175, P722, DOI 10.1016/S0015-3796(80)80059-X; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; McCarter JD, 1997, J AM CHEM SOC, V119, P5792, DOI 10.1021/ja9627454; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAGASHIMA Z, 1959, J AGR CHEM SOC JAPAN, V33, P980; OHTSURU M, 1979, BIOCHIM BIOPHYS ACTA, V567, P384, DOI 10.1016/0005-2744(79)90124-4; PALMIERI S, 1982, ANAL BIOCHEM, V123, P320, DOI 10.1016/0003-2697(82)90452-3; Shikita M, 1999, BIOCHEM J, V341, P725, DOI 10.1042/0264-6021:3410725; TSURUO I, 1967, AGR BIOL CHEM TOKYO, V31, P27; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; WILKINSON AP, 1984, ANAL BIOCHEM, V139, P284, DOI 10.1016/0003-2697(84)90004-6; WITHERS SG, 1988, J BIOL CHEM, V263, P7929; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043	45	154	161	1	51	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39385	39393		10.1074/jbc.M006796200	http://dx.doi.org/10.1074/jbc.M006796200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10978344	hybrid			2022-12-27	WOS:000165953100062
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteine-scanning mutagenesis and reaction with dibromobimane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREDICTED TRANSMEMBRANE DOMAIN; STIMULATED ATPASE ACTIVITY; HIV-1 PROTEASE INHIBITORS; BLOOD-BRAIN-BARRIER; FUNCTIONAL CONSEQUENCES; SUBSTRATE-SPECIFICITY; MUTATIONAL ANALYSIS; EXPRESSION SYSTEM; LABELING SITES; TRANSPORTER	P-glycoprotein (P-gp) can transport a wide variety of cytotoxic compounds that have diverse structures. Therefore, the drug-binding domain of the human multidrug resistance P-gp likely consists of residues from multiple transmembrane (TM) segments. In this study, we completed cysteine-scanning mutagenesis of all the predicted TRI segments of P-gp (TMs 1-5 and 7-10) and tested for inhibition by a thiol-reactive substrate (dibromobimane) to identify residues within the drug-binding domain. The activities of 189 mutants were analyzed. Verapamil-stimulated ATPase activities of seven mutants (Y118C and V125C (TM2), S222C (TM4), I306C (TM5), S766C (TM9), and I868C and G872C (TM10)) were inhibited by more than 50% by dibromobimane. The activities of mutants S222C (TM4), I306C (TM5), I868C (TM10), and G872C (TM10), but not that of mutants Y118C (TM2), V125C (TM2), and S776C (TM9), were protected from inhibition by dibromobimane by pretreatment with verapamil, vinblastine, or colchicine. These results and those from previous studies (Loo, T. W, and Clarke, D. M. (1997) J. BioL Chem 272, 31945-31948; Loo, T. W. and Clarke, D. M. (1999) J. Biol Chem 274, 35388-35392) indicate that the drug-binding domain of P-gp consists of residues in TMs 4 5, 6, 10, 11, and 12.	Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Canadian Inst Hlth Res Grp Membrane Biol, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA80900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BALZI E, 1994, J BIOL CHEM, V269, P2206; BEAUDET L, 1995, J BIOL CHEM, V270, P17159, DOI 10.1074/jbc.270.29.17159; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Chen G, 1997, J BIOL CHEM, V272, P5974, DOI 10.1074/jbc.272.9.5974; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; Demmer A, 1997, J BIOL CHEM, V272, P20913, DOI 10.1074/jbc.272.33.20913; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; Egner R, 1998, MOL BIOL CELL, V9, P523, DOI 10.1091/mbc.9.2.523; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; Hanna M, 1996, BIOCHEMISTRY-US, V35, P3625, DOI 10.1021/bi951333p; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; Kwan T, 1998, BIOCHEMISTRY-US, V37, P3337, DOI 10.1021/bi972680x; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, J BIOL CHEM, V269, P7243; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Loo TW, 1998, J BIOL CHEM, V273, P32373, DOI 10.1074/jbc.273.49.32373; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; Loo TW, 1998, METHOD ENZYMOL, V292, P480; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; Pascaud C, 1998, BIOCHEM J, V333, P351, DOI 10.1042/bj3330351; Ramachandra M, 1996, MOL BIOL CELL, V7, P1485, DOI 10.1091/mbc.7.10.1485; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; Robert J, 1999, EUR J CLIN INVEST, V29, P536, DOI 10.1046/j.1365-2362.1999.00495.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schinkel AH, 1997, SEMIN CANCER BIOL, V8, P161, DOI 10.1006/scbi.1997.0068; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Shapiro AB, 1999, EUR J BIOCHEM, V259, P841, DOI 10.1046/j.1432-1327.1999.00098.x; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; Shoshani T, 1998, MOL PHARMACOL, V54, P623; Subramaniam S, 1999, CURR OPIN STRUC BIOL, V9, P462, DOI 10.1016/S0959-440X(99)80065-7; Taguchi Y, 1997, FEBS LETT, V413, P142, DOI 10.1016/S0014-5793(97)00899-5; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6	58	123	124	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39272	39278		10.1074/jbc.M007741200	http://dx.doi.org/10.1074/jbc.M007741200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11013259	hybrid			2022-12-27	WOS:000165953100046
J	Patil, S; Wildey, GM; Brown, TL; Choy, L; Derynck, R; Howe, PH				Patil, S; Wildey, GM; Brown, TL; Choy, L; Derynck, R; Howe, PH			Smad7 is induced by CD40 and protects WEHI 231 B-lymphocytes from transforming growth factor-beta-induced growth inhibition and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TGF-BETA; TRANSCRIPTIONAL ACTIVATION; LYMPHOMA MODELS; CELL ACTIVATION; RECEPTOR; EXPRESSION; ARREST; INDUCTION; TOLERANCE	Transforming growth factor-beta (TGF-beta) is a potent inducer of apoptosis in B-lymphocytes and is essential for immune regulation and maintenance of self-tolerance, Here we show that concomitant signaling through CD40 sustains proliferation and rescues the premature B cell line WEHI 231 from both TGF-beta -induced and anti-IgM-induced apoptosis. The anti-apoptotic effect of CD40 is associated with the transcriptional activation of the inhibitory Smad7 protein. The transactivation of Smad7 by CD40 is NF kappaB-dependent in that pharmacological inhibitors of this pathway, N-tosyl-L-phenylalanine chloromethyl ketone and pyrrolidine dithiocarbamate, abrogate CD40-induced Smad7 expression. Ectopic overexpression of Smad7 inhibited Smad2 activation, TGF-beta -mediated growth inhibition, and apoptosis in WEHI 231 cells. Consistent with this result, dominant negative interference with Smad2 and Smad3 function also inhibited TGF-beta -induced apoptosis. The inhibitory effects of Smad7 overexpression were specific to TGF-beta -induced apoptosis and were without effect on anti-IgM-induced cell death. These results suggest a mechanism of suppression of TGF-beta -induced apoptosis by CD40, mediated through activation of NF-kappaB and, consequently, induction of Smad7 expression.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Univ Calif San Francisco, Dept Growth Dev, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Growth Dev, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Cell Biol Program, San Francisco, CA 94143 USA	Cleveland Clinic Foundation; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Howe, PH (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	howep@ccf.org		Wildey, Gary/0000-0001-7105-1313	NATIONAL CANCER INSTITUTE [R01CA080095] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060231] Funding Source: NIH RePORTER; NCI NIH HHS [CA80095] Funding Source: Medline; NHLBI NIH HHS [P01HL60231] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; An SK, 1996, FEBS LETT, V386, P115, DOI 10.1016/0014-5793(96)00427-9; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; Bitzer M, 2000, GENE DEV, V14, P187; Brodin G, 1999, CANCER RES, V59, P2731; Brown TL, 1999, J BIOL CHEM, V274, P23256, DOI 10.1074/jbc.274.33.23256; Brown TL, 1998, CELL GROWTH DIFFER, V9, P869; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; Coffer PJ, 1998, BIOCHEM J, V335, P1; Craxton A, 2000, CELL IMMUNOL, V200, P56, DOI 10.1006/cimm.2000.1616; Curnock AP, 1998, CELL IMMUNOL, V187, P77, DOI 10.1006/cimm.1998.1335; FRANCIS DA, 1995, INT IMMUNOL, V7, P151, DOI 10.1093/intimm/7.2.151; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; GOTTSCHALK AR, 1995, IMMUNOL CELL BIOL, V73, P8, DOI 10.1038/icb.1995.2; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Ishisaki A, 1998, J BIOL CHEM, V273, P24293, DOI 10.1074/jbc.273.38.24293; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; JOSEPH LF, 1995, CELL GROWTH DIFFER, V6, P51; Kashiwada M, 1996, EUR J IMMUNOL, V26, P1451, DOI 10.1002/eji.1830260708; Kawabata M, 1999, J BIOCHEM, V125, P9, DOI 10.1093/oxfordjournals.jbchem.a022273; Kehry MR, 1996, J IMMUNOL, V156, P2345; Kuss AW, 1999, EUR J IMMUNOL, V29, P3077, DOI 10.1002/(SICI)1521-4141(199910)29:10<3077::AID-IMMU3077>3.0.CO;2-R; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Lebman DA, 1999, MICROBES INFECT, V1, P1297, DOI 10.1016/S1286-4579(99)00254-3; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MERINO R, 1995, J IMMUNOL, V155, P3830; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ozes ON, 1999, NATURE, V401, P82; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; Schauer SL, 1998, J IMMUNOL, V160, P4398; SCOTT DW, 1993, ADV IMMUNOL, V54, P393, DOI 10.1016/S0065-2776(08)60539-8; SCOTT DW, 1986, J EXP MED, V164, P156, DOI 10.1084/jem.164.1.156; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; Sutherland CL, 1996, J IMMUNOL, V157, P3381; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Uzzo RG, 1999, J CLIN INVEST, V104, P769, DOI 10.1172/JCI6775; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; WARNER GL, 1992, CELL GROWTH DIFFER, V3, P175; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wu M, 1998, J EXP MED, V187, P1671, DOI 10.1084/jem.187.10.1671; Wu M, 1996, MOL CELL BIOL, V16, P5015; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	59	72	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38363	38370		10.1074/jbc.M004861200	http://dx.doi.org/10.1074/jbc.M004861200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10995749	hybrid			2022-12-27	WOS:000165739800032
J	Svaren, J; Ehrig, T; Abdulkadir, SA; Ehrengruber, MU; Watson, MK; Milbrandt, J				Svaren, J; Ehrig, T; Abdulkadir, SA; Ehrengruber, MU; Watson, MK; Milbrandt, J			EGR1 target genes in prostate carcinoma cells identified by microarray analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II GENE; POLYMERASE CHAIN-REACTION; TUMOR SUPPRESSOR WT1; GROWTH-FACTOR-A; BECKWITH-WIEDEMANN-SYNDROME; MESSENGER-RIBONUCLEIC-ACID; PROTEIN NGFI-A; IGF-II; TRANSFORMING GROWTH-FACTOR-BETA-1; NEUROENDOCRINE DIFFERENTIATION	The EGR1 transactivator is overexpressed in prostate cancer, and its expression pattern suggests that EGR1 could potentially regulate a number of steps involved in initiation and progression of prostate cancer, such as mitogenesis, invasiveness, angiogenesis, and metastasis. To identify potential EGR1 target genes in an unbiased manner, we have utilized adenovirus-mediated expression of EGR1 in a prostate cancer cell line to identify specific genes that are induced by EGR1. Using oligonucleotide arrays, a number of EGR1-regulated genes were identified and their regulation was confirmed by quantitative reverse transcription-polymerase chain reaction analysis. One of the largest gene classes identified in this screen includes several neuroendocrine-associated genes (neuron-specific enolase, neurogranin), suggesting that EGR1 overexpression may contribute to the neuroendocrine differentiation that often accompanies prostate cancer progression. This screen also identified several growth factors such as insulin-like growth factor-II, platelet-derived growth factor-A, and transforming growth factor-beta1, which have previously been implicated in enhancing tumor progression. The insulin-like growth factor-II gene lies within the 11p15.5 chromosomal locus, which contains a number of other imprinted genes, and EGR1 expression was found to induce at least two other genes in this locus (IPL, p57(KIP2)). Based on our results, coupling adenoviral overexpression with microarray and quantitative reverse transcription-polymerase chain reaction analyses could be a versatile strategy for identifying target genes of transactivators.	Washington Univ, Sch Med, Dept Pathol, Div Lab Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, Div Lab Med, St Louis, MO 63110 USA; Univ Zurich, Inst Brain Res, CH-8057 Zurich, Switzerland	Washington University (WUSTL); Washington University (WUSTL); University of Zurich	Milbrandt, J (corresponding author), Washington Univ, Sch Med, Dept Pathol, Div Lab Med, 660 S Euclid Ave, St Louis, MO 63110 USA.		Svaren, John/A-1605-2010	Svaren, John/0000-0003-2963-7921; Milbrandt, Jeffrey/0000-0002-5477-7689	NCI NIH HHS [5P01CA49712-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrahamsson PA, 1999, PROSTATE, V39, P135, DOI 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S; Bae SK, 1999, CANCER RES, V59, P5989; Barrack ER, 1997, PROSTATE, V31, P61; BATTEGAY EJ, 1995, J MOL MED, V73, P333; Becker A, 1996, ANAL BIOCHEM, V237, P204, DOI 10.1006/abio.1996.0230; BOSTWICK DG, 1997, UROLOGIC SURG PATHOL, P343; Caspary T, 1999, GENE DEV, V13, P3115, DOI 10.1101/gad.13.23.3115; CHRISTOFORI G, 1995, NAT GENET, V10, P196, DOI 10.1038/ng0695-196; Culig Z, 1996, PROSTATE, V28, P392, DOI 10.1002/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAY ML, 1990, J BIOL CHEM, V265, P15253; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DISANTAGNESE PA, 1994, J UROLOGY, V152, P1927, DOI 10.1016/S0022-5347(17)32417-5; Dong GY, 1997, J CLIN ENDOCR METAB, V82, P2198, DOI 10.1210/jc.82.7.2198; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Eggenschwiler J, 1997, GENE DEV, V11, P3128, DOI 10.1101/gad.11.23.3128; Ehrengruber MU, 1998, METHOD ENZYMOL, V293, P483; Eid MA, 1998, CANCER RES, V58, P2461; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; FEINBERG AP, 1999, CANCER RES, V59, P1743; FUDGE K, 1994, MODERN PATHOL, V7, P549; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; Garabedian EM, 1998, P NATL ACAD SCI USA, V95, P15382, DOI 10.1073/pnas.95.26.15382; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Holthuizen PE, 1999, CONT ENDOCRINOL, V17, P37; IKEJIRI K, 1991, BIOCHEM J, V280, P439, DOI 10.1042/bj2800439; Jarrard DF, 1995, CLIN CANCER RES, V1, P1471; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Lee SL, 1996, MOL CELL BIOL, V16, P4566; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Lee YI, 1996, DNA CELL BIOL, V15, P99, DOI 10.1089/dna.1996.15.99; Li SL, 1998, CELL TISSUE RES, V291, P469, DOI 10.1007/s004410051016; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Liu AY, 1997, PROSTATE, V30, P145, DOI 10.1002/(SICI)1097-0045(19970215)30:3<145::AID-PROS1>3.0.CO;2-L; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257; Qu ZC, 1998, J CELL BIOL, V142, P1075, DOI 10.1083/jcb.142.4.1075; Reik W, 1997, TRENDS GENET, V13, P330, DOI 10.1016/S0168-9525(97)01200-6; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Ririe KM, 1997, ANAL BIOCHEM, V245, P154, DOI 10.1006/abio.1996.9916; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; Rotwein P, 1999, CONT ENDOCRINOL, V17, P19; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Santelli G, 1999, AM J PATHOL, V155, P799, DOI 10.1016/S0002-9440(10)65178-4; SCHNEEBERGER C, 1995, PCR METH APPL, V4, P234; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; Sun FL, 1997, NATURE, V389, P809, DOI 10.1038/39797; Svaren J, 1996, MOL CELL BIOL, V16, P3545; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tennant MK, 1996, J CLIN ENDOCR METAB, V81, P3774, DOI 10.1210/jc.81.10.3774; Thigpen AE, 1996, J UROLOGY, V155, P975, DOI 10.1016/S0022-5347(01)66361-4; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; VANDIJK MA, 1991, MOL CELL ENDOCRINOL, V81, P81, DOI 10.1016/0303-7207(91)90207-9; Watanabe H, 1996, CANCER RES, V56, P2960; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01; Xu ZD, 1999, ENDOCRINOLOGY, V140, P2134, DOI 10.1210/en.140.5.2134; Yan SF, 1998, P NATL ACAD SCI USA, V95, P8298, DOI 10.1073/pnas.95.14.8298; ZHAN SL, 1995, J BIOL CHEM, V270, P27983; Zhu JH, 1999, P NATL ACAD SCI USA, V96, P14911, DOI 10.1073/pnas.96.26.14911	71	156	162	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38524	38531		10.1074/jbc.M005220200	http://dx.doi.org/10.1074/jbc.M005220200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10984481	hybrid			2022-12-27	WOS:000165739800053
J	Gotz, J; Chen, F; Barmettler, R; Nitsch, RM				Gotz, J; Chen, F; Barmettler, R; Nitsch, RM			Tau filament formation in transgenic mice expressing P301L tau	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENT; NEUROFIBRILLARY DEGENERATION; ALZHEIMERS-DISEASE; PROTEIN; BRAIN; MUTATIONS; ISOFORMS; PHOSPHORYLATION; POLYMERIZATION; DEMENTIA	Mutations in the microtubule-associated protein tau, including P301L, are genetically coupled to hereditary frontotemporal dementia with parkinsonism linked to chromosome 17, To determine whether P301L is associated with fibril formation in mice, we expressed the longest human tau isoform, human tau40, with this mutation in transgenic mice by using the neuron-specific mouse Thy1.2 promoter. We obtained mice with high expression of human P301L tau in cortical and hippocampal neurons. Accumulated tau was hyperphosphorylated and translocated from axonal to somatodendritic compartments and was accompanied by astrocytosis and neuronal apoptosis indicated by terminal deoxynucleotidyl transferase-mediated biotinylated dUTP nick end-labeling staining. Moreover, P301L tau formed abnormal filaments. Electron microscopy of sarcosyl-insoluble protein extracts established that the filaments had a straight or twisted structure of variable length and were similar to 15 nm wide. Immunoelcecton microscopy showed that the tau filaments were phosphorylated at the TG3, AT100, AT8, and AD199 epitopes in vivo. In cortex, brain stem, and spinal cord, neurofibrillary tangles were also identified by thioflavin-S fluorescent microscopy and Gallyas silver stains. Together, our results show that expression of the P301L mutation in mice causes neuronal lesions that are similar to those seen in human tauopathies.	Univ Zurich, Div Psychiat Res, CH-8008 Zurich, Switzerland	University of Zurich	Gotz, J (corresponding author), Univ Zurich, Div Psychiat Res, August Forel Str 1, CH-8008 Zurich, Switzerland.		Götz, Jürgen/C-2448-2014	Götz, Jürgen/0000-0001-8501-7896				BRANDT R, 1994, CELL MOTIL CYTOSKEL, V28, P143, DOI 10.1002/cm.970280206; Brion JP, 1999, AM J PATHOL, V154, P255, DOI 10.1016/S0002-9440(10)65272-8; Delacourte A, 1999, NEUROLOGY, V52, P1158, DOI 10.1212/WNL.52.6.1158; Duff K, 2000, NEUROBIOL DIS, V7, P87, DOI 10.1006/nbdi.1999.0279; GALLYAS F, 1971, ACTA MORPHOL HUNG, V19, P1; Goedert M, 1999, AM J PATHOL, V154, P1, DOI 10.1016/S0002-9440(10)65242-X; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1995, NEUROBIOL AGING, V16, P325, DOI 10.1016/0197-4580(95)00017-9; GOTZ J, 1995, EMBO J, V14, P1304, DOI 10.1002/j.1460-2075.1995.tb07116.x; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; HEINS S, 1993, J CELL BIOL, V123, P1517, DOI 10.1083/jcb.123.6.1517; Iqbal K, 1998, J NEURAL TRANSM-SUPP, P169; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Perez M, 1996, J NEUROCHEM, V67, P1183; Probst A, 1996, ACTA NEUROPATHOL, V92, P588, DOI 10.1007/s004010050565; Probst A, 2000, ACTA NEUROPATHOL, V99, P469, DOI 10.1007/s004010051148; Sergeant N, 1999, J NEUROCHEM, V72, P1243, DOI 10.1046/j.1471-4159.1999.0721243.x; Spillantini MG, 1998, AM J PATHOL, V153, P1359, DOI 10.1016/S0002-9440(10)65721-5; Spittaels K, 1999, AM J PATHOL, V155, P2153, DOI 10.1016/S0002-9440(10)65533-2; Trinczek B, 1999, J CELL SCI, V112, P2355; Varani L, 1999, P NATL ACAD SCI USA, V96, P8229, DOI 10.1073/pnas.96.14.8229; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4884, DOI 10.1073/pnas.85.13.4884; YAMAMOTO T, 1986, NEUROPATH APPL NEURO, V12, P3, DOI 10.1111/j.1365-2990.1986.tb00677.x	26	364	386	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					529	534		10.1074/jbc.M006531200	http://dx.doi.org/10.1074/jbc.M006531200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11013246	hybrid			2022-12-27	WOS:000166280700071
J	Racke, FK; Wang, DY; Zaidi, Z; Kelley, J; Visvader, J; Soh, JW; Goldfarb, AN				Racke, FK; Wang, DY; Zaidi, Z; Kelley, J; Visvader, J; Soh, JW; Goldfarb, AN			A potential role for protein kinase C-epsilon in regulating megakaryocytic lineage commitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; GENE-EXPRESSION; PROGENITOR CELLS; DIFFERENTIATION; ACTIVATION; SIGNAL; ALPHA; PATHWAY; APOPTOSIS; GROWTH	Multiple studies have shown that intracellular signal transduction by the protein kinase C (PKC) family participates in the initiation of megakaryocyte differentiation. In this study, multiple approaches addressed the functional contributions by specific PKC isozymes to megakaryocytic lineage commitment of two independent cell lines, K562 and human erythroleukemia (HEL). Pharmacologic profiles of induction and inhibition of megakaryocytic differentiation in both cell lines suggested a role for the calcium-independent novel PKCs, in particular PKC-epsilon. In transfection studies, the isolated variable domain of PKC-epsilon selectively blocked exogenous activation of the megakaryocyte-specific alpha IIb promoter. Constitutively active mutants of PKC-epsilon, but not of other PKC isozymes, cooperated with the transcription factor GATA-1 in the activation of the alpha IIb promoter. The functional cooperation between GATA-1 and PKC-epsilon displayed dependence on cellular milieu, as well as on the promoter context of GATA binding sites. In aggregate, the data suggest that PKC-epsilon specifically participates in megakaryocytic lineage commitment through functional cooperation with GATA-1 in the activation of megakaryocytic promoters.	Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21287 USA; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10027 USA	University of Virginia; Johns Hopkins University; Johns Hopkins Medicine; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Columbia University	Goldfarb, AN (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pathol, HSC Box 800214, Charlottesville, VA 22908 USA.	ang3x@virginia.edu			NCI NIH HHS [CA-72704] Funding Source: Medline; NHLBI NIH HHS [HL-04017] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA072704] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; Asada A, 1998, J BIOL CHEM, V273, P28392, DOI 10.1074/jbc.273.43.28392; Bassini A, 1999, BLOOD, V93, P1178, DOI 10.1182/blood.V93.4.1178.404k28_1178_1188; Debili N, 1996, BLOOD, V88, P1284, DOI 10.1182/blood.V88.4.1284.bloodjournal8841284; Era T, 2000, BLOOD, V95, P870, DOI 10.1182/blood.V95.3.870.003k44_870_878; Fichelson S, 1999, BLOOD, V94, P1601, DOI 10.1182/blood.V94.5.1601.417k19_1601_1613; FONG AM, 1994, J BIOL CHEM, V269, P18441; GOLDFARB AN, 1992, BLOOD, V80, P2858; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Hundle B, 1997, J BIOL CHEM, V272, P15028, DOI 10.1074/jbc.272.23.15028; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; LONG MW, 1984, J CLIN INVEST, V74, P1686, DOI 10.1172/JCI111585; Lumelsky NL, 1997, BBA-MOL CELL RES, V1358, P79, DOI 10.1016/S0167-4889(97)00051-7; MARTIN F, 1993, J BIOL CHEM, V268, P21606; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Myklebust JH, 2000, BLOOD, V95, P510, DOI 10.1182/blood.V95.2.510; Ohoka Y, 1997, J IMMUNOL, V158, P5707; Parissenti AM, 1998, J BIOL CHEM, V273, P8940, DOI 10.1074/jbc.273.15.8940; Pierce A, 1998, J CELL BIOL, V140, P1511, DOI 10.1083/jcb.140.6.1511; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Rossi F, 1996, EMBO J, V15, P1894, DOI 10.1002/j.1460-2075.1996.tb00540.x; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Swanson KD, 1999, J BIOL CHEM, V274, P3385, DOI 10.1074/jbc.274.6.3385; Tang SQ, 1997, J BIOL CHEM, V272, P28704, DOI 10.1074/jbc.272.45.28704; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; Uberall F, 1997, J BIOL CHEM, V272, P4072, DOI 10.1074/jbc.272.7.4072; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VISVADER JE, 1995, MOL CELL BIOL, V15, P634; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156; Weller SG, 1999, GASTROENTEROLOGY, V117, P848, DOI 10.1016/S0016-5085(99)70343-4; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947	36	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					522	528		10.1074/jbc.M005236200	http://dx.doi.org/10.1074/jbc.M005236200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11016926	hybrid			2022-12-27	WOS:000166280700070
J	Kazlauskas, A; Poellinger, L; Pongratz, I				Kazlauskas, A; Poellinger, L; Pongratz, I			The immunophilin-like protein XAP2 regulates ubiquitination and subcellular localization of the dioxin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ARYL-HYDROCARBON RECEPTOR; DNA-BINDING ACTIVITY; HELIX-LOOP-HELIX; AH RECEPTOR; LIGAND-BINDING; GLUCOCORTICOID RECEPTOR; PROGESTERONE-RECEPTOR; NUCLEAR-LOCALIZATION; CORE COMPLEX	The dioxin (aryl hydrocarbon) receptor is a ligand dependent transcription factor that induces expression of a number of genes encoding drug metabolizing enzymes. The nonactivated form of the dioxin receptor is associated with heat shock protein (hsp) 90, the co-chaperone p23, and the immunophilin-like protein XAP2. Whereas hsp90 has a role in maintenance of the high-affinity ligand binding conformation of the dioxin receptor complex, and p23 stabilizes receptor-hsp99 interaction, the exact role of XAP2 is largely unknown. Here we show that XAP2 protected the ligand-free form of receptor against ubiquitination, resulting in increased dioxin receptor protein levels, Upon exposure to ligand, nuclear translocation of the dioxin receptor was markedly delayed by XAP2, indicating an additional role of XAP2 in regulation of the subcellular localization of the receptor by a mechanism of cytoplasmic retention. In order to mediate these effects, XAP2 required stable association with the hsp90-p23 molecular chaperone complex. The association of XAP2 as well as p23 with the dioxin receptor was determined by the functional state of hsp90. These data indicate a novel mode of regulation of dioxin receptor signaling by the hsp90-dependent molecular chaperone machinery.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Poellinger, L (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden.							ANTONSSON C, 1995, MOL CELL BIOL, V15, P756; CARVER LA, 1994, J BIOL CHEM, V269, P30109; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chen HS, 1997, ARCH BIOCHEM BIOPHYS, V348, P190, DOI 10.1006/abbi.1997.0398; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; Davarinos NA, 1999, J BIOL CHEM, V274, P28708, DOI 10.1074/jbc.274.40.28708; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Heid SE, 2000, MOL PHARMACOL, V57, P82; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; Kuzhandaivelu N, 1996, NUCLEIC ACIDS RES, V24, P4741, DOI 10.1093/nar/24.23.4741; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; Ma Q, 2000, J BIOL CHEM, V275, P8432, DOI 10.1074/jbc.275.12.8432; Ma Q, 1997, J BIOL CHEM, V272, P8878; MASON GGF, 1994, J BIOL CHEM, V269, P4438; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Pongratz I, 1998, MOL CELL BIOL, V18, P4079, DOI 10.1128/MCB.18.7.4079; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Roberts BJ, 1999, J BIOL CHEM, V274, P36351, DOI 10.1074/jbc.274.51.36351; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x	40	130	133	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41317	41324		10.1074/jbc.M007765200	http://dx.doi.org/10.1074/jbc.M007765200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11013261	hybrid			2022-12-27	WOS:000166114600087
J	Fagan, KA; Graf, RA; Tolman, S; Schaack, J; Cooper, DMF				Fagan, KA; Graf, RA; Tolman, S; Schaack, J; Cooper, DMF			Regulation of a Ca2+-sensitive adenylyl cyclase in an excitable cell - Role of voltage-gated versus capacitative Ca2+ entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C6-2B GLIOMA-CELLS; CALCIUM-ENTRY; ADENOVIRUS TYPE-5; PITUITARY-CELLS; CYCLIC-AMP; RESPONSE ELEMENT; MESSENGER-RNA; E1A PROTEIN; PC12 CELLS; RAT-BRAIN	In nonexcitable cells, we had previously established that Ca2+-sensitive adenylyl cyclases, whether expressed endogenously or heterologously, were regulated exclusively by capacitative Ca2+ entry (Fagan, K, A, Mahey, R, and Cooper, D, M, F, (1996) J, Biol. Chem. 271, 12438-12444; Fagan, K, A., Mons, N., and Cooper, D. M. F, (1998) J. Biol. Chem, 273, 9297-9305), Relatively little is known about how these enzymes are regulated by Ca2+ in excitable cells, where they predominate. Furthermore, no effort has been made to determine whether the prominent voltage-gated Ca2+ entry, which typifies excitable cells, overwhelms the effect of any capacitative Ca2+ entry that may occur. In the present study, we placed the Ca2+-stimulable, adenylyl cyclase type VIII in an adenovirus vector to optimize its expression in the pituitary-derived GH(4)C(1) cell line. In these cells, a modest degree of capacitative Ca2+ entry could be discerned in the face of a dramatic voltage-gated Ca2+ entry. Nevertheless, both modes of Ca2+ entry were equally efficacious at stimulating adenylyl cyclase, A striking release of Ca2+ from intracellular stores, triggered either by ionophore or thyrotrophin-releasing hormone, was incapable of stimulating the adenylyl cyclase. It thus appears as though the intimate colocalization of adenylyl cyclase with capacitative Ca2+ entry channels is an intrinsic property of these molecules, regardless of whether they are expressed in excitable or nonexcitable cells.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cooper, DMF (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Box C-236,4200 E 9th Ave, Denver, CO 80262 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028389] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28389] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Burnay MM, 1998, BIOCHEM J, V330, P21, DOI 10.1042/bj3300021; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; CHINNADURAI G, 1979, J VIROL, V32, P623, DOI 10.1128/JVI.32.2.623-628.1979; CHINNADURAI G, 1978, J VIROL, V26, P195, DOI 10.1128/JVI.26.1.195-199.1978; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Cooper DMF, 1998, J BIOL CHEM, V273, P27703, DOI 10.1074/jbc.273.42.27703; ENGEL DA, 1991, P NATL ACAD SCI USA, V88, P3957, DOI 10.1073/pnas.88.9.3957; EVANS T, 1984, MOL PHARMACOL, V26, P395; Fagan KA, 1999, J BIOL CHEM, V274, P12445, DOI 10.1074/jbc.274.18.12445; Fagan KA, 2000, J BIOL CHEM, V275, P26530, DOI 10.1074/jbc.M001369200; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; Fomina AF, 1999, J NEUROSCI, V19, P3711; Furukawa T, 1999, J PHARMACOL EXP THER, V291, P464; GEDRICH RW, 1995, J VIROL, V69, P2333, DOI 10.1128/JVI.69.4.2333-2340.1995; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JONES N, 1978, CELL, V13, P181, DOI 10.1016/0092-8674(78)90148-4; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Koizumi S, 1998, BIOCHEM BIOPH RES CO, V244, P293, DOI 10.1006/bbrc.1998.8251; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; Lee BH, 1997, P NATL ACAD SCI USA, V94, P4481, DOI 10.1073/pnas.94.9.4481; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; MOLLARD P, 1990, BIOCHEM J, V268, P345, DOI 10.1042/bj2680345; MOLLARD P, 1994, J BIOL CHEM, V269, P25158; MONS N, 1995, TRENDS NEUROSCI, V18, P536, DOI 10.1016/0166-2236(95)98375-9; Nakahashi Y, 1997, J BIOL CHEM, V272, P18093, DOI 10.1074/jbc.272.29.18093; Naraghi M, 1997, J NEUROSCI, V17, P6961; Otsuka Y, 1998, TOHOKU J EXP MED, V185, P139, DOI 10.1620/tjem.185.139; PASTAN I, 1971, NATURE-NEW BIOL, V229, P5, DOI 10.1038/newbio229005a0; PAULSSEN RH, 1994, EUR J BIOCHEM, V222, P97, DOI 10.1111/j.1432-1033.1994.tb18846.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1999, BIOESSAYS, V21, P38; Rossie S, 1999, ADV SEC MESS PHOSPH, V33, P23; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHAACK J, 1995, J VIROL, V69, P3920, DOI 10.1128/JVI.69.6.3920-3923.1995; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; Shuttleworth TJ, 1999, J BIOL CHEM, V274, P31174, DOI 10.1074/jbc.274.44.31174; SMITH DH, 1985, MOL CELL BIOL, V5, P2684, DOI 10.1128/MCB.5.10.2684; Taylor SC, 1999, J NEUROCHEM, V73, P874, DOI 10.1046/j.1471-4159.1999.0730874.x; Watson EL, 1998, AM J PHYSIOL-CELL PH, V274, pC557, DOI 10.1152/ajpcell.1998.274.3.C557; Whalen SG, 1997, J VIROL, V71, P3545, DOI 10.1128/JVI.71.5.3545-3553.1997; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YU HJ, 1993, MOL PHARMACOL, V44, P689; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209	53	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40187	40194		10.1074/jbc.M006606200	http://dx.doi.org/10.1074/jbc.M006606200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11010970	hybrid			2022-12-27	WOS:000166039500055
J	Pomerance, M; Abdullah, HB; Kamerji, S; Correze, C; Blondeau, JP				Pomerance, M; Abdullah, HB; Kamerji, S; Correze, C; Blondeau, JP			Thyroid-stimulating hormone and cyclic AMP activate p38 mitogen-activated protein kinase cascade - Involvement of protein kinase A, Rac1, and reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; BETA-GAMMA-SUBUNITS; GROWTH FACTOR-I; MAP KINASE; JUN-KINASE; COUPLED RECEPTORS; SUBSTRATE-SPECIFICITY; TRANSCRIPTION FACTORS; DEPENDENT ACTIVATION; ACTIN REORGANIZATION	p38 mitogen-activated protein kinases (p38-MAPKs) are activated by cytokines, cellular stresses, growth factors, and hormones. We show here that p38-MAPKs are activated upon stimulation by thyroid-stimulating hormone (TSH) or cAMP. TSH caused the phosphorylation of p38-MAPK in Chinese hamster ovary cells stably transfected with the human TSH receptor but not in wild-type Chinese hamster ovary cells. The effect of TSH was fully mimicked by the adenylyl cyclase activator, forskolin, and by a permeant analog of cAMP. The effect of forskolin was reproduced in FRTL5 rat thyroid cells. TSH also stimulated the phosphorylation of MAPK kinase 3 or 6, over the same time scale as that of p38-MAPKs. TSH and forskolin stimulated the activity of the cy-isoform of p38-MAPK assayed by phosphorylation of the transcription factor ATF2. The activity of MAPK-activated protein kinase-2 was stimulated by TSH and forskolin. This stimulation was abolished by SB203580, a specific inhibitor of p38-MAPKs. The protein kinase A inhibitor H89 inhibited the stimulation of phosphorylation of p38-MAPKs by forskolin, whereas inhibitors of protein kinase C, p70(S6k), and phosphatidylinositol 3-kinase were ineffective. Expression of the dominant negative form of Rad, but not that of Ras, blocked forskolin-induced p38-MAPK activation. Diphenylene iodonium, a potent inhibitor of NADPH oxidase(s), and ascorbic acid, an effective free radical scavenger, suppressed TSH- or forskolin-stimulated p38-MAPK phosphorylation, indicating that the generation of reactive oxygen species plays a key role in signaling from cAMP to p38-MAPKs. Inhibition of the p38-MAPK pathway with SB203580 partially but significantly, attenuates cAMP- and TSH-induced expression of the sodium iodide symporter in FRTL-5 cells. These results point to a new signaling pathway for the G(s)-coupled TSH receptor, involving cAMP, protein kinase A, Rad, and reactive oxygen species and resulting in the activation of a signaling kinase cascade that includes MAPK kinase 3 or 6, p38-MAPK, and MAPK-activated protein kinase-2.	Fac Pharm Chatenay Malabry, INSERM U486, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Pomerance, M (corresponding author), Fac Pharm Chatenay Malabry, INSERM U486, Tour D1,5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.		Blondeau, Jean-Paul/AAH-6395-2019	Blondeau, Jean-Paul/0000-0003-4520-6822				ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BJORKMAN U, 1992, ENDOCRINOLOGY, V130, P393, DOI 10.1210/en.130.1.393; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; Browning DD, 1999, J BIOL CHEM, V274, P537, DOI 10.1074/jbc.274.1.537; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Correze C, 2000, THYROID, V10, P747, DOI 10.1089/thy.2000.10.747; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEME D, 1994, BIOCHEM J, V301, P75, DOI 10.1042/bj3010075; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dremier S, 1997, MOL CELL BIOL, V17, P6717, DOI 10.1128/MCB.17.11.6717; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; EVANS T, 1984, MOL PHARMACOL, V26, P395; FAURE M, 1994, J BIOL CHEM, V269, P7851; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Guay J, 1997, J CELL SCI, V110, P357; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Kogai T, 1997, ENDOCRINOLOGY, V138, P2227, DOI 10.1210/en.138.6.2227; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lopez-Ilasaca M, 1998, BIOCHEM PHARMACOL, V56, P269, DOI 10.1016/S0006-2952(98)00059-8; Maizels ET, 1998, ENDOCRINOLOGY, V139, P3353, DOI 10.1210/en.139.7.3353; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; PERRET J, 1990, BIOCHEM BIOPH RES CO, V171, P1044, DOI 10.1016/0006-291X(90)90789-P; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Pomerance M, 1996, MOL CELL BIOL, V16, P3179; Pomerance M, 1998, J BIOL CHEM, V273, P24301, DOI 10.1074/jbc.273.38.24301; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Rachdaoui N, 1999, MOL CELL ENDOCRINOL, V156, P35, DOI 10.1016/S0303-7207(99)00147-1; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROGER PP, 1982, MOL CELL ENDOCRINOL, V26, P165, DOI 10.1016/0303-7207(82)90014-4; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Spitzweg C, 2000, THYROID, V10, P321, DOI 10.1089/thy.2000.10.321; TAHARA K, 1991, J BIOL CHEM, V266, P440; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WOLOSHIN PI, 1992, MOL ENDOCRINOL, V6, P1725, DOI 10.1210/me.6.10.1725; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao M, 1999, MOL CELL BIOL, V19, P21; Zhen XC, 1998, MOL PHARMACOL, V54, P453, DOI 10.1124/mol.54.3.453; Zhou TH, 2000, J BIOL CHEM, V275, P2513, DOI 10.1074/jbc.275.4.2513	66	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40539	40546		10.1074/jbc.M002097200	http://dx.doi.org/10.1074/jbc.M002097200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006268	hybrid			2022-12-27	WOS:000166039500099
J	Pykari, M; Toivonen, S; Natunen, J; Niemela, R; Salminen, H; Aitio, O; Ekstrom, M; Parmanne, P; Valimaki, M; Alais, J; Auge, C; Lowe, JB; Renkonen, O; Renkonen, R				Pykari, M; Toivonen, S; Natunen, J; Niemela, R; Salminen, H; Aitio, O; Ekstrom, M; Parmanne, P; Valimaki, M; Alais, J; Auge, C; Lowe, JB; Renkonen, O; Renkonen, R			The acceptor and site specificity of alpha 3-fucosyltransferase V - High reactivity of the proximal and low of the distal, Gal beta 1-4GlcNAc unit in i-type polylactosamines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; BLOOD-GROUP-I; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; LYMPHOCYTE-ENDOTHELIUM ADHESION; LINKED CARBOHYDRATE CHAINS; WGA-AGAROSE CHROMATOGRAPHY; ENDO-BETA-GALACTOSIDASE; MEDIATED CELL-ADHESION; WHEAT-GERM-AGGLUTININ; LACTO-N-NEOHEXAOSE	We report here on in vitro acceptor and site specificity of recombinant alpha3-fucosyltransferase V (Fuc-TV) with 40 oligosaccharide accepters. Gal beta1-4GlcNAc (LN) and GalNAc beta1-4GlcNAc (LDN) reacted rapidly; Gal beta1-3Glc-NAc (LNB) reacted moderately, and GlcNAc beta1-4GlcNAc (N,N'-diacetyl-chitobiose) reacted slowly yet distinctly. In neutral and terminally alpha3-sialylated polylactosamines of i-type, the reducing end LN unit reacted rapidly and the distal (sialyl)LN group very slowly; the midchain LNs revealed intermediate reactivities. The data suggest that a distal LN neighbor enhances but a proximal LN neighbor reduces the reactivity of the midchain LNs. This implies that Fuc-TV may bind preferably the tetrasaccharide sequence Gal beta1-4GlcNAc beta1-3Gal beta1-4GlcNAc for transfer at the underlined monosaccharide. Terminal alpha3-sialylation of i-type polylactosamines almost doubled the reactivities of the LN units at all positions of the chains. We conclude that, in comparison with human Fuc-TIV and Fuc-TIX, Fuc-TV reacted with a highly distinct site specificity with i-type polylactosamines. The Fuc-TV reactivity of free LNB resembled that of LNB beta1-3'R of a polylactosamine, contrasting strongly with the dissimilarity of the reactivities of the analogous pair of LN and LN beta1-3'R. This observation supports the notion that LN and LNB may be functionally bound at distinct sites on Fuc-TV surface. Our data show that Fuc-TV worked well with a very wide range of LN-glycans, showing weak reactivity only with distal (sialyl)LN units of i-type polylactosamines, biantennary N-glycans, and I branches of polylactosamines.	Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Paris 11, Lab Chim Organ Multifonctionelle, F-91405 Orsay, France; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst, FIN-00014 Helsinki, Finland; HUCH Lab Diagnost, FIN-00014 Helsinki, Finland	University of Helsinki; UDICE-French Research Universities; Universite Paris Saclay; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Helsinki	Renkonen, R (corresponding author), Univ Helsinki, Inst Biotechnol, POB 56, FIN-00014 Helsinki, Finland.	risto.renkonen@helsinki.fi		Valimaki, Mika/0000-0002-9687-8197; Parmanne, Pinja/0000-0002-4691-2107	NATIONAL CANCER INSTITUTE [P01CA071932] Funding Source: NIH RePORTER; NCI NIH HHS [1PO1CA71932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALAIS J, 1990, CARBOHYD RES, V207, P11, DOI 10.1016/0008-6215(90)80002-K; BERGWERFF AA, 1992, FEBS LETT, V314, P389, DOI 10.1016/0014-5793(92)81512-K; Boubelik M, 1998, GLYCOBIOLOGY, V8, P139, DOI 10.1093/glycob/8.2.139; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; Chandrasekaran EV, 1996, BIOCHEMISTRY-US, V35, P8925, DOI 10.1021/bi952194e; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; DEVRIES T, 1993, EUR J BIOCHEM, V216, P769, DOI 10.1111/j.1432-1033.1993.tb18197.x; DeVries T, 1997, GLYCOBIOLOGY, V7, P921, DOI 10.1093/glycob/7.7.921; Dupuy F, 1999, J BIOL CHEM, V274, P12257, DOI 10.1074/jbc.274.18.12257; EGGENS I, 1989, J BIOL CHEM, V264, P9476; Geyer A, 1999, ANGEW CHEM INT EDIT, V38, P1466, DOI 10.1002/(SICI)1521-3773(19990517)38:10<1466::AID-ANIE1466>3.0.CO;2-#; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; Goodman JL, 1999, J CLIN INVEST, V103, P407, DOI 10.1172/JCI4230; Grabenhorst E, 1998, J BIOL CHEM, V273, P30985, DOI 10.1074/jbc.273.47.30985; GRINNELL BW, 1994, GLYCOBIOLOGY, V4, P221, DOI 10.1093/glycob/4.2.221; GU J, 1992, J BIOL CHEM, V267, P2994; Hakamori S, 1998, ACTA ANAT, V161, P79; HAKOMORI SI, 1992, HISTOCHEM J, V24, P771, DOI 10.1007/BF01046348; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; Kaneko M, 1999, FEBS LETT, V452, P237, DOI 10.1016/S0014-5793(99)00640-7; Kannagi R, 1997, GLYCOCONJUGATE J, V14, P577, DOI 10.1023/A:1018532409041; KOBATA A, 1979, ANAL BIOCHEM, V100, P1, DOI 10.1016/0003-2697(79)90102-7; Koeller KM, 2000, CHEM-EUR J, V6, P1243, DOI 10.1002/(SICI)1521-3765(20000403)6:7<1243::AID-CHEM1243>3.3.CO;2-A; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; Leppanen A, 1997, BIOCHEMISTRY-US, V36, P7026, DOI 10.1021/bi9627673; LEPPANEN A, 1991, BIOCHEMISTRY-US, V30, P9287, DOI 10.1021/bi00102a022; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MAAHEIMO H, 1994, FEBS LETT, V349, P55, DOI 10.1016/0014-5793(94)00638-5; MAAHEIMO H, 1995, EUR J BIOCHEM, V234, P616, DOI 10.1111/j.1432-1033.1995.616_b.x; MACHYTKA D, 1994, CARBOHYD RES, V254, P289, DOI 10.1016/0008-6215(94)84262-0; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; Murray BW, 1996, BIOCHEMISTRY-US, V35, P11183, DOI 10.1021/bi961065a; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NATUNEN J, 1994, GLYCOBIOLOGY, V4, P577, DOI 10.1093/glycob/4.5.577; NATUNEN J, 1997, GLYCOCONJUGATE J, V14, pS114; Nguyen AT, 1998, J BIOL CHEM, V273, P25244, DOI 10.1074/jbc.273.39.25244; NIEMELA R, 1995, GLYCOCONJUGATE J, V12, P36, DOI 10.1007/BF00731866; Niemela R, 1999, GLYCOBIOLOGY, V9, P517, DOI 10.1093/glycob/9.5.517; Niemela R, 1995, CARBOHYD RES, V279, P331, DOI 10.1016/0008-6215(95)00299-5; Niemela R, 1998, J BIOL CHEM, V273, P4021, DOI 10.1074/jbc.273.7.4021; Nishihara S, 1999, FEBS LETT, V462, P289, DOI 10.1016/S0014-5793(99)01549-5; PALCIC M M, 1991, Glycobiology, V1, P205, DOI 10.1093/glycob/1.2.205; PATEL TP, 1994, BIOCHEMISTRY-US, V33, P14815, DOI 10.1021/bi00253a021; Rabina J, 1997, CARBOHYD RES, V305, P491, DOI 10.1016/S0008-6215(97)00260-7; RENKONEN O, 1989, GLYCOCONJUGATE J, V6, P129, DOI 10.1007/BF01047895; RENKONEN O, 1991, GLYCOCONJUGATE J, V8, P361, DOI 10.1007/BF00731349; Renkonen O, 1997, GLYCOBIOLOGY, V7, P453, DOI 10.1093/glycob/7.4.453-c; RENKONEN O, 1990, BIOCHEM CELL BIOL, V68, P1032, DOI 10.1139/o90-152; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SEPPO A, 1995, BIOCHEMISTRY-US, V34, P4655, DOI 10.1021/bi00014a019; Seppo A, 1996, GLYCOBIOLOGY, V6, P65, DOI 10.1093/glycob/6.1.65; SIUZDAK G, 1993, J AM CHEM SOC, V115, P2877, DOI 10.1021/ja00060a040; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; Toppila S, 1999, EUR J BIOCHEM, V261, P208, DOI 10.1046/j.1432-1327.1999.00257.x; TOWNSEND RR, 1986, BIOCHEMISTRY-US, V25, P5716, DOI 10.1021/bi00367a055; TURUNEN JP, 1995, J EXP MED, V182, P1133, DOI 10.1084/jem.182.4.1133; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WONG CH, 1992, J AM CHEM SOC, V114, P7321, DOI 10.1021/ja00044a068; YAMASHITA K, 1977, J BIOL CHEM, V252, P5408; Zollner O, 1996, J BIOL CHEM, V271, P33002, DOI 10.1074/jbc.271.51.33002	65	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40057	40063		10.1074/jbc.M007922200	http://dx.doi.org/10.1074/jbc.M007922200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007797	hybrid			2022-12-27	WOS:000166039500037
J	Viswanath, RL; Rose, SD; Swift, GH; MacDonald, RJ				Viswanath, RL; Rose, SD; Swift, GH; MacDonald, RJ			A binary mechanism for the selective action of a pancreatic beta-cell transcriptional silencer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; ELASTASE-I ENHANCER; SV40 ENHANCER; NEGATIVE REGULATION; REGULATORY ELEMENT; GENE-EXPRESSION; ACINAR-CELLS; INSULIN GENE; REPRESSION; EXOCRINE	The pancreatic elastase I gene (ELA1) is selectively transcribed to high levels in pancreatic acinar cells. Pancreatic specificity is imparted by a 100-base pair enhancer that activates transcription in beta -cells of the islets of Langerhans as well as in acinar cells. Adjacent to the enhancer is a silencer that renders transcription specific to acinar cells by selectively suppressing the inherent beta -cell activity of the enhancer. We show that the selective repression of beta -cell. transcription is due neither to a beta -cell specific activity of the silencer nor to selective interference with beta -cell-specific transcriptional activators acting on the enhancer. Rather, the silencer is effective in both pancreatic endocrine and acinar cell types against all low and moderate strength enhancers and promoters tested. The silencer appears to act in a binary manner by reducing the probability that a promoter will be active without affecting the rate of transcription from active promoters. We propose that the ELA1 silencer is a weak off switch capable of inactivating enhancer/promoter combinations whose strength is below a threshold level but ineffective against stronger enhancer/promoters. The apparent cell-specific effects on the ELA1 enhancer appear due to the ability of the silencer to inactivate the weak beta -cell activity of the enhancer but not the stronger acinar cell activity.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Integrated DNA Technol, Coralville, IA 52241 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	MacDonald, RJ (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	raymond.macdonald@UTSouthwestern.edu	MacDonald, Ray/AAA-1290-2022		NIDDK NIH HHS [DK27430, DK55266] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055266, R01DK027430] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BOAM DSW, 1990, J BIOL CHEM, V265, P8285; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CLARK SA, 1990, ENDOCRINOLOGY, V127, P2779, DOI 10.1210/endo-127-6-2779; Fiering S, 2000, BIOESSAYS, V22, P381, DOI 10.1002/(SICI)1521-1878(200004)22:4<381::AID-BIES8>3.0.CO;2-E; Goodman PA, 1996, MOL CELL ENDOCRINOL, V120, P139, DOI 10.1016/0303-7207(96)03830-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUERIN SL, 1993, EUR J BIOCHEM, V213, P399, DOI 10.1111/j.1432-1033.1993.tb17774.x; GUZ Y, 1995, DEVELOPMENT, V121, P11; HAMMER RE, 1987, MOL CELL BIOL, V7, P2956, DOI 10.1128/MCB.7.8.2956; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; JACKSON ME, 1991, J CELL SCI, V100, P1; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KRUSE F, 1993, GENE DEV, V7, P774, DOI 10.1101/gad.7.5.774; KRUSE F, 1995, MOL CELL BIOL, V15, P4385; KRUSE F, 1988, MOL CELL BIOL, V8, P893, DOI 10.1128/MCB.8.2.893; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; NIR U, 1986, P NATL ACAD SCI USA, V83, P3180, DOI 10.1073/pnas.83.10.3180; Ogbourne S, 1998, BIOCHEM J, V331, P1; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; ORNITZ DM, 1985, COLD SPRING HARB SYM, V50, P399, DOI 10.1101/SQB.1985.050.01.050; ORNITZ DM, 1985, NATURE, V313, P600, DOI 10.1038/313600a0; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; ROSE SD, 1994, MOL CELL BIOL, V14, P2048, DOI 10.1128/MCB.14.3.2048; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIRM S, 1987, GENE DEV, V1, P65, DOI 10.1101/gad.1.1.65; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SWIFT GH, 1989, GENE DEV, V3, P687, DOI 10.1101/gad.3.5.687; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; WASYLYK B, 1984, NUCLEIC ACIDS RES, V12, P5589, DOI 10.1093/nar/12.14.5589; WEINTRAUB H, 1988, P NATL ACAD SCI USA, V85, P5819, DOI 10.1073/pnas.85.16.5819; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x	50	2	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40273	40281		10.1074/jbc.M007021200	http://dx.doi.org/10.1074/jbc.M007021200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10995768	hybrid			2022-12-27	WOS:000166039500066
J	Weiss, JL; Archer, DA; Burgoyne, RD				Weiss, JL; Archer, DA; Burgoyne, RD			Neuronal Ca2+ sensor-1/frequenin autocrine pathway regulating Ca2+ bovine adrenal chromaffin cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; CA2+-BINDING PROTEIN; SENSOR 1; MODULATION; CHANNELS; FREQUENIN; CURRENTS; FACILITATION; CALMODULIN; NEUROCALCIN	NCS-1/frequenin belongs to a family of EF-hand-containing Ca2+ sensors expressed mainly in neurons. Overexpression of NCS-1/frequenin has been shown to stimulate neurotransmitter release but little else is known of its cellular roles. We have constructed an EF-hand mutant, NCS-1(E120Q), as a likely dominant inhibitor of cellular NCS-1 function. Recombinant NCS-1(E120Q) showed an impaired Ca2+-dependent conformational change but could still bind to cellular proteins. Transient expression of this mutant, but not NCS-1, in bovine adrenal chromaffin cells increased non-L-type Ca2+ channel currents. Cells expressing NCS-1(E120Q) no longer responded effectively to the removal of autocrine purinergic/opioid inhibition of Ca2+ currents but still showed voltage-dependent facilitation. These data are consistent with the existence of both voltage-dependent and voltage-independent pathways for Ca2+ channel inhibition in chromaffin cells. Our results suggest a novel function for NCS-1 specific for the voltage-independent autocrine pathway that negatively regulates non-L-type Ca2+ channels in chromaffin cells.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Burgoyne, RD (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	burgoyne@liverpool.ac.uk	Burgoyne, Robert D/P-6641-2019; Burgoyne, Robert/C-6706-2008	Burgoyne, Robert D/0000-0002-9219-0387; Burgoyne, Robert/0000-0002-9219-0387; Weiss, Jamie L/0000-0001-6784-5831				ALBILLOS A, 1993, FEBS LETT, V336, P259, DOI 10.1016/0014-5793(93)80815-C; Albillos A, 1996, J PHYSIOL-LONDON, V494, P687, DOI 10.1113/jphysiol.1996.sp021524; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Arnot MI, 2000, J PHYSIOL-LONDON, V527, P203, DOI 10.1111/j.1469-7793.2000.00203.x; ARTALEJO CR, 1990, NATURE, V348, P239, DOI 10.1038/348239a0; ARTALEJO CR, 1994, NATURE, V367, P72, DOI 10.1038/367072a0; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; BURGOYNE RD, 1992, NEUROMETHODS, V20, P433; Burley JR, 2000, BIOPHYS J, V78, p104A; Carabelli V, 1998, NEURON, V20, P1255, DOI 10.1016/S0896-6273(00)80505-X; CENA V, 1989, J MEMBRANE BIOL, V112, P255, DOI 10.1007/BF01870956; COX JA, 1994, J BIOL CHEM, V269, P32807; Currie KPM, 1996, NEURON, V16, P1027, DOI 10.1016/S0896-6273(00)80126-9; Delmas P, 1998, EUR J NEUROSCI, V10, P1654, DOI 10.1046/j.1460-9568.1998.00170.x; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; DIVERSEPIERLUISSI M, 1991, P NATL ACAD SCI USA, V88, P1261, DOI 10.1073/pnas.88.4.1261; Dolphin AC, 1998, J PHYSIOL-LONDON, V506, P3, DOI 10.1111/j.1469-7793.1998.003bx.x; DOUPNIK CA, 1992, PFLUG ARCH EUR J PHY, V420, P61, DOI 10.1007/BF00378642; Dunlap KL, 1998, SEMIN NEUROSCI, V9, P198, DOI 10.1006/smns.1997.0119; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Faurobert E, 1996, J BIOL CHEM, V271, P10256, DOI 10.1074/jbc.271.17.10256; FORMENTI A, 2000, J PHYSL, V509, P395; Graham ME, 2000, J NEUROSCI, V20, P1281; Graham ME, 2000, BIOCHIMIE, V82, P469, DOI 10.1016/S0300-9084(00)00196-6; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; LADANT D, 1995, J BIOL CHEM, V270, P3179; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; NEF S, 1995, J RECEPT SIGNAL TR R, V15, P365, DOI 10.3109/10799899509045227; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; Olafsson P, 1997, MOL BRAIN RES, V44, P73, DOI 10.1016/S0169-328X(96)00188-X; OLAFSSON P, 1995, P NATL ACAD SCI USA, V92, P8001, DOI 10.1073/pnas.92.17.8001; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; Powell AD, 2000, J NEUROSCI, V20, P606, DOI 10.1523/JNEUROSCI.20-02-00606.2000; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; RIVOSECCHI R, 1994, J PHYSIOL-LONDON, V474, P223, DOI 10.1113/jphysiol.1994.sp020015; Schaad NC, 1996, P NATL ACAD SCI USA, V93, P9253, DOI 10.1073/pnas.93.17.9253; TANOUYE MA, 1981, P NATL ACAD SCI-BIOL, V78, P6548, DOI 10.1073/pnas.78.10.6548; TWITCHELL WA, 1993, NEURON, V10, P701, DOI 10.1016/0896-6273(93)90171-M; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	44	85	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40082	40087		10.1074/jbc.M008603200	http://dx.doi.org/10.1074/jbc.M008603200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006299	hybrid			2022-12-27	WOS:000166039500040
J	Elizondo, G; Corchero, J; Sterneck, E; Gonzalez, FJ				Elizondo, G; Corchero, J; Sterneck, E; Gonzalez, FJ			Feedback inhibition of the retinaldehyde dehydrogenase gene ALDH1 by retinoic acid through retinoic acid receptor A and CCAAT/enhancer-binding protein beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDEHYDE DEHYDROGENASE; C/EBP-BETA; RESPONSE ELEMENT; TRANSCRIPTIONAL REGULATION; MAMMALIAN-CELLS; PROMOTER; IDENTIFICATION; ALPHA; EXTRACTION; ACTIVATION	Aldehyde dehydrogenase 1 (ALDH1) plays a major role in the biosynthesis of retinoic acid (RA), a hormone required for several essential life processes. Recent evidence, using the aryl hydrocarbon receptor-null mouse, suggests that elevated hepatic RA down-regulates ALDH1 in a unique feedback pathway to control RA biosynthesis. To determine the mechanism of suppression of the ALDH1 gene by RA, transactivation studies were carried out in Hepa-1 mouse hepatoma cells. RA decreased expression of an ALDH1-CAT construct containing -2536 base pairs of DNA upstream of the transcription start site. Retinoic acid receptor alpha (RAR alpha) transactivates the ALDH1 gene promoter through a complex with an RA response-like element (RARE) located at -91/-75 bp, which bound to the RAR alpha /retinoid X receptor beta heterodimer. CCAAT/enhancer-binding protein (C/EBP beta) also transactivates the ALDH1 gene promoter through a CCAAT box located 3' and directly adjacent to the RARE, and the ALDH1 gene is downregulated in C/EBP beta -null mouse liver. Exposure of Hepa-1 cells to RA results in a decrease in C/EBP beta mRNA levels; however, there was no difference in mRNA and protein levels between wild-type and AHR-null mouse liver. These data support a model in which the RAR alpha and C/EBP beta activate the ALDH1 gene promoter through the RARE and C/EBP response elements, and in Hepa-1 cells, high levels of RA inhibit this activation by decreasing cellular levels of C/EBP beta.	NCI, NIH, Lab Metab, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Gonzalez, FJ (corresponding author), NCI, NIH, Lab Metab, Bldg 37,Rm 3E-24, Bethesda, MD 20892 USA.			Sterneck, Esta/0000-0001-7716-8766	NATIONAL CANCER INSTITUTE [Z01BC005708, ZIABC005708] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreola F, 1997, CANCER RES, V57, P2835; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Ausubel F., 1999, CURRENT PROTOCOLS MO; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Crowe DL, 1998, MOL CARCINOGEN, V22, P26; de The H, 1990, Nouv Rev Fr Hematol, V32, P30; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DiSepio D, 1997, J BIOL CHEM, V272, P25555, DOI 10.1074/jbc.272.41.25555; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HAN A, 1983, J BIOL CHEM, V258, P3703; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; HARRINGTON MC, 1988, BIOCHEM SOC T, V16, P239, DOI 10.1042/bst0160239; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; Hsu LC, 1999, BIOCHEM J, V339, P387, DOI 10.1042/0264-6021:3390387; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MACKERELL AD, 1986, BIOCHEMISTRY-US, V25, P5182, DOI 10.1021/bi00366a030; MCCAFFERY P, 1991, DEVELOPMENT, V112, P693; MenendezHurtado A, 1997, BIOCHEM BIOPH RES CO, V234, P605, DOI 10.1006/bbrc.1997.6635; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; OGATA A, 1994, BLOOD, V84, P3040; RICHARD S, 1991, J BIOL CHEM, V266, P21428; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Sporn M.B., 1994, RETINOIDS BIOL CHEM; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Stewart MJ, 1996, GENE, V173, P155, DOI 10.1016/0378-1119(96)00068-6; Wan YJY, 1998, EXP CELL RES, V238, P241, DOI 10.1006/excr.1997.3851; Welm AL, 1999, MOL CELL BIOL, V19, P1695; YANAGAWA Y, 1995, J BIOL CHEM, V270, P17521, DOI 10.1074/jbc.270.29.17521	35	70	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39747	39753		10.1074/jbc.M004987200	http://dx.doi.org/10.1074/jbc.M004987200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995752	hybrid			2022-12-27	WOS:000165953100105
J	Gerner, C; Frohwein, U; Gotzmann, J; Bayer, E; Gelbmann, D; Bursch, W; Schulte-Hermann, R				Gerner, C; Frohwein, U; Gotzmann, J; Bayer, E; Gelbmann, D; Bursch, W; Schulte-Hermann, R			The Fas-induced apoptosis analyzed by high throughput proteome analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MATRIX PROTEINS; DEATH; IDENTIFICATION; ACTIVATION; CELLS; MECHANISMS; RESISTANCE; CASPASES; CALCIUM; FAMILY	The fate of cytosolic proteins was studied during Fas-induced cell death of Jurkat T-lymphocytes by proteome analysis. Among 1000 spots resolved in two-dimensional gels, comparison of control versus apoptotic cells revealed that the signal intensity of 19 spots decreased or even disappeared, whereas 38 novel spots emerged. These proteins were further analyzed with respect to de novo protein synthesis, phosphorylation status, and intracellular localization by metabolic labeling and analysis of subcellular protein fractions in combination with two-dimensional Western blots and mass spectrometry analysis of tryptic digests. We found that ag. hsp27, hsp70B, calmodulin, and H-ras synthesis was induced upon Fas signaling. 34 proteins were affected by dephosphorylation (e.g. endoplasmin) and phosphorylation (e.g. hsc70, hsp57, and hsp90). Nuclear annexin IV translocated to the cytosol, whereas decreasing cytosolic TCP-lar became detectable in the nucleus. In addition, degradation of 12 proteins was observed; among them myosin heavy chain was identified as a novel caspase target. Fas-induced proteome alterations were compared with those of other cell death inducers, indicating specific physiological characteristics of different cell death mechanisms, consequent to as well as independent of caspase activation. Characteristic proteome alterations of apoptotic cells at early time points were found reminiscent of those of malignant cells in vivo.	Univ Vienna, Canc Res Inst, A-1090 Vienna, Austria	University of Vienna	Gerner, C (corresponding author), Univ Vienna, Canc Res Inst, Borschkegasse 8A, A-1090 Vienna, Austria.	Christopher.Gerner@univie.ac.at		Gotzmann, Josef/0000-0001-6392-2115; Gerner, Christopher/0000-0003-4964-0642				Anderson NL, 1998, ELECTROPHORESIS, V19, P1853, DOI 10.1002/elps.1150191103; BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1023, DOI 10.1002/elps.11501401163; Brockstedt E, 1998, J BIOL CHEM, V273, P28057, DOI 10.1074/jbc.273.43.28057; CharriautMarlangue C, 1996, ELECTROPHORESIS, V17, P1781, DOI 10.1002/elps.1150171117; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Egerton M, 1996, BIOCHEM BIOPH RES CO, V224, P666, DOI 10.1006/bbrc.1996.1082; Evan G, 1997, INT J CANCER, V71, P709, DOI 10.1002/(SICI)1097-0215(19970529)71:5<709::AID-IJC2>3.0.CO;2-V; Fountoulakis M, 1997, ANAL BIOCHEM, V250, P153, DOI 10.1006/abio.1997.2213; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Gerner C, 1999, J CELL BIOCHEM, V72, P470, DOI 10.1002/(SICI)1097-4644(19990315)72:4<470::AID-JCB3>3.0.CO;2-V; Gerner C, 1998, J CELL BIOCHEM, V71, P363, DOI 10.1002/(SICI)1097-4644(19981201)71:3<363::AID-JCB5>3.0.CO;2-W; Gerner C, 1998, EXP CELL RES, V238, P472, DOI 10.1006/excr.1997.3866; Gerner C, 1999, J CELL BIOCHEM, V74, P145, DOI 10.1002/(SICI)1097-4644(19990801)74:2<145::AID-JCB1>3.0.CO;2-#; Glinsky GV, 1996, CANCER LETT, V101, P43, DOI 10.1016/0304-3835(96)04112-2; Gotzmann J, 2000, CELL DEATH DIFFER, V7, P425, DOI 10.1038/sj.cdd.4400668; Gotzmann J, 2000, ELECTROPHORESIS, V21, P523, DOI 10.1002/(SICI)1522-2683(20000201)21:3<523::AID-ELPS523>3.0.CO;2-L; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Levy-Strumpf N, 1998, ONCOGENE, V17, P3331, DOI 10.1038/sj.onc.1202588; Ma H, 1999, J CELL BIOL, V146, P531, DOI 10.1083/jcb.146.3.531; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; McCormick TS, 1997, J BIOL CHEM, V272, P6087, DOI 10.1074/jbc.272.9.6087; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Prasad SC, 1999, ELECTROPHORESIS, V20, P1065, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<1065::AID-ELPS1065>3.3.CO;2-D; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Schulte-Hermann R, 1999, IARC SCI PUBL, P273; SchulteHermann R, 1997, CELL BIOL TOXICOL, V13, P339, DOI 10.1023/A:1007495626864; Scoltock AB, 2000, J BIOL CHEM, V275, P30586, DOI 10.1074/jbc.M004058200; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Takayama S, 1998, CANCER RES, V58, P3116; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Uozaki H, 1997, CANCER-AM CANCER SOC, V79, P2336, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2336::AID-CNCR7>3.0.CO;2-J; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; Wilkins MR, 1997, J THEOR BIOL, V186, P7, DOI 10.1006/jtbi.1996.0346; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	48	143	147	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39018	39026		10.1074/jbc.M006495200	http://dx.doi.org/10.1074/jbc.M006495200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10978337	hybrid			2022-12-27	WOS:000165953100012
J	Iwanishi, M; Czech, MP; Cherniack, AD				Iwanishi, M; Czech, MP; Cherniack, AD			The protein-tyrosine kinase Fer associates with signaling complexes containing insulin receptor substrate-1 and phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 ADIPOCYTES; BINDING-PROTEIN; PHOSPHORYLATION; IDENTIFICATION; ACTIVATION; EXPRESSION; TRANSPORT; DOMAIN; CELLS	In a screen for 3T3-F442A adipocyte proteins that bind SH2 domains, we isolated a cDNA encoding Per, a nonreceptor protein-tyrosine kinase of the Fes/Fps family that contains a functional SH2 domain. A truncated splicing variant, iFer, was also cloned, iFer is devoid of both the tyrosine kinase domain and a functional SH2 domain but displays a unique 42-residue C terminus and retains the ability to form oligomers with Per. Expression of both Per and iFer proteins are strikingly increased upon differentiation of 3T3-L1 fibroblasts to adipocytes. Platelet-derived growth factor treatment of the cultured adipocytes caused rapid tyrosine phosphorylation of Per and its recruitment to complexes containing platelet-derived growth factor receptor and the p85 regulatory subunit of phosphatidylinositol (PI) 3-kinase. Insulin treatment of 3T3-L1 adipocytes stimulated association of Per with complexes containing tyrosine phosphorylated IRS-1 and PI 3-kinase but did not stimulate tyrosine phosphorylation of Per, PI 3-kinase activity in anti-Per immunoprecipitates was also acutely activated by insulin treatment of cultured adipocytes. These data demonstrate the presence of Per tyrosine kinase in insulin signaling complexes, suggesting a role of Per in insulin action.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Pharmacol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Cherniack, AD (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.		Cherniack, Andrew D./AAY-8132-2020	Cherniack, Andrew D./0000-0003-0470-0111	NIDDK NIH HHS [DK30648] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allard P, 2000, MOL CELL ENDOCRINOL, V159, P63, DOI 10.1016/S0303-7207(99)00205-1; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; Craig AWB, 1999, J BIOL CHEM, V274, P19934, DOI 10.1074/jbc.274.28.19934; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Dastot F, 1996, P NATL ACAD SCI USA, V93, P10723, DOI 10.1073/pnas.93.20.10723; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELDMAN RA, 1986, MOL CELL BIOL, V6, P1065, DOI 10.1128/MCB.6.4.1065; Halachmy S, 1997, ONCOGENE, V14, P2871, DOI 10.1038/sj.onc.1201145; HAO QL, 1991, MOL CELL BIOL, V11, P1180, DOI 10.1128/MCB.11.2.1180; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Kanzaki M, 2000, J BIOL CHEM, V275, P7167, DOI 10.1074/jbc.275.10.7167; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; KIM L, 1995, MOL CELL BIOL, V15, P4553; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; Read RD, 1997, J BIOL CHEM, V272, P18498, DOI 10.1074/jbc.272.29.18498; REED BC, 1977, P NATL ACAD SCI USA, V74, P4876, DOI 10.1073/pnas.74.11.4876; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; Salvatore P, 1998, J BIOL CHEM, V273, P6989, DOI 10.1074/jbc.273.12.6989; SINGH H, 1989, BIOTECHNIQUES, V7, P252; Smithgall TE, 1998, CRIT REV ONCOGENESIS, V9, P43, DOI 10.1615/CritRevOncog.v9.i1.40; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; Tian L, 2000, J BIOL CHEM, V275, P7854, DOI 10.1074/jbc.275.11.7854; Ueyama T, 2000, BIOCHEM BIOPH RES CO, V269, P557, DOI 10.1006/bbrc.2000.2331	27	17	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					38995	39000		10.1074/jbc.M006665200	http://dx.doi.org/10.1074/jbc.M006665200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11006284	hybrid			2022-12-27	WOS:000165953100009
J	Urizar, NL; Dowhan, DH; Moore, DD				Urizar, NL; Dowhan, DH; Moore, DD			The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; PRIMARY BILIARY-CIRRHOSIS; NUCLEAR RECEPTOR; IDENTIFICATION; CHOLESTEROL; LIGANDS	Bile acids facilitate the absorption of dietary lipids and fat-soluble vitamins and are physiological ligands for the farnesoid X-activated receptor (FXR), a member of the nuclear hormone receptor superfamily, FXR functions as a heterodimer with the retinoid X receptor and in the presence of ligand, the heterodimer binds to specific DNA sequences in the promoters of target genes to regulate gene transcription. Phospholipid transfer protein (PLTP) has been identified as a possible target gene for FXR because the human promoter contains a potential FXR response element, an inverted repeat in which consensus receptor-binding hexamers are separated by one nucleotide (inverted repeat-1). PLTP is essential in the transfer of very low density lipoprotein phospholipids into high density lipoprotein (Jiang, X, C., Bruce, C., Mar, J., Lin, M., Ji, Y., Francone, O. L., and Tall, A. R. (1999) J. Clin. Invest. 103, 907-914), Here we report the regulation of PLTP gene expression by FXR and bile acids. In CV-1 cells, cotransfection of FXR and the retinoid X receptor resulted in bile acid-dependent transactivation of a luciferase reporter construct containing the human PLTP promoter. Mutation analysis demonstrated that the inverted repeat-1 (IR-l) in the PLTP promoter is required for this transactivation. Finally, we demonstrate that bile acids are able to regulate PLTP gene expression in vivo. Mice fed a chow diet supplemented with bile acid showed increased hepatic PLTP mRNA levels. These results suggest that FXR may play a role in high density lipoprotein metabolism via the regulation of PLTP gene expression.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Moore, DD (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053366] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK53366] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERS JJ, 1995, BBA-LIPID LIPID MET, V1258, P27, DOI 10.1016/0005-2760(95)00091-P; Auwerx J, 1999, CELL, V97, P161; Bruce C, 1998, ANNU REV NUTR, V18, P297, DOI 10.1146/annurev.nutr.18.1.297; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; CHIBA H, 1991, BIOCHEM MED METAB B, V46, P329, DOI 10.1016/0885-4505(91)90082-V; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COULHON MP, 1985, CLIN CHIM ACTA, V145, P163, DOI 10.1016/0009-8981(85)90283-9; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; GYLLING H, 1995, HEPATOLOGY, V21, P89, DOI 10.1016/0270-9139(95)90413-1; HIRAOKA H, 1993, HEPATOLOGY, V18, P103, DOI 10.1016/0270-9139(93)90513-M; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Lagrost L, 1998, CURR OPIN LIPIDOL, V9, P203, DOI 10.1097/00041433-199806000-00004; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; POUPON RE, 1993, HEPATOLOGY, V17, P577, DOI 10.1002/hep.1840170408; Qin SC, 2000, J LIPID RES, V41, P269; Rader DJ, 2000, MOL MED TODAY, V6, P170, DOI 10.1016/S1357-4310(00)01673-7; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Srivastava RAK, 2000, EUR J BIOCHEM, V267, P4272, DOI 10.1046/j.1432-1327.2000.01473.x; Tallet F, 1996, CLIN CHIM ACTA, V244, P1, DOI 10.1016/0009-8981(95)06161-4; Tu AY, 1999, BIOCHEM BIOPH RES CO, V264, P802, DOI 10.1006/bbrc.1999.1597; Tu AY, 1995, BIOCHEM BIOPH RES CO, V217, P705, DOI 10.1006/bbrc.1995.2830; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909	28	198	213	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39313	39317		10.1074/jbc.M007998200	http://dx.doi.org/10.1074/jbc.M007998200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10998425	hybrid			2022-12-27	WOS:000165953100052
J	Velasco-Guillen, I; Guerrero, JR; Gomez-Fernandez, JC; Teruel, JA				Velasco-Guillen, I; Guerrero, JR; Gomez-Fernandez, JC; Teruel, JA			Labeling the Ca2+-ATPase of skeletal muscle sarcoplasmic reticulum with maleimidylsalicylic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE SULFHYDRYL-GROUPS; FLUORESCENCE ENERGY-TRANSFER; ADENOSINE-TRIPHOSPHATASE; N-ETHYLMALEIMIDE; CA-ATPASE; ACTIVE-SITE; CONFORMATIONAL CHANGE; CYTOPLASMIC LOOP; TRANSPORT SITES; BINDING SITE	Maleimidylsalicylic acid reacts with the Ca2+-ATPase of skeletal muscle sarcoplasmic reticulum with high affinity and inhibits the ATPase activity following a pseudo-first-order kinetic with a rate constant of 8.3 M-1 s(-1) Calcium binding remains unaffected in the maleimide-inhibited ATPase. However, the presence of ATP, ADP, and, to a lesser extent, AMP protects the enzyme against inhibition. Furthermore, ATPase inhibition is accompanied by a concomitant decrease in ATP binding. The stoichiometry of the nucleotide-dependent maleimidylsalicylic acid binding is 6-10 nmol/mg ATPase, which corresponds to the binding of up to one molecule of maleimide/molecule of ATPase. The stoichiometry of maleimide binding is decreased in the presence of nucleotides and in the ATPase previously labeled with fluorescein-5'-isothiocyanate or N-ethylmaleimide A fluorescent peptide was isolated by high performance liquid chromatography after trypsin digestion of the maleimide-labeled ATPase. Analysis of the sequence and mass spectrometry of the peptide leads us to propose Cys(344) as the target for maleimidylsalicylic acid in the inhibition reaction. The effect of Cys(344) modification on the nucleotide site is discussed.	Univ Murcia, Fac Vet, Dept Bioquim & Biol Mol A, E-30100 Murcia, Spain	University of Murcia	Teruel, JA (corresponding author), Univ Murcia, Fac Vet, Dept Bioquim & Biol Mol A, Campus Espinardo, E-30100 Murcia, Spain.	teruel@um.es	Gomez-Fernandez, Juan C/K-6758-2014; Puche, José Antonio Teruel/R-4137-2018	Gomez-Fernandez, Juan C/0000-0002-5331-9029; Puche, José Antonio Teruel/0000-0003-2256-3368				ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; ANDERSEN JP, 1982, J BIOL CHEM, V257, P8300; BAILIN G, 1989, BIOCHIM BIOPHYS ACTA, V995, P122, DOI 10.1016/0167-4838(89)90070-8; BASTIDE F, 1973, J BIOL CHEM, V248, P8485; BIGELOW DJ, 1991, BIOCHEMISTRY-US, V30, P2113, DOI 10.1021/bi00222a016; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; Chen L, 1996, J BIOL CHEM, V271, P10745, DOI 10.1074/jbc.271.18.10745; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CORBALANGARCIA S, 1993, EUR J BIOCHEM, V217, P737, DOI 10.1111/j.1432-1033.1993.tb18300.x; DAVIDSON GA, 1987, J BIOL CHEM, V262, P7041; DEGANI C, 1973, J BIOL CHEM, V248, P8222; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; GOMEZFERNANDEZ JC, 1980, BIOCHIM BIOPHYS ACTA, V598, P502, DOI 10.1016/0005-2736(80)90031-0; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1990, J MEMBRANE BIOL, V116, P1, DOI 10.1007/BF01871666; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; KAWAKITA M, 1987, J BIOCHEM-TOKYO, V102, P103, DOI 10.1093/oxfordjournals.jbchem.a122021; LACAPERE JJ, 1993, BIOCHEMISTRY-US, V32, P3414, DOI 10.1021/bi00064a027; Lovry O.H., 1951, J BIOL CHEM, V193, P265; MAHANEY JE, 1995, BIOCHEMISTRY-US, V34, P4864, DOI 10.1021/bi00014a044; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; Mintz E, 1997, BBA-BIOENERGETICS, V1318, P52, DOI 10.1016/S0005-2728(96)00132-6; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MOUTIN MJ, 1994, J BIOL CHEM, V269, P11147; NAKAMURA S, 1994, J BIOL CHEM, V269, P16015; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SAITONAKATSUKA K, 1987, J BIOCHEM-TOKYO, V101, P365, DOI 10.1093/oxfordjournals.jbchem.a121921; SQUIER TC, 1987, J BIOL CHEM, V262, P4748; Suzuki H, 1999, BIOCHEMISTRY-US, V38, P820, DOI 10.1021/bi981809f; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; TERUEL JA, 1988, BIOCHEMISTRY-US, V27, P5885, DOI 10.1021/bi00416a010; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Velasco-Guillen I, 1999, ARCH BIOCHEM BIOPHYS, V372, P121, DOI 10.1006/abbi.1999.1464; WAKABAYASHI S, 1990, J BIOCHEM-TOKYO, V107, P563, DOI 10.1093/oxfordjournals.jbchem.a123087; WAWRZYNOW A, 1993, BIOCHIM BIOPHYS ACTA, V1203, P60, DOI 10.1016/0167-4838(93)90036-Q; YAMAMOTO H, 1989, J BIOCHEM-TOKYO, V106, P1121, DOI 10.1093/oxfordjournals.jbchem.a122976; YAMASAKI K, 1990, J BIOCHEM-TOKYO, V108, P918, DOI 10.1093/oxfordjournals.jbchem.a123315; YAMASHITA T, 1987, J BIOCHEM, V101, P377, DOI 10.1093/oxfordjournals.jbchem.a121922	43	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39103	39109		10.1074/jbc.M001871200	http://dx.doi.org/10.1074/jbc.M001871200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993876	hybrid			2022-12-27	WOS:000165953100023
J	Appleyard, SM; McLaughlin, JP; Chavkin, C				Appleyard, SM; McLaughlin, JP; Chavkin, C			Tyrosine phosphorylation of the kappa-opioid receptor regulates agonist efficacy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAT ADIPOCYTES; INSULIN; DESENSITIZATION; INVOLVEMENT; GENISTEIN; SUBUNITS; CHANNELS; MUTATION; PATHWAY	To explore the role of highly conserved tyrosine residues in the putative cytoplasmic domains of the seven transmembrane G protein coupled opioid receptors, we expressed the rat kappa -opioid receptor (KOR) in Xenopus oocytes and then activated the intrinsic insulin receptor tyrosine kinase, KOR activation by the agonist U69593 produced a strong increase in potassium current through coexpressed G protein-gated inwardly rectifying potassium channels (K(IR)3), Brief pretreatment with insulin caused a 60% potentiation of the KOR-activated response. The insulin-induced increase in kappa -opioid response was blocked by the tyrosine kinase inhibitor genistein. In contrast, insulin had no effect on the basal activity of K(IR)3, suggesting that KOR is the target of the tyrosine kinase cascade. Mutation of tyrosine residues to phenylalanines in either the first or second intracellular loop of KOR to produce KOR(Y87F) and KOR(Y157F) had no effect on either the potency or maximal effect of U69593, However, neither KOR(Y87F)- nor KOR(Y157F)-mediated responses were potentiated by insulin treatment. Insulin pretreatment shifted the dose-response curve for U69593 activation of KOR by increasing the maximal response without changing the EC50 value for U69593. These results suggest that insulin increases the efficacy of KOR activation by phosphorylating two tyrosine residues in the first and second intracellular loops of the receptor. Thus, tyrosine phosphorylation may provide an important mechanism for modulation of G protein-coupled receptor signaling.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Neurobiol Program, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Chavkin, C (corresponding author), Univ Washington, Dept Pharmacol, POB 357280, Seattle, WA 98195 USA.		Chavkin, Charles/G-2797-2010		NIDA NIH HHS [DA07278, DA11672, R37 DA011672] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA011672, T32DA007278, R01DA011672] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ABLER A, 1992, J BIOL CHEM, V267, P3946; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Appleyard SM, 1999, J BIOL CHEM, V274, P23802, DOI 10.1074/jbc.274.34.23802; Belcheva MM, 1998, J NEUROCHEM, V70, P635; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; Fukuda K, 1996, J NEUROCHEM, V67, P1309; Georgoussi Z, 1997, BBA-MOL CELL RES, V1359, P263, DOI 10.1016/S0167-4889(97)00097-9; GRIGORESCU F, 1994, HORM RES, V42, P55, DOI 10.1159/000184146; HENRY DJ, 1995, MOL PHARMACOL, V47, P551; Janez A, 2000, J BIOL CHEM, V275, P26870; Karoor V, 1998, J BIOL CHEM, V273, P33035, DOI 10.1074/jbc.273.49.33035; Koch T, 2000, MOL PHARMACOL, V58, P328, DOI 10.1124/mol.58.2.328; Koch T, 1997, J NEUROCHEM, V69, P1767; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; LEONARD JP, 1991, MOL NEUROBIOLOGY PRA, P161; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Nystrom FH, 1999, CELL SIGNAL, V11, P563, DOI 10.1016/S0898-6568(99)00025-X; Olson GA, 1998, PEPTIDES, V19, P1791, DOI 10.1016/S0196-9781(98)00137-5; Pak Y, 1999, J BIOL CHEM, V274, P27610, DOI 10.1074/jbc.274.39.27610; Polakiewicz RD, 1998, J BIOL CHEM, V273, P12402, DOI 10.1074/jbc.273.20.12402; Rogalski SL, 2000, J BIOL CHEM, V275, P25082, DOI 10.1074/jbc.M000183200; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Schmidt H, 2000, J NEUROCHEM, V74, P414, DOI 10.1046/j.1471-4159.2000.0740414.x; Taha C, 1999, J MEMBRANE BIOL, V169, P1, DOI 10.1007/PL00005896; VALIQUETTE M, 1995, EMBO J, V14, P5542, DOI 10.1002/j.1460-2075.1995.tb00241.x; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; Wischmeyer E, 1998, J BIOL CHEM, V273, P34063, DOI 10.1074/jbc.273.51.34063	27	16	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38281	38285		10.1074/jbc.M006756200	http://dx.doi.org/10.1074/jbc.M006756200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10995763	hybrid			2022-12-27	WOS:000165739800022
J	Hammarberg, T; Provost, P; Persson, B; Radmark, O				Hammarberg, T; Provost, P; Persson, B; Radmark, O			The N-terminal domain of 5-lipoxygenase binds calcium and mediates calcium stimulation of enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); PROTEIN-KINASE-C; MEMBRANE TRANSLOCATION; CRYSTAL-STRUCTURE; SYNAPTOTAGMIN-I; 12-LIPOXYGENASE; 15-LIPOXYGENASE; PLATELETS; CELLS; PHOSPHORYLATION	Human 5-lipoxygenase (5-LO) is a key enzyme in the conversion of arachidonic acid into leukotrienes and lipoxins, mediators and modulators of inflammation. In this study, we localized a stimulatory Ca2+-binding site to the N-terminal region of the enzyme. Thus, in a Ca-45(2+) overlay assay, the N-terminal 128 amino acids of recombinant human 5-LO (fused to glutathione S-transferase) bound radioactive calcium to about the same extent as intact 5-LO. The glutathione S-transferase fusion protein of the C-terminal part of 5-LO (amino acids 120-673) showed much weaker binding. A model of a putative 5-LO N-terminal domain was calculated based on the structure of rabbit reticulocyte 15-LO. This model resembles beta -sandwich C2 domains of other Ca2+-binding proteins. Comparison of our model with the C2 domain of cytosolic phospholipase A(2) suggested a number of amino acids, located in the loops that connect the beta -strands, as potential Ca2+ ligands. Indeed, mutations particularly in loop 2 (N43A, D44A, and E46A) led to decreased Ca2+ binding and a requirement for higher Ca2+ concentrations to stimulate enzyme activity. Our data indicate that an N-termind beta -sandwich of 5-LO functions as a C2 domain in the calcium regulation of enzyme activity.	Karolinska Inst, Div Chem 2, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; Karolinska Inst, Stockholm Bioinformat Ctr, SE-17177 Stockholm, Sweden; Karolinska Inst, Div Chem 1, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	Radmark, O (corresponding author), Karolinska Inst, Div Chem 2, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden.	Olof.Radmark@mbb.ki.se	Provost, Patrick/G-2786-2010	Provost, Patrick/0000-0002-6099-6562				Abagyan R, 1997, PROTEINS, P29; BABA A, 1989, J BIOL CHEM, V264, P15790; Ball A, 1999, P NATL ACAD SCI USA, V96, P6637, DOI 10.1073/pnas.96.12.6637; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brinckmann R, 1998, BLOOD, V91, P64, DOI 10.1182/blood.V91.1.64.64_64_74; CHEN XS, 1993, EUR J BIOCHEM, V214, P845, DOI 10.1111/j.1432-1033.1993.tb17988.x; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; Grobler JA, 1997, NAT STRUCT BIOL, V4, P261, DOI 10.1038/nsb0497-261; HAGMANN W, 1993, PROSTAGLANDINS, V46, P471, DOI 10.1016/0090-6980(93)90066-G; HAMASAKI Y, 1984, BIOCHIM BIOPHYS ACTA, V793, P393; HAMBERG M, 1971, ANAL BIOCHEM, V43, P515, DOI 10.1016/0003-2697(71)90282-X; HAMMARBERG T, 1995, EUR J BIOCHEM, V230, P401; Hammarberg T, 1999, BIOCHEMISTRY-US, V38, P4441, DOI 10.1021/bi9824700; IZUMI T, 1990, P NATL ACAD SCI USA, V87, P7477, DOI 10.1073/pnas.87.19.7477; IZUMI T, 1991, EUR J BIOCHEM, V202, P1231, DOI 10.1111/j.1432-1033.1991.tb16495.x; KOCH RB, 1968, ARCH BIOCHEM BIOPHYS, V125, P303, DOI 10.1016/0003-9861(68)90665-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGARDE M, 1984, BIOCHEM J, V222, P495, DOI 10.1042/bj2220495; Lopez-Nicolas JM, 2000, J AGR FOOD CHEM, V48, P292, DOI 10.1021/jf990293j; Martin ACR, 1997, PROTEINS, P14; May C, 2000, EUR J BIOCHEM, V267, P1100, DOI 10.1046/j.1432-1327.2000.01105.x; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; Nalefski EA, 1998, BIOCHEMISTRY-US, V37, P17642, DOI 10.1021/bi982372e; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NOGUCHI M, 1994, BIOCHIM BIOPHYS ACTA, V1212, P300; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Provost P, 1999, P NATL ACAD SCI USA, V96, P1881, DOI 10.1073/pnas.96.5.1881; PUUSTINEN T, 1988, BIOCHIM BIOPHYS ACTA, V960, P261, DOI 10.1016/0005-2760(88)90033-1; RADMARK O, 1999, NOVEL INHIBITORS LEU, P1; Reddy KV, 2000, BIOCHEMISTRY-US, V39, P1840, DOI 10.1021/bi9919246; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Rost B, 1999, PROTEIN ENG, V12, P85, DOI 10.1093/protein/12.2.85; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Serhan CN, 1999, CLIN CHEM LAB MED, V37, P299, DOI 10.1515/CCLM.1999.052; Skorey KI, 1998, BIOCHEMISTRY-US, V37, P8027, DOI 10.1021/bi980371g; SkrzypczakJankun E, 1997, PROTEINS, V29, P15, DOI [10.1002/(SICI)1097-0134(199709)29:1&lt;15::AID-PROT2&gt;3.0.CO;2-E, 10.1002/(SICI)1097-0134(199709)29:1<15::AID-PROT2>3.3.CO;2-F]; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; Tatulian SA, 1998, BIOCHEMISTRY-US, V37, P15481, DOI 10.1021/bi981062t; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WATANABE T, 1993, EUR J BIOCHEM, V212, P605, DOI 10.1111/j.1432-1033.1993.tb17699.x; WATSON A, 1994, BIOCHEM J, V298, P377, DOI 10.1042/bj2980377; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; WONG A, 1991, LIPOXYGENASES THEIR, P67; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874; Zhang XY, 1998, BIOCHEMISTRY-US, V37, P12395, DOI 10.1021/bi9807512; ZHANG YY, 1992, P NATL ACAD SCI USA, V89, P485, DOI 10.1073/pnas.89.2.485	55	138	138	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38787	38793		10.1074/jbc.M006136200	http://dx.doi.org/10.1074/jbc.M006136200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10984486	hybrid			2022-12-27	WOS:000165739800089
J	Scherer, SJ; Maier, SM; Seifert, M; Hanselmann, RG; Zang, KD; Muller-Hermelink, HK; Angel, P; Welter, C; Schartl, M				Scherer, SJ; Maier, SM; Seifert, M; Hanselmann, RG; Zang, KD; Muller-Hermelink, HK; Angel, P; Welter, C; Schartl, M			p53 and c-Jun functionally synergize in the regulation of the DNA repair gene hMSH2 in response to UV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; HUMAN MISMATCH REPAIR; WILD-TYPE P53; NONPOLYPOSIS COLON-CANCER; LI-FRAUMENI SYNDROME; ULTRAVIOLET-LIGHT; PROMOTER REGION; TUMOR-CELLS; APOPTOSIS; MUTATIONS	The tumor suppresser protein p53 is critical for guarding the genome from incorporation of damaged DNA (Lane, D. P. (1992) Nature 358, 15-16). A relevant stress that activates p53 function is UV light (Noda, A, Toma-Aiba, Y., and Fujiwara, Y. (2000) Oncogene 19, 21-31). Another well known component of the mammalian UV response is the transcription factor c-Jun (Angel, P., and Karin, M. (1991) Biochim. Biophys. Acta 1072, 129-157). We show here that upon UV irradiation p53 activates transcription of the human mismatch repair gene MSH2. Interestingly, this up-regulation critically depends on functional interaction with c-Jun. Hence, the synergistic interaction of a proto-oncogene with a tumor suppresser gene is required for the regulation of the mammalian stress response through activation of expression of MSH2.	Univ Wurzburg, Bioctr, Dept Physiol Chem 1, D-97074 Wurzburg, Germany; Univ Saarlandes, Dept Human Genet, D-66421 Homburg, Germany; Univ Saarland, Dept Expt Phys, D-68111 Saarbrucken, Germany; Univ Wurzburg, Dept Pathol, D-97080 Wurzburg, Germany; Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, D-69120 Heidelberg, Germany	University of Wurzburg; Saarland University; Saarland University; University of Wurzburg; Helmholtz Association; German Cancer Research Center (DKFZ)	Schartl, M (corresponding author), Univ Wurzburg, Bioctr, Dept Physiol Chem 1, Hubland, D-97074 Wurzburg, Germany.		Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634; Schartl, Manfred/0000-0001-9882-5948				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; HAVRE PA, 1995, CANCER RES, V55, P4420; Henseleit U, 1997, J INVEST DERMATOL, V109, P722, DOI 10.1111/1523-1747.ep12340708; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li G, 1998, BRIT J DERMATOL, V139, P3; Li G, 1996, AM J PATHOL, V148, P1113; Li G, 1997, AM J PATHOL, V150, P1457; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; McKay BC, 1997, CARCINOGENESIS, V18, P245, DOI 10.1093/carcin/18.2.245; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Noda A, 2000, ONCOGENE, V19, P21, DOI 10.1038/sj.onc.1203230; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Scherer SJ, 1996, BIOCHEM BIOPH RES CO, V221, P722, DOI 10.1006/bbrc.1996.0663; Scherer SJ, 1996, HUM GENET, V97, P114; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SMITH ML, 1995, ONCOGENE, V10, P1053; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; UMAR A, 1994, J BIOL CHEM, V269, P14367; VOGELSTEIN B, 1998, GENETIC BASIS HUMAN, P241; Wang HX, 1999, J BIOL CHEM, V274, P16894, DOI 10.1074/jbc.274.24.16894; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang Y, 1998, J INVEST DERMATOL, V111, P380, DOI 10.1046/j.1523-1747.1998.00319.x; Yamagishi N, 1997, MUTAGENESIS, V12, P191, DOI 10.1093/mutage/12.3.191; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JL, 1995, CARCINOGENESIS, V16, P2295, DOI 10.1093/carcin/16.10.2295; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	49	78	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37469	37473		10.1074/jbc.M006990200	http://dx.doi.org/10.1074/jbc.M006990200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10984493	hybrid			2022-12-27	WOS:000165618700024
J	Jakubowski, H				Jakubowski, H			Amino acid selectivity in the aminoacylation of coenzyme A and RNA minihelices by aminoacyl-tRNA synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE BIOSYNTHESIS; SITE	Coenzyme A (CoA-SH), a cofactor in carboxyl group activation reactions, carries out a function in nonribosomal peptide synthesis that is analogous to the function of tRNA in ribosomal protein synthesis. The amino acid selectivity in the synthesis of aminoacyl-thioesters by nonribosomal peptide synthetases is relaxed, whereas the amino acid selectivity in the synthesis of aminoacyl-tRNA by aminoacyl-tRNA synthetases is restricted. Here I show that isoleucyl-tRNA synthetase aminoacylates CoA-SH with valine, leucine, threonine, alanine, and serine in addition to isoleucine. Valyl-tRNA synthetase catalyzes aminoacylations of CoA-SH with valine, threonine, alanine, serine, and isoleucine. Lysyl-tRNA synthetase aminoacylates CoA-SH with lysine, leucine, threonine, alanine, valine, and isoleucine. Thus, isoleucyl-, valyl-, and lysyl-tRNA synthetases behave as aminoacyl-S-CoA synthetases with relaxed amino acid selectivity. In contrast, RNA minihelices comprised of the acceptor-T psiC helix of tRNA(Ile) or tRNA(Val) were aminoacylated by cognate synthetases selectively with isoleucine or valine, respectively. These and other data support a hypothesis that the present day aminoacyl-tRNA synthetases originated from ancestral forms that were involved in noncoded thioester-dependent peptide synthesis, functionally similar to the present day nonribosomal peptide synthetases.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Jakubowski, H (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, 185 S Orange Ave, Newark, NJ 07103 USA.		Jakubowski, Hieronim/A-2510-2017; Jakubowski, Hieronim/AAA-6834-2019	Jakubowski, Hieronim/0000-0001-5845-4409; 				DEDUVE C, 1994, VITAL DUST, P43; FRUGIER M, 1992, P NATL ACAD SCI USA, V89, P3990, DOI 10.1073/pnas.89.9.3990; Gillet S, 1997, PROTEIN SCI, V6, P2426; JAKUBOWSKI H, 1980, BIOCHEMISTRY-US, V19, P5071, DOI 10.1021/bi00563a021; Jakubowski H, 1996, BIOCHEMISTRY-US, V35, P8252, DOI 10.1021/bi960344v; JAKUBOWSKI H, 1995, NUCLEIC ACIDS RES, V23, P4608, DOI 10.1093/nar/23.22.4608; Jakubowski H, 1996, NUCLEIC ACIDS RES, V24, P2505, DOI 10.1093/nar/24.13.2505; Jakubowski H, 1998, BIOCHEMISTRY-US, V37, P5147, DOI 10.1021/bi972528v; Jakubowski H, 1999, BIOCHEMISTRY-US, V38, P8088, DOI 10.1021/bi990629i; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; Jakubowski H, 1997, BIOCHEMISTRY-US, V36, P11077, DOI 10.1021/bi970589n; JAKUBOWSKI H, 2000, ENCY LIFE SCI; Keating TA, 2000, BIOCHEMISTRY-US, V39, P2297, DOI 10.1021/bi992341z; Kleinkauf H, 1996, EUR J BIOCHEM, V236, P335, DOI 10.1111/j.1432-1033.1996.00335.x; LIPMANN F, 1971, SCIENCE, V173, P875, DOI 10.1126/science.173.4000.875; MARTINIS SA, 1992, P NATL ACAD SCI USA, V89, P65, DOI 10.1073/pnas.89.1.65; Nordin BE, 1999, J BIOL CHEM, V274, P6835, DOI 10.1074/jbc.274.11.6835; SCHIMMEL P, 1994, P NATL ACAD SCI USA, V91, P11283, DOI 10.1073/pnas.91.24.11283; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712	20	18	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34845	34848		10.1074/jbc.C000577200	http://dx.doi.org/10.1074/jbc.C000577200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10995737	hybrid			2022-12-27	WOS:000165422800004
J	Grover, J; Liu, CY; Kao, WWY; Roughley, PJ				Grover, J; Liu, CY; Kao, WWY; Roughley, PJ			Analysis of the human lumican gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATAN SULFATE PROTEOGLYCAN; HUMAN ARTICULAR-CARTILAGE; RNA-POLYMERASE-II; TRANSCRIPTION FACTORS; CHICK LUMICAN; MOUSE LUMICAN; PROTEIN PRELP; EXPRESSION; COLLAGEN; BINDING	The human lumican gene was shown to possess one major transcription start site, resulting in exon 1 of the gene giving rise to the first 74 base pairs (bp) of the 5'-untranslated region. About 1.6 kilobase pairs of up. stream promoter sequence were sequenced and analyzed to identify elements responsible for gene expression. No typical TATAA sequence was identified in the vacinity of the transcription start site, but an atypical TATCA sequence residing 41 bp upstream was shown to be necessary for transcription, although it was incapable of supporting transcription by itself. A GC box residing 74 bp upstream of the transcription start site also was essential for the initiation of transcription. Sp3 was identified as the transcriptional activator binding to the GC box. No additional elements that significantly modulated transcription were noted in the promoter sequence analyzed, when using human adult chondrocytes as the cell source for transfection in reporter assays. In contrast, reporter assays carried out in human fetal lung fibroblasts, where lumican expression is deplete, revealed the presence of a repressor element located between 384 and 598 bp upstream of the transcription start site. A GATA-binding site located between bp -386 and -391 was identified as being necessary for repression of transcription. The mouse lumican promoter does not possess an equivalent site, and this may explain why the lumican gene is expressed in fetal murine cartilage but not in fetal human cartilage.	Shriners Hosp Children, Genet Unit, Montreal, PQ H3G 1A6, Canada; McGill Univ, Dept Surg, Montreal, PQ H3G 1A6, Canada; Univ Cincinnati, Dept Ophthalmol, Cincinnati, OH 45267 USA	McGill University; McGill University; University System of Ohio; University of Cincinnati	Roughley, PJ (corresponding author), Shriners Hosp Children, Genet Unit, 1529 Cedar Ave, Montreal, PQ H3G 1A6, Canada.			Liu, Chia-yang/0000-0002-8398-5516	NATIONAL EYE INSTITUTE [R01EY011845] Funding Source: NIH RePORTER; NEI NIH HHS [EY11845] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; CHAKRAVARTI S, 1995, GENOMICS, V27, P481, DOI 10.1006/geno.1995.1080; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNUET PK, 1994, INVEST OPHTH VIS SCI, V35, P870; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dolhnikoff M, 1998, AM J RESP CELL MOL, V19, P582, DOI 10.1165/ajrcmb.19.4.2979; Dunlevy JR, 1998, J BIOL CHEM, V273, P9615, DOI 10.1074/jbc.273.16.9615; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P24773; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; FUNDERBURGH JL, 1995, INVEST OPHTH VIS SCI, V36, P2296; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; Grover J, 1998, BIOCHEM J, V336, P77, DOI 10.1042/bj3360077; Grover J, 1996, GENOMICS, V38, P109, DOI 10.1006/geno.1996.0605; GROVER J, 1995, J BIOL CHEM, V270, P21942, DOI 10.1074/jbc.270.37.21942; Haenlin M, 1997, GENE DEV, V11, P3096, DOI 10.1101/gad.11.22.3096; Hassell JR, 1998, BBA-GENE STRUCT EXPR, V1397, P119, DOI 10.1016/S0167-4781(98)00022-0; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; Hocking AM, 1998, MATRIX BIOL, V17, P1; Holmes M, 1999, J BIOL CHEM, V274, P23491, DOI 10.1074/jbc.274.33.23491; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Melching LI, 1997, MATRIX BIOL, V16, P1, DOI 10.1016/S0945-053X(97)90111-6; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; Saika S, 2000, J BIOL CHEM, V275, P2607, DOI 10.1074/jbc.275.4.2607; Sambrook J., 2002, MOL CLONING LAB MANU; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; TAKAHASHI T, 1993, J HISTOCHEM CYTOCHEM, V41, P1447, DOI 10.1177/41.10.8245404; Weis L, 1997, MOL CELL BIOL, V17, P2973, DOI 10.1128/MCB.17.6.2973; WHYATT DJ, 1993, EMBO J, V12, P4993, DOI 10.1002/j.1460-2075.1993.tb06193.x; Ying SX, 1997, J BIOL CHEM, V272, P30306, DOI 10.1074/jbc.272.48.30306	33	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40967	40973		10.1074/jbc.M004134200	http://dx.doi.org/10.1074/jbc.M004134200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11016924	hybrid			2022-12-27	WOS:000166114600042
J	Achur, RN; Valiyaveettil, M; Alkhalil, A; Ockenhouse, CF; Gowda, DC				Achur, RN; Valiyaveettil, M; Alkhalil, A; Ockenhouse, CF; Gowda, DC			Characterization of proteoglycans of human placenta and identification of unique chondroitin sulfate proteoglycans of the intervillous spaces that mediate the adherence of Plasmodium falciparum-infected erythrocytes to the placenta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; MICROVASCULAR ENDOTHELIAL-CELLS; RED-BLOOD-CELLS; ANTIGENIC VARIATION; CARTILAGE PROTEOGLYCAN; MEMBRANE GLYCOPROTEIN; FLOW CONDITIONS; CHICK-EMBRYO; VAR GENES; MALARIA	In pregnant women infected with Plasmodium falciparum, the infected red blood cells (IRBCs) selectively accumulate in the intervillous spaces of placenta, leading to poor fetal outcome and severe health complications in the mother. Although chondroitin 4-sulfate is known to mediate IRBC adherence to placenta, the natural receptor has not been identified. In the present study, the chondroitin sulfate proteoglycans (CSPGs) of human placenta were purified and structurally characterized, and adherence of IRBCs to these CSPGs investigated. The data indicate that the placenta contains three distinct types of CSPGs: significant quantities of uniquely low sulfated, extracellular CSPGs localized in the intervillous spaces, minor amounts of two cell-associated CSPGs, and major amounts of dermatan sulfate-like CSPGs of the fibrous tissue. Of the various CSPGs isolated from the placenta, the low sulfated CSPGs of the intervillous spaces most efficiently bind IRBCs. Based on IRBC adherence capacities and localization patterns of various CSPGs, we conclude that the CSPGs of the intervillous spaces are the receptors for placental IRBC adherence. The identification and characterization of these CSPGs provide a valuable tool for understanding the precise molecular interactions involved in placental IRBC adherence and for the development of therapeutic strategies for maternal malaria. In the accompanying paper we report the structural requirements for the IRBC adherence.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Walter Reed Army Inst Res, Dept Immunol, Silver Spring, MD 20910 USA	Georgetown University; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Gowda, DC (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	gowda@bc.georgetown.edu		Achur, Rajeshwara/0000-0001-9867-8917; Gowda, Channe/0000-0002-6860-5108	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI045086, R01AI045086] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45086] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhalil A, 2000, J BIOL CHEM, V275, P40357, DOI 10.1074/jbc.M006399200; BARNWELL JW, 1989, J CLIN INVEST, V84, P765, DOI 10.1172/JCI114234; Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Beeson JG, 2000, NAT MED, V6, P86, DOI 10.1038/71582; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BORST P, 1995, CELL, V82, P1, DOI 10.1016/0092-8674(95)90044-6; BRADBURY S., 1965, J ROY MICROSCOP SOC, V84, P199; BRENNAN MJ, 1984, J BIOL CHEM, V259, P3742; Buffet PA, 1999, P NATL ACAD SCI USA, V96, P12743, DOI 10.1073/pnas.96.22.12743; CALATRONI A, 1969, CARBOHYD RES, V10, P535, DOI 10.1016/S0008-6215(00)80122-6; CARLSON DM, 1968, J BIOL CHEM, V243, P616; CARRINO DA, 1984, J BIOL CHEM, V259, P2419; Chaiyaroj SC, 1996, AM J TROP MED HYG, V55, P76, DOI 10.4269/ajtmh.1996.55.76; CHOI HU, 1989, J BIOL CHEM, V264, P2876; Cooke BM, 1996, BLOOD, V88, P4040, DOI 10.1182/blood.V88.10.4040.bloodjournal88104040; CURRIE GA, 1967, LANCET, V1, P708; DAVIDSON EA, 1954, J BIOL CHEM, V211, P605; DISCHE Z, 1947, J BIOL CHEM, V167, P189; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FISHER LW, 1983, J BIOL CHEM, V258, P6588; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Fried M, 1998, J MOL MED-JMM, V76, P162, DOI 10.1007/s001090050205; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Gardner JP, 1996, P NATL ACAD SCI USA, V93, P3503, DOI 10.1073/pnas.93.8.3503; GILLES HM, 1993, BRUCECHWATTS ESSENTI, P1; Gysin J, 1997, MOL BIOCHEM PARASIT, V88, P267, DOI 10.1016/S0166-6851(97)00082-0; HARDY MR, 1989, METHOD ENZYMOL, V179, P76; Hascall V. C., 1981, BIOL CARBOHYDRATES, V1, P1; HATAE Y, 1975, ANAL BIOCHEM, V64, P30, DOI 10.1016/0003-2697(75)90400-5; HOMMEL M, 1993, ANN TROP MED PARASIT, V87, P627, DOI 10.1080/00034983.1993.11812821; HOVINGH P, 1974, CARBOHYD RES, V37, P181, DOI 10.1016/S0008-6215(00)87073-1; Kaul DK, 1998, AM J TROP MED HYG, V58, P240, DOI 10.4269/ajtmh.1998.58.240; KIMATA K, 1986, J BIOL CHEM, V261, P3517; KRUEGER RC, 1987, ANAL BIOCHEM, V167, P295, DOI 10.1016/0003-2697(87)90167-9; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TY, 1973, PEDIATR RES, V7, P965, DOI 10.1203/00006450-197312000-00005; LIN JH, 1994, J BIOL CHEM, V269, P25021; Lovell D, 1967, J Obstet Gynaecol Br Commonw, V74, P568; MARSH K, 1992, PARASITOLOGY, V104, pS53, DOI 10.1017/S0031182000075247; MARTIN BJ, 1974, ANAT REC, V178, P769, DOI 10.1002/ar.1091780408; MARUYAMA I, 1985, J CELL BIOL, V101, P363, DOI 10.1083/jcb.101.2.363; Maubert B, 1997, INFECT IMMUN, V65, P1251, DOI 10.1128/IAI.65.4.1251-1257.1997; Maubert B, 2000, PARASITE IMMUNOL, V22, P191, DOI 10.1046/j.1365-3024.2000.00292.x; McCormick CJ, 1997, J CLIN INVEST, V100, P2521, DOI 10.1172/JCI119794; MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0; MENENDEZ C, 1995, PARASITOL TODAY, V11, P178, DOI 10.1016/0169-4758(95)80151-0; Miller LH, 1998, NAT MED, V4, P1244, DOI 10.1038/3223; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; OCKENHOUSE CF, 1991, J INFECT DIS, V164, P163, DOI 10.1093/infdis/164.1.163; OCKENHOUSE CF, 1992, J EXP MED, V176, P1183, DOI 10.1084/jem.176.4.1183; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; OTOTANI N, 1979, CARBOHYD RES, V70, P295, DOI 10.1016/S0008-6215(00)87109-8; PASLOSKE BL, 1994, ANNU REV MED, V45, P283; PONTING JM, 1995, J ANAT, V186, P131; POOLE AR, 1986, BIOCHEM J, V236, P1; Pouvelle B, 1997, MOL MED, V3, P508, DOI 10.1007/BF03401697; REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6; Reeder JC, 1999, P NATL ACAD SCI USA, V96, P5198, DOI 10.1073/pnas.96.9.5198; Robert C, 1995, RES IMMUNOL, V146, P383, DOI 10.1016/0923-2494(96)81042-X; Rogerson SJ, 1997, EXP PARASITOL, V86, P8, DOI 10.1006/expr.1996.4142; ROGERSON SJ, 1995, J EXP MED, V182, P15, DOI 10.1084/jem.182.1.15; SAITO H, 1968, J BIOL CHEM, V243, P1536; SALEM HH, 1984, J BIOL CHEM, V259, P2246; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; Steketee RW, 1996, AM J TROP MED HYG, V55, P2, DOI 10.4269/ajtmh.1996.55.2; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; SUNDERLAND CA, 1985, J REPROD IMMUNOL, V8, P197, DOI 10.1016/0165-0378(85)90041-5; SVEJCAR J, 1968, BIOCHIM BIOPHYS ACTA, V165, P84, DOI 10.1016/0304-4165(68)90191-8; Treutiger CJ, 1997, NAT MED, V3, P1405, DOI 10.1038/nm1297-1405; Udomsangpetch R, 1997, J IMMUNOL, V158, P4358; VOGEL KG, 1987, J BIOL CHEM, V262, P13607; WALTER PR, 1982, AM J PATHOL, V109, P330; WARRELL DA, 1987, PARASITOLOGY, V94, pS53, DOI 10.1017/S0031182000085826; WASSERMAN L, 1983, PLACENTA, V4, P101, DOI 10.1016/S0143-4004(83)80021-6; Xiao LH, 1996, EXP PARASITOL, V84, P42, DOI 10.1006/expr.1996.0088; YAMADA M, 1989, AM J TROP MED HYG, V41, P161, DOI 10.4269/ajtmh.1989.41.161; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	84	141	146	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40344	40356		10.1074/jbc.M006398200	http://dx.doi.org/10.1074/jbc.M006398200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11005814	hybrid			2022-12-27	WOS:000166039500075
J	Heath, RJ; Su, N; Murphy, CK; Rock, CO				Heath, RJ; Su, N; Murphy, CK; Rock, CO			The enoyl-[acyl-carrier-protein] reductases FabI and FabL from Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-CARRIER-PROTEIN; FATTY-ACID ELONGATION; ENOYL-ACP REDUCTASE; ESCHERICHIA-COLI; MYCOBACTERIUM-TUBERCULOSIS; TRICLOSAN; GENE; TARGET; INHA; INHIBITION	Enoyl-[acyl-carrier-protein] (ACP) reductase is a key enzyme in type II fatty-acid synthases that catalyzes the last step in each elongation cycle. The FabI component of Bacillus subtilis (bsFabI) was identified in the genomic data base by homology to the Escherichia coli protein, bsFabI was cloned and purified and exhibited properties similar to those of E. coli FabI, including a marked preference for NADH over NADPH as a cofactor. Overexpression of the B. subtilis fabI gene complemented the temperature-sensitive growth phenotype of an E. coli fabI mutant. Triclosan was a slow-binding inhibitor of bsFabI and formed a stable bsFabI NAD(+.) triclosan ternary complex. Analysis of the B. subtilis genomic data base revealed a second open reading frame (ygaA) that was predicted to encode a protein with a relatively low overall similarity to FabI, but contained the Tyr-Xaa(6)-Lys enoyl-ACP reductase catalytic architecture. The purified YgaA protein catalyzed the NADPH-dependent reduction of trans-2-enoyl thioesters of both N-acetylcysteamine and ACP. YgaA was reversibly inhibited by triclosan, but did not form the stable ternary complex characteristic of the FabI proteins. Expression of YgaA complemented the fabI(ts) defect in E. coli and conferred complete triclosan resistance. Single knockouts of the ygaA or fabI gene in B. subtilis were viable, but double knockouts were not obtained. The fabI knockout was as sensitive as the wild-type strain to triclosan, whereas the ygaA knockout was 250-fold more sensitive to the drug. YgaA was renamed FabL to denote the discovery of a new family of proteins that carry out the enoyl-ACP reductase step in type II fatty-acid synthases.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38105 USA; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.			Heath, Richard/0000-0002-1795-1254	NCI NIH HHS [CA21765] Funding Source: Medline; NIGMS NIH HHS [GM34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034496, R37GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAKER ME, 1995, BIOCHEM J, V309, P1029, DOI 10.1042/bj3091029; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BERGLER H, 1992, J GEN MICROBIOL, V138, P2093, DOI 10.1099/00221287-138-10-2093; BERGLER H, 1994, J BIOL CHEM, V269, P5493; CUTTING SM, 1990, MOL BIOL METHODS BAC, P67; de Boer GJ, 1999, MOL MICROBIOL, V31, P443, DOI 10.1046/j.1365-2958.1999.01182.x; Duax WL, 1996, CURR OPIN STRUC BIOL, V6, P813, DOI 10.1016/S0959-440X(96)80012-1; EGAN AF, 1973, GENET RES, V21, P3603; Heath RJ, 2000, NATURE, V406, P145, DOI 10.1038/35018162; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; HEATH RJ, 1995, J BIOL CHEM, V270, P15531, DOI 10.1074/jbc.270.26.15531; Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316; Heath RJ, 2000, J BIOL CHEM, V275, P4654, DOI 10.1074/jbc.275.7.4654; Heath RJ, 1999, J BIOL CHEM, V274, P11110, DOI 10.1074/jbc.274.16.11110; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Levy CW, 1999, NATURE, V398, P383, DOI 10.1038/18803; McMurry LM, 1998, NATURE, V394, P531, DOI 10.1038/28970; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Parikh S, 1999, BIOCHEMISTRY-US, V38, P13623, DOI 10.1021/bi990529c; PETTY KJ, 1994, CURRENT PROTOCOLS MO; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; Rock C. O., 1996, NEW COMPREHENSIVE BI, V31, P35; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; Roujeinikova A, 1999, J MOL BIOL, V294, P527, DOI 10.1006/jmbi.1999.3240; Roujeinikova A, 1999, J BIOL CHEM, V274, P30811, DOI 10.1074/jbc.274.43.30811; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; Wang P, 1996, J BACTERIOL, V178, P6873, DOI 10.1128/jb.178.23.6873-6881.1996; Ward WHJ, 1999, BIOCHEMISTRY-US, V38, P12514, DOI 10.1021/bi9907779; WEEKS G, 1968, J BIOL CHEM, V243, P1180; YOUNGMAN P, 1984, PLASMID, V12, P1, DOI 10.1016/0147-619X(84)90061-1	34	156	175	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40128	40133		10.1074/jbc.M005611200	http://dx.doi.org/10.1074/jbc.M005611200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007778	hybrid			2022-12-27	WOS:000166039500046
J	Chi, YH; Kumar, TKS; Chiu, IM; Yu, C				Chi, YH; Kumar, TKS; Chiu, IM; Yu, C			N-15 NMR relaxation studies of free and ligand-bound human acidic fibroblast growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE RELAXATION; FGF RECEPTOR DIMERIZATION; MODEL-FREE APPROACH; BACKBONE DYNAMICS; 3-DIMENSIONAL STRUCTURE; BINDING; SPECTROSCOPY; POLYANIONS; DOMAIN; OLIGOMERIZATION	N-15 NMR relaxation data have been used to characterize the backbone dynamics of the human acidic fibroblast growth factor (hFGF-1) in its free and sucrose octasulfate (SOS)-bound states. N-15 longitudinal (R-1), transverse (R-2) relaxation rates and {H-1}-N-15 steady-state nuclear Overhauser effects were obtained at 500 and 600 MHz (at 25 degreesC) for all resolved backbone amide groups using H-1- detected two-dimensional NMR experiments. Relaxation data were fit to the extended model free dynamics for each NH group. The overall correlation time (tau (m)) for the free and SOS-bound forms were estimated to be 10.4 +/- 1.07 and 11.1 +/- 1.35 ns, respectively. Titration experiments with SOS reveals that the Ligand binds specifically to the C-terminal domain of the protein in a 1:1 ratio. Binding of SOS to hFGF-1 is found to induce a subtle conformational change in the protein. Significant conformational exchange (R-ex) is observed for several residues in the free form of the protein. How ever, in the SOS-bound form only three residues exhibit significant R-ex values, suggesting that the dynamics on the micro- to millisecond time scale in the free form is coupled to the cts-trans-proline isomerization. hFGF-1 is a rigid molecule with an average generalized parameter (S-2) value of 0.89 +/- 0.03. Upon binding to SOS, there is a marked decrease in the overall flexibility (S-2 = 0.94 +/- 0.02) of the hFGF-1 molecule. However, the segment comprising residues 103-111 shows increased flexibility in the presence of SOS. Significant correlation is found between residues that show high flexibility and the putative receptor binding sites on the protein.	Natl Tsing Hua Univ, Dept Chem, Hsinchu 30043, Taiwan; Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA	National Tsing Hua University; University System of Ohio; Ohio State University	Yu, C (corresponding author), Natl Tsing Hua Univ, Dept Chem, Hsinchu 30043, Taiwan.		Chi, Ya-Hui/B-1080-2010; Chi, Ya-Hui/ABE-8550-2020; Kumar, Dr Suresh/HHZ-2615-2022; Chiu, Ing-Ming/B-1534-2008; Kumar, Suresh Thallapuranam/R-5606-2016; KUMAR, P. SURESH/AAT-8951-2020	Chi, Ya-Hui/0000-0002-9216-0938; Kumar, Dr Suresh/0000-0002-2539-6553; Kumar, Suresh Thallapuranam/0000-0001-7262-1373; KUMAR, P. SURESH/0000-0003-3222-2604				BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BASCILICO C, 1992, ADV CANCER RES, V59, P115; Blaber SI, 1999, BIOPHYS J, V77, P470, DOI 10.1016/S0006-3495(99)76904-3; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURKE CJ, 1993, BIOCHEMISTRY-US, V32, P6419, DOI 10.1021/bi00076a015; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; DABORA JM, 1991, J BIOL CHEM, V266, P23637; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; Faham S, 1998, CURR OPIN STRUC BIOL, V8, P578, DOI 10.1016/S0959-440X(98)80147-4; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; GASPODAROWICZ D, 1986, J CELL PHYSL, V128, P475; Herr AB, 1997, J BIOL CHEM, V272, P16382, DOI 10.1074/jbc.272.26.16382; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; LEATHERBARROW RJ, 1992, GRAFT VERSION 3 0; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MACH H, 1994, ARCH BIOCHEM BIOPHYS, V309, P36, DOI 10.1006/abbi.1994.1080; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; Moy FJ, 1998, BIOCHEMISTRY-US, V37, P1495, DOI 10.1021/bi972181w; Ogura K, 1999, J BIOMOL NMR, V13, P11, DOI 10.1023/A:1008330622467; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; PASCAL SM, 1995, BIOCHEMISTRY-US, V34, P11353, DOI 10.1021/bi00036a008; PinedaLucena A, 1996, J MOL BIOL, V264, P162, DOI 10.1006/jmbi.1996.0631; PINEDALUCENA A, 1994, J MOL BIOL, V242, P81, DOI 10.1006/jmbi.1994.1558; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; PRESS WH, 1992, NUMERICAL RECIPES FO, P48; Sanz JM, 1997, EUR J BIOCHEM, V246, P328, DOI 10.1111/j.1432-1033.1997.00328.x; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; Stivers JT, 1996, BIOCHEMISTRY-US, V35, P16036, DOI 10.1021/bi961834q; STONE MJ, 1993, BIOCHEMISTRY-US, V32, P426, DOI 10.1021/bi00053a007; VOLKIN DB, 1993, BIOCHIM BIOPHYS ACTA, V1203, P18, DOI 10.1016/0167-4838(93)90031-L; Ye JQ, 1999, J BIOMOL NMR, V15, P115, DOI 10.1023/A:1008376728947; Zhu HY, 1997, PROTEIN ENG, V10, P417, DOI 10.1093/protein/10.4.417; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	37	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39444	39450		10.1074/jbc.M007205200	http://dx.doi.org/10.1074/jbc.M007205200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10982816	hybrid			2022-12-27	WOS:000165953100069
J	Jez, JM; Noel, JP				Jez, JM; Noel, JP			Mechanism of chalcone synthase - pK(a) of the catalytic cysteine and the role of the conserved histidine in a plant polyketide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHETASE; ACTIVE-SITE; COMBINATORIAL BIOSYNTHESIS; HETEROLOGOUS EXPRESSION; PAPAIN; RESIDUES; PATHWAY; FAMILY; THIOREDOXIN; MUTAGENESIS	Polyketide synthases (PHS) assemble structurally diverse natural products using a common mechanistic strategy that relies on a cysteine residue to anchor the polyketide during a series of decarboxylative condensation reactions that build the final reaction product. Crystallographic and functional studies of chalcone synthase (CHS), a plant-specific PKS, indicate that a cysteine-histidine pair (Cys(164)His(303)) forms part of the catalytic machinery. Thiol-specific inactivation and the pH dependence of the malonyl-CoA decarboxylation reaction were used to evaluate the potential interaction between these two residues. Inactivation of CHS by iodoacetamide and iodoacetic acid targets Cys(164) in a pH-dependent manner (pK(a) = 5.50). The acidic pK(a) of Cys(164) suggests that an ionic interaction with His(303) stabilizes the thiolate anion. Consistent with this assertion, substitution of a glutamine for His(303) maintains catalytic activity but shifts the pK(a) of the thiol to 6.61. Although the H303A mutant was catalytically inactive, the pH-dependent incorporation of [C-14]iodoacetamide into this mutant exhibits a pK(a) = 7.62. Subsequent analysis of the pH dependence of the malonyl-CoA decarboxylation reaction catalyzed by wild-type CHS and the H303Q and C164A. mutants also supports the presence of an ion pair at the CHS active site. Structural and sequence conservation of a cysteine-histidine pair in the active sites of other PKS implies that a thiolate-imidazolium ion pair plays a central role in polyketide biosynthesis.	Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA	Salk Institute	Noel, JP (corresponding author), Salk Inst Biol Studies, Struct Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Noel, Joseph P/A-9459-2009		NATIONAL CANCER INSTITUTE [F32CA080396] Funding Source: NIH RePORTER; NCI NIH HHS [CA80396] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbadi A, 2000, BIOCHEM J, V345, P153, DOI 10.1042/0264-6021:3450153; Bentley R, 1999, ANNU REV MICROBIOL, V53, P411, DOI 10.1146/annurev.micro.53.1.411; Birt DF, 1996, PROG CLIN BIOL RES, V395, P223; Cleland W W, 1979, Methods Enzymol, V63, P103; Davies C, 2000, STRUCTURE, V8, P185, DOI 10.1016/S0969-2126(00)00094-0; Dillet V, 1998, BIOCHEMISTRY-US, V37, P10298, DOI 10.1021/bi980333x; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085; Dreier J, 2000, BIOCHEMISTRY-US, V39, P2088, DOI 10.1021/bi992121l; EDWARDS ML, 1990, J MED CHEM, V33, P1948, DOI 10.1021/jm00169a021; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; Ferrer JL, 1999, NAT STRUCT BIOL, V6, P775, DOI 10.1038/11553; Funa N, 1999, NATURE, V400, P897, DOI 10.1038/23748; He M, 2000, J BACTERIOL, V182, P2619, DOI 10.1128/JB.182.9.2619-2623.2000; Helariutta Y, 1996, P NATL ACAD SCI USA, V93, P9033, DOI 10.1073/pnas.93.17.9033; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HOPWOOD DA, 1997, CHEM REV, V97, P2365; Hutchinson CR, 1998, CURR OPIN MICROBIOL, V1, P319, DOI 10.1016/S1369-5274(98)80036-2; Jez JM, 2000, BIOCHEMISTRY-US, V39, P890, DOI 10.1021/bi991489f; JUNGHANNS KT, 1995, PLANT MOL BIOL, V27, P681, DOI 10.1007/BF00020222; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; Khosla C, 1999, ANNU REV BIOCHEM, V68, P219, DOI 10.1146/annurev.biochem.68.1.219; KIM ES, 1995, J BACTERIOL, V177, P1202, DOI 10.1128/jb.177.5.1202-1207.1995; KITZ R, 1962, J BIOL CHEM, V237, P3235; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; KREUZALER F, 1978, FEBS LETT, V94, P175, DOI 10.1016/0014-5793(78)80931-4; KREUZALER F, 1975, EUR J BIOCHEM, V56, P203; KYTE J, 1995, STRUCTURE PROTEIN CH, P59; LANZ T, 1991, J BIOL CHEM, V266, P9971; LEWIS SD, 1976, BIOCHEMISTRY-US, V15, P5009, DOI 10.1021/bi00668a010; LEWIS SD, 1981, BIOCHEMISTRY-US, V20, P48, DOI 10.1021/bi00504a009; Li RS, 1995, J MED CHEM, V38, P5031, DOI 10.1021/jm00026a010; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; OESTERHELT D, 1977, EUR J BIOCHEM, V79, P173, DOI 10.1111/j.1432-1033.1977.tb11795.x; OLEARY MH, 1992, ENZYMES, V20, P235; POLGAR L, 1987, J BIOL CHEM, V262, P14448; PREISIGMULLER R, 1995, ARCH BIOCHEM BIOPHYS, V317, P201, DOI 10.1006/abbi.1995.1154; Schlegel BP, 1998, BIOCHEMISTRY-US, V37, P3538, DOI 10.1021/bi9723055; SCHRODER G, 1988, EUR J BIOCHEM, V172, P161, DOI 10.1111/j.1432-1033.1988.tb13868.x; Schroder J, 1997, TRENDS PLANT SCI, V2, P373, DOI 10.1016/S1360-1385(97)01104-7; Setchell KDR, 1999, J NUTR, V129, p758S, DOI 10.1093/jn/129.3.758S; Siggaard-Andersen Mads, 1993, Protein Sequences and Data Analysis, V5, P325; STOECKIGT J, 1975, Zeitschrift fuer Naturforschung Teil C Biochemie Biophysik Biologie Virologie, V30, P352; STOOPS JK, 1983, J BIOL CHEM, V258, P2482; STORER AC, 1994, METHOD ENZYMOL, V244, P486; Tipton K F, 1979, Methods Enzymol, V63, P183; TROPF S, 1995, J BIOL CHEM, V270, P7922, DOI 10.1074/jbc.270.14.7922; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WALSH CT, 1979, ENZYMATIC REACTION M, P26; Witkowski A, 1999, BIOCHEMISTRY-US, V38, P11643, DOI 10.1021/bi990993h; Zwaagstra ME, 1997, J MED CHEM, V40, P1075, DOI 10.1021/jm960628d	51	112	127	3	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39640	39646		10.1074/jbc.M008569200	http://dx.doi.org/10.1074/jbc.M008569200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11006298	hybrid			2022-12-27	WOS:000165953100091
J	Boskovic, DS; Krishnaswamy, S				Boskovic, DS; Krishnaswamy, S			Exosite binding tethers the macromolecular substrate to the prothrombinase complex and directs cleavage at two spatially distinct sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE CHLOROMETHYL KETONES; DEPENDENT ENZYME COMPLEXES; FACTOR-VA; ACTIVE-SITE; FACTOR-XA; CATALYZED ACTIVATION; BLOOD-COAGULATION; PHOSPHOLIPID-VESICLES; SPECTROSCOPIC PROBES; CRYSTAL-STRUCTURE	The prothrombinase complex, composed of the proteinase, factor Xa, bound to factor Va on membranes, catalyzes thrombin formation by the specific and ordered proteolysis of prothrombin at Arg(323)-Ile(324), followed by cleavage at Arg(274)-Thr(275). We have used a fluorescent derivative of meizothrombin des fragment I (mIIa Delta F1) as a substrate analog to assess the mechanism of substrate recognition in the second half-reaction of bovine prothrombin activation. Cleavage of mIIa Delta F1 exhibits pseudo-first order kinetics regardless of the substrate concentration relative to K-m. This phenomenon arises from competitive product inhibition by thrombin, which binds to prothrombinase with exactly the same affinity as mIIa Delta F1. As thrombin is known to bind to an exosite on prothrombinase, initial interactions at an exosite likely play a role in the enzyme-substrate interaction. Occupation of the active site of prothrombinase by a reversible inhibitor does not exclude the binding of mIIa Delta F1 to the enzyme. Specific recognition of mIIa Delta FI is achieved through an initial bimolecular reaction with an enzymic exosite, followed by an active site docking step in an intramolecular reaction prior to bond cleavage. By alternate substrate studies, we have resolved the contributions of the individual binding steps to substrate affinity and catalysis, This pathway for substrate binding is identical to that previously determined with a substrate analog for the first half-reaction of prothrombin activation. We show that differences in the observed kinetic constants for the two cleavage reactions arise entirely from differences in the inferred equilibrium constant for the intramolecular binding step that permits elements surrounding the scissile bond to dock at the active site of prothrombinase. Therefore, substrate specificity is achieved by binding interactions with an enzymic exosite that tethers the protein substrate to prothrombinase and directs cleavage at two spatially distinct scissile bonds.	Childrens Hosp Philadelphia, Joseph Stokes Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Krishnaswamy, S (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Res Inst, 310 Abramson,3516 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	skrishna@mail.med.upenn.edu	Boskovic, Danilo/D-4670-2012; Krishnaswamy, Sriram/Z-4380-2019	Boskovic, Danilo/0000-0001-6919-3726; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062523, R01HL052883] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62523, HL52883] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; BAJAJ SP, 1975, J BIOL CHEM, V250, P2150; Baugh RJ, 2000, J BIOL CHEM, V275, P28826, DOI 10.1074/jbc.M005266200; Betz A, 1997, BIOCHEMISTRY-US, V36, P181, DOI 10.1021/bi962060g; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bevington PR., 2002, DATA REDUCTION ERROR; BOCK PE, 1993, METHOD ENZYMOL, V222, P478; Bock PE, 1997, J BIOL CHEM, V272, P19837, DOI 10.1074/jbc.272.32.19837; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; CARLISLE TL, 1990, J BIOL CHEM, V265, P22044; DOWNING MR, 1975, J BIOL CHEM, V250, P8897; DOYLE MF, 1993, METHOD ENZYMOL, V222, P299; ESMON CT, 1974, J BIOL CHEM, V249, P7791; EVANS SA, 1982, J BIOL CHEM, V257, P3014; Fredenburgh JC, 1997, J BIOL CHEM, V272, P25493, DOI 10.1074/jbc.272.41.25493; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P5290, DOI 10.1021/bi00723a006; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JACKSON CM, 1968, BIOCHEMISTRY-US, V7, P4492, DOI 10.1021/bi00852a046; KALAFATIS M, 1993, METHOD ENZYMOL, V222, P224; KALAFATIS M, 1994, BBA-MOL BASIS DIS, V1227, P113, DOI 10.1016/0925-4439(94)90086-8; KOSOW DP, 1979, J BIOL CHEM, V254, P9448; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P3319, DOI 10.1021/bi9623993; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; LIU LW, 1991, J BIOL CHEM, V266, P23632; LOTTENBERG R, 1986, BIOCHIM BIOPHYS ACTA, V874, P326, DOI 10.1016/0167-4838(86)90032-4; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; Lu YF, 1996, BIOCHEMISTRY-US, V35, P8201, DOI 10.1021/bi960281g; Lundblad R L, 1976, Methods Enzymol, V45, P156; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; Martin PD, 1997, STRUCTURE, V5, P1681, DOI 10.1016/S0969-2126(97)00314-6; MIHALYI E, 1988, BIOCHEMISTRY-US, V27, P976, DOI 10.1021/bi00403a021; MYRMEL KH, 1976, BIOCHEMISTRY-US, V15, P1767, DOI 10.1021/bi00653a027; Nelsestuen GL, 1997, BIOCHEMISTRY-US, V36, P9081, DOI 10.1021/bi970720r; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; NISHIDA S, 1995, BIOCHEMISTRY-US, V34, P1771, DOI 10.1021/bi00005a034; OWEN WG, 1974, J BIOL CHEM, V249, P594; PEI G, 1992, BIOCHEMISTRY-US, V31, P6990, DOI 10.1021/bi00145a017; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Segel IH, 1975, ENZYME KINETICS BEHA; Stanley TB, 1998, BIOCHEMISTRY-US, V37, P13262, DOI 10.1021/bi981031y; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; VANDEGRIFF KD, 1994, METHOD ENZYMOL, V232, P460; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WALKER RK, 1993, J BIOL CHEM, V268, P13920; WALKER RK, 1994, J BIOL CHEM, V269, P27441	61	38	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38561	38570		10.1074/jbc.M006637200	http://dx.doi.org/10.1074/jbc.M006637200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10984491	hybrid			2022-12-27	WOS:000165739800058
J	Somasundaram, R; Ruehl, M; Tiling, N; Ackermann, R; Schmid, M; Riecken, EO; Schuppan, D				Somasundaram, R; Ruehl, M; Tiling, N; Ackermann, R; Schmid, M; Riecken, EO; Schuppan, D			Collagens serve as an extracellular store of bioactive interleukin 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; CELL-PROLIFERATION; RECEPTOR COMPLEX; TYROSINE KINASES; MATRIX PROTEINS; BINDING DOMAINS; T-LYMPHOCYTES; I COLLAGEN; TGF-BETA; PDGF-A	The binding of certain growth factors and cytokines to components of the extracellular matrix can regulate their local availability and modulate their biological activities. We show that interleukin 2 (IL-2), an important stimulator of T cell growth, preferentially binds to collagen types I, III, and VI and to a lesser degree to collagen types II, IV, and V, immobilized on polystyrene or nitrocellulose. These interactions are inhibited by denatured, single collagen chains or a subset of their cyanogen bromide peptides in a dose-dependent manner. Cross-inhibition experiments and ligand blotting of collagen-derived peptides point to a limited set of collagenous consensus sequences mediating the binding of IL-2. This interaction is saturable, with dissociation constants of similar to 10(-8) M, and estimated molar ratios of 4-6 molecules of IL-2 bound to one molecule of triple helical collagen. Furthermore, collagen-bound IL-2 stimulates proliferation of mouse lymphocytes. We conclude that its specific binding to the abundant interstitial collagens leads to a spatial pattern of bioavailable IL-2 which is dictated by the local organization of the collagenous extracellular matrix. This interaction may contribute to the particular phenotype of stromal lymphocytes and could be exploited for devising collagenous peptide analogues that modulate IL-2 bioactivity.	Univ Erlangen Nurnberg, Med Klin 1, Dept Med 1, D-91054 Erlangen, Germany; Free Univ Berlin, Klinikum Benjamin Franklin, Dept Gastroenterol & Hepatol, D-12200 Berlin, Germany	University of Erlangen Nuremberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schuppan, D (corresponding author), Univ Erlangen Nurnberg, Med Klin 1, Dept Med 1, Krankenhausstr 12, D-91054 Erlangen, Germany.	detlef.schuppan@med1.imed.uni-erlangen.de		Somasundaram, Rajan/0000-0003-3461-3326				ALON R, 1994, J IMMUNOL, V152, P1304; Ariel A, 1997, EUR J IMMUNOL, V27, P2562, DOI 10.1002/eji.1830271015; Atkinson JC, 1996, EXP CELL RES, V228, P283, DOI 10.1006/excr.1996.0328; BOTTOMLY K, 1999, CURRENT PROTOCOLS IM; Dai ZH, 1999, CURR OPIN IMMUNOL, V11, P504, DOI 10.1016/S0952-7915(99)00008-4; Geginat J, 1999, J IMMUNOL, V162, P5085; HERSHKOVIZ R, 1994, J IMMUNOL, V153, P554; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Kafienah W, 1998, BIOCHEM J, V330, P897, DOI 10.1042/bj3300897; KELLY JL, 1993, J CELL BIOL, V121, P1153, DOI 10.1083/jcb.121.5.1153; KHACHIGIAN LM, 1994, PEPTIDES, V15, P133, DOI 10.1016/0196-9781(94)90181-3; Kitson RP, 1998, J IMMUNOL, V160, P4248; LORTAT-JACOB H, 1991, J CLIN INVEST, V87, P878, DOI 10.1172/JCI115093; Mangasser-Stephan K, 1999, CELL TISSUE RES, V297, P363, DOI 10.1007/s004410051364; Martino G, 1998, ANN NEUROL, V43, P340, DOI 10.1002/ana.410430312; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Miyazaki T, 1996, CANCER SURV, V27, P25; MOORADIAN DL, 1989, J CELL BIOCHEM, V41, P189, DOI 10.1002/jcb.240410404; MOSER TL, 1993, J BIOL CHEM, V268, P18917; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; PACKARD BZ, 1995, BBA-MOL CELL RES, V1269, P51, DOI 10.1016/0167-4889(95)00114-8; Panayi GS, 1999, RHEUMATOLOGY, V38, P8; PARALKAR VM, 1991, DEV BIOL, V143, P303, DOI 10.1016/0012-1606(91)90081-D; Pollock RA, 1992, GROWTH FACTORS, V7, P267, DOI 10.3109/08977199209046409; RAINES EW, 1992, P NATL ACAD SCI USA, V89, P1281, DOI 10.1073/pnas.89.4.1281; RAMSDEN L, 1992, EUR J IMMUNOL, V22, P3027, DOI 10.1002/eji.1830221139; Rees C, 1998, J CELL BIOCHEM, V71, P375, DOI 10.1002/(SICI)1097-4644(19981201)71:3<375::AID-JCB6>3.0.CO;2-M; Roberts AI, 1999, IMMUNOLOGY, V97, P679; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Saharinen J, 1999, CYTOKINE GROWTH F R, V10, P99, DOI 10.1016/S1359-6101(99)00010-6; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schonherr E, 1998, ARCH BIOCHEM BIOPHYS, V355, P241, DOI 10.1006/abbi.1998.0720; SCHUPPAN D, 1990, J BIOL CHEM, V265, P8823; Schuppan D, 2000, GUT, V47, P12, DOI 10.1136/gut.47.1.12; Schuppan D, 1998, GASTROENTEROLOGY, V114, P139, DOI 10.1016/S0016-5085(98)70642-0; Somasundaram R, 1996, J BIOL CHEM, V271, P26884, DOI 10.1074/jbc.271.43.26884; Streuli C, 1999, CURR OPIN CELL BIOL, V11, P634, DOI 10.1016/S0955-0674(99)00026-5; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Tschoetschel U, 1997, INT IMMUNOL, V9, P147, DOI 10.1093/intimm/9.1.147; Vaday GG, 2000, J LEUKOCYTE BIOL, V67, P149, DOI 10.1002/jlb.67.2.149; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; WALZOG B, 1995, EXP CELL RES, V218, P28, DOI 10.1006/excr.1995.1127; Wettreich A, 1999, J BIOL CHEM, V274, P31468, DOI 10.1074/jbc.274.44.31468; WONG P, 1995, J BIOL CHEM, V270, P25805, DOI 10.1074/jbc.270.43.25805; Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P1495, DOI 10.1177/002215549904701201; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	49	45	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38170	38175		10.1074/jbc.M006616200	http://dx.doi.org/10.1074/jbc.M006616200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10982811	hybrid			2022-12-27	WOS:000165739800007
J	Watanabe, K; Mie, T; Ichihara, A; Oikawa, H; Honma, M				Watanabe, K; Mie, T; Ichihara, A; Oikawa, H; Honma, M			Detailed reaction mechanism of macrophomate synthase - Extraordinary enzyme catalyzing five-step transformation from 2-pyrones to benzoates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIELS-ALDER REACTION; DEHYDROQUINATE SYNTHASE; BIOSYNTHESIS; DECARBOXYLATION; ANTIBIOTICS; OXALACETATE; CATALYSIS; PROBE; NMR	Macrophomate synthase from the fungus Macrophoma commelinae IFO 9570 is a Mg(II)-dependent dimeric enzyme that catalyzes an extraordinary, complex five-step chemical transformation from a-pyrone and oxalacetate to benzoate involving decarboxylation, C-C bond formation, and dehydration. The catalytic mechanism of the whole pathway was investigated in three separate chemical steps. In the first decarboxylation step, the enzyme loses oxalacetate decarboxylation activity upon incubation with EDTA. Activity is fully restored by addition of Mg(II) and is not restored with other divalent metal cations, The dissociation constant of 0.93 x 10(-7) for Mg(II) and atomic absorption analysis established a 1:1 stoichiometric complex, Inhibition of pyruvate formation with 2-pyrone revealed that the actual product in the first step is a pyruvate enolate, which undergoes C-C bond formation in the presence of S-pyrone, Incubation of substrate analogs provided aberrant adducts that were produced via C-C bond formation and rearrangement, This strongly indicates that the second step is two C-C bond formations, affording a bicyclic intermediate, Based on the stereospecificity, involvement of a Diels-Alder reaction at the second step is proposed. Incubation of the stereospecifically deuterium-labeled malate with 2-pyrones in the presence of malate dehydrogenase provided information for the stereochemical course of the reaction catalyzed by macrophomate synthase, indicating that the first decarboxylation provides pyruvate (Z)-[3-H-2]enolate and that dehydration at the final step occurs with anti elimination accompanied by concomitant decarboxylation, Examination of kinetic parameters in the individual steps suggests that the third step is the rate determining step of the overall transformation.	Hokkaido Univ, Grad Sch Agr, Dept Appl Biosci, Kita Ku, Sapporo, Hokkaido 0608589, Japan	Hokkaido University	Oikawa, H (corresponding author), Hokkaido Univ, Grad Sch Agr, Dept Appl Biosci, Kita Ku, Kita 9 Nishi 9, Sapporo, Hokkaido 0608589, Japan.		Watanabe, Kenji/N-2012-2015; Oikawa, Hideaki/F-9128-2012	Watanabe, Kenji/0000-0002-0463-4831; Oikawa, Hideaki/0000-0002-6947-3397				AFARINKIA K, 1992, TETRAHEDRON, V48, P9111, DOI 10.1016/S0040-4020(01)85607-6; Babbitt PC, 1996, BIOCHEMISTRY-US, V35, P16489, DOI 10.1021/bi9616413; BARTLETT PA, 1988, J AM CHEM SOC, V110, P1628, DOI 10.1021/ja00213a049; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BENDER SL, 1989, BIOCHEMISTRY-US, V28, P7560, DOI 10.1021/bi00445a010; BENZIMAN M, 1978, J BACTERIOL, V134, P1; BREWER JM, 1966, J BIOL CHEM, V241, P2550; FUKUSHI Y, 1994, TETRAHEDRON LETT, V35, P599, DOI 10.1016/S0040-4039(00)75848-5; HILVERT D, 1989, J AM CHEM SOC, V111, P9261, DOI 10.1021/ja00208a037; Kudo F, 1999, J ANTIBIOT, V52, P559, DOI 10.7164/antibiotics.52.559; Kudo F, 1999, J ANTIBIOT, V52, P81, DOI 10.7164/antibiotics.52.81; MAGGIO ET, 1975, BIOCHEMISTRY-US, V14, P1131, DOI 10.1021/bi00677a006; OIKAWA H, 1994, J AM CHEM SOC, V116, P3605, DOI 10.1021/ja00087a059; OIKAWA H, 1995, J CHEM SOC CHEM COMM, P1321, DOI 10.1039/c39950001321; Oikawa H, 1999, TETRAHEDRON LETT, V40, P6983, DOI 10.1016/S0040-4039(99)01441-0; Oikawa H., 1997, J CHEM SOC CHEM COMM, P97; PARK SH, 1986, BIOCHEMISTRY-US, V25, P3752, DOI 10.1021/bi00361a004; ROSE IA, 1969, J BIOL CHEM, V244, P6130; SAKURAI I, 1988, CHEM PHARM BULL, V36, P2003; SAKURAI I, 1985, CHEM PHARM BULL, V33, P5141; SAKURAI I, 1988, CHEM PHARM BULL, V36, P1328; SATO H, 1981, AGR BIOL CHEM TOKYO, V45, P1675, DOI 10.1080/00021369.1981.10864745; SATO H, 1981, AGR BIOL CHEM TOKYO, V45, P795, DOI 10.1080/00021369.1981.10864607; SATO H, 1979, AGR BIOL CHEM TOKYO, V43, P2409, DOI 10.1080/00021369.1979.10863831; WALDROP GL, 1994, BIOCHEMISTRY-US, V33, P5262, DOI 10.1021/bi00183a032; Watanabe K, 2000, J BIOCHEM-TOKYO, V127, P467, DOI 10.1093/oxfordjournals.jbchem.a022629; Watanabe K, 2000, BIOSCI BIOTECH BIOCH, V64, P530, DOI 10.1271/bbb.64.530; Watanabe K, 2000, TETRAHEDRON LETT, V41, P1443, DOI 10.1016/S0040-4039(99)02311-4; Xu JA, 1999, SCIENCE, V286, P2345, DOI 10.1126/science.286.5448.2345; YAMADA K, 1962, B CHEM SOC JPN, V35, P1323, DOI 10.1246/bcsj.35.1323	30	74	74	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38393	38401		10.1074/jbc.M003119200	http://dx.doi.org/10.1074/jbc.M003119200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10984474	hybrid			2022-12-27	WOS:000165739800036
J	Ales, E; Gabilan, NH; Cano-Abad, MF; Garcia, AG; Lopez, MG				Ales, E; Gabilan, NH; Cano-Abad, MF; Garcia, AG; Lopez, MG			The sea anemone toxin Bc2 induces continuous or transient exocytosis, in the presence of sustained levels of high cytosolic Ca2+ in chromaffin cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODEL LIPID-MEMBRANES; MOUSE ADRENAL SLICES; PROTEIN-KINASE-C; ALPHA-LATROTOXIN; EQUINATOXIN-II; NEUROTRANSMITTER RELEASE; STICHODACTYLA-HELIANTHUS; TRANSMITTER RELEASE; QUANTAL RELEASE; ACTINIA-EQUINA	We have isolated and characterized a new excitatory toxin from the venom of the sea anemone Bunodosoma caissarum, named Bc2. We investigated the mechanism of action of the toxin on Ca2+-regulated exocytosis in single bovine adrenal chromaffin cells, monitoring simultaneously fura-a fluorescence measurements and electrochemical recordings using a carbon fiber microelectrode. Bc2 induced quantal release of catecholamines in a calcium-dependent manner. This release was associated with a sustained rise in cytosolic Ca2+ and displayed two different patterns of response: a continuous discharge of prolonged duration that changed to a transient burst as the toxin concentration (Or incubation time) increased. Continuous secretion was dependent on the activity of native voltage-dependent Ca2+ channels and showed a pattern similar to that of alpha -latrotoxin; however, its kinetics adjusted better to that of continuous cell depolarization with high Kf concentration. In contrast, transient secretion was independent of Ca2+ entry through native voltage dependent Ca2+ channels and showed inhibition of late vesicle fusion that was accompanied by "freezing" of F-actin disassembly. These new features make Bc2 a promising new tool for studying the machinery of neurotransmitter release.	Univ Autonoma Madrid, Dept Farmacol, Inst Farmacol Teofilo Hernando, Madrid 28029, Spain; Hosp Princesa, Serv Farmacol Clin, Madrid 28006, Spain; Hosp Princesa, Inst Gerontol, Madrid 28006, Spain; Univ Fed Santa Catarina, Dept Bioquim, BR-88049 Florianopolis, SC, Brazil	Autonomous University of Madrid; Hospital de La Princesa; Hospital de La Princesa; Universidade Federal de Santa Catarina (UFSC)	Ales, E (corresponding author), Univ Autonoma Madrid, Dept Farmacol, Inst Farmacol Teofilo Hernando, C Arzobispo Morcillo 4, Madrid 28029, Spain.		GARCIA, ANTONIO G/E-9961-2018; Lopez, Manuela G/D-2164-2015; Ales, Eva/E-6315-2010	GARCIA, ANTONIO G/0000-0002-6517-3565; Lopez, Manuela G/0000-0003-4461-8788; Ales, Eva/0000-0002-5536-4616; Cano-Abad, Maria F./0000-0002-2602-6626				ALMERS W, 1985, FEBS LETT, V192, P13, DOI 10.1016/0014-5793(85)80033-8; Anderluh G, 1999, EUR J BIOCHEM, V263, P128, DOI 10.1046/j.1432-1327.1999.00477.x; Anderluh G, 2000, J MEMBRANE BIOL, V173, P47, DOI 10.1007/s002320001006; ARTALEJO CR, 1986, BIOCHEM BIOPH RES CO, V134, P1, DOI 10.1016/0006-291X(86)90518-8; BELMONTE G, 1993, J MEMBRANE BIOL, V131, P11, DOI 10.1007/BF02258530; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; BURGOYNE RD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P174, DOI 10.1016/0304-4157(91)90024-Q; BURGOYNE RD, 1995, J PHYSIOL PHARMACOL, V46, P273; Chik CL, 1999, ENDOCRINOLOGY, V140, P5682, DOI 10.1210/en.140.12.5682; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; COPOGNA M, 1996, J NEUROPHYSIOL, V76, P3149; Cuchillo-Ibanez I, 1999, FEBS LETT, V459, P22, DOI 10.1016/S0014-5793(99)01115-1; David D, 1998, J CELL BIOL, V143, P1167, DOI 10.1083/jcb.143.5.1167; Davletov BA, 1998, EMBO J, V17, P3909, DOI 10.1093/emboj/17.14.3909; de los Rios V, 1999, FEBS LETT, V455, P27, DOI 10.1016/S0014-5793(99)00846-7; DETOLEDO A, 1993, NATURE, V373, P554; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; Drevensek G, 2000, PFLUG ARCH EUR J PHY, V439, pR150, DOI 10.1007/s004240000126; Frangez R, 2000, PFLUG ARCH EUR J PHY, V439, pR100, DOI 10.1007/s004240000105; GANDFA L, 1993, J PHYSIOL-LONDON, V244, P253; Gil A, 1998, EUR J NEUROSCI, V10, P3369, DOI 10.1046/j.1460-9568.1998.00341.x; GODA Y, 1994, P NATL ACAD SCI USA, V91, P12942, DOI 10.1073/pnas.91.26.12942; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; HEINEMANN C, 1993, PFLUG ARCH EUR J PHY, V424, P105, DOI 10.1007/BF00374600; HEINEMANN C, 1994, BIOPHYS J, V70, P1069; HORRIGAN FT, 1994, NEURON, V13, P1119, DOI 10.1016/0896-6273(94)90050-7; HURLBUT WP, 1994, J MEMBRANE BIOL, V138, P91, DOI 10.1007/BF00211072; Katz B., 1969, RELEASE NEURAL TRANS; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Liu J, 1998, J NEUROSCI, V18, P6113; Liu J, 1998, BRAIN RES, V799, P55, DOI 10.1016/S0006-8993(98)00467-3; LIVETT BG, 1984, PHYSIOL REV, V64, P1103, DOI 10.1152/physrev.1984.64.4.1103; MACEK P, 1994, TOXICOLOGY, V87, P205, DOI 10.1016/0300-483X(94)90252-6; Malovrh P, 2000, BIOCHEM J, V346, P223, DOI 10.1042/0264-6021:3460223; Martin-Benito J, 2000, BIOPHYS J, V78, P3186, DOI 10.1016/S0006-3495(00)76855-X; MELDOLESI J, 1984, P NATL ACAD SCI-BIOL, V81, P620, DOI 10.1073/pnas.81.2.620; Menestrina G, 1999, BIOCHEM BIOPH RES CO, V254, P174, DOI 10.1006/bbrc.1998.9898; Meunier FA, 2000, TOXICON, V38, P1547, DOI 10.1016/S0041-0101(00)00088-X; MICHELENA P, 1993, P NATL ACAD SCI USA, V90, P3284, DOI 10.1073/pnas.90.8.3284; Michelena P, 1997, J PHYSIOL-LONDON, V502, P481, DOI 10.1111/j.1469-7793.1997.481bj.x; Migues PV, 1999, NEUROREPORT, V10, P67, DOI 10.1097/00001756-199901180-00013; MOLLAY C, 1976, FEBS LETT, V64, P65, DOI 10.1016/0014-5793(76)80250-5; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; MORO MA, 1990, ANAL BIOCHEM, V185, P243, DOI 10.1016/0003-2697(90)90287-J; Moser T, 1997, J NEUROSCI, V17, P2314; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; NICHOLLS DG, 1982, P NATL ACAD SCI-BIOL, V79, P7924, DOI 10.1073/pnas.79.24.7924; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; Plattner H, 1997, J CELL BIOL, V139, P1709, DOI 10.1083/jcb.139.7.1709; Poklar N, 1999, BIOCHEMISTRY-US, V38, P14999, DOI 10.1021/bi9916022; RAYA SA, 1994, NAT TOXINS, V1, P263; ROSARIO LM, 1989, NEUROSCIENCE, V29, P735, DOI 10.1016/0306-4522(89)90145-0; ROSENTHAL L, 1990, MOL PHARMACOL, V38, P917; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; Sakaba T, 1997, NEUROSCI RES, V27, P357, DOI 10.1016/S0168-0102(97)01168-1; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; Smith C, 1998, NEURON, V20, P1243, DOI 10.1016/S0896-6273(00)80504-8; Steyer JA, 1997, NATURE, V388, P474, DOI 10.1038/41329; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sullivan R, 1999, J BIOL CHEM, V274, P38140, DOI 10.1074/jbc.274.53.38140; Tejuca M, 1996, BIOCHEMISTRY-US, V35, P14947, DOI 10.1021/bi960787z; THELESTAM M, 1988, TOXICON, V26, P51, DOI 10.1016/0041-0101(88)90137-7; THOMAS P, 1993, NEURON, V11, P93, DOI 10.1016/0896-6273(93)90274-U; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; Voets T, 1999, NEURON, V23, P607, DOI 10.1016/S0896-6273(00)80812-0; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; YOUNES A, 1992, J BIOL CHEM, V267, P842; ZOREC R, 1990, J MEMBRANE BIOL, V118, P243, DOI 10.1007/BF01868608	70	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37488	37495		10.1074/jbc.M007388200	http://dx.doi.org/10.1074/jbc.M007388200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10980205	hybrid			2022-12-27	WOS:000165618700027
J	Bendahan, A; Armon, A; Madani, N; Kavanaugh, MP; Kanner, BI				Bendahan, A; Armon, A; Madani, N; Kavanaugh, MP; Kanner, BI			Arginine 447 plays a pivotal role in substrate interactions in a neuronal glutamate transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; RAT-BRAIN; ESCHERICHIA-COLI; FUNCTIONAL-CHARACTERIZATION; MEMBRANE-VESICLES; LIGAND-BINDING; HIGH-AFFINITY; EXPRESSION; CLONING; GLT-1	Glutamate transporters from the central nervous system play a crucial role in the clearance of the transmitter from the synaptic cleft. Glutamate is cotransported with sodium ions, and the electrogenic translocation cycle is completed by countertransport of potassium. Mutants that cannot interact with potassium are only capable of catalyzing electroneutral exchange. Here we identify a residue involved in controlling substrate recognition in the neuronal transporter EAAC-1 that transports acidic amino acids as well as cysteine, When arginine 447, a residue conserved in all glutamate transporters, is replaced by cysteine, transport of glutamate or aspartate is abolished, but sodium-dependent cysteine transport is left intact. Analysis of other substitution mutants shows that the replacement of arginine rather than the introduced cysteine is responsible for the observed phenotype, In further contrast to wild type, acidic amino acids are unable to inhibit cysteine transport in R447C-EAAC-1, indicating that the selectivity change is manifested at the binding step, Electrophysiological analysis shows that in the mutant cysteine, transport has become electroneutral, and its interaction with the countertransported potassium is impaired. Thus arginine 447 plays a pivotal role in the sequential interaction of acidic amino acids and potassium with the transporter and, thereby, constitutes one of the molecular determinants of coupling their fluxes.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel; Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA	Hebrew University of Jerusalem; Oregon Health & Science University	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel.	kannerb@cc.huji.ac.il						Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; CONRADT M, 1995, J BIOL CHEM, V270, P25207, DOI 10.1074/jbc.270.42.25207; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; Diamond JS, 1997, J NEUROSCI, V17, P4672; Edgar R, 1999, EMBO J, V18, P822, DOI 10.1093/emboj/18.4.822; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; HAMA H, 1993, J BIOL CHEM, V268, P10060; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; Kekuda R, 1996, J BIOL CHEM, V271, P18657, DOI 10.1074/jbc.271.31.18657; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Ogawa W, 1998, J BACTERIOL, V180, P6749, DOI 10.1128/JB.180.24.6749-6752.1998; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Sun JZ, 1998, BIOCHEMISTRY-US, V37, P8020, DOI 10.1021/bi973192s; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Yerushalmi H, 2000, J BIOL CHEM, V275, P5264, DOI 10.1074/jbc.275.8.5264; Zarbiv R, 1998, J BIOL CHEM, V273, P14231, DOI 10.1074/jbc.273.23.14231; Zerangue N, 1996, J BIOL CHEM, V271, P27991, DOI 10.1074/jbc.271.45.27991; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zerangue N, 1996, J PHYSIOL-LONDON, V493, P419, DOI 10.1113/jphysiol.1996.sp021393; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710; Zhang YM, 1998, P NATL ACAD SCI USA, V95, P751, DOI 10.1073/pnas.95.2.751	49	131	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37436	37442		10.1074/jbc.M006536200	http://dx.doi.org/10.1074/jbc.M006536200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978338	Green Published, hybrid			2022-12-27	WOS:000165618700019
J	Kapushoc, ST; Alfonzo, JD; Rubio, MAT; Simpson, L				Kapushoc, ST; Alfonzo, JD; Rubio, MAT; Simpson, L			End processing precedes mitochondrial importation and editing of tRNAs in Leishmania tarentolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODED TRANSFER-RNAS; IN-VITRO IMPORT; TRYPANOSOMA-BRUCEI; PLANT-MITOCHONDRIA; MAXICIRCLE DNA; PROTOZOAN; IDENTIFICATION; CHROMOSOMES; TETRAHYMENA; MARSUPIALS	All mitochondrial tRNAs in Leishmania tarentolae are encoded in the nuclear genome and imported into the mitochondrion from the cytosol, One imported tRNA (tRNA(Trp)) is edited by a C to U modification at the first position of the anticodon, To determine the in vivo substrates for mitochondrial tRNA importation as well as tRNA editing, we examined the subcellular localization and extent of 5'- and 3'-end maturation of tRNA(Trp)(CCA), tRNA(Ile)(UAU), tRNA(Gln)(CUG), tRNA(Lys)(UUU), and tRNA(Val)(CAC), Nuclear, cytosolic, and mitochondrial fractions were obtained with little cross-contamination, as determined by Northern analysis of specific marker RNAs, tRNA(Gln) was mainly cytosolic in localization; tRNA(Ile) and tRNA(Lys) were mainly mitochondrial; and tRNA(Trp) and tRNA(Val) were shared between the two compartments. 5'- and 3'-extended precursors of all five tRNAs were present only in the nuclear fraction, suggesting that the mature tRNAs represent the in vivo substrates for importation into the mitochondrion, Consistent with this model, T7-transcribed mature tRNA(Ile) underwent importation in vitro into isolated mitochondria more efficiently than 5'-extended precursor tRNA(Ile). 5'-Extended precursor tRNA(Trp) was found to be unedited, which is consistent with a mitochondrial localization of this editing reaction, T7-transcribed unedited tRNA(Trp) was imported in vitro more efficiently than edited tRNA(Trp), suggesting the presence of importation determinants in the anticodon.	Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Simpson, L (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, 675 Charles E YOung Dr S, Los Angeles, CA 90095 USA.	simpson@hhmi.ucla.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008375] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GM08375] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adhya S, 1997, J BIOL CHEM, V272, P21396, DOI 10.1074/jbc.272.34.21396; Alfonzo JD, 1999, EMBO J, V18, P7056, DOI 10.1093/emboj/18.24.7056; Aphasizhev R, 1998, MOL BIOCHEM PARASIT, V93, P73, DOI 10.1016/S0166-6851(98)00022-X; Bertrand E, 1998, GENE DEV, V12, P2463, DOI 10.1101/gad.12.16.2463; Borner GV, 1996, EMBO J, V15, P5949, DOI 10.1002/j.1460-2075.1996.tb00981.x; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; CAMPBELL DA, 1987, J MOL BIOL, V196, P113, DOI 10.1016/0022-2836(87)90514-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIETRICH A, 1992, ANNU REV CELL BIOL, V8, P115, DOI 10.1146/annurev.cb.08.110192.000555; GOLD HA, 1989, SCIENCE, V245, P1377, DOI 10.1126/science.2476849; GOMEZEICHELMANN MC, 1988, MOL BIOCHEM PARASIT, V27, P143, DOI 10.1016/0166-6851(88)90034-5; HANCOCK K, 1992, J BIOL CHEM, V267, P23963; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; Hauser R, 1996, J CELL SCI, V109, P517; HAUSER R, 1995, EMBO J, V14, P4212, DOI 10.1002/j.1460-2075.1995.tb00095.x; Kazakova HA, 1999, FEBS LETT, V442, P193, DOI 10.1016/S0014-5793(98)01653-6; Kunzmann A, 1998, P NATL ACAD SCI USA, V95, P108, DOI 10.1073/pnas.95.1.108; LeBlanc AJ, 1999, J BIOL CHEM, V274, P21071, DOI 10.1074/jbc.274.30.21071; Lima BD, 1996, RNA, V2, P429; LYE LF, 1993, MOL BIOCHEM PARASIT, V58, P233, DOI 10.1016/0166-6851(93)90045-Y; MAHAPATRA S, 1994, NUCLEIC ACIDS RES, V22, P3381, DOI 10.1093/nar/22.16.3381; Mahapatra S, 1998, NUCLEIC ACIDS RES, V26, P2037, DOI 10.1093/nar/26.9.2037; Mahapatra S, 1996, J BIOL CHEM, V271, P20432, DOI 10.1074/jbc.271.34.20432; MASLOV DA, 1992, MOL CELL BIOL, V12, P56, DOI 10.1128/MCB.12.1.56; MORL M, 1995, NUCLEIC ACIDS RES, V23, P3380, DOI 10.1093/nar/23.17.3380; Nabholz CE, 1999, MOL BIOL CELL, V10, P2547, DOI 10.1091/mbc.10.8.2547; Reddy R, 1996, MOL BIOL REP, V22, P81, DOI 10.1007/BF00988710; Roberts TG, 1998, MOL CELL BIOL, V18, P4409, DOI 10.1128/MCB.18.8.4409; ROVAI L, 1992, MOL BIOCHEM PARASIT, V50, P115, DOI 10.1016/0166-6851(92)90249-J; Rubio MAT, 2000, RNA, V6, P988, DOI 10.1017/S1355838200991519; Rusconi CP, 1996, GENE DEV, V10, P2870, DOI 10.1101/gad.10.22.2870; Rusconi CP, 1996, EMBO J, V15, P3286, DOI 10.1002/j.1460-2075.1996.tb00693.x; Sampson JR, 1996, METHOD ENZYMOL, V267, P384; Sbicego S, 1998, NUCLEIC ACIDS RES, V26, P5251, DOI 10.1093/nar/26.23.5251; SCHNEIDER A, 1994, NUCLEIC ACIDS RES, V22, P3699, DOI 10.1093/nar/22.18.3699; SHAPIRO SZ, 1982, ANAL BIOCHEM, V127, P112, DOI 10.1016/0003-2697(82)90152-X; SHI XM, 1994, MOL BIOCHEM PARASIT, V65, P23, DOI 10.1016/0166-6851(94)90112-0; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; SIMPSON L, 1978, CELL, V14, P169, DOI 10.1016/0092-8674(78)90311-2; Suyama Y, 1998, BBA-GENE STRUCT EXPR, V1396, P138, DOI 10.1016/S0167-4781(97)00197-8; TOPPER JN, 1992, CELL, V70, P16, DOI 10.1016/0092-8674(92)90529-L; WAUGH DS, 1989, SCIENCE, V244, P1569, DOI 10.1126/science.2472671; Yermovsky-Kammerer AE, 1999, MOL CELL BIOL, V19, P6253	44	31	33	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37907	37914		10.1074/jbc.M007838200	http://dx.doi.org/10.1074/jbc.M007838200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10993905	hybrid			2022-12-27	WOS:000165618700081
J	Patel, CV; Handy, I; Goldsmith, T; Patel, RC				Patel, CV; Handy, I; Goldsmith, T; Patel, RC			PACT, a stress-modulated cellular activator of interferon-induced double-stranded RNA-activated protein kinase, PKR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; EUKARYOTIC TRANSLATION INITIATION-FACTOR-2; DEPENDENT EIF-2-ALPHA KINASE; TUMOR-SUPPRESSOR P53; U937 CELLS; INDUCED APOPTOSIS; BINDING DOMAIN; SUBUNIT; PATHWAY; DEATH	The interferon (IFN)-induced, double-stranded (ds)RNA-activated serine-threonine protein kinase, PKR, is a key mediator of the antiviral activities of IFNs. In addition, PKR activity is also involved in regulation of cell proliferation, apoptosis, and signal transduction. In virally infected cells, dsRNA has been shown to bind and activate PKR kinase function. Implication of PKR activity in normal cellular processes has invoked activators other than dsRNA because RNAs with perfectly duplexed regions of sufficient length that are able to activate PKR are absent in cellular RNAs. We have recently reported cloning of PACT, a novel protein activator of PKR. PACT heterodimerizes with PKR and activates it by direct protein-protein interaction. Overexpression of PACT in mammalian cells leads to phosphorylation of the alpha subunit of the eukaryotic initiation factor 2 (eIF2 alpha), the cellular substrate for PKR, and leads to inhibition of protein synthesis. Here, we present evidence that endogenous PACT acts as a protein activator of PKR in response to diverse stress signals such as serum starvation, and peroxide or arsenite treatment. Following exposure of cells to these stress agents, PACT is phosphorylated and associates with PKR with increased affinity. PACT-mediated activation of PKR leads to enhanced eIF2 alpha phosphorylation followed by apoptosis. Based on the results presented here, we propose that PACT is a novel stress-modulated physiological activator of PKR.	Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Patel, RC (corresponding author), Univ S Carolina, Dept Biol Sci, 700 Sumter St, Columbia, SC 29208 USA.		Patel, Rekha/M-7123-2015	Patel, Rekha/0000-0001-9434-4880				Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; BARBER GN, 1991, BIOCHEMISTRY-US, V30, P10356, DOI 10.1021/bi00106a038; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Dever TE, 1999, TRENDS BIOCHEM SCI, V24, P398, DOI 10.1016/S0968-0004(99)01457-7; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Gil J, 1999, MOL CELL BIOL, V19, P4653; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; JUDWARE R, 1991, MOL CELL BIOL, V11, P3259, DOI 10.1128/MCB.11.6.3259; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Kibler KV, 1997, J VIROL, V71, P1992, DOI 10.1128/JVI.71.3.1992-2003.1997; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Lee SB, 1997, VIROLOGY, V231, P81, DOI 10.1006/viro.1997.8494; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MONTINE KS, 1989, BIOCHIM BIOPHYS ACTA, V1014, P282, DOI 10.1016/0167-4889(89)90224-3; PATEL RC, 1992, J BIOL CHEM, V267, P7671; PATEL RC, 1994, J BIOL CHEM, V269, P18593; PATEL RC, 1995, P NATL ACAD SCI USA, V92, P8283, DOI 10.1073/pnas.92.18.8283; Patel RC, 1998, MOL CELL BIOL, V18, P7009, DOI 10.1128/MCB.18.12.7009; Patel RC, 1996, J BIOL CHEM, V271, P25657, DOI 10.1074/jbc.271.41.25657; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; SALZBERG S, 1995, EXP CELL RES, V219, P223, DOI 10.1006/excr.1995.1222; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yeung MC, 1999, P NATL ACAD SCI USA, V96, P11860, DOI 10.1073/pnas.96.21.11860; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198	49	188	193	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37993	37998		10.1074/jbc.M004762200	http://dx.doi.org/10.1074/jbc.M004762200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10988289	hybrid			2022-12-27	WOS:000165618700092
J	Suh, JR; Oppenheim, EW; Girgis, S; Stover, PJ				Suh, JR; Oppenheim, EW; Girgis, S; Stover, PJ			Purification and properties of a folate-catabolizing enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDASE-GENERATED SUPEROXIDE; INDUCED INSULIN RELEASE; ONE-CARBON METABOLISM; FERRITIN-H-CHAIN; RAT-LIVER; IRON MOBILIZATION; PLACENTAL ISOFERRITIN; SIDEROSOMAL FERRITIN; ANTICONVULSANT DRUGS; PANCREATIC-ISLETS	We have identified and purified to homogeneity an enzyme from rat liver that catalyzes the oxidative catabolism of 5-formyltetrahydrofolate to p-aminobenzoylglutamate and a pterin derivative. Purification of the enzyme utilized six column matrices, including a pterin-6-carboxylic acid affinity column. Treatment of crude rat liver extracts with EDTA or heat decreased the specific activity of the enzyme by up to 85%. Peptides generated from-the purified protein were sequenced and found to be identical to primary sequences present within rat light chain or heavy chain ferritin. Commercial rat ferritin did not display catabolic activity, but activity could be acquired with iron loading. The purified enzyme contained 2000 atoms of iron/ferritin 24-mer and displayed similar electrophoretic properties as commercial rat liver ferritin. The ferritin-catalyzed reaction displayed burst kinetics, and the enzyme catalyzed only a single turnover In vitro. Expression of rat heavy chain ferritin cDNA resulted in increased rates of folate turnover in cultured Chinese hamster ovary cells and human mammary carcinoma cells and reduced intracellular folate concentrations in Chinese hamster ovary cells. These results indicate that ferritin catalyzes folate turnover in vitro: and in vivo and may be an important factor in regulating intracellular folate concentrations.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	Cornell University	Stover, PJ (corresponding author), Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA.	PJS13@cornell.edu			NICHD NIH HHS [HD35678] Funding Source: Medline; NIDDK NIH HHS [DK07158-21] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007158] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS SC, 1992, J INORG BIOCHEM, V47, P161, DOI 10.1016/0162-0134(92)84062-R; ANDREWS SC, 1987, BIOCHEM J, V245, P439, DOI 10.1042/bj2450439; ANDREWS SC, 1987, BIOCHEM J, V245, P447, DOI 10.1042/bj2450447; APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; ARCHER MC, 1972, CAN J BIOCHEM CELL B, V50, P1174, DOI 10.1139/o72-160; AROSIO P, 1978, J BIOL CHEM, V253, P4451; Beljanski M, 1996, INT J ONCOL, V8, P1143; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BOMFORD A, 1981, J BIOL CHEM, V256, P948; Bratton AC, 1939, J BIOL CHEM, V128, P537; Caudill MA, 1998, J NUTR, V128, P204, DOI 10.1093/jn/128.2.204; Chasteen ND, 1999, J STRUCT BIOL, V126, P182, DOI 10.1006/jsbi.1999.4118; CRAGG SJ, 1981, BIOCHEM J, V199, P565, DOI 10.1042/bj1990565; CRICHTON RR, 1980, J INORG BIOCHEM, V13, P305, DOI 10.1016/S0162-0134(00)80251-2; DAVIS MD, 1989, J BIOL CHEM, V264, P8585; DENIS MG, 1992, INT J CANCER, V50, P930, DOI 10.1002/ijc.2910500619; Einstein RS, 1998, J NUTR, V128, P2295, DOI 10.1093/jn/128.12.2295; GEOGHEGAN FL, 1995, J NUTR, V125, P2563; GRADY JK, 1990, IRON BIOMINERALS, P315; Gregory J F 3rd, 1996, Adv Food Nutr Res, V40, P81, DOI 10.1016/S1043-4526(08)60021-2; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; HARRISON PM, 1975, PROTEINS IRON STORAG, P269; HAZARD JT, 1977, BLOOD, V49, P139; Higgy NA, 1997, MOL CARCINOGEN, V20, P332, DOI 10.1002/(SICI)1098-2744(199712)20:4<332::AID-MC2>3.0.CO;2-L; HOOGSTRATEN B, 1965, CANCER RES, V25, P1933; Horne DW, 1997, METHOD ENZYMOL, V281, P38; IHARA K, 1984, J BIOL CHEM, V259, P278; Johnson JL, 1999, BIOCHEMISTRY-US, V38, P4089, DOI 10.1021/bi982690d; JONES T, 1978, BIOCHEMISTRY-US, V17, P4011, DOI 10.1021/bi00612a021; Juan SH, 1999, ARCH BIOCHEM BIOPHYS, V361, P295, DOI 10.1006/abbi.1998.0998; KELLY D, 1979, J CLIN INVEST, V64, P1089, DOI 10.1172/JCI109547; KELLY DA, 1983, CLIN SCI, V65, P303, DOI 10.1042/cs0650303; KIRKALI Z, 1995, EUR UROL, V28, P131; LAVOIE DJ, 1979, BIOCHIM BIOPHYS ACTA, V579, P359, DOI 10.1016/0005-2795(79)90063-1; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LEIBOLD EA, 1984, J BIOL CHEM, V259, P4327; LEWIS GP, 1979, ANAL BIOCHEM, V93, P91, DOI 10.1016/S0003-2697(79)80121-9; LIAU G, 1991, J BIOL CHEM, V266, P18819; Liu ZD, 1999, BIOCHEM PHARMACOL, V57, P559, DOI 10.1016/S0006-2952(98)00319-0; MACDONALD MJ, 1991, J BIOL CHEM, V266, P1335; MACDONALD MJ, 1994, FASEB J, V8, P777, DOI 10.1096/fasebj.8.10.8050678; MACDONALD MJ, 1991, J BIOL CHEM, V266, P22392; MAGNUS EM, 1963, LANCET, V2, P302; MARAS B, 1994, J BIOL CHEM, V269, P18429; MARCUS DM, 1979, J NATL CANCER I, V55, P791; MARUYAMA T, 1978, ANAL BIOCHEM, V84, P277, DOI 10.1016/0003-2697(78)90511-0; MATZNER Y, 1979, BRIT J HAEMATOL, V42, P345, DOI 10.1111/j.1365-2141.1979.tb01142.x; MAXWELL JD, 1972, BRIT MED J, V1, P297, DOI 10.1136/bmj.1.5795.297; Maymon R, 1996, BRIT J OBSTET GYNAEC, V103, P301, DOI 10.1111/j.1471-0528.1996.tb09732.x; MAYMON R, 1989, OBSTET GYNECOL, V74, P597; MCNULTY H, 1993, J NUTR, V123, P1089; MCNULTY H, 1995, J NUTR, V125, P99; MCPARTLIN J, 1993, LANCET, V341, P148, DOI 10.1016/0140-6736(93)90007-4; MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946; MOAD G, 1978, TETRAHEDRON LETT, P2271; Oppenheim EW, 2000, J BIOL CHEM, V275, P19268, DOI 10.1074/jbc.M001610200; Picard V, 1996, BLOOD, V87, P2057; Picard V, 1998, J BIOL CHEM, V273, P15382, DOI 10.1074/jbc.273.25.15382; RAO BPR, 1963, LANCET, V1, P1192; ROBERTSON EF, 1987, ANAL BIOCHEM, V167, P290, DOI 10.1016/0003-2697(87)90166-7; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; Scott J. M., 1984, FOLATES PTERINS, P307; SHANE B, 1989, VITAM HORM, V45, P263; SHAW S, 1989, BIOCHEM J, V257, P277, DOI 10.1042/bj2570277; SHAW S, 1990, FREE RADICAL BIO MED, V9, P11, DOI 10.1016/0891-5849(90)90044-J; STOVER P, 1993, TRENDS BIOCHEM SCI, V18, P102, DOI 10.1016/0968-0004(93)90162-G; STOVER P, 1991, J BIOL CHEM, V266, P1543; TAHER MM, 1987, ARCH BIOCHEM BIOPHYS, V257, P100, DOI 10.1016/0003-9861(87)90547-9; VONDERPORTEN AE, 1992, J NUTR, V122, P1293, DOI 10.1093/jn/122.6.1293; WANG CZ, 1994, NUTR RES, V14, P875, DOI 10.1016/S0271-5317(05)80488-9; WEINSTEIN RE, 1982, CANCER, V50, P2406, DOI 10.1002/1097-0142(19821201)50:11<2406::AID-CNCR2820501127>3.0.CO;2-S; WORWOOD M, 1990, BLOOD REV, V4, P259, DOI 10.1016/0268-960X(90)90006-E; Wu CG, 1997, INT J ONCOL, V11, P187; ZAKRZEWSKI SF, 1966, J BIOL CHEM, V241, P2957; ZAMIEROWSKI MM, 1977, J NUTR, V107, P1937, DOI 10.1093/jn/107.10.1937; ZHU LJ, 1995, ENDOCRINOLOGY, V136, P4106, DOI 10.1210/en.136.9.4106	76	53	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35646	35655		10.1074/jbc.M005864200	http://dx.doi.org/10.1074/jbc.M005864200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10978335	hybrid			2022-12-27	WOS:000165422800108
J	Hirpara, JL; Clement, MV; Pervaiz, S				Hirpara, JL; Clement, MV; Pervaiz, S			Intracellular acidification triggered by mitochondrial-derived hydrogen peroxide is an effector mechanism for drug-induced apoptosis in tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; CASPASE ACTIVATION; SUPEROXIDE ANION; HL-60 CELLS; PROTEASE ACTIVATION; INHIBITOR; LEUKEMIA; AGENTS; DEATH	We recently showed that two photoproducts of merocyanine 540, C2 and C5, triggered cytochrome C release; however, C5 was inefficient in inducing caspase activity and apoptosis in leukemia cells, unlike Ca, Here we show that HL60 cells acidified upon exposure to C2 but not C5, The intracellular drop in pH and caspase activation were dependent upon hydrogen peroxide production, and were inhibited by scavengers of hydrogen peroxide. On the contrary, caspase inhibitors did not block hydrogen peroxide production In turn, increased intracellular hydrogen peroxide concentration was downstream of superoxide anion produced within 2 h of exposure to C2, Inhibitor of NADPH oxidase diphenyleneiodonium neither inhibited superoxide production nor caspase activation triggered by C2, However, exposure of purified mitochondria to C2 resulted in significantly increased superoxide production. Furthermore, cytochrome C release from isolated mitochondria induced by C2 was completely inhibited in the presence of scavengers of hydrogen peroxide. Contrarily, scavenging hydrogen peroxide had no effect on the cyclosporin A-sensitive mitochondrial permeability transition induced by C5, Our data suggest a scenario where drug-induced hydrogen peroxide production induces intracellular acidification and release of cytochrome C, independent of the inner membrane pore, thereby creating an intracellular environment permissive for caspase activation.	Natl Univ Singapore, Dept Physiol, Singapore 119260, Singapore; Natl Univ Singapore, Oncol Res Inst, Singapore 119260, Singapore	National University of Singapore; National University of Singapore	Pervaiz, S (corresponding author), Natl Univ Singapore, Dept Physiol, 2 Med Dr,MD9 03-08, Singapore 117595, Singapore.	phssp@nus.edu.sg						Angoli D, 1996, BIOCHEM BIOPH RES CO, V229, P681, DOI 10.1006/bbrc.1996.1863; BARRY MA, 1993, CANCER RES, V53, P2349; Belhoussine R, 1999, ADV EXP MED BIOL, V457, P365; Benjamin CW, 1998, MOL PHARMACOL, V53, P446, DOI 10.1124/mol.53.3.446; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; Bruce AJ, 1996, P NATL ACAD SCI USA, V93, P2312, DOI 10.1073/pnas.93.6.2312; CASSEL D, 1986, J BIOL CHEM, V261, P5460; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Clement MV, 1998, FEBS LETT, V440, P13, DOI 10.1016/S0014-5793(98)01410-0; Conway RM, 1998, EUR J CANCER, V34, P1741, DOI 10.1016/S0959-8049(98)00234-2; CUTAIA M, 1994, AM J PHYSIOL-LUNG C, V267, pL649, DOI 10.1152/ajplung.1994.267.6.L649; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Decaudin D, 1998, INT J ONCOL, V12, P141; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; Famulski KS, 1999, CELL DEATH DIFFER, V6, P281, DOI 10.1038/sj.cdd.4400495; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Furlong IJ, 1998, CELL DEATH DIFFER, V5, P214, DOI 10.1038/sj.cdd.4400335; Furlong IJ, 1997, J CELL SCI, V110, P653; Gamen S, 1997, FEBS LETT, V417, P360, DOI 10.1016/S0014-5793(97)01282-9; Goossens JF, 2000, EUR J PHARM SCI, V10, P125, DOI 10.1016/S0928-0987(99)00091-3; GOSS GG, 1994, J BIOL CHEM, V269, P8741; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GULLIYA KS, 1995, ANTI-CANCER DRUG, V6, P545, DOI 10.1097/00001813-199508000-00007; GYLLENHAMMAR H, 1987, J IMMUNOL METHODS, V97, P209, DOI 10.1016/0022-1759(87)90461-3; Hirpara JL, 2000, BLOOD, V95, P1773, DOI 10.1182/blood.V95.5.1773.005k17_1773_1780; Hu QH, 1998, CIRC RES, V83, P644, DOI 10.1161/01.RES.83.6.644; KAUFMAN DS, 1993, ARCH BIOCHEM BIOPHYS, V302, P245, DOI 10.1006/abbi.1993.1206; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Liu D, 2000, J BIOL CHEM, V275, P9244, DOI 10.1074/jbc.275.13.9244; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; Matsura T, 1999, FREE RADICAL RES, V30, P73, DOI 10.1080/10715769900300081; Meisenholder GW, 1996, J BIOL CHEM, V271, P16260, DOI 10.1074/jbc.271.27.16260; Musgrove E A, 1990, Methods Cell Biol, V33, P59; PEREZSALA D, 1995, J BIOL CHEM, V270, P6235, DOI 10.1074/jbc.270.11.6235; Pervaiz S, 1998, CANCER LETT, V128, P11, DOI 10.1016/S0304-3835(98)00021-4; Pervaiz S, 1999, BLOOD, V93, P4096, DOI 10.1182/blood.V93.12.4096.412k44_4096_4108; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; Possel H, 1997, FEBS LETT, V416, P175, DOI 10.1016/S0014-5793(97)01197-6; ROBERTSON AK, 1990, J IMMUNOL METHODS, V133, P175, DOI 10.1016/0022-1759(90)90357-2; Samali A, 1998, FEBS LETT, V431, P167, DOI 10.1016/S0014-5793(98)00740-6; Scarlett JL, 1997, FEBS LETT, V418, P282, DOI 10.1016/S0014-5793(97)01391-4; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; SHAW S, 1995, CLIN EXP PHARMACOL P, V22, P817, DOI 10.1111/j.1440-1681.1995.tb01941.x; Simizu S, 1996, CANCER RES, V56, P4978; Simizu S, 1998, J BIOL CHEM, V273, P26900, DOI 10.1074/jbc.273.41.26900; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sohal RS, 1997, FASEB J, V11, P1269, DOI 10.1096/fasebj.11.14.9409545; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Weltin D, 1997, INT J RADIAT BIOL, V72, P685, DOI 10.1080/095530097142843; Williams AC, 1999, ONCOGENE, V18, P3199, DOI 10.1038/sj.onc.1202660; Wu ML, 1996, CIRC RES, V78, P564, DOI 10.1161/01.RES.78.4.564; Ye JP, 1999, MOL CELL BIOCHEM, V202, P9, DOI 10.1023/A:1007078915585; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	64	122	129	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					514	521		10.1074/jbc.M004687200	http://dx.doi.org/10.1074/jbc.M004687200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11016925	hybrid			2022-12-27	WOS:000166280700069
J	Molina-Heredia, FP; Hervas, M; Navarro, JA; De la Rosa, MA				Molina-Heredia, FP; Hervas, M; Navarro, JA; De la Rosa, MA			A single arginyl residue in plastocyanin and in cytochrome c(6) from the cyanobacterium Anabaena sp PCC 7119 is required for efficient reduction of photosystem I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; FLASH ABSORPTION-SPECTROSCOPY; ELECTRON-TRANSFER; SYNECHOCYSTIS PCC-6803; REACTION-MECHANISM; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; TRIPLET-STATE; PROTEIN; PCC-7119	Positively charged plastocyanin from Anabaena sp. PCC 7119 was investigated by site-directed mutagenesis, The reactivity of its mutants toward photosystem I was analyzed by laser flash spectroscopy. Replacement of arginine at position 88, which is adjacent to the copper ligand His-87, by glutamine and, in particular, by glutamate makes plastocyanin reduce its availability for transferring electrons to photosystem I. Such a residue in the copper protein thus appears to be isofunctional with Arg-64 (which is close to the heme group) in cytochrome c(6) from Anabaena (Molina-Heredia, F. P., Diaz-Quintana, A., Hervas, M., Navarro, J. A., and De la Rose, M. A. (1999) J. Biol; Chem, 274, 33565-33570) and Synechocystis (De la Cerda, B., Diaz-Quintana, A., Navarro, J, A, Hervas, M., and De la Rosa, M, a. (1999) J. Biol. Chem. 274, 13292-13297), Other mutations concern specific residues of plastocyanin either at its positively charged east face (D49K, H57A, H57E, K58A, K58E, Y83A, and Y83F) or at its north hydrophobic pole (L12A, K33A, and K33E), Mutations altering the surface electrostatic potential distribution allow the copper protein to modulate its kinetic efficiency: the more positively charged the interaction site, the higher the rate constant, Whereas replacement of Tyr-83 by either alanine or phenylalanine has no effect on the kinetics of photosystem I reduction, Leu-12 and Lys-33 are essential for the reactivity of plastocyanin.	Univ Sevilla, Ctr Invest Cientif Isla Cartuja, Inst Bioquim Vegetal & Fotosintesis, Seville 41092, Spain; CSIC, Seville 41092, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); Consejo Superior de Investigaciones Cientificas (CSIC)	De la Rosa, MA (corresponding author), Univ Sevilla, Ctr Invest Cientif Isla Cartuja, Inst Bioquim Vegetal & Fotosintesis, Americo Vespucio S-N, Seville 41092, Spain.		Molina-Heredia, Fernando P./F-7877-2015; De la Rosa, Miguel/B-2545-2014; navarro, jose a/B-6354-2015; Hervas, Manuel/K-9279-2014	Molina-Heredia, Fernando P./0000-0002-3637-0519; De la Rosa, Miguel/0000-0003-1187-5737; navarro, jose a/0000-0002-0536-6074; Hervas, Manuel/0000-0003-4523-8891				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BENDALL DS, 1999, PHOTOTROPHIC PROKARY, P315; De la Cerda B, 1999, J BIOL CHEM, V274, P13292, DOI 10.1074/jbc.274.19.13292; DelaCerda B, 1997, BIOCHEMISTRY-US, V36, P10125, DOI 10.1021/bi9708601; DIAZ A, 1994, EUR J BIOCHEM, V222, P1001, DOI 10.1111/j.1432-1033.1994.tb18951.x; FRAZAO C, 1995, STRUCTURE, V3, P1159, DOI 10.1016/S0969-2126(01)00252-0; Gross E. L., 1996, OXYGENIC PHOTOSYNTHE, P413; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HE S, 1991, EMBO J, V10, P4011, DOI 10.1002/j.1460-2075.1991.tb04976.x; HERVAS M, 1994, BBA-BIOENERGETICS, V1184, P235, DOI 10.1016/0005-2728(94)90228-3; Hervas M, 1996, BIOCHEMISTRY-US, V35, P2693, DOI 10.1021/bi951876z; HERVAS M, 1995, BIOCHEMISTRY-US, V34, P11321, DOI 10.1021/bi00036a004; HERVAS M, 1993, FEBS LETT, V319, P257, DOI 10.1016/0014-5793(93)80558-C; Hope AB, 2000, BBA-BIOENERGETICS, V1456, P5, DOI 10.1016/S0005-2728(99)00101-2; Inoue T, 1999, BIOCHEMISTRY-US, V38, P6063, DOI 10.1021/bi9824442; Ivkovic-Jensen MM, 1998, BIOCHEMISTRY-US, V37, P9557, DOI 10.1021/bi9802871; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MATHIS P, 1981, ISRAEL J CHEM, V21, P316; MEDINA M, 1993, EUR J BIOCHEM, V213, P1133, DOI 10.1111/j.1432-1033.1993.tb17863.x; Molina-Heredia FP, 1998, BIOCHEM BIOPH RES CO, V243, P302, DOI 10.1006/bbrc.1997.7953; Molina-Heredia FP, 1999, J BIOL CHEM, V274, P33565, DOI 10.1074/jbc.274.47.33565; Navarro JA, 1997, J BIOL INORG CHEM, V2, P11, DOI 10.1007/s007750050101; ORTEGA JM, 1988, EUR J BIOCHEM, V199, P239; ROGNER M, 1990, J BIOL CHEM, V265, P6189; Sambrook J., 2002, MOL CLONING LAB MANU; Sigfridsson K, 1998, PHOTOSYNTH RES, V57, P1, DOI 10.1023/A:1006067631076; Sigfridsson K, 1996, BIOCHEMISTRY-US, V35, P1249, DOI 10.1021/bi9520141; WATKINS JA, 1994, PROTEIN SCI, V3, P2104, DOI 10.1002/pro.5560031124	29	48	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					601	605		10.1074/jbc.M007081200	http://dx.doi.org/10.1074/jbc.M007081200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11013249	Green Published, hybrid			2022-12-27	WOS:000166280700081
J	Okochi, M; Eimer, S; Bottcher, A; Baumeister, R; Romig, H; Walter, J; Capell, A; Steiner, H; Haass, C				Okochi, M; Eimer, S; Bottcher, A; Baumeister, R; Romig, H; Walter, J; Capell, A; Steiner, H; Haass, C			A loss of function mutant of the presenilin homologue SEL-12 undergoes aberrant endoproteolysis in Caenorhabditis elegans and increases A beta 42 generation in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; DISEASE-ASSOCIATED PRESENILIN-1; FAMILIAL ALZHEIMERS-DISEASE; BETA-PEPTIDE PRODUCTION; DROSOPHILA PRESENILIN; INTRACELLULAR DOMAIN; PROTEOLYTIC RELEASE; SECRETASE ACTIVITY; MEMBRANE TOPOLOGY; NOTCH	The familial Alzheimer's disease-associated presenilins (PSs) occur as a dimeric complex of proteolytically generated fragments, which functionally supports endoproteolysis of Notch and the beta -amyloid precursor protein (beta APP). A homologous gene, sel-12, has been identified in Caenorhabditis elegans, We now demonstrate that wild-type (wt) SEL-12 undergoes endoproteolytic cleavage in C. elegans similar to the PSs in human tissue. In contrast, SEL-12 C60S protein expressed from the sel-12(ar131) allele is miscleaved in C. elegans, resulting in a larger mutant N-terminal fragment. Neither SEL-12 wt nor C60S undergo endoproteolytic processing upon expression in human cells, suggesting that SEL-12 is cleaved by a C, elegans-specific endoproteolytic activity. The loss of function of sel-12 in C. elegans is not associated with a dominant negative activity in human cells, because SEL-12 C60S and the corresponding PS1 C92S mutation do not interfere with Notch1 cleavage. Moreover, both mutant variants increase the aberrant production of the highly amyloidogenic 42-amino acid version of amyloid beta -peptide similar to familial Alzheimer's disease-associated human PS mutants. Our data therefore demonstrate that the C60S mutation in SEL-12 is associated with aberrant endoproteolysis and a loss of function in C, elegans, whereas a gain of misfunction is observed upon expression in human cells.	Univ Munich, Genzentrum, D-81377 Munich, Germany; Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers Dis Res, D-80336 Munich, Germany; Boehringer Ingelheim KG, CNS Res, D-55216 Ingelheim, Germany	University of Munich; University of Munich; Boehringer Ingelheim	Baumeister, R (corresponding author), Univ Munich, Genzentrum, Feodor Lynen Str 25, D-81377 Munich, Germany.	bmeister@lmb.uni-muenchen.de; chaass@pbm.med.uni-muenchen.de	Eimer, Stefan/B-1865-2013; Wang, Caihong/T-5837-2019; Walter, Jochen/B-3677-2014	Wang, Caihong/0000-0002-6808-3709; Okochi, Masayasu/0000-0002-2318-7651; Walter, Jochen/0000-0002-4678-2912				Baumeister R, 1997, Genes Funct, V1, P149; Brockhaus M, 1998, NEUROREPORT, V9, P1481, DOI 10.1097/00001756-199805110-00043; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Citron M, 1998, NEUROBIOL DIS, V5, P107, DOI 10.1006/nbdi.1998.0183; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Davis JA, 1998, NEURON, V20, P603, DOI 10.1016/S0896-6273(00)80998-8; De Strooper B, 2000, NATURE, V405, P627, DOI 10.1038/35015193; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Grunberg J, 1998, BIOCHEMISTRY-US, V37, P2263, DOI 10.1021/bi972106l; Guo YQ, 1999, J NEUROSCI, V19, P8435; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Jacobsen H, 1999, J BIOL CHEM, V274, P35233, DOI 10.1074/jbc.274.49.35233; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Kulic L, 2000, P NATL ACAD SCI USA, V97, P5913, DOI 10.1073/pnas.100049897; Leimer U, 1999, BIOCHEMISTRY-US, V38, P13602, DOI 10.1021/bi991453n; Levitan D, 1998, DEVELOPMENT, V125, P3599; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Li XJ, 1997, P NATL ACAD SCI USA, V94, P12204, DOI 10.1073/pnas.94.22.12204; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; LUO KX, 1991, METHOD ENZYMOL, V201, P149; Martinez I, 1996, J VIROL, V70, P6036, DOI 10.1128/JVI.70.9.6036-6043.1996; Murayama O, 1999, NEUROSCI LETT, V265, P61, DOI 10.1016/S0304-3940(99)00187-1; Nakai T, 1999, J BIOL CHEM, V274, P23647, DOI 10.1074/jbc.274.33.23647; Niwa M, 1999, CELL, V99, P691, DOI 10.1016/S0092-8674(00)81667-0; Nowotny P, 2000, MOL CELL NEUROSCI, V15, P88, DOI 10.1006/mcne.1999.0805; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Qian S, 1998, NEURON, V20, P611, DOI 10.1016/S0896-6273(00)80999-X; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Selkoe DJ, 2000, CURR OPIN NEUROBIOL, V10, P50, DOI 10.1016/S0959-4388(99)00054-9; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Shirotani K, 2000, J BIOL CHEM, V275, P3681, DOI 10.1074/jbc.275.5.3681; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Steiner H, 1999, J BIOL CHEM, V274, P7615, DOI 10.1074/jbc.274.12.7615; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; TERRENI L, 2000, NEUROBIOL AGING, V21, pS176; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vito P, 1997, J BIOL CHEM, V272, P28315, DOI 10.1074/jbc.272.45.28315; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Westlund B, 1999, P NATL ACAD SCI USA, V96, P2497, DOI 10.1073/pnas.96.5.2497; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Wittenburg N, 2000, NATURE, V406, P306, DOI 10.1038/35018575; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P11223, DOI 10.1021/bi991080q; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	77	34	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40925	40932		10.1074/jbc.M005254200	http://dx.doi.org/10.1074/jbc.M005254200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11013240	hybrid			2022-12-27	WOS:000166114600036
J	Schmitt-Ney, M; Habener, JF				Schmitt-Ney, M; Habener, JF			CHOP/GADD153 gene expression response to cellular stresses inhibited by prior exposure to ultraviolet light wavelength band C (UVC) - Inhibitory sequence mediating the UVC response localized to exon 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; PROTEIN (C/EBP)-RELATED GENE; AMINO-ACID LIMITATION; NF-KAPPA-B; DNA-DAMAGE; BINDING PROTEIN; GROWTH ARREST; CHOP GADD153; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION	CHOP/GADD153 is both an activating and repressing transcription factor that is markedly induced in response to a variety of cellular stresses. The CHOP/ GADD153 gene was originally cloned because of its inducibility by ultraviolet light wavelength band C UVC and has since been found to be activated in response to many different cellular stresses. Some of the recent studies have questioned the UVC responsiveness of the CHOP gene. Contradiction in our own data led us to reexamine the WC effects on CHOP expression. WC is capable of strongly activating the mouse CHOP promoter in stably transfected NIH 3T3 cells but has only a modest and transient effect on the level of the CHOP messenger RNA. In addition to its positive effect on CHOP promoter activity, we show that UVC negatively affects CHOP mRNA and protein expression. Pretreatment of NIH 3T3 cells with WC markedly attenuates the subsequent induction of CHOP mRNA by the cellular stress activators methylmethane sulfate, tunicamycin, glucose deprivation, and methionine deprivation for as long as at least 16 h. This inhibitory effect of UVC on CHOP expression in response to stress is independent of the presence or absence of p53 and does not involve mRNA degradation as opposed to the WC effect that inhibits p21 expression seen only in the absence of p53. The target of the inhibitory effect of WC on CHOP expression is located in the first exon of the gene, a 5'-untranslated region that is unusually conserved between different species. These findings suggest that an unknown function encoded by the 5'-untranslated region somehow modifies the response of CHOP gene transcription to WC.	Harvard Univ, Mol Endocrinol Lab, Sch Med, Massachusetts Gen Hosp,Howard Hughes Med Inst, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Howard Hughes Medical Institute	Habener, JF (corresponding author), Harvard Univ, Mol Endocrinol Lab, Sch Med, Massachusetts Gen Hosp,Howard Hughes Med Inst, 55 Fruit St,WEL320, Boston, MA 02114 USA.	jhabener@partners.org						Antson AA, 1999, NATURE, V401, P235, DOI 10.1038/45730; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; CHEN Q, 1992, J BIOL CHEM, V267, P8207; CHOI AMK, 1992, EXP CELL RES, V199, P85, DOI 10.1016/0014-4827(92)90464-J; CHOI AMK, 1995, J CELL PHYSIOL, V164, P65, DOI 10.1002/jcp.1041640109; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GARMYN M, 1992, J INVEST DERMATOL, V99, P743, DOI 10.1111/1523-1747.ep12614470; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; Herrlich P, 1997, BIOL CHEM, V378, P1217; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; JACKMAN J, 1994, CANCER RES, V54, P5656; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUETHY JD, 1994, CANCER RES, V54, pS1902; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; LUETHY JD, 1992, CANCER RES, V52, P5; MARTEN NW, 1994, FASEB J, V8, P538, DOI 10.1096/fasebj.8.8.8181673; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; MAYNE LV, 1982, CANCER RES, V42, P1473; Nishigori C, 1996, P NATL ACAD SCI USA, V93, P10354, DOI 10.1073/pnas.93.19.10354; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; PRICE BD, 1992, CANCER RES, V52, P3814; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; SYLVESTER SL, 1994, J BIOL CHEM, V269, P20119; Tornaletti S, 1996, BIOESSAYS, V18, P221, DOI 10.1002/bies.950180309; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; Tyrrell R M, 1996, EXS, V77, P255; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Ubeda M, 1999, BIOCHEM BIOPH RES CO, V262, P31, DOI 10.1006/bbrc.1999.1140; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; WARMUTH I, 1994, CANCER RES, V54, P374; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; YAROSH DB, 1993, J INVEST DERMATOL, V100, P790, DOI 10.1111/1523-1747.ep12476573; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	59	23	23	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40839	40845		10.1074/jbc.M007440200	http://dx.doi.org/10.1074/jbc.M007440200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11010973	hybrid			2022-12-27	WOS:000166114600025
J	Veis, A; Tompkins, K; Alvares, K; Wei, KR; Wang, L; Wang, XS; Brownell, AG; Jengh, SM; Healy, KE				Veis, A; Tompkins, K; Alvares, K; Wei, KR; Wang, L; Wang, XS; Brownell, AG; Jengh, SM; Healy, KE			Specific amelogenin gene splice products have signaling effects on cells in culture and in implants in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROCYTE-SPECIFIC ENHANCER; BONE MORPHOGENETIC PROTEIN-2; DENTIN-MATRIX; OSTEOBLAST DIFFERENTIATION; TOOTH DEVELOPMENT; IN-VIVO; EXPRESSION PATTERNS; CARTILAGE FORMATION; ENAMEL PROTEINS; COLLAGEN GENE	Low molecular mass amelogenin-related polypeptides extracted from mineralized dentin have the ability to affect the differentiation pathway of embryonic muscle fibroblasts in culture and lead to the formation of mineralized matrix in in vivo implants. The objective of the present study was to determine whether the bioactive peptides could have been amelogenin protein degradation products or specific amelogenin gene splice products. Thus, the splice products were prepared, and their activities were determined in vitro and in vivo, A rat incisor tooth odontoblast pulp cDNA library was screened using probes based on the peptide amino acid sequencing data. Two specific cDNAs comprised from amelogenin gene exons 2,3,4,5,6d,7 and 2,3,5,6d,7 were identified. The corresponding recombinant proteins, designated r[A+4] (8.1 kDa) and r[A-4] (6.9 kDa), were produced. Both peptides enhanced in vitro sulfate incorporation into proteoglycan, the induction of type II collagen, and Sox9 or Cbfa1 mRNA expression. In vivo implant assays demonstrated implant mineralization accompanied by vascularization and the presence of the bone matrix proteins, BSP and BAG-75, We postulate that during tooth development these specific amelogenin gene splice products, [A+4] and [A-4], may have a role in preodontoblast maturation. The [A+4] and [A-4] may thus be tissue-specific epithelial mesenchymal signaling molecules.	Northwestern Univ, Sch Dent, Dept Basic & Behav Sci, Chicago, IL 60611 USA	Northwestern University	Veis, A (corresponding author), Northwestern Univ, Sch Dent, Dept Basic & Behav Sci, 303 E Chicago Ave, Chicago, IL 60611 USA.			Alvares, Keith/0000-0003-3710-4367	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE001374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE001374, R01DE008525] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE01374, DE08525] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aberg T, 1997, DEV DYNAM, V210, P383, DOI 10.1002/(SICI)1097-0177(199712)210:4<383::AID-AJA3>3.0.CO;2-C; AMAR S, 1991, J BIOL CHEM, V266, P8609; BANG G, 1967, ARCH SURG-CHICAGO, V94, P781; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; BESSHO K, 1990, J ORAL MAXIL SURG, V48, P162, DOI 10.1016/S0278-2391(10)80204-6; BESSHO K, 1991, J DENT RES, V70, P171, DOI 10.1177/00220345910700030301; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BONASS WA, 1994, BIOCHEM BIOPH RES CO, V198, P755, DOI 10.1006/bbrc.1994.1109; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; Brodt-Eppley J, 1998, BIOL REPROD, V59, P878, DOI 10.1095/biolreprod59.4.878; BUTLER WT, 1977, J DENT RES, V56, P228, DOI 10.1177/00220345770560030601; Castagnola P, 1996, EXP CELL RES, V223, P215, DOI 10.1006/excr.1996.0075; CONOVER MA, 1979, J DENT RES, V58, P1911, DOI 10.1177/00220345790580091201; D'Souza RN, 1999, DEVELOPMENT, V126, P2911; DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; George A, 1998, EUR J ORAL SCI, V106, P221, DOI 10.1111/j.1600-0722.1998.tb02179.x; George A, 1995, Connect Tissue Res, V33, P67, DOI 10.3109/03008209509016984; GEORGE A, 1993, J BIOL CHEM, V268, P12624; GIBSON C, 1991, BIOCHEMISTRY-US, V30, P1075, DOI 10.1021/bi00218a028; GIBSON CW, 1992, BIOCHEMISTRY-US, V31, P8384, DOI 10.1021/bi00150a036; Hammarstrom L, 1997, J CLIN PERIODONTOL, V24, P658, DOI 10.1111/j.1600-051X.1997.tb00247.x; Healy C, 1999, DEV DYNAM, V215, P69, DOI 10.1002/(SICI)1097-0177(199905)215:1<69::AID-DVDY8>3.3.CO;2-E; Healy C, 1996, ANN NY ACAD SCI, V785, P261, DOI 10.1111/j.1749-6632.1996.tb56278.x; HEIKINHEIMO K, 1994, J DENT RES, V73, P590, DOI 10.1177/00220345940730030401; Helder MN, 1998, J DENT RES, V77, P545, DOI 10.1177/00220345980770040701; Hu CC, 1997, J DENT RES, V76, P641, DOI 10.1177/00220345970760020401; INAI T, 1991, ANAT REC, V229, P259, DOI 10.1002/ar.1092290213; Karg HA, 1997, CELL TISSUE RES, V288, P545, DOI 10.1007/s004410050840; Karsenty G, 1999, BONE, V25, P107, DOI 10.1016/S8756-3282(99)00111-8; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KULKARNI GV, 2000, CHEM BIOL MIN TISS P, P161; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Lefebvre V, 1998, MATRIX BIOL, V16, P529; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LUMSDEN AGS, 1988, DEVELOPMENT, V103, P155; MINA M, 1987, ARCH ORAL BIOL, V32, P123, DOI 10.1016/0003-9969(87)90055-0; MoradianOldak J, 1996, CONNECT TISSUE RES, V35, P231, DOI 10.3109/03008209609029196; NAKAMURA M, 1994, ANAT RECORD, V238, P383, DOI 10.1002/ar.1092380313; Nebgen DR, 1999, J DENT RES, V78, P1484, DOI 10.1177/00220345990780090201; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PALMER RM, 1987, ARCH ORAL BIOL, V32, P281, DOI 10.1016/0003-9969(87)90022-7; RITCHIE HH, 1994, J BIOL CHEM, V269, P3698; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SALIDO EC, 1992, AM J HUM GENET, V50, P303; Sambrook J., 2002, MOL CLONING LAB MANU; SAWADA T, 1995, ARCH ORAL BIOL, V40, P1029, DOI 10.1016/0003-9969(95)00073-X; Shapiro I M, 1999, Clin Orthod Res, V2, P42; Simmer JP, 1995, CONNECT TISSUE RES, V32, P131, DOI 10.3109/03008209509013715; Slavkin H.C., 1975, EXTRACELLULAR MATRIX; Thesleff I, 1995, CONNECT TISSUE RES, V32, P9, DOI 10.3109/03008209509013700; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Urist M R, 1982, Prog Clin Biol Res, V101, P61; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; VEIS A, 1990, BIOMATERIALS, V11, P35; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; Whang K, 1998, J BIOMED MATER RES, V42, P491, DOI 10.1002/(SICI)1097-4636(19981215)42:4<491::AID-JBM3>3.0.CO;2-F; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15; Wurtz T, 1996, J BONE MINER RES, V11, P125; Xie WF, 1999, J BONE MINER RES, V14, P757, DOI 10.1359/jbmr.1999.14.5.757; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989	63	203	212	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41263	41272		10.1074/jbc.M002308200	http://dx.doi.org/10.1074/jbc.M002308200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10998415	hybrid			2022-12-27	WOS:000166114600081
J	Hixon, ML; Obejero-Paz, C; Muro-Cacho, C; Wagner, MW; Millie, E; Nagy, J; Hassold, TJ; Gualberto, A				Hixon, ML; Obejero-Paz, C; Muro-Cacho, C; Wagner, MW; Millie, E; Nagy, J; Hassold, TJ; Gualberto, A			Cks1 mediates vascular smooth muscle cell polyploidization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUSLY HYPERTENSIVE RATS; DIFFERENT AGE-GROUPS; GENETIC-HYPERTENSION; RESISTANCE VESSELS; BETA-ADRENOCEPTORS; SPINDLE CHECKPOINT; ANGIOTENSIN-II; HYPERTROPHY; KINASE; EXPRESSION	Vascular smooth muscle cells (VSMC) at capacitance arteries of hypertensive individuals and animals undergo dramatic polyploidization that contributes toward their hypertrophic phenotype. We report here the identification of a defective mitotic spindle cell cycle checkpoint in VSMC isolated from capacitance arteries of pre-hypertensive rats. These cells demonstrated a high predisposition to polyploidization in culture and failed to maintain cyclin B protein levels in response to colcemid, a mitotic inhibitor. Furthermore, this altered mitotic spindle checkpoint status was associated with the overexpression of Cks1, a Cdc2 adapter protein that promotes cyclin B degradation. Cks1 up-regulation, cyclin B down-regulation, and VSMC polyploidization were evidenced at the smooth muscle of capacitance arteries of genetically hypertensive and Goldblatt-operated rats. In addition, angiotensin II infusion dramatically increased Cks1 protein levels at capacitance arteries of normotensive rats, and angiotensin II treatment of isolated VSMC abrogated their ability to down-regulate Cks1 and maintain cyclin B protein expression in response to colcemid. Finally, transduction of VSMC from normotensive animals with a retrovirus that drives the expression of Cks1 was sufficient to alter their mitotic spindle cell cycle checkpoint status and promote unscheduled cyclin B metabolism, cell cycle re-entry, and polyploidization. These data demonstrate that Cks1 regulates cyclin B metabolism and ploidy in VSMC and may contribute to the understanding of the phenomena of VSMC polyploidization during hypertension.	Pfizer Global Res & Dev, Groton Labs, Dept Cardiovasc & Metab Dis, Groton, CT 06340 USA; Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Res Inst, Tampa, FL 33612 USA; Pfizer Global Res & Dev, Dept Cardiovasc & Metab Dis, Groton Labs, Groton, CT 06340 USA	Pfizer; Case Western Reserve University; Case Western Reserve University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Pfizer	Gualberto, A (corresponding author), Pfizer Global Res & Dev, Groton Labs, Dept Cardiovasc & Metab Dis, Eastern Point Rd, Groton, CT 06340 USA.	antonio_gualberto@groton.pfizer.com		Gualberto, Antonio/0000-0002-6590-839X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD021341] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021341] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041618] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41618] Funding Source: Medline; NICHD NIH HHS [HD21341] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARRETT TB, 1983, P NATL ACAD SCI-BIOL, V80, P882, DOI 10.1073/pnas.80.3.882; BASI G, 1995, MOL CELL BIOL, V15, P2028; BLACK MJ, 1995, J HYPERTENS, V13, P683, DOI 10.1097/00004872-199506000-00016; BLACK MJ, 1988, BLOOD VESSELS, V25, P89; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CHOBANIAN AV, 1987, CIRCULATION, V75, P102; CONYERS RB, 1995, J HYPERTENS, V13, P507, DOI 10.1097/00004872-199505000-00005; Conyers RB, 1997, CAN J PHYSIOL PHARM, V75, P375, DOI 10.1139/cjpp-75-5-375; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DEVLIN AM, 1995, J HUM HYPERTENS, V9, P497; Dominiczak AF, 1996, HYPERTENSION, V27, P752, DOI 10.1161/01.HYP.27.3.752; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gatzka CD, 1998, HYPERTENSION, V32, P575, DOI 10.1161/01.HYP.32.3.575; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Hixon ML, 1998, MOL CELL BIOL, V18, P6224, DOI 10.1128/MCB.18.11.6224; Kaiser P, 1999, GENE DEV, V13, P1190, DOI 10.1101/gad.13.9.1190; LEE RMKW, 1992, CAN J PHYSIOL PHARM, V70, P1496, DOI 10.1139/y92-212; LEITSCHUH M, 1987, HYPERTENSION, V9, P106; LICHTENSTEIN AH, 1986, HYPERTENSION, V8, P50; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; OWENS GK, 1983, CIRC RES, V53, P491, DOI 10.1161/01.RES.53.4.491; OWENS GK, 1982, CIRC RES, V51, P280, DOI 10.1161/01.RES.51.3.280; OWENS GK, 1988, HYPERTENSION, V11, P198, DOI 10.1161/01.HYP.11.2.198; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; Patra D, 1998, GENE DEV, V12, P2549, DOI 10.1101/gad.12.16.2549; PRINTSEVA OY, 1992, AM J HYPERTENS, V5, pS118, DOI 10.1093/ajh/5.6.118S; PRINTSEVA OY, 1989, EXP CELL RES, V184, P342, DOI 10.1016/0014-4827(89)90333-9; ROSEN EM, 1986, J CELL PHYSIOL, V128, P337, DOI 10.1002/jcp.1041280228; ROSENDORFF C, 1986, J HYPERTENS, V4, pS109; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Sokal R.R., 2012, BIOMETRY; Sudakin V, 1997, J BIOL CHEM, V272, P18051, DOI 10.1074/jbc.272.29.18051; VANNECK JW, 1992, FEBS LETT, V297, P189, DOI 10.1016/0014-5793(92)80358-N; Walsh K, 1999, J CLIN INVEST, V104, P673, DOI 10.1172/JCI8203; YAMORI Y, 1987, CIRCULATION, V75, P92	39	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40434	40442		10.1074/jbc.M005059200	http://dx.doi.org/10.1074/jbc.M005059200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11005810	hybrid			2022-12-27	WOS:000166039500086
J	Tamai, I; Ohashi, R; Nezu, J; Sai, Y; Kobayashi, D; Oku, A; Shimane, M; Tsuji, A				Tamai, I; Ohashi, R; Nezu, J; Sai, Y; Kobayashi, D; Oku, A; Shimane, M; Tsuji, A			Molecular and functional characterization of organic cation/carnitine transporter family in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC CARNITINE DEFICIENCY; VISCERAL STEATOSIS MICE; LIPID STORAGE MYOPATHY; CATION TRANSPORTER; TISSUE DISTRIBUTION; CLONING; OCTN2; RAT; GENE; EXPRESSION	Carnitine is essential for beta -oxidation of fatty acids, and a defect of cell membrane transport of carnitine leads to fatal systemic carnitine deficiency. We have already shown that a defect of the organic cation/carnitine transporter OCTN2 is a primary cause of systemic carnitine deficiency. In the present study, we further isolated and characterized new members of the OCTN family, OCTN1 and -3, in mice. All three members were expressed commonly in kidney, and OCTN1 and -2 were also expressed in various tissues, whereas OCTN3 was characterized by predominant expression in testis. When their cDNAs were transfected into HEK293 cells, the cells exhibited transport activity for carnitine and/or the organic cation tetraethylammonium (TEA). Carnitine transport by OCTN1 and OCTN2 was Na+-dependent, whereas that by OCTN3 was Na+-independent. TEA was transported by OCTN1 and OCTN2 but not by OCTN3. The relative uptake activity ratios of carnitine to TEA were 1.78, 11.3, and 746 for OCTN1, -2, and -3, respectively, suggesting high specificity of OCTN3 for carnitine and significantly lower carnitine transport activity of OCTN1. Thus, OCTN3 is unique in its limited tissue distribution and Na+-independent carnitine transport, whereas OCTN1 efficiently transported TEA with minimal expression of carnitine transport activity and may have a different role from other members of the OCTN family.	Kanazawa Univ, Fac Pharmaceut Sci, Dept Pharmacobio Dynam, Kanazawa, Ishikawa 9200934, Japan; Japan Sci & Technol Corp, JST, CREST, Kawaguchi 3320012, Japan; Mol Med Inc, Chugai Res Inst, Ibaraki, Osaka 3004101, Japan	Kanazawa University; Japan Science & Technology Agency (JST)	Tsuji, A (corresponding author), Kanazawa Univ, Fac Pharmaceut Sci, Dept Pharmacobio Dynam, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.	tsuji@kenroku.kanazawa-u.ac.jp	Kobayashi, Daisuke/R-7792-2019; SAI, Yoshimichi/L-3828-2015; TAMAI, Ikumi/D-8412-2015	Kobayashi, Daisuke/0000-0003-2087-5130; SAI, Yoshimichi/0000-0003-2954-1532; 				Berardi S, 2000, EUR J BIOCHEM, V267, P1985, DOI 10.1046/j.1432-1327.2000.01198.x; BERARDI S, 1995, BIOCHEM J, V309, P389, DOI 10.1042/bj3090389; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASS EP, 1978, J BIOL CHEM, V253, P2688; BREMER J, 1983, PHYSIOL REV, V63, P1420, DOI 10.1152/physrev.1983.63.4.1420; BRENINGSTALL GN, 1990, PEDIATR NEUROL, V6, P75, DOI 10.1016/0887-8994(90)90037-2; Burwinkel B, 1999, BIOCHEM BIOPH RES CO, V261, P484, DOI 10.1006/bbrc.1999.1060; ENGEL AG, 1973, SCIENCE, V179, P899, DOI 10.1126/science.179.4076.899; FRITZ IB, 1964, AM J PHYSIOL, V206, P531, DOI 10.1152/ajplegacy.1964.206.3.531; Gorboulev V, 1997, DNA CELL BIOL, V16, P871, DOI 10.1089/dna.1997.16.871; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; HINTON BT, 1985, J ANDROL, V6, P300; HINTON BT, 1981, J REPROD FERTIL, V61, P59, DOI 10.1530/jrf.0.0610059; HOPPEL CL, 1986, BIOCHEM SOC T, V14, P673, DOI 10.1042/bst0140673; HORIUCHI M, 1993, FEBS LETT, V326, P267, DOI 10.1016/0014-5793(93)81805-A; Hosoyamada M, 1999, AM J PHYSIOL-RENAL, V276, pF122, DOI 10.1152/ajprenal.1999.276.1.F122; Jeulin C, 1996, HUM REPROD UPDATE, V2, P87, DOI 10.1093/humupd/2.2.87; JOHANSEN L, 1979, ARCH ANDROLOGY, V2, P117, DOI 10.3109/01485017908987302; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; Koizumi A, 1999, HUM MOL GENET, V8, P2247, DOI 10.1093/hmg/8.12.2247; KOIZUMI T, 1988, LAB ANIM, V22, P83, DOI 10.1258/002367788780746511; Kusuhara H, 1999, J BIOL CHEM, V274, P13675, DOI 10.1074/jbc.274.19.13675; Lamhonwah AM, 1998, BIOCHEM BIOPH RES CO, V252, P396, DOI 10.1006/bbrc.1998.9679; LopezNieto CE, 1997, J BIOL CHEM, V272, P6471, DOI 10.1074/jbc.272.10.6471; Lu KM, 1998, BIOCHEM BIOPH RES CO, V252, P590, DOI 10.1006/bbrc.1998.9708; MATSUISHI T, 1985, NEUROPEDIATRICS, V16, P6, DOI 10.1055/s-2008-1052536; Mayatepek E, 2000, Hum Mutat, V15, P118, DOI 10.1002/(SICI)1098-1004(200001)15:1<118::AID-HUMU28>3.0.CO;2-8; Nezu JI, 1999, NAT GENET, V21, P91, DOI 10.1038/5030; Ohashi R, 1999, J PHARMACOL EXP THER, V291, P778; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; Schweifer N, 1996, MAMM GENOME, V7, P735, DOI 10.1007/s003359900223; Sekine T, 1998, BIOCHEM BIOPH RES CO, V251, P586, DOI 10.1006/bbrc.1998.9521; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; SIMONSON GD, 1994, J CELL SCI, V107, P1065; STEINMANN B, 1987, PEDIATR RES, V21, P201, DOI 10.1203/00006450-198702000-00018; STIEGER B, 1995, BIOCHEM J, V309, P643, DOI 10.1042/bj3090643; Tamai I, 1997, FEBS LETT, V419, P107, DOI 10.1016/S0014-5793(97)01441-5; Tamai I, 1998, J BIOL CHEM, V273, P20378, DOI 10.1074/jbc.273.32.20378; Tang NLS, 1999, HUM MOL GENET, V8, P655, DOI 10.1093/hmg/8.4.655; TREEM WR, 1988, NEW ENGL J MED, V319, P1331, DOI 10.1056/NEJM198811173192006; Vaz FM, 1999, HUM GENET, V105, P157, DOI 10.1007/s004390051079; Wang YH, 1999, P NATL ACAD SCI USA, V96, P2356, DOI 10.1073/pnas.96.5.2356; Wu X, 2000, BBA-BIOMEMBRANES, V1466, P315, DOI 10.1016/S0005-2736(00)00189-9; Wu X, 1998, BIOCHEM BIOPH RES CO, V246, P589, DOI 10.1006/bbrc.1998.8669; Wu X, 1999, J PHARMACOL EXP THER, V290, P1482; Yabuuchi H, 1999, J PHARMACOL EXP THER, V289, P768; Yokogawa K, 1999, J PHARM PHARMACOL, V51, P935, DOI 10.1211/0022357991773195; Yokogawa K, 1999, HEPATOLOGY, V30, P997, DOI 10.1002/hep.510300423; Yokogawa K, 1999, J PHARMACOL EXP THER, V289, P224; Zhang L, 1997, MOL PHARMACOL, V51, P913, DOI 10.1124/mol.51.6.913; Zhu YW, 2000, P NATL ACAD SCI USA, V97, P1137, DOI 10.1073/pnas.97.3.1137	51	233	243	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40064	40072		10.1074/jbc.M005340200	http://dx.doi.org/10.1074/jbc.M005340200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11010964	hybrid			2022-12-27	WOS:000166039500038
J	Aguirre, A; Lopez, T; Lopez-Bayghen, E; Ortega, A				Aguirre, A; Lopez, T; Lopez-Bayghen, E; Ortega, A			Glutamate regulates kainate-binding protein expression in cultured chick Bergmann glia through an activator protein-1 binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIAL GLIA; RECEPTOR; CELLS; FAMILY; GENE; LOCALIZATION	The expression of the chick kainate-binding protein, a member of the ionotropic glutamate receptor family, is restricted to the cerebellum, specifically to Bergmann glia. Glutamate induces a membrane to nuclei signaling involved in gene expression regulation. Exposure of cultured chick Bergmann glia cells to glutamate leads to an increase in kainate binding protein and mRNA levels, suggesting a transcriptional level of regulation. The 5 ' proximal region of the chick kainate binding gene was cloned and transfected 4into Bergmann glia cells. Three main regulatory regions could be defined, a minimal promoter region, a negative regulatory region, and interestingly, a glutamate-responsive element. Deletion of this element abolishes the agonist effect. Moreover, electrophoretic mobility shift assays, cotransfection experiments, and site-directed mutagenesis clearly suggest that the glutamate effect is mediated through an AP-1 site by a Fos/Jun heterodimer. The present results favor the notion of a functional role of kainate-binding protein in glutamatergic cerebellar neurotransmission.	Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Genet & Mol Biol, Mexico City 07000, DF, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico	Ortega, A (corresponding author), Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Genet & Mol Biol, Apartado Postal 14-740, Mexico City 07000, DF, Mexico.	arortega@mail.cinvestav.mx	Lopez-Bayghen, Esther/A-8006-2008; Ortega, Arturo/A-2282-2008	Lopez-Bayghen, Esther/0000-0002-2849-7587; Ortega, Arturo/0000-0002-9594-8114				Aguilera P, 1999, NEUROCHEM RES, V24, P981, DOI 10.1023/A:1021044424103; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark BA, 1997, J PHYSIOL-LONDON, V502, P335, DOI 10.1111/j.1469-7793.1997.335bk.x; Condorelli DF, 1999, ADV EXP MED BIOL, V468, P49; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; ESHHAR N, 1992, FEBS LETT, V297, P257, DOI 10.1016/0014-5793(92)80551-Q; Eykholt RL, 2000, BIOTECHNIQUES, V28, P864, DOI 10.2144/00285bm07; GREGOR P, 1992, MOL BRAIN RES, V16, P179, DOI 10.1016/0169-328X(92)90223-X; GREGOR P, 1988, EMBO J, V7, P2673, DOI 10.1002/j.1460-2075.1988.tb03120.x; HENLEY JM, 1994, TRENDS PHARMACOL SCI, V15, P182, DOI 10.1016/0165-6147(94)90146-5; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KIMURA N, 1993, MOL BRAIN RES, V17, P351, DOI 10.1016/0169-328X(93)90022-H; Latchman DS, 1999, J CELL PHYSIOL, V179, P126; LEONARD MW, 1993, DEVELOPMENT, V119, P519; Lopez T, 1998, MOL BRAIN RES, V58, P40, DOI 10.1016/S0169-328X(98)00094-1; Lopez T, 1997, FEBS LETT, V405, P245, DOI 10.1016/S0014-5793(97)00195-6; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; Myers SJ, 1999, ANNU REV PHARMACOL, V39, P221, DOI 10.1146/annurev.pharmtox.39.1.221; OTORI Y, 1994, MOL BRAIN RES, V27, P310, DOI 10.1016/0169-328X(94)90014-0; PECHAN PA, 1993, NEUROSCI LETT, V153, P111, DOI 10.1016/0304-3940(93)90089-4; SANCHEZ G, 1994, NEUROREPORT, V5, P2109, DOI 10.1097/00001756-199410270-00030; SOMOGYI P, 1990, NEUROSCIENCE, V35, P9, DOI 10.1016/0306-4522(90)90116-L; Villmann C, 1997, J NEUROSCI, V17, P7634, DOI 10.1523/jneurosci.17-20-07634.1997	24	23	23	4	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39246	39253		10.1074/jbc.M002847200	http://dx.doi.org/10.1074/jbc.M002847200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993879	hybrid			2022-12-27	WOS:000165953100042
J	Aoki, N; Matsuda, T				Aoki, N; Matsuda, T			A cytosolic protein-tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; INDUCIBLE SH2 PROTEIN; DNA-BINDING ACTIVITY; RECEPTOR-BETA-CHAIN; MAMMARY-GLAND; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; GROWTH-HORMONE; ERYTHROPOIETIN RECEPTOR; NUCLEAR TRANSLOCATION	Prolactin (PRL) plays a central and crucial role in the regulation of milk protein gene expression in mammary epithelial cells. PRL binding to its cognate receptor leads to receptor dimerization and activation of the tyrosine kinase Janus kinase 2 (JAK2), associated with the membrane-proximal, intracellular domain of the receptor. In turn, JAK2 phosphorylates and activates STAT5, a member of the signal transducers and activators of transcription (STAT) family. We have recently reported that 16 different protein-tyrosine phosphatases (PTP) were expressed in lactating mouse mammary gland and mammary epithelial cells (Aoki, N., Kawamura, M., Yamaguchi-Aoki, Y., Ohira, S., and Matsuda, T. (1999) J. Biochem. (Tokyo) 125, 669-675). We investigated the involvement of each PTP in PRL signaling. Among the 12 phosphatases including SHP-2 examined, a cytosolic phosphatase PTP1B was found to specifically dephosphorylate STAT5a and STAT5b, in transfected COS7 and in vitro. Nuclear translocation of STAT5a and STAT5b was largely inhibited upon overexpression of PTP1B. The PRL-dependent transcriptional activation of the p-casein gene promoter was also inhibited by PTP1B. Furthermore, retrovirus-mediated overexpression of PTP1B resulted in dephosphorylation of endogenous STAT5 and down-regulation of beta -casein gene expression in mammary epithelial COMMA-1D cells when the cells were treated with lactogenic hormones. Endogenous tyrosine-phosphorylated STAT5 proteins in mammary epithelial COMMA-1D cells as well as tyrosine-phosphorylated STAT5a and STAT5b expressed in COS7 cells were co-precipitated by substrate-trapping mutants of recombinant PTP1B. These results strongly suggest that PTP1B dephosphorylates PRL-activated STAT5a and STAT5b, thereby negatively regulating PRL-mediated signaling pathway.	Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Nagoya, Aichi 4648601, Japan	Nagoya University	Aoki, N (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Nagoya, Aichi 4648601, Japan.							Ali S, 1998, J BIOL CHEM, V273, P7709, DOI 10.1074/jbc.273.13.7709; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; Aman MJ, 1999, J BIOL CHEM, V274, P30266, DOI 10.1074/jbc.274.42.30266; Aoki N, 1996, J BIOL CHEM, V271, P29422, DOI 10.1074/jbc.271.46.29422; Aoki N, 1999, J BIOCHEM, V125, P669, DOI 10.1093/oxfordjournals.jbchem.a022335; Aoyama K, 1999, BIOCHEM BIOPH RES CO, V266, P523, DOI 10.1006/bbrc.1999.1845; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; Berchtold S, 1998, MOL ENDOCRINOL, V12, P556, DOI 10.1210/me.12.4.556; Boucheron C, 1998, J BIOL CHEM, V273, P33936, DOI 10.1074/jbc.273.51.33936; Callus BA, 1998, BLOOD, V91, P3182, DOI 10.1182/blood.V91.9.3182.3182_3182_3192; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; de Vlaming V.L., 1979, P561; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Frank DA, 1996, LEUKEMIA, V10, P1724; Gadina M, 1998, J IMMUNOL, V160, P4657; GOUILLEUX F, 1995, ENDOCRINOLOGY, V136, P5700, DOI 10.1210/en.136.12.5700; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Heim MH, 1996, EUR J CLIN INVEST, V26, P1, DOI 10.1046/j.1365-2362.1996.103248.x; Helman D, 1998, FEBS LETT, V441, P287, DOI 10.1016/S0014-5793(98)01555-5; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; KAZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598, DOI 10.1210/me.9.11.1598; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Moeslein FM, 1999, J BIOL CHEM, V274, P26697, DOI 10.1074/jbc.274.38.26697; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Pezet A, 1999, J BIOL CHEM, V274, P24497, DOI 10.1074/jbc.274.35.24497; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; RUI H, 1994, J BIOL CHEM, V269, P5364; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; Symes A, 1997, CURR BIOL, V7, P697, DOI 10.1016/S0960-9822(06)00298-3; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tomic S, 1999, MOL CELL ENDOCRINOL, V158, P45, DOI 10.1016/S0303-7207(99)00180-X; TONKS NK, 1988, J BIOL CHEM, V263, P6722; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017	57	141	152	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39718	39726		10.1074/jbc.M005615200	http://dx.doi.org/10.1074/jbc.M005615200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993888	hybrid			2022-12-27	WOS:000165953100101
J	Bandell, M; Lolkema, JS				Bandell, M; Lolkema, JS			Arg-425 of the citrate transporter CitP is responsible for high affinity binding of di- and tricarboxylatese	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTIC-ACID BACTERIA; LACTOCOCCUS-LACTIS; ESCHERICHIA-COLI; MEMBRANE; EXPRESSION; MECHANISM; INSERTION; NISIN; GENES	The citrate transporter of Leuconostoc mesenteroides (CitP) catalyzes exchange of divalent anionic citrate from the medium for monovalent anionic lactate, which is an end product of citrate degradation. The exchange generates a membrane potential and thus metabolic energy for the cell. The mechanism by which CitP transports both a divalent and a monovalent substrate was the subject of this investigation. Previous studies indicated that CitP is specific for substrates containing a 2-hydroxycarboxylate motif, HO-CR2-COO-. CitP has a high affinity for substrates that have a "second" carboxylate at one of the R groups, such as divalent citrate and (S)-malate (Bandell, M., and Lolkema, J. S. (1999) Biochemistry 38, 10352-10360). Monovalent anionic substrates that lack this second carboxylate were found to bind with a low affinity, In the present study we have constructed site-directed mutants, changing Arg-425 into a lysine or a cysteine residue. By using two substrates, Be. (S)-malate and 2-hydroxyisobutyrate, the substrate specificity of the mutants was analyzed. In both mutants the affinity for divalent (S)-malate was strongly decreased, whereas the affinity for monovalent 2-hydroxyisobutyrate was not. The largest effect was seen when the arginine was changed into the neutral cysteine, which reduced the affinity for (S)-malate over 50-fold. Chemical modification of the R425C mutant with the sulfhydryl reagent 2-aminoethyl methanethiosulfonate, which restores the positive charge at position 425, dramatically reactivated the mutant transporter. The R425C and R425K mutants revealed a substrate protectable inhibition by other sulfhydryl reagents and the lysine reagent 2,4,6-trinitrobenzene sulfonate, respectively. It is concluded that Arg-425 complexes the charged carboxylate present in divalent substrates but that is absent in monovalent substrates, and thus plays an important role in the generation of the membrane potential.	Univ Groningen, Dept Microbiol, Ctr Biol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Lolkema, JS (corresponding author), Univ Groningen, Dept Microbiol, Ctr Biol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.							AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Bandell M, 1999, BIOCHEMISTRY-US, V38, P10352, DOI 10.1021/bi9907577; Bandell M, 2000, BIOCHEMISTRY-US, V39, P13059, DOI 10.1021/bi0011882; Bandell M, 1997, J BIOL CHEM, V272, P18140, DOI 10.1074/jbc.272.29.18140; Bandell M, 1998, APPL ENVIRON MICROB, V64, P1594; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; Fields R, 1972, Methods Enzymol, V25, P464, DOI 10.1016/S0076-6879(72)25042-X; GRUBMEYER C, 1993, J BIOL CHEM, V268, P20299; HOLO H, 1989, APPL ENVIRON MICROB, V55, P3119, DOI 10.1128/AEM.55.12.3119-3123.1989; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KUIPERS OP, 1993, EUR J BIOCHEM, V216, P281, DOI 10.1111/j.1432-1033.1993.tb18143.x; LOLKEMA JS, 1996, HDB BIOL PHYSICS, P229; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Magni C, 1999, J BACTERIOL, V181, P1451, DOI 10.1128/JB.181.5.1451-1457.1999; MARTYTEYSSET C, 1995, J BIOL CHEM, V270, P25370, DOI 10.1074/jbc.270.43.25370; MITCHELL JBO, 1992, J MOL BIOL, V226, P251, DOI 10.1016/0022-2836(92)90137-9; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; Putman M, 1999, BIOCHEMISTRY-US, V38, P1002, DOI 10.1021/bi981863w; Ramamoorthy S, 1998, METHOD ENZYMOL, V296, P347; Sambrook J., 2002, MOL CLONING LAB MANU; TEYSSET CM, 1996, J BACTERIOL, V178, P2178; van Geest M, 1999, J BIOL CHEM, V274, P29705, DOI 10.1074/jbc.274.42.29705; van Geest M, 1999, J BIOL CHEM, V274, P2816, DOI 10.1074/jbc.274.5.2816; vanGeest M, 1996, J BIOL CHEM, V271, P25582, DOI 10.1074/jbc.271.41.25582	25	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39130	39136		10.1074/jbc.M005940200	http://dx.doi.org/10.1074/jbc.M005940200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993891	Green Published, hybrid			2022-12-27	WOS:000165953100027
J	Jucker, BM; Ren, JM; Dufour, S; Cao, XY; Previs, SF; Cadman, KS; Shulman, GI				Jucker, BM; Ren, JM; Dufour, S; Cao, XY; Previs, SF; Cadman, KS; Shulman, GI			C-13/P-31 NMR assessment of mitochondrial energy coupling in skeletal muscle of awake fed and fasted rats - Relationship with uncoupling protein 3 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; FREE FATTY-ACIDS; CHROMATOGRAPHY MASS-SPECTROMETRY; GLUCOSE-METABOLISM; THYROID-HORMONE; MESSENGER-RNA; LEPTIN; C-13; THERMOGENESIS; GLUTAMATE	To examine the relationship between mitochondrial energy coupling in skeletal muscle and change in uncoupling protein 3 (UCP3) expression during the transition from the fed to fasted state, we used a novel noninvasive P-31/C-13 NMR spectroscopic approach to measure the degree of mitochondrial energy coupling in the hind limb muscles of awake rats before and after a 48-h fast. Compared with fed levels, UCP3 mRNA and protein levels in the gastrocnemius increased 1.7- (p < 0.01) and 2.9-fold (p < 0.001), respectively, following a 48-h fast. Tricarboxylic acid cycle flux measured using C-13 NMR as an index of mitochondrial substrate oxidation was 212 +/- 23 and 173 +/- 25 nmol/g/min (p not significant) in the fed and 48-h fasted groups, respectively Unidirectional ATP synthesis flux measured using (31)p NMR was 79 +/- 15 and 57 +/- 9 nmol/g/s (p not significant) in the fed and 48-h fasted groups, respectively. Mitochondrial energy coupling as expressed by the ratio of ATP synthesis to tricarboxylic acid cycle flux was not different between the fed and fasted states. To test the hypothesis that UCP3 may be involved in the translocation of long chain free fatty acids (FFA) into the mitochondrial matrix under conditions of elevated FFA availability, [U-C-13]palmitate/albumin was administered in a separate group of rats with (+) or without (-) etomoxir (an inhibitor of carnitine palmitoyltransferase I). The ratio of glutamate enrichment ((+) etomoxir/(-) etomoxir) in the hind limb muscles was the same between groups, indicating that UCP3 does not appear to function as a translocator for long chain FFA in skeletal muscle following a 48-h fast. In summary, these data demonstrate that despite a 2-3-fold increase in UCP3 mRNA and protein expression in skeletal muscle during the transition from the fed to fasted state, mitochondrial energy coupling does not change, Furthermore, UCP3 does not appear to have a major role in FFA translocation into the mitochondria, The physiological role of UCP3 following a 48-h fast in skeletal muscle remains to be elucidated.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Bristol Myers Squibb Co, Dept Metab Res, Princeton, NJ 08543 USA	Howard Hughes Medical Institute; Yale University; Yale University; Bristol-Myers Squibb	Shulman, GI (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, POB 9812,295 Congress Ave, New Haven, CT 06510 USA.	gerald.shulman@yale.edu	Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040936, P30DK045735] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK040936, R01 DK-40936, P30 DK-45735] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEYLOT M, 1993, ANAL BIOCHEM, V212, P532, DOI 10.1006/abio.1993.1364; Bienengraeber M, 1998, BIOCHEMISTRY-US, V37, P3, DOI 10.1021/bi972463w; Boss O, 1999, BIOCHEM BIOPH RES CO, V261, P870, DOI 10.1006/bbrc.1999.1145; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; Brand MD, 1999, INT J OBESITY, V23, pS4, DOI 10.1038/sj.ijo.0800936; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; CHANCE EM, 1983, J BIOL CHEM, V258, P3785; Chung WK, 1999, DIABETES, V48, P1890, DOI 10.2337/diabetes.48.9.1890; Cusin I, 1998, DIABETES, V47, P1014, DOI 10.2337/diabetes.47.7.1014; Field J, 1939, J CELL COMPAR PHYSL, V14, P143, DOI 10.1002/jcp.1030140202; FITZPATRICK SM, 1990, J CEREBR BLOOD F MET, V10, P170, DOI 10.1038/jcbfm.1990.32; GARLAND PB, 1964, BIOCHEM J, V93, P678, DOI 10.1042/bj0930678; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Gomez-Ambrosi J, 1999, CELL MOL LIFE SCI, V55, P992, DOI 10.1007/PL00013203; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; Hwang CS, 1999, BIOCHEM BIOPH RES CO, V258, P464, DOI 10.1006/bbrc.1999.0662; Jucker BM, 1998, J BIOL CHEM, V273, P12187, DOI 10.1074/jbc.273.20.12187; Jucker BM, 2000, P NATL ACAD SCI USA, V97, P6880, DOI 10.1073/pnas.120131997; Jucker BM, 1997, J BIOL CHEM, V272, P10464, DOI 10.1074/jbc.272.16.10464; KEESEY RE, 1988, HDB EATING DISORDE 2, P87; KLINGENBERG M, 1985, EMBO J, V4, P3087, DOI 10.1002/j.1460-2075.1985.tb04049.x; Larkin S, 1997, BIOCHEM BIOPH RES CO, V240, P222, DOI 10.1006/bbrc.1997.7636; Lee FYJ, 1999, AM J PHYSIOL-CELL PH, V276, pC386, DOI 10.1152/ajpcell.1999.276.2.C386; Lehrach H, 1985, Prog Clin Biol Res, V177, P7; MA SWY, 1986, CAN J PHYSIOL PHARM, V64, P1252, DOI 10.1139/y86-211; Mao WG, 1999, FEBS LETT, V443, P326, DOI 10.1016/S0014-5793(98)01713-X; MASON GF, 1992, J CEREBR BLOOD F MET, V12, P434, DOI 10.1038/jcbfm.1992.61; Mataix J, 1998, FREE RADICAL BIO MED, V24, P511, DOI 10.1016/S0891-5849(97)00288-8; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Oakes ND, 1997, DIABETES, V46, P1768, DOI 10.2337/diabetes.46.11.1768; POWERS L, 1995, J MASS SPECTROM, V30, P747, DOI 10.1002/jms.1190300514; RICQUIER D, 1986, J BIOL CHEM, V261, P13905; Samec S, 1998, DIABETES, V47, P1693, DOI 10.2337/diabetes.47.11.1693; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; SEMEC S, 1999, EUR J PHYSL, V438, P452; Sidossis LS, 1996, J CLIN INVEST, V98, P2244, DOI 10.1172/JCI119034; Sivitz WI, 1999, ENDOCRINOLOGY, V140, P1511, DOI 10.1210/en.140.4.1511; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; SMITH D, 1987, METABOLISM, V36, P1167, DOI 10.1016/0026-0495(87)90244-7; TREVISAN C, 1983, NEUROCHEM RES, V8, P551, DOI 10.1007/BF00964696; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Weigle DS, 1998, DIABETES, V47, P298, DOI 10.2337/diabetes.47.2.298; WINKLER E, 1994, J BIOL CHEM, V269, P2508; Yu X, 1995, BIOPHYS J, V69, P2090, DOI 10.1016/S0006-3495(95)80080-9; Zhang CY, 1999, FEBS LETT, V449, P129, DOI 10.1016/S0014-5793(99)00441-X	50	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39279	39286		10.1074/jbc.M007760200	http://dx.doi.org/10.1074/jbc.M007760200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995775	hybrid			2022-12-27	WOS:000165953100047
J	Thorsteinsson, MV; Kerby, RL; Conrad, M; Youn, H; Staples, CR; Lanzilotta, WN; Poulos, TJ; Serate, J; Roberts, GP				Thorsteinsson, MV; Kerby, RL; Conrad, M; Youn, H; Staples, CR; Lanzilotta, WN; Poulos, TJ; Serate, J; Roberts, GP			Characterization of variants altered at the N-terminal proline, a novel heme-axial ligand in CooA, the CO-sensing transcriptional activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; SITE-DIRECTED MUTAGENESIS; SOLUBLE GUANYLATE-CYCLASE; CARBON-MONOXIDE; RHODOSPIRILLUM-RUBRUM; NITRIC-OXIDE; RECEPTOR PROTEIN; FLUORESCENCE POLARIZATION; MYOGLOBIN; LIGATION	Cook the carbon monoxide-sensing transcription factor from Rhodospirillum rubrum, binds CO through a heme moiety resulting in conformational changes that promote DNA binding. The crystal structure shows that the N-terminal Pro(2) Of one subunit (Met(1) is removed post-translationally provides one ligand to the heme of the other subunit in the Cook homodimer. To determine the importance of this novel ligand and the contiguous residues to Cook function, we have altered the N terminus through two approaches: site directed mutagenesis and regional randomization, and characterized the resulting Cook variants. While Pro(2) appears to be optimal for Cook function, it is not essential and a variety of studied variants at this position have substantial CO-sensing function. Surprisingly, even alterations that add a residue (where Pro(2) is replaced by Met(1)-Tyr(2), for example) accumulate heme-containing Cook with functional properties that are similar to those of wild-type Cook Other nearby residues, such as Phe(5) and Asn(6) appear to be important for either the structural integrity or the function of Cook These results are contrasted with those previously reported for alteration of the His(77) ligand on the opposite side of the heme.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA 92697 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Irvine	Roberts, GP (corresponding author), Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053228] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53228] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P44; Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Ausubel F. M., 1995, SHORT PROTOCOLS MOL, P21; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BURSTYN JN, 1995, BIOCHEMISTRY-US, V34, P5896, DOI 10.1021/bi00017a019; CHECOVICH WJ, 1995, NATURE, V375, P254, DOI 10.1038/375254a0; DEDUVE C, 1948, ACTA CHEM SCAND, V2, P264, DOI 10.3891/acta.chem.scand.02-0264; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Denninger JW, 2000, BIOCHEMISTRY-US, V39, P4191, DOI 10.1021/bi992332q; Dhawan IK, 1999, BIOCHEMISTRY-US, V38, P12805, DOI 10.1021/bi991303c; Dykxhoorn DM, 1996, GENE, V177, P133, DOI 10.1016/0378-1119(96)00289-2; EGEBERG KD, 1990, BIOCHEMISTRY-US, V29, P9783, DOI 10.1021/bi00494a004; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Grillo AO, 1999, J MOL BIOL, V287, P539, DOI 10.1006/jmbi.1999.2625; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; KERBY RL, 1995, J BACTERIOL, V177, P2241, DOI 10.1128/jb.177.8.2241-2244.1995; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Lukat-Rodgers GS, 1998, BIOCHEMISTRY-US, V37, P13543, DOI 10.1021/bi981439v; LukatRodgers GS, 1997, BIOCHEMISTRY-US, V36, P4178, DOI 10.1021/bi9628230; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; Makino R, 1999, J BIOL CHEM, V274, P7714, DOI 10.1074/jbc.274.12.7714; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Matsui T, 1996, BIOCHEMISTRY-US, V35, P13118, DOI 10.1021/bi960459z; MILLER CG, 1996, ESCHERICHIA COLI SAL, P945; Morita T, 1997, J BIOL CHEM, V272, P32804, DOI 10.1074/jbc.272.52.32804; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; SHELVER D, 1995, J BACTERIOL, V177, P2157, DOI 10.1128/jb.177.8.2157-2163.1995; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; Sigman JA, 1999, BIOCHEMISTRY-US, V38, P11122, DOI 10.1021/bi990815o; SONO M, 1982, J BIOL CHEM, V257, P8308; SONO M, 1982, J BIOL CHEM, V257, P5496; Stone JR, 1996, BIOCHEMISTRY-US, V35, P3258, DOI 10.1021/bi952386+; Stone JR, 1998, CHEM BIOL, V5, P255, DOI 10.1016/S1074-5521(98)90618-4; Thorsteinsson MV, 2000, BIOCHEMISTRY-US, V39, P8284, DOI 10.1021/bi000327c; TORII K, 1968, J BIOCHEM-TOKYO, V64, P171, DOI 10.1093/oxfordjournals.jbchem.a128877; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VOET D, 1995, BIOCHEMISTRY-US, P576; Vogel KM, 1999, BIOCHEMISTRY-US, V38, P2679, DOI 10.1021/bi982375r; Vogel KM, 1999, J BIOL INORG CHEM, V4, P804, DOI 10.1007/s007750050354; WINTER J, 1996, BACTERIOPHAGE DISPLA, P349; Zakhary R, 1997, P NATL ACAD SCI USA, V94, P14848, DOI 10.1073/pnas.94.26.14848	45	38	38	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39332	39338		10.1074/jbc.M007691200	http://dx.doi.org/10.1074/jbc.M007691200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11007793	hybrid			2022-12-27	WOS:000165953100055
J	Awad, MM; Enslen, H; Boylan, JM; Davis, RJ; Gruppuso, PA				Awad, MM; Enslen, H; Boylan, JM; Davis, RJ; Gruppuso, PA			Growth regulation via p38 mitogen-activated protein kinase in developing liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; MAP KINASE; CYCLIN D1; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; FETAL-RAT; TGF-BETA; STRESS; PATHWAY; PHOSPHORYLATION	During normal development in the rat, hepatocytes undergo marked changes in the rate of proliferation. We have previously observed transient G(1) growth arrest at term, re-activation of proliferation immediately after birth, and a gradual transition to the quiescent adult hepatocyte phenotype after postnatal day 4. We hypothesized that these changes in proliferation are due in part to growth inhibitory effects mediated by the p38 mitogen-activated protein kinase pathway. p38 kinase activity measurements showed an inverse relationship with hepatocyte proliferation during the perinatal and postnatal transitions, whereas p38 content remained constant. Anisomycin activated the p38 pathway in fetal hepatocyte cultures while inducing growth inhibition that was sensitive to the p38 inhibitor, SB203580. Activation of p38 in these cultures, via transient transfection with a constitutively active form of its upstream kinase MKK6, also inhibited DNA synthesis as well as reducing cyclin D1 content. Transfection with inactive MKK6 did neither. Furthermore, MKK6-induced growth arrest was sensitive to SB203580. Finally, administration of SB203580 to near-term fetal rats in utero abrogated the transient hepatocyte growth arrest that occurs at term. These findings indicate a role for the p38 mitogen-activated protein kinase pathway in the physiological regulation of hepatocyte proliferation during normal development in the rat.	Rhode Isl Hosp, Div Pediat Endocrinol & Metab, Dept Pediat, Providence, RI 02903 USA; Brown Univ, Providence, RI 02903 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Mol Med, Dept Biochem & Mol Biol, Worcester, MA 01605 USA	Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Gruppuso, PA (corresponding author), Rhode Isl Hosp, Div Pediat Endocrinol & Metab, Dept Pediat, Providence, RI 02903 USA.		Enslen, Hervé/M-3400-2017; Enslen, Hervé/AAH-4492-2021	Enslen, Hervé/0000-0001-9741-5293; Enslen, Hervé/0000-0001-9741-5293; Awad, Michael/0000-0002-6065-7050	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD024455] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD011343, R01HD035831, P01HD011343] Funding Source: NIH RePORTER; NICHD NIH HHS [HD35831, HD11343, HD24455] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Awad MM, 2000, CELL GROWTH DIFFER, V11, P325; Boylan JM, 1998, J BIOL CHEM, V273, P3784, DOI 10.1074/jbc.273.6.3784; Boylan JM, 1996, CELL GROWTH DIFFER, V7, P1261; CHAPMAN LM, 1984, J CELL PHYSIOL, V121, P7, DOI 10.1002/jcp.1041210103; Craxton A, 1998, J IMMUNOL, V161, P3225; CURRAT R, 1993, J PHYS IV, V3, P209, DOI 10.1051/jp4:1993242; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl NL, 2000, J EXP MED, V191, P321, DOI 10.1084/jem.191.2.321; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; FAUSTO N, 1990, ANN NY ACAD SCI, V593, P231, DOI 10.1111/j.1749-6632.1990.tb16115.x; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; GREENGARD O, 1972, J CELL BIOL, V52, P261, DOI 10.1083/jcb.52.2.261; Gruppuso PA, 1997, IN VITRO CELL DEV-AN, V33, P562; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee JC, 1999, PHARMACOL THERAPEUT, V82, P389, DOI 10.1016/S0163-7258(99)00008-X; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; Merritt C, 2000, MOL CELL BIOL, V20, P936, DOI 10.1128/MCB.20.3.936-946.2000; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Wysk M, 1999, P NATL ACAD SCI USA, V96, P3763, DOI 10.1073/pnas.96.7.3763; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Zhao M, 1999, MOL CELL BIOL, V19, P21; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	45	60	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38716	38721		10.1074/jbc.M008040200	http://dx.doi.org/10.1074/jbc.M008040200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10995779	hybrid			2022-12-27	WOS:000165739800080
J	Cao, WH; Luttrell, LM; Medvedev, AV; Pierce, KL; Daniel, KW; Dixon, TM; Lefkowitz, RJ; Collins, S				Cao, WH; Luttrell, LM; Medvedev, AV; Pierce, KL; Daniel, KW; Dixon, TM; Lefkowitz, RJ; Collins, S			Direct binding of activated c-Src to the beta(3)-adrenergic receptor is required for MAP kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ADRENERGIC-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; BROWN ADIPOCYTES; STRUCTURAL BASIS; GAMMA-SUBUNITS; PHOSPHORYLATION; OBESITY; DOMAINS; DESENSITIZATION	Both beta (2)- and beta (3)-adrenergic receptors (ARs) are able to activate the extracellular signal-regulated kinase (ERK) pathway. We previously showed that c-Src is required for ERK activation by beta (2)AR and that it is recruited to activated beta (2)AR through binding of the Src homology 3 (SH3) domain to proline-rich regions of the adapter protein beta -arrestin1, Despite the absence of sites for phosphorylation and beta -arrestin binding, ERK activation by P(3)AR still requires c-Src. Agonist activation of beta (2)AR, but not beta (3)AR, led to redistribution of green fluorescent protein-tagged p-arrestin to the plasma membrane. In P-arrestin-deficient COS-7 cells, beta -affonist-dependent coprecipitation of c-Src with the beta (2)AR required exogenous p-arrestin, but activated beta (3)AR co-precipitated c-Src in the absence or presence of p-arrestin, ERK activation and Src co-precipitation with beta (3)AR also occurred in adipocytes in an agonist-dependent and pertussis toxin-sensitive manner. Protein interaction studies show that the beta (3)AR interacts directly with the SH3 domain of Src through proline-rich motifs (PXXP) in the third intracellular loop and the carboxyl terminus. ERK activation and Src co-precipitation were abolished in cells expressing point mutations in these PXXP motifs. Together, these data describe a novel mechanism of ERK activation by a G protein-coupled receptor in which the intracellular domains directly recruit c-Src.	Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Howard Hughes Medical Institute	Collins, S (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol, Box 3557, Durham, NC 27710 USA.	colli008@mc.duke.edu	Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949; Medvedev, Alexander/0000-0001-6983-1687				Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; ARCH JRS, 1984, NATURE, V309, P163, DOI 10.1038/309163a0; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Collins S, 1996, J BIOL CHEM, V271, P9437, DOI 10.1074/jbc.271.16.9437; Collins S, 1997, ENDOCRINOLOGY, V138, P405, DOI 10.1210/en.138.1.405; COLLINS S, 2000, IN PRESS RECENT PROG; COOPER DMF, 1979, J BIOL CHEM, V254, P8927; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Gutkind J.S, 2000, SCI STKE; HIMMSHAGEN J, 1994, AM J PHYSIOL, V266, pR1371, DOI 10.1152/ajpregu.1994.266.4.R1371; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Sasaki N, 1998, J VET MED SCI, V60, P465, DOI 10.1292/jvms.60.465; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Soeder KJ, 1999, J BIOL CHEM, V274, P12017, DOI 10.1074/jbc.274.17.12017; Souza SC, 1998, DIABETES, V47, P691, DOI 10.2337/diabetes.47.4.691; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Strosberg AD, 1996, TRENDS PHARMACOL SCI, V17, P373, DOI 10.1016/S0165-6147(96)80011-3; Strosberg AD, 1997, ANNU REV PHARMACOL, V37, P421, DOI 10.1146/annurev.pharmtox.37.1.421; VAN BT, 1995, NATURE, V376, P781; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	40	160	166	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38131	38134		10.1074/jbc.C000592200	http://dx.doi.org/10.1074/jbc.C000592200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11013230	hybrid			2022-12-27	WOS:000165739800002
J	Churchill, GC; Galione, A				Churchill, GC; Galione, A			Spatial control of Ca2+ signaling by nicotinic acid adenine dinucleotide phosphate diffusion and gradients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-ADP-RIBOSE; SEA-URCHIN EGGS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; XENOPUS OOCYTES; ENDOPLASMIC-RETICULUM; RELEASE CHANNEL; LAEVIS OOCYTES; CALCIUM WAVES; TRISPHOSPHATE; FERTILIZATION	Intracellular Ca2+ is able to control numerous cellular responses through complex spatiotemporal organization. Ca2+ waves mediated by inositol trisphosphate or ryanodine receptors propagate by Ca2+-induced Ca2+ release and therefore do not have an absolute requirement for a gradient in either inositol trisphosphate or cyclic ADP-ribose, respectively. In contrast, we report that although Ca2+ increases induced by nicotinic acid adenine dinucleotide phosphate (NAADP) are amplified by Ca2+-induced Ca2+ release locally, Ca2+ waves mediated by NAADP have an absolute requirement for an NAADP gradient. If NAADP is increased such that its concentration is spatially uniform in one region of an egg, the Ca2+ increase occurs simultaneously throughout this area, and only where there is diffusion out of this area to establish an NAADP gradient is there a Ca2+ wave. A local increase in NAADP results in a Ca2+ increase that spreads by NAADP diffusion. NAADP diffusion is restricted at low but not high concentrations of NAADP, indicating that NAADP diffusion is strongly influenced by binding to immobile and saturable sites, probably the NAADP receptor itself. Thus, the range of action of NAADP can be tuned by its concentration from that of a local messenger, like Ca2+, to that of a global messenger, like IP3 or cyclic ADP-ribose.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of Oxford	Churchill, GC (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.	grant.churchill@pharm.ox.ac.uk	Galione, Antony/E-5884-2011	Galione, Antony/0000-0002-4132-7646				Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Albrieux M, 1998, J BIOL CHEM, V273, P14566, DOI 10.1074/jbc.273.23.14566; ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; Bak J, 1999, CURR BIOL, V9, P751, DOI 10.1016/S0960-9822(99)80335-2; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Bird GS, 1999, J BIOL CHEM, V274, P20643, DOI 10.1074/jbc.274.29.20643; Boittin FX, 1998, CELL CALCIUM, V23, P303, DOI 10.1016/S0143-4160(98)90026-4; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Chini EN, 1996, BIOCHEM J, V316, P709, DOI 10.1042/bj3160709; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Fontanilla RA, 1998, BIOPHYS J, V75, P2079, DOI 10.1016/S0006-3495(98)77650-7; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Genazzani AA, 1997, TRENDS PHARMACOL SCI, V18, P108, DOI 10.1016/S0165-6147(96)01036-X; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; Hille B., 1992, IONIC CHANNELS EXCIT; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; Jaffe LF, 1999, BIOESSAYS, V21, P657, DOI 10.1002/(SICI)1521-1878(199908)21:8<657::AID-BIES5>3.3.CO;2-B; JAFFE LF, 1993, CELL CALCIUM, V14, P736, DOI 10.1016/0143-4160(93)90099-R; Koizumi S, 1999, NEURON, V22, P125, DOI 10.1016/S0896-6273(00)80684-4; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; Lee HC, 1997, J BIOL CHEM, V272, P4172, DOI 10.1074/jbc.272.7.4172; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; Marchant J, 1999, EMBO J, V18, P5285, DOI 10.1093/emboj/18.19.5285; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Navazio L, 2000, P NATL ACAD SCI USA, V97, P8693, DOI 10.1073/pnas.140217897; Parker I, 1996, CELL CALCIUM, V20, P105, DOI 10.1016/S0143-4160(96)90100-1; PARYS JB, 1994, DEV BIOL, V161, P466, DOI 10.1006/dbio.1994.1045; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; PerezTerzic CM, 1995, BIOCHEM J, V312, P955, DOI 10.1042/bj3120955; PETERSEN OH, 1995, J PHYSIOLOGY-PARIS, V89, P125, DOI 10.1016/0928-4257(96)80109-4; Santella L, 2000, J BIOL CHEM, V275, P8301, DOI 10.1074/jbc.275.12.8301; Stricker SA, 1999, DEV BIOL, V211, P157, DOI 10.1006/dbio.1999.9340; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; TAKAHASHI M, 1994, J BIOL CHEM, V269, P369; TERASAKI M, 1991, J CELL BIOL, V114, P929, DOI 10.1083/jcb.114.5.929; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; Wilson HL, 1998, BIOCHEM J, V331, P837, DOI 10.1042/bj3310837; YAO Y, 1992, J PHYSIOL-LONDON, V458, P319, DOI 10.1113/jphysiol.1992.sp019420	44	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38687	38692		10.1074/jbc.M005827200	http://dx.doi.org/10.1074/jbc.M005827200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11006280	hybrid			2022-12-27	WOS:000165739800075
J	Costa, ET; Olivera, DS; Meyer, DA; Ferreira, VMM; Soto, EE; Frausto, S; Savage, DD; Browning, MD; Valenzuela, CF				Costa, ET; Olivera, DS; Meyer, DA; Ferreira, VMM; Soto, EE; Frausto, S; Savage, DD; Browning, MD; Valenzuela, CF			Fetal alcohol exposure alters neurosteroid modulation of hippocampal N-methyl-D-aspartate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRENATAL ETHANOL EXPOSURE; NEUROACTIVE STEROID ALLOPREGNANOLONE; BINDING-SITE DENSITY; NMDA RECEPTOR; PREGNENOLONE-SULFATE; ULTRASONIC VOCALIZATIONS; TARGETED DISRUPTION; MEMORY; CALCIUM; NEURONS	The actions of ethanol on brain ligand-gated ion channels have important roles in the pathophysiology of alcohol-related neurodevelopmental disorders and fetal alcohol syndrome. Studies have shown that N-methyl-D-aspartate (NMDA) receptors are among the ligand-gated ion channels affected by prenatal ethanol exposure, We exposed pregnant dams to an ethanol-containing liquid diet that results in blood ethanol levels near the legal intoxication limit in most states (0.08%). Primary cultures of hippocampal neurons were prepared from the neonatal offspring of these dams, and NMDA receptor function was assessed by patch clamp electrophysiological techniques after 6-7 days in culture in ethanol-free media. Unexpectedly, we did not detect any changes in hippocampal NMDA receptor function at either the whole-cell or single-channel levels. However, we determined that fetal alcohol exposure alters the actions of the neurosteroids pregnenolone sulfate and pregnenolone hemisuccinate, which potentiate NMDA receptor function. Western immunoblot analyses demonstrated that this alteration is not due to a change in the expression levels of NMDA receptor subunits. Importantly, in utero ethanol exposure did not affect the actions of neurosteroids that inhibit NMDA receptor function, Moreover, the actions of pregnenolone sulfate on type A gamma -aminobutyric acid and non-NMDA receptor function were unaltered by ethanol exposure in utero, which suggests that the alteration is specific to NMDA receptors. These findings are significant because they provide, at least in part, a plausible mechanistic explanation for the alterations in the behavioral responses to neurosteroids found in neonatal rats prenatally exposed to ethanol and to other forms of maternal stress (Zimmerberg, B,, and McDonald, B, C. (1996) Pharmacol. Biochem. Behav. 55, 541-547).	Univ New Mexico, Hlth Sci Ctr, Dept Neurosci, Albuquerque, NM 87131 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Valenzuela, CF (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Neurosci, Basic Med Sci Bldg,Rm 145, Albuquerque, NM 87131 USA.				NIAAA NIH HHS [AA06548, AA00227] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006548] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ABDOLLAH S, 1995, ALCOHOL, V12, P369, DOI 10.1016/0741-8329(95)00020-R; Allan AM, 1998, J PHARMACOL EXP THER, V284, P250; Bergeron R, 1996, J NEUROSCI, V16, P1193; Calton JL, 2000, J NEUROPHYSIOL, V83, P685, DOI 10.1152/jn.2000.83.2.685; Compagnone NA, 1998, P NATL ACAD SCI USA, V95, P4678, DOI 10.1073/pnas.95.8.4678; Costa ET, 2000, ALCOHOL CLIN EXP RES, V24, P706, DOI 10.1097/00000374-200005000-00016; DiazGranados JL, 1997, ALCOHOL CLIN EXP RES, V21, P874, DOI 10.1097/00000374-199708000-00016; Ebralidze AK, 1996, J NEUROSCI, V16, P5014; Emptage N, 1999, NEURON, V22, P115, DOI 10.1016/S0896-6273(00)80683-2; FFRENCHMULLEN JMH, 1994, J NEUROSCI, V14, P1963; FLOOD JF, 1995, P NATL ACAD SCI USA, V92, P10806, DOI 10.1073/pnas.92.23.10806; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; FRANCISK A, 2000, J NEUROSCI, V20, P3067; Gruol DL, 1998, BRAIN RES, V793, P12, DOI 10.1016/S0006-8993(98)00014-6; Hughes PD, 1998, ALCOHOL CLIN EXP RES, V22, P1255, DOI 10.1111/j.1530-0277.1998.tb03906.x; IRWIN RP, 1992, NEUROSCI LETT, V141, P30, DOI 10.1016/0304-3940(92)90327-4; Iwasato T, 1997, NEURON, V19, P1201, DOI 10.1016/S0896-6273(00)80412-2; Kadotani H, 1996, J NEUROSCI, V16, P7859; Kishimoto Y, 1997, NEUROREPORT, V8, P3717, DOI 10.1097/00001756-199712010-00012; Larkby C, 1997, ALCOHOL HEALTH RES W, V21, P192; LEE YH, 1994, J PHARMACOL EXP THER, V271, P1291; LIEBER CS, 1982, ALCOHOL CLIN EXP RES, V6, P523, DOI 10.1111/j.1530-0277.1982.tb05017.x; MAJEWSKA MD, 1987, BRAIN RES, V404, P355; MATHIS C, 1994, PSYCHOPHARMACOLOGY, V116, P201, DOI 10.1007/BF02245063; Mathis C, 1996, NEUROPHARMACOLOGY, V35, P1057, DOI 10.1016/S0028-3908(96)00041-X; Mattson SN, 1996, ALCOHOL CLIN EXP RES, V20, P810, DOI 10.1111/j.1530-0277.1996.tb05256.x; McHugh TJ, 1996, CELL, V87, P1339, DOI 10.1016/S0092-8674(00)81828-0; MORRISETT RA, 1989, ALCOHOL, V6, P415, DOI 10.1016/0741-8329(89)90013-X; Okabe S, 1998, J NEUROSCI, V18, P4177; Park-Chung M, 1997, MOL PHARMACOL, V52, P1113, DOI 10.1124/mol.52.6.1113; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; SAVAGE DD, 1992, ALCOHOL, V9, P37, DOI 10.1016/0741-8329(92)90007-W; SAVAGE DD, 1991, ALCOHOL, V8, P193, DOI 10.1016/0741-8329(91)90806-8; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; SpuhlerPhillips K, 1997, ALCOHOL CLIN EXP RES, V21, P68; STREISSGUTH AP, 1989, NEUROTOXICOL TERATOL, V11, P493, DOI 10.1016/0892-0362(89)90026-3; Uecker A, 1998, AM J MENT RETARD, V103, P12, DOI 10.1352/0895-8017(1998)103<0012:SBNOMI>2.0.CO;2; Uecker A, 1996, NEUROPSYCHOLOGIA, V34, P209, DOI 10.1016/0028-3932(95)00096-8; Vallee M, 1997, P NATL ACAD SCI USA, V94, P14865, DOI 10.1073/pnas.94.26.14865; WEAVER MS, 1993, ALCOHOL CLIN EXP RES, V17, P643, DOI 10.1111/j.1530-0277.1993.tb00812.x; WU FS, 1991, MOL PHARMACOL, V40, P333; Yaghoubi N, 1998, BRAIN RES, V803, P153, DOI 10.1016/S0006-8993(98)00644-1; ZIMMERBERG B, 1995, PHARMACOL BIOCHEM BE, V51, P463, DOI 10.1016/0091-3057(95)00008-K; Zimmerberg B, 1996, PHARMACOL BIOCHEM BE, V55, P541, DOI 10.1016/S0091-3057(96)00281-X; ZIMMERBERG B, 1994, PHARMACOL BIOCHEM BE, V47, P735, DOI 10.1016/0091-3057(94)90181-3	45	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38268	38274		10.1074/jbc.M004136200	http://dx.doi.org/10.1074/jbc.M004136200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10988286	hybrid			2022-12-27	WOS:000165739800020
J	Sasaki, N; Ohkura, R; Sutoh, K				Sasaki, N; Ohkura, R; Sutoh, K			Insertion or deletion of a single residue in the strut sequence of Dictyostelium myosin II abolishes strong binding to actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY LIGHT-CHAIN; DISCOIDEUM MYOSIN; MOTOR DOMAIN; CHIMERIC SUBSTITUTIONS; IN-VIVO; COMPLEX; SITE; LACKING; MGADP; LOOP	The strut loop, one of the three loops that connects the upper and lower 50K subdomains of myosin, plays a role as a "strut" to keep the relative disposition of the two subdomains. A single residue was either inserted into or deleted from this loop. The insertion or deletion mutation abolished the in vivo motor functions of myosin, as revealed by the fact that the mutant myosins did not complement the phenotypic defects of the myosin-null cells. In vitro studies of purified full-length myosins and their subfragment-1s (S1s) revealed that the insertion mutants virtually lost the strong binding to actin although their motor functions in the absence of actin remained almost normal, showing that only the hydrophobic actin-myosin association was selectively affected by the insertion mutations. Unlike the insertion mutants, the deletion mutant showed defects both in the strong-binding state and the rate limiting step of ATPase cycle. These results indicate the functional importance of the strut loop in establishing the strong-binding state of myosin and thereby achieving successful power strokes.	Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo 1538902, Japan	University of Tokyo	Sutoh, K (corresponding author), Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, 4-6-1 Komaba, Tokyo 1538902, Japan.							ASUKAGAWA H, 1999, MOL INTERACTIONS ACT; CHISHOLM RL, 1988, MOL CELL BIOL, V8, P794, DOI 10.1128/MCB.8.2.794; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; KUBALEK EW, 1992, MOL BIOL CELL, V3, P1455, DOI 10.1091/mbc.3.12.1455; Kuhlman PA, 1998, J MUSCLE RES CELL M, V19, P491, DOI 10.1023/A:1005304408812; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; OHALLORAN TJ, 1990, P NATL ACAD SCI USA, V87, P8110, DOI 10.1073/pnas.87.20.8110; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; Sasaki N, 1998, J BIOL CHEM, V273, P20334, DOI 10.1074/jbc.273.32.20334; Sasaki N, 1999, J BIOL CHEM, V274, P37840, DOI 10.1074/jbc.274.53.37840; Shimada T, 1997, BIOCHEMISTRY-US, V36, P14037, DOI 10.1021/bi971837i; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; TAFURI SR, 1989, MOL CELL BIOL, V9, P3073, DOI 10.1128/MCB.9.7.3073; UYEDA TQP, 1993, SCIENCE, V262, P1867, DOI 10.1126/science.8266074; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; YOUNT RG, 1995, BIOPHYS J, V68, pS44	23	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38705	38709		10.1074/jbc.M001966200	http://dx.doi.org/10.1074/jbc.M001966200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11005804	hybrid			2022-12-27	WOS:000165739800078
J	Bonten, EJ; d'Azzo, A				Bonten, EJ; d'Azzo, A			Lysosomal neuraminidase - Catalytic activation in insect cells is controlled by the protective protein/cathepsin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMBINED BETA-GALACTOSIDASE; PROTEIN CATHEPSIN-A; BACTERIAL SIALIDASE; EXPRESSION VECTORS; CRYSTAL-STRUCTURE; HUMAN-PLACENTA; COMPLEX; PURIFICATION; ASSOCIATION; DEFICIENCY	Lysosomal N-Acetyl-alpha -neuraminidase is active in complex with the protective protein/cathepsin A (PPCA) and beta -galactosidase, The interaction with PPCA is essential for the correct intracellular routing and lysosomal localization of neuraminidase, but the mechanism of its catalytic activation is unclear. To investigate this process, we have used the baculovirus expression system to co-express neuraminidase and PPCA precursors in in sect cells, which resulted in high enzymatic activity of neuraminidase, Both the 34- and 20-kDa PPCA subunits were required for the activation. We further demonstrated that when expressed alone, the neuraminidase precursor remained dimeric (114 kDa) and had low enzymatic activity, but when co-expressed with PPCA and beta -galactosidase, it multimerized in a complex of similar to 1350 kDa, together with the other two proteins. The fully active neuraminidase co-precipitated with full-length PPCA and beta -galactosidase precursors. However, when co-expressed with the individual PPCA subunits, neuraminidase co-precipitated only with the small 20-kDa polypeptide, which therefore must contain a neuraminidase-binding site. Our finding suggests a model of activation of neuraminidase dependent on its oligomerization at acidic pH that is mediated by interaction with PPCA.	St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA	St Jude Children's Research Hospital	d'Azzo, A (corresponding author), St Jude Childrens Res Hosp, Dept Genet, 332 N Lauderdale, Memphis, TN 38105 USA.				NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060950] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NIGMS NIH HHS [R01GM60950] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRIA G, 1981, SIALIDASES SIALIDOSE, P379; Bonten E, 1996, GENE DEV, V10, P3156, DOI 10.1101/gad.10.24.3156; BONTEN EJ, 1995, J BIOL CHEM, V270, P26441, DOI 10.1074/jbc.270.44.26441; Braulke T, 1996, Subcell Biochem, V27, P15; CRENNELL S, 1994, STRUCTURE, V2, P535, DOI 10.1016/S0969-2126(00)00053-8; Crennell SJ, 1996, J MOL BIOL, V259, P264, DOI 10.1006/jmbi.1996.0318; CRENNELL SJ, 1993, P NATL ACAD SCI USA, V90, P9852, DOI 10.1073/pnas.90.21.9852; D'Azzo A, 1995, METABOLIC MOL BASES, V2, P2825; DAZZO A, 1982, P NATL ACAD SCI-BIOL, V79, P4535, DOI 10.1073/pnas.79.15.4535; GALJAARD H, 1980, GENETIC METABOLIC DI, P817; GALJART NJ, 1991, J BIOL CHEM, V266, P14754; GALJART NJ, 1990, J BIOL CHEM, V265, P4678; GASKELL A, 1995, STRUCTURE, V3, P1197, DOI 10.1016/S0969-2126(01)00255-6; HINK WF, 1970, NATURE, V226, P466, DOI 10.1038/226466b0; Hiraiwa M, 1997, BBA-PROTEIN STRUCT M, V1341, P189, DOI 10.1016/S0167-4838(97)00060-5; HIRAIWA M, 1991, BIOCHEM BIOPH RES CO, V177, P1211, DOI 10.1016/0006-291X(91)90670-3; Hiraiwa M, 1996, SEIKAGAKU, V68, P464; HOOGEVEEN AT, 1983, J BIOL CHEM, V258, P2143; HUBBES M, 1992, BIOCHEM J, V285, P827, DOI 10.1042/bj2850827; Kaufman R. J., 1999, BIOCHIM BIOPHYS ACTA, V1423, P13; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MORREAU H, 1989, J BIOL CHEM, V264, P20655; POTIER M, 1990, BIOCHEM J, V267, P197, DOI 10.1042/bj2670197; PROIA RL, 1984, J BIOL CHEM, V259, P3350; Pshezhetsky AV, 1996, J BIOL CHEM, V271, P28359, DOI 10.1074/jbc.271.45.28359; Pshezhetsky AV, 1997, NAT GENET, V15, P316, DOI 10.1038/ng0397-316; PSHEZHETSKY AV, 1994, ARCH BIOCHEM BIOPHYS, V313, P64, DOI 10.1006/abbi.1994.1359; Rottier RJ, 1998, HUM MOL GENET, V7, P313, DOI 10.1093/hmg/7.2.313; RUDENKO G, 1995, STRUCTURE, V3, P1249, DOI 10.1016/S0969-2126(01)00260-X; SCHEIBE R, 1990, BIOMED BIOCHIM ACTA, V49, P547; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; Taylor G, 1996, CURR OPIN STRUC BIOL, V6, P830, DOI 10.1016/S0959-440X(96)80014-5; van der Spoel A, 2000, J BIOL CHEM, V275, P10035, DOI 10.1074/jbc.275.14.10035; van der Spoel A, 1998, EMBO J, V17, P1588, DOI 10.1093/emboj/17.6.1588; VANDERHORST GTJ, 1989, J BIOL CHEM, V264, P1317; VANDIGGELEN OP, 1982, BIOCHIM BIOPHYS ACTA, V703, P69, DOI 10.1016/0167-4838(82)90012-7; VERHEIJEN F, 1982, BIOCHEM BIOPH RES CO, V108, P868, DOI 10.1016/0006-291X(82)90911-1; VERHEIJEN FW, 1987, EUR J BIOCHEM, V162, P63, DOI 10.1111/j.1432-1033.1987.tb10542.x; VERHEIJEN FW, 1985, EUR J BIOCHEM, V149, P315, DOI 10.1111/j.1432-1033.1985.tb08928.x; Vinogradova MV, 1998, BIOCHEM J, V330, P641; WENGER DA, 1978, BIOCHEM BIOPH RES CO, V82, P589, DOI 10.1016/0006-291X(78)90915-4; YAMAMOTO Y, 1987, INT J BIOCHEM, V19, P435, DOI 10.1016/0020-711X(87)90064-4; ZHOU XY, 1995, GENE DEV, V9, P2623, DOI 10.1101/gad.9.21.2623	44	45	48	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37657	37663		10.1074/jbc.M007380200	http://dx.doi.org/10.1074/jbc.M007380200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982818	Green Submitted, hybrid			2022-12-27	WOS:000165618700049
J	Furukawa, K; Iwamura, K; Uchikawa, M; Sojka, BN; Wiels, J; Okajima, T; Urano, T; Furukawa, K				Furukawa, K; Iwamura, K; Uchikawa, M; Sojka, BN; Wiels, J; Okajima, T; Urano, T; Furukawa, K			Molecular basis for the p phenotype - Identification of distinct and multiple mutations in the (alpha 1,4-galactosyltransferase gene in Swedish and Japanese individuals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP; EXPRESSION; ANTIBODIES; INFECTION; ANTIGENS; SYSTEM; CELLS	p phenotype individuals lack both P-k (Gb3) and P (Gb4) glycolipid antigens of the P blood group system. To explore the molecular basis for this phenotype, DNA sequences of Gb3 synthase (alpha1,4-galactosyltransferase; alpha1,4Gal-T) in six p phenotype individuals from Japan and Sweden were analyzed. A missense mutation P251L and a nonsense mutation W261stop in three and one Japanese indivuiduals, respectively, and missense mutations M183K and G187D in one each of two Swedish p individuals were found, indicating that p individuals from Japan and Sweden have distinct and multiple homozygous point mutations in the coding region. In the function analysis of the mutated alpha1,4Gal-Ts by the transfection of the expression vectors, P251L and M183K mutations showed complete loss of enzyme function, and W261stop and G187D mutations resulted in the marginal activity. BLAST analysis of homologous sequences of alpha1,4Gal-T revealed that three residues, Met(183), Gly(187), and Pro(251), at which missense mutations were found, were highly conserved among all species examined, suggesting their importance for the function of alpha1,4Gal-T.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Japanese Red Cross, Cent Blood Ctr, Shibuya Ku, Tokyo 1500012, Japan; Umea Univ Hosp, Dept Transfus Med, S-90185 Umea, Sweden; Inst Gustave Roussy, CNRS, UMR 1598, F-94805 Villejuif, France	Nagoya University; Japanese Red Cross Medical Center; Umea University; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp	Wiels, Joëlle/AGL-2319-2022; Okajima, Tetsuya/I-7332-2014	Wiels, Joëlle/0000-0002-3313-2937; Okajima, Tetsuya/0000-0002-3677-648X; Urano, Takeshi/0000-0003-3383-3554				Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Daniels GL, 1999, VOX SANG, V77, P52, DOI 10.1159/000031074; Hammache D, 1999, J VIROL, V73, P5244, DOI 10.1128/JVI.73.6.5244-5248.1999; KARMALI MA, 1989, CLIN MICROBIOL REV, V2, P15, DOI 10.1128/CMR.2.1.15-38.1989; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KIJIMOTOOCHIAI S, 1977, P NATL ACAD SCI USA, V74, P5407, DOI 10.1073/pnas.74.12.5407; KLEIN G, 1983, INT J CANCER, V31, P535, DOI 10.1002/ijc.2910310503; Kojima Y, 2000, J BIOL CHEM, V275, P15152, DOI 10.1074/jbc.M909620199; Kudo T, 1996, J BIOL CHEM, V271, P9830, DOI 10.1074/jbc.271.16.9830; Landsteiner K, 1927, P SOC EXP BIOL MED, V24, P941; Lopez M, 1998, J BIOL CHEM, V273, P33644, DOI 10.1074/jbc.273.50.33644; MANGENEY M, 1991, EUR J IMMUNOL, V21, P1131, DOI 10.1002/eji.1830210507; MARCUS DM, 1976, P NATL ACAD SCI USA, V73, P3263, DOI 10.1073/pnas.73.9.3263; NAIKI M, 1975, BIOCHEMISTRY-US, V14, P4837, DOI 10.1021/bi00693a010; NAIKI M, 1975, BIOCHEMISTRY-US, V14, P4831, DOI 10.1021/bi00693a009; Nakayama J, 1999, P NATL ACAD SCI USA, V96, P8991, DOI 10.1073/pnas.96.16.8991; Puri A, 1998, P NATL ACAD SCI USA, V95, P14435, DOI 10.1073/pnas.95.24.14435; SODERSTROM T, 1985, J IMMUNOL, V134, P1; Song Y, 1998, J BIOL CHEM, V273, P2517, DOI 10.1074/jbc.273.5.2517; Steffensen R, 2000, J BIOL CHEM, V275, P16723, DOI 10.1074/jbc.M000728200; TOMISAWA S, 1989, SCAND J INFECT DIS, V21, P403, DOI 10.3109/00365548909167444; WIELS J, 1981, P NATL ACAD SCI-BIOL, V78, P6485, DOI 10.1073/pnas.78.10.6485; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YOSHIDA H, 1994, TRANSFUSION, V34, P702, DOI 10.1046/j.1537-2995.1994.34894353467.x; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	25	38	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37752	37756		10.1074/jbc.C000625200	http://dx.doi.org/10.1074/jbc.C000625200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10993874	hybrid			2022-12-27	WOS:000165618700061
J	Yang, L; Chansky, HA; Hickstein, DD				Yang, L; Chansky, HA; Hickstein, DD			EWS center dot Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; EWINGS-SARCOMA TRANSLOCATION; ROUND-CELL TUMOR; BINDING PROTEIN; DNA-BINDING; CHROMOSOME-TRANSLOCATION; TRANSCRIPTION FACTOR; EWS GENE; MYXOID LIPOSARCOMA; MALIGNANT-MELANOMA	Ewing's sarcoma displays a characteristic chromosomal translocation that results in fusion of the N-terminal domain of the Ewing's sarcoma protein (EWS) to the C-terminal DNA-binding domain of the ETS family transcription factor Fli-1 (Friend leukemia integration-1). EWS possesses structural motifs suggesting a role in transactivation as well as RNA binding. We demonstrate that wild-type EWS protein functions as an adapter molecule coupling transcription to RNA splicing by binding to hyperphosphorylated RNA polymerase II through the N-terminal domain of EWS and recruiting serine-arginine (SR) splicing factors through the C-terminal domain of EWS. The oncogenic EWS Fli-1 fusion protein retains the ability to bind to hyperphosphorylated RNA polymerase II but lacks the ability to recruit SR proteins because of replacement of the C-terminal domain of EWS by Fli-1. In an in vivo splicing assay, the EWS.Fli-1 fusion protein inhibits SR protein-mediated E1A pre-mRNA splicing in a dominant-negative manner. These results indicate that EWS Fli-1 interferes with the normal function of EWS and implicate uncoupling of gene transcription from RNA splicing in the pathogenesis of Ewing's sarcoma.	Univ Washington, Sch Med, Dept Med Oncol, Seattle, WA 98108 USA; Univ Washington, Sch Med, Dept Orthoped, Seattle, WA 98108 USA; Vet Affairs Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA 98108 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Hickstein, DD (corresponding author), Univ Washington, Sch Med, Dept Med Oncol, Box 358280,1660 S Columbian Way,GMR 151, Seattle, WA 98108 USA.							BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Barr FG, 1999, CANCER RES, V59, P5443; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hinohara S, 1998, JPN J CANCER RES, V89, P887, DOI 10.1111/j.1349-7006.1998.tb00645.x; Hirose Y, 1999, GENE DEV, V13, P1234, DOI 10.1101/gad.13.10.1234; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; Knoop LL, 2000, J BIOL CHEM, V275, P24865, DOI 10.1074/jbc.M001661200; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; LESSNICK SL, 1995, ONCOGENE, V10, P423; MAO XH, 1994, J BIOL CHEM, V269, P18216; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; Nawa G, 1999, BRIT J CANCER, V80, P1185, DOI 10.1038/sj.bjc.6690484; OHNO T, 1994, ONCOGENE, V9, P3087; Panagopoulos I, 1996, ONCOGENE, V12, P489; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RAUSCHER FJ, 1994, COLD SPRING HARB SYM, V59, P137, DOI 10.1101/SQB.1994.059.01.017; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WANG J, 1995, RNA, V1, P335; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761; Zhang D, 1998, J BIOL CHEM, V273, P18086, DOI 10.1074/jbc.273.29.18086; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	43	116	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37612	37618		10.1074/jbc.M005739200	http://dx.doi.org/10.1074/jbc.M005739200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982800	hybrid			2022-12-27	WOS:000165618700043
J	Cong, YS; Bacchetti, S				Cong, YS; Bacchetti, S			Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TELOMERASE ACTIVITY; IMMORTAL CELLS; LIFE-SPAN; RECONSTITUTION; GENE; MAD; MYC; PROMOTER; CANCER; LEADS	Trancriptional regulation of the human telomerase reverse transcriptase (hTERT) gene, encoding the catalytic protein of human telomerase, plays a critical role in the activation of the enzyme during cell immortalization and tumorigenesis. However, the molecular mechanisms involved in the regulation of hTERT expression are still not fully understood. We have previously cloned and characterized the genomic sequences and promoter of the hTERT gene. Here, we provide evidence that histone deacetylation is involved in the repression of hTERT in human cells. Inhibition of histone deacetylases by trichostatin A in telomerase-negative cells resulted in activation of telomerase activity and upregulation of hTERT mRNA. Transient transfection experiments with a reporter under control of the hTERT promoter indicated that this promoter can be activated by trichostatin A. Finally, our results show that repression of the hTERT promoter by the Mad protein requires histone deacetylase activity, whereas de-repression by trichostatin A is independent of the E-boxes located in its core region.	McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada	McMaster University	Bacchetti, S (corresponding author), McMaster Univ, Dept Pathol & Mol Med, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	bacchett@fhs.mcmaster.ca						Avilion AA, 1996, CANCER RES, V56, P645; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Davie JR, 1999, J CELL BIOCHEM, P141; Dessain SK, 2000, CANCER RES, V60, P537; DEVEREUX TR, 1999, CANCER RES, V59, P6078; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Gunes C, 2000, CANCER RES, V60, P2116; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Horikawa I, 1999, CANCER RES, V59, P826; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Kyo S, 1999, CANCER RES, V59, P5917; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Misiti S, 2000, MOL CELL BIOL, V20, P3764, DOI 10.1128/MCB.20.11.3764-3771.2000; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oulton R, 2000, CURR OPIN ONCOL, V12, P74, DOI 10.1097/00001622-200001000-00013; Price CM, 1999, CURR OPIN GENET DEV, V9, P218, DOI 10.1016/S0959-437X(99)80032-X; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Shay JW, 1999, J NATL CANCER I, V91, P4, DOI 10.1093/jnci/91.1.4; TAKAKURA M, 1999, CANCER RES, P551; Ulaner GA, 1998, CANCER RES, V58, P4168; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	36	136	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35665	35668		10.1074/jbc.C000637200	http://dx.doi.org/10.1074/jbc.C000637200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10986277	hybrid			2022-12-27	WOS:000165382000003
J	Ichiyama, S; Kurihara, T; Li, YF; Kogure, Y; Tsunasawa, S; Esaki, N				Ichiyama, S; Kurihara, T; Li, YF; Kogure, Y; Tsunasawa, S; Esaki, N			Novel catalytic mechanism of nucleophilic substitution by asparagine residue involving cyanoalanine intermediate revealed by mass spectrometric monitoring of an enzyme reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS SP. YL; P-TYPE ATPASE; L-2-HALOACID DEHALOGENASE; BETA-CYANOALANINE; ESTER INTERMEDIATE; SITE; PURIFICATION; IDENTIFICATION; MUTAGENESIS; SYNTHASE	L-2-Haloacid dehalogenase from Pseudomonas sp. YL catalyzes the hydrolytic dehalogenation, in which Asp(10) acts as a nucleophile to attack the Lu-carbon of L-2-haloalkanoates to form an ester intermediate, which is subsequently: hydrolyzed to produce D-2-hydroxyalkanoates. Surprisingly, replacement of the catalytic residue, Asp(10), by Asn did not result in total inactivation of the enzyme (Kurihara, T., Liu, J.-Q., Nardi-Dei, V., Koshikawa, H.,Esaki, N., and Soda, K. (1995) J. Biochem. 117, 1917-1322). In this study, we monitored the D10N mutant enzyme reaction by ion-spray mass spectrometry, and found that the enzyme shows a unique structural change when it was incubated with the substrate, L-2-chloropropionate. LC/MS and tandem MS/MS analyses revealed that Asn(10) attacks the substrate to form an imidate, and a proton and D-lactic acid are eliminated to produce a nitrile (beta -cyanoalanine residue), followed by hydrolysis to reproduce Asn(10). This is the first report of the function of Asn to catalyze nucleophilic substitution through its conversion to beta -cyanoalanine residue as an intermediate structure. Also, these results demonstrate that mass spectrometry is remarkably useful in monitoring enzyme reactions.	Kyushu Univ, Chem Res Inst, Microbial Biochem Lab, Uji, Kyoto 6110011, Japan; Takara Shuzo Co Ltd, Biotechnol Res Labs, Shiga 5250055, Japan	Kyushu University; Takara Holdings Inc.	Esaki, N (corresponding author), Kyushu Univ, Chem Res Inst, Microbial Biochem Lab, Uji, Kyoto 6110011, Japan.	esaki@scl.kyoto-u.ac.jp						AKOPYAN TN, 1975, P NATL ACAD SCI USA, V72, P1617, DOI 10.1073/pnas.72.4.1617; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; CASTRIC PA, 1971, J BACTERIOL, V108, P132, DOI 10.1128/JB.108.1.132-136.1971; DUNNILL PM, 1965, NATURE, V208, P1206, DOI 10.1038/2081206a0; IWASAKI I, 1956, B CHEM SOC JPN, V29, P860, DOI 10.1246/bcsj.29.860; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURIHARA T, 1995, J BIOCHEM, V117, P1317, DOI 10.1093/oxfordjournals.jbchem.a124861; Li YF, 1998, J BIOL CHEM, V273, P15035, DOI 10.1074/jbc.273.24.15035; LIU JQ, 1995, J BIOL CHEM, V270, P18309, DOI 10.1074/jbc.270.31.18309; LIU JQ, 1994, APPL ENVIRON MICROB, V60, P2389, DOI 10.1128/AEM.60.7.2389-2393.1994; Liu JQ, 1997, J BIOL CHEM, V272, P3363, DOI 10.1074/jbc.272.6.3363; Maruyama A, 1998, PLANT CELL PHYSIOL, V39, P671, DOI 10.1093/oxfordjournals.pcp.a029421; MOTOSUGI K, 1984, BIOTECHNOL BIOENG, V26, P805, DOI 10.1002/bit.260260729; Nardi-Dei V, 1999, J BIOL CHEM, V274, P20977, DOI 10.1074/jbc.274.30.20977; PRIES F, 1995, FEBS LETT, V358, P171, DOI 10.1016/0014-5793(94)01420-6; Ridder IS, 1999, BIOCHEM J, V339, P223, DOI 10.1042/0264-6021:3390223; ROY U, 1983, INT J PEPT PROT RES, V22, P525; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; Stokes DL, 2000, BIOPHYS J, V78, P1765, DOI 10.1016/S0006-3495(00)76727-0; SYKES P, 1986, GUIDEBOOK MECH ORGAN, P244; Tarr G E, 1977, Methods Enzymol, V47, P335; TENNANT G, 1979, COMPREHENSIVE ORGANI, V2, P490; TOLOSA EA, 1975, EUR J BIOCHEM, V53, P429, DOI 10.1111/j.1432-1033.1975.tb04083.x; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; WAKABAYASHI S, 1995, THEORY PRACTICE ENZY, P467	26	22	27	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40804	40809		10.1074/jbc.M008065200	http://dx.doi.org/10.1074/jbc.M008065200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11006296	hybrid			2022-12-27	WOS:000166114600021
J	Jongbloed, JDH; Martin, U; Antelmann, H; Hecker, M; Tjalsma, H; Venema, G; Bron, S; van Dijl, JM; Muller, J				Jongbloed, JDH; Martin, U; Antelmann, H; Hecker, M; Tjalsma, H; Venema, G; Bron, S; van Dijl, JM; Muller, J			TatC is a specificity determinant for protein secretion via the twin-arginine translocation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL PEPTIDASE-I; TEMPORALLY CONTROLLED EXPRESSION; COMPLETE GENOME SEQUENCE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; THYLAKOID MEMBRANE; ALKALINE-PHOSPHATASE; POLYACRYLAMIDE GELS; EXPORT PATHWAY; ALPHA-AMYLASE	The recent discovery of a ubiquitous translocation pathway, specifically required for proteins with a twin-arginine motif in their signal peptide, has focused interest on its membrane-bound components, one of which is known as TatC. Unlike most organisms of which the genome has been sequenced completely, the Gram-positive eubacterium Bacillus subtilis contains two tatC-like genes denoted tatCd and tatCy. The corresponding TatCd and TatCy proteins have the potential to be involved in the translocation of 27 proteins with putative twin-arginine signal peptides of which similar to6-14 are likely to be secreted into the growth medium. Using a proteomic approach, we show that PhoD of B. subtilis, a phosphodiesterase belonging to a novel protein family of which all known members are synthesized with typical twin-arginine signal peptides, is secreted via the twin-arginine translocation pathway. Strikingly, TatCd is of major importance for the secretion of PhoD, whereas TatCy is not required for this process. Thus, TatC appears to be a specificity determinant for protein secretion via the Tat pathway, Based on our observations, we hypothesize that the TatC determined pathway specificity is based on specific interactions between TatC-like proteins and other pathway components, such as TatA, of which three paralogues are present in B. subtilis.	Univ Groningen, Dept Pharmaceut Biol, NL-9713 AV Groningen, Netherlands; Groningen Biomol Sci & Biotechnol Inst, Dept Genet, NL-9751 NN Haren, Netherlands; Univ Jena, Inst Mol Biol, D-07745 Jena, Germany; Univ Greifswald, Inst Mikrobiol & Molekularbiol, D-17487 Greifswald, Germany	University of Groningen; University of Groningen; Friedrich Schiller University of Jena; Ernst Moritz Arndt Universitat Greifswald	van Dijl, JM (corresponding author), Univ Groningen, Dept Pharmaceut Biol, Deusinglaan 1, NL-9713 AV Groningen, Netherlands.		Tjalsma, Harold/I-7146-2012; van Dijl, Jan Maarten/G-1205-2013; Antelmann, Haike/I-3129-2019	Antelmann, Haike/0000-0002-1766-4386				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Antelmann H, 2000, J BACTERIOL, V182, P4478, DOI 10.1128/JB.182.16.4478-4490.2000; Antelmann H, 1997, J BACTERIOL, V179, P7251, DOI 10.1128/jb.179.23.7251-7256.1997; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Bernhardt J, 1997, MICROBIOL-UK, V143, P999, DOI 10.1099/00221287-143-3-999; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Bogsch E, 1997, EMBO J, V16, P3851, DOI 10.1093/emboj/16.13.3851; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Bolhuis A, 1999, J BIOL CHEM, V274, P15865, DOI 10.1074/jbc.274.22.15865; Bolhuis A, 1999, APPL ENVIRON MICROB, V65, P2934; Bolhuis A, 1996, MOL MICROBIOL, V22, P605, DOI 10.1046/j.1365-2958.1996.d01-4676.x; Brink S, 1998, FEBS LETT, V434, P425, DOI 10.1016/S0014-5793(98)01028-X; BRON S, 1972, MUTAT RES, V15, P1, DOI 10.1016/0027-5107(72)90086-3; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; Chanal A, 1998, MOL MICROBIOL, V30, P674, DOI 10.1046/j.1365-2958.1998.01095.x; Cristobal S, 1999, EMBO J, V18, P2982, DOI 10.1093/emboj/18.11.2982; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; DONOVAN W, 1987, J MOL BIOL, V196, P1, DOI 10.1016/0022-2836(87)90506-7; Eder S, 1996, MICROBIOL-SGM, V142, P2041, DOI 10.1099/13500872-142-8-2041; Eymann C, 1996, MICROBIOL-UK, V142, P3163, DOI 10.1099/13500872-142-11-3163; GueroutFleury AM, 1995, GENE, V167, P335, DOI 10.1016/0378-1119(95)00652-4; Hirose I, 2000, MICROBIOL-SGM, V146, P65, DOI 10.1099/00221287-146-1-65; HULETT FM, 1990, J BACTERIOL, V172, P735, DOI 10.1128/jb.172.2.735-740.1990; Hynds PJ, 1998, J BIOL CHEM, V273, P34868, DOI 10.1074/jbc.273.52.34868; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER JH, 1982, EXPT MOL BIOL; MOULD RM, 1991, J BIOL CHEM, V266, P12189; Muller JP, 1999, FEMS MICROBIOL LETT, V180, P287; Muller JP, 1997, MICROBIOL-SGM, V143, P947, DOI 10.1099/00221287-143-3-947; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; Otto A, 1996, ELECTROPHORESIS, V17, P1643, DOI 10.1002/elps.1150171027; Pragai Z, 1997, MICROBIOL-UK, V143, P1327, DOI 10.1099/00221287-143-4-1327; Qi Y, 1998, J BACTERIOL, V180, P4007, DOI 10.1128/JB.180.15.4007-4010.1998; ROBINSON C, 1994, EMBO J, V13, P279, DOI 10.1002/j.1460-2075.1994.tb06260.x; Rodrigue A, 1999, J BIOL CHEM, V274, P13223, DOI 10.1074/jbc.274.19.13223; Sambrook J., 2002, MOL CLONING LAB MANU; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Sargent F, 1999, J BIOL CHEM, V274, P36073, DOI 10.1074/jbc.274.51.36073; SCHAEFFER P, 1965, P NATL ACAD SCI USA, V271, P5463; Settles AM, 1998, TRENDS CELL BIOL, V8, P494, DOI 10.1016/S0962-8924(98)01387-7; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; SIMONEN M, 1993, MICROBIOL REV, V57, P109, DOI 10.1128/MMBR.57.1.109-137.1993; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; Stephenson K, 1998, APPL ENVIRON MICROB, V64, P2875; Swaving J, 1999, J BACTERIOL, V181, P7021, DOI 10.1128/JB.181.22.7021-7027.1999; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; Tjalsma H, 1999, J BIOL CHEM, V274, P1698, DOI 10.1074/jbc.274.3.1698; Tjalsma H, 1998, GENE DEV, V12, P2318, DOI 10.1101/gad.12.15.2318; Tjalsma H, 2000, MICROBIOL MOL BIOL R, V64, P515, DOI 10.1128/MMBR.64.3.515-547.2000; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; VANDIJL JM, 1991, MOL GEN GENET, V227, P40, DOI 10.1007/BF00260704; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VANDIJL JM, 1991, J GEN MICROBIOL, V137, P2073, DOI 10.1099/00221287-137-9-2073; VIEIRA J, 1991, GENE, V100, P189, DOI 10.1016/0378-1119(91)90365-I; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6; Wexler M, 2000, J BIOL CHEM, V275, P16717, DOI 10.1074/jbc.M000800200; YU J, 1995, J BACTERIOL, V177, P6751, DOI 10.1128/jb.177.23.6751-6760.1995	66	133	145	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41350	41357		10.1074/jbc.M004887200	http://dx.doi.org/10.1074/jbc.M004887200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007775	hybrid			2022-12-27	WOS:000166114600091
J	Vallee, F; Karaveg, K; Herscovics, A; Moremen, KW; Howell, PL				Vallee, F; Karaveg, K; Herscovics, A; Moremen, KW; Howell, PL			Structural basis for catalysis and inhibition of N-glycan processing class I alpha 1,2-mannosidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; ACID ALPHA-MANNOSIDASE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; GLYCOPROTEIN-BIOSYNTHESIS; ASPERGILLUS-ORYZAE; CRYSTAL-STRUCTURES; SECRETORY PATHWAY; PICHIA-PASTORIS; CALCIUM-BINDING	Endoplasmic reticulum (ER) class I alpha1,2-mannosidase (also known as ER alpha -mannosidase I) is a critical enzyme in the maturation of N-linked oligosaccharides and ER-associated degradation. Trimming of a single mannose residue acts as a signal to target misfolded glycoproteins for degradation by the proteasome. Crystal structures of the catalytic domain of human ER class I alpha1,2-mannosidase have been determined both in the presence and absence of the potent inhibitors kifunensine and 1-deoxymannojirimycin. Both inhibitors bind to the protein at the bottom of the active-site cavity, with the essential calcium ion coordinating the O-2' and O-3' hydroxyls and stabilizing the six-membered rings of both inhibitors in a C-1(4) conformation. This is the first direct evidence of the role of the calcium ion. The lack of major conformational changes upon inhibitor binding and structural comparisons with the yeast alpha1,2-mannosidase enzyme product complex suggest that this class of inverting enzymes has a novel catalytic mechanism. The structures also provide insight into the specificity of this class of enzymes and provide a blueprint for the future design of novel inhibitors that prevent degradation of misfolded proteins in genetic diseases.	Hosp Sick Children, Res Inst, Program Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada; Univ Toronto, Fac Med, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; McGill University; University of Toronto	Howell, PL (corresponding author), Hosp Sick Children, Res Inst, Program Struct Biol & Biochem, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Moremen, Kelley/AAD-4661-2019		NCRR NIH HHS [RR05351] Funding Source: Medline; NIGMS NIH HHS [GM47533, GM31265] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047533] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUSE E, 1992, EUR J BIOCHEM, V208, P451, DOI 10.1111/j.1432-1033.1992.tb17207.x; BETZEL C, 1988, EUR J BIOCHEM, V178, P155, DOI 10.1111/j.1432-1033.1988.tb14440.x; BISCHOFF J, 1984, BIOCHEM BIOPH RES CO, V125, P324, DOI 10.1016/S0006-291X(84)80371-X; Blisnick T, 1998, EUR J BIOCHEM, V252, P537, DOI 10.1046/j.1432-1327.1998.2520537.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BYRD JC, 1982, J BIOL CHEM, V257, P4657; CAMIRAND A, 1991, J BIOL CHEM, V266, P15120; Chung DH, 2000, J BIOL CHEM, V275, P4981, DOI 10.1074/jbc.275.7.4981; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; CREGG JM, 1985, MOL CELL BIOL, V5, P3376, DOI 10.1128/MCB.5.12.3376; DANIEL PF, 1994, GLYCOBIOLOGY, V4, P551, DOI 10.1093/glycob/4.5.551; Davies GJ, 1995, BIOCHEMISTRY-US, V34, P16210, DOI 10.1021/bi00049a037; Degano M, 1998, BIOCHEMISTRY-US, V37, P6277, DOI 10.1021/bi973012e; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Gonzalez DS, 1999, J BIOL CHEM, V274, P21375, DOI 10.1074/jbc.274.30.21375; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; Herscovics A, 1999, BBA-GEN SUBJECTS, V1426, P275, DOI 10.1016/S0304-4165(98)00129-9; HERSCOVICS A, 1999, COMPREHENSIVE NATURA, V3, P13; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Ichishima E, 1999, BIOCHEM J, V339, P589, DOI 10.1042/0264-6021:3390589; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; JELINEKKELLY S, 1985, J BIOL CHEM, V260, P2253; KADZIOLA A, 1994, J MOL BIOL, V239, P104, DOI 10.1006/jmbi.1994.1354; Kawar Z, 2000, GLYCOBIOLOGY, V10, P347, DOI 10.1093/glycob/10.4.347; Knop M, 1996, YEAST, V12, P1229, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1229::AID-YEA15>3.0.CO;2-H; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAL A, 1994, J BIOL CHEM, V269, P9872; Lal A, 1998, GLYCOBIOLOGY, V8, P981, DOI 10.1093/glycob/8.10.981; LASKOWSKI R, 1993, J APPL CRYSTALLOGR, V26, P91; Liao YF, 1996, J BIOL CHEM, V271, P28348, DOI 10.1074/jbc.271.45.28348; LIPARI F, 1995, BIOCHEM BIOPH RES CO, V209, P322, DOI 10.1006/bbrc.1995.1506; Lipari F, 1999, BIOCHEMISTRY-US, V38, P1111, DOI 10.1021/bi981643i; Lipari F, 1996, J BIOL CHEM, V271, P27615, DOI 10.1074/jbc.271.44.27615; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; LOLL PJ, 1995, BIOCHEMISTRY-US, V34, P4316, DOI 10.1021/bi00013a021; Marcus NY, 2000, J BIOL CHEM, V275, P1987, DOI 10.1074/jbc.275.3.1987; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; Merkle RK, 1997, BBA-GEN SUBJECTS, V1336, P132, DOI 10.1016/S0304-4165(97)00023-8; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moremen K., 2000, OLIGOSACCHARIDES CHE, VII, P81; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; Parsiegla G, 1998, EMBO J, V17, P5551, DOI 10.1093/emboj/17.19.5551; Romero PA, 2000, J BIOL CHEM, V275, P11071, DOI 10.1074/jbc.275.15.11071; ROUSSEL A, 1991, TURBO FRODO GRAPHICS; Schmidt A, 1998, PROTEIN SCI, V7, P2081, DOI 10.1002/pro.5560071004; SCHNEIKERT J, 1994, GLYCOBIOLOGY, V4, P445, DOI 10.1093/glycob/4.4.445; SCHUTZBACH JS, 1990, J BIOL CHEM, V265, P2546; Spurway TD, 1997, J BIOL CHEM, V272, P17523, DOI 10.1074/jbc.272.28.17523; SU K, 1993, J BIOL CHEM, V268, P14301; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tremblay LO, 1998, GLYCOBIOLOGY, V8, P585, DOI 10.1093/glycob/8.6.585; Tremblay LO, 1999, GLYCOBIOLOGY, V9, P1073, DOI 10.1093/glycob/9.10.1073; Vallee F, 2000, EMBO J, V19, P581, DOI 10.1093/emboj/19.4.581; van Santen Y, 1999, J BIOL CHEM, V274, P30474, DOI 10.1074/jbc.274.43.30474; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VUILLARD L, 1994, FEBS LETT, V353, P294, DOI 10.1016/0014-5793(94)01060-9; Wang Y, 2000, BIOCHEM BIOPH RES CO, V271, P22, DOI 10.1006/bbrc.2000.2577; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Weng SA, 1996, ARCH BIOCHEM BIOPHYS, V325, P113, DOI 10.1006/abbi.1996.0014; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yoshida T, 1998, BIOSCI BIOTECH BIOCH, V62, P309, DOI 10.1271/bbb.62.309	74	123	125	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41287	41298		10.1074/jbc.M006927200	http://dx.doi.org/10.1074/jbc.M006927200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10995765	hybrid			2022-12-27	WOS:000166114600084
J	Becker, NA; O'Neill, HA; Zimmerman, JM; Maher, LJ				Becker, NA; O'Neill, HA; Zimmerman, JM; Maher, LJ			In vitro and in vivo ligation-mediated polymerase chain reaction analysis of a polypurine/polypyrimidine sequence upstream of the mouse metallothionein-1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPERCOILED PLASMID DNA; ESCHERICHIA-COLI-CELLS; TRIPLE-HELIX FORMATION; H-DNA; HALOBACTERIUM-HALOBIUM; DIETHYL PYROCARBONATE; IN-VIVO; B-DNA; TRANSCRIPTION; BINDING	The mouse metallothionein-1 homopurine/homopyrimidine (MT-I R/Y) sequence is a 128-base pair element located similar to1.2 kilobase pairs upstream of the MT-I gene. Previous in vitro studies of this sequence in purified plasmids indicated the formation of a non-B DNA structure stabilized by acidic pH and negative supercoiling. We now present a detailed in vitro and in vivo analysis of the MT-I R/Y sequence using chemical probes of DNA structure and ligation-mediated polymerase chain reaction. In vivo analysis suggests neither profound base unpairing nor protein binding within the MT-I R/Y sequence before or after metal induction of MT-I. We conclude for this element that the propensity to adopt an unusual DNA structure in vitro does not imply the occurrence of such a structure in vive. We were able to show both in purified genomic DNA and in vive that only isolated thymines and the 3' terminal thymine in strings of consecutive thymines are modified significantly by KMnO4, indicating an altered thymine accessibility pattern within the R/Y sequence. This KMnO4, reactivity pattern is more consistent and predictable within the R/Y sequence when compared with flanking sequences. We propose a simple steric interference model to explain the observed pattern of KMnO4, modification of thymines.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Maher, LJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	maher@mayo.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047814, R01GM054411] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47814, GM54411] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agazie YM, 1996, BIOCHEM J, V316, P461, DOI 10.1042/bj3160461; ANDERSEN RD, 1987, MOL CELL BIOL, V7, P3574, DOI 10.1128/MCB.7.10.3574; Backer NA, 1998, NUCLEIC ACIDS RES, V26, P1951, DOI 10.1093/nar/26.8.1951; BACOLLA A, 1991, NUCLEIC ACIDS RES, V19, P1639, DOI 10.1093/nar/19.7.1639; COLLIER DA, 1990, J BIOL CHEM, V265, P10652; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; FRAPPIER L, 1987, J MOL BIOL, V193, P751, DOI 10.1016/0022-2836(87)90356-1; FREEMAN F, 1976, BIOCHIM BIOPHYS ACTA, V447, P238, DOI 10.1016/0005-2787(76)90346-4; HAMER D H, 1982, Journal of Molecular and Applied Genetics, V1, P273; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292, DOI 10.1073/pnas.85.17.6292; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; Hunter CA, 1997, J MOL BIOL, V265, P603, DOI 10.1006/jmbi.1996.0755; IIDA S, 1970, BIOCHIM BIOPHYS ACTA, V213, P1, DOI 10.1016/0005-2787(70)90002-X; JOHNSTON BH, 1988, SCIENCE, V241, P1800, DOI 10.1126/science.2845572; KARLOVSKY P, 1990, FEBS LETT, V274, P39, DOI 10.1016/0014-5793(90)81324-H; Kelm RJ, 1996, J BIOL CHEM, V271, P24278, DOI 10.1074/jbc.271.39.24278; Kim J, 1996, J BIOL CHEM, V271, P9340, DOI 10.1074/jbc.271.16.9340; Kim JM, 1996, J BIOL CHEM, V271, P19724, DOI 10.1074/jbc.271.33.19724; KOHWI Y, 1993, GENE DEV, V7, P1766, DOI 10.1101/gad.7.9.1766; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWI Y, 1992, J MOL BIOL, V223, P817, DOI 10.1016/0022-2836(92)90242-C; KOHWISHIGEMATSU T, 1992, METHOD ENZYMOL, V212, P155; Krasilnikov AS, 1999, J MOL BIOL, V292, P1149, DOI 10.1006/jmbi.1999.3117; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LYAMICHEV VI, 1986, J BIOMOL STRUCT DYN, V3, P667, DOI 10.1080/07391102.1986.10508454; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCARTHY JG, 1990, BIOCHEMISTRY-US, V29, P6071, DOI 10.1021/bi00477a027; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURCHIE AIH, 1992, METHOD ENZYMOL, V211, P158; Nejedly K, 1998, BIOPHYS CHEM, V73, P205, DOI 10.1016/S0301-4622(98)00145-8; PALECEK E, 1993, J CELL SCI, V104, P653; PALECEK E, 1988, BIOCHEM BIOPH RES CO, V150, P731, DOI 10.1016/0006-291X(88)90452-4; PESTOV DG, 1991, NUCLEIC ACIDS RES, V19, P6527, DOI 10.1093/nar/19.23.6527; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; SPIRO C, 1995, J BIOL CHEM, V270, P27702, DOI 10.1074/jbc.270.46.27702; SPIRO C, 1999, TRANSCRIPTION FACTOR, P27; STEINMETZER K, 1995, J MOL BIOL, V254, P29, DOI 10.1006/jmbi.1995.0596; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; Suzuki M, 1997, J MOL BIOL, V274, P421, DOI 10.1006/jmbi.1997.1406; THIELE DJ, 1992, NUCLEIC ACIDS RES, V20, P1183, DOI 10.1093/nar/20.6.1183; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307	54	1	1	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40218	40225		10.1074/jbc.M909658199	http://dx.doi.org/10.1074/jbc.M909658199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10986295	hybrid			2022-12-27	WOS:000166039500059
J	Fax, P; Lehmkuhler, O; Kuhn, C; Esche, H; Brockmann, D				Fax, P; Lehmkuhler, O; Kuhn, C; Esche, H; Brockmann, D			E1A(12S)-mediated activation of the adenovirus type 12 E2 promoter depends on the histone acetyltransferase activity of p300/CBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENERAL TRANSCRIPTION FACTORS; RNA-POLYMERASE-II; COACTIVATORS P300; ONCOPROTEIN E1A; ONCOGENIC ADENOVIRUS-TYPE-12; TRANSACTIVATION FUNCTION; CBP; ACETYLATION; PROTEINS; PCAF	Activation of the transcription unit early region 2 (E2) promoter of the oncogenic adenovirus serotype 12 (Ad12), which regulates the expression of proteins essential for viral replication, requires the assembly of a ternary complex consisting of cAMP response element-binding protein (CREB)-1/activating transcription factor (ATF)-1, the Ad12 12S oncogene product of early region 1A (E1A(12S)), and the co-activator p300/CBP on the E2(Ad12) cAMP response element (ES-CRE). Here we show that the active E2(Ad12) promoter is associated with acetylated histone H4 whereas an E2-CRE point-mutated promoter which is transcriptionally inactive due to its inability to assemble this ternary complex is not bound by acetylated histone H4. The histone deacetylase 1 as well as Roscovitine, which blocks the activation of the histone acetyltransferase (HAT) activity of CBP by cyclin E-Cdk2, prevents E2(Ad12) promoter activation through E1A(12S). p300/CBP counteracts the repressive function of histone deacetylase 1 in a HAT domain-dependent manner whereas the p300/CBP-associated factor PCAF failed to rescue E2(Ad12) promoter activity. E1A(12S) bound p300/CBP displays strong HAT activity. Most interestingly, E1A(12S)-mediated activation of the E2(Ad12) promoter correlates well with the ability of the viral protein to associate with the HAT activity of p300/CBP in vivo. Taken together these data indicate that the recruitment of the HAT activity of p300/CBP by E1A(12S) plays an important role in E2(Ad12) promoter activation.	Univ Essen Gesamthsch, Sch Med, Inst Mol Biol Canc Res, D-45122 Essen, Germany	University of Duisburg Essen	Fax, P (corresponding author), Univ Essen Gesamthsch, Sch Med, Inst Mol Biol, Hufelandstr 55, D-45122 Essen, Germany.							Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BAYLEY ST, 1994, INT J ONCOL, V5, P425; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BROCKMANN D, 1990, VIROLOGY, V179, P585, DOI 10.1016/0042-6822(90)90125-B; BROCKMANN D, 1995, CURR TOP MICROBIOL, V199, P81; BROCKMANN D, 1995, J BIOL CHEM, V270, P10754, DOI 10.1074/jbc.270.18.10754; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; DEDON PC, 1991, ANAL BIOCHEM, V197, P83, DOI 10.1016/0003-2697(91)90359-2; DERY CV, 1985, J GEN VIROL, V66, P2671, DOI 10.1099/0022-1317-66-12-2671; Fax P, 2000, J BIOL CHEM, V275, P8911, DOI 10.1074/jbc.275.12.8911; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kung AL, 2000, GENE DEV, V14, P272; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Lipinski KS, 1999, VIROLOGY, V255, P94, DOI 10.1006/viro.1998.9583; Lipinski KS, 1998, VIRUS RES, V54, P99, DOI 10.1016/S0168-1702(98)00003-3; Lipinski KS, 1997, J GEN VIROL, V78, P413, DOI 10.1099/0022-1317-78-2-413; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SWAMINATHAN S, 1995, CURR TOP MICROBIOL, V199, P177; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	44	26	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40554	40560		10.1074/jbc.M004626200	http://dx.doi.org/10.1074/jbc.M004626200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006273	hybrid			2022-12-27	WOS:000166039500101
J	Wen, KK; Kuang, B; Rubenstein, PA				Wen, KK; Kuang, B; Rubenstein, PA			Tropomyosin-dependent filament formation by a polymerization-defective mutant yeast actin (V266G,L267G)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TROPOMYOSIN; MUSCLE TROPOMYOSIN; POINTED END; F-ACTIN; BINDING; DEPOLYMERIZATION; IDENTIFICATION; PURIFICATION; STABILITY; TROPONIN	A major function of tropomyosin (TPM) in nonmuscle cells may be stabilization of F-actin by binding longitudinally along the actin filament axis. However, no clear evidence exists in vitro that TPM can significantly affect the critical concentration of actin, We previously made a polymerization-defective mutant actin, GG (V266G, L267G). This actin will not polymerize alone at 25 degreesC but will in the presence of phalloidin or beryllium fluoride, With beryllium fluoride, but not phalloidin, this polymerization rescue is cold-sensitive. We show here that GG-actin polymerizability was restored by cardiac tropomyosin and yeast TPM1 and TPM2 at 25 degreesC with rescue efficiency inversely proportional to TPM length (TPM2 > TPM1 > cardiac tropomyosin), indicating the importance of the ends in polymerization rescue. In the presence of TPM, the apparent critical concentration of actin is 5.5 muM, 10-15-fold higher than that of wild type actin but well below that of the GG-actin alone (>20 muM). Non N-acetylated TPMs did not rescue GG-actin polymerization, The TPMs did not prevent cold-induced depolymerization of GG F-actin, TPM-dependent GG-actin polymerization did not occur at temperatures below 20 degreesC, Polymerization rescue may depend initially on the capture of unstable GG-F-actin oligomers by the TPM, resulting in the strengthening of actin monomer-monomer contacts along the filament axis.	Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Rubenstein, PA (corresponding author), Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA.	peter-rubenstein@uiowa.edu	谢, 飞/C-7706-2009	Rubenstein, Peter/0000-0003-1225-4414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33689] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROSCHAT KO, 1990, J BIOL CHEM, V265, P21323; BROSCHAT KO, 1989, BIOCHEMISTRY-US, V28, P8501, DOI 10.1021/bi00447a035; BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; CHEN X, 1993, J CELL BIOL, V123, P1185, DOI 10.1083/jcb.123.5.1185; Cheng DM, 1999, J BIOL CHEM, V274, P35873, DOI 10.1074/jbc.274.50.35873; COOK RK, 1992, J BIOL CHEM, V267, P9430; DREES B, 1995, J CELL BIOL, V128, P383, DOI 10.1083/jcb.128.3.383; DRUBIN DG, 1993, MOL BIOL CELL, V4, P1277, DOI 10.1091/mbc.4.12.1277; GREENFIELD NJ, 1994, PROTEIN SCI, V3, P402; HILL LE, 1992, J BIOL CHEM, V267, P16106; HitchcockDeGregori SE, 1996, J BIOL CHEM, V271, P3600; HITCHCOCKDEGREGORI SE, 1988, BIOCHEMISTRY-US, V27, P9182, DOI 10.1021/bi00426a016; HUXLEY HE, 1973, NATURE, V244, P445, DOI 10.1038/243445a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kuang B, 1997, J BIOL CHEM, V272, P4412, DOI 10.1074/jbc.272.7.4412; LAL AA, 1986, BIOCHEMISTRY-US, V25, P1154, DOI 10.1021/bi00353a031; Landis C, 1999, J BIOL CHEM, V274, P31279, DOI 10.1074/jbc.274.44.31279; LIU HP, 1989, P NATL ACAD SCI USA, V86, P90, DOI 10.1073/pnas.86.1.90; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MATSUMURA F, 1985, J BIOL CHEM, V260, P3851; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; ORLOVA A, 1992, J MOL BIOL, V227, P1043, DOI 10.1016/0022-2836(92)90520-T; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; STRZELECKAGOLASZEWSKA H, 1993, EUR J BIOCHEM, V211, P731, DOI 10.1111/j.1432-1033.1993.tb17603.x; TOBACMAN LS, 1982, J BIOL CHEM, V257, P4166	26	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40594	40600		10.1074/jbc.M007201200	http://dx.doi.org/10.1074/jbc.M007201200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10998421	hybrid			2022-12-27	WOS:000166039500106
J	Parrill, AL; Wang, DA; Bautista, DL; Van Brocklyn, JR; Lorincz, Z; Fischer, DJ; Baker, DL; Liliom, K; Spiegel, S; Tigyi, G				Parrill, AL; Wang, DA; Bautista, DL; Van Brocklyn, JR; Lorincz, Z; Fischer, DJ; Baker, DL; Liliom, K; Spiegel, S; Tigyi, G			Identification of Edg1 receptor residues that recognize sphingosine 1-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SPHINGOSINE-1-PHOSPHATE; LIGAND; PROLIFERATION; CONSTRUCTION; ACTIVATION	Originating from its DNA sequence, a computational model of the Edg1 receptor has been developed that predicts critical interactions with its ligand, sphingosine I-phosphate. The basic amino acids Arg(120) and Arg(292) ion pair with the phosphate, whereas the acidic Glu(121) residue ion pairs with the ammonium moiety of sphingosine l-phosphate. The requirement of these interactions for specific ligand recognition has been confirmed through examination of site-directed mutants by radioligand binding, ligand-induced [S-35]GTP gammaS binding, and receptor internalization assays. These ion-pairing interactions explain the ligand specificity of the Edg1 receptor and provide insight into ligand specificity differences within the Edg receptor family. This computational map of the ligand binding pocket provides information necessary for understanding the molecular pharmacology of this receptor, thus underlining the potential of the computational method in predicting ligand-receptor interactions.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Memphis, Dept Chem, Memphis, TN 38152 USA; Univ Memphis, Computat Res Mat Inst, Memphis, TN 38152 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Georgetown Univ, Dept Biochem, Washington, DC 20007 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Memphis; University of Memphis; University System of Ohio; Ohio State University; Georgetown University	Tigyi, G (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol & Biophys, 894 Union Ave, Memphis, TN 38163 USA.	gtigyi@physio1.utmem.edu	Liliom, Karoly/A-6563-2011; Van Brocklyn, Jim/A-9733-2010	Liliom, Karoly/0000-0002-7177-6872; Parrill, Abby/0000-0003-1658-8497; Baker, Daniel/0000-0003-1482-0416	NHLBI NIH HHS [HL07641, HL61469] Funding Source: Medline; NIGMS NIH HHS [GM43880] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043880, R37GM043880] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1998, MOL PHARMACOL, V54, P881, DOI 10.1124/mol.54.5.881; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Bautista DL, 2000, J MOL STRUC-THEOCHEM, V529, P219, DOI 10.1016/S0166-1280(00)00549-2; BRAMBLETT RD, 1995, LIFE SCI, V56, P1971, DOI 10.1016/0024-3205(95)00178-9; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024; Finney DJ., 1977, PROBIT ANAL; Fischer DJ, 1998, MOL PHARMACOL, V54, P979, DOI 10.1124/mol.54.6.979; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Im DS, 2000, MOL PHARMACOL, V57, P753, DOI 10.1124/mol.57.4.753; Konvicka K, 1998, BIOPHYS J, V75, P601, DOI 10.1016/S0006-3495(98)77551-4; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1998, J BIOL CHEM, V273, P22105, DOI 10.1074/jbc.273.34.22105; Lefkowitz RJ, 2000, NAT CELL BIOL, V2, pE133, DOI 10.1038/35017152; Liu CH, 1999, MOL BIOL CELL, V10, P1179, DOI 10.1091/mbc.10.4.1179; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parrill AL, 2000, ANN NY ACAD SCI, V905, P330; Pogozheva ID, 1997, BIOPHYS J, V72, P1963, DOI 10.1016/S0006-3495(97)78842-8; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SPIEGEL S, 1994, BREAST CANCER RES TR, V31, P337, DOI 10.1007/BF00666166; Tao Q, 1999, MOL PHARMACOL, V55, P605; Van Brocklyn JR, 2000, BLOOD, V95, P2624; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; vanRhee AM, 1996, DRUG DEVELOP RES, V37, P1, DOI 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S; ZHANG DQ, 1994, FEBS LETT, V337, P207, DOI 10.1016/0014-5793(94)80274-2; Zhang GF, 1999, GENE, V227, P89, DOI 10.1016/S0378-1119(98)00589-7	32	133	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39379	39384		10.1074/jbc.M007680200	http://dx.doi.org/10.1074/jbc.M007680200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10982820	hybrid			2022-12-27	WOS:000165953100061
J	Chen, VC; Chao, L; Chao, J				Chen, VC; Chao, L; Chao, J			Roles of the P1, P2, and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEINASE; BINDING-SITE; CRYSTAL-STRUCTURE; PHE-PHE; HEPARIN; ANTITHROMBIN; EXPRESSION; KININOGEN; MODEL; ACTIVATION	Kallistatin is a serpin with a unique P1 Phe, which confers an excellent inhibitory specificity toward tissue kallikrein, In this study, we investigated the P3-P2-P1 residues (residues 386-388) of human kallistatin in determining inhibitory specificity toward human tissue kallikrein by site-directed mutagenesis and molecular modeling. Human kallistatin mutants with 19 different amino acid substitutions at each P1, P2, or P3 residue were created and purified to compare their kallikrein binding activity. Complex formation assay showed that P1 Arg, P1 Phe (wild type), P1 Lys, PI Tyr, PI Met, and P1 Leu display significant binding activity with tissue kallikrein among the P1 variants. Kinetic analysis showed the inhibitory activities of the P1 mutants toward tissue kallikrein in the order of P1 Arg > P1 Phe > P1 Lys greater than or equal to PI Tyr > P1 Leu greater than or equal to P1 Met. P1 Phe displays a better selectivity for human tissue kallikrein than P1 Arg, since P1 Arg also inhibits several other serine proteinases, Heparin distinguishes the inhibitory specificity of kallistatin toward kallikrein versus chymotrypsin, For the P2 and P3 variants, the mutants with hydrophobic and bulky amino acids at P2 and basic amino acids at P3 display better binding activity with tissue kallikrein, The inhibitory activities of these mutants toward tissue kallikrein are in the order of P2 Phe (wild type) > P2 Leu > P2 Trp > P2 Met and P3 Arg > P3 Lys (wild type). Molecular modeling of the reactive center loop of kallistatin bound to the reactive crevice of tissue kallikrein indicated that the P2 residue required a long and bulky hydrophobic side chain to reach and fill the hydrophobic S2 cleft generated by Tyr(99) and Trp(219) Of tissue kallikrein. Basic amino acids at P3 could stabilize complex formation by forming electrostatic interaction with Asp(98J) and hydrogen bond with Gln(174) of tissue kallikrein, Our results indicate that tissue kallikrein is a specific target proteinase for kallistatin.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Chao, J (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 171 Ashley Ave, Charleston, SC 29425 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044083] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44083] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BODE W, 1983, J MOL BIOL, V164, P237, DOI 10.1016/0022-2836(83)90077-3; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; Bourgeois L, 1997, J BIOL CHEM, V272, P29590, DOI 10.1074/jbc.272.47.29590; CHAGAS JR, 1992, BIOCHEMISTRY-US, V31, P4969, DOI 10.1021/bi00136a008; CHAGAS JR, 1995, BIOCHEM J, V306, P63, DOI 10.1042/bj3060063; CHAI KX, 1993, J BIOL CHEM, V268, P24498; CHAO J, 1997, J CLIN INVEST, V100, P1; Chao JL, 1996, J LAB CLIN MED, V127, P612, DOI 10.1016/S0022-2143(96)90152-3; Chen LM, 1997, HUM GENE THER, V8, P341, DOI 10.1089/hum.1997.8.3-341; Chen VC, 2000, BBA-PROTEIN STRUCT M, V1479, P237, DOI 10.1016/S0167-4838(00)00044-3; DELNERY E, 1995, BIOCHEM J, V312, P233, DOI 10.1042/bj3120233; DESHPANDE MS, 1992, J MED CHEM, V35, P3094, DOI 10.1021/jm00095a002; ECKE S, 1992, J BIOL CHEM, V267, P7048; ERSDALBADJU E, 1997, J BIOL CHEM, V272, P19398; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; FIEDLER F, 1987, EUR J BIOCHEM, V163, P303, DOI 10.1111/j.1432-1033.1987.tb10801.x; Forteza R, 1996, AM J RESP CRIT CARE, V154, P36, DOI 10.1164/ajrccm.154.1.8680696; Geiger R, 1979, Adv Exp Med Biol, V120A, P235; GREER J, 1981, J MOL BIOL, V153, P1043, DOI 10.1016/0022-2836(81)90466-6; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; HERMANN A, 1995, BIOL CHEM H-S, V376, P365, DOI 10.1515/bchm3.1995.376.6.365; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Katz BA, 1998, PROTEIN SCI, V7, P875; KETTNER C, 1980, ARCH BIOCHEM BIOPHYS, V202, P420, DOI 10.1016/0003-9861(80)90446-4; MARGOLIUS HS, 1989, ANNU REV PHARMACOL, V29, P343; Miao RQ, 2000, CIRC RES, V86, P418, DOI 10.1161/01.RES.86.4.418; MULLERESTERL W, 1986, TRENDS BIOCHEM SCI, V11, P336, DOI 10.1016/0968-0004(86)90293-8; PATSTON PA, 1994, THROMB HAEMOSTASIS, V72, P166; Pimenta DC, 1999, BIOCHEM J, V339, P473, DOI 10.1042/0264-6021:3390473; Pimenta DC, 1997, BIOCHEM J, V327, P27, DOI 10.1042/bj3270027; Portaro FCV, 1997, BIOCHEM J, V323, P167, DOI 10.1042/bj3230167; PRATT CW, 1992, J BIOL CHEM, V267, P8795; REHBOCK J, 1995, J CANCER RES CLIN, V121, P64, DOI 10.1007/BF01202732; ROBERTS RA, 1989, J CELL SCI, V94, P527; SHIMAMOTO K, 1980, J CLIN ENDOCR METAB, V51, P840, DOI 10.1210/jcem-51-4-840; TAKAHASHI S, 1988, J BIOCHEM-TOKYO, V104, P22, DOI 10.1093/oxfordjournals.jbchem.a122415; VILLOUTREIX BO, 1994, PROTEIN SCI, V3, P2033, DOI 10.1002/pro.5560031116; VolpeJunior N, 1996, INFLAMM RES, V45, P198, DOI 10.1007/BF02285161; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WORTHY K, 1990, INT J EXP PATHOL, V71, P587; WU HF, 1993, PATHOBIOLOGY, V61, P123, DOI 10.1159/000163780; ZHOU GX, 1992, J BIOL CHEM, V267, P25873	43	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38457	38466		10.1074/jbc.M005605200	http://dx.doi.org/10.1074/jbc.M005605200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10993887	hybrid			2022-12-27	WOS:000165739800044
J	Law, BK; Waltner-Law, ME; Entingh, AJ; Chytil, A; Aakre, ME; Norgaard, P; Moses, HL				Law, BK; Waltner-Law, ME; Entingh, AJ; Chytil, A; Aakre, ME; Norgaard, P; Moses, HL			Salicylate-induced growth arrest is associated with inhibition of p70(s6k) and down-regulation of c-Myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; S6 KINASE; SODIUM-SALICYLATE; FARNESYLTRANSFERASE INHIBITOR; DNA-SYNTHESIS; PHOSPHORYLATION; EXPRESSION; ASPIRIN	Salicylate and its pro-drug form aspirin are widely used medicinally for their analgesic and anti-inflammatory properties, and more recently for their ability to protect against colon cancer and cardiovascular disease, Despite the wide use of salicylate, the mechanisms underlying its biological activities are largely unknown. Recent reports suggest that salicylate may produce some of its effects by modulating the activities of protein kinases. Since we have previously shown that the farnesyltransferase inhibitor L-744,832 inhibits cell proliferation and p70(s6k) activity, and salicylate inhibits cell proliferation, we examined whether salicylate affects p70(s6k) activity. We find that salicylate potently inhibits p70(s6k) activation and phosphorylation in a p38 MAPK-independent manner. Interestingly, low salicylate concentrations (less than or equal to 250 muM) inhibit p70(s6k) activation by phorbol myristate acetate, while higher salicylate concentrations (greater than or equal to5 mM) are required to block p70(s6k) activation by epidermal growth factor + insulin-like growth factor-1, These data suggest that salicylate may selectively inhibit p70(s6k) activation in response to specific stimuli. Inhibition of p70(s6k) by salicylate occurs within 5 min, is independent of the phosphatidylinositol 3-kinase pathway, and is associated with dephosphorylation of p70(s6k) on its major rapamycin-sensitive site, Thr(389). A rapamycin-resistant mutant of p70(s6k) is resistant to salicylate-induced Thr(389) dephosphorylation.	Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Glostrup Univ Hosp, Inst Pathol Anat, DK-2600 Glostrup, Denmark	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Copenhagen	Moses, HL (corresponding author), Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, 649 Preston Bldg MRBII, Nashville, TN 37232 USA.	hal.moses@mcmail.vanderbilt.edu	Law, Brian/L-6043-2019		NCI NIH HHS [CA85492, CA42572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085492, R35CA042572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Baron JA, 2000, ANNU REV MED, V51, P511, DOI 10.1146/annurev.med.51.1.511; BLENIS J, 1987, J BIOL CHEM, V262, P14373; Chen Y, 1996, ONCOGENE, V13, P1765; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; FEUERSTEIN N, 1995, J BIOL CHEM, V270, P9454, DOI 10.1074/jbc.270.16.9454; Fukazawa H, 2000, CANCER RES, V60, P2104; GILMAN AG, 1990, PHARMACOLOGICAL BASI; Grewe M, 1999, CANCER RES, V59, P3581; Hall-Jackson CA, 1999, ONCOGENE, V18, P2047, DOI 10.1038/sj.onc.1202603; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Javier AF, 1997, J CLIN INVEST, V99, P2094, DOI 10.1172/JCI119382; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Law BK, 1999, J BIOL CHEM, V274, P4743, DOI 10.1074/jbc.274.8.4743; Law BK, 2000, J BIOL CHEM, V275, P10796, DOI 10.1074/jbc.275.15.10796; Luo Y, 1996, MOL CELL BIOL, V16, P6744; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Oliff A, 1999, BBA-REV CANCER, V1423, pC19, DOI 10.1016/S0304-419X(99)00007-4; Parrott LA, 1999, J BIOL CHEM, V274, P24731, DOI 10.1074/jbc.274.35.24731; Patrignani P, 2000, TOXICOL LETT, V112, P493, DOI 10.1016/S0378-4274(99)00210-6; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Perugini RA, 2000, J GASTROINTEST SURG, V4, P24, DOI 10.1016/S1091-255X(00)80029-3; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; Sawa H, 1998, ONCOGENE, V16, P1701, DOI 10.1038/sj.onc.1201691; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Seufferlein T, 1996, CANCER RES, V56, P3895; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; SPOHN M, 1980, BIOCHIM BIOPHYS ACTA, V608, P409, DOI 10.1016/0005-2787(80)90186-0; Stevenson MA, 1999, J IMMUNOL, V163, P5608; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vilella-Bach M, 1999, J BIOL CHEM, V274, P4266, DOI 10.1074/jbc.274.7.4266; Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776; WENG QP, 1995, MOL CELL BIOL, V15, P2333; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; Xu XM, 1999, P NATL ACAD SCI USA, V96, P5292, DOI 10.1073/pnas.96.9.5292; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	46	70	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38261	38267		10.1074/jbc.M005545200	http://dx.doi.org/10.1074/jbc.M005545200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10993886	hybrid			2022-12-27	WOS:000165739800019
J	Nakamura, H; Fujii, Y; Inoki, I; Sugimoto, K; Tanzawa, K; Matsuki, H; Miura, R; Yamaguchi, Y; Okada, Y				Nakamura, H; Fujii, Y; Inoki, I; Sugimoto, K; Tanzawa, K; Matsuki, H; Miura, R; Yamaguchi, Y; Okada, Y			Brevican is degraded by matrix metalloproteinases and aggrecanase-1 (ADAMTS4) at different sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHEUMATOID SYNOVIAL FIBROBLASTS; EXTRACELLULAR-MATRIX; ENZYMATIC-PROPERTIES; INTERGLOBULAR DOMAIN; CARTILAGE AGGRECAN; NEURITE OUTGROWTH; CLEAVAGE-SITE; ACTIVATION; PRECURSOR; PURIFICATION	Brevican is a member of the lectican family of chondroitin sulfate proteoglycans that is predominantly expressed in the central nervous system. The susceptibility of brevican to digestion by matrix metalloproteinases (MMP-1, -2, -3, -7, -8, -9, -10, and -13 and membrane type 1 and 3 MMPs) and aggrecanase-1 (ADAMTS4) was examined. MMP-1, -2, -3, -7, -8, -10, and -13 degraded brevican into a few fragments with similar molecular masses, whereas the degradation products of aggrecanase-1 had apparently different sizes. NH2-terminal sequence analyses of the digestion fragments revealed that cleavages of the brevican core protein by these metalloproteinases occurred commonly within the central non-homologous domain. MMP-1, -2, -3, -7, -8, -10, and -13 preferentially attacked the Ala(360)-Phe(361) bond, whereas aggrecanase-1 cleaved the Glu(395)-Ser(396) bond, which are similar to the cleavage sites observed with cartilage proteoglycan (aggrecan) for the MMPs and aggrecanase-1, respectively. These data demonstrate that MMP-1, -2, -3, -7, -8, -10, and -13 and aggrecanase-1 digest brevican in a similar pattern to aggrecan and suggest that they may be responsible for the physiological turnover and pathological degradation of brevican.	Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1600016, Japan; Fukui Med Univ, Dept Chem, Fukui 9101193, Japan; Sankyo Co Ltd, Biol Res Labs, Shinagawa Ku, Tokyo 1408710, Japan; Fuji Chem Ind Co Ltd, Biopharmaceut Dept, Takaoka, Toyama 9338511, Japan; Burnham Inst, La Jolla, CA 92037 USA	Keio University; University of Fukui; Daiichi Sankyo Company Limited; Sanford Burnham Prebys Medical Discovery Institute	Okada, Y (corresponding author), Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1600016, Japan.	okada@med.keio.ac.jp	Okada, Yasunori/B-5550-2014; nakamura, hiroyuki/A-2953-2013	Okada, Yasunori/0000-0001-9208-4755; nakamura, hiroyuki/0000-0002-2524-3063; Fujii, Yutaka/0000-0001-6357-3795				BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; FOSANG AJ, 1995, BIOCHEM J, V310, P337, DOI 10.1042/bj3100337; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; Fosang AJ, 1996, J CLIN INVEST, V98, P2292, DOI 10.1172/JCI119040; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; Gary SC, 1998, CURR OPIN NEUROBIOL, V8, P576, DOI 10.1016/S0959-4388(98)80083-4; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; Imai K, 1997, BIOCHEM J, V322, P809, DOI 10.1042/bj3220809; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; IMAI K, 1994, FEBS LETT, V352, P216, DOI 10.1016/0014-5793(94)00960-0; Jaworski DM, 1996, CANCER RES, V56, P2293; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; Matsuki H, 1996, CLIN CHIM ACTA, V244, P129, DOI 10.1016/0009-8981(95)06197-5; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; Merzak A, 1997, CANCER METAST REV, V16, P155, DOI 10.1023/A:1005760726850; Miura R, 1999, J BIOL CHEM, V274, P11431, DOI 10.1074/jbc.274.16.11431; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Nakamura H, 1998, EUR J BIOCHEM, V253, P67, DOI 10.1046/j.1432-1327.1998.2530067.x; NAKANO A, 1995, J NEUROSURG, V83, P298, DOI 10.3171/jns.1995.83.2.0298; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA Y, 1988, BIOCHEM J, V254, P731, DOI 10.1042/bj2540731; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OKADA Y, 2000, TXB RHEUMATOLOGY; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; Sugimoto K, 1999, J BIOCHEM, V126, P449, DOI 10.1093/oxfordjournals.jbchem.a022471; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; YAMADA H, 1995, BIOCHEM BIOPH RES CO, V216, P957, DOI 10.1006/bbrc.1995.2713; Yamada H, 1997, J NEUROSCI, V17, P7784; YAMADA H, 1994, J BIOL CHEM, V269, P10119; Yamaguchi Y, 2000, CELL MOL LIFE SCI, V57, P276, DOI 10.1007/PL00000690; Zhang H, 1998, J NEUROSCI, V18, P2370	36	134	138	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38885	38890		10.1074/jbc.M003875200	http://dx.doi.org/10.1074/jbc.M003875200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10986281	hybrid			2022-12-27	WOS:000165739800101
J	Norton, AW; D'Amours, MR; Grazio, HJ; Hebert, TL; Cote, RH				Norton, AW; D'Amours, MR; Grazio, HJ; Hebert, TL; Cote, RH			Mechanism of transducin activation of frog rod photoreceptor phosphodiesterase - Allosteric interactions between the inhibitory gamma subunit and the noncatalytic cGMP-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; OUTER SEGMENTS; RETINAL RODS; NUCLEOTIDE PHOSPHODIESTERASES; CATALYTIC SUBUNITS; G-PROTEIN; KINETIC-PARAMETERS; ALPHA-SUBUNIT; HIGH-AFFINITY; BOVINE	The rod photoreceptor phosphodiesterase (PDE) is unique among all known vertebrate PDE families for several reasons. It is a catalytic heterodimer (alpha beta); it is directly activated by a G-protein, transducin; and its active sites are regulated by inhibitory gamma subunits, Rod PDE binds cGMP at two noncatalytic sites on the ap dimer, but their function is unclear. We show that transducin activation of frog rod PDE introduces functional heterogeneity to both the noncatalytic and catalytic sites. Upon PDE activation, one noncatalytic site is converted from a high affinity to low affinity state, whereas the second binding site undergoes modest decreases in binding. Addition of gamma to transducin-activated PDE can restore high affinity binding as well as reducing cGMP exchange kinetics at both sites. A strong correlation exists between cGMP binding and gamma binding to activated PDE; dissociation of bound cGMP accompanies gamma dissociation from PDE, whereas addition of either cGMP or gamma to clip dimers can restore high affinity binding of the other molecule, At the active site, transducin can activate PDE to about one-half the turnover number for catalytic cup dimers completely lacking bound gamma subunit, These results suggest a mechanism in which transducin interacts primarily with one PDE catalytic subunit, releasing its full catalytic activity as well as inducing rapid cGMP dissociation from one noncatalytic site, The state of occupancy of the noncatalytic sites on PDE determines whether gamma remains bound to activated PDE or dissociates from the holoenzyme, and may be relevant to light adaptation in photoreceptor cells.	Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA	University System Of New Hampshire; University of New Hampshire	Cote, RH (corresponding author), Univ New Hampshire, Dept Biochem & Mol Biol, 46 Coll Rd, Durham, NH 03824 USA.		Cote, Rick H/G-3363-2013	Cote, Rick H/0000-0002-1573-6526	NEI NIH HHS [EY05798, R01 EY005798] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005798] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Arshavsky VY, 1998, NEURON, V20, P11, DOI 10.1016/S0896-6273(00)80430-4; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; Artemyev NO, 1998, METHODS, V14, P93, DOI 10.1006/meth.1997.0568; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; BENNETT N, 1989, P NATL ACAD SCI USA, V86, P3634, DOI 10.1073/pnas.86.10.3634; Berger AL, 1999, BIOCHEMISTRY-US, V38, P1293, DOI 10.1021/bi981683m; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; BRUCKERT F, 1994, BIOCHEMISTRY-US, V33, P12625, DOI 10.1021/bi00208a013; BURNS F, 1992, BIOCHEM J, V283, P487, DOI 10.1042/bj2830487; Calvert PD, 1998, J GEN PHYSIOL, V111, P39, DOI 10.1085/jgp.111.1.39; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CLERC A, 1992, J BIOL CHEM, V267, P19948; CLERC A, 1992, J BIOL CHEM, V267, P6620; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; COTE RH, 1993, J BIOL CHEM, V268, P17190; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; Cote RH, 2000, METHOD ENZYMOL, V315, P646; D'Amours MR, 1999, BIOCHEM J, V340, P863, DOI 10.1042/0264-6021:3400863; D'Amours MR, 1999, MOL PHARMACOL, V55, P508; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; DUMKE CL, 1994, J GEN PHYSIOL, V103, P1071, DOI 10.1085/jgp.103.6.1071; Fawcett L, 2000, P NATL ACAD SCI USA, V97, P3702, DOI 10.1073/pnas.050585197; FORGET RS, 1993, ANAL BIOCHEM, V215, P159, DOI 10.1006/abio.1993.1570; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; Gallagher S., 1998, CURRENT PROTOCOLS PR; Granovsky AE, 1997, J BIOL CHEM, V272, P11686, DOI 10.1074/jbc.272.18.11686; Granovsky AE, 2000, METHOD ENZYMOL, V315, P635; GUTFREUD H, 1995, KINETICS LIFE SCI RE; HAMM HE, 1984, J GEN PHYSIOL, V84, P265, DOI 10.1085/jgp.84.2.265; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Helmreich EJM, 1996, BBA-REV BIOMEMBRANES, V1286, P285, DOI 10.1016/S0304-4157(96)00013-5; Hulme E. C., 1992, RECEPTOR LIGAND INTE, P63; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loughney K, 1996, J BIOL CHEM, V271, P796, DOI 10.1074/jbc.271.2.796; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Manganiello VC, 1999, THROMB HAEMOSTASIS, V82, P407, DOI 10.1055/s-0037-1615860; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; Melia TJ, 2000, J BIOL CHEM, V275, P3535, DOI 10.1074/jbc.275.5.3535; Mou HM, 1999, J BIOL CHEM, V274, P18813, DOI 10.1074/jbc.274.26.18813; Natochin M, 1996, J BIOL CHEM, V271, P19964, DOI 10.1074/jbc.271.33.19964; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; STRYER L, 1991, J BIOL CHEM, V266, P10711; TAKEMOTO DJ, 1993, CELL SIGNAL, V5, P549, DOI 10.1016/0898-6568(93)90050-V; Tsang SH, 1996, SCIENCE, V272, P1026, DOI 10.1126/science.272.5264.1026; Turko IV, 1998, BIOCHEM J, V329, P505; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WHALEN MM, 1989, BIOCHEM J, V259, P13, DOI 10.1042/bj2590013; WHALEN MM, 1990, BIOCHEM J, V265, P655, DOI 10.1042/bj2650655; YAMAMOTO T, 1983, J BIOL CHEM, V258, P2526; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; Yamazaki A, 1996, J BIOL CHEM, V271, P32495, DOI 10.1074/jbc.271.51.32495; Yamazaki A, 1996, BIOCHEM BIOPH RES CO, V222, P488, DOI 10.1006/bbrc.1996.0771; Yuasa K, 2000, J BIOL CHEM, V275, P31469, DOI 10.1074/jbc.M003041200	64	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38611	38619		10.1074/jbc.M004606200	http://dx.doi.org/10.1074/jbc.M004606200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10993884	hybrid			2022-12-27	WOS:000165739800064
J	Pekkari, K; Gurunath, R; Arner, ESJ; Holmgren, A				Pekkari, K; Gurunath, R; Arner, ESJ; Holmgren, A			Truncated thioredoxin is a mitogenic cytokine for resting human peripheral blood mononuclear cells and is present in human plasma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-DERIVED FACTOR; CYTOTOXICITY-ENHANCING FACTOR; LYMPHOCYTE-PROLIFERATION; HUMAN EOSINOPHILS; KAPPA-B; GROWTH; INVOLVEMENT; ACTIVATION; EXPRESSION; MECHANISM	Human thioredoxin (Trx) catalyzes intracellular disulfide reductions but has also co-cytokine activity with interleukins after leaderless secretion. A recombinant truncated form of thioredoxin with the 80 N-terminal residues (Trx80) was purified to homogeneity, We discovered that Trx80 by itself is a potent mitogenic cytokine stimulating growth of resting human peripheral blood mononuclear cells. No effect was seen by Trx, but Trx80 at 50-100 nm induced cell proliferation of human peripheral blood mononuclear cells in serum-free synthetic medium, measured as [H-3]thymidine incorporation after 72 h, with a maximum effect being comparable with that of 5 units/ml of interleukin-a. Trx80 lacked redox activity, but CD spectra suggested a secondary structure similar to Trx. Reduced Trx80 had an M-r of 25,000, indicating that it is a dimer in solution. We also developed two different sandwich enzyme-linked immunosorbent assays that distinguish between full-length Trx and Trx80 and determined plasma levels of Trx and Trx80 in blood donors. The levels of Trx80 varied from 2 to 175 ng/ml; in comparison levels of Trx varied from 16 to 55 ng/ml without correlation to Trx80, In conclusion, the naturally occurring Trx80 is a novel mitogenic cytokine for normal resting human blood mononuclear cells.	Karolinska Inst, Dept Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden	Karolinska Institutet	Holmgren, A (corresponding author), Karolinska Inst, Dept Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden.	Arne.Holmgren@mbb.ki.se	Ramanathan, Gurunath/B-4757-2011; Arnér, Elias/K-6737-2019; Arnér, Elias S.J./J-5832-2012; Ramanathan, Gurunath/AAR-3650-2020; Pekkari, Klas/AAA-5124-2022	Ramanathan, Gurunath/0000-0003-4627-1677; Arnér, Elias/0000-0002-4807-6114; Arnér, Elias S.J./0000-0002-4807-6114; Ramanathan, Gurunath/0000-0003-4627-1677; 				Aitken Alastair, 1996, P3, DOI 10.1007/978-1-60327-259-9_1; ARNER ESJ, 1992, J BIOL CHEM, V267, P10968; ARNER ESJ, 1993, ANAL BIOCHEM, V210, P102, DOI 10.1006/abio.1993.1157; BALCEWICZSABLINSKA MK, 1991, J IMMUNOL, V147, P2170; Bertini R, 1999, J EXP MED, V189, P1783, DOI 10.1084/jem.189.11.1783; BIGUET C, 1994, J BIOL CHEM, V269, P28865; BODYCOTE J, 1986, P NATL ACAD SCI USA, V83, P4749, DOI 10.1073/pnas.83.13.4749; DESSEIN AJ, 1984, CELL IMMUNOL, V85, P100, DOI 10.1016/0008-8749(84)90282-X; Di Trapani G, 1998, MOL HUM REPROD, V4, P369, DOI 10.1093/molehr/4.4.369; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; ERICSON ML, 1992, LYMPHOKINE CYTOK RES, V11, P201; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HOLMGREN A, 1978, BIOCHEMISTRY-US, V17, P4071, DOI 10.1021/bi00612a031; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; IWATA S, 1994, J IMMUNOL, V152, P5633; Jiang XM, 1999, J BIOL CHEM, V274, P2416, DOI 10.1074/jbc.274.4.2416; KRAVTSOV VD, 1994, EUR J CANCER, V30A, P1564, DOI 10.1016/0959-8049(94)00291-C; LENZI HL, 1985, CELL IMMUNOL, V94, P333, DOI 10.1016/0008-8749(85)90257-6; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Nakamura H, 1996, INT IMMUNOL, V8, P603, DOI 10.1093/intimm/8.4.603; NAKAMURA H, 1992, CANCER-AM CANCER SOC, V69, P2091, DOI 10.1002/1097-0142(19920415)69:8<2091::AID-CNCR2820690814>3.0.CO;2-X; NEWMAN GW, 1994, J EXP MED, V180, P359, DOI 10.1084/jem.180.1.359; Powis G, 1997, Adv Pharmacol, V38, P329; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; ROSEN A, 1995, INT IMMUNOL, V7, P625, DOI 10.1093/intimm/7.4.625; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; Sahaf B, 1997, EXP CELL RES, V236, P181, DOI 10.1006/excr.1997.3699; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SILBERSTEIN DS, 1993, J BIOL CHEM, V268, P9138; SILBERSTEIN DS, 1995, CRIT REV ONCOL HEMAT, V19, P47, DOI 10.1016/1040-8428(94)00127-F; SILBERSTEIN DS, 1987, J IMMUNOL, V138, P3042; SILBERSTEIN DS, 1989, J IMMUNOL, V143, P979; SLABY I, 1975, J BIOL CHEM, V250, P1340; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; YODOI J, 1991, ADV CANCER RES, V57, P381	45	85	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37474	37480		10.1074/jbc.M001012200	http://dx.doi.org/10.1074/jbc.M001012200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982790	hybrid			2022-12-27	WOS:000165618700025
J	Soyez, D; Toullec, JY; Ollivaux, C; Geraud, G				Soyez, D; Toullec, JY; Ollivaux, C; Geraud, G			L to D amino acid isomerization in a peptide hormone is a late post-translational event occurring in specialized neurosecretory cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRUSTACEAN HYPERGLYCEMIC-HORMONE; PRECURSOR; ISOFORMS; RESIDUE	Modification of the chirality of a single amino acid residue within a peptide chain appears to be novel additional mechanism leading to structural and functional diversification of eukaryotic bioactive peptides. This phenomenon has been studied at the cellular level in a neuroendocrine organ which elaborates a mixture of diastereoisomers of a 72-residue neuropeptide, crustacean hyperglycemic hormone. For the first time, amino acid isomerization has been shown to occur in the perikarya of fully specialized neurosecretory cells, as a late step of the maturation of the hyperglycemic hormone precursor and after propeptide cleavage. The specificity and efficiency of this phenomenon indicates the existence of a new enzyme family involved in the biogenesis of peptide hormones.	Univ Paris 06, Ecole Normale Super, CNRS EP2028, Lab Signaux Endocrines & Toxines Invertebres, F-75005 Paris, France; Univ Paris 06, Inst Jacques Monod, Serv Imagerie, CNRS, F-75251 Paris 05, France; Univ Paris 07, F-75251 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Soyez, D (corresponding author), Univ Paris 06, Ecole Normale Super, CNRS EP2028, Lab Signaux Endocrines & Toxines Invertebres, 46 Rue Ulm, F-75005 Paris, France.	soyez@biologie.ens.fr						Chung JS, 1996, EUR J BIOCHEM, V240, P358, DOI 10.1111/j.1432-1033.1996.0358h.x; Chung JS, 1998, REGUL PEPTIDES, V77, P17, DOI 10.1016/S0167-0115(98)00024-X; DEKLEIJN DPV, 1994, EUR J BIOCHEM, V224, P623, DOI 10.1111/j.1432-1033.1994.00623.x; HECK SD, 1994, SCIENCE, V266, P1065, DOI 10.1126/science.7973665; Herp F. van, 1998, Recent advances in arthropod endocrinology., P53; Jimenez EC, 1996, J BIOL CHEM, V271, P28002, DOI 10.1074/jbc.271.45.28002; Keller R., 1999, RECENT DEV COMP ENDO, P209; KREIL G, 1994, J BIOL CHEM, V269, P10967; Kreil G, 1997, ANNU REV BIOCHEM, V66, P337, DOI 10.1146/annurev.biochem.66.1.337; KUWADA M, 1994, MOL PHARMACOL, V46, P587; MOR A, 1992, TRENDS BIOCHEM SCI, V17, P481, DOI 10.1016/0968-0004(92)90333-5; MOR A, 1991, J BIOL CHEM, V266, P6264; Ollivaux C, 2000, EUR J BIOCHEM, V267, P5106, DOI 10.1046/j.1432-1327.2000.01574.x; ORCI L, 1984, CELL, V39, P39, DOI 10.1016/0092-8674(84)90189-2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Seidah NG, 1998, ANN NY ACAD SCI, V839, P9, DOI 10.1111/j.1749-6632.1998.tb10727.x; SHIKATA Y, 1995, J BIOL CHEM, V270, P16719, DOI 10.1074/jbc.270.28.16719; Soyez D, 1998, NEUROSCIENCE, V82, P935; SOYEZ D, 1994, J BIOL CHEM, V269, P18295; Van Harreveld A, 1936, P SOC EXP BIOL MED, V34, P428; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; YASUDA A, 1994, GEN COMP ENDOCR, V95, P387, DOI 10.1006/gcen.1994.1138; Yasuda-Kamatani Y., 1998, EXS, V85, P37	23	59	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37870	37875		10.1074/jbc.M007302200	http://dx.doi.org/10.1074/jbc.M007302200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10993902	hybrid			2022-12-27	WOS:000165618700076
J	Yue, TL; Gu, JL; Wang, CL; Reith, AD; Lee, JC; Mirabile, RC; Kreutz, R; Wang, YB; Maleeff, B; Parsons, AA; Ohlstein, EH				Yue, TL; Gu, JL; Wang, CL; Reith, AD; Lee, JC; Mirabile, RC; Kreutz, R; Wang, YB; Maleeff, B; Parsons, AA; Ohlstein, EH			Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAT VENTRICULAR MYOCYTES; GENE-EXPRESSION; CARDIAC-HYPERTROPHY; MUSCLE-CELLS; MITOGEN; STIMULATE; INVOLVEMENT; MECHANISMS; PATHWAYS	The extracellular signal-regulated kinase (ERK) pathway is activated by hypertrophic stimuli in cardiomyocytes, However, whether ERK plays an essential role or is implicated in all major components of cardiac hypertrophy remains controversial, Using a selective MEK inhibitor, U0126, and a selective Raf inhibitor, SB-386023, to block the ERK signaling pathway at two different levels and adenovirus-mediated transfection of dominant-negative Raf, we studied the role of ERK signaling in response of cultured rat cardiomyocytes to hypertrophic agonists, endothelin-l (ET-1), and phenylephrine (PE). U0126 and SB-386023 blocked ET I and PE-induced ERK but not p38 and JNK activation in cardiomyocytes. Both compounds inhibited ET-1 and PE-induced protein synthesis and increased cell size, sarcomeric reorganization, and expression of P-myosin heavy chain in myocytes with IC,, values of 1-2 muM. Furthermore, both inhibitors significantly reduced ET-1- and PE-induced expression of atrial natriuretic factor. In cardiomyocytes transfected with a dominant-negative Raf, ET-1- and PE-induced increase in cell size, sarcomeric reorganization, and atrial natriuretic factor production were remarkably attenuated compared with the cells infected with an adenovirus-expressing green fluorescence protein. Taken together, our data strongly support the notion that the ERK signal pathway plays an essential role in ET-1- and PE-induced cardiomyocyte hypertrophy.	SmithKline Beecham Pharmaceut, Dept Cardiovasc Pharmacol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Neurosci, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Bone & Cartilage Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Safety Assessment, King Of Prussia, PA 19406 USA; Univ Maryland, Dept Physiol, Baltimore, MD 21201 USA; Free Univ Berlin, Dept Clin Pharmacol & Toxicol, D-12200 Berlin, Germany	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; University System of Maryland; University of Maryland Baltimore; Free University of Berlin	Yue, TL (corresponding author), SmithKline Beecham Pharmaceut, Dept Cardiovasc Pharmacol, 709 Swedeland Rd,POB 1539,UW2510, King Of Prussia, PA 19406 USA.		Kreutz, Reinhold/AEV-0507-2022	Kreutz, Reinhold/0000-0002-4818-211X; Wang, Yibin/0000-0003-0852-0767				Aoki H, 2000, NAT MED, V6, P183, DOI 10.1038/72287; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; Clerk A, 2000, CIRC RES, V86, P1019, DOI 10.1161/01.RES.86.10.1019; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; Colucci WS., 1997, HEART DIS TXB CARDIO, P394; Eble DM, 1998, J MOL CELL CARDIOL, V30, P55, DOI 10.1006/jmcc.1997.0571; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fuller SJ, 1998, J BIOL CHEM, V273, P18146, DOI 10.1074/jbc.273.29.18146; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hertig CM, 1999, J BIOL CHEM, V274, P37362, DOI 10.1074/jbc.274.52.37362; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUGHES JP, 2000, BIOCH MOL BIOL INT; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; Jette C, 2000, FEBS LETT, V467, P1, DOI 10.1016/S0014-5793(00)01114-5; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kreutz R, 1997, HYPERTENSION, V29, P131, DOI 10.1161/01.HYP.29.1.131; Miyata S, 2000, CIRC RES, V86, P386, DOI 10.1161/01.RES.86.4.386; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Sekiguchi K, 1999, CIRC RES, V85, P1000; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; Sugden PH, 1999, CIRC RES, V84, P633, DOI 10.1161/01.RES.84.6.633; Swynghedauw B, 1999, PHYSIOL REV, V79, P215, DOI 10.1152/physrev.1999.79.1.215; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, J BIOL CHEM, V269, P30580; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Yue TL, 1999, J BIOL CHEM, V274, P1479, DOI 10.1074/jbc.274.3.1479; Yue TL, 2000, CIRC RES, V86, P692, DOI 10.1161/01.RES.86.6.692; YUE TL, 1994, CIRC RES, V75, P1, DOI 10.1161/01.RES.75.1.1	34	162	175	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37895	37901		10.1074/jbc.M007037200	http://dx.doi.org/10.1074/jbc.M007037200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10984495	hybrid			2022-12-27	WOS:000165618700079
J	Atlante, A; Calissano, P; Bobba, A; Azzariti, A; Marra, E; Passarella, S				Atlante, A; Calissano, P; Bobba, A; Azzariti, A; Marra, E; Passarella, S			Cytochrome c is released from mitochondria in a reactive oxygen species (ROS)-dependent fashion and can operate as a ROS scavenger and as a respiratory substrate in cerebellar neurons undergoing excitotoxic death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	Keystone Symposia on Mitochondrial Dysfunction in Pathogenesis	JAN 15-20, 2000	SANTA FE, NM				GRANULE CELLS; GLUTAMATE NEUROTOXICITY; PERMEABILITY TRANSITION; CALPAIN INHIBITORS; APOPTOSIS; CULTURES; DEPOLARIZATION; ACTIVATION; PROTEASE; HYPOXIA	In rat cerebellar granule cells both reactive oxygen species production and release of cytochrome c take place during glutamate toxicity. This investigation was aimed (i) to ascertain whether and how these two processes are related and (ii) to gain insight into the role played by the released cytochrome c in the onset of neurotoxicity. Cytochrome c release takes place owing to the generation of reactive oxygen species both in glutamate-treated cerebellar granule cells and in sister control cultures incubated in the presence of the reactive oxygen species generating system consisting of xanthine plus xanthine oxidase. In the early phase of neurotoxicity (30-min glutamate exposure) about 40% of the maximum las measured at 3 h of glutamate exposure) cytochrome c release was found to occur in cerebellar granule cells from mitochondria that were essentially coupled and intact and that had a negligible production of oxygen free radicals. Contrarily, mitochondria from cells treated with glutamate for 3 h were mostly uncoupled and produced reactive oxygen species at a high rate. The cytosolic fraction containing the released cytochrome c was able to transfer electrons from superoxide anion to molecular oxygen via the respiratory chain and was found to partially prevent glutamate toxicity when added externally to cerebellar neurons undergoing necrosis. In the light of these findings, we propose that in the early phase of neurotoxicity, cytochrome c release can be part of a cellular and mitochondrial defense mechanism against oxidative stress.	Univ Molise, Dipartimento Sci Anim Vegetali & Ambiente, I-86100 Campobasso, Italy; CNR, Ctr Studio Mitocondri & Metab Energet, I-70126 Bari, Italy; CNR, Inst Neurobiol, I-00137 Rome, Italy; Univ Bari, Dipartmento Biochim & Biol Mol, I-70126 Bari, Italy	University of Molise; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); Universita degli Studi di Bari Aldo Moro	Passarella, S (corresponding author), Univ Molise, Dipartimento Sci Anim Vegetali & Ambiente, Via De Sanctis, I-86100 Campobasso, Italy.	csmmaa08@area.ba.cnr.it	atlante, anna/AAT-7764-2021; Bobba, ANTONELLA/AAC-9382-2021; Azzariti, Amalia/K-4498-2016; atlante, anna/AAK-7041-2021	Azzariti, Amalia/0000-0002-6149-5049; atlante, anna/0000-0001-6577-6414				Almeida A, 1998, BRAIN RES PROTOC, V2, P209, DOI 10.1016/S1385-299X(97)00044-5; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; ARAI A, 1990, BRAIN RES, V532, P63, DOI 10.1016/0006-8993(90)91742-Y; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Atlante A, 1997, J NEUROCHEM, V68, P2038, DOI 10.1046/j.1471-4159.1997.68052038.x; Atlante A, 1996, NEUROREPORT, V7, P2519, DOI 10.1097/00001756-199611040-00023; Atlante A, 1999, BRAIN RES PROTOC, V4, P266, DOI 10.1016/S1385-299X(99)00028-8; Atlante A, 1999, J NEUROCHEM, V73, P237, DOI 10.1046/j.1471-4159.1999.0730237.x; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERRY MN, 1991, LAB TECHNIQUES BIOCH, P83; Bobba A, 1999, FEBS LETT, V457, P126, DOI 10.1016/S0014-5793(99)01018-2; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Budd SL, 1996, J NEUROCHEM, V67, P2282; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1994, PROG BRAIN RES, V100, P47; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Du YS, 1997, J NEUROCHEM, V69, P1382; DUGAN LL, 1995, J NEUROSCI, V15, P6377; ELNOUE FK, 1984, BIOENERGETICS, P221; Errede B, 1978, Methods Enzymol, V53, P40; FLOWER RJ, 1985, PHARMACOL BASIS THER, P674; FORMAN HJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P396, DOI 10.1016/0003-9861(73)90636-X; Fujimura M, 2000, J NEUROSCI, V20, P2817; Gorman AM, 1999, EUR J NEUROSCI, V11, P1067, DOI 10.1046/j.1460-9568.1999.00512.x; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kantrow SP, 1997, BIOCHEM BIOPH RES CO, V232, P669, DOI 10.1006/bbrc.1997.6353; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Korshunov SS, 1999, FEBS LETT, V462, P192, DOI 10.1016/S0014-5793(99)01525-2; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LEVI G, 1984, BRAIN RES, V290, P77, DOI 10.1016/0006-8993(84)90737-6; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Minervini M, 1997, BRAIN RES, V768, P57, DOI 10.1016/S0006-8993(97)00547-7; MISRA HP, 1972, J BIOL CHEM, V247, P3170; NICHOLLS D, 1982, BIOENERGETICS; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; Schinder AF, 1996, J NEUROSCI, V16, P6125; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Single B, 1998, CELL DEATH DIFFER, V5, P1001, DOI 10.1038/sj.cdd.4400462; VOLONTE C, 1994, CYTOMETRY, V17, P274, DOI 10.1002/cyto.990170311; WADDELL WJ, 1956, J LAB CLIN MED, V48, P311	44	168	178	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37159	37166		10.1074/jbc.M002361200	http://dx.doi.org/10.1074/jbc.M002361200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	378GY	10980192	hybrid			2022-12-27	WOS:000165577700096
J	Baillet, L; Mullur, RS; Esser, V; McGarry, JD				Baillet, L; Mullur, RS; Esser, V; McGarry, JD			Elucidation of the mechanism by which (+)-acylcarnitines inhibit mitochondrial fatty acid transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARNITINE PALMITOYLTRANSFERASE-I; ACYLCARNITINE TRANSLOCASE SYSTEM; MALONYL-COA; RAT-LIVER; KETOGENESIS; METABOLISM	It is well established that medium and long chain (+)-acylcarnitines (ie. fatty acid esters of the unnatural D-isomer of carnitine) inhibit the oxidation of long chain fatty acids in mammalian tissues by interfering with some component(s) of the mitochondrial carnitine palmitoyltransferase (CPT) system. However, whether their site of action is at the level of CPT I (outer membrane), CPT II (inner membrane), carnitine-acylcarnitine translocase (CACT, inner membrane), or some combination of these elements has never been resolved. Ne chose to readdress this question using rat liver mitochondria and employing a variety of assays that distinguish between the three enzyme activities. The effect on each of (+)-acetylcarnitine, (+)-hexanoylcarnitine, (+)octanoylcarnitine, (+)-decanoylcarnitine, and (+)-palmitoylcarnitine was examined. Contrary to longstanding belief, none of these agents was found to impact significantly upon the activity of CPT I or CPT II. Whereas (+)-acetylcarnitine also failed to influence CACT, both (+) octanoylcarnitine and (+)-palmitoylcarnitine strongly inhibited this enzyme with a similar IC50 value (similar to 35 muM) under the assay conditions employed. Remarkably, (+)-decanoylcarnitine was even more potent (IC50 similar to5 muM), whereas (+)-hexanoylcarnitine was far less potent (IC50 >200 muM). These findings resolve a 35-year-old puzzle by establishing unambiguously that medium and long chain (+)-acylcarnitines suppress mitochondrial fatty acid transport solely through the inhibition of the CACT component. They also reveal a surprising rank order of potency among the various (+)-acylcarnitines in this respect and should prove useful in the design of future experiments in which selective blockade of CACT is desired.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas	McGarry, JD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Dallas, TX 75390 USA.				NIDDK NIH HHS [DK 18573] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018573, R37DK018573] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DELISLE G, 1967, P NATL ACAD SCI USA, V58, P790, DOI 10.1073/pnas.58.2.790; Esser V, 1996, J BIOL CHEM, V271, P6972, DOI 10.1074/jbc.271.12.6972; FRITZ IB, 1965, P NATL ACAD SCI USA, V54, P1226, DOI 10.1073/pnas.54.4.1226; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGARRY JD, 1974, DIABETES, V23, P485, DOI 10.2337/diab.23.6.485; MCGARRY JD, 1973, J BIOL CHEM, V248, P270; MCGARRY JD, 1973, J CLIN INVEST, V52, P877, DOI 10.1172/JCI107252; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1974, J BIOL CHEM, V249, P7984; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MCGARRY JD, 1992, NEW DEV FATTY ACID O, V375, P47; PANDE SV, 1976, J BIOL CHEM, V251, P6683; PANDE SV, 1975, P NATL ACAD SCI USA, V72, P883, DOI 10.1073/pnas.72.3.883; WILLIAMSON JR, 1969, J BIOL CHEM, V244, P5055; WILLIAMSON JR, 1968, DIABETES, V17, P194, DOI 10.2337/diab.17.4.194; WOELTJE KF, 1987, J BIOL CHEM, V262, P9822; ZAMMIT VA, 1984, BIOCHEM J, V222, P335, DOI 10.1042/bj2220335	17	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36766	36768		10.1074/jbc.M008265200	http://dx.doi.org/10.1074/jbc.M008265200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10986294	hybrid			2022-12-27	WOS:000165577700046
J	Yap, DBS; Hsieh, JK; Lu, X				Yap, DBS; Hsieh, JK; Lu, X			Mdm2 inhibits the apoptotic function of p53 mainly by targeting it for degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR-SUPPRESSOR P53; TRANSCRIPTIONAL REPRESSION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; DNA-BINDING; IN-VIVO; PROTEIN; TRANSACTIVATION; STABILITY	The ability of Mdm2 to inhibit the activities of a C-terminal truncated p53 mutant, p53-Delta 30, which can bind Mdm2 but is resistant to Mdm2-mediated protein degradation was investigated. The inhibitory function of an Mdm2, mutant, Mdm2-Delta (222-437), which can bind p53 but is defective in targeting p53 for degradation was also studied. Ne have demonstrated that targeting p53 for degradation is the most effective way for Mdm2 to inhibit the apoptotic function of p53. However, we have also shown that Mdm2 can inhibit the transactivation function of p53 without targeting it for degradation, although Mdm2 releases the transrepression ability of p53 mainly by targeting it for degradation. The ability of Mdm2 to inhibit the apoptotic function of p53 was linked to its ability to inhibit the transrepression but not the transactivation function of p53. Furthermore, we have demonstrated that the transrepression function of p53 was specific to p53-induced apoptosis and was not simply a result of cell death.	Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research	Lu, X (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, St Marys Campus,Norfolk Pl, London W2 1PG, England.			Yap, Damian/0000-0002-5370-4592; Lu, Xin/0000-0002-6587-1152				Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FUCHS B, 1995, ONCOGENE, V10, P789; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUNA RMD, 1995, NATURE, V378, P203; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668	34	18	30	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37296	37302		10.1074/jbc.M004359200	http://dx.doi.org/10.1074/jbc.M004359200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10980197	hybrid			2022-12-27	WOS:000165577700116
J	Chen, DG; Huang, SM; Stallcup, MR				Chen, DG; Huang, SM; Stallcup, MR			Synergistic, p160 coactivator-dependent enhancement of estrogen receptor function by CARM1 and p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; HISTONE ACETYLTRANSFERASES; HORMONE RECEPTORS; STEROID-RECEPTORS; ACTIVATION; BINDING; CBP; PROTEIN; COMPLEXES	Members of the p160 coactivator family (steroid receptor coactivator-l (SRC-1), glucocorticoid receptor interacting protein 1 (GRIP1), and activator of thyroid and retinoic acid receptors (ACTR)) mediate transcriptional activation by nuclear receptors, After being recruited to the promoter by nuclear receptors, the p160 coactivator transmits the activating signal via two C-terminal activation domains, AD1 and AD2, AD1 is a binding site for the related coactivators cAMP-response element binding protein binding protein (CBP) and p300, whereas AD2 binds to another coactivator, coactivator-associated arginine methyltransferase 1 (CARM1), a protein-arginine methyltransferase. The current study explored the cooperative functional and mechanistic relationships among GRIP1, CARM1, and p300 in transient transfection assays, where they enhanced the ability of the estrogen receptor (ER) to activate transcription of a reporter gene. The coactivator functions of p300 and CARM1 depended on the co-expression of GRIP1. Simultaneous co-expression of all three coactivators caused a synergistic enhancement of ER function. Deletion of the AD1 domain of GRIP1 abolished the ability of p300 to potentiate ER activity but had no effect on CARM1-mediated stimulation. In contrast, when the AD2 domain of GRIP1 was deleted, p300 still stimulated ER function through the mutant GRIP1, but CARM1 failed to do so. Thus, both binding of p300 to AD1 and binding of CARM1 to AD2 are required for their respective coactivator functions and for their synergy. Furthermore, CARM1 and p300 function independently through different activating domains of GRIP1, and their synergy suggests that they enhance transcription by different, complementary. mechanisms.	Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol, HMR 301,2011 Zonal Ave, Los Angeles, CA 90089 USA.		zhang, shijun/K-3688-2013		NIDDK NIH HHS [DK55274] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK055274, R01DK055274] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Glass CK, 2000, GENE DEV, V14, P121; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Gregory PD, 1998, CURR OPIN CELL BIOL, V10, P339, DOI 10.1016/S0955-0674(98)80009-4; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Ma H, 1999, MOL CELL BIOL, V19, P6164; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Sladek FM, 1999, MOL CELL BIOL, V19, P6509; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5	37	199	203	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40810	40816		10.1074/jbc.M005459200	http://dx.doi.org/10.1074/jbc.M005459200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11010967	hybrid			2022-12-27	WOS:000166114600022
J	King, CC; Gardiner, EMM; Zenke, FT; Bohl, BP; Newton, AC; Hemmings, BA; Bokoch, GM				King, CC; Gardiner, EMM; Zenke, FT; Bohl, BP; Newton, AC; Hemmings, BA; Bokoch, GM			p21-activated kinase (PAK1) is phosphorylated and activated by 3-phosphoinositide-dependent kinase-1 (PDK1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CELLS; FAMILY; ACTIN; SPHINGOSINE; EXPRESSION; HOMOLOGY; MEMBRANE; SPHINGOSINE-1-PHOSPHATE; TRANSLOCATION	In this study, we show that phosphorylated 3-phosphoinositide-dependent kinase 1 (PDK1) phosphorylates pal-activated kinase 1 (PAK1) in the presence of sphingosine. We identify threonine 423, a conserved threonine in the activation loop of kinase subdomain VIII, as the PDK1 phosphorylation site on PAK1. Threonine 423 is a previously identified PAK1 autophosphorylation site that lies within a PAK consensus phosphorylation sequence. After pretreatment with phosphatases, autophosphorylation of PAK1 occurred at all major sites except threonine 423. A phosphothreonine 423-specific antibody detected phosphorylation of recombinant, catalytically inactive PAK1 after incubation with wild-type PAK1, indicating phosphorylation of threonine 423 occurs by an intermolecular mechanism. The biological significance of PDK1 phosphorylation of PAK1 at threonine 423 in vitro is supported by the observation that these two proteins interact in vivo and that PDK1-phosphorylated PAK1 has an increased activity toward substrate. An increase of phosphorylation of catalytically inactive PAK1 was observed in COS-7 cells expressing wild-type, but not catalytically inactive, PDK1 upon elevation of intracellular sphingosine levels. PDK1 phosphorylation of PAK1 was not blocked by pretreatment with wortmannin or when PDK1 was mutated to prevent phosphatidylinositol binding, indicating this process is independent of phosphatidylinositol 3-kinase activity. The data presented here provide evidence for a novel mechanism for PAK1 regulation and activation.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Diego; Friedrich Miescher Institute for Biomedical Research	Bokoch, GM (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	bokoch@scripps.edu		Zenke, Frank/0000-0002-2226-3755	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043154, R01GM043154, R01GM039434] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39434, GM43154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Deak M, 1999, FEBS LETT, V451, P220, DOI 10.1016/S0014-5793(99)00556-6; DESAI NN, 1992, J BIOL CHEM, V267, P23122; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Fatatis A, 1997, J BIOL CHEM, V272, P4351, DOI 10.1074/jbc.272.7.4351; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; JACOBS LS, 1993, AM J PHYSIOL, V265, pC740, DOI 10.1152/ajpcell.1993.265.3.C740; King CC, 2000, J BIOL CHEM, V275, P18108, DOI 10.1074/jbc.M909663199; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Niederberger C, 1999, MOL GEN GENET, V261, P177, DOI 10.1007/s004380050955; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rudel T, 1998, J IMMUNOL, V160, P7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tuazon PT, 1997, BIOCHEMISTRY-US, V36, P16059, DOI 10.1021/bi9717845; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Wu CL, 1998, J BIOL CHEM, V273, P28107, DOI 10.1074/jbc.273.43.28107; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	53	173	178	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41201	41209		10.1074/jbc.M006553200	http://dx.doi.org/10.1074/jbc.M006553200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10995762	hybrid			2022-12-27	WOS:000166114600073
J	Laumonnier, Y; Nadaud, S; Agrapart, M; Soubrier, F				Laumonnier, Y; Nadaud, S; Agrapart, M; Soubrier, F			Characterization of an upstream enhancer region in the promoter of the human endothelial nitric-oxide synthase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETS TRANSCRIPTION FACTORS; MESSENGER-RNA; CORE PROMOTER; DNA-BINDING; CELLS; EXPRESSION; ACTIVATION; SITE; SP1; CHROMATIN	The endothelial nitric-oxide synthase gene is constitutively expressed in endothelial cells. Several transcriptionally active regulatory elements have been identified in the proximal promoter, including a GATA-2 and an Sp-l binding site. Because they cannot account for the constitutive expression of endothelial nitric-oxide synthase gene in a restricted number of cells, we have searched for other cell-specific regulatory elements. By DNase I hypersensitivity mapping and deletion studies we have identified a 269-base pair activator element located 4.9 kilobases upstream from the transcription start site that acts as an enhancer. DNase I footprinting and linker-scanning experiments showed that several regions within the 269-base pair enhancer are important for transcription factor binding and for full enhancer activity,:The endothelial specificity of this activation seems partly due to interaction between this enhancer in its native configuration and the promoter in endothelial cells. EMSA experiments suggested the implication of MZF-like, AP-2, Sp-1-related, and Ets-related factors, Among Ets factors, Erg was the only one able to bind to cognate sites in the enhancer, as found by EMSA and supershift experiments, and to activate the transcriptional activity of the enhancer in cotransfection experiments, Therefore, multiple protein complexes involving Erg, other Ets-related factors, AP-2, Sp-l-related factor, and MZF-like factors are important for the function of this enhancer in endothelial cells.	Hop St Louis, INSERM U525, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Soubrier, F (corresponding author), Fac Med Pitie Salpetriere, INSERM U525, 91 Bd Hop, F-75013 Paris, France.		Nadaud, Sophie/A-7063-2013; Nadaud, Sophie/GXV-0505-2022; Laumonnier, yves/F-6348-2018	Nadaud, Sophie/0000-0002-1452-6009; 				ALHEID U, 1987, THROMB RES, V47, P561, DOI 10.1016/0049-3848(87)90361-6; Buttice G, 1996, ONCOGENE, V13, P2297; Cieslik K, 1998, J BIOL CHEM, V273, P14885, DOI 10.1074/jbc.273.24.14885; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; Guillot PV, 1999, J CLIN INVEST, V103, P799, DOI 10.1172/JCI6017; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JOHN S, 1995, MOL CELL BIOL, V15, P1786; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Kida M, 1999, J BIOL CHEM, V274, P6138, DOI 10.1074/jbc.274.10.6138; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Mager AM, 1998, INT J DEV BIOL, V42, P561; MORRIS JF, 1995, BLOOD, V86, P3640; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; NADAUD S, 1994, BIOCHEM BIOPH RES CO, V198, P1027, DOI 10.1006/bbrc.1994.1146; Navarro-Antolin J, 2000, J BIOL CHEM, V275, P3075, DOI 10.1074/jbc.275.5.3075; PALMER RMJ, 1988, BIOCHEM BIOPH RES CO, V153, P1251, DOI 10.1016/S0006-291X(88)81362-7; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; Schwachtgen JL, 1997, ONCOGENE, V15, P3091, DOI 10.1038/sj.onc.1201502; Shewchuk BM, 1999, J BIOL CHEM, V274, P35725, DOI 10.1074/jbc.274.50.35725; STEWART AF, 1991, NUCLEIC ACIDS RES, V19, P3157, DOI 10.1093/nar/19.11.3157; TANG JL, 1995, BIOCHEM BIOPH RES CO, V213, P673, DOI 10.1006/bbrc.1995.2184; Teichert AM, 2000, AM J PHYSIOL-HEART C, V278, pH1352, DOI 10.1152/ajpheart.2000.278.4.H1352; WARIISHI S, 1995, BIOCHEM BIOPH RES CO, V216, P729, DOI 10.1006/bbrc.1995.2682; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320; Ziegler T, 1998, HYPERTENSION, V32, P351, DOI 10.1161/01.HYP.32.2.351	32	47	48	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40732	40741		10.1074/jbc.M004696200	http://dx.doi.org/10.1074/jbc.M004696200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11013235	hybrid			2022-12-27	WOS:000166114600012
J	Xie, YQ; Sun, LP; Kodadek, T				Xie, YQ; Sun, LP; Kodadek, T			TATA-binding protein and the Gal4 transactivator do not bind to promoters cooperatively	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION DOMAIN; BOX-BINDING; GLOBAL REPRESSOR; TERMINAL DOMAIN; TBP BINDING; DNA-BINDING; GENE; COMPLEX; P53	The yeast Ga14 protein, like many activators, binds TATA-binding protein (TBP) directly in vitro. It has been speculated that this protein-protein interaction is important for Ga14p-mediated activation of transcription, but little work has been done to test specific models involving this interaction, In this study, the effect of Ga14p on TBP-TATA binding is addressed. Specifically, it is asked if the Ga14p-TBP interaction can support cooperative binding of the two factors to promoters. It is easy to see how such an event could stimulate transcription, particularly horn promoters with a non-consensus TATA box. In vitro, however, a derivative of GaMp (Ga14(1-93+768-881)) containing the DNA-binding, dimerization, and activation domains does not bind to promoter DNA cooperatively with either recombinant, purified TBP, or with protein from a yeast crude extract. In vivo, reporter gene experiments using promoters with differing TBP affinities reveal no major GaMp-mediated stimulation of TBP function from weak TATA boxes, as would be predicted if the proteins bind cooperatively. Furthermore, native Gal4p and a potent Ga14p-based artificial activator lacking a TBP-binding activation domain support similar ratios of transcription from a series of promoters identical except for mutations in the TATA box. It is concluded that Ga14p and TBP do not bind cooperatively to promoters and that this mechanism does not contribute substantially to Ga14p-mediated transcriptional activation.	Univ Texas, SW Med Ctr, Ryburn Ctr Mol Cardiol, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ryburn Ctr Mol Cardiol, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kodadek, T (corresponding author), Univ Texas, SW Med Ctr, Ryburn Ctr Mol Cardiol, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	thomas.kodadek@utsouthwestern.edu		Kodadek, Thomas/0000-0003-1930-4795				AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; Gaudreau L, 1999, P NATL ACAD SCI USA, V96, P2668, DOI 10.1073/pnas.96.6.2668; GILMOUR DS, 1986, MOL CELL BIOL, V6, P3984, DOI 10.1128/MCB.6.11.3984; GonzalezCouto E, 1997, P NATL ACAD SCI USA, V94, P8036, DOI 10.1073/pnas.94.15.8036; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; INOSTROZA JA, 1992, CELL, V70, P477; Jackson-Fisher AJ, 1999, MOL CELL, V3, P717, DOI 10.1016/S1097-2765(01)80004-6; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; Kim S, 1997, P NATL ACAD SCI USA, V94, P820, DOI 10.1073/pnas.94.3.820; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM TK, 1995, J BIOL CHEM, V270, P10976, DOI 10.1074/jbc.270.18.10976; KODADEK T, 1995, CHEM BIOL, V2, P187, DOI 10.1016/1074-5521(95)90268-6; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; Kotani T, 2000, P NATL ACAD SCI USA, V97, P7178, DOI 10.1073/pnas.120074297; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; Mason PB, 1997, J BIOL CHEM, V272, P33227, DOI 10.1074/jbc.272.52.33227; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; POON D, 1993, J BIOL CHEM, V268, P15325; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; REECE RJ, 1993, GENE, V126, P105, DOI 10.1016/0378-1119(93)90596-U; Reindl A, 1998, FEBS LETT, V436, P318, DOI 10.1016/S0014-5793(98)01152-1; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRUANT R, 1993, J BIOL CHEM, V268, P2284; VASHEE S, 1993, J BIOL CHEM, V268, P24699; VASHEE S, 1995, P NATL ACAD SCI USA, V92, P10683, DOI 10.1073/pnas.92.23.10683; Wu YB, 1996, EMBO J, V15, P3951, DOI 10.1002/j.1460-2075.1996.tb00769.x; XIAO H, 1995, MOL CELL BIOL, V15, P5757; Xie YQ, 2000, J BIOL CHEM, V275, P31914, DOI 10.1074/jbc.M003760200; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; Yean D, 1997, MOL CELL BIOL, V17, P3809, DOI 10.1128/MCB.17.7.3809	47	3	3	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40797	40803		10.1074/jbc.M007019200	http://dx.doi.org/10.1074/jbc.M007019200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11006288	hybrid			2022-12-27	WOS:000166114600020
J	Piehler, J; Roisman, LC; Schreiber, G				Piehler, J; Roisman, LC; Schreiber, G			New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ALPHA; BETA; PROTEIN; RESOLUTION; COMPLEX; MODEL; COMPONENTS; AFFINITY	Type I interferons bind to two cell surface receptors, ifnar1 and ifnar2, as the first step in the activation of several signal transduction pathways that elicit an antiviral state and an anti-proliferative response. Here, we quantitatively mapped the complete binding region of ifnar2 on interferon (IFN)alpha2 by 35 individual mutations to alanine and isosteric residues. Of the six "hot-spot" residues identified (Leu-30, Arg-33, Arg-144, Ala-145, Met-148, and Arg-149), four are located on the E-helix, which is located at the center of the binding site flanked by residues on the A-helix and the AD-loop. The contribution of residues of the D-helix, which have been previously implicated in binding, proved to be marginal for the interaction with the extracellular domain of ifnar2. Interestingly, the ifnar2 binding site overlaps the largest continuous hydrophobic patch on IFN alpha2. Thus, hydrophobic interactions seem to play a significant role stabilizing this interaction, with the charged residues contributing toward the rapid association of the complex. Relating the anti-viral and anti-proliferative activity of the various interferon mutants with their affinity toward ifnar2 results in linear function over the whole range of affinities investigated, suggesting that ifnar2 binding is the rate-determining step in cellular activation. Dose-time analysis of the anti-viral response revealed that shortening the incubation time of low-level activation cannot be compensated by higher IFN doses. Considering the strict dependence of the cellular response on affinity, these results suggest that for maintaining transcription of IFN-responsive genes over a longer time period, low but continuous signaling through the IFN receptor is essential.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Piehler, J (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.		Roisman, Laila/D-1827-2010; Roisman, Laila C./P-9129-2019; Schreiber, Gideon/C-7332-2008	Roisman, Laila/0000-0001-8455-9327; Roisman, Laila C./0000-0001-8455-9327; Piehler, Jacob/0000-0002-2143-2270				Albeck S, 1999, BIOCHEMISTRY-US, V38, P11, DOI 10.1021/bi981772z; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BRECHT A, 1993, BIOSENS BIOELECTRON, V8, P387, DOI 10.1016/0956-5663(93)80078-4; CHANG NT, 1983, ARCH BIOCHEM BIOPHYS, V221, P585, DOI 10.1016/0003-9861(83)90179-0; CHEETHAM BF, 1991, ANTIVIR RES, V15, P27, DOI 10.1016/0166-3542(91)90038-S; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COHEN B, 1995, MOL CELL BIOL, V15, P4208; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; GAUGLITZ G, 1993, SENSOR ACTUAT B-CHEM, V11, P21, DOI 10.1016/0925-4005(93)85234-2; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Karpusas M, 1997, P NATL ACAD SCI USA, V94, P11813, DOI 10.1073/pnas.94.22.11813; Klaus W, 1997, J MOL BIOL, V274, P661, DOI 10.1006/jmbi.1997.1396; KORN AP, 1994, J INTERFERON RES, V14, P1, DOI 10.1089/jir.1994.14.1; Lee CK, 1997, J BIOL CHEM, V272, P21872, DOI 10.1074/jbc.272.35.21872; Lewerenz M, 1998, J MOL BIOL, V282, P585, DOI 10.1006/jmbi.1998.2026; Lijnzaad P, 1996, PROTEINS, V26, P192; MITSUI Y, 1993, PHARMACOL THERAPEUT, V58, P93, DOI 10.1016/0163-7258(93)90068-O; Mogensen KE, 1999, J INTERF CYTOK RES, V19, P1069, DOI 10.1089/107999099313019; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Pearce KH, 1999, BIOCHEMISTRY-US, V38, P81, DOI 10.1021/bi9817008; Piehler J, 1999, J MOL BIOL, V289, P57, DOI 10.1006/jmbi.1999.2726; Piehler J, 1999, J MOL BIOL, V294, P223, DOI 10.1006/jmbi.1999.3230; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Radhakrishnan R, 1996, STRUCTURE, V4, P1453, DOI 10.1016/S0969-2126(96)00152-9; Radhakrishnan R, 1999, J MOL BIOL, V286, P151, DOI 10.1006/jmbi.1998.2480; Rani MRS, 1996, J BIOL CHEM, V271, P22878, DOI 10.1074/jbc.271.37.22878; RUBINSTEIN S, 1981, J VIROL, V37, P755, DOI 10.1128/JVI.37.2.755-758.1981; Runkel L, 2000, BIOCHEMISTRY-US, V39, P2538, DOI 10.1021/bi991631c; Schmitt HM, 1997, BIOSENS BIOELECTRON, V12, P809, DOI 10.1016/S0956-5663(97)00046-8; Selzer T, 2000, NAT STRUCT BIOL, V7, P537; Selzer T, 1999, J MOL BIOL, V287, P409, DOI 10.1006/jmbi.1999.2615; SENDA T, 1992, EMBO J, V11, P3193, DOI 10.1002/j.1460-2075.1992.tb05396.x; SETO MH, 1995, PROTEIN SCI, V4, P655; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; UZE G, 1995, J INTERF CYTOK RES, V15, P3, DOI 10.1089/jir.1995.15.3; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0	37	130	156	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40425	40433		10.1074/jbc.M006854200	http://dx.doi.org/10.1074/jbc.M006854200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10984492	hybrid			2022-12-27	WOS:000166039500085
J	Putsep, K; Axelsson, LG; Boman, A; Midtvedt, T; Normark, S; Boman, HG; Andersson, M				Putsep, K; Axelsson, LG; Boman, A; Midtvedt, T; Normark, S; Boman, HG; Andersson, M			Germ-free and colonized mice generate the same products from enteric prodefensins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH PEPTIDES; ANTIMICROBIAL PEPTIDES; DEFENSINS; CRYPTDIN; FAMILY; MATRILYSIN; SECRETION; INTESTINE; IMMUNITY; CELLS	The use of germ-free mice offers the possibility to study antibacterial components in a gut uncolonized by bacteria. We have developed a method to extract and high pressure liquid chromatography-fractionate the antibacterial factors present in the small intestine of a single mouse. By mass spectrometry and sequence analyses of fractions exhibiting antimicrobial activity, we identified and characterized the defensin region in germ-free mice as well as in colonized mice. Defensins made up around 15% of the total antibacterial activity both in germ-free and colonized mice. The intestine of germ-free mice exhibited the same set of mature enteric defensins (defensins 1, 2, 3, 4, and 6) as mice colonized by a normal microflora. Mature defensins are generated through processing of larger precursors by enzymatic removal of a signal peptide and a propiece, We found that all prodefensins were cleaved at a Ser/Ala-Leu bond, giving 34-residue propiece peptides and only trace amounts of the predicted 39-residue peptide. This first step must be followed by the removal of a residual peptide to render the mature defensins, indicating that the processing is more complex than previously anticipated. The same propieces were found in both germ-free and colonized mice, suggesting that the same processing operates independent of bacterial presence in the intestine.	Karolinska Inst, Ctr Microbiol & Tumor Biol, Lab Med Microbial Ecol, SE-17177 Stockholm, Sweden	Karolinska Institutet	Andersson, M (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Lab Med Microbial Ecol, Box 280, SE-17177 Stockholm, Sweden.	mate.andersson@mbb.ki.se	Andersson, Mats L/M-9124-2014; Andersson, Mats/A-2903-2008	Andersson, Mats L/0000-0001-7582-8791; 				Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Bevins CL, 1999, GUT, V45, P911, DOI 10.1136/gut.45.6.911; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOMAN HG, 1989, J BIOL CHEM, V264, P5852; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; DECKX RJ, 1967, BIOCHIM BIOPHYS ACTA, V139, P204, DOI 10.1016/0005-2744(67)90136-2; EISENHAUER PB, 1992, INFECT IMMUN, V60, P3446, DOI 10.1128/IAI.60.8.3446-3447.1992; Elsbach P, 1997, PROG SURG, V24, P17, DOI 10.1159/000075479; Falk PG, 1998, MICROBIOL MOL BIOL R, V62, P1157, DOI 10.1128/MMBR.62.4.1157-1170.1998; GANZ T, 1994, CIBA F SYMP, V186, P62; HARWIG SSL, 1992, BLOOD, V79, P1532; HULTMARK D, 1983, EMBO J, V2, P571, DOI 10.1002/j.1460-2075.1983.tb01465.x; HUTTNER KM, 1994, GENOMICS, V19, P448, DOI 10.1006/geno.1994.1093; HUTTNER KM, 1994, GENOMICS, V24, P99, DOI 10.1006/geno.1994.1586; Lencer WI, 1997, P NATL ACAD SCI USA, V94, P8585, DOI 10.1073/pnas.94.16.8585; Lopez-Boado YS, 2000, J CELL BIOL, V148, P1305, DOI 10.1083/jcb.148.6.1305; LOW TLK, 1984, J CHROMATOGR, V301, P221, DOI 10.1016/S0021-9673(01)89190-1; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; OUELLETTE AJ, 1990, J BIOL CHEM, V265, P9831; Ouellette AJ, 1999, AM J PHYSIOL-GASTR L, V277, pG257, DOI 10.1152/ajpgi.1999.277.2.G257; Porter EM, 1998, FEBS LETT, V434, P272, DOI 10.1016/S0014-5793(98)00994-6; Qu XD, 1996, INFECT IMMUN, V64, P5161, DOI 10.1128/IAI.64.12.5161-5165.1996; QUELLETTE AJ, 1994, INFECT IMMUN, V62, P4040; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SELSTED ME, 1989, J BIOL CHEM, V264, P4003; VALORE EV, 1992, BLOOD, V79, P1538; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113	28	111	113	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40478	40482		10.1074/jbc.M007816200	http://dx.doi.org/10.1074/jbc.M007816200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11010975	hybrid			2022-12-27	WOS:000166039500091
J	Underhill, C; Qutob, MS; Yee, SP; Torchia, J				Underhill, C; Qutob, MS; Yee, SP; Torchia, J			A novel nuclear receptor corepressor complex, N-CoR, contains components of the mammalian SWI/SNF complex and the corepressor KAP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; MEDIATED REPRESSION; NEGATIVE REGULATOR; TIF1 BETA; PROTEIN; BINDING; FAMILY; NUCLEOSOME; INTERACTS	Transcriptional silencing by many transcription factors is mediated by the nuclear receptor corepressor (N-CoR). The mechanism by which N-CoR represses basal transcription involves the direct or indirect recruitment of histone deacetylases (HDACs). We have isolated two multiprotein N-CoR complexes, designated N-CoR-1 and N-CoR-2, which possess histone deacetylase activity that is mediated by distinct HDACs. Based on Western blotting using antibodies against known subunits, the only HDAC found in the N-CoR-1 complex was HDAC3. In contrast, N-CoR-2 contained predominantly HDAC1 and HDAC2 as well as several other subunits that are found in the Sin3A HDAC complex. Using mass spectrometry and Western blotting, we have identified several novel components of the N-CoR-1 complex including the SWI/SNF-related proteins BRG1, BAF 170, BAF 155, BAF 47/INI1, and the corepressor KAP-1 that is involved in silencing heterochromatin. Indirect immunofluorescence has revealed that both KAP-1 and N-CoR colocalize throughout the nucleus. These results suggest that N-CoR is found in distinct multiprotein complexes, which are involved in multiple pathways of transcriptional repression.	Univ Western Ontario, Canc Res Labs, London Reg Canc Ctr, Dept Pharmacol & Toxicol, London, ON N6A 4L6, Canada; Univ Western Ontario, Canc Res Labs, London Reg Canc Ctr, Dept Oncol, London, ON N6A 4L6, Canada; Univ Western Ontario, Canc Res Labs, London Reg Canc Ctr, Dept Biochem, London, ON N6A 4L6, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Torchia, J (corresponding author), Univ Western Ontario, Canc Res Labs, London Reg Canc Ctr, Dept Pharmacol & Toxicol, 790 Commissioners Rd E,Rm 4020, London, ON N6A 4L6, Canada.	jtorchia@julian.uwo.ca						Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Das BK, 1999, MOL CELL BIOL, V19, P6796; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Glass CK, 2000, GENE DEV, V14, P121; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guenther MG, 2000, GENE DEV, V14, P1048; Harlow E., 1999, USING ANTIBODIES LAB; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang EY, 2000, GENE DEV, V14, P45; Johnston H, 1999, J BIOL CHEM, V274, P16370, DOI 10.1074/jbc.274.23.16370; Kao HY, 2000, GENE DEV, V14, P55; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; KRAMER A, 1995, RNA, V1, P260; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEE J, 2000, EMBO J, V19, P1; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wakimoto BT, 1998, CELL, V93, P321, DOI 10.1016/S0092-8674(00)81159-9; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	60	243	253	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40463	40470		10.1074/jbc.M007864200	http://dx.doi.org/10.1074/jbc.M007864200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11013263	hybrid			2022-12-27	WOS:000166039500089
J	Wick, MJ; Dong, LQ; Riojas, RA; Ramos, FJ; Liu, F				Wick, MJ; Dong, LQ; Riojas, RA; Ramos, FJ; Liu, F			Mechanism of phosphorylation of protein kinase B/Akt by a constitutively active 3-phosphoinositide-dependent protein kinase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 TRANSLOCATION; AKT KINASE; ACTIVATION; PDK1; HOMOLOGY; ADIPOCYTES; APOPTOSIS; CERAMIDE; ALPHA	Phosphorylation of Thr(308) in the activation loop and Ser(473) at the carboxyl terminus is essential for protein kinase B (PKB/Akt) activation. However, the biochemical mechanism of the phosphorylation remains to be characterized. Here we show that expression of a constitutively active mutant of mouse 3-phosphoinositide-dependent protein kinase-1 (PDK1(A280V)) in Chinese hamster ovary cells overexpressing the insulin receptor was sufficient to induce PKB phosphorylation at Thr(308) to approximately the same extent as insulin stimulation. Phosphorylation of PKB by PDK1(A280V) was not affected by treatment of cells with inhibitors of phosphatidylinositol S-kinase or by deletion of the pleckstrin homology (PH) domain of PKB. C-2-ceramide, a cell-permeable, indirect inhibitor of PKB phosphorylation, did not inhibit PDK1(A280V)-catalyzed PKB phosphorylation in cells and had no effect on PDK1 activity in vitro. On the other hand, co-expression of full-length protein kinase C-related kinase-l (PRK1/PKN) or 2 (PRK2) inhibited PDK1(A280V)-mediated PKB phosphorylation, Replacing alanine at position 280 with valine or deletion of the PH domain enhanced PDK1 autophosphorylation in vitro. However, deletion of the PH domain of PDK1(A280V) Significantly reduced PDK1(A280V)-mediated phosphorylation of PKB in cells. In resting cells, PDK1(A280V) localized in the cytosol and at the plasma membrane. However, PDK1(A280V) lacking the PH domain localized predominantly in the cytosol. Taken together, our findings suggest that the wild-type PDK1 may not be constitutively active in cells. In addition, activation of PDK1 is sufficient to phosphorylate PRE at Thr(308) in the cytosol. Furthermore, the PH domain of PDK1 may play both positive and negative roles in regulating the in vivo function of the enzyme. Finally, unlike the carboxyl-terminal fragment of PRK2, which has been shown to bind PDK1 and allow the enzyme to phosphorylate PKB at both Thr(308) and Ser(473), full-length PRK2 and its related kinase PRK1/PKN may both play negative roles in PKB-mediated downstream biological events.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Liu, F (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NIDDK NIH HHS [DK56166] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056166] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Coffer PJ, 1998, BIOCHEM J, V335, P1; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Dong LQ, 2000, P NATL ACAD SCI USA, V97, P5089, DOI 10.1073/pnas.090491897; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Hill MM, 1999, MOL CELL BIOL, V19, P7771; King CC, 2000, J BIOL CHEM, V275, P18108, DOI 10.1074/jbc.M909663199; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Meier R, 1999, J RECEPT SIGNAL TR R, V19, P121, DOI 10.3109/10799899909036639; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Salinas M, 2000, MOL CELL NEUROSCI, V15, P156, DOI 10.1006/mcne.1999.0813; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang CN, 1998, DIABETES, V47, P24, DOI 10.2337/diabetes.47.1.24; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	29	113	116	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40400	40406		10.1074/jbc.M003937200	http://dx.doi.org/10.1074/jbc.M003937200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006271	hybrid			2022-12-27	WOS:000166039500082
J	Balaji, RA; Ohtake, A; Sato, K; Gopalakrishnakone, P; Kini, RM; Seow, KT; Bay, BH				Balaji, RA; Ohtake, A; Sato, K; Gopalakrishnakone, P; Kini, RM; Seow, KT; Bay, BH			lambda-conotoxins, a new family of conotoxins with unique disulfide pattern and protein folding - Isolation and characterization from the venom of Conus marmoreus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CONOTOXIN; PEPTIDE; TEXTILE; GI	Conotoxins are multiple disulfide-bonded peptides isolated fk om marine cone snail venom. These toxins have been classified into several families based on their disulfide pattern and biological properties. Here, we report a new family of Conus peptides, which have a novel cysteine motif. Three peptides of this family (CMrVIA, CMrVIB, and CMrX) have been purified from Conus marmoreus venom, and their structures have been determined. Their amino acid sequences are VCCGYKLCHOC (CMrVIA), NGVCCGYKLCHOC (CMrVIB), and GICCGVSFCYOC (CMrX), where O represents 4-transhydroxyproline. Two of these peptides (CMrVIA and CMrX) have been chemically synthesized Using a selective protection and deprotection strategy during disulfide bond formation, peptides with both feasible cysteine-pairing combinations were generated. The disulfide pattern (C-1-C-4, C-2-C-3) in native toxins was identified by their co-elution with the synthetic disulfide-isomeric peptides on reverse-phase high pressure liquid chromatography. Although cysteine residues were found in comparable positions with those of alpha -conotoxins, these toxins exhibited a distinctly different disulfide bonding pattern; we have named this new family "lambda -conotoxins." CMrVIA and CMrX induced different biological effects when injected intra-cerebroventricularly in mice; CMrVIA induces seizures, whereas CMrX induces flaccid paralysis. The synthetic peptide with lambda -conotoxin folding is about 1150-fold more potent in inducing seizures than the mispaired isomer with alpha -conotoxin folding Thus it appears that the unique disulfide pattern, and hence the "ribbon" conformation, in lambda -conotoxins is important for their biological activity.	Natl Univ Singapore, Fac Med, Dept Anat, Venom & Toxin Res Programme, Singapore 117597, Singapore; Natl Univ Singapore, Fac Sci, Dept Sci Biol, Singapore 117597, Singapore; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan	National University of Singapore; National University of Singapore	Gopalakrishnakone, P (corresponding author), Natl Univ Singapore, Fac Med, Dept Anat, Venom & Toxin Res Programme, 4 Med Dr,MD10, Singapore 117597, Singapore.	antgopal@nus.edu.sg	Kini, Manjunatha/H-8029-2012	Kini, Manjunatha/0000-0002-6100-3251				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Balaji RA, 2000, FEBS LETT, V474, P208, DOI 10.1016/S0014-5793(00)01593-3; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; Drakopoulou E, 2000, J PEPT SCI, V6, P175; Duda TF, 1999, P NATL ACAD SCI USA, V96, P6820, DOI 10.1073/pnas.96.12.6820; FAINZILBER M, 1991, EUR J BIOCHEM, V202, P589, DOI 10.1111/j.1432-1033.1991.tb16412.x; FAINZILBER M, 1995, BIOCHEMISTRY-US, V34, P5364, DOI 10.1021/bi00016a007; Favreau P, 1999, BIOCHEMISTRY-US, V38, P6317, DOI 10.1021/bi982817z; Gehrmann J, 1998, J MOL BIOL, V278, P401, DOI 10.1006/jmbi.1998.1701; Hill JM, 1997, STRUCTURE, V5, P571, DOI 10.1016/S0969-2126(97)00212-8; Jones R M, 2000, Curr Opin Drug Discov Devel, V3, P141; McIntosh J M, 1999, Methods Enzymol, V294, P605; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; Mezo G, 2000, J PEPT RES, V55, P7, DOI 10.1034/j.1399-3011.2000.00140.x; NISHIUCHI Y, 1982, FEBS LETT, V148, P260, DOI 10.1016/0014-5793(82)80820-X; OLIVERA BM, 1987, BIOCHEMISTRY-US, V26, P2086, DOI 10.1021/bi00382a004; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; Rigby AC, 1999, P NATL ACAD SCI USA, V96, P5758, DOI 10.1073/pnas.96.10.5758; Shon KJ, 1998, J BIOL CHEM, V273, P33, DOI 10.1074/jbc.273.1.33; ZHANG RM, 1991, BIOCHEMISTRY-US, V30, P11343, DOI 10.1021/bi00111a021	21	71	76	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39516	39522		10.1074/jbc.M006354200	http://dx.doi.org/10.1074/jbc.M006354200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10988292	hybrid			2022-12-27	WOS:000165953100078
J	Compton, SJ; Cairns, JA; Palmer, KJ; Al-Ani, B; Hollenberg, MD; Walls, AF				Compton, SJ; Cairns, JA; Palmer, KJ; Al-Ani, B; Hollenberg, MD; Walls, AF			A polymorphic protease-activated receptor 2 (PAR2) displaying reduced sensitivity to trypsin and differential responses to PAR agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELL TRYPTASE; THROMBIN RECEPTOR; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; CROSS-REACTIVITY; EXPRESSION; PEPTIDES; RECOGNITION; KERATINOCYTES; ANTAGONIST	Protease-activated receptor 2 (PAR2) is a trypsin-activated member of a family of G-protein-coupled PARs. We have identified a polymorphic form of human PARS (PAR(2)F240S) characterized by a phenylalanine to serine mutation at residue 240 within extracellular loop 2, with allelic frequencies of 0.916 (Phe(240)) and 0.084 (Ser(240)) for the wild-type and mutant alleles, respectively. Elevations in intracellular calcium were measured in permanently transfected cell lines expressing the receptors. PAR(2)F240S displayed a significant reduction in sensitivity toward trypsin (similar to3.7-fold) and the PARS-activating peptides, SLIGKV-NH2 (similar to2.5-fold) and SLIGRL-NH2 (similar to2.8-fold), but an increased sensitivity toward the selective PARS agonist, trans- cinnamoyl-LIGRLO-NH2 (similar to4-fold). Increased sensitivity was also observed toward the selective PAR-1 agonist, TFLLR-NH2 (similar to7-fold), but not to other PAR-1 agonists tested. Furthermore, we found that TLIGRL-NH2 and a PAR4-derived peptide, trans-cinnamoyl-YPGKF-NH2, were selective PAR(2)F240S agonists. By introducing the F240S mutation into rat PARS, we observed shifts in agonist potencies that mirrored the human PAR,F240S, suggesting that Phe240 is involved in determining agonist specificity of PARS. Finally, differences in receptor signaling were paralleled in a cell growth assay. We suggest that the distinct pharmacological profile induced by this polymorphism will have important implications for the design of PAR-targeted agonists/antagonists and may contribute to, or be predictive of, an inflammatory disease.	Univ Calgary, Fac Med, Dept Pharmacol & Therapeut, Endocrine Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Med, Calgary, AB T2N 4N1, Canada; Southampton Gen Hosp, Immunopharmacol Grp, Southampton SO16 6YD, Hants, England; Univ Southampton, Southampton Gen Hosp, Surg Unit, Southampton SO16 6YD, Hants, England	University of Calgary; University of Calgary; University of Southampton; University of Southampton	Compton, SJ (corresponding author), Univ Calgary, Fac Med, Dept Pharmacol & Therapeut, Endocrine Res Grp, Calgary, AB T2N 4N1, Canada.		Hollenberg, Morley/AFV-6966-2022	Walls, Andrew/0000-0003-4803-4595				Al-Ani B, 1999, J PHARMACOL EXP THER, V290, P753; Al-Ani B, 1999, BRIT J PHARMACOL, V128, P1105, DOI 10.1038/sj.bjp.0702834; ALANI B, 1995, CAN J PHYSIOL PHARM, V73, P1203, DOI 10.1139/y95-172; Andrade-Gordon P, 1999, P NATL ACAD SCI USA, V96, P12257, DOI 10.1073/pnas.96.22.12257; Bernatowicz MS, 1996, J MED CHEM, V39, P4879, DOI 10.1021/jm960455s; Bertog M, 1999, J PHYSIOL-LONDON, V521, P3, DOI 10.1111/j.1469-7793.1999.00003.x; Blackhart BD, 1996, J BIOL CHEM, V271, P16466, DOI 10.1074/jbc.271.28.16466; Bohm SK, 1996, BIOCHEM J, V314, P1009; Brain SD, 2000, NAT MED, V6, P134, DOI 10.1038/72218; CHEN J, 1994, J BIOL CHEM, V269, P16041; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Compton SJ, 1998, J IMMUNOL, V161, P1939; Corvera CU, 1999, J PHYSIOL-LONDON, V517, P741, DOI 10.1111/j.1469-7793.1999.0741s.x; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Faruqi TR, 2000, J BIOL CHEM, V275, P19728, DOI 10.1074/jbc.M909960199; Hollenberg MD, 1999, TRENDS PHARMACOL SCI, V20, P271, DOI 10.1016/S0165-6147(99)01333-4; Hollenberg MD, 1997, CAN J PHYSIOL PHARM, V75, P832, DOI 10.1139/cjpp-75-7-832; Howells GL, 1997, J CELL SCI, V110, P881; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; JONES AS, 1963, NATURE, V199, P280, DOI 10.1038/199280b0; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Kawabata A, 1999, J PHARMACOL EXP THER, V288, P358; Lerner DJ, 1996, J BIOL CHEM, V271, P13943, DOI 10.1074/jbc.271.24.13943; Mari B, 1996, FASEB J, V10, P309, DOI 10.1096/fasebj.10.2.8641564; Mirza H, 1997, BLOOD, V90, P3914, DOI 10.1182/blood.V90.10.3914; Molino M, 1997, J BIOL CHEM, V272, P11133; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; NANEVICZ T, 1995, J BIOL CHEM, V270, P21619, DOI 10.1074/jbc.270.37.21619; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Steinhoff M, 1999, EXP DERMATOL, V8, P282; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Vergnolle N, 1999, J IMMUNOL, V163, P5064; Vergnolle N, 1999, BRIT J PHARMACOL, V126, P1262, DOI 10.1038/sj.bjp.0702408; Vergnolle N, 1999, BRIT J PHARMACOL, V127, P1083, DOI 10.1038/sj.bjp.0702634; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wakita H, 1997, P ASSOC AM PHYSICIAN, V109, P190; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	40	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39207	39212		10.1074/jbc.M007215200	http://dx.doi.org/10.1074/jbc.M007215200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995771	hybrid			2022-12-27	WOS:000165953100037
J	Paquet, Y; Trottier, E; Beaudet, MJ; Anderson, A				Paquet, Y; Trottier, E; Beaudet, MJ; Anderson, A			Mutational analysis of the CYP2B2 phenobarbital response unit and inhibitory effect of the constitutive androstane receptor on phenobarbital responsiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOCYTE CULTURES; 5'-FLANKING REGION; GENE-TRANSCRIPTION; ENHANCER MODULE; OKADAIC ACID; INDUCTION; CAR; TRANSLOCATION; EXPRESSION; ELEMENTS	A 163-base pair enhancer in the CYP2B2 5' flank confers phenobarbital (PB) inducibility and constitutes a PB response unit (PBRU), By transfection of primary hepatocytes, we analyzed the function of elements comprising the PBRU and evaluated the role of the constitutive androstane receptor (CAR) in PB responsiveness. A 51-base pair PR-responsive enhancer module (PBREM) within the PBRU confers near-maximal PB response when fused to a th promoter. However, replacing the PBRU with the PBREM in the CYP2B2 5' flank in the natural sequence context reduced PB responsiveness by approximately C-fold. Mutational analysis also demonstrated that PBRU sequence elements outside the PBREM are essential for maximal PB responsiveness. The PBRU contains two putative nuclear receptor binding sites, NR1 and NR2, CAR binds to retinoic acid beta2 response elements (beta RARE) and to the NR1 and NR2 sites of the PBRU and activates transcription of reporter genes in cell lines. However, conversion of NR1 into beta RARE was the equivalent of an inactivating mutation, indicating that CAR does not activate PB-dependent transcription via NR1 in the natural sequence context. A beta RARE x 2-tk reporter construct was inducible by all-trans-retinoic acid (at-RA) as expected and also responded to PB, The latter can be attributed to nuclear accumulation of CAR after PB exposure. Exogenous CAR increased both the basal and PB-induced response of beta RAREx2-tk but reduced PBRU dependent PB response. Furthermore, exogenous CAR also reduced the at-RA response of the beta RARE x 2-tk construct, Thus, CAR acts negatively on PB responsiveness mediated by the CYP2B2 PBRU just as it prevents maximal at-RA responsiveness mediated by beta RARE.	Univ Laval, Hotel Dieu, Ctr Rech Cancerol, Ctr Hosp Univ Quebec, Quebec City, PQ G1R 2J6, Canada; Univ Laval, Dept Biol, St Foy, PQ G1K 7P4, Canada	Laval University; Laval University	Anderson, A (corresponding author), Hotel Dieu, Ctr Rech, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada.							BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; CHRISTOU M, 1987, ARCH BIOCHEM BIOPHYS, V258, P519, DOI 10.1016/0003-9861(87)90374-2; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Handschin C, 2000, J BIOL CHEM, V275, P13362, DOI 10.1074/jbc.275.18.13362; Honkakoski P, 1997, J BIOL CHEM, V272, P14943, DOI 10.1074/jbc.272.23.14943; Honkakoski P, 1998, MOL PHARMACOL, V53, P597, DOI 10.1124/mol.53.4.597; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Honkakoski P, 2000, BIOCHEM J, V347, P321, DOI 10.1042/0264-6021:3470321; Honkakoski P, 1998, J BIOCHEM MOL TOXIC, V12, P3; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Kassam A, 2000, J BIOL CHEM, V275, P4345, DOI 10.1074/jbc.275.6.4345; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kemper B, 1998, PROG NUCLEIC ACID RE, V61, P25, DOI 10.1016/S0079-6603(08)60824-7; Kim J, 1997, J BIOL CHEM, V272, P29423, DOI 10.1074/jbc.272.47.29423; Kim J, 2000, NUCLEIC ACIDS RES, V28, P1126, DOI 10.1093/nar/28.5.1126; Liu SQ, 1998, DNA CELL BIOL, V17, P461, DOI 10.1089/dna.1998.17.461; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Park YK, 1996, J BIOL CHEM, V271, P23725, DOI 10.1074/jbc.271.39.23725; POLAND A, 1981, MOL PHARMACOL, V20, P442; Prima V, 2000, J STEROID BIOCHEM, V72, P1, DOI 10.1016/S0960-0760(99)00146-6; Ramsden R, 1999, GENE, V228, P169, DOI 10.1016/S0378-1119(98)00612-X; Sidhu JS, 1997, J PHARMACOL EXP THER, V282, P1122; Stoltz C, 1999, BIOCHEM PHARMACOL, V57, P1073, DOI 10.1016/S0006-2952(98)00367-0; Stoltz C, 1998, J BIOL CHEM, V273, P8528, DOI 10.1074/jbc.273.14.8528; TROTTIER E, 1995, GENE, V158, P263, DOI 10.1016/0378-1119(94)00916-G; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; Wang JC, 1999, MOL ENDOCRINOL, V13, P604, DOI 10.1210/me.13.4.604; WAXMAN DJ, 1990, BIOCHEM J, V271, P113, DOI 10.1042/bj2710113; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351	34	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38427	38436		10.1074/jbc.M005776200	http://dx.doi.org/10.1074/jbc.M005776200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10993889	hybrid			2022-12-27	WOS:000165739800040
J	Dowland, LK; Luyckx, VA; Enck, AH; Leclercq, B; Yu, ASL				Dowland, LK; Luyckx, VA; Enck, AH; Leclercq, B; Yu, ASL			Molecular cloning and characterization of an intracellular chloride channel in the proximal tubule cell line, LLC-PK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED HEREDITARY NEPHROLITHIASIS; TRANS-GOLGI NETWORK; DENTS-DISEASE; ENDOCYTIC PATHWAY; HUMAN KIDNEY; SUBCELLULAR-DISTRIBUTION; CYSTIC-FIBROSIS; RENAL-FAILURE; PROTON PUMP; PIG-KIDNEY	CLC5 is an intracellular chloride channel of unknown function, expressed in the renal proximal tubule, The subcellular localization and function of CLC5 were investigated in the UC-PK1 porcine proximal tubule cell line. We cloned a cDNA for the porcine CLC5 ortholog (pCLC5) that is predicted to encode an 83-kDa protein with 97% amino acid sequence identity to rat and human CLC5, By immunofluorescence, pCLC5 was localized to early endosomes of the apical membrane fluid-phase endocytotic pathway and to the Golgi complex. Xenopus oocytes injected with pCLC5 cRNA exhibited outwardly rectifying whole cell currents with a relative conductance profile (nitrate >> Cl- approximate to Br- > I- > acetate > gluconate) different from that of control oocytes. Acidification of the extracellular medium reversibly inhibited this outward current with a pK(a) of 6.0 and a Hill coefficient of 1. Overexpression of CLC5 in LLC-PK1 cells resulted in morphological changes, including loss of cell-cell contacts and the appearance of multiple prominent vesicles. These findings are consistent with a potential role for CLC5 in the acidification of membrane compartments of both the endocytic and the exocytic pathway and suggest that its function may be important for normal intercellular adhesion and vesicular trafficking.	Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Membrane Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Yu, ASL (corresponding author), Brigham & Womens Hosp, Div Renal, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	ayu@rics.bwh.harvard.edu	Luyckx, Valerie/J-9747-2019; Yu, Alan/AID-7467-2022	Luyckx, Valerie/0000-0001-7066-8135; Yu, Alan/0000-0002-1776-2533				Alami M, 1997, CELL BIOL INT, V21, P145, DOI 10.1006/cbir.1996.0120; ALAWQATI Q, 1995, CURR OPIN CELL BIOL, V7, P504, DOI 10.1016/0955-0674(95)80006-9; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; Bolino A., 1993, European Journal of Human Genetics, V1, P269; Branten AJW, 1999, NEPHRON, V81, P329, DOI 10.1159/000045301; Buyse G, 1998, BIOCHEM J, V330, P1015, DOI 10.1042/bj3301015; Buyse G, 1997, J BIOL CHEM, V272, P3615, DOI 10.1074/jbc.272.6.3615; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHAPMAN RE, 1994, EMBO J, V13, P2305, DOI 10.1002/j.1460-2075.1994.tb06514.x; Chillaron J, 1997, J BIOL CHEM, V272, P9543; Christensen EI, 1999, J AM SOC NEPHROL, V10, P685; CONDAMINE L, 1994, J CLIN INVEST, V94, P1673, DOI 10.1172/JCI117512; Devuyst O, 1999, HUM MOL GENET, V8, P247, DOI 10.1093/hmg/8.2.247; FISHER SE, 1995, GENOMICS, V29, P598, DOI 10.1006/geno.1995.9960; FISHER SE, 1994, HUM MOL GENET, V3, P2053; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; FRYMOYER PA, 1991, NEW ENGL J MED, V325, P681, DOI 10.1056/NEJM199109053251003; GEKLE M, 1995, AM J PHYSIOL-RENAL, V268, pF899, DOI 10.1152/ajprenal.1995.268.5.F899; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LENCER WI, 1990, AM J PHYSIOL, V258, pC309, DOI 10.1152/ajpcell.1990.258.2.C309; LINDENTHAL S, 1997, AM J PHYSIOL, V273, pC1173; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Londono I, 1999, KIDNEY INT, V55, P1407, DOI 10.1046/j.1523-1755.1999.00365.x; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; Luyckx VA, 1999, P NATL ACAD SCI USA, V96, P12174, DOI 10.1073/pnas.96.21.12174; Luyckx VA, 1998, AM J PHYSIOL-RENAL, V275, pF761, DOI 10.1152/ajprenal.1998.275.5.F761; Marshansky V, 1997, ELECTROPHORESIS, V18, P538, DOI 10.1002/elps.1150180334; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Mo L, 1999, J MEMBRANE BIOL, V168, P253, DOI 10.1007/s002329900514; Nielsen R, 1998, J AM SOC NEPHROL, V9, P1767; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Presley JF, 1997, J BIOL CHEM, V272, P13929, DOI 10.1074/jbc.272.21.13929; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; Redhead C, 1997, MOL BIOL CELL, V8, P691, DOI 10.1091/mbc.8.4.691; RODMAN JS, 1991, EXP CELL RES, V192, P445, DOI 10.1016/0014-4827(91)90063-Z; Sakamoto H, 1999, AM J PHYSIOL-RENAL, V277, pF957, DOI 10.1152/ajprenal.1999.277.6.F957; Schapiro FB, 2000, J BIOL CHEM, V275, P21025, DOI 10.1074/jbc.M002386200; SchmidtRose T, 1997, P NATL ACAD SCI USA, V94, P7633, DOI 10.1073/pnas.94.14.7633; Shugrue CA, 1999, J AM SOC NEPHROL, V10, P1649; Steinmeyer K, 1995, J BIOL CHEM, V270, P31172, DOI 10.1074/jbc.270.52.31172; SUMPIO BE, 1985, Q J MED, V57, P611; SUMPIO BE, 1982, AM J PHYSIOL, V243, pF379, DOI 10.1152/ajprenal.1982.243.4.F379; SUNDIN DP, 1994, AM J PHYSIOL, V267, pF380, DOI 10.1152/ajprenal.1994.267.3.F380; Thakkar H, 1998, KIDNEY INT, V54, P1197, DOI 10.1046/j.1523-1755.1998.00098.x; Tulk BM, 1998, AM J PHYSIOL-RENAL, V274, pF1140, DOI 10.1152/ajprenal.1998.274.6.F1140; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; WRONG OM, 1994, Q J MED, V87, P473; XU HX, 1994, J BIOL CHEM, V269, P22875; YET SF, 1994, J CELL PHYSIOL, V158, P506, DOI 10.1002/jcp.1041580315; YU ASL, 1992, AM J PHYSIOL, V263, pF680, DOI 10.1152/ajprenal.1992.263.4.F680	55	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37765	37773		10.1074/jbc.M004840200	http://dx.doi.org/10.1074/jbc.M004840200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978325	hybrid			2022-12-27	WOS:000165618700063
J	Reagan, JM; Hubbert, ML; Shelness, GS				Reagan, JM; Hubbert, ML; Shelness, GS			Posttranslational regulation of acid sphingomyelinase in Niemann-Pick type C1 fibroblasts and free cholesterol-enriched Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE-ACTIVATING PROTEIN; CULTURED FIBROBLASTS; ENDOPLASMIC-RETICULUM; LIPOPROTEIN FRACTION; SKIN FIBROBLASTS; PLASMA-MEMBRANES; DEFICIENT MICE; SAPOSIN-D; DISEASE; LOCALIZATION	Niemann-Pick type C disease is characterized by the accumulation of cholesterol and other lipids within the lysosomal compartment, a process that is often accompanied by a reduction in acid sphingomyelinase activity. These studies demonstrate that a CHO cell mutant (CT 60), which accumulates lysosomal cholesterol because of a defective NP-C1 protein, has approximately 5-10% of the acid sphingomyelinase activity of its parental cell line (25-RA) or wild type (CHO-K1) cells. The cholesterol-induced reduction in acid sphingomyelinase activity can be reproduced in CHO-K1 cells by incubation in the presence of low density lipoprotein (LDL) and progesterone, which impairs the normal egress of LDL derived cholesterol from the lysosomal compartment. Kinetic analysis of sphingomyelin hydrolysis in cell extracts suggests that the CT60 cells have a reduced amount of functional acid sphingomyelinase as indicated by a 10-fold reduction in the apparent V-max. Western blot analysis using antibodies generated to synthetic peptides corresponding to segments within the carboxyl-terminal region of acid sphingomyelinase demonstrate that both the CT60 and the LDL/progesterone-treated CHO-K1 cells possess near normal levels of acid sphingomyelinase protein. Likewise, Niemann-Pick type C fibroblasts also displayed normal acid sphingomyelinase protein but negligible levels of acid sphingomyelinase activity. These data suggest that cholesterol-induced inhibition is a posttranslational event, perhaps involving cofactor mediated modulation of enzymatic activity or alterations in acid sphingomyelinase protein trafficking and maturation.	Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	Reagan, JM (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	jreagan@wfubmc.edu						BARNHOLZ Y, 1966, J BIOL CHEM, V241, P3731; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brown RE, 1998, J CELL SCI, V111, P1; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; CARRE JB, 1989, J NEUROCHEM, V52, P1294, DOI 10.1111/j.1471-4159.1989.tb01878.x; Coleman P S, 1997, Subcell Biochem, V28, P363; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; DEMEL RA, 1977, BIOCHIM BIOPHYS ACTA, V465, P1, DOI 10.1016/0005-2736(77)90350-9; FERLINZ K, 1994, BIOCHEM J, V301, P855, DOI 10.1042/bj3010855; Ferlinz K, 1997, EUR J BIOCHEM, V243, P511, DOI 10.1111/j.1432-1033.1997.511_1a.x; FINDLAY J, 1958, BIOCHEM J, V69, P467, DOI 10.1042/bj0690467; FOWLER S, 1969, BIOCHIM BIOPHYS ACTA, V191, P481, DOI 10.1016/0005-2744(69)90271-X; GATT S, 1980, J BIOL CHEM, V255, P3371; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HURWITZ R, 1994, J BIOL CHEM, V269, P5440; KLANSEK JJ, 1995, J LIPID RES, V36, P2261; Kusuda S, 1998, J INVEST DERMATOL, V111, P733, DOI 10.1046/j.1523-1747.1998.00370.x; LANGE Y, 1989, J BIOL CHEM, V264, P3786; Lansmann S, 1996, FEBS LETT, V399, P227, DOI 10.1016/S0014-5793(96)01331-2; Leppimaki P, 1998, BIOCHEM J, V335, P285, DOI 10.1042/bj3350285; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAZIERE JC, 1981, BIOCHEM BIOPH RES CO, V100, P1299, DOI 10.1016/0006-291X(81)91965-3; MUNFORD RS, 1995, J LIPID RES, V36, P1653; NEWRZELLA D, 1992, BIOL CHEM H-S, V373, P1233, DOI 10.1515/bchm3.1992.373.2.1233; Newrzella D, 1996, J BIOL CHEM, V271, P32089, DOI 10.1074/jbc.271.50.32089; Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235; NOVAK EK, 1991, J BIOL CHEM, V266, P6377; Ohvo H, 1997, BBA-LIPID LIPID MET, V1349, P131, DOI 10.1016/S0005-2760(97)00126-4; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; PONTING CP, 1994, PROTEIN SCI, V3, P359; RIDGWAY ND, 1995, J LIPID RES, V36, P1345; SCHNEIDER PB, 1967, J LIPID RES, V8, P202; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SONDERFELDFRESKO S, 1988, J BIOL CHEM, V263, P13463; SPENCE MW, 1989, METABOLIC BASIS INHE, P1655; Storey MK, 1998, BIOCHEM J, V336, P247, DOI 10.1042/bj3360247; Tatti M, 1999, EUR J BIOCHEM, V263, P486, DOI 10.1046/j.1432-1327.1999.00521.x; THOMAS GH, 1989, J INHERIT METAB DIS, V12, P139, DOI 10.1007/BF01800716; van der Spoel A, 1998, EMBO J, V17, P1588, DOI 10.1093/emboj/17.6.1588; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; Yamamoto T, 1999, HUM GENET, V105, P10, DOI 10.1007/s004390051057; YOSHIKAWA H, 1992, J INHERIT METAB DIS, V15, P155, DOI 10.1007/BF01800359	50	44	46	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38104	38110		10.1074/jbc.M005296200	http://dx.doi.org/10.1074/jbc.M005296200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978332	hybrid			2022-12-27	WOS:000165618700106
J	Tang, Y; Tang, J; Chen, ZG; Trost, C; Flockerzi, V; Lin, M; Ramesh, V; Zhu, MX				Tang, Y; Tang, J; Chen, ZG; Trost, C; Flockerzi, V; Lin, M; Ramesh, V; Zhu, MX			Association of mammalian Trp4 and phospholipase C isozymes with a PDZ domain-containing protein, NHERF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; EXCHANGER REGULATORY FACTOR; CA2+-PERMEABLE CATION CHANNEL; ACTIVATED CA2+ INFLUX; NA+/H+-EXCHANGER; STORE DEPLETION; DROSOPHILA TRP; BETA(2)-ADRENERGIC RECEPTOR; FUNCTIONAL-CHARACTERIZATION; SIGNALING COMPLEXES	Mammalian homologues of Drosophila Trp have been implicated to form channels that are activated following the depletion of Ca2+ from internal stores. Recent studies indicate that actin redistribution is required for the activation of these channels. Here we show that murine Trp4 and Trp5, as well as phospholipase C beta1 and beta2 interact with the first PDZ domain of NHERF, regulatory factor of the Na+/H+ exchanger. We demonstrated the association of Trp4 and phospholipase C-beta1 with NHERF in vivo in an HEK293 cell line expressing Trp4 and in adult mouse brain by immuno-coprecipitation. NIIERF is a two PDZ domain-containing protein that associates with the actin cytoskeleton via interactions with members of ezrin/radixin/moesin family. Thus, store-operated channels involving Trp4 and Trp5 can form signaling complexes with phospholipase C isozymes via interactions with NHERF and thereby linking the lipase and the channels to the actin cytoskeleton. The interaction with the PDZ protein may constitute an important mechanism for distribution and regulation of store-operated channels.	Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA; Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; Univ Saarlandes, Inst Pharmakil & Toxikol, D-66421 Homburg, Germany; Johns Hopkins Univ, Sch Med, Dept Physiol & Neurosci, Baltimore, MD 21205 USA; Massachusetts Gen Hosp, Mol Neurogenet Unit, Charlestown, MA 02129 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Saarland University; Johns Hopkins University; Harvard University; Massachusetts General Hospital	Zhu, MX (corresponding author), Ohio State Univ, Neurobiotechnol Ctr, 168 Rightmire Hall,1060 Carmack Rd, Columbus, OH 43210 USA.		Chen, Zhangguo/AAW-2032-2021	Chen, Zhangguo/0000-0002-2741-0080	NIGMS NIH HHS [GM54235] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054235] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bahner M, 2000, J BIOL CHEM, V275, P2901, DOI 10.1074/jbc.275.4.2901; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; Bretscher A, 1997, J CELL SCI, V110, P3011; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dare E, 1998, J MOL ENDOCRINOL, V21, P7, DOI 10.1677/jme.0.0210007; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; Gillo B, 1996, P NATL ACAD SCI USA, V93, P14146, DOI 10.1073/pnas.93.24.14146; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; HU YF, 1994, BIOCHEM BIOPH RES CO, V201, P1050, DOI 10.1006/bbrc.1994.1808; Huber A, 1998, FEBS LETT, V425, P317, DOI 10.1016/S0014-5793(98)00248-8; Kondo T, 1997, J CELL BIOL, V139, P749, DOI 10.1083/jcb.139.3.749; Kurschner C, 1998, MOL CELL NEUROSCI, V11, P161, DOI 10.1006/mcne.1998.0679; LEVY FO, 1993, P NATL ACAD SCI USA, V90, P10798, DOI 10.1073/pnas.90.22.10798; Liu MY, 2000, J BIOL CHEM, V275, P12194, DOI 10.1074/jbc.275.16.12194; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Minkoff C, 1999, CURR OPIN NEPHROL HY, V8, P603, DOI 10.1097/00041552-199909000-00012; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Philipp S, 1997, FEBS LETT, V413, P243, DOI 10.1016/S0014-5793(97)00877-6; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Ullmer C, 1998, FEBS LETT, V424, P63, DOI 10.1016/S0014-5793(98)00141-0; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; van Huizen R, 1998, EMBO J, V17, P2285, DOI 10.1093/emboj/17.8.2285; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	59	199	211	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37559	37564		10.1074/jbc.M006635200	http://dx.doi.org/10.1074/jbc.M006635200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10980202	hybrid			2022-12-27	WOS:000165618700036
J	Delerive, P; Gervois, P; Fruchart, JC; Staels, B				Delerive, P; Gervois, P; Fruchart, JC; Staels, B			Induction of I kappa B alpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; GENE-EXPRESSION; INHIBITOR; COMPLEX; KINASE; IMMUNOSUPPRESSION; ATHEROSCLEROSIS; MACROPHAGES	Chronic inflammation is a hallmark of degenerative diseases such as atherosclerosis. Peroxisome proliferator-activated receptors (PPARs) are transcription factors belonging to the nuclear receptor superfamily, which are expressed in the cells of the atherosclerosic lesion PPAR alpha ligands have been reported to exert anti-inflammatory activities in different cell types by antagonizing the transcriptional activity of NF-kappaB. In the present study, the influence of PPAR alpha activators on the NF-kappaB signaling pathway was investigated. Our results show that fibrates, synthetic PPAR alpha activators, induced the expression of the inhibitory protein I kappaB alpha in human aortic smooth muscle cells as well as in primary human hepatocytes, whereas neither I kappaB-kinase activity nor the degradation rate of I kappaB alpha: were affected. Using PPAR alpha -null mice, we demonstrated that fibrates induced I kappaB alpha in liver in vivo and that this action required PPAR alpha. Furthermore, fibrate treatment induced I kappaB alpha protein expression in the cytoplasm and also enhanced IL-1 beta induced accumulation of I kappaB alpha protein in the nucleus. These actions of fibrates on I kappaB alpha expression were accompanied by a decrease in NF-kappaB DNA binding activity as demonstrated by electrophoretic mobility shift assays. Taken together, these data provide an additional molecular mechanism for the anti-inflammatory activity of PPAR alpha agonists and reinforce their potential use in the treatment of inflammatory diseases.	Inst Pasteur, Dept Atherosclerose, INSERM, U325, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59000 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille	Staels, B (corresponding author), Inst Pasteur, Dept Atherosclerose, INSERM, U325, 1 Rue Pr Calmette, F-59019 Lille, France.	Bart.Staels@pasteur-lille.fr	Staels, Bart/N-9497-2016	Staels, Bart/0000-0002-3784-1503				ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Delerive P, 1999, CIRC RES, V85, P394, DOI 10.1161/01.RES.85.5.394; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gervois P, 1999, MOL ENDOCRINOL, V13, P1535, DOI 10.1210/me.13.9.1535; Han YQ, 1997, J BIOL CHEM, V272, P9825; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; KLUCIS E, 1984, MOL CELL BIOCHEM, V65, P73; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Marx N, 1999, CIRCULATION, V99, P3125, DOI 10.1161/01.CIR.99.24.3125; Marx N, 1998, CIRC RES, V83, P1097, DOI 10.1161/01.RES.83.11.1097; Marx N, 1999, ARTERIOSCL THROM VAS, V19, P546, DOI 10.1161/01.ATV.19.3.546; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Palmer CNA, 1998, MOL PHARMACOL, V53, P14, DOI 10.1124/mol.53.1.14; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Soliman MS, 1997, BIOCHEM PHARMACOL, V53, P1369, DOI 10.1016/S0006-2952(97)87956-7; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Vu-Dac N, 1998, J CLIN INVEST, V102, P625, DOI 10.1172/JCI1581; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; Yamaoka K, 1998, J IMMUNOL, V160, P838; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	46	385	414	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36703	36707		10.1074/jbc.M004045200	http://dx.doi.org/10.1074/jbc.M004045200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10980195	hybrid			2022-12-27	WOS:000165577700037
J	Aridor, M; Balch, WE				Aridor, M; Balch, WE			Kinase signaling initiates coat complex II (COPII) recruitment and export from the mammalian endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE FORMATION; GOLGI TRANSPORT; PROTEIN; CARGO; ER; CELLS; PATHWAY; SAR1	The events regulating coat complex II (COPII) vesicle formation involved in the export of cargo from the endoplasmic reticulum (ER) are unknown. COPII recruitment to membranes is initiated by the activation of the small GTPase Sari. We have utilized purified COPII components in both membrane recruitment and cargo export assays to analyze the possible role of kinase regulation in ER export. We now demonstrate that Sari recruitment to membranes requires ATP. We find that the serine/threonine kinase inhibitor H89 abolishes membrane recruitment of Sari, thereby preventing COPII polymerization by interfering with the recruitment of the cytosolic Sec23/24 COPII coat complex. Inhibition of COPII recruitment prevents export of cargo from the ER. These results demonstrate that ER export and initiation of COPII vesicle formation in mammalian cells is under kinase regulation.	Scripps Res Inst, Dept Cell, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Inst Childhood & Neglected Dis, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Balch, WE (corresponding author), Scripps Res Inst, Dept Cell, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	webalch@scripps.edu			NIGMS NIH HHS [GM42336] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Aridor M, 1999, J BIOL CHEM, V274, P4389, DOI 10.1074/jbc.274.7.4389; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; Bannykh S, 1995, COLD SPRING HARB SYM, V60, P127, DOI 10.1101/SQB.1995.060.01.016; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FABBRI M, 1994, J BIOL CHEM, V269, P26848; Herrmann JM, 1999, TRENDS CELL BIOL, V9, P5, DOI 10.1016/S0962-8924(98)01414-7; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cb.11.110195.003333; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee TH, 2000, MOL BIOL CELL, V11, P2577, DOI 10.1091/mbc.11.8.2577; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Nelson WJ, 2000, J CELL BIOL, V149, P243, DOI 10.1083/jcb.149.2.243; Rowe T, 1996, J CELL BIOL, V135, P895, DOI 10.1083/jcb.135.4.895; ROWE T, 1995, METHOD ENZYMOL, V257, P49; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236	28	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35673	35676		10.1074/jbc.C000449200	http://dx.doi.org/10.1074/jbc.C000449200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	11001944	hybrid			2022-12-27	WOS:000165382000005
J	Fischer, S; Graber, P; Turina, P				Fischer, S; Graber, P; Turina, P			The activity of the ATP synthase from Escherichia coli is regulated by the transmembrane proton motive force	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SITE NUCLEOTIDE; MITOCHONDRIAL F1-ATPASE; INHIBITOR PROTEIN; BINDING SITES; DELTA-PH; INORGANIC-PHOSPHATE; COUPLING FACTOR; H+-ATPASE; ADP; HYDROLYSIS	The ATP synthase from Escherichia coli was reconstituted into liposomes from phosphatidylcholine/phosphatidic acid. The proteoliposomes were energized by an acid-base transition and a K+/valinomycin diffusion potential, and one second after energization, the electrochemical proton gradient was dissipated by uncouplers, and the ATP hydrolysis measurement was started. In the presence of ADP and P-i, the initial rate of ATP hydrolysis was up to 9-fold higher with pre-energized proteoliposomes than with proteoliposomes that had not seen an electrochemical proton gradient. After dissipating the electrochemical proton gradient, the high rate of ATP hydrolysis decayed to the rate without preenergization within about 15 s. During this decay the enzyme carried out approximately 100 turnovers. In the absence of ADP and P-i, the rate of ATP hydrolysis was already high and could not be significantly increased by pre-energization. It is concluded that ATP hydrolysis is inhibited when ADP and P-i are bound to the enzyme and that a high Delta<(mu)over tilde>(H)+ is required to release ADP and P-i and to convert the enzyme into a high activity state. This high activity state is metastable and decays slowly when Delta<(mu)over tilde>(H)+ is abolished. Thus, the proton motive force does not only supply energy for ATP synthesis but also regulates the fraction of active enzymes.	Univ Bologna, Dept Biol, Biochem & Biophys Lab, I-40126 Bologna, Italy; Univ Freiburg, Inst Phys Chem, D-79104 Freiburg, Germany	University of Bologna; University of Freiburg	Turina, P (corresponding author), Univ Bologna, Dept Biol, Biochem & Biophys Lab, Via Irnerio 42, I-40126 Bologna, Italy.		Turina, Paola/P-9342-2015; Turina, Paola/GYJ-0656-2022	Turina, Paola/0000-0001-9174-511X; 				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BOKRANZ M, 1985, BIOCHIM BIOPHYS ACTA, V810, P332, DOI 10.1016/0005-2728(85)90218-X; Boyer PD, 1998, BBA-BIOENERGETICS, V1365, P3, DOI 10.1016/S0005-2728(98)00066-8; CARMELI C, 1972, BIOCHIM BIOPHYS ACTA, V267, P86, DOI 10.1016/0005-2728(72)90140-5; CHERNYAK BV, 1992, ARCH BIOCHEM BIOPHYS, V295, P247, DOI 10.1016/0003-9861(92)90514-W; DIPIETRO A, 1986, BIOCHIM BIOPHYS ACTA, V851, P283, DOI 10.1016/0005-2728(86)90136-2; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNHAM KR, 1981, J BIOL CHEM, V256, P44; Fillingame RH, 2000, J EXP BIOL, V203, P9; Fischer S, 1999, FEBS LETT, V457, P327, DOI 10.1016/S0014-5793(99)01060-1; FISCHER S, 1994, EUR J BIOCHEM, V225, P167, DOI 10.1111/j.1432-1033.1994.00167.x; Galkin MA, 1999, FEBS LETT, V448, P123, DOI 10.1016/S0014-5793(99)00347-6; GRABER P, 1977, BIOCHIM BIOPHYS ACTA, V461, P426, DOI 10.1016/0005-2728(77)90231-6; GRABER P, 1984, BER BUNSEN PHYS CHEM, V88, P599, DOI 10.1002/bbpc.19840880706; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V502, P87, DOI 10.1016/0005-2728(78)90134-2; HARRIS DA, 1979, BIOCHIM BIOPHYS ACTA, V548, P72, DOI 10.1016/0005-2728(79)90188-9; HUSAIN I, 1983, FEBS LETT, V160, P110, DOI 10.1016/0014-5793(83)80947-8; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; JUNESCH U, 1987, BIOCHIM BIOPHYS ACTA, V893, P275, DOI 10.1016/0005-2728(87)90049-1; JUNGE W, 1970, EUR J BIOCHEM, V14, P582, DOI 10.1111/j.1432-1033.1970.tb00327.x; KLEEFELD S, 1990, BIOCHIM BIOPHYS ACTA, V1019, P11, DOI 10.1016/0005-2728(90)90119-O; KRAMER DM, 1990, PHOTOSYNTH RES, V26, P213, DOI 10.1007/BF00033134; KRAMER DM, 1989, BIOCHIM BIOPHYS ACTA, V976, P28, DOI 10.1016/S0005-2728(89)80186-0; LIPPE G, 1988, BIOCHIM BIOPHYS ACTA, V933, P12, DOI 10.1016/0005-2728(88)90051-5; Lobau S, 1998, BIOCHEMISTRY-US, V37, P10846, DOI 10.1021/bi9807153; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MILGROM YM, 1990, BIOCHIM BIOPHYS ACTA, V1020, P43, DOI 10.1016/0005-2728(90)90091-H; MILLS JD, 1984, BIOCHIM BIOPHYS ACTA, V764, P93, DOI 10.1016/0005-2728(84)90145-2; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; MORIYAMA Y, 1991, J BIOL CHEM, V266, P22141; MUNEYUKI E, 1991, BIOCHIM BIOPHYS ACTA, V1058, P304, DOI 10.1016/S0005-2728(05)80251-8; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; ORT DR, 1992, ANNU REV PLANT PHYS, V43, P269, DOI 10.1146/annurev.pp.43.060192.001413; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; POPOV N, 1975, ACTA BIOL MED GER, V34, P1441; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; ROSING J, 1976, BIOCHEM BIOPH RES CO, V72, P1, DOI 10.1016/0006-291X(76)90952-9; ROSING J, 1972, BIOCHIM BIOPHYS ACTA, V267, P275, DOI 10.1016/0005-2728(72)90116-8; ROSING J, 1975, BIOCHIM BIOPHYS ACTA, V376, P13, DOI 10.1016/0005-2728(75)90201-7; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SCHLODDER E, 1982, ELECTRON TRANSPORT P, P105; SCHUMANN J, 1981, PHOTOSYNTHESIS, V2, P881; SCHWERZMANN K, 1986, ARCH BIOCHEM BIOPHYS, V250, P1, DOI 10.1016/0003-9861(86)90695-8; SHOSHAN V, 1980, J BIOL CHEM, V255, P996; SLOOTEN L, 1989, BIOCHIM BIOPHYS ACTA, V976, P150, DOI 10.1016/S0005-2728(89)80224-5; SLOOTEN L, 1981, BIOCHIM BIOPHYS ACTA, V638, P305, DOI 10.1016/0005-2728(81)90241-3; Strotmann H., 1984, ADV PHOTOSYNTHESIS R, V2, P477; Tsunoda SP, 2000, FEBS LETT, V470, P244, DOI 10.1016/S0014-5793(00)01336-3; TURINA P, 1991, EUR J BIOCHEM, V196, P225, DOI 10.1111/j.1432-1033.1991.tb15808.x; TURINA P, 1992, J BIOL CHEM, V267, P11057; Vinogradov AD, 2000, J EXP BIOL, V203, P41; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBER J, 1995, J BIOL CHEM, V270, P12653, DOI 10.1074/jbc.270.21.12653; ZHOU JM, 1988, BIOCHEMISTRY-US, V27, P5129, DOI 10.1021/bi00414a027	56	68	72	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30157	30162		10.1074/jbc.275.39.30157	http://dx.doi.org/10.1074/jbc.275.39.30157			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	11001951	hybrid			2022-12-27	WOS:000089577900035
J	Nix, SL; Chishti, AH; Anderson, JM; Walther, Z				Nix, SL; Chishti, AH; Anderson, JM; Walther, Z			hCASK and hDlg associate in epithelia, and their Src homology 3 and guanylate kinase domains participate in both intramolecular and intermolecular interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; TIGHT JUNCTION; GLYCOPHORIN-C; MAGUK FAMILY; MOLECULAR CHARACTERIZATION; BASOLATERAL MEMBRANE; PLASMA-MEMBRANE; SH3 DOMAINS; PDZ DOMAIN; COMPLEX	Membrane associated guanylate kinase (MAGUK) proteins act as molecular scaffolds organizing multiprotein complexes at specialized regions of the plasma membrane. All MAGUKs contain a Src homology 3 (SH3) domain and a region homologous to yeast guanylate kinase (GUK). We showed previously that one MAGUK protein, human CASK (hCASK), is widely expressed and associated with epithelial basolateral plasma membranes. We now report that hCASK binds another MAGUK, human discs large (hDlg). Immunofluorescence microscopy demonstrates that hCASK and hDlg colocalize at basolateral membranes of epithelial cells in small and large intestine. These proteins co-precipitate from lysates of an intestinal cell line, Caco-2, The GUK domain of hCASK binds the SH3 domain of hDlg in both yeast two-hybrid and fusion protein binding assays, and it is required for interaction with hDlg in transfected HEK293 cells. In addition, the SH3 and GUK domains of each protein participate in intramolecular binding that in vitro predominates over intermolecular binding. The SH3 and GUK domains of human p55 display the same interactions in yeast two-hybrid assays as those of hCASK. Not all SH3-GUK interactions among these MAGUKs are permissible, however, implying specificity to SH3-GUK interactions in vivo. These results suggest MAGUK scaffold assembly may be regulated through effects on intramolecular SH3-GUK binding.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Tufts Univ, Div Hematol Res, St Elizabeths Med Ctr, Sch Med, Boston, MA 02135 USA	Yale University; Yale University; Yale University; St. Elizabeth's Medical Center; Tufts University	Walther, Z (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St,1080 LMP,POB 208019, New Haven, CT 06520 USA.		House, Stacey/C-8796-2012	Anderson, James/0000-0003-2765-7996	NATIONAL CANCER INSTITUTE [P01CA066263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007017, P30DK034989] Funding Source: NIH RePORTER; NCI NIH HHS [CA66263] Funding Source: Medline; NIDDK NIH HHS [DK34989, T32DK07017] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLOISIO N, 1993, BLOOD, V82, P1323, DOI 10.1182/blood.V82.4.1323.bloodjournal8241323; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Brenman JE, 1998, J NEUROSCI, V18, P8805; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; Deguchi M, 1998, J BIOL CHEM, V273, P26269, DOI 10.1074/jbc.273.41.26269; Dimitratos SD, 1997, MECH DEVELOP, V63, P127, DOI 10.1016/S0925-4773(97)00668-0; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Hata Y, 1996, J NEUROSCI, V16, P2488; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hsueh YP, 1999, J BIOL CHEM, V274, P532, DOI 10.1074/jbc.274.1.532; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Irie M, 1999, ONCOGENE, V18, P2811, DOI 10.1038/sj.onc.1202652; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KISTNER U, 1995, FEBS LETT, V359, P159, DOI 10.1016/0014-5793(95)00030-D; Kuhlendahl S, 1998, EUR J BIOCHEM, V252, P305, DOI 10.1046/j.1432-1327.1998.2520305.x; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; MARFATIA SM, 1997, MOL BIOL CELL, V8, P292; Masuko N, 1999, J BIOL CHEM, V274, P5782, DOI 10.1074/jbc.274.9.5782; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MAZOYER S, 1995, GENOMICS, V28, P25, DOI 10.1006/geno.1995.1101; McGee AW, 1999, J BIOL CHEM, V274, P17431, DOI 10.1074/jbc.274.25.17431; Metzenberg Aida B., 1992, Human Molecular Genetics, V1, P97, DOI 10.1093/hmg/1.2.97; Montell C, 1999, ANNU REV CELL DEV BI, V15, P231, DOI 10.1146/annurev.cellbio.15.1.231; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Mullins RD, 2000, CURR OPIN CELL BIOL, V12, P91, DOI 10.1016/S0955-0674(99)00061-7; NEITHAMMER M, 1996, J NEUROSCI, V16, P2157; NORTON AJ, 1994, J PATHOL, V173, P371, DOI 10.1002/path.1711730413; RIGGS P, 1994, CURRENT PROTOCOLS MO; ROUSSET M, 1986, BIOCHIMIE, V68, P1035, DOI 10.1016/S0300-9084(86)80177-8; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; SMITH DB, 1994, CURRENT PROTOCOLS MO; Smith SA, 1996, GENOMICS, V31, P145, DOI 10.1006/geno.1996.0025; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Wu HJ, 1998, J CELL SCI, V111, P2365	56	90	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41192	41200		10.1074/jbc.M002078200	http://dx.doi.org/10.1074/jbc.M002078200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10993877	hybrid			2022-12-27	WOS:000166114600072
J	Wang, SK; Gustafson, E; Pang, L; Qiao, XD; Behan, J; Maguire, M; Bayne, M; Laz, T				Wang, SK; Gustafson, E; Pang, L; Qiao, XD; Behan, J; Maguire, M; Bayne, M; Laz, T			A novel hepatointestinal leukotriene B-4 receptor - Cloning and functional characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY BOWEL-DISEASE; POLYMORPHONUCLEAR LEUKOCYTES; BIOLOGICAL-ACTIVITY; HUMAN-NEUTROPHILS; EXPRESSION; INHIBITION; ANTAGONIST; BINDING; LIVER; GENE	Leukotriene B-4 (LTB4) is a product of eicosanoid metabolism and acts as an extremely potent chemotactic mediator for inflammation, LTB4 exerts positive effects on the immigration and activation of leukocytes. These effects suggest an involvement of LTB4 in several diseases: inflammatory bowel disease, psoriasis, arthritis, and asthma. LTB4 elicits actions through interaction with one or more cell surface receptors that lead to chemotaxis and inflammation, One leukotriene B-4 receptor-has been recently identified (LTB4-R1). In this report we describe cloning of a cDNA encoding a novel 358-amino acid receptor (LTB4-R2) that possesses seven membrane-spanning domains and is homologous (42%) and genetically linked to LTB4-R1. Expression of LTB4-R2 is broad but highest in liver, intestine, spleen, and kidney. In radioligand binding assays, membranes prepared from COS-7 cells transfected with LTB4-R2 cDNA displayed high affinity (K-d = 0.17 nM) for [H-3]LTB4. Radioligand competition assays revealed high affinities of the receptor for LTB4 and LTB5, and 20-hydroxy-LTB4, and intermediate affinities for 15(5)HETE and 12-oxo-ETE. Three LTB, receptor antagonistst 14,15-dehydro-LTB4, LTB4-3-aminopropylamide, and U-75302, had high affinity for LTB4-R1 but not for LTB4-R2. No apparent affinity binding for the receptors was detected for the CysLT1-selective antagonists montelukast and zafirlukast. LTB, functionally mobilized intracellular calcium and inhibited forskolin-stimulated cAMP production in 293 cells. The discovery of this new receptor should aid in further understanding the roles of LTB, in pathologies in these tissues and may provide a tool in identification of specific antagonists/ agonists for potential therapeutic treatments.	Schering Plough Corp, Inst Res, Kenilworth, NJ 07033 USA	Merck & Company; Schering Plough Corporation	Wang, SK (corresponding author), Schering Plough Corp, Inst Res, 2015 Galloping Hill Rd,K15-E119, Kenilworth, NJ 07033 USA.	suke.wang@spcorp.com						ASANO F, 1993, J GASTROEN HEPATOL, V8, P228, DOI 10.1111/j.1440-1746.1993.tb01191.x; BORGEAT P, 1990, CLIN BIOCHEM, V23, P459, DOI 10.1016/0009-9120(90)90272-V; BRACH MA, 1992, EUR J IMMUNOL, V22, P2705, DOI 10.1002/eji.1830221034; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; CHENG JB, 1986, J PHARMACOL EXP THER, V236, P126; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLANCY RM, 1984, P NATL ACAD SCI-BIOL, V81, P5729, DOI 10.1073/pnas.81.18.5729; DAHINDEN CA, 1984, J IMMUNOL, V133, P1477; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; DOI F, 1993, HEPATOLOGY, V17, P1086, DOI 10.1016/0270-9139(93)90127-9; GOLDMAN DW, 1987, FASEB J, V46, P200; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HUGHES H, 1992, PROSTAG LEUKOTR ESS, V45, P113, DOI 10.1016/0952-3278(92)90226-9; Jackson W T, 1996, Prog Drug Res, V46, P115; Jackson WT, 1999, J PHARMACOL EXP THER, V288, P286; Kasirga E, 1999, TURKISH J PEDIATR, V41, P457; KISHIKAWA K, 1992, PROSTAGLANDINS, V44, P261, DOI 10.1016/0090-6980(92)90002-B; LEVINE JD, 1984, SCIENCE, V225, P743, DOI 10.1126/science.6087456; LIN AH, 1988, ANN NY ACAD SCI, V524, P196, DOI 10.1111/j.1749-6632.1988.tb38542.x; LOBOS EA, 1987, DIGEST DIS SCI, V32, P1380, DOI 10.1007/BF01296664; Lynch KR, 1999, NATURE, V399, P789; Nagata K, 1999, J IMMUNOL, V162, P1278; Nakao A, 1997, KIDNEY INT, pS236; NANJI AA, 1993, ALCOHOL, V10, P443, DOI 10.1016/0741-8329(93)90062-S; Noiri E, 2000, P NATL ACAD SCI USA, V97, P823, DOI 10.1073/pnas.97.2.823; Raport CJ, 1996, J LEUKOCYTE BIOL, V59, P18, DOI 10.1002/jlb.59.1.18; ROHRER L, 1993, P NATL ACAD SCI USA, V90, P4196, DOI 10.1073/pnas.90.9.4196; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; SEGGEV JS, 1995, ANN ALLERG ASTHMA IM, V75, P365; SHAAFI RI, 1981, J CELL PHYSIOL, V108, P401, DOI 10.1002/jcp.1041080314; SHARON P, 1984, GASTROENTEROLOGY, V86, P453; SHIMAZAKI T, 1990, PROSTAGLANDINS, V39, P459, DOI 10.1016/0090-6980(90)90126-G; Showell HJ, 1998, J PHARMACOL EXP THER, V285, P946; SMITH MJH, 1980, J PHARM PHARMACOL, V32, P517, DOI 10.1111/j.2042-7158.1980.tb12985.x; STANKOVA J, 1992, BIOCHEM J, V282, P625; TAYLOR BM, 1991, PROSTAG OTH LIPID M, V42, P211, DOI 10.1016/0090-6980(91)90111-R; Urade M, 1996, HEPATOLOGY, V23, P544; Weringer EJ, 1999, TRANSPLANTATION, V67, P808, DOI 10.1097/00007890-199903270-00005; YAMAMOTO S, 1993, PROSTAGLANDINS, V45, P527, DOI 10.1016/0090-6980(93)90016-Z; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; YOUNG RN, 1983, PROSTAGLANDINS, V26, P605, DOI 10.1016/0090-6980(83)90197-1	42	59	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40686	40694		10.1074/jbc.M004512200	http://dx.doi.org/10.1074/jbc.M004512200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11006272	hybrid			2022-12-27	WOS:000166114600006
J	Inoue, S; Tanaka, K; Arisaka, F; Kimura, S; Ohtomo, K; Mizuno, S				Inoue, S; Tanaka, K; Arisaka, F; Kimura, S; Ohtomo, K; Mizuno, S			Silk fibroin of Bombyx mori is secreted, assembling a high molecular mass elementary unit consisting of H-chain, L-chain, and P25, with a 6 : 6 : 1 molar ratio	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; AMINO-ACID-SEQUENCE; ENDOPLASMIC-RETICULUM; SUBUNIT COMBINATION; IGM POLYMERIZATION; LIGHT-CHAINS; CELL-SURFACE; TRANSPORT; PROTEIN; IDENTIFICATION	Silk fibroin produced by the silkworm Bombyx mori consists of a heavy chain, a light chain, and a glycoprotein, P25. The heavy and light chains are linked by a disulfide bond, and P25 associates with disulfide-linked heavy and light chains by noncovalent interactions. Quantitative enzyme-linked immunosorbent assay revealed that molar ratios of the heavy chain, light chain, and P25 were 6:6:1, both in cocoons and in fibroin secreted into the lumen of posterior silk gland. Trace amounts of fibroin produced by three "naked pupa" mutants of B. mori lacked the light chain, but the molar ratio of heavy chain and P25 was also 6:1. Gel filtration chromatography and sedimentation equilibrium analysis demonstrated that a large protein complex of approximately 2.3 MDa, designated an elementary unit of fibroin having 6:6:1 molar ratios of the heavy chain, light chain, and P25, existed in posterior silk gland cells. Inaccessibility of biotinylated concanavalin A to the native elementary unit and partial dissociation of the elementary unit after incubation with excess N-glycosidase F or endoglycosidase H suggest that a single molecule of P25 is located internally and plays an important role in maintaining integrity of the complex.	Tohoku Univ, Grad Sch Agr Sci, Dept Mol & Cell Biol, Mol Biol Lab,Aoba Ku, Sendai, Miyagi 9818555, Japan; Tokyo Inst Technol, Dept Life Sci, Fac Biosci & Bioengn, Yokohama, Kanagawa 2268501, Japan; Chiba Univ, Fac Sci, Dept Biol, Chiba 2638522, Japan	Tohoku University; Tokyo Institute of Technology; Chiba University	Mizuno, S (corresponding author), Nihon Univ, Coll Bioresource Sci, Dept Agr & Biol Chem, 1866 Kameino, Fujisawa, Kanagawa, Japan.	s-mizuno@brs.nihon-u.ac.jp						AKAI H, 1971, EXP CELL RES, V69, P219, DOI 10.1016/0014-4827(71)90329-6; *APPL BIOS INC, 1985, APPL BIOS US B, V14, P23; BORNEMANN KD, 1995, P NATL ACAD SCI USA, V92, P4912, DOI 10.1073/pnas.92.11.4912; BRENCKLE R, 1980, ARCH BIOCHEM BIOPHYS, V201, P160, DOI 10.1016/0003-9861(80)90499-3; Cals MM, 1996, MOL IMMUNOL, V33, P15, DOI 10.1016/0161-5890(95)00132-8; CHEVILLARD M, 1986, NUCLEIC ACIDS RES, V14, P6341, DOI 10.1093/nar/14.15.6341; Chevillard M., 1986, SERICOLOGIA, V26, P435; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; COUBLE P, 1987, DEV BIOL, V124, P431, DOI 10.1016/0012-1606(87)90496-9; de Lalla C, 1998, MOL IMMUNOL, V35, P837, DOI 10.1016/S0161-5890(98)00073-X; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FAYE L, 1986, EUR J BIOCHEM, V158, P655, DOI 10.1111/j.1432-1033.1986.tb09803.x; GAMO T, 1985, Journal of Sericultural Science of Japan, V54, P412; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; HYODO A, 1980, JPN J GENET, V55, P297, DOI 10.1266/jjg.55.297; Isidoro C, 1996, J BIOL CHEM, V271, P26138, DOI 10.1074/jbc.271.42.26138; KALB AJ, 1968, BIOCHIM BIOPHYS ACTA, V168, P366, DOI 10.1016/0005-2795(68)90161-X; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; MACHAMER CE, 1985, MOL CELL BIOL, V5, P3074, DOI 10.1128/MCB.5.11.3074; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MARUYAMA K, 1984, J BIOCHEM, V95, P1423, DOI 10.1093/oxfordjournals.jbchem.a134750; MORI K, 1995, J MOL BIOL, V251, P217, DOI 10.1006/jmbi.1995.0429; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; OYAMA F, 1984, J BIOCHEM, V96, P1689, DOI 10.1093/oxfordjournals.jbchem.a135001; Reddy PS, 1998, BIOESSAYS, V20, P546, DOI 10.1002/(SICI)1521-1878(199807)20:7<546::AID-BIES5>3.0.CO;2-I; ROBBINS PW, 1984, J BIOL CHEM, V259, P7577; SHIMURA K, 1982, Journal of Sericultural Science of Japan, V51, P20; SHIMURA K, 1983, EXPERIENTIA, V39, P455, DOI 10.1007/BF01965160; TAKEI F, 1984, JPN J GENET, V59, P307, DOI 10.1266/jjg.59.307; TAKEI F, 1984, J CELL BIOL, V99, P2005, DOI 10.1083/jcb.99.6.2005; TAKEI F, 1987, J CELL BIOL, V105, P175, DOI 10.1083/jcb.105.1.175; TANAKA K, 1993, J BIOCHEM-TOKYO, V114, P1; Tanaka K, 1999, BBA-PROTEIN STRUCT M, V1432, P92, DOI 10.1016/S0167-4838(99)00088-6; Tanaka K, 1999, INSECT BIOCHEM MOLEC, V29, P269, DOI 10.1016/S0965-1748(98)00135-0; TARENTINO AL, 1990, J BIOL CHEM, V265, P6961; WANG JL, 1971, P NATL ACAD SCI USA, V68, P1130, DOI 10.1073/pnas.68.6.1130; WORMALD MR, 1991, EUR J BIOCHEM, V198, P131, DOI 10.1111/j.1432-1033.1991.tb15995.x; YAMAGUCHI K, 1989, J MOL BIOL, V210, P127, DOI 10.1016/0022-2836(89)90295-7; Yamamoto K, 1998, METH MOL B, V76, P35; YAMAMOTO K, 1981, BIOCHEMISTRY-US, V20, P5894, DOI 10.1021/bi00523a037; Zurovec M, 1998, J BIOL CHEM, V273, P15423, DOI 10.1074/jbc.273.25.15423	43	478	533	5	128	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40517	40528		10.1074/jbc.M006897200	http://dx.doi.org/10.1074/jbc.M006897200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10986287	hybrid			2022-12-27	WOS:000166039500097
J	Pratta, MA; Tortorella, MD; Arner, EC				Pratta, MA; Tortorella, MD; Arner, EC			Age-related changes in aggrecan glycosylation affect cleavage by aggrecanase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SYNOVIAL-FLUID; INTERGLOBULAR DOMAIN; ARTICULAR-CARTILAGE; ADAMTS FAMILY; CATABOLISM; PROTEOGLYCAN; DEGRADATION; FRAGMENTS; SITE; IDENTIFICATION	Aggrecan degradation involves proteolytic cleavage of the core protein within the interglobular domain. Because aggrecan is highly glycosylated with chondroitin sulfate (CS) and keratan sulfate (KS), we investigated whether glycosylation affects digestion by aggrecanase at the Glu(373)-Ala(374) bond. Treatment of bovine aggrecan monomers to remove CS and BS resulted in loss of cleavage at this site, suggesting that glycosaminoglycans (GAGs) play a role in cleavage at the Glu(373)-Ala(374) bond. In contrast, MMP3 cleavage at the Ser(341)-Phe(342) bond was not affected by glycosidase treatment of aggrecan. Removal of KS, but not CS, prevented cleavage at the Glu(373)-Ala(374) bond. Thus, KS residues may be important for recognition of this cleavage site by aggrecanase. KS glycosylation has been observed at sites adjacent to the Glu(373)-Ala(374) bond in steer aggrecan, but not in calf aggrecan (Barry, F. P., Rosenberg, L. C., Gaw, J. U., Gaw, J. U., Koob, T. J., and Neame, P. J. (1995) J. Biol. Chem. 270, 20516-20524). Interestingly, although we found that aggrecanase degraded both calf and steer cartilage aggrecan, the proportion of fragments generated by cleavage at the Glu(373)-Ala(374) bond was higher in steer than in calf, consistent with our observations using aggrecan treated to remove BS. me conclude that the GAG content of aggrecan influences the specificity of aggrecanase for cleavage at the Glu(373)-Ala(374) bond and suggest that age may be a factor in aggrecanase degradation of cartilage.	Dupont Merck Pharmaceut Co, Expt Stn E400 4237, Inflammatory Dis Res, Wilmington, DE 19880 USA	DuPont	Pratta, MA (corresponding author), Dupont Merck Pharmaceut Co, Expt Stn E400 4237, Inflammatory Dis Res, POB 80400, Wilmington, DE 19880 USA.	Michael.A.Pratta@dupontpharma.com						Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Arner EC, 1999, ANN NY ACAD SCI, V878, P92, DOI 10.1111/j.1749-6632.1999.tb07676.x; Arner EC, 1998, OSTEOARTHR CARTILAGE, V6, P214, DOI 10.1053/joca.1998.0114; Arner EC, 1999, J BIOL CHEM, V274, P6594, DOI 10.1074/jbc.274.10.6594; BARRY FP, 1995, J BIOL CHEM, V270, P20516, DOI 10.1074/jbc.270.35.20516; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; FOSANG AJ, 1995, BIOCHEM J, V310, P337, DOI 10.1042/bj3100337; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; HARDINGHAM TE, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P5; HASCALL VC, 1982, METHOD ENZYMOL, V82, P769; HUANG JJ, 1987, MOL BIOL MED, V4, P169; Hughes CE, 1997, J BIOL CHEM, V272, P20269, DOI 10.1074/jbc.272.32.20269; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; HUTTON S, 1996, T ORTHOP RES SOC, V21, P150; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; MANKIN HJ, 1970, J BONE JOINT SURG AM, VA 52, P424, DOI 10.2106/00004623-197052030-00002; MARCY AI, 1991, BIOCHEMISTRY-US, V30, P6476, DOI 10.1021/bi00240a018; Mercuri FA, 1999, J BIOL CHEM, V274, P32387, DOI 10.1074/jbc.274.45.32387; OIKE Y, 1980, BIOCHEM J, V191, P203, DOI 10.1042/bj1910203; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; Sandy JD, 1995, ACTA ORTHOP SCAND, V66, P26, DOI 10.3109/17453679509157643; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; SANDY JD, 1991, J BIOL CHEM, V266, P8198; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; XUE CB, 1997, Patent No. 9718207	35	66	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39096	39102		10.1074/jbc.M006201200	http://dx.doi.org/10.1074/jbc.M006201200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10991945	hybrid			2022-12-27	WOS:000165953100022
J	Filipenko, NR; Waisman, DM				Filipenko, NR; Waisman, DM			Characterization of the Ca2+-binding sites of annexin II tetramer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BINDING PROTEIN; DIRECTED MUTAGENESIS; PLASMINOGEN; ACTIVATION; CALPACTIN; CALCIUM; ACTIN	Annexin II heterotetramer (AIIt) is a multifunctional Ca2+-binding protein composed of two 11-kDa subunits and two annexin II subunits, The annexin II subunit contains three type II and two type III Ca2+-binding sites which are thought to regulate the interaction of AIIt with anionic phospholipid, F-actin, and heparin, In the present study we utilized site-directed mutagenesis to create AIIt mutants with inactive type III (TM AIIt), type II (CM AIIt), and both type II and III Ca2+-binding sites (TCM AIIt), Surprisingly, we found that in the presence of Ca2+, the TM, CM, and TCM AIIt bound phospholipid and F-actin with similar affinity to the wild type AIIt (WT AIIt). Furthermore, the TCM mutant, and to a lesser extent the TM and CM AIIt displayed dose-dependent Ca2+-independent phospholipid aggregation and binding. While the TM and CM AIIt demonstrated Ca2+-dependent binding to F-actin, the binding of the TCM AIIt was Ca2+-independent. These results suggest that the type II or type III Ca2+-binding sites do not directly participate in anionic phospholipid or F-actin binding, We therefore propose that in the absence of Ca2+, the type II and type III Ca2+-binding sites of AIIt stabilize a conformation of AIIt that is unfavorable for binding phospholipid and F-actin, Ca2+ binding to these sites, or the inactivation of these Ca2+-binding sites by site-directed mutagenesis, results in a conformational change that promotes binding to anionic phospholipid and F-actin. Since the TM, CM, and TCM AIIt require Ca2+ for binding to heparin, we also propose that novel Ca2+-binding sites regulate this binding event.	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Waisman, DM (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Waisman, David/0000-0002-5097-9662	NATIONAL CANCER INSTITUTE [R01CA078639] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA78639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Donnelly SR, 1997, CELL MOL LIFE SCI, V53, P533, DOI 10.1007/s000180050068; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; FOLLENIUSWUND A, 1993, BIOCHEM MOL BIOL INT, V29, P653; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; JOST M, 1992, EUR J BIOCHEM, V207, P923, DOI 10.1111/j.1432-1033.1992.tb17125.x; JOST M, 1994, BIOCHEM J, V298, P553, DOI 10.1042/bj2980553; Kang HM, 1997, BIOCHEMISTRY-US, V36, P2041, DOI 10.1021/bi962569b; Kassam G, 1997, J BIOL CHEM, V272, P15093, DOI 10.1074/jbc.272.24.15093; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; MOSS SE, 1995, NATURE, V378, P446, DOI 10.1038/378446a0; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; REGNOUF F, 1991, J NEUROCHEM, V56, P1985, DOI 10.1111/j.1471-4159.1991.tb03457.x; Siever DA, 1997, INT J BIOCHEM CELL B, V29, P1219, DOI 10.1016/S1357-2725(97)00057-5; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; SWAIRJO MA, 1994, ANNU REV BIOPH BIOM, V23, P193, DOI 10.1146/annurev.bb.23.060194.001205; THIEL C, 1991, J BIOL CHEM, V266, P14732; THIEL C, 1991, FEBS LETT, V285, P59, DOI 10.1016/0014-5793(91)80724-H; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; WENG XW, 1993, PROTEIN SCI, V2, P448	24	14	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38877	38884		10.1074/jbc.M004125200	http://dx.doi.org/10.1074/jbc.M004125200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10980196	hybrid			2022-12-27	WOS:000165739800100
J	Liochev, SI; Fridovich, I				Liochev, SI; Fridovich, I			Copper- and zinc-containing superoxide dismutase can act as a superoxide reductase and a superoxide oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; ESCHERICHIA-COLI; PULSE RADIOLYSIS; CU,ZN-SUPEROXIDE DISMUTASE; ENZYME; SENSITIVITY; MECHANISM	The copper- and zinc-containing superoxide dismutase can catalyze the oxidation of ferrocyanide by O-2(.-) as well as the reduction of ferricyanide by O-2(.-) Thus, it can act as a superoxide dismutase (SOD), a superoxide reductase (SOR), and a superoxide oxidase (SOO). The human manganese-containing SOD does not exert SOR or SOO activities with ferrocyanide or ferricyanide as the redox partners. It is possible that some biological reductants can take the place of ferrocyanide and can also interact with human manganese-containing superoxide dismutase, thus making the SOR activity a reality for both SODs. The consequences of this possibility vis a vis H2O2 production, the overproduction of SODs, and the role of copper- and zinc-containing superoxide dismutase mutations in causing familial amyotrophic lateral sclerosis are discussed, as well as the likelihood that the biologically effective SOD mimics, as described to date, actually function as SORs.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Fridovich, I (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.							AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; FRIDOVICH I, 1958, J BIOL CHEM, V233, P1581; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; Jovanovic T, 2000, J BIOL CHEM, V275, P28439, DOI 10.1074/jbc.M003314200; KEELE BB, 1970, J BIOL CHEM, V245, P6176; KLUG D, 1972, J BIOL CHEM, V247, P4839; Liochev SI, 1997, J BIOL CHEM, V272, P25573, DOI 10.1074/jbc.272.41.25573; Lombard M, 2000, J BIOL CHEM, V275, P27021; Lombard M, 2000, J BIOL CHEM, V275, P115, DOI 10.1074/jbc.275.1.115; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Offer T, 2000, FASEB J, V14, P1215, DOI 10.1096/fasebj.14.9.1215; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P465, DOI 10.1016/0891-5849(90)90123-Z; ROTILIO G, 1973, BIOCHIM BIOPHYS ACTA, V302, P229, DOI 10.1016/0005-2744(73)90151-4; ROTILIO G, 1972, BIOCHIM BIOPHYS ACTA, V268, P605, DOI 10.1016/0005-2744(72)90359-2; SCHELLENBERG KA, 1958, J BIOL CHEM, V231, P547; SCOTT MD, 1989, J BIOL CHEM, V264, P2498; WAUD WR, 1975, ARCH BIOCHEM BIOPHYS, V169, P695, DOI 10.1016/0003-9861(75)90214-3; YOST FJ, 1973, J BIOL CHEM, V248, P4905; Youn HD, 1996, BIOCHEM J, V318, P889, DOI 10.1042/bj3180889; ZEHAVI D, 1972, J PHYS CHEM-US, V76, P3703, DOI 10.1021/j100669a006	23	78	79	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38482	38485		10.1074/jbc.M007891200	http://dx.doi.org/10.1074/jbc.M007891200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11005823	hybrid			2022-12-27	WOS:000165739800047
J	Nakayama, Y; Peng, T; Sands, JM; Bagnasco, SM				Nakayama, Y; Peng, T; Sands, JM; Bagnasco, SM			The TonE/TonEBP pathway mediates tonicity-responsive regulation of UT-A urea transporter expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDOSE REDUCTASE GENE; TRANSCRIPTION; CLONING; RAT; STRESS; INDUCTION; ELEMENT	The rat renal urea transporter UT-A includes four isoforms. UT-A1, UT-A3, and UT-A4 are transcribed from a single initiation site at the 5'-end of the gene; a distinct internal initiation site is used for UT-A2 transcription. We cloned 1.3 kilobases (kb) of the 5'-flanking region upstream of the transcription start site of UT-A1, UT-A3, and UT-A4. This region contains three CCAAT sequences but lacks a TATA motif, A tonicity-responsive enhancer (TonE) was identified at -377bp. The 1.3-kb full fragment subcloned into pGL3 vector induced luciferase activity in Madin-Darby canine kidney cells and in mouse inner medullary collecting duct cells in isotonic medium. Luciferase activity was increased significantly in hypertonic medium, whereas deletion or mutation of the TonE sequence abolished this response. Electrophoretic mobility shift assay using the 5' UT-A TonE sequence as DNA probe showed formation of a specific DNA-protein complex with nuclear extracts from cells exposed to hypertonic medium and was weakly detectable in isotonic controls. A supershift in the mobility of the DNA-protein complex was observed with antiserum targeted to the TonE-binding protein (TonEBP). Cotransfection with dominant-negative TonEBP abolished the luciferase activity induced by the UT-A 1.3-kb construct under hypertonic and isotonic conditions. These data suggest that the TonE/TonEBP pathway mediates tonicity-responsive transcriptional regulation of UT-A1, UT-A3, and UT-A4 expression.	Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Div Renal, Dept Med, Atlanta, GA 30322 USA	Emory University; Emory University	Bagnasco, SM (corresponding author), Emory Univ, Sch Med, Dept Pathol, WMB Rm 7105 A,1639 Pierce Dr NE, Atlanta, GA 30322 USA.				NIDDK NIH HHS [P01DK50268, R01DK41707, R01DK53917, R01 DK041707] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041707, R01DK053917, P01DK050268] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGNASCO S, 1986, J BIOL CHEM, V261, P5872; Bagnasco SM, 2000, J AM SOC NEPHROL, V11, P1980, DOI 10.1681/ASN.V11111980; BAGNASCO SM, 1987, P NATL ACAD SCI USA, V84, P1718, DOI 10.1073/pnas.84.6.1718; CHA JH, 1999, J AM SCO NEPHROL, V10, pA51; Ferraris JD, 1996, J BIOL CHEM, V271, P18318, DOI 10.1074/jbc.271.31.18318; Furuno M, 1996, AM J PHYSIOL-RENAL, V271, pF854, DOI 10.1152/ajprenal.1996.271.4.F854; HAND SC, 1982, J BIOL CHEM, V257, P734; Karakashian A, 1999, J AM SOC NEPHROL, V10, P230; Leroy C, 2000, BIOCHEM BIOPH RES CO, V271, P368, DOI 10.1006/bbrc.2000.2640; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Miyakawa H, 1998, AM J PHYSIOL-RENAL, V274, pF753, DOI 10.1152/ajprenal.1998.274.4.F753; Rim JS, 1998, J BIOL CHEM, V273, P20615, DOI 10.1074/jbc.273.32.20615; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; Shayakul C, 1996, J CLIN INVEST, V98, P2580, DOI 10.1172/JCI119077; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; SMITH CP, 1995, J CLIN INVEST, V96, P1556, DOI 10.1172/JCI118194; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; Tian W, 2000, AM J PHYSIOL-CELL PH, V278, pC372, DOI 10.1152/ajpcell.2000.278.2.C372; UCHIDA S, 1993, J CLIN INVEST, V91, P1604, DOI 10.1172/JCI116367; Woo SK, 2000, AM J PHYSIOL-CELL PH, V278, pC323, DOI 10.1152/ajpcell.2000.278.2.C323; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; YAMNAUCHI A, 1993, AM J PHYSIOL, V264, pF20; Zhang Z, 1999, AM J PHYSIOL-RENAL, V276, pF786, DOI 10.1152/ajprenal.1999.276.5.F786	23	113	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38275	38280		10.1074/jbc.M004678200	http://dx.doi.org/10.1074/jbc.M004678200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10995747	hybrid			2022-12-27	WOS:000165739800021
J	Schmauss, C				Schmauss, C			A single dose of methamphetamine leads to a long term reversal of the blunted dopamine D-1 receptor-mediated neocortical c-fos responses in mice deficient for D-2 and D-3 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSYCHOMOTOR STIMULANT; MESSENGER-RNA; D1 RECEPTORS; EXPRESSION; FOREBRAIN; HALOPERIDOL; CLOZAPINE; LACKING; DRUGS	Dopamine D-1 receptors play an essential role in the induction of expression of the immediate-early gene c-fos in response to pharmacological stimuli. In the forebrain of wild-type mice, administration of a D-1 receptor agonist leads to c-fos mRNA expression levels that are substantially higher than corresponding levels expressed after indirect stimulation of dopamine receptors with methamphetamine. In mice deficient for D-2 and D-3 receptors, c-fos mRNA levels expressed in response to D-1 agonist administration are significantly blunted. However, a single dose of methamphetamine (5 mg/kg) leads to a long lasting reversal of the blunted c-fos responses in these mutants, In the forebrain, this reversal is restricted to the neocortex. Moreover, methamphetamine also enhances c-fos expression levels in preadolescent wild-type mice that normally express low c-fos mRNA in response to D-1 agonist stimulation. Thus, a single dose of methamphetamine leads to a long term increase in D-1 receptor-dependent c-fos responses in brains with either low (preadolescent mice) or blunted (adult D-2 and D-3 mutant mice) c-fos expression levels. A similar long term reversal of the blunted c-fos responses is achieved with a single dose of a full D-1 agonist. These results indicate that the constitutive inactivation of D-2 and D-3 receptors leads to a decrease in agonist-promoted D-1 receptor activity that can be reversed by intermittent agonist stimulation.	Columbia Univ, NYSPI, Dept Psychiat & Neurosci, New York, NY 10032 USA; New York State Psychiat Inst, New York, NY 10032 USA	Columbia University; New York State Psychiatry Institute	Schmauss, C (corresponding author), Columbia Univ, NYSPI, Dept Psychiat & Neurosci, 1051 Riverside Dr,Box 42, New York, NY 10032 USA.				NIMH NIH HHS [MH56123] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH056123] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BALK JH, 1995, NATURE, V377, P424; Castner SA, 2000, SCIENCE, V287, P2020, DOI 10.1126/science.287.5460.2020; Curran EJ, 1996, NEUROCHEM RES, V21, P1425, DOI 10.1007/BF02532384; Fields RD, 1997, J NEUROSCI, V17, P7252; Harlan RE, 1998, MOL NEUROBIOL, V16, P221, DOI 10.1007/BF02741385; Jung MY, 1999, J BIOL CHEM, V274, P29406, DOI 10.1074/jbc.274.41.29406; Jung MY, 1999, NEUROSCIENCE, V91, P911, DOI 10.1016/S0306-4522(98)00705-2; MERCHANT KM, 1994, J PHARMACOL EXP THER, V271, P460; Moratalla R, 1996, P NATL ACAD SCI USA, V93, P14928, DOI 10.1073/pnas.93.25.14928; Okubo Y, 1997, NATURE, V385, P634, DOI 10.1038/385634a0; ROBERTSON GS, 1992, NEUROSCIENCE, V46, P315, DOI 10.1016/0306-4522(92)90054-6; SCHMAUSS C, 1989, NUCLEIC ACIDS RES, V17, P1733, DOI 10.1093/nar/17.4.1733; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; Vanderschuren LJMJ, 1999, J NEUROSCI, V19, P9579, DOI 10.1523/jneurosci.19-21-09579.1999; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0; Xu M, 1997, NEURON, V19, P837, DOI 10.1016/S0896-6273(00)80965-4	16	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38944	38948		10.1074/jbc.M005064200	http://dx.doi.org/10.1074/jbc.M005064200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11007776	hybrid			2022-12-27	WOS:000165739800109
J	Vujcic, S; Halmekyto, M; Diegelman, P; Gan, G; Kramer, DL; Janne, J; Porter, CW				Vujcic, S; Halmekyto, M; Diegelman, P; Gan, G; Kramer, DL; Janne, J; Porter, CW			Effects of conditional overexpression of spermidine/spermine N-1-acetyltransferase on polyamine pool dynamics, cell growth, and sensitivity to polyamine analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE DECARBOXYLASE; SPERMINE N-1-ACETYLTRANSFERASE; IRREVERSIBLE INHIBITION; ORNITHINE DECARBOXYLASE; INDUCED INCREASES; GENE-EXPRESSION; MELANOMA-CELLS; L1210 CELLS; N1-ACETYLTRANSFERASE; DERIVATIVES	Acetylation of polyamines by spermidine/spermine N-1-acetyltransferase (SSAT) has been implicated in their degradation and/or export out of the cell, The relationship of SSAT to polyamine pool dynamics and cell growth is not yet clearly understood. MCF-7 human breast carcinoma cells were transfected with tetracycline-regulated (Tet-off) SSAT human cDNA or murine gene. Doxycycline removal for >2 days caused a similar to 20-fold increase in SSAT RNA and a similar to 10-fold increase in enzyme activity. After 4 days, intracellular putrescine and spermidine pools were markedly lowered, and cell growth was inhibited, Growth inhibition could not be prevented with exogenous polyamines due to a previously unrecognized ability of SSAT to rapidly acetylate influxing polyamines and thereby prevent restoration of the endogenous pools. Instead, cells accumulated high levels of N-1-acetylspermidine, N-1-acetylspermine, and N-1,N-12-diacetylspermine, a metabolite not previously reported in mammalian cells. Doxycycline deprivation before treatment with N-1,N-11-diethylnorspermine markedly increased analog induction of SSAT mRNA and activity and enhanced growth sensitivity to the analog by similar to 100-fold. Overall, the findings demonstrate that conditional overexpression of SSAT lowers polyamine pools, inhibits cell growth and markedly enhances growth sensitivity to certain analogs, The enzyme also plays a remarkably efficient role in maintaining polyamine pool homeostasis during challenges with exogenous polyamines.	Roswell Pk Canc Inst, Grace Canc Drug Ctr, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Porter, CW (corresponding author), Roswell Pk Canc Inst, Grace Canc Drug Ctr, Elm & Carlton Sts, Buffalo, NY 14263 USA.				NCI NIH HHS [CA16056, CA76428, CA22153] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076428, R01CA022153, P30CA016056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alhonen L, 1998, J BIOL CHEM, V273, P1964, DOI 10.1074/jbc.273.4.1964; ALHONENHONGISTO L, 1982, FEBS LETT, V145, P82; BERGERON RJ, 1994, J MED CHEM, V37, P3464, DOI 10.1021/jm00047a004; Bergeron RJ, 1997, J MED CHEM, V40, P1475, DOI 10.1021/jm960849j; BEY P, 1985, J MED CHEM, V28, P1, DOI 10.1021/jm00379a001; BOLKENIUS FN, 1981, INT J BIOCHEM, V13, P287, DOI 10.1016/0020-711X(81)90080-X; CASERO RA, 1990, BIOCHEM J, V270, P615, DOI 10.1042/bj2700615; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; COLEMAN CS, 1995, BIOCHEMISTRY-US, V34, P13423, DOI 10.1021/bi00041a020; DANZIN C, 1990, BIOCHEM PHARMACOL, V40, P1499, DOI 10.1016/0006-2952(90)90446-R; ERWIN BG, 1986, BIOCHEM J, V238, P581, DOI 10.1042/bj2380581; FogelPetrovic M, 1996, BIOCHEMISTRY-US, V35, P14436, DOI 10.1021/bi9612273; FOGELPETROVIC M, 1993, BIOCHIM BIOPHYS ACTA, V1216, P255, DOI 10.1016/0167-4781(93)90152-4; FogelPetrovic M, 1996, FEBS LETT, V391, P89, DOI 10.1016/0014-5793(96)00710-7; FOGELPETROVIC M, 1993, J BIOL CHEM, V268, P19118; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; HESSELS J, 1990, BIOCHEM J, V266, P843; HIRAMATSU K, 1995, J BIOCHEM-TOKYO, V117, P107, DOI 10.1093/oxfordjournals.jbchem.a124694; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; KRAMER DL, 1989, BIOCHEM J, V259, P325, DOI 10.1042/bj2590325; LIBBY PR, 1991, ARCH BIOCHEM BIOPHYS, V284, P238, DOI 10.1016/0003-9861(91)90291-P; LIBBY PR, 1987, BIOCHEM BIOPH RES CO, V144, P528, DOI 10.1016/S0006-291X(87)80541-7; LIBBY PR, 1989, BIOCHEM PHARMACOL, V38, P1435, DOI 10.1016/0006-2952(89)90182-2; LIBBY PR, 1989, CANCER RES, V49, P6226; MAMONT PS, 1978, BIOCHEM BIOPH RES CO, V81, P58, DOI 10.1016/0006-291X(78)91630-3; McCloskey DE, 1999, J BIOL CHEM, V274, P6175, DOI 10.1074/jbc.274.10.6175; McCloskey DE, 2000, J BIOL CHEM, V275, P28708, DOI 10.1074/jbc.M004120200; NOTARANGELO A, 1997, FOCUS, V19, P58; PARRY L, 1995, BIOCHEMISTRY-US, V34, P2701, DOI 10.1021/bi00008a038; PARRY L, 1995, BIOCHEM J, V305, P451, DOI 10.1042/bj3050451; PEGG AE, 1989, J BIOL CHEM, V264, P11744; Pietila M, 1997, J BIOL CHEM, V272, P18746, DOI 10.1074/jbc.272.30.18746; Porter C. W., 1992, V62, P301; PORTER CW, 1991, CANCER RES, V51, P3715; QUEMENER V, 1992, ANTICANCER RES, V12, P1447; REGENASS U, 1994, CANCER RES, V54, P3210; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; SHAPPELL NW, 1992, ANTICANCER RES, V12, P1083; TAMARA A, 1995, CANCER RES, V55, P3500; VARGIU C, 1994, FEBS LETT, V355, P163, DOI 10.1016/0014-5793(94)01183-4; Woolridge DP, 1999, BIOCHEM J, V340, P753, DOI 10.1042/0264-6021:3400753; XIAO L, 1991, BIOCHEM BIOPH RES CO, V179, P407, DOI 10.1016/0006-291X(91)91385-P	44	107	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38319	38328		10.1074/jbc.M003270200	http://dx.doi.org/10.1074/jbc.M003270200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10978316	hybrid			2022-12-27	WOS:000165739800027
J	Dobson, AW; Xu, Y; Kelley, MR; LeDoux, SP; Wilson, GL				Dobson, AW; Xu, Y; Kelley, MR; LeDoux, SP; Wilson, GL			Enhanced mitochondrial DNA repair and cellular survival after oxidative stress by targeting the human 8-oxoguanine glycosylase repair enzyme to mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; ALZHEIMER-DISEASE; NUCLEAR-DNA; HUMAN-CELLS; DAMAGE; ALKYLATION; EXPRESSION; MUTATIONS; APOPTOSIS; SEQUENCE	Oxidative damage to mitochondrial DNA (mtDNA) has been implicated as a causative factor in many disease processes and in aging. We have recently discovered that different cell types vary in their capacity to repair this damage, and this variability correlates with their ability to withstand oxidative stress. To explore strategies to enhance repair of oxidative lesions in mtDNA, we have constructed a vector containing a mitochondrial transport sequence upstream of the sequence for human 8-oxoguanine DNA glycosylase. This enzyme is the glycosylase/AP lyase that participates in repair of purine lesions, such as 8-oxoguanine. Western blot analysis confirmed that this recombinant protein was targeted to mitochondria, Enzyme activity assays showed that mitochondrial extracts from cells transfected with the construct had increased enzyme activity compared with cells transfected with vector only, whereas nuclear enzyme activity was not changed. Repair assays showed that there was enhanced repair of oxidative lesions in mtDNA, Additional studies revealed that this augmented repair led to enhanced cellular viability as determined by reduction of the tetrazolium compound to formazan, trypan blue dye exclusion, and clonogenic assays. Therefore, targeting of DNA repair enzymes to mitochondria may be a viable approach for the protection of cells against some of the deleterious effects of oxidative stress.	Univ S Alabama, Coll Med, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA; Indiana Univ, Sch Med, Wells Ctr Pediat Res, Dept Pediat, Indianapolis, IN 46202 USA	University of South Alabama; Indiana University System; Indiana University-Purdue University Indianapolis	Wilson, GL (corresponding author), Univ S Alabama, Coll Med, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA.			Kelley, Mark/0000-0002-6120-9532	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003456] Funding Source: NIH RePORTER; NIA NIH HHS [AG12422] Funding Source: Medline; NIEHS NIH HHS [ES05865, ES03456] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bandmann O, 1997, J NEUROL, V244, P262, DOI 10.1007/s004150050082; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; Driggers WJ, 1997, NUCLEIC ACIDS RES, V25, P4362, DOI 10.1093/nar/25.21.4362; FREI B, 1986, BIOCHEMISTRY-US, V25, P4438, DOI 10.1021/bi00363a040; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Hollensworth SB, 2000, FREE RADICAL BIO MED, V28, P1161, DOI 10.1016/S0891-5849(00)00214-8; Hudson EK, 1998, FREE RADICAL RES, V29, P573, DOI 10.1080/10715769800300611; HUTCHIN T, 1995, P NATL ACAD SCI USA, V92, P6892, DOI 10.1073/pnas.92.15.6892; LeDoux SP, 1998, GLIA, V24, P304, DOI 10.1002/(SICI)1098-1136(199811)24:3<304::AID-GLIA4>3.3.CO;2-J; LeDoux SP, 1999, MUTAT RES-DNA REPAIR, V434, P149, DOI 10.1016/S0921-8777(99)00026-9; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; Ozawa T, 1997, PHYSIOL REV, V77, P425, DOI 10.1152/physrev.1997.77.2.425; Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; Rotig A, 1996, DIABETES METAB, V22, P291; Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9; Schnopp NM, 1996, CLIN NEUROPATHOL, V15, P348; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SHEN CC, 1995, MUTAT RES-DNA REPAIR, V337, P19, DOI 10.1016/0921-8777(95)00008-8; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; ShimodaMatsubayashi S, 1996, BIOCHEM BIOPH RES CO, V226, P561, DOI 10.1006/bbrc.1996.1394; Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; Souza-Pinto NC, 1999, NUCLEIC ACIDS RES, V27, P1935, DOI 10.1093/nar/27.8.1935; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; Tamura T, 1996, BIOCHEM BIOPH RES CO, V222, P659, DOI 10.1006/bbrc.1996.0800; TANHAUSER SM, 1995, J BIOL CHEM, V270, P24769, DOI 10.1074/jbc.270.42.24769; THOR H, 1982, J BIOL CHEM, V257, P2419; Vialettes B, 1997, DIABETES METAB, V23, P52; Wei YH, 1998, ANN NY ACAD SCI, V854, P155, DOI 10.1111/j.1749-6632.1998.tb09899.x; Wilson GL, 1997, DIABETES, V46, P1291, DOI 10.2337/diabetes.46.8.1291; Wooten GF, 1997, ANN NEUROL, V41, P265, DOI 10.1002/ana.410410218; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Zastawny TH, 1998, FREE RADICAL BIO MED, V24, P722, DOI 10.1016/S0891-5849(97)00331-6; Zharkov DO, 2000, J BIOL CHEM, V275, P28607, DOI 10.1074/jbc.M002441200	42	115	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37518	37523		10.1074/jbc.M000831200	http://dx.doi.org/10.1074/jbc.M000831200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982789	hybrid			2022-12-27	WOS:000165618700031
J	Mikitani, K; Sugasaki, T; Shimada, T; Kobayashi, N; Gustafsson, JA				Mikitani, K; Sugasaki, T; Shimada, T; Kobayashi, N; Gustafsson, JA			The chitinase gene of the silkworm, Bombyx mori, contains a novel Tc-like transposable element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHITINOLYTIC ENZYMES; SEQUENCE; CHITOTRIOSIDASE; INTEGUMENT; HORMONE; CLONING; CDNA	We have determined the cDNA sequence and the genomic organization of the chitinase gene of the silkworm, Bombyx mori. The cDNA encodes 544 amino acids having 83% amino acid homology to the chitinase of the tobacoo hornworm, Manduca sexta. The total length of the gene is larger than 25 kilobase pairs, and it is separated into 11 exons. The intron-exon boundaries are all in accordance with the GT-AG rule. Also, the TATA box sequence was found in the 5' upstream region of the gene, and the gene is mapped on the seventh chromosome. A novel DNA type transposon that shows similarity to the Tc-like element was found in the third intron in some strains of B. mori; other strains, however, lack this element in the same intron. This element has long terminal inverted repeats, presumably encodes a transposase of about 340 amino acids with a DDE motif, and has an amino-terminal domain with a strong nuclear localization function. Seven other transposable elements with homologous but distinct sequences were isolated from the B. mori genome. Together with plaque hybridization results, our findings suggest that these novel elements exist in multiple copies constituting a new Tc-like transposable element family in the silkworm genome.	Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Univ Tokyo, Dept Agr & Environm Biol, Bunkyo Ku, Tokyo 113, Japan; Karolinska Inst, Dept Med Nutr, S-14157 Huddinge, Sweden	Karolinska Institutet; University of Tokyo; Karolinska Institutet	Mikitani, K (corresponding author), Karolinska Inst, Ctr Biotechnol, S-14157 Huddinge, Sweden.	kenichi.mikitani@csb.ki.se	Shimada, Toru/A-2033-2011; Shimada, Toru/AAZ-2703-2021	Shimada, Toru/0000-0002-5791-0000; Shimada, Toru/0000-0002-5791-0000				ARATAKE Y, 1961, B SERICUL EXP STA, V17, P155; BOOT RG, 1995, J BIOL CHEM, V270, P26252, DOI 10.1074/jbc.270.44.26252; Boot RG, 1998, J BIOL CHEM, V273, P25680, DOI 10.1074/jbc.273.40.25680; BUTENANDT A, 1954, Z NATURFORSCH B, V9, P389; Capy P, 1996, J MOL EVOL, V42, P359, DOI 10.1007/BF02337546; CHERBAS L, 1993, INSECT BIOCHEM MOLEC, V23, P81, DOI 10.1016/0965-1748(93)90085-7; Choi HK, 1997, INSECT BIOCHEM MOLEC, V27, P37, DOI 10.1016/S0965-1748(96)00066-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de la Vega H, 1998, INSECT MOL BIOL, V7, P233, DOI 10.1111/j.1365-2583.1998.00065.x; FRANZ G, 1994, P NATL ACAD SCI USA, V91, P4746, DOI 10.1073/pnas.91.11.4746; Fukuda S., 1940, P IMP ACAD TOKYO, V16, P417; FUKUDA SOICHI, 1944, JOUR FAC SCI IMP UNIV TOKYO SECT IV, V6, P477; GAGE LP, 1974, J MOL BIOL, V86, P97; Garel A, 1997, INSECT BIOCHEM MOLEC, V27, P469, DOI 10.1016/S0965-1748(97)00022-2; Hart DL, 1997, ANNU REV GENET, V31, P337, DOI 10.1146/annurev.genet.31.1.337; Hawtin RE, 1997, VIROLOGY, V238, P243, DOI 10.1006/viro.1997.8816; Hoekstra R, 1999, MOL BIOCHEM PARASIT, V102, P157, DOI 10.1016/S0166-6851(99)00094-8; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; KATAOKA H, 1987, AGR BIOL CHEM TOKYO, V51, P1067, DOI 10.1080/00021369.1987.10868149; KAZNOWSKI CE, 1986, J INSECT PHYSIOL, V32, P133, DOI 10.1016/0022-1910(86)90132-0; Kim MG, 1998, INSECT BIOCHEM MOLEC, V28, P163, DOI 10.1016/S0965-1748(97)00112-4; KIMURA S, 1973, J INSECT PHYSIOL, V19, P115, DOI 10.1016/0022-1910(73)90227-8; KOBAYASHI M, 1958, NATURE, V181, P1217, DOI 10.1038/1811217a0; KOGA D, 1989, INSECT BIOCHEM, V19, P123, DOI 10.1016/0020-1790(89)90082-6; KOGA D, 1992, INSECT BIOCHEM MOLEC, V22, P305, DOI 10.1016/0965-1748(92)90068-P; Koga D, 1997, INSECT BIOCHEM MOLEC, V27, P757, DOI 10.1016/S0965-1748(97)00058-1; KRAMER KJ, 1993, INSECT BIOCHEM MOLEC, V23, P691, DOI 10.1016/0965-1748(93)90043-R; KRAMER KJ, 1986, INSECT BIOCHEM, V16, P851, DOI 10.1016/0020-1790(86)90059-4; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; MAEDA S, 1985, NATURE, V315, P592, DOI 10.1038/315592a0; OKAZAKI S, 1993, MOL CELL BIOL, V13, P1424, DOI 10.1128/MCB.13.3.1424; Overdijk B, 1999, MICROBIOL-UK, V145, P259, DOI 10.1099/13500872-145-1-259; Plasterk RHA, 1996, CURR TOP MICROBIOL, V204, P125; Promboon Amornrat, 1995, Genetical Research, V66, P1, DOI 10.1017/S0016672300034339; RASCH EM, 1974, CHROMOSOMA, V45, P1; Robertson HM, 1996, INSECT BIOCHEM MOLEC, V26, P945, DOI 10.1016/S0965-1748(96)00061-6; SURHOLT B, 1975, J COMP PHYSIOL, V102, P135, DOI 10.1007/BF00691299; Yamao M, 1999, GENE DEV, V13, P511, DOI 10.1101/gad.13.5.511; YOSHITAK.N, 1966, JPN J GENET, V41, P259, DOI 10.1266/jjg.41.259	39	23	24	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37725	37732		10.1074/jbc.M005271200	http://dx.doi.org/10.1074/jbc.M005271200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10984482	hybrid			2022-12-27	WOS:000165618700058
J	Webb, P; Nguyen, P; Valentine, C; Weatherman, RV; Scanlan, TS; Kushner, PJ				Webb, P; Nguyen, P; Valentine, C; Weatherman, RV; Scanlan, TS; Kushner, PJ			An antiestrogen-responsive estrogen receptor-alpha mutant (D351Y) shows weak AF-2 activity in the presence of tamoxifen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; PEPTIDE ANTAGONISTS; ER ALPHA; COACTIVATOR; ACTIVATION; CELL; MECHANISMS; IDENTIFICATION; RALOXIFENE; ASPARTATE	Antiestrogens, including tamoxifen and raloxifene, block estrogen receptor (ER) action by blocking the interactions of an estrogen-dependent activation function (AF-2) with p160 coactivators. Although tamoxifen does show some agonist activity in the presence of ER alpha, this stems from a distinct constitutive activation function (AF-1) that lies within the ER alpha N terminus. Previous studies identified a naturally occurring mutation (D351Y) that allows ER alpha to perceive tamoxifen and raloxifene as estrogens. Here, we examine the contributions of ER alpha activation functions to the D351Y phenotype. We find that the AF-2 function of ER alpha D351Y lacks detectable tamoxifen-dependent activity when tested in isolation but does synergize with AF-1 to allow enhanced tamoxifen response. Weak tamoxifen-dependent interactions between the ER alpha D351Y AF-2 function and GRIP1, a representative p160, can be detected in glutathione S-transferase binding assays and mammalian two-hybrid assays. Furthermore, tamoxifen-dependent AF-2 activity can be detected in the presence of ER alpha D351Y and high levels of overexpressed GRIP1, We therefore propose that the D351Y mutation allows weak tamoxifen-dependent AF-2 activity but that this activity is only detectable when AF-1 is strong, and AF-1 and AF-2 synergize, or when p160s are overexpressed. We discuss the possible structural basis of this effect.	Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cellular & Mol Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Webb, P (corresponding author), Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA.	webbp@itsa.ucsf.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057574, R01DK051083] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51083, DK57574] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anghel SI, 2000, J BIOL CHEM, V275, P20867, DOI 10.1074/jbc.M002098200; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Aumais JP, 1997, J BIOL CHEM, V272, P12229, DOI 10.1074/jbc.272.18.12229; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chen SC, 2000, J BIOL CHEM, V275, P15039, DOI 10.1074/jbc.275.20.15039; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Glass CK, 2000, GENE DEV, V14, P121; GRONEMEYER H, 1992, J STEROID BIOCHEM, V41, P217, DOI 10.1016/0960-0760(92)90347-L; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Jordan VC, 1998, SCI AM, V279, P60, DOI 10.1038/scientificamerican1098-60; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LEES JA, 1989, J STEROID BIOCHEM, V34, P33, DOI 10.1016/0022-4731(89)90063-0; Levenson AS, 1998, CANCER RES, V58, P1872; Levenson AS, 1997, J STEROID BIOCHEM, V60, P261, DOI 10.1016/S0960-0760(96)00184-7; Lopez GN, 1999, MOL ENDOCRINOL, V13, P897, DOI 10.1210/me.13.6.897; MCDONNELL DP, 1995, ANN NY ACAD SCI, V761, P121, DOI 10.1111/j.1749-6632.1995.tb31374.x; McInerney EM, 1996, J BIOL CHEM, V271, P24172, DOI 10.1074/jbc.271.39.24172; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; PARKER MG, 1993, ANN NY ACAD SCI, V684, P119, DOI 10.1111/j.1749-6632.1993.tb32276.x; Parker MG, 1998, BIOCHEM SOC SYMP, P45; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; RIBEIRO RCJ, 1995, ANNU REV MED, V46, P443, DOI 10.1146/annurev.med.46.1.443; Saatcioglu F, 1997, MOL CELL BIOL, V17, P4687, DOI 10.1128/MCB.17.8.4687; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Schafer JIM, 1999, CANCER RES, V59, P4308; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; WEBB P, 1992, MOL ENDOCRINOL, V6, P157, DOI 10.1210/me.6.2.157; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443	47	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37552	37558		10.1074/jbc.M007435200	http://dx.doi.org/10.1074/jbc.M007435200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10986290	hybrid			2022-12-27	WOS:000165618700035
J	Feng, W; Liu, GH; Allen, PD; Pessah, IN				Feng, W; Liu, GH; Allen, PD; Pessah, IN			Transmembrane redox sensor of ryanodine receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; INOSITOL TRISPHOSPHATE; GLUTATHIONE DISULFIDE; MOLECULAR INTERACTION; FUNCTIONAL-ROLE; NITRIC-OXIDE; SKELETAL; DEHYDROASCORBATE; SULFHYDRYLS; ACTIVATION	Inositol 1,4,5-trisphosphate receptors (IP3R) and ryanodine receptors (RyR) mediate the release of endoplasmic and sarcoplasmic reticulum (ER/SR) Ca2+ stores and regulate Ca2+ entry through voltage-dependent or ligand-gated channels of the plasma membrane. A prominent property of ER/SR Ca2+ channels is exquisite sensitivity to sulfhydryl-modifying reagents. A plausible role for sulfhydryl chemistry in physiologic regulation of Ca2+ release channels and the fidelity of Ca2+ release from ER/SR is lacking. This study reveals the existence of a transmembrane redox sensor within the RS RI channel complex that confers tight regulation of channel activity in response to changes in transmembrane redox potential produced by cytoplasmic and luminal glutathione, A transporter selective for glutathione is co-localized with RyR1 within the SR membrane to maintain local redox potential gradients consistent with redox regulation of ER/SR Ca2+ release. Hyperreactive sulfhydryls previously shown to reside within the RyR1 complex (Liu, G., and Pessah, I. N. (1994) J, Biol, Chem. 269, 33028-33034) are an essential biochemical component of a transmembrane redox sensor. Transmembrane redox sensing may represent a fundamental mechanism by which ER/SR Ca2+ channels respond to localized changes in transmembrane glutathione redox potential produced by physiologic and pathophysiologic modulators of Ca2+ release from stores.	Univ Calif Davis, Dept Mol Biosci, Sch Vet Med, Davis, CA 95616 USA; Brigham & Womens Hosp, Dept Anesthesia, Boston, MA 02114 USA	University of California System; University of California Davis; Harvard University; Brigham & Women's Hospital	Pessah, IN (corresponding author), Univ Calif Davis, Dept Mol Biosci, Sch Vet Med, 1 Shield Ave, Davis, CA 95616 USA.	inpessah@ucdavis.edu	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043140] Funding Source: NIH RePORTER; NIAMS NIH HHS [4PO1 AR17605, 5RO1 AR43140] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAMSON JJ, 1989, J BIOENERG BIOMEMBR, V21, P283, DOI 10.1007/BF00812073; Aghdasi B, 1997, J BIOL CHEM, V272, P25462, DOI 10.1074/jbc.272.41.25462; Banhegyi G, 1998, J BIOL CHEM, V273, P2758, DOI 10.1074/jbc.273.5.2758; Banhegyi G, 1997, J BIOL CHEM, V272, P13584, DOI 10.1074/jbc.272.21.13584; Banhegyi G, 1999, J BIOL CHEM, V274, P12213, DOI 10.1074/jbc.274.18.12213; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Dulhunty A, 2000, ANTIOXID REDOX SIGN, V2, P27, DOI 10.1089/ars.2000.2.1-27; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Feng W, 1999, MOL PHARMACOL, V55, P821; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JOSEPH SK, 1995, J BIOL CHEM, V270, P3588, DOI 10.1074/jbc.270.8.3588; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; LIU GH, 1994, J BIOL CHEM, V269, P33028; LIU GH, 1994, MOL PHARMACOL, V45, P189; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Marengo JJ, 1998, BIOPHYS J, V74, P1263, DOI 10.1016/S0006-3495(98)77840-3; MEISSNER G, 1988, METHOD ENZYMOL, V157, P417; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; Murayama T, 1999, J BIOL CHEM, V274, P17297, DOI 10.1074/jbc.274.24.17297; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Oba T, 2000, BIOPHYS J, V78, p123A; Pessah IN, 2000, ANTIOXID REDOX SIGN, V2, P17, DOI 10.1089/ars.2000.2.1-17; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; Salama G, 2000, ANTIOXID REDOX SIGN, V2, P5, DOI 10.1089/ars.2000.2.1-5; Sen CK, 1998, BIOCHEM PHARMACOL, V55, P1747, DOI 10.1016/S0006-2952(97)00672-2; Senft AP, 2000, ANAL BIOCHEM, V280, P80, DOI 10.1006/abio.2000.4498; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Vanlingen S, 1999, CELL CALCIUM, V25, P107, DOI 10.1054/ceca.1998.0010; WELLS WW, 1990, J BIOL CHEM, V265, P15361; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Zable AC, 1997, J BIOL CHEM, V272, P7069, DOI 10.1074/jbc.272.11.7069	34	123	126	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35902	35907		10.1074/jbc.C000523200	http://dx.doi.org/10.1074/jbc.C000523200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10998414	hybrid			2022-12-27	WOS:000165382000038
J	Ng, DCH; Bogoyevitch, MA				Ng, DCH; Bogoyevitch, MA			The mechanism of heat shock activation of ERK mitogen-activated protein kinases in the interleukin 3-dependent ProB cell line BaF3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; EPIDERMAL GROWTH-FACTOR; RAS-DEPENDENT ACTIVATION; OKADAIC ACID; DIFFERENTIAL REGULATION; TYROSINE PHOSPHATASES; HEMATOPOIETIC-CELLS; CARDIAC MYOCYTES; RECEPTOR-BINDING; MAP KINASES	We have investigated heat shock stimulation of MAPK cascades in an interleukin 3-dependent cell line, BaF3. Following exposure to 42 degreesC, the stress-activated JNK MAPKs were phosphorylated and activated, but p38 MAPKs remained unaffected. Surprisingly, heat shock also activated ERK MAPKs in a potent (>60-fold), delayed (>30 min), and sustained (greater than or equal to 120 min) manner. These characteristics suggested a novel mechanism of ERK MAPK activation and became the focus of this study. A MEK-specific inhibitor, PD98059, inhibited heat shock ERK MAPK activation by >75%. Surprisingly, a role for Ras in the heat shock response was eliminated by the failure of a dominant-negative Ras(Asn-17) mutant to inhibit ERK MAPK activation and the failure to observe increases in Ras GTP. Heat shock also failed to stimulate activation of A-, B-, and c-Raf. Instead, a serine/threonine phosphatase inhibitor, okadaic acid, activated ERK MAPK in a similar manner to heat shock. Furthermore, pretreatment with suramin, generally recognized as abroad range inhibitor of growth factor receptors, inhibited both okadaic acid-stimulated and heat shock-stimulated ERK MAPK activity by >40%. Inhibiting ERK MAPK activation during heat shock with PD98059 enhanced losses in cell viability. These results demonstrate Ras- and Raf-independent ERK MAPK activation maintains cell viability following heat shock.	Univ Western Australia, Dept Biochem, Nedlands, WA 6907, Australia; Western Australian Inst Med Res, Perth, WA 6000, Australia	University of Western Australia; University of Western Australia	Bogoyevitch, MA (corresponding author), Univ Western Australia, Dept Biochem, Nedlands, WA 6907, Australia.		Ng, Dominic/C-7291-2015	Ng, Dominic/0000-0003-4657-159X; Bogoyevitch, Marie/0000-0001-9745-3716				Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Andersson MB, 1998, BIOCHEM BIOPH RES CO, V251, P328, DOI 10.1006/bbrc.1998.9476; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BENDINELLI P, 1995, BIOCHEM BIOPH RES CO, V216, P54, DOI 10.1006/bbrc.1995.2591; Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; CANO E, 1995, J CELL SCI, V108, P3599; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; CHEN F, 1995, BIOCHEM J, V312, P341, DOI 10.1042/bj3120341; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DUBOIS MF, 1993, FEBS LETT, V324, P191, DOI 10.1016/0014-5793(93)81391-C; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Finlay D, 2000, CELL DEATH DIFFER, V7, P302, DOI 10.1038/sj.cdd.4400652; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GRAZIOLI L, 1992, INT J IMMUNOPHARMACO, V14, P637, DOI 10.1016/0192-0561(92)90125-5; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Han SI, 2000, CELL BIOL INT, V24, P447, DOI 10.1006/cbir.2000.0512; Hu YH, 1997, J BIOL CHEM, V272, P9113; Kim Y, 1997, J CELL BIOCHEM, V67, P43, DOI 10.1002/(SICI)1097-4644(19971001)67:1<43::AID-JCB5>3.0.CO;2-W; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Krady MM, 1998, FEBS LETT, V434, P241, DOI 10.1016/S0014-5793(98)00989-2; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Li S, 1999, J ORTHOP RES, V17, P891, DOI 10.1002/jor.1100170614; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Muda M, 1996, J BIOL CHEM, V271, P4319; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Ping PP, 1999, AM J PHYSIOL-HEART C, V276, pH1468, DOI 10.1152/ajpheart.1999.276.5.H1468; RAMPAL AL, 1995, J BIOL CHEM, V270, P3938, DOI 10.1074/jbc.270.8.3938; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; ROBINS HI, 1995, CANCER LETT, V97, P195, DOI 10.1016/0304-3835(95)03976-4; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STEIN CA, 1993, CANCER RES, V53, P2239; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; van der Wijk T, 1998, BIOCHEM J, V331, P863, DOI 10.1042/bj3310863; Vigh L, 1998, TRENDS BIOCHEM SCI, V23, P369, DOI 10.1016/S0968-0004(98)01279-1; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhang YL, 1998, J BIOL CHEM, V273, P12281, DOI 10.1074/jbc.273.20.12281; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251; Zhuang SG, 2000, AM J PHYSIOL-CELL PH, V278, pC102, DOI 10.1152/ajpcell.2000.278.1.C102	60	40	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40856	40866		10.1074/jbc.M004639200	http://dx.doi.org/10.1074/jbc.M004639200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11005808	hybrid			2022-12-27	WOS:000166114600027
J	Ludwig, MG; Bassett, P; Anglard, P				Ludwig, MG; Bassett, P; Anglard, P			Multiple regulatory elements in the murine stromelysin-3 promoter - Evidence for direct control by CCAAT/enhancer-binding protein beta and thyroid and retinoid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; MOUSE MAMMARY-GLAND; MATRIX METALLOPROTEINASE; BREAST-CARCINOMA; ACID RECEPTORS; TRANSCRIPTIONAL ACTIVATION; ATHEROSCLEROTIC LESIONS; HORMONE RECEPTORS; GENE-EXPRESSION; MESSENGER-RNA	Stromelysin-3 (ST3) belongs to the matrix metalloproteinase (MMPs) family, a protease family involved in tissue remodeling. Although this family of enzymes is regulated by nuclear receptors, few hormone-responsive elements have been demonstrated in MMP promoters. In order to identify regulatory elements and/or factors that control the expression of the mouse st3 gene, we have analyzed genomic sequences encompassing 5 kilobase pairs of the ST3 promoter. Analysis of these sequences revealed several CCAAT/enhancer-binding proteins (C/EBP) and retinoic acid-responsive elements (RAREs), as well as one thyroid-responsive element. However, in contrast to most MMP promoters, no AP-1-binding sites were identified. Specific binding activities were demonstrated for all elements. Consistent with previous reports, retinoid X receptor is required for maximal binding to the ST3 RAREs and the TRE. The ST3-C/EBP element was shown to mediate dose-dependent promoter activation by C/EBP beta, Among the RAREs, the proximal DR1-RARE was shown to be sufficient for ST3 promoter activation by ligand-bound retinoid receptors, whereas the two distal DR2-RAREs appear to be involved more in the control of base-line promoter activity. Accordingly, ST3 expression was induced by retinoic acid and was reduced in cells where specific retinoic acid receptors had been inactivated. The involvement of these conserved regulatory elements is discussed in the context of physiological or pathological situations associated with st3 expression. Our findings therefore assign to C/EBP, retinoids, and thyroid hormone important roles in the regulation of ST3 gene expression.	Univ Strasbourg 1, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France; CU Strasbourg, Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Anglard, P (corresponding author), Univ Strasbourg 1, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch, France.		Anglard, Patrick/M-6618-2019	Anglard, Patrick/0000-0001-5701-441X				Agarwal C, 1999, J BIOL CHEM, V274, P6190, DOI 10.1074/jbc.274.10.6190; Ahmad A, 1998, AM J PATHOL, V152, P721; ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; ANDERSON IC, 1995, CANCER RES, V55, P4120; ANGLARD P, 1995, J BIOL CHEM, V270, P20337, DOI 10.1074/jbc.270.35.20337; ASTROM A, 1994, J BIOL CHEM, V269, P22334; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; Chenard MP, 1996, INT J CANCER, V69, P448, DOI 10.1002/(SICI)1097-0215(19961220)69:6<448::AID-IJC5>3.3.CO;2-4; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Chiba H, 1997, J CELL BIOL, V139, P735, DOI 10.1083/jcb.139.3.735; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Doyle GAR, 1997, J BIOL CHEM, V272, P11840, DOI 10.1074/jbc.272.18.11840; Dupe V, 1999, DEV BIOL, V208, P30, DOI 10.1006/dbio.1998.9176; FUTREAL PA, 1992, CANCER RES, V52, P2624; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; Ghyselinck NB, 1997, INT J DEV BIOL, V41, P425; Guerin E, 1997, J BIOL CHEM, V272, P11088; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; KLAMPFER L, 1994, MOL CELL BIOL, V14, P6561, DOI 10.1128/MCB.14.10.6561; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; LEFEBVRE O, 1995, DEVELOPMENT, V121, P947; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Li JW, 1998, NUCLEIC ACIDS RES, V26, P3018, DOI 10.1093/nar/26.12.3018; LOPEZBARAHONA M, 1995, EMBO J, V14, P1145, DOI 10.1002/j.1460-2075.1995.tb07098.x; Luo DC, 1999, J BIOL CHEM, V274, P37177, DOI 10.1074/jbc.274.52.37177; Maquoi E, 1997, PLACENTA, V18, P277, DOI 10.1016/S0143-4004(97)80062-8; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Noel AC, 1996, J CLIN INVEST, V97, P1924, DOI 10.1172/JCI118624; Okada A, 1997, J CELL BIOL, V137, P67, DOI 10.1083/jcb.137.1.67; OSTEEN KG, 1994, P NATL ACAD SCI USA, V91, P10129, DOI 10.1073/pnas.91.21.10129; PATTERTON D, 1995, DEV BIOL, V167, P252, DOI 10.1006/dbio.1995.1021; POLETTE M, 1993, PATHOL RES PRACT, V189, P1052; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; Puzianowska-Kuznicka M, 1997, MOL CELL BIOL, V17, P4738, DOI 10.1128/MCB.17.8.4738; RANJAN M, 1994, J BIOL CHEM, V269, P24699; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; Rodriguez-Leon J, 1999, NAT CELL BIOL, V1, P125, DOI 10.1038/10098; Sabatakos G, 1998, BIOCHEM J, V334, P205, DOI 10.1042/bj3340205; Schonbeck U, 1999, J EXP MED, V189, P843, DOI 10.1084/jem.189.5.843; SCHRADER M, 1994, DNA CELL BIOL, V13, P333, DOI 10.1089/dna.1994.13.333; Schroen DJ, 1996, GENE EXPRESSION, V6, P197; SELLITTI DF, 1983, CANCER RES, V43, P1030; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; Unden AB, 1996, J INVEST DERMATOL, V107, P147, DOI 10.1111/1523-1747.ep12329541; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; XIE B, 1994, J IMMUNOL, V152, P3637; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x	56	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39981	39990		10.1074/jbc.M007529200	http://dx.doi.org/10.1074/jbc.M007529200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10993903	hybrid			2022-12-27	WOS:000166039500027
J	Pate, P; Mochca-Morales, J; Wu, YJ; Zhang, JZ; Rodney, GG; Serysheva, II; Williams, BY; Anderson, ME; Hamilton, SL				Pate, P; Mochca-Morales, J; Wu, YJ; Zhang, JZ; Rodney, GG; Serysheva, II; Williams, BY; Anderson, ME; Hamilton, SL			Determinants for calmodulin binding on voltage-dependent Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(1C) SUBUNIT; CALCIUM CHANNELS; CA2+-SENSITIVE INACTIVATION; SKELETAL-MUSCLE; MOTIF; INHIBITION; PROTEINS; SEQUENCE	Calmodulin, bound to the alpha (1) subunit of the cardiac L-type calcium channel, is required for calcium-dependent inactivation of this channel. Several laboratories have suggested that the site of interaction of calmodulin with the channel is an IQ-Like motif in the carboxyl-terminal region of the cu, subunit. Mutations in this IQ motif are linked to L-type Ca2+ current (I-Ca) facilitation and inactivation. IQ peptides from L, P/Q, N, and R channels all bind Ca2+ calmodulin but not Ca2+-free calmodulin. Another peptide representing a carboxyl-terminal sequence found only in L-type channels (designated the CB domain) binds Ca2+ calmodulin and enhances Ca2+ dependent Ic, facilitation in cardiac myocytes, suggesting the CB domain is functionally important. Calmodulin blocks the binding of an antibody specific for the CB sequence to the skeletal muscle L-type Ca2+ channel, suggesting that this is a calmodulin binding site on the intact protein. The binding of the IQ and CB peptides to calmodulin appears to be competitive, signifying that the two sequences represent either independent or alternative binding sites for calmodulin rather than both sequences contributing to a single binding site.	Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; Vanderbilt Univ, Med Ctr,Sch Med, Dept Med, Div Cardiol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	Baylor College of Medicine; Vanderbilt University; Vanderbilt University	Hamilton, SL (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, 1 Baylor Plaza, Houston, TX 77030 USA.			Hamilton, Susan/0000-0003-0241-9369	NIAMS NIH HHS [AR44864] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044864] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adams B, 1997, J GEN PHYSIOL, V110, P379, DOI 10.1085/jgp.110.4.379; Bernatchez G, 1998, BIOPHYS J, V75, P1727, DOI 10.1016/S0006-3495(98)77614-3; BERS DM, 1994, METHOD CELL BIOL, V40, P3; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; Gao TY, 2000, J BIOL CHEM, V275, P25436, DOI 10.1074/jbc.M003465200; Gerhardstein BL, 2000, J BIOL CHEM, V275, P8556, DOI 10.1074/jbc.275.12.8556; HADLEY RW, 1991, J PHYSIOL-LONDON, V444, P257, DOI 10.1113/jphysiol.1991.sp018876; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAMILTON SL, 1989, BIOCHEMISTRY-US, V28, P7820, DOI 10.1021/bi00445a044; Hofer GF, 1997, BIOPHYS J, V73, P1857, DOI 10.1016/S0006-3495(97)78216-X; Kepplinger KJF, 2000, FEBS LETT, V477, P161, DOI 10.1016/S0014-5793(00)01791-9; KRETSINGER RH, 1976, ANNU REV BIOCHEM, V45, P239, DOI 10.1146/annurev.bi.45.070176.001323; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; MARBAN E, 1982, J PHYSIOL-LONDON, V329, P589, DOI 10.1113/jphysiol.1982.sp014321; Mukherjea P, 1996, PROTEIN SCI, V5, P468; Peterson BZ, 2000, BIOPHYS J, V78, P1906, DOI 10.1016/S0006-3495(00)76739-7; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Soldatov NM, 1998, J BIOL CHEM, V273, P957, DOI 10.1074/jbc.273.2.957; Wu YJ, 1999, AM J PHYSIOL-HEART C, V276, pH2168, DOI 10.1152/ajpheart.1999.276.6.H2168; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301; Zuhlke RD, 2000, J BIOL CHEM, V275, P21121, DOI 10.1074/jbc.M002986200; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	27	118	119	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39786	39792		10.1074/jbc.M007158200	http://dx.doi.org/10.1074/jbc.M007158200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11005820	hybrid			2022-12-27	WOS:000165953100111
J	Repa, JJ; Lund, EG; Horton, JD; Leitersdorf, E; Russell, DW; Dietschy, JM; Turley, SD				Repa, JJ; Lund, EG; Horton, JD; Leitersdorf, E; Russell, DW; Dietschy, JM; Turley, SD			Disruption of the sterol 27-hydroxylase gene in mice results in hepatomegaly and hypertriglyceridemia - Reversal by cholic acid feeding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYMETHYLGLUTARYL-COA REDUCTASE; BILE-ACID; CEREBROTENDINOUS XANTHOMATOSIS; CHOLESTEROL; METABOLISM; BIOSYNTHESIS; RATES; HYPERCHOLESTEROLEMIA; CHOLESTYRAMINE; CIRCULATION	Sterol 27-hydroxylase (CYP27) participates in the conversion of cholesterol to bile acids, We examined lipid metabolism in mice lacking the Cyp27 gene. On normal rodent chow, Cyp27(-/-) mice have 40% larger livers, 45% larger adrenals, a-fold higher hepatic and plasma triacylglycerol concentrations, a 70% higher rate of hepatic fatty acid synthesis, and a 70% increase in the ratio of oleic to stearic acid in the liver versus Cyp27(+/+) controls, In Cyp27(-/-) mice, cholesterol 7 alpha -hydroxylase activity is increased B-fold, but bile acid synthesis and pool size are 47 and 27%, respectively, of those in Cyp27(+/+) mice, Intestinal cholesterol, absorption decreases from 54 to 4% in knockout mice, while fecal neutral sterol excretion increases 2.5-fold, A compensatory 2.5-fold increase in whole body cholesterol synthesis occurs in Cyp27(-/-) mice, principally in liver, adrenal, small intestine, lung, and spleen. The mRNA for the cholesterogenic transcription factor sterol regulatory element-binding protein-2 (SREBP-2) and mRNAs for SREBP-2-regulated cholesterol biosynthetic genes are elevated in livers of mutant mice. In addition, the mRNAs encoding the lipogenic transcription factor SREBP-1 and SREBP-1-regulated monounsaturated fatty acid biosynthetic enzymes are also increased. Hepatic synthesis of fatty acids and accumulation of triacylglycerols increases in Cyp27-/- mice and is associated with hypertriglyceridemia. Cholic acid feeding reverses hepatomegaly and hypertriglyceridemia but not adrenomegaly in Cyp27(-/-) mice, These studies confirm the importance of CYP27 in bile acid synthesis and they reveal an unexpected function of the enzyme in triacylglycerol metabolism.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, Dallas, TX 75390 USA; Hadassah Univ Hosp, Ctr Res Prevent & Treatment Atherosclerosis, Dept Med, IL-91120 Jerusalem, Israel	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Hebrew University of Jerusalem	Turley, SD (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Repa, Joyce/0000-0001-5740-1954; Russell, David/0000-0002-0277-403X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R37HL009610, R01HL009610] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 09610, HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Babiker A, 1999, J LIPID RES, V40, P1417; BEIL U, 1982, METABOLISM, V31, P438, DOI 10.1016/0026-0495(82)90231-1; BJORKHEM I, 1992, J LIPID RES, V33, P455; BJORKHEM I, 1995, METABOLIC MOL BASES, V2, P2073; del Castillo-Olivares A, 2000, J BIOL CHEM, V275, P17793, DOI 10.1074/jbc.M000996200; DOBS AS, 1995, CARDIOVASC DRUG THER, V9, P677, DOI 10.1007/BF00878550; Duane WC, 1999, J LIPID RES, V40, P1194; ESTERMAN AL, 1983, J LIPID RES, V24, P1304; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Honda A, 1999, HEPATOLOGY, V30, p320A; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; Li-Hawkins J, 2000, J BIOL CHEM, V275, P16543, DOI 10.1074/jbc.M001810200; Li-Hawkins J, 2000, J BIOL CHEM, V275, P16536, DOI 10.1074/jbc.M001811200; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; LUND E, 1992, J BIOL CHEM, V267, P25092; MEIJER GW, 1989, ARTERY, V16, P286; MOLGAARD J, 1989, EUR J CLIN PHARMACOL, V36, P455, DOI 10.1007/BF00558069; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; RENNERT H, 1990, ENDOCRINOLOGY, V127, P738, DOI 10.1210/endo-127-2-738; Repa JJ, 1999, CURR OPIN BIOTECH, V10, P557, DOI 10.1016/S0958-1669(99)00031-2; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SALEN G, 1973, J CLIN INVEST, V52, P2822, DOI 10.1172/JCI107478; SALEN G, 1985, J CLIN INVEST, V76, P744, DOI 10.1172/JCI112030; SALEN G, 1971, ANN INTERN MED, V75, P843, DOI 10.7326/0003-4819-75-6-843; Schwarz M, 1998, J LIPID RES, V39, P1833; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; TURLEY SD, 1981, J LIPID RES, V22, P551; TURLEY SD, 1994, J LIPID RES, V35, P328; Turley SD, 1999, HEPATOLOGY, V30, p320A; Turley SD, 1998, HEPATOLOGY, V28, P1088, DOI 10.1002/hep.510280425; TURLEY SD, 1988, LIVER BIOL PATHOBIOL, P617; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8	34	161	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39685	39692		10.1074/jbc.M007653200	http://dx.doi.org/10.1074/jbc.M007653200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11001949	hybrid			2022-12-27	WOS:000165953100097
J	Treves, S; Feriotto, G; Moccagatta, L; Gambari, R; Zorzato, F				Treves, S; Feriotto, G; Moccagatta, L; Gambari, R; Zorzato, F			Molecular cloning, expression, functional characterization, chromosomal localization, and gene structure of junctate, a novel integral calcium binding protein of sarco(endo)plasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL SARCOPLASMIC-RETICULUM; RABBIT SKELETAL-MUSCLE; CA-2+ RELEASE CHANNEL; RYANODINE RECEPTOR; DIHYDROPYRIDINE RECEPTOR; MALIGNANT HYPERTHERMIA; TERMINAL CISTERNAE; CA2+ RELEASE; CALSEQUESTRIN; OVEREXPRESSION	Screening a cDNA library from human skeletal muscle and cardiac muscle with a cDNA probe derived from junctin led to the isolation of two groups of cDNA clones, The first group displayed a deduced amino acid sequence that is 84% identical to that of dog heart junctin, whereas the second group had a single open reading frame that encoded a polypeptide with a predicted mass of 33 kDa, whose first 78 NH2-terminal residues are identical to junctin whereas its COOH terminus domain is identical to aspartyl beta -hydroxylase, a member of the alpha -ketoglutarate-dependent dioxygenase family. We named the latter amino acid sequence junctate, Northern blot analysis indicates that junctate is expressed in a variety of human tissues including heart, pancreas, brain, lung, liver, kidney, and skeletal muscle, Fluorescence in situ hybridization analysis revealed that the genetic loci of junctin and junctate map to the same cytogenetic band oh human chromosome 8, Analysis of intron/exon boundaries of the genomic BAC clones demonstrate that junctin, junctate, and aspartyl beta -hydroxylase result from alternative splicing of the same gene. The predicted lumenal portion of junctate is enriched in negatively charged residues and is able to bind calcium. Scatchard analysis of equilibrium Ca-45(2+) binding in the presence of a physiological concentration of KCl demonstrate that junctate binds 21.0 mol of Ca2+/mol protein with a k(D) of 217 +/- 20 muM (n = 5), Tagging recombinant junctate with green fluorescent protein and expressing the chimeric polypeptide in COS-7-transfected cells indicates that junctate is located in endoplasmic reticulum membranes and that its presence increases the peak amplitude and transient calcium released by activation of surface membrane receptors coupled to InsP(3) receptor activation. Our study shows that alternative splicing of the same gene generates the following functionally distinct proteins: an enzyme (aspartyl beta -hydroxylase), a structural protein of SR (junctin), and a membrane-bound calcium binding protein (junctate).	Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; Kantonsspital, Dept Anaesthesia, CH-4031 Basel, Switzerland; Kantonsspital, Dept Res, CH-4031 Basel, Switzerland; Univ Ferrara, Ctr Biotechnol, I-44100 Ferrara, Italy; Univ Ferrara, Dept Biochem & Mol Biol, I-44100 Ferrara, Italy	University of Ferrara; Kantonsspital Aarau AG (KSA); University of Basel; Kantonsspital Aarau AG (KSA); University of Basel; University of Ferrara; University of Ferrara	Zorzato, F (corresponding author), Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, Via Borsari 46, I-44100 Ferrara, Italy.	zor@dns.unife.it	Gambari, Roberto/F-9555-2015	Gambari, Roberto/0000-0001-9205-6033; Treves, Susan/0000-0002-0007-9631	Telethon [908] Funding Source: Medline	Telethon(Fondazione Telethon)		ANDERSON K, 1995, J GEN PHYSIOL, V105, P363, DOI 10.1085/jgp.105.3.363; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; CASWELL AH, 1985, J BIOL CHEM, V260, P6892; Celio MR, 1996, GUIDEBOOK CALCIUM BI; Censier K, 1998, J CLIN INVEST, V101, P1233, DOI 10.1172/JCI993; CHU A, 1990, MOL PHARMACOL, V37, P735; COSTELLO B, 1986, J CELL BIOL, V103, P741, DOI 10.1083/jcb.103.3.741; Damiani E, 1997, CELL CALCIUM, V22, P129, DOI 10.1016/S0143-4160(97)90113-5; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; GIROTTI M, 1992, BIOCHEM J, V281, P203, DOI 10.1042/bj2810203; Goetz J, 1996, J BIOL CHEM, V271, P29589, DOI 10.1074/jbc.271.47.29589; Grassel S, 1999, EUR J BIOCHEM, V263, P471, DOI 10.1046/j.1432-1327.1999.00523.x; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; GUO W, 1994, J BIOL CHEM, V269, P28359; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; Jones LR, 1998, J CLIN INVEST, V101, P1385, DOI 10.1172/JCI1362; Jones LR, 1995, J BIOL CHEM, V270, P30787, DOI 10.1074/jbc.270.51.30787; KAWASAKI T, 1994, BIOCHEM BIOPH RES CO, V199, P1120, DOI 10.1006/bbrc.1994.1347; KIM DH, 1988, BIOCHIM BIOPHYS ACTA, V945, P246, DOI 10.1016/0005-2736(88)90486-5; KIM KC, 1990, BIOCHEMISTRY-US, V29, P9281, DOI 10.1021/bi00491a025; Korenberg JR, 1999, GENOME RES, V9, P994, DOI 10.1101/gr.9.10.994; KORIOTH F, 1994, GENE, V150, P395, DOI 10.1016/0378-1119(94)90460-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LAMB GD, 1986, J PHYSIOL-LONDON, V376, P85, DOI 10.1113/jphysiol.1986.sp016143; Lavaissiere L, 1996, J CLIN INVEST, V98, P1313, DOI 10.1172/JCI118918; LIU GH, 1994, J BIOL CHEM, V269, P33028; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1992, SCIENCE, V256, P789, DOI 10.1126/science.1589759; MacLennan DH, 1998, NAT STRUCT BIOL, V5, P409, DOI 10.1038/nsb0698-409; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MELZER W, 1995, BBA-REV BIOMEMBRANES, V1241, P59, DOI 10.1016/0304-4157(94)00014-5; MENEGAZZI P, 1994, BIOCHEMISTRY-US, V33, P9078, DOI 10.1021/bi00197a008; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Mickelson JR, 1996, PHYSIOL REV, V76, P537, DOI 10.1152/physrev.1996.76.2.537; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; Murray BE, 1997, BIOCHEM J, V324, P689, DOI 10.1042/bj3240689; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; PESSAH IN, 1990, MOL PHARMACOL, V37, P503; Pinton P, 1998, BIOFACTORS, V8, P243, DOI 10.1002/biof.5520080312; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SLUPSKY JR, 1987, BIOCHEMISTRY-US, V26, P6539, DOI 10.1021/bi00394a038; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TREVES S, 1990, BIOCHEM J, V271, P473, DOI 10.1042/bj2710473; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	54	74	80	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39555	39568		10.1074/jbc.M005473200	http://dx.doi.org/10.1074/jbc.M005473200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11007777	hybrid			2022-12-27	WOS:000165953100082
J	Carlos, JL; Paetzel, M; Brubaker, G; Karla, A; Ashwell, CM; Lively, MO; Cao, GQ; Bullinger, P; Dalbey, RE				Carlos, JL; Paetzel, M; Brubaker, G; Karla, A; Ashwell, CM; Lively, MO; Cao, GQ; Bullinger, P; Dalbey, RE			The role of the membrane-spanning domain of type I signal peptidases in substrate cleavage site selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI LEADER PEPTIDASE; ESCHERICHIA-COLI; DIRECTED MUTAGENESIS; SECRETORY PRECURSOR; FUNCTIONAL LIMITS; BACILLUS-SUBTILIS; ACTIVE-SITE; NUCLEASE-A; FACTOR-XA; SEQUENCE	Type I signal peptidase (SPase I) catalyzes the cleavage of the amino-terminal signal sequences from preproteins destined for cell export. Preproteins contain a signal sequence with a positively charged n-region, a hydrophobic h-region, and a neutral but polar c-region, Despite having no distinct consensus sequence other than a commonly found c-region "Ala-X-Ala" motif preceding the cleavage site, signal sequences are recognized by SPase I with high fidelity, Remarkably, other potential Ala-X-Ala sites are not cleaved within the preprotein. One hypothesis is that the source of this fidelity is due to the anchoring of both the SPase I enzyme (by way of its transmembrane segment) and the preprotein substrate (by the h-region in the signal sequence) in the membrane, This limits the enzyme-substrate interactions such that cleavage occurs at only one site, In this work we have, for the first time, successfully isolated Bacillus subtilis type I signal peptidase (SipS) and a truncated version lacking the transmembrane domain (SipS-P2), With purified full-length as well. as truncated constructs of both B. subtilis and Escherichia coli (Lep) SPase I, in vitro specificity studies indicate that the transmembrane domains of either enzyme are not important determinants of in vitro cleavage fidelity, since enzyme constructs lacking them reveal no alternate site processing of pro-OmpA nuclease A substrate. In addition, experiments with mutant pro-OmpA nuclease A substrate constructs indicate that the h-region of the signal peptide is also not critical for substrate specificity. In contrast, certain mutants in the c-region of the signal peptide result in alternate site cleavage by both Lep and SipS enzymes.	Ohio State Univ, Dept Chem, Columbus, OH 43210 USA; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Wake Forest Univ, Sch Med, Winston Salem, NC 27157 USA	University System of Ohio; Ohio State University; University of British Columbia; Wake Forest University	Dalbey, RE (corresponding author), Ohio State Univ, Dept Chem, 120 W 18Th Ave, Columbus, OH 43210 USA.	dalbey@chemistry.ohio-state.edu	; Ashwell, Christopher/N-1332-2016	Paetzel, Mark/0000-0002-7408-5487; Ashwell, Christopher/0000-0002-8190-1147	NIGMS NIH HHS [GM32861, GM08512, GM48805] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM048805, R01GM032861, T32GM008512, R15GM132861] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATTERJEE S, 1995, J MOL BIOL, V245, P311, DOI 10.1006/jmbi.1994.0025; Cregg KM, 1996, J BACTERIOL, V178, P5712, DOI 10.1128/jb.178.19.5712-5718.1996; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; DATE T, 1983, J BACTERIOL, V154, P76, DOI 10.1128/JB.154.1.76-83.1983; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FIKES JD, 1990, J BIOL CHEM, V265, P3417; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JAIN RG, 1994, J BIOL CHEM, V269, P16305; Karamyshev AL, 1998, J MOL BIOL, V277, P859, DOI 10.1006/jmbi.1997.1617; Klenotic PA, 2000, J BIOL CHEM, V275, P6490, DOI 10.1074/jbc.275.9.6490; Klug G, 1997, MOL GEN GENET, V253, P666, DOI 10.1007/s004380050370; KUHN A, 1985, J BIOL CHEM, V260, P5914; LAFORET GA, 1991, J BIOL CHEM, V266, P1326; Maniatis T., 1982, MOL CLONING LAB MANU; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NILSSON IM, 1991, J BIOL CHEM, V266, P3408; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Paetzel M, 1997, TRENDS BIOCHEM SCI, V22, P28, DOI 10.1016/S0968-0004(96)10065-7; PATTERSON WR, 1994, J BIOL CHEM, V269, P17020; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; ROSENBLATT M, 1980, P NATL ACAD SCI-BIOL, V77, P3983, DOI 10.1073/pnas.77.7.3983; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SHEN LM, 1991, BIOCHEMISTRY-US, V30, P11775, DOI 10.1021/bi00115a006; Stein RL, 2000, BIOCHEMISTRY-US, V39, P7973, DOI 10.1021/bi000352i; TAKAHARA M, 1985, J BIOL CHEM, V260, P2670; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tjalsma H, 1998, GENE DEV, V12, P2318, DOI 10.1101/gad.12.15.2318; TSCHANTZ WR, 1995, BIOCHEMISTRY-US, V34, P3935, DOI 10.1021/bi00012a010; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VONHEIJNE G, 1989, FEBS LETT, V244, P439, DOI 10.1016/0014-5793(89)80579-4; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1986, J MOL BIOL, V192, P287, DOI 10.1016/0022-2836(86)90365-7; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEARNE SJ, 1990, FEBS LETT, V263, P23, DOI 10.1016/0014-5793(90)80696-G; Zhang YB, 1997, GENE, V194, P249, DOI 10.1016/S0378-1119(97)00198-4; Zhong WY, 1998, ANAL BIOCHEM, V255, P66, DOI 10.1006/abio.1997.2471	40	50	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38813	38822		10.1074/jbc.M007093200	http://dx.doi.org/10.1074/jbc.M007093200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10982814	Green Published, hybrid			2022-12-27	WOS:000165739800092
J	Chen, MC; Hsu, TL; Luh, TY; Hsieh, SL				Chen, MC; Hsu, TL; Luh, TY; Hsieh, SL			Overexpression of Bcl-2 enhances LIGHT- and interferon-gamma-mediated apoptosis in Hep3BT2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR SUPERFAMILY; NECROSIS-FACTOR FAMILY; HERPESVIRUS ENTRY MEDIATOR; LYMPHOTOXIN BETA-RECEPTOR; ALPHA-INDUCED APOPTOSIS; NEWLY IDENTIFIED MEMBER; HUMAN HEPATOMA-CELLS; GROWTH-FACTOR-BETA; CYTOCHROME-C; TNF FAMILY	LIGHT is a member of the tumor necrosis factor superfamily and is the Ligand for LT-betaR, HVEM, and decoy receptor 3. LIGHT has a cytotoxic effect, which is further enhanced by the presence of interferon-gamma (IFN-gamma). Although LIGHT/IFN-gamma can activate caspase activity, neither benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethylketone nor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone can completely inhibit LIGHT/IFN-gamma -mediated apoptosis. Moreover, overexpression of Bcl-2 further enhances LIGHT/IFN-gamma -mediated apoptosis. It appears that LIGHT and IFN-gamma act synergistically to activate caspase-3, with the resultant cleavage of Bcl-2, removal of the BH4 domain, leading to conversion of Bcl-2 from an antiapoptotic to a proapoptotic form in p53-deficient hepatocellular carcinoma Hep3BT2 cells. Thus, LIGHT seems to be able to override the protective effect of Bcl-2 and induce cell death. Although benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethylketone and benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone can prevent the cleavage of Bcl-2 by LIGHT/IFN-gamma they only partially inhibit apoptosis in Hep3BT2 cells that are overexpressing Bcl-2. In contrast, both LIGHT/IFN-gamma -mediated apoptosis and Bcl-2 cleavage are inhibited by free radical scavengers, indicating that free radicals may play an essential role in LIGHT/IFN-gamma -mediated apoptosis at a step upstream of caspase-3 activation. These results suggest that LIGHT signaling may diverge into multiple, separate processes.	Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 11221, Taiwan; Natl Yang Ming Univ, Dept Immunol & Microbiol, Taipei 11221, Taiwan; Natl Taiwan Univ, Dept Chem, Taipei 11221, Taiwan; Natl Yang Ming Univ, Immunol Res Ctr, Taipei 11221, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Taiwan University; National Yang Ming Chiao Tung University	Hsieh, SL (corresponding author), Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 11221, Taiwan.	slhsieh@ym.edu.tw	Hsieh, Shie-Liang Edmond/ABA-9184-2021; Hsu, Tsui-Ling/AAE-8821-2019; Hsu, Tsui-Ling/H-6704-2015	Hsu, Tsui-Ling/0000-0002-2912-3261; Luh, Tien-Yau/0000-0002-0415-6454				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Brustugun OT, 1998, CELL DEATH DIFFER, V5, P660, DOI 10.1038/sj.cdd.4400399; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; Deas O, 1998, J IMMUNOL, V161, P3375; DegliEsposti MA, 1997, J IMMUNOL, V158, P1756; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434; Eby MT, 2000, J BIOL CHEM, V275, P15336, DOI 10.1074/jbc.275.20.15336; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Ettinger R, 1996, P NATL ACAD SCI USA, V93, P13102, DOI 10.1073/pnas.93.23.13102; Fadeel B, 1999, LEUKEMIA, V13, P719, DOI 10.1038/sj.leu.2401411; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; GRUSS HJ, 1995, CYTOKINES MOL THER, V1, P75; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Hirotani M, 1999, J BIOL CHEM, V274, P20415, DOI 10.1074/jbc.274.29.20415; HIRSCH A, 1994, ANGEW CHEM INT EDIT, V33, P437, DOI 10.1002/anie.199404371; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; Hsu SC, 1998, BLOOD, V91, P2658, DOI 10.1182/blood.V91.8.2658.2658_2658_2663; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Huang YL, 1998, EUR J BIOCHEM, V254, P38, DOI 10.1046/j.1432-1327.1998.2540038.x; Huang YL, 1998, J BIOMED SCI, V5, P185; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Kasahara Y, 1997, BLOOD, V89, P1748, DOI 10.1182/blood.V89.5.1748.1748_1748_1753; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kohno T, 1996, J IMMUNOL, V156, P4722; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; Kurokawa H, 1999, ONCOL REP, V6, P33; Kwon BS, 1999, J BIOL CHEM, V274, P6056, DOI 10.1074/jbc.274.10.6056; Kwon BS, 1997, J BIOL CHEM, V272, P14272, DOI 10.1074/jbc.272.22.14272; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LAMPARTH I, 1994, J CHEM SOC CHEM COMM, P1727, DOI 10.1039/c39940001727; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Moore PA, 1999, SCIENCE, V285, P260, DOI 10.1126/science.285.5425.260; Mukhopadhyay A, 1999, J BIOL CHEM, V274, P15978, DOI 10.1074/jbc.274.23.15978; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANDSTROM PA, 1994, J LEUKOCYTE BIOL, V55, P221, DOI 10.1002/jlb.55.2.221; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Shu HB, 1999, J LEUKOCYTE BIOL, V65, P680, DOI 10.1002/jlb.65.5.680; Sidoti-de Fraisse C, 1998, ONCOGENE, V17, P1639, DOI 10.1038/sj.onc.1202094; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; Tamada K, 2000, NAT MED, V6, P283; Tanabe K, 1999, J BIOL CHEM, V274, P15725, DOI 10.1074/jbc.274.22.15725; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wang IC, 1999, J MED CHEM, V42, P4614, DOI 10.1021/jm990144s; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Xie KP, 1996, CANCER IMMUNOL IMMUN, V43, P109, DOI 10.1007/s002620050310; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Yu KY, 1999, J BIOL CHEM, V274, P13733, DOI 10.1074/jbc.274.20.13733; Yue TL, 1999, J BIOL CHEM, V274, P1479, DOI 10.1074/jbc.274.3.1479; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zhai YF, 1998, J CLIN INVEST, V102, P1142, DOI 10.1172/JCI3492; Zhai YF, 1999, FASEB J, V13, P181, DOI 10.1096/fasebj.13.1.181; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zheng TS, 2000, NAT BIOTECHNOL, V18, P717, DOI 10.1038/77276	79	42	49	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38794	38801		10.1074/jbc.M003292200	http://dx.doi.org/10.1074/jbc.M003292200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10993881	hybrid			2022-12-27	WOS:000165739800090
J	Egas, C; Lavoura, N; Resende, R; Brito, RMM; Pires, E; de Lima, MCP; Faro, C				Egas, C; Lavoura, N; Resende, R; Brito, RMM; Pires, E; de Lima, MCP; Faro, C			The saposin-like domain of the plant aspartic proteinase precursor is a potent inducer of vesicle leakage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYNARA-CARDUNCULUS L; NK-LYSIN; PHOSPHOLIPID-MEMBRANES; CRYSTAL-STRUCTURE; BARLEY; GRANULYSIN; PEPTIDES; CARDOSIN; BINDING; FUSION	A unique feature of plant aspartic proteinase precursors is the presence of an internal domain, known as plant-specific insert, whose function is not completely understood. The three-dimensional structure of the plant-specific insert resembles that of saposin-like proteins, a group of lipid-binding proteins involved in a variety of physiological processes. Here we show that recombinant plant-specific insert is able to interact with phospholipid vesicles and to induce leakage of their contents in a pH- and lipid-dependent manner. The leakage activity is higher at pH 4.5 and requires the presence of acidic phospholipids such as phosphatidylserine. To determine whether the same effect could be observed when the plant-specific insert is part of the precursor form, procardosin A and a mutant form lacking this specific domain were produced and characterized. Procardosin A displays a similar activity profile, whereas the mutant without the plant-specific insert shows only residual activity. These findings indicate that the plant-specific insert domain of plant aspartic proteinases mediates an interaction of their precursors with phospholipid membranes and induces membrane permeabilization. It is therefore possible that the plant-specific insert, alone or in conjunction with the proteolytic activity of plant aspartic proteinases, may function either as a defensive weapon against pathogens or in late autolysis of plant cells.	Univ Coimbra, Ctr Neurociencias Coimbra, P-3004517 Coimbra, Portugal; Univ Coimbra, Dept Bioquim, Fac Ciencias & Tecnol, P-3001401 Coimbra, Portugal; Univ Coimbra, Dept Quim, Fac Ciencias & Tecnol, P-3004535 Coimbra, Portugal	Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra	Egas, C (corresponding author), Ctr Neurociencias Coimbra, Dept Biol Mol & Biotecnol, Inst Biomed Invest Luz & Imagem, Azinhaga Santa Comba, P-3000 Coimbra, Portugal.	cve@imagem.ibili.uc.pt	Resende, Rosa/F-4610-2010; de Lima, Maria da Conceição Monteiro/AAS-5602-2021; Resende, Rosa/AFU-7705-2022; Egas, Conceição/K-4866-2014	Resende, Rosa/0000-0002-0504-5756; de Lima, Maria da Conceição Monteiro/0000-0003-1844-5027; Egas, Conceição/0000-0002-2307-5414; Brito, Rui/0000-0001-9128-2557; Faro, Carlos/0000-0002-0480-8379; Pires, Euclides/0000-0002-5853-0165				Andreu D, 1999, BIOCHEM J, V344, P845, DOI 10.1042/0264-6021:3440845; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Beck DC, 2000, J BIOL CHEM, V275, P3365, DOI 10.1074/jbc.275.5.3365; Chang R, 1998, BBA-BIOMEMBRANES, V1371, P254, DOI 10.1016/S0005-2736(98)00031-5; Chen FQ, 1997, PLANT MOL BIOL, V35, P821, DOI 10.1023/A:1005833207707; DEKRUIJFF B, 1994, FEBS LETT, V346, P78, DOI 10.1016/0014-5793(94)00404-8; Faro C, 1999, J BIOL CHEM, V274, P28724, DOI 10.1074/jbc.274.40.28724; Faro C, 1998, ADV EXP MED BIOL, V436, P423; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Frazao C, 1999, J BIOL CHEM, V274, P27694, DOI 10.1074/jbc.274.39.27694; Gamen S, 1998, J IMMUNOL, V161, P1758; Glathe S, 1998, J BIOL CHEM, V273, P31230, DOI 10.1074/jbc.273.47.31230; GURUPRASAD K, 1994, FEBS LETT, V352, P131, DOI 10.1016/0014-5793(94)00935-X; HEELEE I, 1997, FEBS LETT, V400, P158; James MNG, 1998, ASPARTIC PROTEINASES; Kervinen J, 1999, EMBO J, V18, P3947, DOI 10.1093/emboj/18.14.3947; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; Leippe M, 1997, PARASITOL TODAY, V13, P178, DOI 10.1016/S0169-4758(97)01038-7; Liepinsh E, 1997, NAT STRUCT BIOL, V4, P793, DOI 10.1038/nsb1097-793; MagetDana R, 1997, BIOPHYS J, V73, P2527, DOI 10.1016/S0006-3495(97)78281-X; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P11856, DOI 10.1021/bi980539y; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P6521, DOI 10.1021/bi00019a033; Nir S, 1999, MOL MEMBR BIOL, V16, P95, DOI 10.1080/096876899294814; OSTOLAZA H, 1993, BIOCHIM BIOPHYS ACTA, V1147, P81, DOI 10.1016/0005-2736(93)90318-T; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P179, DOI 10.1016/S0968-0004(00)89003-9; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; RAFALSKI M, 1991, BIOCHEMISTRY-US, V30, P10211, DOI 10.1021/bi00106a020; Ramalho-Santos M, 1998, EUR J BIOCHEM, V255, P133, DOI 10.1046/j.1432-1327.1998.2550133.x; RamalhoSantos M, 1997, PLANTA, V203, P204, DOI 10.1007/s004250050183; Runeberg-Roos P, 1998, PLANT J, V15, P139, DOI 10.1046/j.1365-313X.1998.00187.x; Ruysschaert JM, 1998, FEBS LETT, V425, P341, DOI 10.1016/S0014-5793(98)00261-0; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Tatti M, 1999, EUR J BIOCHEM, V263, P486, DOI 10.1046/j.1432-1327.1999.00521.x; Vaccaro AM, 1999, NEUROCHEM RES, V24, P307, DOI 10.1023/A:1022530508763; Vaccaro AM, 1995, J BIOL CHEM, V270, P30576, DOI 10.1074/jbc.270.51.30576; Verissimo P, 1996, EUR J BIOCHEM, V235, P762, DOI 10.1111/j.1432-1033.1996.00762.x; White PC, 1999, J BIOL CHEM, V274, P16685, DOI 10.1074/jbc.274.24.16685	37	50	53	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38190	38196		10.1074/jbc.M006093200	http://dx.doi.org/10.1074/jbc.M006093200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10982803	hybrid			2022-12-27	WOS:000165739800010
J	Leclerc, S; Garnier, M; Hoessel, R; Marko, D; Bibb, JA; Snyder, GL; Greengard, P; Biernat, J; Wu, YZ; Mandelkow, EM; Eisenbrand, G; Meijer, L				Leclerc, S; Garnier, M; Hoessel, R; Marko, D; Bibb, JA; Snyder, GL; Greengard, P; Biernat, J; Wu, YZ; Mandelkow, EM; Eisenbrand, G; Meijer, L			Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease - A property common to most cycline-dependent kinase inhibitors?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE INHIBITOR; CARCINOMA CELLS; XENOPUS EMBRYOS; REPEAT DOMAIN; BETA-CATENIN; CDC2 KINASE; NEURONS; LITHIUM; CDK2; ACTIVATION	The bis-indole indirubin is an active ingredient of Danggui Longhui Wan, a traditional Chinese medicine recipe used in the treatment of chronic diseases such as leukemias. The antitumoral properties of indirubin appear to correlate with their antimitotic effects. Indirubins were recently described as potent (IC50: 50-100 nm) inhibitors of cyclin-dependent kinases (CDKs), We report here that indirubins are also powerful inhibitors (IC50: 5-50 nM) of an evolutionarily related kinase, glycogen synthase kinase-3 beta (GSK-3 beta), Testing of a series of indoles and bis-indoles against GSK-3 beta, CDK1/cyclin B, and CDK5/p25 shows that only indirubins inhibit these kinases, The structure-activity relationship study also suggests that indirubins bind to GSK-3 beta 's ATP binding pocket in a way similar to their binding to CDKs, the details of which were recently revealed by crystallographic analysis. GSK-3 beta, along with CDK5, is responsible for most of the abnormal hyperphosphorylation of the microtubule-binding protein tau observed in Alzheimer's disease. Indirubin-3'-monoxime inhibits tau phosphorylation in vitro and in vivo at Alzheimer's disease-specific sites. Indirubins may thus have important implications in the study and treatment of neurodegenerative disorders. Indirubin-3'-monoxime also inhibits the in vivo phosphorylation of DARPP-32 by CDK5 on Thr-75, thereby mimicking one of the effects of dopamine in the striatum, Finally, we show that many, but not all, reported CDK inhibitors are powerful inhibitors of GSK-3 beta, To which extent these GSK-3 beta effects of: CDK inhibitors actually contribute to their antimitotic and antitumoral properties remains to be determined. Indirubins constitute the first family of low nanomolar inhibitors of GSK-3 beta to be described.	CNRS, Biol Stn, Cell Cycle Grp, F-29682 Roscoff, France; Univ Kaiserslautern, Div Food Chem & Environm Toxicol, Dept Chem, D-67663 Kaiserslautern, Germany; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Max Planck Unit Struct Mol Biol, D-22603 Hamburg, Germany	Centre National de la Recherche Scientifique (CNRS); University of Kaiserslautern; Rockefeller University; Max Planck Society	Meijer, L (corresponding author), CNRS, Biol Stn, Cell Cycle Grp, BP 74, F-29682 Roscoff, France.	meijer@sb-roscoff.fr	Marko, Doris/B-9354-2014; Eisenbrand, Gerhard/AEQ-0284-2022	Marko, Doris/0000-0001-6568-2944; Eisenbrand, Gerhard/0000-0003-4079-2463; Garnier, Matthieu/0000-0001-7391-547X	NIMH NIH HHS [MH40899] Funding Source: Medline; PHS HHS [DQ10044] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Akiyama T, 1997, CANCER RES, V57, P1495; [Anonymous], 1992, CHIN DRUGS PLANT ORI; Balfour-Paul Jenny, 1998, INDIGO; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Bible KC, 1996, CANCER RES, V56, P4856; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; Biernat J, 1999, MOL BIOL CELL, V10, P727, DOI 10.1091/mbc.10.3.727; Borgne A, 1999, J BIOL CHEM, V274, P11977, DOI 10.1074/jbc.274.17.11977; BRUSSELBACH S, 1998, INT J CANCER, P1; Carlson BA, 1996, CANCER RES, V56, P2973; Chang CN, 1985, ADV CHINESE MED MAT, P369; Chang YT, 1999, CHEM BIOL, V6, P361, DOI 10.1016/S1074-5521(99)80048-9; Chen D. W., 1979, COMMUNICATIONS CHINE, V10, P7; CHEN DH, 1984, CHINESE TRAD HERBAL, V15, P6; Cohen P, 1999, PHILOS T R SOC B, V354, P485, DOI 10.1098/rstb.1999.0399; Cooperative Group of Clinical Therapy of Indirubin, 1980, CHINESE J INTERN MED, V1, P132; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DUNPHY WG, 1997, METHOD ENZYMOL, V283, P1; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; Emily-Fenouil F, 1998, DEVELOPMENT, V125, P2489; Gan WJ, 1985, CHIN ACAD MED SCI BE, V6, P611; Garrett MD, 1999, CURR OPIN GENET DEV, V9, P104, DOI 10.1016/S0959-437X(99)80015-X; Godemann R, 1999, FEBS LETT, V454, P157, DOI 10.1016/S0014-5793(99)00741-3; Gray N, 1999, CURR MED CHEM, V6, P859; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Haass Christian, 1999, Trends in Cell Biology, V9, P241, DOI 10.1016/S0962-8924(99)01576-7; HAN R, 1998, J ETHNOPHARMACOL, V24, P1; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; HUGHES K, 1992, EUR J BIOCHEM, V203, P305, DOI 10.1111/j.1432-1033.1992.tb19860.x; HURRY JB, 1930, WOOD PLANT ITS DYE; Imahori K, 1997, J BIOCHEM, V121, P179; Institute of Haematology Chinese Academy of Medical Sciences, 1979, CHINESE J INTERN MED, V18, P83; Institute of Hematology Chinese Academy of Medical Sciences, 1979, CHINESE J INTERN MED, V15, P86; JI XJ, 1981, ACTA PHARM SIN, V16, P146; KITAGAWA M, 1993, ONCOGENE, V8, P2425; Knockaert M, 2000, CHEM BIOL, V7, P411, DOI 10.1016/S1074-5521(00)00124-1; LEE KH, 1993, ACS SYM SER, V534, P170; Lee KY, 1999, NEUROSCI RES, V34, P21, DOI 10.1016/S0168-0102(99)00026-7; Li CM, 1996, B CHEM SOC JPN, V69, P1621, DOI 10.1246/bcsj.69.1621; LIU CX, 1984, ACTA PHARMACOL SIN, V5, P137; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; Lovestone S, 1999, BIOL PSYCHIAT, V45, P995, DOI 10.1016/S0006-3223(98)00183-8; Lucas FR, 1998, J CELL SCI, V111, P1351; Ma M Z, 1983, J Tradit Chin Med, V3, P245; Maggirwar SB, 1999, J NEUROCHEM, V73, P578, DOI 10.1046/j.1471-4159.1999.0730578.x; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2000, CHEM BIOL, V7, P51, DOI 10.1016/S1074-5521(00)00063-6; Meijer L, 1997, METHOD ENZYMOL, V283, P113; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; Nishi A, 1997, J NEUROSCI, V17, P8147; Park SG, 1996, MOL CELLS, V6, P679; RIALET V, 1991, ANTICANCER RES, V11, P1581; Schultz C, 1999, J MED CHEM, V42, P2909, DOI 10.1021/jm9900570; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Senderowicz AM, 1998, J CLIN ONCOL, V16, P2986, DOI 10.1200/JCO.1998.16.9.2986; Sengupta A, 1997, MOL CELL BIOCHEM, V167, P99, DOI 10.1023/A:1006883924775; Sharma P, 1999, P NATL ACAD SCI USA, V96, P11156, DOI 10.1073/pnas.96.20.11156; *SICH I TRAD CHIN, 1981, CHIN TRAD HERB DRUGS, V12, P27; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; TAKAHASHI I, 1987, J ANTIBIOT, V40, P1782, DOI 10.7164/antibiotics.40.1782; Takashima A, 1998, NEUROSCI RES, V31, P317, DOI 10.1016/S0168-0102(98)00061-3; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Tang D, 1996, Prog Cell Cycle Res, V2, P205; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; VOGT PK, 1998, CURR TOP MICROBIOL I, V227, P1; WANG JH, 1981, ACTA PHARM SINICA, V2, P241; Wang JZ, 1999, ALZHEIMER'S DISEASE AND RELATED DISORDERS, P311; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wu G.Y., 1980, CHIN MED J, V60, P451; WU GY, 1982, SCI SIN B-CHEM B A M, V25, P1071; WU LM, 1979, COMM CHINESE HERBAL, V9, P6; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yu LJ, 1998, J BIOL CHEM, V273, P33455, DOI 10.1074/jbc.273.50.33455; Zaharevitz DW, 1999, CANCER RES, V59, P2566; ZHANG L, 1985, ACTA ACAD MED SIN, V7, P112; Zhang Z N, 1985, J Tradit Chin Med, V5, P246; ZHANG ZN, 1985, CHINESE J INTEGRATED, V5, P80; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x	82	645	694	0	88	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					251	260		10.1074/jbc.M002466200	http://dx.doi.org/10.1074/jbc.M002466200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11013232	hybrid			2022-12-27	WOS:000166280700035
J	Wendt, CH; Gick, G; Sharma, R; Zhuang, Y; Deng, WL; Ingbar, DH				Wendt, CH; Gick, G; Sharma, R; Zhuang, Y; Deng, WL; Ingbar, DH			Up-regulation of Na,K-ATPase beta(1) transcription by hyperoxia is mediated by SP1/SP3 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MDCK EPITHELIAL-CELLS; NF-KAPPA-B; SUBUNIT GENE; PROTEINS SP1; SP FAMILY; ACTIVATION; LUNG; GROWTH; EXPRESSION; PROMOTER	The sodium pump, Na,K-ATPase, is an important protein for maintaining intracellular ion concentration, cellular volume, and ion transport and is regulated both transcriptionally and post-transcriptionally. We previously-demonstrated that hyperoxia increased Na,K-ATPase beta (1) gene expression in Madin-Darby canine kidney (MDCK) cells. In this study, we identify a DNA element necessary for up-regulation of the Na,K-ATPase beta (1) transcription by hyperoxia and evaluate the nuclear proteins responsible for this up-regulation. Transient transfection experiments in MOCK cells using sequential 5'-deletions of the rat Na,K-ATPase beta (1) promoter-luciferase fusion gene demonstrated promoter activation by hyperoxia between -102 and +151. The hyperoxia response was localized to a 7-base pair region between -62 and -55, which contained a GC-rich region consistent with a consensus sequence for the SP1 family, that was sufficient for up-regulation by hyperoxia. This GC element exhibited both basal and hyperoxia-induced promoter activity and bound both transcription factors SP1 and SP3 in electrophoretic mobility shift assays. In addition, electrophoretic mobility shift assays demonstrated increased binding of SP1/SP3 in cells exposed to hyperoxia while mutation of this element eliminated protein binding. Other GC sites within the proximal promoter also demonstrated up-regulation of transcription by hyperoxia, however, the site at -55 had higher affinity for SP proteins.	Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; SUNY Hlth Sci Ctr, Dept Biochem, Brooklyn, NY 11203 USA	University of Minnesota System; University of Minnesota Twin Cities; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Wendt, CH (corresponding author), Univ Minnesota, Dept Med, Box 276 Mayo Mail Code,420 Delaware St SE, Minneapolis, MN 55455 USA.	wendt005@tc.umn.edu	Wendt, Chris/C-6823-2012	Ingbar, David H./0000-0003-1695-4493				Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Carter EP, 1997, AM J PHYSIOL-LUNG C, V272, pL542, DOI 10.1152/ajplung.1997.272.3.L542; Chalaka S, 1999, AM J PHYSIOL-LUNG C, V277, pL197, DOI 10.1152/ajplung.1999.277.1.L197; Chu SJ, 1999, AM J PHYSIOL-LUNG C, V276, pL614, DOI 10.1152/ajplung.1999.276.4.L614; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; DREHER D, 1992, AM J PHYSIOL, V262, pC358, DOI 10.1152/ajpcell.1992.262.2.C358; Factor P, 1998, J CLIN INVEST, V102, P1421, DOI 10.1172/JCI3214; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HammKunzelmann B, 1997, FEBS LETT, V403, P87, DOI 10.1016/S0014-5793(97)00029-X; Harris ZL, 1996, EUR RESPIR J, V9, P472, DOI 10.1183/09031936.96.09030472; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; HORISBERGER JD, 1991, ANNU REV PHYSIOL, V53, P565, DOI 10.1146/annurev.physiol.53.1.565; Jiang JG, 1997, ONCOGENE, V14, P3039, DOI 10.1038/sj.onc.1201152; Jyonouchi H, 1997, NUTR CANCER, V28, P115, DOI 10.1080/01635589709514562; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LIU B, 1993, CELL MOL BIOL RES, V39, P221; LIU B, 1992, BIOCHIM BIOPHYS ACTA, V1130, P336, DOI 10.1016/0167-4781(92)90449-A; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MEYER M, 1994, CHEM-BIOL INTERACT, V91, P91, DOI 10.1016/0009-2797(94)90029-9; Murakami Y, 1997, BBA-GENE STRUCT EXPR, V1352, P311, DOI 10.1016/S0167-4781(97)00032-8; Netzker R, 1997, EUR J BIOCHEM, V245, P174, DOI 10.1111/j.1432-1033.1997.00174.x; NICI L, 1994, AM J PHYSIOL, V261, pL307; OLIVERA W, 1994, AM J PHYSIOL, V266, pL577, DOI 10.1152/ajplung.1994.266.5.L577; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; Rajakumar RA, 1998, J BIOL CHEM, V273, P27474, DOI 10.1074/jbc.273.42.27474; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Schanke JT, 1998, MOL ENDOCRINOL, V12, P405, DOI 10.1210/me.12.3.405; SKOU JC, 1988, METHOD ENZYMOL, V156, P1; Toonen RFG, 1996, BIOCHEM J, V316, P467, DOI 10.1042/bj3160467; Wendt CH, 1999, CHEST, V116, p87S, DOI 10.1378/chest.116.suppl_1.87S; Wendt CH, 1998, AM J PHYSIOL-CELL PH, V274, pC356, DOI 10.1152/ajpcell.1998.274.2.C356; Wu XS, 1996, MOL CELL BIOL, V16, P1035; Wu YX, 1998, BIOCHEM J, V330, P1469, DOI 10.1042/bj3301469	37	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41396	41404		10.1074/jbc.M004759200	http://dx.doi.org/10.1074/jbc.M004759200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10988288	hybrid			2022-12-27	WOS:000166114600097
J	Bai, RL; Covell, DG; Pei, XF; Ewell, JB; Nguyen, NY; Brossi, A; Hamel, E				Bai, RL; Covell, DG; Pei, XF; Ewell, JB; Nguyen, NY; Brossi, A; Hamel, E			Mapping the binding site of colchicinoids on beta-tubulin - 2-chloroacetyl-2-demethylthiocolchicine covalently reacts predominantly with cysteine 239 and secondarily with cysteine 354	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN; BIOLOGICAL PROPERTIES; NUCLEOCAPSID PROTEIN; INHIBITOR BINDING; THIOCOLCHICINE; AGENTS; IDENTIFICATION; SEPARATION; KINETICS; RESIDUE	2-Chloroacetyl-2-demethylthiocolchicine (2CTC) and 3-chloroacetyl-3-demethylthiocolchicine (3CTC) resemble colchicine in binding to tubulin and react covalently with beta -tubulin, forming adducts with cysteine residues 239 and 354. The adducts at Cys-239 are less stable than those at Cys-354 during formic acid digestion. Extrapolating to zero time, the Cys-239 to Cys-354 adduct ratio is 77:23 for 2CTC and 27:73 for 3CTC. Using energy minimization modeling to dock colchicinoids into the electron crystallographic model of P-tubulin in protofilaments (Nogales, E., Wolf, S. G., and Downing, K. H. (1998) Nature 391, 199-203), we found two potential binding sites. At one, entirely encompassed within beta -tubulin, the C2- and CS-oxygen atoms of 2CTC and 3CTC overlapped poorly with those of colchicine and thiocolchicine, but distances from the reactive carbon atoms of the analogs to the sulfur atoms of the cysteine residues were qualitatively consistent with reactivity. The other potential binding site was located at the alpha/beta interface. Here, the oxygen atoms of the analogs overlapped well with those of colchicine, but relative distances of the reactive carbons to the cysteine sulfur atoms did not correlate with the observed reactivity. A significant conformational change must occur in the colchicine binding site of tubulin in the transition from the unpolymerized to the polymerized state.	NCI, Screening Technol Branch, Dev Therapeut Program, Div Canc Treatment & Diag,Frederick Canc Res & De, Frederick, MD 21702 USA; NCI, Lab Expt & Computat Biol, Frederick Canc Res & Dev Ctr, Sci Applicat Int Corp, Frederick, MD 21702 USA; NIDDK, Struct Biol Lab, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Facil Biotechnol Resources, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); US Food & Drug Administration (FDA)	Hamel, E (corresponding author), NCI, Screening Technol Branch, Dev Therapeut Program, Div Canc Treatment & Diag,Frederick Canc Res & De, Bldg 469,Rm 104,POB B, Frederick, MD 21702 USA.				NCI NIH HHS [N01CO56000] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai RL, 1999, J BIOL CHEM, V274, P12710, DOI 10.1074/jbc.274.18.12710; Bai RL, 1996, J BIOL CHEM, V271, P12639, DOI 10.1074/jbc.271.21.12639; BAI RL, 1989, BIOCHEMISTRY-US, V28, P5606, DOI 10.1021/bi00439a040; BANERJEE A, 1988, J BIOL CHEM, V263, P3029; BANERJEE A, 1992, J BIOL CHEM, V267, P13335; BANERJEE A, 1994, J BIOL CHEM, V269, P10324; Banerjee A, 1999, BIOCHEM BIOPH RES CO, V254, P334, DOI 10.1006/bbrc.1998.9943; BANERJEE A, 1991, J BIOL CHEM, V266, P1689; Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828; BOYE O, 1992, J LABELLED COMPOUNDS, V33, P293; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; CHABIN RM, 1989, BIOCHEM BIOPH RES CO, V161, P544, DOI 10.1016/0006-291X(89)92633-8; Covell DG, 1998, THEOCHEM-J MOL STRUC, V423, P93, DOI 10.1016/S0166-1280(97)00122-X; Downing KH, 1998, EUR BIOPHYS J BIOPHY, V27, P431, DOI 10.1007/s002490050153; FLOYD LJ, 1989, BIOCHEMISTRY-US, V28, P8515, DOI 10.1021/bi00447a037; GROVER S, 1992, BIOCHEM BIOPH RES CO, V187, P1350, DOI 10.1016/0006-291X(92)90451-P; HAMEL E, 1984, BIOCHEMISTRY-US, V23, P4173, DOI 10.1021/bi00313a026; HASTIE SB, 1991, PHARMACOL THERAPEUT, V51, P377, DOI 10.1016/0163-7258(91)90067-V; Huang MJ, 1998, J MED CHEM, V41, P1371, DOI 10.1021/jm9708543; KANG GJ, 1990, J BIOL CHEM, V265, P10255; Landon, 1977, Methods Enzymol, V47, P145; LEE YC, 1974, J NEUROBIOL, V5, P317, DOI 10.1002/neu.480050404; LUDUENA RF, 1981, BIOCHEMISTRY-US, V20, P4444, DOI 10.1021/bi00518a032; LUDUENA RF, 1991, PHARMACOL THERAPEUT, V49, P133, DOI 10.1016/0163-7258(91)90027-J; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; RAO S, 1994, J BIOL CHEM, V269, P3132; Rice WG, 1996, J MED CHEM, V39, P3606, DOI 10.1021/jm960375o; Rice WG, 1997, NAT MED, V3, P341, DOI 10.1038/nm0397-341; Turpin JA, 1999, J MED CHEM, V42, P67, DOI 10.1021/jm9802517; UPPULURI S, 1993, P NATL ACAD SCI USA, V90, P11598, DOI 10.1073/pnas.90.24.11598; Wallqvist A, 1996, PROTEINS, V25, P403, DOI 10.1002/(SICI)1097-0134(199608)25:4<403::AID-PROT1>3.0.CO;2-E; WALLQVIST A, 1995, PROTEIN SCI, V4, P1881, DOI 10.1002/pro.5560040923; WILLIAMS RF, 1985, J BIOL CHEM, V260, P3794; WILSON L, 1973, J CELL BIOL, V58, P709, DOI 10.1083/jcb.58.3.709; WOLFF J, 1991, P NATL ACAD SCI USA, V88, P2820, DOI 10.1073/pnas.88.7.2820; YEH HJC, 1988, FEBS LETT, V229, P82, DOI 10.1016/0014-5793(88)80802-0; YOUNG L, 1994, PROTEIN SCI, V3, P717	38	93	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40443	40452		10.1074/jbc.M005299200	http://dx.doi.org/10.1074/jbc.M005299200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11005811	hybrid			2022-12-27	WOS:000166039500087
J	Chen, VC; Chao, L; Chao, J				Chen, VC; Chao, L; Chao, J			A positively charged loop on the surface of kallistatin functions to enhance tissue kallikrein inhibition by acting as a secondary binding site for kallikrein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-C INHIBITOR; HEPARIN COFACTOR-II; PLASMINOGEN-ACTIVATOR INHIBITOR-1; ANTITHROMBIN-III; URINARY KALLIKREIN; THROMBIN; SERPIN; ALPHA-1-ANTITRYPSIN; IDENTIFICATION; SPECIFICITY	Kallistatin is a serine proteinase inhibitor (serpin) that specifically inhibits tissue kallikrein, The inhibitory activity of kallistatin is abolished upon heparin binding. The loop between the H helix and C2 sheet of kallistatin containing clusters of basic amino acid residues has been identified as a heparin-binding site. In this study, we investigated the role of the basic residues in this region in tissue kallikrein inhibition. Kallistatin mutants containing double Ala substitutions for these basic residues displayed a 70-80% reduction of association rate constants, indicating the importance of these basic residues in tissue kallikrein inhibition. A synthetic peptide derived from the sequence between the H helix and C2 sheet of kallistatin was shown to suppress the kallistatin-kallikrein interaction through competition for tissue kallikrein binding. To further evaluate the function of this loop, we used alpha1-antitrypsin, a nonheparin-binding serpin and slow tissue kallikrein inhibitor as a scaffold to engineer kallikrein inhibitors. An alpha1-antitrypsin chimera harboring the P3-P2' residues and a sequence homologous to the positively charged region between the H helix and C2 sheet of kallistatin acquired heparin-suppressed inhibitory activity toward tissue kallikrein and exhibited an inhibitory activity 20-fold higher than that of the other chimera, which contained only kallistatin's P3-P2' sequence, and 2300-fold higher than that of wild-type alpha1-antitrypsin. The alpha1-antitrypsin chimera with inhibitory characteristics similar to those of ballistatin demonstrates that the loop between the H helix and C2 sheet of kallistatin is crucial in tissue kallikrein inhibition, and this functional loop can be used as a module to enhance the inhibitory activity of a serpin toward tissue kallikrein. In conclusion, our results indicate that a positively charged loop between the H helix and C2 sheet of a serpin can accelerate the association of a serpin with tissue kallikrein by acting as a secondary binding site.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Chao, J (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 171 Ashley Ave, Charleston, SC 29425 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044083] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44083] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BHOOLA KD, 1992, PHARMACOL REV, V44, P1; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHEN VC, 2001, IN PRESS J BIOL CHEM, V276; CHEN VC, 2000, IN PRESS BIOCH BIOPH; CHEN VC, 2000, IN PRESS J BIOL CHEM, V275; Djie MZ, 1997, J BIOL CHEM, V272, P16268, DOI 10.1074/jbc.272.26.16268; DONOVAN FM, 1994, J BIOL CHEM, V269, P17199; ECKE S, 1992, J BIOL CHEM, V267, P7048; EHRLICH HJ, 1992, J BIOL CHEM, V267, P11606; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; ErsdalBadju E, 1997, J BIOL CHEM, V272, P19393, DOI 10.1074/jbc.272.31.19393; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; GEIGER R, 1981, H-S Z PHYSIOL CHEM, V362, P317, DOI 10.1515/bchm2.1981.362.1.317; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; Jiang H, 1995, INSECT BIOCHEM MOLEC, V25, P1093, DOI 10.1016/0965-1748(95)00042-9; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; JOHANSEN H, 1987, MOL BIOL MED, V4, P291; Katz BA, 1998, PROTEIN SCI, V7, P875; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LEBONNIEC BF, 1995, BIOCHEMISTRY-US, V34, P12241, DOI 10.1021/bi00038a019; MADISON EL, 1990, J BIOL CHEM, V265, P21423; OWEN BA, 1990, BIOCHEMISTRY-US, V29, P9412, DOI 10.1021/bi00492a015; PATSTON PA, 1994, THROMB HAEMOSTASIS, V72, P166; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; PRATT CW, 1992, J BIOL CHEM, V267, P8795; PRATT CW, 1992, J BIOL CHEM, V267, P8789; ROGERS SJ, 1992, J BIOL CHEM, V267, P2613; SHIMAMOTO K, 1980, J CLIN ENDOCR METAB, V51, P840, DOI 10.1210/jcem-51-4-840; SHIRK RA, 1994, J BIOL CHEM, V269, P28690; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WHINNA HC, 1991, J BIOL CHEM, V266, P8129; ZHOU GX, 1992, J BIOL CHEM, V267, P25873	35	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40371	40377		10.1074/jbc.M005691200	http://dx.doi.org/10.1074/jbc.M005691200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10991942	hybrid			2022-12-27	WOS:000166039500078
J	Cohen-Salmon, M; Frenz, D; Liu, W; Verpy, E; Voegeling, S; Petit, C				Cohen-Salmon, M; Frenz, D; Liu, W; Verpy, E; Voegeling, S; Petit, C			Fdp, a new fibrocyte-derived protein related to MIA/CD-RAP, has an in vitro effect on the early differentiation of the inner ear mesenchyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OTIC CAPSULE CHONDROGENESIS; ULTRASTRUCTURAL ANALYSIS; DEVELOPMENTAL DEFECTS; GROWTH-FACTOR; GENE DEFECT; DEAFNESS; CARTILAGE; MOUSE; EXPRESSION; MUTATIONS	During the course of a study aimed at isolating transcripts specifically or preferentially expressed in the inner ear, we identified a novel gene, encoding a fibrocyte-derived protein, that we named Fdp. Fdp is predicted to be a secreted 128-amino acid protein, which is highly homologous to the melanoma-inhibiting activity/cartilage-derived retinoic acid-sensitive protein (MIA/CD-RAP), a cartilage-specific protein also expressed in several tumors. Fdp and MIA/CD-RAP thus define a new family of proteins. Fdp is expressed from embryonic day 10.5 in the mesenchyme surrounding the otic epithelium. During development, these cells progressively aggregate, condense, and differentiate into cartilaginous cells forming the otic capsule, which no longer expresses Fdp, and into fibrocytes surrounding the epithelia, which strongly express Fdp. In order to address the function of Fdp, we developed an in vitro antisense oligonucleotide approach using microdissected periotic mesenchyme micromass cultures, and showed that Fdp antisense oligonucleotide treatment results in a significant reduction in chondrogenesis. Our results demonstrate that Fdp plays a role in the initiation of periotic mesenchyme chondrogenesis. Accordingly, Fdp and its human ortholog FDP, which map to chromosome 2 and band 20p11, respectively, could be candidate genes for forms of dearness associated with malformations of the otic capsule.	Inst Pasteur, CNRS, URA 1968, Unite Genet Deficits Sensoriels, F-75724 Paris 15, France; Yeshiva Univ Albert Einstein Coll Med, Dept Otolaryngol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Inst Pasteur, Unite Genet Mammiferes, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Petit, C (corresponding author), Inst Pasteur, CNRS, URA 1968, Unite Genet Deficits Sensoriels, 25 Rue Dr Roux, F-75724 Paris 15, France.	cpetit@pasteur.fr		Cohen-Salmon, Martine/0000-0002-5312-8476; Petit, Christine/0000-0002-9069-002X				AHRENS PB, 1977, DEV BIOL, V60, P69, DOI 10.1016/0012-1606(77)90110-5; Alloisio N, 1999, EUR J HUM GENET, V7, P255, DOI 10.1038/sj.ejhg.5200273; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BLESCH A, 1994, CANCER RES, V54, P5695; Bosserhoff AK, 1996, J BIOL CHEM, V271, P490, DOI 10.1074/jbc.271.1.490; Bosserhoff AK, 1997, DEV DYNAM, V208, P516, DOI 10.1002/(SICI)1097-0177(199704)208:4<516::AID-AJA7>3.0.CO;2-L; Chansky H, 1998, J ORTHOPAED RES, V16, P521, DOI 10.1002/jor.1100160502; Cohen-Salmon M, 1997, P NATL ACAD SCI USA, V94, P14450, DOI 10.1073/pnas.94.26.14450; DEKOK YJM, 1995, SCIENCE, V267, P685, DOI 10.1126/science.7839145; Denoyelle F, 1999, LANCET, V353, P1298, DOI 10.1016/S0140-6736(98)11071-1; Dietz UH, 1996, J BIOL CHEM, V271, P3311, DOI 10.1074/jbc.271.6.3311; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FRENZ DA, 1994, DEVELOPMENT, V120, P415; Frenz DA, 1996, ANN NY ACAD SCI, V785, P256, DOI 10.1111/j.1749-6632.1996.tb56277.x; FRENZ DA, 1992, DEV BIOL, V153, P324, DOI 10.1016/0012-1606(92)90117-Y; FRENZ DA, 1991, DEV BIOL, V144, P38, DOI 10.1016/0012-1606(91)90476-J; Frenz DA, 1998, GROWTH FACTORS, V15, P173, DOI 10.3109/08977199809002115; GROUP TEB, 1994, HUM MOL GENET, V3, P621; IURATO S, 1962, Z ZELLFORSCH MIK ANA, V56, P40, DOI 10.1007/BF00326848; KIKUCHI T, 1994, ACTA OTO-LARYNGOL, V114, P520, DOI 10.3109/00016489409126097; KIKUCHI T, 1995, ANAT EMBRYOL, V191, P101, DOI 10.1007/BF00186783; KNOWLTON VY, 1967, J MORPHOL, V121, P179, DOI 10.1002/jmor.1051210302; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lautermann J, 1998, CELL TISSUE RES, V294, P415, DOI 10.1007/s004410051192; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; LEV R, 1964, J HISTOCHEM CYTOCHEM, V12, P309, DOI 10.1177/12.4.309; LOHNES D, 1994, DEVELOPMENT, V120, P2723; MCPHEE JR, 1986, J EMBRYOL EXP MORPH, V97, P1; Minowa O, 1999, SCIENCE, V285, P1408, DOI 10.1126/science.285.5432.1408; Mustapha M, 1999, HUM MOL GENET, V8, P409, DOI 10.1093/hmg/8.3.409; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; PETIT C, 2000, IN PRESS METABOLIC M; Phippard D, 1999, J NEUROSCI, V19, P5980, DOI 10.1523/JNEUROSCI.19-14-05980.1999; Phippard D, 1998, HEARING RES, V120, P77, DOI 10.1016/S0378-5955(98)00059-8; Robertson NG, 1997, GENOMICS, V46, P345, DOI 10.1006/geno.1997.5067; ROBERTSON NG, 1994, GENOMICS, V23, P42, DOI 10.1006/geno.1994.1457; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHER AE, 1971, ACTA OTO-LARYNGOL, V285, P5; Simmler MC, 2000, NAT GENET, V24, P139, DOI 10.1038/72793; Spicer SS, 1996, HEARING RES, V100, P80, DOI 10.1016/0378-5955(96)00106-2; SPICER SS, 1991, HEARING RES, V56, P53, DOI 10.1016/0378-5955(91)90153-Z; TAKAHASHI T, 1970, Acta Oto-Laryngologica, V69, P46, DOI 10.3109/00016487009123335; Verhoeven K, 1998, NAT GENET, V19, P60, DOI 10.1038/ng0598-60; Verpy E, 1999, P NATL ACAD SCI USA, V96, P529, DOI 10.1073/pnas.96.2.529; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Xie WF, 1999, J BONE MINER RES, V14, P757, DOI 10.1359/jbmr.1999.14.5.757; Yasunaga S, 1999, NAT GENET, V21, P363, DOI 10.1038/7693	49	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40036	40041		10.1074/jbc.M002876200	http://dx.doi.org/10.1074/jbc.M002876200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10998416	hybrid			2022-12-27	WOS:000166039500034
J	Desai, R; Peretz, A; Idelson, H; Lazarovici, P; Attali, B				Desai, R; Peretz, A; Idelson, H; Lazarovici, P; Attali, B			Ca2+-activated K+ channels in human leukemic Jurkat T cells - Molecular cloning, biochemical, and functional characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; SMALL-CONDUCTANCE; CA CHANNEL; BEE VENOM; RAT-BRAIN; CALCIUM; APAMIN; LYMPHOCYTES; EXPRESSION; CALMODULIN	Previous studies have demonstrated the presence of apamin-sensitive, small-conductance Ca2+-activated K+ currents in human leukemic Jurkat T cells. Using a combined cDNA and reverse transcriptase-polymerase chain reaction cloning strategy, we have isolated from Jurkat T cells a 2.5-kilobase cDNA, hSK2, encoding the human isoform of SK2 channels. Northern blot analysis reveals the presence of a 2.5-kilobase hSK2 transcript in Jurkat T cells. While present in various human tissues, including brain, heart, skeletal muscle, kidney, and liver, no hSK2 mRNA could be detected in resting and activated normal human T cells. The hSK2 gene is encoded by 8 exons and could be assigned to chromosome 5 (q21.2-q22.1). The protein encoded by hSK2 is 579 amino acids long and exhibits 97% identity with its rat counterpart rSK2. When expressed in Chinese hamster ovary cells, hSK2 produces Ca2+-activated K+ currents with a unitary conductance of 9.5 pS and a K-0.5 for calcium of 0.7 muM; hSK2 currents are inhibited by apamin, scyllatoxin, and d-tubocurarine. Overexpression of the Src family tyrosine kinase p56(lck) in Jurkat cells, upregulates SK2 currents by 3-fold. While IKCa channels are transcriptionally induced upon activation of normal human T cells, our results show that in Jurkat cells SK2 channels are constitutively expressed and down-regulated following mitogenic stimulation.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Alomone Labs, IL-91042 Jerusalem, Israel; Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol & Expt Therapeut, IL-91120 Jerusalem, Israel	Weizmann Institute of Science; Hebrew University of Jerusalem	Attali, B (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	attali@weizmann.ac.il						ATTALI B, 1992, J BIOL CHEM, V267, P8650; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; CAI YC, 1992, DNA CELL BIOL, V11, P163, DOI 10.1089/dna.1992.11.163; CASTLE NA, 1989, TRENDS NEUROSCI, V12, P59, DOI 10.1016/0166-2236(89)90137-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Frohman Michael A., 1995, P381; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; GRISSMER S, 1992, J GEN PHYSIOL, V99, P63, DOI 10.1085/jgp.99.1.63; GRISSMER S, 1993, J GEN PHYSIOL, V102, P601, DOI 10.1085/jgp.102.4.601; Gulbins E, 1997, P NATL ACAD SCI USA, V94, P7661, DOI 10.1073/pnas.94.14.7661; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanselmann C, 1996, J PHYSIOL-LONDON, V496, P627, DOI 10.1113/jphysiol.1996.sp021714; HUGUES M, 1982, EMBO J, V1, P1039, DOI 10.1002/j.1460-2075.1982.tb01293.x; HUGUES M, 1982, P NATL ACAD SCI-BIOL, V79, P1308, DOI 10.1073/pnas.79.4.1308; HUGUES M, 1982, J BIOL CHEM, V257, P2762; HUGUES M, 1982, LIFE SCI, V31, P437, DOI 10.1016/0024-3205(82)90328-9; HUGUES M, 1982, BIOCHEM BIOPH RES CO, V107, P1577, DOI 10.1016/S0006-291X(82)80180-0; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Jager H, 2000, FEBS LETT, V469, P196, DOI 10.1016/S0014-5793(00)01236-9; Jensen BS, 1998, AM J PHYSIOL-CELL PH, V275, pC848, DOI 10.1152/ajpcell.1998.275.3.C848; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; Keen JE, 1999, J NEUROSCI, V19, P8830, DOI 10.1523/JNEUROSCI.19-20-08830.1999; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAZDUNSKI M, 1985, BIOCHEM SOC SYMP, P31; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; MOCZYDLOWSKI E, 1988, J MEMBRANE BIOL, V105, P95, DOI 10.1007/BF02009164; MOURRE C, 1986, BRAIN RES, V382, P239, DOI 10.1016/0006-8993(86)91333-8; Pribnow D, 1999, MUSCLE NERVE, V22, P742, DOI 10.1002/(SICI)1097-4598(199906)22:6<742::AID-MUS11>3.0.CO;2-1; ROMEY G, 1984, J PHYSIOL-PARIS, V79, P259; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; SCHMIDANTOMARCHI H, 1986, J BIOL CHEM, V261, P8633; Shah M, 2000, BRIT J PHARMACOL, V129, P627, DOI 10.1038/sj.bjp.0703111; Shirihai O, 1996, PFLUG ARCH EUR J PHY, V431, P632, DOI 10.1007/s004240050045; Sobko A, 1998, EMBO J, V17, P4723, DOI 10.1093/emboj/17.16.4723; Strobaek D, 2000, BRIT J PHARMACOL, V129, P991, DOI 10.1038/sj.bjp.0703120; STRONG PN, 1990, PHARMACOL THERAPEUT, V46, P137, DOI 10.1016/0163-7258(90)90040-9; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; VERHEUGEN JAH, 1995, J GEN PHYSIOL, V105, P765, DOI 10.1085/jgp.105.6.765; Wadsworth JDF, 1997, ARCH BIOCHEM BIOPHYS, V346, P151, DOI 10.1006/abbi.1997.0280; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758	47	48	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39954	39963		10.1074/jbc.M001562200	http://dx.doi.org/10.1074/jbc.M001562200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10991935	hybrid			2022-12-27	WOS:000166039500024
J	Mullins, LJ; Payne, CM; Kotelevtseva, N; Brooker, G; Fleming, S; Harris, S; Mullins, JJ				Mullins, LJ; Payne, CM; Kotelevtseva, N; Brooker, G; Fleming, S; Harris, S; Mullins, JJ			Granulation rescue and developmental marking of juxtaglomerular cells using "piggy-BAC" recombination of the mouse Ren locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; ESCHERICHIA-COLI; ARTIFICIAL CHROMOSOME; HOMOLOGOUS RECOMBINATION; GENE-EXPRESSION; REPORTER GENES; MURINE REN-1; DNA; CLONING; TRANSFORMATION	Mice lacking a functional Ren-1(d) gene exhibit a complete lack of renal juxtaglomerular cell granulation and atypical macula densa morphology. Transgenic mice carrying a 145-kilobase BAC clone encompassing the Ren-1(d) and Ren-2 loci were generated, characterized, and backcrossed with Ren-1(d-/-) mice. Homozygous Ren-1(d)-null mice expressing the BAC clone exhibited complete restoration of normal renal structure. Homologous recombination in Escherichia coli was used to generate a modified version of the BAC clone, in which an IRES beta -geo cassette was inserted specifically into the Ren-1(d) gene. When introduced into the germline, the modified clone provided a marker for juxtaglomerular cell differentiation and beta -geo was expressed appropriately in juxtaglomerular cells throughout development. Parallel backcross experiments onto the Ren-1(d)-null background demonstrated that the juxtaglomerular cells expressed the modified Ren-1(d) locus in the absence of regranulation. These data demonstrate that the nongranulated cells constitute bona fide juxtaglomerular cells despite their altered morphology, that overexpression of renin-2 cannot compensate for the loss of renin-1(d), and that primary structural differences between the two isoforms are responsible for the differences in granulation. The use of BAC modification as part of functional complementation studies illustrates the potential for in vivo molecular dissection of key physiological mechanisms.	Univ Edinburgh, Sch Med, Mol Physiol Lab, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Glaxo Wellcome Res & Dev Ltd, Mol Sci Div, Funct Genom Program, Med Res Ctr, Stevenage SG1 2NY, Herts, England	University of Edinburgh; University of Edinburgh; GlaxoSmithKline	Mullins, LJ (corresponding author), Univ Edinburgh, Sch Med, Mol Physiol Lab, Wilkie Bldg,Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.			Mullins, Linda/0000-0002-6743-8707				ABEL KJ, 1990, GENETICS, V124, P937; ABEL KJ, 1988, NUCLEIC ACIDS RES, V16, P2111, DOI 10.1093/nar/16.5.2111; ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; Clark AF, 1997, J BIOL CHEM, V272, P18185, DOI 10.1074/jbc.272.29.18185; CUI CQ, 1994, TRANSGENIC RES, V3, P182, DOI 10.1007/BF01973986; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; FABIAN JR, 1989, J BIOL CHEM, V264, P17589; GOMEZ RA, 1989, AM J PHYSIOL, V257, pF850, DOI 10.1152/ajprenal.1989.257.5.F850; HACKENTHAL E, 1990, PHYSIOL REV, V70, P1067, DOI 10.1152/physrev.1990.70.4.1067; Jessen JR, 1998, P NATL ACAD SCI USA, V95, P5121, DOI 10.1073/pnas.95.9.5121; MCGOWAN RA, 1987, THESIS SUNY BUFFALO; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; MULLINS JJ, 1982, EMBO J, V1, P1461, DOI 10.1002/j.1460-2075.1982.tb01338.x; MULLINS JJ, 1989, EMBO J, V8, P4065, DOI 10.1002/j.1460-2075.1989.tb08590.x; Mullins LJ, 1997, NUCLEIC ACIDS RES, V25, P2539, DOI 10.1093/nar/25.12.2539; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PANTHIER JJ, 1983, EMBO J, V2, P675, DOI 10.1002/j.1460-2075.1983.tb01483.x; Payne CM, 1999, J HUM HYPERTENS, V13, P845, DOI 10.1038/sj.jhh.1000921; PAYNE CM, 1999, VISUALISING REN 1 GE; SEALY JE, 1990, HYPERTENSION PATHOPH, V1, P1287; Sharp MGF, 1996, HYPERTENSION, V28, P1126, DOI 10.1161/01.HYP.28.6.1126; SHENG Y, 1995, NUCLEIC ACIDS RES, V23, P1990, DOI 10.1093/nar/23.11.1990; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SIGMUND CD, 1991, HYPERTENSION, V18, P446, DOI 10.1161/01.HYP.18.4.446; SIGMUND CD, 1990, BIOCHEM BIOPH RES CO, V170, P344, DOI 10.1016/0006-291X(90)91280-6; Sinn PL, 1999, J BIOL CHEM, V274, P35785, DOI 10.1074/jbc.274.50.35785; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P103, DOI 10.1073/pnas.87.1.103; TAUGNER R, 2000, JUXTAGLOMERULAR APPA, P215; THOREY IS, 1993, DEV BIOL, V160, P519, DOI 10.1006/dbio.1993.1326; TRONIK D, 1987, EMBO J, V6, P983, DOI 10.1002/j.1460-2075.1987.tb04848.x; Yan Y, 1998, HYPERTENSION, V32, P205, DOI 10.1161/01.HYP.32.2.205; Yanai K, 2000, J BIOL CHEM, V275, P5, DOI 10.1074/jbc.275.1.5; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859; Yang XW, 1999, NAT GENET, V22, P327, DOI 10.1038/11896; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417	38	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40378	40384		10.1074/jbc.M007315200	http://dx.doi.org/10.1074/jbc.M007315200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10995772	hybrid			2022-12-27	WOS:000166039500079
J	Visai, L; Xu, Y; Casolini, F; Rindi, S; Hook, M; Speziale, P				Visai, L; Xu, Y; Casolini, F; Rindi, S; Hook, M; Speziale, P			Monoclonal antibodies to CNA, a collagen-binding microbial surface component recognizing adhesive matrix molecules, detach Staphylococcus aureus from a collagen substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN I/II FAMILY; MEDIATES ADHESION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; YADA PROTEIN; I-DOMAIN; INTEGRIN; ADHERENCE; RECEPTOR; ALPHA(1)BETA(1)	Previous studies showed that Staphylococcus aureus expresses a collagen-binding MSCRAMM (Microbial Surface Component Recognizing Adhesive Matrix Molecules), CNA, that is necessary and sufficient for S. aureus cells to adhere to cartilage and is a virulence factor in experimental septic arthritis. We have now used a monoclonal antibody (mAb) approach to further analyze the structure and function of CNA. 22 mAbs raised against the minimal ligand binding domain, CNA-(151-318), were shown to bind to the MSCRAMM with similar affinity. All mAbs appear to recognize conformation-dependent epitopes that were mapped throughout the CNA-(151-318) domain using a chimeric strategy where segments of CNA are grafted on ACE, a structurally related MSCRAMM from Enterococcus faecalis. These mAbs were able to inhibit I-125-collagen binding to CNA(151-318) as well as to intact S. aureus cells. They also interfered with the attachment of bacteria to collagen substrates. Furthermore, some of the mAbs could effectively displace I-125-collagen bound to the bacteria. These displacing mAbs were also able to detach bacteria that had adhered to a collagen substrate in a preincubation, raising the possibility that some of the mAbs may be used as therapeutic agents.	Univ Pavia, Dept Biochem, I-27100 Pavia, Italy; Texas A&M Univ Syst, Hlth Sci Ctr, Inst Biosci & Technol, Dept Biophys & Biochem, Houston, TX 77030 USA	University of Pavia; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Speziale, P (corresponding author), Univ Pavia, Dept Biochem, Viale Taramelli 3-B, I-27100 Pavia, Italy.	pspeziale@unipv.it	Visai, Livia/R-7397-2017	Visai, Livia/0000-0003-1181-3632				Carnoy C, 1997, MOL MICROBIOL, V23, P365, DOI 10.1046/j.1365-2958.1997.2231590.x; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; Eidhin DN, 1998, MOL MICROBIOL, V30, P245; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; GRIPENBERGLERCHE C, 1994, INFECT IMMUN, V62, P5568, DOI 10.1128/IAI.62.12.5568-5575.1994; Holmes AR, 1998, INFECT IMMUN, V66, P4633, DOI 10.1128/IAI.66.10.4633-4639.1998; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Love RM, 1997, INFECT IMMUN, V65, P5157, DOI 10.1128/IAI.65.12.5157-5164.1997; Nilsson IM, 1998, J CLIN INVEST, V101, P2640, DOI 10.1172/JCI1823; Nolte M, 1999, FEBS LETT, V452, P379, DOI 10.1016/S0014-5793(99)00666-3; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PATTI JM, 1993, BIOCHEMISTRY-US, V32, P11428, DOI 10.1021/bi00093a021; PATTI JM, 1995, J BIOL CHEM, V270, P12005, DOI 10.1074/jbc.270.20.12005; PATTI JM, 1994, INFECT IMMUN, V62, P152, DOI 10.1128/IAI.62.1.152-161.1994; Podbielski A, 1999, MOL MICROBIOL, V31, P1051, DOI 10.1046/j.1365-2958.1999.01241.x; Rich RL, 1999, J BIOL CHEM, V274, P26939, DOI 10.1074/jbc.274.38.26939; Rich RL, 1999, J BIOL CHEM, V274, P24906, DOI 10.1074/jbc.274.35.24906; Rich RL, 1998, BIOCHEMISTRY-US, V37, P15423, DOI 10.1021/bi981773r; ROGGENKAMP A, 1995, MOL MICROBIOL, V16, P1207, DOI 10.1111/j.1365-2958.1995.tb02343.x; Roos S, 1996, FEMS MICROBIOL LETT, V144, P33, DOI 10.1016/0378-1097(96)00334-5; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHULZEKOOPS H, 1992, INFECT IMMUN, V60, P2153, DOI 10.1128/IAI.60.6.2153-2159.1992; SCHULZEKOOPS H, 1995, ARTHRITIS RHEUM-US, V38, P1283, DOI 10.1002/art.1780380917; Sebghati TAS, 1998, INFECT IMMUN, V66, P2887, DOI 10.1128/IAI.66.6.2887-2894.1998; SPEZIALE P, 1986, J BACTERIOL, V167, P77, DOI 10.1128/jb.167.1.77-81.1986; STRAWICH E, 1971, BIOCHEMISTRY-US, V10, P3905, DOI 10.1021/bi00797a017; SWITALSKI LM, 1993, INFECT IMMUN, V61, P4119, DOI 10.1128/IAI.61.10.4119-4125.1993; SWITALSKI LM, 1989, J BIOL CHEM, V264, P21080; SWITALSKI LM, 1993, MOL MICROBIOL, V7, P99, DOI 10.1111/j.1365-2958.1993.tb01101.x; Symersky J, 1997, NAT STRUCT BIOL, V4, P833, DOI 10.1038/nsb1097-833; TAMM A, 1993, MOL MICROBIOL, V10, P995, DOI 10.1111/j.1365-2958.1993.tb00971.x; VISAI L, 1995, J BIOL CHEM, V270, P347, DOI 10.1074/jbc.270.1.347; Xiao JG, 1998, FEMS IMMUNOL MED MIC, V21, P287, DOI 10.1111/j.1574-695X.1998.tb01176.x	35	49	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39837	39845		10.1074/jbc.M005297200	http://dx.doi.org/10.1074/jbc.M005297200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10991941	hybrid			2022-12-27	WOS:000166039500009
J	Strassheim, D; Williams, CL				Strassheim, D; Williams, CL			P2Y(2) purinergic and M-3 muscarinic acetylcholine receptors activate different phospholipase C-beta isoforms that are uniquely susceptible to protein kinase C-dependent phosphorylation and inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-BETA-3 PHOSPHORYLATION; COUPLED RECEPTORS; CELLS; DESENSITIZATION; FIBROBLASTS	Activation of phospholipase C-beta (PLC-beta) by G protein-coupled receptors typically results in rapid but transient second messenger generation. Although PLC-beta deactivation may contribute to the transient nature of this response, the mechanisms governing PLC-beta deactivation are poorly characterized. We investigated the involvement of protein kinase C (PKC) in the termination of PLC-beta activation induced by endogenous P2Y(2) purinergic receptors and transfected M-3 muscarinic acetylcholine receptors (mAChR) in Chinese hamster ovary cells. Activation of P2Y(2) receptors causes G alpha (q/11) to associate with PLC-beta3, whereas M3 mAChR activation causes G alpha (q/11) to associate with both PLC-beta1 and PLC-beta3 in these cells. Phosphorylation of PLC-beta3, but not PLC-beta1, is induced by activating either P2Y(2) receptors or M-3 mAChR. We demonstrate that PKC rather than protein kinase A mediates the G protein-coupled receptor-induced phosphorylation of PLC-beta3. The PKC-mediated phosphorylation of PLC-beta3 diminishes the interaction of G alpha (q/11) with PLC-beta3, thereby contributing to the termination PLC-beta3 activity. These findings indicate that the distinct temporal profiles of PLC activation by P2Y(2) receptors and mAChR may arise from the differential activation of PLC-beta1 and PLC-beta3 by the receptors, coupled with a selective PKC-mediated negative feedback mechanism that targets PLC-beta3 but not PLC-beta1.	Guthrie Res Inst, Mol Pharmacol Lab, Sayre, PA 18840 USA		Williams, CL (corresponding author), Guthrie Res Inst, Mol Pharmacol Lab, 1 Guthrie Sq, Sayre, PA 18840 USA.	cwilliam@inet.guthrie.org	STRASSHEIM, DEREK/AHB-1158-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063921] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL063921] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adamson DL, 2000, BASIC RES CARDIOL, V95, P114, DOI 10.1007/s003950050172; Ali H, 1998, J BIOL CHEM, V273, P11012, DOI 10.1074/jbc.273.18.11012; Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Dickenson JM, 1998, BRIT J PHARMACOL, V124, P1491, DOI 10.1038/sj.bjp.0701977; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Hipkin RW, 2000, J BIOL CHEM, V275, P5591, DOI 10.1074/jbc.275.8.5591; LOS GV, 1996, BIOCHEM J, V311, P225; May LG, 1999, CELL SIGNAL, V11, P179, DOI 10.1016/S0898-6568(98)00053-9; Murthy KS, 1998, J BIOL CHEM, V273, P4695, DOI 10.1074/jbc.273.8.4695; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PLEVIN R, 1991, BIOCHEM J, V280, P609, DOI 10.1042/bj2800609; PLEVIN R, 1990, BIOCHEM J, V268, P605, DOI 10.1042/bj2680605; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Rosado JA, 2000, J BIOL CHEM, V275, P9110, DOI 10.1074/jbc.275.13.9110; RYU SH, 1990, J BIOL CHEM, V265, P17941; Strassheim D, 1998, MOL PHARMACOL, V53, P1047; Strassheim D, 1999, J BIOL CHEM, V274, P18675, DOI 10.1074/jbc.274.26.18675; Strassheim D, 2000, CANCER RES, V60, P2730; Tobin AB, 1997, PHARMACOL THERAPEUT, V75, P135, DOI 10.1016/S0163-7258(97)00053-3; Vazquez-Prado J, 2000, J BIOL CHEM, V275, P6553, DOI 10.1074/jbc.275.9.6553; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Willars GB, 1998, BIOCHEM J, V333, P301, DOI 10.1042/bj3330301; WILLIAMS CL, 1990, J BIOL CHEM, V265, P1443; Williams RL, 1999, BBA-MOL CELL BIOL L, V1441, P255, DOI 10.1016/S1388-1981(99)00150-X; Yue CP, 1998, J BIOL CHEM, V273, P18023, DOI 10.1074/jbc.273.29.18023	30	48	48	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39767	39772		10.1074/jbc.M007775200	http://dx.doi.org/10.1074/jbc.M007775200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995776	hybrid			2022-12-27	WOS:000165953100108
J	Goswami, PC; Sheren, J; Albee, LD; Parsian, A; Sim, JE; Ridnour, LA; Higashikubo, R; Gius, D; Hunt, CR; Spitz, DR				Goswami, PC; Sheren, J; Albee, LD; Parsian, A; Sim, JE; Ridnour, LA; Higashikubo, R; Gius, D; Hunt, CR; Spitz, DR			Cell cycle-coupled variation in topoisomerase II alpha mRNA is regulated by the 3 '-untranslated region - Possible role of redox-sensitive protein binding in mRNA accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; AU-RICH ELEMENTS; DNA TOPOISOMERASES; PHOSPHATASE-ACTIVITY; GENE-EXPRESSION; MAMMALIAN-CELLS; HEAT-SHOCK; DEGRADATION; CLONING; PHOSPHORYLATION	Mammalian topoisomerase II alpha (Topo II) is a highly regulated enzyme essential for many cellular processes including the G(2) cell cycle checkpoint. Because Topo II gene expression is regulated posttranscriptionally during the cell cycle, we investigated the possible role of the 3'-untranslated region (3'-UTR) in controlling Topo II mRNA accumulation. Reporter assays in stably transfected cells demonstrated that, similar to endogenous Topo II mRNA levels, the mRNA levels of reporter genes containing the Topo II 3'-UTR varied during the cell cycle and were maximal in S and G(2)/M relative to G(1). Topo II 3'-UTR sequence analysis and RNA-protein binding assays identified a 177-nucleotide (base pairs 4772-4949) region containing an AUUUUUA motif sufficient for protein binding. Multiple proteins (84, 70, 44, and 37 kDa) bound this region, and the binding of 84- and 37-kDa (tentatively identified as the adenosine- or uridine-rich element-binding factor AUF1) proteins was enhanced in G(1), correlating with decreased Topo II mRNA levels. The binding activity was enhanced in cellular extracts or cells treated with thiol-reducing agents, and increased binding correlated with decreased Topo II mRNA levels. These results support the hypothesis that cell cycle-coupled Topo II gene expression is regulated by interaction of the 3'-UTR with redox-sensitive protein complexes.	Univ Iowa, Dept Radiol, Free Radical & Radiat Biol Program, Iowa City, IA 52242 USA; Washington Univ, Sch Med, Radiat Oncol Ctr, MIR, St Louis, MO 63108 USA	University of Iowa; Washington University (WUSTL)	Goswami, PC (corresponding author), Univ Iowa, Dept Radiol, Free Radical & Radiat Biol Program, B180 Med Labs, Iowa City, IA 52242 USA.			Ridnour, Lisa A./0000-0001-9446-8349; Spitz, Douglas/0000-0002-1254-8765; Goswami, Prabhat/0000-0002-5700-2096	NATIONAL CANCER INSTITUTE [R29CA069593] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051469] Funding Source: NIH RePORTER; NCI NIH HHS [CA50950, R29CA69593] Funding Source: Medline; NHLBI NIH HHS [R01HL51469] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson ME, 1985, HDB METHODS OXYGEN R, P317; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Blackburn RV, 1999, FREE RADICAL BIO MED, V26, P419, DOI 10.1016/S0891-5849(98)00217-2; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DETOLEDO SM, 1995, INT J RADIAT BIOL, V67, P135, DOI 10.1080/09553009514550171; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Duret L, 1997, CURR OPIN STRUC BIOL, V7, P399, DOI 10.1016/S0959-440X(97)80058-9; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; EARNSHAW WC, 1988, CELL CYCLE CONTROL E, P176; ELDIERY WS, 1993, CELL, V75, P817; Falck J, 1999, J BIOL CHEM, V274, P18753, DOI 10.1074/jbc.274.26.18753; GIACCONE G, 1992, CANCER RES, V52, P1666; GILLIS P, 1991, J BIOL CHEM, V266, P3172; Goswami PC, 1996, MOL CELL BIOL, V16, P1500; GOSWAMI PC, 1992, RADIAT RES, V132, P162, DOI 10.2307/3578522; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HENTZ MW, 1991, SCIENCE, V244, P357; HOCHHAUSER D, 1992, J BIOL CHEM, V267, P18961; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Jarvinen TAH, 1996, AM J PATHOL, V148, P2073; KALWINSKY DK, 1983, CANCER RES, V43, P1592; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Li N, 1998, J CELL PHYSIOL, V177, P148, DOI 10.1002/(SICI)1097-4652(199810)177:1<148::AID-JCP16>3.0.CO;2-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MALTER JS, 1991, J BIOL CHEM, V266, P3167; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; McPherson JP, 1998, CANCER RES, V58, P4519; NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; Ridnour LA, 1999, METHOD ENZYMOL, V299, P258; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; ROSS J, 1994, RNA PROCESSING PRACT, V2, P107; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	47	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38384	38392		10.1074/jbc.M005298200	http://dx.doi.org/10.1074/jbc.M005298200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10986283	hybrid			2022-12-27	WOS:000165739800035
J	Scheidegger, KJ; Cenni, B; Picard, D; Delafontaine, P				Scheidegger, KJ; Cenni, B; Picard, D; Delafontaine, P			Estradiol decreases IGF-1 and IGF-1 receptor expression in rat aortic smooth muscle cells - Mechanisms for its atheroprotective effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; HORMONE-REPLACEMENT THERAPY; BREAST-CANCER CELLS; CORONARY HEART-DISEASE; NF-KAPPA-B; ESTROGEN-RECEPTOR; GENE-EXPRESSION; POSTMENOPAUSAL WOMEN; RESPONSIVE ELEMENT; MESSENGER-RNA	Insulin-like growth factor (IGF-1) is a potent mitogen for vascular smooth muscle cells, Both IGF-1 and its receptor have been shown to be highly expressed in atherosclerotic lesions. Here we investigated whether part of the vasculoprotective properties of E-2 may be mediated by its negative regulation of the IGF-1 system. HeLa cells, which do not contain endogenous estrogen receptors (ER), were transiently 'transfected with IGF-1R promoter constructs with or without a plasmid encoding human ER alpha or ER beta and treated with 100 nM 17 beta -estradiol (E-2) for 24 h. E-2 treatment decreased basal luciferase activity by 51%, and this effect was dependent on co-expression of ER alpha, whereas no repression was observed with ER beta. A mutation within the DNA binding domain of the ER alpha abolished the repressor function of the ER receptor. Similarly, E-2 decreased IGF-1R transcription by 21% in rat aortic smooth muscle cells (RASMC), which express endogenous ER, This effect was specific for E-2, because it was inhibited by an antiestrogen and because progesterone did not have any effect on IGF-1R expression in HeLa or RASMC transfected with progesterone receptor. Accordingly, E-2 decreased IGF-1R and IGF-1 mRNA in RASMC by 47% and 33%, Western blot analysis and radioligand binding studies showed that E-2 also dose-dependently decreased IGF-1R protein expression in RASMC by 40% and 30%, respectively, and that IGF-1 protein was reduced by 43%. Repression of IGF-1R promoter activity by a combination of ER alpha and E-2 did not appear to be mediated via direct binding of ER to the IGP-1R promoter but rather by inhibition of SP1 binding to the IGF-1R promoter. Thus, E-2 down-regulates IGF-1R and IGF-1 expression in vascular smooth muscle cells, This may have important implications for the understanding of the beneficial effects of estrogen in the cardiovascular system.	Univ Hosp Geneva, Div Cardiol, CH-1211 Geneva 14, Switzerland; Univ Geneva, Dept Cell Biol, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Delafontaine, P (corresponding author), Univ Hosp Geneva, Div Cardiol, Rue Micheli du Crest 24, CH-1211 Geneva 14, Switzerland.			Cenni, Bruno/0000-0002-8603-2032; Delafontaine, Patrice/0000-0003-3744-3617	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045317, R01HL047035, R01HL045317] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47035, HL45317] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; An JP, 1999, P NATL ACAD SCI USA, V96, P15161, DOI 10.1073/pnas.96.26.15161; Anwar A, 2000, ARTERIOSCL THROM VAS, V20, P370, DOI 10.1161/01.ATV.20.2.370; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BAYARD F, 1995, ENDOCRINOLOGY, V136, P1523, DOI 10.1210/en.136.4.1523; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEITNERJOHNSON D, 1995, MOL ENDOCRINOL, V9, P1147, DOI 10.1210/me.9.9.1147; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Bhalla RC, 1997, AM J PHYSIOL-HEART C, V272, pH1996, DOI 10.1152/ajpheart.1997.272.4.H1996; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; BORNFELDT KE, 1992, DIABETOLOGIA, V35, P104, DOI 10.1007/BF00402540; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CAULEY JA, 1983, ATHEROSCLEROSIS, V49, P31, DOI 10.1016/0021-9150(83)90005-9; Cenni B, 1999, TRENDS ENDOCRIN MET, V10, P41, DOI 10.1016/S1043-2760(98)00121-0; CERCEK B, 1990, CIRC RES, V66, P1755, DOI 10.1161/01.RES.66.6.1755; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Chen ZG, 1999, MOL CELL ENDOCRINOL, V158, P131, DOI 10.1016/S0303-7207(99)00172-0; CLEMMONS DR, 1985, J CLIN INVEST, V75, P1914, DOI 10.1172/JCI111906; CLEMMONS DR, 1980, P NATL ACAD SCI-BIOL, V77, P6644, DOI 10.1073/pnas.77.11.6644; COHICK WS, 1993, J CELL PHYSIOL, V157, P52, DOI 10.1002/jcp.1041570107; COLLINS P, 1994, CIRCULATION, V90, P1964, DOI 10.1161/01.CIR.90.4.1964; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; Couse JF, 1999, SCIENCE, V286, P2328, DOI 10.1126/science.286.5448.2328; DELAFONTAINE P, 1995, J BIOL CHEM, V270, P14383, DOI 10.1074/jbc.270.24.14383; DELAFONTAINE P, 1991, HYPERTENSION, V17, P693, DOI 10.1161/01.HYP.17.5.693; DELAFONTAINE P, 1994, J MOL CELL CARDIOL, V26, P1659, DOI 10.1006/jmcc.1994.1185; Delafontaine P, 1996, J CLIN INVEST, V97, P139, DOI 10.1172/JCI118381; deMedeiros SRB, 1997, J BIOL CHEM, V272, P18250, DOI 10.1074/jbc.272.29.18250; DU J, 1995, CIRC RES, V76, P963, DOI 10.1161/01.RES.76.6.963; ERNST M, 1991, MOL ENDOCRINOL, V5, P1081, DOI 10.1210/mend-5-8-1081; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Garnero P, 1999, J CLIN ENDOCR METAB, V84, P2390, DOI 10.1210/jc.84.7.2390; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Guetta V, 1996, CIRCULATION, V93, P1928, DOI 10.1161/01.CIR.93.10.1928; Homma H, 2000, J BIOL CHEM, V275, P11404, DOI 10.1074/jbc.275.15.11404; HONG MK, 1992, AM J CARDIOL, V69, P176, DOI 10.1016/0002-9149(92)91300-S; HORWITZ KB, 1978, CANCER RES, V38, P2434; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Huynh H, 1996, CLIN CANCER RES, V2, P2037; JIANG CW, 1992, AM J PHYSIOL, V263, pH271, DOI 10.1152/ajpheart.1992.263.1.H271; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Koike H, 1996, J VASC SURG, V23, P477, DOI 10.1016/S0741-5214(96)80014-0; Kolodgie FD, 1996, AM J PATHOL, V148, P969; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Li GH, 1999, CIRCULATION, V100, P1639, DOI 10.1161/01.CIR.100.15.1639; Lindner V, 1998, CIRC RES, V83, P224, DOI 10.1161/01.RES.83.2.224; Lou H, 1998, CIRC RES, V83, P947; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; Makela S, 1999, P NATL ACAD SCI USA, V96, P7077, DOI 10.1073/pnas.96.12.7077; MATHIEU M, 1991, MOL ENDOCRINOL, V5, P815, DOI 10.1210/mend-5-6-815; McCarthy TL, 1997, J BIOL CHEM, V272, P18132, DOI 10.1074/jbc.272.29.18132; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; MENDELSON ME, 1994, CURR OPIN CARDIOL, V9, P619, DOI 10.1097/00001573-199409000-00018; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; MURPHY LJ, 1988, ENDOCRINOLOGY, V122, P325, DOI 10.1210/endo-122-1-325; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; Nickenig G, 1998, CIRCULATION, V97, P2197, DOI 10.1161/01.CIR.97.22.2197; ORIMO A, 1993, BIOCHEM BIOPH RES CO, V195, P730, DOI 10.1006/bbrc.1993.2106; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PFEIFLE B, 1982, HORM METAB RES, V14, P409, DOI 10.1055/s-2007-1019031; POLANCO JI, 1995, BIOCHEM BIOPH RES CO, V209, P182, DOI 10.1006/bbrc.1995.1487; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; PROUDLER AJ, 1995, LANCET, V346, P89, DOI 10.1016/S0140-6736(95)92114-1; RAY A, 1994, J BIOL CHEM, V269, P12940; REDMOND EM, 1994, CIRCULATION, V90, P2519, DOI 10.1161/01.CIR.90.5.2519; RUBINI M, 1994, EXP CELL RES, V211, P374, DOI 10.1006/excr.1994.1101; SAHLIN L, 1994, STEROIDS, V59, P421, DOI 10.1016/0039-128X(94)90011-6; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Scheidegger KJ, 1999, J BIOL CHEM, V274, P3522, DOI 10.1074/jbc.274.6.3522; SHEWMON DA, 1994, ARTERIOSCLER THROMB, V14, P1586, DOI 10.1161/01.ATV.14.10.1586; SIDAWY AN, 1990, SURGERY, V108, P165; Somjen D, 1998, HYPERTENSION, V32, P39, DOI 10.1161/01.HYP.32.1.39; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STEVENSON JC, 1994, DRUGS, V47, P35, DOI 10.2165/00003495-199400472-00007; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; VERVERIS J, 1994, AM J MED SCI, V307, P77, DOI 10.1097/00000441-199402000-00001; VERVERIS JJ, 1993, CIRC RES, V72, P1285, DOI 10.1161/01.RES.72.6.1285; Wang F, 1998, NUCLEIC ACIDS RES, V26, P3044, DOI 10.1093/nar/26.12.3044; Watanabe T, 1997, BIOCHEM BIOPH RES CO, V236, P140, DOI 10.1006/bbrc.1997.6915; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERNER H, 1992, MOL ENDOCRINOL, V6, P1545, DOI 10.1210/me.6.10.1545; WERNER H, 1990, BIOCH CELL BIOL, V19, P1021; WHITE RE, 1995, CIRC RES, V77, P936, DOI 10.1161/01.RES.77.5.936; Xie W, 1999, ENDOCRINOLOGY, V140, P219, DOI 10.1210/en.140.1.219; YAMAMOTO M, 1994, EXP CELL RES, V212, P62, DOI 10.1006/excr.1994.1118; ZHANG F, 1994, AM J PHYSIOL, V266, P975	99	44	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38921	38928		10.1074/jbc.M004691200	http://dx.doi.org/10.1074/jbc.M004691200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10982795	hybrid			2022-12-27	WOS:000165739800106
J	Hoffman, GA; Garrison, TR; Dohlman, HG				Hoffman, GA; Garrison, TR; Dohlman, HG			Endoproteolytic processing of Sst2, a multidomain regulator of G protein signaling in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; PHEROMONE RESPONSE PATHWAY; SACCHAROMYCES-CEREVISIAE; ALPHA-SUBUNIT; TRANSITION-STATE; POINT MUTATION; GAMMA-SUBUNIT; RGS PROTEINS; P115 RHOGEF; IN-VITRO	Regulators of G protein signaling (RGS proteins) constitute a large family of G protein-binding proteins. All RGS proteins contain a conserved core domain that can accelerate Gr protein GTPase activity. In addition, many family members contain a unique N-terminal domain of unknown function. Here, we demonstrate that the RGS protein in yeast, Sst2, is proteolytically processed in vivo to yield separate but functional N-terminal and RGS core domain fragments. In whole cell lysates, the full-length SST2 product (82 kDa) as well as a prominent 36 kDa species are specifically recognized by antibodies against the C terminus of the Sst2 protein. Purification and chemical sequencing of the 36-kDa species revealed cleavage sites after Ser-414 and Ser-416, just preceding the region of RGS homology. Expression of a mutationally truncated form of the protein (C-Sst2) could not restore function to an sst2 Delta mutant strain. In contrast, co-expression of C-Sst2 with the N-terminal domain (N-Sst2) partially restored the ability to regulate the growth arrest response but not the transcription induction response. Whereas the full-length protein was localized to the microsomal and plasma membrane fractions, the N-Sst2 species was predominantly in the microsomal fraction, and C-Sst2 was in the soluble fraction. Mutations that block proteasome or vacuolar protease function, or mutations in the cleavage site Ser residues of Sst2, did not alter processing. However, Sst2 processing did require expression of other components of the pheromone response pathway, including the receptor and the G protein. These results indicate that Sst2 is proteolytically processed, that this event is regulated by the signaling pathway, and that processing can profoundly alter the function and subcellular localization of the protein.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Interdepartmental Neurosci Program, New Haven, CT 06536 USA	Yale University; Yale University	Dohlman, HG (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, 295 Congress Ave,Rm 436,POB 9812, New Haven, CT 06536 USA.	henrik.dohlman@yale.edu		Dohlman, Henrik/0000-0003-2443-0729	NIGMS NIH HHS [GM59167, R01 GM055316, GM55316, R01 GM059167] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059167, R01GM055316, R29GM055316] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apanovitch DM, 1998, BIOCHEMISTRY-US, V37, P4815, DOI 10.1021/bi9729965; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; AZARIAN SM, 1995, J BIOL CHEM, V270, P24375, DOI 10.1074/jbc.270.41.24375; BAUM P, 1978, P NATL ACAD SCI USA, V75, P4962, DOI 10.1073/pnas.75.10.4962; Benzing T, 2000, J BIOL CHEM, V275, P28167; Benzing T, 1999, NAT MED, V5, P913, DOI 10.1038/11354; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Dohlman HG, 1998, SEMIN CELL DEV BIOL, V9, P135, DOI 10.1006/scdb.1998.0218; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Dulin NO, 1999, MOL CELL BIOL, V19, P714; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; Fischer T, 2000, P NATL ACAD SCI USA, V97, P4040, DOI 10.1073/pnas.97.8.4040; Flanary PL, 2000, J BIOL CHEM, V275, P18462, DOI 10.1074/jbc.M002163200; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; JACKSON CL, 1991, CELL, V67, P389, DOI 10.1016/0092-8674(91)90190-A; Khan AR, 1998, PROTEIN SCI, V7, P815; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; KLEIN BG, 1991, J AM COLL TOXICOL, V10, P555, DOI 10.3109/10915819109078652; Kobe B, 1999, NATURE, V402, P373, DOI 10.1038/46478; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; MA D, 1995, MOL BIOL CELL, V6, P889, DOI 10.1091/mbc.6.7.889; McEntaffer RL, 1999, BIOCHEMISTRY-US, V38, P4931, DOI 10.1021/bi982636x; Moy FJ, 2000, BIOCHEMISTRY-US, V39, P7063, DOI 10.1021/bi992760w; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Pedram A, 2000, J BIOL CHEM, V275, P7365, DOI 10.1074/jbc.275.10.7365; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Popov SG, 2000, J BIOL CHEM, V275, P18962, DOI 10.1074/jbc.M001128200; Rahman Z, 1999, J NEUROSCI, V19, P2016; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; Sato-Kusubata K, 2000, BIOCHEM J, V347, P733, DOI 10.1042/0264-6021:3470733; Schauber C, 1998, GENES CELLS, V3, P307, DOI 10.1046/j.1365-2443.1998.00192.x; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; SIKORSKI RS, 1989, GENETICS, V122, P19; Skiba NP, 1999, J BIOL CHEM, V274, P8770, DOI 10.1074/jbc.274.13.8770; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Sommers CM, 1997, J MOL BIOL, V266, P559, DOI 10.1006/jmbi.1996.0816; Song JP, 1996, J BIOL CHEM, V271, P20273, DOI 10.1074/jbc.271.34.20273; Song JP, 1996, BIOCHEMISTRY-US, V35, P14806, DOI 10.1021/bi961846b; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	65	33	33	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37533	37541		10.1074/jbc.M005751200	http://dx.doi.org/10.1074/jbc.M005751200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982801	hybrid			2022-12-27	WOS:000165618700033
J	Pombo, PMG; Barettino, D; Espliguero, G; Metsis, M; Iglesias, T; Rodriguez-Pena, A				Pombo, PMG; Barettino, D; Espliguero, G; Metsis, M; Iglesias, T; Rodriguez-Pena, A			Transcriptional repression of neurotrophin receptor trkB by thyroid hormone in the developing rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; CELL-ADHESION MOLECULE; NEGATIVE REGULATION; NERVOUS-SYSTEM; DEPENDENT TRANSACTIVATION; NEUROBLASTOMA-CELLS; NEURAL DEVELOPMENT; RESPONSE ELEMENTS; NUCLEAR RECEPTORS; GENE PROMOTER	Expression of the neurotrophin receptor trkB is regulated by thyroid hormone (T3) during development of the rat brain. trkB mRNA levels, coding for the full-length and the truncated isoforms, are increased in the cerebral cortex of neonatal experimental hypothyroid animals. Run-on transcription assays with nuclei from postnatal day 15, hypothyroid, and control cerebral cortices demonstrated that an increase in the transcription rate of the trkB gene accounts for the observed effect, Transient transfection experiments using a reporter plasmid containing a 7-kilobase pair DNA fragment upstream of the mouse trkB gene showed that unliganded thyroid hormone receptor (T3R) increases promoter activity, whereas addition of T3 reverses that activity below basal levels. Deletion analysis shows that the TS-dependent repression requires binding of the T3R to a specific region located downstream of the transcription start site. This region, at nucleotide position -465/-432, contains an array of thyroid hormone response half-sites that bind preferentially T3R as heterodimers with retinoid X receptor and whose deletion causes loss of the TS-dependent repression. These half-sites are able to confer negative regulation by T3 to a heterologous promoter, thus indicating the functionality of these sequences. These results demonstrate that, in the developing rat brain, T3 down-regulates the expression of the trkB gene through the active repression of a novel negative response element located downstream of its transcription initiation site.	CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain; Univ Autonoma Madrid, E-28029 Madrid, Spain; Karolinska Inst, Mol Neurobiol Lab, S-17177 Stockholm, Sweden	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Karolinska Institutet	Rodriguez-Pena, A (corresponding author), CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, E-28029 Madrid, Spain.	arodriguez@iib.uam.es	Metsis, Madis/F-7080-2016; Vacas, Teresa Iglesias/ABF-8663-2020	Metsis, Madis/0000-0003-1667-677X; Vacas, Teresa Iglesias/0000-0002-4326-9005; Rodriguez-Pena, Angeles/0000-0002-2515-4626				Awad TA, 1999, J BIOL CHEM, V274, P27092, DOI 10.1074/jbc.274.38.27092; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARDE YA, 1994, J NEUROBIOL, V25, P1329, DOI 10.1002/neu.480251102; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BARETTINO D, 1999, BIOCHIM BIOPHYS ACTA, V1146, P24; Baxter GT, 1997, J NEUROSCI, V17, P2683; Belandia B, 1998, J BIOL CHEM, V273, P30366, DOI 10.1074/jbc.273.46.30366; BIGLER J, 1995, EMBO J, V14, P5710, DOI 10.1002/j.1460-2075.1995.tb00258.x; CARR FE, 1994, J BIOL CHEM, V269, P4175; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN O, 1995, J BIOL CHEM, V270, P13899, DOI 10.1074/jbc.270.23.13899; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Dowling ALS, 2000, J NEUROSCI, V20, P2255; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Ibarrola N, 1997, BRAIN RES, V752, P285, DOI 10.1016/S0006-8993(96)01480-1; Iglesias T, 1996, EMBO J, V15, P4307, DOI 10.1002/j.1460-2075.1996.tb00805.x; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEGRAND C, 1991, DEV NEUROSCI-BASEL, V13, P382, DOI 10.1159/000112189; MADISON LD, 1993, MOL CELL ENDOCRINOL, V94, P129, DOI 10.1016/0303-7207(93)90060-W; Neveu I, 1996, J CELL BIOL, V133, P631, DOI 10.1083/jcb.133.3.631; PASTOR R, 1994, ONCOGENE, V9, P1081; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; RODRIGUEZPENA A, 1993, J CLIN INVEST, V91, P812, DOI 10.1172/JCI116301; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; Sasaki S, 1999, EMBO J, V18, P5389, DOI 10.1093/emboj/18.19.5389; Satoh T, 1996, J BIOL CHEM, V271, P27919, DOI 10.1074/jbc.271.44.27919; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; WOOD WM, 1989, J BIOL CHEM, V264, P14840	42	21	21	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37510	37517		10.1074/jbc.M006440200	http://dx.doi.org/10.1074/jbc.M006440200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978336	hybrid			2022-12-27	WOS:000165618700030
J	Festa, M; Ricciardelli, G; Mele, G; Pietropaolo, C; Ruffo, A; Colonna, A				Festa, M; Ricciardelli, G; Mele, G; Pietropaolo, C; Ruffo, A; Colonna, A			Overexpression of H ferritin and up-regulation of iron regulatory protein genes during differentiation of 3T3-L1 pre-adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING; TRANSCRIPTIONAL REGULATION; MESSENGER-RNA; EXPRESSION; ACONITASE; OXIDATION; SEQUENCE; SUBUNIT; INVITRO; LIVER	The role of iron-dependent oxidative metabolism in protecting the oxidable substrates contained in mature adipocytes is still unclear. Because differentiation increases ferritin formation in several cell types, thereby leading to an accumulation of H-rich isoferritins, we investigated whether differentiation affects iron metabolism in 3T3-L1 pre-adipocytes. To this aim, we evaluated the expression of the genes coding for the H and L ferritin subunits and for cytoplasmic iron regulatory protein (IRP) during the differentiation of 3T3-L1 cells in adipocytes induced by the addition of isobutylmethylxanthine, insulin, and dexamethasone, Differentiation enhanced ferritin formation and caused overexpression of the H subunit, thus altering the Hn subunit ratio. Northern blot analysis showed increased levels of H subunit mRNA A gel retardation assay of cytoplasmic extract from differentiated cells, using an iron-responsive element as a probe, revealed enhanced an RNA binding capacity of IRP1, which correlated with the increase of IRP1 mRNA The observed correlation between differentiation and iron metabolism in adipocytes suggests that an accumulation of H-rich isoferritin may limit the toxicity of iron in adipose tissue, thus exerting an antioxidant function.	Univ Naples Federico II, Dipartimento Farmacol Sperimentale, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Chim Sostanze Nat, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy	University of Naples Federico II; University of Naples Federico II; University of Naples Federico II	Colonna, A (corresponding author), Univ Naples Federico II, Dipartimento Farmacol Sperimentale, Via Domenico Montesano 49, I-80131 Naples, Italy.	alfcolon@unina.it						BALLA G, 1992, J BIOL CHEM, V267, P18148; BEAUMONT C, 1989, J BIOL CHEM, V264, P7498; CHOU CC, 1986, MOL CELL BIOL, V6, P566, DOI 10.1128/MCB.6.2.566; COCCIA EM, 1995, BLOOD, V86, P1570, DOI 10.1182/blood.V86.4.1570.bloodjournal8641570; Eisenstein RS, 2000, ANNU REV NUTR, V20, P627, DOI 10.1146/annurev.nutr.20.1.627; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; Festa M, 2000, BIOCHEM J, V348, P315, DOI 10.1042/0264-6021:3480315; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; Hanson ES, 1999, GENE EXPRESSION, V7, P367; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KIM HY, 1995, J BIOL CHEM, V270, P4983, DOI 10.1074/jbc.270.10.4983; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; Kuhn LC, 1998, NUTR REV, V56, pS11; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MIN HY, 1986, NUCLEIC ACIDS RES, V14, P8879; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; PHILPOTT CC, 1991, NUCLEIC ACIDS RES, V19, P6333, DOI 10.1093/nar/19.22.6333; Recalcati S, 1999, EUR J BIOCHEM, V259, P304, DOI 10.1046/j.1432-1327.1999.00038.x; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; Theil EC, 2000, BIOCHEM PHARMACOL, V59, P87, DOI 10.1016/S0006-2952(99)00300-7; TORTI SV, 1988, J BIOL CHEM, V263, P12638; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1	30	59	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36708	36712		10.1074/jbc.M004988200	http://dx.doi.org/10.1074/jbc.M004988200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10978328	hybrid			2022-12-27	WOS:000165577700038
J	Citron, BA; SantaCruz, KS; Davies, PJA; Festoff, BW				Citron, BA; SantaCruz, KS; Davies, PJA; Festoff, BW			Intron-exon swapping of transglutaminase mRNA and neuronal tau aggregation in Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; TISSUE-TYPE TRANSGLUTAMINASE; PIG LIVER TRANSGLUTAMINASE; CATALYZED CROSS-LINKING; AMYLOID BETA-A4 PEPTIDE; ACID-INDUCED EXPRESSION; RETINOIC ACID; DIFFERENTIAL EXPRESSION; RESPONSE ELEMENT; GENE PROMOTER	In order to understand the mechanism for insoluble neurotoxic protein polymerization in Alzheimer's disease (AD) brain neurons, we examined protein and gene expression for transglutaminase (TGase 2; tissue transglutaminase (tTG)) in hippocampus and isocortex. We found co-localization of tTG protein and activity with tau-positive neurofibrillary tangles, whereas mRNA and sequence analysis indicated an absolute increase in tTG; synthesized. Although apoptosis in AD hippocampus is now an established mode of neuronal cell death, no definite underlying mechanism(s) is known. Since TGase-mediated protein aggregation is implicated in polyglutamine ((CAG)(n)/Q(n) expansion) disorder apoptosis, and expanded Q(n) repeats are excellent TGase substrates, a role for TG;ase in AD is possible. However, despite such suggestions almost 20 years ago, the molecular mechanism remained elusive. We now present one possible molecular mechanism for tTG-mediated, neurotoxic protein polymerization leading to neuronal apoptosis in AD that involves not its substrates (like Q(n) repeats) but rather the unique presence of alternative transcripts of tTG; mRNA In addition to a full-length (L) isoform in aged non-demented brains, we found a short isoform (S) lacking a binding domain in all AD brains. Our current results identify intron-exon "switching" between L and S isoforms, implicating G-protein-coupled signaling pathways associated with tTG that may help to determine the dual roles of this enzyme in neuronal life and death processes.	Heartland Vet Integrated Serv Network, Neurobiol Res Lab, Kansas City, MO 64128 USA; Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, Kansas City, KS 66160 USA; Univ Texas, Hlth Sci Ctr, Dept Integrated Biol Pharmacol & Physiol, Houston, TX 77225 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Texas System; University of Texas Health Science Center Houston	Festoff, BW (corresponding author), Vet Affairs Med Ctr, Neurobiol Res Lab 151, Heartland Vet Hlth Serv Network, 4801 Linwood Blvd, Kansas City, MO 64128 USA.	serpin@eagle.cc.ukans.edu						ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; Aeschlimann D, 1998, J BIOL CHEM, V273, P3452, DOI 10.1074/jbc.273.6.3452; ANDO M, 1993, BRAIN RES, V604, P64, DOI 10.1016/0006-8993(93)90352-N; Appelt DM, 1996, J HISTOCHEM CYTOCHEM, V44, P1421, DOI 10.1177/44.12.8985134; Appelt DM, 1997, BRAIN RES, V745, P21, DOI 10.1016/S0006-8993(96)01121-3; Barinaga M, 1998, SCIENCE, V281, P1303, DOI 10.1126/science.281.5381.1303; Birckbichler P J, 1980, Prog Clin Biol Res, V41, P845; Braak H, 1997, NEUROBIOL AGING, V18, pS85, DOI 10.1016/S0197-4580(97)00062-6; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Casadio R, 1999, EUR J BIOCHEM, V262, P672, DOI 10.1046/j.1432-1327.1999.00437.x; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; CHIOCCA EA, 1989, J CELL BIOCHEM, V39, P293, DOI 10.1002/jcb.240390309; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Citron BA, 2000, NEUROCHEM INT, V37, P337, DOI 10.1016/S0197-0186(00)00044-9; Cooper AJL, 1997, J NEUROCHEM, V69, P431; Cooper AJL, 1999, J NEUROCHEM, V72, P889, DOI 10.1046/j.1471-4159.1999.0720889.x; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Cotman CW, 1998, NEUROBIOL AGING, V19, pS29, DOI 10.1016/S0197-4580(98)00042-6; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; DAVIES PJA, 1985, J BIOL CHEM, V260, P5166; DAVIES PJA, 1988, AM J MED SCI, V296, P164, DOI 10.1097/00000441-198809000-00004; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; ELALAOUI S, 1991, INT J CANCER, V48, P221; Feng JF, 1999, BIOCHEMISTRY-US, V38, P2224, DOI 10.1021/bi9823176; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; Ferrari N, 1998, MOL CELL BIOL, V18, P6482, DOI 10.1128/MCB.18.11.6482; Fesus L, 1996, EXPERIENTIA, V52, P942, DOI 10.1007/BF01920102; FRAIJ BM, 1992, J BIOL CHEM, V267, P22616; Fraij BM, 1996, BIOCHEM BIOPH RES CO, V218, P45, DOI 10.1006/bbrc.1996.0009; Fraij BM, 1997, BBA-GENE STRUCT EXPR, V1354, P65, DOI 10.1016/S0167-4781(97)00132-2; Fraij BM, 1996, BBA-GENE STRUCT EXPR, V1306, P63, DOI 10.1016/0167-4781(95)00219-7; Gentile V, 1998, ARCH BIOCHEM BIOPHYS, V352, P314, DOI 10.1006/abbi.1998.0592; GENTILE V, 1991, J BIOL CHEM, V266, P478; Gill LS, 1998, BRAIN RES, V788, P95, DOI 10.1016/S0006-8993(97)01526-6; GOBBI G, 1992, LANCET, V340, P439; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1999, NEURON, V22, P416, DOI 10.1016/S0896-6273(00)80695-9; Han KJ, 1998, LIFE SCI, V62, P1809, DOI 10.1016/S0024-3205(98)00143-X; HO GJ, 1994, BIOMED PHARMACOTHER, V48, P296, DOI 10.1016/0753-3322(94)90175-9; HO GJ, 1994, FEBS LETT, V349, P151, DOI 10.1016/0014-5793(94)00663-6; Holmes FE, 1996, NEUROSCI LETT, V213, P185; Horn V, 1996, FASEB J, V10, P1071, DOI 10.1096/fasebj.10.9.8801169; HWANG KC, 1995, J BIOL CHEM, V270, P27058, DOI 10.1074/jbc.270.45.27058; Hyman BT, 1997, J NEUROPATH EXP NEUR, V56, P1095, DOI 10.1097/00005072-199710000-00002; Iismaa SE, 1997, BIOCHEMISTRY-US, V36, P11655, DOI 10.1021/bi970545e; IKURA K, 1993, FEBS LETT, V326, P109, DOI 10.1016/0014-5793(93)81772-R; IKURA K, 1994, BIOSCI BIOTECH BIOCH, V58, P1540, DOI 10.1271/bbb.58.1540; Im MJ, 1997, CELL SIGNAL, V9, P477, DOI 10.1016/S0898-6568(97)00049-1; Jellinger KA, 1998, J NEURAL TRANSM-SUPP, P77; JENSEN PH, 1995, BIOCHEM J, V310, P91, DOI 10.1042/bj3100091; Johnson GVW, 1997, BRAIN RES, V751, P323, DOI 10.1016/S0006-8993(96)01431-X; Kahlem P, 1996, P NATL ACAD SCI USA, V93, P14580, DOI 10.1073/pnas.93.25.14580; Kahlem P, 1998, MOL CELL, V1, P595, DOI 10.1016/S1097-2765(00)80059-3; Kahlem P, 1998, PATHOL BIOL, V46, P681; Karpuj MV, 1999, P NATL ACAD SCI USA, V96, P7388, DOI 10.1073/pnas.96.13.7388; Kim SY, 1999, J BIOL CHEM, V274, P30715, DOI 10.1074/jbc.274.43.30715; Klein ES, 1996, J BIOL CHEM, V271, P22692, DOI 10.1074/jbc.271.37.22692; KSIEZAKREDING H, 1995, J NEUROSCI RES, V41, P583, DOI 10.1002/jnr.490410504; Kuncio GS, 1998, AM J PHYSIOL-GASTR L, V274, pG240, DOI 10.1152/ajpgi.1998.274.2.G240; Lai TS, 1996, J BIOL CHEM, V271, P31191, DOI 10.1074/jbc.271.49.31191; Lefebvre O, 1999, CELL DEATH DIFFER, V6, P433, DOI 10.1038/sj.cdd.4400510; Lu S, 1997, P NATL ACAD SCI USA, V94, P4692, DOI 10.1073/pnas.94.9.4692; LU S, 1995, J BIOL CHEM, V270, P9748, DOI 10.1074/jbc.270.17.9748; MADDOX AM, 1988, EXP CELL BIOL, V56, P49; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; McLean CA, 1997, NEUROBIOL AGING, V18, pS89, DOI 10.1016/S0197-4580(97)00061-4; Melino G, 1997, J NEURO-ONCOL, V31, P65, DOI 10.1023/A:1005733430435; Melino G, 1997, EXP CELL RES, V235, P55, DOI 10.1006/excr.1997.3656; Monsonego A, 1997, J BIOL CHEM, V272, P3724, DOI 10.1074/jbc.272.6.3724; MURTAUGH MP, 1986, J BIOL CHEM, V261, P614; Nagy L, 1996, J BIOL CHEM, V271, P4355; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nanda N, 1999, ARCH BIOCHEM BIOPHYS, V366, P151, DOI 10.1006/abbi.1999.1189; Norlund MA, 1999, BRAIN RES, V851, P154, DOI 10.1016/S0006-8993(99)02179-4; O'Neill R R, 1989, Appl Theor Electrophor, V1, P163; PERRY MJM, 1995, NEUROSCIENCE, V65, P1063, DOI 10.1016/0306-4522(94)00556-K; PIACENTINI M, 1991, EUR J CELL BIOL, V54, P246; Piacentini M, 1995, Curr Top Microbiol Immunol, V200, P163; RASMUSSEN LK, 1994, FEBS LETT, V338, P161, DOI 10.1016/0014-5793(94)80356-0; Ritter SJ, 1998, J BIOL CHEM, V273, P12798, DOI 10.1074/jbc.273.21.12798; SCHUTZE S, 1992, SEMIN ONCOL, V19, P16; SELKOE DJ, 1982, P NATL ACAD SCI-BIOL, V79, P6070, DOI 10.1073/pnas.79.19.6070; Singh US, 1996, J BIOL CHEM, V271, P27292, DOI 10.1074/jbc.271.44.27292; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUTO N, 1993, J BIOL CHEM, V268, P7469; SWINGLER S, 1994, BIOCHEM BIOPH RES CO, V203, P623, DOI 10.1006/bbrc.1994.2228; Szondy Z, 1997, FEBS LETT, V404, P307, DOI 10.1016/S0014-5793(97)00140-3; TROJANOWSKI JQ, 1997, NEUROBIOL AGING S4, V18, P1; Yan ZH, 1996, MOL CELL ENDOCRINOL, V120, P203, DOI 10.1016/0303-7207(96)03826-9; Zainelli GM, 2000, J NEUROCHEM, V74, pS27; Zemaitiaitis MO, 2000, J NEUROCHEM, V74, pS27; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022; Zhang W, 1998, ACTA NEUROPATHOL, V96, P395, DOI 10.1007/s004010050910; Zhang W, 1997, LIFE SCI, V60, P2323, DOI 10.1016/S0024-3205(97)00288-9	96	85	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3295	3301		10.1074/jbc.M004776200	http://dx.doi.org/10.1074/jbc.M004776200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11013236	hybrid			2022-12-27	WOS:000166784900042
J	Fukushi, Y; Kato, I; Takasawa, S; Sasaki, T; Ong, BH; Sato, M; Ohsaga, A; Sato, K; Shirato, K; Okamoto, H; Maruyama, Y				Fukushi, Y; Kato, I; Takasawa, S; Sasaki, T; Ong, BH; Sato, M; Ohsaga, A; Sato, K; Shirato, K; Okamoto, H; Maruyama, Y			Identification of cyclic ADP-ribose-dependent mechanisms in pancreatic muscarinic Ca2+ signaling using CD38 knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; SINGLE-CHANNEL CURRENTS; LEUKOCYTE ANTIGEN CD38; INOSITOL TRISPHOSPHATE; INSULIN-SECRETION; CALCIUM RELEASE; BETA-CELLS; RAT; MOBILIZATION; 1,4,5-TRISPHOSPHATE	We showed that muscarinic acetylcholine (ACh)-stimulation increased the cellular content of cADPR in the pancreatic acinar cells from normal mice but not in those from CD38 knockout mice. By monitoring ACh-evoked increases in the cytosolic Ca2+ concentration ([Ca2+](i)) using fura-2 microfluorimetry, we distinguished and characterized the Ca2+ release mechanisms responsive to cADPR, The Ca2+ response from the cells of the knockout mice (KO cells) lacked two components of the muscarinic Ca2+ release present in wild mice. The first component inducible by the low concentration of ACh contributed to regenerative Ca2+ spikes. This component was abolished by ryanodine treatment in the normal cells and was severely impaired in KO cells, indicating that the low ACh-induced regenerative spike responses were caused by cADPR-dependent Ca2+ release from a pool regulated by a class of ryanodine receptors, The second component inducible by the high concentration of ACh was involved in the phasic Ca2+ response, and it was not abolished by ryanodine treatment. Overall, we conclude that muscarinic Ca2+ signaling in pancreatic acinar cells involves a CD38-dependent pathway responsible for two cADPR-dependent Ca2+ release mechanisms in which the one sensitive to ryanodine plays a crucial role for the generation of repetitive Ca2+ spikes.	Tohoku Univ, Grad Sch Med, Dept Physiol 1, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Grad Sch Med, Dept Internal Med, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Grad Sch Med, Dept Biochem, Aoba Ku, Sendai, Miyagi 9808575, Japan	Tohoku University; Tohoku University; Tohoku University	Maruyama, Y (corresponding author), Tohoku Univ, Grad Sch Med, Dept Physiol 1, Aoba Ku, Seiryo Cho 2-1, Sendai, Miyagi 9808575, Japan.							BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; FUKUSHI Y, 1995, TOHOKU J EXP MED, V176, P83, DOI 10.1620/tjem.176.83; Fukushi Y, 1999, EUR J PHARMACOL, V364, P55, DOI 10.1016/S0014-2999(98)00824-3; Fukushi Y, 1997, EUR J PHARMACOL, V336, P89, DOI 10.1016/S0014-2999(97)01228-4; Fukushi Y, 1996, TOHOKU J EXP MED, V178, P399, DOI 10.1620/tjem.178.399; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P304, DOI 10.1016/0165-6147(92)90096-O; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; IKEDA M, 1992, J PHYSIOL-LONDON, V447, P711, DOI 10.1113/jphysiol.1992.sp019025; Kato I, 1999, J BIOL CHEM, V274, P1869, DOI 10.1074/jbc.274.4.1869; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; MARTY A, 1989, J PHYSIOL-LONDON, V419, P665, DOI 10.1113/jphysiol.1989.sp017892; MARUYAMA Y, 1982, NATURE, V299, P159, DOI 10.1038/299159a0; MARUYAMA Y, 1988, J PHYSIOL-LONDON, V406, P299, DOI 10.1113/jphysiol.1988.sp017381; MARUYAMA Y, 1994, CELL CALCIUM, V16, P419, DOI 10.1016/0143-4160(94)90035-3; MARUYAMA Y, 1993, J PHYSIOL-LONDON, V463, P729, DOI 10.1113/jphysiol.1993.sp019619; MARUYAMA Y, 1982, NATURE, V300, P61, DOI 10.1038/300061a0; MARUYAMA Y, 1989, J PHYSIOL-LONDON, V417, P343, DOI 10.1113/jphysiol.1989.sp017805; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; Noguchi N, 1997, J BIOL CHEM, V272, P3133, DOI 10.1074/jbc.272.6.3133; Okamoto H, 1997, METHOD ENZYMOL, V280, P306; Ozawa T, 1997, J MEMBRANE BIOL, V156, P231, DOI 10.1007/s002329900203; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; TAKAHASHI K, 1995, FEBS LETT, V371, P204, DOI 10.1016/0014-5793(95)00914-U; Takasawa S, 1998, J BIOL CHEM, V273, P2497, DOI 10.1074/jbc.273.5.2497; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; Takasawa S, 1995, J BIOL CHEM, V270, P30257, DOI 10.1074/jbc.270.51.30257; TAYLOR CW, 1992, TRENDS BIOCHEM SCI, V17, P403, DOI 10.1016/0968-0004(92)90009-X; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S	39	69	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					649	655		10.1074/jbc.M004469200	http://dx.doi.org/10.1074/jbc.M004469200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11001947	hybrid			2022-12-27	WOS:000166280700087
J	Kardassis, D; Pardali, K; Zannis, VI				Kardassis, D; Pardali, K; Zannis, VI			SMAD proteins transactivate the human apoCIII promoter by interacting physically and functionally with hepatocyte nuclear factor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-C-III; GROWTH-FACTOR-BETA; TGF-BETA; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; A-I; LIPOPROTEIN-LIPASE; SIGNALING PATHWAYS; PROXIMAL PROMOTER; TRANSGENIC MICE	Cotransfection of HepG2 cells with SMADs established that SMAD3 and SMAD3-SMAD4 transactivated (15-70-fold) the -890/+24 apoCIII promoter and shorter promoter segments, whereas cotransfection with a dominant negative SMAD4 mutant repressed the apoCIII promoter activity by 50%, suggesting that SMAD proteins participate in apoCIII gene regulation. Transactivation required the presence of a hormone response element, despite the fact that SMADs could not bind directly to it. Cotransfection of SMAD3-SMAD4 along with hepatocyte nuclear factor-4 resulted in a strong synergistic transactivation of the -890/+24 apoCIII promoter, proximal promoter segments, or synthetic promoters containing either the apoCIII enhancer or the proximal apoCIII hormone response element. Inhibition of endogenous hepatocyte nuclear factor-4 synthesis by an antisense ribozyme construct reduced the constitutive activity of the apoCIII promoter in HepG2 cells to 10% and abolished the SMAD-mediated transactivation. Co-immunoprecipitation and GST pull-down assays provided evidence for physical interactions between SMAD3, SMAD4, and hepatic nuclear factor-4, Our findings indicate that transforming growth factor beta and its signal transducer SMAD proteins can modulate gene transcription by novel mechanisms that involve their physical and functional interaction with hepatocyte nuclear factor-4, suggesting that SMAD proteins may play an important role in apolipoprotein gene expression and lipoprotein metabolism.	Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Iraklion, Greece; FORTH, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Greece	University of Crete; Foundation for Research & Technology - Hellas (FORTH)	Kardassis, D (corresponding author), Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Iraklion, Greece.			Pardali, Katerina/0000-0002-4360-730X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033952] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33952] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BISAHA JG, 1995, J BIOL CHEM, V270, P19979, DOI 10.1074/jbc.270.34.19979; BROWN WV, 1972, BIOCHEM BIOPH RES CO, V46, P375; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUBER PJ, 1994, NUCLEIC ACIDS RES, V22, P2417, DOI 10.1093/nar/22.12.2417; Gu ZY, 1999, DEVELOPMENT, V126, P2551; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; Hadzopoulou-Cladaras M, 1998, BIOCHEMISTRY-US, V37, P14078, DOI 10.1021/bi9804176; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; Hammann C, 1999, METHODS, V18, P273, DOI 10.1006/meth.1999.0784; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Herbert P. N., 1982, METABOLIC BASIS INHE, P589; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kan HY, 2000, J BIOL CHEM, V275, P30423, DOI 10.1074/jbc.M005641200; Kardassis D, 1998, J BIOL CHEM, V273, P17810, DOI 10.1074/jbc.273.28.17810; Kardassis D, 1997, ARTERIOSCL THROM VAS, V17, P222, DOI 10.1161/01.ATV.17.1.222; KARDASSIS D, 1992, J BIOL CHEM, V267, P2622; KRAUSS RM, 1973, CIRC RES, V33, P403, DOI 10.1161/01.RES.33.4.403; Ktistaki E, 1997, MOL CELL BIOL, V17, P2790, DOI 10.1128/MCB.17.5.2790; Lacorte JM, 1997, J BIOL CHEM, V272, P23578, DOI 10.1074/jbc.272.38.23578; Lacorte JM, 1997, FEBS LETT, V415, P217, DOI 10.1016/S0014-5793(97)01127-7; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lavrentiadou SN, 1999, BIOCHEMISTRY-US, V38, P964, DOI 10.1021/bi981068i; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nastos A, 1998, NUCLEIC ACIDS RES, V26, P5602, DOI 10.1093/nar/26.24.5602; OGAMI K, 1990, J BIOL CHEM, V265, P9808; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; SHELBURNE F, 1980, J CLIN INVEST, V65, P652, DOI 10.1172/JCI109710; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; WINDLER E, 1980, J BIOL CHEM, V255, P8303; Yanagi Y, 1999, J BIOL CHEM, V274, P12971, DOI 10.1074/jbc.274.19.12971; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	48	37	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41405	41414		10.1074/jbc.M007896200	http://dx.doi.org/10.1074/jbc.M007896200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10995777	hybrid			2022-12-27	WOS:000166114600098
J	Paramio, JM; Segrelles, C; Casanova, ML; Jorcano, JL				Paramio, JM; Segrelles, C; Casanova, ML; Jorcano, JL			Opposite functions for E2F1 and E2F4 in human epidermal keratinocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; UBIQUITIN-PROTEASOME PATHWAY; RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F1; DEREGULATED EXPRESSION; FIBROBLASTS LEADS; FAMILY PROTEINS; PROLIFERATION; MEMBER; APOPTOSIS	Proteins of the retinoblastoma family (pRb, p107, and p130) modulate cell proliferation, a function related to their capacity to control the activity of the E2F transcription factor family. The Rb proteins also control cell differentiation in different tissues. We have recently described their involvement in human epidermal keratinocyte differentiation (Paramio, J. M., Lain, S., Segrelles, C., Lane, E. B., and Jorcano, J. L. (1998) Oncogene 17, 949-957), Here we show that E2F proteins are also involved in this process. We found that E2F1 and E2F4 are expressed differentially during the in vitro differentiation of human epidermal keratinocytes, with the former uniformly present throughout the process, whereas the second is predominantly expressed at the onset of differentiation. This pattern is also observed in human skin by confocal microscopy. Electrophoretic mobility shift assays and immunoprecipitation experiments demonstrated that the complexes formed by E2F1 and E2F4 and Rb family proteins vary throughout in vitro keratinocyte differentiation. In agreement with this observation, several E2F-responsive genes are differentially regulated during this process. To test the functional implications of these observations, we transfected Ha-CaT keratinocytes with plasmids coding for E2F1 and E2F4. Transfected cells display opposite in vitro differentiation properties. Although E2F1-transfected cells are unable to differentiate, E2F4-transfected cells show an increased differentiation rate compared with Neo-transfected control cells. Our data demonstrate that the differential and coordinated expression and interaction of E2F and Rb proteins modulate the process of epidermal differentiation and provide clear evidence that members of the E2F family of transcription factors play specific and opposite roles during cell differentiation.	CIEMAT, Cell & Mol Biol Program, E-28040 Madrid, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	Paramio, JM (corresponding author), CIEMAT, Cell & Mol Biol Program, Edificio 7,Av Complutense 22, E-28040 Madrid, Spain.		Paramio, Jesus M/M-8482-2014; Segrelles, Carmen/E-3655-2016	Paramio, Jesus M/0000-0001-7520-3177; Segrelles, Carmen/0000-0001-9340-2102; Casanova, M. Llanos/0000-0001-7742-8265				BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Botz J, 1996, MOL CELL BIOL, V16, P3401; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dagnino L, 1997, CELL GROWTH DIFFER, V8, P553; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Geng Y, 1996, ONCOGENE, V12, P1173; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Huet X, 1996, MOL CELL BIOL, V16, P3789; JOHNSON DG, 1993, NATURE, V365, P849; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Paramio JM, 1997, BRIT J DERMATOL, V137, P44, DOI 10.1111/j.1365-2133.1997.tb03699.x; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Richon VM, 1996, CELL GROWTH DIFFER, V7, P31; Rodriguez-Puebla ML, 1998, ONCOGENE, V17, P2251, DOI 10.1038/sj.onc.1202131; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2, P1; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Soucek T, 1997, ONCOGENE, V14, P2251, DOI 10.1038/sj.onc.1201061; Strom DK, 1998, CELL GROWTH DIFFER, V9, P59; Tevosian SG, 1996, CELL GROWTH DIFFER, V7, P43; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zacksenhaus E, 1996, EMBO J, V15, P5917, DOI 10.1002/j.1460-2075.1996.tb00978.x	54	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41219	41226		10.1074/jbc.M004973200	http://dx.doi.org/10.1074/jbc.M004973200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11005809	hybrid			2022-12-27	WOS:000166114600075
J	Urlaub, H; Hartmuth, K; Kostka, S; Grelle, G; Luhrmann, R				Urlaub, H; Hartmuth, K; Kostka, S; Grelle, G; Luhrmann, R			A general approach for identification of RNA-Protein cross-linking sites within native human spliceosomal small nuclear ribonucleoproteins (snRNPs) - Analysis of RNA-protein contacts in native U1 and U4/U6.U5 snRNPs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SM-LIKE PROTEINS; IONIZATION MASS-SPECTROMETRY; U5 SNRNP; U6 SNRNA; CRYSTAL-STRUCTURE; SEQUENCE-ANALYSIS; GU DINUCLEOTIDE; CATALYTIC STEP; BINDING DOMAIN; RIBOSOMAL-RNA	We describe a novel approach to identify RNA-protein cross-linking sites within native small nuclear ribonucleoprotein (snRNP) particles from HeLa cells. It combines immunoprecipitation of the UV-irradiated particles under semi-denaturing conditions with primer extension analysis of the cross-linked RNA moiety. In a feasibility study, we initially identified the exact crosslinking sites of the U1 70-kDa (70K) protein in stem-loop I of U1 small nuclear RNA (snRNA) within purified U1 snRNPs and then confirmed the results by a large-scale preparation that allowed N-terminal sequencing and matrix-assisted laser desorption ionization mass spectrometry of purified cross-linked peptide-oligonucleotide complexes. We identified Tyr(112) and Leu(175) within the RNA-binding domain of the U1 70K protein to be cross-linked to G(28) and U-30 in stem-loop I, respectively. We further applied our immunoprecipitation approach to HeLa US snRNP, as part of purified 25 S U4/U6.U5 tri-snRNPs. Cross-linking sites between the US-specific 220-kDa protein (human homologue of Prp8p) and the U5 snRNA were located at multiple nucleotides within the highly conserved loop I and at one site in internal loop 1 of U5 snRNA The cross-linking of four adjacent nucleotides indicates an extended interaction surface between loop 1 and the 220-kDa protein. In summary, our approach provides a rapid method for identification of RNA-protein contact sites within native snRNP particles as well as other ribonucleoprotein particles.	Max Planck Inst Biophys Chem, Abt Zellulare Biochem, D-37077 Gottingen, Germany; Max Delbruck Ctr Mol Med, Prot Chem Abt, D-13125 Berlin, Germany	Max Planck Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Luhrmann, R (corresponding author), Max Planck Inst Biophys Chem, Abt Zellulare Biochem, Fassberg 11, D-37077 Gottingen, Germany.	reinhard.luehrmann@mpi-bpc.mpg.de						Achsel T, 1999, EMBO J, V18, P5789, DOI 10.1093/emboj/18.20.5789; Achsel T, 1998, MOL CELL BIOL, V18, P6756, DOI 10.1128/MCB.18.11.6756; BACH M, 1990, NUCLEIC ACIDS RES, V18, P449, DOI 10.1093/nar/18.3.449; Burge CB, 1999, RNA WORLD, P525; Chiara MD, 1997, EMBO J, V16, P4746, DOI 10.1093/emboj/16.15.4746; Collins CA, 1999, GENE DEV, V13, P1970, DOI 10.1101/gad.13.15.1970; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dix I, 1998, RNA, V4, P1674, DOI 10.1017/S1355838298412998; Fabrizio P, 1997, EMBO J, V16, P4092, DOI 10.1093/emboj/16.13.4092; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Hartmuth K, 1999, J MOL BIOL, V285, P133, DOI 10.1006/jmbi.1998.2300; HEINRICHS V, 1992, J MOL BIOL, V227, P15, DOI 10.1016/0022-2836(92)90678-D; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; Kambach C, 1999, CURR OPIN STRUC BIOL, V9, P222, DOI 10.1016/S0959-440X(99)80032-3; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; KASTNER B, 1992, J CELL BIOL, V116, P839, DOI 10.1083/jcb.116.4.839; Kastner B., 1998, RNP PARTICLES SPLICI, P95; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Laggerbauer B, 1996, NUCLEIC ACIDS RES, V24, P868, DOI 10.1093/nar/24.5.868; Lauber J, 1996, EMBO J, V15, P4001, DOI 10.1002/j.1460-2075.1996.tb00774.x; LUTZREYERMUTH C, 1989, MOL CELL BIOL, V9, P2975, DOI 10.1128/MCB.9.7.2975; Mayes AE, 1999, EMBO J, V18, P4321, DOI 10.1093/emboj/18.15.4321; METZBOUTIGUE MH, 1989, FEBS LETT, V245, P194, DOI 10.1016/0014-5793(89)80220-0; NELISSEN RLH, 1994, EMBO J, V13, P4113, DOI 10.1002/j.1460-2075.1994.tb06729.x; Newman AJ, 1995, RNA, V1, P968; NORDHOFF E, 1993, NUCLEIC ACIDS RES, V21, P3347, DOI 10.1093/nar/21.15.3347; Nottrott S, 1999, EMBO J, V18, P6119, DOI 10.1093/emboj/18.21.6119; OKeefe RT, 1996, CELL, V86, P679, DOI 10.1016/S0092-8674(00)80140-3; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; QUERY CC, 1989, MOL CELL BIOL, V9, P4872, DOI 10.1128/MCB.9.11.4872; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; Reyes J, 1996, RNA, V2, P213; Reyes JL, 1999, RNA, V5, P167, DOI 10.1017/S1355838299981785; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Salgado-Garrido J, 1999, EMBO J, V18, P3451, DOI 10.1093/emboj/18.12.3451; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; Segault V, 1999, MOL CELL BIOL, V19, P2782; Siatecka M, 1999, GENE DEV, V13, P1983, DOI 10.1101/gad.13.15.1983; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; SUROWY CS, 1989, MOL CELL BIOL, V9, P4179, DOI 10.1128/MCB.9.10.4179; TEIGELKAMP S, 1995, EMBO J, V14, P2602, DOI 10.1002/j.1460-2075.1995.tb07258.x; Thiede B, 1999, METH MOL B, V118, P63; Umen JG, 1996, GENETICS, V143, P723; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; Urlaub H, 1997, J BIOL CHEM, V272, P14547, DOI 10.1074/jbc.272.23.14547; URLAUB H, 1995, EMBO J, V14, P4578, DOI 10.1002/j.1460-2075.1995.tb00137.x; Vidal VPI, 1999, RNA, V5, P1470, DOI 10.1017/S1355838299991355; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8; WILL CL, 1997, EUKARYOTIC MRNA PROC, P130; WILLIS MC, 1994, NUCLEIC ACIDS RES, V22, P4947, DOI 10.1093/nar/22.23.4947; WOPPMANN A, 1988, NUCLEIC ACIDS RES, V16, P10985, DOI 10.1093/nar/16.23.10985	57	52	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41458	41468		10.1074/jbc.M007434200	http://dx.doi.org/10.1074/jbc.M007434200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11006293	hybrid			2022-12-27	WOS:000166114600104
J	Kottom, TJ; Limper, AH				Kottom, TJ; Limper, AH			Cell wall assembly by Pneumocystis carinii - Evidence for a unique Gsc-1 subunit mediating beta-1,3-glucan deposition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; BETA-GLUCAN RECEPTORS; SACCHAROMYCES-CEREVISIAE; ALVEOLAR MACROPHAGES; CANDIDA-ALBICANS; 1,3-BETA-D-GLUCAN SYNTHASE; LIFE-CYCLE; CYST WALL; 1,3-BETA-GLUCAN SYNTHESIS; ARACHIDONIC-ACID	Pneumocystis carinii remains a persistent cause of severe pneumonia in immune compromised patients. Recent studies indicate that P. carinii is a fungal species possessing a glucan-rich cyst wall. Pneumocandin antagonists of beta -1,3-glucan synthesis rapidly suppress infection in animal models of P. carinii pneumonia. We, therefore, sought to define the molecular mechanisms of P-glucan cell wall assembly by P. carinii. Membrane extracts derived from freshly purified P. carinii incorporate uridine 5'-diphosphoglucose into insoluble carbohydrate, in a manner that was completely inhibited by the pneumocandin L733-560, an antagonist of Gsc-1-type p-glucan synthetases. Using degenerative polymerase chain reaction and library screening, the P. carinii Gsc-1 catalytic subunit of beta -1,3-glucan synthetase was cloned and characterized. P. carinii gsc1 exhibited homology to phylogenetically related fungal beta -1,3-glucan synthetases, encoding a predicted 214-kDa integral membrane protein with 12 transmembrane domain structure. Immunoprecipitation of P. carinii extracts, with a synthetic peptide anti-Gsc-1 antibody, specifically yielded a protein of 219.4 kDa, which was also capable of incorporating 5'-diphosphoglucose into insoluble glucan carbohydrate. As opposed to other fungi, the expression of gsc-1 mRNA is uniquely regulated over P. carinii's life cycle, having minimal expression in trophic forms, but substantial expression in the thick-walled cystic form of the organism. These results indicate that P. carinii contains a unique catalytic subunit of beta -1,3-glucan synthetase utilized in cyst wall formation. Because synthesis of beta -1,3-glucan is absent in mammalian cells, inhibition of the P. carinii Gsc-1 represents an attractive molecular target for therapeutic exploitation.	Mayo Clin, Thorac Dis Res Unit, Dept Med, Rochester, MN 55905 USA; Mayo Clin, Thorac Dis Res Unit, Dept Biochem, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Limper, AH (corresponding author), Mayo Clin, Thorac Dis Res Unit, Dept Med, 601C Guggenheim Bldg, Rochester, MN 55905 USA.				NHLBI NIH HHS [R01 HL062150] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062150] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BACON JSD, 1969, BIOCHEM J, V114, P557, DOI 10.1042/bj1140557; Bartlett MS, 1996, ANTIMICROB AGENTS CH, V40, P1811, DOI 10.1128/AAC.40.8.1811; Bruns TD, 1992, MOL PHYLOGENET EVOL, V1, P231, DOI 10.1016/1055-7903(92)90020-H; CABIB E, 1987, METHOD ENZYMOL, V138, P637; CAMPBELL WG, 1972, ARCH PATHOL, V93, P312; Carlson CR, 1997, YEAST, V13, P1329; CASTRO C, 1995, J BACTERIOL, V177, P5732, DOI 10.1128/jb.177.20.5732-5739.1995; CASTRO M, 1994, INFECT IMMUN, V62, P3138, DOI 10.1128/IAI.62.8.3138-3145.1994; CROSS CE, 1995, INFECT IMMUN, V63, P2604, DOI 10.1128/IAI.63.7.2604-2611.1995; CUSHION MT, 1993, INFECT IMMUN, V61, P4801, DOI 10.1128/IAI.61.11.4801-4813.1993; CZOP JK, 1985, P NATL ACAD SCI USA, V82, P2751, DOI 10.1073/pnas.82.9.2751; DAUM T, 1992, FEBS LETT, V309, P119, DOI 10.1016/0014-5793(92)81077-Y; DESTEFANO JA, 1990, J PROTOZOOL, V37, P428; DURKIN ME, 1991, J PROTOZOOL, V38, P210; EDMAN JC, 1988, NATURE, V334, P519, DOI 10.1038/334519a0; ELSADR W, 1988, AM REV RESPIR DIS, V137, P1264, DOI 10.1164/ajrccm/137.6.1264; ELSHERBEINI M, 1995, J BACTERIOL, V177, P3227, DOI 10.1128/jb.177.11.3227-3234.1995; ENDERLIN CS, 1994, P NATL ACAD SCI USA, V91, P9500, DOI 10.1073/pnas.91.20.9500; FLETCHER LD, 1993, GENE, V129, P167, DOI 10.1016/0378-1119(93)90265-5; FLETCHER LD, 1994, GENETICS, V137, P743; GIGLIOTTI F, 1993, J INFECT DIS, V168, P191, DOI 10.1093/infdis/168.1.191; HIDALGO HA, 1991, J PROTOZOOL, V38, pS30; HOFFMAN OA, 1993, J IMMUNOL, V150, P3932; HOFFMAN OA, 1993, IMMUNOL LETT, V37, P19, DOI 10.1016/0165-2478(93)90127-N; INOUE SB, 1995, EUR J BIOCHEM, V231, P845, DOI 10.1111/j.1432-1033.1995.tb20770.x; Itatani CA, 1996, J PARASITOL, V82, P163, DOI 10.2307/3284134; JANUSZ MJ, 1988, IMMUNOLOGY, V65, P181; JANUSZ MJ, 1987, J IMMUNOL, V138, P3897; Kelly R, 1996, J BACTERIOL, V178, P4381, DOI 10.1128/jb.178.15.4381-4391.1996; Kollar R, 1997, J BIOL CHEM, V272, P17762, DOI 10.1074/jbc.272.28.17762; Kurtz MB, 1996, INFECT IMMUN, V64, P3244, DOI 10.1128/IAI.64.8.3244-3251.1996; LIMPER AH, 1990, J CLIN INVEST, V85, P391, DOI 10.1172/JCI114451; Limper AH, 1997, J CLIN INVEST, V99, P2110, DOI 10.1172/JCI119384; LIMPER AH, 1989, AM REV RESPIR DIS, V140, P1204, DOI 10.1164/ajrccm/140.5.1204; Limper AH, 1997, J EUKARYOT MICROBIOL, V44, p32S, DOI 10.1111/j.1550-7408.1997.tb05756.x; Limper AH, 1998, J CLIN INVEST, V101, P1148, DOI 10.1172/JCI659; Limper AH, 1997, J LAB CLIN MED, V130, P132, DOI 10.1016/S0022-2143(97)90089-5; LINKE MJ, 1989, INFECT IMMUN, V57, P1547, DOI 10.1128/IAI.57.5.1547-1555.1989; LUNDGREN B, 1991, J CLIN INVEST, V87, P163, DOI 10.1172/JCI114966; MACNEILL SA, 1995, CELL CYCLE CONTROL, P63; MANNERS DJ, 1973, BIOCHEM J, V135, P19, DOI 10.1042/bj1350019; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; Merali S, 1999, P NATL ACAD SCI USA, V96, P2402, DOI 10.1073/pnas.96.5.2402; Mio T, 1997, J BACTERIOL, V179, P4096, DOI 10.1128/jb.179.13.4096-4105.1997; NOLLSTADT KH, 1994, ANTIMICROB AGENTS CH, V38, P2258, DOI 10.1128/AAC.38.10.2258; Olson EJ, 1996, INFECT IMMUN, V64, P3548, DOI 10.1128/IAI.64.9.3548-3554.1996; Powles MA, 1998, ANTIMICROB AGENTS CH, V42, P1985, DOI 10.1128/AAC.42.8.1985; RASSMUSSEN LT, 1992, J CELL BIOCHEM, V46, P60; Roth A, 1997, PARASITOL RES, V83, P177, DOI 10.1007/s004360050229; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMATZ DM, 1995, ANTIMICROB AGENTS CH, V39, P1320, DOI 10.1128/AAC.39.6.1320; SCHMATZ DM, 1990, P NATL ACAD SCI USA, V87, P5950, DOI 10.1073/pnas.87.15.5950; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SLOAND E, 1993, J EUKARYOT MICROBIOL, V40, P188, DOI 10.1111/j.1550-7408.1993.tb04902.x; STRINGER SL, 1993, J EUKARYOT MICROBIOL, V40, P821, DOI 10.1111/j.1550-7408.1993.tb04481.x; SUNKIN SM, 1995, J EUKARYOT MICROBIOL, V42, P12, DOI 10.1111/j.1550-7408.1995.tb01534.x; Tentler S, 1997, CURR MICROBIOL, V34, P303, DOI 10.1007/s002849900186; Thomas C F Jr, 1998, Semin Respir Infect, V13, P289; Thomas CF, 1999, INFECT IMMUN, V67, P6157, DOI 10.1128/IAI.67.11.6157-6160.1999; Thomas CF, 1998, AM J RESP CELL MOL, V18, P297, DOI 10.1165/ajrcmb.18.3.3122; THOMAS CF, 1998, AM J PHYSIOL, V275, P193; VANDEPEER Y, 1992, SYST APPL MICROBIOL, V15, P250, DOI 10.1016/S0723-2020(11)80099-8; Vassallo R, 1999, J LAB CLIN MED, V133, P535, DOI 10.1016/S0022-2143(99)90182-8; Yale SH, 1996, MAYO CLIN PROC, V71, P5, DOI 10.4065/71.1.5; Yasuoka A, 1996, CLIN DIAGN LAB IMMUN, V3, P197, DOI 10.1128/CDLI.3.2.197-199.1996; Yu ML, 1997, AM J PHYSIOL-LUNG C, V273, pL1103, DOI 10.1152/ajplung.1997.273.6.L1103	68	75	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40628	40634		10.1074/jbc.M002103200	http://dx.doi.org/10.1074/jbc.M002103200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11013231	hybrid			2022-12-27	WOS:000166039500111
J	Lin, XY; Choi, MSK; Porter, AG				Lin, XY; Choi, MSK; Porter, AG			Expression analysis of the human caspase-1 subfamily reveals specific regulation of the CASP5 gene by lipopolysaccharide and interferon-gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOTIC CELL-DEATH; INTERLEUKIN-1-BETA-CONVERTING ENZYME; CYSTEINE PROTEASES; FAMILY; ICE; IDENTIFICATION; PATHWAY; ACTIVATION; MEMBERS	Based on high sequence homology, there are six members in the caspase-1 subfamily: caspases 1, 4, 5, and 13 in humans and caspases 1, 11, and 12 in mice. Only caspase-1 is known to activate interleukin-1 beta and interleukin-18, and caspase-11 activates pro-caspase-1 in vivo. Almost nothing is known about caspases 4, 5, and 13. Here we report a sensitive and specific polymerase chain reaction system to analyze closely related genes. We employed this system to analyze the gene expression and regulation of human caspases 1, 4, 5, and 13, demonstrating that they have different expression patterns in normal tissues and cell lines, Interferon-gamma strongly induced CASP1 and CASP5 but not CASP4 or CASP13 gene expression in HT-29 colon carcinoma cells. In contrast to the mRNA, interferon-gamma up-regulated caspase-1 but not caspase-5 protein. In the monocytic cell line THP-1, CASP1 mRNA and caspase-1 protein are expressed constitutively, and their levels were not increased by lipopolysaccharide, whereas both GASPS mRNA and caspase-5 protein were induced by lipopolysaccharide. Caspase-1 subfamily members displayed different in vitro activities toward pro-caspases 1 and 3 and pro-interleukin-1 beta. Our results demonstrate that caspase-1 and caspase-5 levels are modulated by interferon-gamma and lipopolysaccharide, respectively, and suggest that caspase-1 subfamily members are differentially regulated and may have distinct functions.	Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Porter, AG (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.							Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Fantuzzi G, 1999, J CLIN IMMUNOL, V19, P1, DOI 10.1023/A:1020506300324; Fassy F, 1998, EUR J BIOCHEM, V253, P76, DOI 10.1046/j.1432-1327.1998.2530076.x; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; Faucheu C, 1996, EUR J BIOCHEM, V236, P207, DOI 10.1111/j.1432-1033.1996.t01-1-00207.x; FENTON MJ, 1987, J IMMUNOL, V138, P3972; Friedlander RM, 1998, CELL DEATH DIFFER, V5, P823, DOI 10.1038/sj.cdd.4400433; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Humke EW, 1998, J BIOL CHEM, V273, P15702, DOI 10.1074/jbc.273.25.15702; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; Kamada S, 1997, ONCOGENE, V15, P285, DOI 10.1038/sj.onc.1201192; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; Kang SJ, 2000, J CELL BIOL, V149, P613, DOI 10.1083/jcb.149.3.613; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Schwartz S, 1999, CANCER RES, V59, P2995; Tamura T, 1996, BIOCHEM BIOPH RES CO, V229, P21, DOI 10.1006/bbrc.1996.1752; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593	23	159	167	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39920	39926		10.1074/jbc.M007255200	http://dx.doi.org/10.1074/jbc.M007255200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10986288	hybrid			2022-12-27	WOS:000166039500020
J	Smith, T; McCracken, J; Shin, YK; DeWitt, D				Smith, T; McCracken, J; Shin, YK; DeWitt, D			RETRACTED: Arachidonic acid and nonsteroidal anti-inflammatory drugs induce conformational changes in the human prostaglandin endoperoxide H-2 synthase-2 (cyclooxygenase-2) (Retracted Article. See vol 279, pg 6204, 2004)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							H-SYNTHASE; CRYSTAL-STRUCTURE; DNA DUPLEX; SITE; ACTIVATION; BINDING; PROTEIN; AGENTS; PROTEOLYSIS; INHIBITION	By using the technique of site-directed spin labeling combined with EPR spectroscopy, we have observed that binding of arachidonic acid and nonsteroidal antiinflammatory drugs induces conformational changes in the human prostaglandin endoperoxide H-2 synthase enzyme (PGHS-2), Line shape broadening resulting from spin-spin coupling of nitroxide pairs introduced into the membrane-binding helices of PGHS-2 was used to calculate the inter-helical distances and changes in these distances that occur in response to binding various ligands, The inter-residue distances determined for the PGHS-2 holoenzyme using EPR were 1-7.9 Angstrom shorter than those of the crystal structure of the PGHS-8 holoenzyme, However, inter-helical distances calculated and determined by EPR for PGHS-S complexed with arachidonic acid, flurbiprofen, and CS-58125 were in close agreement with those obtained from the cognate crystal structures. These results indicate that the structure of the solubilized PGHS-S holoenzyme measured in solution differs from the crystal structure of PGHS-2 holoenzyme obtained by x-ray analysis. Furthermore, binding of ligands induces a conformational change in the holo-PGHS-2, converting it to a structure similar to those obtained by x-ray analysis. Proteolysis protection assays had previously provided circumstantial evidence that binding of heme and non-steroidal anti-inflammatory drugs alters the conformation of PGHS, but the present experiments are the first to directly measure such changes. The finding that arachidonate can also induce a conformational change in PGHS-2 was unexpected, and the magnitude of changes suggests this structural flexibility may be integral to the cyclooxygenase catalytic mechanism.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA; Iowa State Univ Sci & Technol, Dept Biochem & Biophys, Ames, IA 50011 USA	Michigan State University; Michigan State University; Iowa State University	DeWitt, D (corresponding author), Michigan State Univ, Dept Biochem, 519 Biochem, E Lansing, MI 48824 USA.	dewittd@msu.edu			NIGMS NIH HHS [GM57323] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN YNP, 1987, J BIOL CHEM, V262, P16892; DeWitt DL, 1999, MOL PHARMACOL, V55, P625; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FEIX JB, 1998, BIO MAGN RE, V14, P251; Gross A, 1999, BIOCHEMISTRY-US, V38, P10324, DOI 10.1021/bi990856k; Hall JA, 1997, J BIOL CHEM, V272, P17610, DOI 10.1074/jbc.272.28.17610; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; JOSHUATOR L, 1988, NATURE, V334, P82, DOI 10.1038/334082a0; Kalgutkar AS, 1996, BIOCHEMISTRY-US, V35, P9076, DOI 10.1021/bi9605752; KULMACZ RJ, 1989, J BIOL CHEM, V264, P14136; KULMACZ RJ, 1982, BIOCHEM BIOPH RES CO, V104, P758, DOI 10.1016/0006-291X(82)90702-1; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; Marnett LJ, 1998, CURR OPIN CHEM BIOL, V2, P482, DOI 10.1016/S1367-5931(98)80124-5; MILLER M, 1988, NATURE, V334, P85, DOI 10.1038/334085a0; Ottemann KM, 1998, BIOCHEMISTRY-US, V37, P7062, DOI 10.1021/bi980305e; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; Smith T, 2000, ARCH BIOCHEM BIOPHYS, V375, P195, DOI 10.1006/abbi.1999.1659; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SMITH WL, 1996, THERAPEUTIC IMMUNOLO, P119; So OY, 1998, J BIOL CHEM, V273, P5801, DOI 10.1074/jbc.273.10.5801; Thuresson ED, 2000, J BIOL CHEM, V275, P8501, DOI 10.1074/jbc.275.12.8501	25	20	20	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40407	40415		10.1074/jbc.M005563200	http://dx.doi.org/10.1074/jbc.M005563200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006278	hybrid			2022-12-27	WOS:000166039500083
J	Butt, AJ; Firth, SM; King, MA; Baxter, RC				Butt, AJ; Firth, SM; King, MA; Baxter, RC			Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; IGF-I RECEPTOR; GENE-EXPRESSION; FACTOR-BETA; RETINOIC ACID; DEATH; INHIBITION; FIBROBLASTS; INDUCTION; RESISTANCE	We report that transfection of insulin-like growth factor-binding protein-3 (IGPBP-3) cDNA in human breast cancer cell lines expressing either mutant p53 (T47D) or wild-type p53 (MCF-7) induces apoptosis, IGFBP-3 also increases the ratio of pro-apoptotic to anti-apoptotic members of the Bcl-2 family. In MCF-7, an increase in Bad and Bax protein expression and a decrease in Bcl-x(L) protein and Bcl-2 protein and mRNA were observed. In T47D, Bax and Bad proteins were up-regulated; Bcl-2 protein is undetectable in these cells. As T47D expresses mutant p53 protein, these modulations of pro-apoptotic proteins and induction of apoptosis are independent of p53. The effect of IGFBP-3 on the response of T47D to ionizing radiation (IR) was examined. These cells do not G(1) arrest in response to IR and are relatively radioresistant. Transfection of IGFBP-3 increased the radiosensitivity of T47D and increased IR-induced apoptosis but did not effect a rapid G(1) arrest. IR also caused a much greater increase in Bax protein in IGFBP-3 transfectants compared with vector controls. Thus, IGFBP-3 increases the expression of pro-apoptotic proteins and apoptosis both basally and in response to IR, suggesting it may be a p53-independent effector of apoptosis in breast cancer cells via its modulation of the Bax:Bcl-2 protein ratio.	Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia; Royal N Shore Hosp, Dept Clin Immunol, St Leonards, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research; Royal North Shore Hospital	Butt, AJ (corresponding author), Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.		Baxter, Robert C/F-3927-2012	Baxter, Robert C/0000-0001-5061-2142; Butt, Alison/0000-0002-6216-5105				BAXTER RC, 1986, J CLIN INVEST, V78, P1504, DOI 10.1172/JCI112742; Blagosklonny MV, 1997, CANCER RES, V57, P130; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Butt AJ, 1999, IMMUNOL CELL BIOL, V77, P256, DOI 10.1046/j.1440-1711.1999.00822.x; CHEN JC, 1994, J CELL PHYSIOL, V158, P69, DOI 10.1002/jcp.1041580110; COHEN P, 1993, GROWTH REGULAT, V3, P23; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delhanty PJD, 1998, ENDOCRINOLOGY, V139, P260, DOI 10.1210/en.139.1.260; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; FIGUEROA JA, 1992, BREAST CANCER RES TR, V22, P81, DOI 10.1007/BF01833336; Firth SM, 1998, BIOCHEM BIOPH RES CO, V246, P325, DOI 10.1006/bbrc.1998.8615; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; Gucev ZS, 1996, CANCER RES, V56, P1545; Guo YP, 1999, CANCER RES, V59, P1366; Harima Y, 1998, J CANCER RES CLIN, V124, P503, DOI 10.1007/s004320050206; Kanatani Y, 1999, CELL GROWTH DIFFER, V10, P705; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Krajewski S, 1997, CLIN CANCER RES, V3, P199; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LOVE SW, 1993, NATURE, V362, P847; Martin JL, 1999, J BIOL CHEM, V274, P16407, DOI 10.1074/jbc.274.23.16407; MARTIN JL, 1995, ENDOCRINOLOGY, V136, P1219, DOI 10.1210/en.136.3.1219; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nickerson T, 1998, ENDOCRINOLOGY, V139, P807, DOI 10.1210/en.139.2.807; Nickerson T, 1999, J ENDOCRINOL, V160, P223, DOI 10.1677/joe.0.1600223; Nickerson T, 1997, BIOCHEM BIOPH RES CO, V237, P690, DOI 10.1006/bbrc.1997.7089; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; OH YM, 1993, J BIOL CHEM, V268, P14964; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OSBORNE CK, 1989, MOL ENDOCRINOL, V3, P1701, DOI 10.1210/mend-3-11-1701; OSBORNE RJ, 1991, CANCER RES, V51, P6194; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1355, DOI 10.1210/en.138.3.1355; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Rozen F, 1998, INT J ONCOL, V13, P865; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; Sakakura C, 1996, INT J CANCER, V67, P101, DOI 10.1002/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shen L, 1998, BIOCHEM PHARMACOL, V55, P1711, DOI 10.1016/S0006-2952(98)00045-8; Siles E, 1996, BRIT J CANCER, V73, P581, DOI 10.1038/bjc.1996.101; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; Williams AC, 2000, CANCER RES, V60, P22; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509	51	176	186	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39174	39181		10.1074/jbc.M908888199	http://dx.doi.org/10.1074/jbc.M908888199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10998426	hybrid			2022-12-27	WOS:000165953100033
J	Shan, LX; Qiao, XD; Crona, JH; Behan, J; Wang, S; Laz, T; Bayne, M; Gustafson, EL; Monsma, FJ; Hedrick, JA				Shan, LX; Qiao, XD; Crona, JH; Behan, J; Wang, S; Laz, T; Bayne, M; Gustafson, EL; Monsma, FJ; Hedrick, JA			Identification of a novel neuromedin U receptor subtype expressed in the central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL-CHARACTERIZATION; CLONING; U-25	Neuromedin U is a neuropeptide prominently expressed in the upper gastrointestinal tract and central nervous system. Recently, GPR66/FM-3 (NmU-R1) was identified as a specific receptor for neuromedin U. A BLAST search of the GenBank(TM) genomic database using the NmU-R1 cDNA sequence revealed a human genomic fragment encoding a G protein-coupled receptor that we designated NmU-R2 based on its homology to NmU-R1. The full-length NmU-R2 cDNA was subsequently cloned stably expressed in 293 cells, and shown to mobilize intracellular calcium in response to neuromedin U. This response was dose-dependent (EC50 = 5 nm) and specific in that other neuromedins did not induce a calcium flux in receptor-transfected cells. Expression analysis of human NmU-R2 demonstrated its mRNA to be most highly expressed in central nervous system tissues. Based on these data, we conclude that NmU-R2 is a novel neuromedin U receptor subtype that is likely to mediate central nervous system-specific neuromedin U effects.	Schering Plough Res Inst, Human Genome Res, Kenilworth, NJ 07033 USA; Schering Plough Res Inst, Cardiovasc Cent Nervous Syst Res, Kenilworth, NJ 07033 USA	Merck & Company; Schering-Plough Research Institute; Merck & Company; Schering-Plough Research Institute	Hedrick, JA (corresponding author), Schering Plough Res Inst, Human Genome Res, 2015 Galloping Hill Rd,K-15-1-1800, Kenilworth, NJ 07033 USA.	joseph.hedrick@spcorp.com						AUSTIN C, 1995, J MOL ENDOCRINOL, V14, P157, DOI 10.1677/jme.0.0140157; BENITOORFILA MA, 1991, EUR J PHARMACOL, V193, P329, DOI 10.1016/0014-2999(91)90147-I; BOCKMAN CS, 1989, EUR J PHARMACOL, V171, P255, DOI 10.1016/0014-2999(89)90117-9; BROWN DR, 1988, EUR J PHARMACOL, V155, P159, DOI 10.1016/0014-2999(88)90415-3; CONLON JM, 1988, J NEUROCHEM, V51, P988, DOI 10.1111/j.1471-4159.1988.tb01837.x; Coward P, 1999, ANAL BIOCHEM, V270, P242, DOI 10.1006/abio.1999.4061; DOMIN J, 1992, REGUL PEPTIDES, V41, P1, DOI 10.1016/0167-0115(92)90508-R; Feighner SD, 1999, SCIENCE, V284, P2184, DOI 10.1126/science.284.5423.2184; Fujii R, 2000, J BIOL CHEM, V275, P21068, DOI 10.1074/jbc.M001546200; GARDINER SM, 1990, AM J PHYSIOL, V258, pR32, DOI 10.1152/ajpregu.1990.258.1.R32; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hedrick JA, 2000, MOL PHARMACOL, V58, P870, DOI 10.1124/mol.58.4.870; Hosoya M, 2000, J BIOL CHEM, V275, P29528, DOI 10.1074/jbc.M004261200; Howard AD, 2000, NATURE, V406, P70, DOI 10.1038/35017610; KAGE R, 1991, REGUL PEPTIDES, V33, P191, DOI 10.1016/0167-0115(91)90213-Z; LO G, 1992, MOL ENDOCRINOL, V6, P1538, DOI 10.1210/me.6.10.1538; MAGGI CA, 1990, BRIT J PHARMACOL, V99, P186, DOI 10.1111/j.1476-5381.1990.tb14675.x; Malendowicz L K, 1993, In Vivo, V7, P419; MALENDOWICZ LK, 1994, NEUROPEPTIDES, V26, P47, DOI 10.1016/0143-4179(94)90092-2; MINAMINO N, 1988, BIOCHEM BIOPH RES CO, V156, P355, DOI 10.1016/S0006-291X(88)80848-9; MINAMINO N, 1985, PEPTIDES, V6, P245, DOI 10.1016/0196-9781(85)90381-X; MINAMINO N, 1985, BIOCHEM BIOPH RES CO, V130, P1078, DOI 10.1016/0006-291X(85)91726-7; MURPHY R, 1990, PEPTIDES, V11, P613, DOI 10.1016/0196-9781(90)90066-E; Nandha KA, 1999, PEPTIDES, V20, P1203, DOI 10.1016/S0196-9781(99)00124-2; NANDHA KA, 1993, ENDOCRINOLOGY, V133, P482, DOI 10.1210/en.133.2.482; OHARTE F, 1991, PEPTIDES, V12, P11, DOI 10.1016/0196-9781(91)90159-M; Raddatz R, 2000, J BIOL CHEM, V275, P32452, DOI 10.1074/jbc.M004613200; Salmon AL, 2000, J BIOL CHEM, V275, P4549, DOI 10.1074/jbc.275.7.4549; Sullivan E, 1999, METH MOL B, V114, P125; SUMI S, 1987, LIFE SCI, V41, P1585, DOI 10.1016/0024-3205(87)90725-9; Szekeres PG, 2000, J BIOL CHEM, V275, P20247, DOI 10.1074/jbc.C000244200; Tan CP, 1998, GENOMICS, V52, P223, DOI 10.1006/geno.1998.5441	32	93	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39482	39486		10.1074/jbc.C000522200	http://dx.doi.org/10.1074/jbc.C000522200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11010960	hybrid			2022-12-27	WOS:000165953100074
J	Taboy, CH; Faulkner, KM; Kraiter, D; Bonaventura, C; Crumbliss, AL				Taboy, CH; Faulkner, KM; Kraiter, D; Bonaventura, C; Crumbliss, AL			Concentration-dependent effects of anions on the anaerobic oxidation of hemoglobin and myoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CHLORIDE-BINDING SITES; REDOX POTENTIALS; ELECTRON-TRANSFER; SPECTROELECTROCHEMICAL METHOD; APLYSIA MYOGLOBIN; OXYGEN-AFFINITY; HEME-PROTEINS; MECHANISM; AUTOXIDATION	The redox potentials of hemoglobin and myoglobin and the shapes of their anaerobic oxidation curves are sensitive indicators of globin alterations surrounding the active site. This report documents concentration-dependent effects of anions on the ease of anaerobic oxidation of representative hemoglobins and myoglobins. Hemoglobin (Hb) oxidation curves reflect the cooperative transition from the T state of deoxyHb to the more readily oxidized R-like conformation of metHb. Shifts in the oxidation curves for Hb A(0) as Cl- concentrations are increased to 0.2 M at pH 7.1 indicate preferential anion binding to the T state and destabilization of the R-like state of metHb, leading to reduced cooperativity in the oxidation process. A dramatic reversal of trend occurs above 0.2 M Cl- as anions bind to lower affinity sites and shift the conformational equilibrium toward the R state. This pattern has been observed for various hemoglobins with a variety of small anions. Steric rather than electronic effects are invoked to explain the fact that no comparable reversal of oxygen affinity is observed under identical conditions. Evidence is presented to show that increases in hydrophilicity in the distal heme pocket can decrease oxygen affinity via steric hindrance effects while increasing the ease of anaerobic oxidation.	Duke Univ, Dept Chem, Durham, NC 27708 USA; Duke Univ, Marine Lab, Nicholas Sch Environm, Beaufort, NC 28516 USA	Duke University; Duke University	Crumbliss, AL (corresponding author), Duke Univ, Dept Chem, Durham, NC 27708 USA.				NHLBI NIH HHS [HL-58248] Funding Source: Medline; NIEHS NIH HHS [ESO 1908] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P50ES001908, P30ES001908] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANTONINI E, 1964, J BIOL CHEM, V239, P907; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; ARNONE A, 1974, NATURE, V249, P34, DOI 10.1038/249034a0; BELLELLI A, 1994, METHOD ENZYMOL, V232, P56; BENESCH R, 1969, NATURE, V221, P618, DOI 10.1038/221618a0; BENESCH RE, 1969, BIOCHEMISTRY-US, V8, P2567, DOI 10.1021/bi00834a046; BOLOGNESI M, 1989, J MOL BIOL, V205, P529, DOI 10.1016/0022-2836(89)90224-6; BONAVENTURA C, 1991, J BIOL CHEM, V266, P23033; Bonaventura C, 1998, BIOCHEMISTRY-US, V37, P496, DOI 10.1021/bi971574s; BONAVENTURA C, 1980, HEMOGLOBIN, V4, P275; BONAVENTURA C, 1976, J BIOL CHEM, V251, P1871; BONAVENTURA C, 1994, J MOL BIOL, V239, P561, DOI 10.1006/jmbi.1994.1395; BONAVENTURA C, 1978, BIOCH CLIN ASPECTS H, P647; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BRUNORI M, 1971, BIOCHEMISTRY-US, V10, P1604, DOI 10.1021/bi00785a016; CHIANCONE E, 1975, EUR J BIOCHEM, V55, P385, DOI 10.1111/j.1432-1033.1975.tb02173.x; CHIANCONE E, 1975, BIOPHYS CHEM, V3, P56, DOI 10.1016/0301-4622(75)80037-8; CHIANCONE E, 1972, J MOL BIOL, V70, P675, DOI 10.1016/0022-2836(72)90566-9; COLLMAN JP, 1975, J AM CHEM SOC, V97, P1427, DOI 10.1021/ja00839a026; DESBOIS A, 1975, J MOL BIOL, V92, P479, DOI 10.1016/0022-2836(75)90293-4; Di Cera E, 1998, CHEM REV, V98, P1563, DOI 10.1021/cr960135g; DICKERSON LD, 1993, J AM CHEM SOC, V115, P3623, DOI 10.1021/ja00062a028; FAULKNER KM, 1994, INORG CHIM ACTA, V226, P187, DOI 10.1016/0020-1693(94)04086-9; FAULKNER KM, 1995, J BIOL CHEM, V270, P13604, DOI 10.1074/jbc.270.23.13604; FONTICELLI C, 1994, J BIOL CHEM, V269, P23965; Gunner MR, 1997, J BIOL INORG CHEM, V2, P126, DOI 10.1007/s007750050116; Hu XH, 1997, BIOCHEMISTRY-US, V36, P15701, DOI 10.1021/bi971136l; KASSNER RJ, 1972, P NATL ACAD SCI USA, V69, P2263, DOI 10.1073/pnas.69.8.2263; KASSNER RJ, 1973, J AM CHEM SOC, V95, P2674, DOI 10.1021/ja00789a044; KLEINSCHMIDT T, 1983, BIOMED BIOCHIM ACTA, V42, P685; KRISTENSEN EW, 1991, J ELECTROANAL CHEM, V309, P61, DOI 10.1016/0022-0728(91)87004-N; LopezCastillo JM, 1997, J AM CHEM SOC, V119, P1978, DOI 10.1021/ja961978s; Mathews J.B., 1979, BIOCHEMISTRY-US, V18, P1928; Mauk AG, 1997, J BIOL INORG CHEM, V2, P119, DOI 10.1007/s007750050115; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOOPENN WF, 1978, FEBS LETT, V92, P53, DOI 10.1016/0014-5793(78)80720-0; MOORE GR, 1986, P NATL ACAD SCI USA, V83, P4998, DOI 10.1073/pnas.83.14.4998; Mylvaganam SE, 1996, NAT STRUCT BIOL, V3, P275, DOI 10.1038/nsb0396-275; PERELLA M, 1994, BIOCHEMISTRY-US, V33, P10358; PERUTZ M, 1997, SCI NOT QUIET LIFE; PERUTZ MF, 1993, J MOL BIOL, V233, P536, DOI 10.1006/jmbi.1993.1530; PERUTZ MF, 1960, NATURE, V185, P491; ROLLEMA HS, 1975, J BIOL CHEM, V250, P1333; RUSSU IM, 1986, BIOCHEMISTRY-US, V25, P1706, DOI 10.1021/bi00355a040; Shikama K, 1998, CHEM REV, V98, P1357, DOI 10.1021/cr970042e; SMERDON SJ, 1995, BIOCHEMISTRY-US, V34, P8715, DOI 10.1021/bi00027a022; SZABO A, 1972, J MOL BIOL, V72, P163, DOI 10.1016/0022-2836(72)90077-0; Taboy CH, 1999, BIOELECTROCH BIOENER, V48, P79, DOI 10.1016/S0302-4598(98)00236-0; Tezcan FA, 1998, J AM CHEM SOC, V120, P13383, DOI 10.1021/ja982536e; VALLONE B, 1993, FEBS LETT, V324, P117, DOI 10.1016/0014-5793(93)81375-A; VANDEGRIFF KD, 1995, BLOOD SUBSTITUTES PH, P134; WALLACE WJ, 1982, J BIOL CHEM, V257, P4966; WALLACE WJ, 1974, FEBS LETT, V43, P33, DOI 10.1016/0014-5793(74)81099-9; Warshel A, 1997, J BIOL INORG CHEM, V2, P143, DOI 10.1007/s007750050119; Zhou HX, 1997, J BIOL INORG CHEM, V2, P109, DOI 10.1007/s007750050113	55	32	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39048	39054		10.1074/jbc.M004547200	http://dx.doi.org/10.1074/jbc.M004547200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10984477	hybrid			2022-12-27	WOS:000165953100016
J	Black, PN; DiRusso, CC; Sherin, D; MacColl, R; Knudsen, J; Weimar, JD				Black, PN; DiRusso, CC; Sherin, D; MacColl, R; Knudsen, J; Weimar, JD			Affinity labeling fatty acyl-CoA synthetase with 9-p-azidophenoxy nonanoic acid and the identification of the fatty acid-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR FADR; COENZYME-A SYNTHETASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; RAT-LIVER; TRANSPORT PROTEIN; METABOLISM; BIOSYNTHESIS; ESTERS; SUPERFAMILY	Fatty acyl-CoA synthetase (FACS, fatty acid:CoA ligase, AMP-forming, EC 6.2.1.3) catalyzes the esterification of fatty acids to CoA thioesters for further metabolism and is hypothesized to play a pivotal role in the coupled transport and activation of exogenous long-chain fatty acids in Escherichia coli, Previous work on the bacterial enzyme identified a highly conserved region (FACS signature motif) common to long- and medium-chain acyl-CoA synthetases, which appears to contribute to the fatty acid binding pocket. In an effort to further define the fatty acid-binding domain within this enzyme, we employed the affinity labeled long-chain fatty acid [H-3]9-p-azidophenoxy nonanoic acid (APNA) to specifically modify the E. coli FAGS. [H-3]APNA labeling of the purified enzyme was saturable and specific for long-chain fatty acids as shown by the inhibition of modification with increasing concentrations of palmitate, The site of APNA modification was identified by digestion of [H-3]APNA cross-linked FAGS with trypsin and separation and purification of the resultant peptides using reverse phase high performance liquid chromatography, One specific H-3-labeled peptide, T33, was identified and following purification subjected to NH2-terminal sequence analysis. This approach yielded the peptide sequence PDATDEIIK which corresponded to residues 422 to 430 of FAGS. This peptide is immediately adjacent to the region of the enzyme that contains the FAGS signature motif (residues 431-455), This work represents the first direct identification of the carboxyl-containing substrate-binding domain within the adenylate-forming family of enzymes. The structural model for the E, coli FAGS predicts this moth lies within a cleft separating two distinct domains of the enzyme and is adjacent to a region that contains the AMP/ATP signature motif, which together are likely to represent the catalytic core of the enzyme.	Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA; Wadsworth Ctr, Div Mol Med, Albany, NY 12201 USA; Univ So Denmark, Inst Biochem & Mol Biol, Odense M, Denmark	Albany Medical College; Wadsworth Center; University of Southern Denmark	Black, PN (corresponding author), Albany Med Coll, Ctr Cardiovasc Sci, 47 New Scotland Ave,MC-8, Albany, NY 12208 USA.	blackp@mail.amc.edu	DiRusso, Concetta C/M-1884-2014	Black, Paul/0000-0002-6272-6881; DiRusso, Concetta/0000-0001-7388-9152				AIHAUD GP, 1994, FATTY ACIDS LIPIDS B; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; Black PN, 2000, J NUTR, V130, p305S, DOI 10.1093/jn/130.2.305S; BLACK PN, 1992, J BIOL CHEM, V267, P25513; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; Chang KH, 1997, BIOCHEMISTRY-US, V36, P15650, DOI 10.1021/bi971262p; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DiRusso CC, 1999, MOL CELL BIOCHEM, V192, P41, DOI 10.1023/A:1006823831984; DiRusso CC, 2000, EUR J BIOCHEM, V267, P4422, DOI 10.1046/j.1432-1327.2000.01489.x; DiRusso CC, 1999, PROG LIPID RES, V38, P129, DOI 10.1016/S0163-7827(98)00022-8; DiRusso CC, 1998, J BIOL CHEM, V273, P33652, DOI 10.1074/jbc.273.50.33652; DIRUSSO CC, 1993, MOL MICROBIOL, V7, P311, DOI 10.1111/j.1365-2958.1993.tb01122.x; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; Faergeman N J, 2000, Subcell Biochem, V34, P175; Faergeman NJ, 1997, J BIOL CHEM, V272, P8531, DOI 10.1074/jbc.272.13.8531; FUJIMOTO Y, 1995, PROSTAG LEUKOTR ESS, V52, P255, DOI 10.1016/0952-3278(95)90046-2; FULCERI R, 1995, BIOCHEM J, V307, P391, DOI 10.1042/bj3070391; Gargiulo CE, 1999, J LIPID RES, V40, P881; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GORDON JI, 1991, J BIOL CHEM, V266, P8647; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; KAMEDA K, 1981, J BIOL CHEM, V256, P5702; KNOLL LJ, 1995, J BIOL CHEM, V270, P10861, DOI 10.1074/jbc.270.18.10861; KNOLL LJ, 1994, J BIOL CHEM, V269, P16348; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI JCK, 1993, RES COMMUN CHEM PATH, V82, P331; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Nimchuk Z, 2000, CELL, V101, P353, DOI 10.1016/S0092-8674(00)80846-6; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; PAVELAVRANCIC M, 1994, BIOCHEMISTRY-US, V33, P6276, DOI 10.1021/bi00186a030; Raman N, 1997, J BIOL CHEM, V272, P30645, DOI 10.1074/jbc.272.49.30645; RAMAN N, 1995, J BIOL CHEM, V270, P1092, DOI 10.1074/jbc.270.3.1092; RICH GT, 1995, BIOCHEM J, V306, P703, DOI 10.1042/bj3060703; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SHRAGO E, 1995, PROSTAG LEUKOTR ESS, V52, P163, DOI 10.1016/0952-3278(95)90016-0; Singh RK, 1996, COMPUT APPL BIOSCI, V12, P191; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; VANBEILEN JB, 1992, MOL MICROBIOL, V6, P3121; YAMASHITA A, 1995, BIOCHEM J, V312, P301, DOI 10.1042/bj3120301	44	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38547	38553		10.1074/jbc.M006413200	http://dx.doi.org/10.1074/jbc.M006413200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10995760	hybrid			2022-12-27	WOS:000165739800056
J	Goode, BL; Chau, M; Denis, PE; Feinstein, SC				Goode, BL; Chau, M; Denis, PE; Feinstein, SC			Structural and functional differences between 3-repeat and 4-repeat tau isoforms - Implications for normal tau function and the onset of neurodegenerative disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-BINDING DOMAINS; PERIPHERAL NERVOUS-SYSTEM; PAIRED HELICAL FILAMENTS; MOLECULAR-WEIGHT TAU; PROTEIN-TAU; DYNAMIC INSTABILITY; KINETIC STABILIZATION; BIG-TAU; EXPRESSION; PHOSPHORYLATION	Tau, MAP2, and MAP4 are members of a microtubule-associated protein (MAP) family that are each expressed as "3-repeat" and "4-repeat" isoforms. These isoforms arise from tightly controlled tissue-specific and/or developmentally regulated alternative splicing of a 31-amino acid long "inter-repeat:repeat module," raising the possibility that different MAP isoforms may possess some distinct functional capabilities. Consistent with this hypothesis, regulatory mutations in the human tau gene that disrupt the normal balance between 3-repeat and 4-repeat tau isoform expression lead to a collection of neurodegenerative diseases known as FTDP-17 (fronto-temporal dementias and Parkinsonism Linked to chromosome 17), which are characterized by the formation of pathological tau filaments and neuronal cell death. Unfortunately, very little is known regarding structural and functional differences between the isoforms. In our previous analyses, we focused on 4-repeat tau structure and function. Here, we investigate 3-repeat tau, generating a series of truncations, amino acid substitutions, and internal deletions and examining the functional consequences. 3-Repeat tau possesses a "core microtubule binding domain" composed of its first two repeats and the intervening inter-repeat. This observation is in marked contrast to the widely held notion that tau possesses multiple independent tubulin-binding sites aligned in sequence along the length of the protein. In addition, we observed that the carboxyl-terminal sequences downstream of the repeat region make a strong but indirect contribution to microtubule binding activity in 5-repeat tan, which is in contrast to the negligible effect of these same sequences in 4-repeat tau. Taken together with previous work, these data suggest that 3-repeat and 4-repeat tau assume complex and distinct structures that are regulated differentially, which in turn suggests that they may possess isoform-specific functional capabilities. The relevance of isoform-specific structure and function to normal tan action and the onset of neurodegenerative disease are discussed.	Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Feinstein, SC (corresponding author), Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.				NINDS NIH HHS [R01NS35010] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035010] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackmann M, 2000, J BIOL CHEM, V275, P30335, DOI 10.1074/jbc.M002590200; BOYNE LJ, 1995, J COMP NEUROL, V358, P279, DOI 10.1002/cne.903580209; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; BULINSKI JC, 1994, MICROTUBULES, P145; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; COUCHIE D, 1992, P NATL ACAD SCI USA, V89, P4378, DOI 10.1073/pnas.89.10.4378; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; GEORGIEFF IS, 1993, J CELL SCI, V105, P729; GOEDERT M, 1992, P NATL ACAD SCI USA, V89, P1983, DOI 10.1073/pnas.89.5.1983; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Goedert M., 1994, V13, P183; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; JOLY JC, 1990, BIOCHEMISTRY-US, V29, P8916, DOI 10.1021/bi00490a006; Jordan MA, 1996, CANCER RES, V56, P816; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; Koshland DE, 1998, NAT MED, V4, P1112, DOI 10.1038/2605; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEE VM, 1995, PATHOLOGY ALZHEIMERS; Lee VMY, 1999, NEURON, V24, P507, DOI 10.1016/S0896-6273(00)81106-X; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; LINDWALL G, 1984, J BIOL CHEM, V259, P2241; Lo Matthew M. S., 1993, Molecular Brain Research, V20, P209, DOI 10.1016/0169-328X(93)90043-O; Lovestone S, 1997, NEUROSCIENCE, V78, P309; Matus Andrew, 1994, V13, P155; PANDA D, 1995, BIOCHEMISTRY-US, V34, P11117, DOI 10.1021/bi00035a017; SACKETT DL, 1994, BIOCHEMISTRY-US, V33, P12868, DOI 10.1021/bi00209a019; Sahara N, 2000, J NEUROSCI RES, V60, P380, DOI 10.1002/(SICI)1097-4547(20000501)60:3<380::AID-JNR13>3.0.CO;2-5; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; TOSO RJ, 1993, BIOCHEMISTRY-US, V32, P1285, DOI 10.1021/bi00056a013; TRINCZEK B, 1995, MOL BIOL CELL, V6, P1887, DOI 10.1091/mbc.6.12.1887; WANG DS, 1988, NUCLEIC ACIDS RES, V16, P11369, DOI 10.1093/nar/16.23.11369; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573	48	170	175	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38182	38189		10.1074/jbc.M007489200	http://dx.doi.org/10.1074/jbc.M007489200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10984497	hybrid			2022-12-27	WOS:000165739800009
J	Razandi, M; Pedram, A; Levin, ER				Razandi, M; Pedram, A; Levin, ER			Estrogen signals to the preservation of endothelial cell form and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HEAT-SHOCK PROTEIN-27; MAPKAP KINASE-2; TRANSCRIPTION FACTORS; ACTIN POLYMERIZATION; GENE-TRANSCRIPTION; RESPONSE ELEMENT; OXIDATIVE STRESS; BINDING-SITES; CROSS-TALK	Estrogen is important for the primary prevention of vascular disease in young women, but the mechanisms of protection at the vascular cell are still largely unknown. Although traditionally thought of as a nuclear transcription factor, the estrogen receptor has also been identified in the cell plasma membrane to signal but serve largely undefined roles. Here we show that estradiol (E2) rapidly activates p38 beta mitogen-activated protein kinase in endothelial cells (EC), which activates the mitogen-activated protein kinase-activated protein kinase-2 and the phosphorylation of heat shock protein 27. The sex steroid preserves the EC stress fiber formation and actin and membrane integrity in the setting of metabolic insult. E2 also prevents hypoxia-induced apoptosis and induces both the migration of EC and the formation of primitive capillary tubes. These effects are reversed by the inhibition of p38 beta, by the expression of a dominant-negative mitogen-activated protein kinase-activated protein kinase-2 protein, or by the expression of a phosphorylation site mutant heat shock protein 27. E2 signaling from the membrane helps preserve the EC structure and function, defining potentially important vascular-protective effects of this sex steroid.	Vet Affairs Med Ctr, Div Endocrinol, Long Beach, CA 90822 USA; Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92717 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine	Levin, ER (corresponding author), Vet Affairs Med Ctr, Med Serv 3 1, 5901 E 7th St, Long Beach, CA 90822 USA.	ellis.levin@med.va.gov	Levin, Ellis/J-5402-2013		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059890] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59890] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Biegelsen ES, 1999, CORONARY ARTERY DIS, V10, P241; BLACKMORE PF, 1991, J BIOL CHEM, V266, P18655; Budhram-Mahadeo V, 1998, MOL CELL BIOL, V18, P1029, DOI 10.1128/MCB.18.2.1029; Carraway CAC, 1999, J BIOL CHEM, V274, P25659, DOI 10.1074/jbc.274.36.25659; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; GARRIDO C, 1993, GROWTH FACTORS, V8, P109, DOI 10.3109/08977199309046931; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; Huot J, 1996, CANCER RES, V56, P273; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KUHNE W, 1993, AM J PHYSIOL, V264, pH1599, DOI 10.1152/ajpheart.1993.264.5.H1599; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; Larsen JK, 1997, AM J PHYSIOL-LUNG C, V273, pL930, DOI 10.1152/ajplung.1997.273.5.L930; LeMellay V, 1997, J BIOL CHEM, V272, P11902, DOI 10.1074/jbc.272.18.11902; Lemieux Pierre, 1997, Invasion and Metastasis, V17, P113; Loktionova SA, 1998, AM J PHYSIOL-HEART C, V275, pH2147, DOI 10.1152/ajpheart.1998.275.6.H2147; Machesky LM, 1999, NATURE, V401, P542, DOI 10.1038/44044; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; MORALES DE, 1995, CIRCULATION, V91, P755, DOI 10.1161/01.CIR.91.3.755; Morey AK, 1997, ENDOCRINOLOGY, V138, P3330, DOI 10.1210/en.138.8.3330; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; OESTERREICH S, 1993, CANCER RES, V53, P4443; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; Piotrowicz RS, 1998, FASEB J, V12, P1481, DOI 10.1096/fasebj.12.14.1481; Porter W, 1996, MOL ENDOCRINOL, V10, P1371, DOI 10.1210/me.10.11.1371; Pugazhenthi S, 1999, J BIOL CHEM, V274, P2829, DOI 10.1074/jbc.274.5.2829; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; SHASBY DM, 1982, CIRC RES, V51, P657, DOI 10.1161/01.RES.51.5.657; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; Stevis PE, 1999, ENDOCRINOLOGY, V140, P5455, DOI 10.1210/en.140.11.5455; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; SUNNERGREN KP, 1987, AM J PHYSIOL, V252, pH1211, DOI 10.1152/ajpheart.1987.252.6.H1211; SVENDSEN JH, 1991, CIRC RES, V68, P174, DOI 10.1161/01.RES.68.1.174; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Wagstaff MJD, 1999, J BIOL CHEM, V274, P5061, DOI 10.1074/jbc.274.8.5061; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; WEHLING M, 1995, STEROIDS, V60, P153, DOI 10.1016/0039-128X(94)00027-A; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WONG MKK, 1986, ARTERIOSCLEROSIS, V6, P212, DOI 10.1161/01.ATV.6.2.212; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	53	160	169	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38540	38546		10.1074/jbc.M007555200	http://dx.doi.org/10.1074/jbc.M007555200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10988297	hybrid			2022-12-27	WOS:000165739800055
J	Chiarugi, P; Taddei, ML; Cirri, P; Talini, D; Buricchi, F; Camici, G; Manao, G; Raugei, G; Ramponi, G				Chiarugi, P; Taddei, ML; Cirri, P; Talini, D; Buricchi, F; Camici, G; Manao, G; Raugei, G; Ramponi, G			Low molecular weight protein-tyrosine phosphatase controls the rate and the strength of NIH-3T3 cells adhesion through its phosphorylation on tyrosine 131 or 132	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; UP-REGULATION; KAPPA-B; C-SRC; TRANSCRIPTION; FIBROBLASTS; EXPRESSION; GENE; MECHANISMS; COLLAGENASE	The low molecular weight protein-tyrosine phosphatase (LMW-PTP) is an enzyme involved in platelet-derived growth factor (PDGF)-induced mitogenesis and cytoskeleton rearrangement. Our previous results demonstrated that LMW-PTP is able to bind and dephosphorylate activated PDGF receptor, thus inhibiting cell proliferation. Recently we have shown that LMW-PTP is specifically phosphorylated by c-Src in a cytoskeleton-associated fraction in response to PDGF, and this phosphorylation increases LMW-PTP activity about 20-fold. LMW-PTP strongly influences cell adhesion, spreading, and chemotaxis induced by PDGF stimulation, by regulating the phosphorylation level of p190Rho-GAP, a protein that is able to regulate Rho activity and hence cytoskeleton rearrangement. In the present study we investigate the physiological role of the two LMW-PTP tyrosine phosphorylation sites, using LMW-PTP mutants on tyrosine 131 or 132, We demonstrate that each tyrosine residue is involved in specific LMW-PTP functions. Both of them are phosphorylated during PDGF signaling, Phosphorylation on tyrosine 131 influences mitogenesis, dephosphorylating activated PDGF-R and cytoskeleton rearrangement, acting on p190RhoGAP. Phosphorylation on tyrosine 132 leads to an increase in the strength of cell substrate adhesion, down-regulating matrix metalloproteases expression, through the inhibition of Grb2/MAPK pathway, In conclusion, LMW-PTP tyrosine phosphorylation on both Tyr(131) Or Tyr(132) cooperate to determine a faster and stronger adhesion to extracellular matrix, although these two events may diverge in timing and relative amount.	Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy	University of Florence	Ramponi, G (corresponding author), Univ Florence, Dipartimento Sci Biochim, Viale Morgagni 50, I-50134 Florence, Italy.		Chiarugi, Paola/CDD-7988-2022; Camici, Giovanni/H-1631-2018	Chiarugi, Paola/0000-0001-7655-2969; Camici, Giovanni/0000-0002-0523-0695; raugei, giovanni/0000-0003-1294-786X				Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; Besser D, 1997, ONCOGENE, V14, P705, DOI 10.1038/sj.onc.1200879; Blanchetot C, 2000, J BIOL CHEM, V275, P12446, DOI 10.1074/jbc.275.17.12446; Bond M, 1999, BIOCHEM BIOPH RES CO, V264, P561, DOI 10.1006/bbrc.1999.1551; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Bucciantini M, 1999, FEBS LETT, V456, P73, DOI 10.1016/S0014-5793(99)00828-5; CHANG JH, 1995, J CELL BIOL, V130, P335; Chiarugi P, 1998, J BIOL CHEM, V273, P6776, DOI 10.1074/jbc.273.12.6776; Chiarugi P, 2000, J BIOL CHEM, V275, P4640, DOI 10.1074/jbc.275.7.4640; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Cirri P, 1998, J BIOL CHEM, V273, P32522, DOI 10.1074/jbc.273.49.32522; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Fibbi G, 1999, HEPATOLOGY, V29, P868, DOI 10.1002/hep.510290343; Ganju RK, 2000, J BIOL CHEM, V275, P17263, DOI 10.1074/jbc.M000689200; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Lau HKF, 1999, CARDIOVASC RES, V43, P1049, DOI 10.1016/S0008-6363(99)00136-4; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Mott JD, 2000, J BIOL CHEM, V275, P1384, DOI 10.1074/jbc.275.2.1384; RAMPONI G, 1994, ADV PROT PHOSPHATASE, V8, P1; Reddy KB, 1999, INT J CANCER, V82, P268, DOI 10.1002/(SICI)1097-0215(19990719)82:2<268::AID-IJC18>3.3.CO;2-W; Ried S, 1999, J BIOL CHEM, V274, P16377, DOI 10.1074/jbc.274.23.16377; Rigacci S, 1996, J BIOL CHEM, V271, P1278, DOI 10.1074/jbc.271.3.1278; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; Sieuwerts AM, 1999, BREAST CANCER RES TR, V55, P9, DOI 10.1023/A:1006190729866; Singer CF, 1999, EUR J BIOCHEM, V259, P40, DOI 10.1046/j.1432-1327.1999.00001.x; Tailor P, 1997, J BIOL CHEM, V272, P5371, DOI 10.1074/jbc.272.9.5371; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271	36	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37619	37627		10.1074/jbc.M006375200	http://dx.doi.org/10.1074/jbc.M006375200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10980198	hybrid			2022-12-27	WOS:000165618700044
J	Seo, BB; Wang, JM; Flotte, TR; Yagi, T; Matsuno-Yagi, A				Seo, BB; Wang, JM; Flotte, TR; Yagi, T; Matsuno-Yagi, A			Use of the NADH-quinone oxidoreductase (NDI1) gene of Saccharomyces cerevisiae as a possible cure for complex I defects in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOASSOCIATED VIRUS VECTORS; ROTENONE-INSENSITIVE NADH; DNA POLYMERASE-ALPHA; OXIDATIVE-PHOSPHORYLATION; VIRAL VECTORS; ELECTRON-TRANSPORT; MITOCHONDRIA; DELIVERY; DISEASES; THERAPY	The Ndi1 enzyme of Saccharomyces cerevisiae is a single subunit rotenone-insensitive NADH-quinone oxidoreductase that is located on the matrix side of the inner mitochondrial membrane. We have shown previously that the NDI1 gene can be functionally expressed in Chinese hamster cells (Seo, B. B., Kitajima-Ihara, T., Chan, E. K., Scheffler, I. E., Matsuno-Yagi, A., and Yagi, T. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 9167-9171) and human embryonal kidney 293 (HEK 293) cells (Seo, B. B., Matsuno-Yagi, A., and Yagi, T. (1999) Biochim. Biochem. Acta 1412, 56-65) and that the Ndi1 protein is capable of compensating respiratory deficiencies caused by defects in the host NADH-quinone oxidoreductase (complex I). To extend the potential use of this enzyme to repair complex I deficiencies in vivo, we constructed a recombinant adeno-associated virus vector carrying the NDI1 gene (rAAV-NDI1). With rAAV-NDI1 as the gene delivery method, we were able to achieve high transduction efficiencies (nearly 100%) even in 143B cells that are difficult to transfect by lipofection or calcium phosphate precipitation methods. The NDI1 gene was successfully introduced into non-proliferating human cells using rAAV-NDI1. The expressed Ndi1 protein was shown to be functionally active just as seen for proliferating cells. Furthermore, when cells were cultured under the conditions where energy has to be provided by respiration, the NDI1-transduced cells were able to grow even in the presence of added complex I inhibitor such as rotenone and 1-methyl-4-phenylpyridinium ion. In contrast, control cells that did not receive the NDI1 gene failed to survive as anticipated. The Ndi1 protein has a great potential as a molecular remedy for complex I defects, and it is highly likely that the same strategy can be extended to correction of other mitochondrial disorders.	Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA 92037 USA; Univ Florida, Inst Genet, Powell Gene Therapy Ctr, Gainesville, FL 32610 USA	Scripps Research Institute; State University System of Florida; University of Florida	Matsuno-Yagi, A (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053244, R01DK051809] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK53244, R01DK51809] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JD, 1993, FREE RADICAL BIO MED, V15, P181, DOI 10.1016/0891-5849(93)90057-2; Au HC, 1999, P NATL ACAD SCI USA, V96, P4354, DOI 10.1073/pnas.96.8.4354; Beck SE, 1999, J VIROL, V73, P9446, DOI 10.1128/JVI.73.11.9446-9455.1999; Bueler H, 1999, BIOL CHEM, V380, P613, DOI 10.1515/BC.1999.078; BYRNES JJ, 1984, MOL CELL BIOCHEM, V62, P13; CHAN EKL, 1987, J EXP MED, V166, P1627, DOI 10.1084/jem.166.6.1627; CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430; CHOMYN A, 1985, NATURE, V314, P591; de Grey ADNJ, 2000, TRENDS BIOTECHNOL, V18, P394, DOI 10.1016/S0167-7799(00)01476-1; Desai VG, 1996, BRAIN RES, V715, P1, DOI 10.1016/0006-8993(95)01255-9; DEVRIES S, 1988, EUR J BIOCHEM, V176, P377; FLOTTE TR, 1993, P NATL ACAD SCI USA, V90, P10613, DOI 10.1073/pnas.90.22.10613; FLOTTE TR, 1995, GENE THER, V2, P357; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; HATEFI Y, 1985, ENZYMES BIOL MEMBR, P1; Hernandez YJ, 1999, J VIROL, V73, P8549, DOI 10.1128/JVI.73.10.8549-8558.1999; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; Jooss K, 1998, J VIROL, V72, P4212, DOI 10.1128/JVI.72.5.4212-4223.1998; Kitajima-Ihara T, 1998, FEBS LETT, V421, P37, DOI 10.1016/S0014-5793(97)01533-0; Klimatcheva Ekaterina, 1999, Frontiers in Bioscience, V4, pD481, DOI 10.2741/Klimatcheva; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Monahan PE, 2000, GENE THER, V7, P24, DOI 10.1038/sj.gt.3301109; MUZYCZKA N, 1994, J CLIN INVEST, V94, P1351, DOI 10.1172/JCI117468; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Owen R, 2000, HUM GENE THER, V11, P2067, DOI 10.1089/104303400750001381; Rabinowitz JE, 1998, CURR OPIN BIOTECH, V9, P470, DOI 10.1016/S0958-1669(98)80031-1; RAMSAY RR, 1992, BIOCHEM BIOPH RES CO, V189, P47, DOI 10.1016/0006-291X(92)91523-S; Robbins PD, 1998, PHARMACOL THERAPEUT, V80, P35, DOI 10.1016/S0163-7258(98)00020-5; Robinson BH, 1998, BBA-BIOENERGETICS, V1364, P271, DOI 10.1016/S0005-2728(98)00033-4; Schapira AHV, 1998, BBA-BIOENERGETICS, V1364, P261, DOI 10.1016/S0005-2728(98)00032-2; SCHEFFLER IE, 1986, CARBOHYD METABOL, P77; Seo BB, 1998, P NATL ACAD SCI USA, V95, P9167, DOI 10.1073/pnas.95.16.9167; Seo BB, 1999, BBA-BIOENERGETICS, V1412, P56, DOI 10.1016/S0005-2728(99)00051-1; SHOFFNER JM, 1994, ANNU REV NUTR, V14, P535, DOI 10.1146/annurev.nu.14.070194.002535; Skehel JM, 1998, FEBS LETT, V438, P301, DOI 10.1016/S0014-5793(98)01317-9; Snyder RO, 1999, J GENE MED, V1, P166; Todd S, 2000, BBA-PROTEIN STRUCT M, V1477, P168, DOI 10.1016/S0167-4838(99)00272-1; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wu NX, 2000, CURR OPIN BIOTECH, V11, P205, DOI 10.1016/S0958-1669(00)00080-X; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1; ZIMMERMANN W, 1980, J BIOL CHEM, V255, P1847; Zolotukhin S, 1999, GENE THER, V6, P973, DOI 10.1038/sj.gt.3300938	42	66	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37774	37778		10.1074/jbc.M007033200	http://dx.doi.org/10.1074/jbc.M007033200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982813	hybrid			2022-12-27	WOS:000165618700064
J	Ettaiche, M; Pichot, R; Vincent, JP; Chabry, J				Ettaiche, M; Pichot, R; Vincent, JP; Chabry, J			In vivo cytotoxicity of the prion protein fragment 106-126	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; SCRAPIE AGENT; CELL-DEATH; MICE; PRP; NEUROTOXICITY; RESISTANT; DISEASE; RESIDUES-106-126; DEGENERATION	Transmissible spongiform encephalopathies are fatal neurological diseases characterized by astroglyosis, neuronal loss, and by the accumulation of the abnormal isoform of the prion protein, The amyloid prion protein fragment 106-126 (P106-126) has been shown to be toxic in cultured hippocampal neurons (1). Here, we show that P106-126 is also cytotoxic in vivo, Taking advantage of the fact that retina is an integral part of the central nervous system, the toxic effect of the peptide was investigated by direct intravitreous injection. Aged solutions of P106-126 induced apoptotic-mediated retinal cell death and irreversibly altered the electrical activity of the retina. Neither apoptosis nor electroretinogram damages were observed with freshly diluted P106-126, suggesting that the toxicity is linked to the aggregation state of the peptide. The retina provides a convenient in vivo system to look for potential inhibitors of cytotoxicity associated with spongiform encephalopathies.	IPMC, CNRS, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Chabry, J (corresponding author), IPMC, CNRS, 660 Route Lucioles, F-06560 Valbonne, France.		Chabry, Joelle/O-2101-2016					Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; Brown DR, 1998, EUR J CELL BIOL, V75, P29, DOI 10.1016/S0171-9335(98)80043-5; BROWN DR, 1994, NEUROREPORT, V5, P2057, DOI 10.1097/00001756-199410270-00017; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUYUKMIHCI N, 1980, P NATL ACAD SCI-BIOL, V77, P1169, DOI 10.1073/pnas.77.2.1169; BUYUKMIHCI NC, 1987, EXP NEUROL, V97, P201, DOI 10.1016/0014-4886(87)90294-9; CARLSON GA, 1994, P NATL ACAD SCI USA, V91, P5690, DOI 10.1073/pnas.91.12.5690; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Chishti MA, 1997, NEUROSCI LETT, V234, P11; Ettaiche M, 1999, INVEST OPHTH VIS SCI, V40, P729; Florio T, 1998, J NEUROSCI RES, V54, P341, DOI 10.1002/(SICI)1097-4547(19981101)54:3<341::AID-JNR5>3.0.CO;2-G; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; FRASER H, 1993, BRIT MED BULL, V49, P792, DOI 10.1093/oxfordjournals.bmb.a072647; GIESE A, 1995, BRAIN PATHOL, V5, P213, DOI 10.1111/j.1750-3639.1995.tb00597.x; Gray F, 1999, J NEUROPATH EXP NEUR, V58, P321, DOI 10.1097/00005072-199904000-00002; HOGAN RN, 1981, LAB INVEST, V44, P34; Hope J, 1996, NEURODEGENERATION, V5, P1, DOI 10.1006/neur.1996.0001; Jen LS, 1998, NATURE, V392, P140, DOI 10.1038/32327; Jobling MF, 1999, J NEUROCHEM, V73, P1557, DOI 10.1046/j.1471-4159.1999.0731557.x; Kawahara M, 2000, J BIOL CHEM, V275, P14077, DOI 10.1074/jbc.275.19.14077; Lasmezas CI, 1996, J GEN VIROL, V77, P1601, DOI 10.1099/0022-1317-77-7-1601; Lin MX, 1997, J BIOL CHEM, V272, P44; Manunta M, 2000, FEBS LETT, V474, P255, DOI 10.1016/S0014-5793(00)01603-3; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MULLER WEG, 1993, EUR J PHARM-MOLEC PH, V246, P261, DOI 10.1016/0922-4106(93)90040-G; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SAFAR J, 1993, J BIOL CHEM, V268, P20276; Salmona M, 1999, BIOCHEM J, V342, P207, DOI 10.1042/0264-6021:3420207; SELVAGGINI C, 1993, BIOCHEM BIOPH RES CO, V194, P1380, DOI 10.1006/bbrc.1993.1977; TAGLIAVINI F, 1993, P NATL ACAD SCI USA, V90, P9678, DOI 10.1073/pnas.90.20.9678; Theil D, 1999, J COMP PATHOL, V121, P357, DOI 10.1053/jcpa.1999.0333; Tremblay P, 1998, P NATL ACAD SCI USA, V95, P12580, DOI 10.1073/pnas.95.21.12580	37	121	128	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36487	36490		10.1074/jbc.C000579200	http://dx.doi.org/10.1074/jbc.C000579200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	11007766	hybrid			2022-12-27	WOS:000165577700003
J	Polevoda, B; Sherman, F				Polevoda, B; Sherman, F			N alpha-terminal acetylation of eukaryotic proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							COLI METHIONINE AMINOPEPTIDASE; STRANDED-RNA VIRUS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; ACETYLTRANSFERASE; YEAST; IDENTIFICATION; SPECIFICITIES; PURIFICATION; SEQUENCE		Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Sherman, F (corresponding author), Univ Rochester, Dept Biochem & Biophys, Sch Med, Box 712, Rochester, NY 14642 USA.		Polevoda, Bogdan/A-4880-2008		NIGMS NIH HHS [GM12702] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe A, 2000, BIOCHEM BIOPH RES CO, V268, P14, DOI 10.1006/bbrc.1999.2069; Arendt CS, 1999, EMBO J, V18, P3575, DOI 10.1093/emboj/18.13.3575; Arnold RJ, 1999, J BIOL CHEM, V274, P37035, DOI 10.1074/jbc.274.52.37035; AUGEN J, 1986, TRENDS BIOCHEM SCI, V11, P494, DOI 10.1016/0968-0004(86)90075-7; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BERGER EM, 1981, BIOCHEM GENET, V19, P321, DOI 10.1007/BF00504277; BOISSEL JP, 1988, J BIOL CHEM, V263, P8443; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; CHANG YH, 1990, J BIOL CHEM, V265, P19892; CUMBERLIDGE AG, 1979, J MOL BIOL, V131, P169, DOI 10.1016/0022-2836(79)90072-X; DALBOGE H, 1990, FEBS LETT, V266, P1, DOI 10.1016/0014-5793(90)90001-B; DEVLIN PE, 1988, GENE, V65, P13, DOI 10.1016/0378-1119(88)90412-X; DORES RM, 1990, BRAIN BEHAV EVOLUT, V36, P80, DOI 10.1159/000115300; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; Garrels JI, 1997, ELECTROPHORESIS, V18, P1347, DOI 10.1002/elps.1150180810; Groll M, 1999, P NATL ACAD SCI USA, V96, P10976, DOI 10.1073/pnas.96.20.10976; Hansen JE, 2000, BIOCHEMISTRY-US, V39, P1792, DOI 10.1021/bi991873c; HERSHKO A, 1984, P NATL ACAD SCI USA, V81, P7051; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; KENDALL RL, 1990, METHOD ENZYMOL, V185, P398; Kimura Y, 2000, J BIOL CHEM, V275, P4635, DOI 10.1074/jbc.275.7.4635; Li X, 1995, P NATL ACAD SCI USA, V92, P12357, DOI 10.1073/pnas.92.26.12357; Lowther WT, 1999, BIOCHEMISTRY-US, V38, P7678, DOI 10.1021/bi990684r; MATSUURA S, 1981, P NATL ACAD SCI-BIOL, V78, P4368, DOI 10.1073/pnas.78.7.4368; MAYER A, 1989, SCIENCE, V244, P1480, DOI 10.1126/science.2544030; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; PARK EC, 1992, EMBO J, V11, P2087, DOI 10.1002/j.1460-2075.1992.tb05267.x; Perrot M, 1999, ELECTROPHORESIS, V20, P2280, DOI 10.1002/(SICI)1522-2683(19990801)20:11<2280::AID-ELPS2280>3.3.CO;2-H; PERSSON B, 1985, EUR J BIOCHEM, V152, P523, DOI 10.1111/j.1432-1033.1985.tb09227.x; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; PRCHAL JT, 1986, P NATL ACAD SCI USA, V83, P24, DOI 10.1073/pnas.83.1.24; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; SHERMAN F, 1985, BIOESSAYS, V3, P27, DOI 10.1002/bies.950030108; SIDDIG MAM, 1980, J MOL BIOL, V137, P125, DOI 10.1016/0022-2836(80)90320-4; STONE EM, 1991, MOL CELL BIOL, V11, P2253, DOI 10.1128/MCB.11.4.2253; SYMTH DG, 1979, NATURE, V279, P252; SYMTH DG, 1980, NATURE, V288, P613; TERCERO JC, 1992, J BIOL CHEM, V267, P20270; TERCERO JC, 1992, J BIOL CHEM, V267, P20277; TERCERO JC, 1993, J BACTERIOL, V175, P3192, DOI 10.1128/JB.175.10.3192-3194.1993; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; WERTMAN KF, 1992, GENETICS, V132, P337; WINGFIELD P, 1989, EUR J BIOCHEM, V180, P23, DOI 10.1111/j.1432-1033.1989.tb14610.x; YAMADA T, 1986, BIOCHEM BIOPH RES CO, V135, P837, DOI 10.1016/0006-291X(86)91004-1	48	279	289	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36479	36482		10.1074/jbc.R000023200	http://dx.doi.org/10.1074/jbc.R000023200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	11013267	hybrid			2022-12-27	WOS:000165577700001
J	Almeida, PC; Nantes, IL; Chagas, JR; Rizzi, CCA; Faljoni-Alario, A; Carmona, E; Juliano, L; Nader, HB; Tersariol, ILS				Almeida, PC; Nantes, IL; Chagas, JR; Rizzi, CCA; Faljoni-Alario, A; Carmona, E; Juliano, L; Nader, HB; Tersariol, ILS			Cathepsin B activity regulation - Heparin-like glycosaminoglycans protect human cathepsin B from alkaline pH-induced inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE PROTEOGLYCANS; SULFATE PROTEOGLYCANS; OCCLUDING LOOP; CYSTEINE PROTEINASES; TUMOR PROGRESSION; ENZYME-ACTIVITY; INHIBITORS; PROTEASES; RECEPTOR; TISSUE	It has been shown that lysosomal cysteine proteinases, specially cathepsin B, has been implicated in a variety of diseases involving tissue remodeling states, such as inflammation, parasite infection, and tumor metastasis, by degradation of extracellular matrix components. Recently, we have shown that heparin and heparan sulfate bind to papain specifically; this interaction induces an increase of its alpha -helix content and stabilizes the enzyme structure even at alkaline pH (Almeida, P. C., Nantes, I. L,, Rizzi, C, C. A., Judice, W.A.S., Chagas, J. R., Juliano, L., Nader, H. B., and Tersariol, I. L. S. (1999) J. Biol. Chem. 274, 30433-30438). In the present work, a combination of circular dichroism analysis, affinity chromatography, cathepsin B mutants, and fluorogenic substrate assays were used to characterize the interaction of human cathepsin B with glycosaminoglycans. The nature of the cathepsin B-glycosaminoglycans interaction was sensitive to the charge and type of polysaccharide, Like papain, heparin and heparan sulfate bind cathepsin B specifically, and this interaction reduces the loss of cathepsin B alpha -helix content at alkaline pH. Our data show that the coupling of cathepsin B with heparin or heparan sulfate can potentiate the endopeptidase activity of the cathepsin B, increasing B-fold the half-life (t(1/2)) of the enzyme at alkaline pH, Most of these effects are related to the interaction of heparin and heparan sulfate with His(111) residue of the cathepsin B occluding loop. These results strongly suggest that heparan sulfate may be an important binding site for cathepsin B at cell surface, reporting a novel physiological role for heparan sulfate proteoglycans.	Univ Mogi das Cruzes, Ctr Interdisciplinar Invest Bioquim, Ctr Ciencias Technol, BR-08780911 Mogi Das Cruzes, SP, Brazil; Univ Sao Paulo, Inst Quim, Dept Bioquim, Sao Paulo, Brazil; Inst Butantan, Farmacol Lab, Sao Paulo, Brazil; Univ Fed Sao Paulo, Escola Paulista Med, Disciplina Biol Mol, Inst Nacl Farmacol, Sao Paulo, Brazil	Universidade de Mogi das Cruzes; Universidade de Sao Paulo; Instituto Butantan; Universidade Federal de Sao Paulo (UNIFESP)	Tersariol, ILS (corresponding author), Univ Mogi das Cruzes, Ctr Interdisciplinar Invest Bioquim, Ctr Ciencias Technol, Sala IS-15,Av Dr Candido C Almeida Souza 200, BR-08780911 Mogi Das Cruzes, SP, Brazil.	ivarne@ccb.umc.br	de Almeida, Paulo C/D-8285-2014; Nantes, Iseli Lourenço/B-9517-2012; Juliano, Luiz/D-7204-2012; Chagas, Jair R/A-1701-2012; Chagas, Jair Ribeiro/AFV-6501-2022; Dos Santos Tersariol, Ivarne Luis/G-4042-2012; de Almeida, Paulo/D-4794-2012; Nader, Helena Bonciani/D-9253-2012	de Almeida, Paulo C/0000-0002-5136-5152; Nantes, Iseli Lourenço/0000-0003-1434-3154; Juliano, Luiz/0000-0002-5589-2822; Chagas, Jair R/0000-0002-0357-8276; Chagas, Jair Ribeiro/0000-0002-0357-8276; Dos Santos Tersariol, Ivarne Luis/0000-0002-8399-4535; NADER, HELENA/0000-0002-7569-2166				Almeida PC, 1999, J BIOL CHEM, V274, P30433, DOI 10.1074/jbc.274.43.30433; Bahr MJ, 1999, HEPATOLOGY, V29, P839, DOI 10.1002/hep.510290333; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BIENKOWSKI MJ, 1984, J BIOL CHEM, V259, P2989; BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; CHAGAS JR, 1991, ANAL BIOCHEM, V192, P419, DOI 10.1016/0003-2697(91)90558-B; Conrad H. E., 1998, HEPARIN BINDING PROT; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DelNery E, 1997, J BIOL CHEM, V272, P25713, DOI 10.1074/jbc.272.41.25713; DeStafanis D, 1997, CELL TISSUE RES, V289, P109; Dietrich CP, 1998, CELL MOL BIOL, V44, P417; DIETRICH CP, 1983, BIOCHEM BIOPH RES CO, V111, P865, DOI 10.1016/0006-291X(83)91379-7; ELENIUS K, 1994, J CELL SCI, V107, P2975; ERMOLIEFF J, 1994, J BIOL CHEM, V269, P29502; Fath MA, 1998, J BIOL CHEM, V273, P13563, DOI 10.1074/jbc.273.22.13563; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; HANEWINKEL H, 1987, J BIOL CHEM, V262, P12351; Hirata IY, 1995, LETT PEPT SCI, V1, P299, DOI DOI 10.1007/BF00119771; IacobuzioDonahue CA, 1997, J BIOL CHEM, V272, P29190, DOI 10.1074/jbc.272.46.29190; Illy C, 1997, J BIOL CHEM, V272, P1197, DOI 10.1074/jbc.272.2.1197; IOZZO R, 1995, BIOCHEM J, V302, P625; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; Jerala R, 1998, J BIOL CHEM, V273, P11498, DOI 10.1074/jbc.273.19.11498; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; Kassam G, 1997, J BIOL CHEM, V272, P15093, DOI 10.1074/jbc.272.24.15093; KATUNUMA N, 1995, METHOD ENZYMOL, V251, P382, DOI 10.1016/0076-6879(95)51142-3; KATUNUMA N, 1989, INTRACELLULAR PROTEO; KOBLINSKI JE, 1997, MED ASPECTS PROTEASE, V110, P1235; KOGA H, 1991, J BIOCHEM-TOKYO, V110, P179, DOI 10.1093/oxfordjournals.jbchem.a123554; KORNFELD S, 1990, BIOCHEM SOC T, V18, P367, DOI 10.1042/bst0180367; Kos J, 1998, ONCOL REP, V5, P1349; KRAEMER PM, 1971, BIOCHEMISTRY-US, V10, P1437, DOI 10.1021/bi00784a026; Linebaugh BE, 1999, EUR J BIOCHEM, V264, P100, DOI 10.1046/j.1432-1327.1999.00582.x; Ma JX, 2000, J BIOL CHEM, V275, P12806, DOI 10.1074/jbc.275.17.12806; MACH L, 1994, J BIOL CHEM, V269, P13030; MENARD R, 1990, BIOCHEMISTRY-US, V29, P6706, DOI 10.1021/bi00480a021; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MORT JS, 1986, BIOCHEM J, V233, P57, DOI 10.1042/bj2330057; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; Nagler DK, 1997, BIOCHEMISTRY-US, V36, P12608, DOI 10.1021/bi971264+; Nagler DK, 1999, BIOCHEMISTRY-US, V38, P4868, DOI 10.1021/bi982632s; Quraishi O, 1999, BIOCHEMISTRY-US, V38, P5017, DOI 10.1021/bi981950o; REILAND J, 1993, J CELL SCI, V105, P1085; Sloane B F, 1988, Adv Exp Med Biol, V233, P259; SLOANE BF, 1986, P NATL ACAD SCI USA, V83, P2483, DOI 10.1073/pnas.83.8.2483; Sloane BF, 1996, NAT BIOTECHNOL, V14, P826, DOI 10.1038/nbt0796-826b; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STARKEY PM, 1977, PROTEINASES MAMMALIA, P57; TURK B, 1994, BIOCHEMISTRY-US, V33, P14800, DOI 10.1021/bi00253a019; Turk B, 1997, BIOL CHEM, V378, P141; WEISS RE, 1990, J UROLOGY, V144, P798, DOI 10.1016/S0022-5347(17)39595-2; Yan SQ, 1998, BIOL CHEM, V379, P113; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YANAGISHITA M, 1984, J BIOL CHEM, V259, P260	56	154	162	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					944	951		10.1074/jbc.M003820200	http://dx.doi.org/10.1074/jbc.M003820200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11016923	hybrid			2022-12-27	WOS:000166430900013
J	Tsuchida, K; Arai, KY; Kuramoto, Y; Yamakawa, N; Hasegawa, Y; Sugino, H				Tsuchida, K; Arai, KY; Kuramoto, Y; Yamakawa, N; Hasegawa, Y; Sugino, H			Identification and characterization of a novel follistatin-like protein as a binding protein for the TGF-beta family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MORPHOGENETIC PROTEIN; GROWTH-FACTOR-BETA; ACTIVIN-BINDING; HEPARAN-SULFATE; XENOPUS EMBRYO; INHIBIN; CELL; CLONING; GENE; RECEPTORS	Follistatin is an activin-binding protein that prevents activin from binding to its receptors and neutralizes its activity. Follistatin also binds bone morphogenetic proteins (BMPs). In this study, we report the identification of a novel follistatin-like protein from mouse. The mouse cDNA encodes a 256-residue precursor and most likely a mouse homologue of human FLRG, which was found at the breakpoint of the chromosomal rearrangement in a B-cell line. Whereas follistatin has three follistatin domains, which are presumed to be growth factor binding motifs, FLRG possesses only two follistatin domains. Northern blotting revealed that mRNAs for FLRG were abundantly expressed in heart, lung, kidney, and testis in mouse. The recombinant mouse FLRG proteins were found to have binding activity for both activin and bone morphogenetic protein-2. Like follistatin, FLRG has higher affinity for activin than for BMP-S. The FLRG protein inhibited activin-induced and BMP-2-induced transcriptional responses in a dose-dependent manner. Glutathione S-transferase fusion proteins encoding various regions of FLRG were produced and studied. Ligand blotting using I-125-activin revealed that the COOH-terminal region containing the second follistatin domain was able to bind activin. Our finding implies that cellular signaling by activin and BMPs is tightly regulated by multiple members of the follistatin family.	Univ Tokushima, Inst Enzyme Res, Tokushima 7708503, Japan; Kitasato Univ, Sch Vet Med & Anim Sci, Lab Expt Anim Sci, Towada, Aomori 0348628, Japan	Tokushima University; Kitasato University	Tsuchida, K (corresponding author), Univ Tokushima, Inst Enzyme Res, 3-18-15 Kuramoto, Tokushima 7708503, Japan.	tsuchida@ier.tokushima-u.ac.jp	ARAI, Koji/G-1144-2013; Tsuchida, Kunihiro/A-4501-2012	Tsuchida, Kunihiro/0000-0002-3983-5756				Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; deWinter JP, 1996, MOL CELL ENDOCRINOL, V116, P105, DOI 10.1016/0303-7207(95)03705-5; Gray PC, 2000, J BIOL CHEM, V275, P3206, DOI 10.1074/jbc.275.5.3206; Guo QX, 1998, MOL ENDOCRINOL, V12, P96, DOI 10.1210/mend.12.1.0053; Hashimoto O, 2000, CELL SIGNAL, V12, P565, DOI 10.1016/S0898-6568(00)00099-1; Hashimoto O, 1997, J BIOL CHEM, V272, P13835, DOI 10.1074/jbc.272.21.13835; Hayette S, 1998, ONCOGENE, V16, P2949, DOI 10.1038/sj.onc.1201807; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; INOUYE S, 1992, MOL CELL ENDOCRINOL, V90, P1, DOI 10.1016/0303-7207(92)90094-M; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KRUMMEN LA, 1993, ENDOCRINOLOGY, V132, P431, DOI 10.1210/en.132.1.431; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; MAURER P, 1995, J MOL BIOL, V253, P347, DOI 10.1006/jmbi.1995.0557; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; McFarlane JR, 1999, ENDOCRINOLOGY, V140, P4745, DOI 10.1210/en.140.10.4745; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Okabayashi K, 1999, BIOCHEM BIOPH RES CO, V254, P42, DOI 10.1006/bbrc.1998.9892; Pearce JJH, 1999, DEV BIOL, V209, P98, DOI 10.1006/dbio.1999.9240; RAINES EW, 1992, P NATL ACAD SCI USA, V89, P1281, DOI 10.1073/pnas.89.4.1281; SCHNEYER AL, 1994, ENDOCRINOLOGY, V135, P667, DOI 10.1210/en.135.2.667; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SHIMASAKI S, 1988, BIOCHEM BIOPH RES CO, V152, P717, DOI 10.1016/S0006-291X(88)80097-4; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; Shoji H, 2000, J BIOL CHEM, V275, P5485, DOI 10.1074/jbc.275.8.5485; Smith WC, 1999, TRENDS GENET, V15, P3, DOI 10.1016/S0168-9525(98)01641-2; SUGINO K, 1993, J BIOL CHEM, V268, P15579; SUGINO K, 1989, BIOCHEM BIOPH RES CO, V159, P1323, DOI 10.1016/0006-291X(89)92255-9; Sumitomo K, 2000, CANCER LETT, V155, P37, DOI 10.1016/S0304-3835(00)00407-9; SUMITOMO S, 1995, BIOCHEM BIOPH RES CO, V208, P1, DOI 10.1006/bbrc.1995.1297; Tanaka M, 1998, INT IMMUNOL, V10, P1305, DOI 10.1093/intimm/10.9.1305; TSUCHIDA K, 1995, ENDOCRINOLOGY, V136, P5493, DOI 10.1210/en.136.12.5493; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; VALE W, 1988, RECENT PROG HORM RES, V44, P1; VAUGHAN JM, 1993, ENDOCRINOLOGY, V132, P2038, DOI 10.1210/en.132.5.2038; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Yamane Y, 1998, J BIOL CHEM, V273, P7375, DOI 10.1074/jbc.273.13.7375; ZWIJSEN A, 1994, EUR J BIOCHEM, V225, P937, DOI 10.1111/j.1432-1033.1994.0937b.x	42	166	182	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40788	40796		10.1074/jbc.M006114200	http://dx.doi.org/10.1074/jbc.M006114200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11010968	hybrid			2022-12-27	WOS:000166114600019
J	Ivanina, T; Blumenstein, Y; Shistik, E; Barzilai, R; Dascal, N				Ivanina, T; Blumenstein, Y; Shistik, E; Barzilai, R; Dascal, N			Modulation of L-type Ca2+ channels by G beta gamma and calmodulin via interactions with N and C termini of alpha(1C)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CALCIUM CHANNELS; G-PROTEIN MODULATION; RAT SYMPATHETIC NEURONS; I-II LOOP; XENOPUS-OOCYTES; ION CHANNELS; K+ CHANNEL; KINASE-C; DIFFERENTIAL INTERACTIONS; PREPULSE FACILITATION	Neuronal voltage-dependent Ca2+ channels of the N (alpha (1B)) and P/Q (alpha (1A)) type are inhibited by neurotransmitters that activate G(i/o) G proteins; a major part of the inhibition is voltage-dependent, relieved by depolarization, and results from a direct binding of G beta gamma subunit of G proteins to the channel. Since cardiac and neuronal L-type (alpha (1C)) voltage-dependent Ca2+ channels are not modulated in this way, they are presumed to lack interaction with G beta gamma. However, here we demonstrate that both G beta gamma and cahmodulin directly bind to cytosolic N and C termini of the alpha (1C) subunit. Coexpression of G beta gamma reduces the current via the L-type channels. The inhibition depends on the presence of calmodulin, occurs at basal cellular levels of Ca2+, and is eliminated by EGTA. The N and C termini of alpha (1C) appear to serve as partially independent but interacting inhibitory gates. Deletion of the N terminus or of the distal half of the C terminus eliminates the inhibitory effect of G beta gamma. Deletion of the N terminus profoundly impairs the Ca2+/calmodulin-dependent inactivation. We propose that G beta gamma and calmodulin regulate the L-type Ca2+ channel in a concerted manner via a molecular inhibitory scaffold formed by N and C termini of alpha (1C).	Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Dascal, N (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel.		Dascal, Nathan/O-3915-2015	Dascal, Nathan/0000-0002-5397-4146	PHS HHS [R0156260] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akopian A, 2000, J NEUROSCI, V20, P929, DOI 10.1523/JNEUROSCI.20-03-00929.2000; Armstrong CM, 1998, NEURON, V20, P371, DOI 10.1016/S0896-6273(00)80981-2; BERNHEIM L, 1991, NEURON, V6, P859, DOI 10.1016/0896-6273(91)90226-P; BOURINET E, 1994, EMBO J, V13, P5032, DOI 10.1002/j.1460-2075.1994.tb06832.x; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; Bunemann M, 1999, J BIOL CHEM, V274, P33851, DOI 10.1074/jbc.274.48.33851; Canti C, 1999, J NEUROSCI, V19, P6855, DOI 10.1523/JNEUROSCI.19-16-06855.1999; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Dai SP, 1999, FEBS LETT, V442, P70, DOI 10.1016/S0014-5793(98)01632-9; DASCAL N, 1995, P NATL ACAD SCI USA, V92, P6758, DOI 10.1073/pnas.92.15.6758; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; DIVERSEPIERLUISSI M, 1993, NEURON, V10, P753, DOI 10.1016/0896-6273(93)90175-Q; Dolphin AC, 1998, J PHYSIOL-LONDON, V506, P3, DOI 10.1111/j.1469-7793.1998.003bx.x; ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9; Finkbeiner S, 1998, J NEUROBIOL, V37, P171, DOI 10.1002/(SICI)1097-4695(199810)37:1<171::AID-NEU13>3.0.CO;2-H; Fraser IDC, 1999, NEURON, V23, P423, DOI 10.1016/S0896-6273(00)80795-3; Furukawa T, 1998, J BIOL CHEM, V273, P17595, DOI 10.1074/jbc.273.28.17595; Furukawa T, 1998, J BIOL CHEM, V273, P17585, DOI 10.1074/jbc.273.28.17585; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Garcia DE, 1998, J NEUROSCI, V18, P9163; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; HESCHELER J, 1994, ANN NY ACAD SCI, V733, P306, DOI 10.1111/j.1749-6632.1994.tb17280.x; Hille B., 1992, IONIC CHANNELS EXCIT; Hosey MM, 1996, TRENDS CARDIOVAS MED, V6, P265, DOI 10.1016/S1050-1738(96)00109-0; Ikeda SR, 1999, ADV SEC MESS PHOSPH, V33, P131; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; Jing J, 1999, EMBO J, V18, P1245, DOI 10.1093/emboj/18.5.1245; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLOCKNER U, 1995, J BIOL CHEM, V270, P17306, DOI 10.1074/jbc.270.29.17306; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Levitan IB, 1999, NEURON, V22, P645, DOI 10.1016/S0896-6273(00)80722-9; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Liu MY, 1997, J BIOL CHEM, V272, P18801, DOI 10.1074/jbc.272.30.18801; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; O'Connor V, 1999, SCIENCE, V286, P1180, DOI 10.1126/science.286.5442.1180; Page KM, 1998, J NEUROSCI, V18, P4815; Patil PG, 1996, BIOPHYS J, V71, P2509, DOI 10.1016/S0006-3495(96)79444-4; Perez-Reyes E, 1998, J BIOENERG BIOMEMBR, V30, P313, DOI 10.1023/A:1021981420839; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; ROSENTHAL W, 1988, EMBO J, V7, P1627, DOI 10.1002/j.1460-2075.1988.tb02989.x; Ruiz-Velasco V, 2000, J NEUROSCI, V20, P2183; SCULPTOREANU A, 1993, P NATL ACAD SCI USA, V90, P10135, DOI 10.1073/pnas.90.21.10135; Shapiro MS, 1999, P NATL ACAD SCI USA, V96, P10899, DOI 10.1073/pnas.96.19.10899; SHAPIRO MS, 1994, J NEUROSCI, V14, P7109; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; Shistik E, 1999, J BIOL CHEM, V274, P31145, DOI 10.1074/jbc.274.44.31145; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; Simen AA, 1998, J NEUROSCI, V18, P3689; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; WEI XY, 1994, J BIOL CHEM, V269, P1635; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Ye CP, 1999, J MOL CELL CARDIOL, V31, P1771, DOI 10.1006/jmcc.1999.1015; Zamponi GW, 1998, CURR OPIN NEUROBIOL, V8, P351, DOI 10.1016/S0959-4388(98)80060-3; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zamponi GW, 1998, P NATL ACAD SCI USA, V95, P4035, DOI 10.1073/pnas.95.7.4035; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	73	103	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39846	39854		10.1074/jbc.M005881200	http://dx.doi.org/10.1074/jbc.M005881200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10995757	hybrid			2022-12-27	WOS:000166039500010
J	Ravanat, JL; Di Mascio, P; Martinez, GR; Medeiros, MHG; Cadet, J				Ravanat, JL; Di Mascio, P; Martinez, GR; Medeiros, MHG; Cadet, J			Singlet oxygen induces oxidation of cellular DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE DAMAGE; VISIBLE-LIGHT; 8-HYDROXY-2'-DEOXYGUANOSINE; RADIATION; ASSAY; ENDOPEROXIDE; THERMOLYSIS; RIBOFLAVIN; PRODUCTS; ACID	The aim of the present work was to evaluate the potential for O-1(2) to induce oxidation of cellular DNA. For this purpose cells were incubated in the presence of a water-soluble endoperoxide whose thermal decomposition leads to the formation of singlet oxygen. Thereafter, DNA was extracted and the level of several modified DNA bases was determined by HPLC analysis coupled to a tandem mass spectrometric detection. A significant increase in the level of 8-oxo-7,8-dihydro-2'-deoxyguanosine was observed upon incubation of the cells with the chemical generator of O-1(2), whereas the level of the other DNA bases measured remained unchanged. To demonstrate that singlet oxygen is directly involved in the formation of 8-oxo-7,8-dihydro-2'-deoxyguanosine, the corresponding O-18-labeled endoperoxide was used. Incubation of the cells with such a generator of O-18-labeled singlet oxygen results in the formation of O-18-labeled 8-oxo-7,8-dihydro-2'-deoxyguanosine in the nuclear DNA. This result clearly demonstrates that singlet oxygen, when released within cells, is able to directly oxidize cellular DNA.	CEA, SCIB,UMR CNRS 5046, DRFMC, Lab Les Acides Nucl, F-38054 Grenoble 9, France; Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05513970 Sao Paulo, SP, Brazil	CEA; Universidade de Sao Paulo	Cadet, J (corresponding author), CEA, SCIB,UMR CNRS 5046, DRFMC, Lab Les Acides Nucl, 17 Ave Martyrs, F-38054 Grenoble 9, France.		Ravanat, Jean-Luc/E-3452-2018; Martinez, Glaucia Regina/I-3110-2016; Cadet, Jean/M-2971-2018; Di Mascio, Paolo/D-1264-2014; de Medeiros, Marisa Helena Gennari/AAA-8015-2019; Medeiros, Marisa H. G./A-5212-2008	Ravanat, Jean-Luc/0000-0002-7123-6358; Martinez, Glaucia Regina/0000-0002-2628-4406; Cadet, Jean/0000-0003-2594-9485; Di Mascio, Paolo/0000-0003-4125-8350; de Medeiros, Marisa Helena Gennari/0000-0002-5438-1174; Medeiros, Marisa H. G./0000-0002-5438-1174				Alapetite C, 1996, INT J RADIAT BIOL, V69, P359, DOI 10.1080/095530096145922; BASUMODAK S, 1993, CANCER RES, V53, P4505; BUCHKO GW, 1992, NUCLEIC ACIDS RES, V20, P4847, DOI 10.1093/nar/20.18.4847; CADENAS E, 1983, HOPPESEYLERS Z PHYSL, V364, P515; CADET J, 1994, METHOD ENZYMOL, V234, P79; Cadet J, 1998, FREE RADICAL RES, V29, P541, DOI 10.1080/10715769800300581; Cadet J, 1997, BIOL CHEM, V378, P1275; CADET J, 1978, PHOTOCHEM PHOTOBIOL, V28, P661, DOI 10.1111/j.1751-1097.1978.tb06991.x; Cadet J, 2000, METHOD ENZYMOL, V319, P143; CLAYCAMP HG, 1993, INT J RADIAT BIOL, V63, P597, DOI 10.1080/09553009314450781; Dewilde A, 1996, J PHOTOCH PHOTOBIO B, V36, P23, DOI 10.1016/S1011-1344(96)07323-X; Dewilde A, 1998, BIOL CHEM, V379, P1377; DI MASCIO P, 1989, J AM CHEM SOC, V111, P2909, DOI 10.1021/ja00190a027; Douki T., 1995, P213; EPE B, 1991, CHEM-BIOL INTERACT, V80, P239, DOI 10.1016/0009-2797(91)90086-M; Frelon S, 2000, CHEM RES TOXICOL, V13, P1002, DOI 10.1021/tx000085h; Hall DB, 1996, NATURE, V382, P731, DOI 10.1038/382731a0; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KASAI H, 1992, J AM CHEM SOC, V114, P9692, DOI 10.1021/ja00050a078; KHAN AU, 1992, P NATL ACAD SCI USA, V89, P11428, DOI 10.1073/pnas.89.23.11428; Kielbassa C, 1997, CARCINOGENESIS, V18, P811, DOI 10.1093/carcin/18.4.811; Klotz LO, 1999, EUR J BIOCHEM, V260, P917, DOI 10.1046/j.1432-1327.1999.00255.x; Lafleur M V, 1987, Free Radic Res Commun, V2, P343, DOI 10.3109/10715768709065301; Loft S, 1996, J MOL MED, V74, P297, DOI 10.1007/BF00207507; LOFT S, 1993, J TOXICOL ENV HEALTH, V40, P391, DOI 10.1080/15287399309531806; Martinez GR, 2000, J AM CHEM SOC, V122, P10212, DOI 10.1021/ja0016452; Pierlot C, 1996, J PHOTOCH PHOTOBIO B, V36, P31, DOI 10.1016/S1011-1344(96)07324-1; Pierlot C, 2000, METHOD ENZYMOL, V319, P3; PIETTE J, 1991, J PHOTOCH PHOTOBIO B, V11, P241, DOI 10.1016/1011-1344(91)80030-L; PIETTE J, 1990, J PHOTOCH PHOTOBIO B, V4, P335, DOI 10.1016/1011-1344(90)85039-Y; Pouget JP, 1999, INT J RADIAT BIOL, V75, P51, DOI 10.1080/095530099140807; Ravanat JL, 1998, J CHROMATOGR B, V715, P349, DOI 10.1016/S0378-4347(98)00259-X; RAVANAT JL, 1995, CHEM RES TOXICOL, V8, P379, DOI 10.1021/tx00045a009; SHEU C, 1993, J AM CHEM SOC, V115, P10446, DOI 10.1021/ja00075a105; SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697; STEINBECK MJ, 1992, J BIOL CHEM, V267, P13425	37	247	251	2	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40601	40604		10.1074/jbc.M006681200	http://dx.doi.org/10.1074/jbc.M006681200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007783	Green Published, hybrid			2022-12-27	WOS:000166039500107
J	Ray, A; Fields, AP; Ray, BK				Ray, A; Fields, AP; Ray, BK			Activation of transcription factor SAF involves its phosphorylation by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM-AMYLOID-A; ZINC-FINGER PROTEIN; GENE-EXPRESSION; MONOCYTE/MACROPHAGE CELLS; SYNOVIAL FIBROBLASTS; INDUCTION; PROMOTER; BINDING; COLLAGENASE; SEQUENCES	The transcription factor serum amyloid A (SAA)-activating factor (SAF), a family of zinc finger proteins, plays a significant role in the induced expression of the SAA gene. Activity of SAF is regulated by a phosphorylation event involving serine/threonine protein kinase (Ray, A, Schatten, H., and Ray, B. K. (1999) J. Biol. Chem. 274, 4300-4308; Ray, A., and Ray, B. K. (1998) Mol. Cell. Biol. 18, 7327-7335). However, the identity of the protein kinase has so far remained unknown, Induction of SAA by phorbol 12-myristate 13-acetate, a known agonist of protein kinase C (PKC), suggested a potential role of the PHC signaling pathway in the activation process. The DNA binding activity of endogenous SAF was increased by agonists of PKC. In vitro phosphorylation of SAF-1 by PRC-beta markedly increased its DNA binding ability. Consistent with these findings, treatment of cells with activators of PKC or overexpression of PKC-beta II in transfected cells increased expression of an SAF-regulated promoter. Further analysis with a GAL4 reporter system indicated that PKC-mediated phosphorylation mostly increases the DNA binding activity of SAF-1. Together these data indicated that the PKC signaling pathway plays a major role in controlling expression of SAF-regulated genes by increasing the interaction between promoter DNA and phosphorylated SAF.	Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA; Univ Texas, Med Branch, Dept Pharmacol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Missouri System; University of Missouri Columbia; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Ray, BK (corresponding author), Univ Missouri, Dept Vet Pathobiol, 124 Connaway Hall, Columbia, MO 65211 USA.				NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049205, R56DK049205] Funding Source: NIH RePORTER; NCI NIH HHS [CA56869] Funding Source: Medline; NIDDK NIH HHS [DK49205] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINCKERHOFF CE, 1989, SCIENCE, V243, P655, DOI 10.1126/science.2536953; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; EDBROOKE MR, 1989, MOL CELL BIOL, V9, P1908, DOI 10.1128/MCB.9.5.1908; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GANAPATHI MK, 1991, J IMMUNOL, V147, P1261; Gekeler V, 1996, BRIT J CANCER, V74, P897, DOI 10.1038/bjc.1996.454; GHEZZI P, 1988, LYMPHOKINE RES, V7, P157; Huberman E, 1985, Carcinog Compr Surv, V10, P263; HUSEBEKK A, 1985, SCAND J IMMUNOL, V21, P283, DOI 10.1111/j.1365-3083.1985.tb01431.x; JARVIS WD, 1994, CANCER RES, V54, P1704; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; Kolomytkin OV, 1999, AM J PHYSIOL-CELL PH, V276, pC9, DOI 10.1152/ajpcell.1999.276.1.C9; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACKIEWICZ A, 1988, BIOCHEM J, V253, P851, DOI 10.1042/bj2530851; MASTRO AM, 1983, CELL BIOL INT REP, V7, P881, DOI 10.1016/0309-1651(83)90206-0; MITCHELL TI, 1991, J CLIN INVEST, V87, P1177, DOI 10.1172/JCI115116; MURRAY NR, 1997, PROTEIN KINASE C, P97; MURRAY NR, 1993, J BIOL CHEM, V268, P15747; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Parks CL, 1996, J BIOL CHEM, V271, P4417; PELICCI PG, 1983, HAEMATOLOGICA, V68, P411; Ray A, 1999, J BIOL CHEM, V274, P4300, DOI 10.1074/jbc.274.7.4300; Ray A, 1998, MOL CELL BIOL, V18, P7327, DOI 10.1128/MCB.18.12.7327; Ray A, 1996, MOL CELL BIOL, V16, P1584; Ray BK, 1999, DNA CELL BIOL, V18, P65, DOI 10.1089/104454999315637; Ray BK, 1997, BIOCHEMISTRY-US, V36, P4662, DOI 10.1021/bi9624595; Sambrook J., 2002, MOL CLONING LAB MANU; Strissel KJ, 1997, EXP CELL RES, V237, P275, DOI 10.1006/excr.1997.3783; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; URIELISHOVAL S, 1994, AM J PATHOL, V145, P650; VANDENBARK GR, 1984, J NATL CANCER I, V73, P1013	37	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39727	39733		10.1074/jbc.M007907200	http://dx.doi.org/10.1074/jbc.M007907200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995778	hybrid			2022-12-27	WOS:000165953100102
J	Zheng, XY; Johansson, M; Karlsson, A				Zheng, XY; Johansson, M; Karlsson, A			Retroviral transduction of cancer cell lines with the gene encoding Drosophila melanogaster multisubstrate deoxyribonucleoside kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX-VIRUS TYPE-1; HUMAN DEOXYCYTIDINE KINASE; THYMIDINE KINASE; SUICIDE GENE; NUCLEOSIDE ANALOGS; TUMOR-CELLS; THERAPY; ADENOVIRUS; VECTOR; CYTOTOXICITY	Nucleoside kinases from several species are investigated as "suicide genes" for treatment of malignant tumors by combined gene/chemotherapy, We have recently cloned a multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster (Dm-dNK), and we have shown that the enzyme phosphorylates cytotoxic pyrimidine and purine nucleoside analogs. The broad substrate specificity of the enzyme, as well as its very high catalytic rate, makes it a unique member of the nucleoside kinase enzyme family. In the present study, we evaluated Dm-dNK as a suicide gene by constructing a replication-deficient retroviral vector that expresses the enzyme, The human pancreatic adenocarcinoma cell line MIA PaCa-2 and a thymidine kinase deficient osteosarcoma cell line were transduced with the recombinant virus. We showed that Dm-dNK can be expressed in human cells, that the enzyme retained its enzymatic activity, and that it is localized in the cell nuclei due to a nuclear localization signal in its C-terminal region. The cells expressing Dm-dNK exhibited increased sensitivity to several cytotoxic nucleoside analogs, such as 1-beta -D-arabinofuranosylcytosine, 1-beta -D-arabinofuranosylthymine, (E)-5-(2-bromovinyl)-2'-deoxyuridine, 2-chloro-2'-deoxyadenosine, and 2',2'-difluorodeoxycytidine. These findings suggest that Dm-dNK may be used as a suicide gene in combined gene/chemotherapy of cancer.	Huddinge Univ Hosp, Karolinska Inst, Div Clin Virol, S-14186 Huddinge, Sweden	Karolinska Institutet	Karlsson, A (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Div Clin Virol, S-14186 Huddinge, Sweden.	anna.karlsson@mbb.bi.se	Karlsson, Anna/E-7945-2018; Zheng, Xinyu/O-9847-2018	Zheng, Xinyu/0000-0001-8425-3379; Karlsson, Anna/0000-0001-6843-6685				ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6; BALZARINI J, 1993, J BIOL CHEM, V268, P6332; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; BERK AJ, 1973, J BIOL CHEM, V248, P2722; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Black ME, 1996, P NATL ACAD SCI USA, V93, P3525, DOI 10.1073/pnas.93.8.3525; Boucher PD, 2000, CANCER RES, V60, P1631; Cao G, 1999, GENE THER, V6, P83, DOI 10.1038/sj.gt.3300823; Chen J, 1998, CANCER RES, V58, P3504; Christians FC, 1999, NAT BIOTECHNOL, V17, P259, DOI 10.1038/7003; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; Davis AF, 1996, J CELL BIOL, V135, P883, DOI 10.1083/jcb.135.4.883; Degreve B, 1998, J VIROL, V72, P9535; Degreve B, 1997, GENE THER, V4, P1107, DOI 10.1038/sj.gt.3300502; FREEMAN SM, 1993, CANCER RES, V53, P5274; GrignetDebrus C, 1997, GENE THER, V4, P560, DOI 10.1038/sj.gt.3300435; Hapke DM, 1996, CANCER RES, V56, P2343; Hui YF, 1997, AM J HEALTH-SYST PH, V54, P162, DOI 10.1093/ajhp/54.2.162; Johansson M, 1999, J BIOL CHEM, V274, P23814, DOI 10.1074/jbc.274.34.23814; Johansson M, 1997, P NATL ACAD SCI USA, V94, P11941, DOI 10.1073/pnas.94.22.11941; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Klatzmann D, 1998, HUM GENE THER, V9, P2595, DOI 10.1089/hum.1998.9.17-2595; Kokoris MS, 1999, GENE THER, V6, P1415, DOI 10.1038/sj.gt.3300966; Latham JPF, 2000, CANCER RES, V60, P334; Manome Y, 1996, NAT MED, V2, P567, DOI 10.1038/nm0596-567; Mawatari F, 1998, CANCER GENE THER, V5, P301; Mesnil M, 1996, P NATL ACAD SCI USA, V93, P1831, DOI 10.1073/pnas.93.5.1831; MOOLTEN FL, 1986, CANCER RES, V46, P5276; MOOLTEN FL, 1990, J NATL CANCER I, V82, P297, DOI 10.1093/jnci/82.4.297; Munch-Petersen B, 2000, J BIOL CHEM, V275, P6673, DOI 10.1074/jbc.275.9.6673; Munch-Petersen B, 1998, J BIOL CHEM, V273, P3926, DOI 10.1074/jbc.273.7.3926; Ram Z, 1997, NAT MED, V3, P1354, DOI 10.1038/nm1297-1354; REARDON JE, 1989, J BIOL CHEM, V264, P19039; Romano G, 2000, STEM CELLS, V18, P19, DOI 10.1634/stemcells.18-1-19; Siders WM, 1998, CANCER GENE THER, V5, P281; SODERLUND JCF, 1994, ADV EXP MED BIOL, V370, P201; Wettin K, 1999, FEBS LETT, V460, P103, DOI 10.1016/S0014-5793(99)01325-3; WILDIERS J, 1984, EUR J CANCER CLIN ON, V20, P471, DOI 10.1016/0277-5379(84)90231-1; Wildner O, 1999, CANCER RES, V59, P410; Zhu CY, 1998, J BIOL CHEM, V273, P14707, DOI 10.1074/jbc.273.24.14707	40	53	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39125	39129		10.1074/jbc.M006212200	http://dx.doi.org/10.1074/jbc.M006212200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993893	hybrid			2022-12-27	WOS:000165953100026
J	Baumer, M; Kunzler, M; Steigemann, P; Braus, GH; Irniger, S				Baumer, M; Kunzler, M; Steigemann, P; Braus, GH; Irniger, S			Yeast Ran-binding protein Yrb1p is required for efficient proteolysis of cell cycle regulatory proteins Pds1p and Sic1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEAR IMPORT; CHROMOSOME SEGREGATION; PHOSPHATASE CDC14; TRANSPORT; IDENTIFICATION; KINASE; EXIT; PHOSPHORYLATION; EXPRESSION	Ubiquitin dependent proteolysis of specific target proteins is required for several important steps during the cell cycle, Degradation of such proteins is strictly cell cycle-regulated and triggered by two large ubiquitin ligases, termed anaphase-promoting complex (APC) and Skp1/Cullin/F-box complex (SCF), Here we show that yeast Ran-binding protein 1 (Yrb1p), a predominantly cytoplasmic protein implicated in nucleocytoplasmic transport, is required for cell cycle regulated protein degradation. Depletion of Yrb1p results in the accumulation of unbudded G(1) cells and of cells arrested in mitosis implying a function of Yrb1p in the G(1)/S transition and in the progression through mitosis, Temperature-sensitive yrb1-51 mutants are defective in APC-mediated degradation of the anaphase inhibitor protein Pds1p and in degradation of the cyclin-dependent kinase inhibitor Sic1p, a target of SCF. Thus, Yrb1p is crucial for efficient APC- and SCF-mediated proteolysis of important cell cycle regulatory proteins. We have identified the UBS1 gene as a multicopy suppressor of yrb1-51 mutants. Ubs1p is a nuclear protein, and its deletion is synthetic lethal with a yrb1-51 mutation. Interestingly, UBS1 was previously identified as a multicopy suppressor of cdc34-2 mutants, which are defective in SCF activity. We suggest that Ubs1p may represent a link between nucleocytoplasmic transport and ubiquitin ligase activity.	Univ Gottingen, Inst Genet & Microbiol, D-37077 Gottingen, Germany; Heidelberg Univ, Zentrum Biochem, D-69120 Heidelberg, Germany	University of Gottingen; Ruprecht Karls University Heidelberg	Irniger, S (corresponding author), Univ Gottingen, Inst Genet & Microbiol, Grisebachstr 8, D-37077 Gottingen, Germany.	sirnige@gwdg.de	Braus, Gerhard H/G-3999-2012; Braus, Gerhard/ABC-6293-2021	Braus, Gerhard H/0000-0002-3117-5626; Braus, Gerhard/0000-0002-3117-5626; Kunzler, Markus/0000-0003-1275-0629				Adam SA, 1999, CURR OPIN CELL BIOL, V11, P402, DOI 10.1016/S0955-0674(99)80056-8; Azuma Y, 2000, CURR OPIN CELL BIOL, V12, P302, DOI 10.1016/S0955-0674(00)00093-4; Battistoni A, 1997, J CELL SCI, V110, P2345; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; BUTLER G, 1994, BBA-GENE STRUCT EXPR, V1219, P711, DOI 10.1016/0167-4781(94)90233-X; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Deshaies RJ, 1997, CURR OPIN GENET DEV, V7, P7, DOI 10.1016/S0959-437X(97)80103-7; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Goldfarb DS, 1997, SCIENCE, V276, P1814, DOI 10.1126/science.276.5320.1814; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; IMIGER S, 1995, CELL, V81, P269; Jones AL, 2000, P NATL ACAD SCI USA, V97, P3224, DOI 10.1073/pnas.050432997; Jorgensen P, 1999, CURR OPIN MICROBIOL, V2, P610, DOI 10.1016/S1369-5274(99)00030-2; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; KATZ ME, 1987, GENETICS, V115, P627; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Knapp D, 1996, MOL CELL BIOL, V16, P5701; Kunzler M, 2000, MOL CELL BIOL, V20, P4295, DOI 10.1128/MCB.20.12.4295-4308.2000; Lau D, 2000, J BIOL CHEM, V275, P467, DOI 10.1074/jbc.275.1.467; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Ogryzko VV, 1997, BIOCHEMISTRY-US, V36, P9493, DOI 10.1021/bi970236o; OUSPENSKI II, 1995, J BIOL CHEM, V270, P1975, DOI 10.1074/jbc.270.5.1975; Ouspenski II, 1998, EXP CELL RES, V244, P171, DOI 10.1006/excr.1998.4174; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Plafker K, 2000, MOL CELL BIOL, V20, P3510, DOI 10.1128/MCB.20.10.3510-3521.2000; Prendergast JA, 1996, MOL CELL BIOL, V16, P677; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rose M, 1990, LAB COURSE MANUAL ME; SCHAAFFGERSTENSCHLAGER I, 1993, YEAST, V9, P915, DOI 10.1002/yea.320090811; SCHIRMAIER F, 1984, EMBO J, V3, P3311, DOI 10.1002/j.1460-2075.1984.tb02295.x; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Willems AR, 1999, PHILOS T ROY SOC B, V354, P1533, DOI 10.1098/rstb.1999.0497; XIAO ZX, 1993, MOL CELL BIOL, V13, P4691, DOI 10.1128/MCB.13.8.4691; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zachariae W, 1999, CURR OPIN CELL BIOL, V11, P708, DOI 10.1016/S0955-0674(99)00041-1	57	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38929	38937		10.1074/jbc.M007925200	http://dx.doi.org/10.1074/jbc.M007925200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10991951	hybrid			2022-12-27	WOS:000165739800107
J	Chui, KK; Rogers, GC; Kashina, AM; Wedaman, KP; Sharp, DJ; Nguyen, DT; Wilt, F; Scholey, JM				Chui, KK; Rogers, GC; Kashina, AM; Wedaman, KP; Sharp, DJ; Nguyen, DT; Wilt, F; Scholey, JM			Roles of two homotetrameric kinesins in sea urchin embryonic cell division	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE BUNDLES; MITOTIC SPINDLES; BIPOLAR KINESIN; PROTEIN; MOTOR; ANTIBODY; IDENTIFICATION; CYTOKINESIS; EGGS	To improve our understanding of the roles of microtubule cross-linking motors in mitosis, we analyzed two sea urchin embryonic kinesin-related proteins. It is striking to note that both of these proteins behave as homotetramers, but one behaves as a more compact molecule than the other. These observations suggest that these two presumptive motors could cross-link microtubules into bundles with different spacing. Both motors localize to mitotic spindles, and antibody microinjection experiments suggest that they have mitotic functions. Thus, one of these kinesin-related proteins may crosslink spindle microtubules into loose bundles that are "tightened" by the other.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA	University of California System; University of California Davis; University of California System; University of California Berkeley	Scholey, JM (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, 1 Shields Ave, Davis, CA 95616 USA.	jmscholey@ucdavis.edu			NIGMS NIH HHS [GM55507] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams RR, 1998, GENE DEV, V12, P1483, DOI 10.1101/gad.12.10.1483; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; BUSTER D, 1991, J CELL SCI, P109; COLE DG, 1994, J BIOL CHEM, V269, P22913; Field CM, 1998, METHOD ENZYMOL, V298, P525, DOI 10.1016/S0076-6879(98)98043-0; Gordon DM, 1999, J BIOL CHEM, V274, P28779, DOI 10.1074/jbc.274.40.28779; Jantsch-Plunger V, 2000, J CELL BIOL, V149, P1391, DOI 10.1083/jcb.149.7.1391; Kashina AS, 1996, NATURE, V384, P225, DOI 10.1038/384225a0; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Morris RL, 1997, J CELL BIOL, V138, P1009, DOI 10.1083/jcb.138.5.1009; NISLOW C, 1990, J CELL BIOL, V111, P511, DOI 10.1083/jcb.111.2.511; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; Powers J, 1998, CURR BIOL, V8, P1133, DOI 10.1016/S0960-9822(98)70470-1; Raich WB, 1998, MOL BIOL CELL, V9, P2037, DOI 10.1091/mbc.9.8.2037; RAPPAPORT R, 1996, CYTOKINESIS ANIMAL C, P1; Robinson DN, 2000, TRENDS CELL BIOL, V10, P228, DOI 10.1016/S0962-8924(00)01747-5; Rogers GC, 2000, J CELL BIOL, V150, P499, DOI 10.1083/jcb.150.3.499; Rogers GC, 1999, J MOL BIOL, V294, P1, DOI 10.1006/jmbi.1999.3249; Savoian MS, 1999, MOL BIOL CELL, V10, P297, DOI 10.1091/mbc.10.2.297; SCHOLEY JM, 1984, J BIOL CHEM, V259, P6516; Scholey JM, 1998, CELL MOTIL CYTOSKEL, V39, P257, DOI 10.1002/(SICI)1097-0169(1998)39:4<257::AID-CM1>3.0.CO;2-0; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; SELLITTO C, 1988, J CELL BIOL, V106, P431, DOI 10.1083/jcb.106.2.431; Sharp DJ, 2000, MOL BIOL CELL, V11, P241, DOI 10.1091/mbc.11.1.241; Sharp DJ, 1999, J CELL BIOL, V144, P125, DOI 10.1083/jcb.144.1.125; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; WRIGHT BD, 1993, J CELL BIOL, V123, P681, DOI 10.1083/jcb.123.3.681; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	30	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38005	38011		10.1074/jbc.M005948200	http://dx.doi.org/10.1074/jbc.M005948200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	11006281	hybrid			2022-12-27	WOS:000165618700094
J	Li, Y; Li, M; Xing, GC; Hu, ZY; Wang, QM; Dong, CN; Wei, HD; Fan, GC; Chen, JZ; Yang, XM; Zhao, SF; Chen, HP; Guan, KL; Wu, CS; Zhang, CG; He, FC				Li, Y; Li, M; Xing, GC; Hu, ZY; Wang, QM; Dong, CN; Wei, HD; Fan, GC; Chen, JZ; Yang, XM; Zhao, SF; Chen, HP; Guan, KL; Wu, CS; Zhang, CG; He, FC			Stimulation of the mitogen-activated protein kinase cascade and tyrosine phosphorylation of the epidermal growth factor receptor by hepatopoietin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE-1; REGENERATION ALR GENE; LIVER-REGENERATION; EGF RECEPTOR; CELLS; EXPRESSION; RAT; AUGMENTOR; SUBSTANCE; HEPATOMA	Hepatopoietin (HPO) is a novel human hepatotrophic growth factor, which specifically stimulates proliferation of cultured primary hepatocytes in vitro and liver regeneration after liver partial hepatectomy in vivo. Recently, the identification of the mitogenic effect of HPO on hepatoma cell lines and the existence of HPO-specific receptors indicate that HPO acts via its specific cell surface receptor, However, the molecular mechanism of HPO action is not fully elucidated. In this report, we examined the signal transduction events induced by HPO in hepatoma cell line (HepG2), Our results demonstrated that HPO induces phosphorylation of mitogen-activated protein kinase kinase and mitogen-activated protein kinase (MAPK) in a rapid and transient manner. HPO stimulates tyrosine phosphorylation of epidermal growth factor receptor (EGFR). Furthermore, we observed that both MAPK activation and the mitogenic effect of HPO on HepG2 cells were completely blocked by AG1478, a specific inhibitor of EGFR tyrosine kinase activity. However, the effects of HPO were not antagonized by an EGFR-blocking antibody, mAb528, which blocks the interaction between epidermal growth factor and EGFR, indicating that stimulation of tyrosine phosphorylation of EGFR by HPO was not mediated by epidermal growth factor. In contrast, genistein, a general tyrosine kinase inhibitor, significantly attenuated the tyrosine phosphorylation of EGFR in response to HPO, In conclusion, our results suggest that tyrosine phosphorylation of EGFR may play a critical role in MAPK activation and mitogenic stimulation by HPO.	Beijing Inst Radiat Med, Chinese Natl Human Genome Ctr, Dept Genomics & Proteom, Beijing 100850, Peoples R China; Acad Sinica, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Academy of Military Medical Sciences - China; Chinese Academy of Sciences; Institute of Biophysics, CAS	He, FC (corresponding author), Beijing Inst Radiat Med, Chinese Natl Human Genome Ctr, Dept Genomics & Proteom, 27 Taiping Rd, Beijing 100850, Peoples R China.		Zhang, Chenggang/B-1480-2009	Zhang, Chenggang/0000-0002-4521-3304				Chaudhary LR, 1997, BIOCHEM BIOPH RES CO, V238, P134, DOI 10.1006/bbrc.1997.7256; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Dabrowski A, 1997, AM J PHYSIOL-CELL PH, V273, pC1472, DOI 10.1152/ajpcell.1997.273.5.C1472; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Diehl AM, 1996, FASEB J, V10, P215, DOI 10.1096/fasebj.10.2.8641555; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; GABELMAN BM, 1992, EXP CELL RES, V201, P113, DOI 10.1016/0014-4827(92)90354-B; Giorda R, 1996, MOL MED, V2, P97, DOI 10.1007/BF03402206; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; HAGIYA M, 1994, P NATL ACAD SCI USA, V91, P8142, DOI 10.1073/pnas.91.17.8142; He FC, 1997, CHINESE SCI BULL, V42, P1505; LABRECQUE DR, 1991, DIGEST DIS SCI, V36, P669, DOI 10.1007/BF01297036; LABRECQUE DR, 1975, J PHYSIOL-LONDON, V248, P273, DOI 10.1113/jphysiol.1975.sp010973; LABRECQUE DR, 1994, AM J GASTROENTEROL S, V89, P90; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LISOWSKY T, 1995, GENOMICS, V29, P690, DOI 10.1006/geno.1995.9950; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Putz T, 1999, CANCER RES, V59, P227; Wang G, 1999, J BIOL CHEM, V274, P11469, DOI 10.1074/jbc.274.17.11469; YAMAGUCHI K, 1995, J SURG ONCOL, V58, P240; Yang EB, 1996, BIOCHEM MOL BIOL INT, V38, P813; Yang XM, 1997, SCI CHINA SER C, V40, P642, DOI 10.1007/BF02882695; YANG XM, 1997, ACTA BIOCH BIOPH SIN, V29, P72; YANG XM, 1997, ACTA PHYSL SINICA, V49, P557; Zanella CL, 1996, CANCER RES, V56, P5334	25	57	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37443	37447		10.1074/jbc.M004373200	http://dx.doi.org/10.1074/jbc.M004373200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982794	hybrid			2022-12-27	WOS:000165618700020
J	Lee, SJ; Beckingham, K; Stull, JT				Lee, SJ; Beckingham, K; Stull, JT			Mutations at lysine 525 of inducible nitric-oxide synthase affect its Ca2+-independent activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; ELECTRON-TRANSFER; MOLECULAR-CLONING; CATALYTIC ACTIVITY; OXYGENASE DOMAIN; NO SYNTHASE; CELL-LINE; EXPRESSION; PURIFICATION; CDNA	Calmodulin binding to inducible nitric-oxide synthase may play an important role in its Ca2+-independent activity. Studies of inducible nitric-oxide synthase chimeras containing the calmodulin binding sequence of neuronal or endothelial nitric-oxide synthases show that the calmodulin binding sequence of inducible nitric-oxide synthase is necessary but not sufficient for the Ca2+- independent activity. The mutations at lysine 525 located at the C terminus of the calmodulin binding sequence of inducible nitric-oxide synthase were examined for the effects on the Ca2+-independent activity with chimeras containing the oxygenase or reductase domains of inducible or neuronal nitric-oxide synthases. Results show that the Ca2+-independent binding of calmodulin is not solely responsible for maximal Ca2+-independent activity of inducible nitric-oxide synthase, Lysine 525 of inducible nitric-oxide synthase may also play an important role in coordinating the maximal Ca2+-independent activity.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Rice University	Lee, SJ (corresponding author), Res Genet Inc, Dept Res & Dev, 2130 Mem Pkwy, Huntsville, AL 35801 USA.		Lee, Shiow-Ju/C-1380-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026043, R01HL026043] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06296, HL26043] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; EVANS T, 1992, P NATL ACAD SCI USA, V89, P5361, DOI 10.1073/pnas.89.12.5361; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; GAO ZH, 1993, J BIOL CHEM, V268, P20096; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; IIDA S, 1992, J BIOL CHEM, V267, P25385; Lee SJ, 1998, J BIOL CHEM, V273, P27430, DOI 10.1074/jbc.273.42.27430; Lin AW, 1996, J BIOL CHEM, V271, P11911, DOI 10.1074/jbc.271.20.11911; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MAIER R, 1994, BBA-PROTEIN STRUCT M, V1208, P145, DOI 10.1016/0167-4838(94)90171-6; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Martasek P, 1998, J BIOL CHEM, V273, P34799, DOI 10.1074/jbc.273.52.34799; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; Perry JM, 1998, P NATL ACAD SCI USA, V95, P11101, DOI 10.1073/pnas.95.19.11101; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; REGULSKI M, 1995, P NATL ACAD SCI USA, V92, P9072, DOI 10.1073/pnas.92.20.9072; Ruan J, 1996, J BIOL CHEM, V271, P22679, DOI 10.1074/jbc.271.37.22679; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SHERMAN PA, 1993, BIOCHEMISTRY-US, V32, P11600, DOI 10.1021/bi00094a017; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; StevensTruss R, 1997, BIOCHEMISTRY-US, V36, P12337, DOI 10.1021/bi970973k; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; Watanabe Y, 1997, FEBS LETT, V403, P75, DOI 10.1016/S0014-5793(97)00012-4; YUI Y, 1991, J BIOL CHEM, V266, P12544; Zoche M, 1997, BIOL CHEM, V378, P851, DOI 10.1515/bchm.1997.378.8.851	42	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36067	36072		10.1074/jbc.M003935200	http://dx.doi.org/10.1074/jbc.M003935200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10978319	hybrid			2022-12-27	WOS:000165382000061
J	Ramamurthy, L; Barbour, V; Tuckfield, A; Clouston, DR; Topham, D; Cunningham, JM; Jane, SM				Ramamurthy, L; Barbour, V; Tuckfield, A; Clouston, DR; Topham, D; Cunningham, JM; Jane, SM			Targeted disruption of the CP2 gene, a member of the NTF family of transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; BETA-GLOBIN LOCUS; DNA-BINDING; FACTOR GRAINYHEAD; FACTOR NF-E2; IN-VITRO; DROSOPHILA; EXPRESSION; PROTEIN; LSF	The NTF-like family of transcription factors have been implicated in developmental regulation in organisms as diverse as Drosophila and man. The two mammalian members of this family, CP2 (LBP-1c/LSF) and LBP-1a (NF2d9), are highly related proteins sharing an overall amino acid identity of 72%. CP2, the best characterized of these factors, is a ubiquitously expressed 66-kDa protein that binds the regulatory regions of many diverse genes. Consequently, a role for CP2 has been proposed in globin gene expression, T-cell responses to mitogenic stimulation, and several other cellular processes. To elucidate the in vivo role of CP2, we have generated mice nullizygous for the CP2 allele, These animals were born in a normal Mendelian distribution and displayed no defects in growth, behavior, fertility, or development. Specifically, no perturbation of hematopoietic differentiation, globin gene expression, or immunological responses to T- and B-cell mitogenic stimulation was observed. RNA and protein analysis confirmed that the nullizygous mice expressed no full-length or truncated version of CP2. Electrophoretic mobility shift assays with nuclear extracts from multiple tissues demonstrated loss of CP2 DNA binding activity in the -/- lines. However, a slower migrating complex that was ablated with antiserum to NF2d9, the murine homologue of LBP-1a, was observed with these extracts. Furthermore, we demonstrate that recombinant LBP-1a can bind to known CP2 consensus sites and form protein complexes with previously defined heteromeric partners of CP2. These results suggest that LBP-1a/NF2d9 may compensate for loss of CP2 expression in vivo and that further analysis of the role of the NTF family of proteins requires the targeting of the NF2d9 gene.	St Jude Childrens Res Hosp, Div Expt Hematol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; Royal Melbourne Hosp Res Fdn, Rotary Bone Marrow Res Lab, Parkville, Vic 3050, Australia	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; Royal Melbourne Hospital	Cunningham, JM (corresponding author), St Jude Childrens Res Hosp, Div Expt Hematol, 332 N Lauderdale St, Memphis, TN 38105 USA.		Jane, Stephen/D-6659-2011	Barbour, Virginia/0000-0002-2358-2440; Jane, Stephen Marsden/0000-0002-1045-0481	NCI NIH HHS [P30 CA 21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL53749] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amrolia PJ, 1998, J BIOL CHEM, V273, P13593, DOI 10.1074/jbc.273.22.13593; ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; BRAY SJ, 1991, GENE DEV, V5, P1672, DOI 10.1101/gad.5.9.1672; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAENSLER KML, 1993, P NATL ACAD SCI USA, V90, P11381, DOI 10.1073/pnas.90.23.11381; GUMUCIO DL, 1994, J BIOL CHEM, V269, P15371; GUMUCIO DL, 1993, P NATL ACAD SCI USA, V90, P6018, DOI 10.1073/pnas.90.13.6018; Huang JD, 1995, GENE DEV, V9, P3177, DOI 10.1101/gad.9.24.3177; JANE SM, 1995, EMBO J, V14, P97, DOI 10.1002/j.1460-2075.1995.tb06979.x; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KIM CH, 1987, P NATL ACAD SCI USA, V84, P6025, DOI 10.1073/pnas.84.17.6025; Liaw GJ, 1995, GENE DEV, V9, P3163, DOI 10.1101/gad.9.24.3163; LIM LC, 1993, J BIOL CHEM, V268, P18008; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; PARADA CA, 1995, J BIOL CHEM, V270, P2274, DOI 10.1074/jbc.270.5.2274; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P11207, DOI 10.1073/pnas.90.23.11207; Romerio F, 1997, J VIROL, V71, P9375, DOI 10.1128/JVI.71.12.9375-9382.1997; Shavit JA, 1998, GENE DEV, V12, P2164, DOI 10.1101/gad.12.14.2164; SHIRRA MK, 1994, MOL CELL BIOL, V14, P5076, DOI 10.1128/MCB.14.8.5076; Shirra MK, 1998, J BIOL CHEM, V273, P19260, DOI 10.1074/jbc.273.30.19260; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; SUEYOSHI T, 1995, MOL CELL BIOL, V15, P4158; SWENDEMAN SL, 1994, J BIOL CHEM, V269, P11663; Uv AE, 1997, MOL CELL BIOL, V17, P6727, DOI 10.1128/MCB.17.11.6727; UV AE, 1994, MOL CELL BIOL, V14, P4020, DOI 10.1128/MCB.14.6.4020; Volker JL, 1997, GENE DEV, V11, P1435, DOI 10.1101/gad.11.11.1435; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; YOON JB, 1994, MOL CELL BIOL, V14, P1776, DOI 10.1128/MCB.14.3.1776; Zindy F, 1997, CELL GROWTH DIFFER, V8, P1139	34	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7836	7842		10.1074/jbc.M004351200	http://dx.doi.org/10.1074/jbc.M004351200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	10995745	Green Published, hybrid			2022-12-27	WOS:000167474900024
J	Fujii, T; Brandsma, JL; Peng, XY; Srimatkandada, S; Li, L; Canaan, A; Deisseroth, AB				Fujii, T; Brandsma, JL; Peng, XY; Srimatkandada, S; Li, L; Canaan, A; Deisseroth, AB			High and low levels of cottontail rabbit papillomavirus E2 protein generate opposite effects on gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECURRENT RESPIRATORY PAPILLOMATOSIS; CELLULAR TRANSCRIPTION FACTORS; OPEN READING FRAMES; DNA-BINDING DOMAIN; BOVINE PAPILLOMAVIRUS; REPLICATION PROTEIN; ACTIVATION DOMAINS; CRYSTAL-STRUCTURE; IN-VIVO; E1	The papillomavirus E2 protein plays an important role in viral transcriptional regulation and replication. We chose to study the cottontail rabbit papillomavirus (CRPV) E2 protein as a transcriptional regulator because of the availability of an animal model for papilloma formation, which may be relevant for human papillomavirus (HPV) infection and replication. We studied the effect of expression levels of E2 on the long control region, which contains transcriptional promoter and enhancer elements, and synthetic E2-dependent artificial promoters in which the E2 was the dominant factor in the transcriptional activation. These experiments indicated that high levels of E2 were inhibitory and low levels were stimulatory for transactivation. In addition, we showed that the complex formed between CRPV E2 and the cognate binding site was less stable than the complex formed between HPV E2 and the same cognate binding site, Furthermore, we showed that CRPV E2 binding to its transcriptional regulatory sequence was stabilized by other proteins such as El, which produced increments in transcriptional activation of E2-dependent genes. The data may be used to define conditions in which the rabbit model can be used for the screening of drugs which are inhibitory to the HPV and CRPV replication and gene expression.	Yale Univ, Sch Med, Dept Internal Med, Sect Med Oncol, New Haven, CT 06520 USA; Yale Univ, Ctr Canc, Genet Therapy Program, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Comparat Med, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Deisseroth, AB (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Sect Med Oncol, 333 Cedar St, New Haven, CT 06520 USA.	albert.deisseroth@yale.edu						Antson AA, 2000, NATURE, V403, P805, DOI 10.1038/35001638; BARBOSA MS, 1988, J VIROL, V62, P3242, DOI 10.1128/JVI.62.9.3242-3249.1988; Berg M, 1997, J VIROL, V71, P3853, DOI 10.1128/JVI.71.5.3853-3863.1997; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; BRANDSMA JL, 1995, J VIROL, V69, P2716, DOI 10.1128/JVI.69.4.2716-2721.1995; BRANDSMA JL, 1993, J VIROL, V67, P567, DOI 10.1128/JVI.67.1.567-571.1993; BRANDSMA JL, 1994, INTERVIROLOGY, V37, P189, DOI 10.1159/000150377; CHIANG CM, 1992, P NATL ACAD SCI USA, V89, P5799, DOI 10.1073/pnas.89.13.5799; COBB MW, 1990, J AM ACAD DERMATOL, V22, P547, DOI 10.1016/0190-9622(90)70073-Q; Coll DA, 1997, AM J OTOLARYNG, V18, P283, DOI 10.1016/S0196-0709(97)90012-0; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; Demeret C, 1998, VIROLOGY, V242, P378, DOI 10.1006/viro.1997.9023; GIRI I, 1985, P NATL ACAD SCI USA, V82, P1580, DOI 10.1073/pnas.82.6.1580; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; HAM J, 1994, EMBO J, V13, P147, DOI 10.1002/j.1460-2075.1994.tb06244.x; HAM J, 1991, EMBO J, V10, P2931, DOI 10.1002/j.1460-2075.1991.tb07843.x; Harris SF, 1999, SCIENCE, V284, P1673, DOI 10.1126/science.284.5420.1673; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hegde RS, 1998, J MOL BIOL, V284, P1479, DOI 10.1006/jmbi.1998.2260; Ilves I, 1999, J VIROL, V73, P4404, DOI 10.1128/JVI.73.5.4404-4412.1999; KASHIMA H, 1993, ANN OTO RHINOL LARYN, V102, P580, DOI 10.1177/000348949310200802; Kovelman R, 1996, J VIROL, V70, P7549, DOI 10.1128/JVI.70.11.7549-7560.1996; KREIDER JW, 1981, ADV CANCER RES, V35, P81, DOI 10.1016/S0065-230X(08)60909-4; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; Lehman CW, 1998, P NATL ACAD SCI USA, V95, P4338, DOI 10.1073/pnas.95.8.4338; LEMOAL MA, 1994, J VIROL, V68, P1085, DOI 10.1128/JVI.68.2.1085-1093.1994; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; MEYERS C, 1991, VIROLOGY, V181, P637, DOI 10.1016/0042-6822(91)90897-K; Morgan IM, 1998, J GEN VIROL, V79, P501, DOI 10.1099/0022-1317-79-3-501; MULLER F, 1994, J BIOL CHEM, V269, P17086; Phelps WC, 1998, ANTIVIR CHEM CHEMOTH, V9, P359, DOI 10.1177/095632029800900501; PICCINI A, 1995, J GEN VIROL, V76, P2909, DOI 10.1099/0022-1317-76-11-2909; RANK NM, 1995, J VIROL, V69, P6323, DOI 10.1128/JVI.69.10.6323-6334.1995; RIESE DJ, 1990, J VIROL, V64, P944, DOI 10.1128/JVI.64.2.944-949.1990; SANDERS CM, 1994, NUCLEIC ACIDS RES, V22, P4890, DOI 10.1093/nar/22.23.4890; Sanders CM, 1998, EMBO J, V17, P7044, DOI 10.1093/emboj/17.23.7044; SANDLER AB, 1993, J VIROL, V67, P5079, DOI 10.1128/JVI.67.9.5079-5087.1993; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sedman T, 1997, J VIROL, V71, P2887, DOI 10.1128/JVI.71.4.2887-2896.1997; SHAH KV, 1988, ANNU REV MED, V39, P371, DOI 10.1146/annurev.med.39.1.371; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; Steger G, 1997, J VIROL, V71, P50, DOI 10.1128/JVI.71.1.50-58.1997; STEGER G, 1995, EMBO J, V14, P329, DOI 10.1002/j.1460-2075.1995.tb07007.x; TAN SH, 1994, J VIROL, V68, P6411, DOI 10.1128/JVI.68.10.6411-6420.1994; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Thain A, 1997, J BIOL CHEM, V272, P8236, DOI 10.1074/jbc.272.13.8236; USHIKAI M, 1994, J VIROL, V68, P6655, DOI 10.1128/JVI.68.10.6655-6666.1994; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x	49	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					867	874		10.1074/jbc.M007120200	http://dx.doi.org/10.1074/jbc.M007120200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11013251	hybrid			2022-12-27	WOS:000166430900003
J	Yousef, GM; Scorilas, A; Jung, K; Ashworth, LK; Diamandis, EP				Yousef, GM; Scorilas, A; Jung, K; Ashworth, LK; Diamandis, EP			Molecular cloning of the human kallikrein 15 gene (KLK15) - Up-regulation in prostate cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNEUM CHYMOTRYPTIC ENZYME; HUMAN GLANDULAR KALLIKREIN; SERINE-PROTEASE; MESSENGER-RNA; SEQUENCE-ANALYSIS; HUMAN NEUROPSIN; EXPRESSION; ANTIGEN; BREAST; IDENTIFICATION	Kallikreins are a subgroup of serine proteases with diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis. By using molecular cloning techniques, we identified a new human kallikrein gene, tentatively named KLK15 (for Kallikrein 15 gene). This new gene maps to chromosome 19q13.4 and is located between the KLK1 and KLK3 genes. KLK15 is formed of five coding exons and four introns, and shows structural similarity to other kallikreins and kallikrein-like genes. KLK15 has three alternatively spliced forms and is primarily expressed in the thyroid gland and to a lower extent in the prostate, salivary, and adrenal glands and in the colon testis and kidney. Our preliminary results indicate that the expression of KLK15 is up-regulated by steroid hormones in the LNCaP prostate cancer cell line. The KLK15 gene is also up-regulated, at the mRNA level, in prostate cancer in comparison to normal prostatic tissue. KLK15 up-regulation was found to be associated with more aggressive forms of prostate cancer. This newly discovered gene has the potential of being used as a diagnostic and/or prognostic marker for prostate cancer.	Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Humboldt Univ, Univ Hosp Berlin, Charite, Dept Urol, D-10048 Berlin, Germany; Lawrence Livermore Natl Lab, Biol & Biotechnol Program, Livermore, CA 94551 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Diamandis, EP (corresponding author), Mt Sinai Hosp, Dept Pathol & Lab Med, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	ediamandis@mtsinai.on.ca	Jung, Klaus/Z-2122-2018	Jung, Klaus/0000-0001-9797-5362; Scorilas, Andreas/0000-0003-2427-4949; Diamandis, Eleftherios/0000-0002-1589-820X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anisowicz A, 1996, MOL MED, V2, P624, DOI 10.1007/BF03401646; ASHLEY PL, 1985, BIOCHEMISTRY-US, V24, P4520, DOI 10.1021/bi00338a006; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Black MH, 1999, CLIN CHEM, V45, P790; CHEN LM, 1994, BRAZ J MED BIOL RES, V27, P1829; CLEMENTS J, 1997, KININ SYSTEM, P71; CUMMING AD, 1994, CLIN SCI, V87, P5, DOI 10.1042/cs0870005; DAYHOFF MO, 1978, NATL BIOMED RES FOUN, V5, P79; Diamandis EP, 2000, CLIN CHEM, V46, P1855; Diamandis EP, 1998, TRENDS ENDOCRIN MET, V9, P310, DOI 10.1016/S1043-2760(98)00082-4; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; Ekholm E, 1999, ARCH DERMATOL RES, V291, P195, DOI 10.1007/s004030050393; EVANS BA, 1987, J BIOL CHEM, V262, P8027; Goyal J, 1998, CANCER RES, V58, P4782; HANSSON L, 1994, J BIOL CHEM, V269, P19420; Heuze N, 1999, CANCER RES, V59, P2820; IIDA Y, 1990, J THEOR BIOL, V145, P523, DOI 10.1016/S0022-5193(05)80486-2; JAFFA AA, 1992, KIDNEY INT, V41, P789, DOI 10.1038/ki.1992.122; Keil B., 1971, ENZYMES, V3, P249, DOI [10.1016/S1874-6047(08)60399-6., 10.1021/bi00843a047, DOI 10.1021/BI00843A047]; Kishi A, 1999, J BIOL CHEM, V274, P4220, DOI 10.1074/jbc.274.7.4220; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kraut H, 1930, H-S Z PHYSIOL CHEM, V189, P97, DOI 10.1515/bchm2.1930.189.3-4.97; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Little SP, 1997, J BIOL CHEM, V272, P25135, DOI 10.1074/jbc.272.40.25135; Liu XL, 1996, CANCER RES, V56, P3371; Luo LY, 1998, BIOCHEM BIOPH RES CO, V247, P580, DOI 10.1006/bbrc.1998.8793; MARGOLIUS HS, 1974, CIRC RES, V35, P820, DOI 10.1161/01.RES.35.6.820; Meyer A, 1997, INT J CANCER, V74, P630, DOI 10.1002/(SICI)1097-0215(19971219)74:6<630::AID-IJC13>3.0.CO;2-9; Mitsui S, 1999, EUR J BIOCHEM, V260, P627, DOI 10.1046/j.1432-1327.1999.00213.x; MIYATA T, 1979, J MOL EVOL, V12, P219, DOI 10.1007/BF01732340; Momota Y, 1998, EUR J NEUROSCI, V10, P760, DOI 10.1046/j.1460-9568.1998.00068.x; Nelson PS, 1999, P NATL ACAD SCI USA, V96, P3114, DOI 10.1073/pnas.96.6.3114; Partin AW, 1999, UROLOGY, V54, P839, DOI 10.1016/S0090-4295(99)00270-8; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REIGMAN PHJ, 1989, BIOCHEM BIOPH RES CO, V159, P95, DOI 10.1016/0006-291X(89)92409-1; RIEGMAN PHJ, 1991, MOL CELL ENDOCRINOL, V76, P181, DOI 10.1016/0303-7207(91)90272-T; RIEGMAN PHJ, 1988, BIOCHEM BIOPH RES CO, V155, P181, DOI 10.1016/S0006-291X(88)81066-0; RIEGMAN PHJ, 1992, GENOMICS, V14, P6, DOI 10.1016/S0888-7543(05)80275-7; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; Sondell B, 1996, ACTA DERM-VENEREOL, V76, P177; Stenman UH, 1999, CLIN CHEM, V45, P753; Tanimoto H, 1999, CANCER, V86, P2074, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2074::AID-CNCR27>3.3.CO;2-V; Underwood LJ, 1999, CANCER RES, V59, P4435; Werle E, 1934, BIOCHEM Z, V269, P415; Yoshida S, 1998, GENE, V213, P9, DOI 10.1016/S0378-1119(98)00232-7; Yousef GM, 2000, GENOMICS, V65, P184, DOI 10.1006/geno.2000.6159; Yousef GM, 2000, J BIOL CHEM, V275, P11891, DOI 10.1074/jbc.275.16.11891; Yousef GM, 2000, BIOCHEM BIOPH RES CO, V276, P125, DOI 10.1006/bbrc.2000.3448; Yousef GM, 1999, CANCER RES, V59, P4252; Yousef GM, 1999, GENOMICS, V62, P251, DOI 10.1006/geno.1999.6012; Yousef GM, 1999, J BIOL CHEM, V274, P37511, DOI 10.1074/jbc.274.53.37511; Yousef GM, 1999, ANTICANCER RES, V19, P2843	55	102	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					53	61		10.1074/jbc.M005432200	http://dx.doi.org/10.1074/jbc.M005432200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11010966	hybrid			2022-12-27	WOS:000166280700009
J	Martin-Belmonte, F; Alonso, MA; Zhang, XQ; Arvan, P				Martin-Belmonte, F; Alonso, MA; Zhang, XQ; Arvan, P			Thyroglobulin is selected as luminal protein cargo for apical transport via detergent-resistant membranes in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEINS; INFLUENZA-VIRUS HEMAGGLUTININ; RAFT-ASSOCIATED PROTEIN; CANINE KIDNEY-CELLS; RAT PAROTID-GLAND; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; MDCK CELLS; POLARIZED SECRETION; MOLECULAR CHAPERONE	Thyroid hormone synthesis by thyrocytes depends upon apical secretion of thyroglobulin (Tg), the glycoprotein prohormone, In stably transfected MDCK cells, recombinant Tg is also secreted apically. All secreted Tg has undergone Golgi carbohydrate modification, whereas most intracellular Tg (which is slow to exit the endoplasmic reticulum) is sensitive to digestion with endoglycosidase H. However, in MDCK cells and PC C13 thyrocytes, a subpopulation of newly synthesized recombinant and endogenous Tg, respectively, is recovered in a Triton X-100 insoluble, glycosphingolipid/cholesterol-enriched (GEM/raft) fraction, and this small subpopulation is overwhelmingly endoglycosidase H resistant. Upon apical secretion, Tg solubility is restored. Apical secretion of Tg is inhibited by cellular cholesterol depletion. In FRT cells, recombinant Tg becomes Triton X-100 insoluble within 60 min after synthesis and a portion is actually endoglycosidase H-sensitive, suggesting early Tg entry into GEMs/rafts, Interestingly in FRT cells,Tg remains associated with the apical plasma membrane upon exocytosis, and all surface Tg is GEM/raft-associated. Thus, Tg is the first secretory protein demonstrated to enter Triton X-100 insoluble membranes en route to the apical surface of epithelial cells. The data imply that Tg utilizes a cargo-selective mechanism for apical sorting.	Albert Einstein Coll Med, Div Endocrinol, Bronx, NY 10461 USA; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Yeshiva University; Albert Einstein College of Medicine	Arvan, P (corresponding author), Albert Einstein Coll Med, Div Endocrinol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	arvan@aecom.yu.edu	Alonso, Miguel A/J-3945-2016; Martin-Belmonte, Fernando/J-8029-2014	Alonso, Miguel A/0000-0002-7001-8826; Martin-Belmonte, Fernando/0000-0002-2564-4430	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040344, R01DK040344] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40344] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; Alonso MA, 1997, J BIOL CHEM, V272, P30748, DOI 10.1074/jbc.272.49.30748; Arvan P, 1997, THYROID, V7, P89, DOI 10.1089/thy.1997.7.89; Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; ARVAN P, 1982, J CELL BIOL, V95, P8, DOI 10.1083/jcb.95.1.8; ARVAN P, 1991, J CELL BIOL, V112, P365, DOI 10.1083/jcb.112.3.365; ARVAN P, 1987, J CELL BIOL, V104, P243, DOI 10.1083/jcb.104.2.243; BALCAROVASTANDER J, 1984, EMBO J, V3, P2687, DOI 10.1002/j.1460-2075.1984.tb02194.x; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; BJORKMAN U, 1978, ENDOCRINOLOGY, V102, P460, DOI 10.1210/endo-102-2-460; Blazquez M, 2000, BIOCHEM J, V349, P843, DOI 10.1042/bj3490843; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CAMERON RS, 1984, J MEMBRANE BIOL, V79, P127, DOI 10.1007/BF01872117; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CHAMBARD M, 1990, J MOL ENDOCRINOL, V4, P193, DOI 10.1677/jme.0.0040193; Cheong KH, 1999, P NATL ACAD SCI USA, V96, P6241, DOI 10.1073/pnas.96.11.6241; DESRUISSEAUGONZALVEZ S, 1993, IN VITRO CELL DEV-AN, V29, P161; Dhanvantari S, 2000, J BIOL CHEM, V275, P29887, DOI 10.1074/jbc.M005364200; EKHOLM R, 1990, INT REV CYTOL, V120, P243; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FORMISANO S, 1983, ARCH BIOCHEM BIOPHYS, V227, P351, DOI 10.1016/0003-9861(83)90463-0; Graichen R, 1996, J BIOL CHEM, V271, P15854, DOI 10.1074/jbc.271.27.15854; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; HERZOG V, 1984, INT REV CYTOL, V91, P107; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; KIM PS, 1991, J BIOL CHEM, V266, P12412; KIM PS, 1993, J BIOL CHEM, V268, P4873; Kim PS, 1996, J CELL BIOL, V133, P517, DOI 10.1083/jcb.133.3.517; Kim PS, 1998, P NATL ACAD SCI USA, V95, P9909, DOI 10.1073/pnas.95.17.9909; KOSTROUCH Z, 1991, ENDOCRINOLOGY, V129, P2202, DOI 10.1210/endo-129-4-2202; Lipardi C, 1999, BIOCHIMIE, V81, P347, DOI 10.1016/S0300-9084(99)80080-7; Lipardi C, 2000, MOL BIOL CELL, V11, P531, DOI 10.1091/mbc.11.2.531; Marino M, 2000, J BIOL CHEM, V275, P7125, DOI 10.1074/jbc.275.10.7125; Marino M, 2000, THYROID, V10, P461, DOI 10.1089/thy.2000.10.461; Marzolo MP, 1997, P NATL ACAD SCI USA, V94, P1834, DOI 10.1073/pnas.94.5.1834; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; MEDEIROSNETO G, 1993, ENDOCR REV, V14, P165, DOI 10.1210/er.14.2.165; Mora R, 1999, J BIOL CHEM, V274, P25708, DOI 10.1074/jbc.274.36.25708; Muniz M, 2000, EMBO J, V19, P10, DOI 10.1093/emboj/19.1.10; Muresan Z, 1997, J BIOL CHEM, V272, P26095, DOI 10.1074/jbc.272.42.26095; Muresan Z, 1998, MOL ENDOCRINOL, V12, P458, DOI 10.1210/me.12.3.458; Parolini I, 1999, J BIOL CHEM, V274, P25718, DOI 10.1074/jbc.274.36.25718; PETELL JK, 1990, EXP CELL RES, V187, P299, DOI 10.1016/0014-4827(90)90095-R; Prabakaran D, 1999, J CELL SCI, V112, P1247; PRABAKARAN D, 1993, J BIOL CHEM, V268, P9041; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Puertollano R, 1999, MOL BIOL CELL, V10, P3435, DOI 10.1091/mbc.10.10.3435; Puertollano R, 1999, J CELL BIOL, V145, P141, DOI 10.1083/jcb.145.1.141; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Zhang XQ, 2000, J BIOL CHEM, V275, P31946, DOI 10.1074/jbc.M003559200; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031; ZURZOLO C, 1992, J CELL BIOL, V117, P551, DOI 10.1083/jcb.117.3.551; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x	57	27	27	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41074	41081		10.1074/jbc.M005429200	http://dx.doi.org/10.1074/jbc.M005429200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11013241	hybrid			2022-12-27	WOS:000166114600056
J	Pruitt, K; Pestell, RG; Der, CJ				Pruitt, K; Pestell, RG; Der, CJ			Ras inactivation of the retinoblastoma pathway by distinct mechanisms in NIH 3T3 fibroblast and RIE-1 epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN D1; DOWN-REGULATION; KINASE CASCADE; G(1) PROGRESSION; S-PHASE; TRANSFORMATION; PROTEIN; EXPRESSION; GROWTH; ACTIVATION	Although Ras and Raf cause transformation of NIH 3T3 fibroblasts, only Ras causes transformation of RIE-1 intestinal epithelial cells. To determine if the inability of Raf to transform RIE-1 cells is due to a failure to deregulate cell cycle progression, we evaluated the consequences of sustained Ras and Raf activation on steady state levels of cyclin D1, p21(CIP/WAF), and p27(KIP1). Both Ras- and Raf-transformed NIH 3T3 cells showed up-regulated expression of cyclin D1, p21, and p27 protein, increased retinoblastoma (Rb) hyperphosphorylation, and increased activation of E2F-mediated transcription. Similarly, Ras transformed RIE-1 cells also showed upregulation of cyclin D1, p21, and hyperphosphorylated Rb, In contrast, Ras-mediated down-regulation of p27 was seen in RIE-1 cells. Conversely, stable expression of activated Raf alone caused only a partial up-regulation of p21 and Rb hyperphosphorylation but no activation of E2F-responsive transcription or down-regulation of p27 in RIE-1 cells. Moreover, we found that the AP-I site was dispensable for Ras-mediated stimulation of the cyclin-D1 promoter in NIH 3T3 cells but was essential for Ras-mediated stimulation in RIE-1 cells. Thus, up-regulation of p21, rather than the down-regulation seen in previous transient expression studies, is seen with sustained Ras activation. Additionally, p27 may serve a positive (NIH 3T3) or negative (RIE-1) regulatory role in Ras transformation that is cell type-dependent. The involvement of Raf and phosphatidylinositol 3-kinase in mediating Ras changes in cyclin D1, pal, and p27 was also very distinct in NIH 3T3 and RIE-1 cells. Taken together, these results demonstrate the importance of Raf-independent pathways in mediating oncogenic Ras deregulation of cell cycle progression in epithelial cells.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Albert Einstein Canc Ctr, Dept Med, Bronx, NY 10461 USA; Albert Einstein Canc Ctr, Dept Dev & Mol Biol, Bronx, NY 10461 USA	University of North Carolina; University of North Carolina Chapel Hill; Yeshiva University; Yeshiva University	Der, CJ (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, CB 7295, Chapel Hill, NC 27599 USA.			Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA55008, CA63071, CA42978] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055008, R01CA063071, R01CA042978] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Arber N, 1996, ONCOGENE, V12, P1903; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BOS JL, 1989, CANCER RES, V49, P4682; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Downward J, 1997, CURR BIOL, V7, P258; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; FILMUS J, 1994, ONCOGENE, V9, P3627; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; Florenes VA, 1996, ONCOGENE, V13, P2447; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; Michieli P, 1996, ONCOGENE, V12, P775; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Phelps DE, 1997, METHOD ENZYMOL, V283, P194; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Rivard N, 1999, AM J PHYSIOL-CELL PH, V277, pC652, DOI 10.1152/ajpcell.1999.277.4.C652; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; YANG JJ, 1996, MOL CELL BIOL, V16, P3370; YEN A, 1994, EUR J CELL BIOL, V65, P103	57	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40916	40924		10.1074/jbc.M006682200	http://dx.doi.org/10.1074/jbc.M006682200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007784	hybrid, Green Published			2022-12-27	WOS:000166114600035
J	Ladoux, A; Frelin, C				Ladoux, A; Frelin, C			Coordinated up-regulation by hypoxia of adrenomedullin and one of its putative receptors (RDC-1) in cells of the rat blood-brain barrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; HUMAN ERYTHROPOIETIN GENE; CYCLIC-AMP FORMATION; ADENYLATE-CYCLASE; TRANSCRIPTIONAL ACTIVATION; INDUCIBLE FACTOR-1; RESPONSE ELEMENTS; MESSENGER-RNA; BINDING-SITES; EXPRESSION	Adrenomedullin (ADM) is a potent hypotensive peptide, which is produced during sepsis and ischemia. We demonstrate here that hypoxia induced a time-dependent increase of both ADM mRNA and protein expressions in cultured astrocytes and endothelial cells from rat brain microvessels. Gene reporter analyses showed a 2-fold increase in ADM gene transcription which was suppressed when the ADM promoter was deleted of its hypoxia responsive element. Hypoxia increased 7-fold the stability of pre-formed ADM mRNAs. Rat brain microvessels expressed mRNAs coding for the different putative ADM receptors but they did not respond to exogenous ADM and calcitonin gene-related peptide by the formation of cAMP. In contrast, ADM and calcitonin gene-related peptide increased the formation of cAMP in astrocytes and their actions were potentiated about 2-fold after hypoxia. Messenger RNA species coding for three putative ADM receptors (the L1 orphan receptor, RDC-1, and calcitonin receptor-like receptor) and accessory proteins (receptor-activity modifying proteins) were present in astrocytes. Hypoxia selectively up-regulated expression of RDC-1 receptor mRNAs. The results indicate that ADM and RDC-1 are hypoxia-sensitive genes and that RDC-1 receptors may mediate some actions of ADM in hypoxic astrocytes.	CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Ladoux, A (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, 660 Route Lucioles, F-06560 Valbonne, France.		LADOUX, ANNIE/S-2077-2019; LADOUX, ANNIE/O-4267-2016	LADOUX, ANNIE/0000-0003-3857-2621; LADOUX, ANNIE/0000-0003-3857-2621				BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BOZOU JC, 1986, MOL PHARMACOL, V29, P489; Chakravarty P, 2000, BRIT J PHARMACOL, V130, P189, DOI 10.1038/sj.bjp.0702975; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; D'Angelo G, 2000, BIOCHEM BIOPH RES CO, V267, P334, DOI 10.1006/bbrc.1999.1947; DEHOUCK MP, 1990, J NEUROCHEM, V54, P1798, DOI 10.1111/j.1471-4159.1990.tb01236.x; Frayon S, 2000, BIOCHEM BIOPH RES CO, V270, P1063, DOI 10.1006/bbrc.2000.2552; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Hofbauer KH, 2000, AM J PHYSIOL-REG I, V278, pR513, DOI 10.1152/ajpregu.2000.278.2.R513; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; ISHIZAKA Y, 1994, BIOCHEM BIOPH RES CO, V200, P642, DOI 10.1006/bbrc.1994.1496; Kapas S, 1995, BIOCHEM BIOPH RES CO, V217, P832, DOI 10.1006/bbrc.1995.2847; KAPAS S, 1995, J BIOL CHEM, V270, P25344, DOI 10.1074/jbc.270.43.25344; Kennedy SP, 1998, BIOCHEM BIOPH RES CO, V244, P832, DOI 10.1006/bbrc.1998.8349; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; LADOUX A, 1991, BIOCHEM BIOPH RES CO, V180, P169, DOI 10.1016/S0006-291X(05)81271-9; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Moreno MJ, 1999, J CEREBR BLOOD F MET, V19, P1270, DOI 10.1097/00004647-199911000-00012; Nagata D, 1999, KIDNEY INT, V55, P1259, DOI 10.1046/j.1523-1755.1999.00361.x; Nakayama M, 1999, PEPTIDES, V20, P769, DOI 10.1016/S0196-9781(99)00061-3; Nakayama M, 1998, BIOCHEM BIOPH RES CO, V243, P514, DOI 10.1006/bbrc.1998.8131; Oliver KR, 1998, MOL BRAIN RES, V57, P149, DOI 10.1016/S0169-328X(98)00052-7; Ono Y, 1998, SHOCK, V10, P243, DOI 10.1097/00024382-199810000-00003; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SHIMEKAKE Y, 1995, J BIOL CHEM, V270, P4412, DOI 10.1074/jbc.270.9.4412; Upton PD, 1997, ENDOCRINOLOGY, V138, P2508, DOI 10.1210/en.138.6.2508; VIGNE P, 1989, J BIOL CHEM, V264, P7663; VIGNE P, 1994, J NEUROCHEM, V62, P2269; Wang G L, 1996, Curr Opin Hematol, V3, P156; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WANG XK, 1995, P NATL ACAD SCI USA, V92, P11480, DOI 10.1073/pnas.92.25.11480; Webb TE, 1996, BRIT J PHARMACOL, V119, P1385, DOI 10.1111/j.1476-5381.1996.tb16050.x; Yoshitomi Y, 1998, CLIN SCI, V94, P135, DOI 10.1042/cs0940135; Zhou M, 1999, BBA-MOL BASIS DIS, V1453, P273, DOI 10.1016/S0925-4439(98)00111-2; Zimmermann U, 1996, BRAIN RES, V724, P238, DOI 10.1016/0006-8993(96)00337-X	44	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39914	39919		10.1074/jbc.M006512200	http://dx.doi.org/10.1074/jbc.M006512200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10980200				2022-12-27	WOS:000166039500019
J	Patel, PH; Loeb, LA				Patel, PH; Loeb, LA			Multiple amino acid substitutions allow DNA polymerases to synthesize RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I KLENOW FRAGMENT; REVERSE-TRANSCRIPTASE; TERNARY COMPLEXES; CRYSTAL-STRUCTURE; SINGLE RESIDUE; PURIFICATION; SITE	DNA and RNA polymerase exhibit similarities in structures and catalytic mechanisms, suggesting that both classes of enzymes are evolutionarily related. To probe the biochemical and structure-function relationship between the two classes of polymerases, a large library (200,000 members) of mutant Thermus aquaticus DNA polymerase I (Taq pol I) was created containing random substitutions within a portion of the dNTP binding site (motif A; amino acids 605-617), and a fraction of all selected active Tag pol I (291 of 8000) was tested for the ability to incorporate successive ribonucleotides; 23 unique mutants that added rNTPs into a growing polynucleotide chain were identified and sequenced. These mutants, each containing one to four substitutions, incorporate ribonucleotides at a efficiency approaching 10(3)-fold greater than that of wild type Tag pol I. Several mutants added successive ribonucleotides and thus can catalyze the synthesis of RNA. Sequence analysis of these mutants demonstrates that at least two amino acid residues are involved in excluding ribonucleotides from the active site. Interestingly, wild type DNA polymerases from several distinct families selectively discriminate against rUTP. This study suggests that current DNA and RNA polymerases could have evolved by divergent evolution from an ancestor that shared a common mechanism for polynucleotide synthesis.	Univ Washington, Sch Med, Dept Pathol, Joseph Gottstein Mem Canc Lab, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Loeb, LA (corresponding author), Univ Washington, Sch Med, Dept Pathol, Joseph Gottstein Mem Canc Lab, Seattle, WA 98195 USA.	laloeb@u.washington.edu			NATIONAL CANCER INSTITUTE [R35CA039903, R01CA078885] Funding Source: NIH RePORTER; NCI NIH HHS [R35CA39903, CA78885] Funding Source: Medline; PHS HHS [5T3207266] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Astatke M, 1998, P NATL ACAD SCI USA, V95, P3402, DOI 10.1073/pnas.95.7.3402; BARNES WM, 1978, J MOL BIOL, V119, P83, DOI 10.1016/0022-2836(78)90271-1; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Bonnin A, 1999, J MOL BIOL, V290, P241, DOI 10.1006/jmbi.1999.2900; BONURA T, 1982, BIOCHEMISTRY-US, V21, P2548, DOI 10.1021/bi00539a039; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DESAI UJ, 1995, BIOTECHNIQUES, V19, P780; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; DUNCAN BK, 1982, J BACTERIOL, V151, P750, DOI 10.1128/JB.151.2.750-755.1982; ENGELKE DR, 1990, ANAL BIOCHEM, V191, P396, DOI 10.1016/0003-2697(90)90238-5; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; GRIMM E, 1995, NUCLEIC ACIDS RES, V23, P4518, DOI 10.1093/nar/23.21.4518; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Joyce GF, 1996, CURR BIOL, V6, P965, DOI 10.1016/S0960-9822(02)00640-1; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; Kornberg A., 1992, DNA REPLICATION; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; Moreira LM, 1997, ARCH MICROBIOL, V168, P92, DOI 10.1007/s002030050474; OLIVERA BM, 1979, J MOL BIOL, V128, P265, DOI 10.1016/0022-2836(79)90087-1; Patel PH, 2000, P NATL ACAD SCI USA, V97, P5095, DOI 10.1073/pnas.97.10.5095; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361	28	84	89	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40266	40272		10.1074/jbc.M005757200	http://dx.doi.org/10.1074/jbc.M005757200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11005812	hybrid			2022-12-27	WOS:000166039500065
J	Abdulaev, NG; Ngo, T; Chen, RW; Lu, ZJ; Ridge, KD				Abdulaev, NG; Ngo, T; Chen, RW; Lu, ZJ; Ridge, KD			Functionally discrete mimics of light-activated rhodopsin identified through expression of soluble cytoplasmic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; C-TERMINAL PEPTIDES; CONNECTING HELIX-C; F LOOP REGION; ESCHERICHIA-COLI; BOVINE RHODOPSIN; DEPENDENT PHOSPHORYLATION; CONSTITUTIVE ACTIVATION; CONFORMATIONAL-CHANGES; TRANSDUCIN ACTIVATION	Numerous studies on the seven-helix receptor rhodopsin have implicated the cytoplasmic loops and carboxyl-terminal region in the binding and activation of proteins involved in visual transduction and desensitization. In our continuing studies on rhodopsin folding, assembly, and structure, we have attempted to reconstruct the interacting surface(s) for these proteins by inserting fragments corresponding to the cytoplasmic loops and/or the carboxyl-terminal tail of bovine opsin either singly, or in combination, onto a surface loop in thioredoxin. The purpose of the thioredoxin fusion is to provide a soluble scaffold for the cytoplasmic fragments thereby allowing them sufficient conformational freedom to fold to a structure that mimics the protein-binding sites on light-activated rhodopsin. All of the fusion proteins are expressed to relatively high levels in Escherichia coli and can be purified using a two- or three-step chromatography procedure. Biochemical studies show that some of the fusion proteins effectively mimic the activated conformation(s) of rhodopsin in stimulating G-protein or competing with the light-activated rhodopsin/G-protein interaction, in supporting phosphorylation of the carboxyl-terminal opsin fragment by rhodopsin kinase, and/or phosphopeptide-stimulated arrestin binding. These results suggest that specific segments of the cytoplasmic surface of rhodopsin can adopt functionally discrete conformations in the absence of the connecting transmembrane helices and retinal chromophore.	NIST, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Univ Maryland, Inst Biotechnol, Rockville, MD 20850 USA; Genet Inst Inc, Cambridge, MA 02140 USA	National Institute of Standards & Technology (NIST) - USA; University System of Maryland; University of Maryland Baltimore	Ridge, KD (corresponding author), NIST, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA.				NATIONAL EYE INSTITUTE [R55EY011112, R29EY011112] Funding Source: NIH RePORTER; NEI NIH HHS [EY11112] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; Acharya S, 1997, J BIOL CHEM, V272, P6519, DOI 10.1074/jbc.272.10.6519; Acharya S, 1996, J BIOL CHEM, V271, P25406, DOI 10.1074/jbc.271.41.25406; Altenbach C, 1999, BIOCHEMISTRY-US, V38, P7931, DOI 10.1021/bi9900121; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Altenbach C, 1999, BIOCHEMISTRY-US, V38, P7945, DOI 10.1021/bi990014l; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BROWN NG, 1992, EUR J BIOCHEM, V208, P659, DOI 10.1111/j.1432-1033.1992.tb17232.x; Cai KW, 1999, BIOCHEMISTRY-US, V38, P7925, DOI 10.1021/bi9900119; Chen GQ, 1998, PROTEIN SCI, V7, P2623, DOI 10.1002/pro.5560071216; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; DONOSO LA, 1990, CURR EYE RES, V9, P343, DOI 10.3109/02713689008999622; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; Frayser M, 1999, PROTEIN EXPRES PURIF, V15, P105, DOI 10.1006/prep.1998.0987; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUY PM, 1990, BIOCHEMISTRY-US, V29, P6954, DOI 10.1021/bi00482a003; Han M, 1998, BIOCHEMISTRY-US, V37, P8253, DOI 10.1021/bi980147r; HAWES BE, 1994, J BIOL CHEM, V269, P15776; Herzyk P, 1998, J MOL BIOL, V281, P741, DOI 10.1006/jmbi.1998.1981; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HOFMANN KP, 1999, RHODOPSINS PHOTOTRAN, P158; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; Kim JM, 1997, P NATL ACAD SCI USA, V94, P14273, DOI 10.1073/pnas.94.26.14273; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; KUHN H, 1982, BIOCHIM BIOPHYS ACTA, V679, P95, DOI 10.1016/0005-2728(82)90259-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; LI TS, 1995, P NATL ACAD SCI USA, V92, P3551, DOI 10.1073/pnas.92.8.3551; Lu ZJ, 1996, J BIOL CHEM, V271, P5059; MAO QC, 1995, J BIOL CHEM, V270, P18295, DOI 10.1074/jbc.270.31.18295; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; McDowell JH, 1999, BIOCHEMISTRY-US, V38, P6119, DOI 10.1021/bi990175p; Melia TJ, 1997, BIOPHYS J, V73, P3182, DOI 10.1016/S0006-3495(97)78344-9; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIN KC, 1993, J BIOL CHEM, V268, P9400; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; PAULSEN R, 1983, NATURE, V302, P417, DOI 10.1038/302417a0; PELLICONE C, 1985, BIOCHEM BIOPH RES CO, V127, P816, DOI 10.1016/S0006-291X(85)80016-4; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Pogozheva ID, 1997, BIOPHYS J, V72, P1963, DOI 10.1016/S0006-3495(97)78842-8; PUIG J, 1995, FEBS LETT, V362, P185, DOI 10.1016/0014-5793(95)00225-X; Raman D, 1999, BIOCHEMISTRY-US, V38, P5117, DOI 10.1021/bi9824588; Rao VR, 1996, ANNU REV BIOPH BIOM, V25, P287; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P8804, DOI 10.1021/bi00027a032; Ridge KD, 1996, J BIOL CHEM, V271, P7860, DOI 10.1074/jbc.271.13.7860; RIDGE KD, 1995, P NATL ACAD SCI USA, V92, P3204, DOI 10.1073/pnas.92.8.3204; Ridge KD, 1999, J BIOL CHEM, V274, P21437, DOI 10.1074/jbc.274.30.21437; RIM J, 1995, BIOCHEMISTRY-US, V34, P11938, DOI 10.1021/bi00037a035; Rim J, 1997, BIOCHEMISTRY-US, V36, P7064, DOI 10.1021/bi970470e; ROBINSON PR, 1994, P NATL ACAD SCI USA, V91, P5411, DOI 10.1073/pnas.91.12.5411; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5467; SHI W, 1995, J BIOL CHEM, V270, P2112, DOI 10.1074/jbc.270.5.2112; Shi W, 1998, BIOCHEMISTRY-US, V37, P4869, DOI 10.1021/bi9731100; Struthers M, 1999, BIOCHEMISTRY-US, V38, P6597, DOI 10.1021/bi9902384; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; TAKEMOTO DJ, 1986, BIOCHEM J, V235, P309, DOI 10.1042/bj2350309; Thurmond RL, 1997, P NATL ACAD SCI USA, V94, P1715, DOI 10.1073/pnas.94.5.1715; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P5654, DOI 10.1021/bi00139a032; WEISS ER, 1988, J BIOL CHEM, V263, P6150; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3967; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t; Yeagle PL, 1997, BIOCHEMISTRY-US, V36, P9649, DOI 10.1021/bi970908a; YEAGLE PL, 1995, BIOCHEMISTRY-US, V34, P14621, DOI 10.1021/bi00045a002; YEAGLE PL, 1995, NAT STRUCT BIOL, V2, P832, DOI 10.1038/nsb1095-832; Yeagle PL, 1997, BIOCHEMISTRY-US, V36, P3864, DOI 10.1021/bi962403a; YEAGLE PL, 1996, MOL VISION, V2; Yu HB, 1999, BIOCHEMISTRY-US, V38, P12033, DOI 10.1021/bi9909492; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002	89	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39354	39363		10.1074/jbc.M005642200	http://dx.doi.org/10.1074/jbc.M005642200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10988291	hybrid			2022-12-27	WOS:000165953100058
J	Larouche, K; Leclerc, S; Salesse, C; Guerin, SL				Larouche, K; Leclerc, S; Salesse, C; Guerin, SL			Expression of the alpha(5) integrin subunit gene promoter is positively regulated by the extracellular matrix component fibronectin through the transcription factor Sp1 in corneal epithelial cells in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; DNA-BINDING; BASEMENT-MEMBRANE; GROWTH-FACTOR; 5-FLANKING REGION; ONCOSTATIN M; RECEPTOR; KINASE; SITE; PHOSPHORYLATION	The accumulation of fibronectin (FN) in response to corneal epithelium injury has been postulated to turn on expression of the FN-binding integrin alpha (5)beta (1). In this work, we determined whether the activity directed by the ct, gene promoter can be modulated by FN in rabbit corneal epithelial cells (RCEC). The activity driven by chloramphenicol acetyltransferase/alpha (5) promoter-bearing plasmids was drastically increased when transfected into RCEC grown on FN-coated culture dishes. The promoter sequence mediating FN responsiveness was shown to bear a perfect inverted repeat that we designated the fibronectin-responsive element (FRE). Analyses in electrophoretic mobility shift assays provided evidence that Spl is the predominant transcription factor binding the FRE. Its DNA binding affinity was found to be increased when RCEC are grown on FN-coated dishes. The addition of the MER kinase inhibitor PD98059 abolished FN responsiveness suggesting that alteration in the state of phosphorylation of Spl likely accounts for its increased binding to the a, FRE. The FRE also proved sufficient to confer FN responsiveness to an otherwise unresponsive heterologous promoter. However, site-directed mutagenesis indicated that only the 3 ' half-site of the FRE was required to direct FN responsiveness. Collectively, binding of FN to its alpha (5)beta (1) integrin activates a signal transduction pathway that results in the transcriptional activation of the alpha (5) gene likely through altering the phosphorylation state of Sp1.	CHU Laval, Res Ctr, Oncol & Mol Endocrinol Res Ctr, Quebec City, PQ G1V 4G2, Canada; CHU Laval, CHUQ, Ophthalmol Res Unit, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University; Laval University	Guerin, SL (corresponding author), CHU Laval, Res Ctr, Oncol & Mol Endocrinol Res Ctr, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	Sylvain.guerin@crchul.ulaval.ca		Salesse, Christian/0000-0003-1795-7338; Guerin, Sylvain/0000-0002-6767-5833				Alroy I, 1999, MOL CELL BIOL, V19, P1961; ARAKI K, 1994, CURR EYE RES, V13, P203, DOI 10.3109/02713689408995778; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; BALDWIN TJ, 1989, NATURE, V341, P716, DOI 10.1038/341716a0; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BOISJOLY HM, 1993, EXP EYE RES, V57, P293, DOI 10.1006/exer.1993.1127; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; CAI XX, 1993, INVEST OPHTH VIS SCI, V34, P3585; CHEN QM, 1994, J BIOL CHEM, V269, P26602; DALTON SL, 1992, J BIOL CHEM, V267, P8186; DEVRIES E, 1987, EMBO J, V6, P161, DOI 10.1002/j.1460-2075.1987.tb04734.x; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ESKILD W, 1994, MOL ENDOCRINOL, V8, P732, DOI 10.1210/me.8.6.732; ESPAILLAT A, 1994, CURR EYE RES, V13, P325, DOI 10.3109/02713689409167295; FUJIKAWA LS, 1981, LAB INVEST, V45, P120; FUJIKAWA LS, 1984, J CELL BIOL, V98, P128, DOI 10.1083/jcb.98.1.128; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GARANA RMR, 1992, INVEST OPHTH VIS SCI, V33, P3271; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; GUERIN SL, 1990, J BIOL CHEM, V265, P22035; Gundorova R A, 1994, Eur J Ophthalmol, V4, P202; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUANG S, 1994, J CELL PHYSIOL, V161, P470, DOI 10.1002/jcp.1041610310; HUMPHRIES MJ, 1989, CANCER INVEST, V7, P373, DOI 10.3109/07357908909039866; HYNES RO, 1986, SCI AM, V254, P42, DOI 10.1038/scientificamerican0686-42; Laniel MA, 1997, BIOCHEM CELL BIOL, V75, P427, DOI 10.1139/bcb-75-4-427; Li C, 1999, J BIOL CHEM, V274, P6747, DOI 10.1074/jbc.274.10.6747; Lin CS, 1997, DNA CELL BIOL, V16, P929, DOI 10.1089/dna.1997.16.929; Liu JW, 1997, J LIPID RES, V38, P2035; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; MILLS JS, 1987, EMBO J, V6, P3711, DOI 10.1002/j.1460-2075.1987.tb02705.x; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MOORADIAN DL, 1993, INVEST OPHTH VIS SCI, V34, P153; MURAKAMI J, 1992, J LAB CLIN MED, V120, P86; Nakamura M, 1997, EXP EYE RES, V64, P1043, DOI 10.1006/exer.1997.0302; NISHIDA T, 1988, INVEST OPHTH VIS SCI, V29, P1820; NISHIDA T, 1990, J CELL PHYSIOL, V145, P549, DOI 10.1002/jcp.1041450323; OHagan RC, 1996, ONCOGENE, V13, P1323; Omigbodun A, 1998, ENDOCRINOLOGY, V139, P2190, DOI 10.1210/en.139.4.2190; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; Rajagopal S, 1997, J CELL PHYSIOL, V170, P138, DOI 10.1002/(SICI)1097-4652(199702)170:2<138::AID-JCP5>3.0.CO;2-P; REGNAULT V, 1990, REV FR TRANSFUS HEM, V33, P391, DOI 10.1016/S1140-4639(05)80056-5; Reim M, 1997, PROG RETIN EYE RES, V16, P183, DOI 10.1016/S1350-9462(96)00031-6; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3796, DOI 10.1128/MCB.12.9.3796; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; ROY RJ, 1991, BIOTECHNIQUES, V11, P770; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SAIKA S, 1993, CORNEA, V12, P383, DOI 10.1097/00003226-199309000-00003; SCHNEIDER R, 1986, NUCLEIC ACIDS RES, V14, P1303, DOI 10.1093/nar/14.3.1303; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SRAMEK SJ, 1987, INVEST OPHTH VIS SCI, V28, P500; Stepp MA, 1997, J HISTOCHEM CYTOCHEM, V45, P189, DOI 10.1177/002215549704500205; Stepp MA, 1996, INVEST OPHTH VIS SCI, V37, P1593; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; SUSKE G, 2000, METHOD MOL BIOL, V130, P176; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tuori A, 1996, CORNEA, V15, P286, DOI 10.1097/00003226-199605000-00010; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZHU L, 1996, INVEST OPHTH VIS SCI, V37, pS1011; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689	63	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39182	39192		10.1074/jbc.M002945200	http://dx.doi.org/10.1074/jbc.M002945200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995740	hybrid			2022-12-27	WOS:000165953100034
J	Mueller, HT; Borg, JP; Margolis, B; Turner, RS				Mueller, HT; Borg, JP; Margolis, B; Turner, RS			Modulation of amyloid precursor protein metabolism by X11 alpha/Mint-1 - A deletion analysis of protein-protein interaction domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN; INTRACELLULAR DOMAIN; NMDA RECEPTOR; FE65 PROTEIN; X11 PROTEIN; COMPLEX; FAMILY; ASSOCIATION; SECRETION; HOMOLOG	Modulation of amyloid precursor protein (APP) metabolism plays a pivotal role in the pathogenesis of Alzheimer's disease. The phosphotyrosine-binding/protein interaction (PTB/PI) domain of X11 alpha, a neuronal cytosolic adaptor protein, binds to the YENPTY sequence in the cytoplasmic carboxyl terminus of APP. This interaction prolongs the half-life of APP and inhibits A beta 40 and A beta 42 secretion. X11 alpha /Mint-1 has multiple protein-protein interaction domains, a (M) under bar unc-18 (int) under bar eraction domain (MID), a Cask/Lin-2 interaction domain (CID), a PTB/PI domain, and two PDZ domains. These X11 alpha protein interaction domains may modulate its effect on APP processing. To test this hypothesis, we performed a deletion analysis of X11 alpha: effects on metabolism of APP,,, Swedish (K595N/M596L) (APP,) by transient cotransfection of HEK 293 cells with: 1) X11 alpha (X11 alpha -wt, N-MID-CID-PTB-PDZ-PDZ-C), 2) amino-terminal deletion (X11 alpha-DeltaN, PTB-PDZ-PDZ), 3) carboxyl-terminal deletion (X11 alpha-Delta PDZ, MID-CID-PTB), or 4) deletion of both termini (PTB domain only, PTB), The carboxyl terminus of X11 alpha was required for stabilization of APP, in cells. In contrast, the amino terminus of X11 alpha was required to stimulate APPs secretion. X11 alpha, X11 alpha-DeltaN, and X11 alpha -PTB, but not X11 alpha-Delta PDZ, were effective inhibitors of A beta 40 and A beta 42 secretion. These results suggest that additional protein interaction domains of X11 alpha modulate various aspects of APP metabolism.	Univ Michigan, Med Ctr, Program Neurosci, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Neurol, Ann Arbor, MI 48109 USA; Vet Adm Med Ctr, GRECC, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Turner, RS (corresponding author), Vet Adm Med Ctr, GRECC, 2215 Fuller Rd, Ann Arbor, MI 48105 USA.	raymondt@umich.edu	Borg, Jean-Paul/AAX-8096-2020; Turner, Raymond Scott/G-2263-2011	Borg, Jean-Paul/0000-0001-8418-3382; Turner, Raymond Scott/0000-0001-7534-2935	NATIONAL INSTITUTE ON AGING [P50AG008671] Funding Source: NIH RePORTER; NIA NIH HHS [P50 AG08671, P50 AG008671] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1999, J NEUROSCI, V19, P1307; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Bredt DS, 1998, CELL, V94, P691, DOI 10.1016/S0092-8674(00)81727-4; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Davis GW, 2000, NEURON, V26, P551, DOI 10.1016/S0896-6273(00)81190-3; De Strooper B, 2000, J CELL SCI, V113, P1857; Duilio A, 1998, BIOCHEM J, V330, P513, DOI 10.1042/bj3300513; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Forman MS, 1997, J BIOL CHEM, V272, P32247, DOI 10.1074/jbc.272.51.32247; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Guenette SY, 1999, J NEUROCHEM, V73, P985, DOI 10.1046/j.1471-4159.1999.0730985.x; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Homayouni R, 1999, J NEUROSCI, V19, P7507, DOI 10.1523/JNEUROSCI.19-17-07507.1999; Ide N, 1998, BIOCHEM BIOPH RES CO, V244, P258, DOI 10.1006/bbrc.1998.8243; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lee DS, 2000, J BIOL CHEM, V275, P23134, DOI 10.1074/jbc.C000302200; MARTIN BL, 1995, J BIOL CHEM, V270, P26727, DOI 10.1074/jbc.270.45.26727; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; McLoughlin DM, 1999, EUR J NEUROSCI, V11, P1988, DOI 10.1046/j.1460-9568.1999.00610.x; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; Perez RG, 1997, J NEUROSCI, V17, P9407; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Rao A, 2000, NAT NEUROSCI, V3, P747, DOI 10.1038/77636; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Tanahashi H, 1999, BIOCHEM BIOPH RES CO, V255, P663, DOI 10.1006/bbrc.1999.0265; Tanahashi H, 1999, NEUROREPORT, V10, P2575, DOI 10.1097/00001756-199908200-00025; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Torroja L, 1999, J NEUROSCI, V19, P7793; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Whitfield CW, 1999, MOL BIOL CELL, V10, P2087, DOI 10.1091/mbc.10.6.2087; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141	48	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39302	39306		10.1074/jbc.M008453200	http://dx.doi.org/10.1074/jbc.M008453200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11010978	hybrid			2022-12-27	WOS:000165953100050
J	Overall, CM; Tam, E; McQuibban, GA; Morrison, C; Wallon, UM; Bigg, HF; King, AE; Roberts, CR				Overall, CM; Tam, E; McQuibban, GA; Morrison, C; Wallon, UM; Bigg, HF; King, AE; Roberts, CR			Domain interactions in the gelatinase A center dot TIMP-2 center dot MT1-MMP activation complex - The ectodomain of the 44-kDa form of membrane type-I matrix metalloproteinase does not modulate gelatinase A activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; HUMAN 72-KDA GELATINASE; HIGH-AFFINITY BINDING; HEMOPEXIN-LIKE DOMAIN; 72 KDA PROGELATINASE; TISSUE INHIBITOR; CELL-SURFACE; EXTRACELLULAR-MATRIX; FULL-LENGTH; CRYSTAL-STRUCTURE	On the cell surface, the 59-kDa membrane type I-matrix metalloproteinase (MT1-MMP) activates the 72-kDa progelatinase A (MMP-2) after binding the tissue inhibitor of metalloproteinases (TIMP)-2, A 44-kDa remnant of MT1-MMP, with an N terminus at Gly(285), is also present on the cell after autolytic shedding of the catalytic domain from the hemopexin carboxyl (C) domain, but its role in gelatinase A activation is unknown. We investigated intermolecular interactions in the gelatinase A activation complex using recombinant proteins, domains, and peptides, yeast two-hybrid analysis, solid- and solution-phase assays, cell culture, and immunocytochemistry, A strong interaction between the TIMP-2 C domain (Glu(153)-Pro(221)) and the gelatinase A hemopexin C domain (Gly(446)-Cys(660)) was demonstrated by the yeast two-hybrid system, Epitope masking studies showed that the anionic TIMP-2 C tail lost immunoreactivity after binding, indicating that the tail was buried in the complex. Using recombinant MT1-MMP hemopexin C domain (Gly(285)-Cys(508)), no direct role for the 44-kDa form of MT1-MMP in cell surface activation of progelatinase A was found, Exogenous hemopexin C domain of gelatinase A, but not that of MT1-MMP, blocked the cleavage of the 68-kDa gelatinase A activation intermediate to the fully active 66-kDa enzyme by concanavalin A-stimulated cells. The MT1-MMP hemopexin C domain did not form homodimers nor did it bind the gelatinase A hemopexin C domain, the C tail of TIMP-2, or full-length TIMP-2, Hence, the ectodomain of the remnant 44-kDa form of MT1-MMP appears to play little if any role in the activation of gelatinase A favoring the hypothesis that it accumulates on the cell surface as an inactive, stable degradation product.	Univ British Columbia, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Overall, CM (corresponding author), Univ British Columbia, Dept Oral Biol & Med Sci, 2199 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.							Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; AZZAM HS, 1992, CANCER RES, V52, P4540; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; CRABBE T, 1993, EUR J BIOCHEM, V218, P431, DOI 10.1111/j.1432-1033.1993.tb18393.x; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Ellerbroek SM, 1999, CANCER RES, V59, P1635; EMMERTBUCK MR, 1995, FEBS LETT, V364, P28, DOI 10.1016/0014-5793(95)00345-A; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; Gilles C, 1997, LAB INVEST, V76, P651; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Higashi S, 1999, J BIOL CHEM, V274, P10497, DOI 10.1074/jbc.274.15.10497; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; Hutton M, 1998, BIOCHEMISTRY-US, V37, P10094, DOI 10.1021/bi980616p; Itoh Y, 1998, J BIOL CHEM, V273, P24360, DOI 10.1074/jbc.273.38.24360; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LIBSON AM, 1995, NAT STRUCT BIOL, V2, P938, DOI 10.1038/nsb1195-938; Miller J.H., 1972, EXPT MOL GENETICS; Morrison CJ, 1997, BIOTECHNOL BIOENG, V53, P594, DOI 10.1002/(SICI)1097-0290(19970320)53:6<594::AID-BIT7>3.3.CO;2-M; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Olsen M.W., 1997, J BIOL CHEM, V272, P29975; Overall CM, 1999, J BIOL CHEM, V274, P4421, DOI 10.1074/jbc.274.7.4421; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Stanton H, 1998, J CELL SCI, V111, P2789; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; Steffensen B, 1998, J BIOL CHEM, V273, P20622, DOI 10.1074/jbc.273.32.20622; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILCHEK M, 1980, BIOCHEM BIOPH RES CO, V92, P1215, DOI 10.1016/0006-291X(80)90416-7; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Wingfield PT, 1999, J BIOL CHEM, V274, P21362, DOI 10.1074/jbc.274.30.21362; ZUCKER S, 1990, INT J CANCER, V45, P1137, DOI 10.1002/ijc.2910450625	52	82	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39497	39506		10.1074/jbc.M005932200	http://dx.doi.org/10.1074/jbc.M005932200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10991943	hybrid			2022-12-27	WOS:000165953100076
J	Ram, PK; Waxman, DJ				Ram, PK; Waxman, DJ			Role of the cytokine-inducible SH2 protein CIS in desensitization of STAT5b signaling by continuous growth hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOCS-BOX MOTIF; TYROSINE PHOSPHORYLATION; RAT-LIVER; SEXUAL DIMORPHISM; GENE-EXPRESSION; CYTOPLASMIC DOMAIN; BINDING PROTEIN; DOWN-REGULATION; GH RECEPTOR; ACTIVATION	Growth hormone (GH)-inducible suppressors of cytokine signaling (SOCS/CIS proteins) inhibit GH receptor (GHR) signaling to STAT5b via phosphotyrosine-dependent binding interactions with the tyrosine kinase JAK2 (SOCS-1) and/or the cytoplasmic tail of GHR (CIS and SOCS-3). Presently, we investigate the mechanism of CLS inhibition and CIS's role in down-regulating GHR JAK2 signaling to STAT5b in cells exposed to GH continuously, CLS is shown to inhibit GHR-JAK2 signaling by two distinct mechanisms: by a partial inhibition that is decreased at elevated STAT5b levels and may involve competition between CLS and STAT5b for common GHR cytoplasmic tail phosphotyrosine-binding sites; and by a time-dependent inhibition, not seen with SOCS-1 or SOCS-3, that involves proteasome action. Investigation of the latter mechanism revealed that GH stimulates degradation of CIS, but not SOCS-3, The proteasome inhibitor MG132 blocked this protein degradation and also blocked the inhibitory action of CIS, but not that of SOCS-1 or SOCS-3, on STAT5b signaling. Proteasome-dependent degradation of CIS, most likely in the form of a (GHR-JAK2)-CIS complex, is therefore proposed to be an important step in the time-dependent CIS inhibition mechanism. Finally, the down-regulation of GHR-JAK2 signaling to STAT5b seen in continuous GH-treated cells could be prevented by treatment of cells with the proteasome inhibitor MG132 or by expression of CIS-R107K, a selective, dominant-negative inhibitor of CIS activity. These findings lead us to propose that the cytokine signaling inhibitor CIS is a key mediator of the STAT5b desensitization response seen in cells and tissues exposed to GH chronically, such as adult female rat liver.	Boston Univ, Dept Biol, Div Cell & Mol Biol, Boston, MA 02215 USA	Boston University	Waxman, DJ (corresponding author), Boston Univ, Dept Biol, Div Cell & Mol Biol, 5 Cummington St, Boston, MA 02215 USA.			Waxman, David/0000-0001-7982-9206	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033765] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK033765, DK33765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; ALLEVATO G, 1995, J BIOL CHEM, V270, P17210, DOI 10.1074/jbc.270.29.17210; Aman MJ, 1999, J BIOL CHEM, V274, P30266, DOI 10.1074/jbc.274.42.30266; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; Choi HK, 1999, ENDOCRINOLOGY, V140, P5126, DOI 10.1210/en.140.11.5126; Choi HK, 2000, ENDOCRINOLOGY, V141, P3245, DOI 10.1210/en.141.9.3245; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Davey HW, 1999, AM J HUM GENET, V65, P959, DOI 10.1086/302599; Davey HW, 1999, J BIOL CHEM, V274, P35331, DOI 10.1074/jbc.274.50.35331; Davey HW, 1999, MOL CELL ENDOCRINOL, V158, P111, DOI 10.1016/S0303-7207(99)00175-6; Fernandez L, 1998, ENDOCRINOLOGY, V139, P1815, DOI 10.1210/en.139.4.1815; Ganguly TC, 1997, J CLIN INVEST, V99, P2906, DOI 10.1172/JCI119485; Gebert CA, 1999, MOL ENDOCRINOL, V13, P213, DOI 10.1210/me.13.2.213; Gebert CA, 1999, MOL ENDOCRINOL, V13, P38, DOI 10.1210/me.13.1.38; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Hackett RH, 1997, J BIOL CHEM, V272, P11128; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Hansen JA, 1997, J MOL ENDOCRINOL, V18, P213, DOI 10.1677/jme.0.0180213; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Karlsson H, 1999, MOL CELL ENDOCRINOL, V154, P37, DOI 10.1016/S0303-7207(99)00101-X; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Maamra M, 1999, J BIOL CHEM, V274, P14791, DOI 10.1074/jbc.274.21.14791; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1999, MOL CELL BIOL, V19, P6396; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Okabe S, 1999, EXP HEMATOL, V27, P1542, DOI 10.1016/S0301-472X(99)00094-6; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; Pezet A, 1999, J BIOL CHEM, V274, P24497, DOI 10.1074/jbc.274.35.24497; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tollet-Egnell P, 1999, ENDOCRINOLOGY, V140, P3693, DOI 10.1210/en.140.8.3693; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Vleurick L, 1999, MOL ENDOCRINOL, V13, P1823, DOI 10.1210/me.13.11.1823; Wang XZ, 1996, MOL ENDOCRINOL, V10, P1249, DOI 10.1210/me.10.10.1249; Waxman D J, 2000, Novartis Found Symp, V227, P61; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; Waxman DJ, 2000, PRINCIPLES OF MOLECULAR REGULATION, P55; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425; Yoshimura A, 1998, CYTOKINE GROWTH F R, V9, P197, DOI 10.1016/S1359-6101(98)00019-7; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	60	91	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39487	39496		10.1074/jbc.M004755200	http://dx.doi.org/10.1074/jbc.M004755200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10991939	hybrid			2022-12-27	WOS:000165953100075
J	Hatley, ME; Benton, BK; Xu, J; Manfredi, JP; Gilman, AG; Sunahara, RK				Hatley, ME; Benton, BK; Xu, J; Manfredi, JP; Gilman, AG; Sunahara, RK			Isolation and characterization of constitutively active mutants of mammalian adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC MECHANISM; GUANYLYL CYCLASES; CYTOSOLIC DOMAINS; CRYSTAL-STRUCTURE; POLYMERASE-I; FORSKOLIN; COMPLEX; CONSTRUCTION; G(S-ALPHA)	A genetic screen in Saccharomyces cerevisiae identified mutations in mammalian adenylyl cyclase that activate the enzyme in the absence of G(s)alpha. Thirteen of these mutant proteins were characterized biochemically in an assay system that depends on a mixture of the two cytosolic domains (C-1 and C-2) of mammalian adenylyl cyclases. Three mutations, I1010M, K1014N, and P1015Q located in the beta4-beta5 loop of the C-2 domain of type Il adenylyl cyclase, increase enzymatic activity in the absence of activators. The K1014N mutation displays both increased maximal activity and apparent affinity for the C-2 domain of type II adenylyl cyclase in the absence of activators of the enzyme. The increased affinity of the mutant C-2 domain of adenylyl cyclase for the wild type C-1 domain was exploited to isolate a complex containing VC1, IIC2, and G(s)alpha -guanosine 5'-3-O-(thio)triphosphate (GTP gammaS) in the absence of forskolin and a complex of VC1, IIC2, forskolin, and P-site inhibitor in the absence of G(s)alpha -GTP gammaS. The isolation of these complexes should facilitate solution of crystal structures of low activity states of adenylyl cyclase and thus determination of the mechanism of activation of the enzyme by forskolin and G(s)alpha.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Cadus Pharmaceut Corp, New York, NY 10153 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gilman, AG (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Sunahara, Roger/AAJ-8667-2020; Hatley, Mark Edward/G-8764-2018	Hatley, Mark Edward/0000-0001-7147-3946	NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artymiuk PJ, 1997, NATURE, V388, P33, DOI 10.1038/40310; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLARKE L, 1980, NATURE, V287, P504, DOI 10.1038/287504a0; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEE E, 1994, METHOD ENZYMOL, V237, P146; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; Rose MD., 1990, METHODS YEAST GENETI; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Smit Martine J., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P1; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 1997, J BIOL CHEM, V272, P12342, DOI 10.1074/jbc.272.19.12342; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; Zimmermann G, 1999, MOL PHARMACOL, V56, P895, DOI 10.1124/mol.56.5.895; Zimmermann G, 1998, J BIOL CHEM, V273, P6968, DOI 10.1074/jbc.273.12.6968; Zimmermann G, 1998, J BIOL CHEM, V273, P19650, DOI 10.1074/jbc.273.31.19650	29	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38626	38632		10.1074/jbc.M007148200	http://dx.doi.org/10.1074/jbc.M007148200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10982815	hybrid			2022-12-27	WOS:000165739800066
J	Morikawa, W; Yamamoto, K; Ishikawa, S; Takemoto, S; Ono, M; Fukushi, J; Naito, S; Nozaki, C; Iwanaga, S; Kuwano, M				Morikawa, W; Yamamoto, K; Ishikawa, S; Takemoto, S; Ono, M; Fukushi, J; Naito, S; Nozaki, C; Iwanaga, S; Kuwano, M			Angiostatin generation by cathepsin D secreted by human prostate carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; PROCATHEPSIN-D ACTIVATION; LEWIS-LUNG-CARCINOMA; ANGIOGENESIS INHIBITOR; PROTON-PUMP; ENDOTHELIAL-CELLS; HUMAN PLASMINOGEN; BONE-RESORPTION; TUMOR-GROWTH; PROTEOLYSIS	Angiostatin, a potent endogenous inhibitor of angiogenesis, is generated by cancer-mediated proteolysis of plasminogen. The culture medium of human prostate carcinoma cells, when incubated with plasminogen at a variety of pH values, generated angiostatic peptides and miniplasminogen. The enzyme(s) responsible for this reaction was purified and identified as procathepsin D. The purified procathepsin D, as well as cathepsin D, generated two angiostatic peptides having the same NH2-terminal amino acid sequences and comprising kringles 1-4 of plasminogen in the pH range of 3.0-6.8, most strongly at pH 4.0 in vitro. This reaction required the concomitant conversion of procathepsin D to catalytically active pseudocathepsin D. The conversion of pseudocathepsin D to the mature cathepsin D was not observed by the prolonged incubation. The affinity-purified angiostatic peptides inhibited angiogenesis both in vitro and in vivo. Importantly, procathepsin D secreted by human breast carcinoma cells showed a significantly lower angiostatin-generating activity than that by human prostate carcinoma cells. Since deglycosylated procathepsin D from both prostate and breast carcinoma cells exhibited a similar low angiostatin-generating activity, this discrepancy appeared to be attributed to the difference in carbohydrate structures of procathepsin D molecules between the two cell types. The seminal vesicle fluid from patients with prostate carcinoma contained the mature cathepsin D and procathepsin D, but not pseudocathepsin D, suggesting that pseudocathepsin D is not a normal intermediate of procathepsin D processing in vivo. The present study provides evidence for the first time that cathepsin D secreted by human prostate carcinoma cells is responsible for angiostatin generation, thereby causing the prevention of tumor growth and angiogenesis-dependent growth of metastases.	Kyushu Univ, Fac Dent, Dept Pharmacol, Higashi Ku, Fukuoka 8128582, Japan; Kikuchi Res Ctr, Chemoserotherapeut Res Inst, Kumamoto 8691298, Japan; Kyushu Univ, Dept Biochem Med, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Dept Urol, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University; Kyushu University	Yamamoto, K (corresponding author), Kyushu Univ, Fac Dent, Dept Pharmacol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	kyama@dent.kyushu-u.ac.jp						AKISAKA T, 1986, CELL TISSUE RES, V245, P507; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BRIOZZO P, 1988, CANCER RES, V48, P3688; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; CAPONY F, 1989, CANCER RES, V49, P3904; CAVAILLES V, 1993, P NATL ACAD SCI USA, V90, P203, DOI 10.1073/pnas.90.1.203; CHEN C, 1995, CANCER RES, V55, P4230; CONNER GE, 1992, BIOCHEMISTRY-US, V31, P1142, DOI 10.1021/bi00119a024; CONNER GE, 1989, BIOCHEM J, V263, P601, DOI 10.1042/bj2630601; DAS B, 1994, J EXP MED, V180, P273, DOI 10.1084/jem.180.1.273; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; EMMERTBUCK MR, 1994, AM J PATHOL, V145, P1285; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; FRIBERGER P, 1978, HAEMOSTASIS, V7, P138; Gately S, 1996, CANCER RES, V56, P4887; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; HASILIK A, 1982, EUR J BIOCHEM, V125, P317, DOI 10.1111/j.1432-1033.1982.tb06685.x; Ji WR, 1998, BIOCHEM BIOPH RES CO, V247, P414, DOI 10.1006/bbrc.1998.8825; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; LARSEN LB, 1993, FEBS LETT, V319, P54, DOI 10.1016/0014-5793(93)80036-T; Lijnen HR, 1998, BIOCHEMISTRY-US, V37, P4699, DOI 10.1021/bi9731798; MacDonald N., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P46; Martinez-Zaguilan R, 1998, J CELL PHYSIOL, V176, P196, DOI 10.1002/(SICI)1097-4652(199807)176:1<196::AID-JCP21>3.0.CO;2-4; MAWATARI M, 1989, J IMMUNOL, V143, P1619; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; O'Reilly MS, 1999, J BIOL CHEM, V274, P29568, DOI 10.1074/jbc.274.41.29568; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; RICHO GR, 1994, J BIOL CHEM, V269, P14806; SAMAREL AM, 1986, AM J PHYSIOL, V250, pC589, DOI 10.1152/ajpcell.1986.250.4.C589; Sim BKL, 1997, CANCER RES, V57, P1329; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; Stathakis P, 1999, J BIOL CHEM, V274, P8910, DOI 10.1074/jbc.274.13.8910; VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305; VACLAV V, 1995, ARCH BIOCHEM BIOPHYS, V322, P295, DOI 10.1006/abbi.1995.1466; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; WESTLEY BR, 1987, NUCLEIC ACIDS RES, V15, P3773, DOI 10.1093/nar/15.9.3773; Wu ZG, 1997, BIOCHEM BIOPH RES CO, V236, P651, DOI 10.1006/bbrc.1997.7032; YAMAMOTO K, 1984, BIOCHIM BIOPHYS ACTA, V790, P208, DOI 10.1016/0167-4838(84)90024-4	47	73	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38912	38920		10.1074/jbc.M005402200	http://dx.doi.org/10.1074/jbc.M005402200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10986284	hybrid			2022-12-27	WOS:000165739800105
J	Pani, G; Colavitti, R; Bedogni, B; Anzevino, R; Borrello, S; Galeotti, T				Pani, G; Colavitti, R; Bedogni, B; Anzevino, R; Borrello, S; Galeotti, T			A redox signaling mechanism for density-dependent inhibition of cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHATASES; HYDROGEN-PEROXIDE; OXYGEN RADICALS; FACTOR RECEPTOR; PHOSPHORYLATION; FIBROBLASTS; RAC; PROLIFERATION; GENERATION; ACTIVATION	Reactive oxygen species (ROS) have recently drawn significant attention as putative mitogenic mediators downstream of activated growth factor receptors and oncogenic Ras; however, the possibility that a redox-related mechanism also operates in the negative control of cell proliferation by inhibitory signals has not been investigated thus far. Here we show that the arrest of growth induced by cell confluence ("contact inhibition") is due, at least in part, to a decrease in the steady-state levels of intracellular ROS and the consequent impairment of mitogenic redox signaling. In confluent fibroblast cultures, the decrease in the concentration of oxygen species was associated with diminished activity of the small GTPase Rac-1, a signal transducer directly involved in the ligand dependent generation of oxygen-derived molecules, and was effectively mimicked by exposure of sparse cultures to dithiothreitol (DTT) and inhibitors of enzymes (phospholipase A2 and Lipoxygenase) acting in the arachidonic acid cascade downstream of growth factor receptors and Rac-1, Sparse fibroblasts treated with nontoxic amounts of DTT underwent growth arrest, whereas a low concentration of hydrogen peroxide significantly increased thymidine incorporation in confluent cultures, demonstrating a causal link between redox changes and growth control by cell density. Removal of oxygen species from sparse cultures was accompanied by a drastic decrease of protein tyrosine phosphorylation after epidermal growth factor stimulation, which, at a biochemical level, reproduced the signaling hallmarks of contact inhibition, Moreover, the cytosolic tyrosine phosphatase SHP-2 was identified as a putative target for redox signaling by cell density because the enzyme itself and the associated substrates appear markedly dephosphorylated in both confluent and reductant-treated cells after exposure to epidermal growth factor, and SHP-2 enzymatic activity is strongly activated by DTT in vitro. Taken together, these data support a model in which impaired generation of ROS and increased protein tyrosine phosphatase activity impede mitogenic signaling in contact-inhibited cells.	Univ Cattolica Sacro Cuore, Inst Gen Pathol, Sch Med, I-00168 Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Galeotti, T (corresponding author), Univ Cattolica Sacro Cuore, Inst Gen Pathol, Sch Med, Largo F Vito 1, I-00168 Rome, Italy.	Tgaleotti@rm.unicatt.it	Pani, Giovambattista/AAB-1446-2019	Pani, Giovambattista/0000-0001-7133-8728				Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Batt DB, 1998, J BIOL CHEM, V273, P3408, DOI 10.1074/jbc.273.6.3408; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ELING TE, 1994, CANCER METAST REV, V13, P397, DOI 10.1007/BF00666106; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fialkow L, 1997, J IMMUNOL, V158, P5409; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Huang S, 1998, MOL BIOL CELL, V9, P3179, DOI 10.1091/mbc.9.11.3179; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Monteiro HP, 1996, FREE RADICAL BIO MED, V21, P323, DOI 10.1016/0891-5849(96)00051-2; Moore KA, 1997, BIOCHEM J, V326, P17, DOI 10.1042/bj3260017; ODonnell VB, 1996, BIOCHEM J, V318, P805, DOI 10.1042/bj3180805; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; Pani G, 1997, CLIN IMMUNOL IMMUNOP, V84, P1, DOI 10.1006/clin.1996.4326; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Pani G, 2000, BIOCHEM J, V347, P173, DOI 10.1042/0264-6021:3470173; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sorby M, 1996, J BIOL CHEM, V271, P10963; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TRUDEL S, 1991, BIOCHEM J, V276, P611, DOI 10.1042/bj2760611; WIESER RJ, 1990, J CELL BIOL, V111, P2681, DOI 10.1083/jcb.111.6.2681; WIESER RJ, 1990, ENVIRON HEALTH PERSP, V88, P251, DOI 10.2307/3431085	45	124	131	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38891	38899		10.1074/jbc.M007319200	http://dx.doi.org/10.1074/jbc.M007319200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10988296	hybrid			2022-12-27	WOS:000165739800102
J	Taylor, SW; Craig, AG; Fischer, WH; Park, M; Lehrer, RI				Taylor, SW; Craig, AG; Fischer, WH; Park, M; Lehrer, RI			Styelin D, an extensively modified antimicrobial peptide from ascidian hemocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIONA-INTESTINALIS; BLOOD-CELLS; HALOCYNTHIA-RORETZI; IN-VITRO; TUNICATE HEMOCYTES; CYTOTOXIC ACTIVITY; SOLITARY TUNICATE; ESCHERICHIA-COLI; CARCINUS-MAENAS; MYTILUS-EDULIS	We isolated styelin D, a 32-residue, C-terminally amidated antimicrobial peptide, from the blood cells (hemocytes) of the solitary ascidian, Styela clava, Styelin D had remarkably extensive post-translational modifications, containing two novel amino acids, dihydroxyarginine and dihydroxylysine, and two distinctly unusual ones, 6-bromotryptophan and 3,4-dihydroxyphenylalanine. In addition, the peptide exhibited microheterogeneity because of differential mono- and dihydroxylation of several lysine residues. The primary sequence of one variant was: GW*LR**K**AAK**SVGK**FY*Y*K**HK*Y* Y*IK*AAWQIGKHAL-NH2, where W* is 6-bromotryptophan, R** is dihydroxyarginine, Y* is 3,4-dihydroxyphenylalanine, K* is B-hydroxylysine, and K** is dihydroxylysine, Styelin D exhibited activity against Gram-negative and Gram-positive bacteria, and this activity was retained in 200 mM NaCl, The role of the extensive modifications may be to preserve activity at low pH and/or high salinity because, under these conditions, the native peptide was considerably more active against the Gram-positive bacterial strains than its unmodified synthetic analogue. The peptide was also hemolytic and quite cytotoxic to eukaryotic cells. These broad ranging activities, combined with its relative abundance in ascidian hemocytes, suggest that styelin D plays a significant role in the innate immune mechanisms of S. clava.	Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA; Salk Inst, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; Salk Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Taylor, SW (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA.							AGUDELO MI, 1983, COMP BIOCHEM PHYS A, V75, P211, DOI 10.1016/0300-9629(83)90072-5; Arizza V, 1997, J MAR BIOTECHNOL, V5, P31; AZUMI K, 1990, BIOCHEMISTRY-US, V29, P159, DOI 10.1021/bi00453a021; AZUMI K, 1991, DEV COMP IMMUNOL, V15, P1, DOI 10.1016/0145-305X(91)90041-V; AZUMI K, 1990, EXPERIENTIA, V46, P1066, DOI 10.1007/BF01940675; AZUMI K, 1991, DEV COMP IMMUNOL, V15, P9, DOI 10.1016/0145-305X(91)90042-W; BALDWIN JE, 1993, TETRAHEDRON LETT, V34, P5645, DOI 10.1016/S0040-4039(00)73905-0; Ballarin L, 1998, DEV COMP IMMUNOL, V22, P479, DOI 10.1016/S0145-305X(98)00035-4; Beaven AE, 1999, BIOL BULL-US, V196, P26, DOI 10.2307/1543163; Bechinger B, 1997, J MEMBRANE BIOL, V156, P197, DOI 10.1007/s002329900201; Cammarata M, 1997, EUR J CELL BIOL, V74, P302; Charlet M, 1996, J BIOL CHEM, V271, P21808, DOI 10.1074/jbc.271.36.21808; Craig AG, 1997, J BIOL CHEM, V272, P4689, DOI 10.1074/jbc.272.8.4689; DELEO G, 1992, B ZOOL, V59, P195, DOI 10.1080/11250009209386669; DeLeo G, 1997, J INVERTEBR PATHOL, V69, P14, DOI 10.1006/jipa.1996.4621; Destoumieux D, 1997, J BIOL CHEM, V272, P28398, DOI 10.1074/jbc.272.45.28398; DORSETT LC, 1987, BIOCHEMISTRY-US, V26, P8078, DOI 10.1021/bi00399a009; Euli D, 1999, J CHROMATOGR B, V724, P373, DOI 10.1016/S0378-4347(98)00539-8; FRANK H, 1978, J CHROMATOGR, V167, P187, DOI 10.1016/S0021-9673(00)91157-9; Frank P, 1998, J BIOL CHEM, V273, P24498, DOI 10.1074/jbc.273.38.24498; FUKE MT, 1980, BIOL BULL, V158, P305; Hackam DJ, 1997, J BIOL CHEM, V272, P29810, DOI 10.1074/jbc.272.47.29810; Hata S, 1998, COMP BIOCHEM PHYS B, V119, P769, DOI 10.1016/S0305-0491(98)00054-6; HAWKINS CJ, 1983, COMP BIOCHEM PHYS B, V76, P559, DOI 10.1016/0305-0491(83)90293-6; IWANAGA S, 1994, CIBA F SYMP, V186, P160; Jimenez EC, 1997, BIOCHEMISTRY-US, V36, P989, DOI 10.1021/bi962840p; KELLY KL, 1992, J EXP ZOOL, V262, P202, DOI 10.1002/jez.1402620210; Lee IH, 1997, COMP BIOCHEM PHYS B, V118, P515, DOI 10.1016/S0305-0491(97)00109-0; Lee IH, 1997, INFECT IMMUN, V65, P2898, DOI 10.1128/IAI.65.7.2898-2903.1997; Lee IH, 1997, FEBS LETT, V400, P158, DOI 10.1016/S0014-5793(96)01374-9; LEE JY, 1989, P NATL ACAD SCI USA, V86, P9159, DOI 10.1073/pnas.86.23.9159; LEHRER RI, 1988, J IMMUNOL METHODS, V108, P153, DOI 10.1016/0022-1759(88)90414-0; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; LEIMER KR, 1977, J CHROMATOGR, V141, P121, DOI 10.1016/S0021-9673(00)99131-3; PAPOV VV, 1995, J BIOL CHEM, V270, P20183, DOI 10.1074/jbc.270.34.20183; Parrinello N, 1996, BIOL BULL, V190, P418, DOI 10.2307/1543035; PEDDIE CM, 1994, J EXP ZOOL, V270, P335, DOI 10.1002/jez.1402700402; PEDDIE CM, 1993, J EXP ZOOL, V267, P616, DOI 10.1002/jez.1402670609; POSTELS HT, 1994, TETRAHEDRON LETT, V35, P535; Raftos DA, 1995, DEV COMP IMMUNOL, V19, P463, DOI 10.1016/0145-305X(95)00028-R; Reddy MVR, 1998, TETRAHEDRON, V54, P10649; Relf JM, 1999, EUR J BIOCHEM, V264, P350, DOI 10.1046/j.1432-1327.1999.00607.x; Schnapp D, 1996, EUR J BIOCHEM, V240, P532, DOI 10.1111/j.1432-1033.1996.0532h.x; SCIPPA S, 1985, ACTA EMBRYOL MORPHOL, V6, P285; Shinnar A.E., 1996, P 14 PEPT AM S COL O, P189; Steinbeg Deborah A., 1997, V78, P169; Taylor SW, 1995, ARCH BIOCHEM BIOPHYS, V324, P228, DOI 10.1006/abbi.1995.0035; Taylor SW, 1997, ARCH BIOCHEM BIOPHYS, V348, P278, DOI 10.1006/abbi.1997.0371; Tincu JA, 2000, BIOCHEM BIOPH RES CO, V270, P421, DOI 10.1006/bbrc.2000.2449; TSUGITA A, 1987, J BIOCH, V102, P1592; Vervoort H, 2000, J ORG CHEM, V65, P782, DOI 10.1021/jo991425a; Watters Diane, 1993, Molecular Marine Biology and Biotechnology, V2, P28; Zhao CQ, 1997, FEBS LETT, V410, P490, DOI 10.1016/S0014-5793(97)00646-7; Zhao CQ, 1997, FEBS LETT, V412, P144, DOI 10.1016/S0014-5793(97)00769-2	54	83	91	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38417	38426		10.1074/jbc.M006762200	http://dx.doi.org/10.1074/jbc.M006762200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10978343	hybrid			2022-12-27	WOS:000165739800039
J	Clark, AB; Valle, F; Drotschmann, K; Gary, RK; Kunkel, TA				Clark, AB; Valle, F; Drotschmann, K; Gary, RK; Kunkel, TA			Functional interaction of proliferating cell nuclear antigen with MSH2-MSH6 and MSH2-MSH3 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-DELTA; BASE EXCISION-REPAIR; MISMATCH REPAIR; SACCHAROMYCES-CEREVISIAE; PCNA BINDING; REPLICATION; IDENTIFICATION; MUTATIONS; P21(WAF1); INHIBITOR	Eukaryotic DNA mismatch repair requires the concerted action of several proteins, including proliferating cell nuclear antigen (PCNA) and heterodimers of MSH2 complexed with either MSH3 or MSH6. Here we report that MSH3 and MSH6, but not MSH2, contain N-terminal sequence moths characteristic of proteins that bind to PCNA. MSH3 and MSH6 peptides containing these motifs bound PCNA, as did the intact Msh2-Msh6 complex. This binding was strongly reduced when alanine was substituted for conserved residues in the moth. Yeast strains containing alanine substitutions in the PCNA binding motif of Msh6 or Msh3 had elevated mutation rates, indicating that these interactions are important for genome stability. When human MSH3 or MSH6 peptides containing the PCNA binding motif were added to a human cell extract, mismatch repair activity was inhibited at a step preceding DNA resynthesis. Thus, MSH3 and MSH6 interactions with PCNA may facilitate early steps in DNA mismatch repair and may also be important for other roles of these eukaryotic MutS homologs.	NIEHS, Mol Genet Lab, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, Res Triangle Pk, NC 27709 USA; Univ Nevada, Dept Chem, Las Vegas, NV 89154 USA; Univ Nevada, UNLV Canc Inst, Las Vegas, NV 89154 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas	Kunkel, TA (corresponding author), NIEHS, Mol Genet Lab, Res Triangle Pk, NC 27709 USA.		Kunkel, Thomas A./D-5088-2019; Gary, Ronald K/A-8650-2008	Kunkel, Thomas A./0000-0002-9900-1788; Gary, Ronald K/0000-0001-5079-1953	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065089, Z01ES065089] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Chen C, 1999, MOL CELL BIOL, V19, P7801; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Drotschmann K, 1999, P NATL ACAD SCI USA, V96, P2970, DOI 10.1073/pnas.96.6.2970; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gary R, 1999, MOL CELL BIOL, V19, P5373; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Harfe BD, 2000, GENETICS, V156, P571; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; Kokoska RJ, 1999, GENETICS, V151, P511; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Longley MJ, 1997, J BIOL CHEM, V272, P10917; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Thomas David C., 1995, Methods (Orlando), V7, P187, DOI 10.1006/meth.1995.1024; Tran HT, 1997, MOL CELL BIOL, V17, P2859, DOI 10.1128/MCB.17.5.2859; Tran HT, 1999, MOL CELL BIOL, V19, P2000; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3	30	177	184	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36498	36501		10.1074/jbc.C000513200	http://dx.doi.org/10.1074/jbc.C000513200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	11005803	hybrid			2022-12-27	WOS:000165577700006
J	Lin, X; Liang, M; Feng, XH				Lin, X; Liang, M; Feng, XH			Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED TRANSCRIPTION; TUMOR-SUPPRESSOR; PROTEIN; COACTIVATORS; SMAD4/DPC4; COOPERATION; ONCOPROTEIN; RESPONSES; ACTIVATOR; CBP/P300	Smads are important intracellular signaling effecters for transforming growth factor-beta (TGF-beta) and related factors. Proper TGF-beta signaling requires precise control of Smad functions. In this study, we have identified a novel HECT class ubiquitin E3 ligase, designated Smurf2, that negatively regulates Smad2 signaling. In both yeast two-hybrid and in vitro binding assays, we found that Smurf2 could interact with receptor-activated Smads (R-Smads), including Smad1, Smad2, and Smad3 but not Smad4. Ectopic expression of Smurf2 was sufficient to reduce the steady-state levels of Smad1 and Smad2 but not Smad8 or Smad4. Significantly, Smurf2 displayed preference to Smad2 as its target for degradation. Furthermore, Smurf2 exhibited higher binding affinity to activated Smad2 upon TGF-beta stimulation. The ability of Smurf2 to promote Smad2 destruction required the HECT catalytic activity of Smurf2 and depended on the proteasome-dependent pathway. Consistent with these results, Smurf2 potently reduced the transcriptional activity of Smad2. These data suggest that a ubiquitin/proaeasome-dependent mechanism is important for proper regulation of TGF-beta signaling.	Baylor Coll Med, Dept Surg, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Feng, XH (corresponding author), Baylor Coll Med, Dept Surg, 1 Baylor Plaza,404D, Houston, TX 77030 USA.							Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Datto M, 2000, CYTOKINE GROWTH F R, V11, P37, DOI 10.1016/S1359-6101(99)00027-1; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Massague J, 2000, GENE DEV, V14, P627; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; Sambrook J., 2002, MOL CLONING LAB MANU; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	36	387	414	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36818	36822		10.1074/jbc.C000580200	http://dx.doi.org/10.1074/jbc.C000580200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	11016919	hybrid			2022-12-27	WOS:000165577700054
J	Foehr, ED; Bohuslav, J; Chen, LF; DeNoronha, C; Geleziunas, R; Lin, X; O'Mahony, A; Greene, WC				Foehr, ED; Bohuslav, J; Chen, LF; DeNoronha, C; Geleziunas, R; Lin, X; O'Mahony, A; Greene, WC			The NF-kappa B-inducing kinase induces PC12 cell differentiation and prevents apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; IKK-BETA; ALPHA PROTEOLYSIS; ACTIVATION; PHOSPHORYLATION; NEURONS; SITE; DEATH; TNF; IDENTIFICATION	NF-kappaB has been implicated in the survival and differentiation of PC12 cells. In this study, we examined the effect of the NF-kappaB-inducing kinase (NIK) on these processes. When inducibly expressed in PC12 cells, a kinase-proficient but not -deficient form of NIK promoted neurite process formation and mediated anti-apoptotic signaling. As expected, NIK expression led to I kappaB kinase activation and induced nuclear translocation of NF-kappaB, However, NIK-induced neurite outgrowth was only partially blocked by concomitant expression of a nondegradable form of I kappaB alpha that completely blocks NF-kappaB induction. In search of additional signaling pathways activated by NIX, we now demonstrate that NIR. activates MEK1 phosphorylation and induces the Erk1/Erk2 MAPK pathway. Treatment of PC12 cells with PD98059, a MEK1 inhibitor, potently blocked neurite process formation; however, a dominantly interfering mutant of the upstream Shc adapter failed to alter this response. These findings reveal a new function for MK as a MEK1-dependent activator of the MAPK pathway and implicate both the I kappaB kinase and MAPK signaling cascades in NIK-induced differentiation of PC12 cells.	Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Foehr, ED (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA.	efoehr@gladstone.ucsf.edu			NIMH NIH HHS [P30MH59037] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH059037] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aronsson FC, 1998, HUM GENET, V103, P340, DOI 10.1007/s004390050827; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bethea JR, 1998, J NEUROSCI, V18, P3251; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HATTORI A, 1993, J BIOL CHEM, V268, P2577; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	42	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34021	34024		10.1074/jbc.C000507200	http://dx.doi.org/10.1074/jbc.C000507200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10980190	hybrid			2022-12-27	WOS:000165095300004
J	Wu, XL; McMurray, CT				Wu, XL; McMurray, CT			Calmodulin kinase II attenuation of gene transcription by preventing cAMP response element-binding protein (CREB) dimerization and binding of the CREB-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEIN; CYCLIC-AMP; PHOSPHORYLATED CREB; SECONDARY STRUCTURE; COACTIVATOR CBP; ACTIVATION; IV; DNA; EXPRESSION; MONOMERS	Calmodulin Kinase II (CamKII) inhibits the transcription of many CRE-dependent genes, but the mechanism of dominant transcriptional inhibition is unknown. Here we show that phosphorylation of serine 142 in CREB by CamKII leads to dissociation of the CREB dimer without impeding DNA binding capacity. CamKII-modified CREB binds to DNA efficiently as a monomer; however, monomeric CREB is unable to recruit the CREB-binding protein (CBP) even when phosphorylated at serine 133. Thus, CamKII confers a dominant inhibitory effect on transcription by preventing dimerization of CREB, and this mechanism may account for the attenuation of gene expression.	Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Grad Sch, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mol Neurosci Program, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	McMurray, CT (corresponding author), Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH056207] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43694-01A2] Funding Source: Medline; NIMH NIH HHS [MH-56207] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COLLINSHICOK J, 1994, MOL CELL BIOL, V14, P2837, DOI 10.1128/MCB.14.5.2837; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Hagiwara M, 1996, Adv Pharmacol, V36, P277, DOI 10.1016/S1054-3589(08)60586-4; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; Kohler JJ, 1999, P NATL ACAD SCI USA, V96, P11735, DOI 10.1073/pnas.96.21.11735; KRAJEWSKI W, 1994, MOL CELL BIOL, V14, P7204, DOI 10.1128/MCB.14.11.7204; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lisman J, 1997, SCIENCE, V276, P2001, DOI 10.1126/science.276.5321.2001; LORIAUX MM, 1993, P NATL ACAD SCI USA, V90, P9046, DOI 10.1073/pnas.90.19.9046; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Metallo SJ, 1997, NAT STRUCT BIOL, V4, P115, DOI 10.1038/nsb0297-115; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; ORR MD, 1972, ANAL BIOCHEM, V45, P68, DOI 10.1016/0003-2697(72)90008-5; Parker D, 1998, MOL CELL, V2, P353, DOI 10.1016/S1097-2765(00)80279-8; Press W. H., 1992, NUMERICAL RECIPES C, V2nd, P656; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Shimomura A, 1996, J BIOL CHEM, V271, P17957, DOI 10.1074/jbc.271.30.17957; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; SPIRO C, 1993, P NATL ACAD SCI USA, V90, P4606, DOI 10.1073/pnas.90.10.4606; SPIRO C, 1995, J BIOL CHEM, V270, P27702, DOI 10.1074/jbc.270.46.27702; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Tompa P, 1998, TRENDS NEUROSCI, V21, P97, DOI 10.1016/S0166-2236(97)01176-4; VANHOLDE KE, 1985, PHYSICAL BIOCH; Wu XL, 1998, J BIOL CHEM, V273, P20820, DOI 10.1074/jbc.273.33.20820; Xia ZG, 1997, CURR OPIN NEUROBIOL, V7, P391, DOI 10.1016/S0959-4388(97)80068-2; Zhang F, 1998, MOL CELL, V2, P141, DOI 10.1016/S1097-2765(00)80123-9	47	79	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1735	1741		10.1074/jbc.M006727200	http://dx.doi.org/10.1074/jbc.M006727200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11013247	hybrid			2022-12-27	WOS:000166528000013
J	Hoy, M; Bokvist, K; Weng, XG; Hansen, J; Juhl, K; Berggren, PO; Buschard, K; Gromada, J				Hoy, M; Bokvist, K; Weng, XG; Hansen, J; Juhl, K; Berggren, PO; Buschard, K; Gromada, J			Phentolamine inhibits exocytosis of glucagon by G(i2) protein-dependent activation of calcineurin in rat pancreatic alpha-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNELS; BETA-CELLS; INSULIN RELEASE; A-CELLS; SECRETION; GLUCOSE; ISLETS; SULFONYLUREA; CURRENTS; LOCALIZATION	Capacitance measurements were used to investigate the molecular mechanisms by which imidazoline compounds inhibit glucagon release in rat pancreatic alpha -cells, The imidazoline compound phentolamine reversibly decreased depolarization-evoked exocytosis >80% without affecting the whole-cell Ca2+ current. During intracellular application through the recording pipette, phentolamine produced a concentration-dependent decrease in the rate of exocytosis (IC50 = 9.7 muM). Another imidazoline compound, RX871024, exhibited similar effects on exocytosis (IC50 = 13 muM). These actions were dependent on activation of pertussis toxin-sensitive G(i2) proteins but were not associated with stimulation of ATP-sensitive K+ channels or adenylate cyclase activity. The inhibitory effect of phentolamine on exocytosis resulted from activation of the protein phosphatase calcineurin and was abolished by cyclosporin A and deltamethrin. Exocytosis was not affected by intracellular application of specific alpha (2), I-1, and I-2, ligands. Phentolamine reduced glucagon release (IC50 = 1.2 muM) from intact islets by 40%, an effect abolished by pertussis toxin, cyclosporin A, and deltamethrin, These data suggest that imidazoline compounds inhibit glucagon secretion via G(i2)-dependent activation of calcineurin in the pancreatic alpha -cell, The imidazoline binding site is likely to be localized intracellularly and probably closely associated with the secretory granules.	Novo Nordisk AS, Lab Islet Cell Physiol, DK-2880 Bagsvaerd, Denmark; Kommunehosp, Bartholin Inst, DK-1353 Copenhagen, Denmark; Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res, S-17176 Stockholm, Sweden	Novo Nordisk; Karolinska Institutet	Gromada, J (corresponding author), Lilly Forsch GMBH, Lilly Res Labs, Essener Str 93, D-22419 Hamburg, Germany.			Buschard, Karsten/0000-0002-0126-7423; Berggren, Per-Olof/0000-0001-8991-413X				Ahnert-Hilger G, 1998, EMBO J, V17, P406, DOI 10.1093/emboj/17.2.406; AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; AMMALA C, 1993, J PHYSIOL-LONDON, V472, P665, DOI 10.1113/jphysiol.1993.sp019966; ARONIN N, 1992, J NEUROSCI, V12, P3435; BERROW NS, 1992, J MOL ENDOCRINOL, V8, P103, DOI 10.1677/jme.0.0080103; Bokvist K, 1999, PFLUG ARCH EUR J PHY, V438, P428, DOI 10.1007/s004240051058; BUSE MG, 1970, METABOLIS, V19, P219, DOI 10.1016/0026-0495(70)90055-7; CERASI E, 1969, LANCET, V2, P301; Detimary P, 1998, J BIOL CHEM, V273, P33905, DOI 10.1074/jbc.273.51.33905; DUNNE MJ, 1991, BRIT J PHARMACOL, V103, P1847, DOI 10.1111/j.1476-5381.1991.tb12340.x; DUNNE MJ, 1995, ANN NY ACAD SCI, V763, P242; Efanova IB, 1998, BIOCHEM BIOPH RES CO, V252, P162, DOI 10.1006/bbrc.1998.9635; EFENDIC S, 1975, DIABETOLOGIA, V11, P407, DOI 10.1007/BF00429908; GAGLIARDINO JJ, 1991, BIOCHIM BIOPHYS ACTA, V1091, P370, DOI 10.1016/0167-4889(91)90202-9; GARRINO MG, 1990, DIABETOLOGIA, V33, P145, DOI 10.1007/BF00404040; Gromada J, 1997, J GEN PHYSIOL, V110, P217, DOI 10.1085/jgp.110.3.217; HEIMBERG H, 1995, J BIOL CHEM, V270, P8971, DOI 10.1074/jbc.270.15.8971; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; ITOH H, 1988, J BIOL CHEM, V263, P6656; Jena BP, 1997, P NATL ACAD SCI USA, V94, P13317, DOI 10.1073/pnas.94.24.13317; JONAS JC, 1992, BRIT J PHARMACOL, V107, P8, DOI 10.1111/j.1476-5381.1992.tb14456.x; JONES DT, 1987, J BIOL CHEM, V262, P14241; Josefsen K, 1996, J ENDOCRINOL, V149, P145, DOI 10.1677/joe.0.1490145; KASHIWAGI A, 1986, DIABETES, V35, P1085, DOI 10.2337/diabetes.35.10.1085; LEE K, 1995, EUR J PHARMACOL, V285, P309, DOI 10.1016/0014-2999(95)00525-P; MARTELL AE, 1971, CRITICAL STABILITY C, V1; MISBIN RI, 1970, DIABETES, V19, P688, DOI 10.2337/diab.19.10.688; Mourtada M, 1997, BIOCHEM BIOPH RES CO, V236, P162, DOI 10.1006/bbrc.1997.6922; PLANT TD, 1990, BRIT J PHARMACOL, V101, P115, DOI 10.1111/j.1476-5381.1990.tb12099.x; Poulsen CR, 1999, DIABETES, V48, P2171, DOI 10.2337/diabetes.48.11.2171; Proks P, 1997, P NATL ACAD SCI USA, V94, P11716, DOI 10.1073/pnas.94.21.11716; Renstrom E, 1996, NEURON, V17, P513, DOI 10.1016/S0896-6273(00)80183-X; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; RORSMAN P, 1986, J PHYSIOL-LONDON, V374, P531, DOI 10.1113/jphysiol.1986.sp016096; SAKURA H, 1995, FEBS LETT, V377, P228; Suzuki M, 1999, DIABETOLOGIA, V42, P1204, DOI 10.1007/s001250051293; Takano K, 1997, J PHYSIOL-LONDON, V502, P559, DOI 10.1111/j.1469-7793.1997.559bj.x; VITALE N, 1994, J BIOL CHEM, V269, P30293; Zaitsev SV, 1996, DIABETES, V45, P1610, DOI 10.2337/diabetes.45.11.1610	39	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					924	930		10.1074/jbc.M007562200	http://dx.doi.org/10.1074/jbc.M007562200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	10995774	hybrid			2022-12-27	WOS:000166430900010
J	Hackam, AS; Yassa, AS; Singaraja, R; Metzler, M; Gutekunst, CA; Gan, L; Warby, S; Wellington, CL; Vaillancourt, J; Chen, NS; Gervais, FG; Raymond, L; Nicholson, DW; Hayden, MR				Hackam, AS; Yassa, AS; Singaraja, R; Metzler, M; Gutekunst, CA; Gan, L; Warby, S; Wellington, CL; Vaillancourt, J; Chen, NS; Gervais, FG; Raymond, L; Nicholson, DW; Hayden, MR			Huntingtin interacting protein 1 induces apoptosis via a novel caspase-dependent death effector domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; DNA FRAGMENTATION; SACCHAROMYCES-CEREVISIAE; INTRANUCLEAR INCLUSIONS; NUCLEAR-LOCALIZATION; POLYGLUTAMINE TRACT; MUTANT HUNTINGTIN; DISEASE STRIATUM; NECROSIS-FACTOR; REPEAT LENGTH	Huntington disease is a devastating neurodegenerative disease caused by the expansion of a polymorphic glutamine tract in huntingtin. The huntingtin interacting protein (HIP-1) was identified by its altered interaction with mutant huntingtin, However, the function of HIP-1 was not known. In this study, we identify HIP-I as a proapoptotic protein. Overexpression of HIP-1 resulted in rapid caspase 5-dependent cell death. Bioinformatics analyses identified a novel domain in HIP-1 with homology to death effector domains (DEDs) present in proteins involved in apoptosis. Expression of the HIP-1 DED alone resulted in cell death indistinguishable from HIP-1, indicating that the DED is responsible for HIP-1 toxicity. Furthermore, substitution of a conserved hydrophobic phenylalanine residue within the HIP-1 DED at position 398 eliminated HIP-1 toxicity entirely. HIP-1 activity was found to be independent of the DED-containing caspase 8 but was significantly inhibited by the antiapoptotic protein Bcl-x(L), implicating the intrinsic pathway of apoptosis in HIP-1-induced cell death. Coexpression of a normal huntingtin fragment capable of binding HIP-1 significantly reduced cell death. Our data identify HIP-1 as a novel proapoptotic mediator and suggest that HIP-1 may be a molecular accomplice in the pathogenesis of Huntington disease.	Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 4H4, Canada; Emory Univ, Sch Med, Atlanta, GA 30322 USA; Merck Frosst Canada Inc, Merck Frosst Ctr Therapeut Res, Pointe Claire, PQ H9R 4P8, Canada; Univ British Columbia, Dept Psychiat, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Div Neurosci, Vancouver, BC V5Z 4H4, Canada	University of British Columbia; University of British Columbia; Emory University; Merck & Company; University of British Columbia; University of British Columbia	Hayden, MR (corresponding author), Univ British Columbia, Ctr Mol Med & Therapeut, 980 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	mrh@cmmt.ubc.ca	Raymond, Lynn A./R-6707-2016; Raymond, Lynn A/A-6664-2010; Chen, Nansheng/E-6450-2012; Hayden, Michael R/D-8581-2011	Raymond, Lynn A./0000-0002-8610-1042; Raymond, Lynn A/0000-0002-8610-1042; Hayden, Michael R/0000-0001-5159-1419; Singaraja, Roshni/0000-0002-3418-3867				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Boutell JM, 1999, HUM MOL GENET, V8, P1647, DOI 10.1093/hmg/8.9.1647; Butterworth NJ, 1998, NEUROSCIENCE, V87, P49, DOI 10.1016/S0306-4522(98)00129-8; CARMICHAEL J, 1987, CANCER RES, V47, P936; Chai YH, 1999, J NEUROSCI, V19, P10338; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chopra VS, 2000, MAMM GENOME, V11, P1006, DOI 10.1007/s003350010195; Clarke G, 2000, NATURE, V406, P195, DOI 10.1038/35018098; Cohen O, 1999, J CELL BIOL, V146, P141; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DRAGUNOW M, 1995, NEUROREPORT, V6, P1053, DOI 10.1097/00001756-199505090-00026; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Engqvist-Goldstein AEY, 1999, J CELL BIOL, V147, P1503, DOI 10.1083/jcb.147.7.1503; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; Kim M, 1999, J NEUROSCI, V19, P964; Kim M, 1999, NEUROSCIENCE, V89, P1159, DOI 10.1016/S0306-4522(98)00400-X; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Leavitt BR, 1999, AM J HUM GENET, V65, pA457; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; LI R, 1995, J CELL BIOL, V128, P599, DOI 10.1083/jcb.128.4.599; Li SH, 1998, HUM MOL GENET, V7, P777, DOI 10.1093/hmg/7.5.777; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAO SQ, 1995, J BIOL CHEM, V270, P6815, DOI 10.1074/jbc.270.12.6815; Neelands TR, 1998, J NEUROSCI, V18, P4993; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Sawa A, 1999, NAT MED, V5, P1194, DOI 10.1038/13518; Seki N, 1998, J HUM GENET, V43, P268, DOI 10.1007/s100380050087; Sharp AH, 1996, NEUROBIOL DIS, V3, P3, DOI 10.1006/nbdi.1996.0002; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Steininger TL, 1997, J COMP NEUROL, V382, P302, DOI 10.1002/(SICI)1096-9861(19970609)382:3<302::AID-CNE2>3.0.CO;2-7; THOMAS LB, 1995, EXP NEUROL, V133, P265, DOI 10.1006/exnr.1995.1029; Vander Heiden MG, 1999, MOL CELL, V3, P159; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VISTICA DT, 1991, CANCER RES, V51, P2515; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; Wellington CL, 2000, J BIOL CHEM, V275, P19831, DOI 10.1074/jbc.M001475200; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Wellington CL, 1997, BRAIN PATHOL, V7, P979, DOI 10.1111/j.1750-3639.1997.tb00897.x; Wesp A, 1997, MOL BIOL CELL, V8, P2291, DOI 10.1091/mbc.8.11.2291; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597	58	102	105	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41299	41308		10.1074/jbc.M008408200	http://dx.doi.org/10.1074/jbc.M008408200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007801	hybrid			2022-12-27	WOS:000166114600085
J	Chave, KJ; Auger, IE; Galivan, J; Ryan, TJ				Chave, KJ; Auger, IE; Galivan, J; Ryan, TJ			Molecular modeling and site-directed mutagenesis define the catalytic motif in human gamma-glutamyl hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; FOLYLPOLYGLUTAMATE SYNTHETASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; METHOTREXATE; POLYGLUTAMYLATION; RESISTANCE; RESIDUES; SUBUNIT; TRIAD	Human gamma -glutamyl hydrolase (hGH) is a central enzyme in folyl and antifolylpoly-gamma -glutamate metabolism, which functions by catalyzing the cleavage of the gamma -glutamyl chain of substrates. We previously reported that Cys-110 is essential for activity. Using the sequence of hGH as a query, alignment searches of protein data bases were made using the SSearch and TPROBE programs. Significant similarity was found between hGH and the glutamine amidotransferase type I domain of Escherichia coli carbamoyl phosphate synthetase. The resulting hypothesis is that the catalytic fold of hGH is similar to the folding of this domain in carbamoyl phosphate synthetase. This model predicts that Cys-110 of hGH is the active site nucleophile and forms a catalytic triad with residues His-220 and Glu-222. The hGH mutants C110A, H220A, and E222A were prepared. Consistent with the model, mutants C110A and H220A were inactive. However, the V-max of the E222A hGH mutant was reduced only g-fold relative to the wild-type enzyme. The model also predicted that His-171 in hGH may be involved in substrate binding. The H171N hGH mutant was found to have a 250-fold reduced V-max, These studies to determine the catalytic mechanism begin to define the three dimensional interactions of hGH with poly-gamma -glutamate substrates.	New York State Dept Hlth, Wadsworth Ctr Labs & Res, Div Mol Med, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center	Ryan, TJ (corresponding author), New York State Dept Hlth, Wadsworth Ctr Labs & Res, Div Mol Med, Albany, NY 12201 USA.	thomas.ryan@wadsworth.org			NATIONAL CANCER INSTITUTE [R01CA025933, R01CA082425] Funding Source: NIH RePORTER; NCI NIH HHS [CA25933, CA82425] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMURO N, 1985, J BIOL CHEM, V260, P4844; CHABNER BA, 1985, J CLIN INVEST, V76, P907, DOI 10.1172/JCI112088; Chave KJ, 1999, BIOCHEM J, V343, P551, DOI 10.1042/0264-6021:3430551; Chazal M, 1997, CLIN CANCER RES, V3, P553; GALIVAN J, 1980, MOL PHARMACOL, V17, P105; Galivan J, 2000, PHARMACOL THERAPEUT, V85, P207, DOI 10.1016/S0163-7258(99)00063-7; GALIVAN J, 1998, HDB PROTEOLYTIC ENZY, P7983; Hewagama A, 1998, BBA-PROTEIN STRUCT M, V1388, P489, DOI 10.1016/S0167-4838(98)00212-X; Huang XY, 1999, BIOCHEMISTRY-US, V38, P15909, DOI 10.1021/bi991805q; Knochel T, 1999, P NATL ACAD SCI USA, V96, P9479, DOI 10.1073/pnas.96.17.9479; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEVITT M, 1983, J MOL BIOL, V170, P723, DOI 10.1016/S0022-2836(83)80129-6; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Liu YN, 1998, BIOCHEM PHARMACOL, V55, P2031, DOI 10.1016/S0006-2952(98)00089-6; Longo GSA, 1997, ONCOL RES, V9, P259; MCCLOSKEY DE, 1991, J BIOL CHEM, V266, P6181; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MIRAN SG, 1991, BIOCHEMISTRY-US, V30, P7901, DOI 10.1021/bi00246a005; Neuwald AF, 1997, NUCLEIC ACIDS RES, V25, P1665, DOI 10.1093/nar/25.9.1665; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PEARSON WR, 1995, PROTEIN SCI, V4, P1145, DOI 10.1002/pro.5560040613; RHEE MS, 1993, CANCER RES, V53, P2227; Rhee MS, 1998, MOL PHARMACOL, V53, P1040; Rots MG, 1999, BLOOD, V93, P1677, DOI 10.1182/blood.V93.5.1677.405a16_1677_1683; ROUX B, 1993, BIOCHEMISTRY-US, V32, P3763, DOI 10.1021/bi00065a031; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; RUMBERGER BG, 1990, CANCER COMMUN, V2, P305; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P16158, DOI 10.1021/bi991741j; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P8825, DOI 10.1021/bi9807761; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; VERNET T, 1995, J BIOL CHEM, V270, P16645, DOI 10.1074/jbc.270.28.16645; Waltham MC, 1997, MOL PHARMACOL, V51, P825, DOI 10.1124/mol.51.5.825; YAO R, 1995, MOL PHARMACOL, V48, P505	39	22	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40365	40370		10.1074/jbc.M007908200	http://dx.doi.org/10.1074/jbc.M007908200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11005824	hybrid			2022-12-27	WOS:000166039500077
J	Chi, MMY; Pingsterhaus, J; Carayannopoulos, M; Moley, KH				Chi, MMY; Pingsterhaus, J; Carayannopoulos, M; Moley, KH			Decreased glucose transporter expression triggers BAX-dependent apoptosis in the murine blastocyst	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MOUSE; DEPRIVATION; EMBRYOS; PAX-3; MALFORMATIONS; PERICYTES; PATHWAY; DEATH; MICE	We report that a decrease in facilitative glucose transporter (GLUT1) expression and reduced glucose transport trigger apoptosis in the murine blastocyst. Inhibition of GLUT1 expression either by high glucose conditions or with antisense oligodeoxynucleotides significantly lowers protein expression and function of GLUT1 and as a result induces a high rate of apoptosis at the blastocyst stage. Similar to wild-type mice, embryos from streptozotocin-induced diabetic Box -/-mice experienced a significant decrease in glucose transport compared with embryos from non-diabetic Box -/- mice. However, despite this decrease, these blastocysts demonstrate significantly fewer apoptotic nuclei as compared with blastocysts from hyperglycemic wild-type mice. This decrease in preimplantation apoptosis correlates with a decrease in resorptions and malformations among the infants of the hyperglycemic Box -/- mice versus the Box +/+ and +/- mice. These findings suggest that hyperglycemia by decreasing glucose transport acts as a cell death signal to trigger a BAX-dependent apoptotic cascade in the murine blastocyst. This work also supports the hypothesis that increased apoptosis at a blastocyst stage because of maternal hyperglycemia may result in loss of key progenitor cells and manifest as a resorption or malformation, two adverse pregnancy outcomes more common in diabetic women.	Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Moley, KH (corresponding author), Washington Univ, Sch Med, Dept Obstet & Gynecol, 4911 Barnes Jewish Hosp Plaza,6th Floor Maternity, St Louis, MO 63110 USA.	moleyk@msnotes.wustl.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD034693] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030579] Funding Source: NIH RePORTER; NICHD NIH HHS [R03HD34693] Funding Source: Medline; NIDDK NIH HHS [T32DK38496-20, P60DK30579] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; BAUMGARTNERPARZER SM, 1995, DIABETES, V44, P1323, DOI 10.2337/diabetes.44.11.1323; Berridge MV, 1996, J IMMUNOL, V156, P4092; Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403; Blackburn RV, 1999, FREE RADICAL BIO MED, V26, P419, DOI 10.1016/S0891-5849(98)00217-2; BRINSTER RL, 1966, EXP CELL RES, V42, P308, DOI 10.1016/0014-4827(66)90295-3; Brison Daniel R., 1994, Zygote, V2, P69; Brison DR, 1996, MOL REPROD DEV, V44, P171, DOI 10.1002/(SICI)1098-2795(199606)44:2&lt;171::AID-MRD5&gt;3.0.CO;2-K; Cai J, 1998, DIABETES, V47, P1803, DOI 10.2337/diabetes.47.11.1803; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CHI MMY, 1993, P NATL ACAD SCI USA, V90, P10023, DOI 10.1073/pnas.90.21.10023; Deckwerth TL, 1998, EXP NEUROL, V152, P150, DOI 10.1006/exnr.1998.6846; Di Wu Q, 1999, AM J PHYSIOL-CELL PH, V277, pC1229, DOI 10.1152/ajpcell.1999.277.6.C1229; Diabet Control Complications Trial Res Grp, 1996, AM J OBSTET GYNECOL, V174, P1343; Donath MY, 1999, DIABETES, V48, P738, DOI 10.2337/diabetes.48.4.738; Eriksson UJ, 1996, DIABETES, V45, P1497, DOI 10.2337/diabetes.45.11.1497; GREENE MF, 1989, TERATOLOGY, V39, P225, DOI 10.1002/tera.1420390303; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Hawthorne G, 1997, BRIT MED J, V315, P279, DOI 10.1136/bmj.315.7103.279; Hill AL, 1998, DEV GENES EVOL, V208, P128, DOI 10.1007/s004270050163; HOMMA S, 1994, J COMP NEUROL, V345, P377, DOI 10.1002/cne.903450305; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Lee YJ, 1997, J CELL SCI, V110, P681; Leese HJ, 1995, HUM REPROD UPDATE, V1, P63, DOI 10.1093/humupd/1.1.63; LEESE HJ, 1991, EARLY EMBRYO DEV PAR, P117; Li WY, 1998, INVEST OPHTH VIS SCI, V39, P1535; Malhotra R, 1999, J BIOL CHEM, V274, P12567, DOI 10.1074/jbc.274.18.12567; MANDARINO LJ, 1994, INVEST OPHTH VIS SCI, V35, P964; MARTIN KL, 1995, MOL REPROD DEV, V40, P436, DOI 10.1002/mrd.1080400407; Moley KH, 1998, AM J PHYSIOL-ENDOC M, V275, pE38, DOI 10.1152/ajpendo.1998.275.1.E38; Moley KH, 2000, APOPTOSIS, V5, P99, DOI 10.1023/A:1009697908332; Moley KH, 1998, NAT MED, V4, P1421, DOI 10.1038/4013; MOLEY KH, 1991, J REPROD FERTIL, V93, P325; Pantaleon M, 1997, P NATL ACAD SCI USA, V94, P3795, DOI 10.1073/pnas.94.8.3795; Phelan SA, 1997, DIABETES, V46, P1189, DOI 10.2337/diabetes.46.7.1189; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Siman CM, 1997, DIABETES, V46, P1054, DOI 10.2337/diabetes.46.6.1054; Siman CM, 1997, DIABETOLOGIA, V40, P1416, DOI 10.1007/s001250050844; WALES RG, 1986, J REPROD FERTIL, V76, P717, DOI 10.1530/jrf.0.0760717; Wentzel P, 1998, DIABETES, V47, P677, DOI 10.2337/diabetes.47.4.677	41	117	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40252	40257		10.1074/jbc.M005508200	http://dx.doi.org/10.1074/jbc.M005508200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10995754	hybrid			2022-12-27	WOS:000166039500063
J	Gonzalez-Huici, V; Salas, M; Hermoso, JM				Gonzalez-Huici, V; Salas, M; Hermoso, JM			Sequence requirements for protein-primed initiation and elongation of phage O29 DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLIDING-BACK MECHANISM; PHI-29 TERMINAL PROTEIN; IN-VITRO; BACTERIOPHAGE PRD1; LINEAR TEMPLATE; POLYMERASE; ORIGINS; RECOGNITION; ACTIVATION; FIDELITY	The double-stranded linear DNA of Bacillus subtilis phage empty set29 is replicated by a mechanism in which a terminal protein (TP) acts as a primer. The second 3'-terminal nucleotide of the template directs the incorporation of the 5'-terminal nucleotide into the TP, giving rise to the initiation complex TP-dAMP. Elongation then proceeds by a sliding-back mechanism in which the dAMP covalently linked to the TP pairs to the S'-terminal nucleotide of the template strand to recover full-length DNA, We have studied the sequence requirements for efficient initiation of replication using mutated TP-free double-stranded DNA fragments. Efficient initiation only requires the terminal repetition 5'-AA The S'-terminal T, although not used as template, increases the affinity of DNA polymerase for the initiator nucleotide; in addition, although to a minor extent, the third 3'-terminal position also directs the formation of the initiation complex and modulates the initiation rate at the second position. Efficient elongation requires a previous sliding-back, demanding again a repetition of two nucleotides at the 3' end; if the sliding-back is prevented, a residual elongation can proceed directly from the second position or after jumping back from the third to the first position.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Salas, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Salas, Margarita/J-9873-2014; Gonzalez-Huici, Victor/ABB-4680-2020	Salas, Margarita/0000-0001-5939-3441; Gonzalez Huici, Victor/0000-0002-6977-1060	NIGMS NIH HHS [2R02GM27242-20] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BLANCO L, 1992, J BIOL CHEM, V267, P1225; BRAVO A, 1994, GENE, V148, P107, DOI 10.1016/0378-1119(94)90242-9; CALDENTEY J, 1993, NUCLEIC ACIDS RES, V21, P3725, DOI 10.1093/nar/21.16.3725; deVega M, 1996, EMBO J, V15, P1182, DOI 10.1002/j.1460-2075.1996.tb00457.x; Donaldson AD, 1999, CURR OPIN GENET DEV, V9, P62, DOI 10.1016/S0959-437X(99)80009-4; ESTEBAN JA, 1992, BIOCHEMISTRY-US, V31, P350, DOI 10.1021/bi00117a006; ESTEBAN JA, 1993, J BIOL CHEM, V268, P2719; Gonzalez-Huici V, 2000, J BIOL CHEM, V275, P14678, DOI 10.1074/jbc.M910058199; Goodman MF, 1997, P NATL ACAD SCI USA, V94, P10493, DOI 10.1073/pnas.94.20.10493; GUTIERREZ J, 1986, VIROLOGY, V155, P474, DOI 10.1016/0042-6822(86)90209-6; GUTIERREZ J, 1988, NUCLEIC ACIDS RES, V16, P5895, DOI 10.1093/nar/16.13.5895; GUTIERREZ J, 1986, GENE, V43, P1, DOI 10.1016/0378-1119(86)90002-8; Illana B, 1999, J BIOL CHEM, V274, P15073, DOI 10.1074/jbc.274.21.15073; Illana B, 1996, J MOL BIOL, V264, P453, DOI 10.1006/jmbi.1996.0653; INCIARTE MR, 1976, VIROLOGY, V74, P314, DOI 10.1016/0042-6822(76)90338-X; KING AJ, 1994, EMBO J, V13, P5786, DOI 10.1002/j.1460-2075.1994.tb06917.x; Lazaro JM, 1995, METHOD ENZYMOL, V262, P42; Martin AC, 1996, J MOL BIOL, V260, P369, DOI 10.1006/jmbi.1996.0407; Mendez J, 1997, EMBO J, V16, P2519, DOI 10.1093/emboj/16.9.2519; MENDEZ J, 1992, P NATL ACAD SCI USA, V89, P9579, DOI 10.1073/pnas.89.20.9579; MESSER W, 1996, ESCHERICHIA COLI SAL, V2, P1579; Moran S, 1997, P NATL ACAD SCI USA, V94, P10506, DOI 10.1073/pnas.94.20.10506; Ritzi M, 2000, GENE, V245, P13, DOI 10.1016/S0378-1119(00)00020-2; Salas M, 1991, ANNU REV BIOCHEM, V60, P37; SALAS M, 1996, DNA REPLICATION EUKA, P131; TEMPERLEY SM, 1992, EMBO J, V11, P761, DOI 10.1002/j.1460-2075.1992.tb05109.x; YOO SK, 1991, J MOL BIOL, V218, P779, DOI 10.1016/0022-2836(91)90266-9	28	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40547	40553		10.1074/jbc.M007170200	http://dx.doi.org/10.1074/jbc.M007170200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006291	hybrid			2022-12-27	WOS:000166039500100
J	Kataoka, H; Shimomura, T; Kawaguchi, T; Hamasuna, R; Itoh, H; Kitamura, N; Miyazawa, K; Koono, M				Kataoka, H; Shimomura, T; Kawaguchi, T; Hamasuna, R; Itoh, H; Kitamura, N; Miyazawa, K; Koono, M			Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SINGLE CHAIN FORM; 2 KUNITZ DOMAINS; SERINE-PROTEASE; PLACENTAL BIKUNIN; MOLECULAR-CLONING; TISSUE-INJURY; PRECURSOR; PURIFICATION; EXPRESSION	Hepatocyte growth factor activator (HGFA) is responsible for proteolytic activation of the precursor form of hepatocyte growth factor in injured tissues. To date, two specific inhibitors of HGFA have been identified, namely HGFA inhibitor type 1 (HAI-1) and type 2 (HAI-2)/placental bikunin (PB). Both inhibitors are first synthesized as integral membrane proteins having two Kunitz domains and a transmembrane domain, and are subsequently released from cell surface by shedding. Here we show that an active form of HGFA is specifically complexed with membrane-form HAI-1, but not with HAI-2/PB, on the surface of epithelial cells expressing both inhibitors. This binding required the enzyme activity of HGFA. The selective binding of HGFA to the cell surface HAI-1 was further confirmed in an engineered system using Chinese hamster ovary cells, in which only the cells expressing HAI-1 retained exogenous HGFA. The binding of HGFA to HAI-1 was reversible, and no irreversible modifications affecting the enzyme activity occurred during the binding. Importantly, HAI-1 and the HGFA HAI-1 complex were quickly released from the cell surface by treatment with phorbol 12-myristate 13-acetate or interleukin 1 beta accompanying the generation of 58-kDa fragments of HAI-1, which are less potent against HGFA, as well as significant recovery of HGFA activity in the culture supernatant. This regulated shedding was completely inhibited by BB3103, a synthetic zinc-metalloproteinase inhibitor. We conclude that HAI-1 is not only an inhibitor but also a specific acceptor of active HGFA, acting as a reservoir of this enzyme on the cell surface. The latter property appears to ensure the concentrated pericellular HGFA activity in certain cellular conditions, such as tissue injury and inflammation, via the up-regulated shedding of HGFA.HAI-1 complex. These findings shed light on a novel function of the integral membrane Kunitz-type inhibitor in the regulation of pericellular proteinase activity.	Miyazaki Med Coll, Dept Pathol 2, Miyazaki 8891692, Japan; Mitsubishi Tokyo Pharmaceut Inc, Yokohama Res Ctr, Aoba Ku, Yokohama, Kanagawa 2278502, Japan; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan	University of Miyazaki; Tokyo Institute of Technology	Kataoka, H (corresponding author), Miyazaki Med Coll, Dept Pathol 2, 5200 Kihara, Miyazaki 8891692, Japan.	mejina@fc.miyazaki-med.ac.jp	MIYAZAWA, KEIJI/I-9713-2014					Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; Delaria KA, 1997, J BIOL CHEM, V272, P12209, DOI 10.1074/jbc.272.18.12209; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Itoh H, 2000, BBA-GENE STRUCT EXPR, V1491, P295, DOI 10.1016/S0167-4781(00)00029-4; Itoh H, 2000, AM J PHYSIOL-GASTR L, V278, pG635, DOI 10.1152/ajpgi.2000.278.4.G635; Itoh M, 2000, EUR J BIOCHEM, V267, P3351, DOI 10.1046/j.1432-1327.2000.01368.x; Kataoka H, 1998, CANCER LETT, V128, P219, DOI 10.1016/S0304-3835(98)00067-6; Kataoka H, 1999, J HISTOCHEM CYTOCHEM, V47, P673, DOI 10.1177/002215549904700509; Kataoka H, 2000, CANCER LETT, V148, P127, DOI 10.1016/S0304-3835(99)00322-5; Kawaguchi T, 1997, J BIOL CHEM, V272, P27558, DOI 10.1074/jbc.272.44.27558; KAWAIDA K, 1994, P NATL ACAD SCI USA, V91, P4357, DOI 10.1073/pnas.91.10.4357; Kinoshita Y, 1997, DIGESTION, V58, P225, DOI 10.1159/000201448; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Marlor CW, 1997, J BIOL CHEM, V272, P12202, DOI 10.1074/jbc.272.18.12202; Matsubara Y, 1998, BIOCHEM BIOPH RES CO, V253, P477, DOI 10.1006/bbrc.1998.9808; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; Mitsiades N, 1998, AM J PATHOL, V153, P1947, DOI 10.1016/S0002-9440(10)65708-2; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; Miyazawa K, 1996, J BIOL CHEM, V271, P3615; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; MORISHITA H, 1994, THROMB RES, V73, P193, DOI 10.1016/0049-3848(94)90098-1; Muller-Pillasch F, 1998, BBA-GENE STRUCT EXPR, V1395, P88, DOI 10.1016/S0167-4781(97)00129-2; NAKA D, 1992, J BIOL CHEM, V267, P20114; Ohmichi H, 1996, AM J PHYSIOL-LUNG C, V270, pL1031, DOI 10.1152/ajplung.1996.270.6.L1031; Okajima A, 1997, HEPATOLOGY, V25, P97, DOI 10.1002/hep.510250118; PARK LS, 1986, J BIOL CHEM, V261, P205; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Qin L, 1998, FEBS LETT, V436, P111, DOI 10.1016/S0014-5793(98)01105-3; Schmassmann A, 1997, GASTROENTEROLOGY, V113, P1858, DOI 10.1016/S0016-5085(97)70005-2; Seguchi K, 1999, BIOL CHEM, V380, P473, DOI 10.1515/BC.1999.061; Shimomura T, 1999, J BIOCHEM-TOKYO, V126, P821, DOI 10.1093/oxfordjournals.jbchem.a022522; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; SHIMOMURA T, 1995, EUR J BIOCHEM, V229, P257, DOI 10.1111/j.1432-1033.1995.0257l.x; SHIMOMURA T, 1992, CYTOTECHNOLOGY, V8, P219, DOI 10.1007/BF02522039; SHIMOMURA T, 1993, J BIOL CHEM, V268, P22927; Stella MC, 1999, INT J BIOCHEM CELL B, V31, P1357, DOI 10.1016/S1357-2725(99)00089-8; TAMURA M, 1993, J BIOL CHEM, V268, P8140; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; Xu YB, 1998, J MOL BIOL, V276, P955, DOI 10.1006/jmbi.1997.1582	41	111	124	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40453	40462		10.1074/jbc.M006412200	http://dx.doi.org/10.1074/jbc.M006412200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11013244	hybrid			2022-12-27	WOS:000166039500088
J	Quinn, LM; Dorstyn, L; Mills, K; Colussi, PA; Chen, P; Coombe, M; Abrams, J; Kumar, S; Richardson, H				Quinn, LM; Dorstyn, L; Mills, K; Colussi, PA; Chen, P; Coombe, M; Abrams, J; Kumar, S; Richardson, H			An essential role for the caspase dronc in developmentally programmed cell death in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EYE IMAGINAL DISC; INDUCED APOPTOSIS; CYCLIN-E; PROTEASE; GENE; INHIBITOR; EXPRESSION; ACTIVATION; PATHWAY; REAPER	Drone is a caspase recruitment domain-containing Drosophila caspase that is expressed in a temporally and spatially restricted fashion during development. Drone is the only fly caspase known to be regulated by the hormone ecdysone. Here we show that ectopic expression of drone in the developing fly eye leads to increased cell death and an ablated eye phenotype that can be suppressed by halving the dosage of the genes in the H99 complex (reaper, hid, and grim) and enhanced by mutations in diap1. In contrast to previous reports, we show that the drone eye ablation phenotype can be suppressed by coexpression of the baculoviral caspase inhibitor p35. Drone also interacts, both genetically and biochemically, with the CED-4/Apaf-1 fly homolog, Dark. Furthermore, extracts made from Dark homozygous mutant flies have reduced ability to process Drone, showing that Dark is required for Drone processing. Finally, using the RNA interference technique, we show that loss of Drone function in early Drosophila embryos results in a dramatic decrease in cell death, indicating that Drone is important for programmed cell death during embryogenesis. These results suggest that Drone is a key caspase mediating programmed cell death in Drosophila.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Genet, Adelaide, SA 5001, Australia; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA	Institute Medical & Veterinary Science Australia; University of Adelaide; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kumar, S (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia.		Richardson, Helena E/A-8080-2013; Kumar, Sharad/AAX-7787-2020; Dorstyn, Loretta/F-3673-2013	Richardson, Helena E/0000-0003-3852-4953; Kumar, Sharad/0000-0001-7126-9814; Dorstyn, Loretta/0000-0001-9886-0989; Quinn, Leonie/0000-0002-3911-6508				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRAND AH, 1993, DEVELOPMENT, V118, P401; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; Claveria C, 1998, EMBO J, V17, P7199, DOI 10.1093/emboj/17.24.7199; Colussi PA, 2000, J CELL BIOL, V148, P703, DOI 10.1083/jcb.148.4.703; Colussi PA, 1998, J BIOL CHEM, V273, P26566, DOI 10.1074/jbc.273.41.26566; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1999, J BIOL CHEM, V274, P30778, DOI 10.1074/jbc.274.43.30778; ELLIS MC, 1993, DEVELOPMENT, V119, P855; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; Hawkins CJ, 1999, P NATL ACAD SCI USA, V96, P2885, DOI 10.1073/pnas.96.6.2885; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hunter CP, 1999, CURR BIOL, V9, pR440, DOI 10.1016/S0960-9822(99)80276-0; Igaki T, 2000, P NATL ACAD SCI USA, V97, P662, DOI 10.1073/pnas.97.2.662; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Jones G, 2000, J BIOL CHEM, V275, P22157, DOI 10.1074/jbc.M000369200; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Kumar S, 2000, CELL DEATH DIFFER, V7, P1039, DOI 10.1038/sj.cdd.4400756; Kumar S, 1999, TRENDS BIOCHEM SCI, V24, P1, DOI 10.1016/S0968-0004(98)01332-2; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; McCall K, 1998, SCIENCE, V279, P230, DOI 10.1126/science.279.5348.230; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; RICHARDSON H, 1995, DEVELOPMENT, V121, P3371; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Secombe J, 1998, GENETICS, V149, P1867; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Vernooy SY, 2000, J CELL BIOL, V150, pF69, DOI 10.1083/jcb.150.2.F69; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1997, MOL CELL BIOL, V17, P667, DOI 10.1128/MCB.17.2.667; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; Wianny F, 2000, NAT CELL BIOL, V2, P70, DOI 10.1038/35000016; Wing JP, 1998, CELL DEATH DIFFER, V5, P930, DOI 10.1038/sj.cdd.4400423; Zhou L, 1999, MOL CELL, V4, P745, DOI 10.1016/S1097-2765(00)80385-8; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2	54	125	132	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40416	40424		10.1074/jbc.M002935200	http://dx.doi.org/10.1074/jbc.M002935200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10984473	hybrid			2022-12-27	WOS:000166039500084
J	Weisz, OA; Wang, JM; Edinger, RS; Johnson, JP				Weisz, OA; Wang, JM; Edinger, RS; Johnson, JP			Non-coordinate regulation of endogenous epithelial sodium channel (ENaC) subunit expression at the apical membrane of A6 cells in response to various transporting conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL COLLECTING TUBULE; LUNG LIQUID CLEARANCE; SENSITIVE NA+ CHANNEL; BETA-SUBUNIT; SURFACE EXPRESSION; RECEPTOR SUBUNITS; XENOPUS-OOCYTES; ALDOSTERONE; KIDNEY; MICE	In many epithelial tissues in the body (e.g. kidney distal nephron, colon, airways) the rate of Na+ reabsorption is governed by the activity of the epithelial Na+ channel (ENaC), ENaC activity in turn is regulated by a number of factors including hormones, physiological conditions, and other ion channels. To begin to understand the mechanisms by which ENaC is regulated, we have examined the trafficking and turnover of ENaC subunits in A6 cells, a polarized, hormonally responsive Xenopus kidney cell line. As previously observed by others, the half-life of newly synthesized ENaC subunits was universally short (similar to2 h). However, the half-lives of alpha- and gamma -ENaC subunits that reached the apical cell surface were considerably longer (t(1/2) > 24 h), whereas intriguingly, the half-life of cell surface beta -ENaC was only approximately 6 h. We then examined the effects of various modulators of sodium transport on cell surface levels of individual ENaC subunits, Up-regulation of ENaC-mediated sodium conductance by overnight treatment with aldosterone or by short term incubation with vasopressin dramatically increased cell surface levels of beta -ENaC without affecting alpha- or gamma -ENaC levels. Conversely, treatment with brefeldin A selectively decreased the amount of beta -ENaC at the apical membrane. Short term treatment with aldosterone or insulin had no effect on cell surface amounts of any subunits, Subcellular fractionation revealed a selective loss of beta -ENaC from early endosomal pools in response to vasopressin, Our data suggest the possibility that trafficking and turnover of individual ENaC subunits at the apical membrane of A6 cells is non-coordinately regulated. The selective trafficking of beta -ENaC may provide a mechanism for regulating sodium conductance in response to physiological stimuli.	Univ Pittsburgh, Renal Electrolyte Div, Lab Epithelial Cell Biol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Johnson, JP (corresponding author), Univ Pittsburgh, Renal Electrolyte Div, Lab Epithelial Cell Biol, 3550 Terrace St, Pittsburgh, PA 15261 USA.	johnson@msx.dept-med.pitt.edu			NIDDK NIH HHS [R01DK47874] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047874] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CM, 1997, J BIOL CHEM, V272, P27295, DOI 10.1074/jbc.272.43.27295; Asher C, 1996, AM J PHYSIOL-CELL PH, V271, pC605, DOI 10.1152/ajpcell.1996.271.2.C605; Barker PM, 1998, J CLIN INVEST, V102, P1634, DOI 10.1172/JCI3971; Barnard EA, 1998, PHARMACOL REV, V50, P291; Blazer-Yost BL, 1998, AM J PHYSIOL-CELL PH, V274, pC1373, DOI 10.1152/ajpcell.1998.274.5.C1373; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; BURCH LH, 1995, AM J PHYSIOL-CELL PH, V269, pC511, DOI 10.1152/ajpcell.1995.269.2.C511; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; Cheng C, 1998, J BIOL CHEM, V273, P22693, DOI 10.1074/jbc.273.35.22693; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; ERLIJ D, 1994, J PHYSL, V481, P553; Escoubet B, 1997, AM J PHYSIOL-CELL PH, V272, pC1482, DOI 10.1152/ajpcell.1997.272.5.C1482; Eskandari S, 1999, J BIOL CHEM, V274, P27281, DOI 10.1074/jbc.274.38.27281; Farman N, 1997, AM J PHYSIOL-CELL PH, V272, pC131, DOI 10.1152/ajpcell.1997.272.1.C131; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Fisher RS, 1996, AM J PHYSIOL-CELL PH, V270, pC138, DOI 10.1152/ajpcell.1996.270.1.C138; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; HELMAN SI, 1983, J GEN PHYSIOL, V82, P201, DOI 10.1085/jgp.82.2.201; Helman SI, 1998, AM J PHYSIOL-CELL PH, V274, pC947, DOI 10.1152/ajpcell.1998.274.4.C947; Hummler E, 1999, AM J PHYSIOL-GASTR L, V276, pG567, DOI 10.1152/ajpgi.1999.276.3.G567; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; Ismailov II, 1996, J BIOL CHEM, V271, P807, DOI 10.1074/jbc.271.2.807; KELYMAN TR, 1994, AM J PHYSIOL, V266, pF506; KEMENDY AE, 1992, AM J PHYSIOL, V263, pC825, DOI 10.1152/ajpcell.1992.263.4.C825; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; Le KT, 1999, J BIOL CHEM, V274, P15415, DOI 10.1074/jbc.274.22.15415; Le KT, 1998, J NEUROSCI, V18, P7152; Leung SM, 2000, MOL BIOL CELL, V11, P2131, DOI 10.1091/mbc.11.6.2131; LING BN, 1989, AM J PHYSIOL, V256, pF1094, DOI 10.1152/ajprenal.1989.256.6.F1094; MARUNAKA Y, 1991, AM J PHYSIOL, V260, pC1071, DOI 10.1152/ajpcell.1991.260.5.C1071; MARUNAKA Y, 1992, AM J PHYSIOL, V263, pF392, DOI 10.1152/ajprenal.1992.263.3.F392; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; MATSUMOTO PS, 1993, AM J PHYSIOL, V264, pC246, DOI 10.1152/ajpcell.1993.264.1.C246; May A, 1997, J AM SOC NEPHROL, V8, P1813; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; PACHA J, 1993, J GEN PHYSIOL, V102, P25, DOI 10.1085/jgp.102.1.25; PALMER LG, 1983, AM J PHYSIOL, V244, pF195, DOI 10.1152/ajprenal.1983.244.2.F195; Palmer LG, 1996, J GEN PHYSIOL, V107, P35, DOI 10.1085/jgp.107.1.35; PALMER LG, 1988, J GEN PHYSIOL, V92, P121, DOI 10.1085/jgp.92.1.121; PRadervand S, 1999, P NATL ACAD SCI USA, V96, P1732, DOI 10.1073/pnas.96.4.1732; Prince LS, 1998, BIOCHEM J, V336, P705, DOI 10.1042/bj3360705; PUOTI A, 1995, AM J PHYSIOL, V269, pC1868; RENARD S, 1995, PFLUG ARCH EUR J PHY, V430, P299, DOI 10.1007/BF00373903; Rokaw MD, 1998, J BIOL CHEM, V273, P28746, DOI 10.1074/jbc.273.44.28746; Rokaw MD, 1996, AM J PHYSIOL-CELL PH, V270, pC600, DOI 10.1152/ajpcell.1996.270.2.C600; Ruknudin A, 1998, J BIOL CHEM, V273, P14165, DOI 10.1074/jbc.273.23.14165; SARIBANSOHRABY S, 1983, AM J PHYSIOL, V245, pC167, DOI 10.1152/ajpcell.1983.245.3.C167; Schaedel C, 1999, J PEDIATR-US, V135, P739, DOI 10.1016/S0022-3476(99)70094-6; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; STEELE RE, 1986, AM J PHYSIOL, V251, pC186; STEINMAN RM, 1976, J CELL BIOL, V68, P665, DOI 10.1083/jcb.68.3.665; TCHEPICHEV S, 1995, AM J PHYSIOL-CELL PH, V269, pC805, DOI 10.1152/ajpcell.1995.269.3.C805; Torres GE, 1998, MOL PHARMACOL, V54, P989, DOI 10.1124/mol.54.6.989; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; Valentijn JA, 1998, J BIOL CHEM, V273, P30344, DOI 10.1074/jbc.273.46.30344; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; Yeager M, 1998, CURR OPIN STRUC BIOL, V8, P517, DOI 10.1016/S0959-440X(98)80131-0; Zuckerman JB, 1999, J BIOL CHEM, V274, P23286, DOI 10.1074/jbc.274.33.23286	70	90	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39886	39893		10.1074/jbc.M003822200	http://dx.doi.org/10.1074/jbc.M003822200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10978318	hybrid			2022-12-27	WOS:000166039500015
J	Kumazaki, S; Nakajima, H; Sakaguchi, T; Nakagawa, E; Shinohara, H; Yoshihara, K; Aono, S				Kumazaki, S; Nakajima, H; Sakaguchi, T; Nakagawa, E; Shinohara, H; Yoshihara, K; Aono, S			Dissociation and recombination between ligands and heme in a CO-sensing transcriptional activator CooA - A flash photolysis study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOSPIRILLUM-RUBRUM; RAMAN-SPECTROSCOPY; CARBON-MONOXIDE; HISTIDINE 77; MYOGLOBIN; PROTEIN; PHOTODISSOCIATION; IDENTIFICATION; RELAXATION; ABSORPTION	CooA from Rhodospirillum rubrum is a transcriptional activator in which a heme prosthetic group acts as a CO sensor and regulates the activity of the protein. In this study, the electronic relaxation of the heme, and the concurrent recombination between ligands and the heme at similar to 280 K were examined in an effort to understand the environment around the heme and the dynamics of the ligands, Upon photoexcitation of the reduced CooA at 400 nm, electronic relaxation of the heme occurred with time constants of 0.8 and 1.7 ps, The ligand rebinding was substantially completed with a time constant of 6.5 ps, followed by a slow relaxation process with a time constant of 173 ps, In the case of GO-bound CooA, relaxation of the excited heme occurred with two time constants, 1.1 and 2.4 ps, which were largely similar to those with reduced CooA. The subsequent CO recombination process was remarkably fast compared with that of other GO-bound heme proteins. It was well described as a biphasic geminate recombination process with time constants of 78 ps (60%) and 386 ps (30%). About 10% of the excited heme remained unligated at 1.9 ns, The dynamics of rebinding of CO thus will help us to understand how the physiologically relevant diatomic molecule approaches the heme binding site in CooA with picosecond resolution.	Japan Adv Inst Sci & Technol, Sch Mat Sci, Tatsunokuchi, Ishikawa 9231292, Japan	Japan Advanced Institute of Science & Technology (JAIST)	Kumazaki, S (corresponding author), Japan Adv Inst Sci & Technol, Sch Mat Sci, Tatsunokuchi, Ishikawa 9231292, Japan.	kumazaki@jaist.ac.jp	Aono, Shigetoshi/ABD-7618-2020	Aono, Shigetoshi/0000-0002-2870-3694; Kumazaki, Shigeichi/0000-0003-0008-4200				Aono S, 1997, BIOCHEM BIOPH RES CO, V240, P783, DOI 10.1006/bbrc.1997.7746; Aono S, 1996, BIOCHEM BIOPH RES CO, V228, P752, DOI 10.1006/bbrc.1996.1727; Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Fox JD, 1996, J BACTERIOL, V178, P6200, DOI 10.1128/jb.178.21.6200-6208.1996; He YP, 1996, J BIOL CHEM, V271, P120, DOI 10.1074/jbc.271.1.120; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; JACKSON TA, 1994, CHEM PHYS, V180, P131, DOI 10.1016/0301-0104(93)E0414-Q; JONGEWARD KA, 1988, J BIOL CHEM, V263, P6027; Kholodenko Y, 1999, BIOCHEMISTRY-US, V38, P5918, DOI 10.1021/bi983022v; Lim MH, 1996, J PHYS CHEM-US, V100, P12043, DOI 10.1021/jp9536458; MARTIN CT, 1985, J BIOL CHEM, V260, P2857; MARTIN JL, 1992, ANNU REV BIOPH BIOM, V21, P199, DOI 10.1146/annurev.bb.21.060192.001215; Mizutani Y, 1997, SCIENCE, V278, P443, DOI 10.1126/science.278.5337.443; Mizutani Y, 1999, INT CONGR SER, V1194, P85; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; PETRICH JW, 1989, CHEM PHYS, V131, P31, DOI 10.1016/0301-0104(89)87079-X; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; SCHELVIS JP, 1997, J AM CHEM SOC, V119, P8400; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; STOUTLAND PO, 1991, J PHYS CHEM-US, V95, P6406, DOI 10.1021/j100170a004; Uchida T, 1998, J BIOL CHEM, V273, P19988, DOI 10.1074/jbc.273.32.19988; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; XIE XL, 1991, BIOCHEMISTRY-US, V30, P3682, DOI 10.1021/bi00229a013	26	43	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38378	38383		10.1074/jbc.M005533200	http://dx.doi.org/10.1074/jbc.M005533200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10978334	hybrid			2022-12-27	WOS:000165739800034
J	Mechanic, LE; Frankel, BA; Matson, SW				Mechanic, LE; Frankel, BA; Matson, SW			Escherichia coli MutL loads DNA helicase II onto DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MISMATCH REPAIR; BACTERIOPHAGE-T7 DEOXYRIBONUCLEIC-ACID; SINGLE-STRANDED-DNA; GENE-PRODUCT; REPLICATION FIDELITY; GENOME INSTABILITY; UVRD PROTEIN; BINDING; CANCER; HETERODUPLEX	Previous studies have shown that MutL physically interacts with UvrD (DNA helicase II) (Hall, M. C., Jordan, J. R., and Matson, S. W. (1998) EMBO J. 17, 1535-1541) and dramatically stimulates the unwinding reaction catalyzed by UvrD in the presence and absence of the other protein components of the methyl-directed mismatch repair pathway (Yamaguchi, M., Dao, V., and Modrich, P. (1998) J. Biol. Chem. 273, 9197-9201). The mechanism of this stimulation was investigated using DNA binding assays, single-turnover helicase assays, and unwinding assays involving long duplex DNA substrates. The results indicate that MutL binds DNA and loads UvrD onto the DNA substrate, The interaction between MutL and DNA and that between MutL and UvrD are both important for stimulation of UvrD-catalyzed unwinding. MutL does not clamp UvrD onto the substrate; and therefore, the processivity of unwinding is not increased in the presence of MutL. The implications of these results are discussed, and models are presented for the mechanism of MutL stimulation as well as for the role of MutL as a master coordinator in the methyl-directed mismatch repair pathway.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Prot Engn, Chapel Hill, NC 27599 USA; Univ N Carolina, Mol Genet Training Program, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Matson, SW (corresponding author), Univ N Carolina, Dept Biol, CB 3280,Coker Hall, Chapel Hill, NC 27599 USA.	smatson@tbio.unc.edu			NIGMS NIH HHS [GM33476] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033476] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ail JA, 1999, J MOL BIOL, V293, P815, DOI 10.1006/jmbi.1999.3185; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; AU KG, 1992, J BIOL CHEM, V267, P12142; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; BENDE SM, 1991, NUCLEIC ACIDS RES, V19, P1549, DOI 10.1093/nar/19.7.1549; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; BROSH RM, 1995, J BACTERIOL, V177, P5612, DOI 10.1128/jb.177.19.5612-5621.1995; Brosh RM, 1996, J BIOL CHEM, V271, P25360, DOI 10.1074/jbc.271.41.25360; COOPER DL, 1993, J BIOL CHEM, V268, P11823; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; GEORGE JW, 1994, J MOL BIOL, V235, P424, DOI 10.1006/jmbi.1994.1003; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; Hall MC, 1998, J MOL BIOL, V277, P257, DOI 10.1006/jmbi.1997.1614; HALL MH, 1998, THESIS U N CAROLINA; Jiricny J, 1996, CANCER SURV, V28, P47; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1986, J BIOL CHEM, V261, P169; Mechanic LE, 1999, J BACTERIOL, V181, P2519, DOI 10.1128/JB.181.8.2519-2526.1999; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1987, ANNU REV BIOCHEM, V56, P435, DOI 10.1146/annurev.biochem.56.1.435; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; RUNYON GT, 1990, P NATL ACAD SCI USA, V87, P6383, DOI 10.1073/pnas.87.16.6383; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; Smith J.A., 2000, CURRENT PROTOCOLS MO; Spampinato C, 2000, J BIOL CHEM, V275, P9863, DOI 10.1074/jbc.275.13.9863; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; WELSH KM, 1987, J BIOL CHEM, V262, P15624; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197	48	98	105	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38337	38346		10.1074/jbc.M006268200	http://dx.doi.org/10.1074/jbc.M006268200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10984488	hybrid, Green Published			2022-12-27	WOS:000165739800029
J	Njau, RK; Herndon, CA; Hawes, JW				Njau, RK; Herndon, CA; Hawes, JW			Novel beta-hydroxyacid dehydrogenases in Escherichia coli and Haemophilus influenzae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; 3-HYDROXYISOBUTYRATE DEHYDROGENASE; GENE; 6-PHOSPHOGLUCONATE	Our laboratory has previously reported a structurally and mechanistically related family of beta -hydroxyacid dehydrogenases with significant homology to beta -hydroxyisobutyrate dehydrogenase. A large number of the members of this family are hypothetical proteins of bacterial origin with unknown identity in terms of their substrate specificities and metabolic roles. The Escherichia coli beta -hydroxyacid dehydrogenase homologue corresponding to the AE000157 locus was cloned and expressed with a 6-histidine tag for specific purification. The purified recombinant protein very specifically catalyzed the NAD(+)-dependent oxidation of D-glycerate and the NADH-dependent reduction of tartronate semialdehyde, identifying this protein as a tartronate semialdehyde reductase. Further evidence for identification as tartronate semialdehyde reductase is the observation that the coding region for this protein is directly preceded by genes coding for hydroxypyruvate isomerase and glyoxylate carboligase, two enzymes that synthesize tartronate semialdehyde, producing an operon clearly designed for D-glycerate biosynthesis from tartronate semialdehyde. The single beta -hydroxyacid dehydrogenase homologue from Haemophilus influenzae was also cloned, expressed, and purified with a g-histidine tag. This protein also catalyzed the NAD(+)-dependent oxidation of D-glycerate but was significantly more efficient in the oxidation of four-carbon beta -hydroxyacids like D-hydroxybutyrate and D-threonine. This enzyme differs from all the presently known beta -hydroxybutyrate dehydrogenases which are well established members of the short chain dehydrogenase/reductase superfamily.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Hawes, JW (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	jhawes@iupui.edu						ADAMS MJ, 1994, STRUCTURE, V2, P651, DOI 10.1016/S0969-2126(00)00066-6; ANDERSON AJ, 1990, MICROBIOL REV, V54, P450, DOI 10.1128/MMBR.54.4.450-472.1990; Aneja P, 1999, J BACTERIOL, V181, P849, DOI 10.1128/JB.181.3.849-857.1999; Ashiuchi M, 1999, BBA-PROTEIN STRUCT M, V1435, P153, DOI 10.1016/S0167-4838(99)00216-2; BERGMEYER HU, 1967, BIOCHEM J, V102, P423, DOI 10.1042/bj1020423; Gamble MV, 1999, J LIPID RES, V40, P2279; HAWES JW, 1995, BIOCHEMISTRY-US, V34, P4231, DOI 10.1021/bi00013a012; Hawes JW, 1996, FEBS LETT, V389, P263, DOI 10.1016/0014-5793(96)00597-2; HAWES JW, 1996, ENZYMOLOGY MOL BIOL, P395; Jia Y, 2000, BIOCHEMISTRY-US, V39, P3927, DOI 10.1021/bi9928086; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KOHN LD, 1968, J BIOL CHEM, V243, P2465; KOHN LD, 1968, J BIOL CHEM, V243, P4426; Kruger K, 1999, APPL MICROBIOL BIOT, V52, P666, DOI 10.1007/s002530051576; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mirny LA, 1999, J MOL BIOL, V291, P177, DOI 10.1006/jmbi.1999.2911; ROUGRAFF PM, 1988, J BIOL CHEM, V263, P327; STEELE MI, 1992, J BIOL CHEM, V267, P13585; WILLIAMSON DH, 1974, METHODS ENZYMATIC AN; ZHANG L, 1999, BIOCHEMITRY, V18, P11231; ZHAO Y, 1994, J BIOL CHEM, V269, P18583	21	17	19	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38780	38786		10.1074/jbc.M007432200	http://dx.doi.org/10.1074/jbc.M007432200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10978349	hybrid			2022-12-27	WOS:000165739800088
J	Roshick, C; Iliffe-Lee, ER; McClarty, G				Roshick, C; Iliffe-Lee, ER; McClarty, G			Cloning and characterization of ribonucleotide reductase from Chlamydia trachomatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA SECONDARY STRUCTURE; ESCHERICHIA-COLI; LARGE SUBUNIT; HYDROXYUREA RESISTANCE; TRANSLATION INITIATION; DIPHOSPHATE REDUCTASE; QUANTITATIVE-ANALYSIS; ALLOSTERIC REGULATION; TRYPANOSOMA-BRUCEI; RECOMBINANT MOUSE	In all organisms the deoxyribonucleotide precursors required for DNA synthesis are synthesized from ribonucleotides, a reaction catalyzed by ribonucleotide reductase. In a previous study we showed that Chlamydia trachomatis growth was inhibited by hydroxyurea, an inhibitor of ribonucleotide reductase, and a mutant resistant to the cytotoxic effects of the drug was isolated. Here we report the cloning, expression, and purification of the R1 and R2 subunits of the C. trachomatis ribonucleotide reductase. In comparison with other ribonucleotide reductases, the primary sequence of protein R1 has an extended amino terminus, and the R2 protein has a phenylalanine where the essential tyrosine is normally located. Despite its unusual primary structure, the recombinant enzyme catalyzes the reduction of CDP to dCDP. Results from deletion mutagenesis experiments indicate that while the extended amino terminus of the R1 protein is not required for enzyme activity, it is needed for allosteric inhibition mediated by dATP. Results with site directed mutants of protein R2 suggest that the essential tyrosine is situated two amino acids downstream of its normal location. Finally, Western blot analysis show that the hydroxyurea-resistant mutant C. trachomatis isolate overexpresses both subunits of ribonucleotide reductase. At the genetic level, compared with wild type C. trachomatis, the resistant isolate has a single base mutation just upstream of the ATG start codon of the R2 protein. The possibility that this mutation affects translational efficiency is discussed.	Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E 0W3, Canada	University of Manitoba	McClarty, G (corresponding author), Univ Manitoba, Dept Med Microbiol, 730 William Ave, Winnipeg, MB R3E 0W3, Canada.	mcclart@cc.umanitoba.ca						BARRICK D, 1994, NUCLEIC ACIDS RES, V22, P1287, DOI 10.1093/nar/22.7.1287; BERGLUND O, 1972, J BIOL CHEM, V247, P7276; BOOKER S, 1994, BIOCHEMISTRY-US, V33, P12676, DOI 10.1021/bi00208a019; BOOKER S, 1993, P NATL ACAD SCI USA, V90, P8352, DOI 10.1073/pnas.90.18.8352; CALDWELL HD, 1981, INFECT IMMUN, V31, P1161, DOI 10.1128/IAI.31.3.1161-1176.1981; Chabes A, 2000, P NATL ACAD SCI USA, V97, P2474, DOI 10.1073/pnas.97.6.2474; CHOY BK, 1988, CANCER RES, V48, P2029; DAVIS R, 1994, J BIOL CHEM, V269, P23171; Davydov A, 1996, BIOCHEM BIOPH RES CO, V219, P213, DOI 10.1006/bbrc.1996.0207; DESMIT MH, 1994, J MOL BIOL, V244, P144, DOI 10.1006/jmbi.1994.1714; DESMIT MH, 1994, J MOL BIOL, V235, P173, DOI 10.1016/S0022-2836(05)80024-5; EHRENBERG A, 1972, J BIOL CHEM, V247, P3485; Eklund H, 1997, BIOL CHEM, V378, P821; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; FAHR MJ, 1995, J BACTERIOL, V177, P4252, DOI 10.1128/jb.177.15.4252-4260.1995; FAN HZ, 1991, J BACTERIOL, V173, P6670, DOI 10.1128/jb.173.21.6670-6677.1991; FLENSBURG J, 1987, EUR J BIOCHEM, V162, P473, DOI 10.1111/j.1432-1033.1987.tb10664.x; FRAIZ J, 1988, ANNU REV MED, V39, P357, DOI 10.1146/annurev.me.39.020188.002041; FUCHS JA, 1976, J BACTERIOL, V128, P810, DOI 10.1128/JB.128.3.810-814.1976; FURLONG J, 1991, VIROLOGY, V182, P846, DOI 10.1016/0042-6822(91)90627-N; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; HANKE PD, 1983, J BACTERIOL, V156, P1192, DOI 10.1128/JB.156.3.1192-1197.1983; Hofer A, 1997, P NATL ACAD SCI USA, V94, P6959, DOI 10.1073/pnas.94.13.6959; Hofer A, 1998, J BIOL CHEM, V273, P34098, DOI 10.1074/jbc.273.51.34098; Iliffe-Lee ER, 1999, MOL MICROBIOL, V33, P177, DOI 10.1046/j.1365-2958.1999.01464.x; Jordan A, 1997, P NATL ACAD SCI USA, V94, P13487, DOI 10.1073/pnas.94.25.13487; Jordan A, 1999, J BACTERIOL, V181, P3974, DOI 10.1128/JB.181.13.3974-3980.1999; JORDAN A, 1994, P NATL ACAD SCI USA, V91, P12892, DOI 10.1073/pnas.91.26.12892; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Kalman S, 1999, NAT GENET, V21, P385, DOI 10.1038/7716; LACY MJ, 1986, J IMMUNOL METHODS, V87, P169, DOI 10.1016/0022-1759(86)90527-2; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LESAGE P, 1992, J MOL BIOL, V228, P366, DOI 10.1016/0022-2836(92)90827-7; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MATHEWS SA, 1994, J BACTERIOL, V176, P3785, DOI 10.1128/JB.176.12.3785-3789.1994; MCCLARTY G, 1991, J BACTERIOL, V173, P4922, DOI 10.1128/jb.173.16.4922-4931.1991; McClarty G, 1999, CHLAMYDIA, P69; MCCLARTY GA, 1987, BIOCHEMISTRY-US, V26, P8004, DOI 10.1021/bi00398a068; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; NILSSON O, 1988, Nucleic Acids Research, V16, P4174, DOI 10.1093/nar/16.9.4174; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; Potsch S, 1999, J BIOL CHEM, V274, P17696, DOI 10.1074/jbc.274.25.17696; Read TD, 2000, NUCLEIC ACIDS RES, V28, P1397, DOI 10.1093/nar/28.6.1397; Riera J, 1997, P NATL ACAD SCI USA, V94, P475, DOI 10.1073/pnas.94.2.475; RINGQUIST S, 1992, MOL MICROBIOL, V6, P1219, DOI 10.1111/j.1365-2958.1992.tb01561.x; Sauge-Merle S, 1999, EUR J BIOCHEM, V266, P62, DOI 10.1046/j.1432-1327.1999.00814.x; Schachter J, 1999, CHLAMYDIA, P139; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SLABAUGH MB, 1986, J VIROL, V60, P506, DOI 10.1128/JVI.60.2.506-514.1986; SLABAUGH MB, 1993, J BIOL CHEM, V268, P17803; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; Storz J., 1988, Microbiology of Chlamydia., P167; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; THELANDER M, 1989, EMBO J, V8, P2475, DOI 10.1002/j.1460-2075.1989.tb08383.x; TIPPLES G, 1993, MOL MICROBIOL, V8, P1105, DOI 10.1111/j.1365-2958.1993.tb01655.x; TIPPLES G, 1991, J BACTERIOL, V173, P4932, DOI 10.1128/jb.173.16.4932-4940.1991; TIPPLES G, 1995, J BIOL CHEM, V270, P7908, DOI 10.1074/jbc.270.14.7908; WALKER D, 1992, J MOL BIOL, V228, P265, DOI 10.1016/0022-2836(92)90505-E; Wylie JL, 1996, MOL MICROBIOL, V22, P631, DOI 10.1046/j.1365-2958.1996.d01-1717.x; Zhong GM, 1999, J EXP MED, V189, P1931, DOI 10.1084/jem.189.12.1931	65	63	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38111	38119		10.1074/jbc.M006367200	http://dx.doi.org/10.1074/jbc.M006367200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10984489	hybrid			2022-12-27	WOS:000165618700107
J	Sotgia, F; Lee, JK; Das, K; Bedford, M; Petrucci, TC; Macioce, P; Sargiacomo, M; Bricarelli, FD; Minetti, C; Sudol, M; Lisanti, MP				Sotgia, F; Lee, JK; Das, K; Bedford, M; Petrucci, TC; Macioce, P; Sargiacomo, M; Bricarelli, FD; Minetti, C; Sudol, M; Lisanti, MP			Caveolin-3 directly interacts with the C-terminal tail of beta-dystroglycan - Identification of a central WW-like domain within caveolin family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-ASSOCIATED GLYCOPROTEINS; RICH MEMBRANE DOMAINS; SCAFFOLDING DOMAIN; INTEGRAL COMPONENT; PLASMA-MEMBRANE; PROTEIN; TYROSINE; EXPRESSION; SEQUENCE; ASSOCIATION	Caveolin-3, the most recently recognized member of the caveolin gene family, is muscle-specific and is found in both cardiac and skeletal muscle, as well as smooth muscle cells. Several independent lines of evidence indicate that caveolin-3 is localized to the sarcolemma, where it associates with the dystrophin-glycoprotein complex. However, it remains unknown which component of the dystrophin complex interacts with caveolin-3. Here, we demonstrate that caveolin-3 directly interacts with beta -dystroglycan, an integral membrane component of the dystrophin complex. Our results indicate that caveolin-3 co-localizes, co-fractionates, and coimmunoprecipitates with a fusion protein containing the cytoplasmic tail of beta -dystroglycan. In addition, we show that a novel WW-like domain within caveolin-3 directly recognizes the extreme C terminus of beta -dystroglycan that contains a PPXY motif. As the WW domain of dystrophin recognizes the same site within beta -dystroglycan, we also demonstrate that caveolin-3 can effectively block the interaction of dystrophin with beta -dystroglycan. In this regard, interaction of caveolin-3 with beta -dystroglycan may competitively regulate the recruitment of dystrophin to the sarcolemma. We discuss the possible implications of our findings in the context of Duchenne muscular dystrophy.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Univ Genoa, Ist Gaslini, Serv Malattie Neuro Muscolari, I-16147 Genoa, Italy; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Ist Super Sanita, Biol Cellulaire Lab, I-00161 Rome, Italy; Ist Super Sanita, Dept Hematol Oncol, I-00161 Rome, Italy; CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA; EO Osped Galliera, Lab Genet Umana, I-16128 Genoa, Italy	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Genoa; IRCCS Istituto Giannina Gaslini; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Harvard Medical School; Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Ente Ospedaliero Ospedali Galliera	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Macioce, Pompeo/H-2142-2016; Minetti, Carlo/K-4666-2018; Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013; Bedford, Mark T/E-7856-2011	Macioce, Pompeo/0000-0002-1829-9448; Minetti, Carlo/0000-0002-0640-1804; Lisanti, Michael/0000-0003-2034-1382; Sotgia, Federica/0000-0003-2826-4529; Sargiacomo, Massimo/0000-0003-4040-706X	Telethon [1111] Funding Source: Medline	Telethon(Fondazione Telethon)		BONILLA E, 1981, AM J PATHOL, V104, P167; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Crosbie RH, 1998, FEBS LETT, V427, P279, DOI 10.1016/S0014-5793(98)00442-6; Das K, 1999, J BIOL CHEM, V274, P18721, DOI 10.1074/jbc.274.26.18721; di Vignano AT, 2000, FEBS LETT, V471, P229, DOI 10.1016/S0014-5793(00)01400-9; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Galbiati F, 2000, P NATL ACAD SCI USA, V97, P9689, DOI 10.1073/pnas.160249097; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Irusta PM, 1998, EMBO J, V17, P6912, DOI 10.1093/emboj/17.23.6912; James M, 2000, J CELL SCI, V113, P1717; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; MCFARLAND EDC, 1995, J BIOL CHEM, V270, P28103; NORTH AJ, 1993, J CELL BIOL, V120, P1159, DOI 10.1083/jcb.120.5.1159; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Razani B, 2000, J CELL SCI, V113, P2103; Rentschler S, 1999, BIOL CHEM, V380, P431, DOI 10.1515/BC.1999.057; Repetto S, 1999, BIOCHEM BIOPH RES CO, V261, P547, DOI 10.1006/bbrc.1999.1055; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Rosa G, 1996, BIOCHEM BIOPH RES CO, V223, P272, DOI 10.1006/bbrc.1996.0883; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SARGIACOMO M, 1994, ONCOGENE, V9, P2589; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schlegel A, 2000, J BIOL CHEM, V275, P21605, DOI 10.1074/jbc.M002558200; Schlegel A, 1999, J BIOL CHEM, V274, P22660, DOI 10.1074/jbc.274.32.22660; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SEVERS NJ, 1988, J CELL SCI, V90, P341; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711	60	172	178	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38048	38058		10.1074/jbc.M005321200	http://dx.doi.org/10.1074/jbc.M005321200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10988290	hybrid			2022-12-27	WOS:000165618700099
J	Verhaegh, GW; van Bokhoven, A; Smit, F; Schalken, JA; Bussemakers, MJG				Verhaegh, GW; van Bokhoven, A; Smit, F; Schalken, JA; Bussemakers, MJG			Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROGEN-REGULATED EXPRESSION; TISSUE-SPECIFIC EXPRESSION; DNA-BINDING; MEMBRANE ANTIGEN; TRANSGENIC MICE; THERAPY; IDENTIFICATION; ENHANCERS; PROTEINS; CLONING	Recently, we have described a novel gene, DD3, which is one of the most prostate cancer-specific genes described to date (Bussemakers, M. J. G., van Bokhoven, A., Verhaegh, G. W,, Smit, F. P., Karthaus, H. F. M., Schalken, J. A, Debruyne, F. M. J., Ru, N., and Isaacs, W. B. (1999) Cancer Res. 59, 5975-5979). The prostate cancer-specific expression of DD3 indicates that the DD3 gene promoter is a promising tool for the treatment of prostate cancer. To identify the promoter elements that are responsible for the prostate cancer-specific expression of DD3, we have isolated and characterized the DD3 promoter. Sequence analysis of the DD3 B'-flanking region was performed and several promoter-human growth hormone reporter constructs were prepared, which were transiently transfected in the DD3-positive cell line LNCaP and several DD3-negative cell lines. Using a 500-base pair DD3 promoter construct, we could detect promoter activity in LNCaP cells, which was not affected by increasing the size of the constructs. Truncated constructs, however, showed an increased transcriptional activity, suggesting the presence of a silencer that negatively regulates the expression of DD3. DNase-I footprint analysis, using nuclear extracts from LNCaP cells, revealed the presence of three DNase-I-protected areas within the DD3 proximal promoter. We show that the high mobility group I(Y) protein binds to one of the DNase-I-protected areas and recruits another, yet unidentified, protein to the DD3 promoter in LNCaP cells.	Catholic Univ Nijmegen, Med Ctr, Urol Res Lab, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Verhaegh, GW (corresponding author), Catholic Univ Nijmegen, Med Ctr, Urol Res Lab, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Verhaegh, Gerald/L-4708-2015; Schalken, Jack A/B-1277-2014; Bussemakers, Marion JG/D-4259-2012	Verhaegh, Gerald/0000-0003-0227-2280; Schalken, Jack A/0000-0001-8274-7797; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Boulikas T, 1997, ANTICANCER RES, V17, P1471; Brakebusch C, 1997, J BIOL CHEM, V272, P3674, DOI 10.1074/jbc.272.6.3674; Bussemakers MJG, 1999, CANCER RES, V59, P5975; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dubbink HJ, 1996, BIOCHEM J, V315, P901, DOI 10.1042/bj3150901; Gotoh A, 1998, J UROLOGY, V160, P220, DOI 10.1016/S0022-5347(01)63094-5; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; ISRAELI RS, 1993, CANCER RES, V53, P227; Israeli RS, 1997, UROL CLIN N AM, V24, P439, DOI 10.1016/S0094-0143(05)70391-8; Kaluz S, 1999, J BIOL CHEM, V274, P32588, DOI 10.1074/jbc.274.46.32588; LIN MF, 1992, CANCER RES, V52, P4600; Martiniello-Wilks R, 1998, HUM GENE THER, V9, P1617, DOI 10.1089/hum.1998.9.11-1617; MCCORMACK RT, 1995, UROLOGY, V45, P729, DOI 10.1016/S0090-4295(99)80076-4; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Overdier DG, 1997, J BIOL CHEM, V272, P13725, DOI 10.1074/jbc.272.21.13725; Pang S, 1997, CANCER RES, V57, P495; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Reiter RE, 1998, P NATL ACAD SCI USA, V95, P1735, DOI 10.1073/pnas.95.4.1735; Sambrook J., 2002, MOL CLONING LAB MANU; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Sokoll LJ, 1997, UROL CLIN N AM, V24, P253, DOI 10.1016/S0094-0143(05)70370-0; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; TAMIMI Y, 1993, CANCER RES, V53, P5512; TANEJA SS, 1995, CANCER SURV, V23, P247; vanWeerden WM, 1996, AM J PATHOL, V149, P1055; Wei CW, 1997, P NATL ACAD SCI USA, V94, P6369, DOI 10.1073/pnas.94.12.6369; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; YE JP, 1994, J BIOL CHEM, V269, P25728	37	35	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37496	37503		10.1074/jbc.M006293200	http://dx.doi.org/10.1074/jbc.M006293200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982808	hybrid, Green Published			2022-12-27	WOS:000165618700028
J	Studer, S; Narberhaus, F				Studer, S; Narberhaus, F			Chaperone activity and homo- and hetero-oligomer formation of bacterial small heat shock proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; QUATERNARY STRUCTURE; LENS ALPHA; EXPRESSION; HSP25; IBPB; COMPLEX; BINDING	Rhizobia are the only bacteria known to induce a multitude of small heat shock proteins (sHsps) upon temperature upshift. The sHsps of Bradyrhizobium japonicum fall into two different classes, class A and class B. Here, we studied the chaperone activity and oligomeric features of two representative members of each class. The purified sHsps were efficient chaperones, as demonstrated by their ability to prevent thermally induced aggregation of citrate synthase in vitro. Homo-oligomer formation of all four sHsps was demonstrated by gel filtration and by two independent co-purification approaches. Mixed oligomers were readily observed between members of the same class, even when these proteins originated from different species such as Escherichia coli and B. japonicum. The chaperone activity of purified hetero oligomers was indistinguishable from the activity of homo-oligomers. Heteromeric complexes were never obtained between class A and class B sHsps, indicating that hetero-oligomer formation is restricted to sHsps of the same class.	Swiss Fed Inst Technol, Inst Microbiol, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Narberhaus, F (corresponding author), Swiss Fed Inst Technol, Inst Microbiol, Schmelzbergstr 7, CH-8092 Zurich, Switzerland.	fnarber@micro.biol.ethz.ch		Narberhaus, Franz/0000-0002-8552-5310				ALLEN SP, 1992, J BACTERIOL, V174, P6938, DOI 10.1128/JB.174.21.6938-6947.1992; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Chang ZY, 1996, J BIOL CHEM, V271, P7218, DOI 10.1074/jbc.271.12.7218; Cobb BA, 2000, J BIOL CHEM, V275, P6664, DOI 10.1074/jbc.275.9.6664; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; Haley DA, 2000, J MOL BIOL, V298, P261, DOI 10.1006/jmbi.2000.3657; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Helm KW, 1997, PLANT PHYSIOL, V114, P1477, DOI 10.1104/pp.114.4.1477; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kitagawa M, 2000, FEMS MICROBIOL LETT, V184, P165, DOI 10.1111/j.1574-6968.2000.tb09009.x; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; Lindner RA, 2000, EUR J BIOCHEM, V267, P1923, DOI 10.1046/j.1432-1327.2000.01188.x; MERCK KB, 1993, J BIOL CHEM, V268, P1046; Munchbach M, 1999, J BACTERIOL, V181, P83; Munchbach M, 1999, EUR J BIOCHEM, V264, P39, DOI 10.1046/j.1432-1327.1999.00567.x; Roy SK, 1999, EUR J BIOCHEM, V262, P406, DOI 10.1046/j.1432-1327.1999.00380.x; Shearstone JR, 1999, J BIOL CHEM, V274, P9937, DOI 10.1074/jbc.274.15.9937; Soto A, 1999, PLANT PHYSIOL, V120, P521, DOI 10.1104/pp.120.2.521; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; Thomas JG, 1998, J BACTERIOL, V180, P5165, DOI 10.1128/JB.180.19.5165-5172.1998; van Boekel MAM, 1999, BBA-PROTEIN STRUCT M, V1434, P114, DOI 10.1016/S0167-4838(99)00178-8; van de Klundert FAJM, 1998, EUR J BIOCHEM, V258, P1014, DOI 10.1046/j.1432-1327.1998.2581014.x; Waters ER, 1996, J EXP BOT, V47, P325, DOI 10.1093/jxb/47.3.325; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936	34	75	81	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37212	37218		10.1074/jbc.M004701200	http://dx.doi.org/10.1074/jbc.M004701200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10978322	hybrid			2022-12-27	WOS:000165577700103
J	Li, Y; Pursell, ZF; Linn, S				Li, Y; Pursell, ZF; Linn, S			Identification and cloning of two histone fold motif-containing subunits of HeLa DNA polymerase epsilon. (vol 275, 23247, 2000)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Correction																		Li Y, 2000, J BIOL CHEM, V275, P23247, DOI 10.1074/jbc.M002548200	1	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31554	31554						1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	11013269				2022-12-27	WOS:000089762700111
J	Yamada, A; Yamada, M; Fujita, Y; Nishigami, T; Nakasho, K; Uematsu, K				Yamada, A; Yamada, M; Fujita, Y; Nishigami, T; Nakasho, K; Uematsu, K			Self-augmentation effect of male-specific products on sexually differentiated progesterone metabolism in adult male rat liver microsomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE; 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE; STEROID 5-ALPHA-REDUCTASE; HEPATIC CYTOCHROME-P450; DEPENDENT EXPRESSION; BINDING SITE; DWARF RATS; PROFILE; PLASMA; GENE	It is well known that several 3-keto-4-ene steroids such as progesterone and testosterone are metabolized in a gender-specific or -predominant manner by adult rat liver microsomes. In the male, these steroids are primarily metabolized into two oxidized (16 alpha -hydroxyl and 6 beta -hydroxyl) products mainly by the respective, male-specific cytochrome P450 subforms, CYP2C11 and CYP3A2, while they are primarily metabolized into the 5 alpha -reduced products by female-predominant 5 alpha -reductase in the female. These sexually differentiated enzyme activities are largely regulated at the transcription level under endocrine control. In the present study, we show that unlabeled 16 alpha -hydroxyprogesterone and 6 beta -hydroxyprogesterone inhibited the 5 alpha -reductive [H-3]progesterone metabolism by adult male rat liver microsomes without significantly inhibiting the CYP2C11 and CYP3A2 activities producing themselves, whereas 3 alpha -hydroxy-5 alpha -pregnan-20-one and 5 alpha -pregnane-3,20-dione not only stimulated the 5 alpha -reductive metabolism producing themselves but also inhibited the male-specific oxidative metabolism. This finding compels us to propose a novel hypothesis that adult male rat liver microsomes may possess a self-augmentation system regulated by the male-specific products on sexually differentiated steroid metabolism, besides regulation by gene expressions of the related enzymes.	Hyogo Coll Med, Dept Pathol 2, Nishinomiya, Hyogo 6638501, Japan; Hyogo Coll Med, Dept Chem, Nishinomiya, Hyogo 6638501, Japan	Hyogo College of Medicine; Hyogo College of Medicine	Yamada, A (corresponding author), Hyogo Coll Med, Dept Pathol 2, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.							AOSHIMA Y, 1964, ENDOCRINOLOGY, V74, P521, DOI 10.1210/endo-74-4-521; BIRMINGHAM MK, 1958, ENDOCRINOLOGY, V62, P47, DOI 10.1210/endo-62-1-47; BLANCK A, 1986, CANCER RES, V46, P5072; CARSIA RV, 1984, ENDOCRINOLOGY, V115, P2464, DOI 10.1210/endo-115-6-2464; CATANIA VA, 1995, BIOCHEM PHARMACOL, V50, P509, DOI 10.1016/0006-2952(95)00166-W; Chang TKH, 1996, J PHARMACOL EXP THER, V278, P1383; CORPECHOT C, 1993, ENDOCRINOLOGY, V133, P1003, DOI 10.1210/en.133.3.1003; DANNAN GA, 1986, J BIOL CHEM, V261, P728; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; HEINRICH.WL, 1966, STEROIDS, V7, P91, DOI 10.1016/0039-128X(66)90137-1; KINOSHITA Y, 1981, ENDOCRINOL JAPON, V28, P499; Lancel M, 1996, AM J PHYSIOL-ENDOC M, V271, pE763, DOI 10.1152/ajpendo.1996.271.4.E763; LEGRAVEREND C, 1992, FASEB J, V6, P711, DOI 10.1096/fasebj.6.2.1537461; MODE A, 1981, ENDOCRINOLOGY, V108, P2103, DOI 10.1210/endo-108-6-2103; MONSALVE A, 1977, STEROIDS, V30, P41, DOI 10.1016/0039-128X(77)90135-0; MURRAY M, 1991, ARCH BIOCHEM BIOPHYS, V286, P618, DOI 10.1016/0003-9861(91)90089-2; NORMINGTON K, 1992, J BIOL CHEM, V267, P19548; Pampori NA, 1999, ENDOCRINOLOGY, V140, P1245, DOI 10.1210/en.140.3.1245; Pampori NA, 1996, MOL PHARMACOL, V50, P1148; RIBEIRO V, 1992, ARCH BIOCHEM BIOPHYS, V293, P147, DOI 10.1016/0003-9861(92)90377-9; RUNGEMORRIS M, 1991, BIOCHEM BIOPH RES CO, V175, P1051, DOI 10.1016/0006-291X(91)91671-X; Shimada M, 1997, ARCH BIOCHEM BIOPHYS, V337, P34, DOI 10.1006/abbi.1996.9764; SMITHGALL TE, 1985, CANCER RES, V45, P4946; STOLZ A, 1991, J BIOL CHEM, V266, P15253; SWINNEY DC, 1990, DRUG METAB DISPOS, V18, P859; WAXMAN DJ, 1989, ENDOCRINOLOGY, V124, P2954, DOI 10.1210/endo-124-6-2954; WIEBEL FJ, 1971, ARCH BIOCHEM BIOPHYS, V144, P78, DOI 10.1016/0003-9861(71)90456-5; YAMADA M, 1974, ENDOCRINOLOGY, V94, P777, DOI 10.1210/endo-94-3-777; YAMADA M, 1990, J BIOL CHEM, V265, P11035; YAMADA M, 1994, HEPATOLOGY, V20, P1271, DOI 10.1016/0270-9139(94)90768-4; YAMAZOE Y, 1989, MOL PHARMACOL, V35, P707	31	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4604	4610		10.1074/jbc.M003355200	http://dx.doi.org/10.1074/jbc.M003355200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	10995741	hybrid			2022-12-27	WOS:000168484300013
J	Vyas, DR; McCarthy, JJ; Tsika, GL; Tsika, RW				Vyas, DR; McCarthy, JJ; Tsika, GL; Tsika, RW			Multiprotein complex formation at the beta myosin heavy chain distal muscle CAT element correlates with slow muscle expression but not mechanical overload responsiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX ZIPPER PROTEIN; SKELETAL-MUSCLE; TRANSCRIPTION FACTORS; REGULATORY ELEMENTS; GENE-EXPRESSION; CARDIAC-MUSCLE; ENHANCER; BINDING; TEF-1; MAX	To examine the role of the P-myosin heavy chain (beta MyHC) distal muscle CAT (MCAT) element in muscle fiber type-specific expression and mechanical overload (MOV) responsiveness, we conducted transgenic and in vitro experiments. In adult transgenic mice, mutation of the distal MCAT element led to significant reductions in chloramphenicol acetyltransferase (CAT) specific activity measured in control soleus and plantaris muscles when compared with wild type transgene beta 293WT but did not abolish MOV-induced CAT specific activity. Electrophoretic mobility shift assay revealed the formation of a specific low migrating nuclear protein complex (LMC) at the beta MyHC MCAT element that was highly enriched only when using either MOV plantaris or control soleus nuclear extract. Scanning mutagenesis of the beta MyHC distal MCAT element revealed that only the nucleotides comprising the core MCAT element were essential for LMC formation. The proteins within the LMC when using either MOV plantaris or control soleus nuclear extracts were antigenically related to nominal transcription enhancer factor 1 (NTEF-1), poly(ADP-ribose) polymerase (PARP), and Max, Only in vitro translated TEF-1 protein bound to the distal MCAT element, suggesting that this multiprotein complex is tethered to the DNA via TEF-1. Protein-protein interaction assays revealed interactions between nominal TEF-1, PARP, and Max. Our studies show that for transgene beta 293 the distal MCAT element is not required for MOV responsiveness but suggest that a multiprotein complex likely comprised of nominal TEF-1, PARP, and Max forms at this element to contribute to basal slow fiber expression.	Univ Missouri, Dept Vet Biomed Sci, Sch Vet Med, Columbia, MO 65211 USA; Univ Missouri, Sch Med, Dept Biochem, Columbia, MO 65211 USA; Univ Missouri, Dalton Cardiovasc Res Ctr, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Tsika, RW (corresponding author), Univ Missouri, Dept Vet Biomed Sci, Sch Vet Med, 1600 E Rollins Ave,W112 VET Med Bldg, Columbia, MO 65211 USA.				NIAMS NIH HHS [R01-AR47197, R01-AR41464] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041464, R01AR047197] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; FabreSuver C, 1996, J BIOL CHEM, V271, P4646, DOI 10.1074/jbc.271.9.4646; Farrance IKG, 1996, J BIOL CHEM, V271, P8266, DOI 10.1074/jbc.271.14.8266; Gupta MP, 1997, MOL CELL BIOL, V17, P3924, DOI 10.1128/MCB.17.7.3924; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; Gupta MP, 2000, NUCLEIC ACIDS RES, V28, P3168, DOI 10.1093/nar/28.16.3168; Homburg S, 2000, J CELL BIOL, V150, P293, DOI 10.1083/jcb.150.2.293; Jacquemin P, 1997, TRENDS CARDIOVAS MED, V7, P192, DOI 10.1016/S1050-1738(97)00052-2; Jacquemin P, 1996, J BIOL CHEM, V271, P21775, DOI 10.1074/jbc.271.36.21775; Jacquemin P, 1997, J BIOL CHEM, V272, P12928, DOI 10.1074/jbc.272.20.12928; Jiang SW, 2000, BIOCHEMISTRY-US, V39, P3505, DOI 10.1021/bi991048w; KNOTTS S, 1994, J BIOL CHEM, V269, P31275; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; LARKIN SB, 1999, HEART DEV, P307; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; McCarthy JJ, 1999, J BIOL CHEM, V274, P14270, DOI 10.1074/jbc.274.20.14270; McCarthy JJ, 1997, AM J PHYSIOL-REG I, V272, pR1552, DOI 10.1152/ajpregu.1997.272.5.R1552; Ojamaa K, 1995, J BIOL CHEM, V270, P31276, DOI 10.1074/jbc.270.52.31276; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; RINDT H, 1995, P NATL ACAD SCI USA, V92, P1540, DOI 10.1073/pnas.92.5.1540; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Tsika GL, 1996, AM J PHYSIOL-CELL PH, V271, pC690, DOI 10.1152/ajpcell.1996.271.2.C690; Tsika R W, 1994, Exerc Sport Sci Rev, V22, P361; TSIKA RW, 1995, AM J PHYSIOL-CELL PH, V269, pC665, DOI 10.1152/ajpcell.1995.269.3.C665; Ueyama T, 2000, J BIOL CHEM, V275, P17476, DOI 10.1074/jbc.M001970200; Vyas DR, 1999, J BIOL CHEM, V274, P30832, DOI 10.1074/jbc.274.43.30832; VYAS DR, 2000, BASIC APPL MYOL, V10, P5; Wiedenman JL, 1996, AM J PHYSIOL-CELL PH, V270, pC1111, DOI 10.1152/ajpcell.1996.270.4.C1111; Wiedenman JL, 1996, AM J PHYSIOL-REG I, V271, pR688, DOI 10.1152/ajpregu.1996.271.3.R688; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; [No title captured]	37	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1173	1184		10.1074/jbc.M007750200	http://dx.doi.org/10.1074/jbc.M007750200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11010974	hybrid			2022-12-27	WOS:000166430900045
J	Deregnaucourt, C; Schrevel, J				Deregnaucourt, C; Schrevel, J			Bee venom phospholipase A(2) induces stage-specific growth arrest of the intraerythrocytic Plasmodium falciparum via modifications of human serum components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; MEMBRANE; LYSOPHOSPHATIDYLCHOLINE; ERYTHROCYTES; ORGANIZATION; INHIBITION; EXPRESSION; CELLS; PUMP; PH	Secreted phospholipases A(2) (sPLA(2)s) from snake and insect venoms and from mammalian pancreas are structurally related enzymes that have been associated with several toxic, pathological, or physiological processes. We addressed the issue of whether toxic sPLA(2)s might exert specific effects on the Plasmodium falciparum intraerythrocytic development. We showed that both toxic and non-toxic sPLA(2)s are lethal to P. falciparum grown in vitro, with large discrepancies between respective IC50 values; IC50 values from toxic PLA(2)s ranged from 1.1 to 200 pM, and IC50 values from non-toxic PLA(2)s ranged from 0.14 to 1 muM. Analysis of the molecular mechanisms responsible for cytotoxicity of bee venom PLA(2) (toxic) and hog pancreas PLA, (non-toxic) demonstrated that, in both cases, enzymatic hydrolysis of serum phospholipids present in the culture medium was responsible for parasite growth arrest. However, bee PLA(2)-lipolyzed serum induced stage-specific inhibition of P. falciparum development, whereas hog PLA(2)-lipolyzed serum killed parasites at either stage. Sensitivity to bee PLA(2)-treated serum appeared restricted to the 19-26-h period of the 48 h parasite cycle. Analysis of the respective role of the different lipoprotein classes as substrates of bee PLA(2) showed that enzyme treatment of high density lipoproteins, low density lipoproteins, and very low density lipoproteins/chylomicrons fractions induces cytotoxicity of either fraction. In conclusion, our results demonstrate that toxic and non-toxic PLA(2)s 1) are cytotoxic to P. falciparum via hydrolysis of lipoprotein phospholipids and 2) display different killing processes presumably involving lipoprotein by-products recognizing different targets on the infected red blood cell.	Museum Natl Hist Nat, Lab Biochem Parasitaire, F-75231 Paris 05, France	Museum National d'Histoire Naturelle (MNHN)	Deregnaucourt, C (corresponding author), Museum Natl Hist Nat, Lab Biochem Parasitaire, IFR 63,61 Rue Buffon, F-75231 Paris 05, France.	schrevel@mnhn.fr	Schrevel, Joseph/AAG-7085-2020					ARITA H, 1991, J BIOL CHEM, V266, P19139; ATKINSON CT, 1990, BLOOD CELLS, V16, P351; Cantrill RC, 1997, ADV EXP MED BIOL, V400, P539; CHWETZOFF S, 1989, J BIOL CHEM, V264, P13289; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DEARAUJO AL, 1987, TOXICON, V25, P1181, DOI 10.1016/0041-0101(87)90136-X; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; DENNIS EA, 1987, BIO-TECHNOL, V5, P1294, DOI 10.1038/nbt1287-1294; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; DIEZ E, 1994, BIOCHEM J, V301, P721, DOI 10.1042/bj3010721; ESTERBAUER H, 1990, CHEM RES TOXICOL, V3, P77, DOI 10.1021/tx00014a001; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Francis GA, 2000, BBA-MOL CELL BIOL L, V1483, P217, DOI 10.1016/S1388-1981(99)00181-X; GHOMASHCHI F, 1991, BIOCHEMISTRY-US, V30, P7318, DOI 10.1021/bi00243a037; GRELLIER P, 1991, J CELL BIOL, V112, P267, DOI 10.1083/jcb.112.2.267; GUTIERREZ JM, 1995, TOXICON, V33, P1405, DOI 10.1016/0041-0101(95)00085-Z; Hawgood B., 1991, HDB NATURAL TOXINS R, V5, P3; HSIAO LL, 1991, BIOCHEM J, V274, P121, DOI 10.1042/bj2740121; JOSHI P, 1987, BIOCHEM J, V246, P103, DOI 10.1042/bj2460103; KISHINO J, 1994, J BIOL CHEM, V269, P5092; KISHINO J, 1995, J BIOCHEM-TOKYO, V117, P420, DOI 10.1093/jb/117.2.420; KRUGLIAK M, 1995, EXP PARASITOL, V81, P97, DOI 10.1006/expr.1995.1097; KUMARATILAKE LM, 1992, J CLIN INVEST, V89, P961, DOI 10.1172/JCI115678; Kundu GC, 1997, J BIOL CHEM, V272, P2346; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LANGE Y, 1982, J LIPID RES, V23, P1121; Le Bonniec S, 1999, J BIOL CHEM, V274, P14218, DOI 10.1074/jbc.274.20.14218; LIJNEN P, 1990, METHOD FIND EXP CLIN, V12, P281; MOLL GN, 1990, BIOCHIM BIOPHYS ACTA, V1024, P189, DOI 10.1016/0005-2736(90)90224-C; OHARA O, 1995, PROG LIPID RES, V34, P117, DOI 10.1016/0163-7827(94)00009-B; OISHI K, 1990, J BIOL CHEM, V265, P70; PASVOL G, 1978, ANN TROP MED PARASIT, V72, P87, DOI 10.1080/00034983.1978.11719283; ROBERTS MF, 1977, J BIOL CHEM, V252, P2405; ROSSI JPFC, 1995, BIOCHEMISTRY-US, V34, P3802, DOI 10.1021/bi00011a038; SAKATA T, 1989, BIOCHIM BIOPHYS ACTA, V1007, P124, DOI 10.1016/0167-4781(89)90141-3; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; Snitko Y, 1997, BIOCHEM J, V321, P737, DOI 10.1042/bj3210737; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; UN D, 1990, NUTRITION, V6, P429; Vadas P, 1997, BBA-LIPID LIPID MET, V1346, P193, DOI 10.1016/S0005-2760(97)00029-5; VANDERSCHAFT PH, 1987, BIOCHIM BIOPHYS ACTA, V901, P1, DOI 10.1016/0005-2736(87)90250-1; *WHO, 1998, WEEKLY EPIDEMIOL REC, V72, P269	46	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39973	39980		10.1074/jbc.M006712200	http://dx.doi.org/10.1074/jbc.M006712200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10988294	hybrid			2022-12-27	WOS:000166039500026
J	Jutras, I; Seidah, NG; Reudelhuber, TL				Jutras, I; Seidah, NG; Reudelhuber, TL			A predicted alpha-helix mediates targeting of the proprotein convertase PC1 to the regulated secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; C-TERMINAL REGION; CARBOXYPEPTIDASE-E; PROHORMONE CONVERTASES; CPE(FAT)/CPE(FAT) MICE; CELLULAR TRAFFICKING; PRECURSOR PROTEINS; MEMBRANE-BINDING; ATT-20 CELLS; ACIDIC PH	The proprotein convertase PC1 is a protease whose activity is largely confined to the dense core secretory granules of neuroendocrine cells. Efficient processing of PC1 substrates in granules requires a mechanism that will both limit the activity of the enzyme to these organelles and promote its targeting to the nascent secretory granules. In the current study, we provide evidence that targeting of PC1 to secretory granules is mediated by alpha -helical structures in its C-terminal tail and, at least in part, is dependent on interactions with specific components of the secretory granule membrane.	Inst Rech Clin Montreal, Lab Mol Biochem Hypertens, Montreal, PQ H2W 1R7, Canada; Inst Rech Clin Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Reudelhuber, TL (corresponding author), Inst Rech Clin Montreal, Lab Mol Biochem Hypertens, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	reudelt@ircm.qc.ca	Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342				Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; Brechler V, 1996, J BIOL CHEM, V271, P20636, DOI 10.1074/jbc.271.34.20636; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; HILL RM, 1995, J NEUROCHEM, V65, P2318; Irminger JC, 1997, J BIOL CHEM, V272, P27532, DOI 10.1074/jbc.272.44.27532; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Jutras I, 1997, J BIOL CHEM, V272, P15184, DOI 10.1074/jbc.272.24.15184; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; Laine J, 1999, BIOCHEM J, V338, P289, DOI 10.1042/0264-6021:3380289; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lusson J, 1997, BIOCHEM J, V326, P737, DOI 10.1042/bj3260737; MITRA A, 1994, J BIOL CHEM, V269, P19876; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Natori S, 1996, P NATL ACAD SCI USA, V93, P4431, DOI 10.1073/pnas.93.9.4431; Rovere C, 1999, J BIOL CHEM, V274, P12461, DOI 10.1074/jbc.274.18.12461; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; SHENNAN KIJ, 1995, J BIOL CHEM, V270, P1402, DOI 10.1074/jbc.270.3.1402; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Varlamov O, 1996, J BIOL CHEM, V271, P6077, DOI 10.1074/jbc.271.11.6077; Varlamov O, 1997, ENDOCRINOLOGY, V138, P4883, DOI 10.1210/en.138.11.4883; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; YI Z, 1993, J BIOL CHEM, V268, P5615; Zhou A, 1998, J BIOL CHEM, V273, P11107, DOI 10.1074/jbc.273.18.11107; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509; ZHOU Y, 1994, J BIOL CHEM, V269, P18408; ZHOU Y, 1995, J BIOL CHEM, V270, P24702, DOI 10.1074/jbc.270.42.24702; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	37	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40337	40343		10.1074/jbc.M004757200	http://dx.doi.org/10.1074/jbc.M004757200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006274	hybrid			2022-12-27	WOS:000166039500074
J	Sudhahar, GCP; Balamurugan, K; Chin, DH				Sudhahar, GCP; Balamurugan, K; Chin, DH			Release of the neocarzinostatin chromophore from the holoprotein does not require major conformational change of the tertiary and secondary structures induced by trifluoroethanol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL SOLUTION STRUCTURE; HEME ORIENTATIONAL DISORDER; REVISED PRIMARY STRUCTURE; FAST ATOM BOMBARDMENT; APO-NEOCARZINOSTATIN; ANTITUMOR PROTEIN; STREPTOMYCES-CARZINOSTATICUS; MASS-SPECTROMETRY; NATURAL-ABUNDANCE; CRYSTAL-STRUCTURE	Neocarzinostatin is a potent enediyne antitumor antibiotic complex in which a chromophore is noncovalently bound to a carrier protein. The protein regulates availability of the drug by proper release of the biologically active chromophore, To understand the physiological mechanism of the drug delivery system, we have examined the trifluoroethanol (TFE)-induced conformational changes of the protein with special emphasis on their relation to the release of the chromophore from holoneocarzinostatin. The effect of the (alpha helix-inducing agent, TFE, on all the beta -sheet neocarzinostatin proteins was studied by circular dichroism, fluorescence, and H-1 NMR studies. By using binding of anilinonaphthalene sulfonic acid as a probe, we observed that the protein exists in a stable, partially structured intermediate state around 45-50% TFE, which is consistent with the results from tryptophan fluorescence and circular dichroism studies. The native state is stable until 20% TFE and is half-converted into the intermediate state at 30% TFE, which starts to collapse beyond 50%. High pressure liquid chromatographic analysis of the release of the chromophore caused by TFE treatment at 0 degreesC suggests that the release process, which occurs below 20% TFE, does not result from an observable conformational change in the protein. Kinetic measurements of the release of chromophore at 25 degreesC reveal that TFE does stimulate the rate of release, which increases sharply at 15% and reaches a maximum at 20% TFE, although no major secondary or tertiary structural change of the carrier protein is observed under these same conditions. Our data suggest that chromophore release results from a fluctuation of the protein structure that is stimulated by TFE. Complete release of the chromophore occurs at TFE concentrations where no overall observable unfolding of the apoprotein is seen. Thus, the results suggest that denaturation of the protein by TFE is not a necessary step for release of the tightly bound chromophore.	Natl Changhua Univ Educ, Dept Chem, Changhua 50058, Taiwan	National Changhua University of Education	Chin, DH (corresponding author), Natl Changhua Univ Educ, Dept Chem, Changhua 50058, Taiwan.	chdhchin@cc.ncue.edu.tw		Balamurugan, Prof. Dr. Krishnaswamy/0000-0001-9316-8141				ADJADJ E, 1992, EUR J BIOCHEM, V203, P505, DOI 10.1111/j.1432-1033.1992.tb16576.x; ADJADJ E, 1992, BIOCHIMIE, V74, P853, DOI 10.1016/0300-9084(92)90068-P; ADJADJ E, 1990, EUR J BIOCHEM, V190, P263, DOI 10.1111/j.1432-1033.1990.tb15571.x; ANANTHASAMY TS, 1977, BIOCHEMISTRY-US, V16, P5573, DOI 10.1021/bi00644a029; BLACKWELL LF, 1987, BIOCHEM J, V242, P803, DOI 10.1042/bj2420803; Chin DH, 1997, TETRAHEDRON LETT, V38, P2891, DOI 10.1016/S0040-4039(97)00498-X; Chin DH, 1997, BBA-GEN SUBJECTS, V1336, P43, DOI 10.1016/S0304-4165(97)00008-1; CHIN DH, 1993, J AM CHEM SOC, V115, P9341, DOI 10.1021/ja00073a081; Chin DH, 1999, CHEM-EUR J, V5, P1084, DOI 10.1002/(SICI)1521-3765(19990301)5:3<1084::AID-CHEM1084>3.0.CO;2-K; DEDON PC, 1992, BIOCHEMISTRY-US, V31, P1909, DOI 10.1021/bi00122a003; Digits JA, 1999, BIOCHEMISTRY-US, V38, P2295, DOI 10.1021/bi982305k; EDO K, 1985, TETRAHEDRON LETT, V26, P331, DOI 10.1016/S0040-4039(01)80810-8; GAO XL, 1991, BIOCHEMISTRY-US, V30, P7730, DOI 10.1021/bi00245a009; GAO XL, 1992, J MOL BIOL, V225, P125, DOI 10.1016/0022-2836(92)91030-S; GIBSON BW, 1984, J BIOL CHEM, V259, P801; GOLDBERG IH, 1991, ACCOUNTS CHEM RES, V24, P191, DOI 10.1021/ar00007a001; GOLDBERG IH, 1985, CELLULAR REGULATION, P483; Heyd B, 2000, J BACTERIOL, V182, P1812, DOI 10.1128/JB.182.7.1812-1818.2000; HIRAMA M, 1994, PURE APPL CHEM, V66, P791, DOI 10.1351/pac199466040791; HIRAYAMA K, 1986, B CHEM SOC JPN, V59, P1371, DOI 10.1246/bcsj.59.1371; IMAJO S, 1995, BIOORGAN MED CHEM, V3, P429, DOI 10.1016/0968-0896(95)00032-C; ISHIDA N, 1965, J ANTIBIOT, V18, P68; JOHNSON JP, 1989, J CANCER RES CLIN, V115, P494, DOI 10.1007/BF00393348; JUNG G, 1981, BIOCHEM BIOPH RES CO, V98, P176, DOI 10.1016/0006-291X(81)91885-4; KAPPEN LS, 1978, NUCLEIC ACIDS RES, V5, P2959, DOI 10.1093/nar/5.8.2959; KAPPEN LS, 1979, BIOCHEMISTRY-US, V18, P5647, DOI 10.1021/bi00592a020; KIM KH, 1993, SCIENCE, V262, P1042, DOI 10.1126/science.8235619; KUROMIZU K, 1986, ARCH BIOCHEM BIOPHYS, V246, P199, DOI 10.1016/0003-9861(86)90464-9; LAMAR GN, 1983, J MOL BIOL, V168, P887, DOI 10.1016/S0022-2836(83)80080-1; LECOMTE JTJ, 1985, BIOCHIM BIOPHYS ACTA, V829, P268, DOI 10.1016/0167-4838(85)90197-9; LEFEVRE C, 1994, J BIOMOL NMR, V4, P689, DOI 10.1007/BF00404278; MAEDA H, 1974, ARCH BIOCHEM BIOPHYS, V164, P379, DOI 10.1016/0003-9861(74)90046-0; MAEDA H, 1975, CANCER RES, V35, P554; MEIENHOFER J, 1972, SCIENCE, V178, P875, DOI 10.1126/science.178.4063.875; MISPELTER J, 1995, J BIOMOL NMR, V5, P233; Mizutani K, 2000, BIOCHEMISTRY-US, V39, P3258, DOI 10.1021/bi992574q; Okuno Y, 2000, J AM CHEM SOC, V122, P6848, DOI 10.1021/ja994323a; POSNER RG, 1992, BIOCHEMISTRY-US, V31, P5350, DOI 10.1021/bi00138a015; POVIRK LF, 1980, BIOCHEMISTRY-US, V19, P4773, DOI 10.1021/bi00562a009; Ptitsyn Oleg B., 1992, P243; REMEROWSKI ML, 1990, BIOCHEMISTRY-US, V29, P8401, DOI 10.1021/bi00488a029; SAKATA N, 1993, BIOL PHARM BULL, V16, P26; SIEKER LC, 1976, BIOCHEM BIOPH RES CO, V68, P358, DOI 10.1016/0006-291X(76)91152-9; TAKASHIMA H, 1991, J BIOCHEM-TOKYO, V109, P807, DOI 10.1093/oxfordjournals.jbchem.a123462; TANAKA T, 1991, TETRAHEDRON LETT, V32, P3175, DOI 10.1016/S0040-4039(00)79715-2; TANAKA T, 1993, J CHEM SOC CHEM COMM, P1205, DOI 10.1039/c39930001205; TEPLYAKOV A, 1993, EUR J BIOCHEM, V213, P737, DOI 10.1111/j.1432-1033.1993.tb17814.x; Thorson JS, 1999, BIOORG CHEM, V27, P172, DOI 10.1006/bioo.1998.1122	48	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39900	39906						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10982812				2022-12-27	WOS:000166039500017
J	Barresi, R; Moore, SA; Stolle, CA; Mendell, JR; Campbell, KP; Campbell, P				Barresi, R; Moore, SA; Stolle, CA; Mendell, JR; Campbell, KP; Campbell, P			Expression of gamma-sarcoglycan in smooth muscle and its interaction with the smooth muscle sarcoglycan-sarcospan complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIRDLE MUSCULAR-DYSTROPHY; NITRIC-OXIDE SYNTHASE; DELTA-SARCOGLYCAN; BETA-SARCOGLYCAN; ALPHA-SARCOGLYCAN; EPSILON-SARCOGLYCAN; GLYCOPROTEIN; GENE; CARDIOMYOPATHY; PROTEIN	The sarcoglycan complex in striated muscle is a heterotetrameric unit integrally associated with sarcospan in the dystrophin-glycoprotein complex. The sarcoglycans, alpha, beta, gamma, and delta, are mutually dependent with regard to their localization at the sarcolemma, and mutations in any of the sarcoglycan genes lead to limb-girdle muscular dystrophies type 2C-2F. In smooth muscle beta- and delta -sarcoglycans are associated with epsilon -sarcoglycan, a glycoprotein homologous to alpha -sarcoglycan. Here, we demonstrate that gamma -sarcoglycan is also a component of the sarcoglycan complex in the smooth muscle. First, we show the presence of gamma -sarcoglycan in a number of smooth muscle containing organs, and we verify the existence of identical transcripts in skeletal and smooth muscle. The specificity of the expression of gamma -sarcoglycan in smooth muscle was confirmed by analysis of smooth muscle cells in culture. Next, we provide evidence for the association of gamma -sarcoglycan with the sarcoglycan-sarcospan complex by biochemical analysis and comparison among animal models for muscular dystrophy. Moreover, we find disruption of the sarcoglycan complex in the vascular smooth muscle of a patient with gamma -sarcoglycanopathy. Taken together, our results prove that the sarcoglycan complex in vascular and visceral smooth muscle consists of epsilon- beta-, gamma-, and delta -sarcogIycans and is associated with sarcospan.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA; Univ Penn, Sch Med, Genet Diagnost Lab, Philadelphia, PA 19104 USA; Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa; University of Pennsylvania; Ohio State University	Campbell, KP (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, 400 EMRB, Iowa City, IA 52242 USA.	campbell@uiowa.edu	Barresi, Rita/AAB-9569-2022	Barresi, Rita/0000-0001-7351-959X; Moore, Steven/0000-0002-6353-7900; Campbell, Kevin/0000-0003-2066-5889	Fondazione Telethon Funding Source: Custom; Telethon [305/B] Funding Source: Medline	Fondazione Telethon(Fondazione Telethon); Telethon(Fondazione Telethon)		Araishi K, 1999, HUM MOL GENET, V8, P1589, DOI 10.1093/hmg/8.9.1589; Barresi R, 2000, J MED GENET, V37, P102, DOI 10.1136/jmg.37.2.102; Betto R, 1999, J BIOL CHEM, V274, P7907, DOI 10.1074/jbc.274.12.7907; Blake DJ, 1996, J BIOL CHEM, V271, P7802, DOI 10.1074/jbc.271.13.7802; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Chang WJ, 1996, P NATL ACAD SCI USA, V93, P9142, DOI 10.1073/pnas.93.17.9142; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; Crosbie RH, 1999, J CELL BIOL, V145, P153, DOI 10.1083/jcb.145.1.153; Crosbie RH, 1997, J BIOL CHEM, V272, P31221, DOI 10.1074/jbc.272.50.31221; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Durbeej M, 2000, MOL CELL, V5, P141, DOI 10.1016/S1097-2765(00)80410-4; Durbeej M, 1999, J BIOL CHEM, V274, P26609, DOI 10.1074/jbc.274.37.26609; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Ettinger AJ, 1997, J BIOL CHEM, V272, P32534, DOI 10.1074/jbc.272.51.32534; Gnecchi-Ruscone T, 1999, MUSCLE NERVE, V22, P1549, DOI 10.1002/(SICI)1097-4598(199911)22:11<1549::AID-MUS10>3.0.CO;2-A; Grady RM, 1999, NAT CELL BIOL, V1, P215, DOI 10.1038/12034; Hack AA, 2000, J CELL SCI, V113, P2535; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; Henry MD, 1999, CURR OPIN CELL BIOL, V11, P602, DOI 10.1016/S0955-0674(99)00024-1; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; Holt KH, 1998, J BIOL CHEM, V273, P34667, DOI 10.1074/jbc.273.52.34667; Holt KH, 1998, MOL CELL, V1, P841, DOI 10.1016/S1097-2765(00)80083-0; Jung D, 1996, J BIOL CHEM, V271, P32321, DOI 10.1074/jbc.271.50.32321; Lebakken CS, 2000, MOL CELL BIOL, V20, P1669, DOI 10.1128/MCB.20.5.1669-1677.2000; LEFAUCHEUR JP, 1995, ANAT REC, V242, P70, DOI 10.1002/ar.1092420109; Lim LE, 1998, CURR OPIN NEUROL, V11, P443, DOI 10.1097/00019052-199810000-00006; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; Liu LA, 1999, J BIOL CHEM, V274, P38171, DOI 10.1074/jbc.274.53.38171; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; McNally EM, 1998, FEBS LETT, V422, P27, DOI 10.1016/S0014-5793(97)01593-7; Moreira ES, 1998, J MED GENET, V35, P951, DOI 10.1136/jmg.35.11.951; Nigro V, 1996, HUM MOL GENET, V5, P1179, DOI 10.1093/hmg/5.8.1179; Nigro V, 1997, HUM MOL GENET, V6, P601, DOI 10.1093/hmg/6.4.601; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; Ozawa E, 1998, MUSCLE NERVE, V21, P421, DOI 10.1002/(SICI)1097-4598(199804)21:4<421::AID-MUS1>3.3.CO;2-W; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PICCOLO F, 1995, NAT GENET, V10, P243, DOI 10.1038/ng0695-243; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; SadouletPuccio HM, 1996, HUM MOL GENET, V5, P489, DOI 10.1093/hmg/5.4.489; Sakamoto A, 1999, FEBS LETT, V447, P124, DOI 10.1016/S0014-5793(99)00267-7; Sakamoto A, 1997, P NATL ACAD SCI USA, V94, P13873, DOI 10.1073/pnas.94.25.13873; Straub V, 1999, J BIOL CHEM, V274, P27989, DOI 10.1074/jbc.274.39.27989; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; van der Kooi AJ, 1998, HEART, V79, P73, DOI 10.1136/hrt.79.1.73; WELLER B, 1990, J NEUROL SCI, V100, P9, DOI 10.1016/0022-510X(90)90005-8; YAMAMOTO H, 1994, J BIOCHEM-TOKYO, V115, P162, DOI 10.1093/oxfordjournals.jbchem.a124294	53	39	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38554	38560		10.1074/jbc.M007799200	http://dx.doi.org/10.1074/jbc.M007799200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10993904	hybrid			2022-12-27	WOS:000165739800057
J	Klose, R; Fresser, F; Kochl, S; Parson, W; Kapetanopoulos, A; Fruchart-Najib, J; Baier, G; Utermann, G				Klose, R; Fresser, F; Kochl, S; Parson, W; Kapetanopoulos, A; Fruchart-Najib, J; Baier, G; Utermann, G			Mapping of a minimal apolipoprotein(a) interaction motif conserved in fibrin(ogen) beta- and gamma-chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; PLASMINOGEN-BINDING-SITES; LOW-DENSITY-LIPOPROTEIN; GROWTH-FACTOR-BETA; TRANSGENIC MICE; SIZE HETEROGENEITY; FIBRINOGEN BINDING; MOLECULAR-BASIS; LYSINE ANALOGS; KRINGLE IV-10	Lipoprotein(a) (Lp(a)) is a major independent risk factor for atherothrombotic disease in humans. The physiological function(s) of Lp(a) as well as the precise mechanism(s) by which high plasma levels of Lp(a) increase risk are unknown. Binding of apolipoprotein(a) (apo(a)) to fibrin(ogen) and other components of the blood clotting cascade has been demonstrated in vitro, but the domains in fibrin(ogen) critical for interaction are undefined. We used apo(a) kringle IV subtypes to screen a human liver cDNA library by the yeast GAL4 two-hybrid interaction trap system. Among positive clones that emerged from the screen, clones were identified as fibrinogen beta- and gamma -chains. Peptide-based pull-down experiments confirmed that the emerging peptide motif, conserved in the carboxyl-terminal globular domains of the fibrinogen beta- and gamma modules specifically interacts with apo(a)np(a) in human plasma as well as in cell culture supernatants of HepG2 and Chinese hamster ovary cells, ectopically expressing apo(a)/Lp(a). The influence of lysine in the fibrinogen peptides and of lysine binding sites in apo(a) for the interaction was evaluated by binding experiments with apo(a) mutants and a mutated fibrin(ogen) peptid. This confirmed the lysine binding sites in kringle IV type 10 of apo(a) as the major fibrin(ogen) binding site but also demonstrated lysine-independent interactions.	Univ Innsbruck, Inst Med Biol & Human Genet, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Legal Med, A-6020 Innsbruck, Austria; Inst Pasteur, U325, INSERM, Dept Atherosclerose, F-59019 Lille, France	University of Innsbruck; University of Innsbruck; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Baier, G (corresponding author), Univ Innsbruck, Inst Med Biol & Human Genet, Schoepfstr 41, A-6020 Innsbruck, Austria.	Gottfried.Baier@uibk.ac.at	Baier, Gottfried/E-8755-2012; Parson, Walther/AAD-6845-2020	Parson, Walther/0000-0002-5692-2392; Baier, Gottfried/0000-0002-2085-8325				ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ANGLESCANO E, 1994, CHEM PHYS LIPIDS, V67-8, P353, DOI 10.1016/0009-3084(94)90157-0; Boonmark NW, 1997, J CLIN INVEST, V100, P558, DOI 10.1172/JCI119565; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DIEPLINGER H, 1995, J LIPID RES, V36, P813; EDELBERG JM, 1990, THROMB RES, V57, P155, DOI 10.1016/0049-3848(90)90203-O; ERNST A, 1995, J BIOL CHEM, V270, P6227, DOI 10.1074/jbc.270.11.6227; Fless GM, 1996, BIOCHEMISTRY-US, V35, P2289, DOI 10.1021/bi951792q; Fless GM, 2000, BIOCHEMISTRY-US, V39, P2740, DOI 10.1021/bi991961x; FRANK S, 1994, BIOCHEM J, V304, P27, DOI 10.1042/bj3040027; FRANK S, 1994, BIOCHEMISTRY-US, V33, P12329, DOI 10.1021/bi00206a041; GABEL B, 1994, FEBS LETT, V350, P77, DOI 10.1016/0014-5793(94)00737-3; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; GUEVARA J, 1992, PROTEINS, V12, P188, DOI 10.1002/prot.340120212; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; Hobbs HH, 1999, CURR OPIN LIPIDOL, V10, P225, DOI 10.1097/00041433-199906000-00005; Klezovitch O, 1996, ARTERIOSCL THROM VAS, V16, P392, DOI 10.1161/01.ATV.16.3.392; Klezovitch O, 1996, J CLIN INVEST, V98, P185, DOI 10.1172/JCI118765; Kochl S, 1997, BLOOD, V90, P1482, DOI 10.1182/blood.V90.4.1482.1482_1482_1489; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; KOSCHINSKY ML, 1990, BIOCHEMISTRY-US, V29, P640, DOI 10.1021/bi00455a007; Kraft HG, 1996, EUR J HUM GENET, V4, P74; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; Liu JN, 1998, BIOCHEMISTRY-US, V37, P3949, DOI 10.1021/bi972585o; Lou XJ, 1998, P NATL ACAD SCI USA, V95, P12591, DOI 10.1073/pnas.95.21.12591; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1995, THROMB HAEMOSTASIS, V73, P458; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; Nielsen LB, 1996, CIRC RES, V78, P615, DOI 10.1161/01.RES.78.4.615; Ogorelkova M, 1999, HUM MOL GENET, V8, P2087, DOI 10.1093/hmg/8.11.2087; PALABRICA TM, 1995, NAT MED, V1, P256, DOI 10.1038/nm0395-256; Papagrigorakis E, 1997, CLIN GENET, V52, P262; PEPIN JM, 1991, J LIPID RES, V32, P317; Romanic AM, 1998, CIRC RES, V83, P264, DOI 10.1161/01.RES.83.3.264; ROUY D, 1991, ARTERIOSCLER THROMB, V11, P629, DOI 10.1161/01.ATV.11.3.629; ROUY D, 1992, BIOCHEMISTRY-US, V31, P6333, DOI 10.1021/bi00142a024; SCANU AM, 1994, BBA-MOL BASIS DIS, V1227, P41, DOI 10.1016/0925-4439(94)90104-X; SIMON DI, 1991, BIOCHEMISTRY-US, V30, P6671, DOI 10.1021/bi00241a006; Spraggon G, 1997, NATURE, V389, P455, DOI 10.1038/38947; SUTER M, 1986, IMMUNOL LETT, V13, P313, DOI 10.1016/0165-2478(86)90064-7; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; Tang LP, 1996, J CLIN INVEST, V97, P1329, DOI 10.1172/JCI118549; TROMMSDORFF M, 1995, J CLIN INVEST, V96, P150, DOI 10.1172/JCI118015; Ugarova TP, 1998, J BIOL CHEM, V273, P22519, DOI 10.1074/jbc.273.35.22519; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; UTERMANN G, 1995, METABOLIC MOL BASES; VARADI A, 1983, BIOCHEMISTRY-US, V22, P2440, DOI 10.1021/bi00279a021; WINN ES, 1980, EUR J BIOCHEM, V104, P579, DOI 10.1111/j.1432-1033.1980.tb04461.x; Yano Y, 1997, J HISTOCHEM CYTOCHEM, V45, P559, DOI 10.1177/002215549704500408; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8	52	9	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38206	38212		10.1074/jbc.M003640200	http://dx.doi.org/10.1074/jbc.M003640200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10980194	hybrid			2022-12-27	WOS:000165739800012
J	Bruhns, P; Vely, F; Malbec, O; Fridman, WH; Vivier, E; Daeron, M				Bruhns, P; Vely, F; Malbec, O; Fridman, WH; Vivier, E; Daeron, M			Molecular basis of the recruitment of the SH2 domain-containing inositol 5-phosphatases SHIP1 and SHIP2 by Fc gamma RIIB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELL ACTIVATION; NEGATIVE REGULATION; INHIBITORY RECEPTORS; PHOSPHATASE SHIP; NK CELLS; TYROSINE; KILLER; MOTIFS; ASSOCIATION; RESPONSES	Fc gamma RIIB are single chain low affinity receptors for IgG that negatively regulate immunoreceptor tyrosine-based activation motif-dependent cell activation. They bear one immunoreceptor tyrosine-based inhibition motif (ITIM) that becomes tyrosyl-phosphorylated upon coaggregation of Fc gamma RIIB with immunoreceptor tyrosine-based activation motif-bearing receptors and that recruits SH2 domain-containing inositol 5-phosphatases (SHIPs) in vivo. Synthetic Fc gamma RIIB ITIM phosphopeptides, however, also bind SH2 domain-containing protein-tyrosine phosphatases (SHPs) in vitro. To identify SHIP-binding sites, we exchanged residues between the Fc gamma RIIB ITIM and the N-terminal ITIM of a killer cell Ig-like receptor that does not bind SHIPs, Loss of function and gain of function substitutions identified the Y+2 leucine, in the Fc gamma RIIB ITIM, as determining the binding of both SHIP1 and SHIPS, but not the binding of SHP-1 or SHP-2, Conversely, the Y-2 isoleucine that determines the in vitro binding of SHP-1 and SHP-2 affected neither the binding nor the recruitment of SHIP1 or SHIP2, One hydrophobic residue, in the ITIM. of Fc gamma RIIB therefore determines the affinity for SHIPs. This residue is symmetrical to the hydrophobic residue that determines the affinity of all ITIMs for SHPs, It defines a SHIP-binding site, distinct from a SHP-binding site, that enables Fc gamma RIIB to recruit SHIP1 and SHIP2 and that is preferentially used in vivo.	Inst Curie, INSERM U255, Lab Immunol Cellulaire & Clin, F-75005 Paris, France; Ctr Immunol, INSERM, CNRS, F-13288 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Daeron, M (corresponding author), Inst Curie, INSERM U255, Lab Immunol Cellulaire & Clin, 26 Rue Ulm, F-75005 Paris, France.		Vivier, Eric/F-8939-2010; Bruhns, Pierre/F-5567-2013; Vély, Frédéric/HHM-3894-2022	Vivier, Eric/0000-0001-7022-8287; Bruhns, Pierre/0000-0002-4709-8936; Vely, Frederic/0000-0002-1682-0949; fridman, wolf herman/0000-0002-1332-0973				Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; Blery M, 1997, J BIOL CHEM, V272, P8989; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Bruhns P, 1999, J IMMUNOL, V162, P3168; Burshtyn DN, 1997, J BIOL CHEM, V272, P13066, DOI 10.1074/jbc.272.20.13066; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Cambier JC, 1999, CURR TOP MICROBIOL, V244, P43; DAERON M, 1992, J IMMUNOL, V149, P1365; Daeron M, 1999, CURR TOP MICROBIOL, V244, P1; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; Fong DC, 2000, J IMMUNOL, V165, P4453, DOI 10.4049/jimmunol.165.8.4453; Fong DC, 1996, IMMUNOL LETT, V54, P83, DOI 10.1016/S0165-2478(96)02654-5; Gadina M, 1998, J IMMUNOL, V160, P4657; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kuroiwa A, 1998, J BIOL CHEM, V273, P1070, DOI 10.1074/jbc.273.2.1070; Lanier LL, 1997, IMMUNOL REV, V155, P145, DOI 10.1111/j.1600-065X.1997.tb00947.x; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Malbec O, 1998, J IMMUNOL, V160, P1647; Malbec O, 1999, J IMMUNOL, V162, P4424; Mason JM, 2000, J BIOL CHEM, V275, P4398, DOI 10.1074/jbc.275.6.4398; Moretta A, 1997, IMMUNOL REV, V155, P105, DOI 10.1111/j.1600-065X.1997.tb00943.x; Muraille E, 2000, IMMUNOL LETT, V72, P7, DOI 10.1016/S0165-2478(00)00162-0; Nakamura K, 1998, J IMMUNOL, V161, P684; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Sato K, 1998, J IMMUNOL, V161, P2716; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SONGYANG Z, 1993, CELL, V72, P1; Symes A, 1997, CURR BIOL, V7, P697, DOI 10.1016/S0960-9822(06)00298-3; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; Tsubokawa H, 1996, J PHYSIOL-LONDON, V497, P67, DOI 10.1113/jphysiol.1996.sp021750; Vely F, 1997, EUR J IMMUNOL, V27, P1994, DOI 10.1002/eji.1830270825; Vivier E, 1997, IMMUNOL TODAY, V18, P286, DOI 10.1016/S0167-5699(97)80025-4; WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; Yamashita Y, 1998, J BIOCHEM-TOKYO, V123, P358, DOI 10.1093/oxfordjournals.jbchem.a021945; ZHENKUN L, 2000, J EXP MED, V191, P347	41	75	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37357	37364		10.1074/jbc.M003518200	http://dx.doi.org/10.1074/jbc.M003518200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	11016922	hybrid			2022-12-27	WOS:000165618700009
J	Lampio, A; Kilpelainen, I; Pesonen, S; Karhi, K; Auvinen, P; Somerharju, P; Kaariainen, L				Lampio, A; Kilpelainen, I; Pesonen, S; Karhi, K; Auvinen, P; Somerharju, P; Kaariainen, L			Membrane binding mechanism of an RNA virus-mapping enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PROTEIN SECONDARY STRUCTURE; PHOSPHOLIPASE A(2); PHOSPHATIDYLCHOLINE VESICLES; TRYPTOPHAN FLUORESCENCE; ESCHERICHIA-COLI; MODEL MEMBRANES; CAPPING ENZYME; BHK CELLS; PEPTIDE	The RNA replication complex of Semliki Forest virus is bound to cytoplasmic membranes via the mRNA-capping enzyme Nsp1. Here we have studied the structure and liposome interactions of a synthetic peptide (245)GSTLYTESRKLLRSWHLPSV(264) corresponding to the membrane binding domain of Nsp1. The peptide interacted with liposomes only if negatively charged lipids were present that induced a structural change in the peptide from a random coil to a partially cu-helical conformation. NMR structure shows that the Lu-helix is amphipathic, the hydrophobic surface consisting of several leucines, a valine, and a tryptophan moiety (Trp-259). Fluorescence studies revealed that this tryptophan intercalates in the bilayer to the depth of the ninth and tenth carbons of lipid acyl chains. Mutation W259A altered the mode of bilayer association of the peptide and abolished its ability to compete for membrane association of intact Nsp1, demonstrating its crucial role in the membrane association and function of Nsp1.	Viikki Bioctr, Program Cellular Biotechnol, FIN-00014 Helsinki, Finland; Viikki Bioctr, Inst Biotechnol, NMR Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biomed, Dept Med Chem, FIN-00014 Helsinki, Finland	University of Helsinki	Kaariainen, L (corresponding author), Viikki Bioctr, Program Cellular Biotechnol, POB 56, FIN-00014 Helsinki, Finland.		Auvinen, Petri/D-5044-2009; Auvinen, Petri/AAP-8117-2021	Auvinen, Petri/0000-0002-3947-4778; 				ACHESON NH, 1967, VIROLOGY, V32, P128, DOI 10.1016/0042-6822(67)90261-9; Ahola T, 1999, EMBO J, V18, P3164, DOI 10.1093/emboj/18.11.3164; Ahola T, 1997, J VIROL, V71, P392, DOI 10.1128/JVI.71.1.392-397.1997; Ahola T, 2000, J VIROL, V74, P6725, DOI 10.1128/JVI.74.15.6725-6733.2000; AHOLA T, 1995, P NATL ACAD SCI USA, V92, P507, DOI 10.1073/pnas.92.2.507; Allan D, 1996, MOL MEMBR BIOL, V13, P81, DOI 10.3109/09687689609160580; Baker SF, 1998, BIOCHEMISTRY-US, V37, P13203, DOI 10.1021/bi981223t; BERKHOUT TA, 1987, BIOCHIM BIOPHYS ACTA, V897, P1, DOI 10.1016/0005-2736(87)90308-7; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOLEN EJ, 1990, BIOCHEMISTRY-US, V29, P9638, DOI 10.1021/bi00493a019; CLAGUE MJ, 1991, BIOCHEMISTRY-US, V30, P5491, DOI 10.1021/bi00236a023; Dunne SJ, 1996, BIOCHEMISTRY-US, V35, P11975, DOI 10.1021/bi960821+; FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075; Gelb MH, 1999, CURR OPIN STRUC BIOL, V9, P428, DOI 10.1016/S0959-440X(99)80059-1; GRIMLEY PM, 1968, J VIROL, V2, P1326, DOI 10.1128/JVI.2.11.1326-1338.1968; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; JOHNSON JE, 1994, BIOCHEMISTRY-US, V33, P4327, DOI 10.1021/bi00180a029; Johnson JE, 1998, BIOCHEMISTRY-US, V37, P9509, DOI 10.1021/bi980340l; KILLIAN JA, 1990, BIOCHEMISTRY-US, V29, P8131, DOI 10.1021/bi00487a021; KUGE O, 1989, BIOCHIM BIOPHYS ACTA, V986, P61, DOI 10.1016/0005-2736(89)90272-1; Kujala P, 1999, J VIROL, V73, P7805, DOI 10.1128/JVI.73.9.7805-7811.1999; LAAKKONEN P, 1994, J VIROL, V68, P7418, DOI 10.1128/JVI.68.11.7418-7425.1994; Laakkonen P, 1998, J VIROL, V72, P10265, DOI 10.1128/JVI.72.12.10265-10269.1998; Laakkonen P, 1996, J BIOL CHEM, V271, P28567, DOI 10.1074/jbc.271.45.28567; LEAR JD, 1987, J BIOL CHEM, V262, P6500; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; Magliano D, 1998, VIROLOGY, V240, P57, DOI 10.1006/viro.1997.8906; MARKELLO T, 1985, BIOCHEMISTRY-US, V24, P2895, DOI 10.1021/bi00333a012; PERANEN J, 1995, VIROLOGY, V208, P610, DOI 10.1006/viro.1995.1192; PERANEN J, 1991, J VIROL, V65, P1623; PERANEN J, 1993, J HISTOCHEM CYTOCHEM, V41, P447, DOI 10.1177/41.3.8429208; PICOT D, 1994, FEBS LETT, V346, P21, DOI 10.1016/0014-5793(94)00314-9; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROZANOV MN, 1992, J GEN VIROL, V73, P2129, DOI 10.1099/0022-1317-73-8-2129; Saleh MT, 1996, BIOCHEMISTRY-US, V35, P9325, DOI 10.1021/bi960177z; SOMERHARJU PJ, 1985, BIOCHEMISTRY-US, V24, P2773, DOI 10.1021/bi00332a027; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; Sumandea M, 1999, BIOCHEMISTRY-US, V38, P16290, DOI 10.1021/bi9921384; TEALE FWJ, 1960, BIOCHEM J, V76, P381, DOI 10.1042/bj0760381; TENNYSON J, 1986, J BIOL CHEM, V261, P14196; VAUHKONEN M, 1989, EUR J BIOCHEM, V186, P465, DOI 10.1111/j.1432-1033.1989.tb15230.x; White SH, 1998, BBA-REV BIOMEMBRANES, V1376, P339, DOI 10.1016/S0304-4157(98)00021-5; Wutrich K., 1986, NMR PROTEINS NUCL AC	47	74	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37853	37859		10.1074/jbc.M004865200	http://dx.doi.org/10.1074/jbc.M004865200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10984480	hybrid			2022-12-27	WOS:000165618700074
J	Tchan, MC; Choy, KJ; Mackay, JP; Lyons, ATL; Bains, NPS; Weiss, AS				Tchan, MC; Choy, KJ; Mackay, JP; Lyons, ATL; Bains, NPS; Weiss, AS			Interfacial asparagine residues within an amide tetrad contribute to Max helix-loop-helix leucine zipper homodimer stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARALLEL COILED-COIL; SECONDARY STRUCTURE; ESCHERICHIA-COLI; B/HLH/Z DOMAIN; MYC; PROTEIN; DNA; INSIGHTS; HETERODIMERIZATION; TRANSFORMATION	The transcription factor Max is the obligate dimerization partner of the Myc oncoprotein. The pivotal role of Max within the Myc regulatory network is dependent upon its ability to dimerize via the helix-loop-helix leucine zipper domain. The Max homodimer contains a tetrad of polar residues at the interface of the leucine zipper domain. A conserved interfacial Asn residue at an equivalent position in two other leucine zipper proteins has been shown to decrease homodimer stability. The unusual arrangement of this Gln-Asn/Gln'-Asn' tetrad prompted us to investigate whether Asn(92) plays a similar role in destabilizing the Max homodimer. This residue was sequentially replaced with aliphatic and charged residues. Thermal denaturation, redox time course and analytical ultracentrifugation studies show that the N92V mutation does not increase homodimer stability. Replacing this residue with negatively charged side chains in N92D and N92E destabilizes the mutant homodimer. Further replacement of Gln(91) indicated that H bonding between Gln(91) and Asn(92) residues is not significant to the stability of the native protein. These data collectively demonstrate the central role of Asn(92) in homodimer interactions. Molecular modelling studies illustrate the favorable packing of the native Asn residue at the dimer interface compared with that of the mutant Max peptides.	Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA	University of Sydney; University of Connecticut	Weiss, AS (corresponding author), Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia.		Weiss, Anthony S/GYV-0157-2022; Weiss, Anthony S/F-8103-2010; Mackay, Joel/D-6834-2011	Weiss, Anthony S/0000-0002-8106-4836; Mackay, Joel/0000-0001-7508-8033				Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; *BIOS TECHN, 1993, INS US GUID VERS 2 3; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Brownlie P, 1997, STRUCTURE, V5, P509, DOI 10.1016/S0969-2126(97)00207-4; CADWELL RC, 1994, PCR METH APPL, V3, P136; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Fairman R, 1997, PROTEIN SCI, V6, P175; FERREDAMARE AR, 1994, STRUCTURE, V2, P357, DOI 10.1016/S0969-2126(00)00037-X; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; Gupta MP, 1997, MOL CELL BIOL, V17, P3924, DOI 10.1128/MCB.17.7.3924; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hayes D. B., 1995, SEDNTERP; Horiuchi M, 1997, J BIOCHEM-TOKYO, V122, P711; Hurlin PJ, 1997, CURR TOP MICROBIOL, V224, P115; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JUNIUS FK, 1995, BIOCHEMISTRY-US, V34, P6164, DOI 10.1021/bi00018a020; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Lavigne P, 1998, J MOL BIOL, V281, P165, DOI 10.1006/jmbi.1998.1914; LAVIGNE P, 1995, J MOL BIOL, V254, P505, DOI 10.1006/jmbi.1995.0634; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; MARTIN SL, 1995, GENE, V154, P159, DOI 10.1016/0378-1119(94)00848-M; MERELO JJ, 1994, NEUROCOMPUTING, V6, P443, DOI 10.1016/0925-2312(94)90021-3; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; MUHLEGOLL C, 1995, BIOCHEMISTRY-US, V34, P13554, DOI 10.1021/bi00041a035; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Wendt H, 1998, J BIOL CHEM, V273, P5735, DOI 10.1074/jbc.273.10.5735; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	37	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37454	37461		10.1074/jbc.M004264200	http://dx.doi.org/10.1074/jbc.M004264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978321	hybrid			2022-12-27	WOS:000165618700022
J	Miura, K; Ohgiya, S; Hoshino, T; Nemoto, N; Suetake, T; Miura, A; Spyracopoulos, L; Kondo, H; Tsuda, S				Miura, K; Ohgiya, S; Hoshino, T; Nemoto, N; Suetake, T; Miura, A; Spyracopoulos, L; Kondo, H; Tsuda, S			NMR analysis of type III antifreeze protein intramolecular dimer - Structural basis for enhanced activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE RELAXATION; MODEL-FREE APPROACH; THERMAL HYSTERESIS; BINDING; MACROMOLECULES; ASSIGNMENTS; MECHANISM; DOMAIN; HELIX; H-1	The structure of a new antifreeze protein (AFP) variant, RD3, from antarctic eel pout (Rhigophila dearborni) with enhanced activity has been determined for the first time by nuclear magnetic resonance spectroscopy. RD3 comprises a unique translational topology of two homologous type III AFP globular domains, each containing one flat, ice binding plane. The ice binding plane of the N domain is located similar to3.5 Angstrom "behind" that of the C domain. The two ice binding planes are located laterally with an angle of 32 +/- 12 degrees between the planes. These results suggest that the C domain plane of RD3 binds first to the ice {1010} prism plane in the (0001) direction, which induces successive ice binding of the N domain in the (0101) direction. This manner of ice binding caused by the unique structural topology of RD3 is thought to be crucial for the significant enhancement of antifreeze activity, especially at low AFP concentrations.	Hokkaido Natl Ind Res Inst, Biosci & Chem Div, Sapporo, Hokkaido 0628517, Japan; Varian Japan, Minato Ku, Tokyo 1080023, Japan; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	National Institute of Advanced Industrial Science & Technology (AIST); University of Alberta	Tsuda, S (corresponding author), Hokkaido Natl Ind Res Inst, Biosci & Chem Div, 2-17-2-1 Tsukisamu Higashi, Sapporo, Hokkaido 0628517, Japan.	tsuda@hniri.go.jp	Hoshino, Tamotsu/F-3357-2017; Kondo, Hidemasa/M-7465-2018; NEMOTO, Nobuaki/ABA-8644-2020; HOSHINO, Tamotsu/R-2959-2019; Tsuda, Sakae/M-2756-2018; Ohgiya, Satoru/V-3117-2018	Hoshino, Tamotsu/0000-0001-5211-6425; Kondo, Hidemasa/0000-0003-2799-1775; Tsuda, Sakae/0000-0002-1399-0619; Ohgiya, Satoru/0000-0001-8257-8284				BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BRUNGER AT, 1987, XPLOR VERSION 3 1 SY; Davies PL, 1997, CURR OPIN STRUC BIOL, V7, P828, DOI 10.1016/S0959-440X(97)80154-6; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; DeLuca CI, 1998, BIOPHYS J, V74, P1502, DOI 10.1016/S0006-3495(98)77862-2; Graether SP, 2000, NATURE, V406, P325, DOI 10.1038/35018610; Graham LA, 1997, NATURE, V388, P727, DOI 10.1038/41908; HEW CL, 1992, EUR J BIOCHEM, V203, P33, DOI 10.1111/j.1432-1033.1992.tb19824.x; Hobbs P.V., 1974, ICE PHYSICS, P18; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Jia ZC, 1996, NATURE, V384, P285, DOI 10.1038/384285a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liou YC, 2000, NATURE, V406, P322, DOI 10.1038/35018604; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Low WK, 1998, J BIOL CHEM, V273, P23098, DOI 10.1074/jbc.273.36.23098; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miura K, 1999, J BIOCHEM-TOKYO, V126, P387, DOI 10.1093/oxfordjournals.jbchem.a022462; Miura K, 2000, J BIOMOL NMR, V16, P273, DOI 10.1023/A:1008326207444; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; SICHERI F, 1995, NATURE, V375, P427, DOI 10.1038/375427a0; SONNICHSEN FD, 1993, SCIENCE, V259, P1154, DOI 10.1126/science.8438165; Sonnichsen FD, 1996, STRUCTURE, V4, P1325, DOI 10.1016/S0969-2126(96)00140-2; WANG X, 1995, BBA-PROTEIN STRUCT M, V1247, P163, DOI 10.1016/0167-4838(94)00205-U; WILSON PW, 1994, CRYOBIOLOGY, V31, P406, DOI 10.1006/cryo.1994.1049; WILSON PW, 1993, CRYO-LETT, V14, P31; WISHART DS, 1994, VADAR COMPREHENSIVE; Worrall D, 1998, SCIENCE, V282, P115, DOI 10.1126/science.282.5386.115; Yang DSC, 1998, BIOPHYS J, V74, P2142, DOI 10.1016/S0006-3495(98)77923-8; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	33	43	50	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1304	1310		10.1074/jbc.M007902200	http://dx.doi.org/10.1074/jbc.M007902200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11010977	hybrid			2022-12-27	WOS:000166430900061
J	Jakupciak, JP; Wells, RD				Jakupciak, JP; Wells, RD			Gene conversion (recombination) mediates expansions of CTG-CAG repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTER-DOT-CAG; STRAND-BREAK REPAIR; MYOTONIC-DYSTROPHY GENE; FRAGILE-X-SYNDROME; ESCHERICHIA-COLI; TRIPLET REPEATS; MISMATCH REPAIR; TRINUCLEOTIDE REPEATS; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION	Genetic recombination is a robust mechanism for expanding CTG-CAG triplet repeats involved in the etiology of hereditary neurological diseases (Jakupciak, J. P., and Wells, R. D. (1999) J. Biol. Chem. 274, 23468-23479). This two-plasmid recombination system in Escherichia coli with derivatives of pUC19 and pACYC184 was used to investigate the effect of triplet repeat orientation on recombination and extent of expansions; tracts of 36, 50, 80, and 36, 100, and 175 repeats in length, respectively, in all possible permutations of length and in both orientations (relative to the unidirectional replication origins) revealed little or no effect of orientation of expansions. The extent of expansions was generally severalfold the length of the progenitor tract and frequently exceeded the combined length of the two tracts in the cotransformed plasmids. Expansions were much more frequent than deletions. Repeat tracts bearing two G-to-A interruptions (polymorphisms) within either 171- or 219-base pair tracts substantially reduced the expansions compared with uninterrupted repeat tracts of similar lengths. Gene conversion, rather than crossing over, was the recombination mechanism. Prior studies showed that DNA replication, repair, and tandem duplication also mediated genetic instabilities of the triplet repeat sequence. However, gene conversion (recombinational repair) is by far the most powerful expansion mechanism. Thus, we propose that gene conversion is the likely expansion mechanism for myotonic dystrophy, spinocerebellar ataxia type 8, and fragile X syndrome.	Texas A&M Univ, Texas Med Ctr, Ctr Genome Res, Inst Biosci & Technol, Houston, TX 77030 USA	Baylor College of Medicine; Texas A&M University System	Wells, RD (corresponding author), Texas A&M Univ, Texas Med Ctr, Ctr Genome Res, Inst Biosci & Technol, 2121 Holcombe Blvd, Houston, TX 77030 USA.	rwells@ibt.tamu.edu			NIGMS NIH HHS [GM52982] Funding Source: Medline; NINDS NIH HHS [NS37554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashizawa T, 1996, GENOMICS, V36, P47, DOI 10.1006/geno.1996.0424; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; Balakumaran BS, 2000, HUM MOL GENET, V9, P93, DOI 10.1093/hmg/9.1.93; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Bowater RP, 1997, NUCLEIC ACIDS RES, V25, P2861, DOI 10.1093/nar/25.14.2861; BRINGHAM PM, 1995, NAT GENET, V9, P191; Brown WT, 1996, AM J MED GENET, V64, P287, DOI 10.1002/(SICI)1096-8628(19960809)64:2<287::AID-AJMG11>3.0.CO;2-B; Cohen H, 1999, MOL CELL BIOL, V19, P4153; Cordeiro-Stone M, 1999, J MOL BIOL, V289, P1207, DOI 10.1006/jmbi.1999.2847; Cox MM, 1998, GENES CELLS, V3, P65, DOI 10.1046/j.1365-2443.1998.00175.x; Cummings CJ, 1999, PHILOS T ROY SOC B, V354, P1079, DOI 10.1098/rstb.1999.0462; DARDENLYONS T, 1999, J BIOL CHEM, V274, P25975; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; Elliott B, 1998, MOL CELL BIOL, V18, P93, DOI 10.1128/MCB.18.1.93; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; GACY AM, 1995, CELL, V81, P533; Gangloff S, 1996, EMBO J, V15, P1715, DOI 10.1002/j.1460-2075.1996.tb00517.x; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Iyer RR, 2000, J BIOL CHEM, V275, P2174, DOI 10.1074/jbc.275.3.2174; Iyer RR, 1999, J BIOL CHEM, V274, P3865, DOI 10.1074/jbc.274.6.3865; Jakupciak JP, 1999, J BIOL CHEM, V274, P23468, DOI 10.1074/jbc.274.33.23468; JANSEN G, 1994, AM J HUM GENET, V54, P575; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; Kang S, 1996, J MOL BIOL, V258, P543, DOI 10.1006/jmbi.1996.0266; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kokoska RJ, 1998, MOL CELL BIOL, V18, P2779, DOI 10.1128/MCB.18.5.2779; Koob MD, 1999, NAT GENET, V21, P379, DOI 10.1038/7710; Kramer PR, 1996, HUM GENET, V98, P151, DOI 10.1007/s004390050179; Kunst CB, 1996, AM J HUM GENET, V58, P513; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; Lin YF, 1999, MOL CELL BIOL, V19, P8353; Losekoot M, 1997, J MED GENET, V34, P924, DOI 10.1136/jmg.34.11.924; Mangiarini L, 1997, NAT GENET, V15, P197, DOI 10.1038/ng0297-197; Maurer DJ, 1996, MOL CELL BIOL, V16, P6617; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Miret JJ, 1997, MOL CELL BIOL, V17, P3382, DOI 10.1128/MCB.17.6.3382; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; Monckton DG, 1997, NAT GENET, V15, P193, DOI 10.1038/ng0297-193; Moore H, 1999, P NATL ACAD SCI USA, V96, P1504, DOI 10.1073/pnas.96.4.1504; OHOY KL, 1993, SCIENCE, V259, P809, DOI 10.1126/science.8094260; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Parniewski P, 1999, NUCLEIC ACIDS RES, V27, P616, DOI 10.1093/nar/27.2.616; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; Richard GF, 1999, MOL GEN GENET, V261, P871, DOI 10.1007/s004380050031; RICHARDS RI, 1991, J MED GENET, V28, P818, DOI 10.1136/jmg.28.12.818; RICHARDS RI, 1992, NAT GENET, V1, P7, DOI 10.1038/ng0492-7; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schumacher S, 1998, J MOL BIOL, V279, P1101, DOI 10.1006/jmbi.1998.1827; Schweitzer JK, 1997, HUM MOL GENET, V6, P349, DOI 10.1093/hmg/6.3.349; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; SZEMRAJ J, 1995, GENE, V152, P261, DOI 10.1016/0378-1119(94)00709-2; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; TSILFIDIS C, 1992, NAT GENET, V1, P192, DOI 10.1038/ng0692-192; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; UZEST M, 1995, MOL MICROBIOL, V17, P1177, DOI 10.1111/j.1365-2958.1995.mmi_17061177.x; VANDENOUWELAND AMW, 1994, HUM MOL GENET, V3, P1823, DOI 10.1093/hmg/3.10.1823; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; Wells R.D., 1998, GENETIC INSTABILITIE; Wells RD, 1998, J BIOL CHEM, V273, P19532, DOI 10.1074/jbc.273.31.19532; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; Zhong N, 1996, AM J MED GENET, V64, P226, DOI 10.1002/(SICI)1096-8628(19960712)64:1<226::AID-AJMG41>3.0.CO;2-M	72	55	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40003	40013		10.1074/jbc.M007153200	http://dx.doi.org/10.1074/jbc.M007153200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11005819	hybrid			2022-12-27	WOS:000166039500030
J	Kanzok, SM; Schirmer, RH; Turbachova, I; Iozef, R; Becker, K				Kanzok, SM; Schirmer, RH; Turbachova, I; Iozef, R; Becker, K			The thioredoxin system of the malaria parasite Plasmodium falciparum - Glutathione reduction revisited	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN THIOREDOXIN; OXIDIZED GLUTATHIONE; ESCHERICHIA-COLI; REDOX REGULATION; HUMAN PLACENTA; ACTIVE-SITE; CELL; DEHYDROGENASE; MECHANISM; KINETICS	In most living cells, redox homeostasis is based both on the glutathione and the thioredoxin system. In the malaria parasite Plasmodium falciparum antioxidative proteins represent promising targets for the development of antiparasitic drugs. We cloned and expressed a thioredoxin of P. falciparum (pftrx), and we improved the stable expression of the thioredoxin reductase (PfTrxR) of the parasite by multiple silent mutagenesis. Both proteins were biochemically characterized and compared with the human host thioredoxin system. Intriguingly, the 13-kDa protein PfTrx is a better substrate for human TrxR (K-m = 2 muM, K-cat = 3300 min(-1)) than for P. falciparum TrxR (K-m = 10.4 muM, k(cat) = 3100 min(-1)). Possessing a midpoint potential of -270 mV, PfTrx was found to reduce the disease-related metabolites S-nitrosoglutathione and GSSG;. The rate constant Fz, for the reaction between reduced P. falciparum thioredoxin and GSSG was determined to be 0.039 muM(-1) min(-1) at 25 degreesC and pH 7.4. The k(2) for thioredoxins from man, Drosophila melanogaster, and Escherichia coli was similar to5 times lower. Our data suggest that GSSG reduction can be supported at a high rate by the TrxR/Trx system in glutathione reductase-deficient cells; this may be relevant for certain stages of the malarial parasite but also for cells containing high [GSSG] of other organisms like dormant forms of Neurospora, glutathione reductase-deficient yeast mutants, or CD4(+) lymphocytes of AIDS patients.	Univ Wurzburg, Res Ctr Infect Dis, D-97070 Wurzburg, Germany; Heidelberg Univ, Ctr Biochem, D-69120 Heidelberg, Germany; Ctr Mol Biol, D-69120 Heidelberg, Germany	University of Wurzburg; Ruprecht Karls University Heidelberg	Becker, K (corresponding author), Univ Wurzburg, Res Ctr Infect Dis, Roentgenring 11, D-97070 Wurzburg, Germany.	becker.katja@gmx.de						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; [Anonymous], 1989, COENZYMES COFACTORS; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1999, METHOD ENZYMOL, V300, P226; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; Atamna H, 1997, EUR J BIOCHEM, V250, P670, DOI 10.1111/j.1432-1033.1997.00670.x; AUKRUST P, 1995, BLOOD, V86, P258, DOI 10.1182/blood.V86.1.258.bloodjournal861258; BECKER K, 1995, METHOD ENZYMOL, V251, P173, DOI 10.1016/0076-6879(95)51120-2; Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; Berggren M, 1996, ANTICANCER RES, V16, P3459; Butler D, 1997, NATURE, V386, P535, DOI 10.1038/42306; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P4061, DOI 10.1021/bi9628580; Clark IA, 1999, PARASITOL TODAY, V15, P458, DOI 10.1016/S0169-4758(99)01535-5; FAHEY RC, 1975, J BACTERIOL, V121, P144, DOI 10.1128/JB.121.1.144-151.1975; Farber PM, 1998, FEBS LETT, V422, P311, DOI 10.1016/S0014-5793(98)00031-3; Follmann H, 1995, BIOFACTORS, V5, P147; Gilberger TW, 2000, MOL BIOCHEM PARASIT, V107, P169, DOI 10.1016/S0166-6851(00)00188-2; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Gromer S, 1999, REDOX REP, V4, P221, DOI 10.1179/135100099101534936; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1998, OXIDATIVE STRESS CAN, P229; KrauthSiegel RL, 1996, EUR J BIOCHEM, V235, P345, DOI 10.1111/j.1432-1033.1996.00345.x; Lennon BW, 1996, BIOCHEMISTRY-US, V35, P4704, DOI 10.1021/bi952521i; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; Muller S, 1996, MOL BIOCHEM PARASIT, V80, P215, DOI 10.1016/0166-6851(96)02694-1; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; Pan WQ, 1999, NUCLEIC ACIDS RES, V27, P1094, DOI 10.1093/nar/27.4.1094; POWIS G, 1994, ONCOL RES, V6, P539; Savvides SN, 1996, J BIOL CHEM, V271, P8101, DOI 10.1074/jbc.271.14.8101; SCHIRMER RH, 1995, ANGEW CHEM INT EDIT, V34, P141, DOI 10.1002/anie.199501411; Schneider D, 2000, SCIENCE, V288, P2376, DOI 10.1126/science.288.5475.2376; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Wang PF, 1999, BIOCHEMISTRY-US, V38, P3187, DOI 10.1021/bi982674g; Williams CH, 2000, EUR J BIOCHEM, V267, P6110, DOI 10.1046/j.1432-1327.2000.01702.x; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897	42	217	219	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40180	40186		10.1074/jbc.M007633200	http://dx.doi.org/10.1074/jbc.M007633200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11013257	hybrid			2022-12-27	WOS:000166039500054
J	Zhang, ZQ; Apse, K; Pang, JD; Stanton, RC				Zhang, ZQ; Apse, K; Pang, JD; Stanton, RC			High glucose inhibits glucose-6-phosphate dehydrogenase via cAMP in aortic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; GROWTH-FACTOR; COMPLICATIONS; ACTIVATION; EXPRESSION; RELEASE; ENZYME	Recent studies have shown that hyperglycemia is a principal cause of cellular damage in patients with diabetes mellitus, A major consequence of hyperglycemia is increased oxidative stress. Glucose-8-phosphate dehydrogenase (G6PD) plays an essential role in the regulation of oxidative stress by primarily regulating NADPH, the main intracellular reductant. In this paper we show that increased glucose (10-25 mM) caused inhibition of G6PD resulting in decreased NADPH levels in bovine aortic endothelial cells (BAEC), Inhibition was seen within 15 min. High glucose-induced inhibition of G6PD predisposed cells to cell death. High glucose via increased activity of adenylate cyclase also stimulated an increase in cAMP levels in BAEC. Agents that increased cAMP caused a decrease in G6PD activity. Inhibition of cAMP-dependent protein kinase A ameliorated the high glucose-induced inhibition of G6PD, Finally, high glucose stimulated phosphorylation of G6PD. These results suggest that, in BAEC, high glucose stimulated increased cAMP, which led to increased protein kinase A activity, phosphorylation of G6PD, and inhibition of G6PD activity. We conclude that these changes in G6PD activity play an important role in high glucose-induced cell damage/death.	Beth Israel Deaconess Med Ctr, Joslin Diabet Ctr, Div Renal, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Joslin Diabet Ctr, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; So Connecticut State Univ, Dept Chem, New Haven, CT 06515 USA	Harvard University; Beth Israel Deaconess Medical Center; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Connecticut State University System; Southern Connecticut State University	Stanton, RC (corresponding author), Beth Israel Deaconess Med Ctr, Joslin Diabet Ctr, Div Renal, 1 Joslin Pl, Boston, MA 02215 USA.		Stanton, Robert C/AAG-7584-2020	Stanton, Robert C/0000-0002-3056-1277				ASAHINA T, 1995, DIABETES, V44, P520, DOI 10.2337/diabetes.44.5.520; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; Chakraborti T, 1998, MOL CELL BIOCHEM, V187, P1; Cramer C T, 1995, J Biochem Toxicol, V10, P293, DOI 10.1002/jbt.2570100603; FISHER AB, 1988, UPJ S OX RAD PARK CI, P34; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; FRIDOVICH I, 1988, UPJ S OX RAD PARK CI, P1; Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257; HA HJ, 1994, KIDNEY INT, V46, P1620, DOI 10.1038/ki.1994.461; HORECKER BL, 1965, J CHEM EDUC, V42, P244, DOI 10.1021/ed042p244; JACKOWSKI MM, 1978, J CYCLIC NUCL PROT, V4, P323; Kamal K, 1998, J CELL BIOCHEM, V71, P491, DOI 10.1002/(SICI)1097-4644(19981215)71:4<491::AID-JCB4>3.0.CO;2-P; KLETZIEN RF, 1994, FASEB J, V8, P174, DOI 10.1096/fasebj.8.2.8119488; LOW PA, 1997, DIABETES S2, V46, P38; Morishita R, 1997, DIABETES, V46, P138, DOI 10.2337/diabetes.46.1.138; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; ROSA LFBPC, 1995, BIOCHEM J, V310, P709, DOI 10.1042/bj3100709; ROSENSTRAUS M, 1975, P NATL ACAD SCI USA, V72, P493, DOI 10.1073/pnas.72.2.493; Salvemini F, 1999, J BIOL CHEM, V274, P2750, DOI 10.1074/jbc.274.5.2750; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; STANTON RC, 1988, AM J PHYSIOL, V254, pC267, DOI 10.1152/ajpcell.1988.254.2.C267; STANTON RC, 1991, J BIOL CHEM, V266, P12442; Tian WN, 1998, J BIOL CHEM, V273, P10609, DOI 10.1074/jbc.273.17.10609; Tian WN, 1999, AM J PHYSIOL-CELL PH, V276, pC1121, DOI 10.1152/ajpcell.1999.276.5.C1121; TIAN WN, 1994, J BIOL CHEM, V269, P14798; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Ursini MV, 1997, BIOCHEM J, V323, P801, DOI 10.1042/bj3230801; Wang Hwei-Zu, 1997, Kaohsiung Journal of Medical Sciences, V13, P566; ZAWALICH WS, 1975, DIABETOLOGIA, V11, P231, DOI 10.1007/BF00422327; Zhang ZQ, 2000, ANAL BIOCHEM, V285, P163, DOI 10.1006/abio.2000.4701	32	171	181	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40042	40047		10.1074/jbc.M007505200	http://dx.doi.org/10.1074/jbc.M007505200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007790	hybrid			2022-12-27	WOS:000166039500035
J	Francis, JM; Heyworth, CM; Spooncer, E; Pierce, A; Dexter, TM; Whetton, AD				Francis, JM; Heyworth, CM; Spooncer, E; Pierce, A; Dexter, TM; Whetton, AD			Transforming growth factor-beta 1 induces apoptosis independently of p53 and selectively reduces expression of Bcl-2 in multipotent hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; COLONY-STIMULATING FACTOR; MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; BONE-MARROW-CELLS; TGF-BETA; RECEPTOR EXPRESSION; EPITHELIAL-CELLS; PROGENITOR CELLS; SUPPRESSOR GENE; TNF-ALPHA	Transforming growth factor-pi (TGF-beta1) can inhibit cell proliferation or induce apoptosis in multipotent hematopoietic cells. To study the mechanisms of TGF-beta1 action on primitive hematopoietic cells, we used the interleukin-3 (IL-3)-dependent, multipotent FDCP-Mix cell line. TGF-beta1-mediated growth inhibition was observed in high concentrations of IL-3, while at lower IL-3 concentrations TGF-beta1 induced apoptosis. The proapoptotic effects of TGF-beta1 occur via a p53-independent pathway, since p53(null) FDCP-Mix demonstrated the same responses to TGF-beta1. IL-3 has been suggested to enhance survival via an increase in (antiapoptotic) Bcl-x(L) expression. In FDCP-Mix cells, neither IL-3 nor TGF-beta1 induced any change in Bcl-x(L) protein levels or the proapoptotic proteins Bad or Bax. However, TGF-beta1 had a major effect on Bcl-2 levels, reducing them in the presence of high and low concentrations of IL-3. Overexpression of Bcl-2 in FDCP-Mix cells rescued them from TGF-beta1-induced apoptosis but was incapable of inhibiting TGF-beta1-mediated growth arrest. We conclude that TGF-beta1-induced cell death is independent of p53 and inhibited by Bcl-2, with no effect on Bcl-x(L). The significance of these results for stem cell survival in bone marrow are discussed.	Univ Manchester, Leukaemia Res Fund, Cellular Dev Unit, Manchester M60 1QD, Lancs, England; Univ Manchester, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Christie Hosp, NHS Trust, Paterson Inst Canc Res, Dept Expt Haematol,Canc Res Campaign, Manchester M20 9BX, Lancs, England	University of Manchester; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Whetton, AD (corresponding author), Univ Manchester, Leukaemia Res Fund, Cellular Dev Unit, Sackville St, Manchester M60 1QD, Lancs, England.	Tony.Whetton@UMIST.ac.uk		WHETTON, ANTHONY D/0000-0002-1098-3878; Pierce, Andrew/0000-0001-5995-2469				BONNET D, 1995, EXP HEMATOL, V23, P551; BROXMEYER HE, 1996, BLOOD CELL BIOCH, P121; BURSUKER I, 1992, EXP HEMATOL, V20, P431; Cashman JD, 1998, BLOOD, V92, P2338, DOI 10.1182/blood.V92.7.2338.2338_2338_2344; CELADA A, 1992, J IMMUNOL, V148, P1102; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHEN AR, 1993, BLOOD, V81, P2539; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Chen Q, 1997, ONCOGENE, V15, P2249, DOI 10.1038/sj.onc.1201371; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; delPeso L, 1997, SCIENCE, V278, P687; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; DUBOIS CM, 1994, BLOOD, V83, P3138; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; EAVES CJ, 1991, BLOOD, V78, P110; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FAN K, 1992, BLOOD, V79, P1679; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GOEY H, 1989, J IMMUNOL, V143, P877; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HESTDAL K, 1993, EXP HEMATOL, V21, P799; HEYWORTH CM, 1995, GROWTH FACTORS, V12, P165, DOI 10.3109/08977199509036876; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; JACOBSEN FW, 1995, BLOOD, V86, P2957; JACOBSEN SEW, 1993, J IMMUNOL, V151, P4534; JACOBSEN SEW, 1991, BLOOD, V77, P1706; JACOBSEN SEW, 1991, BLOOD, V78, P2239, DOI 10.1182/blood.V78.9.2239.bloodjournal7892239; JETTEN AM, 1986, EXP CELL RES, V167, P539, DOI 10.1016/0014-4827(86)90193-X; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KELLER JR, 1994, BLOOD, V84, P2175; KELLER JR, 1988, J EXP MED, V168, P737, DOI 10.1084/jem.168.2.737; KELLER JR, 1991, P NATL ACAD SCI USA, V88, P7190, DOI 10.1073/pnas.88.16.7190; KLETSAS D, 1995, EXP CELL RES, V217, P477, DOI 10.1006/excr.1995.1112; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; LOTEM J, 1992, BLOOD, V80, P1750; MARVEL J, 1994, ONCOGENE, V9, P1117; MAY WS, 1994, J BIOL CHEM, V269, P26865; MICHISHITA M, 1991, EXP CELL RES, V196, P107, DOI 10.1016/0014-4827(91)90461-3; Migdalska A, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104820; Motyl T, 1998, EUR J CELL BIOL, V75, P367, DOI 10.1016/S0171-9335(98)80070-8; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; NAAS SJ, 1996, BIOCH CELL BIOL COMM, V227, P248; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTTMANN OG, 1988, J IMMUNOL, V140, P2661; Pierce A, 1998, J CELL SCI, V111, P815; REDDY KB, 1993, J CELL PHYSIOL, V156, P48, DOI 10.1002/jcp.1041560108; REISS M, 1992, ONCOL RES, V4, P349; REISS M, 1993, CANCER RES, V53, P899; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; Saltzman A, 1998, EXP CELL RES, V242, P244, DOI 10.1006/excr.1998.4096; Sasaki H, 1997, LEUKEMIA, V11, P239, DOI 10.1038/sj.leu.2400548; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; Silva A, 1997, BLOOD, V89, P2717, DOI 10.1182/blood.V89.8.2717; Sitnicka E, 1996, BLOOD, V88, P82; SMELAND EB, 1987, EXP CELL RES, V171, P213, DOI 10.1016/0014-4827(87)90264-3; Soma T, 1996, BLOOD, V87, P4561, DOI 10.1182/blood.V87.11.4561.bloodjournal87114561; SPOONCER E, 1994, LEUKEMIA, V8, P620; SPOONCER E, 1985, NATURE, V316, P62, DOI 10.1038/316062a0; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; STOECK M, 1989, J CELL PHYSIOL, V141, P65, DOI 10.1002/jcp.1041410111; TAETLE R, 1993, CANCER RES, V53, P3386; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; TSUKADA T, 1995, BIOCHEM BIOPH RES CO, V210, P1076, DOI 10.1006/bbrc.1995.1766; Veiby OP, 1996, J IMMUNOL, V157, P2953; WeberNordt RM, 1996, BLOOD, V88, P2549, DOI 10.1182/blood.V88.7.2549.bloodjournal8872549; WYLLIE FS, 1991, MOL CELL ENDOCRINOL, V76, P13, DOI 10.1016/0303-7207(91)90255-Q; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	74	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39137	39145		10.1074/jbc.M007212200	http://dx.doi.org/10.1074/jbc.M007212200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993901	hybrid			2022-12-27	WOS:000165953100028
J	Klostermann, A; Lutz, B; Gertler, F; Behl, C				Klostermann, A; Lutz, B; Gertler, F; Behl, C			The orthologous human and murine semaphorin 6A-1 proteins (SEMA6A-1/Sema6A-1) bind to the enabled/vasodilator-stimulated phosphoprotein-like protein (EVL) via a novel carboxyl-terminal zyxin-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; EVH1 DOMAIN; GUIDANCE; EXPRESSION; RECEPTOR; VASP; MENA; ABL; DYNAMICS; PROFILIN	Neuronal development and apoptosis critically depend on the transformation of extracellular signals to intracellular actions resulting in cytoskeletal rearrangements. Ena/VASP (enabled/vasodilator-stimulated phosphoprotein) proteins play an important role in actin and filament dynamics, whereas members of the semaphorin protein family are guidance signals in embryo- and organogenesis. Here, we report the identification of two novel transmembranous human and murine semaphorins, (HSA)SEMA6A-1 and (MMU)Sema6A-1. These semaphorin 6 variants directly link the Ena/VASP and the semaphorin protein family, since SEMA6A-1/Sema6A-1 is capable of a selective binding to the protein EVL (Ena/VASP-like protein). EVL is the third member of the Ena/VASP family of proteins that was identified sharing the same structural features as Mena (mammalian enabled) and VASP, although its functionality seems to be different from that of the other members. Here we demonstrate that SEMA6A-1/Sema6A-1 is colocalized with EVL via its zyxin-like carboxyl-terminal domain that contains a modified binding motif, which further stresses the existence of functional differences between EVL and Mena/VASP, In addition these findings suggest a completely new role for transmembranous semaphorins such as SEMA6A-1/Sema6A-1 in retrograde signaling.	MPI Psychiat, Independent Res Grp Neurodegenerat, D-80804 Munich, Germany; MPI Psychiat, Independent Res Grp Mol Genet Behav, D-80804 Munich, Germany; MIT, Dept Biol, Cambridge, MA 02142 USA	Max Planck Society; Max Planck Society; Massachusetts Institute of Technology (MIT)	Behl, C (corresponding author), MPI Psychiat, Independent Res Grp Neurodegenerat, Kraepelinstr 2, D-80804 Munich, Germany.	chris@mpipsykl.mpg.de	Lutz, Beat/AFK-6229-2022	Behl, Christian/0000-0001-8453-2378				Ahern-Djamali SM, 1999, P NATL ACAD SCI USA, V96, P4977, DOI 10.1073/pnas.96.9.4977; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Carl UD, 1999, CURR BIOL, V9, P715, DOI 10.1016/S0960-9822(99)80315-7; Culotti JG, 1996, CURR OPIN NEUROBIOL, V6, P81, DOI 10.1016/S0959-4388(96)80012-2; Drees BE, 1999, J CELL BIOL, V147, P1549, DOI 10.1083/jcb.147.7.1549; Eckhardt F, 1997, MOL CELL NEUROSCI, V9, P409, DOI 10.1006/mcne.1997.0644; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Fedorov AA, 1999, NAT STRUCT BIOL, V6, P661, DOI 10.1038/10717; Gagliardini V, 1999, MOL CELL NEUROSCI, V14, P301, DOI 10.1006/mcne.1999.0787; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1990, SCIENCE, V248, P857, DOI 10.1126/science.2188361; Goodman CS, 1999, CELL, V97, P551, DOI 10.1016/S0092-8674(00)80766-7; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; Holder N, 1999, DEVELOPMENT, V126, P2033; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Klein R, 1999, CURR BIOL, V9, pR691, DOI 10.1016/S0960-9822(99)80441-2; Klostermann A, 1998, J BIOL CHEM, V273, P7326, DOI 10.1074/jbc.273.13.7326; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Koppel AM, 1998, J BIOL CHEM, V273, P15708, DOI 10.1074/jbc.273.25.15708; LAMBRECHTS A, 2000, IN PRESS J BIOL CHEM; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Macalma T, 1996, J BIOL CHEM, V271, P31470, DOI 10.1074/jbc.271.49.31470; Marsicano G, 1999, EUR J NEUROSCI, V11, P4213, DOI 10.1046/j.1460-9568.1999.00847.x; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; Puschel AW, 1999, NAT NEUROSCI, V2, P777, DOI 10.1038/12140; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Rottner K, 1999, NAT CELL BIOL, V1, P321, DOI 10.1038/13040; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cellbio.11.1.497; Shirvan A, 1999, J NEUROCHEM, V73, P961, DOI 10.1046/j.1471-4159.1999.0730961.x; Strittmatter SM, 2000, NATURE, V404, P557, DOI 10.1038/35007181; Ueno K, 1998, HUM GENET, V102, P63, DOI 10.1007/s004390050655; Van Vactor D, 1999, CURR BIOL, V9, pR201; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Wills Z, 1999, NEURON, V22, P291, DOI 10.1016/S0896-6273(00)81090-9; Wills Z, 1999, NEURON, V22, P301, DOI 10.1016/S0896-6273(00)81091-0; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Wong JTW, 1999, NAT NEUROSCI, V2, P798, DOI 10.1038/12168; Xu XM, 2000, J NEUROSCI, V20, P2638; Zhou L, 1997, MOL CELL NEUROSCI, V9, P26, DOI 10.1006/mcne.1997.0607	49	58	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39647	39653		10.1074/jbc.M006316200	http://dx.doi.org/10.1074/jbc.M006316200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993894	hybrid			2022-12-27	WOS:000165953100092
J	Ohki, G; Miyoshi, T; Murata, M; Ishibashi, K; Imai, M; Suzuki, M				Ohki, G; Miyoshi, T; Murata, M; Ishibashi, K; Imai, M; Suzuki, M			A calcium-activated cation current by an alternatively spliced form of Trp3 in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CA2+ ENTRY; ENDOTHELIAL-CELLS; PURKINJE-FIBERS; CHANNEL; EXPRESSION; CLONING; RECEPTOR; HOMOLOG; RAT; MEMBRANE	To investigate a cDNA encoding cation current, we isolated an alternatively spliced form of a rat Trp3, designated Trp3sv, Trp3sv encodes 736 amino acids with a unique N terminus and six transmembrane segments. Expression of the cRNA in Xenopus oocytes was successfully performed. The cation selective current appeared after the addition of ionomycin or induced by prolonged depolarization but not by hyperpolarization. This induction was not observed by a treatment with thapsigargin, phorbol ester, or ATP, Na+, K+, tetraethylammonium, and divalent cations were permeable, while N-methyl-glucamine and chloride were nominally impermeable ions, The currents were not inhibited by flufenamate ruthenium red but nonspecifically by 2 mM Gd3+. Northern as well as Western blot suggested lower levels of the expression observed in some organs, while reverse transcriptase-polymerase chain reaction suggested that it widely spread among various organs. Therefore, we may conclude that N-terminal spliced valiant of Trp3, Trp3sv, encodes a calcium-activated cation channel in various organs.	Jichi Med Sch, Dept Pharmacol, Minami Kawachi, Tochigi 3290498, Japan	Jichi Medical University	Suzuki, M (corresponding author), Jichi Med Sch, Dept Pharmacol, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.							Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Carmeliet E, 1999, PHYSIOL REV, V79, P917, DOI 10.1152/physrev.1999.79.3.917; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CHAMPIGNY G, 1991, BIOCHEM BIOPH RES CO, V176, P1196, DOI 10.1016/0006-291X(91)90412-Z; COLQUHOUN D, 1981, NATURE, V294, P752, DOI 10.1038/294752a0; Eguiguren AL, 1996, BIOCHEM BIOPH RES CO, V225, P505, DOI 10.1006/bbrc.1996.1203; EHARA T, 1988, J PHYSIOL-LONDON, V403, P117, DOI 10.1113/jphysiol.1988.sp017242; Freichel M, 1999, CELL PHYSIOL BIOCHEM, V9, P270, DOI 10.1159/000016321; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; HILL JA, 1988, CIRC RES, V62, P411, DOI 10.1161/01.RES.62.2.411; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Ishibashi K, 1997, J BIOL CHEM, V272, P20782, DOI 10.1074/jbc.272.33.20782; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; KASS RS, 1978, J PHYSIOL-LONDON, V281, P187, DOI 10.1113/jphysiol.1978.sp012416; Lan L, 1996, BIOCHEM J, V316, P793, DOI 10.1042/bj3160793; MARCUS DC, 1992, AM J PHYSIOL, V262, pC1423, DOI 10.1152/ajpcell.1992.262.6.C1423; Mizuno N, 1999, MOL BRAIN RES, V64, P41, DOI 10.1016/S0169-328X(98)00296-4; Mori Y, 1998, NEUROREPORT, V9, P507; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; Preuss KD, 1997, BIOCHEM BIOPH RES CO, V240, P167, DOI 10.1006/bbrc.1997.7528; ROUSSEAU E, 1986, BIOPHYS J, V50, P1009, DOI 10.1016/S0006-3495(86)83543-3; SAUNDERS JH, 1973, CIRC RES, V32, P610; Schumacher MA, 2000, J BIOL CHEM, V275, P2756, DOI 10.1074/jbc.275.4.2756; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; TEULON J, 1987, BIOCHIM BIOPHYS ACTA, V905, P125, DOI 10.1016/0005-2736(87)90016-2; Tomita Y, 1998, NEUROSCI LETT, V248, P195, DOI 10.1016/S0304-3940(98)00362-0; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	30	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39055	39060		10.1074/jbc.M003606200	http://dx.doi.org/10.1074/jbc.M003606200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10984475	hybrid			2022-12-27	WOS:000165953100017
J	Walter, JC				Walter, JC			Evidence for sequential action of cdc7 and cdk2 protein kinases during initiation of DNA replication in Xenopus egg extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; REGULATORY SUBUNIT; MCM PROTEINS; ORIGINS; CHROMATIN; INHIBITOR; ASSOCIATION; REQUIRES	To investigate how the protein kinase cdc7 stimulates DNA replication in metazoans, a soluble cell-free replication system derived from Xenopus eggs was used. DNA was incubated in egg cytosol to form prereplication complexes and then in nucleoplasmic extract to initiate DNA synthesis. We find that cdc7 is greatly enriched in nucleoplasmic extract and that this high concentration is essential for efficient DNA replication, supporting previous models that the nucleus activates replication indirectly by sequestering essential components, cdc7 binds to chromatin at the G(1)/S transition before initiation occurs, and it dissociates from chromatin as S phase progresses, The chromatin association of cdc7 requires chromatin-bound MCM. In turn, cdc7 is required to load the initiation factor cdc45 onto the DNA,Finally, efficient replication is observed when chromatin is exposed first to cdc7 and then to cdk2 but not when it is exposed to cdk2 before cdc7. Therefore, the cdc7- and cdk2-dependent initiation steps can be separated, indicating the existence of a novel, stable initiation intermediate. Moreover, the data suggest that cdk2 can only act after cdc7 has executed its function.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Walter, JC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	johannes_walter@hms.harvard.edu		Walter, Johannes/0000-0002-4186-7570				Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Dimitrova DS, 1999, CRIT REV EUKAR GENE, V9, P353, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.200; Donaldson AD, 1998, MOL CELL, V2, P173, DOI 10.1016/S1097-2765(00)80127-6; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Geraghty DS, 2000, J BIOL CHEM, V275, P18011, DOI 10.1074/jbc.M909787199; Hardy CFJ, 1997, P NATL ACAD SCI USA, V94, P3151, DOI 10.1073/pnas.94.7.3151; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Jares P, 2000, GENE DEV, V14, P1528; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mimura S, 2000, GENES CELLS, V5, P439, DOI 10.1046/j.1365-2443.2000.00340.x; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Nougarede R, 2000, MOL CELL BIOL, V20, P3795, DOI 10.1128/MCB.20.11.3795-3806.2000; Owens JC, 1997, P NATL ACAD SCI USA, V94, P12521, DOI 10.1073/pnas.94.23.12521; Pasero P, 1999, GENE DEV, V13, P2159, DOI 10.1101/gad.13.16.2159; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Roberts BT, 1999, P NATL ACAD SCI USA, V96, P2800, DOI 10.1073/pnas.96.6.2800; Rowles A, 1999, J CELL SCI, V112, P2011; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; Sclafani RA, 2000, J CELL SCI, V113, P2111; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Tanaka TU, 1998, EMBO J, V17, P5182, DOI 10.1093/emboj/17.17.5182; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Waiter J, 1997, SCIENCE, V275, P993, DOI 10.1126/science.275.5302.993; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; You ZY, 1999, MOL CELL BIOL, V19, P8003; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	43	122	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39773	39778		10.1074/jbc.M008107200	http://dx.doi.org/10.1074/jbc.M008107200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11005825	hybrid			2022-12-27	WOS:000165953100109
J	Zheng, WH; Kar, S; Quirion, R				Zheng, WH; Kar, S; Quirion, R			Insulin-like growth factor-1-induced phosphorylation of the Forkhead family transcription factor FKHRL1 is mediated by Akt kinase in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; ACTIVATED PROTEIN-KINASE; SERINE-THREONINE KINASE; FACTOR-I RECEPTOR; NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3'-KINASE; CAENORHABDITIS-ELEGANS; SIGNAL-TRANSDUCTION; GENE; INHIBITOR	The Forkhead family transcription factor FKHRL1, a mammalian homolog of DAF16 in the nematode Caenorhabditis elegans, is an inducer of apoptosis in its unphosphorylated form and was recently reported as a substrate of Akt kinases. Insulin-like growth factor (IGF-I) is a potent stimulant of Akt kinase, leading to inhibition of the apoptotic pathway. In this study, we characterized the phosphorylation of FKHRL1 induced by IGF-1 in PC12 cells and various neuronal cell types and examined the potential role of Akt in this regard. IGF-I rapidly induced the phosphorylation of Akt and FKHRL1 in PC12 cells. The phosphorylation of Akt and FRHRL1 induced by 10 nM IGF-1 was inhibited by the phosphatidylinositide S-kinase (PI3K) inhibitors wort-mannin (0.25-2 muM) and LY294002 (12.5-100 muM), but not by the MEK inhibitor PD98059 (50 muM) or the p70 S6 kinase pathway inhibitor rapamycin (50 nM), suggesting that the phosphorylation of FKHRL1 induced by IGF-I is mediated by the PI3K pathway. As observed for IGF-1, an in vitro kinase assay with purified active Akt kinase demonstrated that the kinase is capable of directly phosphorylating FKHRL1 at Thr(32) and Ser(253), leading to inhibition of its pro-apoptotic properties. Moreover, transient expression of constitutively active Akt (MS-Akt, where MS is a myristylation signal) increased the phosphorylation of FKHRL1, whereas the expression of kinase-dead Akt (M179A Akt) attenuated the phosphorylation of FKHRL1 induced by 10 nM IGF-1 in PC12 cells. Interestingly, FKHRL1 co-immunoprecipitated with Akt in PC12 cells, indicating that these two proteins can associate in these cells. As IGF-1 also induced the phosphorylation of FKHRL1 in primary cortical and cerebellar neuronal cultures, these data, taken together, demonstrate that IGF-1, acting via the PI3K/Akt kinase pathway, can regulate the phosphorylation of FKHRL1, leading to inhibition of this apoptotic transcription factor in neuronal cells.	Douglas Hosp, Res Ctr, Dept Psychiat, Verdun, PQ H4H 1R3, Canada; McGill Univ, Dept Pharmacol & Therapeut, Verdun, PQ H4H 1R3, Canada	McGill University; McGill University	Quirion, R (corresponding author), Douglas Hosp, Res Ctr, Dept Psychiat, 6875 LaSalle Blvd, Verdun, PQ H4H 1R3, Canada.	Quirem@douglas.mcgill.ca	yang, chao/AAV-5929-2021					Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; delPeso L, 1997, SCIENCE, V278, P687; Dore S, 1997, P NATL ACAD SCI USA, V94, P4772, DOI 10.1073/pnas.94.9.4772; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ozes ON, 1999, NATURE, V401, P82; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wijkander J, 1997, J BIOL CHEM, V272, P21520, DOI 10.1074/jbc.272.34.21520; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zheng WH, 2000, J BIOL CHEM, V275, P13377, DOI 10.1074/jbc.275.18.13377; Zheng WH, 1996, J NEUROCHEM, V66, P1868	52	129	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39152	39158		10.1074/jbc.M002417200	http://dx.doi.org/10.1074/jbc.M002417200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995739	hybrid			2022-12-27	WOS:000165953100030
J	Wielowieyski, PA; Sevinc, S; Guzzo, R; Salih, M; Wigle, JT; Tuana, BS				Wielowieyski, PA; Sevinc, S; Guzzo, R; Salih, M; Wigle, JT; Tuana, BS			Alternative splicing, expression, and genomic structure of the 3 ' region of the gene encoding the sarcolemmal-associated proteins (SLAPs) defines a novel class of coiled-coil tail-anchored membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOBREVIN; SYNTAXIN; DOCKING; PATHWAY; FUSION; YEAST; SNARE	The sarcolemmal associated proteins (SLAPs) are encoded by multiple mRNAs that are presumably generated by alternative splicing mechanisms. The amino acid sequence of the SLAP1 isoform exhibited 76% identity with TOP,, a topographically graded antigen of the chick visual system. The regions of coiled-coil structure including an Il-heptad acidic amphipathic alpha -helical segment was conserved with a major divergence in sequence noted in the hydrophobic C termini predicted to be transmembrane domains in the two polypeptides. The genomic organization of the 3' region of the SLAP gene indicated that SLAP1 and TOP, are generated by alternative splicing mechanisms, which are conserved among mammalian and avian species. SLAP1/TOPAP were encoded by II exons distributed over a minimum of 35 kilobase pairs of continuous DNA; 9 of the exons were constitutively expressed, and 2 were alternatively spliced. The exons range in size from 60 to 321 base pairs, and the predicted functional domains within the polypeptides were encompassed by single exons, The introns vary from 0.2 to 10 kilobase pairs and conform to consensus dinucleotide splicing signals. Reverse transcriptase-polymerase chain reaction studies demonstrated that alternative exons (IV and X) of SLAP were expressed in a tissue-specific fashion and developmentally regulated. The alternatively spliced exon X, which encodes the putative transmembrane anchor in TOPAP, and a constitutively expressed exon XI, which encodes the putative transmembrane domain in SLAP, were found to target these polypeptides to membrane structures. The presence and conservation of termination codons in exons X and XI render expression of the two SLAP1/TOPAP transmembrane domains mutually exclusive. These data reveal that TOP, and SLAP are alternatively spliced products of a single gene that encodes a unique class of tail-anchored membrane proteins.	Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Tuana, BS (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.		Guzzo, Raquel Souza Lobo/E-6730-2019; Wigle, J.t./G-2005-2014	Guzzo, Raquel Souza Lobo/0000-0002-7029-2913; Wigle, J.t./0000-0002-4985-7684				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SAVITT JW, 1995, NEURON, V14, P253, DOI 10.1016/0896-6273(95)90283-X; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SPRING J, 1993, TRENDS BIOCHEM SCI, V18, P124, DOI 10.1016/0968-0004(93)90018-I; Wigle JT, 1997, J BIOL CHEM, V272, P32384, DOI 10.1074/jbc.272.51.32384; ZHANG P, 1997, BIOCHEMISTRY-US, V36, P4317	16	23	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38474	38481		10.1074/jbc.M007682200	http://dx.doi.org/10.1074/jbc.M007682200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10986292	hybrid			2022-12-27	WOS:000165739800046
J	Yang, Y; Hwang, CK; Junn, E; Lee, G; Mouradian, MM				Yang, Y; Hwang, CK; Junn, E; Lee, G; Mouradian, MM			ZIC2 and Sp3 repress Sp1-induced activation of the human D-1A dopamine receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; BINDING-SITES; CELL LINEAGE; SP FAMILY; EXPRESSION; PROMOTER; ENHANCEMENT; AMPHETAMINE; MODULATION; AGONISTS	The human D-1A dopamine receptor is transcribed from a tissue-specific regulated gene under the control of two promoters. An activator region (AR1) located between nucleotides -1154 and -1136 (relative to the first ATG) enhances transcription from the upstream promoter that is active in the brain. In this investigation, we sought to identify the nuclear factors that regulate the D-1A gene through their binding to AR1 using yeast one-hybrid screening. Sp3 and Zic2 were among the positive clones isolated. Although Sp1 was not isolated from this screening and purified Sp1 alone does not bind to AR1 in gel shift experiments, this general transcription factor binds to AR1 in the presence of D-1A expressing NS20Y nuclear extract and activates the D-1A promoter. Thus, Sp1 appears to require an unknown factor(s) or post-translational modification to interact with AR1. On the other hand, Zic2 and Sp3 inhibit Sp1-induced activation of the D-1A gene in an AR1-dependent manner. Zic2 and D-1A genes have reciprocal brain regional distributions; Zic2 is expressed primarily in the cerebellum, and D-1A is highly expressed in corpus striatum. These observations collectively suggest that one of the physiologic functions of Zic2 is repression of D-1A gene transcription and that the intracellular balance among Sp1, Sp3 and Zic2 is important for regulating the tissue-specific expression of this dopamine receptor.	NINDS, Genet Pharmacol Unit, Expt Therapeut Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Mouradian, MM (corresponding author), NINDS, Genet Pharmacol Unit, Expt Therapeut Branch, NIH, 10 Ctr Dr,MSC 1406, Bethesda, MD 20892 USA.			Mouradian, M. Maral/0000-0002-9937-412X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002826] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aruga J, 1998, J NEUROSCI, V18, P284; ARUGA J, 1994, J NEUROCHEM, V63, P1880; Aruga J, 1996, J BIOL CHEM, V271, P1043, DOI 10.1074/jbc.271.2.1043; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Brown SA, 1998, NAT GENET, V20, P180, DOI 10.1038/2484; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUREY AJ, 1993, TRANSCRIPTIONAL REGU, P743; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; Ding H, 1999, J BIOL CHEM, V274, P19573, DOI 10.1074/jbc.274.28.19573; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; Hussain T, 1998, HYPERTENSION, V32, P187, DOI 10.1161/01.HYP.32.2.187; Imafuku I, 1996, BIOCHEM BIOPH RES CO, V222, P736, DOI 10.1006/bbrc.1996.0813; Jung AB, 1996, DEV BRAIN RES, V94, P109, DOI 10.1016/0165-3806(96)00033-8; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Lee SH, 1996, J BIOL CHEM, V271, P25292, DOI 10.1074/jbc.271.41.25292; Lee SH, 1999, NEUROSCI RES, V34, P225, DOI 10.1016/S0168-0102(99)00055-3; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MINOWA MT, 1993, J BIOL CHEM, V268, P23544; Morris ED, 1999, J CEREBR BLOOD F MET, V19, P218, DOI 10.1097/00004647-199902000-00013; Muller S, 1999, BIOCHEM BIOPH RES CO, V259, P364, DOI 10.1006/bbrc.1999.0677; Okazawa H, 1996, P NATL ACAD SCI USA, V93, P11933, DOI 10.1073/pnas.93.21.11933; PHILLIPS GD, 1994, PSYCHOPHARMACOLOGY, V114, P477, DOI 10.1007/BF02249339; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Ritchie S, 2000, J BIOL CHEM, V275, P847, DOI 10.1074/jbc.275.2.847; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586; Tsai CN, 1999, VIROLOGY, V261, P288, DOI 10.1006/viro.1999.9851; Vanderschuren LJMJ, 1999, J NEUROSCI, V19, P9579, DOI 10.1523/jneurosci.19-21-09579.1999; WADDINGTON JL, 1986, CLIN NEUROPHARMACOL, V9, P20; WADDINGTON JL, 1989, PHARMACOL THERAPEUT, V43, P1, DOI 10.1016/0163-7258(89)90046-6; Wang Y, 1998, SYNAPSE, V30, P56, DOI 10.1002/(SICI)1098-2396(199809)30:1<56::AID-SYN7>3.0.CO;2-J; WHITE NM, 1991, BEHAV NEURAL BIOL, V55, P255, DOI 10.1016/0163-1047(91)90609-T; WHITE NM, 1993, BEHAV NEURAL BIOL, V59, P230, DOI 10.1016/0163-1047(93)90998-W; Yajima S, 1998, DNA CELL BIOL, V17, P471, DOI 10.1089/dna.1998.17.471; Yokota N, 1996, CANCER RES, V56, P377; Zheng XL, 2000, J BIOL CHEM, V275, P31747, DOI 10.1074/jbc.M000621200	43	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38863	38869		10.1074/jbc.M007906200	http://dx.doi.org/10.1074/jbc.M007906200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10984499	hybrid			2022-12-27	WOS:000165739800098
J	Bae, SH; Seo, YS				Bae, SH; Seo, YS			Characterization of the enzymatic properties of the yeast Dna2 helicase/endonuclease suggests a new model for Okazaki fragment processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; SINGLE-STRANDED-DNA; PROKARYOTIC RNASE HII; REPLICATION FACTOR-C; SACCHAROMYCES-CEREVISIAE; SV40 ORIGIN; SCHIZOSACCHAROMYCES-POMBE; ENDONUCLEASE ACTIVITY; HELICASE; RAD27	The Saccharomyces cerevisiae Dna2, which contains single-stranded DNA-specific endonuclease activity, interacts genetically and physically with Fen-l, a structure-specific endonuclease implicated in Okazaki fragment maturation during lagging strand synthesis. In this report, we investigated the properties of the Dna2 helicase/endonuclease activities in search of their in vivo physiological functions in eukaryotes. We found that the Dnaa helicase activity translocates in the 5' to 3' direction and uses DNA with free ends as the preferred substrate. Furthermore, the endonucleolytic cleavage activity of Dna2 was markedly stimulated, by the presence of an RNA segment at the 5'-end of single-stranded DNA and occurred within the DNA, ensuring the complete removal of the initiator RNA segment on the Okazaki fragment. In addition, we demonstrated that the removal of pre-existing initiator 5'-terminal RNA segments depended on a displacement reaction carried out during the DNA polymerase delta -catalyzed elongation of the upstream Okazaki fragments. These properties indicate that Dna2 is well suited to remove the primer RNA on the Okazaki fragment. Based op this information, we propose a new model in which Dna2 plays a direct role in Okazaki fragment maturation in conjunction with Fen-l.	Sungkyunkwan Univ, Sch Med, Natl Creat Res Initiat Ctr Cell Cycle Control, Samsung Biomed Res Inst,Changan Ku, Suwon 440746, Kyunggi Do, South Korea	Sungkyunkwan University (SKKU)	Seo, YS (corresponding author), Sungkyunkwan Univ, Sch Med, Natl Creat Res Initiat Ctr Cell Cycle Control, Samsung Biomed Res Inst,Changan Ku, 300 Chunchun Dong, Suwon 440746, Kyunggi Do, South Korea.	ysseo@med.skku.ac.kr	Seo, Yeonsoo/C-1605-2011					AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; Bae SH, 1998, J BIOL CHEM, V273, P26880, DOI 10.1074/jbc.273.41.26880; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; Budd ME, 2000, J BIOL CHEM, V275, P16518, DOI 10.1074/jbc.M909511199; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Fiorentino DF, 1997, MOL BIOL CELL, V8, P2519, DOI 10.1091/mbc.8.12.2519; Formosa T, 1999, GENETICS, V151, P1459; Frank P, 1998, P NATL ACAD SCI USA, V95, P12872, DOI 10.1073/pnas.95.22.12872; Frank P, 1998, FEBS LETT, V421, P23, DOI 10.1016/S0014-5793(97)01528-7; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gary R, 1999, MOL CELL BIOL, V19, P5373; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Kang HY, 2000, GENETICS, V155, P1055; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kornberg A., 1992, DNA REPLICATION; Lee KH, 2000, NUCLEIC ACIDS RES, V28, P2873, DOI 10.1093/nar/28.15.2873; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Mossi R, 1998, J BIOL CHEM, V273, P14322, DOI 10.1074/jbc.273.23.14322; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1998, P NATL ACAD SCI USA, V95, P2244, DOI 10.1073/pnas.95.5.2244; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; NASMYTH KA, 1977, CELL, V12, P1109, DOI 10.1016/0092-8674(77)90173-8; Parenteau J, 1999, MOL CELL BIOL, V19, P4143; Park JS, 1997, J BIOL CHEM, V272, P18910, DOI 10.1074/jbc.272.30.18910; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; VALLEN EA, 1995, MOL CELL BIOL, V15, P4291; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153	52	153	154	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38022	38031		10.1074/jbc.M006513200	http://dx.doi.org/10.1074/jbc.M006513200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10984490	hybrid			2022-12-27	WOS:000165618700096
J	Hallstrom, TC; Moye-Rowley, WS				Hallstrom, TC; Moye-Rowley, WS			Multiple signals from dysfunctional mitochondria activate the pleiotropic drug resistance pathway in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MULTIDRUG-RESISTANCE; BETA-SUBUNIT PRECURSOR; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; TRANSPORTER GENES; OXIDATIVE STRESS; METAL RESISTANCE; REGULATORY GENE; INNER MEMBRANE; PROTEIN	Multiple or pleiotropic drug resistance most often occurs in Saccharomyces cerevisiae due to substitution mutations within the Cys(6)-Zn(II) transcription factors Pdr1p and Pdr3p. These dominant transcriptional regulatory proteins cause elevated drug resistance and overexpression of the ATP-binding cassette transporter-encoding gene, PDR5. We have carried out a genetic screen to identify negative regulators of PDR5 expression and found that loss of the mitochondrial genome (rho (o) cells) causes up-regulation of Pdr3p but not Pdr1p function. Additionally, loss of the mitochondrial inner membrane protein Oxa1p generates a signal that results in increased Pdr3p activity. Both of these mitochondrial defects lead to increased expression of the PDR3 structural gene. Importantly, the signaling pathway used to enhance Pdr3p function in rho (o) cells is not the same as in oral cells. Loss of previously described nuclear-mitochondrial signaling genes like RTG1 reduce the level of PDR5 expression and drug resistance seen in rho (o) cells but has no effect on oxa1-induced phenotypes. These data uncover a new regulatory pathway connecting expression of multidrug resistance genes with mitochondrial function.	Univ Iowa, Mol Biol Program, Iowa City, IA 52242 USA; Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Moye-Rowley, WS (corresponding author), Univ Iowa, Mol Biol Program, Iowa City, IA 52242 USA.	moyerowl@blue.weeg.uiowa.edu	Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120	NIGMS NIH HHS [GM49825] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altamura N, 1996, FEBS LETT, V382, P111, DOI 10.1016/0014-5793(96)00165-2; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BALZI E, 1994, J BIOL CHEM, V269, P2206; BALZI E, 1991, BIOCHIM BIOPHYS ACTA, V1073, P241, DOI 10.1016/0304-4165(91)90128-4; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; Bomer U, 1997, EMBO J, V16, P2205, DOI 10.1093/emboj/16.9.2205; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Carvajal E, 1997, MOL GEN GENET, V256, P406, DOI 10.1007/s004380050584; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Coleman ST, 1999, MOL CELL BIOL, V19, P8302; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; Dujon B., 1981, MOL BIOL YEAST SACCH, P505; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; FOGEL S, 1982, P NATL ACAD SCI-BIOL, V79, P5342, DOI 10.1073/pnas.79.17.5342; FOX TD, 1991, METHOD ENZYMOL, V194, P149; FRIDEN P, 1989, MOL CELL BIOL, V9, P4056, DOI 10.1128/MCB.9.9.4056; FRIDEN P, 1987, MOL CELL BIOL, V7, P2708, DOI 10.1128/MCB.7.8.2708; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRANT CE, 1994, CANCER RES, V54, P357; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hallstrom TC, 1998, MOL CELL BIOL, V18, P1147, DOI 10.1128/MCB.18.3.1147; HARTIG A, 1986, EUR J BIOCHEM, V160, P487, DOI 10.1111/j.1432-1033.1986.tb10065.x; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jia YK, 1997, MOL CELL BIOL, V17, P1110, DOI 10.1128/MCB.17.3.1110; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; KIM KS, 1986, MOL CELL BIOL, V6, P1936, DOI 10.1128/MCB.6.6.1936; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Lemaire C, 2000, J BIOL CHEM, V275, P23471, DOI 10.1074/jbc.M002045200; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MAARSE AC, 1994, FEBS LETT, V349, P215, DOI 10.1016/0014-5793(94)00669-5; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Miyahara K, 1996, CURR GENET, V29, P103, DOI 10.1007/s002940050023; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; Nourani A, 1997, MOL GEN GENET, V256, P397, DOI 10.1007/s004380050583; Poch O, 1997, GENE, V184, P229, DOI 10.1016/S0378-1119(96)00602-6; PRAEKELT UM, 1990, MOL GEN GENET, V223, P97, DOI 10.1007/BF00315801; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; SEWELL AK, 1995, J BIOL CHEM, V270, P25079, DOI 10.1074/jbc.270.42.25079; Sherman F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Stephen DWS, 1997, MOL MICROBIOL, V23, P203, DOI 10.1046/j.1365-2958.1997.2081572.x; STONE G, 1993, EMBO J, V12, P1375, DOI 10.1002/j.1460-2075.1993.tb05782.x; SZE JY, 1992, SCIENCE, V258, P1143, DOI 10.1126/science.1439822; TAKEDA M, 1985, J BIOL CHEM, V260, P5458; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WU AL, 1993, J BIOL CHEM, V268, P18850; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; ZALKIN H, 1982, J BIOL CHEM, V257, P1491; ZHOU K, 1987, NUCLEIC ACIDS RES, V15, P5261, DOI 10.1093/nar/15.13.5261	63	144	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37347	37356		10.1074/jbc.M007338200	http://dx.doi.org/10.1074/jbc.M007338200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10980204	hybrid			2022-12-27	WOS:000165618700008
J	Suzuki, H; Okazawa, Y; Komiya, T; Saeki, K; Mekada, E; Kitada, S; Ito, A; Mihara, K				Suzuki, H; Okazawa, Y; Komiya, T; Saeki, K; Mekada, E; Kitada, S; Ito, A; Mihara, K			Characterization of rat TOM40, a central component of the preprotein translocase of the mitochondrial outer membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; PROTEIN IMPORT RECEPTOR; INNER MEMBRANE; CYTOPLASMIC CHAPERONES; PRECURSOR PROTEINS; COMPLEX; IDENTIFICATION; INSERTION; YEAST; PORE	We cloned a 38-kDa rat mitochondrial outer membrane protein (OM38) with structural homology to the central component of preprotein translocase of the fungal mitochondrial outer membrane, Tom40. Although it has no predictable alpha -helical transmembrane segments, OM38 is resistant to alkaline carbonate extraction and is inaccessible to proteases and polyclonal antibodies added from outside the mitochondria, suggesting that it is embedded in the membrane, probably in a beta -barrel structure, as has been similarly speculated for fungal Tom40. Immunoprecipitation demonstrated that OM38 is associated with the major import receptors rTOM20 and rTOM22, and several other unidentified components with molecular masses of 5-10 kDa in digitonin-solubilized membrane: OM10, OM7.5, and OM5. Blue native polyacrylamide gel electrophoresis revealed that OM38 is a component of a similar to 400-kDa complex, firmly associating with rTOM22 and loosely associating with rTOM20. The preprotein in transit to the matrix interacted with the TOM complex containing OM38, and immunodepletion of OM38 resulted in the loss of preprotein import activity of the detergent-solubilized and reconstituted outer membrane vesicles. Taken together, these results indicate that OM38 is a structural and functional homolog of fungal Tom40 and functions as a component of the preprotein import machinery of the rat mitochondrial outer membrane.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8120054, Japan; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan; Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan	Kyushu University; Kurume University; Kyushu University	Mihara, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8120054, Japan.			Mekada, Eisuke/0000-0001-8858-4781				Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; Armstrong LC, 1997, J BIOL CHEM, V272, P6510, DOI 10.1074/jbc.272.10.6510; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; Davis AJ, 1998, MOL BIOL CELL, V9, P2577, DOI 10.1091/mbc.9.9.2577; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; GOPING IS, 1995, FEBS LETT, V373, P45; HACHIYA N, 1994, EMBO J, V13, P5246; Hanson B, 1996, EUR J BIOCHEM, V235, P750, DOI 10.1111/j.1432-1033.1996.t01-1-00750.x; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Ishihara N, 1998, J BIOCHEM-TOKYO, V123, P722; ISHIHARA S, 1990, J BIOCHEM-TOKYO, V108, P899, DOI 10.1093/oxfordjournals.jbchem.a123310; IWAHASHI J, 1994, J BIOCHEM-TOKYO, V116, P156, DOI 10.1093/oxfordjournals.jbchem.a124488; Iwahashi J, 1997, J BIOL CHEM, V272, P18467, DOI 10.1074/jbc.272.29.18467; Jansch L, 1998, J BIOL CHEM, V273, P17251, DOI 10.1074/jbc.273.27.17251; Kerscher O, 2000, MOL BIOL CELL, V11, P103, DOI 10.1091/mbc.11.1.103; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141; Komiya T, 1996, EMBO J, V15, P399, DOI 10.1002/j.1460-2075.1996.tb00370.x; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; MATSUMOTO T, 1986, J BIOCHEM-TOKYO, V100, P1359, DOI 10.1093/oxfordjournals.jbchem.a121842; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; Mayer A, 1995, METHOD ENZYMOL, V260, P252, DOI 10.1016/0076-6879(95)60143-0; Mihara K, 1996, TRENDS CELL BIOL, V6, P104, DOI 10.1016/0962-8924(96)81000-2; MIHARA K, 1990, J BIOCHEM-TOKYO, V108, P1022, DOI 10.1093/oxfordjournals.jbchem.a123301; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Nuttall SD, 1997, DNA CELL BIOL, V16, P1067, DOI 10.1089/dna.1997.16.1067; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; Rapaport D, 1997, J BIOL CHEM, V272, P18725, DOI 10.1074/jbc.272.30.18725; Rassow J, 1999, J MOL BIOL, V286, P105, DOI 10.1006/jmbi.1998.2455; Saeki K, 2000, J BIOL CHEM, V275, P31996, DOI 10.1074/jbc.M004794200; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SEKI N, 1995, FEBS LETT, V375, P307, DOI 10.1016/0014-5793(95)01229-8; Shimokata K, 1998, J BIOL CHEM, V273, P25158, DOI 10.1074/jbc.273.39.25158; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Tokatlidis K, 1999, J BIOL CHEM, V274, P35285, DOI 10.1074/jbc.274.50.35285; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6	43	71	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37930	37936		10.1074/jbc.M006558200	http://dx.doi.org/10.1074/jbc.M006558200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10980201	hybrid			2022-12-27	WOS:000165618700084
J	Zeghouf, M; Fontecave, M; Coves, J				Zeghouf, M; Fontecave, M; Coves, J			A simplifed functional version of the Escherichia coli sulfite reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVIN ADENINE-DINUCLEOTIDE; FLAVOPROTEIN COMPONENT; PROSTHETIC GROUPS; RIBONUCLEOTIDE REDUCTASE; CATALYTIC PARAMETERS; HEMOPROTEIN SUBUNIT; HEMOFLAVOPROTEIN; MONONUCLEOTIDE; ENTEROBACTERIA; EXPRESSION	Escherichia coli sulfite reductase (SiR) is a large and soluble enzyme with an alpha (8)beta (4) quaternary structure, Protein alpha (or sulfite reductase flavoprotein) contains both FAD and FMN, whereas protein beta (or sulfite reductase hemoprotein (SiR-HP)) contains an iron-sulfur cluster coupled to a siroheme, The enzyme is set up to arrange the redox cofactors in a FAD-FMN-Fe4S4-Heme sequence to make an electron pathway between NADPH and sulfite. Whereas alpha spontaneously polymerizes, we have been able to produce SiR-FP60, a monomeric but fully active truncated version of it, lacking the N-terminal part (Zeghouf, M., Fontecave, M,, Macherel, D., and Coves, J. (1998) Biochemistry 37, 6114-6123). Here we report the cloning, overproduction, and characterization of the beta subunit. Pure recombinant SiR-HP behaves as a monomer in solution and is identical to the native protein in all its characteristics. Moreover, we demonstrate that the combination of SiR-FP60 and SiR-HP produces a functional 1:1 complex with tight interactions retaining about 20% of the activity of the native SiR, In addition, fully active SiR can be reconstituted by incubation of the octameric sulfite reductase flavoprotein with recombinant SiR-HP. Titration experiments and spectroscopic properties strongly suggest that the holoenzyme should be described as an alpha (8)beta (4) with equal amounts of alpha and beta subunits and that the alpha (8)beta (4) structure is probably not correct.	Univ Grenoble 1, CEA, CNRS 5047, UMR,DBMS,CB,Lab Chim & Biochim,Ctr Redox Biol, F-38054 Grenoble 9, France	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Fontecave, M (corresponding author), Univ Grenoble 1, CEA, CNRS 5047, UMR,DBMS,CB,Lab Chim & Biochim,Ctr Redox Biol, 17 Ave Martyrs, F-38054 Grenoble 9, France.			Zeghouf, Mahel/0000-0003-3686-2510				AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; BEINERT H, 1983, ANAL BIOCHEM, V78, P248; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; COVES J, 1993, J BIOL CHEM, V268, P18604; Coves J, 1997, BIOCHEMISTRY-US, V36, P5921, DOI 10.1021/bi9623744; Crane BR, 1997, BIOCHEMISTRY-US, V36, P12120, DOI 10.1021/bi971066i; CRANE BR, 1995, SCIENCE, V270, P59, DOI 10.1126/science.270.5233.59; ESCHENBRENNER M, 1995, FEBS LETT, V374, P82, DOI 10.1016/0014-5793(95)01081-O; ESCHENBRENNER M, 1995, J BIOL CHEM, V270, P20550, DOI 10.1074/jbc.270.35.20550; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; Gruez A, 2000, J MOL BIOL, V299, P199, DOI 10.1006/jmbi.2000.3748; JANICK PA, 1982, BIOCHEMISTRY-US, V21, P3538, DOI 10.1021/bi00258a003; Jelesarov Ilian, 1996, Methods (Orlando), V9, P533, DOI 10.1006/meth.1996.0061; KARPLUS PA, 1994, J BIOENERG BIOMEMBR, V26, P89, DOI 10.1007/BF00763221; KREDICH NM, 1971, J BIOL CHEM, V246, P3474; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; Siegel L M, 1978, Methods Enzymol, V52, P436; SIEGEL LM, 1982, J BIOL CHEM, V257, P6343; SIEGEL LM, 1974, J BIOL CHEM, V249, P1587; SIEGEL LM, 1973, J BIOL CHEM, V248, P251; SIEGEL LM, 1974, J BIOL CHEM, V249, P1572; SIEGEL LM, 1971, FLAVINS FLAVOPROTEIN, P523; WU JY, 1991, J BACTERIOL, V173, P325, DOI 10.1128/jb.173.1.325-333.1991; YONEDA F, 1976, J CHEM SOC PERK T 1, P1805, DOI 10.1039/p19760001805; Zeghouf M, 1998, BIOCHEM BIOPH RES CO, V246, P602, DOI 10.1006/bbrc.1998.8671; Zeghouf M, 1998, BIOCHEMISTRY-US, V37, P6114, DOI 10.1021/bi9728699	31	26	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37651	37656		10.1074/jbc.M005619200	http://dx.doi.org/10.1074/jbc.M005619200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10984484	hybrid			2022-12-27	WOS:000165618700048
J	He, W; Lu, LS; Zhang, X; El-Hodiri, HM; Chen, CK; Slep, KC; Simon, MI; Jamrich, M; Wensel, TG				He, W; Lu, LS; Zhang, X; El-Hodiri, HM; Chen, CK; Slep, KC; Simon, MI; Jamrich, M; Wensel, TG			Modules in the photoreceptor RGS9-1 center dot G(beta 5L) GTPase-accelerating protein complex control effector coupling, GTPase acceleration, protein folding, and stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RGS PROTEINS; BETA-SUBUNIT; TARGET ENZYME; GAMMA; TRANSDUCIN; DOMAIN; DEACTIVATION; EXPRESSION; REGULATORS; DISTINCT	RGS (regulators of G protein signaling proteins regulate G protein signaling by accelerating GTP hydrolysis, but little is known about regulation of GTPase-accelerating protein (GAP) activities or roles of domains and subunits outside the catalytic cores. RGS9-1 is the GAP required for rapid recovery of light responses in vertebrate photoreceptors and the only mammalian RGS protein with a defined physiological function. It belongs to an RGS subfamily whose members have multiple domains, including G gamma -like domains that bind G(beta5) proteins. Members of this subfamily play important roles in neuronal signaling, Within the GAP complex organized around the RGS domain of RGS9-1, we have identified a functional role for the G gamma -like-G(beta 5L) complex in regulation of GAP activity by an effector subunit, cGMP phosphodiesterase gamma and in protein folding and stability of RGS9-1, The C-terminal domain of RGS9-1 also plays a major role in conferring effector stimulation. The sequence of the RGS domain determines whether the sign of the effector effect will be positive or negative. These roles were observed in, vitro using full-length proteins or fragments for RGS9-1, RGS7, G(beta 5S), and G(beta 5s), The dependence of RGS9-1 on Gp, co-expression for folding, stability, and function has been confirmed in vivo using transgenic Xenopus laevis, These results reveal how multiple domains and regulatory polypeptides work together to fine tune G(t alpha) inactivation.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; Yale Univ, Dept Biochem & Mol Biophys, New Haven, CT 06511 USA	Baylor College of Medicine; Baylor College of Medicine; California Institute of Technology; Yale University	Wensel, TG (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.	twensel@bcm.tmc.edu	El-hodiri, Heithem/E-3019-2011	Wensel, Theodore/0000-0003-3518-9352				ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Cowan CW, 2001, PROG NUCLEIC ACID RE, V65, P341; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; Cowan CW, 2000, METHOD ENZYMOL, V315, P524; Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636; HARPER JW, 1993, CELL, V75, P805; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Kovoor A, 2000, J BIOL CHEM, V275, P3397, DOI 10.1074/jbc.275.5.3397; Kroll KL, 1996, DEVELOPMENT, V122, P3173; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; McEntaffer RL, 1999, BIOCHEMISTRY-US, V38, P4931, DOI 10.1021/bi982636x; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PENG HB, 1991, METHOD CELL BIOL, V36, P657; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; Rahman Z, 1999, J NEUROSCI, V19, P2016; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; Shuey DJ, 1998, J NEUROCHEM, V70, P1964; Siderovski DP, 1999, CRIT REV BIOCHEM MOL, V34, P215, DOI 10.1080/10409239991209273; Skiba NP, 1999, J BIOL CHEM, V274, P8770, DOI 10.1074/jbc.274.13.8770; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Sowa ME, 2000, P NATL ACAD SCI USA, V97, P1483, DOI 10.1073/pnas.030409597; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zhang JH, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-03-j0004.2000; Zhang K, 1999, GENE, V240, P23, DOI 10.1016/S0378-1119(99)00393-5	38	76	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37093	37100		10.1074/jbc.M006982200	http://dx.doi.org/10.1074/jbc.M006982200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10978345	hybrid, Green Accepted			2022-12-27	WOS:000165577700089
J	Tan, J; Town, T; Mullan, M				Tan, J; Town, T; Mullan, M			CD45 inhibits CD40L-induced microglial activation via negative regulation of the Src/p44/42 MAPK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; GERMINAL CENTER FORMATION; FAMILY TYROSINE KINASES; IMMATURE B-CELLS; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; DEFICIENT MICE; T-LYMPHOCYTES; LYN KINASE; LIGAND	It has been reported that Ligation of CD40 with CD40 ligand (CD40L) results in microglial activation as evidenced by p44/42 mitogen-activated protein kinase (MAPK) dependent tumor necrosis factor alpha (TNF-alpha) production. Previous studies have shown that CD45, a functional transmembrane protein-tyrosine phosphatase, is constitutively expressed at moderate levels on microglial cells and this expression is greatly elevated on activated microglia. To investigate the possibility that CD45 might modulate CD40L-induced microglial activation, we treated primary cultured microglial cells with CD40L and anti-CD45 antibody. Data show that crosslinking of CD45 markedly inhibits CD40L-induced activity of the Src family kinases Lck and Lyn. Further, cotreatment of microglia with CD40L and anti-CD45 antibody results in significant inhibition of microglial TNF-alpha production through inhibition of p44/42 MAPK activity, a downstream signaling event resulting from Src activation. Accordingly, primary cultured microglial cells from mice deficient in CD45 demonstrate hyper-responsiveness to ligation of CD40, as evidenced by increased p44/42 MAPK activation and TNF-alpha production. Taken together, these results show that CD45 plays a novel role in suppressing CD40L-induced microglial activation via negative regulation of the Src/p44/42 MAPK cascade.	Univ S Florida, Dept Psychiat, Roskamp Inst, Tampa, FL 33613 USA	State University System of Florida; University of South Florida	Tan, J (corresponding author), Univ S Florida, Dept Psychiat, Roskamp Inst, 3515 E Fletcher Ave, Tampa, FL 33613 USA.		Tan, Jun/I-5339-2012	Mullan, Michael/0000-0002-1473-7527				Aloisi F, 1998, J IMMUNOL, V160, P4671; Ashwell JD, 1999, IMMUNOL TODAY, V20, P412, DOI 10.1016/S0167-5699(99)01505-4; Bhat NR, 1998, J NEUROSCI, V18, P1633; Brenner B, 1997, BIOCHEM BIOPH RES CO, V239, P11, DOI 10.1006/bbrc.1997.7415; Brenner B, 1997, FEBS LETT, V417, P301, DOI 10.1016/S0014-5793(97)01306-9; BURNS CM, 1994, J BIOL CHEM, V269, P13594; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; Carson MJ, 1998, GLIA, V22, P72, DOI 10.1002/(SICI)1098-1136(199801)22:1<72::AID-GLIA7>3.0.CO;2-A; CHENG HC, 1992, J BIOL CHEM, V267, P9248; Combs CK, 1999, J NEUROSCI, V19, P928; Daulhac L, 1999, J BIOL CHEM, V274, P20657, DOI 10.1074/jbc.274.29.20657; Diehl L, 1999, NAT MED, V5, P774, DOI 10.1038/10495; Downen M, 1999, GLIA, V28, P114, DOI 10.1002/(SICI)1098-1136(199911)28:2<114::AID-GLIA3>3.0.CO;2-O; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; Gebicke-Haerter PJ, 1998, NERVENARZT, V69, P752, DOI 10.1007/s001150050339; Gulbins E, 1997, P NATL ACAD SCI USA, V94, P7661, DOI 10.1073/pnas.94.14.7661; Gulbins E, 1996, J IMMUNOL, V157, P2844; Iciek LA, 1997, J IMMUNOL, V158, P4769; Imbert V, 1996, J INFLAMM, V46, P65; Jeohn GH, 1998, J NEUROIMMUNOL, V85, P1, DOI 10.1016/S0165-5728(97)00204-X; Justement LB, 1997, ADV IMMUNOL, V66, P1, DOI 10.1016/S0065-2776(08)60595-7; Kalaria R N, 1999, Curr Opin Hematol, V6, P15, DOI 10.1097/00062752-199901000-00004; KATAGIRI T, 1995, J BIOL CHEM, V270, P27987; Katagiri T, 1999, J IMMUNOL, V163, P1321; Kato J, 1998, J IMMUNOL, V160, P4788; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; LOH RKS, 1995, IMMUNOL LETT, V45, P99, DOI 10.1016/0165-2478(94)00233-H; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; Meng FY, 1997, J EXP MED, V185, P1661, DOI 10.1084/jem.185.9.1661; Nguyen VT, 1998, EUR J IMMUNOL, V28, P2537, DOI 10.1002/(SICI)1521-4141(199808)28:08<2537::AID-IMMU2537>3.0.CO;2-1; Orlicek SL, 1999, SHOCK, V12, P350, DOI 10.1097/00024382-199911000-00004; Purkerson JM, 1998, J IMMUNOL, V160, P2121; Pyo H, 1998, NEUROREPORT, V9, P871, DOI 10.1097/00001756-199803300-00020; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Suttles J, 1999, J BIOL CHEM, V274, P5835, DOI 10.1074/jbc.274.9.5835; Tan J, 1999, SCIENCE, V286, P2352, DOI 10.1126/science.286.5448.2352; Tan J, 1999, J NEUROIMMUNOL, V97, P77, DOI 10.1016/S0165-5728(99)00053-3; Tan J, 1999, J IMMUNOL, V163, P6614; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; TsujiTakayama K, 1997, BIOCHEM BIOPH RES CO, V237, P126, DOI 10.1006/bbrc.1997.7099; van der Bruggen T, 1999, INFECT IMMUN, V67, P3824, DOI 10.1128/IAI.67.8.3824-3829.1999; Wang JY, 1996, J EXP MED, V184, P831, DOI 10.1084/jem.184.3.831; YOSJIMOTO T, 1997, EUR J IMMUNOL, V27, P3461; Zhou L, 1999, CLIN IMMUNOL, V93, P232, DOI 10.1006/clim.1999.4796	47	74	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37224	37231		10.1074/jbc.M002006200	http://dx.doi.org/10.1074/jbc.M002006200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10978311	hybrid			2022-12-27	WOS:000165577700105
J	Fuki, IV; Iozzo, RV; Williams, KJ				Fuki, IV; Iozzo, RV; Williams, KJ			Perlecan heparan sulfate proteoglycan. A novel receptor that mediates a distinct pathway for ligand catabolism. (vol 275, pg 25742, 2000)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Correction									Thomas Jefferson Univ, Div Endocrinol Diabet & Metab Dis, Philadelphia, PA 19107 USA	Jefferson University	Williams, KJ (corresponding author), Thomas Jefferson Univ, Div Endocrinol Diabet & Metab Dis, Jefferson Alumni Hall,Rm 349,1020 Locust St, Philadelphia, PA 19107 USA.							Fuki IV, 2000, J BIOL CHEM, V275, P25742, DOI 10.1074/jbc.M909173199	1	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31554	31554						1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	11013268				2022-12-27	WOS:000089762700112
J	Chang, DK; Ricciardiello, L; Goel, A; Chang, CL; Boland, CR				Chang, DK; Ricciardiello, L; Goel, A; Chang, CL; Boland, CR			Steady-state regulation of the human DNA mismatch repair system. (vol 275, pg 18424, 2000)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Correction													Chang, Christina/B-9650-2009; RICCIARDIELLO, LUIGI/K-7269-2016	RICCIARDIELLO, LUIGI/0000-0003-2568-6208; Goel, Ajay/0000-0003-1396-6341				Chang DK, 2000, J BIOL CHEM, V275, P18424, DOI 10.1074/jbc.M001140200	1	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29178	29178						1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10979986				2022-12-27	WOS:000089330700109
J	Hannemann, F; Rottmann, M; Schiffler, B; Zapp, J; Bernhardt, R				Hannemann, F; Rottmann, M; Schiffler, B; Zapp, J; Bernhardt, R			The loop region covering the iron-sulfur cluster in bovine adrenodoxin comprises a new interaction site for redox partners	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ELECTRON-TRANSFER FUNCTION; DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; FERREDOXIN REDUCTASE; MOLECULAR-CLONING; 2FE-2S FERREDOXIN; EXPRESSION; BINDING; IDENTIFICATION	The amino acid in position 49 in bovine adrenodoxin is conserved among vertebrate [2Fe-2S] ferredoxins as hydroxyl function. A corresponding residue is missing in the cluster-coordinating loop of plant-type [2Fe-2S] ferredoxins. To probe the function of Thr-49 in a vertebrate ferredoxin, replacement mutants T49A, T49S, T49L, and T49Y, and a deletion mutant, T49 Delta, were generated and expressed in Escherichia cold, CD spectra of purified proteins indicate changes of the [2Fe-2S] center geometry only for mutant T49 Delta, whereas NMR studies reveal no transduction of structural changes to the interaction domain. The redox potential of T49 Delta (-370 mV) is lowered by similar to 100 mV compared with wild type adrenodoxin and reaches the potential range of plant-type ferredoxins (-305 to -455 mV), Substitution mutants show moderate changes in the binding affinity to the redox partners. In contrast, the binding affinity of T49 Delta to adrenodoxin reductase and cytochrome P-450 11A1 (CYP11A1) is dramatically reduced. These results led to the conclusion that Thr-49 modulates the redox potential in adrenodoxin and that the cluster-binding loop around Thr-49 represents a new interaction region with the redox partners adrenodoxin reductase and CYP11A1, In addition, variations of the apparent rate constants of all mutants for CYP11A1 reduction indicate the participation of residue 49 in the electron transfer pathway between adrenodoxin and CYP11A1.	Univ Saarlandes, Fachrichtung Biochem 8 8, D-60041 Saarbrucken, Germany; Univ Saarlandes, Fachrichtung Pharmakognosie & Analyt Phytochem 8, D-60041 Saarbrucken, Germany	Saarland University; Saarland University	Bernhardt, R (corresponding author), Univ Saarlandes, Fachrichtung Biochem 8 8, D-60041 Saarbrucken, Germany.			Hannemann, Frank/0000-0001-7991-9033; Rottmann, Matthias/0000-0002-2207-7899				AKHREM AA, 1979, ACTA BIOL MED GER, V38, P257; BECKERT V, 1995, EUR J BIOCHEM, V231, P226, DOI 10.1111/j.1432-1033.1995.tb20691.x; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; Bernhardt R, 1996, REV PHYSIOL BIOCH P, V127, P137, DOI 10.1007/BFb0048267; BOHME H, 1988, MOL GEN GENET, V214, P278, DOI 10.1007/BF00337722; BRANDT ME, 1993, J BIOL CHEM, V268, P17126; BUROVA TV, 1995, PROTEIN SCI, V4, P909; CAMMACK R, 1977, BIOCHEM J, V168, P205, DOI 10.1042/bj1680205; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; ESTABROOK RW, 1973, IRON SULPHUR PROTEIN, V1, P193; Farver O, 1997, J AM CHEM SOC, V119, P5453, DOI 10.1021/ja964386i; Grinberg AV, 1998, PROTEIN ENG, V11, P1057, DOI 10.1093/protein/11.11.1057; Grinberg AV, 2000, PROTEINS, V40, P590, DOI 10.1002/1097-0134(20000901)40:4<590::AID-PROT50>3.0.CO;2-P; HASE T, 1980, BIOCHIM BIOPHYS ACTA, V623, P139, DOI 10.1016/0005-2795(80)90016-1; HASE T, 1976, J BIOCHEM-TOKYO, V79, P329, DOI 10.1093/oxfordjournals.jbchem.a131076; HASE T, 1977, J BIOCHEM-TOKYO, V82, P277, DOI 10.1093/oxfordjournals.jbchem.a131680; HIWATASHI A, 1976, BIOCHEMISTRY-US, V15, P3091, DOI 10.1021/bi00659a024; Holden M, 1997, J BIOL CHEM, V272, P21720, DOI 10.1074/jbc.272.35.21720; ICHIKAWA Y, 1987, IRON SULFUR PROTEIN, P97; KIDO T, 1979, J BIOL CHEM, V254, P1806; Kimura T., 1968, STRUCTURE BONDING, V5, P1; LAMBETH JD, 1979, J BIOL CHEM, V254, P2766; LAMBETH JD, 1985, J BIOL CHEM, V260, P8810; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; Muller A, 1998, STRUCTURE, V6, P269, DOI 10.1016/S0969-2126(98)00031-8; OKAMURA T, 1985, P NATL ACAD SCI USA, V82, P5705, DOI 10.1073/pnas.82.17.5705; PETERSON JA, 1990, J BIOL CHEM, V265, P6066; PETERSON JA, 1992, J BIOL CHEM, V267, P14193; Pikuleva IA, 2000, ARCH BIOCHEM BIOPHYS, V373, P44, DOI 10.1006/abbi.1999.1536; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; SAGARA Y, 1993, BIOL PHARM BULL, V16, P627; Shimada H, 1999, J BIOL CHEM, V274, P9363, DOI 10.1074/jbc.274.14.9363; SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; Sugano S, 1996, J BIOCHEM-TOKYO, V120, P780; TA DT, 1992, J BIOL CHEM, V267, P11120; TUCKEY RC, 1983, J BIOL CHEM, V258, P4232; UHLMANN H, 1994, J BIOL CHEM, V269, P22557; UHLMANN H, 1995, J BIOL CHEM, V270, P29959; UHLMANN H, 1992, BIOCHEM BIOPH RES CO, V188, P1131, DOI 10.1016/0006-291X(92)91349-U; Vickery LE, 1997, STEROIDS, V62, P124, DOI 10.1016/S0039-128X(96)00170-5; VIDAKOVIC M, 1995, BIOCHEMISTRY-US, V34, P13906, DOI 10.1021/bi00042a023; WADA A, 1992, J BIOL CHEM, V267, P22877; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	45	35	35	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1369	1375		10.1074/jbc.M007589200	http://dx.doi.org/10.1074/jbc.M007589200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11013256	hybrid			2022-12-27	WOS:000166430900069
J	Hong, TM; Chen, JJW; Peck, K; Yang, PC; Wu, CW				Hong, TM; Chen, JJW; Peck, K; Yang, PC; Wu, CW			p53 amino acids 339-346 represent the minimal p53 repression domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TATA-BINDING PROTEIN; TRANSCRIPTIONAL REPRESSION; TUMOR-SUPPRESSOR; OLIGOMERIZATION DOMAIN; HISTONE DEACETYLASES; CRYSTAL-STRUCTURE; SITE; ACTIVATION; MUTATIONS	The p53 tumor suppressor protein functions as an activator and also as a repressor of gene transcription. Currently, the mechanism of transcriptional repression by p53 remains poorly understood. To help clarify this mechanism, we carried out studies designed to identify the minimal repression domain that inhibits p53 transcriptional activities. We found only eight amino acids (339-346) of the COOH-terminal domain (termed P53MRD) that possess activities of repression, The exact location of this minimal domain is on the EG-binding region, and it lacks the ability of tetramerization. P53MRD is able to repress the transcription of p53 while not affecting VP16. The mutants (amino acids M340P and F341D) of native p53 also lost transcriptional repression of the thymidine kinase chloramphenicol acetyltransferase promoter. These results suggest that this eight-amino acid element is required for the repression of p53.	Natl Taiwan Univ, Coll Med, Grad Inst Mol Biol, Taipei 100, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Natl Taiwan Univ Hosp, Off Clin Res, Taipei 100, Taiwan; Natl Taiwan Univ, Sch Med, Dept Internal Med, Taipei 100, Taiwan; Natl Hlth Res Inst, Taipei 115, Taiwan	National Taiwan University; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Health Research Institutes - Taiwan	Yang, PC (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, 7 Chung Shan S Rd, Taipei 100, Taiwan.		Yang, Pan-Chyr/B-8808-2009	YANG, PAN-CHYR/0000-0001-6330-6048; Chen, Jeremy J.W./0000-0003-1049-3825				BIRCH JM, 1994, CANCER RES, V54, P1298; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HELLSTEIN M, 1991, SCIENCE, V253, P49; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HORIO Y, 1994, ONCOGENE, V9, P1231; HSU YS, 1995, J BIOL CHEM, V270, P6966, DOI 10.1074/jbc.270.12.6966; HUANG JY, 1995, J BIOL CHEM, V270, P23899; ISHIOKA C, 1995, ONCOGENE, V10, P1485; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; JOLLY KW, 1994, ONCOGENE, V9, P97; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEE W, 1994, STRUCT BIOL, V1, P887; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MAZOYER S, 1994, ONCOGENE, V9, P1237; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; PELLEGATA NS, 1995, ONCOGENE, V11, P337; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Tung SF, 1999, J BIOL CHEM, V274, P7748, DOI 10.1074/jbc.274.12.7748; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	44	19	21	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1510	1515		10.1074/jbc.M008231200	http://dx.doi.org/10.1074/jbc.M008231200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11007800	hybrid			2022-12-27	WOS:000166430900087
J	Arlandson, M; Decker, T; Roongta, VA; Bonilla, L; Mayo, KH; MacPherson, JC; Hazen, SL; Slungaard, A				Arlandson, M; Decker, T; Roongta, VA; Bonilla, L; Mayo, KH; MacPherson, JC; Hazen, SL; Slungaard, A			Eosinophil peroxidase oxidation of thiocyanate - Characterization of major reaction products and a potential sulfhydryl-targeted cytotoxicity system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOPEROXIDASE-CATALYZED OXIDATION; NUCLEAR-MAGNETIC-RESONANCE; SCHISTOSOMA-MANSONI; HYDROGEN-PEROXIDE; MOLECULAR-CLONING; VIRUS TYPE-1; INHIBITION; TOXICITY; INVITRO; MYELOPEROXIDASE	Although the pseudohalide thiocyanate (SCN-) is the preferred substrate for eosinophil peroxidase (EPO) in fluids of physiologic halide composition, the product(s) of this reaction have not been directly identified, and mechanisms underlying their cytotoxic potential are poorly characterized. We used nuclear magnetic resonance spectroscopy (NMR), electrospray ionization mass spectrometry, and quantitative chemical analysis to identify the principal reaction products of both the EPO/SCN-/H2O2 system and activated eosinophils as roughly equimolar amounts of OSCN- (hypothiocyanite) and OCN- (cyanate). Red blood cells exposed to increasing concentrations of OSCN-/OCN- are first depleted of glutathione, after which glutathione S-transferase and glyceraldehyde-3-phosphate dehydrogenase then ATPases undergo sulfhydryl (SH) reductant-reversible inactivation before lysing. OSCN-/OCN- inactivates red blood cell membrane ATPases 10-1000 times more potently than do HOCl, HOBr, and H2O2. Exposure of glutathione S-transferase to [C-14]OSCN-/OCN- causes SH reductant-reversible disulfide bonding and covalent isotope labeling. We propose that EPO/SCN-/H2O2 reaction products comprise a potential SH-targeted cytotoxic system that functions in striking contrast to HOCl, the highly but relatively indiscriminantly reactive product of the neutrophil myeloperoxidase system.	Univ Minnesota, Ctr Canc, Dept Internal Med, Sch Med, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Dept Biochem, Sch Med, Minneapolis, MN 55455 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Slungaard, A (corresponding author), Univ Minnesota, Ctr Canc, Dept Internal Med, Sch Med, Box 480 FUMC, Minneapolis, MN 55455 USA.	slung001@tc.umn.edu	Hazen, Stanley L/ABD-5845-2021		NHLBI NIH HHS [HL 61878, R0-1-HL48915] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061878, R01HL048915] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUGHAZALEH RI, 1992, J LEUKOCYTE BIOL, V52, P611, DOI 10.1002/jlb.52.6.611; AGOSTI JM, 1987, J ALLERGY CLIN IMMUN, V79, P496, DOI 10.1016/0091-6749(87)90368-X; ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; Andersson LA, 1996, J BIOL CHEM, V271, P3406, DOI 10.1074/jbc.271.7.3406; AUNE TM, 1977, BIOCHEMISTRY-US, V16, P4611, DOI 10.1021/bi00640a013; BAGINSKI ES, 1967, CLIN CHIM ACTA, V15, P155, DOI 10.1016/0009-8981(67)90340-3; BHARGAVA KK, 1983, MOL BIOCHEM PARASIT, V9, P29, DOI 10.1016/0166-6851(83)90054-3; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V784, P177, DOI 10.1016/0167-4838(84)90125-0; BRODIE AE, 1990, ARCH BIOCHEM BIOPHYS, V276, P212, DOI 10.1016/0003-9861(90)90028-W; CARLSON MGC, 1985, J IMMUNOL, V134, P1875; DIRNHUBER P, 1948, BIOCHEM J, V42, P628, DOI 10.1042/bj0420628; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FREEDMAN ML, 1975, J PHARMACOL EXP THER, V195, P340; GLADER BE, 1972, NATURE, V237, P336, DOI 10.1038/237336a0; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GRISHAM MB, 1990, AM J PHYSIOL, V258, pC115, DOI 10.1152/ajpcell.1990.258.1.C115; GUILLOTON M, 1985, ANAL BIOCHEM, V149, P291, DOI 10.1016/0003-2697(85)90572-X; HANSEL TT, 1990, J IMMUNOL METHODS, V127, P153, DOI 10.1016/0022-1759(90)90064-3; HEBBEL RP, 1986, BIOCHIM BIOPHYS ACTA, V862, P8, DOI 10.1016/0005-2736(86)90463-3; HIMMELHOCH SR, 1969, BIOCHEMISTRY-US, V8, P914, DOI 10.1021/bi00831a022; HOLZBECHER J, 1980, CLIN BIOCHEM, V13, P277, DOI 10.1016/S0009-9120(80)80009-9; IDE M, 1994, J IMMUNOL METHODS, V168, P187, DOI 10.1016/0022-1759(94)90054-X; JONG EC, 1984, AM J TROP MED HYG, V33, P104, DOI 10.4269/ajtmh.1984.33.104; JONG EC, 1981, J IMMUNOL, V126, P468; JONG EC, 1980, J IMMUNOL, V124, P1949; JONG EC, 1980, J IMMUNOL, V124, P1378; KAZURA JW, 1981, J CLIN INVEST, V67, P93, DOI 10.1172/JCI110037; Klebanoff S.J., 1982, ADV HOST DEFENSE MEC, P111; Klebanoff SJ, 1996, AIDS RES HUM RETROV, V12, P25, DOI 10.1089/aid.1996.12.25; LENANDERLUMIKARI M, 1992, ORAL MICROBIOL IMMUN, V7, P315, DOI 10.1111/j.1399-302X.1992.tb00595.x; LOVAAS E, 1992, FREE RADICAL BIO MED, V13, P187, DOI 10.1016/0891-5849(92)90014-8; MAYENO AN, 1989, J BIOL CHEM, V264, P5660; Mazumdar A, 1996, BIOCHEM J, V314, P413, DOI 10.1042/bj3140413; MIKOLA H, 1995, ANTIVIR RES, V26, P161, DOI 10.1016/0166-3542(94)00073-H; MKOJI GM, 1989, BIOCHEM PHARMACOL, V38, P4307, DOI 10.1016/0006-2952(89)90530-3; MODI S, 1991, BIOCHEMISTRY-US, V30, P118, DOI 10.1021/bi00215a018; MOON RB, 1974, PHYSIOL CHEM PHYS M, V6, P31; NATHAN CF, 1982, J EXP MED, V155, P1291, DOI 10.1084/jem.155.5.1291; OKA S, 1981, ANAL CHEM, V53, P588, DOI 10.1021/ac00227a007; POLLOCK JR, 1992, BIOCHIM BIOPHYS ACTA, V1159, P279, DOI 10.1016/0167-4838(92)90057-K; Qian MW, 1997, BIOCHEM J, V326, P159, DOI 10.1042/bj3260159; RIVOLTINI L, 1993, INT J CANCER, V54, P8, DOI 10.1002/ijc.2910540103; ROSEN H, 1982, J BIOL CHEM, V257, P13731; SAKAMAKI K, 1989, J BIOL CHEM, V264, P16828; SALMASO BLN, 1994, BIOPHYS J, V67, P436, DOI 10.1016/S0006-3495(94)80499-0; SCHRAUFSTATTER IU, 1990, J CLIN INVEST, V85, P554, DOI 10.1172/JCI114472; SHEN H, 1991, ARCH BIOCHEM BIOPHYS, V286, P178, DOI 10.1016/0003-9861(91)90025-E; SIBBETT SS, 1985, FEBS LETT, V189, P271, DOI 10.1016/0014-5793(85)81038-3; SLUNGAARD A, 1991, J EXP MED, V173, P117, DOI 10.1084/jem.173.1.117; SLUNGAARD A, 1991, J BIOL CHEM, V266, P4903; SLUNGAARD A, 1992, BLOOD, V80, P96; STARK GR, 1960, J BIOL CHEM, V235, P3177; Tanigawa T, 1996, J CHROMATOGR B, V683, P135, DOI 10.1016/0378-4347(96)00115-6; TEN RM, 1989, J EXP MED, V169, P1757, DOI 10.1084/jem.169.5.1757; TENOVUO J, 1984, ARCH ORAL BIOL, V29, P445, DOI 10.1016/0003-9969(84)90025-6; THOMAS EL, 1986, J BIOL CHEM, V261, P9694; Thomas EL, 1985, LACTOPEROXIDASE SYST, P31; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; Wu WJ, 2000, J CLIN INVEST, V105, P1455, DOI 10.1172/JCI9702; Wu WJ, 1999, J BIOL CHEM, V274, P25933, DOI 10.1074/jbc.274.36.25933; Wu WJ, 1999, BIOCHEMISTRY-US, V38, P3538, DOI 10.1021/bi982401l	62	110	110	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					215	224		10.1074/jbc.M004881200	http://dx.doi.org/10.1074/jbc.M004881200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11013238	hybrid			2022-12-27	WOS:000166280700031
J	Bjorge, JD; Pang, A; Fujita, DJ				Bjorge, JD; Pang, A; Fujita, DJ			Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATORY SITE; KINASE-ACTIVITY; SH2 DOMAIN; FAMILY KINASES; TRANSFORMING PROTEIN; MEDIATED ADHESION; CATALYTIC DOMAIN; PDGF RECEPTOR; SARCOMA VIRUS; NEU ONCOGENE	c-Src tyrosine kinase activity is elevated in several types of human cancer, and this has been attributed to elevated c-Src expression levels, increased c-Src specific activity, and activating mutations in c-Src, We have found a number of human breast cancer cell lines with elevated c-Src specific activity that also possess elevated phosphatase activity directed against the carboxyl-terminal negative regulatory domain of Src family kinases, To identify this phosphatase, cell extracts from MDA-MB-435S cells were chromatographed and the fractions were assayed for phosphatase activity. Four peaks of phosphatase activity directed against the nonspecific substrate poly(Glu/Tyr) were detected. One peak also dephosphorylated a peptide modeled against the c-Src carboxyl-terminal negative regulatory domain and intact human c-Src. Immunoblotting and immunodepletion experiments identified the phosphatase as protein-tyrosine phosphatase 1B (PTP1B), Examination of several human breast cancer cell lines with increased c-Src activity showed elevated levels of PTP1B protein relative to normal control breast cells. In vitro c-Src reactivation experiments confirmed the ability of PTP1B to dephosphorylate and activate c-Src, In vivo overexpression of PTP1B in 293 cells caused a 2-fold increase of endogenous c-Src kinase activity. Our findings indicate that PTP1B is the primary protein-tyrosine phosphatase capable of dephosphorylating c-Src in several human breast cancer cell lines and suggests a regulatory role for PTP1B in the control of c-Src kinase activity.	Univ Calgary, Dept Biochem & Mol Biol, Hlth Sci Ctr, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	Fujita, DJ (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Hlth Sci Ctr, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada.							Agostinis P, 1996, EUR J BIOCHEM, V236, P548, DOI 10.1111/j.1432-1033.1996.00548.x; AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Albrecht JC, 1999, J VIROL, V73, P4631, DOI 10.1128/JVI.73.6.4631-4639.1999; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Balsamo J, 1998, J CELL BIOL, V143, P523, DOI 10.1083/jcb.143.2.523; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; BJORGE JD, 2000, IN PRESS ONCOGENE; Broome MA, 1997, ONCOGENE, V14, P17, DOI 10.1038/sj.onc.1200798; BROWNSHIMER S, 1992, CANCER RES, V52, P478; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHENG HC, 1992, J BIOL CHEM, V267, P9248; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; Egan C, 1999, ONCOGENE, V18, P1227, DOI 10.1038/sj.onc.1202233; FANG KS, 1994, J BIOL CHEM, V269, P20194; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; GERVAIS FG, 1993, MOL CELL BIOL, V13, P7112, DOI 10.1128/MCB.13.11.7112; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Grgurevich S, 1997, GROWTH FACTORS, V14, P103, DOI 10.3109/08977199709021514; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JACOBS C, 1983, CANCER RES, V43, P1696; Jung EJ, 1998, BIOCHEM BIOPH RES CO, V246, P238, DOI 10.1006/bbrc.1998.8605; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; LIU XQ, 1993, ONCOGENE, V8, P1119; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Pellegrini MC, 1998, BIOCHEMISTRY-US, V37, P15598, DOI 10.1021/bi981427+; PENG ZY, 1995, ONCOGENE, V11, P1955; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; Stover DR, 1996, J BIOL CHEM, V271, P12481, DOI 10.1074/jbc.271.21.12481; Sun GQ, 1998, ONCOGENE, V17, P1587, DOI 10.1038/sj.onc.1202076; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TANAKA A, 1986, MOL CELL BIOL, V6, P3900, DOI 10.1128/MCB.6.11.3900; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Walter AO, 1999, ONCOGENE, V18, P1911, DOI 10.1038/sj.onc.1202513; WIENER JR, 1994, AM J OBSTET GYNECOL, V170, P1177, DOI 10.1016/S0002-9378(94)70118-0; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; ZHAI YF, 1993, CANCER RES, V53, P2272; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	67	257	270	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41439	41446		10.1074/jbc.M004852200	http://dx.doi.org/10.1074/jbc.M004852200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007774	hybrid			2022-12-27	WOS:000166114600102
J	Hermanns, HM; Radtke, S; Schaper, F; Heinrich, PC; Behrmann, I				Hermanns, HM; Radtke, S; Schaper, F; Heinrich, PC; Behrmann, I			Non-redundant signal transduction of interleukin-6-type cytokines - The adapter protein Shc is specifically recruited to the oncostatin M receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; GROWTH-FACTOR RECEPTOR; PHOSPHOTYROSINE-BINDING DOMAIN; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 5-PHOSPHATASE; TYROSINE-PHOSPHATASE SHP-2; COLONY-STIMULATING FACTOR; CELL-CYCLE PROGRESSION; GENE-EXPRESSION; KINASE ACTIVATION; MITOGEN	The common use of the cytokine receptor gp130 has served as an explanation for the extremely redundant biological activities exerted by interleukin (IL)-6-type cytokines.Indeed, hardly any differences in signal transduction initiated by these cytokines are known. In the present study, we demonstrate that oncostatin M (OSM), but not IL-6 or leukemia inhibitory factor, induces tyrosine phosphorylation of the Shc isoforms p52 and p66 and their association with Grb2. Concomitantly, OSM turns out to be a stronger activator of ERK1/2 MAPKs, Shc is recruited to the OSM receptor (OSMR), but not to gp130. Binding involves Tyr(816) Of the OSMR, located within a consensus binding sequence for the Shc PTB domain. Moreover, Tyr(861) is essential for activation of ERK1/2 and for full activation of the alpha (2)-macroglobulin promoter, but not for an exclusively STAT-responsive promoter. This study therefore provides evidence for qualitative differential signaling mechanisms exerted by IL-6-type cytokines.	Rhein Westfal TH Klinikum, Inst Biochem, D-52074 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital	Behrmann, I (corresponding author), Rhein Westfal TH Klinikum, Inst Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.		Schaper, Fred/F-1403-2013	Schaper, Fred/0000-0002-8899-5414; Behrmann, Iris/0000-0003-3688-3645				ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Bamber B, 1998, J MOL MED-JMM, V76, P61, DOI 10.1007/s109-1998-8105-3; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; Behrmann I, 1997, J BIOL CHEM, V272, P5269, DOI 10.1074/jbc.272.8.5269; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Berger LC, 1997, BLOOD, V89, P261, DOI 10.1182/blood.V89.1.261.261_261_271; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; Collins LR, 1999, J CELL BIOL, V147, P1561, DOI 10.1083/jcb.147.7.1561; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gatsios P, 1996, EUR J BIOCHEM, V241, P56, DOI 10.1111/j.1432-1033.1996.0056t.x; Giordano V, 1997, J IMMUNOL, V158, P4097; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Grant SL, 1999, MOL MED TODAY, V5, P406, DOI 10.1016/S1357-4310(99)01540-3; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hermanns HM, 1999, J IMMUNOL, V163, P6651; Ichihara M, 1997, BLOOD, V90, P165; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; KUMAR G, 1994, J IMMUNOL, V153, P4436; Kuropatwinski KK, 1997, J BIOL CHEM, V272, P15135, DOI 10.1074/jbc.272.24.15135; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LANFRANCONE L, 1995, ONCOGENE, V10, P907; Li WQ, 1998, J IMMUNOL, V161, P5000; Liu JW, 1997, CELL GROWTH DIFFER, V8, P667; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Neumann C, 1996, EUR J IMMUNOL, V26, P379, DOI 10.1002/eji.1830260217; Ogata A, 1997, J IMMUNOL, V159, P2212; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; OWENLYNCH PJ, 1995, J BIOL CHEM, V270, P5956, DOI 10.1074/jbc.270.11.5956; Palmer HJ, 1999, J BIOL CHEM, V274, P11424, DOI 10.1074/jbc.274.16.11424; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; RICHARDS CD, 1993, J IMMUNOL, V150, P5596; Sakaguchi K, 1998, MOL ENDOCRINOL, V12, P536, DOI 10.1210/me.12.4.536; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sato K, 1997, FEBS LETT, V410, P136, DOI 10.1016/S0014-5793(97)00539-5; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; Schiemann WP, 1997, J BIOL CHEM, V272, P16631, DOI 10.1074/jbc.272.26.16631; Schmitz J, 2000, J IMMUNOL, V164, P848, DOI 10.4049/jimmunol.164.2.848; Senaldi G, 1999, P NATL ACAD SCI USA, V96, P11458, DOI 10.1073/pnas.96.20.11458; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stevenson LE, 1999, CELL GROWTH DIFFER, V10, P61; Symes A, 1997, CURR BIOL, V7, P697, DOI 10.1016/S0960-9822(06)00298-3; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; THOMA B, 1994, J BIOL CHEM, V269, P6215; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Wallace PM, 1999, J IMMUNOL, V162, P5547; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784	73	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40742	40748		10.1074/jbc.M005408200	http://dx.doi.org/10.1074/jbc.M005408200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11016927	hybrid			2022-12-27	WOS:000166114600013
J	Matsuo, M; Trapp, S; Tanizawa, Y; Kioka, N; Amachi, T; Oka, Y; Ashcroft, FM; Ueda, K				Matsuo, M; Trapp, S; Tanizawa, Y; Kioka, N; Amachi, T; Oka, Y; Ashcroft, FM; Ueda, K			Functional analysis of a mutant sulfonylurea receptor, SUR1-R1420C, that is responsible for persistent hyperinsulinemic hypoglycemia of infancy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNEL; SENSITIVE POTASSIUM CHANNELS; PANCREATIC BETA-CELLS; FAMILIAL HYPERINSULINISM; SUBUNIT STOICHIOMETRY; INSULIN-SECRETION; KIR6.2; SUR1; MUTATIONS; GENE	The ATP-sensitive potassium (K-ATP(+)) channel is crucial for the regulation of insulin secretion from the pancreatic beta -cell, and mutations in either the sulfonylurea receptor:type 1 (SUR1) or Kir6.2 subunit of this channel can cause persistent hyperinsulinemic hypoglycemia of infancy (PHHI), We analyzed the functional consequences of the PHHI missense mutation R1420C, which lies in the second nucleotide-binding fold (NBF2) of SUR1, Mild tryptic digestion of SUR1 after photoaffinity labeling allowed analysis of the nucleotide-binding properties of NBF1 and NBF2, Labeling of NBF1 with 8-azido-[alpha-P-32]ATP was inhibited by MgATP and MgADP with similar K-i for wild-type SUR1 and SUR1-R1420C. However, the MgATP and MgADP affinities of NBF2 of SUR1-R1420C were about 5-fold lower than those of wild-type SUR1, MgATP and MgADP stabilized 8-azido-ATP binding at NBF1 of wild-type SUR1 by interacting with NBF2, but this cooperative nucleotide binding was not observed for SUR1-R1420C. Studies on macroscopic currents recorded in inside-out membrane patches revealed that the SUR1-R1420C mutation exhibits reduced expression but does not affect inhibition by ATP or tolbutamide or activation by diazoxide, However, co-expression with Kir6.2-R50G, which renders the channel less sensitive to ATP inhibition, revealed that the SUR1-R1420C mutation increases the EC50 for MgADP activation from 74 to 197 muM. We suggest that the lower expression of the mutant channel and the reduced affinity of NBF2 for MgADP may lead to a smaller K-ATP(+) current in R1420C-PHHI beta -cells and thereby to the enhanced insulin secretion. We also propose a new model for nucleotide activation of K-ATP(+) channels.	Kyoto Univ, Grad Sch Agr, Biochem Lab, Div Appl Life Sci, Kyoto 6068502, Japan; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Yamaguchi Univ, Sch Med, Dept Internal Med 3, Ube, Yamaguchi 7558505, Japan	Kyoto University; University of Oxford; Yamaguchi University	Ueda, K (corresponding author), Kyoto Univ, Grad Sch Agr, Biochem Lab, Div Appl Life Sci, Kyoto 6068502, Japan.		Trapp, Stefan/D-9240-2011	Trapp, Stefan/0000-0003-0665-4948; Kioka, Noriyuki/0000-0002-2708-537X; Ueda, Kazumitsu/0000-0003-2980-6078				Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Dunne MJ, 1997, NEW ENGL J MED, V336, P703, DOI 10.1056/NEJM199703063361005; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Gribble FM, 1998, P NATL ACAD SCI USA, V95, P7185, DOI 10.1073/pnas.95.12.7185; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Kane C, 1996, NAT MED, V2, P1344, DOI 10.1038/nm1296-1344; KOZLOWSKI RZ, 1989, BRIT J PHARMACOL, V97, P1039, DOI 10.1111/j.1476-5381.1989.tb12560.x; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; Nestorowicz A, 1996, HUM MOL GENET, V5, P1813, DOI 10.1093/hmg/5.11.1813; Nestorowicz A, 1997, DIABETES, V46, P1743, DOI 10.2337/diabetes.46.11.1743; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Otonkoski T, 1999, DIABETES, V48, P408, DOI 10.2337/diabetes.48.2.408; Proks P, 1999, J PHYSIOL-LONDON, V514, P19, DOI 10.1111/j.1469-7793.1999.019af.x; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Shyng SL, 1998, DIABETES, V47, P1145, DOI 10.2337/diabetes.47.7.1145; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Tanabe K, 2000, BIOCHEM BIOPH RES CO, V272, P316, DOI 10.1006/bbrc.2000.2780; Tanabe K, 1999, J BIOL CHEM, V274, P3931, DOI 10.1074/jbc.274.7.3931; Tanizawa Y, 2000, DIABETES, V49, P114, DOI 10.2337/diabetes.49.1.114; Thomas P, 1996, HUM MOL GENET, V5, P1809, DOI 10.1093/hmg/5.11.1809; Thomas PM, 1996, AM J HUM GENET, V59, P510; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Trapp S, 1997, P NATL ACAD SCI USA, V94, P8872, DOI 10.1073/pnas.94.16.8872; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Ueda K, 1999, BBA-BIOMEMBRANES, V1461, P305, DOI 10.1016/S0005-2736(99)00157-1; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; Verkarre V, 1998, J CLIN INVEST, V102, P1286, DOI 10.1172/JCI4495; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	39	36	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41184	41191		10.1074/jbc.M006503200	http://dx.doi.org/10.1074/jbc.M006503200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10993895	hybrid			2022-12-27	WOS:000166114600071
J	Thomas, D; Becker, A; Surdin-Kerjan, Y				Thomas, D; Becker, A; Surdin-Kerjan, Y			Reverse methionine biosynthesis from S-adenosylmethionine in eukaryotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE DISRUPTION; METHYLMETHIONINE; METABOLISM; DNA; METHYLTRANSFERASES; HYBRIDIZATION; HOMOCYSTEINE; EXPRESSION; DEPLETION	The intracellular ratio between methionine and its activated form S-adenosylmethionine (AdoMet) is of crucial importance for the one-carbon metabolism, AdoMet recycling into methionine was believed to be largely achieved through the methyl and the thiomethyladenosine cycles. We show here that in yeast, AdoMet recycling: actually occurs mainly through the direct AdoMet-dependent remethylation of homocysteine, Compelling evidences supporting this result were obtained owing to the identification and functional characterization of two new genes, SAM4 and MHT1, that encode the yeast AdoMet-homocysteine methyltransferase and S-methylmethionine-homocysteine methyltransferase, respectively. Homologs of the Sam4 and Mht1 proteins exist in other eucaryotes, indicating that such enzymes would be universal and not restricted to the bacterial or fungal kingdoms. New pathways for AdoMet or S-methylmethionine-dependent methionine synthesis are presented.	CNRS, Ctr Mol Genet, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Surdin-Kerjan, Y (corresponding author), CNRS, Ctr Mol Genet, F-91198 Gif Sur Yvette, France.	yolande.kerjan@cgm.cnrs-gif.fr						BACKLUND PS, 1981, J BIOL CHEM, V256, P1533; BACKLUND PS, 1982, BIOCHEM BIOPH RES CO, V108, P687, DOI 10.1016/0006-291X(82)90884-1; BURTON E, 1969, BIOCHEM J, V111, P793, DOI 10.1042/bj1110793; CANTONI GL, 1977, BIOCH ADENOSYLMETHIO, P557; CHEREST H, 1992, GENETICS, V130, P51; Cornell KA, 1996, BIOCHEM J, V317, P285, DOI 10.1042/bj3170285; CSAIKL U, 1986, GENE, V46, P207, DOI 10.1016/0378-1119(86)90405-1; DICKSON DM, 1980, PLANTA, V150, P158, DOI 10.1007/BF00582360; DICKSON DMJ, 1986, PLANTA, V167, P536, DOI 10.1007/BF00391230; Donoviel MS, 1996, GENETICS, V143, P1137; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HANSEN J, 1994, J BACTERIOL, V176, P6050, DOI 10.1128/jb.176.19.6050-6058.1994; Higgins D G, 1994, Methods Mol Biol, V25, P307; HODGSON CP, 1987, NUCLEIC ACIDS RES, V15, P6295, DOI 10.1093/nar/15.15.6295; Hoshiya Y, 1997, ANTICANCER RES, V17, P4371; Kokkinakis DM, 1997, NUTR CANCER, V29, P195, DOI 10.1080/01635589709514624; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; Malinow MR, 1997, ARTERIOSCL THROM VAS, V17, P1157, DOI 10.1161/01.ATV.17.6.1157; Mallet L, 1996, YEAST, V12, P1351, DOI 10.1002/(SICI)1097-0061(199610)12:13<1351::AID-YEA24>3.0.CO;2-6; MOUNTAIN HA, 1991, YEAST, V7, P781, DOI 10.1002/yea.320070804; MUDD SH, 1990, PLANT PHYSIOL, V93, P623, DOI 10.1104/pp.93.2.623; Neuhierl B, 1999, J BIOL CHEM, V274, P5407, DOI 10.1074/jbc.274.9.5407; OLD IG, 1991, PROG BIOPHYS MOL BIO, V56, P145, DOI 10.1016/0079-6107(91)90012-H; Ranocha P, 2000, J BIOL CHEM, V275, P15962, DOI 10.1074/jbc.M001116200; Rouillon A, 2000, EMBO J, V19, P282, DOI 10.1093/emboj/19.2.282; Rouillon A, 1999, J BIOL CHEM, V274, P28096, DOI 10.1074/jbc.274.40.28096; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SHAPIRO SK, 1964, J BIOL CHEM, V239, P1551; SHERMAN F, 1979, METHODS YEAST GENETI, P61; SIKORSKI RS, 1989, GENETICS, V122, P19; SPENCE KD, 1977, BIOCH ADENOSYLMETHIO, P77; THOMAS D, 1988, MOL CELL BIOL, V8, P5132, DOI 10.1128/MCB.8.12.5132; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Trossat C, 1998, PLANT PHYSIOL, V116, P165, DOI 10.1104/pp.116.1.165	35	36	39	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40718	40724		10.1074/jbc.M005967200	http://dx.doi.org/10.1074/jbc.M005967200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11013242	hybrid			2022-12-27	WOS:000166114600010
J	Yeung, F; Li, XY; Ellett, J; Trapman, J; Kao, CH; Chung, LWK				Yeung, F; Li, XY; Ellett, J; Trapman, J; Kao, CH; Chung, LWK			Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED GENE-EXPRESSION; RECEPTOR GENE; TRANSCRIPTIONAL SYNERGY; HORMONAL-REGULATION; RESPONSIVE ELEMENT; LNCAP MODEL; LINE LNCAP; PROTEIN; KINASE; ADENOCARCINOMA	Prostate-specific antigen (PSA) is expressed primarily by both normal prostate epithelium and the vast majority of prostate cancers. Increases in serum PSA during endocrine therapy are generally considered as evidence for prostate cancer recurrence or progression to androgen independence. The mechanisms by which PSA upregulation occurs in androgen-refractory prostate cancer cells are unknown. In this study, by using LNCaP and its lineage-derived androgen-independent PSA-producing subline, C4-2, we identified two cis-elements within the 5.8-bilobase pair PSA promoter that are essential for the androgen-independent activity of PSA promoter in prostate cancer cells. First, a previously reported 440-bp androgen-responsive Element enhancer core (AREc) was found to be important for the high basal PSA promoter activity in C4-2 cells. Both mutation analysis and supershift experiments demonstrated that androgen receptor (AR) binds to the AREs within the AREc and activate the basal PSA promoter activity in C4-2 cells under androgen-deprived conditions. Second, a 150-bp pN/H region was demonstrated to be a strong AR-independent positive-regulatory element of the PSA promoter in both LNCaP and C4-2 cells. Through DNase I footprinting and linker scan mutagenesis, a 17-bp RI site was identified as the key cis-element within the pN/H region. Data from electrophoretic mobility shift analysis and UV cross-linking experiments further indicated that a 45-kDa (p45) cell-specific transcription factor associates with RI in prostate cancer cells and may be responsible for driving the PSA promoter activity independent of androgen and AR. Furthermore, by juxtaposing AREc and pN/H, we produced a chimeric PSA promoter (supra-PSA) that exhibits 2-3-fold higher activity than the wild type PSA promoter in both LNCaP and C4-2 cells.	Univ Virginia, Dept Cell Biol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Urol, Charlottesville, VA 22908 USA; Erasmus Univ, Dept Pathol, NL-3000 DR Rotterdam, Netherlands; Indiana Canc Pavil, Dept Urol, Indianapolis, IN 46202 USA	University of Virginia; University of Virginia; Erasmus University Rotterdam	Chung, LWK (corresponding author), Univ Virginia, Dept Cell Biol, Charlottesville, VA 22908 USA.				NATIONAL CANCER INSTITUTE [R29CA074042, R01CA076620, R01CA074042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008136] Funding Source: NIH RePORTER; NCI NIH HHS [CA76620, CA74042] Funding Source: Medline; NIGMS NIH HHS [5T32GMO8136] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUMULLER G, 1990, PROSTATE, V17, P31, DOI 10.1002/pros.2990170105; Ausubel F., 1999, CURRENT PROTOCOLS MO; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Carey M, 2000, TRANSCRIPTIONAL REGU; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; CULIG Z, 1994, CANCER RES, V54, P5474; DERUITER PE, 1995, MOL CELL ENDOCRINOL, V110, pR1, DOI 10.1016/0303-7207(95)03534-E; ELO JP, 1995, J CLIN ENDOCR METAB, V80, P3494, DOI 10.1210/jc.80.12.3494; GLEAVE M, 1991, CANCER RES, V51, P3753; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; HSIEH JT, 1993, CANCER RES, V53, P2852; Huang WB, 1999, J BIOL CHEM, V274, P25756, DOI 10.1074/jbc.274.36.25756; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; Koivisto PA, 1999, J PATHOL, V189, P219, DOI 10.1002/(SICI)1096-9896(199910)189:2<219::AID-PATH423>3.0.CO;2-F; KUIPER GGJM, 1993, BIOCHEM J, V291, P95, DOI 10.1042/bj2910095; LILJA H, 1985, J CLIN INVEST, V76, P1899, DOI 10.1172/JCI112185; Marcelli M, 2000, CANCER RES, V60, P944; MEPHAUL MJ, 1996, ANDROGEN RECEPTOR PR, P307; MONTGOMERY BT, 1992, PROSTATE, V21, P63, DOI 10.1002/pros.2990210107; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; Reinikainen P, 1996, ENDOCRINOLOGY, V137, P4351, DOI 10.1210/en.137.10.4351; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Sambrook J., 2002, MOL CLONING LAB MANU; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; STAMEY TA, 1989, J UROLOGY, V141, P1088, DOI 10.1016/S0022-5347(17)41177-3; SUZUKI H, 1993, J STEROID BIOCHEM, V46, P759, DOI 10.1016/0960-0760(93)90316-O; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; THALMANN GN, 1994, CANCER RES, V54, P2577; Thalmann GN, 2000, PROSTATE, V44, P91; Trapman J, 1997, SEMIN CANCER BIOL, V8, P29, DOI 10.1006/scbi.1997.0050; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; Yeh SY, 1999, ENDOCRINE, V11, P195, DOI 10.1385/ENDO:11:2:195; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; YOUNG CYF, 1991, CANCER RES, V51, P3748; Zhang SB, 1997, BIOCHEM BIOPH RES CO, V231, P784, DOI 10.1006/bbrc.1997.6197; Zhau HE, 1997, IN VITRO CELL DEV-AN, V33, P375	45	61	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40846	40855		10.1074/jbc.M002755200	http://dx.doi.org/10.1074/jbc.M002755200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11006269	hybrid			2022-12-27	WOS:000166114600026
J	Aimond, F; Rauzier, JM; Bony, C; Vassort, G				Aimond, F; Rauzier, JM; Bony, C; Vassort, G			Simultaneous activation of p38 MAPK and p42/44 MAPK by ATP stimulates the K+ current I-TREK in cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); POLYUNSATURATED FATTY-ACIDS; PIG ATRIAL CELLS; PROTEIN-KINASE; EXTRACELLULAR ATP; CARDIAC MYOCYTES; ARACHIDONIC-ACID; FUNCTIONAL EXPRESSION; VENTRICULAR MYOCYTES; POTASSIUM CHANNELS	Living cells exhibit multiple K+ channel proteins; among these is the recently reported atypical two-pore domain K+ channel protein TREK-1. Most K+ currents are modulated by neurohormones and under various pathological conditions. Here, in rat ventricular cardiomyocytes using the whole-cell patch-clamp technique, we characterize for the first time a native TREK-1-like current (I-TREK) that is activated by ATP, a purine agonist applied at a micromolar range. This current is sensitive to arachidonic acid, intracellular acidosis, and various K+ current inhibitors. Reverse transcription-polymerase chain reaction reveals the presence of a TREK-1-Iike mRNA in rat cardiomyocytes that shows 93% identity with mouse TREK-1. ATP effects are greatly attenuated in the presence of arachidonic acid or HCO3--induced intracellular acidosis. Using a series of inhibitors, we further demonstrate that the ATP-induced stimulation of I-TREK implies the activation of cytosolic phospholipase A(2) and the release of arachidonic acid. These events require the simultaneous involvement of p38 MAPK and p42/44 MAPK, respectively, via a cAMP-dependent protein kinase and a tyrosine kinase pathway, whereas the two MAPKs conjugate to activate a mitogen- and stress-activated protein kinase (MSK-1). Our results thus demonstrate the occurrence of a TREK-1-like current in cardiac cells whose activation by purine agonists implies a dual-MAPK cytosolic pathway.	CHU Arnaud Villleneuve, IFR N 3, INSERM, U390, F-34295 Montpellier 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Vassort, G (corresponding author), CHU Arnaud Villleneuve, IFR N 3, INSERM, U390, F-34295 Montpellier 5, France.		AIMOND, Franck/B-6024-2017	AIMOND, Franck/0000-0001-9124-0066				Aimond F, 1999, CARDIOVASC RES, V42, P402, DOI 10.1016/S0008-6363(99)00070-X; Barry DM, 1996, ANNU REV PHYSIOL, V58, P363, DOI 10.1146/annurev.ph.58.030196.002051; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; Bogdanov KY, 1998, AM J PHYSIOL-HEART C, V274, pH571, DOI 10.1152/ajpheart.1998.274.2.H571; Bolego C, 1997, BRIT J PHARMACOL, V121, P1692, DOI 10.1038/sj.bjp.0701294; Borsch-Haubold AG, 1999, EUR J BIOCHEM, V265, P195, DOI 10.1046/j.1432-1327.1999.00722.x; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Firestein BL, 1996, AM J PHYSIOL-RENAL, V271, pF610, DOI 10.1152/ajprenal.1996.271.3.F610; Gao ZH, 1999, J BIOL CHEM, V274, P5972, DOI 10.1074/jbc.274.9.5972; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Hazan-Halevy I, 2000, J BIOL CHEM, V275, P12416, DOI 10.1074/jbc.275.17.12416; Hiller G, 1999, CELL SIGNAL, V11, P863, DOI 10.1016/S0898-6568(99)00058-3; HONORE E, 1994, P NATL ACAD SCI USA, V91, P1937, DOI 10.1073/pnas.91.5.1937; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; Kim D, 1998, CIRC RES, V82, P513, DOI 10.1161/01.RES.82.4.513; KIM DH, 1990, CIRC RES, V67, P1040, DOI 10.1161/01.RES.67.4.1040; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Kuzmin AI, 1998, AM J PHYSIOL-CELL PH, V275, pC766, DOI 10.1152/ajpcell.1998.275.3.C766; Lesage F, 1997, FEBS LETT, V402, P28, DOI 10.1016/S0014-5793(96)01491-3; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691; Matsubayashi T, 1999, PFLUG ARCH EUR J PHY, V437, P635; Matsuura H, 1996, J PHYSIOL-LONDON, V490, P659, DOI 10.1113/jphysiol.1996.sp021175; Matsuura H, 1997, J PHYSIOL-LONDON, V503, P45, DOI 10.1111/j.1469-7793.1997.045bi.x; Ni H, 1998, BIOCHEM BIOPH RES CO, V243, P492, DOI 10.1006/bbrc.1998.8135; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Puceat M, 1998, J CELL BIOL, V141, P1637, DOI 10.1083/jcb.141.7.1637; PUCEAT M, 1991, BIOCHEM J, V274, P55, DOI 10.1042/bj2740055; Puceat M, 1998, FEBS LETT, V431, P189, DOI 10.1016/S0014-5793(98)00747-9; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; Ralevic V, 1998, PHARMACOL REV, V50, P413; Richards SM, 1999, J CELL SCI, V112, P1519; Ryder JW, 2000, J BIOL CHEM, V275, P1457, DOI 10.1074/jbc.275.2.1457; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Wu ML, 2000, CIRC RES, V86, pE55; Xing MB, 1996, J CLIN INVEST, V97, P1302, DOI 10.1172/JCI118546; ZHENG JS, 1994, CIRC RES, V74, P1034, DOI 10.1161/01.RES.74.6.1034; [No title captured]	49	79	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39110	39116		10.1074/jbc.M008192200	http://dx.doi.org/10.1074/jbc.M008192200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993907	hybrid			2022-12-27	WOS:000165953100024
J	Besset, V; Scott, RP; Ibanez, CF				Besset, V; Scott, RP; Ibanez, CF			Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; MICE LACKING GDNF; SYMPATHETIC NEURON SURVIVAL; NEOPLASIA TYPE 2B; NEUROTROPHIC FACTOR; ADAPTER PROTEINS; TRANSDUCTION PATHWAYS; CELL; SHC; MUTATION	Proximal signaling events and protein-protein interactions initiated after activation of the c-Ret receptor tyrosine kinase by its ligand, glial cell line-derived neurotrophic factor (GDNF), were investigated in cells carrying native and mutated forms of this receptor. Mutation of Tyr-1062 (Y1062F) in the cytoplasmic tail of c-Ret abolished receptor binding and phosphorylation of the adaptor Shc and eliminated activation of Ras by GDNF. Phosphorylation of Erk kinases was also greatly attenuated but not eliminated by this mutation. This residual wave of Erk phosphorylation was independent of the kinase activity of c-Ret. Mutation of Tyr-1096 (Y1096F), a binding site for the adaptor Grb2, had no effect on Erk activation by GDNF, Activation of phosphatidylinositol-3 kinase (PI3K) and its downstream effector Akt was also reduced in the Y1082F mutant but not completely abolished unless Tyr-1096 was also mutated, Ligand stimulation of neuronal cells induced the assembly of a large protein complex containing c-Ret, Grb2, and tyrosine-phosphorylated forms of Shc, p85(PI3K), the adaptor Gab2, and the protein-tyrosine phosphatase SHP-2. In agreement with Ras-independent activation of PI3K by GDNF in neuronal cells, survival of sympathetic neurons induced by GDNF was dependent on PI3K but was not affected by microinjection of blocking anti-Pas antibodies, which did compromise neuronal survival by nerve growth factor, suggesting that Ras is not required for GDNF-induced survival of sympathetic neurons. These results indicate that upon ligand stimulation, at least two distinct protein complexes assemble on phosphorylated Tyr-1062 of c-Ret via Shc, one leading to activation of the Ras/Erk pathway through recruitment of Grb2/Sos and another to the PI3K/Akt pathway through recruitment of Grb2/Gab2 followed by p85(PI3K) and SHP-2. This latter complex can also assemble directly onto phosphorylated Tyr-1096, offering an alternative route to PI3K activation by GDNF.	Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, S-17177 Stockholm, Sweden	Karolinska Institutet	Ibanez, CF (corresponding author), Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, Berzelius Vag 1, S-17177 Stockholm, Sweden.		Scott, Rizaldy/Y-7584-2019; Scott, Rizaldy/AAC-5264-2020	Scott, Rizaldy/0000-0002-0288-8862; 				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Bocciardi R, 1997, ONCOGENE, V15, P2257, DOI 10.1038/sj.onc.1201413; BORRELLO MG, 1994, ONCOGENE, V9, P1661; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Edery P, 1997, BIOESSAYS, V19, P389, DOI 10.1002/bies.950190506; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Ishiguro Y, 1999, ENDOCRINOLOGY, V140, P3992, DOI 10.1210/en.140.9.3992; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Klesse LJ, 1998, J NEUROSCI, V18, P10420; Korhonen JM, 1999, J BIOL CHEM, V274, P37307, DOI 10.1074/jbc.274.52.37307; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Mazzoni IE, 1999, J NEUROSCI, V19, P9716; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Murakami H, 1999, BIOCHEM BIOPH RES CO, V262, P68, DOI 10.1006/bbrc.1999.1186; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; NOBES CD, 1995, EUR J NEUROSCI, V7, P344, DOI 10.1111/j.1460-9568.1995.tb01069.x; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; Ohiwa M, 1997, BIOCHEM BIOPH RES CO, V237, P747, DOI 10.1006/bbrc.1997.7225; PARATCHA G, IN PRESS NEURON; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Poteryaev D, 1999, FEBS LETT, V463, P63, DOI 10.1016/S0014-5793(99)01590-2; Rizzo C, 1996, J BIOL CHEM, V271, P29497, DOI 10.1074/jbc.271.46.29497; SALAZARGRUESO EF, 1991, NEUROREPORT, V2, P505, DOI 10.1097/00001756-199109000-00002; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Santoro W, 1999, J ENDOCRINOL INVEST, V22, P811, DOI 10.1007/BF03343650; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yu T, 1998, J NEUROSCI, V18, P4684; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	54	199	205	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39159	39166		10.1074/jbc.M006908200	http://dx.doi.org/10.1074/jbc.M006908200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995764	hybrid			2022-12-27	WOS:000165953100031
J	Chan, SY; Wong, RWC				Chan, SY; Wong, RWC			Expression of epidermal growth factor in transgenic mice causes growth retardation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEIN-3; EGF-RECEPTOR; TGF-ALPHA; FACTOR PRECURSOR; FACTOR-I; SIGNALING NETWORK; MAMMARY-GLAND; HUMAN-FETUS; GENE; OVEREXPRESSION	The epidermal growth factor (EGF) family of peptides signals through the erbB family of receptor tyrosine kinases and plays important roles in development and tumorigenesis. Both EGF and transforming growth factor (TGF)-alpha only bind to erbB1 and activate it. The precursor of EGF is distinct from that of TGF-alpha in having eight additional EGF-like repeats. We have recently shown that the EGF precursor without these repeats is biologically active and leads to hypospermatogenesis in transgenic mice. Here we present evidence that the growth of transgenic mice widely expressing this engineered EGF precursor is also stunted. These mice were consistently born at half the normal weight and reached almost 80% of normal weight at adulthood. The mechanism involved a reduction of serum insulin-like growth factor-binding protein-3. Chondrocyte development in the growth plate was affected, and osteoblasts accumulated in the endosteum and periosteum. Besides these novel findings on the in vivo effects of EGF on bone development, we observed no sign of tumor formation in our transgenic animals. In contrast to previous reports on TGF-alpha transgenic mice, we show that the biological functions of EGF and TGF-alpha are clearly distinct.	Univ Hong Kong, Queen Mary Hosp, Dept Paediat, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Chan, SY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Paediat, Hong Kong, Hong Kong, Peoples R China.		Wong, Richard W./E-9155-2011	Chan, Siu Yuen/0000-0001-7262-1293				Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; BAXTER RC, 1986, J CLIN INVEST, V78, P1504, DOI 10.1172/JCI112742; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BROWN G, 1978, INTRO HISTOLOGY MANU; CHARD T, 1989, J ENDOCRINOL, V123, P3, DOI 10.1677/joe.0.1230003; COHEN S, 1962, J BIOL CHEM, V237, P1555; Cook PW, 1997, J CLIN INVEST, V100, P2286, DOI 10.1172/JCI119766; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DeBenedetti F, 1997, J CLIN INVEST, V99, P643, DOI 10.1172/JCI119207; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; Edmondson SR, 1999, J CELL PHYSIOL, V179, P201, DOI 10.1002/(SICI)1097-4652(199905)179:2<201::AID-JCP10>3.0.CO;2-9; FREY P, 1979, P NATL ACAD SCI USA, V76, P6294, DOI 10.1073/pnas.76.12.6294; Frystyk J, 1996, GROWTH REGULAT, V6, P48; Giovannucci E, 1999, HORM RES, V51, P34, DOI 10.1159/000053160; Giraud AS, 2000, AM J PHYSIOL-GASTR L, V278, pG501, DOI 10.1152/ajpgi.2000.278.4.G501; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; HEMBREE JR, 1994, CANCER RES, V54, P3160; Hui YF, 1996, BLOOD, V88, P4021, DOI 10.1182/blood.V88.10.4021.bloodjournal88104021; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Kwan RWP, 1999, INT J ONCOL, V15, P281; LASSARRE C, 1991, PEDIATR RES, V29, P219, DOI 10.1203/00006450-199103000-00001; Lee DCW, 1998, J UROLOGY, V159, P291, DOI 10.1016/S0022-5347(01)64084-9; LEFEBVRE V, 1995, J CELL BIOL, V128, P239, DOI 10.1083/jcb.128.1.239; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MARTINEAUDOIZE B, 1988, ENDOCRINOLOGY, V123, P841, DOI 10.1210/endo-123-2-841; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; MROCZKOWSKI B, 1989, MOL CELL BIOL, V9, P2771, DOI 10.1128/MCB.9.7.2771; MURPHY LJ, 1995, J MOL ENDOCRINOL, V15, P293, DOI 10.1677/jme.0.0150293; MURPHY RA, 1980, J HISTOCHEM CYTOCHEM, V28, P890, DOI 10.1177/28.8.6969274; Niemeyer CC, 1999, INT J CANCER, V81, P588, DOI 10.1002/(SICI)1097-0215(19990517)81:4<588::AID-IJC14>3.0.CO;2-I; RAISZ LG, 1980, ENDOCRINOLOGY, V107, P270, DOI 10.1210/endo-107-1-270; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Schneider MR, 2000, FASEB J, V14, P629, DOI 10.1096/fasebj.14.5.629; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; TAJIMA Y, 1993, J ANAT, V182, P291; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; van Neck JW, 2000, J ENDOCRINOL, V165, P115, DOI 10.1677/joe.0.1650115; WEBBER EM, 1994, AM J PATHOL, V145, P398; Wong RWC, 2000, J BIOL CHEM, V275, P18297, DOI 10.1074/jbc.M001965200; Wong RWC, 2000, MOL BIOTECHNOL, V15, P155, DOI 10.1385/MB:15:2:155; Wong RWC, 2000, MOL BIOTECHNOL, V15, P65, DOI 10.1385/MB:15:1:65; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	49	59	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38693	38698		10.1074/jbc.M004189200	http://dx.doi.org/10.1074/jbc.M004189200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11001946	hybrid			2022-12-27	WOS:000165739800076
J	Hu, LYA; Tang, YT; Miller, WE; Cong, M; Lau, AG; Lefkowitz, RJ; Hall, RA				Hu, LYA; Tang, YT; Miller, WE; Cong, M; Lau, AG; Lefkowitz, RJ; Hall, RA			beta 1-adrenergic receptor association with PSD-95 - Inhibition of receptor internalization and facilitation of beta(1)-adrenergic receptor interaction with N-methyl-D-aspartate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; LONG-TERM POTENTIATION; EXCHANGER REGULATORY FACTOR; HIPPOCAMPAL CA1 REGION; BETA(2)-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTORS; SYNAPTIC PLASTICITY; PDZ-DOMAIN; IN-VIVO; FREQUENCY STIMULATION	The beta (1)-adrenergic receptor (beta (1)AR) is the most abundant subtype of beta -adrenergic receptor in the mammalian brain and is known to potently regulate synaptic plasticity. To search for potential neuronal beta (1)AR-interacting proteins, we screened a rat brain cDNA library using the beta (1)AR carboxyl terminus (beta (1)AR-CT) as bait in the yeast two-hybrid system. These screens identified PSD-95, a multiple PDZ domain-containing scaffolding protein, as a specific binding partner of the beta (1)AR-CT. This interaction was confirmed by in vitro fusion protein pull-down and blot overlay experiments, which demonstrated that the beta (1)ARCT binds specifically to the third PDZ domain of PSD-95, Furthermore, the full-length beta (1)AR associates with PSD-95 in cells, as determined by co-immunoprecipitation experiments and immunofluorescence co-localization studies. The interaction between beta (1)AR and PSD-95 is mediated by the last few amino acids of the beta (1)AR, and mutation of the beta (1)AR carboxyl terminus eliminated the binding and disrupted the co-localization of the beta (1)AR and PSD-95 in cells. Agonist-induced internalization of the beta (1)AR in HEK-293 cells was markedly attenuated by PSD-95 co-expression, whereas co-expression of PSD-95 has no significant effect on either desensitization of the beta (1)AR or beta (1)AR-induced cAMP accumulation. Furthermore, PSD-95 facilitated the formation of a complex between the beta (1)AR and N-methyl-D-aspartate receptors, as assessed by co-immunoprecipitation. These data reveal that PSD-95 is a specific beta (1)AR binding partner that modulates beta (1)AR function and facilitates physical association of the beta (1)AR with synaptic proteins, such as the N-methyl-D-aspartate receptors, which are known to be regulated by beta (1)AR stimulation.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA; Emory Univ, Sch Med, Rollins Res Ctr, Dept Pharmacol, Atlanta, GA 30322 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Emory University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3821, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021	Hall, Randy/0000-0002-8318-8728	NHLBI NIH HHS [HL16037] Funding Source: Medline; NIGMS NIH HHS [GM60982] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060982] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOKI C, 1987, BRAIN RES, V437, P264, DOI 10.1016/0006-8993(87)91642-8; BELLOREUSS E, 1980, AM J PHYSIOL, V238, pF347, DOI 10.1152/ajprenal.1980.238.5.F347; Bramham CR, 1997, NEUROREPORT, V8, P719, DOI 10.1097/00001756-199702100-00028; CAHILL L, 1994, NATURE, V371, P702, DOI 10.1038/371702a0; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; CASH R, 1986, BRAIN RES, V370, P127, DOI 10.1016/0006-8993(86)91112-1; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Chruscinski AJ, 1999, J BIOL CHEM, V274, P16694, DOI 10.1074/jbc.274.24.16694; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; Cohen AS, 1999, J NEUROPHYSIOL, V82, P3139, DOI 10.1152/jn.1999.82.6.3139; FLEXNER JB, 1985, P NATL ACAD SCI USA, V82, P7458, DOI 10.1073/pnas.82.21.7458; FOWLER JC, 1988, EUR J PHARMACOL, V153, P105, DOI 10.1016/0014-2999(88)90593-6; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17935; GEAN PW, 1992, BRAIN RES, V594, P331, DOI 10.1016/0006-8993(92)91146-6; GREEN SA, 1994, J BIOL CHEM, V269, P26215; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; HOPKINS WF, 1988, J NEUROPHYSIOL, V59, P667, DOI 10.1152/jn.1988.59.2.667; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; HUANG CC, 1993, NEUROSCI LETT, V161, P207, DOI 10.1016/0304-3940(93)90295-V; Huang YY, 1996, NEURON, V16, P611, DOI 10.1016/S0896-6273(00)80080-X; Ikegaya Y, 1997, NEUROREPORT, V8, P3143, DOI 10.1097/00001756-199709290-00027; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Jugloff DGM, 2000, J BIOL CHEM, V275, P1357, DOI 10.1074/jbc.275.2.1357; Katsuki H, 1997, J NEUROPHYSIOL, V77, P3013, DOI 10.1152/jn.1997.77.6.3013; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lefkowitz RJ, 1996, GOODMAN GILMANS PHAR, P105; MADISON DV, 1986, J PHYSIOL-LONDON, V372, P221, DOI 10.1113/jphysiol.1986.sp016006; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; MANTYH PW, 1995, J NEUROSCI, V15, P152; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; Moody TD, 1998, BRAIN RES, V794, P75, DOI 10.1016/S0006-8993(98)00217-0; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; NIELSON KA, 1994, BEHAV NEURAL BIOL, V62, P190, DOI 10.1016/S0163-1047(05)80017-2; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Niethammer M, 1996, J NEUROSCI, V16, P2157; Przybyslawski J, 1999, J NEUROSCI, V19, P6623; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; Rohrer DK, 1999, J BIOL CHEM, V274, P16701, DOI 10.1074/jbc.274.24.16701; Rousseau G, 1996, MOL PHARMACOL, V49, P752; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; SEGAL M, 1991, PROG BRAIN RES, V88, P323; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STRADER CD, 1983, P NATL ACAD SCI-BIOL, V80, P1840, DOI 10.1073/pnas.80.7.1840; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; Thomas MJ, 1996, NEURON, V17, P475, DOI 10.1016/S0896-6273(00)80179-8; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; van Stegeren AH, 1998, PSYCHOPHARMACOLOGY, V138, P305, DOI 10.1007/s002130050675; WAEBER C, 1991, SYNAPSE, V8, P270, DOI 10.1002/syn.890080405; Wang SJ, 1999, J NEUROSCI, V19, P570; Watanabe Y, 1996, NEUROSCIENCE, V71, P1031, DOI 10.1016/0306-4522(95)00498-X; WEINMAN EJ, 1982, J MEMBRANE BIOL, V69, P107, DOI 10.1007/BF01872270; Winder DG, 1999, NEURON, V24, P715, DOI 10.1016/S0896-6273(00)81124-1; XIAO RP, 1994, J BIOL CHEM, V269, P19151; XIAO RP, 1993, CIRC RES, V73, P286, DOI 10.1161/01.RES.73.2.286; Zhang WD, 1999, J NEUROSCI, V19, P96, DOI 10.1523/JNEUROSCI.19-01-00096.1999	60	135	140	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38659	38666		10.1074/jbc.M005938200	http://dx.doi.org/10.1074/jbc.M005938200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10995758	hybrid			2022-12-27	WOS:000165739800071
J	Boone, E; Vanden Berghe, T; Van Loo, G; De Wilde, G; De Wael, N; Vercammen, D; Fiers, W; Haegeman, G; Vandenabeele, P				Boone, E; Vanden Berghe, T; Van Loo, G; De Wilde, G; De Wael, N; Vercammen, D; Fiers, W; Haegeman, G; Vandenabeele, P			Structure/function analysis of p55 tumor necrosis factor receptor and Fas-associated death domain - Effect on necrosis in L929sA cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF RECEPTOR; SIGNALING COMPLEX; INDUCED APOPTOSIS; CD95 FAS/APO-1; PROTEIN; CYTOTOXICITY; INVOLVEMENT; INTERACTS; MEMBRANE; PATHWAYS	Tumor necrosis factor (TNF) induces a typical apoptotic cell death program in various cell lines by interacting with the p55 tumor necrosis factor receptor (TNF-R55), In contrast, triggering of the fibrosarcoma cell line L929sA gives rise to characteristic cellular changes resulting in necrosis, The intracellular domain of TNF-R55 can be subdivided into two parts: a membrane-proximal domain (amino acids 202-325) and a C-terminal death domain (DD) (amino acids 326-413), which has been shown to be necessary and sufficient for apoptosis, Structure/function analysis of TNF-R55-mediated necrosis in L929sA cells demonstrated that initiation of necrotic cell death, as defined by swelling of the cells, rapid membrane permeabilization, absence of nuclear condensation, absence of DNA hypoploidy, and generation of mitochondrial reactive oxygen intermediates, is also confined to the DD, The striking synergistic effect of the caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone on TNF-induced necrosis was also observed with receptors solely containing the DD, TNF-R55-mediated necrosis is not affected by the dominant negative deletion mutant of the Fas-associated death domain (FADD-(80-205)) that lacks the N-terminal death effector domain. Moreover, overexpression of FADD-(80-205) in L929sA is cytotoxic and insensitive to CrmA, while the cytotoxicity due to over-expression of the deletion mutant FADD-(1-111) lacking the DD is prevented by CrmA These results demonstrate that the death domain of FADD can elicit an active necrotic cell death pathway.	Flanders Interuniv Inst Biotechnol, Dept Mol Biol, B-9000 Ghent, Belgium; State Univ Ghent, B-9000 Ghent, Belgium	Ghent University	Vandenabeele, P (corresponding author), Flanders Interuniv Inst Biotechnol, Dept Mol Biol, KL Ledeganckstr 35, B-9000 Ghent, Belgium.		Vercammen, Dominique/A-4237-2008; , van Loo Geert/AAD-1220-2019; Vanden Berghe, Tom/C-4916-2009; Berghe, Tom Vanden/N-2902-2019; Vandenabeele, Peter/C-8597-2009; van Loo, Geert/C-1505-2009; Vandenabeele, Peter/AAD-5793-2022	, van Loo Geert/0000-0002-8427-4775; Vanden Berghe, Tom/0000-0002-1633-0974; Berghe, Tom Vanden/0000-0002-1633-0974; Vandenabeele, Peter/0000-0002-6669-8822				Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Boone E, 1998, FEBS LETT, V441, P275, DOI 10.1016/S0014-5793(98)01567-1; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Fiers W, 1996, J INFLAMM, V47, P67; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; FONES E, 1989, BIOCHEM PHARMACOL, V38, P3443, DOI 10.1016/0006-2952(89)90113-5; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; GROOTEN J, 1993, CYTOKINE, V5, P546, DOI 10.1016/S1043-4666(05)80003-1; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Jones SJ, 1999, J IMMUNOL, V162, P1042; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LASTER SM, 1988, J IMMUNOL, V141, P2629; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lemasters JJ, 1998, BIOFACTORS, V8, P283, DOI 10.1002/biof.5520080316; Luschen S, 2000, J BIOL CHEM, V275, P24670, DOI 10.1074/jbc.M003280200; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; VANDENABEELE P, 1995, J IMMUNOL, V154, P2904; VANHAESEBROECK B, 1991, CANCER RES, V51, P2469; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1997, CYTOKINE, V9, P801, DOI 10.1006/cyto.1997.0252; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	48	28	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37596	37603		10.1074/jbc.M007166200	http://dx.doi.org/10.1074/jbc.M007166200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10988295	hybrid			2022-12-27	WOS:000165618700041
J	Chi, A; Kemp, RG				Chi, A; Kemp, RG			The primordial high energy compound: ATP or inorganic pyrophosphate?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPI-DEPENDENT PHOSPHOFRUCTOKINASE; ESCHERICHIA-COLI; IDENTIFICATION; SPECIFICITY	The pyrophosphate-dependent phosphofructokinase (PPi-PFK) of Entamoeba histolytica displays a millionfold preference for inorganic pyrophosphate (PP,) over ATP (calculated as the ratio of k(cat)/K-m). The introduction of a single mutation by site-directed mutagenesis changes its preference from PP, to ATP. The single mutant has an 8-fold preference for ATP whereas a related double mutant shows a preference exceeding 10,000-fold. The results suggest the presence of a latent nucleotide binding site aligned for a catalytic role in PPi-PFK. It is proposed that the ancestral PFK was an ATP-dependent enzyme and that PPi-PFKs are a later evolving adaptation.	Chicago Med Sch, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA	Chicago Medical School	Kemp, RG (corresponding author), Chicago Med Sch, Dept Biochem & Mol Biol, 3333 Green Bay Rd, N Chicago, IL 60064 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034527] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34527] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alves AMCR, 1997, APPL ENVIRON MICROB, V63, P956, DOI 10.1128/AEM.63.3.956-961.1997; Calvin M., 1963, GRADUATE J, V5, P319; CHEN RD, 1995, P NATL ACAD SCI USA, V92, P11666, DOI 10.1073/pnas.92.25.11666; Deng ZH, 1998, BIOCHEM J, V329, P659, DOI 10.1042/bj3290659; Hinds RM, 1998, ARCH BIOCHEM BIOPHYS, V349, P47, DOI 10.1006/abbi.1997.0434; LINDBERG M, 1975, EUR J BIOCHEM, V53, P481, DOI 10.1111/j.1432-1033.1975.tb04089.x; Lipmann F., 1965, The origins of pre-biological systems and of their molecular matrices., P259; Mertens E, 1998, J MOL EVOL, V47, P739, DOI 10.1007/PL00006433; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; Siebers B, 1998, J BACTERIOL, V180, P2137, DOI 10.1128/JB.180.8.2137-2143.1998; Wang XJ, 1999, BIOCHEMISTRY-US, V38, P4313, DOI 10.1021/bi982940q	11	51	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35677	35679		10.1074/jbc.C000581200	http://dx.doi.org/10.1074/jbc.C000581200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	11001940	hybrid			2022-12-27	WOS:000165382000006
J	Bausek, N; Waclawek, M; Schneider, WJ; Wohlrab, F				Bausek, N; Waclawek, M; Schneider, WJ; Wohlrab, F			The major chicken egg envelope protein ZP1 is different from ZPB and is synthesized in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN ZONA-PELLUCIDA; MOLECULAR-CLONING; COORDINATE EXPRESSION; STRUCTURAL-ANALYSIS; RADIATA-PROTEINS; GRANULOSA-CELLS; GENE-EXPRESSION; CDNA CLONING; INNER-EAR; IDENTIFICATION	The extracellular matrix surrounding vertebrate oocytes is called the zona pellucida in mammals and perivitelline membrane (pvm) in birds. We have analyzed this structure in chicken follicles and laid eggs and have identified a 95-kDa component of the pvm, which, by protein sequencing, shows homology to mammalian zona pellucida proteins. Surprisingly, we could not detect this protein in ovarian granulosa cells or oocytes but instead found high levels in the liver of the laying hen. In contrast, it is absent in rooster liver but can be efficiently induced by estrogen treatment of the animal. An immunoscreen of a liver lambda-ZAP library yielded a cDNA coding for a protein of 934 amino acids. It displayed significant homology to members of the ZP1/ZPB family from other species, notably to mouse and rat ZP1, and was therefore designated chkZP1, It is clearly different from a protein designated chkZPB that had been deposited in the data base previously. Alignment of the known members of the ZP1/ZPB family demonstrated the existence of at least three subgroups, with representatives of both the ZP1 and the ZPB sequence homology group occurring in vertebrates. Northern blot analysis of liver extracts revealed the presence of a single 3.2-kilobase mRNA coding for chkZP1, distinct from the chkZPB transcript detectable in follicles, Immunohistochemical analysis of follicle sections demonstrates that chkZP1 can be found in the blood vessels of the theca cell layer as well as in the pvm surrounding the oocyte, Thus, in the chicken, at least one of the major pvm components is synthesized in the liver and is transported via the bloodstream to the follicle.	Univ Vienna, Dept Mol Genet, Inst Med Biochem, A-1030 Vienna, Austria; Bioctr Vienna, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC)	Wohlrab, F (corresponding author), Univ Vienna, Dept Mol Genet, Inst Med Biochem, Dr Bohr Gasse 9-2, A-1030 Vienna, Austria.	wohlrab@mol.univie.ac.at		Bausek, Nina/0000-0003-2415-1463				BACK JF, 1982, BIOCHIM BIOPHYS ACTA, V705, P12, DOI 10.1016/0167-4838(82)90329-6; Barros C, 1996, CELL BIOL INT, V20, P33, DOI 10.1006/cbir.1996.0006; BELLAIRS RUTH, 1963, JOUR ULTRASTRUCTURE RES, V8, P339, DOI 10.1016/S0022-5320(63)90012-1; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; Chang YS, 1997, MOL REPROD DEV, V46, P258, DOI 10.1002/(SICI)1098-2795(199703)46:3&lt;258::AID-MRD4&gt;3.0.CO;2-O; COTELLI F, 1988, J ULTRA MOL STRUCT R, V99, P70, DOI 10.1016/0889-1605(88)90034-1; Coutinho P, 1999, HEARING RES, V130, P62, DOI 10.1016/S0378-5955(98)00213-5; Del Giacco L, 2000, DEV GENES EVOL, V210, P41, DOI 10.1007/PL00008187; DelGiacco L, 1998, MOL REPROD DEV, V49, P58, DOI 10.1002/(SICI)1098-2795(199801)49:1&lt;58::AID-MRD7&gt;3.0.CO;2-N; Dumont J N, 1985, Dev Biol (N Y 1985), V1, P235; EPIFANO O, 1995, DEVELOPMENT, V121, P1947; GILBERT AB, 1977, J REPROD FERTIL, V50, P179, DOI 10.1530/jrf.0.0500179; GREVE JM, 1985, J MOL BIOL, V181, P253, DOI 10.1016/0022-2836(85)90089-0; Haines BP, 1999, MOL REPROD DEV, V52, P174, DOI 10.1002/(SICI)1098-2795(199902)52:2<174::AID-MRD8>3.0.CO;2-7; HARRIS JD, 1994, DNA SEQUENCE, V4, P361, DOI 10.3109/10425179409010186; HESSION C, 1987, SCIENCE, V237, P1479, DOI 10.1126/science.3498215; HOFFMANN W, 1993, TRENDS BIOCHEM SCI, V18, P239, DOI 10.1016/0968-0004(93)90170-R; HOOPS TC, 1991, J BIOL CHEM, V266, P4257; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Hughes DC, 1999, BBA-GENE STRUCT EXPR, V1447, P303, DOI 10.1016/S0167-4781(99)00181-5; KIDO S, 1992, BIOCHEM J, V286, P17, DOI 10.1042/bj2860017; KILLICK R, 1995, J CELL BIOL, V129, P535, DOI 10.1083/jcb.129.2.535; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; Liang LF, 1997, DEVELOPMENT, V124, P4939; LIU DY, 1993, BIOL REPROD, V48, P340, DOI 10.1095/biolreprod48.2.340; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LYONS CE, 1993, J BIOL CHEM, V268, P21351; Martinez ML, 1996, J REPROD FERTIL, P35; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Moore DD, 1995, GLOB MOB SURV; Murata K, 1997, P NATL ACAD SCI USA, V94, P2050, DOI 10.1073/pnas.94.5.2050; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OPPENBERNTSEN DO, 1992, J ENDOCRINOL, V135, P293, DOI 10.1677/joe.0.1350293; OPPENBERNTSEN DO, 1992, INT J DEV BIOL, V36, P247; ORAND MG, 1988, GAMETE RES, V19, P315, DOI 10.1002/mrd.1120190402; PENNICA D, 1987, SCIENCE, V236, P83, DOI 10.1126/science.3453112; Prasad SV, 1996, MOL REPROD DEV, V43, P519, DOI 10.1002/(SICI)1098-2795(199604)43:4&lt;519::AID-MRD15&gt;3.0.CO;2-U; Prasad SV, 1997, I C S S, V12, P129; Sambrook J, 1989, MOL CLONING; Stockinger W, 1998, J BIOL CHEM, V273, P32213, DOI 10.1074/jbc.273.48.32213; Sugiyama H, 1998, DEV GROWTH DIFFER, V40, P35; Takeuchi Y, 1999, EUR J BIOCHEM, V260, P736, DOI 10.1046/j.1432-1327.1999.00203.x; Waclawek M, 1998, BIOL REPROD, V59, P1230, DOI 10.1095/biolreprod59.5.1230; Wassarman P, 1999, J EXP ZOOL, V285, P251, DOI 10.1002/(SICI)1097-010X(19991015)285:3&lt;251::AID-JEZ8&gt;3.0.CO;2-1; WASSARMAN PM, 1990, J REPROD FERTIL, P79; Yonezawa N, 1997, EUR J BIOCHEM, V248, P86, DOI 10.1111/j.1432-1033.1997.00086.x; YONEZAWA N, 1995, EUR J BIOCHEM, V233, P35, DOI 10.1111/j.1432-1033.1995.035_1.x; Yurewicz EC, 1998, J BIOL CHEM, V273, P7488, DOI 10.1074/jbc.273.13.7488	49	97	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28866	28872		10.1074/jbc.275.37.28866	http://dx.doi.org/10.1074/jbc.275.37.28866			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10979984	hybrid			2022-12-27	WOS:000089330700070
J	Lin, HJ; Wing, SS				Lin, HJ; Wing, SS			Identification of rabbit reticulocyte E2(17K) as a UBC7 homologue and functional characterization of its core domain loop. (vol 274, pg 14685, 1999)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Correction																		Lin HJ, 1999, J BIOL CHEM, V274, P14685, DOI 10.1074/jbc.274.21.14685	1	0	0	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29178	29178						1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10979987				2022-12-27	WOS:000089330700108
J	Pietri, S; Martel, S; Culcasi, M; Delmas-Beauvieux, MC; Canioni, P; Gallis, JL				Pietri, S; Martel, S; Culcasi, M; Delmas-Beauvieux, MC; Canioni, P; Gallis, JL			Use of diethyl(2-methylpyrrolidin-2-yl)phosphonate as a highly sensitive extra- and intracellular P-31 NMR pH indicator in isolated organs - Direct NMR evidence of acidic compartments in the ischemic and reperfused rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; HEART; SPECTROSCOPY; METHYLPHOSPHONATE; HEPATOCYTES; PHOSPHONATE; PHOSPHATE; EXCHANGE; VOLUME; CELLS	The novel phosphorylated pyrrolidine diethyl(2-methylpyrrolidin-2-yl)phosphonate (DEPMPH) was evaluated as a P-31 NMR probe of the pH changes associated with ischemia/reperfusion of rat isolated hearts and livers. In vitro titration curves indicated that DEPMPH exhibited a 4-fold larger amplitude of chemical shift variation than inorganic phosphate yielding an enhanced NMR sensitivity in the pH range of 5.0-7.5 that allowed us to assess pH variations of less than 0.1 pH units. At the non-toxic concentration of 5 mM, DEPMPH distributed into external and cytosolic compartments in both normoxic organs, as assessed by the appearance of two resonance peaks. An additional peak was observed in normoxic and ischemic livers, assigned to DEPMPH in acidic vesicles (pH 5.3-5.6). During severe myocardial ischemia, a third peak corresponding to DEPMPH located in ventricular and atrial cavities appeared (pH 6.9). Mass spectrometry and NMR analyses of perchloric extracts showed that no significant metabolism of DEPMPH occurred in the ischemic liver. Reperfusion with plain buffer resulted in a rapid washout of DEPMPH from both organs. It was concluded that the highly pH-sensitive DEPMPH could be of great interest in noninvasive ex vivo studies of pH gradients that may be involved in many pathological processes.	Univ Aix Marseille 1, SREP, CNRS, UMR 6517, F-13397 Marseille 20, France; Univ Aix Marseille 3, SREP, CNRS, UMR 6517, F-13397 Marseille, France; Univ Bordeaux 2, CNRS, UMR 5536, F-33076 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Pietri, S (corresponding author), Univ Aix Marseille 1, SREP, CNRS, UMR 6517, Case 521,Ave Escadrille Normandie Niemen, F-13397 Marseille 20, France.							ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; BOYER JL, 1992, ANNU REV PHYSIOL, V54, P415, DOI 10.1146/annurev.ph.54.030192.002215; BRENOT F, 1992, BIOCHIMIE, V74, P883, DOI 10.1016/0300-9084(92)90072-M; BRONK SF, 1991, HEPATOLOGY, V14, P626; Bruynseels K, 1997, NMR BIOMED, V10, P263, DOI 10.1002/(SICI)1099-1492(199709)10:6<263::AID-NBM472>3.0.CO;2-J; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; CLARKE K, 1994, MAGNET RESON MED, V32, P181, DOI 10.1002/mrm.1910320206; CLARKE K, 1993, NMR BIOMED, V6, P278, DOI 10.1002/nbm.1940060407; COHEN SM, 1983, J BIOL CHEM, V258, P4294; CONOREV EA, 1991, CARDIOVASC RES, V25, P164, DOI 10.1093/cvr/25.2.164; DAVIES L, 1993, CELL, V75, P321, DOI 10.1016/0092-8674(93)80073-N; DEFRONZO M, 1987, J BIOL CHEM, V262, P11032; DESMOULIN F, 1987, HEPATOLOGY, V7, P315, DOI 10.1002/hep.1840070217; Dufour S, 1996, J MAGN RESON SER B, V113, P125, DOI 10.1006/jmrb.1996.0165; DURAND T, 1993, AM J PHYSIOL, V265, pG43, DOI 10.1152/ajpgi.1993.265.1.G43; FISHER MJ, 1987, CIRC RES, V60, P472, DOI 10.1161/01.RES.60.4.472; GARLICK PB, 1979, BIOCHEM J, V184, P547, DOI 10.1042/bj1840547; GILLIES RJ, 1994, AM J PHYSIOL, V267, pC195, DOI 10.1152/ajpcell.1994.267.1.C195; GILLIES RJ, 1982, INTRACELLULAR PH ITS, P79; HENDERSON RM, 1987, AM J PHYSIOL, V252, pG109, DOI 10.1152/ajpgi.1987.252.1.G109; INGWALL JS, 1982, AM J PHYSIOL, V242, pH729, DOI 10.1152/ajpheart.1982.242.5.H729; JACOBUS WE, 1982, INTRACELLULAR PH ITS, P537; KELLER SK, 1986, AM J PHYSIOL, V250, pC124, DOI 10.1152/ajpcell.1986.250.1.C124; LABOTKA RJ, 1983, BIOCHEMISTRY-US, V22, P6089, DOI 10.1021/bi00295a008; LIN LE, 1985, AM J PHYSIOL, V248, pC177, DOI 10.1152/ajpcell.1985.248.1.C177; LUNDBERG P, 1990, ANAL BIOCHEM, V191, P193, DOI 10.1016/0003-2697(90)90210-Z; MCLAUGHLIN AC, 1978, FRONTIERS BIOL ENERG, V2, P1351; MOON RB, 1973, J BIOL CHEM, V248, P7276; NAVON G, 1979, BIOCHEMISTRY-US, V18, P4487, DOI 10.1021/bi00588a006; Pietri S, 1998, EUR J BIOCHEM, V254, P256, DOI 10.1046/j.1432-1327.1998.2540256.x; Pietri S, 2000, J BIOL CHEM, V275, P19505, DOI 10.1074/jbc.M001784200; Piper HM, 1996, BASIC RES CARDIOL, V91, P191, DOI 10.1007/BF00788905; PISSAREK M, 1995, MOL CELL BIOCHEM, V145, P121, DOI 10.1007/BF00935484; Raghunand N, 1999, BIOCHEM PHARMACOL, V57, P309, DOI 10.1016/S0006-2952(98)00306-2; RENNER EL, 1989, AM J PHYSIOL, V256, pG44, DOI 10.1152/ajpgi.1989.256.1.G44; SALHANY JM, 1979, J MOL CELL CARDIOL, V11, P601, DOI 10.1016/0022-2828(79)90434-6; SCHARSCHMIDT BF, 1997, ANNU REV PHYSIOL, V49, P69; SCHLISELFELD LH, 1982, BIOCHEMISTRY-US, V21, P317, DOI 10.1021/bi00531a018; SLONCZEWSKI JL, 1981, P NATL ACAD SCI-BIOL, V78, P6271, DOI 10.1073/pnas.78.10.6271; STEWART IM, 1986, BIOCHIM BIOPHYS ACTA, V885, P23, DOI 10.1016/0167-4889(86)90034-0; SZWERGOLD BS, 1992, ANNU REV PHYSIOL, V54, P775, DOI 10.1146/annurev.ph.54.030192.004015; SZWERGOLD BS, 1989, J CELL PHYSIOL, V138, P227, DOI 10.1002/jcp.1041380203; THOMA WJ, 1986, BIOCHEM BIOPH RES CO, V138, P1106, DOI 10.1016/S0006-291X(86)80396-5; *US DEP HHS, 1985, NIH PUBL, V8523; Vidal G, 2000, NMR BIOMED, V13, P289, DOI 10.1002/1099-1492(200008)13:5<289::AID-NBM647>3.3.CO;2-7; VOOGD A, 1992, J CLIN INVEST, V90, P2050, DOI 10.1172/JCI116086; WADSWORTH SJ, 1994, J MEMBRANE BIOL, V142, P21, DOI 10.1007/BF00233380	47	25	29	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1750	1758		10.1074/jbc.M008023200	http://dx.doi.org/10.1074/jbc.M008023200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11013264	hybrid			2022-12-27	WOS:000166528000015
J	Fadok, VA; de Cathelineau, A; Daleke, DL; Henson, PM; Bratton, DL				Fadok, VA; de Cathelineau, A; Daleke, DL; Henson, PM; Bratton, DL			Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; VITRONECTIN RECEPTOR; PLASMA-MEMBRANE; ANNEXIN-V; TRANSBILAYER MOVEMENT; ENDOTHELIAL-CELLS; GENERAL FEATURE; LIPID PACKING; T-LYMPHOCYTES; FLIP-FLOP	Removal of apoptotic cells during tissue remodeling or resolution of inflammation is critical to the restoration of normal tissue structure and function. During apoptosis, early surface changes occur, which trigger recognition and removal by macrophages and other phagocytes. Loss of phospholipid asymmetry results in exposure of phosphatidylserine (PS), one of the surface markers recognized by macrophages. However, a number of receptors have been reported to mediate macrophage recognition of apoptotic cells, not all of which bind to phosphatidylserine, We therefore examined the role of membrane phospholipid symmetrization and PS externalization in uptake of apoptotic cells by mouse macrophages and human HT-1080 fibrosarcoma cells by exposing them to cells that had undergone apoptosis without loss of phospholipid asymmetry. Neither mouse macrophages nor HT-1080 cells recognized or engulfed apoptotic targets that failed to express PS, in comparison to PS-expressing apoptotic cells. If, however, their outer leaflets were repleted with the L-, but not the D-, stereoisomer of sn-1,2-PS by liposome transfer, engulfment by both phagocytes was restored. These observations directly demonstrate that loss of phospholipid asymmetry and PS expression is required for phagocyte engulfment of apoptotic cells and imply a critical, if not obligatory, role for PS recognition in the uptake process.	Natl Jewish Med & Res Ctr, Cell Biol Program, Denver, CO 80206 USA; Indiana Univ, Dept Biochem & Mol Biol Med Sci, Bloomington, IN 47405 USA	National Jewish Health; Indiana University System; Indiana University Bloomington	Fadok, VA (corresponding author), Natl Jewish Med & Res Ctr, Cell Biol Program, Denver, CO 80206 USA.		Daleke, David/T-3123-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047230, R01GM048211] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30343, HL 60980] Funding Source: Medline; NIGMS NIH HHS [GM 48211, GM 47230] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT MR, 1995, CIRC RES, V77, P1136, DOI 10.1161/01.RES.77.6.1136; Bratton DL, 1999, J BIOL CHEM, V274, P28113, DOI 10.1074/jbc.274.40.28113; Bratton DL, 1997, J BIOL CHEM, V272, P26159, DOI 10.1074/jbc.272.42.26159; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V467, P146; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; CONNOR J, 1988, BIOCHEMISTRY-US, V27, P848, DOI 10.1021/bi00403a002; CONNOR J, 1991, BIOCHIM BIOPHYS ACTA, V1066, P37, DOI 10.1016/0005-2736(91)90247-6; CONNOR J, 1990, BIOCHEMISTRY-US, V29, P37, DOI 10.1021/bi00453a005; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; DINI L, 1995, J CELL SCI, V108, P967; Dini L, 1998, BIOCHEM SOC T, V26, P635, DOI 10.1042/bst0260635; DUVALL E, 1985, IMMUNOLOGY, V56, P351; FADOK VA, 1992, J IMMUNOL, V149, P4029; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; FADOK VA, 1993, J IMMUNOL, V151, P4274; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fadok VA, 1998, J IMMUNOL, V161, P6250; Falasca L, 1996, EXP CELL RES, V224, P152, DOI 10.1006/excr.1996.0123; HALL SE, 1994, J IMMUNOL, V153, P3218; HOMBURG CHE, 1995, BLOOD, V85, P532; Johnson JE, 1998, BIOCHEMISTRY-US, V37, P12020, DOI 10.1021/bi981107q; JUNEJA LR, 1989, BIOCHIM BIOPHYS ACTA, V1003, P227; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Krahling S, 1999, CELL DEATH DIFFER, V6, P183, DOI 10.1038/sj.cdd.4400473; Marguet D, 1999, NAT CELL BIOL, V1, P454, DOI 10.1038/15690; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MCEVOY L, 1986, P NATL ACAD SCI USA, V83, P3311, DOI 10.1073/pnas.83.10.3311; Mevorach D, 1998, J EXP MED, V188, P2313, DOI 10.1084/jem.188.12.2313; Moffatt OD, 1999, J IMMUNOL, V162, P6800; MORRIS RG, 1984, AM J PATHOL, V115, P426; MOWER DA, 1994, J IMMUNOL, V152, P4832; Oka K, 1998, P NATL ACAD SCI USA, V95, P9535, DOI 10.1073/pnas.95.16.9535; PERKINS SL, 1991, J LEUKOCYTE BIOL, V50, P427, DOI 10.1002/jlb.50.5.427; Pradhan D, 1997, MOL BIOL CELL, V8, P767, DOI 10.1091/mbc.8.5.767; PRADHAN D, 1994, MOL MEMBR BIOL, V11, P181, DOI 10.3109/09687689409162237; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; RICHES DWH, 1988, J IMMUNOL, V141, P180; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SCHLEGEL RA, 1993, IMMUNOL LETT, V36, P283, DOI 10.1016/0165-2478(93)90101-7; Schlegel RA, 1999, CELL DEATH DIFFER, V6, P583, DOI 10.1038/sj.cdd.4400529; SCHLEGEL RA, 1985, BIBL HAEMATOL, V51, P150; SCHROIT AJ, 1985, J BIOL CHEM, V260, P5131; SCHROIT AJ, 1984, BIOL CELL, V51, P227, DOI 10.1111/j.1768-322X.1984.tb00303.x; SCHWARTZ RS, 1985, J CLIN INVEST, V75, P1965, DOI 10.1172/JCI111913; Shiratsuchi A, 1998, BIOCHEM BIOPH RES CO, V246, P549, DOI 10.1006/bbrc.1998.8663; Shiratsuchi A, 1997, J BIOL CHEM, V272, P2354, DOI 10.1074/jbc.272.4.2354; SMITH DM, 1993, J CELL PHYSIOL, V156, P182, DOI 10.1002/jcp.1041560124; Tait JF, 1999, J BIOL CHEM, V274, P3048, DOI 10.1074/jbc.274.5.3048; TANAKA Y, 1983, J BIOL CHEM, V258, P1335; TUCKER KA, 1987, BLOOD, V70, P372; van den Eijnde SM, 1999, EUR J NEUROSCI, V11, P712, DOI 10.1046/j.1460-9568.1999.00477.x; vandenEijnde SM, 1997, CYTOMETRY, V29, P313, DOI 10.1002/(SICI)1097-0320(19971201)29:4<313::AID-CYTO8>3.0.CO;2-A; Verhoven B, 1999, CELL DEATH DIFFER, V6, P262, DOI 10.1038/sj.cdd.4400491; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; Wang PY, 1998, J BIOL CHEM, V273, P24309, DOI 10.1074/jbc.273.38.24309; ZACHOWSKI A, 1987, BIOCHIM BIOPHYS ACTA, V897, P197, DOI 10.1016/0005-2736(87)90328-2	60	491	517	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1071	1077		10.1074/jbc.M003649200	http://dx.doi.org/10.1074/jbc.M003649200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	10986279	hybrid			2022-12-27	WOS:000166430900030
J	Chen, C; Yang, MCK; Yang, TP				Chen, C; Yang, MCK; Yang, TP			Evidence that silencing of the HPRT promoter by DNA methylation is mediated by critical CpG sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE GENE; INACTIVE X-CHROMOSOMES; HISTONE DEACETYLASE; TRICHOSTATIN-A; 5' REGION; CHROMATIN STRUCTURE; LINKED GENES; EXPRESSION; TRANSCRIPTION; DEMETHYLATION	The strong correlation between promoter hypermethylation and gene silencing suggests that promoter methylation represses transcription. To identify methylation sites that may be critical for maintaining repression of the human HPRT gene, we treated human/hamster hybrid cells containing an inactive human X chromosome with the DNA demethylating agent 5-azadeoxycytidine (5aCdr), and we then examined the high resolution methylation pattern of the HPRT promoter in single cell-derived lines. Reactivation of HPRT correlated with complete promoter demethylation, In contrast, the 61 BaCdr-treated clones that failed to reactivate HPRT exhibited sporadic promoter demethylation. However, three specific CpG sites remained methylated in all unreactivated clones, suggesting these sites may be critical for maintaining transcriptional silencing of the HPRT gene. Re-treatment of partially demethylated land unreactivated) clones with a second round of 5aCdr did not increase the frequency of HPRT reactivation. This is consistent with mechanisms of methylation-mediated repression requiring methylation at specific critical sites and argues against models invoking overall levels or a threshold of promoter methylation. Treatment of cells with the histone deacetylase inhibitor, trichostatin A, failed to reactivate HPRT on the inactive X chromosome, even when the promoter was partially demethylated by 5aCdr treatment, suggesting that transcriptional repression by DNA methylation is unlikely to depend upon a trichostatin A-sensitive histone deacetylase.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Ctr Mammalian Genet, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Div Pediat Genet, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Stat, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Yang, TP (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, 1600 SW Archer Rd, Gainesville, FL 32610 USA.	yang@cmg.health.ufl.edu		Chen, Chien/0000-0002-8406-9659	NIGMS NIH HHS [R01 GM44286] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044286] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Broday L, 1999, MOL CELL BIOL, V19, P3198; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Carmen AA, 1999, P NATL ACAD SCI USA, V96, P12356, DOI 10.1073/pnas.96.22.12356; DRACOPOLI NC, 1985, AM J HUM GENET, V37, P199; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; ELLIS N, 1987, SOMAT CELL MOLEC GEN, V13, P191, DOI 10.1007/BF01535202; Hata K, 1997, GENE, V189, P227, DOI 10.1016/S0378-1119(96)00856-6; HORNSTRA IK, 1993, ANAL BIOCHEM, V213, P179, DOI 10.1006/abio.1993.1407; HORNSTRA IK, 1994, MOL CELL BIOL, V14, P1419, DOI 10.1128/MCB.14.2.1419; HORNSTRA IK, 1992, MOL CELL BIOL, V12, P5345, DOI 10.1128/MCB.12.12.5345; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; KIM SH, 1986, NUCLEIC ACIDS RES, V14, P3103, DOI 10.1093/nar/14.7.3103; LEVINE A, 1992, P NATL ACAD SCI USA, V89, P10119, DOI 10.1073/pnas.89.21.10119; Litt MD, 1996, MOL CELL BIOL, V16, P6190; Maxam A M, 1980, Methods Enzymol, V65, P499; MIYASHITA T, 1994, FEBS LETT, V353, P225, DOI 10.1016/0014-5793(94)01034-X; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; PARK JG, 1994, MOL CELL BIOL, V14, P7975, DOI 10.1128/MCB.14.12.7975; PATEL PI, 1986, MOL CELL BIOL, V6, P393, DOI 10.1128/MCB.6.2.393; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; Riggs AD, 1998, CIBA F SYMP, V214, P214; SASAKI T, 1992, MOL CELL BIOL, V12, P3819, DOI 10.1128/MCB.12.9.3819; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P3418, DOI 10.1073/pnas.79.11.3418; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; TOMMASI S, 1993, SOMAT CELL MOLEC GEN, V19, P529, DOI 10.1007/BF01233380; TONIOLO D, 1988, EMBO J, V7, P401, DOI 10.1002/j.1460-2075.1988.tb02827.x; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; YISRAELI J, 1988, P NATL ACAD SCI USA, V85, P4638, DOI 10.1073/pnas.85.13.4638; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	39	42	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					320	328		10.1074/jbc.M007096200	http://dx.doi.org/10.1074/jbc.M007096200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11013250	hybrid			2022-12-27	WOS:000166280700044
J	Wei, LN; Hu, XL; Chandra, D; Seto, E; Farooqui, M				Wei, LN; Hu, XL; Chandra, D; Seto, E; Farooqui, M			Receptor-interacting protein 140 directly recruits histone deacetylases for gene silencing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; LIGAND-BINDING; NUCLEAR; COREPRESSOR; ACTIVATION; COMPLEX; YEAST; REPRESSION; MECHANISM	Receptor-interacting protein 140 (RIP140) encodes a histone deacetylase (HDAC) inhibitor-sensitive repressive activity. Direct interaction of RIP140 with HDAC1 and HDAC3 occurs in vitro and in vivo as demonstrated in co-immunoprecipitation and glutathione S-transferase pull-down experiments. The HDAC-interacting domain of RIP140 is mapped to its N-terminal domain, between amino acids 78 and 303 based upon glutathione S-transferase pull-down experiments. In chromatin immunoprecipitation assays, it is demonstrated that histone deacetylation occurs at the chromatin region of the Ga14 binding sites as a result of Ga14 DNA binding domain-tethered RIP expression. The immunocomplexes of RIP140 from cells transfected with RIP140 and HDAC are able to deacetylate histone proteins in vitro. This study presents the first evidence for RIP140 as a negative coregulator for nuclear receptor actions by directly recruiting histone deacetylases and categorizes RIP140 as a novel negative coregulator that is able to directly interact with HDACs.	Univ Minnesota, Dept Pharmacol, Sch Med, Minneapolis, MN 55455 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	University of Minnesota System; University of Minnesota Twin Cities; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Wei, LN (corresponding author), Univ Minnesota, Dept Pharmacol, Sch Med, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	weixx009@maroon.tc.umn.edu		Farooqui, Mariya/0000-0002-2136-8694; Chandra, Dhyan/0000-0001-7272-9384	NIDDK NIH HHS [DK54733] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054733] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen WY, 2000, P NATL ACAD SCI USA, V97, P377, DOI 10.1073/pnas.97.1.377; Chuang FM, 1997, MOL ENDOCRINOL, V11, P1332, DOI 10.1210/me.11.9.1332; Dudley MW, 2000, P NATL ACAD SCI USA, V97, P3696, DOI 10.1073/pnas.040558197; Eng FCS, 1998, J BIOL CHEM, V273, P28371, DOI 10.1074/jbc.273.43.28371; Grant PA, 1999, METH MOL B, V119, P311; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Hampsey M, 1997, TRENDS GENET, V13, P427, DOI 10.1016/S0168-9525(97)01292-4; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kolle D, 1998, METHODS, V15, P323, DOI 10.1006/meth.1998.0636; Lee CH, 1999, J BIOL CHEM, V274, P31320, DOI 10.1074/jbc.274.44.31320; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; Miyata KS, 1998, MOL CELL ENDOCRINOL, V146, P69; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Subramaniam N, 1999, J BIOL CHEM, V274, P18121, DOI 10.1074/jbc.274.25.18121; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TURNER BM, 1991, J CELL SCI, V99, P13; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400	42	124	130	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40782	40787		10.1074/jbc.M004821200	http://dx.doi.org/10.1074/jbc.M004821200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11006275	hybrid			2022-12-27	WOS:000166114600018
J	Cain, C; Miller, S; Ahn, J; Prives, C				Cain, C; Miller, S; Ahn, J; Prives, C			The N terminus of p53 regulates its dissociation from DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; PHOSPHORYLATED IN-VITRO; TRANSCRIPTIONAL ACTIVATION; BINDING FUNCTION; MUTANT P53; MONOCLONAL-ANTIBODIES; IONIZING-RADIATION; GROWTH SUPPRESSION; KINASE-C; DOMAIN	It is important to gain insight into p53 DNA binding and how it is regulated. By using electrophoretic mobility shift assays and DNase I footprinting, we show that a region within the N terminus of the protein controls the dissociation of p53 from a p53-binding site. When p53 is bound by a number of N-terminal-specific monoclonal antibodies, its rate of dissociation from DNA is reduced, and its ability to protect a cognate site from DNase I digestion is increased. Moreover, greatly reduced dissociation is observed with p53 protein lacking the N-terminal 96 amino acids. By contrast, deletion of the C terminus does not affect p53 dissociation from DNA or DNase I protection. p53 protein expressed in and purified from bacterial cells displays markedly more instability on its consensus DNA-binding site than does p53 produced in insect cells, suggesting that post-translational modifications may affect the stability of the protein. Our results provide evidence that the N terminus of p53 possesses an auto-inhibitory function that is mechanistically different from the inhibitory region at the C terminus.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.				NATIONAL CANCER INSTITUTE [R01CA077742] Funding Source: NIH RePORTER; NCI NIH HHS [CA77742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABARZUA P, 1995, CANCER RES, V55, P3490; Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; BRAIN R, 1994, ONCOGENE, V9, P1775; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Fourie AM, 1997, J BIOL CHEM, V272, P19471, DOI 10.1074/jbc.272.31.19471; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hansen S, 1996, J BIOL CHEM, V271, P3917; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1997, METHOD ENZYMOL, V283, P245; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; JAYARAMAN L, 1995, CELL, V81, P10021; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEGROS Y, 1994, ONCOGENE, V9, P2071; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; Liu L, 1999, MOL CELL BIOL, V19, P1202; LIU X, 1995, MOL CELL BIOL, V15, P6474; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; Martinez JD, 1997, ONCOGENE, V14, P2511, DOI 10.1038/sj.onc.1201095; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Scolnick DM, 1997, CANCER RES, V57, P3693; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TRUANT R, 1993, J BIOL CHEM, V268, P2284; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; VOJTESEK B, 1995, ONCOGENE, V10, P389; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	89	44	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39944	39953		10.1074/jbc.M002509200	http://dx.doi.org/10.1074/jbc.M002509200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10993878	hybrid			2022-12-27	WOS:000166039500023
J	Hamano-Takaku, F; Iwama, T; Saito-Yano, S; Takaku, K; Monden, Y; Kitabatake, M; Soll, D; Nishimura, S				Hamano-Takaku, F; Iwama, T; Saito-Yano, S; Takaku, K; Monden, Y; Kitabatake, M; Soll, D; Nishimura, S			A mutant Escherichia coli tyrosyl-tRNA synthetase utilizes the unnatural amino acid azatyrosine more efficiently than tyrosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIES SPECIFICITY; GENETIC-CODE; PROTEIN; BINDING; AMINOACYLATION; CONVERSION; EVOLUTION; CELLS; YEAST; RAS	Alloproteins, proteins that contain unnatural amino acids, have immense potential in biotechnology and medicine, Although various approaches for alloprotein production exist, there is no satisfactory method to produce large quantities of alloproteins containing unnatural amino acids in specific positions. The tyrosine analogue azatyrosine, L-beta-(5-hydroxy-2-pyridyl)-alanine, can convert the ras-transformed phenotype to normal phenotype, presumably by its incorporation into cellular proteins. This provided the stimulus for isolation of a mutant tyrosyl-tRNA synthetase (TyrRS) capable of charging azatyrosine to tRNA. A plasmid library of randomly mutated Escherichia coli tyrS (encoding TyrRS) was made by polymerase chain reaction techniques. The desired TyrRS mutants were selected by screening for in vivo azatyrosine incorporation of E. coli cells transformed with the mutant tyrS plasmids. One of the clones thus isolated, R-6-A-7, showed a 17-fold higher in vivo activity for azatyrosine incorporation than wild-type TyrRS, The mutant tyrS gene contained a single point mutation resulting in replacement of phenylalanine by serine at position 130 in the protein. Structural modeling revealed that position 130 is located close to Asp(182) which directly interacts with tyrosyladenylate. Kinetic analysis of aminoacyl-tRNA formation by the wild-type and mutated F130S TyrRS enzymes showed that the specificity for azatyrosine, measured by the ratios of k(cat)/K-m for tyrosine and the analogue, increased from 17 to 36 as a result of the F130S mutation. Thus, the high discrimination against azatyrosine is significantly reduced in the mutant enzyme. These results suggest that utilization of F130S TyrRS for in vivo protein biosynthesis may lead to efficient production of azatyrosine-containing alloproteins.	Merck Res Labs, Banyu Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Merck & Company; Yale University	Nishimura, S (corresponding author), Merck Res Labs, Banyu Tsukuba Res Inst, Okubo 3, Tsukuba, Ibaraki 3002611, Japan.	nismrasm@banyu.co.jp						Agou F, 1998, BIOCHEMISTRY-US, V37, P11309, DOI 10.1021/bi9805590; BARKER DG, 1982, FEBS LETT, V150, P419, DOI 10.1016/0014-5793(82)80781-3; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BUOROCORE V, 1972, J BIOL CHEM, V247, P4843; DOCTOR BP, 1966, COLD SPRING HARB SYM, V31, P543, DOI 10.1101/SQB.1966.031.01.070; FERSHT AR, 1980, BIOCHEMISTRY-US, V19, P5520, DOI 10.1021/bi00565a009; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; GAY GD, 1993, FEBS LETT, V318, P167, DOI 10.1016/0014-5793(93)80014-L; HAYASHI H, 1966, J MOL BIOL, V19, P161, DOI 10.1016/S0022-2836(66)80058-X; HOBEN P, 1985, METHOD ENZYMOL, V113, P55; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; IBBA M, 1994, BIOCHEMISTRY-US, V33, P7107, DOI 10.1021/bi00189a013; INOUYE S, 1975, CHEM PHARM BULL, V23, P2669; JAKES R, 1975, BIOCHEMISTRY-US, V14, P3344, DOI 10.1021/bi00686a009; Kigawa T, 1999, FEBS LETT, V442, P15, DOI 10.1016/S0014-5793(98)01620-2; KOHNO T, 1990, J BIOL CHEM, V265, P6931; KOIDE H, 1988, P NATL ACAD SCI USA, V85, P6237, DOI 10.1073/pnas.85.17.6237; Leung DW, 1989, TECHNIQUE, V1, P11; Liu DR, 1999, P NATL ACAD SCI USA, V96, P4780, DOI 10.1073/pnas.96.9.4780; LOWE DM, 1987, BIOCHEMISTRY-US, V26, P6038, DOI 10.1021/bi00393a014; Monden Y, 1996, ONCOL REP, V3, P625; Monden Y, 1996, ONCOL REP, V3, P33; MONDEN Y, 2000, ANN NY ACAD SCI, V886, P109; Sever S, 1996, BIOCHEMISTRY-US, V35, P32, DOI 10.1021/bi952103d; SHINDOOKADA N, 1989, MOL CARCINOGEN, V2, P159, DOI 10.1002/mc.2940020309; Sprinzl M., 1989, Nucleic Acids Research, V17, P1; TEMPEST DW, 1970, J GEN MICROBIOL, V64, P171, DOI 10.1099/00221287-64-2-171; Wakasugi K, 1998, EMBO J, V17, P297, DOI 10.1093/emboj/17.1.297	30	32	101	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40324	40328		10.1074/jbc.M003696200	http://dx.doi.org/10.1074/jbc.M003696200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006270	hybrid			2022-12-27	WOS:000166039500072
J	Buch-Pedersen, MJ; Venema, K; Serrano, R; Palmgren, MG				Buch-Pedersen, MJ; Venema, K; Serrano, R; Palmgren, MG			Abolishment of proton pumping and accumulation in the E1P conformational state of a plant plasma membrane H+-ATPase by substitution of a conserved aspartyl residue in transmembrane segment 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE ALPHA-SUBUNIT; SARCOPLASMIC-RETICULUM; COORDINATING RESIDUES; RENAL NA,K-ATPASE; ESCHERICHIA-COLI; K+ IONS; DOMAIN; YEAST; CA2+-ATPASE; ASP(804)	The plasma membrane H+-ATPase AHA2 ofArabidopsis thaliana, which belongs to the P-type ATPase superfamily of cation-transporting ATPases, pumps protons out of the cell, To investigate the mechanism of ion transport by P-type ATPases we have mutagenized Asp(684), a residue in transmembrane segment M6 of AHA2 that is conserved in Ca2+-, Na+/K+-, H+/K-, and H+-ATPases and which coordinates Ca2+ ions in the SERCA1 Ca2+-ATPase. We describe the expression, purification, and biochemical analysis of the Asp(684) -->Asn mutant, and provide evidence that Asp(684) in the plasma membrane H+-ATPase is required for any coupling between ATP hydrolysis, enzyme conformational changes, and H+-transport. Proton pumping by the reconstituted mutant enzyme was completely abolished, whereas ATP was still hydrolyzed, The mutant was insensitive to the inhibitor vanadate, which preferentially binds to P-type ATPases in the E-2 conformation. During catalysis the Asp684, Asn enzyme accumulated a phosphorylated intermediate whose stability was sensitive to addition of ADP. We conclude that the mutant enzyme is locked in the E-1 conformation and is unable to proceed through the E1P-E2P transition.	Royal Danish Vet & Agr Univ, Dept Plant Biol, DK-1871 Frederiksberg C, Denmark; Univ Politecn Valencia, Inst Biol Mol & Celular Plantas, S-22012 Valencia, Spain	University of Copenhagen; Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Politecnica de Valencia; CSIC-UPV - Instituto de Biologia Molecular y Celular de Plantas (IBMCP)	Palmgren, MG (corresponding author), Royal Danish Vet & Agr Univ, Dept Plant Biol, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.	palmgren@biobase.dk	Venema, Kees/G-9558-2015; Palmgren, Michael/A-9808-2013	Venema, Kees/0000-0001-5177-6464; Palmgren, Michael/0000-0002-9982-6114				ADEBAYO AO, 1995, J BIOL CHEM, V270, P27812, DOI 10.1074/jbc.270.46.27812; Ambesi A, 2000, J BIOL CHEM, V275, P20545, DOI 10.1074/jbc.M001682200; Arguello JM, 1996, J BIOL CHEM, V271, P24610, DOI 10.1074/jbc.271.40.24610; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; Axelsen KB, 1999, BIOCHEMISTRY-US, V38, P7227, DOI 10.1021/bi982482l; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Briskin DP, 1998, PLANT PHYSIOL BIOCH, V36, P293, DOI 10.1016/S0981-9428(98)80043-0; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Dutra MB, 1998, J BIOL CHEM, V273, P17411, DOI 10.1074/jbc.273.28.17411; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Gatto C, 1999, J BIOL CHEM, V274, P13737, DOI 10.1074/jbc.274.20.13737; Gatto C, 1998, J BIOL CHEM, V273, P10578, DOI 10.1074/jbc.273.17.10578; Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jahn T, 1997, PLANT CELL, V9, P1805, DOI 10.1105/tpc.9.10.1805; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; Lanfermeijer FC, 1998, PROTEIN EXPRES PURIF, V12, P29, DOI 10.1006/prep.1997.0788; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Morsomme P, 2000, BBA-BIOMEMBRANES, V1465, P1, DOI 10.1016/S0005-2736(00)00128-0; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; Pedersen PA, 1997, FEBS LETT, V400, P206, DOI 10.1016/S0014-5793(96)01381-6; REGENBERG B, 1995, PLANT CELL, V7, P1655, DOI 10.1105/tpc.7.10.1655; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VanHuysse JW, 1996, FEBS LETT, V389, P179, DOI 10.1016/0014-5793(96)00578-9; VENEMA K, 1995, J BIOL CHEM, V270, P19659, DOI 10.1074/jbc.270.33.19659; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; Vilsen B, 1997, BIOCHEMISTRY-US, V36, P13312, DOI 10.1021/bi971030q; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	40	43	45	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39167	39173		10.1074/jbc.M007537200	http://dx.doi.org/10.1074/jbc.M007537200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995773	hybrid			2022-12-27	WOS:000165953100032
J	Davare, MA; Horne, MC; Hell, JW				Davare, MA; Horne, MC; Hell, JW			Protein phosphatase 2A is associated with class C L-type calcium channels (Ca(v)1.2) and antagonizes channel phosphorylation by cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE PHOSPHATASES; D-ASPARTATE RECEPTOR; NEURONAL CLASS-C; CA2+ CHANNELS; HIPPOCAMPAL-NEURONS; DIFFERENTIAL PHOSPHORYLATION; BETA(2)-ADRENERGIC RECEPTORS; CHANNEL-ALPHA-1 SUBUNITS; CATALYTIC SUBUNIT; SIGNALING COMPLEX	Phosphorylation by cAMP-dependent protein kinase (PKA) regulates a vast number of cellular functions. An important target for PKA in brain and heart is the class C L-type Ca2+ channel (Ca(v)1.2). PKA phosphorylates serine 1928 in the central, pore-forming alpha (1C) subunit of this channel. Regulation of channel activity by PRA requires a proper balance between phosphorylation and dephosphorylation. For hat and specific signaling, PKA is recruited to this channel by an protein kinase A anchor protein (Davare, M. A, Dong, F., Rubin, C. S., and Hell, J.W (1999) J. Biol. Chem. 274, 39280-39287), A phosphatase may be associated with the channel to effectively balance serine 1928 phosphorylation by channel-bound PKA Dephosphorylation of this site is mediated by a serine/threonine phosphatase that is inhibited by okadaic acid and microcystin. We show that immunoprecipitation of the channel complex hom rat brain results in coprecipitation of PP2A Stoichiometric: analysis indicates that about 80% of the channel complexes contain PP2A PP2A directly and stably binds to the C-terminal 557 amino acids of alpha (1C). This interaction does not depend on serine 1928 phosphorylation and is not altered by PP2A catalytic site inhibitors. These results indicate that the PP2A-alpha (1C) interaction constitutively recruits PP2A to the channel complex rather than being a transient substrate-catalytic site interaction. Functional assays with the immunoisolated class C channel complex showed that channel-associated PP2A effectively reverses serine 1928 phosphorylation by endogenous PHA. Our findings demonstrate that both PKA and PP2A are integral components of the class C L-type Ca2+ channel that determine the phosphorylation level of serine 1928 and thereby channel activity.	Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Hell, JW (corresponding author), Univ Wisconsin, Dept Pharmacol, 3770 MSC,1300 Univ Ave, Madison, WI 53706 USA.	jwhell@facstaff.wisc.edu	Hell, Johannes W./P-5085-2019	Davare, Monika/0000-0003-1802-7597; Horne, Mary/0000-0002-2799-3212	NIA NIH HHS [R01-AG17502] Funding Source: Medline; NIGMS NIH HHS [R01-GM56900] Funding Source: Medline; NINDS NIH HHS [R01-NS35563] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017502] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baharians Z, 1998, J BIOL CHEM, V273, P19019, DOI 10.1074/jbc.273.30.19019; BEAN BP, 1984, NATURE, V307, P371, DOI 10.1038/307371a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; Bunemann M, 1999, J BIOL CHEM, V274, P33851, DOI 10.1074/jbc.274.48.33851; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Cheng Q, 1996, BIOCHEMISTRY-US, V35, P15593, DOI 10.1021/bi960709b; Christie BR, 1997, J NEUROPHYSIOL, V77, P1651, DOI 10.1152/jn.1997.77.3.1651; COEN DM, 1997, CURRENT PROTOCOLS MO, V2; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1991, METHOD ENZYMOL, V201, P389; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; Davare MA, 1999, J BIOL CHEM, V274, P30280, DOI 10.1074/jbc.274.42.30280; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; Fraser IDC, 2000, CURR BIOL, V10, P409, DOI 10.1016/S0960-9822(00)00419-X; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gerhardstein BL, 2000, J BIOL CHEM, V275, P8556, DOI 10.1074/jbc.275.12.8556; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Gray PC, 1998, CURR OPIN NEUROBIOL, V8, P330, DOI 10.1016/S0959-4388(98)80057-3; Groschner K, 1996, BIOCHEM J, V318, P513, DOI 10.1042/bj3180513; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; Gupta V, 1997, J MED CHEM, V40, P3199, DOI 10.1021/jm960873x; HELL JW, 1995, EMBO J, V14, P3036, DOI 10.1002/j.1460-2075.1995.tb07306.x; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; Hell JW, 1996, P NATL ACAD SCI USA, V93, P3362, DOI 10.1073/pnas.93.8.3362; HELL JW, 1993, J BIOL CHEM, V268, P19451; HELL JW, 1994, ANN NY ACAD SCI, V747, P282; HESS P, 1984, NATURE, V311, P538, DOI 10.1038/311538a0; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; Kamp TJ, 2000, AM J PHYSIOL-HEART C, V278, pH126, DOI 10.1152/ajpheart.2000.278.1.H126; KINGSTON RE, 1997, CURRENT PROTOCOLS MO; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; Marrion NV, 1998, NATURE, V395, P900, DOI 10.1038/27674; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; OMALLEY RP, 1986, CELL, V44, P391, DOI 10.1016/0092-8674(86)90460-5; ONO K, 1993, J PHYSIOL-LONDON, V470, P73, DOI 10.1113/jphysiol.1993.sp019848; ONO K, 1992, J PHYSIOL-LONDON, V454, P673, DOI 10.1113/jphysiol.1992.sp019286; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCULPTOREANU A, 1993, P NATL ACAD SCI USA, V90, P10135, DOI 10.1073/pnas.90.21.10135; Seibold A, 1998, J BIOL CHEM, V273, P7637, DOI 10.1074/jbc.273.13.7637; SHENOLIKAR S, 1984, METHOD ENZYMOL, V107, P102; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; USUI H, 1988, J BIOL CHEM, V263, P3752; VALLEE RB, 1981, J CELL BIOL, V90, P568, DOI 10.1083/jcb.90.3.568; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; WEI XY, 1994, J BIOL CHEM, V269, P1635; WERA S, 1995, J BIOL CHEM, V270, P21374, DOI 10.1074/jbc.270.36.21374; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; WIECHEN K, 1995, J PHYSIOL-LONDON, V484, P583, DOI 10.1113/jphysiol.1995.sp020688; Yan Z, 1999, NAT NEUROSCI, V2, P13, DOI 10.1038/4516	70	138	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39710	39717		10.1074/jbc.M005462200	http://dx.doi.org/10.1074/jbc.M005462200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10984483	hybrid			2022-12-27	WOS:000165953100100
J	Votsch, W; Templin, MF				Votsch, W; Templin, MF			Characterization of a beta-N-acetylglucosaminidase of Escherichia coli and elucidation of its role in muropeptide recycling and beta-lactamase induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL PEPTIDES; LYTIC TRANSGLYCOSYLASE; MUREIN SACCULUS; MOLECULAR-CLONING; D-GLUCOSAMINIDASE; GENE; GROWTH; AMPD; IDENTIFICATION; PROTEIN-7/8	Using the known mapping position the gene encoding a beta -1,4-N-acetylglucosaminidase needed for the degradation of muropeptides could be identified, nagZ encodes a cytosolic enzyme active on N-actylglucosamyl-beta -1,4-(1,6)-anhydromuramic acid containing muropeptides. These degradation products of the peptidoglycan are formed during the enlargement of the murein sacculus as a consequence of a growth mechanism, which couples the controlled degradation of the cell wall polymer with the insertion of new material. NagZ is needed for the formation of monosaccharides from the released disaccharides during the cytosolic steps of the muropeptide-recycling pathway. The formation of intracellular 1,6-anhydro-N-acetylmuramyl-peptides is important for the expression control of the inducible beta -lactamases of the AmpC type. A mutant lacking active NagZ cannot establish AmpC mediated beta -lactam resistance. The biochemical characterization of the enzyme showed its activity on different muropeptides and inhibitors of enzyme activity could be identified, This observation might be important for designing inhibitors of NagZ that could prevent the establishment of beta -lactam resistance of Enterobacteria possessing inducible beta -lactamases.	Max Planck Inst Entwicklungsbiol, Biochem Abt, D-72076 Tubingen, Germany	Max Planck Society	Templin, MF (corresponding author), Univ Tubingen, NMI, Markwiesenstr 55, D-72770 Reutlingen, Germany.	Templin@nmi.de						Altschul SF, 1998, TRENDS BIOCHEM SCI, V23, P444, DOI 10.1016/S0968-0004(98)01298-5; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BISSWANGER H, 1994, ENZYMKINETIK; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Chitlaru E, 1996, J BIOL CHEM, V271, P33433, DOI 10.1074/jbc.271.52.33433; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; GOODELL EW, 1985, J BACTERIOL, V162, P391, DOI 10.1128/JB.162.1.391-397.1985; GOODELL EW, 1987, J BACTERIOL, V169, P3861, DOI 10.1128/jb.169.8.3861-3865.1987; GOODELL EW, 1985, J BACTERIOL, V163, P305, DOI 10.1128/JB.163.1.305-310.1985; Holtje JV, 1996, MICROBIOL-SGM, V142, P1911, DOI 10.1099/13500872-142-8-1911; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; HOLTJE JV, 1975, J BACTERIOL, V124, P1067; HOLTJE JV, 1994, FEMS MICROBIOL LETT, V122, P159, DOI 10.1111/j.1574-6968.1994.tb07159.x; HOLTJE JV, 1995, ARCH MICROBIOL, V164, P243, DOI 10.1007/s002030050261; HREBENDA J, 1979, ACTA MICROBIOL POL, V28, P53; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Jacobs C, 1997, CELL, V88, P823, DOI 10.1016/S0092-8674(00)81928-5; JACOBS C, 1995, MOL MICROBIOL, V15, P553, DOI 10.1111/j.1365-2958.1995.tb02268.x; JACOBS C, 1994, EMBO J, V13, P4684, DOI 10.1002/j.1460-2075.1994.tb06792.x; Jacobs C, 1997, SCIENCE, V278, P1731, DOI 10.1126/science.278.5344.1731b; KECK W, 1990, MOL MICROBIOL, V4, P209, DOI 10.1111/j.1365-2958.1990.tb00588.x; KOHLRAUSCH U, 1991, J BACTERIOL, V173, P3425, DOI 10.1128/jb.173.11.3425-3431.1991; KOPP U, 1993, ANTIMICROB AGENTS CH, V37, P224, DOI 10.1128/AAC.37.2.224; KORAT B, 1991, MOL MICROBIOL, V5, P675, DOI 10.1111/j.1365-2958.1991.tb00739.x; Kraft AR, 1999, J BACTERIOL, V181, P7192, DOI 10.1128/JB.181.23.7192-7198.1999; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; MenginLecreulx D, 1996, J BACTERIOL, V178, P5347, DOI 10.1128/jb.178.18.5347-5352.1996; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; PARK JT, 1993, J BACTERIOL, V175, P7, DOI 10.1128/JB.175.1.7-11.1993; PARK JT, 1995, MOL MICROBIOL, V17, P421, DOI 10.1111/j.1365-2958.1995.mmi_17030421.x; Park JT, 1996, MICROB DRUG RESIST, V2, P105, DOI 10.1089/mdr.1996.2.105; Park JT, 1998, J BACTERIOL, V180, P1215, DOI 10.1128/JB.180.5.1215-1223.1998; ROMEIS T, 1994, J BIOL CHEM, V269, P21603; ROMEIS T, 1994, EUR J BIOCHEM, V224, P597, DOI 10.1111/j.1432-1033.1994.00597.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; TEMPLIN MF, 1992, J BIOL CHEM, V267, P20039; Templin MF, 1999, EMBO J, V18, P4108, DOI 10.1093/emboj/18.15.4108; THUNNISSEN AMWH, 1995, PROTEINS, V22, P245, DOI 10.1002/prot.340220305; Vocadlo DJ, 2000, BIOCHEMISTRY-US, V39, P117, DOI 10.1021/bi991958d; Vollmer W, 1999, J BIOL CHEM, V274, P6726, DOI 10.1074/jbc.274.10.6726; WEIDEL W, 1964, ADV ENZYMOL REL S BI, V26, P193; Wiedemann B, 1998, CLIN INFECT DIS, V27, pS42, DOI 10.1086/514921; Yang M, 1996, MICROBIOL-SGM, V142, P1659, DOI 10.1099/13500872-142-7-1659; YEM DW, 1976, J BACTERIOL, V125, P324, DOI 10.1128/JB.125.1.324-331.1976; YEM DW, 1976, J BACTERIOL, V125, P372, DOI 10.1128/JB.125.1.372-373.1976	48	102	103	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39032	39038		10.1074/jbc.M004797200	http://dx.doi.org/10.1074/jbc.M004797200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10978324	hybrid			2022-12-27	WOS:000165953100014
J	Barthelmes, HU; Grue, P; Feineis, S; Straub, T; Boege, F				Barthelmes, HU; Grue, P; Feineis, S; Straub, T; Boege, F			Active DNA topoisomerase II alpha is a component of the salt-stable centrosome core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; PROTEIN-KINASE; HEAT-SHOCK; EXPRESSION; ORGANIZATION; ASSOCIATION; MITOSIS; TISSUES; KI-S1	Recently, we reported that the monoclonal antibody specific for human DNA topoisomerase II alpha, Ki-S1, stains not only the nuclei of human A431 cells but also extranuclear structures suggestive of centrosomes (Meyer, K. N., Kjeldsen, E., Straub, T., Knudsen, B. K., Kikuchi, A., Hickson, I. D., Kreipe, H., and Boege, F. (1997) J. Cell Biol. 136, 775-788). Here, we confirm colocalization of Ki-S1 with the centrosomal marker gamma -tubulin. In addition, we show labeling of centrosomes by peptide antibodies against the N and C termini of human topoisomerase II alpha. Probing Western blots of isolated centrosomes with topoisomerase II alpha antibodies, we demonstrate a protein band of 170 kDa. Moreover, isolated centrosomes exhibited DNA decatenation and relaxation activity correlated to the amount of topoisomerase II alpha protein in the same way as seen in the pure recombinant enzyme. Topoisomerase II alpha epitopes could not be removed from centrosomes by salt extraction, DNase treatment, or RNase treatment, procedures that completely removed the enzyme from nuclei. Taken together, these observations suggest that active topoisomerase II alpha is bound tightly to the centrosome in a DNA-independent manner. Because such centrosomal topoisomerase II alpha was also present in quiescent lymphocytes devoid of topoisomerase II alpha in the nuclei, we assume that it might be a long-lived storage form.	Univ Wurzburg, Med Poliklin, D-97070 Wurzburg, Germany	University of Wurzburg	Boege, F (corresponding author), Univ Wurzburg, Med Poliklin, Klin Str 6, D-97070 Wurzburg, Germany.		Boege, Fritz/H-3261-2019; Straub, Tobias/B-2023-2009	Straub, Tobias/0000-0002-0547-0453				Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; BOEGE F, 1995, AM J PATHOL, V146, P1302; BORNENS M, 1987, CELL MOTIL CYTOSKEL, V8, P238, DOI 10.1002/cm.970080305; BOVERI T, 1901, JENA Z MED NATURWISS, V28, P1; Brown CR, 1996, J BIOL CHEM, V271, P833, DOI 10.1074/jbc.271.2.833; Chaly N, 1996, CHROMOSOME RES, V4, P457, DOI 10.1007/BF02265053; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Gieseler F., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P209; Goswami PC, 1996, MOL CELL BIOL, V16, P1500; Grue P, 1998, J BIOL CHEM, V273, P33660, DOI 10.1074/jbc.273.50.33660; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Isaacs RJ, 1996, J BIOL CHEM, V271, P16741, DOI 10.1074/jbc.271.28.16741; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; KREIPE H, 1993, AM J PATHOL, V142, P3; KUBO T, 1995, CANCER RES, V55, P3860; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; MELLER VH, 1994, J CELL BIOL, V126, P1331, DOI 10.1083/jcb.126.6.1331; Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Pietromonaco SF, 1996, BLOOD CELL MOL DIS, V22, P225, DOI 10.1006/bcmd.1996.0103; Schmidt PH, 1999, J BIOL CHEM, V274, P3055, DOI 10.1074/jbc.274.5.3055; Stearns T, 1997, CELL, V91, P303, DOI 10.1016/S0092-8674(00)80414-6; SUMNER AT, 1996, CHROMOSOME RES, V4, P4; Turley H, 1997, BRIT J CANCER, V75, P1340, DOI 10.1038/bjc.1997.227; Warburton PE, 1997, BIOESSAYS, V19, P97, DOI 10.1002/bies.950190203; Wigley WC, 1999, J CELL BIOL, V145, P481; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; Yang X, 2000, SCIENCE, V287, P131, DOI 10.1126/science.287.5450.131; Young A, 2000, MOL BIOL CELL, V11, P2047, DOI 10.1091/mbc.11.6.2047; Zimmerman W, 1999, CURR OPIN CELL BIOL, V11, P122, DOI 10.1016/S0955-0674(99)80015-5	35	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38823	38830		10.1074/jbc.M007044200	http://dx.doi.org/10.1074/jbc.M007044200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11006289	hybrid			2022-12-27	WOS:000165739800093
J	O'Donnell, VB; Coles, B; Lewis, MJ; Crews, BC; Marnett, LJ; Freeman, BA				O'Donnell, VB; Coles, B; Lewis, MJ; Crews, BC; Marnett, LJ; Freeman, BA			Catalytic consumption of nitric oxide by prostaglandin H synthase-1 regulates platelet function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE SYNTHASE; HYDROGEN-PEROXIDE; ARACHIDONIC-ACID; RELAXING FACTOR; RABBIT AORTA; RELEASE; FLAVOHEMOGLOBIN; PEROXYNITRITE; AGGREGATION; ACTIVATION	Nitric oxide ((NO)-N-.) plays a central role in vascular homeostasis via regulation of smooth muscle relaxation and platelet aggregation. Although mechanisms for (NO)-N-. formation are well known, removal pathways are less well characterized, particularly in cells that respond to (NO)-N-. through activation of soluble guanylate cyclase. Herein, we report that (NO)-N-. is catalytically consumed by prostaglandin H synthase-1 (PGHS-1) through acting as a reducing peroxidase substrate. With purified ovine PGHS-1, (NO)-N-. consumption requires peroxide (LOOH or H2O2), with a K-m ((app)) for 15(S)hydroperoxyeicosatetraenoic acid (HPETE) of 3.27 +/- 0.35 muM. During this, 2 mol (NO)-N-. are consumed per mol HPETE, and loss of HPETE hydroperoxy group occurs with retention of the conjugated diene spectrum. Hydroperoxide-stimulated (NO)-N-. consumption requires heme incorporation, is not inhibited by indomethacin, and is further stimulated by the reducing peroxidase substrate, phenol. PGHS-1-dependent (NO)-N-. consumption also occurs during arachidonate, thrombin, or A23187 activation of platelets (1-2 muM.min(-1) for typical plasma platelet concentrations) and prevents (NO)-N-. stimulation of platelet soluble guanylate cyclase. Platelet sensitivity to (NO)-N-. as an inhibitor of aggregation is greater using a platelet-activating stimulus (U46619) that does not cause (NO)-N-. consumption, indicating that this mechanism overcomes the anti-aggregatory effects of (NO)-N-., Catalytic consumption of (NO)-N-. during eicosanoid synthesis thus represents both a novel pro-aggregatory function for PGHS-1 and a regulated mechanism for vascular (NO)-N-. removal.	Cardiff Univ, Wales Heart Res Inst, Cardiff CF4 4XN, S Glam, Wales; Vanderbilt Univ, Sch Med, Dept Biochem, Ctr Mol Toxicol, Nashville, TN 37232 USA; Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Biochem, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Mol Genet, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35233 USA	Cardiff University; Vanderbilt University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	O'Donnell, VB (corresponding author), Cardiff Univ, Wales Heart Res Inst, Heath Pk, Cardiff CF4 4XN, S Glam, Wales.	o-donnellvb@cardiff.ac.uk	Freeman, Bruce A/H-9342-2012; O'Donnell, Valerie/C-6948-2012	/0000-0003-4089-8460	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064937, P60HL058418, R01HL058115] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL58115, R01HL64937, P6HL58418] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKKERMAN JWN, 1979, ANAL BIOCHEM, V97, P387, DOI 10.1016/0003-2697(79)90090-3; AUERBACH BJ, 1992, ANAL BIOCHEM, V201, P375, DOI 10.1016/0003-2697(92)90354-A; BALDUINI CL, 1988, BIOCHEM BIOPH RES CO, V156, P823; Caccese D, 2000, THROMB HAEMOSTASIS, V83, P485, DOI 10.1055/s-0037-1613841; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; Curtis JF, 1996, ARCH BIOCHEM BIOPHYS, V335, P369, DOI 10.1006/abbi.1996.0518; Freedman JE, 1997, J CLIN INVEST, V100, P350, DOI 10.1172/JCI119540; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; GASSAMADIAGNE A, 1992, J LIPID MEDIATOR, V5, P61; Glover RE, 1999, NITRIC OXIDE-BIOL CH, V3, P439, DOI 10.1006/niox.1999.0256; Goodwin DC, 1999, FASEB J, V13, P1121, DOI 10.1096/fasebj.13.10.1121; Goodwin DC, 1998, J BIOL CHEM, V273, P8903, DOI 10.1074/jbc.273.15.8903; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; IGNARRO LJ, 1988, J PHARMACOL EXP THER, V246, P218; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; Ischiropoulos H, 1996, FREE RADICAL BIO MED, V20, P373, DOI 10.1016/0891-5849(95)02098-5; KELM M, 1990, CIRC RES, V66, P1561, DOI 10.1161/01.RES.66.6.1561; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; LANTOINE F, 1995, BIOCHEM BIOPH RES CO, V215, P842, DOI 10.1006/bbrc.1995.2540; Liao JC, 1999, P NATL ACAD SCI USA, V96, P8757, DOI 10.1073/pnas.96.15.8757; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V194, P960, DOI 10.1006/bbrc.1993.1914; MALLE E, 1987, PROSTA LEUKOTR MED, V27, P53, DOI 10.1016/0262-1746(87)90059-X; Marnett L. J., 1991, PEROXIDASES CHEM BIO, V1, P293; MARNETT LJ, 1984, MOL PHARMACOL, V26, P328; McNicol A., 1996, PRACT APPROACH SER, P1; MINOR RL, 1990, J CLIN INVEST, V86, P2109, DOI 10.1172/JCI114949; O'Donnell VB, 1999, J BIOL CHEM, V274, P20083, DOI 10.1074/jbc.274.29.20083; ODENWALLER R, 1990, METHOD ENZYMOL, V187, P479; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Pigazzi A, 1999, J BIOL CHEM, V274, P14368, DOI 10.1074/jbc.274.20.14368; Pignatelli P, 1998, BLOOD, V91, P484, DOI 10.1182/blood.V91.2.484.484_484_490; RADOMSKI MW, 1992, BRIT J PHARMACOL, V107, P745, DOI 10.1111/j.1476-5381.1992.tb14517.x; SANE DC, 1989, BIOCHEM BIOPH RES CO, V165, P708, DOI 10.1016/S0006-291X(89)80024-5; SCHAFER AI, 1982, BIOCHIM BIOPHYS ACTA, V712, P535, DOI 10.1016/0005-2760(82)90281-8; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; STAMLER JS, 1996, METHODS NITRIC OXIDE, P521; TSAI AL, 1994, ARCH BIOCHEM BIOPHYS, V313, P367, DOI 10.1006/abbi.1994.1400; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; VARGAS JR, 1982, PROSTAGLANDINS, V23, P929, DOI 10.1016/0090-6980(82)90135-6; VERBEUREN TJ, 1990, EUR J PHARMACOL, V191, P173, DOI 10.1016/0014-2999(90)94145-N; Wang GR, 1998, P NATL ACAD SCI USA, V95, P4888, DOI 10.1073/pnas.95.9.4888; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044	46	60	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38239	38244		10.1074/jbc.M001802200	http://dx.doi.org/10.1074/jbc.M001802200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10993875	hybrid			2022-12-27	WOS:000165739800016
J	Perdomo, J; Holmes, M; Chong, E; Crossley, M				Perdomo, J; Holmes, M; Chong, E; Crossley, M			Eos and Pegasus, two members of the Ikaros family of proteins with distinct DNA binding activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSCRIPTION FACTOR; HISTONE DEACETYLASE; CENTROMERIC HETEROCHROMATIN; LYMPHOCYTE DEVELOPMENT; GENE; EXPRESSION; REPRESSION; COMPLEXES; ISOFORMS	Members of the Ikaros family of transcription factors, Ikaros, Aiolos, and Hellos, are expressed in lymphocytes and have been implicated in controlling lymphoid development. These proteins contain two characteristic clusters of zinc fingers, an N-terminal domain important for DNA recognition, and a C-terminal domain that mediates homo- and heterotypic associations between family members. The conservation of these domains is such that all three proteins recognize related DNA sequences, and all are capable of dimerizing with other family members. Here we describe two additional Ikaros family proteins, Eos and Pegasus. Eos is most highly related to Hellos and shares its DNA binding and protein association properties. Pegasus is related to other Ikaros proteins in its C-terminal dimerization domain but contains a divergent N-terminal zinc finger domain, Pegasus self-associates and binds to other family members but recognizes distinct DNA-binding sites, Eos and Pegasus repress the expression of reporter genes containing their recognition elements. Our results suggest that these proteins may associate with previously described Ikaros family proteins in lymphoid cells and play additional roles in other tissues.	Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; Univ New S Wales, Sch Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia	University of Sydney; University of New South Wales Sydney	Crossley, M (corresponding author), Univ Sydney, Dept Biochem, G08, Sydney, NSW 2006, Australia.		Crossley, Merlin/D-7888-2011; Perdomo, Jose/H-8871-2019	Crossley, Merlin/0000-0003-2057-3642; Perdomo, Jose/0000-0002-1554-708X; Holmes, Melissa/0000-0001-5894-6649				Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Georgopoulos K, 1997, ANNU REV IMMUNOL, V15, P155, DOI 10.1146/annurev.immunol.15.1.155; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Hahm K, 1998, GENE DEV, V12, P782, DOI 10.1101/gad.12.6.782; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; Honma Y, 1999, FEBS LETT, V447, P76, DOI 10.1016/S0014-5793(99)00265-3; Hosokawa Y, 1999, IMMUNOGENETICS, V50, P106, DOI 10.1007/s002510050696; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kelley CM, 1998, CURR BIOL, V8, P508, DOI 10.1016/S0960-9822(98)70202-7; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; KLEVIT RE, 1991, SCIENCE, V253, P1367, DOI 10.1126/science.1896847; KLEVIT RE, 1991, SCIENCE, V253, P1393; Klug CA, 1998, P NATL ACAD SCI USA, V95, P657, DOI 10.1073/pnas.95.2.657; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Momeni P, 2000, NAT GENET, V24, P71, DOI 10.1038/71717; Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004; Nietfeld W, 1996, IMMUNOL LETT, V49, P139, DOI 10.1016/0165-2478(95)02479-4; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; Sambrook J., 2002, MOL CLONING LAB MANU; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Sun L, 1999, J CLIN ONCOL, V17, P3753, DOI 10.1200/JCO.1999.17.12.3753; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; Wang JH, 1998, IMMUNITY, V9, P543, DOI 10.1016/S1074-7613(00)80637-8; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	36	92	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38347	38354		10.1074/jbc.M005457200	http://dx.doi.org/10.1074/jbc.M005457200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10978333	hybrid			2022-12-27	WOS:000165739800030
J	Xiao, KH; Yu, L; Yu, CA				Xiao, KH; Yu, L; Yu, CA			Confirmation of the involvement of protein domain movement during the catalytic cycle of the cytochrome bc1 complex by the formation of an intersubunit disulfide bond between cytochrome b and the iron-sulfur protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER-SOLUBLE FRAGMENT; BC(1) COMPLEX; RHODOBACTER-SPHAEROIDES; BOVINE HEART; ELECTRON-TRANSFER; Q0 SITE; MITOCHONDRIAL; UBIQUINONE; CAPSULATUS; BINDING	To study the essentiality of head domain movement of the Rieske iron-sulfur protein (ISP) during bc(1) catalysis, Rhodobacter sphaeroides mutants expressing His-tagged cytochrome be, complexes with three pairs of cysteines engineered (one cysteine each) on the interface between cytochrome b and ISP, A185C(cytb)/K70C(ISP), I326C(cytb)/G165C(ISP), and T386C(cytb)/K164C(ISP), were generated and characterized. Formation of an intersubunit disulfide bond between cytochrome b and ISP is detected in membrane (intracytoplasmic membrane and air-aged chromatophore), and purified be, complex was prepared from the A185C(cytb)/K70C(ISP) mutant cells. Formation of the intersubunit disulfide bond in this cysteine pair mutant complex is concurrent with the loss of its be, activity. Reduction of this disulfide bond by P-mercaptoethanol restores activity, indicating that mobility of the head domain of ISP is functionally important in the cytochrome be, complex. The rate of intramolecular electron transfer, between 2Fe2S and heme c(1), in the A185C(cytb)/K70C(ISP) mutant complex is much lower than that in the wild type or in their respective single cysteine mutant complexes, indicating that formation of an intersubunit disulfide bond between cytochrome b and ISP arrests the head domain of ISP in the "fixed state" position, which is too far for electron transfer to heme c(1).	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Yu, CA (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.		Xiao, Kunhong/AAG-4275-2020	Xiao, Kunhong/0000-0002-1069-1226	NIGMS NIH HHS [GM30721] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS KM, 1990, BIOCHEMISTRY-US, V29, P2645, DOI 10.1021/bi00463a004; ATTAASAFOADJEI E, 1991, P NATL ACAD SCI USA, V88, P492, DOI 10.1073/pnas.88.2.492; BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3342, DOI 10.1021/bi00128a006; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; GRAY KA, 1992, BIOCHEMISTRY-US, V31, P11864, DOI 10.1021/bi00162a027; Guergova-Kuras M, 1999, PROTEIN EXPRES PURIF, V15, P370, DOI 10.1006/prep.1998.1018; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Link TA, 1996, EUR J BIOCHEM, V237, P71, DOI 10.1111/j.1432-1033.1996.0071n.x; Link TA, 1996, BIOCHEMISTRY-US, V35, P7546, DOI 10.1021/bi960004+; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHER MW, 1995, J BIOL CHEM, V270, P28668, DOI 10.1074/jbc.270.48.28668; MCCURLEY JP, 1990, BIOCHIM BIOPHYS ACTA, V1020, P176, DOI 10.1016/0005-2728(90)90049-A; MEINHARDT SW, 1987, J BIOL CHEM, V262, P8702; ROBERTSON DE, 1990, BIOCHEMISTRY-US, V29, P11249, DOI 10.1021/bi00503a014; Tian H, 1999, J BIOL CHEM, V274, P7146, DOI 10.1074/jbc.274.11.7146; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; Tian H, 1997, J BIOL CHEM, V272, P23722, DOI 10.1074/jbc.272.38.23722; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Tso SC, 2000, J BIOL CHEM, V275, P15287, DOI 10.1074/jbc.M907367199; Ugulava NB, 1998, FEBS LETT, V440, P409, DOI 10.1016/S0014-5793(98)01493-8; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YU CA, 1982, BIOCHEMISTRY-US, V21, P4096, DOI 10.1021/bi00260a028; YU L, 1986, BIOCHIM BIOPHYS ACTA, V852, P203, DOI 10.1016/0005-2728(86)90225-2; YU L, 1992, J BIOL CHEM, V267, P24508; Zhang L, 2000, J BIOL CHEM, V275, P7656, DOI 10.1074/jbc.275.11.7656; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	30	62	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38597	38604		10.1074/jbc.M007444200	http://dx.doi.org/10.1074/jbc.M007444200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10978350	hybrid			2022-12-27	WOS:000165739800062
J	Bogdanovic, A; Bruckert, F; Morio, T; Satre, M				Bogdanovic, A; Bruckert, F; Morio, T; Satre, M			A syntaxin 7 homologue is present in Dictyostelium discoideum endosomes and controls their homotypic fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TRANSPORT; SNARE COMPLEX; MAGNETIC FRACTIONATION; LYSOSOMAL-ENZYMES; MEMBRANE-FUSION; IN-VITRO; T-SNARE; YEAST; VACUOLE; ENDOCYTOSIS	Endo-phagocytic activity is prominent in Dictyostelium discoideum and makes it a good model organism to study the molecular organization of membrane traffic in this pathway. We have identified a syntaxin 7 homologue (26% identity and 54% similarity to human syntaxin 7) in Dictyostelium cDNA and genomic data banks. In addition to the Habc and H3 helices and the C-terminal transmembrane domain characteristic of syntaxins, this protein contains a repetitive N-terminal extension of 68 amino acids. We first showed that Dictyostelium syntaxin 7 was able to form a complex with N-ethylmaleimide-sensitive fusion protein and alpha- and gamma -soluble Nethylmaleimide-sensitive fusion protein attachment protein. Its intracellular localization was then studied by cell fractionation techniques and magnetic purification of the endocytic compartments. Most of D. discoideum syntaxin 7 is contained in endosomes. Finally, an in vitro endosome homotypic fusion assay (Laurent, O., Bruckert, F., Adessi, C., and Satre, M. (1998) J. Biol Chem. 273, 793-799) was used to study a possible role for syntaxin 7 in this process. Purified anti-syntaxin 7 antibodies and a recombinant soluble fragment of syntaxin 7 both strongly inhibited fusion activity, indicating that this protein was necessary for endosome-endosome fusion. These results demonstrate the importance of this syntaxin 7 homologue in the early phases of Dictyostelium endo-phagocytic pathway.	CEA Grenoble, UMR5092, BBSI, DBMS,Lab Biochim & Biophys Syst Integres, F-38054 Grenoble 09, France; Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3050006, Japan	CEA; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); University of Tsukuba	Bogdanovic, A (corresponding author), CEA Grenoble, UMR5092, BBSI, DBMS,Lab Biochim & Biophys Syst Integres, 17 Rue Martyrs, F-38054 Grenoble 09, France.	abogdanovic@cea.fr		MORIO, Takahiro/0000-0002-4007-881X				ADESSI C, 1995, J CELL SCI, V108, P3331; AUBRY L, 1993, J CELL SCI, V105, P861; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; Beinert H, 1978, Methods Enzymol, V54, P435; Bruckert F, 2000, PROTOPLASMA, V210, P108, DOI 10.1007/BF01276850; Buczynski G, 1997, MOL BIOL CELL, V8, P1343, DOI 10.1091/mbc.8.7.1343; Bush J, 1996, MOL BIOL CELL, V7, P1623, DOI 10.1091/mbc.7.10.1623; CARDELLI JA, 1990, DEV GENET, V11, P454, DOI 10.1002/dvg.1020110522; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; Dembinsky A, 1997, J BIOL CHEM, V272, P828, DOI 10.1074/jbc.272.2.828; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Gotte M, 1997, FEBS LETT, V411, P48, DOI 10.1016/S0014-5793(97)00575-9; Hackam DJ, 1996, J IMMUNOL, V156, P4377; Hacker U, 1997, J CELL SCI, V110, P105; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; HARLOW H, 1988, ANTIBODIES LAB MANUA, P313; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; Journet A, 1999, J CELL SCI, V112, P3833; Laurent O, 1998, J BIOL CHEM, V273, P793, DOI 10.1074/jbc.273.2.793; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Nakamura N, 2000, J BIOL CHEM, V275, P6523, DOI 10.1074/jbc.275.9.6523; NOLTA KV, 1994, J BIOL CHEM, V269, P2225; NOLTA KV, 1991, J BIOL CHEM, V266, P18318; NOLTA KV, 1994, BBA-MOL CELL RES, V1224, P237, DOI 10.1016/0167-4889(94)90196-1; PADH H, 1993, J BIOL CHEM, V268, P6742; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Pelham HRB, 1999, EXP CELL RES, V247, P1, DOI 10.1006/excr.1998.4356; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; PITT A, 1992, METHOD ENZYMOL, V219, P21; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Prekeris R, 1999, MOL BIOL CELL, V10, P3891, DOI 10.1091/mbc.10.11.3891; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; RODRIGUEZPARIS JM, 1993, J BIOL CHEM, V268, P9110; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sanderfoot AA, 1998, P NATL ACAD SCI USA, V95, P9920, DOI 10.1073/pnas.95.17.9920; Sato MH, 1997, J BIOL CHEM, V272, P24530, DOI 10.1074/jbc.272.39.24530; Seron K, 1998, MOL BIOL CELL, V9, P2873, DOI 10.1091/mbc.9.10.2873; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Subramaniam VN, 2000, J CELL SCI, V113, P997; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; THILO L, 1980, P NATL ACAD SCI-BIOL, V77, P1015, DOI 10.1073/pnas.77.2.1015; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Valdez AC, 1999, J CELL SCI, V112, P845; Wada Y, 1997, J CELL SCI, V110, P1299; Ward DM, 2000, MOL BIOL CELL, V11, P2327, DOI 10.1091/mbc.11.7.2327; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; Weber T, 2000, J CELL BIOL, V149, P1063, DOI 10.1083/jcb.149.5.1063; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weidenhaupt M, 2000, EUR J BIOCHEM, V267, P2062, DOI 10.1046/j.1432-1327.2000.01212.x; Wickner W, 2000, ANNU REV BIOCHEM, V69, P247, DOI 10.1146/annurev.biochem.69.1.247; Wong SH, 1998, J BIOL CHEM, V273, P375, DOI 10.1074/jbc.273.1.375	57	18	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36691	36697		10.1074/jbc.M006710200	http://dx.doi.org/10.1074/jbc.M006710200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10978342	hybrid			2022-12-27	WOS:000165577700035
J	Palmieri, L; Agrimi, G; Runswick, MJ; Fearnley, IM; Palmieri, F; Walker, JE				Palmieri, L; Agrimi, G; Runswick, MJ; Fearnley, IM; Palmieri, F; Walker, JE			Identification in Saccharomyces cerevisiae of two isoforms of a novel mitochondrial transporter for 2-oxoadipate and 2-oxoglutarate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; BACTERIAL EXPRESSION; FUNCTIONAL RECONSTITUTION; OXOGLUTARATE CARRIER; ALPHA-AMINOADIPATE; GENE-EXPRESSION; YEAST; PROTEINS; PURIFICATION; SEQUENCE	The nuclear genome of Saccharomyces cerevisiae encodes 35 members of a family of membrane proteins, Known members transport substrates and products across the inner membranes of mitochondria. We have localized two hitherto unidentified family members, Odc1p and Odc2p, to the inner membranes of mitochondria. They are isoforms with 61% sequence identity, and we have shown in reconstituted liposomes that they transport the oxodicarboxylates 2-oxoadipate and 2-oxoglutarate by a strict counter exchange mechanism. Intraliposomal adipate and glutarate and to a lesser extent malate and citrate supported [C-14]oxoglutarate uptake. The expression of Odc1p, the more abundant isoform, made in the presence of nonfermentable carbon sources, is repressed by glucose. The main physiological roles of Odc1p and Odc2p are probably to supply 2-oxoadipate and a-oxoglutarate from the mitochondrial matrix to the cytosol where they are used in the biosynthesis of lysine and glutamate, respectively, and in lysine catabolism.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2, England; Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, I-70125 Bari, Italy	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; Universita degli Studi di Bari Aldo Moro	Walker, JE (corresponding author), MRC, Dunn Human Nutr Unit, HIlls Rd, Cambridge CB2 2, England.	walker@mrc-dunn.cam.ac.uk	Agrimi, Gennaro/D-4001-2018; agrimi, gennaro/C-6020-2009	Agrimi, Gennaro/0000-0002-5219-4412; Walker, John/0000-0001-7929-2162				BHATTACHARJEE JK, 1985, CRC CR REV MICROBIOL, V12, P131, DOI 10.3109/10408418509104427; BISACCIA F, 1985, BIOCHIM BIOPHYS ACTA, V810, P362, DOI 10.1016/0005-2728(85)90222-1; CROMPTON M, 1974, BIOCHEM J, V142, P127, DOI 10.1042/bj1420127; DAUM G, 1982, J BIOL CHEM, V257, P3075; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; Fiermonte G, 1998, J BIOL CHEM, V273, P24754, DOI 10.1074/jbc.273.38.24754; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; GOODMAN SI, 1995, METABOLIC MOL BASIS, V1, P1451; HIGASHINO K, 1971, ARCH BIOCHEM BIOPHYS, V142, P606, DOI 10.1016/0003-9861(71)90525-X; HOLLENBERG CP, 1970, BIOCHIM BIOPHYS ACTA, V201, P13, DOI 10.1016/0304-4165(70)90004-8; KLINGENBERG M, 1975, EUR J BIOCHEM, V52, P351, DOI 10.1111/j.1432-1033.1975.tb04003.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MITCHELL AP, 1983, J BIOL CHEM, V258, P119; NIHIZUKA Y, 1970, METHOD ENZYMOL, V17, P463; Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3; PALMIERI F, 1972, EUR J BIOCHEM, V26, P587, DOI 10.1111/j.1432-1033.1972.tb01801.x; PALMIERI F, 1972, EUR J BIOCHEM, V29, P408, DOI 10.1111/j.1432-1033.1972.tb02003.x; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Palmieri Ferdinando, 1999, P489; Palmieri L, 1999, FEBS LETT, V462, P472, DOI 10.1016/S0014-5793(99)01555-0; Palmieri L, 1999, J BIOL CHEM, V274, P22184, DOI 10.1074/jbc.274.32.22184; Palmieri L, 2000, J BIOENERG BIOMEMBR, V32, P67, DOI 10.1023/A:1005564429242; Palmieri L, 1997, FEBS LETT, V417, P114, DOI 10.1016/S0014-5793(97)01269-6; Palmieri L, 1996, FEBS LETT, V399, P299, DOI 10.1016/S0014-5793(96)01350-6; PERKINS M, 1973, BIOCHEM J, V134, P923, DOI 10.1042/bj1340923; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Valenzuela L, 1998, J BACTERIOL, V180, P3533, DOI 10.1128/JB.180.14.3533-3540.1998; Walker J.E., 1992, CURR OPIN STRUC BIOL, V2, P519, DOI DOI 10.1016/0959-440X(92)90081-H; Zhao WN, 1996, BIOCHEMISTRY-US, V35, P7873, DOI 10.1021/bi9605189	31	87	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1916	1922		10.1074/jbc.M004332200	http://dx.doi.org/10.1074/jbc.M004332200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11013234	hybrid			2022-12-27	WOS:000166528000038
J	Armstrong, JL; Bonavaud, SM; Toole, BJ; Yeaman, SJ				Armstrong, JL; Bonavaud, SM; Toole, BJ; Yeaman, SJ			Regulation of glycogen synthesis by amino acids in cultured human muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; ACTIVATED PROTEIN-KINASE; RABBIT SKELETAL-MUSCLE; SYNTHASE KINASE-3; IN-VITRO; MAMMALIAN TARGET; PHOSPHOINOSITIDE 3-KINASE; INTACT-CELLS; INSULIN; PHOSPHORYLATION	Insulin and a number of metabolic factors stimulate glycogen synthesis and the enzyme glycogen synthase. Using human muscle cells we find that glycogen synthesis is stimulated by treatment of the cells with lithium ions, which inhibit glycogen synthase kinase 3. Insulin further stimulates glycogen synthesis in the presence of lithium ions, an effect abolished by wortmannin and rapamycin. We report also that amino acids stimulate glycogen synthesis and glycogen synthase, these effects also being blocked by rapamycin and wortmannin. Amino acids stimulate p70(s6k) and transiently inhibit glycogen synthase kinase 3 without effects on the activity of protein kinase B or the mitogen-activated protein kinase pathway. Thus, the work reported here demonstrates that amino acid availability can regulate glycogen synthesis. Furthermore, it demonstrates that glycogen synthase kinase 3 can be inactivated within cells independent of activation of protein kinase B and p90(rsk).	Univ Newcastle Upon Tyne, Sch Med, Sch Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Yeaman, SJ (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Sch Biochem & Genet, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Armstrong, Jane/0000-0002-5822-0597				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Campbell LE, 1999, BIOCHEM J, V344, P433, DOI 10.1042/0264-6021:3440433; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COHEN P, 1993, BIOCHEM SOC T, V21, P555, DOI 10.1042/bst0210555; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3; Halse R, 1999, J BIOL CHEM, V274, P776, DOI 10.1074/jbc.274.2.776; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hurel SJ, 1996, BIOCHEM J, V320, P871, DOI 10.1042/bj3200871; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Markuns JF, 1999, J BIOL CHEM, V274, P24896, DOI 10.1074/jbc.274.35.24896; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Peyrollier K, 2000, BIOCHEM J, V350, P361, DOI 10.1042/0264-6021:3500361; PRICE TB, 1994, J APPL PHYSIOL, V76, P104, DOI 10.1063/1.357116; Ryves WJ, 1998, ANAL BIOCHEM, V264, P124, DOI 10.1006/abio.1998.2832; Sanchez-Margalet V, 2000, J CELL PHYSIOL, V182, P182, DOI 10.1002/(SICI)1097-4652(200002)182:2<182::AID-JCP6>3.0.CO;2-X; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SKURAT AV, 1994, J BIOL CHEM, V269, P25534; SKURAT AV, 1995, J BIOL CHEM, V270, P12491, DOI 10.1074/jbc.270.21.12491; Skurat AV, 2000, DIABETES, V49, P1096, DOI 10.2337/diabetes.49.7.1096; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Sung CK, 1998, J RECEPT SIGNAL TR R, V18, P243, DOI 10.3109/10799899809047746; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; Welsh GI, 1997, ANAL BIOCHEM, V244, P16, DOI 10.1006/abio.1996.9838; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Withers DJ, 1997, BIOCHEM BIOPH RES CO, V241, P704, DOI 10.1006/bbrc.1997.7878	43	95	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					952	956		10.1074/jbc.M004812200	http://dx.doi.org/10.1074/jbc.M004812200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11013237	hybrid, Green Accepted			2022-12-27	WOS:000166430900014
J	Pucar, D; Janssen, E; Dzeja, PP; Juranic, N; Macura, S; Wieringa, B; Terzic, A				Pucar, D; Janssen, E; Dzeja, PP; Juranic, N; Macura, S; Wieringa, B; Terzic, A			Compromised energetics in the adenylate kinase AK1 gene knockout heart under metabolic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE K+ CHANNELS; ACTIVATED PROTEIN-KINASE; CREATINE-KINASE; CATALYZED PHOSPHOTRANSFER; PHOSPHORYL TRANSFER; SKELETAL-MUSCLE; ATP; ENERGY; MITOCHONDRIAL; ADENOSINE	Rapid exchange of high energy carrying molecules between intracellular compartments is essential in sustaining cellular energetic homeostasis, Adenylate kinase (AK)-catalyzed transfer of adenine nucleotide beta- and gamma -phosphoryls has been implicated in intracellular energy communication and nucleotide metabolism. To demonstrate the significance of this reaction in cardiac energetics, phosphotransfer dynamics were determined by [O-18]phosphoryl oxygen analysis using P-31 NMR and mass spectrometry. In hearts with a null mutation of the AK1 gene, which encodes the major AK isoform, total AX activity and beta -phosphoryl transfer was reduced by 94% and 36%, respectively. This was associated with up-regulation of phosphoryl flux through remaining minor AK isoforms and the glycolytic phosphotransfer enzyme, S-phosphoglycerate kinase, In the absence of metabolic stress, deletion of AK1 did not translate into gross abnormalities in nucleotide levels, gamma -ATP turnover rate or creatine kinase-catalyzed phosphotransfer. However, under hypoxia AK1-deficient hearts, compared with the wild type, had a blunted AK-catalyzed phosphotransfer response, lowered intracellular ATP levels, increased P-i/ATP ratio, and suppressed generation of adenosine, Thus, although lack of AK1 phosphotransfer can be compensated in the absence of metabolic challenge, under hypoxia AK1-knockout hearts display compromised energetics and impaired cardioprotective signaling, This study, therefore, provides first direct evidence that AK1 is essential in maintaining myocardial energetic homeostasis, in particular under metabolic stress.	Mayo Clin, Div Cardiovasc Dis, Dept Med, Rochester, MN 55905 USA; Mayo Clin, Div Cardiovasc Dis, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin, Div Cardiovasc Dis, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Univ Nijmegen, Dept Cell Biol, Med Ctr, NL-6525 Nijmegen, Netherlands	Mayo Clinic; Mayo Clinic; Mayo Clinic; Radboud University Nijmegen	Terzic, A (corresponding author), Mayo Clin, Div Cardiovasc Dis, Dept Med, Guggenheim 7, Rochester, MN 55905 USA.		Wieringa, Berend/A-5346-2011	Wieringa, Berend/0000-0001-9192-8020	NHLBI NIH HHS [HL64822, HL07111] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064822] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; Bienengraeber M, 2000, FASEB J, V14, P1943, DOI 10.1096/fj.00-0027com; Boyer P.D, 1973, ENZYMES, P279; COHN M, 1978, P NATL ACAD SCI USA, V75, P200, DOI 10.1073/pnas.75.1.200; Colowick SP, 1943, J BIOL CHEM, V148, P117; Dougherty C, 1998, FASEB J, V12, P1785, DOI 10.1096/fasebj.12.15.1785; Dzeja P P, 2000, Curr Cardiol Rep, V2, P212, DOI 10.1007/s11886-000-0071-9; Dzeja PP, 1996, J BIOL CHEM, V271, P12847, DOI 10.1074/jbc.271.22.12847; Dzeja PP, 1999, CIRC RES, V84, P1137, DOI 10.1161/01.RES.84.10.1137; Dzeja PP, 1999, MOL CELL BIOCHEM, V201, P33, DOI 10.1023/A:1007016703229; Dzeja PP, 1998, MOL CELL BIOCHEM, V184, P169, DOI 10.1023/A:1006859632730; Dzeja PP, 1998, FASEB J, V12, P523, DOI 10.1096/fasebj.12.7.523; ElvirMairena JR, 1996, J BIOL CHEM, V271, P31903, DOI 10.1074/jbc.271.50.31903; Gross GJ, 1999, CIRC RES, V84, P973, DOI 10.1161/01.RES.84.9.973; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; HIMORI N, 1993, PSYCHOPHARMACOLOGY, V111, P153, DOI 10.1007/BF02245517; Ingwall J S, 1980, Methods Cell Biol, V21A, P167, DOI 10.1016/S0091-679X(08)60765-7; JANSSEN E, 2000, IN PRESS EMBO J, V19; Jovanovic A, 1998, ANN THORAC SURG, V65, P586, DOI 10.1016/S0003-4975(97)01240-X; Jovanovic A, 1998, CIRCULATION, V98, P1548, DOI 10.1161/01.CIR.98.15.1548; Jovanovic N, 1999, FASEB J, V13, P923, DOI 10.1096/fasebj.13.8.923; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Kitakaze M, 1999, JPN CIRC J, V63, P231, DOI 10.1253/jcj.63.231; KLETHI J, 1968, NATURE, V218, P467, DOI 10.1038/218467a0; Kloner RA, 1998, CIRCULATION, V97, P1848, DOI 10.1161/01.CIR.97.18.1848; KONRAD M, 1993, J BIOL CHEM, V268, P11326; KROLL K, 1993, CIRC RES, V73, P846, DOI 10.1161/01.RES.73.5.846; KUBO S, 1974, EUR J BIOCHEM, V48, P325, DOI 10.1111/j.1432-1033.1974.tb03772.x; Laterveer FD, 1997, MOL CELL BIOCHEM, V174, P43, DOI 10.1023/A:1006899621926; Loh E, 1999, CIRCULATION, V99, P1422, DOI 10.1161/01.CIR.99.11.1422; Nascimben L, 1996, CIRCULATION, V94, P1894, DOI 10.1161/01.CIR.94.8.1894; Neubauer S, 1997, CIRCULATION, V96, P2190; Olson LK, 1996, J BIOL CHEM, V271, P16544, DOI 10.1074/jbc.271.28.16544; OROURKE JF, 1996, J PHARM, V24, P403; Saks VA, 1996, MOL CELL BIOCHEM, V161, P195, DOI 10.1007/BF00240050; Saupe KW, 1998, CIRC RES, V82, P898; SCHULZ GE, 1987, COLD SPRING HARB SYM, V52, P429, DOI 10.1101/SQB.1987.052.01.050; Shen WQ, 1999, CIRCULATION, V100, P2113, DOI 10.1161/01.CIR.100.20.2113; Steeghs K, 1998, MOL CELL BIOCHEM, V184, P183, DOI 10.1023/A:1006811717709; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; TANABE T, 1993, J BIOCHEM-TOKYO, V113, P200, DOI 10.1093/oxfordjournals.jbchem.a124026; Terzic A, 1999, CLIN PHARMACOL THER, V66, P105, DOI 10.1053/cp.1999.v66.99991; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; Ventura-Clapier R, 1998, MOL CELL BIOCHEM, V184, P231, DOI 10.1023/A:1006840508139; Williams JP, 1996, BBA-BIOENERGETICS, V1276, P71, DOI 10.1016/0005-2728(96)00036-9; ZELEZNIKAR RJ, 1990, J BIOL CHEM, V265, P300; ZELEZNIKAR RJ, 1995, J BIOL CHEM, V270, P7311, DOI 10.1074/jbc.270.13.7311	48	72	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41424	41429		10.1074/jbc.M007903200	http://dx.doi.org/10.1074/jbc.M007903200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11006295	hybrid, Green Published			2022-12-27	WOS:000166114600100
J	Ingram, AJ; James, L; Cai, L; Thai, K; Ly, H; Scholey, JW				Ingram, AJ; James, L; Cai, L; Thai, K; Ly, H; Scholey, JW			NO inhibits stretch-induced MAPK activity by cytoskeletal disruption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ACTIVATED PROTEIN-KINASES; FOCAL ADHESION KINASE; RAT MESANGIAL CELLS; GLOMERULAR INJURY; EXTRACELLULAR-MATRIX; DIETARY SUPPLEMENTATION; SIGNAL-TRANSDUCTION; MECHANICAL STRAIN; ACTIN-FILAMENTS	Mesangial cells (MC) grown on extracellular matrix protein-coated plates and exposed to cyclic strain/relaxation proliferate and produce extracellular matrix protein, providing an in vitro model of signaling in stretched MC, Intracellular transduction of mechanical strain involves mitogen-activated protein kinases, and we have shown that p42/44 mitogen-activated protein kinase (extracellular signal-regulated kinase (ERK)) is activated by cyclic strain in MC,ln vivo studies show that increased production of nitric oxide (NO) in the remnant kidney limits glomerular injury without reducing glomerular capillary pressure, and we have observed that NO attenuates stretch-induced ERK activity in MC via generation of cyclic guanosine monophosphate (cGMP), Accordingly, we sought to determine whether NO affects strain-induced ERK activity after strain and how this is mediated. Strain-induced ERK activity was dependent on time and magnitude of stretch and was maximal after 10 min at -27 kilopascals, Actin cytoskeleton disruption with cytochalasin D abrogated this. The non-metabolizable cGMP analogue 8-bromo cyclic GMP (8-Br-cGMP) dose-dependently attenuated strain-induced ERK activity. Cytoskeletal stabilization with jas-plakinolide prevented this inhibitory effect of 8-Br-cGMP, Cyclic strain increased nuclear translocation of phospho-ERK by immunofluorescent microscopy, again attenuated by 8-Br-cGMP. Jasplakinolide prevented the inhibitory effect of 8-Br-cGMP on activated ERK nuclear translocation after strain. Strain increased ERK-dependent AP-1 nuclear protein binding, which was attenuated by cytochalasin D and 8-Br-cGMP, These data indicate that cGMP can inhibit cyclic strain-induced ERK activity, nuclear translocation, and AP-1 nuclear protein binding. Cytoskeletal disruption leads to the same effect, whereas cytoskeleton stabilization reverses the effect of 8-Br-cGMP, Thus, NO inhibits strain-induced ERK activity by cytoskeletal destabilization.	McMaster Univ, Dept Med, Hamilton, ON L8N 1Y2, Canada; Univ Toronto, Dept Med, Toronto, ON M5C 1A1, Canada	McMaster University; University of Toronto	Ingram, AJ (corresponding author), 500-25 Charlton Ave E, Hamilton, ON L8N 1Y2, Canada.			James, Leighton/0000-0002-7613-705X				AKAI Y, 1994, AM J PHYSIOL, V267, pC482, DOI 10.1152/ajpcell.1994.267.2.C482; ANDERSON S, 1985, J CLIN INVEST, V76, P612, DOI 10.1172/JCI112013; Arnautov A M, 1998, Tsitologiia, V40, P639; Bubb MR, 2000, J BIOL CHEM, V275, P5163, DOI 10.1074/jbc.275.7.5163; BUBB MR, 1994, J BIOL CHEM, V269, P14869; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DWORKIN LD, 1986, J CLIN INVEST, V77, P797, DOI 10.1172/JCI112377; DWORKIN LD, 1984, J CLIN INVEST, V73, P1448, DOI 10.1172/JCI111349; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gorodeski GI, 2000, AM J PHYSIOL-CELL PH, V278, pC942, DOI 10.1152/ajpcell.2000.278.5.C942; Gruden G, 1997, P NATL ACAD SCI USA, V94, P12112, DOI 10.1073/pnas.94.22.12112; Hamaguchi A, 1998, J AM SOC NEPHROL, V9, P372; HAMASAKI K, 1995, BIOCHEM BIOPH RES CO, V212, P544, DOI 10.1006/bbrc.1995.2004; HARRIS RC, 1994, KIDNEY INT, V45, pS17; HARRIS RC, 1992, LAB INVEST, V66, P548; HEIDECKER M, 1995, BIOCHEMISTRY-US, V34, P11017, DOI 10.1021/bi00035a007; Hirakata M, 1997, KIDNEY INT, V51, P1028, DOI 10.1038/ki.1997.144; Hirshman CA, 1999, AM J PHYSIOL-LUNG C, V277, pL653, DOI 10.1152/ajplung.1999.277.3.L653; INGRAM A, 1995, KIDNEY INT, V48, P1857, DOI 10.1038/ki.1995.484; Ingram AJ, 2000, CURR OPIN NEPHROL HY, V9, P49, DOI 10.1097/00041552-200001000-00009; Ingram AJ, 1999, KIDNEY INT, V55, P476, DOI 10.1046/j.1523-1755.1999.00276.x; Ingram AJ, 2000, KIDNEY INT, V58, P1067, DOI 10.1046/j.1523-1755.2000.00264.x; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kawata Y, 1998, BBA-MOL CELL RES, V1401, P195, DOI 10.1016/S0167-4889(97)00112-2; Kawata Y, 1998, J BIOL CHEM, V273, P16905, DOI 10.1074/jbc.273.27.16905; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; Leinweber BD, 1999, BIOCHEM J, V344, P117, DOI 10.1042/0264-6021:3440117; Li CH, 1999, J BIOL CHEM, V274, P25273, DOI 10.1074/jbc.274.36.25273; MEYER TW, 1985, AM J MED, V79, P31, DOI 10.1016/0002-9343(85)90077-4; Numaguchi K, 1999, CIRC RES, V85, P5; REYES AA, 1992, AM J KIDNEY DIS, V20, P168, DOI 10.1016/S0272-6386(12)80546-4; RISER BL, 1992, J CLIN INVEST, V90, P1932, DOI 10.1172/JCI116071; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; TOGASHI H, 1998, AM J PHYSIOL, V274, pL808; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293; Xu QB, 1996, J CLIN INVEST, V97, P508, DOI 10.1172/JCI118442; Yao J, 1998, KIDNEY INT, V53, P598, DOI 10.1046/j.1523-1755.1998.00793.x; Yasuda T, 1996, CONTRIB NEPHROL, V118, P222; Yasuda T, 1996, J CLIN INVEST, V98, P1991, DOI 10.1172/JCI119003	45	51	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40301	40306		10.1074/jbc.M007018200	http://dx.doi.org/10.1074/jbc.M007018200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10984494	hybrid			2022-12-27	WOS:000166039500069
J	Wu, WH; Lee, WL; Wu, YY; Chen, D; Liu, TJ; Jang, A; Sharma, PM; Wang, PH				Wu, WH; Lee, WL; Wu, YY; Chen, D; Liu, TJ; Jang, A; Sharma, PM; Wang, PH			Expression of constitutively active phosphatidylinositol 3-kinase inhibits activation of caspase 3 and apoptosis of cardiac muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; PROTEIN-KINASE PATHWAYS; HEART-FAILURE; CARDIOMYOCYTE APOPTOSIS; AKT PHOSPHORYLATION; SIGNALING PATHWAYS; CYTOCHROME-C; INSULIN; DEATH; TRANSDUCTION	Apoptosis of cardiac muscle cells contributes to the development of cardiomyopathy. Recent studies showed that insulin-like growth factor I (IGF-I) inhibits apoptosis of cardiac muscle cells and improves myocardial function in experimental heart failure. This study was carried out to elucidate the role of phosphatidylinositol 3-kinase (PI 3-kinase) in the anti-apoptotic actions of IGF-I in cardiomyocytes and to explore whether expression of constitutively active PI 3-kinase can inhibit apoptosis in cardiomyocytes. Apoptosis of primary cardiomyocytes was induced by doxorubicin treatment and serum withdrawal. Transduction of cardiomyocytes with constitutively active PI 3-kinase specifically lead to serine phosphorylation of Akt, whereas phosphorylation of IGF-I receptor, IRS1/2 and p44/42 mitogen-activated protein kinase were not increased. In the cardiomyocytes transduced with constitutively active PI 3-kinase, activation of the pro-apoptotic caspase 3 was attenuated and fragmentation of DNA was reduced. Preincubating cells with PI 3-kinase inhibitor LY294002 was associated with loss of anti-apoptotic actions of IGF-I and PI S-kinase. Neither IGF-I nor constitutively active PI 3-kinase lead to serine phosphorylation of Bad, suggesting that the anti-apoptotic effects of PI 3-kinase are not mediated through Bad phosphorylation in cardiac muscle cells. To determine whether activation of caspase 3 is sufficient to induce apoptosis in cardiomyocytes, an engineered TAT-caspase 3 protein was introduced to cardiomyocytes. Significant reduction of cell viability occurred in the cardiomyocytes transduced with active caspase 3, indicating that activation of caspase 3 is sufficient to cause cardiomyocyte death. These findings indicate the existence of an IGF-I receptor-PI 3-kinase-caspase 3 pathway in cardiomyocytes that plays an important role in the anti-apoptotic actions of IGF-I in heart. Moreover, these data suggest that modulation of PI 3-kinase activities may represent a potential therapeutic strategy to counteract the occurrence of apoptosis in cardiomyopathy.	Univ Calif Irvine, Dept Med, Div Hematol & Oncol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Med & Biol Chem, Div Endocrinol Diabet & Metab, Irvine, CA 92697 USA; Univ Calif San Diego, Dept Med, Div Endocrinol, San Diego, CA 92162 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California San Diego	Wang, PH (corresponding author), Univ Calif Irvine, Dept Med, Div Hematol & Oncol, C240, Irvine, CA 92697 USA.							Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403; BUERKE M, 1995, P NATL ACAD SCI USA, V92, P8031, DOI 10.1073/pnas.92.17.8031; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; Colussi PA, 1999, IMMUNOL CELL BIOL, V77, P58, DOI 10.1046/j.1440-1711.1999.00788.x; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DECLERCK LS, 1994, J IMMUNOL METHODS, V172, P115, DOI 10.1016/0022-1759(94)90384-0; Delpy E, 1999, CARDIOVASC RES, V43, P398, DOI 10.1016/S0008-6363(99)00142-X; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FLINK IL, 1992, J BIOL CHEM, V267, P9917; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; James TN, 1999, AM J MED, V107, P606, DOI 10.1016/S0002-9343(99)00308-3; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Koglin J, 1999, CIRCULATION, V99, P836, DOI 10.1161/01.CIR.99.6.836; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Lee WL, 1999, ENDOCRINOLOGY, V140, P4831, DOI 10.1210/en.140.10.4831; Li Q, 1997, J CLIN INVEST, V100, P1991, DOI 10.1172/JCI119730; MacLellan WR, 1997, CIRC RES, V81, P137, DOI 10.1161/01.RES.81.2.137; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Matsuzaki H, 1999, J NEUROCHEM, V73, P2037; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Narula J, 1999, P NATL ACAD SCI USA, V96, P8144, DOI 10.1073/pnas.96.14.8144; OLSON RD, 1990, FASEB J, V4, P3076, DOI 10.1096/fasebj.4.13.2210154; Parrizas M, 1997, J BIOL CHEM, V272, P154; Rosen A, 1997, J CELL BIOCHEM, V64, P50, DOI 10.1002/(SICI)1097-4644(199701)64:1<50::AID-JCB8>3.0.CO;2-Z; Ryu BR, 1999, J NEUROBIOL, V39, P536, DOI 10.1002/(SICI)1097-4695(19990615)39:4<536::AID-NEU7>3.0.CO;2-J; Saraste A, 1999, EUR J CLIN INVEST, V29, P380; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Wang L, 1998, CIRC RES, V83, P516, DOI 10.1161/01.RES.83.5.516; Wang L, 1998, ENDOCRINOLOGY, V139, P1354, DOI 10.1210/en.139.3.1354; Williams RS, 1999, NEW ENGL J MED, V341, P759, DOI 10.1056/NEJM199909023411012; Yue TL, 1998, J MOL CELL CARDIOL, V30, P495, DOI 10.1006/jmcc.1997.0614; Zhu WD, 1999, CIRCULATION, V100, P2100, DOI 10.1161/01.CIR.100.20.2100	40	112	117	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40113	40119		10.1074/jbc.M004108200	http://dx.doi.org/10.1074/jbc.M004108200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007772	hybrid			2022-12-27	WOS:000166039500044
J	Ki, SW; Ishigami, K; Kitahara, T; Kasahara, K; Yoshida, M; Horinouchi, S				Ki, SW; Ishigami, K; Kitahara, T; Kasahara, K; Yoshida, M; Horinouchi, S			Radicicol binds and inhibits mammalian ATP citrate lyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; SELECTIVE DEPLETION; EXPRESSION; TRANSFORMATION; KINASE; HSP90; COMPLEX; AGENT; RAS; DIFFERENTIATION	Six different biotinylated radicicol derivatives were synthesized as affinity probes for identification of cellular radicicol-binding proteins. Derivatives biotinylated at the C-17 (BR-1) and C-11 (BR-6) positions retained the activity of morphological reversion in v-src-transformed 3Y1 fibroblasts. Two radicicol-binding proteins, 120 and 90-kDa in size, were detected in HeLa cell extracts by employing BR-1 and BR-6, respectively. The 90-kDa protein bound to BR-6 was identified to be Hsp90 by immunoblotting. The 120-kDa protein bound to BR-1 was purified from rabbit reticulocyte lysate, and its internal amino acid sequence was identical to that of human and rat ATP citrate lyase. The identity of the 120-kDa protein as ATP citrate lyase was confirmed by immunoblotting. Interaction between BR-1 and ATP citrate lyase was blocked by radicicol but not by herbimycin A that interacts with Hsp90. These results suggest that radicicol binds the two proteins through different molecular portions of its structure. BR-1-bound ATP citrate lyase isolated from rabbit reticulocyte lysate showed no enzymatic activity. The activity of rat liver ATP citrate lyase was inhibited by radicicol and BR-1 but not by BR-6. Kinetic analysis demonstrated that radicicol was a noncompetitive inhibitor of ATP citrate lyase with K-i values for citrate and ATP of 13 and 7 muM, respectively.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo; University of Tokyo	Yoshida, M (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1138657, Japan.		Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674; Ishigami, Ken/0000-0002-6917-1532				BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHANMUGAM P, 1995, J BIOL CHEM, V270, P5418, DOI 10.1074/jbc.270.10.5418; CREWS CM, 1994, J BIOL CHEM, V269, P15411; DELMOTTE P, 1953, NATURE, V171, P344, DOI 10.1038/171344a0; ELSHOURBAGY NA, 1990, J BIOL CHEM, V265, P1430; Gribble AD, 1996, J MED CHEM, V39, P3569, DOI 10.1021/jm960167w; Ki SW, 1998, J ANTIBIOT, V51, P936, DOI 10.7164/antibiotics.51.936; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; KWON HJ, 1995, J BIOCHEM-TOKYO, V118, P221, DOI 10.1093/oxfordjournals.jbchem.a124882; KWON HJ, 1992, CANCER RES, V52, P6926; Kwon HJ, 1997, ONCOGENE, V15, P2625, DOI 10.1038/sj.onc.1201443; KWON HJ, 1992, BIOSCI BIOTECH BIOCH, V56, P538; McCAPRA FRANK, 1964, TETRAHEDRON LETT, V15/16, P869; OIKAWA T, 1993, EUR J PHARMACOL, V241, P221, DOI 10.1016/0014-2999(93)90206-W; Pizer ES, 1998, CANCER-AM CANCER SOC, V83, P528, DOI 10.1002/(SICI)1097-0142(19980801)83:3<528::AID-CNCR22>3.0.CO;2-X; Pizer ES, 2000, CANCER RES, V60, P213; Rashid A, 1997, AM J PATHOL, V150, P201; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Schulte TW, 1998, CELL STRESS CHAPERON, V3, P100, DOI 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2; Sharma SV, 1998, ONCOGENE, V16, P2639, DOI 10.1038/sj.onc.1201790; SHIMADA Y, 1995, J ANTIBIOT, V48, P824, DOI 10.7164/antibiotics.48.824; Soga S, 1999, CANCER RES, V59, P2931; Soga S, 1998, J BIOL CHEM, V273, P822, DOI 10.1074/jbc.273.2.822; Takeda Y., 1969, METHOD ENZYMOL, V13, P153, DOI [DOI 10.1016/0076-6879(69)13032-3, 10.1016/0076-6879(69)13032-3]; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; ZHAO JF, 1995, ONCOGENE, V11, P161	29	53	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39231	39236		10.1074/jbc.M006192200	http://dx.doi.org/10.1074/jbc.M006192200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11007781	hybrid			2022-12-27	WOS:000165953100040
J	Kusch, A; Tkachuk, S; Haller, H; Dietz, R; Gulba, DC; Lipp, M; Dumler, I				Kusch, A; Tkachuk, S; Haller, H; Dietz, R; Gulba, DC; Lipp, M; Dumler, I			Urokinase stimulates human vascular smooth muscle cell migration via a phosphatidylinositol 3-kinase-Tyk2 interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PLASMINOGEN-ACTIVATOR; SIGNAL-TRANSDUCTION; PHOSPHOINOSITIDE 3-KINASES; RECOMBINANT ADENOVIRUS; ENDOTHELIAL-CELLS; HUMAN-NEUTROPHILS; MAMMALIAN-CELLS; RECEPTOR; CHEMOTAXIS	Janus kinases Jak1 and Tyk2 play an important role in urokinase-type plasminogen activator (uPA)-dependent signaling. We have recently demonstrated that both kinases are associated with the uPA receptor (uPAR) and mediate uPA-induced activation of signal transducers and activators of transcription (Stat1, Stat2, and Stat4) in human vascular smooth muscle cells (VSMC). Janus kinases are not only required for Stat activation but may also interfere with other intracellular signaling pathways. Here we report that in VSMC, Tyk2 interacts with a downstream signaling cascade involving phosphatidylinositol S-kinase (PI3-K). me demonstrate that uPA induces PI3-K activation, which is abolished in VSMC expressing the dominant negative form of Tyk2. The regulatory subunit p85 of PI3-K. co-immunoprecipitates with Tyk2 but not with Jak1, Jak2, or Jak3, and uPA stimulation increases the PI3-K activity in Tyk2 immunoprecipitates. Tyk2 directly binds to either of the two Src homology 2(SH2)p85 domains in a uPA-dependent fashion. me provide evidence that the Tyk2-mediated PI3-K activation in response to uPA is required for VSMC migration. Thus, two unrelated structurally distinct specific inhibitors of PI3-K, wortmannin and LY294002, prevent VSMC migration induced by uPA. No migratory effect of uPA was observed in VSMC expressing the dominant negative form of Tyk2. Our results underscore the versatile function of Tyk2 in uPA-related intracellular signaling and indicate that PI3-K plays a selective role in the regulation of VSMC migration.	Humboldt Univ, Charite Franz Volhard Clin, D-13125 Berlin, Germany; Humboldt Univ, Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Hannover Med Sch, D-30625 Hannover, Germany	Humboldt University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Hannover Medical School	Dumler, I (corresponding author), Humboldt Univ, Charite Franz Volhard Clin, Wiltberg Str 50, D-13125 Berlin, Germany.		Lipp, Martin/G-2235-2010	Lipp, Martin/0000-0002-0087-2672				Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Al-Shami A, 1999, J BIOL CHEM, V274, P5333, DOI 10.1074/jbc.274.9.5333; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; Blasi F, 1999, APMIS, V107, P96, DOI 10.1111/j.1699-0463.1999.tb01531.x; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; Carmeliet P, 1998, THROMB RES, V91, P255, DOI 10.1016/S0049-3848(98)00122-4; Carmeliet P, 1997, J CLIN INVEST, V99, P200, DOI 10.1172/JCI119148; Carriero MV, 1999, CANCER RES, V59, P5307; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Chatterjee-Kishore M, 2000, TRENDS CELL BIOL, V10, P106, DOI 10.1016/S0962-8924(99)01709-2; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chiaradonna F, 1999, EMBO J, V18, P3013, DOI 10.1093/emboj/18.11.3013; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dear AE, 1998, EUR J BIOCHEM, V252, P185, DOI 10.1046/j.1432-1327.1998.2520185.x; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; DELROSSO M, 1993, BIOCHEM BIOPH RES CO, V190, P347, DOI 10.1006/bbrc.1993.1054; Dumler I, 1999, ARTERIOSCL THROM VAS, V19, P290, DOI 10.1161/01.ATV.19.2.290; DUMLER I, 1994, FEBS LETT, V343, P103, DOI 10.1016/0014-5793(94)80298-X; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; Dumler I, 1999, J BIOL CHEM, V274, P24059, DOI 10.1074/jbc.274.34.24059; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; FIBBI G, 1988, EXP CELL RES, V179, P385, DOI 10.1016/0014-4827(88)90277-7; GUDEWICZ PW, 1987, BIOCHEM BIOPH RES CO, V147, P1176, DOI 10.1016/S0006-291X(87)80193-6; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; ODEKON LE, 1992, J CELL PHYSIOL, V150, P258, DOI 10.1002/jcp.1041500206; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; SHARFE N, 1995, BLOOD, V86, P2077, DOI 10.1182/blood.V86.6.2077.bloodjournal8662077; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vicente-Manzanares M, 1999, J IMMUNOL, V163, P4001; Ward AC, 2000, BLOOD, V95, P19; Webb DJ, 2000, J CELL SCI, V113, P123; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	55	69	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39466	39473		10.1074/jbc.M003626200	http://dx.doi.org/10.1074/jbc.M003626200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995743	hybrid			2022-12-27	WOS:000165953100072
J	Tang, YY; Shi, JX; Zhang, LN; Davis, A; Bravo, J; Warren, AJ; Speck, NA; Bushweller, JH				Tang, YY; Shi, JX; Zhang, LN; Davis, A; Bravo, J; Warren, AJ; Speck, NA; Bushweller, JH			Energetic and functional contribution of residues in the core binding factor beta (CBF beta) subunit to heterodimerization with CBF alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; FETAL LIVER HEMATOPOIESIS; DNA-BINDING; RUNT DOMAIN; CLEIDOCRANIAL DYSPLASIA; AML1 GENE; PROTEIN INTERFACES; HOT-SPOT	Core-binding factors (CBFs) are a small family of heterodimeric transcription factors that play critical roles in several developmental pathways, including hematopoiesis and bone development. Mutations in CBF genes are found in leukemias and bone disorders. CBFs consist of a DNA-binding CBF alpha subunit (Runx1, Runx2, or Runx3) and a non-DNA-binding CEF beta subunit. CBF alpha binds DNA in a sequence-specific manner, whereas CBF beta enhances DNA binding by CBF alpha. Recent structural analyses of the DNA-binding Runt domain of CBF alpha and the CBF beta subunit identified the heterodimerization surfaces on each subunit. Here we identify amino acids in CBF beta that mediate binding to CBF alpha. We determine the energy contributed by each of these amino acids to heterodimerization and the importance of these residues for in vivo function. These data refine the structural analyses and further support the hypothesis that CBF beta enhances DNA binding by inducing a conformational change in the Runt domain.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA; Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22906 USA; 3MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Dartmouth College; University of Virginia; MRC Laboratory Molecular Biology	Tang, YY (corresponding author), Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA.	Yen-Yee.Tang@dartmouth.edu	Bravo, Jeronimo/K-9103-2014	Bravo, Jeronimo/0000-0001-6695-2846; Bushweller, John/0000-0002-5386-1758	NCI NIH HHS [R01-CA75611, R01-CA58343] Funding Source: Medline; NIAID NIH HHS [T32-AI07363] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075611, R01CA058343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007363] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAE SC, 1993, ONCOGENE, V8, P809; Berardi MJ, 1999, STRUCT FOLD DES, V7, P1247, DOI 10.1016/S0969-2126(00)80058-1; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Chen CZ, 1999, BIOCHEMISTRY-US, V38, P9273, DOI 10.1021/bi990762a; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Crute BE, 1996, J BIOL CHEM, V271, P26251, DOI 10.1074/jbc.271.42.26251; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Goger M, 1999, NAT STRUCT BIOL, V6, P620; Golling G, 1996, MOL CELL BIOL, V16, P932; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; HAWLEY RG, 1994, GENE THER, V1, P136; Huang XM, 1998, J BIOL CHEM, V273, P2480, DOI 10.1074/jbc.273.4.2480; Huang XM, 1999, NAT STRUCT BIOL, V6, P624; Huang XM, 1998, J BIOMOL NMR, V12, P459, DOI 10.1023/A:1008306026814; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KELLER HU, 1993, ADV SPACE RES, V13, P73; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nagata T, 1999, NAT STRUCT BIOL, V6, P615; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Perez-Alvarado GC, 2000, FEBS LETT, V470, P125, DOI 10.1016/S0014-5793(00)01296-5; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Roulston D, 1998, BLOOD, V92, P2879, DOI 10.1182/blood.V92.8.2879.420k22_2879_2885; Rubnitz J E, 1998, Curr Opin Hematol, V5, P264; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Tang YY, 2000, FEBS LETT, V470, P167, DOI 10.1016/S0014-5793(00)01312-0; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Warren AJ, 2000, EMBO J, V19, P3004, DOI 10.1093/emboj/19.12.3004; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; Zhou G, 1999, HUM MOL GENET, V8, P2311, DOI 10.1093/hmg/8.12.2311	53	51	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39579	39588		10.1074/jbc.M007350200	http://dx.doi.org/10.1074/jbc.M007350200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10984496	hybrid			2022-12-27	WOS:000165953100084
J	Forster, C; Kane, PM				Forster, C; Kane, PM			Cytosolic Ca2+ homeostasis is a constitutive function of the V-ATPase in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; YEAST-CELLS; ADENOSINE-TRIPHOSPHATASES; CALCIUM; CALCINEURIN; GENE; DISRUPTION; MUTANTS; HOMOLOG	The vacuole is the major site of intracellular Ca2+ storage in yeast and functions to maintain cytosolic Ca2+ levels within a narrow physiological range via a Ca2+ pump (Pmc1p) and a H+/Ca2+ antiporter (Vcx1p) driven by the vacuolar H+-ATPase (V-ATPase). We examined the function of the V-ATPase in cytosolic Ca2+ homeostasis by comparing responses to a brief Ca2+ challenge of a V-ATPase mutant (vma2 Delta) and wild-type cells treated with the V-ATPase inhibitor concanamycin A. The kinetics of the Ca2+ response were determined using transgenic aequorin as an in vivo cytosolic Ca2+ reporter system. In wild-type cells, the V-ATPase-driven Vcx1p was chiefly responsible for restoring cytosolic Ca2+ concentrations after a brief pulse. In cells lacking V-ATPase activity, brief exposure to elevated Ca2+ compromised viability, even when there was little change in the final cytosolic Ca2+ concentration. vma2 Delta cells were more efficient at restoring cytosolic [Ca2+] after a pulse than concanamycin-treated wild-type cells, suggesting long term loss of V-ATPase triggers compensatory mechanisms. This compensation was dependent on calcineurin, and was mediated primarily by Pmc1p.	SUNY Syracuse, Dept Biochem & Mol Biol, Upstate Med Univ, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Kane, PM (corresponding author), SUNY Syracuse, Dept Biochem & Mol Biol, Upstate Med Univ, 750 E Adams St, Syracuse, NY 13210 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM050322, R01GM50322] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN DG, 1976, SCIENCE, V195, P966; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; Bowman EJ, 2000, J BIOL CHEM, V275, P167, DOI 10.1074/jbc.275.1.167; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Conboy IM, 1999, P NATL ACAD SCI USA, V96, P6324, DOI 10.1073/pnas.96.11.6324; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; DAVIS TN, 1995, ADV SEC MESS PHOSPH, V30, P339; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; DUNN T, 1994, J BIOL CHEM, V269, P7273; Forgac M, 1999, J BIOENERG BIOMEMBR, V31, P57, DOI 10.1023/A:1005496530380; Forster C, 1999, J BIOL CHEM, V274, P9442, DOI 10.1074/jbc.274.14.9442; Fu LW, 2000, J BIOL CHEM, V275, P5431, DOI 10.1074/jbc.275.8.5431; GARRETTENGELE P, 1995, MOL CELL BIOL, V15, P4103; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Graham LA, 1999, J BIOENERG BIOMEMBR, V31, P39, DOI 10.1023/A:1005492429471; HALACHMI D, 1993, FEBS LETT, V316, P73, DOI 10.1016/0014-5793(93)81739-M; IIDA H, 1990, J BIOL CHEM, V265, P13391; Kane PM, 1999, J BIOENERG BIOMEMBR, V31, P49, DOI 10.1023/A:1005444513542; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Miseta A, 1999, J BIOL CHEM, V274, P5939, DOI 10.1074/jbc.274.9.5939; Miseta A, 1999, FEBS LETT, V451, P132, DOI 10.1016/S0014-5793(99)00519-0; NAKAJIMASHIMADA J, 1991, P NATL ACAD SCI USA, V88, P6878, DOI 10.1073/pnas.88.15.6878; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OHYA Y, 1991, J BIOL CHEM, V266, P13971; Paidhungat M, 1997, MOL CELL BIOL, V17, P6339, DOI 10.1128/MCB.17.11.6339; Plant PJ, 1999, J BIOL CHEM, V274, P37270, DOI 10.1074/jbc.274.52.37270; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Schiavo G, 1998, ESSAYS BIOCHEM, V33, P29, DOI 10.1042/bse0330029; SHERMAN F, 1982, METHODS YEAST GENETI, P177; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; TANIDA I, 1995, J BIOL CHEM, V270, P10113, DOI 10.1074/jbc.270.17.10113; van Leeuwen JEM, 1999, CURR OPIN IMMUNOL, V11, P242, DOI 10.1016/S0952-7915(99)80040-5; WILLIAMS RJP, 1990, ADV EXP MED BIOL, V269, P7; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZHANG JW, 1998, J BIOL CHEM, V26, P99763	42	64	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38245	38253		10.1074/jbc.M006650200	http://dx.doi.org/10.1074/jbc.M006650200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10991947	hybrid			2022-12-27	WOS:000165739800017
J	Joseph, JD; Means, AR				Joseph, JD; Means, AR			Identification and characterization of two Ca2+/CaM-dependent protein kinases required for normal nuclear division in Aspergillus nidulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIH 3T3 CELLS; CA2+/CALMODULIN-DEPENDENT KINASE; CDNA CLONING; CAMK-II; CALMODULIN; CALCIUM; EXPRESSION; ACTIVATION; CYCLE; G(1)	We utilized an expression screen to identify two novel Ca2+/calmodulin (CaM)-regulated protein kinases in Aspergillus nidulans. The two kinases, CMKB and CMKC, possess high sequence identity with mammalian CaM kinases (CaMKs) I/IV and CaMKK alpha/beta, respectively. In vitro CMKC phosphorylates and increases the activity of CMKB, indicating they are biochemical homologues of CaMKK alpha/beta and CaMKI/IV. The disruption of CMKB is lethal; however, when protein expression is postponed, the spores germinate with delayed kinetics. The observed lag corresponds to a delay in the G(1)-phase activation of the cyclin-dependent kinase NIMXcdc2. Disruption of cmkC is not lethal, but spores lacking CMKC also germinate with delayed kinetics and a lag in the activation of NIMXcdc2. Analysis of Delta cmkC suggests a role for CMKC in regulating the first and subsequent nuclear division cycles. We conclude that both CMKB and CMKC are required for the proper temporal activation of NIMXcdc2 as spores enter the cell cycle hom quiescence and suggest that this relationship exists during the G(1)/S transition of subsequent cell divisions.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Means, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.				NIGMS NIH HHS [GM33976] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; CHAFOULEAS JG, 1984, CELL, V36, P73, DOI 10.1016/0092-8674(84)90075-8; Dayton JS, 1997, J BIOL CHEM, V272, P3223, DOI 10.1074/jbc.272.6.3223; Dayton JS, 1996, MOL BIOL CELL, V7, P1511, DOI 10.1091/mbc.7.10.1511; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HARRIS SD, 1994, GENETICS, V136, P517; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; HIDAKA H, 1996, INTRACELLULAR SIGNAL, P193; Hook SS, 1999, J BIOL CHEM, V274, P20215, DOI 10.1074/jbc.274.29.20215; LU KP, 1993, J CELL BIOL, V121, P621, DOI 10.1083/jcb.121.3.621; LU KP, 1993, METH MOL G, V2, P255; Means AR, 1999, CALCIUM AS A CELLULAR REGULATOR, P512; Morris TA, 1998, EXP CELL RES, V240, P218, DOI 10.1006/excr.1997.3925; OSMANI AH, 1994, J CELL SCI, V107, P1519; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; RASMUSSEN C, 1994, EMBO J, V13, P3917, DOI 10.1002/j.1460-2075.1994.tb06703.x; RASMUSSEN CD, 1990, J BIOL CHEM, V265, P13767; Rasmussen CD, 2000, J BIOL CHEM, V275, P685, DOI 10.1074/jbc.275.1.685; RASMUSSEN G, 1995, BIOCHEM CELL BIOL, V73, P201, DOI 10.1139/o95-024; S~anchez O, 1996, FUNGAL GENET REP, V43, P21; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SEBERT MA, 1995, J BIOL CHEM, V270, P17616; STIRLING DA, 1992, MOL MICROBIOL, V6, P703, DOI 10.1111/j.1365-2958.1992.tb01519.x; Taules M, 1998, J BIOL CHEM, V273, P33279, DOI 10.1074/jbc.273.50.33279; TOMBES RM, 1995, CELL GROWTH DIFFER, V6, P1063; WARING RB, 1989, GENE, V79, P119, DOI 10.1016/0378-1119(89)90097-8; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	28	62	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38230	38238		10.1074/jbc.M006422200	http://dx.doi.org/10.1074/jbc.M006422200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10988293	hybrid			2022-12-27	WOS:000165739800015
J	Williams, DM; Wang, DX; Cole, PA				Williams, DM; Wang, DX; Cole, PA			Chemical rescue of a mutant protein-tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC MECHANISM; ESCHERICHIA-COLI; GUANIDINE DERIVATIVES; TRANSITION-STATE; CSK; ACTIVATION; SPECIFICITY; INSIGHTS; CELLS; BASE	Protein-tyrosine kinases contain a catalytic loop Arg residue located either two or four positions downstream of a highly conserved Asp residue, In this study, the role of this Arg (Arg-318) in the protein-tyrosine kinase C-terminal Src kinase (Csk) was investigated, The observed k(cat) for phosphorylation of the random copolymer poly(Glu,Tyr) substrate by Csk R318A is similar to 3000-fold smaller compared with that of wild type Csk, whereas the K-m values for ATP and poly(Glu,Tyr) are only mildly affected. The k(cat) value for poly(Glu,Tyr) phosphorylation by the Csk double mutant A316R,R318A is 100-fold greater than the k(cat) value for the single R318A mutant, suggesting that an Arg positioned at the alternative location fulfills a similar function as in wild type, Csk R318A kinase activity can also be partially recovered by several exogenous small molecules including guanidinium and imidazole, These molecules contain key features whose roles in catalysis can be rationalized from a known x-ray structure of the insulin receptor tyrosine kinase, Imidazole is the best of these activators, enhancing phosphorylation rates by Csk R318A up to 100-fold for poly(Glu,Tyr) and significantly stimulating Csk R318A phosphorylation of the physiologic substrate Src. This chemical rescue of mutant protein kinase activity might find applications in cell signal transduction experiments.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Johns Hopkins University	Cole, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Rm 316,Hunterian Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL CANCER INSTITUTE [R01CA074305, R29CA074305, T32CA009243] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09243, CA74305-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Admiraal SJ, 1999, BIOCHEMISTRY-US, V38, P4701, DOI 10.1021/bi9827565; Boehlein SK, 1997, J BIOL CHEM, V272, P12384, DOI 10.1074/jbc.272.19.12384; BOUGERET C, 1993, ONCOGENE, V8, P1241; CARTER P, 1987, SCIENCE, V237, P394, DOI 10.1126/science.3299704; COLE PA, 1995, J BIOL CHEM, V270, P22105, DOI 10.1074/jbc.270.38.22105; COLE PA, 1994, J BIOL CHEM, V269, P30880; Curley K, 1998, J AM CHEM SOC, V120, P8573, DOI 10.1021/ja981786s; DHALLA AM, 1994, PROTEIN SCI, V3, P476; EHRIG T, 1991, BIOCHEMISTRY-US, V30, P1062, DOI 10.1021/bi00218a026; Grace MR, 1997, BIOCHEMISTRY-US, V36, P1874, DOI 10.1021/bi962138t; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jiang WJ, 2000, BIOCHEMISTRY-US, V39, P7990, DOI 10.1021/bi000630d; Kim K, 1997, J AM CHEM SOC, V119, P11096, DOI 10.1021/ja972110k; Kim K, 1998, J AM CHEM SOC, V120, P6851, DOI 10.1021/ja9808393; Lee CL, 1999, NAT BIOTECHNOL, V17, P759, DOI 10.1038/11691; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705; Nagai Y, 2000, NAT BIOTECHNOL, V18, P313, DOI 10.1038/73767; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; PERONA JJ, 1994, BIOCHEMISTRY-US, V33, P3252, DOI 10.1021/bi00177a016; PHILLIPS MA, 1992, PROTEIN SCI, V1, P517; Rynkiewicz MJ, 1996, BIOCHEMISTRY-US, V35, P16174, DOI 10.1021/bi961311i; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEKIMOTO T, 1993, J BIOL CHEM, V268, P27039; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; SHOKAT KM, 1995, CHEM BIOL, V2, P509, DOI 10.1016/1074-5521(95)90183-3; Sober H. A., 1970, CRC HDB BIOCH SELECT; Sondhi D, 1999, BIOCHEMISTRY-US, V38, P11147, DOI 10.1021/bi990827+; Sondhi D, 1998, BIOCHEMISTRY-US, V37, P165, DOI 10.1021/bi9722960; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054	35	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38127	38130		10.1074/jbc.C000606200	http://dx.doi.org/10.1074/jbc.C000606200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11006267	hybrid			2022-12-27	WOS:000165739800001
J	Harada, Y; Sanada, K; Fukada, Y				Harada, Y; Sanada, K; Fukada, Y			Circadian activation of bullfrog retinal mitogen-activated protein kinase associates with oscillator function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLTRANSFERASE ACTIVITY; ENDOGENOUS DOPAMINE RELEASE; DROSOPHILA CLOCK GENE; CHICKEN PINEAL-GLAND; MAP KINASE; PERIOD PROTEIN; IN-VITRO; SUPRACHIASMATIC NUCLEI; TYROSINE-HYDROXYLASE; BEHAVIORAL RHYTHMS	The vertebrate retina retains a circadian oscillator, and its oscillation is self-sustained with a period close to 24 h under constant environmental conditions. Here we show that bullfrog retinal mitogen-activated protein kinase (MAPK) exhibits an in vivo circadian rhythm in phosphorylation with a peak at night in a light/dark cycle. The phosphorylation rhythm of MAPK persists in constant darkness with a peak at subjective night, and this self-sustained rhythm is also observed in cultured retinas, indicating its close interaction with the retinal oscillator. The rhythmically phosphorylated MAPK. is detected only in a discrete subset of amacrine cells despite ubiquitous distribution of MAPK throughout the retinal layers. Treatment of the cultured retinas with MAPK kinase (MEK) inhibitor PD98059 suppresses MAPK phosphorylation during the subjective night, and this pulse perturbation of MEK activity induces a significant phase delay (4-8 h) of the retinal circadian rhythm in MAPK and MEK phosphorylation. These observations strongly suggest that the site-specific and time-of-day-specific activation of MAPK contributes to the circadian time-keeping mechanism of the retinal clock system.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1130033, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Fukada, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.		SANADA, YOSHIKADO/G-5014-2014; 吉孝, 深田/G-5090-2014	Sanada, Kamon/0000-0002-0280-8957				Adachi A, 1998, BRAIN RES, V792, P361, DOI 10.1016/S0006-8993(98)00206-6; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Belvin MP, 1999, NEURON, V22, P777, DOI 10.1016/S0896-6273(00)80736-9; BESHARSE JC, 1983, EXP EYE RES, V36, P567, DOI 10.1016/0014-4835(83)90051-9; BOATRIGHT JH, 1994, VISUAL NEUROSCI, V11, P1013, DOI 10.1017/S0952523800003941; BOATRIGHT JH, 1994, VISUAL NEUROSCI, V11, P1003, DOI 10.1017/S095252380000393X; CAHILL GM, 1993, NEURON, V10, P573, DOI 10.1016/0896-6273(93)90160-S; CAHILL GM, 1990, J NEUROCHEM, V54, P716, DOI 10.1111/j.1471-4159.1990.tb01932.x; CROOKS J, 1992, J COMP NEUROL, V315, P287, DOI 10.1002/cne.903150305; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; DEGUCHI T, 1979, SCIENCE, V203, P1245, DOI 10.1126/science.424750; DJAMGOZ MBA, 1992, NEUROCHEM INT, V20, P139, DOI 10.1016/0197-0186(92)90166-O; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Dunlap JC, 1999, GENES CELLS, V4, P1, DOI 10.1046/j.1365-2443.1999.00239.x; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; Greve P, 1996, BIOCHEM J, V319, P761, DOI 10.1042/bj3190761; Harada Y, 1998, BIOL RHYTHM RES, V29, P30, DOI 10.1076/brhm.29.1.30.3043; Hardin PE, 1999, SCIENCE, V286, P2460, DOI 10.1126/science.286.5449.2460; KASAL CA, 1979, SCIENCE, V203, P656, DOI 10.1126/science.569904; KAZULA A, 1993, VISUAL NEUROSCI, V10, P621, DOI 10.1017/S0952523800005320; KEMALI M, 1983, EXP BRAIN RES, V53, P193, DOI 10.1007/BF00239412; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Kolb H, 1997, EYE, V11, P904, DOI 10.1038/eye.1997.230; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; LAM DMK, 1979, NATURE, V278, P565, DOI 10.1038/278565a0; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; Liu C, 1997, NEURON, V19, P91, DOI 10.1016/S0896-6273(00)80350-5; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; Naidoo N, 1999, SCIENCE, V285, P1737, DOI 10.1126/science.285.5434.1737; Nakahara K, 1997, BRAIN RES, V774, P242, DOI 10.1016/S0006-8993(97)81713-1; Obrietan K, 1998, NAT NEUROSCI, V1, P693, DOI 10.1038/3695; Obrietan K, 1999, J BIOL CHEM, V274, P17748, DOI 10.1074/jbc.274.25.17748; OSBORNE NN, 1984, HISTOCHEMISTRY, V80, P389, DOI 10.1007/BF00495423; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Reppert SM, 1998, NEURON, V21, P1, DOI 10.1016/S0896-6273(00)80234-2; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sanada K, 2000, J NEUROSCI, V20, P986, DOI 10.1523/JNEUROSCI.20-03-00986.2000; Sassone-Corsi P, 1998, NATURE, V392, P871, DOI 10.1038/31821; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; Tosini G, 1998, BRAIN RES, V789, P221, DOI 10.1016/S0006-8993(97)01446-7; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Whitmore D, 1998, NAT NEUROSCI, V1, P701, DOI 10.1038/3703; WIRZJUSTICE A, 1984, NEUROSCI LETT, V45, P21, DOI 10.1016/0304-3940(84)90323-9; WITKOVSKY P, 1991, VISUAL NEUROSCI, V7, P113, DOI 10.1017/S0952523800010981; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	63	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37078	37085		10.1074/jbc.M004706200	http://dx.doi.org/10.1074/jbc.M004706200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10978323	hybrid			2022-12-27	WOS:000165577700087
J	Vos, MD; Ellis, CA; Bell, A; Birrer, MJ; Clark, GJ				Vos, MD; Ellis, CA; Bell, A; Birrer, MJ; Clark, GJ			Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENIC RAS; INCREASING COMPLEXITY; EPITHELIAL-CELLS; HUMAN CANCER; PROTEIN; GROWTH; TRANSFORMATION; KINASE; DIFFERENTIATION; REQUIREMENT	Although activated Ras proteins are usually associated with driving growth and transformation, they may also induce senescence, apoptosis, and terminal differentiation. The subversion of these anti-neoplastic effects during Ras-dependent tumor development may be as important as the acquisition of the pro-neoplastic effects. None of the currently identified potential Ras effector proteins can satisfactorily explain the apoptotic action of Ras. Consequently, we have sought to identify novel Ras effecters that may be responsible for apoptosis induction. By examining the EST data base, we identified a potential. Ras association domain in the tumor suppressor RASSF1. We now show that RASSF1 binds Ras in a GTP-dependent manner, both in vivo and directly in vitro. Moreover, activated Ras enhances and dominant negative Ras inhibits the cell death induced by transient transfection of RASSF1 into 293-T cells. This cell death appears to be apoptotic in nature, as RASSF1-transfected 293-T cells exhibit membrane blebbing and can be rescued by the addition of a caspase inhibitor. Thus, the RASSF1 tumor suppressor may serve as a novel Ras effector that mediates the apoptotic effects of oncogenic Ras.	NCI, Dept Cell & Canc Biol, NIH, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Clark, GJ (corresponding author), NCI, Dept Cell & Canc Biol, NIH, 9610 Med Ctr Dr, Rockville, MD 20850 USA.				DIVISION OF CLINICAL SCIENCES - NCI [Z01SC010359] Funding Source: NIH RePORTER	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOS JL, 1989, CANCER RES, V49, P4682; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEN CY, 1995, ONCOGENE, V11, P1487; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Ellis CA, 2000, CELL SIGNAL, V12, P425, DOI 10.1016/S0898-6568(00)00084-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fullwood P, 1999, CANCER RES, V59, P4662; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; HUBER BE, 1988, ONCOGENE, V3, P245; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; OCHIENG J, 1991, INVAS METAST, V11, P38; PATERSON H, 1987, CELL, V51, P803, DOI 10.1016/0092-8674(87)90103-6; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; TAKIGUCHI Y, 1992, CLIN EXP METASTAS, V10, P351, DOI 10.1007/BF00058175; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; Wyllie AH, 1997, EUR J CELL BIOL, V73, P189; YUSPA SH, 1985, NATURE, V314, P459, DOI 10.1038/314459a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	52	238	259	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35669	35672		10.1074/jbc.C000463200	http://dx.doi.org/10.1074/jbc.C000463200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10998413	hybrid			2022-12-27	WOS:000165382000004
J	Tokita, K; Hocart, SJ; Katsuno, T; Mantey, SA; Coy, DH; Jensen, RT				Tokita, K; Hocart, SJ; Katsuno, T; Mantey, SA; Coy, DH; Jensen, RT			Tyrosine 220 in the 5th transmembrane domain of the neuromedin B receptor is critical for the high selectivity of the peptoid antagonist PD168368	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIN-RELEASING PEPTIDE; SITE-DIRECTED MUTAGENESIS; PROTEIN-COUPLED RECEPTORS; MAMMALIAN BOMBESIN RECEPTORS; HUMAN NEUROKININ-1 RECEPTOR; CATION-PI INTERACTIONS; HIGH-AFFINITY; BINDING-SITES; AGONIST-BINDING; ORBITAL ELECTRONEGATIVITY	Peptoid antagonists are increasingly being described for G; protein-coupled receptors; however, little is known about the molecular basis of their binding, Recently, the peptoid PD168368 was found to be a potent selective neuromedin B receptor (MMBR) antagonist. To investigate the molecular basis for its selectivity for the NMBR over the closely related receptor for gastrin-releasing peptide (GRPR), we used a chimeric receptor approach and a site-directed mutagenesis approach. Mutated receptors were transiently expressed in Balb 3T3. The extracellular domains of the NMBR were not important for the selectivity of PD168368, However, substitution of the 5th upper transmembrane domain (uTM5) of the NMBR by the comparable GRPR domains decreased the affinity Is-fold. When the reverse study was performed by substituting the uTM5 of NMBR into the GRPR, a 9-fold increase in affinity occurred. Each of the 4 amino acids that differed between NMBR and GRPR in the uTM5 region were exchanged, but only the substitution of Phe(220) for Tyr in the NMBR caused a decrease in affinity, When the reverse study was performed to attempt to demonstrate a gain of affinity in the GRPR, the substitution of Tyr(219) for phe caused an increase in affinity. These results suggest that the hydroxyl group of Tyr(220) in uTM5 of NMBR plays a critical role for high selectivity of PD168368 for NMBR over GRPR. Receptor and ligand modeling suggests that the hydroxyl of the Tyr(220) interacts with nitrophenyl group of PD168368 likely primarily by hydrogen bonding; This result shows the selectivity of the peptoid PD168368, similar to that reported for numerous non-peptide analogues with other G protein-coupled receptors, is primarily dependent on interaction with transmembrane amino acids.	NIDDK, Digest Dis Branch, NIH, Bethesda, MD 20892 USA; Tulane Univ, Hlth Sci Ctr, Dept Med, Peptide Res Labs, New Orleans, LA 70112 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Tulane University	Jensen, RT (corresponding author), NIDDK, Digest Dis Branch, NIH, Bldg 10,Rm 9C-103,10 Ctr Dr,MSC 1804, Bethesda, MD 20892 USA.	robertj@bdg10.niddk.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK053100, ZIADK053100] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERS HE, 1991, J NEUROSCI, V11, P846; Ashwood V, 1998, BIOORG MED CHEM LETT, V8, P2589, DOI 10.1016/S0960-894X(98)00462-4; Bastian S, 2000, J BIOL CHEM, V275, P6107, DOI 10.1074/jbc.275.9.6107; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BENYA RV, 1994, MOL PHARMACOL, V46, P235; Boden P, 1996, J MED CHEM, V39, P1664, DOI 10.1021/jm950892r; BODEN PR, 1993, J MED CHEM, V36, P552, DOI 10.1021/jm00057a005; Boyle S, 1994, Bioorg Med Chem, V2, P101, DOI 10.1016/S0968-0896(00)82006-4; BREU V, 1995, EUR J BIOCHEM, V231, P266, DOI 10.1111/j.1432-1033.1995.0266f.x; BROWN MR, 1988, ANN NY ACAD SCI, V547, P174, DOI 10.1111/j.1749-6632.1988.tb23885.x; CASCIERI MA, 1995, MOL PHARMACOL, V47, P660; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; CRIDLAND RA, 1992, BRAIN RES, V584, P163, DOI 10.1016/0006-8993(92)90890-L; DELAFUENTE M, 1993, J NEUROIMMUNOL, V48, P143, DOI 10.1016/0165-5728(93)90186-3; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Du P, 1997, PROTEIN ENG, V10, P109, DOI 10.1093/protein/10.2.109; Eden JM, 1996, BIOORG MED CHEM LETT, V6, P2617, DOI 10.1016/0960-894X(96)00481-7; ENDO T, 1991, J ENDOCRINOL, V131, P313, DOI 10.1677/joe.0.1310313; FATHI Z, 1993, J BIOL CHEM, V268, P14622; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1577, DOI 10.1021/bi00405a027; FONG TM, 1992, J BIOL CHEM, V267, P25664; FUNK CD, 1993, MOL PHARMACOL, V44, P934; GASTEIGER J, 1978, TETRAHEDRON LETT, P3181; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GHATEI MA, 1982, J CLIN ENDOCR METAB, V54, P980, DOI 10.1210/jcem-54-5-980; Gigoux V, 1999, J BIOL CHEM, V274, P20457, DOI 10.1074/jbc.274.29.20457; Gouldson PR, 1997, J MED CHEM, V40, P3871, DOI 10.1021/jm960647n; Hammerland LG, 1999, MOL PHARMACOL, V55, P642; HILL DJ, 1992, ENDOCRINOLOGY, V130, P2811, DOI 10.1210/en.130.5.2811; Horwell D C, 1994, Drug Des Discov, V12, P63; HORWELL DC, 1995, TRENDS BIOTECHNOL, V13, P132; HUNYADY L, 1995, J BIOL CHEM, V270, P9702, DOI 10.1074/jbc.270.17.9702; Jensen RT, 1997, CURRENT CLINICAL TOPICS IN GASTROINTESTINAL PHARMACOLOGY, P144; JENSEN RT, 1988, ANN NY ACAD SCI, V547, P138, DOI 10.1111/j.1749-6632.1988.tb23882.x; JENSEN RT, 1991, TRENDS PHARMACOL SCI, V12, P13, DOI 10.1016/0165-6147(91)90483-9; JI H, 1994, J BIOL CHEM, V269, P16533; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Kobayashi T, 1997, J BIOL CHEM, V272, P15154, DOI 10.1074/jbc.272.24.15154; KOPIN AS, 1995, J BIOL CHEM, V270, P5019, DOI 10.1074/jbc.270.10.5019; KROOG GS, 1995, MED RES REV, V15, P389, DOI 10.1002/med.2610150502; KRYSTEK SR, 1994, J BIOL CHEM, V269, P12383; LEE JA, 1994, BIOCHEMISTRY-US, V33, P14543, DOI 10.1021/bi00252a022; Liaw CW, 1997, MOL ENDOCRINOL, V11, P2048, DOI 10.1210/me.11.13.2048; LIN JT, 1995, J PHARMACOL EXP THER, V275, P285; MAGGI CA, 1993, EUR J PHARMACOL, V234, P83, DOI 10.1016/0014-2999(93)90709-Q; MALATYNSKA E, 1995, NEUROREPORT, V6, P1325, DOI 10.1097/00001756-199506090-00024; Mantey SA, 1997, J BIOL CHEM, V272, P26062, DOI 10.1074/jbc.272.41.26062; MARSILI M, 1980, CROAT CHEM ACTA, V53, P601; MCCOY JG, 1990, PEPTIDES, V11, P595, DOI 10.1016/0196-9781(90)90064-C; Mecozzi S, 1996, P NATL ACAD SCI USA, V93, P10566, DOI 10.1073/pnas.93.20.10566; MOODY TW, 1992, J PHARMACOL EXP THER, V263, P311; Moody TW., 1996, GROWTH FACTORS, P491; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4417, DOI 10.1073/pnas.91.10.4417; NOVOTNY EA, 1994, BIOCHEM BIOPH RES CO, V201, P523, DOI 10.1006/bbrc.1994.1733; PEARLMAN RS, 2000, CONCORD VERSION 4 02; Pearlman RS, 1987, CHEM DES AUTOM NEWS, V2, P1; PERLMAN JH, 1994, J BIOL CHEM, V269, P1610; PINNOCK RD, 1994, BRAIN RES, V653, P119, DOI 10.1016/0006-8993(94)90379-4; RETTORI V, 1989, P NATL ACAD SCI USA, V86, P4789, DOI 10.1073/pnas.86.12.4789; Rodriguez R, 1998, BIOINFORMATICS, V14, P523, DOI 10.1093/bioinformatics/14.6.523; ROUISSI N, 1991, BRIT J PHARMACOL, V103, P1141, DOI 10.1111/j.1476-5381.1991.tb12314.x; RUFFOLO RR, 1993, ANNU REV PHARMACOL, V33, P243, DOI 10.1146/annurev.pharmtox.33.1.243; Ryan FR, 1999, J PHARMACOL EXP THER, V290, P1202; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; Silvente-Poirot S, 1998, MOL PHARMACOL, V54, P364, DOI 10.1124/mol.54.2.364; SINGH L, 1995, EUR J PHARMACOL, V286, P185, DOI 10.1016/0014-2999(95)00445-Q; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; SUNDAY ME, 1993, ANAT REC, V236, P25, DOI 10.1002/ar.1092360107; TACHE Y, 1988, ANN NY ACAD SCI, V547, P183, DOI 10.1111/j.1749-6632.1988.tb23886.x; Tran TA, 1998, J MED CHEM, V41, P2679, DOI 10.1021/jm970393l; Trivedi BK, 1998, J MED CHEM, V41, P38, DOI 10.1021/jm970065l; VARGA G, 1995, EUR J PHARMACOL, V286, P109, DOI 10.1016/0014-2999(95)00567-5; VIGNE P, 1997, EUR J BIOCHEM, V272, pR433; Vogel WK, 1997, MOL PHARMACOL, V52, P1087, DOI 10.1124/mol.52.6.1087; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang WW, 1995, P NATL ACAD SCI USA, V92, P12436, DOI 10.1073/pnas.92.26.12436; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WESS J, 1993, LIFE SCI, V53, P1447, DOI 10.1016/0024-3205(93)90618-D	80	28	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					495	504		10.1074/jbc.M006059200	http://dx.doi.org/10.1074/jbc.M006059200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11013243	hybrid			2022-12-27	WOS:000166280700067
J	Zamostiano, R; Pinhasov, A; Gelber, E; Steingart, RA; Seroussi, E; Giladi, E; Bassan, M; Wollman, Y; Eyre, HJ; Mulley, JC; Brenneman, DE; Gozes, I				Zamostiano, R; Pinhasov, A; Gelber, E; Steingart, RA; Seroussi, E; Giladi, E; Bassan, M; Wollman, Y; Eyre, HJ; Mulley, JC; Brenneman, DE; Gozes, I			Cloning and characterization of the human activity-dependent neuroprotective protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; COMPARATIVE GENOMIC HYBRIDIZATION; BREAST-CANCER; IN-VITRO; RECEPTOR; LOCALIZATION; GROWTH; VIP; IDENTIFICATION; HOMEODOMAIN	We have recently cloned the mouse activity-dependent neuroprotective protein (ADNP). Here, we disclose the cloning of human ADNP (hADNP) from a fetal brain cDNA library. Comparative sequence analysis of these two ADNP orthologs indicated 90% identity at the mRNA level. Several single nucleotide polymorphic sites were noticed. The deduced protein structure contained nine zinc fingers, a proline-rich region, a nuclear bipartite localization signal, and a homeobox domain profile, suggesting a transcription factor function. Further comparative analysis identified an ADNP paralog (33% identity and 46% similarity), indicating that these genes belong to a novel protein family with a nine-zinc finger motif followed by a homeobox domain. The hADNP gene structure spans similar to 40 kilobases and includes five exons and four introns with alternative splicing of an untranslated second exon. The hADNP gene was mapped to chromosome 20q12-13.2, a region associated with aggressive tumor growth, frequently amplified in many neoplasias, including breast, bladder, ovarian, pancreatic, and colon cancers, hADNP mRNA is abundantly expressed in distinct normal tissues, and high expression levels were encountered in malignant cells. Down-regulation of ADNP by antisense oligodeoxynucleotides up-regulated the tumor suppressor p53 and reduced the viability of intestinal cancer cells by 90%. Thus, ADNP is implicated in maintaining cell survival, perhaps through modulation of p53.	Tel Aviv Univ, Sackler Fac Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel; Agr Res Org, Volcani Ctr, Inst Anim Sci, IL-50250 Bet Dagan, Israel; Tel Aviv Med Ctr & Sch Med, Dept Nephrol, IL-64239 Tel Aviv, Israel; Univ Adelaide, Dept Genet, Adelaide, SA 5006, Australia; NICHD, Dev Neurobiol Lab, Sect Dev & Mol Pharmacol, NIH, Bethesda, MD 20892 USA	Tel Aviv University; Sackler Faculty of Medicine; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; Tel Aviv University; Sackler Faculty of Medicine; University of Adelaide; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Gozes, I (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel.	igozes@post.tau.ac.il	Pinhasov, Albert/X-5304-2019	Pinhasov, Albert/0000-0001-8116-4565	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000047] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Amson R, 2000, P NATL ACAD SCI USA, V97, P5346, DOI 10.1073/pnas.97.10.5346; Ashur-Fabian O, 1997, J MOL NEUROSCI, V9, P211, DOI 10.1007/BF02800503; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; Bassan M, 1999, J NEUROCHEM, V72, P1283, DOI 10.1046/j.1471-4159.1999.0721283.x; BRENNEMAN DE, 1990, J NEUROSCI RES, V25, P386, DOI 10.1002/jnr.490250316; Buniatian G, 1999, BIOL CELL, V91, P675, DOI 10.1016/S0248-4900(00)88531-7; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; DILLOM PJ, 1990, SCIENCE, V248, P1650; El-Rifai W, 1998, CANCER RES, V58, P34; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Gozes I, 1999, CURR MED CHEM, V6, P1019; GOZES I, 1991, J PHARMACOL EXP THER, V257, P959; GOZES I, 2000, IN PRESS ANN N Y ACA; GRESSENS P, 1993, NATURE, V362, P155, DOI 10.1038/362155a0; Hill JM, 1999, NEUROSCIENCE, V93, P783, DOI 10.1016/S0306-4522(99)00155-4; Hoyle J, 1997, HUM GENET, V99, P285, DOI 10.1007/s004390050356; ISOLA JJ, 1995, AM J PATHOL, V147, P905; Jeong J, 2000, DNA CELL BIOL, V19, P291, DOI 10.1089/10445490050021203; JOHNSON GP, 1991, VIROLOGY, V181, P378, DOI 10.1016/0042-6822(91)90508-9; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Lange D, 1999, HISTOL HISTOPATHOL, V14, P821, DOI 10.14670/HH-14.821; Lee TJF, 2000, J BIOMED SCI, V7, P16; LILLING G, 1994, J MOL NEUROSCI, V5, P231, DOI 10.1007/BF02736724; Maizel A, 1999, DEVELOPMENT, V126, P3183; Maruno K, 1998, P NATL ACAD SCI USA, V95, P14373, DOI 10.1073/pnas.95.24.14373; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; Palmedo G, 1997, LAB INVEST, V77, P633; Reichwald K, 2000, MAMM GENOME, V11, P182, DOI 10.1007/s003350010035; Reubi JC, 1996, ANN NY ACAD SCI, V805, P753; SAID SI, 1972, EUR J BIOCHEM, V28, P199, DOI 10.1111/j.1432-1033.1972.tb01903.x; Sonoda G, 1997, GENE CHROMOSOME CANC, V20, P320; Taguchi E, 1998, J BIOCHEM, V124, P1220, DOI 10.1093/oxfordjournals.jbchem.a022241; Tew KD, 1998, CHEM-BIOL INTERACT, V112, P199, DOI 10.1016/S0009-2797(97)00162-2; Virgolini I, 1997, EUR J CLIN INVEST, V27, P793, DOI 10.1046/j.1365-2362.1997.1990742.x; Williams SC, 1997, GENE EXPRESSION, V6, P371; Zabarovsky ER, 2000, NUCLEIC ACIDS RES, V28, P1635, DOI 10.1093/nar/28.7.1635; Zia H, 1996, CANCER RES, V56, P3486; Zupan V, 1998, J NEUROCHEM, V70, P2165	41	180	191	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					708	714		10.1074/jbc.M007416200	http://dx.doi.org/10.1074/jbc.M007416200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11013255	hybrid			2022-12-27	WOS:000166280700095
J	Jui, HY; Tseng, RJ; Wen, X; Fang, HI; Huang, LM; Chen, KY; Kung, HJ; Ann, DK; Shih, HM				Jui, HY; Tseng, RJ; Wen, X; Fang, HI; Huang, LM; Chen, KY; Kung, HJ; Ann, DK; Shih, HM			Protein-tyrosine phosphatase D1, a potential regulator and effector for Tec family kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; PLECKSTRIN HOMOLOGY DOMAINS; RI CROSS-LINKING; BRUTON TYROSINE; SIGNALING PATHWAY; SRC FAMILY; PH DOMAIN; CYTOSKELETAL PROTEIN-4.1; CONSTITUTIVE ACTIVATION; INTERLEUKIN-6 FAMILY	Etk, also named Bmx, is a member of the Tec tyrosine kinase family, which is characterized by a multimodular structure including a pleckstrin homology (PH) domain, an SH3 domain, an SH2 domain, and a catalytic domain. The signaling mechanisms regulating Etk kinase activity remain largely unknown. To identify factor(s) regulating Etk activity, we used the PH domain and a linker region of Etk as a bait for a yeast two-hybrid screen. Three independent clones encoding protein-tyrosine phosphatase D1 (PTPD1) fragments were isolated. The binding of PTPD1 to Etk is specific since PTPD1 cannot associate with either the Akt PH domain or lamin. In vitro and in vivo binding studies demonstrated that PTPD1 can interact with Etk and that residues 726-848 of PTPD1 are essential for this interaction. Deletion analysis of Etk indicated that the PH domain is essential for PTPD1 interaction. Furthermore, the Etk-PTPD1 interaction stimulated the kinase activity of Etk, resulting in an increased phosphotyrosine content in both factors. The Etk-PTPD1 interaction also increased Stat3 activation. The-effect of PTPD1 on Etk activation is specific since PTPD1 cannot potentiate Jak2 activity upon Stat3 activation In addition, Tec (but not Btk) kinase can also be activated by PTPD1. Taken together, these findings indicate that PTPD1 can selectively associate with and stimulate Tec family kinases and modulate Stat3 activation.	Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 11529, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei 11529, Taiwan; Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA	National Health Research Institutes - Taiwan; National Defense Medical Center; University of Southern California; University of California System; University of California Davis	Shih, HM (corresponding author), Natl Hlth Res Inst, Div Mol & Genom Med, 128 Sect 2,Yen Chiu Yuan Rd, Taipei 11529, Taiwan.		Kung, Hsing-Jien/C-7651-2013; Shih, Hsiu-Ming/S-7023-2018		NCI NIH HHS [CA39207] Funding Source: Medline; NIDCR NIH HHS [R01DE10742] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039207, R37CA039207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010742] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P4204, DOI 10.1073/pnas.91.10.4204; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Bhandari V, 1998, J BIOL CHEM, V273, P8691, DOI 10.1074/jbc.273.15.8691; Cao XM, 1996, MOL CELL BIOL, V16, P1595; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; Dorner C, 1998, J BIOL CHEM, V273, P20267, DOI 10.1074/jbc.273.32.20267; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Gibson S, 1996, J IMMUNOL, V156, P2716; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; HIGASHITSUJI H, 1995, ONCOGENE, V10, P407; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Ma YC, 1998, P NATL ACAD SCI USA, V95, P12197, DOI 10.1073/pnas.95.21.12197; MACHIDE M, 1995, ONCOGENE, V11, P619; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MANO H, 1995, BLOOD, V85, P343; MANO H, 1994, ONCOGENE, V9, P3205; Mano H, 1999, CYTOKINE GROWTH F R, V10, P267, DOI 10.1016/S1359-6101(99)00019-2; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; Miyazato A, 1996, CELL GROWTH DIFFER, V7, P1135; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Novina CD, 1999, MOL CELL BIOL, V19, P5014; Okoh MP, 1999, BIOCHEM BIOPH RES CO, V265, P151, DOI 10.1006/bbrc.1999.1407; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Saharinen P, 1997, BLOOD, V90, P4341; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Sartor CI, 1997, CANCER RES, V57, P978; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SAWADA M, 1994, BIOCHEM BIOPH RES CO, V203, P479, DOI 10.1006/bbrc.1994.2207; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SMITH AL, 1995, BIOCHEM BIOPH RES CO, V209, P959, DOI 10.1006/bbrc.1995.1591; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; Tomlinson MG, 1999, J BIOL CHEM, V274, P13577, DOI 10.1074/jbc.274.19.13577; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; VIHINEN M, 1995, BIOCHEMISTRY-US, V34, P1475, DOI 10.1021/bi00005a002; Vihinen M, 1996, IMMUNOL TODAY, V17, P502, DOI 10.1016/0167-5699(96)30058-3; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; WeberNordt RM, 1996, BLOOD, V88, P809; Weil D, 1997, BLOOD, V90, P4332, DOI 10.1182/blood.V90.11.4332.4332_4332_4340; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; Yamashita Y, 1997, EXP HEMATOL, V25, P211; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yao LB, 1999, J BIOL CHEM, V274, P19752, DOI 10.1074/jbc.274.28.19752; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	74	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41124	41132		10.1074/jbc.M007772200	http://dx.doi.org/10.1074/jbc.M007772200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11013262	hybrid			2022-12-27	WOS:000166114600063
J	Spittaels, K; Van den Haute, C; Van Dorpe, J; Geerts, H; Mercken, M; Bruynseels, K; Lasrado, R; Vandezande, K; Laenen, I; Boon, T; Van Lint, J; Vandenheede, J; Moechars, D; Loos, R; Van Leuven, F				Spittaels, K; Van den Haute, C; Van Dorpe, J; Geerts, H; Mercken, M; Bruynseels, K; Lasrado, R; Vandezande, K; Laenen, I; Boon, T; Van Lint, J; Vandenheede, J; Moechars, D; Loos, R; Van Leuven, F			Glycogen synthase kinase-3 beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; AMYLOID PRECURSOR PROTEIN; DISEASE-LIKE PHOSPHORYLATION; ALZHEIMER-LIKE STATE; HUMAN BRAIN TAU; INTACT-CELLS; KINASE-I; MICROTUBULE-BINDING; NEUROFIBRILLARY TANGLES; MONOCLONAL-ANTIBODIES	Protein tau filaments in brain of patients suffering from Alzheimer's disease, frontotemporal dementia, and other tauopathies consist of protein tau that is hyperphosphorylated.,The responsible kinases operating in vivo in neurons still need to be identified. Here we demonstrate that glycogen synthase kinase-3 beta (GSK-3 beta) is an effective kinase for protein tau in cerebral neurons in vivo in adult GSK-3 beta and GSK-3 beta x human tau40 transgenic mice; Phosphorylated protein tau migrates slower during electrophoretic separation and is revealed by phosphorylation-dependent anti-tau antibodies in Western blot analysis. In addition, its capacity to bind to re-assembled paclitaxel (Taxol(R))-stabilized microtubules is reduced, compared with protein tau isolated from mice not overexpressing GSK-3 beta. Co-expression of GSK-3 beta reduces the number of axonal dilations and alleviates the motoric impairment that was typical for single htau40 transgenic animals (Spittaels, K., Van den Haute, C., Van Dorpe, J., Bruynseels, K., Vandezande, K., Laenen, I., Geerts, H., Mercken, M., Sciot, R., Van Lommel, A., Loos, R., and Van Leuven, F. (1999) Am. J. Pathol. 155, 2153-2165). Although more hyperphosphorylated protein tau is available, neither an increase in insoluble protein tau aggregates nor the presence of paired helical filaments or tangles was observed. These findings could have therapeutic implications in the field of neurodegeneration, as discussed.	Katholieke Univ Leuven VIB, Ctr Human Genet, Expt Genet Grp, B-3000 Leuven, Belgium; Janssen Res Fdn, B-2340 Beerse, Belgium; Katholieke Univ Leuven, Fac Med, Dept Biochem, B-3000 Leuven, Belgium; Katholieke Univ Leuven, Dept Genet Epidemiol, B-3000 Leuven, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; Johnson & Johnson; KU Leuven; KU Leuven	Van Leuven, F (corresponding author), Katholieke Univ Leuven VIB, Ctr Human Genet, Expt Genet Grp, Campus Gasthuisberg O&N 06, B-3000 Leuven, Belgium.	fredvl@med.kuleuven.ac.be	Van Lint, Johan/P-9073-2019; Loos, Ruth J F/Q-2862-2016; Loos, Ruth/GON-5877-2022	Loos, Ruth J F/0000-0002-8532-5087; Van Lint, Johan/0000-0002-0275-571X				ANDERTON BH, 1995, NEUROBIOL AGING, V16, P389, DOI 10.1016/0197-4580(94)00160-3; Arawaka S, 1999, NEUROREPORT, V10, P993, DOI 10.1097/00001756-199904060-00018; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; Billingsley ML, 1997, BIOCHEM J, V323, P577, DOI 10.1042/bj3230577; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; Brion JP, 1999, AM J PATHOL, V154, P255, DOI 10.1016/S0002-9440(10)65272-8; Brownlees J, 1997, NEUROREPORT, V8, P3251, DOI 10.1097/00001756-199710200-00013; BueeScherrer V, 1996, MOL BRAIN RES, V39, P79, DOI 10.1016/0169-328X(96)00003-4; Dayanandan R, 1999, FEBS LETT, V446, P228, DOI 10.1016/S0014-5793(99)00222-7; DREWES G, 1997, CELL, V89, P397; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; FEIGUIN F, 1994, J CELL BIOL, V127, P1021, DOI 10.1083/jcb.127.4.1021; Gartner U, 1998, NEUROBIOL AGING, V19, P535, DOI 10.1016/S0197-4580(98)00094-3; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOTZ J, 1995, EMBO J, V14, P1304, DOI 10.1002/j.1460-2075.1995.tb07116.x; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Hall GF, 2000, J CELL SCI, V113, P1373; Hall GF, 1997, P NATL ACAD SCI USA, V94, P4733, DOI 10.1073/pnas.94.9.4733; Hanger DP, 1998, J NEUROCHEM, V71, P2465; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Hartigan JA, 1999, J BIOL CHEM, V274, P21395, DOI 10.1074/jbc.274.30.21395; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Hasegawa M, 1999, FEBS LETT, V443, P93, DOI 10.1016/S0014-5793(98)01696-2; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; Hong M, 1997, J BIOL CHEM, V272, P19547, DOI 10.1074/jbc.272.31.19547; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; ISHIGURO K, 1992, NEUROSCI LETT, V148, P202, DOI 10.1016/0304-3940(92)90839-Y; ISHIGURO K, 1993, FEBS LETT, V325, P167, DOI 10.1016/0014-5793(93)81066-9; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; Ishihara T, 1999, NEURON, V24, P751, DOI 10.1016/S0896-6273(00)81127-7; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; LAMBERTY Y, 1991, PHYSIOL BEHAV, V51, P81; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Lovestone S, 1996, NEUROSCIENCE, V73, P1145, DOI 10.1016/0306-4522(96)00126-1; Lovestone S, 1997, NEUROSCIENCE, V78, P309; MANDELKOW EM, 1995, NEUROBIOL AGING, V16, P355, DOI 10.1016/0197-4580(95)00025-A; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MASUROVSKY EB, 1983, NEUROSCIENCE, V10, P491, DOI 10.1016/0306-4522(83)90148-3; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; MERCKEN M, 1992, ACTA NEUROPATHOL, V84, P265, DOI 10.1007/BF00227819; Michel G, 1998, BBA-GEN SUBJECTS, V1380, P177, DOI 10.1016/S0304-4165(97)00139-6; Moechars D, 1996, EMBO J, V15, P1265, DOI 10.1002/j.1460-2075.1996.tb00468.x; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; Nonaka S, 1998, P NATL ACAD SCI USA, V95, P2642, DOI 10.1073/pnas.95.5.2642; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; Preuss U, 1997, J CELL SCI, V110, P789; Probst A, 2000, ACTA NEUROPATHOL, V99, P469, DOI 10.1007/s004010051148; SatoHarada R, 1996, CELL STRUCT FUNCT, V21, P283, DOI 10.1247/csf.21.283; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; Sengupta A, 1998, ARCH BIOCHEM BIOPHYS, V357, P299, DOI 10.1006/abbi.1998.0813; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; Shiurba RA, 1996, BRAIN RES, V737, P119, DOI 10.1016/0006-8993(96)00717-2; SPERBER BR, 1995, NEUROSCI LETT, V197, P149, DOI 10.1016/0304-3940(95)11902-9; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Spittaels K, 1999, AM J PATHOL, V155, P2153, DOI 10.1016/S0002-9440(10)65533-2; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; TAKEMURA R, 1992, J CELL SCI, V103, P953; Tatebayashi Y, 1999, J NEUROSCI, V19, P5245; Tesseur I, 2000, AM J PATHOL, V156, P951, DOI 10.1016/S0002-9440(10)64963-2; Torroja L, 1999, CURR BIOL, V9, P489, DOI 10.1016/S0960-9822(99)80215-2; Trinczek B, 1999, J CELL SCI, V112, P2355; Utton MA, 1997, BIOCHEM J, V323, P741, DOI 10.1042/bj3230741; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; Van Dorpe J, 2000, AM J PATHOL, V157, P1283, DOI 10.1016/S0002-9440(10)64644-5; VANLINT J, 1993, ANAL BIOCHEM, V208, P132, DOI 10.1006/abio.1993.1018; Wagner U, 1996, J CELL SCI, V109, P1537; WEBB BC, 1980, BIOCHEMISTRY-US, V19, P1993, DOI 10.1021/bi00550a041; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Yabe JT, 1999, J CELL SCI, V112, P3799; Yamaguchi H, 1996, ACTA NEUROPATHOL, V92, P232, DOI 10.1007/s004010050513	81	258	272	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41340	41349		10.1074/jbc.M006219200	http://dx.doi.org/10.1074/jbc.M006219200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007782	hybrid			2022-12-27	WOS:000166114600090
J	Attur, MG; Dave, M; Cipolletta, C; Kang, P; Goldring, MB; Patel, IR; Abramson, SB; Amin, AR				Attur, MG; Dave, M; Cipolletta, C; Kang, P; Goldring, MB; Patel, IR; Abramson, SB; Amin, AR			Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type IIIL-1 decoy receptor - Potential for pharmacological intervention	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; ARTICULAR CHONDROCYTES; ALGINATE BEADS; II RECEPTOR; IN-VIVO; RHEUMATOID-ARTHRITIS; SIGNAL-TRANSDUCTION; AFFECTED CARTILAGE; MESSENGER-RNA; EXPRESSION	Interleukin 1 (IL-1), produced by both synovial cells and chondrocytes, plays a pivotal role in the pathogenesis of cartilage destruction in osteoarthritis (OA). We examined the specific expression and function of IL-1 receptor family-related genes in human joint tissues. Gene array analysis of human normal and OA-affected cartilage showed mRNA expression of IL-1 receptor accessory protein (IL-1RAcp) and IL-1 type I receptor (IL-1RI), but not IL-1 antagonist (IL-1ra) and IL-1 type II decoy receptor (IL-1RII). Similarly, human synovial and epithelial cells showed an absence of IL-1RII mRNA. Functional genomic analyses showed that soluble (s) IL-1RII, at picomolar concentrations, but not soluble TNF receptor:Fc, significantly inhibited LL-1 beta -induced nitric oxide (NO) and/or prostaglandin E-2 production in chondrocytes, synovial and epithelial cells. In OA-affected cartilage, the IC50 for inhibition of NO production by sIL-1RII was 2 log orders lower than that for sIL-1RI. Human chondrocytes that overexpressed IL-1RII were resistant to IL-l-induced IL-1 beta mRNA accumulation and inhibition of proteoglycan synthesis. In osteoarthritis, deficient expression by chondrocytes of innate regulators or antagonists of IL-1 such as IL-1ra and IL-1RII (soluble or membrane form) may allow the catabolic effects of IL-1 to proceed unopposed. The sensitivity of IL-1 action to inhibition by sIL-1RII has therapeutic implications that could be directed toward correcting this unfavorable tissue(s) dependent imbalance.	Hosp Joint Dis & Med Ctr, Dept Rheumatol, New York, NY 10003 USA; NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Dept Med, New York, NY 10016 USA; CNRS, UMR 7561, Pharmacol Lab, F-54505 Vandoeuvre Les Nancy, France; NYU, Kaplan Canc Ctr, New York, NY 10016 USA; Beth Israel Deaconess Med Ctr, Div Rheumatol, Boston, MA 02115 USA; Harvard Univ, New England Baptist Bone & Joint Inst, Inst Med, Boston, MA 02115 USA	NYU Langone Medical Center; Hospital for Joint Disease NYULMC; New York University; New York University; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; New York University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; New England Baptist Hospital	Amin, AR (corresponding author), Hosp Joint Dis & Med Ctr, Dept Rheumatol, 301 E 17th St,Rm 1600, New York, NY 10003 USA.	amina01@popmail.med.nyu.edu		Abramson, Steven/0000-0002-0668-6344				ADAMS ME, 1992, ANAL BIOCHEM, V202, P89, DOI 10.1016/0003-2697(92)90211-O; Amin AR, 1997, J CLIN INVEST, V99, P1231, DOI 10.1172/JCI119280; Amin AR, 1996, J INFLAMM, V47, P190; Amin Ashok R., 1998, Current Opinion in Rheumatology, V10, P263, DOI 10.1097/00002281-199805000-00018; AREND WP, 1994, J IMMUNOL, V153, P4766; Attur MG, 1998, OSTEOARTHR CARTILAGE, V6, P269, DOI 10.1053/joca.1998.0120; Attur MG, 2000, J IMMUNOL, V164, P2684, DOI 10.4049/jimmunol.164.5.2684; Attur MG, 1998, P ASSOC AM PHYSICIAN, V110, P65; Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; Bendele A, 1999, ARTHRITIS RHEUM, V42, P498, DOI 10.1002/1529-0131(199904)42:3<498::AID-ANR15>3.0.CO;2-A; BURGER D, 1995, J CLIN INVEST, V96, P38, DOI 10.1172/JCI118045; Clancy RM, 1997, J CELL PHYSIOL, V172, P183, DOI 10.1002/(SICI)1097-4652(199708)172:2<183::AID-JCP5>3.0.CO;2-K; COLOTTA F, 1994, IMMUNOL TODAY, V15, P562, DOI 10.1016/0167-5699(94)90217-8; Coulter KR, 1999, AM J RESP CELL MOL, V20, P964, DOI 10.1165/ajrcmb.20.5.3458; Crofford LJ, 1997, J RHEUMATOL, V24, P15; Daun JM, 1999, J LEUKOCYTE BIOL, V65, P863, DOI 10.1002/jlb.65.6.863; Dawson J, 1999, RHEUMATOLOGY, V38, P401, DOI 10.1093/rheumatology/38.5.401; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; Ghivizzani SC, 1997, J IMMUNOL, V159, P3604; GOLDRING MB, 1986, J BIOL CHEM, V261, P9049; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; GOLDRING MB, 1988, J CLIN INVEST, V82, P2026, DOI 10.1172/JCI113823; GUO JF, 1989, CONNECT TISSUE RES, V19, P277, DOI 10.3109/03008208909043901; HAUSELMANN HJ, 1994, J CELL SCI, V107, P17; HAUSELMANN HJ, 1992, MATRIX, V12, P116; Heaney ML, 1998, J LEUKOCYTE BIOL, V64, P135, DOI 10.1002/jlb.64.2.135; Homandberg Gene A., 1999, Frontiers in Bioscience, V4, pd713, DOI 10.2741/Homandberg; Horai R, 2000, J EXP MED, V191, P313, DOI 10.1084/jem.191.2.313; Jouvenne P, 1998, ARTHRITIS RHEUM, V41, P1083, DOI 10.1002/1529-0131(199806)41:6<1083::AID-ART15>3.0.CO;2-9; LEFEBVRE V, 1991, BIOCHIM BIOPHYS ACTA, V1094, P8, DOI 10.1016/0167-4889(91)90020-X; Ma YH, 1998, ARTHRITIS RHEUM, V41, P1798, DOI 10.1002/1529-0131(199810)41:10<1798::AID-ART11>3.3.CO;2-C; Malinowsky D, 1998, FEBS LETT, V429, P299, DOI 10.1016/S0014-5793(98)00467-0; Martel-Pelletier Johanne, 1999, Frontiers in Bioscience, V4, pd694, DOI 10.2741/Martel; Melchiorri C, 1998, ARTHRITIS RHEUM-US, V41, P2165, DOI 10.1002/1529-0131(199812)41:12<2165::AID-ART11>3.3.CO;2-F; Moos V, 1999, J RHEUMATOL, V26, P870; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; PELLETIER JP, 1995, J RHEUMATOL, V22, P109; Pelletier JP, 1998, ARTHRITIS RHEUM-US, V41, P1275, DOI 10.1002/1529-0131(199807)41:7<1275::AID-ART19>3.0.CO;2-T; PENTON RG, 1997, EUR CYTOKINE NETW, V8, P265; Rauschmayr T, 1997, P NATL ACAD SCI USA, V94, P5814, DOI 10.1073/pnas.94.11.5814; RE F, 1994, J EXP MED, V179, P739, DOI 10.1084/jem.179.2.739; SYMONS JA, 1995, P NATL ACAD SCI USA, V92, P1714, DOI 10.1073/pnas.92.5.1714; Towle CA, 1997, OSTEOARTHR CARTILAGE, V5, P293, DOI 10.1016/S1063-4584(97)80008-8; van den Berg WB, 1999, Z RHEUMATOL, V58, P136, DOI 10.1007/s003930050163; Webb GR, 1998, OSTEOARTHR CARTILAGE, V6, P167, DOI 10.1053/joca.1998.0109; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	48	94	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40307	40315		10.1074/jbc.M002721200	http://dx.doi.org/10.1074/jbc.M002721200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007768	hybrid			2022-12-27	WOS:000166039500070
J	Jensen, TC; Crosson, SM; Kartha, PM; Brady, MJ				Jensen, TC; Crosson, SM; Kartha, PM; Brady, MJ			Specific desensitization of glycogen synthase activation by insulin in 3T3-L1 adipocytes - Connection between enzymatic activation and subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GLUCOSE-TRANSPORT; SKELETAL-MUSCLE; HORMONAL-STIMULATION; RAT ADIPOCYTES; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; RESISTANCE	A protocol was developed in 3T3-L1 adipocytes that resulted in the specific desensitization of glycogen synthase activation by insulin. Cells were pretreated for 15 min with 100 nM insulin, and then recovered for 1.5 h in the absence of hormone. Subsequent basal and insulin-induced phosphorylation of the insulin receptor, IRS-1, MAPK, Akt kinase, and GSK-3 were similar in control and pretreated cells. Additionally, enhanced glucose transport and incorporation into lipid in response to insulin were unaffected. However, pretreatment reduced insulin-stimulated glycogen synthesis by over 50%, due to a nearly complete inhibition of glycogen synthase activation. Removal of extracellular glucose during the recovery period blocked the increase in glycogen levels, and restored insulin-induced glycogen synthase activation. Furthermore, incubation of pretreated 3T3-L1 adipocytes with glycogenolytic agents reversed the desensitization event. Separation of cellular lysates on sucrose gradients revealed that glycogen synthase was primarily located in the dense pellet fraction, with lesser amounts in the lighter fractions. Insulin induced glycogen synthase translocation from the lighter to the denser glycogen-containing fractions. Interestingly, insulin preferentially activated translocated enzyme while having little effect on the majority of glycogen synthase activity in the pellet fraction. In insulin-pretreated cells, glycogen synthase did not return to the lighter fractions during recovery, and thus did not move in response to the second insulin exposure. These results suggest that, in 3T3-L1 adipocytes, the translocation of glycogen synthase may be an important step in the regulation of glycogen synthesis by insulin. Furthermore, intracellular glycogen levels can regulate glycogen synthase activation, potentially through modulation of enzymatic localization.	Pfizer Global Res & Dev, Dept Cell Biol, Ann Arbor, MI 48105 USA; Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	Pfizer; University of Michigan System; University of Michigan	Brady, MJ (corresponding author), Pfizer Global Res & Dev, Dept Cell Biol, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.							ALURENT D, 2000, AM J PHYSIOL, V278, pE663; Azpiazu I, 2000, AM J PHYSIOL-ENDOC M, V278, pE234, DOI 10.1152/ajpendo.2000.278.2.E234; Brady MJ, 1999, J BIOL CHEM, V274, P27497, DOI 10.1074/jbc.274.39.27497; Brady MJ, 1999, TRENDS ENDOCRIN MET, V10, P408, DOI 10.1016/S1043-2760(99)00201-5; Brady MJ, 1997, J BIOL CHEM, V272, P29698, DOI 10.1074/jbc.272.47.29698; Brady MJ, 1998, J BIOL CHEM, V273, P14063, DOI 10.1074/jbc.273.23.14063; Brau L, 1997, BIOCHEM J, V322, P303; BURANT CF, 1984, AM J PHYSIOL, V247, pE657, DOI 10.1152/ajpendo.1984.247.5.E657; Cadefau J, 1997, BIOCHEM J, V322, P745, DOI 10.1042/bj3220745; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; CONSIDINE RV, 1993, J CELL BIOCHEM, V52, P8, DOI 10.1002/jcb.240520103; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; De Luca JP, 1999, AM J PHYSIOL-HEART C, V276, pH1520, DOI 10.1152/ajpheart.1999.276.5.H1520; DELPRATO S, 1994, DIABETOLOGIA, V37, P1025, DOI 10.1007/BF00400466; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; Derave W, 1999, AM J PHYSIOL-ENDOC M, V277, pE1103, DOI 10.1152/ajpendo.1999.277.6.E1103; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V288, P497, DOI 10.1042/bj2880497; FLORESRIVEROS JR, 1993, P NATL ACAD SCI USA, V90, P512, DOI 10.1073/pnas.90.2.512; Franch J, 1999, BIOCHEM J, V344, P231, DOI 10.1042/0264-6021:3440231; GARETTO LP, 1984, AM J PHYSIOL, V246, pE471, DOI 10.1152/ajpendo.1984.246.6.E471; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Henry RR, 1996, DIABETES, V45, P400, DOI 10.2337/diabetes.45.4.400; HEYDRICK SJ, 1991, DIABETES, V40, P1707, DOI 10.2337/diabetes.40.12.1707; Holloszy John O., 1998, Frontiers in Bioscience, V3, pD1011; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; Kawanaka K, 1999, AM J PHYSIOL-ENDOC M, V276, pE907, DOI 10.1152/ajpendo.1999.276.5.E907; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; LAWRENCE JC, 1978, J BIOL CHEM, V253, P2104; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LAWRENCE JC, 1984, J BIOL CHEM, V259, P7975; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Montell E, 1999, AM J PHYSIOL-REG I, V276, pR1489, DOI 10.1152/ajpregu.1999.276.5.R1489; MOULE SK, 1995, BIOCHEM J, V311, P595, DOI 10.1042/bj3110595; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; Orena SJ, 2000, J BIOL CHEM, V275, P15765, DOI 10.1074/jbc.M910002199; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Ragolia L, 1998, MOL CELL BIOCHEM, V182, P49, DOI 10.1023/A:1006827227162; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; RICORT JM, 1995, DIABETOLOGIA, V38, P1148, DOI 10.1007/s001250050406; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SMITH RL, 1988, J BIOL CHEM, V263, P658; SMITH RL, 1984, J BIOL CHEM, V259, P2201; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; Summers SA, 1999, J BIOL CHEM, V274, P23858, DOI 10.1074/jbc.274.34.23858; TANTI JF, 1993, AM J PHYSIOL, V264, pE868, DOI 10.1152/ajpendo.1993.264.6.E868; Thomson MJ, 1997, J BIOL CHEM, V272, P7759, DOI 10.1074/jbc.272.12.7759; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078; VILLARPALASI C, 1995, BBA-GEN SUBJECTS, V1244, P203, DOI 10.1016/0304-4165(95)00006-W; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442	54	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40148	40154		10.1074/jbc.M004902200	http://dx.doi.org/10.1074/jbc.M004902200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11013239	hybrid			2022-12-27	WOS:000166039500049
J	Morris, DP; Greenleaf, AL				Morris, DP; Greenleaf, AL			The splicing factor, Prp40, binds the phosphorylated carboxyl-terminal domain of RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; UBIQUITIN-PROTEIN LIGASE; SACCHAROMYCES-CEREVISIAE; LARGEST SUBUNIT; CAPPING ENZYME; IN-VIVO; 3'-END FORMATION; NUCLEAR MATRIX; WW DOMAINS; TRANSCRIPTION	We showed previously that the WW domain of the prolyl isomerase, Ess1, can bind the phosphorylated carboxyl-terminal domain (phospho-CTD) of the largest subunit of RNA Polymerase II. Analysis of phospho-CTD binding by four other WW domain-containing Saccharomyces cerevisiae proteins indicates the splicing factor, Prp40, and the RNA polymerase II ubiquitin ligase, Rsp5, can also bind the phospho-CTD. The identification of Prp40 as a phospho-CTD binding protein represents the first demonstration of direct interaction between a documented splicing factor and the phospho-CTD. Domain dissection studies reveal that phospho-CTD binding occurs at multiple locations in Prp40, including sites in both the WW and FF domain regions. Because the conserved repeats of the CTD make it an ideal ligand for multi-site binding events, the implications of multi-site binding are discussed. Our data suggest a mechanism by which the phospho-CTD of elongating RNA polymerase II facilitates commitment complex formation by juxtaposing the 5' and 3' splice sites.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Greenleaf, AL (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.							Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; Beaudenon SL, 1999, MOL CELL BIOL, V19, P6972; Bedford MT, 1999, TRENDS BIOCHEM SCI, V24, P264, DOI 10.1016/S0968-0004(99)01417-6; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Burge CB, 1999, RNA WORLD, P525; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CAGAS PM, 1995, PROTEINS, V21, P149, DOI 10.1002/prot.340210209; Carty SM, 2000, P NATL ACAD SCI USA, V97, P9015, DOI 10.1073/pnas.160266597; Cho EJ, 1998, GENE DEV, V12, P3482, DOI 10.1101/gad.12.22.3482; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; GREENLEAF AL, 1993, TRENDS BIOCHEM SCI, V18, P117, DOI 10.1016/0968-0004(93)90016-G; Hani J, 1999, J BIOL CHEM, V274, P108, DOI 10.1074/jbc.274.1.108; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; Hirose Y, 1999, GENE DEV, V13, P1234, DOI 10.1101/gad.13.10.1234; Hirose Y, 2000, GENE DEV, V14, P1415; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; JENCKS WP, 1981, P NATL ACAD SCI USA, V78, P4056; Kao HY, 1996, MOL CELL BIOL, V16, P960; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; Linn H, 1997, BIOL CHEM, V378, P531, DOI 10.1515/bchm.1997.378.6.531; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Morris DP, 1997, METHODS, V12, P264, DOI 10.1006/meth.1997.0478; Morris DP, 1999, J BIOL CHEM, V274, P31583, DOI 10.1074/jbc.274.44.31583; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; Neubauer G, 1997, P NATL ACAD SCI USA, V94, P385, DOI 10.1073/pnas.94.2.385; Neugebauer KM, 1997, GENE DEV, V11, P3279, DOI 10.1101/gad.11.24.3279; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Snaar SP, 1999, J HISTOCHEM CYTOCHEM, V47, P245, DOI 10.1177/002215549904700213; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; Tanner S, 1997, BIOL CHEM, V378, P565; Vincent M, 1996, NUCLEIC ACIDS RES, V24, P4649, DOI 10.1093/nar/24.23.4649; Wang GL, 1999, MOL CELL BIOL, V19, P342; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975	45	147	148	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39935	39943		10.1074/jbc.M004118200	http://dx.doi.org/10.1074/jbc.M004118200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10978320	hybrid			2022-12-27	WOS:000166039500022
J	Okajima, T; Nakamura, Y; Uchikawa, M; Haslam, DB; Numata, S; Furukawa, K; Urano, T; Furukawa, K				Okajima, T; Nakamura, Y; Uchikawa, M; Haslam, DB; Numata, S; Furukawa, K; Urano, T; Furukawa, K			Expression cloning of human globoside synthase cDNAs - Identification of beta 3Gal-T3 as UDP-N-acetylgalactosamine: Globotriaosylceramide beta 1,3-N-acetylgalactosaminyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; BINDING-SPECIFICITY; GENE; GALACTOSE; BETA-1,3-GALACTOSYLTRANSFERASE; FAMILY; CELLS; PK; BIOSYNTHESIS; GLYCOLIPIDS	By using a eukaryocytic cell expression cloning system, we have isolated cDNAs of the globoside synthase (beta1,3-N-acetylgalactosaminyltransferase) gene. Mouse fibroblast L cells transfected with SV40 large T antigen and previously cloned Gb3/CD77 synthase cDNAs were co-transfected with a cDNA library prepared from mRNA from human kidney together with Forssman synthase cDNA, and Forssman antigen-positive cells were panned using an anti-Forssman monoclonal antibody. The isolated cDNAs contained a single open reading frame predicting a type II membrane protein with 351 amino acids. Surprisingly, the cDNA clones turned out to be identical with previously reported beta 3Gal-T3, which had been cloned by sequence homology with other galactosyltransferases. Substrate specificity analysis with extracts from cDNA-transfected L cells confirmed that the gene product was actually pl,3-N-acetylgalactosaminyltransferase that specifically catalyzes the transfer of N-acetylgalactosamine onto globotriaosylceramide. Results of TLC immunostaining of neutral glycolipids from the cDNA-transfected cells also supported the identity of the newly synthesized component as globoside. The results show that glycosyltransferases apparently belonging to a single glycosyltransferase family do not necessarily catalyze reactions utilizing the same acceptor or even the same sugar donor. The globoside synthase gene was expressed in many tissues, such as heart, brain, testis, etc. We propose the designation beta 3GalNAc-T1 for the cloned globoside synthase gene.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Japanese Red Cross Cent Blood Ctr, Shibuya Ku, Tokyo 150, Japan; Washington Univ, Sch Med, Dept Pediat, Child Hlth Res Ctr Excellence Dev Biol, St Louis, MO 63110 USA	Nagoya University; Japanese Red Cross Medical Center; Washington University (WUSTL)	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp	Okajima, Tetsuya/I-7332-2014; Haslam, David/G-3825-2012	Okajima, Tetsuya/0000-0002-3677-648X; Urano, Takeshi/0000-0003-3383-3554	NIAID NIH HHS [R29 AI042817] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI042817] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; Bennett EP, 1999, FEBS LETT, V460, P226, DOI 10.1016/S0014-5793(99)01268-5; BOYD B, 1993, J EXP MED, V177, P1745, DOI 10.1084/jem.177.6.1745; CHIEN JL, 1973, J BIOL CHEM, V248, P1778; DEGRANDIS S, 1989, J BIOL CHEM, V264, P12520; FELLOUS M, 1974, VOX SANG, V26, P518, DOI 10.1111/j.1423-0410.1974.tb02729.x; FURUKAWA K, 1985, BIOCHEMISTRY-US, V24, P7820, DOI 10.1021/bi00347a047; HAKOMORI SI, 1986, CHEM PHYS LIPIDS, V42, P209, DOI 10.1016/0009-3084(86)90054-X; Haslam DB, 1996, P NATL ACAD SCI USA, V93, P10697, DOI 10.1073/pnas.93.20.10697; HILDEBRAND J, 1969, J BIOL CHEM, V244, P5170; ISHIBASHI T, 1974, BIOCHIM BIOPHYS ACTA, V337, P92; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; Keusch JJ, 2000, J BIOL CHEM, V275, P25315, DOI 10.1074/jbc.M002630200; KIJIMOTOOCHIAI S, 1977, P NATL ACAD SCI USA, V74, P5407, DOI 10.1073/pnas.74.12.5407; Kojima Y, 2000, J BIOL CHEM, V275, P15152, DOI 10.1074/jbc.M909620199; Kolbinger F, 1998, J BIOL CHEM, V273, P433, DOI 10.1074/jbc.273.1.433; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUND B, 1985, J BACTERIOL, V162, P1293, DOI 10.1128/JB.162.3.1293-1301.1985; MARCUS DM, 1976, P NATL ACAD SCI USA, V73, P3263, DOI 10.1073/pnas.73.9.3263; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NAIKI M, 1975, BIOCHEMISTRY-US, V14, P4837, DOI 10.1021/bi00693a010; NAIKI M, 1975, BIOCHEMISTRY-US, V14, P4831, DOI 10.1021/bi00693a009; Okajima T, 1999, J BIOL CHEM, V274, P11479, DOI 10.1074/jbc.274.17.11479; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Song Y, 1998, J BIOL CHEM, V273, P2517, DOI 10.1074/jbc.273.5.2517; Steffensen R, 2000, J BIOL CHEM, V275, P16723, DOI 10.1074/jbc.M000728200; SUZUKI A, 1980, J LIPID RES, V21, P473; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P455; TAKI T, 1994, ANAL BIOCHEM, V221, P312, DOI 10.1006/abio.1994.1418; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; TYRRELL GJ, 1992, P NATL ACAD SCI USA, V89, P524, DOI 10.1073/pnas.89.2.524; WIELS J, 1981, P NATL ACAD SCI-BIOL, V78, P6485, DOI 10.1073/pnas.78.10.6485; Xu HJ, 1999, J BIOL CHEM, V274, P29390, DOI 10.1074/jbc.274.41.29390; YAMAKAWA T, 1952, J BIOCHEM-TOKYO, V39, P393, DOI 10.1093/oxfordjournals.jbchem.a126309; YAMASHIRO S, 1995, J BIOL CHEM, V270, P6149, DOI 10.1074/jbc.270.11.6149; Zhou DP, 1999, EUR J BIOCHEM, V263, P571, DOI 10.1046/j.1432-1327.1999.00541.x; Zhou DP, 2000, J BIOL CHEM, V275, P22631, DOI 10.1074/jbc.C000263200; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	43	55	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40498	40503		10.1074/jbc.M006902200	http://dx.doi.org/10.1074/jbc.M006902200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10993897	hybrid			2022-12-27	WOS:000166039500094
J	Perzov, N; Nelson, H; Nelson, N				Perzov, N; Nelson, H; Nelson, N			Altered distribution of the yeast plasma membrane H+-ATPase as a feature of vacuolar H+-ATPase null mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; SACCHAROMYCES-CEREVISIAE; PHOSPHORYLATION DOMAIN; ENDOPLASMIC-RETICULUM; DIRECTED MUTAGENESIS; SECRETORY PATHWAY; PROTEIN; ACIDIFICATION; TRANSPORT; GOLGI	The effect of vacuolar H+-ATPase (V-ATPase) null mutations on the targeting of the plasma membrane HC ATPase (Pma1p) through the secretory pathway was analyzed. Gas1p, which is another plasma membrane component, was used as a control for the experiments with Pma1p. Contrary to Gas1p, which is not affected by the deletion of the V-ATPase complex in the V-ATPase null mutants, the amount of Pma1p in the plasma membrane is markedly reduced, and there is a large accumulation of the protein in the endoplasmic reticulum. Kex2p and Gef1p, which are considered to reside in the post-Golgi vesicles, were suggested as required for the V-ATPase function; hence, their null mutant phenotype should have been similar to the V-ATPase null mutants. We show that, in addition to the known differences between those yeast phenotypes, deletions of KEX2 or GEF1 in yeast do not affect the distribution of Pma1p as the V-ATPase null mutant does. The possible location of the vital site of acidification by V-ATPase along the secretory pathway is discussed.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel	Tel Aviv University	Nelson, N (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.	nelson@post.tau.ac.il						Ambesi A, 2000, J EXP BIOL, V203, P155; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; BLANPAIN JP, 1992, J BIOL CHEM, V267, P3735; BRADA D, 1988, J BACTERIOL, V170, P2775, DOI 10.1128/jb.170.6.2775-2783.1988; Catty P, 1997, FEBS LETT, V409, P325, DOI 10.1016/S0014-5793(97)00446-8; CHANG A, 1995, J CELL BIOL, V128, P39, DOI 10.1083/jcb.128.1.39; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; Cohen A, 1999, J BIOL CHEM, V274, P26885, DOI 10.1074/jbc.274.38.26885; Cohen A, 2000, J BIOL CHEM, V275, P33388, DOI 10.1074/jbc.M004611200; DeWitt ND, 1998, J BIOL CHEM, V273, P21744, DOI 10.1074/jbc.273.34.21744; dExaerde AD, 1996, YEAST, V12, P907; Doering TL, 1996, EMBO J, V15, P182, DOI 10.1002/j.1460-2075.1996.tb00346.x; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; FANKHAUSER C, 1991, EUR J BIOCHEM, V195, P439, DOI 10.1111/j.1432-1033.1991.tb15723.x; Forgac M, 1998, FEBS LETT, V440, P258, DOI 10.1016/S0014-5793(98)01425-2; Gaxiola RA, 1998, P NATL ACAD SCI USA, V95, P4046, DOI 10.1073/pnas.95.7.4046; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KLIONSKY DJ, 1992, J BIOL CHEM, V267, P3416; KOLAND JG, 1986, J BIOL CHEM, V261, P5936; Linstedt AD, 1997, MOL BIOL CELL, V8, P1073, DOI 10.1091/mbc.8.6.1073; Luo WJ, 1997, J CELL BIOL, V138, P731, DOI 10.1083/jcb.138.4.731; Luo WJ, 2000, MOL BIOL CELL, V11, P579, DOI 10.1091/mbc.11.2.579; Lupashin VV, 1997, MOL BIOL CELL, V8, P2659, DOI 10.1091/mbc.8.12.2659; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MELLMAN I, 1992, J EXP BIOL, V172, P39; MORANO KA, 1994, J CELL SCI, V107, P2813; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; Nakamoto RK, 1998, J BIOL CHEM, V273, P7338, DOI 10.1074/jbc.273.13.7338; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1983, METHOD ENZYMOL, V97, P510; Nelson N, 1996, EXPERIENTIA, V52, P1101, DOI 10.1007/BF01952108; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; Oluwatosin YE, 1998, MOL CELL BIOL, V18, P1534, DOI 10.1128/MCB.18.3.1534; Palokangas H, 1998, MOL BIOL CELL, V9, P3561, DOI 10.1091/mbc.9.12.3561; PERLIN DS, 1992, ACTA PHYSIOL SCAND, V146, P183; Perzov N, 1998, ACTA PHYSIOL SCAND, V163, P185; PETROV VV, 1995, J BIOL CHEM, V270, P28535, DOI 10.1074/jbc.270.48.28535; RAO R, 1993, J BIOL CHEM, V268, P6708; Roberg KJ, 1999, J CELL BIOL, V145, P659, DOI 10.1083/jcb.145.4.659; Roberg KJ, 1997, J CELL BIOL, V137, P1469, DOI 10.1083/jcb.137.7.1469; Schwappach B, 1998, J BIOL CHEM, V273, P15110, DOI 10.1074/jbc.273.24.15110; SERRANO R, 1993, FEBS LETT, V325, P108, DOI 10.1016/0014-5793(93)81424-X; SetoYoung D, 1997, BBA-BIOMEMBRANES, V1326, P249, DOI 10.1016/S0005-2736(97)00028-X; SLAYMAN CL, 1987, J BIOENERG BIOMEMBR, V19, P1; Sorin A, 1997, J BIOL CHEM, V272, P9895; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; Wang GF, 1996, J BIOL CHEM, V271, P25438, DOI 10.1074/jbc.271.41.25438; Wang QQ, 1999, EMBO J, V18, P5972, DOI 10.1093/emboj/18.21.5972; Wendland B, 1998, CURR OPIN CELL BIOL, V10, P513, DOI 10.1016/S0955-0674(98)80067-7; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; YAVER DS, 1993, J BIOL CHEM, V268, P10564	59	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40088	40095		10.1074/jbc.M007011200	http://dx.doi.org/10.1074/jbc.M007011200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007788	hybrid, Green Submitted			2022-12-27	WOS:000166039500041
J	Brin, E; Yi, JZ; Skalka, AM; Leis, J				Brin, E; Yi, JZ; Skalka, AM; Leis, J			Modeling the late steps in HIV-1 retroviral integrase-catalyzed DNA integration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; IN-VITRO; VIRAL-DNA; SUBSTRATE-SPECIFICITY; PROTEIN; REQUIREMENT; DOMAIN; ENDS; ENDONUCLEASE; SEQUENCES	Model oligodeoxyribonucleotide substrates representing viral DNA integration intermediates with a gap and a two-nucleotide 5 ' overhang were used to examine late steps in human immunodeficiency virus, type 1 (HIV-1) retroviral integrase (IN)-cataIyzed DNA integration in vitro. HIV-1 or avian myeloblastosis virus reverse transcriptase (RT) were capable of quantitatively filling in the gap to create a nicked substrate but did not remove the 5 ' overhang. HIV-1 IN also failed to remove the 5 ' overhang with the gapped substrate. However, with a nicked substrate formed by RT, HIV-1 IN removed the overhang and covalently closed the nick in a disintegration-like reaction. The efficiency of this closure reaction was very low, Such closure was not stimulated by the addition of HMG-(I/Y), suggesting that this protein only acts during the early processing and joining reactions. Addition of Flap endonuclease-1, a nuclease known to remove 5 ' overhangs, abolished the closure reaction catalyzed by IN, A series of base pair inversions, introduced into the HIV-1 U5 long terminal repeat sequence adjacent to and/or including the conserved CA dinucleotide, produced no or only a small. decrease in the HIV-1 IN-dependent strand closure reaction. These same mutations caused a significant decrease in the efficiency of concerted DNA integration by a modified donor DNA in vitro, suggesting that recognition of the ends of the long terminal repeat sequence is required only in the early steps of DNA integration, Finally, a combination of HIV-1 RT,Flap endonuclease-1, and DNA ligase is capable of quantitatively forming covalently closed DNA with these model substrates, These results support the hypothesis that cellular enzyme(s) may catalyze the late steps of retroviral DNA integration.	Northwestern Univ, Sch Med, Dept Microbiol & Immunol, Chicago, IL 60611 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Northwestern University; Fox Chase Cancer Center	Leis, J (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol & Immunol, 303 E Chicago Ave, Chicago, IL 60611 USA.				NCI NIH HHS [CA38046, CA49042, CA06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049042, R01CA038046, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aiyar A, 1996, J VIROL, V70, P3571, DOI 10.1128/JVI.70.6.3571-3580.1996; Balakrishnan M, 1997, J VIROL, V71, P1025, DOI 10.1128/JVI.71.2.1025-1035.1997; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; Carteau S, 1999, J VIROL, V73, P6670, DOI 10.1128/JVI.73.8.6670-6679.1999; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; COLLETT MS, 1978, J VIROL, V26, P498, DOI 10.1128/JVI.26.2.498-509.1978; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hindmarsh P, 1999, J VIROL, V73, P2994, DOI 10.1128/JVI.73.4.2994-3003.1999; Hindmarsh P, 1999, MICROBIOL MOL BIOL R, V63, P836, DOI 10.1128/MMBR.63.4.836-843.1999; HOTTIGER M, 1994, J BIOL CHEM, V269, P986; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KUKOLJ G, 1995, GENE DEV, V9, P2556, DOI 10.1101/gad.9.20.2556; KULKOSKY J, 1995, VIROLOGY, V206, P448, DOI 10.1016/S0042-6822(95)80060-3; MARUSYK R, 1980, ANAL BIOCHEM, V105, P403, DOI 10.1016/0003-2697(80)90477-7; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; MURANTE RS, 1994, J BIOL CHEM, V270, P30377; NISSEN MS, 1995, J BIOL CHEM, V270, P4355, DOI 10.1074/jbc.270.9.4355; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SHERMAN PA, 1992, J VIROL, V66, P3593, DOI 10.1128/JVI.66.6.3593-3601.1992; VANDENENT FMI, 1994, J VIROL, V68, P7825, DOI 10.1128/JVI.68.12.7825-7832.1994; VINCENT KA, 1990, NUCLEIC ACIDS RES, V18, P6045, DOI 10.1093/nar/18.20.6045; VINK C, 1990, J VIROL, V64, P5626, DOI 10.1128/JVI.64.11.5626-5627.1990; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036	32	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39287	39295		10.1074/jbc.M006929200	http://dx.doi.org/10.1074/jbc.M006929200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11006285	hybrid			2022-12-27	WOS:000165953100048
J	Chimploy, K; Tassotto, ML; Mathews, CK				Chimploy, K; Tassotto, ML; Mathews, CK			Ribonucleotide reductase, a possible agent in deoxyribonucleotide pool asymmetries induced by hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-SYNTHESIS; RECOMBINANT MOUSE; MECHANISM; SUBUNIT; CELLS; PURIFICATION; REPLICATION; OXYGEN; ASSAY; R2	While investigating the basis for marked natural asymmetries in deoxyribonucleoside triphosphate (dNTP) pools in mammalian cells, we observed that culturing V79 hamster lung cells in a 2% oxygen atmosphere causes 2-3-fold expansions of the dATP, dGTP, and dTTP pools, whereas dCTP declines by a comparable amount. Others have made similar observations and have proposed that, because O-2 is required for formation of the catalytically essential oxygen-bridged iron center in ribonucleotide reductase, dCTP depletion at low oxygen tension results from direct or indirect effects upon ribonucleotide reductase, We have tested the hypothesis that oxygen limitation affects ribonucleotide specificity using recombinant mouse ribonucleotide reductase and an assay that permits simultaneous monitoring of the reduction of all four nucleotide substrates, Preincubation and assay of the enzyme in an anaerobic chamber caused only partial activity loss. Accordingly, me treated the enzyme with hydroxyurea, followed by removal of the hydroxyurea and exposure to atmospheres of varying oxygen content. The activity was totally depleted by hydroxyurea treatment and nearly fully regained by exposure to air. By the criterion of activities regained at different oxygen tensions, we found CDP reduction not to be specifically sensitive to oxygen depletion; however, GDP reduction was specifically sensitive, The basis for the differential response to reactivation by O-2 is not known, but it evidently does not involve varying rates of reactivation of different allosteric forms of the enzyme or altered response to allosteric effecters at reduced oxygen tension.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Mathews, CK (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 55134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARECCO A, 1988, MUTAT RES, V200, P165, DOI 10.1016/0027-5107(88)90079-6; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; Brischwein K, 1997, EUR J BIOCHEM, V244, P286, DOI 10.1111/j.1432-1033.1997.00286.x; DAVIS R, 1994, J BIOL CHEM, V269, P23171; Hendricks SP, 1998, J BIOL CHEM, V273, P29512, DOI 10.1074/jbc.273.45.29512; Hendricks SP, 1997, J BIOL CHEM, V272, P2861, DOI 10.1074/jbc.272.5.2861; LEEDS JM, 1987, MOL CELL BIOL, V7, P532, DOI 10.1128/MCB.7.1.532; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MATHERLY LH, 1989, ANAL BIOCHEM, V182, P338, DOI 10.1016/0003-2697(89)90605-2; MATHEWS CK, 1992, BIOESSAYS, V14, P295, DOI 10.1002/bies.950140502; Mole ML, 1998, ANAL BIOCHEM, V259, P245, DOI 10.1006/abio.1998.2647; NORTH TW, 1980, J BIOL CHEM, V255, P6640; OCHIAI EI, 1990, J BIOL CHEM, V265, P15758; Probst G, 1999, BIOL CHEM, V380, P1371, DOI 10.1515/BC.1999.177; PROBST H, 1988, CANCER RES, V48, P2053; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Schmidt PP, 1998, J BIOL CHEM, V273, P21463, DOI 10.1074/jbc.273.34.21463; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Sjoberg BM, 1997, STRUCT BOND, V88, P139; SLABAUGH MB, 1984, J VIROL, V52, P501, DOI 10.1128/JVI.52.2.501-506.1984; THELANDER L, 1983, BIOCHEM BIOPH RES CO, V110, P859, DOI 10.1016/0006-291X(83)91040-9; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361	23	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39267	39271		10.1074/jbc.M006233200	http://dx.doi.org/10.1074/jbc.M006233200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11006282	hybrid			2022-12-27	WOS:000165953100045
J	Gesbert, F; Sellers, WR; Signoretti, S; Loda, M; Griffin, JD				Gesbert, F; Sellers, WR; Signoretti, S; Loda, M; Griffin, JD			BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27(Kip1) through the phosphatidylinositol 3-kinase/AKT pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL ONCOGENE; HEMATOPOIETIC-CELLS; TYROSINE KINASE; C-ABL; SIGNAL TRANSDUCERS; PROGENITOR CELLS; POSITIVE CELLS; CDK INHIBITORS	Deregulation of cell cycle checkpoints is an almost universal abnormality in human cancers and is most often due to loss-of-function mutations of tumor suppressor genes such as Rb, p53, or p16(INK4a). In this study, we demonstrate that BCR/ABL inhibits the expression of a key cell cycle inhibitor, p27(Kip1), by signaling through a pathway involving phosphatidylinositol 3-kinase (PI3K). p27(Kip1) is a widely expressed inhibitor of cdk2, an essential cell cycle kinase regulating entry into S phase. We demonstrate that the decrease of p27(Kip1) is directly due to BCR/ABL in hematopoietic cells by two different approaches. First, induction of BCR/ABL by a tetracycline-regulated promoter is associated with a reversible down-regulation of p27(Kip1). Second, inhibition of BCR/ABL kinase activity with the Abl tyrosine kinase inhibitor STI571 rapidly increases p27(Kip1) levels. The PI3K inhibitor LY-294002 blocks the ability of BCR/ABL to induce p27(Kip1) down-regulation and inhibits BCR/ ABL-induced entry into S phase. The serine/threonine kinase AKT/protein kinase B is a known downstream target of PI3K. Transient expression of an activated mutant of AKT was found to decrease expression of p27(Kip1), even when PI3K was inhibited by LY-294002. The mechanism of p27(Kip1) regulation is primarily related to protein stability, since inhibition of proteasome activity increased p27(Kip1) levels in BCR/ABL-transformed cells, whereas very little change in p27 transcription was found. Overall, these data are consistent with a model in which BCR/ABL suppresses p27(Kip1) protein levels through PI3K/AKT, leading to accelerated entry into S phase. This activity is likely to explain in part previous studies showing that activation of PI3K was required for optimum transformation of hematopoietic cells by BCR/ABL in vitro and in vivo.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Griffin, JD (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.			Gesbert, Franck/0000-0002-5800-8385				AFAR DEH, 1995, P NATL ACAD SCI USA, V92, P9540, DOI 10.1073/pnas.92.21.9540; AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; BEDI A, 1994, BLOOD, V83, P2038; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; DellaRagione F, 1997, BIOCHEM BIOPH RES CO, V231, P73, DOI 10.1006/bbrc.1997.5938; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; EAVES AC, 1986, P NATL ACAD SCI USA, V83, P5306, DOI 10.1073/pnas.83.14.5306; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; GORDON MY, 1989, CURR TOP MICROBIOL, V149, P151; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; Kramer A, 1999, P NATL ACAD SCI USA, V96, P2087, DOI 10.1073/pnas.96.5.2087; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; LI Y, 1994, ONCOGENE, V9, P2261; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MANDANAS RA, 1992, LEUKEMIA, V6, P796; MANDANAS RA, 1993, BLOOD, V82, P1838; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Melo JV, 1996, LEUKEMIA, V10, P751; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; ODA T, 1994, J BIOL CHEM, V269, P22925; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PELICCI G, 1995, ONCOGENE, V11, P899; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Quackenbush RC, 2000, BLOOD, V95, P2913, DOI 10.1182/blood.V95.9.2913.009k32_2913_2921; Salgia R, 1996, EXP HEMATOL, V24, P310; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; Sattler M, 1996, ONCOGENE, V12, P839; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Shuai K, 1996, ONCOGENE, V13, P247; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334	65	188	194	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39223	39230		10.1074/jbc.M007291200	http://dx.doi.org/10.1074/jbc.M007291200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11010972	hybrid			2022-12-27	WOS:000165953100039
J	Kim, TH; Zhao, YG; Barber, MJ; Kuharsky, DK; Yin, XM				Kim, TH; Zhao, YG; Barber, MJ; Kuharsky, DK; Yin, XM			Bid-induced cytochrome c release is mediated by a pathway independent of mitochondrial permeability transition pore and bax	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; LIVER-MITOCHONDRIA; OUTER-MEMBRANE; DEFICIENT MICE; CELL-DEATH; APOPTOSIS; ACTIVATION; PROTEINS; CHANNEL; TRANSIENT	Bid, a pro-apoptosis "BH3-only" member of the Bcl-2 family, can be cleaved by caspase-8 after Fas/TNF-R1 engagement. The p15 form of truncated Bid (tBid) translocates to mitochondria and induces cytochrome c release, leading to the activation of downstream caspases and apoptosis. In the current study, we investigated the mechanism by which tBid regulated cytochrome c release in terms of its relationship to mitochondrial permeability transition and Bax, another Bcl-2 family protein. We employed an in vitro reconstitution system as well as cell cultures and an animal model to reflect the physiological environment where Bid could be functional. We found that induction of cytochrome c release by tBid was not accompanied by a permeability transition even at high doses. Indeed, inhibition of permeability transition did not suppress the activity of tBid in vitro nor could they block Pas activation-induced, Bid-dependent hepatocyte apoptosis in cultures. Furthermore, Mg2+, although inhibiting permeability transition, actually enhanced the ability of tBid to induce cytochrome c release. We also found that tBid did not require Bax to induce cytochrome c release in vitro. In addition, mice deficient in bat were still highly susceptible to anti-Fas-induced hepatocyte apoptosis, in which cytochrome c release was unaffected. Moreover, although Bax-induced cytochrome c release was not dependent on tBid, the two proteins could function synergistically. We conclude that Bid possesses the biochemical activity to induce cytochrome c release through a mechanism independent of mitochondrial permeability transition pore and Bax.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University System of Florida; University of South Florida	Yin, XM (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, 200 Lothrop St, Pittsburgh, PA 15261 USA.	xmyin@pitt.edu			NCI NIH HHS [K01-CA74885] Funding Source: Medline; NIGMS NIH HHS [GM-32696] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA074885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032696] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; ELLIS RE, 1991, GENETICS, V129, P79; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Feldmann G, 2000, HEPATOLOGY, V31, P674, DOI 10.1002/hep.510310318; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HASHIMOTO K, 1983, BIOCHEMISTRY-US, V22, P5738, DOI 10.1021/bi00294a010; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kantrow SP, 1997, BIOCHEM BIOPH RES CO, V232, P669, DOI 10.1006/bbrc.1997.6353; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Lemasters JJ, 1998, BIOFACTORS, V8, P283, DOI 10.1002/biof.5520080316; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; ROBERTSON DE, 1983, J BIOL CHEM, V258, P1039; ROTTENBERG H, 1984, J MEMBRANE BIOL, V81, P127, DOI 10.1007/BF01868977; Scarlett JL, 1997, FEBS LETT, V418, P282, DOI 10.1016/S0014-5793(97)01391-4; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1997, BRIT MED BULL, V53, P478; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	52	156	165	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39474	39481		10.1074/jbc.M003370200	http://dx.doi.org/10.1074/jbc.M003370200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10982793	hybrid			2022-12-27	WOS:000165953100073
J	Lin, FLM; Majumdar, A; Klotz, LC; Reszka, AP; Neidle, S; Seidman, MM				Lin, FLM; Majumdar, A; Klotz, LC; Reszka, AP; Neidle, S; Seidman, MM			Stability of DNA triplexes on shuttle vector plasmids in the replication pool in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM-MEDIATED INHIBITION; POTENTIAL ANTICANCER AGENTS; KI-RAS PROMOTER; HELIX FORMATION; 3RD STRAND; FORMING OLIGONUCLEOTIDES; INTRACELLULAR STABILITY; KINETIC-ANALYSIS; BINDING PROTEIN; IN-VITRO	Triple helix-forming oligonucleotides may be useful as gene-targeting reagents in vivo, for applications such as gene knockout. One important property of these complexes is their often remarkable stability, as demonstrated in solution and in cells following transfection, Although encouraging, these measurements do not necessarily report tripler stability in cellular compartments that support DNA functions such as replication and mutagenesis. We have devised a shuttle vector plasmid assay that reports the stability of triplexes on DNA that undergoes replication and mutagenesis. The assay is based on plasmids with novel variant supF tRNA genes containing embedded sequences for tripler formation and psoralen cross-linking. Triple helix-forming oligonucleotides were linked to psoralen and used to form triplexes on the plasmids, At various times after introduction into cells, the psoralen was activated by exposure to long wave ultraviolet light (WA). After time for replication and mutagenesis, progeny plasmids were recovered and the frequency of plasmids with mutations in the supF gene determined. Site-specific mutagenesis by psoralen cross-links was dependent on precise placement of the psoralen by the triple helix-forming oligonucleotide at the time of WA treatment. The results indicated that both pyrimidine and purine motif triplexes were much less stable on replicated DNA than on DNA in vitro or in total transfected DNA. Incubation of cells with amidoanthraquinone-based tripler stabilizing compounds enhanced the stability of the pyrimidine triplex.	NIA, Mol Genet Lab, NIH, Baltimore, MD 21224 USA; LCK Associates, Gloucester, MA 01930 USA; Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Seidman, MM (corresponding author), NIA, Mol Genet Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	seidmanm@grc.nia.nih.gov			NATIONAL INSTITUTE ON AGING [Z01AG000738, ZIAAG000738] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGBANDJE M, 1992, J MED CHEM, V35, P1418, DOI 10.1021/jm00086a010; Agrawal S, 1997, P NATL ACAD SCI USA, V94, P2620, DOI 10.1073/pnas.94.6.2620; AlunniFabbroni M, 1996, BIOCHEMISTRY-US, V35, P16361, DOI 10.1021/bi961750h; AlunniFabbroni M, 1996, EUR J BIOCHEM, V238, P143, DOI 10.1111/j.1432-1033.1996.0143q.x; Barre FX, 2000, P NATL ACAD SCI USA, V97, P3084, DOI 10.1073/pnas.050368997; Belousov ES, 1998, NUCLEIC ACIDS RES, V26, P1324, DOI 10.1093/nar/26.5.1324; Blommers MJJ, 1998, BIOCHEMISTRY-US, V37, P17714, DOI 10.1021/bi9816352; Blume SW, 1999, NUCLEIC ACIDS RES, V27, P695, DOI 10.1093/nar/27.2.695; BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273; Chan PP, 1997, J MOL MED, V75, P267, DOI 10.1007/s001090050112; Cheng AJ, 1998, ANTISENSE NUCLEIC A, V8, P215, DOI 10.1089/oli.1.1998.8.215; CHUBB JM, 1992, TRENDS BIOTECHNOL, V10, P132, DOI 10.1016/0167-7799(92)90195-2; Coonrod A, 1997, GENE THER, V4, P1313, DOI 10.1038/sj.gt.3300536; Dagle JM, 1996, NUCLEIC ACIDS RES, V24, P2143, DOI 10.1093/nar/24.11.2143; Debin A, 1997, NUCLEIC ACIDS RES, V25, P1965, DOI 10.1093/nar/25.10.1965; Escude C, 1996, P NATL ACAD SCI USA, V93, P4365, DOI 10.1073/pnas.93.9.4365; Faruqi AF, 1997, NUCLEIC ACIDS RES, V25, P633, DOI 10.1093/nar/25.3.633; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FOSSELLA JA, 1993, NUCLEIC ACIDS RES, V21, P4511, DOI 10.1093/nar/21.19.4511; FOX KR, 1995, P NATL ACAD SCI USA, V92, P7887, DOI 10.1073/pnas.92.17.7887; Giovannangeli C, 1996, J MOL BIOL, V261, P386, DOI 10.1006/jmbi.1996.0471; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Guieysse AL, 1997, J MOL BIOL, V267, P289, DOI 10.1006/jmbi.1997.0884; Keppler M, 1999, FEBS LETT, V447, P223, DOI 10.1016/S0014-5793(99)00284-7; Keppler MD, 1999, EUR J BIOCHEM, V263, P817, DOI 10.1046/j.1432-1327.1999.00566.x; KIYAMA R, 1991, P NATL ACAD SCI USA, V88, P10450, DOI 10.1073/pnas.88.23.10450; KLEINA LG, 1990, J MOL BIOL, V213, P705, DOI 10.1016/S0022-2836(05)80257-8; Kopel V, 1996, NUCLEIC ACIDS RES, V24, P330, DOI 10.1093/nar/24.2.330; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LATIMER LJP, 1995, BIOCHEM CELL BIOL, V73, P11, DOI 10.1139/o95-002; LEE JS, 1984, NUCLEIC ACIDS RES, V12, P6603, DOI 10.1093/nar/12.16.6603; LEE JS, 1993, BIOCHEMISTRY-US, V32, P5591, DOI 10.1021/bi00072a014; Levy DD, 1996, J MOL BIOL, V255, P435, DOI 10.1006/jmbi.1996.0036; Luo D, 2000, NAT BIOTECHNOL, V18, P33, DOI 10.1038/71889; MAHER LJ, 1990, BIOCHEMISTRY-US, V29, P8820, DOI 10.1021/bi00489a045; Maher LJ, 1996, CANCER INVEST, V14, P66, DOI 10.3109/07357909609018437; Majumdar A, 1998, NAT GENET, V20, P212, DOI 10.1038/2530; Marchand C, 1996, BIOCHEMISTRY-US, V35, P5022, DOI 10.1021/bi952908l; MERGNY JL, 1991, BIOCHEMISTRY-US, V30, P9791, DOI 10.1021/bi00104a031; MoraruAllen AA, 1997, NUCLEIC ACIDS RES, V25, P1890, DOI 10.1093/nar/25.10.1890; Musso M, 1998, BIOCHEMISTRY-US, V37, P3086, DOI 10.1021/bi9717486; Neidle S, 1997, ANTI-CANCER DRUG DES, V12, P433; NOONBERG SB, 1995, NUCLEIC ACIDS RES, V23, P1956, DOI 10.1093/nar/23.11.1956; OLIVAS WM, 1995, BIOCHEMISTRY-US, V34, P278, DOI 10.1021/bi00001a034; PARRIS CN, 1992, GENE, V117, P1, DOI 10.1016/0378-1119(92)90482-5; PEDEN KWC, 1980, SCIENCE, V209, P1392, DOI 10.1126/science.6251547; PLUM GE, 1995, ANNU REV BIOPH BIOM, V24, P319; Poon J, 1997, BIOPHYS J, V73, P3257, DOI 10.1016/S0006-3495(97)78350-4; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; Raha M, 1998, PHOTOCHEM PHOTOBIOL, V67, P289, DOI 10.1111/j.1751-1097.1998.tb05201.x; Ren JS, 1999, BIOCHEMISTRY-US, V38, P16067, DOI 10.1021/bi992070s; ROBERTS RW, 1991, P NATL ACAD SCI USA, V88, P9397, DOI 10.1073/pnas.88.21.9397; ROUGEE M, 1992, BIOCHEMISTRY-US, V31, P9269, DOI 10.1021/bi00153a021; Sedelnikova OA, 1999, NUCLEIC ACIDS RES, V27, P3844, DOI 10.1093/nar/27.19.3844; SEIDMAN MM, 1985, GENE, V38, P233, DOI 10.1016/0378-1119(85)90222-7; SHIMIZU M, 1992, FEBS LETT, V302, P155, DOI 10.1016/0014-5793(92)80428-J; SKOOG JU, 1993, NUCLEIC ACIDS RES, V21, P4055, DOI 10.1093/nar/21.17.4055; SMITH JD, 1970, J MOL BIOL, V54, P1, DOI 10.1016/0022-2836(70)90442-0; Spink CH, 1999, BIOCHEMISTRY-US, V38, P496, DOI 10.1021/bi9820154; STROBEL SA, 1992, METHOD ENZYMOL, V216, P309; SVINARCHUK F, 1995, J BIOL CHEM, V270, P14068, DOI 10.1074/jbc.270.23.14068; SVINARCHUK F, 1995, NUCLEIC ACIDS RES, V23, P3831, DOI 10.1093/nar/23.19.3831; Svinarchuk F, 1996, NUCLEIC ACIDS RES, V24, P3858, DOI 10.1093/nar/24.19.3858; Svinarchuk F, 1996, NUCLEIC ACIDS RES, V24, P295, DOI 10.1093/nar/24.2.295; SVINARCHUK F, 1994, NUCLEIC ACIDS RES, V22, P3742, DOI 10.1093/nar/22.18.3742; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; Vasquez KM, 1999, NUCLEIC ACIDS RES, V27, P1176, DOI 10.1093/nar/27.4.1176; Vasquez KM, 1998, TRENDS BIOCHEM SCI, V23, P4, DOI 10.1016/S0968-0004(97)01158-4; Venitt S, 1998, J MED CHEM, V41, P3748, DOI 10.1021/jm980167r; WANG G, 1995, MOL CELL BIOL, V15, P1759; Wang G, 1996, SCIENCE, V271, P802, DOI 10.1126/science.271.5250.802; WEAVER JC, 1993, J CELL BIOCHEM, V51, P426, DOI 10.1002/jcb.2400510407; XODO LE, 1995, EUR J BIOCHEM, V228, P918, DOI 10.1111/j.1432-1033.1995.tb20340.x; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	74	13	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39117	39124		10.1074/jbc.M005404200	http://dx.doi.org/10.1074/jbc.M005404200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993885	hybrid			2022-12-27	WOS:000165953100025
J	Cook, BC; Rudolph, AE; Kurumbail, RG; Porche-Sorbet, R; Miletich, JP				Cook, BC; Rudolph, AE; Kurumbail, RG; Porche-Sorbet, R; Miletich, JP			Directed glycosylation of human coagulation factor X at residue 333 - Insight into factor Va-dependent prothrombin catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RUSSELLS VIPER VENOM; BINDING-SITE; AUTOLYSIS LOOP; PROTEASE; PROTEOLYSIS; INHIBITOR; THROMBIN	Based on homology, amino acids 326-336 (143-154 in chymotrypsin numbering) of factor X (fX) comprise a flexible surface loop, which is susceptible to self-proteolysis and influences substrate catalysis, To investigate the role of this autolysis loop in fg function, a recombinant variant with a new site for asparagine-linked glycosylation has been produced by changing glutamine 333 to asparagine. Q333N fX is activated normally by factor Wa and tissue factor, factors IXa and VIIIa, and Russell's viper venom. Proteolysis of the loop is prevented by the mutation. Reactivity of the free enzyme toward substrates and inhibitors is attenuated 4-20-fold; relative to wild type fXa, Spectrozyme Xa(TM) hydrolysis is 25%, inhibition by antithrombin III and the tissue factor pathway inhibitor is similar to 20%, and prothrombin activation in the absence of the cofactor Va is only 5%. Surprisingly, activities of the variant and wild type enzymes are equivalent when part of the prothrombinase complex. N-Glycanase cleaves the new oligosaccharide from Q333N Ma leaving aspartic acid. Q333D Ma is similar to1.6-fold more reactive with Spectrozyme Xa(TM), antithrombin III and tissue factor pathway inhibitor, and prothrombin than its glycosylated counterpart, Q333N Ma, but still quite abnormal relative to wild type Ma. Like Q333N Ma, Q333D fXa is fully functional as part of the prothrombinase complex. me conclude that Gln-333 is geographically close to a site of proteolytic degradation but not to activator, cofactor, or membrane binding sites. Mutation of Gln-333 impairs catalytic function, but given normal prothrombin activation by the complexed enzyme, the importance of Gln-333 for catalysis is not manifest in the prothrombinase assembly, suggesting a conformational change in complexed fXa.	Washington Univ, Sch Med, Dept Pathol, Div Lab Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Pharmacia Corp, Div Biochem & Mol Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Pfizer	Cook, BC (corresponding author), Marquette Univ, Clin Lab Sci, POB 1881, Milwaukee, WI 53201 USA.				NHLBI NIH HHS [HL60567, HL14147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R15HL060567] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; BROZE GJ, 1984, J CLIN INVEST, V73, P933, DOI 10.1172/JCI111317; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; FASS DN, 1982, BLOOD, V59, P594; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Inui Y, 1998, BIOSCI BIOTECH BIOCH, V62, P1612, DOI 10.1271/bbb.62.1612; KATAKURA S, 1993, BIOCHEM BIOPH RES CO, V197, P965, DOI 10.1006/bbrc.1993.2573; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; Mathur A, 1997, J BIOL CHEM, V272, P23418, DOI 10.1074/jbc.272.37.23418; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; ROVELLI G, 1992, BIOCHEMISTRY-US, V31, P3542, DOI 10.1021/bi00128a031; RUDOLPH A, 1996, J BIOL CHEM, V272, P28601; Rudolph AE, 1997, PROTEIN EXPRES PURIF, V10, P373, DOI 10.1006/prep.1997.0752; Sabharwal AK, 1997, J BIOL CHEM, V272, P22037, DOI 10.1074/jbc.272.35.22037; STONE SR, 1987, ARCH BIOCHEM BIOPHYS, V252, P237, DOI 10.1016/0003-9861(87)90028-2; Tams JW, 1999, BBA-PROTEIN STRUCT M, V1432, P214, DOI 10.1016/S0167-4838(99)00103-X; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; Ueda T, 1996, J BIOCHEM-TOKYO, V119, P157	22	8	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38774	38779		10.1074/jbc.M004573200	http://dx.doi.org/10.1074/jbc.M004573200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10995746	hybrid			2022-12-27	WOS:000165739800087
J	Janssen, JWH; Bovee-Geurts, PHM; Peeters, ZPA; Bowmaker, JK; Cooper, HM; David-Gray, ZA; Nevo, E; DeGrip, WJ				Janssen, JWH; Bovee-Geurts, PHM; Peeters, ZPA; Bowmaker, JK; Cooper, HM; David-Gray, ZA; Nevo, E; DeGrip, WJ			A fully functional rod visual pigment in a blind mammal - A case for adaptive functional reorganization?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-SCALE PRODUCTION; RAT SPALAX-EHRENBERGI; MOLE-RAT; BOVINE RHODOPSIN; IONIC-STRENGTH; PINEAL ORGAN; PURIFICATION; PHOTORECEPTORS; LOCALIZATION; EVOLUTION	In the blind subterranean mole rat Spalax ehrenbergi superspecies complete ablation of the visual image-forming capability has been accompanied by an expansion of the bilateral projection from the retina to the suprachiasmatic nucleus. We have cloned the open reading frame of a visual pigment from Spalax that shows >90% homology with mammalian rod pigments. Baculovirus expression yields a membrane protein with all functional characteristics of a rod visual pigment (lambda (max) = 497 +/- 2 nm; pK(alpha) of meta I/meta II equilibrium = 6.5; rapid activation of transducin in the light). We not only provide evidence that this Spalax rod pigment is fully functional in vitro but also show that all requirements for a functional pigment are present in vivo. The physiological consequences of this unexpected finding are discussed. One attractive option is that during adaptation to a subterranean lifestyle, the visual system of this mammal has undergone mosaic reorganization, and the visual pigments have adapted to a function in circadian photoreception.	Univ Nijmegen, Inst Cellular Signalling, Dept Biochem UMC 160, NL-6500 HB Nijmegen, Netherlands; UCL, Inst Ophthalmol, Dept Visual Sci, London EC1V 9EL, England; Cerveau & Vis, INSERM U 371, F-69500 Bron, France; Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2AZ, England; Univ Haifa, Inst Evolut, IL-31905 Haifa, Israel	Radboud University Nijmegen; University of London; University College London; Institut National de la Sante et de la Recherche Medicale (Inserm); Imperial College London; University of Haifa	DeGrip, WJ (corresponding author), Univ Nijmegen, Inst Cellular Signalling, Dept Biochem UMC 160, POB 9101, NL-6500 HB Nijmegen, Netherlands.	WDeGrip@baserv.uci.kun.nl	COOPER, HOWARD/M-7304-2014; DeGrip, Willem/L-4335-2015	DeGrip, Willem/0000-0001-7637-4920				Archer SN, 1999, ADAPTIVE MECH ECOLOG, DOI [10.1007/978-94-017-0619-3, DOI 10.1007/978-94-017-0619-3]; COOPER HM, 1993, NATURE, V361, P156, DOI 10.1038/361156a0; Crandall KA, 1997, NATURE, V387, P667, DOI 10.1038/42628; DARTNALL HJA, 1983, PROC R SOC SER B-BIO, V220, P115, DOI 10.1098/rspb.1983.0091; David-Gray ZK, 1998, NAT NEUROSCI, V1, P655, DOI 10.1038/3656; DeGrip WJ, 1998, BIOCHEM J, V330, P667; DEGRIP WJ, 1992, SIGNAL TRANSDUCTION, P42; DeLange F, 1997, EUR J BIOCHEM, V243, P174, DOI 10.1111/j.1432-1033.1997.0174a.x; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P9165, DOI 10.1021/bi00086a023; FOSTER RG, 1987, CELL TISSUE RES, V248, P161, DOI 10.1007/BF01239977; FOSTER RG, 1993, J COMP PHYSIOL A, V172, P33, DOI 10.1007/BF00214713; FOSTER RG, 1991, J COMP PHYSIOL A, V169, P39, DOI 10.1007/BF00198171; Freedman MS, 1999, SCIENCE, V284, P502, DOI 10.1126/science.284.5413.502; GROOS G, 1982, EXPERIENTIA, V38, P929; JANSSEN JJM, 1995, J BIOL CHEM, V270, P11222, DOI 10.1074/jbc.270.19.11222; Klaassen CHW, 1999, BIOCHEM J, V342, P293, DOI 10.1042/0264-6021:3420293; KORF HW, 1994, ANN NY ACAD SCI, V719, P13, DOI 10.1111/j.1749-6632.1994.tb56818.x; LEWIS JW, 1991, BIOCHEMISTRY-US, V30, P11372, DOI 10.1021/bi00112a003; Lupi D, 1999, NEUROSCIENCE, V89, P363, DOI 10.1016/S0306-4522(98)00353-4; Menaker M, 1997, BRAZ J MED BIOL RES, V30, P305, DOI 10.1590/S0100-879X1997000300003; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; NECKER R, 1992, NEUROREPORT, V3, P505, DOI 10.1097/00001756-199206000-00012; Neitz M., 1998, COLOR VISION PERSPEC, P101, DOI [10.1515/9783110806984.101, DOI 10.1515/9783110806984.101]; NELSON DE, 1991, J PHYSIOL-LONDON, V439, P115, DOI 10.1113/jphysiol.1991.sp018660; Nevo, 1999, MOSAIC EVOLUTION SUB; Okano T, 1997, J PINEAL RES, V22, P145, DOI 10.1111/j.1600-079X.1997.tb00316.x; PEVET P, 1984, J EXP ZOOL, V232, P41, DOI 10.1002/jez.1402320106; REHKAMPER G, 1994, J COMP NEUROL, V347, P570, DOI 10.1002/cne.903470408; SANYAL S, 1990, INVEST OPHTH VIS SCI, V31, P1398; SPIEGEL AM, 1990, BIOL COUN S, P31; Springer MS, 1997, P NATL ACAD SCI USA, V94, P13754, DOI 10.1073/pnas.94.25.13754; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; Vigh B, 1998, BIOL CELL, V90, P653, DOI 10.1016/S0248-4900(99)80022-7; Vissers PMAM, 1998, BIOCHEM J, V330, P1201, DOI 10.1042/bj3301201; YOKOYAMA S, 1995, MOL BIOL EVOL, V12, P527	35	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38674	38679		10.1074/jbc.M008254200	http://dx.doi.org/10.1074/jbc.M008254200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10984500	hybrid, Green Published			2022-12-27	WOS:000165739800073
J	Ohmori, Y; Hamilton, TA				Ohmori, Y; Hamilton, TA			Interleukin-4/STAT6 represses STAT1 and NF-kappa B-dependent transcription through distinct mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; GERMLINE EPSILON-PROMOTER; NECROSIS-FACTOR-ALPHA; CREB-BINDING PROTEIN; MONOCYTIC CELL-LINES; GENE-EXPRESSION; IFN-GAMMA; NUCLEAR FACTOR; INTERFERON-GAMMA; DNA-BINDING	STAT6 mediates interleukin-4 (IL-4)-dependent positive and negative regulation of inflammatory gene expression. In the present report we examined the molecular mechanisms involved in IL-4-induced repression of reporter gene transcription driven by STAT1 and/or NF-kappaB. Transient expression of STAT6 in a STAT6-deficient cell line (HEK 293) conferred sensitivity to IL-4 for STAT6-dependent transcription and for repression of interferon-gamma (IFN gamma)/STAT1- and/or tumor necrosis factor-alpha (TNF alpha)/NF-kappaB driven reporter gene expression. In cells transfected with a deletion mutant of STAT6 lacking its transactivating domain, IL-4 could not mediate either positive or negative control of reporter gene expression. Overexpression of CREB-binding protein dramatically enhanced IL-4/STAT6-stimulated transcription and overcame IL-4-mediated repression of TNF alpha /NF-kappaB-dependent but not IFN gamma /STAT1-dependent transcription. A single amino acid change in the DNA-binding domain of STAT6 (H415A) selectively reduced the affinity of STAT6 for IL-4-responsive STAT sequence motifs (N4) without affecting the affinity for IFN gamma -responsive (GAS) sequences (N3) and, accordingly, eliminated transcription from an IL-4-responsive promoter. Interestingly, this mutation eliminated IL-4-mediated suppression of reporter gene transcription stimulated by TNF alpha /NF-kappaB but retained nearly full capacity to suppress IFN gamma /STAT1-stimulated transcription. Taken together these results demonstrate that STAT6 mediates suppression of STAT1 and NF-kappaB-dependent transcription by distinct mechanisms. Both processes are dependent upon the STAT6 transactivation domain and may involve sequestration of necessary but different transcriptional coactivator proteins. These two suppressive mechanisms are controlled differentially by the nature of the STAT6 DNA-binding site (i.e. N3 versus N4).	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Ohmori, Y (corresponding author), Meikai Univ, Sch Dent, Ctr Biol Mol, 1-1 Keyakidai, Kawagoe, Saitama 3500283, Japan.	ohmori@dent.meikai.ac.jp		Hamilton, Thomas/0000-0002-9817-242X; Ohmori, Yoshihiro/0000-0002-6069-357X	NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER; NCI NIH HHS [CA62220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Bennett BL, 1997, J BIOL CHEM, V272, P10212; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BOGDAN C, 1994, J LEUKOCYTE BIOL, V55, P227, DOI 10.1002/jlb.55.2.227; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; DENG WL, 1994, J IMMUNOL, V153, P2130; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dokter WHA, 1996, LEUKEMIA, V10, P1308; DOKTER WHA, 1993, BLOOD, V81, P337; DONNELLY RP, 1993, J IMMUNOL, V151, P5603; DONNELLY RP, 1991, J IMMUNOL, V146, P3431; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; ESSNER R, 1989, J IMMUNOL, V142, P3857; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; GAUTAM S, 1992, J IMMUNOL, V148, P1725; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Goenka S, 1999, J IMMUNOL, V163, P4663; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Kotanides H, 1996, J BIOL CHEM, V271, P25555, DOI 10.1074/jbc.271.41.25555; LARNER AC, 1993, J IMMUNOL, V150, P1944; Luo GY, 2000, MOL ENDOCRINOL, V14, P114, DOI 10.1210/me.14.1.114; Manna SK, 1998, J BIOL CHEM, V273, P33333, DOI 10.1074/jbc.273.50.33333; MARFAINGKOKA A, 1995, J IMMUNOL, V154, P1870; McDonald C, 1999, J INTERF CYTOK RES, V19, P711, DOI 10.1089/107999099313550; Mikita T, 1998, J IMMUNOL, V161, P1822; Mikita T, 1996, MOL CELL BIOL, V16, P5811; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; OHMORI Y, 1994, J IMMUNOL, V153, P2204; Ohmori Y, 1997, J IMMUNOL, V159, P5474; OHMORI Y, 1994, PHARMACOL THERAPEUT, V63, P235, DOI 10.1016/0163-7258(94)90026-4; Ohmori Y, 1996, J IMMUNOL, V157, P2058; Ohmori Y, 1998, J BIOL CHEM, V273, P29202, DOI 10.1074/jbc.273.44.29202; OHMORI Y, 1994, J BIOL CHEM, V269, P17684; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; Pine R, 1997, NUCLEIC ACIDS RES, V25, P4346, DOI 10.1093/nar/25.21.4346; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RENKONEN R, 1992, SCAND J IMMUNOL, V35, P525; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SEDER RA, 1999, FUNDAMENTAL IMMUNOLO, P879; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Sidhu JS, 1998, J BIOL CHEM, V273, P4769, DOI 10.1074/jbc.273.8.4769; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; Takeshita S, 1996, J IMMUNOL, V156, P2591; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; VANNIER E, 1992, P NATL ACAD SCI USA, V89, P4076, DOI 10.1073/pnas.89.9.4076; VELDE AAT, 1990, J IMMUNOL, V144, P3046; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	66	87	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38095	38103		10.1074/jbc.M006227200	http://dx.doi.org/10.1074/jbc.M006227200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982806	hybrid			2022-12-27	WOS:000165618700105
J	Yu, R; Heaney, AP; Lu, WG; Chen, JD; Melmed, S				Yu, R; Heaney, AP; Lu, WG; Chen, JD; Melmed, S			Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYC-INDUCED APOPTOSIS; CELL-CYCLE ARREST; P53; PTTG; EXPRESSION; PROLIFERATION; ACTIVATION	The pituitary tumor transforming gene, PTTG, is abundantly expressed in several neoplasms. We recently showed that PTTG overexpression is associated with apoptosis and therefore have now studied the role of p53 in this process. In MCF-7 breast cancer cells that express wild type p53, PTTG overexpression caused apoptosis. p53 was translocated to the nuclei in cells expressing PTTG. Overexpression of p53, along with PTTG, augmented apoptosis, whereas expression of the human papillomavirus E6 protein inhibited PTTG-induced apoptosis. In MG-63 osteosarcoma cells that are deficient in p53, PTTG caused cell cycle arrest and subsequent apoptosis that was inhibited by caspase inhibitors. A proteasome inhibitor augmented PTTG expression in stable PTTG transfectants, suggesting that down-regulated PTTG expression is required for cell survival. Finally, MG-63 cells expressing PTTG showed signs of aneuploidy including the presence of micronuclei and multiple nuclei. These results indicate that PTTG overexpression causes p53-dependent and p53-independent apoptosis. In the absence of p58, PTTG causes aneuploidy. These results may provide a mechanism for PTTG-induced tumorigenesis whereby PTTG mediates aneuploidy and subsequent cell transformation.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Los Angeles, CA 90048 USA; H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; H Lee Moffitt Cancer Center & Research Institute	Melmed, S (corresponding author), Cedars Sinai Med Ctr, 8700 Beverly Blvd, Los Angeles, CA 90048 USA.	melmed@csmc.edu			NATIONAL CANCER INSTITUTE [R01CA075979] Funding Source: NIH RePORTER; NCI NIH HHS [CA75979] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; ELSTNER E, 1995, CANCER RES, V55, P2822; Heaney AP, 1999, NAT MED, V5, P1317, DOI 10.1038/15275; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; Kakar SS, 1999, CYTOGENET CELL GENET, V84, P211, DOI 10.1159/000015261; Lu WG, 2000, ONCOGENE, V19, P232, DOI 10.1038/sj.onc.1203262; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Panvichian R, 1998, CANCER RES, V58, P4667; Sakamuro D, 1995, ONCOGENE, V11, P2411; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shostak LD, 1999, EXP CELL RES, V251, P156, DOI 10.1006/excr.1999.4568; Suganuma M, 1999, CANCER RES, V59, P5887; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang ZY, 2000, J BIOL CHEM, V275, P7459, DOI 10.1074/jbc.275.11.7459; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Yu R, 2000, MOL ENDOCRINOL, V14, P1137, DOI 10.1210/me.14.8.1137; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	26	95	116	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36502	36505		10.1074/jbc.C000546200	http://dx.doi.org/10.1074/jbc.C000546200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	11013229	hybrid			2022-12-27	WOS:000165577700007
J	Jacques, SL; LeMasurier, M; Sheridan, PJ; Seeley, SK; Kuliopulos, A				Jacques, SL; LeMasurier, M; Sheridan, PJ; Seeley, SK; Kuliopulos, A			Substrate-assisted catalysis of the PAR1 thrombin receptor - Enhancement of macromolecular association and cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLATELET; ACTIVATION; HIRUDIN; SPECIFICITY; MECHANISM; BINDING; SITE; IDENTIFICATION; ANTITHROMBIN; PREVENTION	Platelet activation and aggregation are mediated by thrombin cleavage of the exodomain of the PAR1 receptor. The specificity of thrombin for PAR1 is enhanced by binding to a hirudin-like region (Hir) located in the receptor exodomain, Here, we examine the mechanism of thrombin-PAR1 recognition and cleavage by steady-state kinetic measurements using soluble PAR1 N-terminal exodomains. We determined that the primary role of the PAR1 Hir sequence is to reduce the kinetic barriers to formation of the docked thrombin-PAR1 complex rather than to form high affinity ground-state interactions. In addition, the exosite I-bound Hir motif facilitates the productive interaction of the PARI (LDPR)-L-38/SFL44 sequence with the active site of thrombin, This locking process is the most energetically unfavorable step of the overall reaction. The subsequent irreversible steps of peptide bond cleavage are rapid and allosterically enhanced by the presence of the docked Hir sequence. Furthermore, the C-terminal exodomain product of thrombin cleavage, corresponding to the activated receptor, binds tightly to thrombin, This would suggest that an additional role of the Hir sequence in the thrombin-activated receptor is to sequester thrombin to the platelet surface and modulate cleavage of other platelet receptors such as the PAR4 thrombin receptor, which lacks a functional Hir sequence.	Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Tufts Univ, Sch Med, New England Med Ctr, Mol Cardiol Res Inst,Div Hematol Oncol, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts Medical Center; Tufts University	Kuliopulos, A (corresponding author), Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA.				NHLBI NIH HHS [R01HL57905] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057905] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn HS, 1997, MOL PHARMACOL, V51, P350, DOI 10.1124/mol.51.2.350; AYALA YM, 1995, J MOL BIOL, V253, P787, DOI 10.1006/jmbi.1995.0591; BAHOU WF, 1994, BLOOD, V84, P4195, DOI 10.1182/blood.V84.12.4195.bloodjournal84124195; BONNIEC BFL, 1996, BIOCHEMISTRY-US, V35, P7114; BRASS LF, 1992, J BIOL CHEM, V267, P13795; CHEN J, 1994, J BIOL CHEM, V269, P16041; CLELAND WW, 1986, INVESTIGATION RATE 1, P791; Covic L, 2000, BIOCHEMISTRY-US, V39, P5458, DOI 10.1021/bi9927078; Doolittle RF, 1994, MOL BASIS BLOOD DIS, P701; FERSHT A, 1985, ENZYME STRUCTURE MEC, P121; Hayes KL, 1999, J BIOL CHEM, V274, P972, DOI 10.1074/jbc.274.2.972; ISHII K, 1995, J BIOL CHEM, V270, P16435, DOI 10.1074/jbc.270.27.16435; JACKMAN MP, 1992, J BIOL CHEM, V267, P15375; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; KULIOPULOS A, 1990, BIOCHEMISTRY-US, V29, P10271, DOI 10.1021/bi00496a017; KULIOPULOS A, 1994, J AM CHEM SOC, V116, P4599, DOI 10.1021/ja00090a008; KULIOPULOS A, 1989, BIOCHEMISTRY-US, V28, P149, DOI 10.1021/bi00427a022; Kuliopulos A, 1999, BIOCHEMISTRY-US, V38, P4572, DOI 10.1021/bi9824792; LATALLO ZS, 1986, THROMB RES, V43, P507, DOI 10.1016/0049-3848(86)90071-X; LIU LW, 1991, J BIOL CHEM, V266, P16977; MATTEWS II, 1994, BIOCHEMISTRY-US, V33, P3266; Miyata S, 2000, J BIOL CHEM, V275, P4592, DOI 10.1074/jbc.275.7.4592; MOLINO M, 1995, J BIOL CHEM, V270, P11168, DOI 10.1074/jbc.270.19.11168; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; NANEVICZ T, 1995, J BIOL CHEM, V270, P21619, DOI 10.1074/jbc.270.37.21619; Parry MAA, 1996, BIOCHEM J, V320, P335, DOI 10.1042/bj3200335; PARRY MAA, 1994, BIOCHEMISTRY-US, V33, P14807, DOI 10.1021/bi00253a020; PICOZZI M, 1993, BIOCHEM J, V294, P563, DOI 10.1042/bj2940563; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; STONE SR, 1995, BIOCHEMISTRY-US, V34, P5164, DOI 10.1021/bi00015a030; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WASIEWSKI W, 1976, THROMB RES, V8, P881, DOI 10.1016/0049-3848(76)90017-7; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	36	65	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40671	40678		10.1074/jbc.M004544200	http://dx.doi.org/10.1074/jbc.M004544200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11005807	hybrid			2022-12-27	WOS:000166114600004
J	Rybin, VO; Xu, XH; Lisanti, MP; Steinberg, SF				Rybin, VO; Xu, XH; Lisanti, MP; Steinberg, SF			Differential targeting of beta-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae - A mechanism to functionally regulate the cAMP signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; PROTEIN-KINASE; PLASMA-MEMBRANE; BETA-2-ADRENERGIC RECEPTORS; BETA-1-ADRENERGIC RECEPTOR; VENTRICULAR MYOCYTES; CELLS; TRANSDUCTION; CHOLESTEROL; EXPRESSION	Differential modes for beta (1)- and beta (2)-adrenergic receptor (AR) regulation of adenylyl cyclase in cardiomyocytes is most consistent with spatial regulation in microdomains of the plasma membrane. This study examines whether caveolae represent specialized subdomains that concentrate and organize these moieties in cardiomyocytes. Caveolae from quiescent rat ventricular cardiomyocytes are highly enriched in beta (2)-ARs, G alpha (i), protein kinase A RII alpha subunits, caveolin-3, and flotillins (caveolin functional homologues); beta (1)-ARs, m(2)-muscarinic cholinergic receptors, G alpha (s), and cardiac types V/VI adenylyl cyclase distribute between caveolae and other cell fractions, whereas protein kinase A RI alpha subunits, G protein-coupled receptor kinase-a, and clathrin are largely excluded from caveolae, Cell surface beta (2)-ARs localize to caveolae in cardiomyocytes and cardiac fibroblasts (with markedly different beta (2)-AR expression levels), indicating that the fidelity of beta (2)-AR targeting to caveolae is maintained over a physiologic range of beta (2)-AR expression. In cardiomyocytes, agonist stimulation leads to a marked decline in the abundance of beta (2)-ARs (but not beta (1)-ARs) in caveolae. Other studies show co-immunoprecipitation of cardiomyocytes adenylyl cyclase V/VI and caveolin-3, suggesting their in vivo association. However, caveolin is not required for adenylyl cyclase targeting to low density membranes, since adenylyl cyclase targets to low buoyant density membrane fractions of HEK cells that lack prototypical caveolins, Nevertheless, cholesterol depletion with cyclodextrin augments agonist-stimulated cAMP accumulation, indicating that caveolae function as negative regulators of cAMP accumulation. The inhibitory interaction between caveolae and the cAMP signaling pathway as well as domain-specific differences in the stoichiometry of individual elements in the beta -AR signaling cascade represent important modifiers of cAMP dependent signaling in the heart.	Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Columbia University; Columbia University; Yeshiva University; Albert Einstein College of Medicine	Steinberg, SF (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pharmacol, 630 W 168th St, New York, NY 10032 USA.	sfs1@columbia.edu	Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028958] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007328] Funding Source: NIH RePORTER; NCI NIH HHS [CA80251] Funding Source: Medline; NHLBI NIH HHS [HL28958] Funding Source: Medline; NIDDK NIH HHS [2T32DK07328-18] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aprigliano O, 1997, AM J PHYSIOL-HEART C, V272, pH2726, DOI 10.1152/ajpheart.1997.272.6.H2726; BARNETT JV, 1989, J BIOL CHEM, V264, P10779; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BRISTOW MR, 1989, MOL PHARMACOL, V35, P295; BUXTON ILO, 1983, J BIOL CHEM, V258, P233; Carman CV, 1999, J BIOL CHEM, V274, P8858, DOI 10.1074/jbc.274.13.8858; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FAGAN KA, 2000, J BIOL CHEM, V275; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GADBUT AP, 1994, J BIOL CHEM, V269, P30707; GREEN SA, 1994, J BIOL CHEM, V269, P26215; GREEN SA, 1992, MOL PHARMACOL, V41, P889; Hare JM, 2000, CIRC RES, V86, P1085, DOI 10.1161/01.RES.86.10.1085; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HOHL CM, 1991, CIRC RES, V69, P1369, DOI 10.1161/01.RES.69.5.1369; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Ishikawa Y, 1997, CIRC RES, V80, P297, DOI 10.1161/01.RES.80.3.297; Kohout TA, 1996, CIRC RES, V78, P971, DOI 10.1161/01.RES.78.6.971; LEVY FO, 1993, P NATL ACAD SCI USA, V90, P10798, DOI 10.1073/pnas.90.22.10798; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lin FB, 2000, J BIOL CHEM, V275, P19025, DOI 10.1074/jbc.275.25.19025; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ostrom RS, 2000, MOL PHARMACOL, V57, P1075; Puceat M, 1998, FEBS LETT, V431, P189, DOI 10.1016/S0014-5793(98)00747-9; RAPOSO G, 1987, BIOL CELL, V60, P117, DOI 10.1111/j.1768-322X.1987.tb00551.x; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Rohrer DK, 1996, P NATL ACAD SCI USA, V93, P7375, DOI 10.1073/pnas.93.14.7375; RYBIN VO, 1994, CIRC RES, V74, P299, DOI 10.1161/01.RES.74.2.299; Rybin VO, 1999, CIRC RES, V84, P980, DOI 10.1161/01.RES.84.9.980; Sabri A, 2000, CIRC RES, V86, P1054, DOI 10.1161/01.RES.86.10.1054; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Schwencke C, 1999, J CELL BIOCHEM, V75, P64, DOI 10.1002/(SICI)1097-4644(19991001)75:1<64::AID-JCB7>3.0.CO;2-L; Schwencke C, 1999, MOL ENDOCRINOL, V13, P1061, DOI 10.1210/me.13.7.1061; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Steinberg SF, 1999, CIRC RES, V85, P1101; Stulnig TM, 1997, J BIOL CHEM, V272, P19242, DOI 10.1074/jbc.272.31.19242; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Toya Y, 1998, ENDOCRINOLOGY, V139, P2025, DOI 10.1210/en.139.4.2025; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; Yamamoto M, 1999, LIFE SCI, V64, P1349, DOI 10.1016/S0024-3205(99)00070-3	52	443	449	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41447	41457		10.1074/jbc.M006951200	http://dx.doi.org/10.1074/jbc.M006951200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11006286	hybrid			2022-12-27	WOS:000166114600103
J	Roper, JM; Raux, E; Brindley, AA; Schubert, HL; Gharbia, SE; Shah, HN; Warren, MJ				Roper, JM; Raux, E; Brindley, AA; Schubert, HL; Gharbia, SE; Shah, HN; Warren, MJ			The enigma of cobalamin (vitamin B-12) biosynthesis in Porphyromonas gingivalis - Identification and characterization of a functional corrin pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; PROTEIN; GENES; BACTERIA	The ability of Porphyromonas gingivalis to biosynthesize tetrapyrroles de novo has been investigated. Extracts of the bacterium do not possess activity for 5-aminolevulinic-acid dehydratase or porphobilinogen deaminase, two key enzymes involved in the synthesis of uroporphyrinogen III. Similarly, it was not possible to detect any genetic evidence for these early enzymes with the use of degenerate polymerase chain reaction. However, the bacterium does appear to harbor some of the enzymes for cobalamin biosynthesis since cobyric acid, a pathway intermediate, was converted into cobinamide. Furthermore, degenerate polymerase chain reaction with primers to cbiP, which encodes cobyric-acid synthase, produced a fragment with a high degree of identity to Salmonella typhimurium cbiP. Indeed, the recently released genome sequence data confirmed the presence of cbiP together with 14 other genes of the cobalamin pathway. A number of these genes were cloned and functionally characterized. Although P. gingivalis harbors all the genes necessary to convert precorrin-2 into cobalamin, it is missing the genes for the synthesis of precorrin-2. Either the organism has a novel pathway for the synthesis of precorrin-2, or more likely, it has lost this early part of the pathway. The remainder of the pathway may be being maintained to act as a salvage route for corrin synthesis.	Univ London Queen Mary Coll, Sch Biol Sci, London E1 4NS, England; Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA; Univ E London, Dept Life Sci, London E15 4LZ, England; Cent Publ Hlth Lab, Publ Hlth Lab Serv, London NW9 5HT, England	University of London; Queen Mary University London; Utah System of Higher Education; University of Utah; University of East London; Public Health England	Warren, MJ (corresponding author), Univ London Queen Mary Coll, Sch Biol Sci, Mile End Rd, London E1 4NS, England.			Warren, Martin/0000-0002-6028-6456				AduseOpoku J, 1997, J BACTERIOL, V179, P4778, DOI 10.1128/jb.179.15.4778-4788.1997; BLANCHE F, 1993, ANGEW CHEM INT EDIT, V32, P1651, DOI 10.1002/anie.199316511; BLANCHE F, 1995, ANGEW CHEM INT EDIT, V34, P383, DOI 10.1002/anie.199503831; BONNETT R, 1969, J CHEM SOC C, P1163, DOI 10.1039/j39690001163; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Dashper SG, 2000, J BACTERIOL, V182, P6456, DOI 10.1128/JB.182.22.6456-6462.2000; Finegold S M, 1995, Clin Infect Dis, V20 Suppl 2, P205; GRIFFITHS L, 1987, ARCH MICROBIOL, V147, P364, DOI 10.1007/BF00406134; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HENDTLASS A, 2001, IN PRESS ORAL MICROB; HENDTLASS AJ, 1997, Patent No. 9700212; Ishida T, 1998, P NATL ACAD SCI USA, V95, P4853, DOI 10.1073/pnas.95.9.4853; Jackson CA, 1995, GENE, V167, P127, DOI 10.1016/0378-1119(95)00682-6; JORDAN PM, 1988, BIOCHEM J, V254, P427, DOI 10.1042/bj2540427; LAWRENCE JG, 1995, J BACTERIOL, V177, P6371, DOI 10.1128/jb.177.22.6371-6380.1995; Lawrence JG, 1996, GENETICS, V142, P11; Lecerof D, 2000, J MOL BIOL, V297, P221, DOI 10.1006/jmbi.2000.3569; LOEB MR, 1995, J BACTERIOL, V177, P3613, DOI 10.1128/jb.177.12.3613-3615.1995; Maggio-Hall LA, 1999, P NATL ACAD SCI USA, V96, P11798, DOI 10.1073/pnas.96.21.11798; Marsh ENG, 1999, ESSAYS BIOCHEM, V34, P139; Milner P, 1996, FEMS MICROBIOL LETT, V140, P125, DOI 10.1016/0378-1097(96)00159-0; Raux E, 1997, J BACTERIOL, V179, P3202, DOI 10.1128/jb.179.10.3202-3212.1997; Raux E, 1998, BIOCHEM J, V335, P159, DOI 10.1042/bj3350159; Raux E, 1999, BIOCHEM J, V338, P701, DOI 10.1042/0264-6021:3380701; Raux E, 1999, BIOORG CHEM, V27, P100, DOI 10.1006/bioo.1998.1125; Raux E, 1996, J BACTERIOL, V178, P753, DOI 10.1128/jb.178.3.753-767.1996; RAUX E, 1999, THESIS U LONDON; Rose TM, 1998, NUCLEIC ACIDS RES, V26, P1628, DOI 10.1093/nar/26.7.1628; ROSS B, 1998, Patent No. 980123; ROTH JR, 1993, J BACTERIOL, V175, P3303, DOI 10.1128/jb.175.11.3303-3316.1993; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Sambrook J., 2002, MOL CLONING LAB MANU; Santander PJ, 1997, CHEM BIOL, V4, P659, DOI 10.1016/S1074-5521(97)90221-0; Scannapleco FA, 1999, J PERIODONTAL RES, V34, P340, DOI 10.1111/j.1600-0765.1999.tb02263.x; Schubert HL, 1999, BIOCHEMISTRY-US, V38, P10660, DOI 10.1021/bi9906773; Schubert HL, 1998, NAT STRUCT BIOL, V5, P585, DOI 10.1038/846; Senior NM, 1996, BIOCHEM J, V320, P401; SHAH H, 1981, THESIS U LONDON; Shah HN, 1996, TRENDS MICROBIOL, V4, P372, DOI 10.1016/0966-842X(96)30026-7; Spencer P, 1998, BIOCHEMISTRY-US, V37, P14917, DOI 10.1021/bi981366f; Thomas MG, 2000, J BACTERIOL, V182, P4227, DOI 10.1128/JB.182.15.4227-4233.2000; WARREN MJ, 1990, TRENDS BIOCHEM SCI, V15, P486, DOI 10.1016/0968-0004(90)90304-T	42	52	55	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40316	40323		10.1074/jbc.M007146200	http://dx.doi.org/10.1074/jbc.M007146200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007789	hybrid			2022-12-27	WOS:000166039500071
J	Ogilvie, M; Yu, XB; Nicolas-Metral, V; Pulido, SM; Liu, C; Ruegg, UT; Noguchi, CT				Ogilvie, M; Yu, XB; Nicolas-Metral, V; Pulido, SM; Liu, C; Ruegg, UT; Noguchi, CT			Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIC MOUSE MUSCLE; HELIX-LOOP-HELIX; STEM-CELL-FACTOR; ENDOTHELIAL-CELLS; SIGNAL-TRANSDUCTION; ERYTHROID-CELLS; CYTOKINE RECEPTORS; PROLACTIN RECEPTOR; CALCIUM CHANNELS; SKELETAL-MUSCLE	Erythropoietin (Epo) is required for the production of mature red blood cells. The requirement for Epo and its receptor (EpoR) for normal heart development and the response of vascular endothelium and cells of neural origin to Epo provide evidence that the function of Epo as a growth factor or cytokine to protect cells from apoptosis extends beyond the hematopoietic lineage. me now report that the EpoR is expressed on myoblasts and can mediate a biological response of these cells to treatment with Epo. Primary murine satellite cells and myoblast C2C12 cells, both of which express endogenous EpoR, exhibit a proliferative response to Epo and a marked decrease in terminal differentiation to form myotubes. me also observed that Epo stimulation activates Jak2/Stat5 signal transduction and increases cytoplasmic calcium, which is dependent on tyrosine phosphorylation. In erythroid progenitor cells, Epo stimulates induction of transcription factor GATA-1 and EpoR; in C2C12 cells, GATA-3 and EpoR expression are induced. The decrease in differentiation of C2C12 cells is concomitant with an increase in Myf-5 and MyoD expression and inhibition of myogenin induction during differentiation, altering the pattern of expression of the MyoD family of transcription factors during muscle differentiation. These data suggest that, rather than acting in an instructive or specific mode for differentiation, Epo can stimulate proliferation of myoblasts to expand the progenitor population during differentiation and may have a potential role in muscle development or repair.	NIDDK, Biol Chem Lab, NIH, Bethesda, MD 20892 USA; Univ Lausanne, Sch Pharm, Pharmacol Grp, CH-1015 Lausanne, Switzerland	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Lausanne	Noguchi, CT (corresponding author), NIDDK, Biol Chem Lab, NIH, Bethesda, MD 20892 USA.	cnoguchi@helix.nih.gov		RUEGG, Urs/0000-0001-6078-8280	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK025061, Z01DK025061] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANAGNOSTOU A, 1990, P NATL ACAD SCI USA, V87, P5978, DOI 10.1073/pnas.87.15.5978; ANAGNOSTOU A, 1994, P NATL ACAD SCI USA, V91, P3974, DOI 10.1073/pnas.91.9.3974; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Blaveri K, 1999, DEV DYNAM, V216, P244, DOI 10.1002/(SICI)1097-0177(199911)216:3<244::AID-DVDY3>3.0.CO;2-9; BROUDY VC, 1991, BLOOD, V77, P2583, DOI 10.1182/blood.V77.12.2583.2583; Cheung JY, 1997, BLOOD, V89, P92, DOI 10.1182/blood.V89.1.92.92_92_100; CHIN K, 1995, NUCLEIC ACIDS RES, V23, P3041, DOI 10.1093/nar/23.15.3041; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; FIBACH E, 1994, BRIT J HAEMATOL, V88, P39, DOI 10.1111/j.1365-2141.1994.tb04974.x; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Jacobs-Helber SM, 1998, MOL CELL BIOL, V18, P3699, DOI 10.1128/MCB.18.7.3699; KIMATA H, 1991, CLIN EXP IMMUNOL, V85, P151; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liu C, 1997, J BIOL CHEM, V272, P32395, DOI 10.1074/jbc.272.51.32395; LIU ZY, 1994, DEV BIOL, V166, P159, DOI 10.1006/dbio.1994.1304; Marrero MB, 1998, KIDNEY INT, V53, P1259, DOI 10.1046/j.1523-1755.1998.00887.x; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; MILLER BA, 1989, BLOOD, V73, P1188; Miller BA, 1999, J BIOL CHEM, V274, P20465, DOI 10.1074/jbc.274.29.20465; MILLER BA, 1994, P SOC EXP BIOL MED, V206, P263; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Morakkabati N, 1996, EXP HEMATOL, V24, P392; MUTA K, 1994, J CLIN INVEST, V94, P34, DOI 10.1172/JCI117327; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; NOGUCHI CT, 1991, BLOOD, V78, P2548; OHNEDA O, 1993, EXP CELL RES, V208, P327, DOI 10.1006/excr.1993.1253; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; ORLIC D, 1995, P NATL ACAD SCI USA, V92, P4601, DOI 10.1073/pnas.92.10.4601; PAPAYANNOPOULOU T, 1988, BLOOD, V72, P1029; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Ribatti D, 1999, BLOOD, V93, P2627, DOI 10.1182/blood.V93.8.2627.408k21_2627_2636; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Sawyer ST, 1996, J BIOL CHEM, V271, P32430, DOI 10.1074/jbc.271.50.32430; Socolovsky M, 1998, P NATL ACAD SCI USA, V95, P6573, DOI 10.1073/pnas.95.12.6573; Socolovsky M, 1998, BLOOD, V92, P1491, DOI 10.1182/blood.V92.5.1491.417k40_1491_1496; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; STOCKDALE FE, 1992, DEV BIOL, V154, P284, DOI 10.1016/0012-1606(92)90068-R; Vogel V, 1997, AM J HYPERTENS, V10, P289, DOI 10.1016/S0895-7061(96)00410-4; Wald MR, 1996, J CELL PHYSIOL, V167, P461, DOI 10.1002/(SICI)1097-4652(199606)167:3<461::AID-JCP10>3.3.CO;2-N; Watowich SS, 1999, J BIOL CHEM, V274, P5415, DOI 10.1074/jbc.274.9.5415; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Wu H, 1999, DEVELOPMENT, V126, P3597; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yasuda Y, 1998, J BIOL CHEM, V273, P25381, DOI 10.1074/jbc.273.39.25381; Zaman K, 1999, J NEUROSCI, V19, P9821	60	213	223	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39754	39761		10.1074/jbc.M004999200	http://dx.doi.org/10.1074/jbc.M004999200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995753	hybrid			2022-12-27	WOS:000165953100106
J	Raussens, V; Mah, MKH; Kay, CM; Sykes, BD; Ryan, RO				Raussens, V; Mah, MKH; Kay, CM; Sykes, BD; Ryan, RO			Structural characterization of a low density lipoprotein receptor-active apolipoprotein E peptide, ApoE3-(126-183)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; CELL-SURFACE RECEPTORS; LDL-RECEPTOR; SYNTHETIC PEPTIDES; APOLIPOPHORIN-III; ALPHA-HELIX; PLASMA-LIPOPROTEINS; AQUEOUS-SOLUTION; BINDING DOMAIN; PROTEIN	Apolipoprotein E (apoE) plays a critical role in lipoprotein particle clearance from blood plasma through its interaction with the low density lipoprotein (LDL) receptor and other related receptors, Here, we studied a 58-residue peptide encompassing the receptor binding region of apoE, ApoE3-(126-183) was generated by cyanogen bromide cleavage of recombinant apoE3-(1-183), purified by reversed-phase high pressure liquid chromatography, and characterized by mass spectrometry, Far UV CD spectroscopy of the peptide showed that it is unstructured in aqueous solution, The addition of trifluoroethanol or dodecylphosphocholine induces the peptide to adopt an alpha -helical conformation, ApoE3-(126-183) efficiently transforms dimyristoylphosphatidyl-glycerol (DMPG) vesicles into peptide-lipid complexes. Analysis of apoE3-(126-183) DMPG; complexes by electron microscopy revealed disc-shaped particles with an average diameter of 13 +/- 3 nm, Flotation equilibrium analysis yielded a particle molecular mass of 252 kDa. Far UV CD analysis of apoE3-(126-183) DMPG discs provided evidence that the peptide adopts a helical conformation. Competition binding experiments with I-125-labeled low density lipoprotein (LDL) were conducted to assess the ability of apoE3-(126-183).DMPG complexes to bind to the LDL receptor. Both N-terminal apoE and the peptide, when complexed with DMPG, competed with I-125-LDL for binding sites on the surface of cultured human skin fibroblasts, Under the conditions employed, apoE3-(126-183).DMPG complexes were similar to apoE3-(1-183).DMPG discs in their ability to bind to the receptor, demonstrating that the peptide represents a good model to study the interaction between apoE and the LDL receptor. Preliminary NMR results indicated that a high resolution structure of the apoE3-(126-183) peptide is obtainable.	Univ Alberta, Dept Biochem, Lipid Biol Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Prot Engn Network Ctr Excellence, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Raussens, V (corresponding author), Univ Alberta, Dept Biochem, Lipid Biol Res Grp, 327 HMRC, Edmonton, AB T6G 2S2, Canada.				NHLBI NIH HHS [HL64159] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064159, R37HL064159] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; Benzinger TLS, 1998, BIOCHEMISTRY-US, V37, P13222, DOI 10.1021/bi980482f; Braddock DT, 1996, BIOCHEMISTRY-US, V35, P13975, DOI 10.1021/bi960006u; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; BUCH M, 1995, BIOCHEMISTRY-US, V34, P13219; Clayton D, 1999, PROTEIN SCI, V8, P1797, DOI 10.1110/ps.8.9.1797; Dominguez SR, 1999, J LIPID RES, V40, P753; Dong LM, 1996, NAT STRUCT BIOL, V3, P718, DOI 10.1038/nsb0896-718; DYER CA, 1995, J LIPID RES, V36, P80; DYER CA, 1991, J BIOL CHEM, V266, P22803; FAN P, 1993, BIOCHEMISTRY-US, V32, P1573, DOI 10.1021/bi00057a023; Fisher CA, 1999, J LIPID RES, V40, P93; Fisher CA, 1997, BIOCHEM CELL BIOL, V75, P45, DOI 10.1139/bcb-75-1-45; HENRY GD, 1994, METHOD ENZYMOL, V239, P515; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; Kumaran S, 1999, J PEPT RES, V53, P284, DOI 10.1034/j.1399-3011.1999.00027.x; LALAZAR A, 1989, J BIOL CHEM, V264, P8447; LANGER T, 1972, J CLIN INVEST, V51, P1528, DOI 10.1172/JCI106949; LAUTERWEIN J, 1979, BIOCHIM BIOPHYS ACTA, V556, P244, DOI 10.1016/0005-2736(79)90046-4; Luo PZ, 1997, BIOCHEMISTRY-US, V36, P8413, DOI 10.1021/bi9707133; LUO PZ, 1994, BIOCHEMISTRY-US, V33, P12367, DOI 10.1021/bi00207a003; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MAHLEY RW, 1977, J BIOL CHEM, V252, P7279; MIMS MP, 1994, J BIOL CHEM, V269, P20539; Morrow JA, 2000, J BIOL CHEM, V275, P2576, DOI 10.1074/jbc.275.4.2576; NELSON CA, 1974, ANAL BIOCHEM, V59, P69, DOI 10.1016/0003-2697(74)90010-4; NELSON JW, 1989, BIOCHEMISTRY-US, V28, P5256, DOI 10.1021/bi00438a050; Nikoulin IR, 1998, J CLIN INVEST, V101, P223, DOI 10.1172/JCI1099; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; POWNALL HJ, 1978, BIOCHEMISTRY-US, V17, P1183, DOI 10.1021/bi00600a008; RYAN RO, 1993, J BIOL CHEM, V268, P1525; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; SPARROW JT, 1992, BIOCHEMISTRY-US, V31, P1065, DOI 10.1021/bi00119a015; SPARROW JT, 1985, BIOCHEMISTRY-US, V24, P6984, DOI 10.1021/bi00345a035; Wang GS, 1996, BIOCHEMISTRY-US, V35, P10358, DOI 10.1021/bi960934t; Weers PMM, 1999, J BIOL CHEM, V274, P21804, DOI 10.1074/jbc.274.31.21804; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WEISGRABER KH, 1992, HIGH DENSITY LIPOPRO, V3, P175; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WIENTZEK M, 1994, J BIOL CHEM, V269, P4605; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	48	15	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38329	38336		10.1074/jbc.M005732200	http://dx.doi.org/10.1074/jbc.M005732200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10986285	hybrid			2022-12-27	WOS:000165739800028
J	Gilbert, SL; Pehrson, JR; Sharp, PA				Gilbert, SL; Pehrson, JR; Sharp, PA			XIST RNA associates with specific regions of the inactive X chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOSAGE COMPENSATION; CHROMOSOME INACTIVATION; FEMALE MAMMALS; DROSOPHILA; GENES; ACETYLATION; H4; EXPRESSION; NUCLEUS; DOMAINS	Microscopy studies have shown that XIST RNA colocalizes with the inactive X chromosome (Xi). However, the molecular basis for this colocalization is unknown, Here we provide two lines of evidence from chromatin immunoprecipitation experiments that XTST RNA physically associates with the Xi chromatin. First, XTST RNA can be co-precipitated by antiserum against macroH2A, a histone H2A variant enriched in the Xi. Second, XIST RNA can be co-precipitated by antisera that recognize unacetylated, but not acetylated, isoforms of histones H3 and H4. The specificity of XIST RNA association with hypoacetylated chromatin, together with the previous finding that hypoacetylated histone H4 is enriched at promoters of X-inactivated genes, raises the possibility that XIST RNA may contribute to the hypoacetylation of specific regions of the Xi so as to alter the expression of X-linked genes.	MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA; Univ Penn, Sch Vet Med, Dept Biol Anim, Philadelphia, PA 19104 USA	Massachusetts Institute of Technology (MIT); University of Pennsylvania	Sharp, PA (corresponding author), MIT, Ctr Canc Res, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.				NCI NIH HHS [P30-CA14051] Funding Source: Medline; NIGMS NIH HHS [R37-GM34277] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034277] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Belyaev ND, 1996, HUM GENET, V97, P573; Boggs BA, 1996, CHROMOSOMA, V105, P303, DOI 10.1007/BF02524648; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; Brown CJ, 1997, AM J HUM GENET, V60, P1333, DOI 10.1086/515488; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; Costanzi C, 2000, DEVELOPMENT, V127, P2283; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; Csankovszki G, 1999, NAT GENET, V22, P323, DOI 10.1038/11887; Gilbert SL, 1999, P NATL ACAD SCI USA, V96, P13825, DOI 10.1073/pnas.96.24.13825; Gu WG, 1998, DEV GENET, V22, P56, DOI 10.1002/(SICI)1520-6408(1998)22:1<56::AID-DVG6>3.0.CO;2-6; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; Kelley RL, 1999, CELL, V98, P513, DOI 10.1016/S0092-8674(00)81979-0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; Meller VH, 2000, CURR BIOL, V10, P136, DOI 10.1016/S0960-9822(00)00311-0; Mermoud JE, 1999, J CELL BIOL, V147, P1399, DOI 10.1083/jcb.147.7.1399; Pehrson JR, 1998, NUCLEIC ACIDS RES, V26, P2837, DOI 10.1093/nar/26.12.2837; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B	26	57	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36491	36494		10.1074/jbc.C000409200	http://dx.doi.org/10.1074/jbc.C000409200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	11006266	hybrid			2022-12-27	WOS:000165577700004
J	D'Souza, S; Xin, H; Walter, S; Choubey, D				D'Souza, S; Xin, H; Walter, S; Choubey, D			The gene encoding p202, an interferon-inducible negative regulator of the p53 turner suppressor, is a target of p53-mediated transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TATA-BINDING PROTEIN; DNA-BINDING; CELL-PROLIFERATION; FUNCTIONAL DOMAIN; INHIBITION; EXPRESSION; APOPTOSIS; ACTIVATORS; GROWTH	The p53 tumor suppressor protein regulates the transcription of regulatory genes involved in cell cycle arrest and apoptosis. We reported previously that overexpression of p202, an interferon-inducible negative regulator of cell growth, negatively regulates the transcriptional activity of p53. Now we identify the gene encoding p202 as one whose mRNA and protein expression decrease in cells following the expression of wildtype, but not mutant, p53. Furthermore, the levels of p202 also decrease after exposure of cells to ultra violet light, which correlate with increase in the levels of p53. We report that the sequence-specific DNA binding of p53 to the 5'-regulatory region of the 202 gene contributes to the transcriptional repression of the 202 gene. Interestingly, overexpression of p202 in cells induced to undergo p53-dependent apoptosis significantly delays this process, indicating that the negative regulation of the 202 gene by wild-type p53 is important to potentiate apoptosis.	Loyola Univ, Med Ctr, Dept Radiat Oncol, Stritch Sch Med, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Program Mol Biol, Stritch Sch Med, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago	Choubey, D (corresponding author), Loyola Univ, Med Ctr, Dept Radiat Oncol, Stritch Sch Med, 2160 S 1st Ave,Bldg 1, Maywood, IL 60153 USA.		Choubey, Divaker/A-4771-2008		PHS HHS [C69031] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Basu A, 1998, MOL HUM REPROD, V4, P1099, DOI 10.1093/molehr/4.12.1099; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; Choubey D, 2000, J BIOL REG HOMEOS AG, V14, P187; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; GRIBAUDO G, 1987, J BIOL CHEM, V262, P11878; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Koul D, 1998, BIOCHEM BIOPH RES CO, V247, P379, DOI 10.1006/bbrc.1998.8804; Lee KC, 1999, MOL CELL BIOL, V19, P1279; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Martinez JD, 1998, ONCOGENE, V16, P453, DOI 10.1038/sj.onc.1201565; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Pitkanen K, 1998, ONCOGENE, V16, P459, DOI 10.1038/sj.onc.1201528; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SAMANTA H, 1986, J BIOL CHEM, V261, P1849; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang H, 2000, J BIOL CHEM, V275, P27377; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Zhao RB, 2000, GENE DEV, V14, P981; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	50	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					298	305		10.1074/jbc.M007155200	http://dx.doi.org/10.1074/jbc.M007155200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11013253	hybrid			2022-12-27	WOS:000166280700041
J	Bandyopadhyay, G; Sajan, MP; Kanoh, Y; Standaert, ML; Burke, TR; Quon, MJ; Reed, BC; Dikic, I; Noel, LE; Newgard, CB; Farese, R				Bandyopadhyay, G; Sajan, MP; Kanoh, Y; Standaert, ML; Burke, TR; Quon, MJ; Reed, BC; Dikic, I; Noel, LE; Newgard, CB; Farese, R			Glucose activates mitogen-activated protein kinase (extracellular signal-regulated kinase) through proline-rich tyrosine kinase-2 and the glut1 glucose transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-STIMULATED TRANSLOCATION; RAT ADIPOSE CELL; C-ZETA; MAP KINASE; INCREASES DIACYLGLYCEROL; ADIPOCYTES; RECEPTOR; BETA; SECRETION; ALPHA	Glucose serves as both a nutrient and regulator of physiological and pathological processes. Presently, we found that glucose and certain sugars rapidly activated extracellular signal-regulated kinase (ERK) by a mechanism that was: (a) independent of glucose uptake/metabolism and protein kinase C but nevertheless cytochalasin B-inhibitable; (b) dependent upon proline-rich tyrosine kinase-2 (PYK2), GRBB, SOS, RAS, RAF, and MEK1; and (c) amplified by overexpression of the Glut1, but not Glut2, Gluts, or Glut4, glucose transporter. This amplifying effect was independent of glucose uptake but dependent on residues 463-468, IASGFR, in the Glut1 C terminus. Accordingly, glucose effects on ERK were amplified by expression of Glut 4/Glut1 or Glut2/Glut1 chimeras containing IASGFR but not by Glut1/Glut4 or Glut1/Grlut4 chimeras lacking these residues. Also, deletion of Glut1 residues 469-492 was without effect, but mutations involving serine 465 or arginine 468 yielded dominant-negative forms that inhibited glucose-dependent ERK activation. Glucose stimulated the phosphorylation of tyrosine residues 402 and 881 in PYK2 and binding of PYK2 to Myc-Glut1. Our findings suggest that: (a) glucose activates the GRB2/SOS/RAS/RAF/ MEK1/ERK pathway by a mechanism that requires PYK2 and residues 463-468, LASGFR, in the Glut1 C terminus and (b) Glutl serves as a sensor, transducer, and amplifier for glucose signaling to PYK2 and ERK.	James A Haley Vet Hosp, Res Serv VAR 151, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Internal Med, Tampa, FL 33612 USA; NHLBI, Hypertens Endocrine Branch, NIH, Bethesda, MD 20892 USA; NCI, NIH, Bethesda, MD 20892 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Gifford Labs Diabet Res, Dallas, TX 75235 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Ludwig Institute for Cancer Research; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Farese, R (corresponding author), James A Haley Vet Hosp, Res Serv VAR 151, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	rfarese@com1.med.usf.edu	Quon, Michael/B-1970-2008; Burke, Terrence R/N-2601-2014; Dikic, Ivan/O-4650-2015	Dikic, Ivan/0000-0001-8156-9511; QUON, MICHAEL/0000-0002-5289-3707; Quon, Michael/0000-0002-9601-9915; Burke, Terrence/0000-0001-9925-8586	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL003608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038079] Funding Source: NIH RePORTER; NIDDK NIH HHS [2R01DK38079-09A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1999, BIOCHEM J, V337, P461, DOI 10.1042/0264-6021:3370461; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Benes C, 1998, J BIOL CHEM, V273, P15507, DOI 10.1074/jbc.273.25.15507; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; BOYD AE, 1992, J CELL BIOCHEM, V48, P234, DOI 10.1002/jcb.240480303; CHIN JE, 1993, J BIOL CHEM, V268, P6338; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DERUBERTIS FR, 1994, DIABETES, V43, P1, DOI 10.2337/diabetes.43.1.1; DRAZNIN B, 1987, DIABETES, V36, P174, DOI 10.2337/diabetes.36.2.174; DRAZNIN B, 1988, BIOCHEM BIOPH RES CO, V156, P570, DOI 10.1016/S0006-291X(88)80880-5; FARESE RV, 1987, SCIENCE, V236, P586, DOI 10.1126/science.3107122; FARESE RV, 1994, J CLIN INVEST, V93, P1894, DOI 10.1172/JCI117180; FARESE RV, 1988, BIOCHEM J, V256, P175, DOI 10.1042/bj2560175; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; Haneda M, 1995, J DIABETES COMPLICAT, V9, P246, DOI 10.1016/1056-8727(95)80013-5; HARING H, 1986, J BIOL CHEM, V261, P3869; HOFFMAN JM, 1991, ENDOCRINOLOGY, V128, P2937, DOI 10.1210/endo-128-6-2937; ISHIZUKA T, 1989, FEBS LETT, V249, P234, DOI 10.1016/0014-5793(89)80630-1; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; LEE TS, 1989, P NATL ACAD SCI USA, V86, P5141, DOI 10.1073/pnas.86.13.5141; LONGO EA, 1991, J BIOL CHEM, V266, P9314; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; MULLER HK, 1991, DIABETES, V40, P1440, DOI 10.2337/diabetes.40.11.1440; MURAOKA A, 1995, BIOCHEM J, V311, P699, DOI 10.1042/bj3110699; Noel LE, 1997, BIOCHEMISTRY-US, V36, P5465, DOI 10.1021/bi9630624; PETERSEN OH, 1987, PHYSIOL REV, V67, P1054, DOI 10.1152/physrev.1987.67.3.1054; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; WEBER TM, 1988, RECEPTOR BIOCH MET B, V12, P171; WOLLHEIM CB, 1986, ANN NY ACAD SCI, V488, P317; YANG YC, 1993, FEBS LETT, V333, P287, DOI 10.1016/0014-5793(93)80672-H; Yao ZJ, 1999, J MED CHEM, V42, P25, DOI 10.1021/jm980388x	40	58	60	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40817	40826		10.1074/jbc.M007920200	http://dx.doi.org/10.1074/jbc.M007920200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007796	hybrid			2022-12-27	WOS:000166114600023
J	Mo, YY; Wang, CY; Beck, WT				Mo, YY; Wang, CY; Beck, WT			A novel nuclear localization signal in human DNA topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL DOMAIN; POINT MUTATION; HEAT-SHOCK; II-ALPHA; IDENTIFICATION; PROTEINS; SITE; EXPRESSION; CLONING; CELLS	DNA topoisomerase (topo) I is a nuclear enzyme that plays an important role in DNA metabolism. Based on conserved nuclear targeting sequences, four classic nuclear localization signals (NLSs) have been proposed at the N terminus of human topo I, but studies with yeast have suggested that only one of them (amino acids (aa) 150-156) is sufficient to direct the enzyme to the nucleus. In this study, we expressed human topo I fused to enhanced green fluorescent protein (EGFP) in mammalian cells and demonstrated that whereas aa 150-156 are sufficient for nuclear localization, the nucleolar localization requires as 157-199. More importantly, we identified a novel NLS within aa 117-146. In contrast to the classic MLSs that are rich in basic amino acids, the novel NLS identified in this study is rich in acidic amino acids, Furthermore, this novel NLS alone is sufficient to direct not only EGFP into the nucleus but also topo I; and the EGFP topo I fusion driven by the novel NLS is as active in vivo as the wild-type topo I in response to the topo I inhibitor topotecan. Together, our results suggest that human topo I carries two independent NLSs that have opposite amino acid compositions.	Univ Illinois, Div Mol Pharmacol, Dept Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Pharmaceut & Pharmacodynam, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Beck, WT (corresponding author), Univ Illinois, Div Mol Pharmacol, Dept Mol Genet, MC 669,900 S Ashland Ave, Chicago, IL 60607 USA.	wtbeck@uic.edu	Mo, Yin-Yuan/B-6141-2011; Mo, Yin-Yuan/R-8255-2019		NCI NIH HHS [CA27469, CA30103, CA40570] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040570, R01CA030103, U10CA027469] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALSNER J, 1992, J BIOL CHEM, V267, P12408; Ausubel FM, 1988, MOL REPROD DEV; BAKER SD, 1995, CYTOMETRY, V19, P134, DOI 10.1002/cyto.990190208; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Castano IB, 1996, GENE DEV, V10, P2564, DOI 10.1101/gad.10.20.2564; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; Cowell IG, 1998, EXP CELL RES, V243, P232, DOI 10.1006/excr.1998.4150; DARPA P, 1990, CANCER RES, V50, P6919; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FLEISCHMANN G, 1984, P NATL ACAD SCI-BIOL, V81, P6958, DOI 10.1073/pnas.81.22.6958; Ginisty H, 1999, J CELL SCI, V112, P761; Gobert C, 1999, P NATL ACAD SCI USA, V96, P10355, DOI 10.1073/pnas.96.18.10355; Haluska P, 1998, NUCLEIC ACIDS RES, V26, P1841, DOI 10.1093/nar/26.7.1841; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; Hann C, 1998, J BIOL CHEM, V273, P8425, DOI 10.1074/jbc.273.14.8425; HASHIMOTO S, 1995, ONCOL RES, V7, P21; HIRANO T, 1989, J CELL BIOL, V108, P243, DOI 10.1083/jcb.108.2.243; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KOIWAI O, 1993, GENE, V125, P211, DOI 10.1016/0378-1119(93)90331-V; Mirski SEL, 1999, EXP CELL RES, V251, P329, DOI 10.1006/excr.1999.4587; Mo YY, 1998, BIOTECHNIQUES, V25, P1052, DOI 10.2144/98256cr04; Mo YY, 1999, EXP CELL RES, V252, P50, DOI 10.1006/excr.1999.4616; Mo YY, 2000, EXP CELL RES, V256, P480, DOI 10.1006/excr.2000.4864; Morcillo G, 1997, EXP CELL RES, V236, P361, DOI 10.1006/excr.1997.3726; MULLER MT, 1985, EMBO J, V4, P1237, DOI 10.1002/j.1460-2075.1985.tb03766.x; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nitiss JL, 1998, CONT CANC RES, P517; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; Rossi F, 1998, NUCLEIC ACIDS RES, V26, P2963, DOI 10.1093/nar/26.12.2963; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; SCHEER U, 1994, CURR OPIN CELL BIOL, V6, P354, DOI 10.1016/0955-0674(94)90026-4; Sekiguchi J, 1997, MOL CELL, V1, P89, DOI 10.1016/S1097-2765(00)80010-6; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; SUGIMOTO Y, 1990, CANCER RES, V50, P6925; TANIZAWA A, 1993, J BIOL CHEM, V268, P25463; Trowbridge PW, 1999, MOL CELL BIOL, V19, P1686; Ueki N, 1998, BIOCHEM BIOPH RES CO, V252, P97, DOI 10.1006/bbrc.1998.9606; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; VINCENT M, 1979, NATURE, V281, P501, DOI 10.1038/281501a0; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223	45	42	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41107	41113		10.1074/jbc.M003135200	http://dx.doi.org/10.1074/jbc.M003135200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11016921	hybrid			2022-12-27	WOS:000166114600061
J	Scherer, A; Graff, JM				Scherer, A; Graff, JM			Calmodulin differentially modulates Smad1 and Smad2 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA SUPERFAMILY; FAMILY MEDIATOR SMAD1; MAD-RELATED PROTEIN; TUMOR-SUPPRESSOR; GROWTH-FACTOR; TRANSDUCTION PATHWAY; MESODERM INDUCTION; IN-VIVO; XENOPUS; RECEPTOR	The members of the Smad protein family are intracellular mediators of transforming growth factor beta (TGF-beta) signaling. Smad1 transduces bone morphogenetic protein signals, inducing formation of ventral mesoderm in Xenopus embryos, whereas Smad2 transduces activin/TGF-beta signals, generating dorsal mesoderm. Calmodulin directly binds to-many Smads and was shown to downregulate Smad2 activity in a cell culture system (Zimmerman, C. M., Kariapper, M. S. T., and Mathews, L. S. (1997) J. Biol. Chen. 273, 677-680). Here, we extend those data and demonstrate that calmodulin alters Smad signaling in living embryos, increasing Smad1 activity while inhibiting Smad2 function. To characterize this regulation, we undertook a structure-function analysis and found that calmodulin binds to two distinct and conserved;regions in both Smad1 and Smad2. Receptor tyrosine kinase signaling also modifies Smad activity (Kretzschmar, M., Doody, J., and Massague, J. (1997) Nature 389, 618-622; Kretzschmar, M Doody, J., Timokhina, I., and Massague, J. (1999) Genes Dev. 13, 804-816; de Caestecker, M. P., Parks, W. T., Frank, C. J., Castagnino, P., Bottaro, D. P., Roberts, A. B., and Lechleider, R. J. (1998) Genes Dev. 12, 1587-1592). We show that calmodulin binding to Smads inhibits subsequent Erk2-dependent phosphorylation of Smads and vice versa. These observations suggest the presence of a cross-talk between three major signaling cascades as follows: Ca2+/calmodulin, receptor tyrosine kinase, and TGF-beta pathways.	Univ Texas, SW Med Ctr, Ctr Dev Biol, Dept Mol Biol & Oncol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Graff, JM (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, Dept Mol Biol & Oncol, 5323 Harry Hines Blvd,NB 5-118A, Dallas, TX 75390 USA.		Scherer, Andreas/ABD-8660-2020	Scherer, Andreas/0000-0002-4254-7122	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036001] Funding Source: NIH RePORTER; NICHD NIH HHS [R01HD3600101A1] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; Ault KT, 1996, DEVELOPMENT, V122, P2033; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BUSA WB, 1989, DEV BIOL, V132, P315, DOI 10.1016/0012-1606(89)90228-5; Casellas R, 1998, DEV BIOL, V198, P1; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Clements D, 1999, DEVELOPMENT, V126, P4903; COOKE J, 1989, DEVELOPMENT, V105, P549; Creton R, 2000, DEV BIOL, V217, P375, DOI 10.1006/dbio.1999.9542; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Dick A, 2000, GENE, V246, P69, DOI 10.1016/S0378-1119(00)00056-1; Eisaki A, 2000, BIOCHEM BIOPH RES CO, V271, P151, DOI 10.1006/bbrc.2000.2545; Ferguson EL, 1996, CURR OPIN GENET DEV, V6, P424, DOI 10.1016/S0959-437X(96)80063-3; Fritz JL, 2000, DEVELOPMENT, V127, P1991; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hedgepeth CM, 1999, MOL CELL BIOL, V19, P7147; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HINRICHSEN RD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P277, DOI 10.1016/0304-419X(93)90010-A; Holley SA, 1997, BIOESSAYS, V19, P281, DOI 10.1002/bies.950190404; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Howell M, 1999, DEV BIOL, V214, P354, DOI 10.1006/dbio.1999.9430; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; Lebman DA, 1999, MICROBES INFECT, V1, P1297, DOI 10.1016/S1286-4579(99)00254-3; LeSuer JA, 1999, DEVELOPMENT, V126, P137; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Masuyama N, 1999, J BIOL CHEM, V274, P12163, DOI 10.1074/jbc.274.17.12163; Miyanaga Y, 1999, DEV GENES EVOL, V209, P69, DOI 10.1007/s004270050229; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Muller F, 1999, MECH DEVELOP, V88, P73, DOI 10.1016/S0925-4773(99)00173-2; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nishimatsu S, 1998, MECH DEVELOP, V74, P75, DOI 10.1016/S0925-4773(98)00070-7; Onions J, 2000, BIOCHEMISTRY-US, V39, P4366, DOI 10.1021/bi992533u; Osada SI, 1999, DEVELOPMENT, V126, P3229; Patterson GI, 2000, TRENDS GENET, V16, P27, DOI 10.1016/S0168-9525(99)01916-2; Pouliot F, 1999, INT J CANCER, V81, P98, DOI 10.1002/(SICI)1097-0215(19990331)81:1<98::AID-IJC17>3.0.CO;2-9; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Riggins GJ, 1997, CANCER RES, V57, P2578; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Schutte M, 1996, CANCER RES, V56, P2527; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; SWANLJUNGCOLLINS H, 1991, J BIOL CHEM, V266, P1312; Tada M, 2000, DEVELOPMENT, V127, P2227; Watanabe M, 1999, CELL MOL BIOL, V45, P537; Watanabe M, 1999, DEVELOPMENT, V126, P5621; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; Xu RH, 1999, BIOCHEM BIOPH RES CO, V258, P366, DOI 10.1006/bbrc.1999.0598; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4; Zimmerman CM, 1998, J BIOL CHEM, V273, P677, DOI 10.1074/jbc.273.2.677	78	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41430	41438		10.1074/jbc.M005727200	http://dx.doi.org/10.1074/jbc.M005727200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007779	hybrid			2022-12-27	WOS:000166114600101
J	Huttunen, HJ; Kuja-Panula, J; Sorci, G; Agneletti, AL; Donato, R; Rauvala, H				Huttunen, HJ; Kuja-Panula, J; Sorci, G; Agneletti, AL; Donato, R; Rauvala, H			Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DEVELOPING NERVOUS-SYSTEM; CALCIUM-BINDING PROTEINS; HIPPOCAMPAL-NEURONS; ALZHEIMERS-DISEASE; S-100 PROTEINS; OXIDANT STRESS; GROWTH-FACTOR; CYTOCHROME-C; BRAIN	Amphoterin is a protein enhancing process extension and migration in embryonic neurons and in tumor cells through binding to receptor for advanced glycation end products (RAGE), a multiligand transmembrane receptor. S100 proteins, especially S100B, are abundantly expressed in the nervous system and are suggested to function as cytokines with both neurotrophic and neurotoxic effects. However, the cell surface receptor for the cytokine function of S100B has not been identified. Here we show that two S100 family proteins, S100B and S100A1, activate RAGE in concert with amphoterin inducing neurite outgrowth and activation of transcription factor NF-kappaB. Furthermore, activation of RAGE by amphoterin and S100B promotes cell survival through increased expression of the anti-apoptotic protein Bcl-2. However, whereas nanomolar concentrations of S100B induce trophic effects in RAGE-expressing cells, micromolar concentrations of S100B induce apoptosis in an oxidant-dependent manner. Both trophic and toxic effects are specific for cells expressing full-length RAGE since cells expressing a cytoplasmic domain deletion mutant of RAGE are unresponsive to these stimuli. These findings suggest that activation of RAGE by multiple ligands is able to promote trophic effects whereas hyperactivation of RAGE signaling pathways promotes apoptosis, We suggest that RAGE is a signal-transducing receptor for both trophic and toxic effects of S100B.	Univ Helsinki, Inst Biotechnol, Program Mol Neurobiol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland; Univ Perugia, Dept Expt Med & Biochem Sci, Sect Anat, I-06122 Perugia, Italy	University of Helsinki; University of Helsinki; University of Perugia	Huttunen, HJ (corresponding author), Univ Helsinki, Inst Biotechnol, Program Mol Neurobiol, POB 56,Viikinkaari 5, FIN-00014 Helsinki, Finland.		Donato, Rosario/I-3943-2019	Huttunen, Henri/0000-0002-9867-4438; Sorci, Guglielmo/0000-0002-1973-9679; Rauvala, Heikki/0000-0001-7809-9811				Alexanian AR, 1999, FASEB J, V13, P1611, DOI 10.1096/fasebj.13.12.1611; ALLORE R, 1988, SCIENCE, V239, P1311, DOI 10.1126/science.2964086; AZMITIA EC, 1990, BRAIN RES, V516, P354, DOI 10.1016/0006-8993(90)90942-5; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; BHATTACHARYYA A, 1992, J NEUROBIOL, V23, P451, DOI 10.1002/neu.480230410; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; DONATO R, 1988, J BIOL CHEM, V263, P106; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Garbuglia M, 1999, BIOCHEM BIOPH RES CO, V254, P36, DOI 10.1006/bbrc.1998.9881; Goncalves DS, 2000, NEUROREPORT, V11, P807, DOI 10.1097/00001756-200003200-00030; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Holm K, 1999, TRENDS NEUROSCI, V22, P269, DOI 10.1016/S0166-2236(98)01352-6; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Hu JG, 1996, J BIOL CHEM, V271, P2543, DOI 10.1074/jbc.271.5.2543; Hu JR, 1997, J NEUROCHEM, V69, P2294; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; IVANENKOV VV, 1995, J BIOL CHEM, V270, P14651, DOI 10.1074/jbc.270.24.14651; Iwasaki Y, 1997, J NEUROL SCI, V151, P7, DOI 10.1016/S0022-510X(97)00073-7; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; KUBE E, 1992, J BIOL CHEM, V267, P14175; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; LIU JP, 1992, J NEUROSCI RES, V33, P248, DOI 10.1002/jnr.490330208; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MARIGGIO MA, 1994, NEUROSCIENCE, V60, P29, DOI 10.1016/0306-4522(94)90201-1; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Milev P, 1998, J BIOL CHEM, V273, P6998, DOI 10.1074/jbc.273.12.6998; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Nair SM, 1997, J NEUROCHEM, V68, P1286; Osterloh D, 1998, CELL CALCIUM, V24, P137, DOI 10.1016/S0143-4160(98)90081-1; PANDE SV, 1994, ANAL BIOCHEM, V220, P424, DOI 10.1006/abio.1994.1361; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; Petrova TV, 2000, BRAIN RES, V853, P74, DOI 10.1016/S0006-8993(99)02251-9; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Rauvala H, 2000, MATRIX BIOL, V19, P377, DOI 10.1016/S0945-053X(00)00084-6; RAUVALA H, 1988, J CELL BIOL, V107, P2293, DOI 10.1083/jcb.107.6.2293; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; Rety S, 2000, STRUCTURE, V8, P175, DOI 10.1016/S0969-2126(00)00093-9; Rety S, 1999, NAT STRUCT BIOL, V6, P89; SALMIVIRTA M, 1992, EXP CELL RES, V200, P444, DOI 10.1016/0014-4827(92)90194-D; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VANELDIK LJ, 1987, BRAIN RES, V436, P367, DOI 10.1016/0006-8993(87)91681-7; VANELDIK LJ, 1991, BRAIN RES, V542, P280, DOI 10.1016/0006-8993(91)91579-P; Wang S, 1999, MOL BRAIN RES, V70, P167, DOI 10.1016/S0169-328X(99)00145-X; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Zhang KZ, 1996, P NATL ACAD SCI USA, V93, P4504, DOI 10.1073/pnas.93.9.4504; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	63	483	508	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40096	40105		10.1074/jbc.M006993200	http://dx.doi.org/10.1074/jbc.M006993200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007787	hybrid			2022-12-27	WOS:000166039500042
J	Lake, MW; Temple, CA; Rajagopalan, KV; Schindelin, H				Lake, MW; Temple, CA; Rajagopalan, KV; Schindelin, H			The crystal structure of the Escherichia coli MobA protein provides insight into molybdopterin guanine dinucleotide biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMETHYL-SULFOXIDE REDUCTASE; MOLYBDENUM COFACTOR BIOSYNTHESIS; ANGSTROM RESOLUTION; FERREDOXIN OXIDOREDUCTASE; RHODOBACTER-CAPSULATUS; NITRATE REDUCTASE; DMSO REDUCTASE; DEHYDROGENASE; REFINEMENT; PRODUCT	The molybdenum cofactor (Moco) is found in a variety of enzymes present in all phyla and comprises a family of related molecules containing molybdopterin (MPT), a tricyclic pyranopterin with a cis-dithiolene group, as the invariant essential moiety, MPT biosynthesis involves a conserved pathway, but some organisms perform additional reactions that modify MPT. In eubacteria, the cofactor is often present in a dinucleotide form combining MPT and a purine or pyrimidine nucleotide via a pyrophosphate linkage. In Escherichia coli, the MobA protein links a guanosine 5'-phosphate to MPT forming molybdopterin guanine dinucleotide. This reaction requires GTP, MgCl2,, and the MPT form of the cofactor and can efficiently reconstitute Rhodobacter sphaeroides apo-DMSOR, an enzyme that requires molybdopterin guanine dinucleotide for activity. In this paper, we present the crystal structure of MobA, a protein containing 194 amino acids. The MobA monomer has an alpha/beta architecture in which the N-terminal half of the molecule adopts a Rossman fold. The structure of MobA has striking similarity to Bacillus subtilis SpsA, a nucleotide-diphospho-sugar transferase involved in sporulation, The cocrystal structure of MobA and GTP reveals that the GTP-binding site is located in the N-terminal half of the molecule. Conserved residues located primarily in three signature sequence motifs form crucial interactions with the bound nucleotide, The binding site for MPT is located adjacent to the GTP-binding site in the C-terminal half of the molecule, which contains another set of conserved residues presumably involved in MPT binding.	SUNY Stony Brook, Dept Biochem, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Struct Biol, Stony Brook, NY 11794 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Duke University	Schindelin, H (corresponding author), SUNY Stony Brook, Dept Biochem, Stony Brook, NY 11794 USA.	hermann.schindelin@sunysb.edu	Schindelin, Hermann/Q-2697-2019		NIDDK NIH HHS [DK54835] Funding Source: Medline; NIGMS NIH HHS [GM00091] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054835] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Boyington JC, 1997, SCIENCE, V275, P1305, DOI 10.1126/science.275.5304.1305; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; Christopher JA, 1998, J MOL GRAPH MODEL, V16, P285; Czjzek M, 1998, J MOL BIOL, V284, P435, DOI 10.1006/jmbi.1998.2156; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dias JM, 1999, STRUCTURE, V7, P65, DOI 10.1016/S0969-2126(99)80010-0; Dobbek H, 1999, P NATL ACAD SCI USA, V96, P8884, DOI 10.1073/pnas.96.16.8884; Eaves DJ, 1997, EUR J BIOCHEM, V246, P690, DOI 10.1111/j.1432-1033.1997.t01-1-00690.x; Hanzelmann P, 1998, EUR J BIOCHEM, V255, P755, DOI 10.1046/j.1432-1327.1998.2550755.x; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Hu YL, 1999, J MOL BIOL, V286, P899, DOI 10.1006/jmbi.1998.2488; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; HUTCHINSON EG, 1994, PROTEIN SCI, V3, P2207, DOI 10.1002/pro.5560031206; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li HK, 2000, J AM CHEM SOC, V122, P7673, DOI 10.1021/ja000643e; MASUI H, 1994, J BACTERIOL, V176, P1624, DOI 10.1128/jb.176.6.1624-1629.1994; McAlpine AS, 1997, J BIOL INORG CHEM, V2, P690, DOI 10.1007/s007750050185; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MEYER O, 1993, MOLYBDENUM ENZYMES C; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; PALMER T, 1994, EUR J BIOCHEM, V222, P687, DOI 10.1111/j.1432-1033.1994.tb18913.x; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; Rajagopalan KV, 1997, BIOCHEM SOC T, V25, P757, DOI 10.1042/bst0250757; Rajagopalan KV, 1996, ESCHERICHIA COLI SAL, P674; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; ROTHERY RA, 1995, J BACTERIOL, V177, P2057, DOI 10.1128/jb.177.8.2057-2063.1995; Rothery RA, 1998, J BIOL CHEM, V273, P7462, DOI 10.1074/jbc.273.13.7462; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; Schneider F, 1996, J MOL BIOL, V263, P53, DOI 10.1006/jmbi.1996.0555; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; Temple CA, 2000, J BIOL CHEM, V275, P40202, DOI 10.1074/jbc.M007407200; Vetter IR, 1999, Q REV BIOPHYS, V32, P1, DOI 10.1017/S0033583599003480	48	63	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40211	40217		10.1074/jbc.M007406200	http://dx.doi.org/10.1074/jbc.M007406200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10978347	hybrid			2022-12-27	WOS:000166039500058
J	Ravindranath, RMH; Tam, WY; Nguyen, P; Fincham, AG				Ravindranath, RMH; Tam, WY; Nguyen, P; Fincham, AG			The enamel protein amelogenin binds to the N-acetyl-D-glucosamine-mimicking peptide motif of cytokeratins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MATRIX PROTEINS; DNA-SEQUENCE; BOVINE; CONSERVATION; EXPRESSION; CLEAVAGE; CDNA; RAT	Amelogenins bind to GlcNAc of the dentine-enamel matrix proteins (Ravindranath, R. M. H., Moradian-Oldak, J., Fincham, A. G. (1999) J. Biol Chem, 274, 2464-2471). The hypothesis that amelogenins may interact with the peptides that mimic GlcNAc is tested. GlcNAc-mimicking peptide (SFGSGFGGGY) but not its variants with single amino acid substitution at serine, tyrosine, or phenylalanine residues inhibited hemagglutination of amelogenins and the terminal, tyrosine-rich amelogenin polypeptide (TRAP). The binding affinity of SFGSGFGGGY to amelogenins was confirmed by dosimetric binding of amelogenins or TRAP with [H-3]peptide, specific binding in varying concentrations of the peptide, Scatchard plot analysis, and competitive inhibition with the unlabeled peptide. The ability of the peptide or GlcNAc to stoichiometrically inhibit TRAP binding of [C-14]GlcNAc or [H-3]peptide indicated that both the peptide and GlcNAc compete for a single binding site. Using different fragments of amelogenins, we have identified the peptide-binding motif in amelogenin to be the same as the GlcNAc-binding "amelogenin trityrosyl motif peptide." The GlcNAc-mimicking peptide failed to bind to the amelogenin trityrosyl moth peptide when the tyrosyl residues were substituted with phenylalanine or when the third proline was replaced with threonine, as in some cases of human X-linked amelogenesis imperfecta. This study documents that molecular mimicry may play a role in stability and organization of amelogenin during amelogenesis.	Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA	University of Southern California	Ravindranath, RMH (corresponding author), Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, 2250 Alcazar St, Los Angeles, CA 90033 USA.	rravindr@hsc.usc.edu			NIDCR NIH HHS [DE-03660] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AKITA H, 1992, ARCH ORAL BIOL, V37, P953, DOI 10.1016/0003-9969(92)90067-I; BONA CA, 1992, MOL IMMUNOBIOLOGY SE, P239; BONASS WA, 1994, BIOCHEM BIOPH RES CO, V198, P755, DOI 10.1006/bbrc.1994.1109; Collier PM, 1997, ARCH ORAL BIOL, V42, P235, DOI 10.1016/S0003-9969(96)00099-4; CUNNINGHAM MW, 1991, MICROBIAL ADHESION I, P150; Domingues MG, 2000, EUR J ORAL SCI, V108, P43, DOI 10.1034/j.1600-0722.2000.00717.x; EASTOE JE, 1979, J DENT RES, V58, P753, DOI 10.1177/00220345790580022701; EASTOE JE, 1963, ARCH ORAL BIOL, V8, P633, DOI 10.1016/0003-9969(63)90078-5; FINCHAM AG, 1995, J STRUCT BIOL, V115, P50, DOI 10.1006/jsbi.1995.1029; FINCHAM AG, 1994, J STRUCT BIOL, V112, P103, DOI 10.1006/jsbi.1994.1011; FINCHAM AG, 1981, BIOSCIENCE REP, V1, P771, DOI 10.1007/BF01114799; FINCHAM AG, 1992, INT CONGR SER, V1002, P187; FINCHAM AG, 1982, CARIES RES, V16, P64, DOI 10.1159/000260578; FINCHAM AG, 1991, ARCH ORAL BIOL, V36, P305, DOI 10.1016/0003-9969(91)90101-Y; FINCHAM AG, 1990, CALCIFIED TISSUE INT, V47, P105, DOI 10.1007/BF02555993; FINCHAM AG, 1983, BIOCHEM J, V211, P149, DOI 10.1042/bj2110149; FINCHAM AG, 1993, BIOCHEM BIOPH RES CO, V197, P248, DOI 10.1006/bbrc.1993.2468; Foisner R, 1991, CURR OPIN CELL BIOL, V3, P75, DOI 10.1016/0955-0674(91)90168-X; HANUKOGLU I, 1982, CELL, V31, P243, DOI 10.1016/0092-8674(82)90424-X; HOESS R, 1993, GENE, V128, P43, DOI 10.1016/0378-1119(93)90151-R; KASPER M, 1989, DIFFERENTIATION, V40, P207, DOI 10.1111/j.1432-0436.1989.tb00600.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU EC, 1992, BIOCHEM BIOPH RES CO, V188, P1253, DOI 10.1016/0006-291X(92)91366-X; Luo P, 2000, J BIOL CHEM, V275, P16146, DOI 10.1074/jbc.M909121199; MARCHUK D, 1984, CELL, V39, P491, DOI 10.1016/0092-8674(84)90456-2; MERRIFIELD B, 1986, SCIENCE, V232, P341, DOI 10.1126/science.3961484; OGATA C, 1987, NATURE, V328, P739, DOI 10.1038/328739a0; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; Paine ML, 1997, J BONE MINER RES, V12, P221, DOI 10.1359/jbmr.1997.12.2.221; Ravindranath RMH, 1999, J BIOL CHEM, V274, P2464, DOI 10.1074/jbc.274.4.2464; RAVINDRANATH RMH, 1992, VIROLOGY, V188, P143, DOI 10.1016/0042-6822(92)90743-9; RAVINDRANATH RMH, 1990, J VIROL, V64, P5430, DOI 10.1128/JVI.64.11.5430-5440.1990; Robinson C, 1989, Connect Tissue Res, V22, P93; RUGG EL, 1994, GENE DEV, V8, P2563, DOI 10.1101/gad.8.21.2563; Ryu OH, 1999, J DENT RES, V78, P743, DOI 10.1177/00220345990780030601; Sasaki S, 1991, MECH PHYLOGENY MINER, P79; SCOTT JK, 1992, P NATL ACAD SCI USA, V89, P5398, DOI 10.1073/pnas.89.12.5398; SHIKHMAN AR, 1994, J IMMUNOL, V153, P5593; SIMMER JP, 1994, CALCIFIED TISSUE INT, V54, P312, DOI 10.1007/BF00295956; SNEAD ML, 1985, BIOCHEM BIOPH RES CO, V129, P812, DOI 10.1016/0006-291X(85)91964-3; Tabata MJ, 1996, ARCH ORAL BIOL, V41, P1019, DOI 10.1016/S0003-9969(96)00087-8; TAKAGI T, 1984, BIOCHEM BIOPH RES CO, V121, P592, DOI 10.1016/0006-291X(84)90223-7; Tan J, 1998, J DENT RES, V77, P1388, DOI 10.1177/00220345980770060301; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Woessner JF, 1998, CONNECT TISSUE RES, V39, P69, DOI 10.3109/03008209809023913; WRIGHT CS, 1984, J MOL BIOL, V178, P91, DOI 10.1016/0022-2836(84)90232-8; Wright John Timothy, 1992, Pediatric Dentistry, V14, P331; WRIGHT JT, 1993, ORAL SURG ORAL MED O, V76, P192, DOI 10.1016/0030-4220(93)90204-H; Wright JT, 1997, ARCH ORAL BIOL, V42, P149, DOI 10.1016/S0003-9969(96)00096-9; YAMAMOTO K, 1992, J BIOCHEM-TOKYO, V111, P436, DOI 10.1093/oxfordjournals.jbchem.a123775; ZEICHNERDAVID M, 1995, INT J DEV BIOL, V39, P69	51	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39654	39661		10.1074/jbc.M006471200	http://dx.doi.org/10.1074/jbc.M006471200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10980199	hybrid			2022-12-27	WOS:000165953100093
J	Widen, C; Zilliacus, J; Gustafsson, JA; Wikstrom, AC				Widen, C; Zilliacus, J; Gustafsson, JA; Wikstrom, AC			Glucocorticoid receptor interaction with 14-3-3 and Raf-1, a proposed mechanism for cross-talk of two signal transduction pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK; ACTIVATION; PROTEIN; BINDING; 14-3-3-PROTEINS; HSP90	The glucocorticoid receptor (GR) functions as a ligand-dependant transcription factor. In the present study we describe a specific immunoaffinity chromatography purification of GR from liver cytosol from adrenalectomized rats that may be used to identify hitherto unknown cytosolic GR interacting proteins. me have identified the ubiquitously expressed 14-3-3 as well as Raf-1, a downstream effector of Ras, as GR co-purifying proteins. In our semi-quantitative analysis liganded/activated GR showed the strongest interaction with 14-3-3 and Raf-l, but 14-3-3 was also found to co-purify with GR in a nonliganded/nonactivated state. By extensive salt washes we were also able to demonstrate that the glucocorticoid induced interaction between GR, 14-3-3, and Raf-1, respectively, is remarkably stable and withstood 2.4 M salt. The interaction between GR and 14-3-3 was also verified by 14-3-3 co-immunoprecipitation studies. Our observations that GR and Raf-1 are found within the same protein complex ("receptosome") in the cytoplasm of rat liver cells could provide a mechanistic explanation for glucocorticoid effects on the Raf-1-Ras signaling pathway.	Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden	Karolinska Institutet	Wikstrom, AC (corresponding author), Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden.	lotta.wikstrom@mednut.ki.se						AKNER G, 1992, EUR J CELL BIOL, V58, P356; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cenni B, 1999, TRENDS ENDOCRIN MET, V10, P41, DOI 10.1016/S1043-2760(98)00121-0; Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272; Evans-Storms RB, 2000, ENDOCRINOLOGY, V141, P1854, DOI 10.1210/en.141.5.1854; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; King KL, 1998, ANNU REV PHYSIOL, V60, P601, DOI 10.1146/annurev.physiol.60.1.601; LEACH KL, 1979, J BIOL CHEM, V254, P1884; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; MCEWAN IJ, 1994, J BIOL CHEM, V269, P25629; MERRY WH, 1994, SURGERY, V116, P1095; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEMOTO T, 1990, BIOCHEMISTRY-US, V29, P1880, DOI 10.1021/bi00459a031; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; OKRET S, 1984, P NATL ACAD SCI-BIOL, V81, P1609, DOI 10.1073/pnas.81.6.1609; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; SUEN KL, 1995, ONCOGENE, V11, P825; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607	31	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39296	39301		10.1074/jbc.M006943200	http://dx.doi.org/10.1074/jbc.M006943200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11005817	hybrid			2022-12-27	WOS:000165953100049
J	Bastie, C; Luquet, S; Holst, D; Jehl-Pietri, C; Grimaldi, PA				Bastie, C; Luquet, S; Holst, D; Jehl-Pietri, C; Grimaldi, PA			Alterations of peroxisome proliferator-activated receptor delta activity affect fatty acid-controlled adipose differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREADIPOCYTE CLONAL LINE; AP2 GENE-EXPRESSION; CELL-DIFFERENTIATION; BINDING DOMAIN; PPAR-GAMMA; LIGAND; ADIPOGENESIS; FIBROBLASTS; INDUCTION; AF-2	Fatty acids have been postulated to regulate adaptation of adipose mass to nutritional changes by controlling expression of genes implicated in lipid metabolism via activation of nuclear receptors. Ectopic expression of the nuclear receptors PPAR gamma or PPAR delta promotes adipogenesis in fibroblastic cells exposed to thiazolidinediones or long-chain fatty acids. To investigate the role of PPAR delta in fatty acid regulation of gene expression and adipogenesis in a preadipose cellular context, we studied the effects of overexpressing the native receptor or the dominant-negative PPAR delta mutant in Ob1771 and 3T3-F442A cells. Overexpression of PPAR delta enhanced fatty acid induction of the adipose-related genes for fatty acid translocase, adipocyte lipid binding protein, and PPAR gamma and fatty acid effects on terminal differentiation. A transactivation deficient form of PPAR delta mutated in the AF2 domain severely reduced these effects. Findings are similar in Ob1771 or 3T3-F442A preadipose cells. These data demonstrate that PPAR delta plays a central role in fatty acid-controlled differentiation of preadipose cells. Furthermore, they suggest that modulation of PPAR delta expression or activity could affect adaptive responses of white adipose tissue to nutritional changes.	Univ Nice, Fac Sci, Ctr Biochim, INSERM U470,Inst Rech Signalisat Biol Dev & Canc, F-06108 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Grimaldi, PA (corresponding author), Univ Nice, Fac Sci, Ctr Biochim, INSERM U470,Inst Rech Signalisat Biol Dev & Canc, Parc Valrose, F-06108 Nice 2, France.		Luquet, serge/AAT-1809-2021	Luquet, serge/0000-0001-8668-6645; Bastie, Claire/0000-0001-8178-4748				AMRI EZ, 1994, J LIPID RES, V35, P930; AMRI EZ, 1991, J LIPID RES, V32, P1449; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; AMRI EZ, 1986, BIOCHEM J, V238, P115, DOI 10.1042/bj2380115; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; Bastie C, 1999, J BIOL CHEM, V274, P21920, DOI 10.1074/jbc.274.31.21920; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FAUST IM, 1978, AM J PHYSIOL, V235, pE279, DOI 10.1152/ajpendo.1978.235.3.E279; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FRITSCH M, 1992, BIOCHEMISTRY-US, V31, P5303, DOI 10.1021/bi00138a009; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GRIMALDI PA, 1992, P NATL ACAD SCI USA, V89, P10930, DOI 10.1073/pnas.89.22.10930; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KLYDE JB, 1979, J LIPID RES, V20, P705; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LOWRY OH, 1951, J BIOL CHEM, V193, P173; NEGREL R, 1978, P NATL ACAD SCI USA, V75, P6054, DOI 10.1073/pnas.75.12.6054; NEGREL R, 1981, BIOCHEM BIOPH RES CO, V98, P768, DOI 10.1016/0006-291X(81)91178-5; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; SHILLABEER G, 1994, J LIPID RES, V35, P592; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; TATE BF, 1995, J BIOL CHEM, V270, P20258, DOI 10.1074/jbc.270.35.20258; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VIVILLE S, 1995, METHOD MOL BIOL, V31, P57; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0	31	90	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38768	38773		10.1074/jbc.M006450200	http://dx.doi.org/10.1074/jbc.M006450200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10991946	hybrid			2022-12-27	WOS:000165739800086
J	Brandon, NJ; Delmas, P; Kittler, JT; McDonald, BJ; Sieghart, W; Brown, DA; Smart, TG; Moss, SJ				Brandon, NJ; Delmas, P; Kittler, JT; McDonald, BJ; Sieghart, W; Brown, DA; Smart, TG; Moss, SJ			GABA(A) receptor phosphorylation and functional modulation in cortical neurons by a protein kinase C-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; A RECEPTORS; INTRACELLULAR DOMAINS; SUBUNIT COMPOSITION; MICE LACKING; BETA-SUBUNIT; ACTIVATION; EXPRESSION; CURRENTS; SITES	GABA(A) receptors are critical mediators of fast synaptic inhibition in the brain, and the predominant receptor subtype in the central nervous system is believed to be a pentamer composed of alpha, beta, and gamma subunits. Previous studies on recombinant receptors have shown that protein kinase C (PRC) and PHA directly phosphorylate intracellular serine residues within the receptor beta subunit and modulate receptor function. However, the relevance of this regulation for neuronal receptors remains poorly characterized. To address this critical issue, we have studied phosphorylation and functional modulation of GABA(A) receptors in cultured cortical neurons. Here we show that the neuronal beta3 subunit is basally phosphorylated on serine residues by a PHC-dependent pathway. PKC inhibitors abolish basal phosphorylation, increasing receptor activity, whereas activators of PKC enhance beta3 phosphorylation with a concomitant decrease in receptor activity. PKA activators were shown to increase the phosphorylation of the beta3 subunit only in the presence of PKC inhibitors, We also show that the main sites of phosphorylation within the neuronal beta3 subunit are likely to include Ser-408 and Ser-409, residues that are important for the functional modulation of beta3-containing recombinant receptors, Furthermore, PHC activation did not change the total number of GABA(A) receptors in the plasma membrane, suggesting that the effects of PKC activation are on the gating or conductance of the channel. Together, these results illustrate that cell-signaling pathways that activate PKC may have profound effects on the efficacy of synaptic inhibition by directly modulating GABA(A) receptor function.	UCL, MRC, Lab Mol Cell Biol, London WC1E 6BT, England; UCL, Dept Pharmacol, London WC1E 6BT, England; UCL, Wellcome Lab Mol Pharmacol, London WC1E 6BT, England; Univ Vienna, Psychiat Clin, A-1090 Vienna, Austria; Univ London, Sch Pharm, Dept Pharmacol, London WC1N 1AX, England	University of London; University College London; University of London; University College London; University of London; University College London; University of Vienna; University of London; University College London; University of London School of Pharmacy	Moss, SJ (corresponding author), UCL, MRC, Lab Mol Cell Biol, Gower St, London WC1E 6BT, England.	steve.moss@ucl.ac.uk	Brown, David A/J-9019-2012; Sieghart, Werner/A-4877-2013; Kittler, Josef T/E-9113-2010; Kittler, Josef/N-7589-2019	Sieghart, Werner/0000-0002-0443-0302; Kittler, Josef T/0000-0002-3437-9456; Kittler, Josef/0000-0002-3437-9456; Brandon, Nicholas/0000-0002-3917-0096				BENKE D, 1994, J BIOL CHEM, V269, P27100; Bonnert TP, 1999, P NATL ACAD SCI USA, V96, P9891, DOI 10.1073/pnas.96.17.9891; Brandon NJ, 1999, J NEUROSCI, V19, P9228; BROWNING MD, 1993, NEUROCHEM RES, V18, P95, DOI 10.1007/BF00966927; BROWNING MD, 1990, P NATL ACAD SCI USA, V87, P1315, DOI 10.1073/pnas.87.4.1315; Brunig I, 1999, P NATL ACAD SCI USA, V96, P2456, DOI 10.1073/pnas.96.5.2456; Chapell R, 1998, J BIOL CHEM, V273, P32595, DOI 10.1074/jbc.273.49.32595; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Connolly CN, 1999, J BIOL CHEM, V274, P36565, DOI 10.1074/jbc.274.51.36565; Cooper ST, 1999, J BIOL CHEM, V274, P27145, DOI 10.1074/jbc.274.38.27145; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRIS RA, 1995, P NATL ACAD SCI USA, V92, P3658, DOI 10.1073/pnas.92.9.3658; Hodge CW, 1999, NAT NEUROSCI, V2, P997, DOI 10.1038/14795; Jechlinger M, 1998, J NEUROSCI, V18, P2449; Jones MV, 1997, J NEUROSCI, V17, P7626; KIRKNESS EF, 1989, BIOCHEM J, V259, P613, DOI 10.1042/bj2590613; KRISHEK BJ, 1994, NEURON, V12, P1081, DOI 10.1016/0896-6273(94)90316-6; LEIDENHEIMER NJ, 1992, MOL PHARMACOL, V41, P1116; Lin YF, 1996, MOL PHARMACOL, V50, P185; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; McDonald BJ, 1997, NEUROPHARMACOLOGY, V36, P1377, DOI 10.1016/S0028-3908(97)00111-1; McDonald BJ, 1998, NAT NEUROSCI, V1, P23, DOI 10.1038/223; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; Moss SJ, 1996, INT REV NEUROBIOL, V39, P1, DOI 10.1016/S0074-7742(08)60662-5; Nusser Z, 1999, J PHYSIOL-LONDON, V521, P421, DOI 10.1111/j.1469-7793.1999.00421.x; Poisbeau P, 1999, J NEUROSCI, V19, P674; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; Smart TG, 1997, CURR OPIN NEUROBIOL, V7, P358, DOI 10.1016/S0959-4388(97)80063-3; Tretter V, 1997, J NEUROSCI, V17, P2728; VALENZUELA CF, 1995, MOL BRAIN RES, V31, P165, DOI 10.1016/0169-328X(95)00048-W; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; WISDEN W, 1992, J NEUROSCI, V12, P1040	36	153	159	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38856	38862		10.1074/jbc.M004910200	http://dx.doi.org/10.1074/jbc.M004910200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10978327	hybrid			2022-12-27	WOS:000165739800097
J	Dale, LB; Bhattacharya, M; Anborgh, PH; Murdoch, B; Bhatia, M; Nakanishi, S; Ferguson, SSG				Dale, LB; Bhattacharya, M; Anborgh, PH; Murdoch, B; Bhatia, M; Nakanishi, S; Ferguson, SSG			G protein coupled receptor kinase-mediated desensitization of metabotropic glutamate receptor 1A protects against cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; RAPID DESENSITIZATION; HORMONE RECEPTOR; PHOSPHORYLATION; RAT; GLUTAMATE-RECEPTOR-1; INTERNALIZATION; MECHANISM; MUTATIONS	Metabotropic glutamate receptors (mGluRs) constitute a unique subclass of G protein-coupled receptors (GPCRs) that bear little sequence homology to other members of the G;PCR superfamily. The mGluR subtypes that are coupled to the hydrolysis of phosphoinositide contribute to both synaptic plasticity and glutamate-mediated excitotoxicity in neurons. In the present study, the expression of mGluR1a in HEK 293 cells led to agonist-independent cell death. Since G protein-coupled receptor kinases (GRKs) desensitize a diverse variety of GPCRs, we explored whether GRKs contributed to the regulation of both constitutive and agonist-stimulated mGluR1a activity and thereby may prevent mGluR1a-mediated excitotoxicity associated with mGluR1a overactivation. We find that the co-expression of mGluR1a with GRK2 and GRK5, but not GRK4 and GRK6, reduced both constitutive and agonist-stimulated mGluR1a activity. Agonist-stimulated mGluR1a phosphorylation was enhanced by the co-expression of GRK2 and was blocked by two different GRK2 dominant-negative mutants. Furthermore, GRK2-dependent mGluR1a desensitization protected against mGluR1a-mediated cell death, at least in part by blocking mGluR1a-stimulated apoptosis. Our data indicate that as with other members of the GPCR superfamily, a member of the structurally distinct mGluR family (mGluR1a) serves as a substrate for GRK-mediated phosphorylation and that GRK-dependent "feedback" modulation of mGluR1a responsiveness protects against pathophysiological mGluR1a signaling.	John P Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON, Canada; Univ Western Ontario, Dept Physiol, London, ON, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON, Canada; Kyoto Univ, Sch Med, Kyoto 606, Japan	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Kyoto University	Ferguson, SSG (corresponding author), John P Robarts Res Inst, 100 Perth Dr,POB 5015, London, ON N6A 5K8, Canada.							Ankarcrona M, 1998, PROG BRAIN RES, V116, P265, DOI 10.1016/S0079-6123(08)60442-2; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; Bordi F, 1999, PROG NEUROBIOL, V59, P55, DOI 10.1016/S0301-0082(98)00095-1; Bruno V, 1998, PROG BRAIN RES, V116, P209, DOI 10.1016/S0079-6123(08)60439-2; Calabresi P, 1999, EXP NEUROL, V158, P97, DOI 10.1006/exnr.1999.7092; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Desai MA, 1996, BRIT J PHARMACOL, V118, P1558, DOI 10.1111/j.1476-5381.1996.tb15574.x; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; Gereau RW, 1998, NEURON, V20, P143, DOI 10.1016/S0896-6273(00)80442-0; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; HERRERO I, 1994, EUR J NEUROSCI, V6, P115, DOI 10.1111/j.1460-9568.1994.tb00253.x; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KONG GH, 1994, J BIOL CHEM, V269, P13084; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Loo DT, 1998, METHOD CELL BIOL, V57, P251; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Nicoletti F, 1996, TRENDS NEUROSCI, V19, P267, DOI 10.1016/S0166-2236(96)20019-0; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Ozawa K, 1999, J BIOL CHEM, V274, P6397, DOI 10.1074/jbc.274.10.6397; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Prezeau L, 1996, MOL PHARMACOL, V49, P422; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; REN Q, 1993, J BIOL CHEM, V268, P16483; Riedel G, 1996, TRENDS NEUROSCI, V19, P219; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; Thomas WG, 2000, J BIOL CHEM, V275, P2893, DOI 10.1074/jbc.275.4.2893; WATSON S, 1994, G PROTEIN LINHED REC, P131; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	39	104	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38213	38220		10.1074/jbc.M006075200	http://dx.doi.org/10.1074/jbc.M006075200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10982802	hybrid			2022-12-27	WOS:000165739800013
J	Hahn, JS; Oh, SY; Chater, KF; Cho, YH; Roe, JH				Hahn, JS; Oh, SY; Chater, KF; Cho, YH; Roe, JH			H2O2-sensitive fur-like repressor CatR regulating the major catalase gene in Streptomyces coelicolor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTAINING SUPEROXIDE-DISMUTASE; ESCHERICHIA-COLI; OXIDATIVE STRESS; BACILLUS-SUBTILIS; SALMONELLA-TYPHIMURIUM; HYDROGEN-PEROXIDE; SIGMA-FACTOR; PROTEIN; MULLER; A3(2)	Streptomyces coelicolor produces three distinct catalases to cope with oxidative and osmotic stresses and allow proper growth and differentiation. The major vegetative catalase A (CatA) is induced by H2O2 and is required for efficient aerobic growth. In order to investigate the H2O2-dependent regulatory mechanism, an H2O2-resistant mutant (HR40) overproducing CatA was isolated from S. coelicolor A3(2). Based on the genetic map location of the mutated locus in HR40, the wild type catR gene was isolated from the ordered cosmid library of S. coelicolor by screening for its ability to suppress the HR40 phenotype. catR encodes a protein of 138 amino acids (15319 Da), with sequence homology to ferric uptake regulator (Fur)-like proteins. Disruption of catR caused CatA overproduction as observed in the HR40 mutant, confirming the role of CatR as a negative regulator of catA expression. The levels of catA and catR transcripts were higher in HR40 than in the wild type, implying that CatR represses transcription of these genes. Transcripts from the catA and catR genes were induced within 10 min of H2O2 treatment, suggesting that the repressor activity of CatR may be directly modulated by H2O2. A putative CatR-binding site containing an inverted repeat of 23 base pairs was localized upstream of the catA and catR gene, on the basis of sequence comparison and deletion analysis, CatR protein purified in the presence of dithiothreitol bound to this region, whereas oxidized CatR, treated with H2O2 or diamide, did not. The redox shift of CatR involved thiol-disulfide exchange as judged by modification of free thiols with 4-acetamido-4'-maleimidylstilbene-2,2'-disulfonate. From these results we propose that CatR regulates its downstream target genes as a repressor whose DNA binding ability is directly modulated by redox changes in the cell.	Seoul Natl Univ, Mol Microbiol Lab, Sch Biol Sci, Seoul 151742, South Korea; Seoul Natl Univ, Inst Microbiol, Seoul 151742, South Korea; John Innes Ctr Plant Sci Res, Dept Genet, Norwich NR4 7UH, Norfolk, England	Seoul National University (SNU); Seoul National University (SNU); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Roe, JH (corresponding author), Seoul Natl Univ, Mol Microbiol Lab, Sch Biol Sci, Seoul 151742, South Korea.		Rho, Hyunji/R-6242-2016; Cho, You-Hee/AAF-8582-2020	Rho, Hyunji/0000-0001-7650-8933; Cho, You-Hee/0000-0001-7942-5893				BIERMAN M, 1992, GENE, V116, P43, DOI 10.1016/0378-1119(92)90627-2; Bsat N, 1998, MOL MICROBIOL, V29, P189, DOI 10.1046/j.1365-2958.1998.00921.x; Bsat N, 1999, J BACTERIOL, V181, P4299, DOI 10.1128/JB.181.14.4299-4307.1999; CHEN L, 1995, P NATL ACAD SCI USA, V92, P8190, DOI 10.1073/pnas.92.18.8190; Cho YH, 1997, J BACTERIOL, V179, P4049, DOI 10.1128/jb.179.12.4049-4052.1997; Cho YH, 2000, MOL MICROBIOL, V35, P150, DOI 10.1046/j.1365-2958.2000.01685.x; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; CHUNG HJ, 1993, KOREAN J MICROBIOL, V31, P166; COY M, 1994, BIOMETALS, V7, P292; de Peredo AG, 1999, BIOCHEMISTRY-US, V38, P8582, DOI 10.1021/bi9902283; Deretic V, 1997, TRENDS MICROBIOL, V5, P367, DOI 10.1016/S0966-842X(97)01112-8; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; Facey SJ, 1996, MICROBIOL-UK, V142, P657, DOI 10.1099/13500872-142-3-657; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; Gaballa A, 1998, J BACTERIOL, V180, P5815, DOI 10.1128/JB.180.22.5815-5821.1998; Hahn JS, 2000, J BACTERIOL, V182, P3767, DOI 10.1128/JB.182.13.3767-3774.2000; Hahn JS, 2000, J MICROBIOL, V38, P18; HAHN JS, 1999, THESIS SEOUL NAT U S; Hidalgo E, 1997, CELL, V88, P121, DOI 10.1016/S0092-8674(00)81864-4; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Hopwood D.A., 1985, GENETIC MANIPULATION; INGRAM C, 1989, J BACTERIOL, V171, P6617, DOI 10.1128/jb.171.12.6617-6624.1989; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Kang JG, 1999, EMBO J, V18, P4292, DOI 10.1093/emboj/18.15.4292; KELEMEN GH, 1995, MOL MICROBIOL, V17, P221, DOI 10.1111/j.1365-2958.1995.mmi_17020221.x; Kim EJ, 1998, MOL MICROBIOL, V27, P187, DOI 10.1046/j.1365-2958.1998.00674.x; Kim EJ, 1998, J BACTERIOL, V180, P2014, DOI 10.1128/JB.180.8.2014-2020.1998; Koh YS, 1996, MOL GEN GENET, V251, P591, DOI 10.1007/s004380050206; MACNEIL DJ, 1992, GENE, V111, P61, DOI 10.1016/0378-1119(92)90603-M; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; MAZODIER P, 1989, J BACTERIOL, V171, P3583, DOI 10.1128/jb.171.6.3583-3585.1989; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; Oh SH, 1997, J BACTERIOL, V179, P122, DOI 10.1128/jb.179.1.122-127.1997; Pagan-Ramos E, 1998, J BACTERIOL, V180, P4856; Paget MSB, 1998, EMBO J, V17, P5776, DOI 10.1093/emboj/17.19.5776; Redenbach M, 1996, MOL MICROBIOL, V21, P77, DOI 10.1046/j.1365-2958.1996.6191336.x; SMITH CP, 1991, ESSENTIAL MOL BIOL P, P237; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; van Vliet AHM, 1999, J BACTERIOL, V181, P6371, DOI 10.1128/JB.181.20.6371-6376.1999; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; Zou PJ, 1999, MICROBIOL-SGM, V145, P549, DOI 10.1099/13500872-145-3-549	41	62	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38254	38260		10.1074/jbc.M006079200	http://dx.doi.org/10.1074/jbc.M006079200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10991944	hybrid			2022-12-27	WOS:000165739800018
J	Longenecker, KL; Zhang, BL; Derewenda, U; Sheffield, PJ; Dauter, Z; Parsons, JT; Zheng, Y; Derewenda, ZS				Longenecker, KL; Zhang, BL; Derewenda, U; Sheffield, PJ; Dauter, Z; Parsons, JT; Zheng, Y; Derewenda, ZS			Structure of the BH domain from Graf and its implications for Rho GTPase recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; ACTIVATING-PROTEIN; CRYSTAL-STRUCTURE; P50RHOGAP; COMPLEX; BINDING; P190; P85	Cellular signaling by small G-proteins is down-regulated by GTPase-activating proteins (GAPs), which increase the rate of GTP hydrolysis, The GTPase regulator associated with focal adhesion kinase (Graf) exhibits GAP activity toward the RhoA and Cdc42 GTPases, but is only weakly active toward the closely related Rad. We determined the crystal structure of a 231-residue fragment of Graf (GrafGAP), a domain containing the GAP activity, at 2.4-Angstrom resolution The structure clarifies the boundaries of the functional domain and yields insight to the mechanism of substrate recognition. Modeling its interaction with substrate suggested that a favorable interaction with Glu-95 of Cdc42 (Glu-97 of RhoA) would be absent with the corresponding Ala-95 of Rad. Indeed, GrafGAP activity is diminished similar to 40-fold toward a Cdc42 E95A mutant, whereas a similar to 10-fold increase is observed for a Rad A95E mutant. The GrafGAP epitope that apparently interacts with Glu-95(Glu-97) contains Asn-225, which was recently found mutated in some myeloid leukemia patients. We conclude that position 95 of the GTPase is an important determinant for GrafGAP specificity in cellular function and tumor suppression.	Univ Virginia Hlth Syst, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA; NCI, Frederick, MD 21702 USA; Brookhaven Natl Lab, Upton, NY 11973 USA; Univ Virginia, Ctr Canc, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Tennessee System; University of Tennessee Health Science Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Energy (DOE); Brookhaven National Laboratory; University of Virginia	Derewenda, ZS (corresponding author), Univ Virginia Hlth Syst, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA.	ZSD4N@virginia.edu	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048807] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060523] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48807] Funding Source: Medline; NIGMS NIH HHS [GM60523] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Billuart P, 1998, NATURE, V392, P923, DOI 10.1038/31940; Borkhardt A, 2000, P NATL ACAD SCI USA, V97, P9168, DOI 10.1073/pnas.150079597; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gamblin SJ, 1998, CURR OPIN STRUC BIOL, V8, P195, DOI 10.1016/S0959-440X(98)80038-9; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Sheffield PJ, 1999, ACTA CRYSTALLOGR D, V55, P356, DOI 10.1107/S0907444998009032; Sheldrick GM, 1998, NATO ADV SCI I C-MAT, V507, P401; Taylor JM, 1999, J CELL SCI, V112, P231; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Zhang BL, 1998, BIOCHEMISTRY-US, V37, P5249, DOI 10.1021/bi9718447; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	27	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38605	38610		10.1074/jbc.M007574200	http://dx.doi.org/10.1074/jbc.M007574200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10982819	hybrid			2022-12-27	WOS:000165739800063
J	Machaca, K; Haun, S				Machaca, K; Haun, S			Store-operated calcium entry inactivates at the germinal vesicle breakdown stage of Xenopus meiosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; ADRENAL CHROMAFFIN CELLS; MEIOTIC MATURATION; DOWN-REGULATION; LAEVIS OOCYTES; T-LYMPHOCYTES; CL CURRENTS; DEPLETION; INFLUX; CHANNELS	Store-operated calcium entry (SOCE) is the predominant Ca2+ influx pathway in non-excitable cells and is activated in response to depletion of intracellular Ca2+ stores. We have studied SOCE regulation during Xenopus oocyte meiosis. SOCE can be measured readily in stage VI Xenopus oocytes arrested at the G(2)-M transition of the cell cycle, either by Ca2+ imaging or by recording the SOCE current. However, following meiotic maturation, SOCE can no longer be activated by store depletion. We have characterized the time course of SOCE inactivation during oocyte maturation, and show that SOCE inactivates almost completely, in a very short time period, at the germinal vesicle breakdown stage of meiosis. This acute inactivation offers an opportunity to better understand SOCE regulation.	Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Machaca, K (corresponding author), Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA.		Machaca, Khaled/AAF-3579-2019	Machaca, Khaled/0000-0001-6215-2411	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061829] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM061829-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; COOMBS JL, 1992, DEV BIOL, V153, P272, DOI 10.1016/0012-1606(92)90112-T; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; DAY ML, 1993, NATURE, V365, P560, DOI 10.1038/365560a0; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; Fomina AF, 1999, J NEUROSCI, V19, P3711; GILON P, 1995, J BIOL CHEM, V270, P8050, DOI 10.1074/jbc.270.14.8050; GREY RD, 1982, DEV BIOL, V89, P475, DOI 10.1016/0012-1606(82)90335-9; GREY RD, 1974, DEV BIOL, V36, P44, DOI 10.1016/0012-1606(74)90189-4; Hartzell HC, 1996, J GEN PHYSIOL, V108, P157, DOI 10.1085/jgp.108.3.157; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Machaca K, 1999, J GEN PHYSIOL, V113, P249, DOI 10.1085/jgp.113.2.249; MIYAZAKI S, 1995, CIBA F SYMP, V188, P235; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; Pardo LA, 1998, J CELL BIOL, V143, P767, DOI 10.1083/jcb.143.3.767; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PRESTON SF, 1991, CELL REGUL, V2, P915, DOI 10.1091/mbc.2.11.915; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RICHTER HP, 1984, J MEMBRANE BIOL, V79, P203, DOI 10.1007/BF01871059; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; SCHMALZING G, 1990, AM J PHYSIOL, V258, pC179, DOI 10.1152/ajpcell.1990.258.1.C179; SERAFINI AT, 1995, IMMUNITY, V3, P239, DOI 10.1016/1074-7613(95)90093-4; SMITH LD, 1989, DEVELOPMENT, V107, P685; SOMASUNDARAM B, 1995, BIOCHEM J, V309, P725, DOI 10.1042/bj3090725; Stricker SA, 1999, DEV BIOL, V211, P157, DOI 10.1006/dbio.1999.9340; Takahashi A, 1996, AM J PHYSIOL-CELL PH, V271, pC1887, DOI 10.1152/ajpcell.1996.271.6.C1887; VASILETS LA, 1990, J MEMBRANE BIOL, V118, P131, DOI 10.1007/BF01868470; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4; Yao Y, 1997, J GEN PHYSIOL, V109, P703, DOI 10.1085/jgp.109.6.703	32	62	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38710	38715		10.1074/jbc.M007887200	http://dx.doi.org/10.1074/jbc.M007887200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10991950	Green Accepted, hybrid			2022-12-27	WOS:000165739800079
J	Qing, J; Zhang, Y; Derynck, R				Qing, J; Zhang, Y; Derynck, R			Structural and functional characterization of the transforming growth factor-beta-induced Smad3/c-Jun transcriptional cooperativity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEINS; ACTIVATOR INHIBITOR-1 GENE; DNA-BINDING PROTEIN; SMAD PROTEINS; TUMOR-SUPPRESSOR; CRYSTAL-STRUCTURE; AP-1 COMPLEX; PROMOTER; JUN; ACTIVIN	Smads are intracellular proteins that act as central effecters for transforming growth factor-beta (TGF-beta) and related proteins from the activated receptor into the nucleus, where they regulate Ligand-induced gene expression. AP-1 binding sites have been functionally linked to the transcriptional activation of various genes in response to TGF-beta. Accordingly, we have previously shown that the heteromeric complex of Smad3 and Smad4 synergizes with c-Jun/c-Fos at the AP-1 binding site of the collagenase I promoter to induce transcriptional activation in response to TGF-beta. Using the collagenase I promoter as model system, we have now investigated the role of the c-Jun and Smad3 interactions with the promoter DNA and have further characterized the physical basis of the c-Jun/Smad3 interaction in the transcriptional response. Mutational analyses of the c-Jun protein and the AP-1 binding site in the promoter revealed that the interaction of c-Jun with DNA is necessary for transcriptional activation by TGF-beta and Smads. Similar analyses of Smad3 and the Smad binding sites revealed that binding of Smad3 to DNA is also required, but that its DNA sequence-specific recognition is not essential. We also found that the basic leucine zipper domain of c-Jun and a short sequence close to the N terminus of Smad3 mediate their physical interaction, and that these regions are critical for their DNA-binding function. Our studies provide a basis for understanding the functional cooperativity of Smads with the diversity of transcription factors, which underlies the Smad-induced transcriptional activation in response to TGF-beta and related factors.	Univ Calif San Francisco, Dept Growth & Dev, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Program Dev Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Derynck, R (corresponding author), Univ Calif San Francisco, Dept Growth & Dev, San Francisco, CA 94143 USA.		Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601	NATIONAL CANCER INSTITUTE [ZIABC010419, Z01BC010419] Funding Source: NIH RePORTER; NCI NIH HHS [CA63301] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Attisano L, 1996, MOL CELL BIOL, V16, P1066; Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen Y, 1996, J BIOL CHEM, V271, P31602, DOI 10.1074/jbc.271.49.31602; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Derynck Rik, 1998, P593; Eresh S, 1997, EMBO J, V16, P2014, DOI 10.1093/emboj/16.8.2014; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jin G, 1997, J BIOL CHEM, V272, P26620, DOI 10.1074/jbc.272.42.26620; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu B, 1999, MOL CELL BIOL, V19, P424; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCKNIGHT SL, 1992, COLD SPRINGER HARBOR, V22; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; ROBERTS A, 1990, PEPTIDE GROWTH FACTO, V1; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Tan S, 1998, NATURE, V391, P660, DOI 10.1038/35563; Tang WL, 1998, J BIOL CHEM, V273, P5506, DOI 10.1074/jbc.273.10.5506; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	58	89	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38802	38812		10.1074/jbc.M004731200	http://dx.doi.org/10.1074/jbc.M004731200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10995748	hybrid			2022-12-27	WOS:000165739800091
J	Sousa, MM; Norden, AGW; Jacobsen, C; Willnow, TE; Christensen, EI; Thakker, RV; Verroust, PJ; Moestrup, SK; Saraiva, MJ				Sousa, MM; Norden, AGW; Jacobsen, C; Willnow, TE; Christensen, EI; Thakker, RV; Verroust, PJ; Moestrup, SK; Saraiva, MJ			Evidence for the role of megalin in renal uptake of transthyretin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT PROTEINURIA; DENTS-DISEASE; RECEPTOR; BINDING; PLASMA; RETINOL; ENDOCYTOSIS; FAMILY; GP330; MICE	The kidney is a major organ for uptake of the thyroid hormone thyroxine (T-4) and its conversion to the active form, triiodothyronine. In the plasma, one of the T-4 carriers is transthyretin (TTR). In the present study we observed that TTR, the transporter of both T-4 and retinol-binding protein, binds to megalin, the multiligand receptor expressed on the luminal surface of various epithelia including the renal proximal tubules. In the kidney, megalin plays an important role in tubular uptake of macromolecules filtered through the glomerulus. To evaluate the importance of megalin for renal uptake of TTR, we performed binding/uptake assays using immortalized rat yolk sac cells with high expression levels of megalin. Radiolabeled TTR, free as well as in complex with thyroxine or retinol-binding protein, was rapidly taken up by the cells, and the uptake was strongly inhibited by a polyclonal megalin antibody and by the receptor-associated protein, a chaperone-like protein inhibiting ligand binding to megalin. In cell culture, different TTR mutations presented different levels of cell association and degradation, suggesting that the structure of TTR is important for megalin recognition. Both the apo form and the T-4-bound form were taken up by the cells. Analysis of urine from patients with Dent's disease, a renal tubular disorder that alters receptor-mediated endocytic reabsorption of proteins, identified TTR as an abundant excreted protein. Furthermore, analysis of kidney sections of megalin-deficient mice revealed no immunohistochemical TTR labeling in intracellular vesicles in the proximal tubule cells when compared with wild type control littermates. Taken together, the present data indicate that TTR represents a novel megalin Ligand of importance in the thyroid hormone homeostasis.	Univ Porto, Amyloid Unit, Inst Biol Mol & Celular, P-4150 Porto, Portugal; Univ Porto, Inst Ciencias Biomed Abel Salazar, P-4150 Porto, Portugal; Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QR, England; Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Cell Biol, DK-8000 Aarhus C, Denmark; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Univ Oxford, Mol Endocrinol Grp, Nuffield Dept Med, Oxford OX3 9DU, England; Hop Tenon, INSERM, U489, F-75020 Paris, France	Universidade do Porto; Universidade do Porto; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Aarhus University; Aarhus University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Oxford; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Saraiva, MJ (corresponding author), Univ Porto, Amyloid Unit, Inst Biol Mol & Celular, Rua Campo Alegre 823, P-4150 Porto, Portugal.		Sousa, Monica/K-4367-2013; Saraiva, Maria João/K-3907-2013; Moestrup, Søren Kragh/AAD-1735-2019; Moestrup, Søren Kragh/A-1403-2014	Sousa, Monica/0000-0002-4524-2260; Saraiva, Maria João/0000-0002-3360-6899; Moestrup, Søren Kragh/0000-0003-3862-2107; Willnow, Thomas/0000-0001-9515-7921; Thakker, Rajesh/0000-0002-1438-3220				Alves IL, 1997, EUR J BIOCHEM, V249, P662, DOI 10.1111/j.1432-1033.1997.00662.x; ANDRADE C, 1952, BRAIN, V75, P408, DOI 10.1093/brain/75.3.408; Birn H, 2000, J AM SOC NEPHROL, V11, P191, DOI 10.1681/ASN.V112191; BOOMSMA F, 1991, J PHARMACOL EXP THER, V259, P551; Cheek AO, 1999, ENVIRON HEALTH PERSP, V107, P273, DOI 10.2307/3434593; CHRISTENSEN EI, 1992, J HISTOCHEM CYTOCHEM, V40, P1481, DOI 10.1177/40.10.1382088; Christensen EI, 1999, J AM SOC NEPHROL, V10, P685; Christensen EI, 1998, INT REV CYTOL, V180, P237; CHRISTENSEN EI, 1995, EUR J CELL BIOL, V66, P349; Devuyst O, 1999, HUM MOL GENET, V8, P247, DOI 10.1093/hmg/8.2.247; DIVINO CM, 1990, J BIOL CHEM, V265, P1425; EPISKOPOU V, 1993, P NATL ACAD SCI USA, V90, P2375, DOI 10.1073/pnas.90.6.2375; ERNSTROM U, 1995, FEBS LETT, V360, P177, DOI 10.1016/0014-5793(95)00095-Q; GRAY HDA, 1985, VIRCHOWS ARCH A, V406, P463, DOI 10.1007/BF00710237; Green M. H., 1994, Vitamin A in health and disease., P119; HERZ J, 1991, J BIOL CHEM, V266, P21232; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; KATO M, 1985, P NATL ACAD SCI USA, V82, P2488, DOI 10.1073/pnas.82.8.2488; Leheste JR, 1999, AM J PATHOL, V155, P1361, DOI 10.1016/S0002-9440(10)65238-8; MAKOVER A, 1989, J LIPID RES, V30, P171; MAKOVER A, 1988, J BIOL CHEM, V263, P8598; MARTONE R, 1996, J RHEUMATOL, V20, P176; Moestrup SK, 1998, J CLIN INVEST, V102, P902, DOI 10.1172/JCI3772; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; Moestrup SK, 1998, J BIOL CHEM, V273, P5235, DOI 10.1074/jbc.273.9.5235; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; Palha JA, 1997, AM J PHYSIOL-ENDOC M, V272, pE485, DOI 10.1152/ajpendo.1997.272.3.E485; RAZ A, 1970, J BIOL CHEM, V245, P1903; SARAIVA MJM, 1985, J CLIN INVEST, V76, P2171, DOI 10.1172/JCI112224; SARAIVA MJM, 1995, HUM MUTAT, V5, P191; SMITH TJ, 1994, BBA-GEN SUBJECTS, V1199, P76, DOI 10.1016/0304-4165(94)90099-X; Willnow TE, 1998, BIOL CHEM, V379, P1025; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; WRONG OM, 1994, Q J MED, V87, P473; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	35	94	100	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38176	38181		10.1074/jbc.M002886200	http://dx.doi.org/10.1074/jbc.M002886200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10982792	hybrid			2022-12-27	WOS:000165739800008
J	Xia, GQ; Evers, MR; Kang, HG; Schachner, M; Baenziger, JU				Xia, GQ; Evers, MR; Kang, HG; Schachner, M; Baenziger, JU			Molecular cloning and expression of the pituitary glycoprotein hormone N-acetylgalactosamine-4-O-sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; BETA 1,4GLCNAC BETA; N-ACETYLGALACTOSAMINE; SULFATED OLIGOSACCHARIDES; SIALYLATED OLIGOSACCHARIDES; HNK-1 SULFOTRANSFERASE; L2/HNK-1 CARBOHYDRATE; GALNAC-TRANSFERASE; CRYSTAL-STRUCTURE; MONOCLONAL IGM	N-Linked oligosaccharides terminating with the sequence SO4-4-GalNAc beta1,4GlcNAc beta1,2Man alpha are present on the pituitary hormones lutropin (LH), thyrotropin, and pro-opiomelanocortin. The sulfated structures on LII are essential for expression of its biologic function in vivo. We have cloned the N-acetglgalactosamine-4-sulfo-transferase (GalNac-4-ST1, GenBank(TM) accession number AF300612), which mediates sulfate addition to the N-linked oligosaccharides on LH and other pituitary glycoproteins with terminal (beta1,4-linked GalNAc based on its homology to HNK-1 sulfotransferase (HNK-1 ST). GalNAc-4-ST1 displays 23% identity to HNK-1 ST and 28% to chondroitin 4-sulfotransferase I (C4ST-1) and 26% to chondroitin 4-sulfotransferase 2 (C4ST-2), The cDNA predicts a type II transmembrane protein of 424 amino acids with four potential N-linked glycosylation sites and a single membrane-spanning domain. GalNAc-4-ST1 has putative 5'-phosphosulfonate and S'-phosphate binding sites, Three more carboxyl-terminal regions of unknown function also show a high degree of identity with HNK-1 ST, C4ST-1, and C4ST-2. The membrane-bound form of GalNAc-4-ST1 transfers sulfate to GalNAc beta1,4GlcNAc beta -R but not to chondroitin, whereas truncated forms of GalNAc-4-ST1 that are released into the medium transfer sulfate to both GalNAc beta1, 4GlcNAc beta -R and chondroitin, The first 118 amino acids of GalNAc-4-ST1 appear to contribute to both its activity and specificity for terminal beta1,4-linked GalNAc. GalNAc-4-ST1 also efficiently transfers sulfate to N-linked oligosaccharides on native LH and other glycoproteins terminating with beta1,4-linked GalNAc. A single transcript of 2.4 kilobases is most highly expressed in the pituitary and other regions of the central nervous system. The GalNAc-4-ST1 gene is located on human chromosome 19q13.1.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ Hamburg, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany	Washington University (WUSTL); University of Hamburg; University Medical Center Hamburg-Eppendorf	Baenziger, JU (corresponding author), Washington Univ, Sch Med, Dept Pathol, 660 S Euclid Ave, St Louis, MO 63110 USA.	baenziger@pathology.wustl.edu	Xia, Guoqing/C-2365-2015; Baenziger, Jacques U/E-9430-2012	Xia, Guoqing/0000-0003-4492-9156; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK41738] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; Baenziger JU, 1996, ENDOCRINOLOGY, V137, P1520, DOI 10.1210/en.137.5.1520; BAENZIGER JU, 1994, FASEB J, V8, P1019, DOI 10.1096/fasebj.8.13.7926366; BAENZIGER JU, 1991, BIOL CARBOHYDRATES, V3; Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; BERGWERFF AA, 1995, EUR J BIOCHEM, V228, P1009; CHAN A L, 1991, Glycobiology, V1, P173, DOI 10.1093/glycob/1.2.173; CHOU KH, 1985, BIOCHEM BIOPH RES CO, V128, P383, DOI 10.1016/0006-291X(85)91690-0; CODDEVILLE B, 1992, CARBOHYD RES, V236, P145, DOI 10.1016/0008-6215(92)85013-P; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; DHARMESH SM, 1993, P NATL ACAD SCI USA, V90, P11127, DOI 10.1073/pnas.90.23.11127; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; Fiete D, 1997, J BIOL CHEM, V272, P14629, DOI 10.1074/jbc.272.23.14629; Fiete D, 1997, P NATL ACAD SCI USA, V94, P11256, DOI 10.1073/pnas.94.21.11256; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; Fiete DJ, 1998, P NATL ACAD SCI USA, V95, P2089, DOI 10.1073/pnas.95.5.2089; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; Hall A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [citeulike-article-id:691774, DOI 10.1021/BK-1999-0734.CH008]; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; HARTREE AS, 1992, BIOCHEM J, V287, P665, DOI 10.1042/bj2870665; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; Hooper LV, 1996, FASEB J, V10, P1137, DOI 10.1096/fasebj.10.10.8751716; HOOPER LV, 1995, J BIOL CHEM, V270, P5985, DOI 10.1074/jbc.270.11.5985; HOOPER LV, 1995, J BIOL CHEM, V270, P16327, DOI 10.1074/jbc.270.27.16327; JUNGALWALA FB, 1994, NEUROCHEM RES, V19, P945, DOI 10.1007/BF00968704; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LITJENS T, 1991, BIOCHEM INT, V24, P209; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; MANZELLA SM, 1995, J BIOL CHEM, V270, P21665, DOI 10.1074/jbc.270.37.21665; Manzella SM, 1997, J BIOL CHEM, V272, P4775, DOI 10.1074/jbc.272.8.4775; MARTINI R, 1994, J NEUROSCI, V14, P7180; MENGELING BJ, 1995, P NATL ACAD SCI USA, V92, P502, DOI 10.1073/pnas.92.2.502; MOHAN PS, 1990, J NEUROCHEM, V54, P2024, DOI 10.1111/j.1471-4159.1990.tb04907.x; Mukherjee S, 1999, P NATL ACAD SCI USA, V96, P493, DOI 10.1073/pnas.96.2.493; NAKATA N, 1993, BIOCHEMISTRY-US, V32, P4369, DOI 10.1021/bi00067a029; Ong E, 1999, J BIOL CHEM, V274, P25608, DOI 10.1074/jbc.274.36.25608; PFEIFFER G, 1992, GLYCOBIOLOGY, V2, P411, DOI 10.1093/glycob/2.5.411; Roseman DS, 2000, P NATL ACAD SCI USA, V97, P9949, DOI 10.1073/pnas.170184597; Saghatelyan AK, 2000, EUR J NEUROSCI, V12, P3331, DOI 10.1046/j.1460-9568.2000.00216.x; Salamov AA, 2000, GENOME RES, V10, P516, DOI 10.1101/gr.10.4.516; SATO T, 1995, J BIOCHEM-TOKYO, V117, P147, DOI 10.1093/oxfordjournals.jbchem.a124702; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SCHMITZ B, 1994, GLYCOCONJUGATE J, V11, P345, DOI 10.1007/BF00731208; SICILIANO RA, 1993, GLYCOBIOLOGY, V3, P225, DOI 10.1093/glycob/3.3.225; SICILIANO RA, 1994, J BIOL CHEM, V269, P910; SKELTON TP, 1991, J BIOL CHEM, V266, P17142; SKELTON TP, 1992, J BIOL CHEM, V267, P12998; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1992, J BIOL CHEM, V267, P19140; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; STECK AJ, 1983, NEUROLOGY, V33, P19, DOI 10.1212/WNL.33.1.19; Van Rooijen JJM, 1998, EUR J BIOCHEM, V256, P471, DOI 10.1046/j.1432-1327.1998.2560471.x; Yamauchi S, 1999, J BIOL CHEM, V274, P2456, DOI 10.1074/jbc.274.4.2456; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975; YAN SB, 1993, GLYCOBIOLOGY, V3, P597, DOI 10.1093/glycob/3.6.597	64	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38402	38409		10.1074/jbc.M007821200	http://dx.doi.org/10.1074/jbc.M007821200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10988300	hybrid, Green Published			2022-12-27	WOS:000165739800037
J	Yu, JC; Koenig, RJ				Yu, JC; Koenig, RJ			Regulation of hepatocyte thyroxine 5 '-deiodinase by T3 and nuclear receptor coactivators as a model of the sick euthyroid syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; SERUM RESPONSE ELEMENT; CREB-BINDING-PROTEIN; NONTHYROIDAL ILLNESS; MEDIATED TRANSACTIVATIONS; CBP; 3,5,3'-TRIIODOTHYRONINE; TRIIODOTHYRONINE; INTERLEUKIN-6; TRANSCRIPTION	The syndrome of nonthyroidal illness, also known as the sick euthyroid syndrome, is characterized by a low plasma T3 and an "inappropriately normal" plasma thyrotropin in the absence of intrinsic disease of the hypothalamic-pituitary-thyroid axis, The syndrome is due in part to decreased activity of type I iodothyronine 5'-deiodinase (5' D-I), the hepatic enzyme that converts thyroxine to T3 and that is induced at the transcriptional level by T3, The hypothesis tested is that cytokines decrease T3 induction of 5' D-I, resulting in decreased T3 production and hence a further decrease in 5' D-I. The proposed mechanism is competition for limiting amounts of nuclear receptor coactivators between the 5' D-I promoter and the promoters of cytokine-induced genes, Using primary cultures of rat hepatocytes, we demonstrate that interleukins 1 and 6 inhibit the T3 induction of 5' D-I RNA and enzyme activity. This effect is at the level of transcription and can be partially overcome by exogenous steroid receptor coactivator-1 (SRC-1). The physical. mass of endogenous SRC-1 is not affected by cytokine exposure, and exogenous SRC-1 does not affect 5' D-I in the absence of cytokines. The data support the hypothesis that cytokine-induced competition for limiting amounts of coactivators decreases hepatic 5' D-I expression, contributing to the etiology of the sick euthyroid syndrome.	Univ Michigan, Med Ctr, Div Endocrinol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Koenig, RJ (corresponding author), Univ Michigan, Med Ctr, Div Endocrinol, 5560 MSRB 2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044155] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44155] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACCI V, 1982, J CLIN ENDOCR METAB, V54, P1229, DOI 10.1210/jcem-54-6-1229; Bartalena L, 1998, EUR J ENDOCRINOL, V138, P603, DOI 10.1530/eje.0.1380603; BECKER RA, 1982, CRIT CARE MED, V10, P870, DOI 10.1097/00003246-198212000-00014; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Boelen A, 1996, ENDOCRINOLOGY, V137, P5250, DOI 10.1210/en.137.12.5250; BOELEN A, 1995, J ENDOCRINOL, V146, P475, DOI 10.1677/joe.0.1460475; BOELEN A, 1993, J CLIN ENDOCR METAB, V77, P1695, DOI 10.1210/jcem.77.6.8263160; BRENT GA, 1986, J CLIN ENDOCR METAB, V63, P1; Brown SB, 1997, J BIOL CHEM, V272, P2163, DOI 10.1074/jbc.272.4.2163; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chopra IJ, 1997, J CLIN ENDOCR METAB, V82, P329, DOI 10.1210/jc.82.2.329; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; De Groot LJ, 1999, J CLIN ENDOCR METAB, V84, P151, DOI 10.1210/jc.84.1.151; DOZIN B, 1985, BIOCHEMISTRY-US, V24, P5581, DOI 10.1021/bi00341a044; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Ikeda M, 1999, MOL CELL ENDOCRINOL, V147, P103, DOI 10.1016/S0303-7207(98)00211-1; JUMP DB, 1989, J BIOL CHEM, V264, P4698; Kahl S, 2000, DOMEST ANIM ENDOCRIN, V18, P133, DOI 10.1016/S0739-7240(99)00069-7; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kaptein EM, 1986, THYROID HORMONE META, P297; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; Koenig RJ, 1998, THYROID, V8, P703, DOI 10.1089/thy.1998.8.703; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; MALDONADO LS, 1992, THYROID, V2, P119, DOI 10.1089/thy.1992.2.119; McIver B, 1997, THYROID, V7, P125, DOI 10.1089/thy.1997.7.125; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; NICOLOFF JT, 1996, WERNER INGBARS THYRO, P286; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Oate SA, 1995, SCIENCE, V270, P1354, DOI DOI 10.1126/SCIENCE.270.5240.1354.PUBMED:7481822; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Ramadori G, 1999, SEMIN LIVER DIS, V19, P141, DOI 10.1055/s-2007-1007106; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; SARNE DH, 1985, J CLIN ENDOCR METAB, V61, P1046, DOI 10.1210/jcem-61-6-1046; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Stylianou E, 1998, INT J BIOCHEM CELL B, V30, P1075, DOI 10.1016/S1357-2725(98)00081-8; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torpy DJ, 1998, METABOLISM, V47, P1289, DOI 10.1016/S0026-0495(98)90338-9; TOYODA N, 1995, MOL CELL BIOL, V15, P5100; TOYODA N, 1994, J BIOL CHEM, V269, P20329; Weiss RE, 1999, EMBO J, V18, P1900, DOI 10.1093/emboj/18.7.1900; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	49	74	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38296	38301		10.1074/jbc.M004866200	http://dx.doi.org/10.1074/jbc.M004866200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10995750	hybrid			2022-12-27	WOS:000165739800024
J	Gautier, T; Masson, D; de Barros, JPP; Athias, A; Gambert, P; Aunis, D; Metz-Boutigue, MH; Lagrost, L				Gautier, T; Masson, D; de Barros, JPP; Athias, A; Gambert, P; Aunis, D; Metz-Boutigue, MH; Lagrost, L			Human apolipoprotein C-I accounts for the ability of plasma nigh density lipoproteins to inhibit the cholesteryl ester transfer protein activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID TRANSFER; TRANSGENIC MICE; A-I; HDL; ACYLTRANSFERASE; TRIGLYCERIDE; PARTICLES; LECITHIN; HYPERLIPIDEMIA; PEPTIDES	The aim of the present study was to identify the protein that accounts for the cholesteryl ester transfer protein (CETP)-inhibitory activity that is specifically associated with human plasma high density lipoproteins (HDL). To this end, human HDL apolipoproteins were fractionated by preparative polyacrylamide gradient gel electrophoresis, and 30 distinct protein fractions with molecular masses ranging from 80 down to 2 kDa were tested for their ability to inhibit CETP activity. One single apolipoprotein fraction was able to completely inhibit CETP activity. The N-terminal sequence of the 6-kDa protein inhibitor matched the N-terminal sequence of human apoC-I, the inhibition was completely blocked by specific anti-apolipoprotein C-I antibodies, and mass spectrometry analysis confirmed the identity of the isolated inhibitor with full-length human apoC-I. Pure apoC-I was able to abolish CETP activity in a concentration-dependent manner and with a high efficiency (IC50 = 100 nmol/liter). The inhibitory potency of total delipidated HDL apolipoproteins completely disappeared after a treatment with anti-apolipoprotein C-I antibodies, and the apoC-I deprivation of native plasma HDL by immunoaffinity chromatography produced a mean 43% rise in cholesteryl ester transfer rates. The main localization of apoC-I in HDL and not in low density lipoprotein in normolipidemic plasma provides further support for the specific property of HDL in inhibiting CETP activity.	Hop Bocage, INSERM U498, Lab Biochim Lipoprot, F-21034 Dijon, France; CNRS, Ctr Neurochim, INSERM U338, Lab Biol Commun Cellulaire, F-67084 Strasbourg, France	CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Lagrost, L (corresponding author), Hop Bocage, INSERM U498, Lab Biochim Lipoprot, BP1542, F-21034 Dijon, France.	laurent.lagrost@u-bourgogne.fr	MASSON, David/AAC-8896-2022; Gautier, Thomas/Q-5371-2018; Masson, David/R-6633-2019; MASSON, David/R-4557-2017; Dominique, Aunis/W-1419-2019	MASSON, David/0000-0003-1692-0699; Gautier, Thomas/0000-0003-1119-7382; MASSON, David/0000-0003-1692-0699; 				BARTER PJ, 1980, J LIPID RES, V21, P238; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; Cho KH, 1998, BBA-LIPID LIPID MET, V1391, P133, DOI 10.1016/S0005-2760(97)00197-5; Connolly DT, 1996, BBA-LIPID LIPID MET, V1304, P145, DOI 10.1016/S0005-2760(96)00115-4; Goumon Y, 1998, J BIOL CHEM, V273, P29847, DOI 10.1074/jbc.273.45.29847; Guyard-Dangremont V, 1998, COMP BIOCHEM PHYS B, V120, P517, DOI 10.1016/S0305-0491(98)10038-X; GUYARDDANGREMONT V, 1994, J LIPID RES, V35, P982; HA YC, 1982, COMP BIOCHEM PHYS B, V71, P265, DOI 10.1016/0305-0491(82)90252-8; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; IHM J, 1982, J LIPID RES, V23, P1328; JACKSON RL, 1986, METHOD ENZYMOL, V128, P288; JONAS A, 1984, J BIOL CHEM, V259, P6369; Jong MC, 1998, J CLIN INVEST, V101, P145, DOI 10.1172/JCI791; KINNUNEN PKJ, 1976, FEBS LETT, V65, P354, DOI 10.1016/0014-5793(76)80145-7; KUSHWAHA RS, 1993, J LIPID RES, V34, P1285; LAGROST L, 1994, J BIOL CHEM, V269, P3189; LAGROST L, 1994, BBA-LIPID LIPID MET, V1215, P209, DOI 10.1016/0005-2760(94)90047-7; LAGROST L, 1991, BIOCHIM BIOPHYS ACTA, V1085, P209, DOI 10.1016/0005-2760(91)90096-Z; LAGROST L, 1994, J LIPID RES, V35, P825; MALMENDIER CL, 1986, ATHEROSCLEROSIS, V62, P167, DOI 10.1016/0021-9150(86)90063-8; Masson D, 1997, J BIOL CHEM, V272, P24287, DOI 10.1074/jbc.272.39.24287; MERRIL CR, 1990, METHOD ENZYMOL, V182, P477; METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x; MORTON RE, 1994, J LIPID RES, V35, P836; MORTON RE, 1993, ARTERIOSCLER THROMB, V13, P1843, DOI 10.1161/01.ATV.13.12.1843; MORTON RE, 1981, J BIOL CHEM, V256, P1992; MOULIN P, 1994, J LIPID RES, V35, P793; NISHIDA HI, 1990, J BIOL CHEM, V265, P4876; NISHIDE T, 1989, J LIPID RES, V30, P149; NISHIKAWA O, 1988, J BIOCHEM, V103, P188, DOI 10.1093/oxfordjournals.jbchem.a122229; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; POENSGEN J, 1990, BIOCHIM BIOPHYS ACTA, V1042, P188, DOI 10.1016/0005-2760(90)90006-J; SEHAYEK E, 1991, J BIOL CHEM, V266, P18259; Shachter NS, 1996, J CLIN INVEST, V98, P846, DOI 10.1172/JCI118857; SHULMAN RS, 1975, J BIOL CHEM, V250, P182; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SON YSC, 1984, BIOCHIM BIOPHYS ACTA, V795, P473; SPARKS DL, 1989, J LIPID RES, V30, P1491; STEYRER E, 1988, BIOCHIM BIOPHYS ACTA, V958, P484, DOI 10.1016/0005-2760(88)90235-4; SWANEY JB, 1994, J LIPID RES, V35, P134; TOLLEFSON JH, 1988, AM J PHYSIOL, V255, pE894, DOI 10.1152/ajpendo.1988.255.6.E894; TOURNIER JF, 1984, BIOCHIM BIOPHYS ACTA, V804, P216, DOI 10.1016/0167-4889(84)90152-6; VANREE JH, 1995, BIOCHEM J, V305, P905, DOI 10.1042/bj3050905; Wang XX, 1999, J BIOL CHEM, V274, P1814, DOI 10.1074/jbc.274.3.1814; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; ZHONG SB, 1994, J CLIN INVEST, V94, P2457, DOI 10.1172/JCI117614	46	106	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37504	37509		10.1074/jbc.M007210200	http://dx.doi.org/10.1074/jbc.M007210200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978346	hybrid			2022-12-27	WOS:000165618700029
J	Lim, KB; Walker, CRB; Guo, L; Pellett, S; Shabanowitz, J; Hunt, DF; Hewlett, EL; Ludwig, A; Goebel, W; Welch, RA; Hackett, M				Lim, KB; Walker, CRB; Guo, L; Pellett, S; Shabanowitz, J; Hunt, DF; Hewlett, EL; Ludwig, A; Goebel, W; Welch, RA; Hackett, M			Escherichia coli alpha-hemolysin (HlyA) is heterogeneously acylated in vivo with 14-, 15-, and 17-carbon fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERTUSSIS ADENYLATE-CYCLASE; TARGET-CELL SPECIFICITY; CHROMOSOMAL HEMOLYSIN; BORDETELLA-PERTUSSIS; MASS-SPECTROMETRY; NUCLEOTIDE-SEQUENCE; TOXIN FUNCTION; ACTIVATION; PROHAEMOLYSIN; PEPTIDES	alpha -Hemolysin (HlyA) is a secreted protein virulence factor observed in certain uropathogenic strains of Escherichia coli. The active, mature form of HlyA is produced by posttranslational modification of the protoxin that is mediated by acyl carrier protein and an acyltransferase, HlyC. We have now shown using mass spectrometry that these modifications, when observed in protein isolated in vivo, consist of acylation at the E-amino groups of two internal lysine residues, at positions 564 and 690, with saturated 14- (68%), 15- (26%), and 17- (6%) carbon amide-linked side chains. Thus, HlyA activated in vivo consists of a heterogeneous family of up to nine different covalent structures, and the substrate specificity of the HlyC acyltransferase appears to differ from that of the closely related CyaC acyltransferase expressed by Bordetella pertussis.	Univ Washington, Dept Med Chem, Seattle, WA 98195 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22901 USA; Univ Virginia, Dept Med & Pharmacol, Charlottesville, VA 22901 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22901 USA; Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI 53706 USA; Univ Wurzburg, Lehrstuhl Mikrobiol, D-97074 Wurzburg, Germany	University of Washington; University of Washington Seattle; University of Virginia; University of Virginia; University of Virginia; University of Wisconsin System; University of Wisconsin Madison; University of Wurzburg	Hackett, M (corresponding author), Univ Washington, Dept Med Chem, Box 357610, Seattle, WA 98195 USA.	mhackett@u.washington.edu	Hunt, Donald F/I-6936-2012; Bazemore-Walker, Carthene/I-1879-2013	Hunt, Donald F/0000-0003-2815-6368; 	NIAID NIH HHS [AI18000, AI20323] Funding Source: Medline; NIDDK NIH HHS [R01 DK063250] Funding Source: Medline; NIGMS NIH HHS [GM37537] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018000, R01AI020323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Basar T, 1999, J BIOL CHEM, V274, P10777, DOI 10.1074/jbc.274.16.10777; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; FORESTIER C, 1991, INFECT IMMUN, V59, P4212, DOI 10.1128/IAI.59.11.4212-4220.1991; GULDEN PH, 1996, MASS SPECTROMETRY BI, P281; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HACKETT M, 1995, J BIOL CHEM, V270, P20250, DOI 10.1074/jbc.270.35.20250; HARDIE KR, 1991, MOL MICROBIOL, V5, P1669, DOI 10.1111/j.1365-2958.1991.tb01914.x; HESS J, 1986, FEMS MICROBIOL LETT, V34, P1, DOI 10.1016/0378-1097(86)90261-2; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HUNT DF, 1991, TECHNIQUES PROTEIN C, V2, P441; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; JOSEPH M, 1995, J BIOL CHEM, V270, P16749, DOI 10.1074/jbc.270.28.16749; KENNEDY RT, 1989, ANAL CHEM, V61, P1128, DOI 10.1021/ac00185a016; KERWIN JL, 1994, ACS SYM SER, V562, P163; Lally ET, 1997, J BIOL CHEM, V272, P30463, DOI 10.1074/jbc.272.48.30463; LEPAGE G, 1986, J LIPID RES, V27, P114; Ludwig A, 1996, J BACTERIOL, V178, P5422, DOI 10.1128/jb.178.18.5422-5430.1996; Moayeri M, 1997, INFECT IMMUN, V65, P2233, DOI 10.1128/IAI.65.6.2233-2239.1997; MOSELEY MA, 1991, ANAL CHEM, V63, P1467, DOI 10.1021/ac00014a023; NEIDHARDT FC, 1996, ESCHERICHIA COLI SAL, P13; Pellett S, 1996, INFECT IMMUN, V64, P3081, DOI 10.1128/IAI.64.8.3081-3087.1996; STANLEY P, 1994, SCIENCE, V266, P1992, DOI 10.1126/science.7801126; Stanley P, 1998, MICROBIOL MOL BIOL R, V62, P309, DOI 10.1128/MMBR.62.2.309-333.1998; Swenson DL, 1996, INFECT IMMUN, V64, P3736, DOI 10.1128/IAI.64.9.3736-3743.1996; Wang HL, 1997, ANAL BIOCHEM, V250, P162, DOI 10.1006/abio.1997.2214; WELCH RA, 1983, INFECT IMMUN, V42, P178, DOI 10.1128/IAI.42.1.178-186.1983; WELCH RA, 1981, NATURE, V294, P665, DOI 10.1038/294665a0; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; Welch RA, 1995, INFECT AGENT DIS, V4, P254	32	40	40	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36698	36702		10.1074/jbc.C000544200	http://dx.doi.org/10.1074/jbc.C000544200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10978310	hybrid			2022-12-27	WOS:000165577700036
J	Patel, S; Churchill, GC; Sharp, T; Galione, A				Patel, S; Churchill, GC; Sharp, T; Galione, A			Widespread distribution of binding sites for the novel Ca2+-mobilizing messenger, nicotinic acid adenine dinucleotide phosphate, in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; SENSITIVE CA2+ RELEASE; INOSITOL TRISPHOSPHATE; CALCIUM-RELEASE; NAADP; CHANNELS; INACTIVATION; MICROSOMES; RECEPTORS; AGONIST	Nicotinic acid adenine dinucleotide phosphate (NAADP) is a potent Ca2+-mobilizing agent in invertebrate eggs that has recently been shown to be active in certain mammalian and plant systems, Little, however, is known concerning the properties of putative NAADP receptors. Here, for the first time, we report binding sites for NAADP in brain. In contrast to sea urchin egg homogenates, [P-32]NAADP bound reversibly to multiple sites in brain membranes. The rank order of potency of NAADP, 2',3'-cyclic NAADP and 3'-NAADP in displacing [P-32]NAADP was, however, the same in the two systems and in agreement with their ability to mobilize Ca2+ from homogenates, These data indicate that [P-32]NAADP likely binds to receptors mediating Ca2+ mobilization. Autoradiography revealed striking heterogeneity in the distribution of [P-32]NAADP binding sites throughout the brain. Our data strongly support a role for NAADP-induced Ca2+ signaling in the brain.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of Oxford	Patel, S (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.		Galione, Antony/E-5884-2011; Patel, Sandip/O-9591-2015	Sharp, Trevor/0000-0001-7434-9713; Patel, Sandip/0000-0001-7247-2013; Galione, Antony/0000-0002-4132-7646				Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Bak J, 1999, CURR BIOL, V9, P751, DOI 10.1016/S0960-9822(99)80335-2; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Berridge MJ, 1997, J EXP BIOL, V200, P315; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; Chini EN, 1996, BIOCHEM J, V316, P709, DOI 10.1042/bj3160709; CHINI EN, 1995, BIOCHEM BIOPH RES CO, V209, P167, DOI 10.1006/bbrc.1995.1485; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; GALIONE A, 1994, MOL CELL ENDOCRINOL, V98, P125, DOI 10.1016/0303-7207(94)90130-9; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 1997, J BIOL CHEM, V272, P20378, DOI 10.1074/jbc.272.33.20378; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; MILLER RJ, 1991, PROG NEUROBIOL, V37, P255, DOI 10.1016/0301-0082(91)90028-Y; Navazio L, 2000, P NATL ACAD SCI USA, V97, P8693, DOI 10.1073/pnas.140217897; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SHARP AH, 1993, J NEUROSCI, V13, P3051; Sorrentino V, 1995, Adv Pharmacol, V33, P67, DOI 10.1016/S1054-3589(08)60666-3; Taylor CW, 1998, BBA-MOL CELL BIOL L, V1436, P19, DOI 10.1016/S0005-2760(98)00122-2; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296	25	52	53	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36495	36497		10.1074/jbc.C000458200	http://dx.doi.org/10.1074/jbc.C000458200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	11010959	hybrid			2022-12-27	WOS:000165577700005
J	Tye, BK; Sawyer, S				Tye, BK; Sawyer, S			The hexameric eukaryotic MCM helicase: Building symmetry from nonidentical parts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MINICHROMOSOME MAINTENANCE PROTEIN; DNA-REPLICATION; COMPLEX; INITIATION; COMPONENT; ORIGINS; CEREVISIAE; MECHANISM; CDC7-DBF4; MUTANTS		Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University	Tye, BK (corresponding author), Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA.	bt16@cornell.edu		SAWYER, SARA/0000-0002-6965-1085	NIGMS NIH HHS [GM34190, T32 GM07617] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034190, T32GM007617] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Geraghty DS, 2000, J BIOL CHEM, V275, P18011, DOI 10.1074/jbc.M909787199; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Hardy CFJ, 1997, P NATL ACAD SCI USA, V94, P3151, DOI 10.1073/pnas.94.7.3151; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; Holthoff HP, 1998, J BIOL CHEM, V273, P7320, DOI 10.1074/jbc.273.13.7320; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Kearsey SE, 1998, BBA-GENE STRUCT EXPR, V1398, P113, DOI 10.1016/S0167-4781(98)00033-5; KELMAN Z, 1995, CURR BIOL, V5, P1239, DOI 10.1016/S0960-9822(95)00247-8; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; Kim DE, 1999, J BIOL CHEM, V274, P32667, DOI 10.1074/jbc.274.46.32667; Kim DE, 1999, J BIOL CHEM, V274, P11623, DOI 10.1074/jbc.274.17.11623; Kornberg A., 1992, DNA REPLICATION; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lei M, 1996, MOL CELL BIOL, V16, P5081; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAINE GT, 1984, GENETICS, V106, P365; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Pereverzeva I, 2000, MOL CELL BIOL, V20, P3667, DOI 10.1128/MCB.20.10.3667-3676.2000; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; San Martin C, 1998, STRUCTURE, V6, P501; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Shechter DF, 2000, J BIOL CHEM, V275, P15049, DOI 10.1074/jbc.M000398200; Soultanas P, 2000, CURR OPIN STRUC BIOL, V10, P124, DOI 10.1016/S0959-440X(99)00059-7; TAKAHASHI K, 1994, MOL BIOL CELL, V5, P1145, DOI 10.1091/mbc.5.10.1145; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; Tye BK, 2000, P NATL ACAD SCI USA, V97, P2399, DOI 10.1073/pnas.97.6.2399; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Valle M, 2000, MOL CELL BIOL, V20, P34, DOI 10.1128/MCB.20.1.34-41.2000; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; Yankulov K, 1999, MOL CELL BIOL, V19, P6154; You ZY, 1999, MOL CELL BIOL, V19, P8003; Young MR, 1997, MOL BIOL CELL, V8, P1587, DOI 10.1091/mbc.8.8.1587	49	78	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34833	34836		10.1074/jbc.R000018200	http://dx.doi.org/10.1074/jbc.R000018200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10980206	hybrid			2022-12-27	WOS:000165422800001
J	Prufer, K; Racz, A; Lin, GC; Barsony, J				Prufer, K; Racz, A; Lin, GC; Barsony, J			Dimerization with retinoid X receptors promotes nuclear localization and subnuclear targeting of vitamin D receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENT PROTEIN CHIMERA; LIVING CELLS; PROGESTERONE-RECEPTOR; 1,25-DIHYDROXYVITAMIN D-3; ACID RECEPTORS; DNA-BINDING; IN-VIVO; EXPRESSION; VISUALIZATION; TRANSCRIPTION	The vitamin D receptor (VDR) acts as heterodimer with the retinoid X receptor alpha (RXR) to control transcriptional activity of target genes. To explore the influence of heterodimerization on the subcellular distribution of these receptors in living cells, we developed a series of fluorescent-protein chimeras. The steady-state distribution of the yellow fluorescent protein-RXR was more nuclear than the unliganded green fluorescent protein (GFP)-VDR. Coexpression of RXR-blue fluorescent protein (BFP) promoted nuclear accumulation of GFP-VDR by influencing both nuclear import and retention. Fluorescence resonance energy transfer microscopy (FRET) demonstrated that the unliganded GFP-VDR and RXR-BFP form heterodimers. The increase in nuclear heterodimer content correlated with an increase in basal transcriptional activity. FRET also revealed that calcitriol induces formation of multiple nuclear foci of heterodimers. Mutational analysis showed a correlation; between hormone-dependent nuclear VDR foci formation and DNA binding. RXR-BFP also promoted hormone-dependent nuclear accumulation and intranuclear foci formation of a nuclear localization signal mutant receptor (nlsGFP-VDR) and rescued its transcriptional activity. Heterodimerization mutant RXR failed to alter GFP-VDR and nlsGFP-VDR distribution or activity. These experiments suggest that RXR has a profound effect on VDR distribution. This effect of RXR to promote nuclear accumulation and intranuclear targeting contributes to the regulation of VDR activity and probably the activity of other heterodimerization partners.	NIDDK, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Barsony, J (corresponding author), NIDDK, Lab Cell Biochem & Biol, NIH, Bldg 8,Rm 422,8 Ctr Dr, Bethesda, MD 20892 USA.	jul@helix.nih.gov	Stone, Kirsten/AAB-3804-2019	Stone, Kirsten/0000-0001-5511-1638	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060051, Z01DK060050] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barsony J, 1997, J BIOL CHEM, V272, P5774, DOI 10.1074/jbc.272.9.5774; BARSONY J, 1999, 81 ANN M END SOC JUN, P415; BARSONY J, 1997, MICROSC MICROANAL S2, V3, P131; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; Carlberg C, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 1, APRIL 1996, V1, P82; Castillo AI, 1999, MOL ENDOCRINOL, V13, P1141, DOI 10.1210/me.13.7.1141; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; Chen SC, 1999, J BIOL CHEM, V274, P11260, DOI 10.1074/jbc.274.16.11260; Dabrowski M, 1998, MOL CELL ENDOCRINOL, V142, P131, DOI 10.1016/S0303-7207(98)00111-7; Day RN, 1998, MOL ENDOCRINOL, V12, P1410, DOI 10.1210/me.12.9.1410; Ellenberg J, 1998, BIOTECHNIQUES, V25, P838, DOI 10.2144/98255bt01; Feng X, 1997, GENE DEV, V11, P59, DOI 10.1101/gad.11.1.59; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; GUIOCHONMANTEL A, 1992, J STEROID BIOCHEM, V41, P209; GUIOCHONMANTEL A, 1994, BIOCHEM PHARMACOL, V47, P21, DOI 10.1016/0006-2952(94)90433-2; Harnish DC, 1996, J BIOL CHEM, V271, P13621, DOI 10.1074/jbc.271.23.13621; HOLLEY SJ, 1995, MOL BIOL CELL, V6, P1833, DOI 10.1091/mbc.6.12.1833; Hopper AK, 1999, CURR BIOL, V9, pR803, DOI 10.1016/S0960-9822(99)80494-1; Hsieh JC, 1998, J CELL BIOCHEM, V70, P94, DOI 10.1002/(SICI)1097-4644(19980701)70:1<94::AID-JCB10>3.3.CO;2-Q; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Janssen JJM, 1999, CURR EYE RES, V19, P338, DOI 10.1076/ceyr.19.4.338.5307; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kahlen JP, 1997, NUCLEIC ACIDS RES, V25, P4307, DOI 10.1093/nar/25.21.4307; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kephart DD, 1996, MOL ENDOCRINOL, V10, P408, DOI 10.1210/me.10.4.408; KimmelJehan C, 1997, ARCH BIOCHEM BIOPHYS, V341, P75, DOI 10.1006/abbi.1997.9952; Kohler M, 1999, EXP NEPHROL, V7, P290; Lemon BD, 1996, MOL CELL BIOL, V16, P1006; Li C, 1997, P NATL ACAD SCI USA, V94, P2278, DOI 10.1073/pnas.94.6.2278; Lim CS, 1999, MOL ENDOCRINOL, V13, P366, DOI 10.1210/me.13.3.366; LUO ZJ, 1994, EUR J BIOCHEM, V223, P381, DOI 10.1111/j.1432-1033.1994.tb19004.x; Michigami T, 1999, J BIOL CHEM, V274, P33531, DOI 10.1074/jbc.274.47.33531; Periasamy A, 1999, METHOD CELL BIOL, V58, P293; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; Prufer K, 1999, J CHEM NEUROANAT, V16, P135, DOI 10.1016/S0891-0618(99)00002-2; Racz A, 1999, J BIOL CHEM, V274, P19352, DOI 10.1074/jbc.274.27.19352; Reichrath J, 1997, HISTOCHEM J, V29, P127, DOI 10.1023/A:1026481205135; Sanno N, 1997, NEUROENDOCRINOLOGY, V65, P299, DOI 10.1159/000127188; Schulman IG, 1997, GENE DEV, V11, P299, DOI 10.1101/gad.11.3.299; SONE T, 1990, MOL ENDOCRINOL, V4, P623, DOI 10.1210/mend-4-4-623; SONE T, 1991, J BIOL CHEM, V266, P23296; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Sugawara A, 1997, ENDOCRINOLOGY, V138, P3175, DOI 10.1210/en.138.8.3175; Tagami T, 1998, BIOCHEM BIOPH RES CO, V253, P358, DOI 10.1006/bbrc.1998.9799; Thompson PD, 1998, J BIOL CHEM, V273, P8483, DOI 10.1074/jbc.273.14.8483; WHITFIELD GK, 1995, MOL ENDOCRINOL, V9, P1166, DOI 10.1210/me.9.9.1166; Zhu XG, 1998, J BIOL CHEM, V273, P27058, DOI 10.1074/jbc.273.42.27058	48	111	115	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41114	41123		10.1074/jbc.M003791200	http://dx.doi.org/10.1074/jbc.M003791200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11001945	hybrid			2022-12-27	WOS:000166114600062
J	Alonso, G; Ambrosino, C; Jones, M; Nebreda, AR				Alonso, G; Ambrosino, C; Jones, M; Nebreda, AR			Differential activation of p38 mitogen-activated protein kinase isoforms depending on signal strength	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING SITE; MAP KINASE; CELLULAR STRESSES; SELECTIVE ACTIVATION; MAMMALIAN-CELLS; SAP KINASES; CASCADE; PHOSPHORYLATION; MKK6; TRANSDUCTION	We have investigated the ability of the mitogen-activated protein kinase (MAPK) kinase MKK6 to activate different members of the p38 subfamily of MAPKs and found that some MKK6 mutants can efficiently activate p38 alpha but not p38 gamma. In contrast, a constitutively active MKK6 mutant activated both p38 MAPK isoforms to similar extents. The same results were obtained upon coexpression in Xenopus oocytes and in vitro using either MKK6 immunoprecipitates from transfected cells or bacterially produced recombinant proteins. We also found that the preferential activation of p38 alpha by MKK6 correlated with more efficient binding of MKK6 to p38 alpha than to p38 gamma. Furthermore, increasing concentrations of constitutively active MKK6 differentially activated either p38 alpha alone (low MKK6 activity) or both p38 alpha and p38 gamma (high MKK6 activity), both in vitro and in injected oocytes. The determinants for selectivity are located at the carboxyl-terminal lobe of p38 MAPKs but do not correspond to the activation loop or common docking sequences. We also showed that different stimuli can induce different levels of endogenous MKK6 activity that correlate with differential activation of p38 MAPKs. Our results suggest that the level of MKK6 activity triggered by a given stimulus may determine the pattern of downstream p38 MAPK activation in the particular response.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Nebreda, AR (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Nebreda, Angel Rodriguez/R-9594-2019; ambrosino, concetta/AAB-3452-2019					Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOZA YN, 1995, FEBS LETT, V364, P223, DOI 10.1016/0014-5793(95)00346-B; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; Hale KK, 1999, J IMMUNOL, V162, P4246; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Howell M, 1997, EMBO J, V16, P7411, DOI 10.1093/emboj/16.24.7411; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531	49	78	85	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40641	40648		10.1074/jbc.M007835200	http://dx.doi.org/10.1074/jbc.M007835200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11010976	hybrid			2022-12-27	WOS:000166039500113
J	Fujimori, K; Kanaoka, T; Sakaguchi, Y; Urade, Y				Fujimori, K; Kanaoka, T; Sakaguchi, Y; Urade, Y			Transcriptional activation of the human hematopoietic prostaglandin D synthase gene in megakaryoblastic cells - Roles of the Oct-1 element in the 5 '-flanking region and the AP-2 element in the untranslated exon 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; D SYNTHETASE; PHORBOL ESTER; D-2 SYNTHASE; PPAR-GAMMA; MAST-CELLS; EXPRESSION; PROMOTER; DIFFERENTIATION; LOCALIZATION	The human hematopoietic prostaglandin D synthase (H-PGDS) gene is highly expressed in human megakaryoblastic cells, in which phorbol ester induces its expression. We characterized the promoter activity of the 5'-flanking region and the untranslated exon 1 (-1044 to +290) of the human H-PGDS gene in human megakaryoblastic Dami cells, Transient expression analysis using the luciferase reporter gene revealed that the 5'-flanking region and the untranslated exon 1 were sufficient for efficient expression of the H-PGDS gene in Dami cells, but not in monocytic U937 cells. Deletion and site-directed mutagenesis of the Oct-1 element in the 5'-flanking region decreased the promoter activity by similar to 30% compared with that of the entire region from -1044 to +290. An electrophoretic mobility shift assay demonstrated that Oct-1 specifically bound to the promoter region. Interestingly, even only untranslated exon 1 (+1 to +290) showed similar to 60% of the promoter activity of the entire region from -1044 to +290. Site-directed mutagenesis of the AP-2 element within the untranslated exon 1 abolished the basal promoter activity as well as its phorbol ester-mediated up-regulation. In AP-2-deficient HepG2 cells, the H-PGDS promoter activity was enhanced by coexpression with AP-2 alpha. These findings indicate that the Oct-1 element in the 5'-flanking region acts as a positive cis-acting element and that the AP-2 element in the untranslated exon 1 is crucial for both basal and phorbol ester-mediated up-regulation of human H-PGDS gene expression in megakaryoblastic Dami cells.	Japan Sci & Technol Corp, Osaka Biosci Inst, Dept Mol Behav Biol, Osaka 5650874, Japan; Japan Sci & Technol Corp, Osaka Biosci Inst, Core Res Evolut Sci & Technol, Osaka 5650874, Japan; Harvard Univ, Sch Med, Dept Med,Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; ALOKA Co Ltd, Tokyo 1818622, Japan	Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Harvard University; Brigham & Women's Hospital; Harvard Medical School	Urade, Y (corresponding author), Japan Sci & Technol Corp, Osaka Biosci Inst, Dept Mol Behav Biol, 6-2-4 Furuedai, Osaka 5650874, Japan.		Fujimori, Ko/AAD-5428-2021	Fujimori, Ko/0000-0002-2506-0769				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTHAZELHOF E, 1979, BIOCHIM BIOPHYS ACTA, V572, P43, DOI 10.1016/0005-2760(79)90198-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FONG CLW, 1995, J INTERF CYTOK RES, V15, P887, DOI 10.1089/jir.1995.15.887; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GILES H, 1988, PROSTAGLANDINS, V35, P277, DOI 10.1016/0090-6980(88)90093-7; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Kanaoka Y, 2000, EUR J BIOCHEM, V267, P3315, DOI 10.1046/j.1432-1327.2000.01362.x; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KOMATSU N, 1989, BLOOD, V74, P42; Lee KD, 1996, BIOCHEM J, V319, P783, DOI 10.1042/bj3190783; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; Mahmud I, 1997, J BIOL CHEM, V272, P28263, DOI 10.1074/jbc.272.45.28263; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; MEDCALF RL, 1990, J BIOL CHEM, V265, P14618; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; PARK K, 1993, J BIOL CHEM, V268, P17811; Pinzar E, 2000, J BIOL CHEM, V275, P31239, DOI 10.1074/jbc.M000750200; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Suzuki T, 1997, BIOCHEM BIOPH RES CO, V241, P288, DOI 10.1006/bbrc.1997.7803; Tanaka K, 2000, J IMMUNOL, V164, P2277, DOI 10.4049/jimmunol.164.5.2277; Thomson AM, 1998, BIOCHEM J, V333, P317, DOI 10.1042/bj3330317; Urade Y, 2000, VITAM HORM, V58, P89, DOI 10.1016/S0083-6729(00)58022-4; URADE Y, 1989, J IMMUNOL, V143, P2982; URADE Y, 1987, J BIOL CHEM, V262, P3820; URADE Y, 1990, J BIOL CHEM, V265, P371; VOSS J, 1997, GENE DEV, V5, P1309; WANG LH, 1993, BIOCHEM BIOPH RES CO, V190, P406, DOI 10.1006/bbrc.1993.1062; Warren G, 1996, GENOMICS, V31, P234, DOI 10.1006/geno.1996.0037; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WIDEN SG, 1988, J BIOL CHEM, V263, P16992; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Williamson JA, 1996, GENOMICS, V35, P262, DOI 10.1006/geno.1996.0351	38	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40511	40516		10.1074/jbc.M007688200	http://dx.doi.org/10.1074/jbc.M007688200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10998423	hybrid			2022-12-27	WOS:000166039500096
J	Lerin, C; Montell, E; Berman, HK; Newgard, CB; Gomez-Foix, AM				Lerin, C; Montell, E; Berman, HK; Newgard, CB; Gomez-Foix, AM			Overexpression of protein targeting to glycogen in cultured human muscle cells stimulates glycogen synthesis independent of glycogen and glucose 6-phosphate levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PHOSPHATASE 1; PHOSPHORYLASE; EXPRESSION; PTG; SUBUNITS; SYNTHASE; IDENTIFICATION; ACTIVATION; INCREASES	There is growing evidence that glycogen targeting subunits of protein phosphatase-l play a critical role in regulation of glycogen metabolism. In the current study, we have investigated the effects of adenovirus-mediated overexpression of a specific glycogen targeting subunit known as protein targeting to glycogen (PTG) in cultured human muscle cells. PTG; was overexpressed both in muscle cells cultured at high glucose (glycogen replete) or in cells incubated for 18 h in the absence of glucose and then incubated in high glucose (glycogen re-synthesizing). In both glycogen replete and glycogen resynthesizing cells, PTG overexpression caused glycogen to be synthesized at a linear rate 1-5 days after viral treatment, while in cells treated with a virus lacking a cDNA insert (control virus), glycogen content reached a plateau at day 1 with no further increase, In the glycogen replete PTG overexpressing cells, glycogen content was 20 times that in controls at day 5, Furthermore, in cells undergoing glycogen resynthesis, PTG overexpression caused a doubling of the initial rate of glycogen synthesis over the first 24 h relative to cells treated with control virus. In both sets of experiments, the effects of PTG; on glycogen synthesis were correlated with a 2-3-fold increase in glycogen synthase activity state, with no changes in glycogen phosphorylase activity. The alterations in glycogen synthase activity were not accompanied by changes in the intracellular concentration of glucose 6-phosphate, We conclude that PTG; overexpression activates glycogen synthesis in a glucose 6-phosphate-independent manner in human muscle cells while overriding glycogen-mediated inhibition. Our findings suggest that modulation of PTG expression in muscle may be a mechanism for enhancing muscle glucose disposal and improving glucose tolerance in diabetes.	Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dallas, TX 75235 USA	University of Barcelona; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gomez-Foix, AM (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Marti Franques 1, E-08028 Barcelona, Spain.	anamaria@sun.bq.ub.es	Lerin, Carles/AAP-9916-2020	Lerin, Carles/0000-0003-0950-4363	NIDDK NIH HHS [P01DK58398] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058398] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Armstrong CG, 1997, FEBS LETT, V418, P210, DOI 10.1016/S0014-5793(97)01385-9; Armstrong CG, 1998, BIOCHEM J, V336, P699, DOI 10.1042/bj3360699; Askanas V, 1992, HDB CLIN NEUROL, P85; BAK JF, 1990, AM J PHYSIOL, V258, pE957, DOI 10.1152/ajpendo.1990.258.6.E957; Baque S, 1998, DIABETES, V47, P1185, DOI 10.2337/diabetes.47.8.1185; Baque S, 1998, DIABETES, V47, P1392, DOI 10.2337/diabetes.47.9.1392; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Berman HK, 1998, J BIOL CHEM, V273, P26421, DOI 10.1074/jbc.273.41.26421; Brady MJ, 1997, J BIOL CHEM, V272, P20198, DOI 10.1074/jbc.272.32.20198; Brau L, 1997, BIOCHEM J, V322, P303; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; Gasa R, 2000, J BIOL CHEM, V275, P26396, DOI 10.1074/jbc.M002427200; GILBOE DP, 1972, ANAL BIOCHEM, V47, P20, DOI 10.1016/0003-2697(72)90274-6; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; JIMENEZCHILLARO.JC, 1999, FASEB J, V13, P2513; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; Laurent D, 2000, AM J PHYSIOL-ENDOC M, V278, pE663, DOI 10.1152/ajpendo.2000.278.4.E663; MELLGREN RL, 1983, BIOCHEM BIOPH RES CO, V114, P148, DOI 10.1016/0006-291X(83)91606-6; Montell E, 1999, AM J PHYSIOL-REG I, V276, pR1489, DOI 10.1152/ajpregu.1999.276.5.R1489; MUNGER R, 1993, METABOLISM, V42, P36, DOI 10.1016/0026-0495(93)90169-O; O'Doherty RM, 2000, J CLIN INVEST, V105, P479, DOI 10.1172/JCI8673; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; TANG PM, 1991, J BIOL CHEM, V266, P15782; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078; VILLARPALASI C, 1991, BIOCHIM BIOPHYS ACTA, V1095, P261, DOI 10.1016/0167-4889(91)90109-B	29	31	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39991	39995		10.1074/jbc.M006251200	http://dx.doi.org/10.1074/jbc.M006251200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10998419	hybrid			2022-12-27	WOS:000166039500028
J	Rekdal, C; Sjottem, E; Johansen, T				Rekdal, C; Sjottem, E; Johansen, T			The nuclear factor SPBP contains different functional domains and stimulates the activity of various transcriptional activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; PROTEIN; ENHANCER; GENE; DROSOPHILA; FAMILY; SIGNAL; RECOGNITION; EXPRESSION; INDUCTION	SPBP (stromelysin-1 platelet-derived growth factor-responsive element binding protein) was originally cloned from a cDNA expression library by virtue of its ability to bind to a platelet-derived growth factor-responsive element in the human stromelysin-1 promoter. A 937-amino acid-long protein was deduced from a 3995-nucleotide murine cDNA sequence. By analyses of both human and murine cDNAs, we now show that SPBP is twice as large as originally found. The human SPBP gene contains six exons and is located on chromosome 22q13.1-13.3. Two isoforms differing in their C termini are expressed due to alternative splicing. PCR analyses of multitissue cDNA panels showed that SPBP is expressed in most tissues except for ovary and prostate. Functional mapping revealed that SPBP is a nuclear, multidomain protein containing an N-terminal region with transactivating ability, a novel type of DNA-binding domain containing an AT hook motif, and a bipartite nuclear localization signal as well as a C-terminal zinc finger domain. This type of zinc finger domain is also found in the trithorax family of chromatin-based transcriptional regulator proteins. Using cotransfection experiments, we find that SPBP enhances the transcriptional activity of various transcription factors such as c-Sun, Ets1, Spl, and Pax6. Hence, SPBP seems to act as a transcriptional coactivator.	Univ Tromso, Inst Med Biol, Dept Biochem, N-9037 Tromso, Norway	UiT The Arctic University of Tromso	Johansen, T (corresponding author), Univ Tromso, Inst Med Biol, Dept Biochem, POB 977, N-9037 Tromso, Norway.	terjej@fagmed.uit.no	Johansen, Terje/AAY-1753-2021; Johansen, Terje/N-2971-2015	Johansen, Terje/0000-0003-1451-9578; Johansen, Terje/0000-0003-1451-9578; Sjottem, Eva/0000-0003-2668-1708				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FUNAHASHI J, 1993, DEVELOPMENT, V119, P433; Girard F, 1998, EMBO J, V17, P2079, DOI 10.1093/emboj/17.7.2079; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; IMAI Y, 1995, MOL BRAIN RES, V31, P1, DOI 10.1016/0169-328X(95)00020-S; JOHANSEN T, 1993, NUCLEIC ACIDS RES, V21, P475, DOI 10.1093/nar/21.3.475; Kahari VM, 1999, ANN MED, V31, P34, DOI 10.3109/07853899909019260; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kirstein M, 1996, J BIOL CHEM, V271, P18231, DOI 10.1074/jbc.271.30.18231; Lemon BD, 1999, CURR OPIN GENET DEV, V9, P499, DOI 10.1016/S0959-437X(99)00010-6; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Matrisian LM, 1999, CURR BIOL, V9, pR776, DOI 10.1016/S0960-9822(00)80011-1; Mikkola I, 1999, J BIOL CHEM, V274, P15115, DOI 10.1074/jbc.274.21.15115; Nornes S, 1998, MECH DEVELOP, V77, P185, DOI 10.1016/S0925-4773(98)00156-7; Ohara O, 1997, DNA Res, V4, P53, DOI 10.1093/dnares/4.1.53; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Prasad R, 1997, ONCOGENE, V15, P549, DOI 10.1038/sj.onc.1201211; Rajadhyaksha A, 1998, CYTOGENET CELL GENET, V81, P176, DOI 10.1159/000015021; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; REEVES R, 1990, J BIOL CHEM, V265, P8573; SANZ L, 1994, J BIOL CHEM, V269, P10044; SANZ L, 1995, MOL CELL BIOL, V15, P3164; SETH A, 1992, J BIOL CHEM, V267, P24796; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Sjottem E, 1996, J VIROL, V70, P188; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Watanabe G, 1997, J BIOL CHEM, V272, P20063, DOI 10.1074/jbc.272.32.20063; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	41	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40288	40300		10.1074/jbc.M006978200	http://dx.doi.org/10.1074/jbc.M006978200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10995766	hybrid			2022-12-27	WOS:000166039500068
J	Serna-Rico, A; Illana, B; Salas, M; Meijer, WJJ				Serna-Rico, A; Illana, B; Salas, M; Meijer, WJJ			The putative coiled coil domain of the phi 29 terminal protein is a major determinant involved in recognition of the origin of replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC MODEL PROTEINS; PRIMED DNA-REPLICATION; BACILLUS-SUBTILIS; PHAGE-PHI-29 DNA; INITIATION; POLYMERASE; TEMPLATE; BACTERIOPHAGE-PHI-29; STABILITY; SEQUENCE	The linear double-stranded genome of phage phi 29 contains a terminal protein (TP) covalently linked at each 5' DNA end, called parental TP. Initiation of phi 29 DNA replication starts with the recognition of the origins of replication, constituted by the parental TP-containing DNA ends, by a heterodimer containing phi 29 DNA polymerase and primer TP. It has been argued that origin recognition involves protein-protein interactions between parental and primer TP. Analysis of the TP sequence revealed that the region between amino acids 84 and 118 has a high probability to form an amphipatic alpha -helix that could be involved in the interaction between parental and primer TP. Therefore, this TP region may be important for origin recognition. To test this hypothesis we introduced various mutations in the predicted amphipatic alpha -helix and analyzed the functionality of the corresponding purified TP mutants. The results obtained show that the identified putative amphipatic alpha -helix of TP is an important determinant involved in origin recognition.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Salas, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Salas, Margarita/J-9873-2014	Salas, Margarita/0000-0001-5939-3441; Meijer, Wilfried/0000-0003-1842-0049	NIGMS NIH HHS [2R01GM27242-20] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANCO L, 1987, J VIROL, V61, P3983, DOI 10.1128/JVI.61.12.3983-3991.1987; BLANCO L, 1984, P NATL ACAD SCI-BIOL, V81, P5325, DOI 10.1073/pnas.81.17.5325; BLANCO L, 1992, J BIOL CHEM, V267, P1225; BLANCO L, 1994, P NATL ACAD SCI USA, V91, P12198, DOI 10.1073/pnas.91.25.12198; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; GARCIA JA, 1984, P NATL ACAD SCI-BIOL, V81, P80, DOI 10.1073/pnas.81.1.80; GARMENDIA C, 1988, NUCLEIC ACIDS RES, V16, P5727, DOI 10.1093/nar/16.13.5727; Gonzalez-Huici V, 2000, J BIOL CHEM, V275, P14678, DOI 10.1074/jbc.M910058199; GUTIERREZ C, 1991, J MOL BIOL, V222, P983, DOI 10.1016/0022-2836(91)90589-X; GUTIERREZ J, 1986, VIROLOGY, V155, P474, DOI 10.1016/0042-6822(86)90209-6; GUTIERREZ J, 1986, GENE, V43, P1, DOI 10.1016/0378-1119(86)90002-8; HERMOSO JM, 1985, NUCLEIC ACIDS RES, V13, P7715, DOI 10.1093/nar/13.21.7715; HODGES R S, 1992, Current Biology, V2, P122, DOI 10.1016/0960-9822(92)90241-2; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; Illana B, 1999, J BIOL CHEM, V274, P15073, DOI 10.1074/jbc.274.21.15073; Illana B, 1998, VIROLOGY, V248, P12, DOI 10.1006/viro.1998.9276; INCIARTE MR, 1980, J VIROL, V34, P187, DOI 10.1128/JVI.34.1.187-199.1980; KOHN WD, 1995, J BIOL CHEM, V270, P25495, DOI 10.1074/jbc.270.43.25495; Kornberg A., 1992, DNA REPLICATION; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Mendez J, 1997, EMBO J, V16, P2519, DOI 10.1093/emboj/16.9.2519; MENDEZ J, 1992, P NATL ACAD SCI USA, V89, P9579, DOI 10.1073/pnas.89.20.9579; ORTIN J, 1971, NATURE-NEW BIOL, V234, P275, DOI 10.1038/newbio234275a0; Pecenkova T, 1999, J MOL EVOL, V48, P197, DOI 10.1007/PL00006458; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; SALAS M, 1978, J MOL BIOL, V119, P269, DOI 10.1016/0022-2836(78)90438-2; SALAS M, 1996, DNA REPLICATION EUKA, P131; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHON U, 1994, GENE, V147, P91, DOI 10.1016/0378-1119(94)90044-2; SERRANO M, 1993, TRENDS BIOCHEM SCI, V18, P202, DOI 10.1016/0968-0004(93)90187-R; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZABALLOS A, 1989, NUCLEIC ACIDS RES, V17, P10353, DOI 10.1093/nar/17.24.10353; ZHOU NE, 1992, J BIOL CHEM, V267, P2664; ZHOU NE, 1992, BIOCHEMISTRY-US, V31, P5739, DOI 10.1021/bi00140a008	38	23	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40529	40538		10.1074/jbc.M007855200	http://dx.doi.org/10.1074/jbc.M007855200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11005822	hybrid			2022-12-27	WOS:000166039500098
J	Wang, ZF; Morris, JC; Drew, ME; Englund, PT				Wang, ZF; Morris, JC; Drew, ME; Englund, PT			Inhibition of Trypanosoma brucei gene expression by RNA interference using an integratable vector with opposing T7 promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; CRITHIDIA-FASCICULATA; C-ELEGANS; NEUROSPORA; POLYMERASE; PROTEIN; REPLICATION; HELICASE; CLONING; DSRNA	RNA interference is a powerful method for inhibition of gene expression in Trypanosoma brucei (Ngo, H., Tschudi, C,, Gull, K,, and Ullu, E. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 14687-14692), Here we describe a vector (pZJM) for in vivo tetracycline-inducible synthesis of double-stranded RNA (dsRNA) in stably transformed cells. The dsRNA is synthesized from opposing T7 promoters. We tested the vector with genes involved in processes such as kinetoplast DNA replication, mitochondrial mRNA synthesis, glycosyl phosphatidylinositol biosynthesis, glycosome biogenesis, and polyamine biosynthesis, In most cases the induction of dsRNA caused specific and dramatic loss of the appropriate mRNA and in many cases there was growth inhibition or cell death. One striking phenotype was the loss of kinetoplast DNA after interference with expression of a topoisomerase II. The gene being analyzed by this procedure need not even be fully sequenced. In fact, many of the genes we tested were derived from partial sequences in the T. brucei genome data base that were identified by homology with known proteins. It takes as little as 3 weeks from identification of a gene sequence in the data base to the appearance of a phenotype.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Englund, PT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.			Morris, James/0000-0003-2515-5714	NIAID NIH HHS [AI21334] Funding Source: Medline; NIGMS NIH HHS [GM27608] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027608, R37GM027608] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarado AS, 1999, P NATL ACAD SCI USA, V96, P5049, DOI 10.1073/pnas.96.9.5049; Bass BL, 2000, CELL, V101, P235, DOI 10.1016/S0092-8674(02)71133-1; Bastin P, 2000, J CELL SCI, V113, P3321; CAMPBELL AG, 1993, P NATL ACAD SCI USA, V90, P9350, DOI 10.1073/pnas.90.20.9350; Cogoni C, 1999, SCIENCE, V286, P2342, DOI 10.1126/science.286.5448.2342; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; DALTON S, 1995, P NATL ACAD SCI USA, V92, P2514, DOI 10.1073/pnas.92.7.2514; Engel ML, 1998, NUCLEIC ACIDS RES, V26, P4733, DOI 10.1093/nar/26.20.4733; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grishok A, 2000, SCIENCE, V287, P2494, DOI 10.1126/science.287.5462.2494; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Li F, 1996, MOL BIOCHEM PARASIT, V78, P227, DOI 10.1016/S0166-6851(96)02630-8; Li YX, 2000, DEV BIOL, V217, P394, DOI 10.1006/dbio.1999.9540; Lorenz P, 1998, EMBO J, V17, P3542, DOI 10.1093/emboj/17.13.3542; Nagamune K, 2000, P NATL ACAD SCI USA, V97, P10336, DOI 10.1073/pnas.180230697; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; Schrader M, 1998, J BIOL CHEM, V273, P29607, DOI 10.1074/jbc.273.45.29607; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; STRAUSS PR, 1990, MOL BIOCHEM PARASIT, V38, P141, DOI 10.1016/0166-6851(90)90214-7; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; TORRI AF, 1995, J BIOL CHEM, V270, P3495, DOI 10.1074/jbc.270.8.3495; TZFATI Y, 1992, P NATL ACAD SCI USA, V89, P6891, DOI 10.1073/pnas.89.15.6891; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; Wianny F, 2000, NAT CELL BIOL, V2, P70, DOI 10.1038/35000016; Wirtz E, 1998, NUCLEIC ACIDS RES, V26, P4626, DOI 10.1093/nar/26.20.4626; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zhang J, 1997, MOL BIOCHEM PARASIT, V87, P145, DOI 10.1016/S0166-6851(97)00060-1	33	437	455	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40174	40179		10.1074/jbc.M008405200	http://dx.doi.org/10.1074/jbc.M008405200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11013266	hybrid			2022-12-27	WOS:000166039500053
J	Farsetta, DL; Chandran, K; Nibert, ML				Farsetta, DL; Chandran, K; Nibert, ML			Transcriptional activities of reovirus RNA polymerase in recoated cores - Initiation and elongation are regulated by separate mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; SUBVIRAL PARTICLES; NUCLEOTIDE-SEQUENCES; MAMMALIAN REOVIRUSES; LAMBDA-2 PROTEIN; ACTIVE-SITE; RICH RNA; OLIGONUCLEOTIDES; VIRUS; PHOSPHORYLATION	The particle-associated reovirus polymerase synthesizes mRNA within only certain viral particle types. Reovirus cores, subviral particles lacking outer capsid proteins mu1, sigma3, and sigma1, produce mRNA and abortive transcripts. Reovirus virions, which contain complete outer capsids, cannot produce mRNA and produce few abortive transcripts. Recoated cores are virion-like particles generated by the addition of recombinant outer capsid proteins to cores, We used-recoated cores to analyze transcriptional regulation by reovirus outer capsid proteins. Partially recoated particles, containing less than virion amounts of mu1 and sigma3, synthesized mRNA at levels inversely proportional to outer capsid protein levels, Fully recoated cores exhibited undetectable mRNA synthesis levels, as did virions. However, recoated cores produced high levels of abortive transcripts. Recoated core abortive transcripts remained particle-associated and appeared to inhibit further abortive transcript production, Proteolysis of recoated cores removing mu1 and sigma3 released accumulated abortive transcripts and relieved inhibition of mRNA and abortive transcript synthesis. These results suggest transcriptional elongation, but not initiation, is blocked by virion-like amounts of mu1 and sigma3, Particle-associated abortive transcripts may down-regulate transcriptional initiation. Minor outer capsid protein sigma1 had no demonstrable effect on transcriptional activities, Transcriptional regulation may ensure progeny virions do not compete with transcribing particles for ribonucleoside triphosphates.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Inst Mol Virol, Madison, WI 53706 USA; Univ Wisconsin, Cell & Mol Biol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Nibert, ML (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 220 Longwood Ave, Boston, MA 02115 USA.	mnibert@hms.harvard.edu	Chandran, Kartik/I-2232-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI039533] Funding Source: NIH RePORTER; NIAID NIH HHS [AI39533] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arnold JJ, 1999, J BIOL CHEM, V274, P37060, DOI 10.1074/jbc.274.52.37060; BABLANIAN R, 1986, P NATL ACAD SCI USA, V83, P1290, DOI 10.1073/pnas.83.5.1290; BANERJEE AK, 1970, J VIROL, V6, P1; BELLAMY AR, 1972, NATURE-NEW BIOL, V238, P49, DOI 10.1038/newbio238049a0; BELLAMY AR, 1967, P NATL ACAD SCI USA, V58, P1389, DOI 10.1073/pnas.58.4.1389; BELLAMY AR, 1970, VIROLOGY, V40, P808, DOI 10.1016/0042-6822(70)90126-1; BELLAMY AR, 1970, VIROLOGY, V42, P415, DOI 10.1016/0042-6822(70)90284-9; BORSA J, 1968, BIOCHEM BIOPH RES CO, V33, P895, DOI 10.1016/0006-291X(68)90396-3; BORSA J, 1981, VIROLOGY, V111, P191, DOI 10.1016/0042-6822(81)90664-4; Broering TJ, 2000, J VIROL, V74, P5516, DOI 10.1128/JVI.74.12.5516-5524.2000; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CARTER C, 1974, J VIROL, V13, P1331, DOI 10.1128/JVI.13.6.1331-1337.1974; Chandran K, 1999, J VIROL, V73, P3941, DOI 10.1128/JVI.73.5.3941-3950.1999; Chen DY, 1999, VIROLOGY, V265, P120, DOI 10.1006/viro.1999.0029; CLEVELAND DR, 1986, J VIROL, V60, P307, DOI 10.1128/JVI.60.1.307-311.1986; Coombs KM, 1998, VIROLOGY, V243, P218, DOI 10.1006/viro.1998.9061; DRAYNA D, 1982, J VIROL, V41, P110, DOI 10.1128/JVI.41.1.110-118.1982; Dryden KA, 1998, VIROLOGY, V245, P33, DOI 10.1006/viro.1998.9146; DRYDEN KA, 1993, J CELL BIOL, V122, P1023, DOI 10.1083/jcb.122.5.1023; Dupuy LC, 1999, J VIROL, V73, P8384, DOI 10.1128/JVI.73.10.8384-8392.1999; FARRELL JA, 1974, VIROLOGY, V62, P145, DOI 10.1016/0042-6822(74)90310-9; FAUSNAUGH J, 1990, J BIOL CHEM, V265, P7669; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; FURUICHI Y, 1975, P NATL ACAD SCI USA, V72, P362, DOI 10.1073/pnas.72.1.362; GOMATOS PJ, 1963, BIOCHIM BIOPHYS ACTA, V72, P651; Gralla JD, 1996, METHOD ENZYMOL, V273, P99; GROSS L, 1992, J MOL BIOL, V228, P488, DOI 10.1016/0022-2836(92)90837-A; ITO Y, 1972, VIROLOGY, V50, P189, DOI 10.1016/0042-6822(72)90359-5; Johnston D. E., 1976, RNA POLYMERASE, P413; JOKLIK WK, 1972, VIROLOGY, V49, P700, DOI 10.1016/0042-6822(72)90527-2; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; KOONIN EV, 1993, J GEN VIROL, V74, P733, DOI 10.1099/0022-1317-74-4-733; Lawton JA, 1999, P NATL ACAD SCI USA, V96, P5428, DOI 10.1073/pnas.96.10.5428; Lawton JA, 1997, NAT STRUCT BIOL, V4, P118, DOI 10.1038/nsb0297-118; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEVIN DH, 1970, P NATL ACAD SCI USA, V66, P890, DOI 10.1073/pnas.66.3.890; Lu CX, 1996, P NATL ACAD SCI USA, V93, P2037, DOI 10.1073/pnas.93.5.2037; Luongo CL, 1998, J BIOL CHEM, V273, P23773, DOI 10.1074/jbc.273.37.23773; Luongo CL, 1997, J VIROL, V71, P8035, DOI 10.1128/JVI.71.10.8035-8040.1997; Luongo CL, 2000, J BIOL CHEM, V275, P2804, DOI 10.1074/jbc.275.4.2804; MAO ZX, 1991, VIROLOGY, V185, P377, DOI 10.1016/0042-6822(91)90785-A; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Millward S, 1983, REOVIRIDAE, P107; MORGAN EM, 1975, VIROLOGY, V68, P455, DOI 10.1016/0042-6822(75)90286-X; MULLER DK, 1988, BIOCHEMISTRY-US, V27, P5763, DOI 10.1021/bi00415a055; NAGAMINE Y, 1978, BIOCHIM BIOPHYS ACTA, V519, P440, DOI 10.1016/0005-2787(78)90097-7; Nagy PD, 1997, P NATL ACAD SCI USA, V94, P1113, DOI 10.1073/pnas.94.4.1113; Nibert ML, 1998, CURR TOP MICROBIOL, V233, P1; NIBERT ML, 1992, J VIROL, V66, P6408, DOI 10.1128/JVI.66.11.6408-6418.1992; NIBERT ML, 1996, FIELDS VIROLOGY, P1557; NICHOLS JL, 1972, VIROLOGY, V49, P562, DOI 10.1016/0042-6822(72)90507-7; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; RECORD J, 1996, ESCHERICHIA COLI SAL, P792; Reinisch KM, 2000, NATURE, V404, P960, DOI 10.1038/35010041; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SELIGER LS, 1987, J BIOL CHEM, V262, P16289; SHATKIN AJ, 1974, P NATL ACAD SCI USA, V71, P3204, DOI 10.1073/pnas.71.8.3204; SHATKIN AJ, 1968, P NATL ACAD SCI USA, V61, P1462, DOI 10.1073/pnas.61.4.1462; SHATKIN AJ, 1968, P NATL ACAD SCI USA, V59, P246, DOI 10.1073/pnas.59.1.246; SHATKIN AJ, 1972, J VIROL, V10, P698, DOI 10.1128/JVI.10.4.698-706.1972; SKEHEL JJ, 1969, VIROLOGY, V39, P822, DOI 10.1016/0042-6822(69)90019-1; SMITH RE, 1969, VIROLOGY, V39, P791, DOI 10.1016/0042-6822(69)90017-8; Sun JH, 1996, VIROLOGY, V226, P1, DOI 10.1006/viro.1996.0622; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; YAMAKAWA M, 1981, J BIOL CHEM, V256, P6507; YAMAKAWA M, 1982, VIROLOGY, V118, P157, DOI 10.1016/0042-6822(82)90329-4; ZWEERINK HJ, 1976, VIROLOGY, V73, P442, DOI 10.1016/0042-6822(76)90405-0; ZWEERINK HJ, 1970, VIROLOGY, V41, P501, DOI 10.1016/0042-6822(70)90171-6	72	34	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39693	39701		10.1074/jbc.M004562200	http://dx.doi.org/10.1074/jbc.M004562200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11007773	hybrid			2022-12-27	WOS:000165953100098
J	Jang, BC; Sanchez, T; Schaefers, HJ; Trifan, OC; Liu, CH; Creminon, C; Huang, CK; Hla, T				Jang, BC; Sanchez, T; Schaefers, HJ; Trifan, OC; Liu, CH; Creminon, C; Huang, CK; Hla, T			Serum withdrawal-induced post-transcriptional stabilization of cyclooxygenase-2 mRNA in MDA-MB-231 mammary carcinoma cells requires the activity of the p38 stress-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; MESSENGER-RNA STABILITY; RENAL MESANGIAL CELLS; POSTTRANSCRIPTIONAL REGULATION; PROSTAGLANDIN; EXPRESSION; GENE; DEXAMETHASONE; FIBROBLASTS; SYNTHASE-2	Overexpression of the cyclooxygenase-2 (COX-2) gene is observed in several neoplastic diseases. However, molecular mechanisms involved in the regulation of expression of COX-2 are not well understood. In this report, we describe a unique post-transcriptional regulatory mechanism of COX-2 mRNA stabilization in MDA-MB-231 cells, a highly metastatic cell line derived from a human mammary tumor. High levels of COX-2 mRNA, protein, and enzyme activity were induced by serum withdrawal, which were potently inhibited by the addition of serum or >100-kDa serum factor. Nuclear run-on analysis and actinomycin D chase experiments indicate that regulation is primarily at the level of post-transcriptional mRNA stability. Interestingly, SB203580, an inhibitor of the p38 stress-activated protein kinase (SAPK), and overexpression of the dominant-negative p38 alpha construct potently inhibited the serum withdrawal-induced COX-2 mRNA levels. Indeed, the half-life of COX-2 mRNA decreased from 9 to 4.5 h after SB203580 treatment, suggesting that signal transduction by the p38 SAPK pathway is required for COX-2 mRNA stability.	Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Dept Physiol, Farmington, CT 06030 USA; CEA, Serv Physiol & Pharmacol, F-91191 Gif Sur Yvette, France; Univ Connecticut, Ctr Hlth, Dept Pathol, Farmington, CT 06030 USA; CEA Saclay, Serv Physiol & Pharmacol, F-91191 Gif Sur Yvette, France	University of Connecticut; CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Connecticut; CEA; UDICE-French Research Universities; Universite Paris Saclay	Hla, T (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Dept Physiol, 263 Farmington Ave, Farmington, CT 06030 USA.		Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065; Jang, Byeong-Churl/0000-0002-2691-5503	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049094, P01HL054710] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54710, HL49094] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; BAILEY JM, 1985, J LIPID RES, V26, P54; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CELANO P, 1989, BIOTECHNIQUES, V7, P942; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P341, DOI 10.1016/0005-2760(94)00197-7; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; CUENDA A, 1995, FEBS LETT, V364, P3985; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DELATORRE M, 1993, ANTICANCER RES, V13, P1425; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; HANNIGAN M, 1998, BIOCH CELL BIOL COMM, V46, P55; Herschman HR, 1997, ADV EXP MED BIOL, V407, P61; HLA T, 1993, ANN NY ACAD SCI, V696, P197; Hla T, 1999, INT J BIOCHEM CELL B, V31, P551, DOI 10.1016/S1357-2725(98)00152-6; KYRIAKIS JM, 1994, NATURE, V369, P150; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Liu XH, 1996, CANCER RES, V56, P5125; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; Miller WE, 1999, TRENDS MICROBIOL, V7, P453, DOI 10.1016/S0966-842X(99)01605-4; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Montero L, 1999, CANCER RES, V59, P5286; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; ROLLAND PH, 1980, JNCI-J NATL CANCER I, V64, P1061; SANO H, 1995, CANCER RES, V55, P3785; SCHREY MP, 1995, BRIT J CANCER, V72, P1412, DOI 10.1038/bjc.1995.523; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; SRIVASTAVA SK, 1994, AM J PHYSIOL, V267, pF504, DOI 10.1152/ajprenal.1994.267.3.F504; Subbaramaiah K, 1996, CANCER RES, V56, P4424; TAN WC, 1974, CANCER RES, V34, P3229; Trifan OC, 1999, J BIOL CHEM, V274, P34141, DOI 10.1074/jbc.274.48.34141; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97	44	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39507	39515		10.1074/jbc.M003224200	http://dx.doi.org/10.1074/jbc.M003224200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993880	hybrid			2022-12-27	WOS:000165953100077
J	Kitazume, T; Takaya, N; Nakayama, N; Shoun, H				Kitazume, T; Takaya, N; Nakayama, N; Shoun, H			Fusarium oxysporum fatty-acid subterminal hydroxylase (CYP505) is a membrane-bound eukaryotic: Counterpart of Bacillus megaterium cytochrome P450BM3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE REDUCTASE; CRYSTAL-STRUCTURE; AMINO-ACID; MYCOBACTERIUM-TUBERCULOSIS; OMEGA-HYDROXYLASE; CODING NUCLEOTIDE; SEQUENCES; PROTEINS; GENE; IDENTIFICATION	The gene of a fatty-acid hydroxylase of the fungus Fusarium oxtysporum (P450foxy) was cloned and expressed in yeast. The putative primary structure reveal ed the close relationship of P450foxy to the bacterial cytochrome P450BM3, a fused protein of cytochrome P450 and its reductase from Bacillus megaterium. The amino acid sequence identities of the P450 and P450 reductase domains of P450foxy were highest (40.6 and 35.3%, respectively) to the corresponding domains of P450BM3. Recombinant P450foxy expressed in yeast was catalytically and spectrally indistinguishable from the native protein, except most of the recombinant P450foxy was recovered in the soluble fraction of the yeast cells, in marked contrast to native P450foxy, which was exclusively recovered in the membrane fraction of the fungal cells. This difference implies that a post (or co)-translational mechanism functions in the fungal cells to target and bind the protein to the membrane. These results provide conclusive evidence that P450foxy is the eukaryotic counterpart of bacterial P450BM3, which evokes interest in the evolutionary aspects concerning the P450 superfamily along with its reducing systems. P450foxy was classified in the new family, CYP505.	Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba	Shoun, H (corresponding author), Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan.							AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; Aoyama Y, 1998, J BIOCHEM-TOKYO, V124, P694; BALLANCE DJ, 1986, YEAST, V2, P229, DOI 10.1002/yea.320020404; Bellamine A, 1999, P NATL ACAD SCI USA, V96, P8937, DOI 10.1073/pnas.96.16.8937; Benveniste I, 1998, BIOCHEM BIOPH RES CO, V243, P688, DOI 10.1006/bbrc.1998.8156; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOTOH O, 1992, J BIOL CHEM, V267, P83; Gotoh O., 1993, CYTOCHROME P450, P255; GrahamLorence S, 1996, FASEB J, V10, P206, DOI 10.1096/fasebj.10.2.8641554; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KIMURA S, 1989, DNA-J MOLEC CELL BIO, V8, P503, DOI 10.1089/dna.1.1989.8.503; KIZAWA H, 1991, J BIOL CHEM, V266, P10632; KLEIN ML, 1994, BBA-GEN SUBJECTS, V1201, P245; KUSUNOSE M, 1964, J BIOL CHEM, V239, P1374; LIANG QW, 1995, J BIOL CHEM, V270, P4438, DOI 10.1074/jbc.270.9.4438; Makita K, 1996, FASEB J, V10, P1456, DOI 10.1096/fasebj.10.13.8940291; MCKENNA EJ, 1970, J BIOL CHEM, V245, P3882; MORRISON JFJ, 1995, PCR2 PRACTICAL APPRO, P181; NAKAHARA K, 1993, J BIOL CHEM, V268, P8350; Nakayama N, 1996, J BIOCHEM-TOKYO, V119, P435; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; NELSON DR, 1987, MOL BIOL EVOL, V4, P572; NELSON DR, 1989, BIOCHEMISTRY-US, V28, P656, DOI 10.1021/bi00428a036; OHKUMA M, 1995, DNA CELL BIOL, V14, P163, DOI 10.1089/dna.1995.14.163; Omura T, 1999, BIOCHEM BIOPH RES CO, V266, P690, DOI 10.1006/bbrc.1999.1887; OMURA T, 1964, J BIOL CHEM, V239, P2379; Park SY, 1997, NAT STRUCT BIOL, V4, P827, DOI 10.1038/nsb1097-827; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; Salaun Jean-Pierre, 1995, Drug Metabolism and Drug Interactions, V12, P261; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; TOMURA D, 1994, J BIOCHEM-TOKYO, V116, P88, DOI 10.1093/oxfordjournals.jbchem.a124508; Urban P, 1997, J BIOL CHEM, V272, P19176, DOI 10.1074/jbc.272.31.19176; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Williams PA, 2000, MOL CELL, V5, P121, DOI 10.1016/S1097-2765(00)80408-6; YOSHIDA Y, 1993, CYTOCHROME P 450, P1	44	64	68	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39734	39740		10.1074/jbc.M005617200	http://dx.doi.org/10.1074/jbc.M005617200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995755	hybrid			2022-12-27	WOS:000165953100103
J	Ohashi, E; Bebenek, K; Matsuda, T; Feaver, WJ; Gerlach, VL; Friedberg, EC; Ohmori, H; Kunkel, TA				Ohashi, E; Bebenek, K; Matsuda, T; Feaver, WJ; Gerlach, VL; Friedberg, EC; Ohmori, H; Kunkel, TA			Fidelity and processivity of DNA synthesis by DNA polymerase kappa, the product of the human DINB1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; ESCHERICHIA-COLI; NUCLEOTIDE INCORPORATION; BASE SUBSTITUTION; MOUSE HOMOLOGS; MUTAGENESIS; REPLICATION; BETA; ENCODES; PROTEIN	Mammalian DNA polymerase kappa (pol kappa), a member of the UmuC/DinB nucleotidyl transferase superfamily, has been implicated in spontaneous mutagenesis. Here we show that human pol kappa copies undamaged DNA with average single-base substitution and deletion error rates of 7 x 10(-3) and 2 x 10(-3), respectively. These error rates are high when compared to those of most other DNA polymerases. pol kappa also has unusual error specificity, producing a high proportion of T.CMP mispairs and deleting and adding non-reiterated nucleotides at extraordinary rates. Unlike other members of the UmuC/DinB family, pol kappa can processively synthesize chains of 25 or more nucleotides. This moderate processivity may reflect a contribution of C-terminal residues, which include two zinc clusters. The very low fidelity and moderate processivity of pol kappa is novel in comparison to any previously studied DNA polymerase, and is consistent with a role in spontaneous mutagenesis.	NIEHS, Struct Biol Lab, Res Triangle Pk, NC 27709 USA; NIEHS, Mol Genet Lab, Res Triangle Pk, NC 27709 USA; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75390 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Kyoto University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kunkel, TA (corresponding author), NIEHS, Struct Biol Lab, POB 12233,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	kunkel@niehs.nih.gov	Ohashi, Eiji/AAO-5794-2021; Kunkel, Thomas A./D-5088-2019	Ohashi, Eiji/0000-0002-1771-5585; Kunkel, Thomas A./0000-0002-9900-1788	NATIONAL CANCER INSTITUTE [R01CA069029, F32CA075733] Funding Source: NIH RePORTER; NCI NIH HHS [CA-69029, CA-75733] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Beard WA, 1998, J BIOL CHEM, V273, P30435, DOI 10.1074/jbc.273.46.30435; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345; BROTCORNELANNOYE A, 1986, P NATL ACAD SCI USA, V83, P3904, DOI 10.1073/pnas.83.11.3904; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Efrati E, 1997, J BIOL CHEM, V272, P2559; Friedberg EC, 1999, CELL, V98, P413, DOI 10.1016/S0092-8674(00)81970-4; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; GERLACH VL, 2000, IN PRESS J BIOL CHEM; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Kelman Z, 1998, STRUCTURE, V6, P121, DOI 10.1016/S0969-2126(98)00014-8; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; Ohashi E, 2000, GENE DEV, V14, P1589; Osheroff WP, 1999, J BIOL CHEM, V274, P20749, DOI 10.1074/jbc.274.30.20749; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Osheroff WP, 2000, J BIOL CHEM, V275, P28033; Roberts J.D., 1996, DNA REPLICATION EUKA, P217; Sharief FS, 1999, GENOMICS, V59, P90, DOI 10.1006/geno.1999.5843; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; Vaisman A, 2000, BIOCHEMISTRY-US, V39, P4575, DOI 10.1021/bi000130k; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7	45	214	220	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39678	39684		10.1074/jbc.M005309200	http://dx.doi.org/10.1074/jbc.M005309200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11006276	hybrid			2022-12-27	WOS:000165953100096
J	Sawai, H; Okamoto, Y; Luberto, C; Mao, CG; Bielawska, A; Domae, N; Hannun, YA				Sawai, H; Okamoto, Y; Luberto, C; Mao, CG; Bielawska, A; Domae, N; Hannun, YA			Identification of ISC1 (YER019w) as inositol phosphosphingolipid phospholipase C in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOMYELINASE ACTIVITY; NEUTRAL SPHINGOMYELINASE; ACID SPHINGOMYELINASE; YEAST SPHINGOLIPIDS; CERAMIDE; GENE; STRESS; PHOSPHORYLCERAMIDE; PURIFICATION; RESPONSES	Sphingolipids have emerged as novel bioactive mediators in eukaryotic cells including yeast. It has been proposed that sphingomyelin (SM) hydrolysis and the concomitant generation of ceramide are involved in various stress responses in mammalian cells, The yeast Saccharomyces cerevisiae has inositol phosphosphingolipids (IPS) instead of SM and glycolipids, and synthesis of IFS is indispensable to its growth. Although the genes responsible for the synthesis of IFS have been identified, the gene(s) for the degradation of IFS has not been reported, Here we show that ISC1 (YER019w), which has homology to bacterial neutral sphingomyelinase (SMase), encodes IFS phospholipase C (IPS-PLC). First, we observed that overexpression of ISC1 greatly increased neutral SMase activity, and this activity was dependent on the presence of phosphatidylserine. Cells deleted in ISC1 demonstrated negligible neutral SMase activity. Because yeast cells have IFS instead of SM, we investigated whether IFS are the physiologic substrates of this enzyme. Lysates of ISC1-overexpressing cells demonstrated very high PLC activities on IFS. Deletion of ISC1 eliminated endogenous IPS-PLC activities, Labeling yeast cells with [H-3]dihydrosphingosine showed that IFS were increased in the deletion mutant cells, This study identifies the first enzyme involved in catabolism of complex sphingolipids in S. cerevisiae.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Ralph H Johnson Vet Adm Hosp, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Osaka Dent Univ, Dept Med, Hirakata, Osaka 573, Japan	Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.		OKAMOTO, Yasuo/J-8438-2015		NIGMS NIH HHS [GM43825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beeler TJ, 1997, MOL GEN GENET, V255, P570, DOI 10.1007/s004380050530; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Dickson RC, 1999, BBA-GEN SUBJECTS, V1426, P347, DOI 10.1016/S0304-4165(98)00135-4; DUAN RD, 1995, BBA-LIPID LIPID MET, V1259, P49, DOI 10.1016/0005-2760(95)00137-2; Ella KM, 1997, ARCH BIOCHEM BIOPHYS, V340, P101, DOI 10.1006/abbi.1997.9897; Fensome AC, 2000, J BIOL CHEM, V275, P1128, DOI 10.1074/jbc.275.2.1128; FOLCH J, 1957, J BIOL CHEM, V226, P497; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANSON BA, 1980, J LIPID RES, V21, P309; Liu B, 1998, J BIOL CHEM, V273, P34472, DOI 10.1074/jbc.273.51.34472; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; QUINTERN LE, 1989, EMBO J, V8, P2469, DOI 10.1002/j.1460-2075.1989.tb08382.x; Sawai H, 1999, J BIOL CHEM, V274, P38131, DOI 10.1074/jbc.274.53.38131; Sawai H, 1997, J BIOL CHEM, V272, P2452; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SMITH SW, 1974, J BIOL CHEM, V249, P3395; STEINER S, 1969, P NATL ACAD SCI USA, V64, P1042, DOI 10.1073/pnas.64.3.1042; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wells GB, 1998, J BIOL CHEM, V273, P7235, DOI 10.1074/jbc.273.13.7235	29	125	134	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39793	39798		10.1074/jbc.M007721200	http://dx.doi.org/10.1074/jbc.M007721200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11006294	hybrid			2022-12-27	WOS:000165953100112
J	Xu, Y; Gurusiddappa, S; Rich, RL; Owens, RT; Keene, DR; Mayne, R; Hook, A; Hook, M				Xu, Y; Gurusiddappa, S; Rich, RL; Owens, RT; Keene, DR; Mayne, R; Hook, A; Hook, M			Multiple binding sites in collagen type I for the integrins alpha(1)beta(1) and alpha(2)beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; A-DOMAIN; ALPHA-2-BETA-1 VLA-2; PLATELET-ADHESION; IDENTIFICATION; SEQUENCE; SUBUNIT; INTEGRIN-ALPHA-2-BETA-1; ALPHA-1-BETA-1; SPECIFICITY	Integrins alpha (1)beta (1) and alpha (2)beta (1) are two major collagen receptors on the surface of eukaryotic cells. Binding to collagen is primarily due to an A-domain near the N terminus of the alpha chains. Previously, we reported that recombinant A-domain of alpha (1)beta (1) (alpha (1)A) had at least two affinity classes of binding sites in type I collagen (Rich, R. L., ct al. (1999) J. Biol. Chem. 274, 24906-24913), Here, we compared the binding of the recombinant A-domain of alpha (2)beta (1) (alpha (2)A) to type I collagen with that of alpha (1)A using surface plasmon resonance and showed that alpha (2)A exhibited only one detectable class of binding sites in type I collagen, with a K-D of similar to 10 muM at similar to3 binding sites per collagen molecule. We further demonstrated that alpha (1)A and alpha (2)A competed with each other for binding to type I collagen in enzyme-linked immunosorbent assay (ELISA), suggesting that the binding sites in collagen for the two A-domains overlap or are adjacent to each other. By using rotary shadowing, the complexes of alpha (1)A- and alpha (2)A-procollagen were visualized. Morphometric analyses indicated three major binding regions (near the N terminus, in the central part, and near the C terminus) along the type I procollagen molecule for both A-domains. The positions of the respective binding regions for alpha (1)A and alpha (2)A were overlapping with or adjacent to each other, consistent with the ELISA results. Analysis of the sequences of type I collagen revealed that GER or GER-like motifs are present at each of the binding regions, and notably, the central region contains the GFOGER sequence, which was previously identified as a high affinity site for both alpha (1)A and alpha (2)A (Knight, C. G., ct al. (2000) J. Biol. Chem. 275, 35-40). Peptides containing GLOGERGRO (peptide I, near the N terminus), GFOGERGVQ (peptide II, central), and GASGERGPO (peptide III, near the C terminus) were synthesized. Peptides I and II effectively inhibited the binding of cli,A and alpha (2)A to type I collagen, while peptide III did so moderately, The N-terminal site in type I collagen has the sequence GLOGER in all three chains. Thus, it seems that peptide I represents a newly discovered native high affinity site for alpha (1)A and alpha (2)A.	Texas A&M Univ, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA; Shriners Hosp Children, Portland, OR 97201 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	Texas A&M University System; University of Alabama System; University of Alabama Birmingham	Hook, M (corresponding author), Texas A&M Univ, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044415, R01AR030481, R37AR030481] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR30481, AR44415] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIEKOWSKA J, 1997, J BIOL CHEM, V272, P25162; BRODSKY B, 1992, BIOPOLYMERS, V32, P447, DOI 10.1002/bip.360320423; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; Dickeson SK, 1998, CELL MOL LIFE SCI, V54, P556, DOI 10.1007/s000180050184; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; FIELDS C G, 1991, Peptide Research, V4, P95; Golbik R, 2000, J MOL BIOL, V297, P501, DOI 10.1006/jmbi.2000.3575; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; HIGHBERGER JH, 1982, BIOCHEMISTRY-US, V21, P2048, DOI 10.1021/bi00538a011; Humphries MJ, 2000, TRENDS PHARMACOL SCI, V21, P29, DOI 10.1016/S0165-6147(99)01410-8; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Kamata T, 1999, J BIOL CHEM, V274, P32108, DOI 10.1074/jbc.274.45.32108; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; Kapyla J, 2000, J BIOL CHEM, V275, P3348, DOI 10.1074/jbc.275.5.3348; Kern A, 1998, J CELL PHYSIOL, V176, P634, DOI 10.1002/(SICI)1097-4652(199809)176:3<634::AID-JCP20>3.3.CO;2-J; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; Messent AJ, 1998, J CELL SCI, V111, P1127; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; MORTON LF, 1994, BIOCHEM J, V299, P791, DOI 10.1042/bj2990791; Nolte M, 1999, FEBS LETT, V452, P379, DOI 10.1016/S0014-5793(99)00666-3; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Rich RL, 1999, J BIOL CHEM, V274, P26939, DOI 10.1074/jbc.274.38.26939; Rich RL, 1999, J BIOL CHEM, V274, P24906, DOI 10.1074/jbc.274.35.24906; Rich RL, 1998, BIOCHEMISTRY-US, V37, P15423, DOI 10.1021/bi981773r; SAELMAN EUM, 1993, BLOOD, V82, P3029; SARANTAKIS D, 1976, BIOCHEM BIOPH RES CO, V73, P336, DOI 10.1016/0006-291X(76)90712-9; Smith C, 2000, J BIOL CHEM, V275, P4205, DOI 10.1074/jbc.275.6.4205; SWASDISON S, 1992, MATRIX, V12, P56, DOI 10.1016/S0934-8832(11)80105-8; Symersky J, 1997, NAT STRUCT BIOL, V4, P833, DOI 10.1038/nsb1097-833; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; VISAI L, 2000, IN PRESS J BIOL CHEM, V275	48	204	212	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					38981	38989		10.1074/jbc.M007668200	http://dx.doi.org/10.1074/jbc.M007668200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10986291	hybrid			2022-12-27	WOS:000165953100007
J	Chen, DX; Stetler, RA; Cao, GD; Pei, W; O'Horo, C; Yin, XM; Chen, J				Chen, DX; Stetler, RA; Cao, GD; Pei, W; O'Horo, C; Yin, XM; Chen, J			Characterization of the rat DNA fragmentation factor 35/inhibitor of caspase-activated DNase (short form) - The endogenous inhibitor of caspase-dependent DNA fragmentation in neuronal apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; CHROMATIN CONDENSATION; NEURODEGENERATIVE DISEASES; PROTEASES; NUCLEASE; FAMILY; INDUCTION; ISCHEMIA; EXTRACTS; PROTEIN	Nuclear changes, including internucleosomal DNA fragmentation, are classical manifestations of apoptosis for which the biochemical mechanisms have not been fully elucidated, particularly in neuronal cells. We have cloned the rat DNA fragmentation factor 35/inhibitor of caspase-activated DNase (short form) (DFF35/ICAD(S)) and found it to be the predominant form of ICAD present in rodent brain cells as well as in many other types of cells. DFF35/ICAD(S) forms a functional complex with DFF40/caspase-activated DNase (CAD) in the nucleus, and when its caspase-resistant mutant is over-expressed, it inhibits the nuclease activity, internucleosomal DNA fragmentation and nuclear fragmentation but not the shrinkage and condensation of the nucleus, in neuron-differentiated PC12 cells in response to apoptosis inducers. DFF40/CAD is found to be localized mainly in the nucleus, and during neuronal apoptosis, there is no evidence of further nuclear translocation of this molecule. It is further suggested that inactivation of DFF40/CAD-bound DFF35 and subsequent activation of DFF40/CAD during apoptosis of neuronal cells may not occur in the cytosol but rather in the nucleus through a novel mechanism that requires nuclear translocation of caspases. These results establish that DFF35/ICAD(S) is the endogenous inhibitor of DFF40/CAD and caspase-dependent apoptotic DNA fragmentation in neurons.	Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Pittsburgh Inst Neurodegenerat Disorders, Pittsburgh, PA 15213 USA; Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System	Chen, J (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, S-506 Biomed Sci Tower, Pittsburgh, PA 15213 USA.			Chen, Jun/0000-0002-8077-3403	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS035965, R01NS036736, R01NS038560] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35965, NS36736, NS38560] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Chen J, 1998, J NEUROSCI, V18, P4914; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gu JJ, 1999, J BIOL CHEM, V274, P20759, DOI 10.1074/jbc.274.30.20759; Hajimohamadreza I, 1997, Prog Drug Res, V48, P55; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Inohara N, 1999, J BIOL CHEM, V274, P270, DOI 10.1074/jbc.274.1.270; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Sakahira H, 1999, J BIOL CHEM, V274, P15740, DOI 10.1074/jbc.274.22.15740; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samejima K, 2000, EXP CELL RES, V255, P314, DOI 10.1006/excr.2000.4801; Schulz JB, 1999, ANN NEUROL, V45, P421, DOI 10.1002/1531-8249(199904)45:4<421::AID-ANA2>3.0.CO;2-Q; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zamzami N, 1999, NATURE, V401, P127, DOI 10.1038/43591; Zhang JH, 1999, J BIOL CHEM, V274, P37450, DOI 10.1074/jbc.274.52.37450; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480	33	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38508	38517		10.1074/jbc.M003906200	http://dx.doi.org/10.1074/jbc.M003906200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10984476	hybrid			2022-12-27	WOS:000165739800051
J	Chi, NW; Lodish, HF				Chi, NW; Lodish, HF			Tankyrase is a Golgi-associated mitogen-activated protein kinase substrate that interacts with IRAP in GLUT4 vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; INSULIN; DOMAIN; RAT; TRANSLOCATION; LOCALIZATION; ANKYRIN	The poly(ADP-ribose) polymerase tankyrase was originally described as a telomeric protein whose catalytic activity was proposed to regulate telomere function. Subsequent studies revealed that most tankyrase is actually extranuclear, but a discordant pattern of cytoplasmic targeting was reported, Here we used fractionation and immunofluorescence to show in 3T3-L1 fibroblasts that tankyrase is a peripheral membrane protein associated with the Golgi. We further colocalized tankyrase with GLUT4 storage vesicles in the juxtanuclear region of adipocytes. Consistent with this colocalization, we found that tankyrase binds specifically to a resident protein of GLUT4 vesicles, IRAP (insulin-responsive amino peptidase). The binding of tankyrase to IRAP involves the ankyrin repeats of tankyrase and a defined sequence ((96)RQSPDG(101)) in the IRAP cytosolic domain (IRAP(1-109)). Tankyrase is a novel signaling target of mitogen-activated protein kinase (MAPK); it is stoichiometrically phosphorylated upon insulin stimulation. Phosphorylation enhances the poly(ADP-ribose) polymerase activity of tankyrase but apparently does not mediate the acute effect of insulin on GLUT4 targeting. Taken together, tankyrase is a novel target of MAPK. signaling in the Golgis, where it is tethered to GLUT4 vesicles by binding to IRAP. We speculate that tankyrase may be involved in the long term effect of the MAPK cascade on the metabolism of GLUT4 vesicles.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Med Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047618, K08DK002540] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37DK47618, DK02540] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Batrukova MA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P395; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FINGAR DC, 1994, J BIOL CHEM, V269, P10127; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gao YS, 1998, J BIOL CHEM, V273, P33825, DOI 10.1074/jbc.273.50.33825; GARZA LA, 1997, J BIOL CHEM, V272, pE600; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; Herbst JJ, 1997, AM J PHYSIOL-ENDOC M, V272, pE600, DOI 10.1152/ajpendo.1997.272.4.E600; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lee W, 1997, J BIOL CHEM, V272, P21427, DOI 10.1074/jbc.272.34.21427; Lippincott-Schwartz J, 1998, CURR OPIN CELL BIOL, V10, P52, DOI 10.1016/S0955-0674(98)80086-0; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; Martinez-Arca S, 2000, J CELL SCI, V113, P1705; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SCHIEMANN WP, 1995, P NATL ACAD SCI USA, V92, P5361, DOI 10.1073/pnas.92.12.5361; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Smith S, 1999, J CELL SCI, V112, P3649; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Spanfo S, 1999, J BIOL CHEM, V274, P17705, DOI 10.1074/jbc.274.25.17705; STECK TL, 1974, J CELL BIOL, V62, P1, DOI 10.1083/jcb.62.1.1; Subtil A, 2000, J BIOL CHEM, V275, P4787, DOI 10.1074/jbc.275.7.4787; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; Waters SB, 1997, J BIOL CHEM, V272, P23323, DOI 10.1074/jbc.272.37.23323; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Yamamoto Y, 2000, DIABETES, V49, P332, DOI 10.2337/diabetes.49.3.332; Zhang ZS, 1998, J BIOL CHEM, V273, P18681, DOI 10.1074/jbc.273.30.18681	41	236	258	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38437	38444		10.1074/jbc.M007635200	http://dx.doi.org/10.1074/jbc.M007635200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10988299	hybrid			2022-12-27	WOS:000165739800041
J	Goumon, Y; Lugardon, K; Gadroy, P; Strub, JM; Welters, ID; Stefano, GB; Aunis, D; Metz-Boutigue, MH				Goumon, Y; Lugardon, K; Gadroy, P; Strub, JM; Welters, ID; Stefano, GB; Aunis, D; Metz-Boutigue, MH			Processing of proenkephalin-A in bovine chromaffin cells - Identification of natural derived fragments by N-terminal sequencing and matrix-assisted laser desorption ionization-time of flight mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE THIOL PROTEASE; ADRENAL-MEDULLA; ANTIBACTERIAL ACTIVITY; SECRETORY VESICLES; MONONUCLEAR-CELLS; CHROMOGRANIN-A; GROWTH-FACTOR; GRANULES; ENKEPHALIN; ENZYME	A large variety of proenkephalin-A-derived peptides (PEAPs) are present in bovine adrenal medulla secretory granules that are cosecreted with catecholamines upon stimulation of chromaffin cells. In the present paper, after reverse phase high performance liquid chromatography of intragranular soluble material, PEAPs were immunodetected with antisera raised against specific proenkephalin-A (PEA) sequences (PEA63-70 and PEA224-237) and analyzed by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry, Thirty PEAPs were characterized in addition to enkephalins and whole PEA, indicating that preferential proteolytic attacks occurred at both N- and C-terminal regions. A similar approach was used to characterize PEA-derived fragments exocytotically released into the extracellular space that showed five additional minor PEAPs. Among all these naturally generated peptides, enkelytin, the antibacterial bisphosphorylated C-terminal peptide (PEA209-237), was predominantly generated, as shown by MALDI-TOF mass spectrometry analysis, which constituted an efficient method for its identification. Finally, the data on PEA intragranular and extracellular processing in adrenal medulla are discussed in regard to the known enzymatic processing mechanisms. We note the high conservation of the cleavage points in evolutionarily diverse organisms, highlighting an important biological function for the released PEAPs.	INSERM, U338, F-67084 Strasbourg, France; Univ Giessen, Dept Anaesthesiol & Intens Care Med, D-35385 Giessen, Germany; SUNY Coll Old Westbury, Neurosci Res Inst, Old Westbury, NY 11568 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Justus Liebig University Giessen; State University of New York (SUNY) System; SUNY Old Westbury	Metz-Boutigue, MH (corresponding author), INSERM, U338, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	metz@neurochem.u-strasbg.fr	Dominique, Aunis/W-1419-2019; Stefano, George Bogdan/ABD-9152-2021	Stefano, George Bogdan/0000-0002-8146-0740; Welters, Ingeborg/0000-0002-3408-8798; Strub, Jean-Marc/0000-0001-6224-3428				AUNIS D, 1977, J NEUROCHEM, V29, P439, DOI 10.1111/j.1471-4159.1977.tb10692.x; Aunis D, 1998, INT REV CYTOL, V181, P213, DOI 10.1016/S0074-7696(08)60419-2; AZARYAN AV, 1992, BIOCHEM BIOPH RES CO, V185, P398, DOI 10.1016/S0006-291X(05)80999-4; AZARYAN AV, 1994, FEBS LETT, V341, P197, DOI 10.1016/0014-5793(94)80456-7; AZARYAN AV, 1995, J NEUROCHEM, V65, P1771; AZARYAN AV, 1995, BIOCHEMISTRY-US, V34, P7988; BANKS P, 1965, BIOCHEM J, V97, pC40, DOI 10.1042/bj0970040C; BASTIAENSEN E, 1989, FEBS LETT, V244, P477, DOI 10.1016/0014-5793(89)80587-3; Bongiorno L, 1999, GERONTOLOGY, V45, P10, DOI 10.1159/000022049; Brar BK, 1999, J ENDOCRINOL, V161, P475, DOI 10.1677/joe.0.1610475; Danielson PB, 1999, GEN COMP ENDOCR, V113, P169, DOI 10.1006/gcen.1998.7206; DILLEN L, 1993, NEUROCHEM INT, V22, P315, DOI 10.1016/0197-0186(93)90016-X; EVANGELISTA R, 1982, BIOCHEM BIOPH RES CO, V106, P895, DOI 10.1016/0006-291X(82)91795-8; FERRO ES, 1995, J CELL BIOCHEM, V57, P311, DOI 10.1002/jcb.240570215; FRICKER LD, 1986, NATURE, V323, P461, DOI 10.1038/323461a0; Goumon Y, 1996, EUR J BIOCHEM, V235, P516, DOI 10.1111/j.1432-1033.1996.t01-1-00516.x; Goumon Y, 1998, J BIOL CHEM, V273, P29847, DOI 10.1074/jbc.273.45.29847; HOLLT V, 1982, EUR J PHARMACOL, V85, P355, DOI 10.1016/0014-2999(82)90226-6; Hook VYH, 1999, J BIOL CHEM, V274, P3165, DOI 10.1074/jbc.274.5.3165; HOOK VYH, 1982, NATURE, V295, P341, DOI 10.1038/295341a0; HOOK VYH, 1984, FEBS LETT, V172, P212, DOI 10.1016/0014-5793(84)81128-X; Hook VYH, 1999, ENDOCRINOLOGY, V140, P3744, DOI 10.1210/en.140.8.3744; HOOK VYH, 1994, FASEB J, V8, P1269, DOI 10.1096/fasebj.8.15.8001739; Hook VYH, 1996, ARCH BIOCHEM BIOPHYS, V328, P107, DOI 10.1006/abbi.1996.0149; INTURRISI CE, 1980, P NATL ACAD SCI-BIOL, V77, P5512, DOI 10.1073/pnas.77.9.5512; Johanning K, 1998, J BIOL CHEM, V273, P22672, DOI 10.1074/jbc.273.35.22672; KOJIMA K, 1982, ARCH BIOCHEM BIOPHYS, V215, P638, DOI 10.1016/0003-9861(82)90125-4; KRIEGER TJ, 1991, J BIOL CHEM, V266, P8376; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG I, 1982, LIFE SCI, V31, P1713, DOI 10.1016/0024-3205(82)90192-8; LISTON D, 1984, SCIENCE, V225, P734, DOI 10.1126/science.6547780; Liu F, 1996, J NEUROCHEM, V67, P1457; Loewe H, 1999, ARZNEIMITTEL-FORSCH, V49, P297; Lugardon K, 2000, J BIOL CHEM, V275, P10745, DOI 10.1074/jbc.275.15.10745; Mains RE, 1996, ANN NY ACAD SCI, V805, P10; Marx R, 1999, J NEUROSCI, V19, P8300; MATHIS JP, 1992, ENDOCRINOLOGY, V131, P2287, DOI 10.1210/en.131.5.2287; METTERS KM, 1988, J BIOL CHEM, V263, P12543; Metz-Boutigue MH, 1998, CELL MOL NEUROBIOL, V18, P249, DOI 10.1023/A:1022573004910; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; MIZUNO K, 1985, BIOCHEM BIOPH RES CO, V128, P884, DOI 10.1016/0006-291X(85)90129-9; NODA M, 1982, NATURE, V295, P202, DOI 10.1038/295202a0; PADROS MR, 1995, J NEUROIMMUNOL, V61, P79, DOI 10.1016/0165-5728(95)00077-F; PAYNE CM, 1989, ARCH HISTOL CYTOL, V52, P277, DOI 10.1679/aohc.52.Suppl_277; Plotnikoff NP, 1997, CLIN IMMUNOL IMMUNOP, V82, P93, DOI 10.1006/clin.1996.4287; ROBERTS SF, 1992, J NEUROCHEM, V58, P593, DOI 10.1111/j.1471-4159.1992.tb09760.x; ROSTOVTSEV AP, 1994, MOL CELL ENDOCRINOL, V101, P277, DOI 10.1016/0303-7207(94)90244-5; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SARAVIA F, 1993, ENDOCRINOLOGY, V132, P1431, DOI 10.1210/en.132.4.1431; Saravia F, 1998, NEUROPEPTIDES, V32, P351, DOI 10.1016/S0143-4179(98)90058-0; SCHNEIDER FH, 1967, BRIT J PHARM CHEMOTH, V31, P94, DOI 10.1111/j.1476-5381.1967.tb01980.x; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHEN FS, 1989, J BIOL CHEM, V264, P15600; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMITH AD, 1967, BIOCHEM J, V103, P480, DOI 10.1042/bj1030480; Stefano GB, 1999, INT REV CYTOL, V187, P261, DOI 10.1016/S0074-7696(08)62420-1; Stefano GB, 1998, IMMUNOL TODAY, V19, P265, DOI 10.1016/S0167-5699(98)01268-7; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; STEINER DF, 1992, J BIOL CHEM, V267, P23435; Strub JM, 1996, FEBS LETT, V379, P273, DOI 10.1016/0014-5793(95)01529-9; Strub JM, 1996, J BIOL CHEM, V271, P28533, DOI 10.1074/jbc.271.45.28533; STRUB JM, 1995, EUR J BIOCHEM, V229, P356, DOI 10.1111/j.1432-1033.1995.0356k.x; Tasiemski A, 2000, MOL BRAIN RES, V76, P237, DOI 10.1016/S0169-328X(00)00005-X; TEZAPSIDIS N, 1994, BIOCHEM J, V301, P607, DOI 10.1042/bj3010607; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UDENFRIEND S, 1984, PEPTIDES, V6, P25; VIDA MIR, 1994, DEV BRAIN RES, V77, P151; Vindrola O, 1998, ENDOCRINE, V8, P231, DOI 10.1385/ENDO:8:3:231; VINDROLA O, 1990, J CLIN INVEST, V86, P531, DOI 10.1172/JCI114740; VORM O, 1994, J AM SOC MASS SPECTR, V5, P955, DOI 10.1016/1044-0305(94)80013-8; Yasothornsrikul S, 1999, BIOCHEMISTRY-US, V38, P7421, DOI 10.1021/bi990239w; Zagon IS, 1999, BRAIN RES, V839, P313, DOI 10.1016/S0006-8993(99)01753-9	74	27	27	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38355	38362		10.1074/jbc.M007557200	http://dx.doi.org/10.1074/jbc.M007557200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10988298	hybrid			2022-12-27	WOS:000165739800031
J	Kato, M; Miyazawa, K; Kitamura, N				Kato, M; Miyazawa, K; Kitamura, N			A deubiquitinating enzyme UBPY interacts with the Src homology 3 domain of Hrs-binding protein via a novel binding motif PX(V/I)(D/N)RXXKP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCING ADAPTER MOLECULE; LIGAND-INDUCED POLYUBIQUITINATION; GROWTH-FACTOR RECEPTOR; ZINC-FINGER DOMAIN; SH3 DOMAINS; CELL-GROWTH; UBIQUITIN; GRB2; SIGNAL; DEGRADATION	Hrs-binding protein (Hbp) is a Src homology 3 (SH3) domain-containing protein that tightly associates with Hrs. Hbp together with Hrs is thought to play a regulatory role in endocytic trafficking of growth factor-receptor complexes through early endosomes. Association of Hbp with a binding partner(s) via the SH3 domain seems to be essential for Hbp to exert its function. In this study, we searched for Hbp-binding proteins by a far Western screening and isolated a mouse cDNA clone encoding a deubiquitinating enzyme mUBPY as an Hbp SH3-binding protein, mUBPY has two Hbp-SH3 domain binding sites. Mutagenic analysis identified a consensus sequence PX(V/I)(D/N)RXXKP as the Hbp-SH3 domain binding motif. It is a novel SH3-binding motif and does not contain the canonical proline-rich consensus binding motif, PXXP. Ubiquitination of growth factor receptors is thought to regulate their intracellular degradation. Thus, UBPY may play a regulatory role in the degradation by interaction with the SH3 domain of Hbp via the novel SH3-binding motif.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Kitamura, N (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Sci, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	nkitamur@bio.titech.ac.jp	MIYAZAWA, KEIJI/I-9713-2014					Amerik AY, 1997, EMBO J, V16, P4826; Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HADARI T, 1992, J BIOL CHEM, V267, P719; Hofmann K, 1998, J MOL BIOL, V282, P195, DOI 10.1006/jmbi.1998.1998; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1995, BIOCHEM BIOPH RES CO, V213, P32, DOI 10.1006/bbrc.1995.2094; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Okkenhaug K, 1998, J BIOL CHEM, V273, P21194, DOI 10.1074/jbc.273.33.21194; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; She HY, 1997, MOL BIOL CELL, V8, P1709, DOI 10.1091/mbc.8.9.1709; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Takata H, 2000, GENES CELLS, V5, P57, DOI 10.1046/j.1365-2443.2000.00303.x; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; Takeshita T, 1996, BIOCHEM BIOPH RES CO, V225, P1035, DOI 10.1006/bbrc.1996.1290; Tanaka N, 1999, J BIOL CHEM, V274, P19129, DOI 10.1074/jbc.274.27.19129; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543	39	183	188	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37481	37487		10.1074/jbc.M007251200	http://dx.doi.org/10.1074/jbc.M007251200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982817	hybrid			2022-12-27	WOS:000165618700026
J	Steele-Mortimer, O; Knodler, LA; Marcus, SL; Scheid, MP; Goh, B; Pfeifer, CG; Duronio, V; Finlay, BB				Steele-Mortimer, O; Knodler, LA; Marcus, SL; Scheid, MP; Goh, B; Pfeifer, CG; Duronio, V; Finlay, BB			Activation of Akt/protein kinase B in epithelial cells by the Salmonella typhimurium effector SigD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; BACTERIAL INVASION; NUCLEAR RESPONSES; HOST-CELLS; APOPTOSIS; VIRULENCE; AKT; INHIBITION	The serine-threonine kinase Akt is a protooncogene involved in the regulation of cell proliferation and survival. Activation of Abt is initiated by binding to the phospholipid products of phosphoinositide 3-kinase at the inner leaflet of the plasma membranes followed by phosphorylation at Ser(473) and Thr(308). We have found that Akt is activated by Salmonella enterica serovar Typhimurium in epithelial cells. A bacterial effector protein, SigD, which is translocated into host cells via the specialized type III secretion system, is essential for Akt activation. In HeLa cells, wild type S. typhimurium induced translocation of Akt to membrane ruffles and phosphorylation at residues Thr(308) and Ser(473) and increased kinase activity. In contrast, infection with a SigD deletion mutant did not induce phosphorylation or activity although Akt was translocated to membrane ruffles. Complementation of the SigD deletion strain with a mutant containing a single Cys to Ser mutation (C462S), did not restore the Akt activation phenotype, This residue has previously been shown to be essential for inositol phosphatase activity of the SigD homologue, SopB, Our data indicate a novel mechanism of Akt activation in which the endogenous cellular pathway does not convert membrane-associated Akt into its active form. SigD is also the first bacterial effector to be identified as an activator of Akt.	Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Steele-Mortimer, O (corresponding author), Washington Univ, Dept Cell Biol & Physiol, Box 8228,660 S Euclid, St Louis, MO 63110 USA.	osteelem@cellbio.wustl.edu		Pfeifer, Cheryl/0000-0001-8584-228X; Knodler, Leigh/0000-0002-3028-2198				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Clifton DR, 1998, P NATL ACAD SCI USA, V95, P4646, DOI 10.1073/pnas.95.8.4646; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Eaves-Pyles T, 1999, INFECT IMMUN, V67, P800, DOI 10.1128/IAI.67.2.800-804.1999; Eckmann L, 1997, P NATL ACAD SCI USA, V94, P14456, DOI 10.1073/pnas.94.26.14456; Edwards RA, 1998, GENE, V207, P149, DOI 10.1016/S0378-1119(97)00619-7; Elewaut D, 1999, J IMMUNOL, V163, P1457; Fan T, 1998, J EXP MED, V187, P487, DOI 10.1084/jem.187.4.487; FINLAY BB, 1991, J CELL SCI, V99, P283; FRANCIS CL, 1993, NATURE, V364, P639, DOI 10.1038/364639a0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Fu YX, 1998, MOL MICROBIOL, V27, P359, DOI 10.1046/j.1365-2958.1998.00684.x; Galan JE, 1999, CURR OPIN MICROBIOL, V2, P46, DOI 10.1016/S1369-5274(99)80008-3; GALAN JE, 1992, J BACTERIOL, V174, P4338; Galyov EE, 1997, MOL MICROBIOL, V25, P903, DOI 10.1111/j.1365-2958.1997.mmi525.x; GARCIADELPORTILLO F, 1994, J CELL SCI, V107, P2005; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hersh D, 1999, P NATL ACAD SCI USA, V96, P2396, DOI 10.1073/pnas.96.5.2396; Hilbi H, 1998, J BIOL CHEM, V273, P32895, DOI 10.1074/jbc.273.49.32895; Hobbie S, 1997, J IMMUNOL, V159, P5550; Hong KH, 1998, J BACTERIOL, V180, P1793, DOI 10.1128/JB.180.7.1793-1802.1998; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JONES BD, 1993, P NATL ACAD SCI USA, V90, P10390, DOI 10.1073/pnas.90.21.10390; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; KANIGA K, 1995, J BACTERIOL, V177, P3965, DOI 10.1128/jb.177.14.3965-3971.1995; Marcus SL, 2000, MICROBES INFECT, V2, P145, DOI 10.1016/S1286-4579(00)00273-2; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Monack DM, 2000, J EXP MED, V192, P249, DOI 10.1084/jem.192.2.249; NORRIS FA, 1994, J BIOL CHEM, V269, P8716; Norris FA, 1998, P NATL ACAD SCI USA, V95, P14057, DOI 10.1073/pnas.95.24.14057; Ozes ON, 1999, NATURE, V401, P82; Pfeifer CG, 1999, INFECT IMMUN, V67, P5690, DOI 10.1128/IAI.67.11.5690-5698.1999; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Steele-Mortimer O, 1999, CELL MICROBIOL, V1, P33, DOI 10.1046/j.1462-5822.1999.00003.x; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4	45	154	158	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37718	37724		10.1074/jbc.M008187200	http://dx.doi.org/10.1074/jbc.M008187200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978351	hybrid			2022-12-27	WOS:000165618700057
J	Vonakis, BM; Haleem-Smith, H; Benjamin, P; Metzger, H				Vonakis, BM; Haleem-Smith, H; Benjamin, P; Metzger, H			Interaction between the unphosphorylated receptor with high affinity for IgE and Lyn kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; DETERGENT-RESISTANT MEMBRANES; BASOPHILIC LEUKEMIA-CELLS; IMMUNOGLOBULIN-E RECEPTOR; PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; T-CELL; BETA-SUBUNIT; MAST-CELLS; ACTIVATION	Chinese hamster ovary fibroblasts previously transfected with the high affinity receptor for IgE (Fc epsilon RI) were further transfected with the cu subunit of the receptor for interleukin 2 (Tac) or with chimeric constructs in which the cytoplasmic domain of Tac was replaced with the C-terminal cytoplasmic domain of either the beta subunit or the gamma subunit of Fc epsilon RI. Whereas native Tac failed to affect the aggregation-induced phosphorylation of Fc epsilon RI, both chimeric constructs substantially inhibited this reaction. Alternatively, the Fc epsilon RI-bearing fibroblasts were transfected with two chimeric constructs in which the cytoplasmic domain of Tac was replaced with a modified short form of Lyn kinase. The Lyn in both of the chimeric constructs had been mutated to remove the sites that are normally myristoylated and palmitoylated, respectively; one of the constructs had in addition been altered to be catalytically inactive. The catalytically active construct enhanced, and the inactive construct inhibited, aggregation-induced phosphorylation of the receptors. All of the chimeric constructs were largely distributed outside the detergent resistant microdomains, and whereas aggregation caused them to move to the domains in part, their aggregation was neither necessary nor enhanced their effects. These results and others indicate that the receptor and Lyn interact through protein-protein interactions that neither are dependent upon either the posttranslational modification of the kinase with lipid moieties nor result exclusively from their co-localization in specialized membrane domains.	NIAMS, Sect Chem Immunol, Arthrit & Rheumatism Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Metzger, H (corresponding author), NIAMS, Sect Chem Immunol, Arthrit & Rheumatism Branch, NIH, Bldg 10,Rm 9N-228,10 Ctr Dr,MSC-1820, Bethesda, MD 20892 USA.	metzgerh@exchange.nih.gov		Vonakis, Becky/0000-0003-4174-6514				ALBER G, 1992, J IMMUNOL, V149, P2428; Baird B, 1999, BIOPHYS CHEM, V82, P109, DOI 10.1016/S0301-4622(99)00110-6; BARCLAY AN, 1993, LEUKOCYTE ANTIGEN FA; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CHENG HC, 1991, J BIOL CHEM, V266, P17919; EISEMAN E, 1992, J BIOL CHEM, V267, P21027; EISEMAN E, 1992, NATURE, V355, P78; Field KA, 1999, J BIOL CHEM, V274, P1753, DOI 10.1074/jbc.274.3.1753; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Junghans RP, 1999, IMMUNOL TODAY, V20, P401, DOI 10.1016/S0167-5699(97)01178-X; KOVAROVA L, COMMUNICATION; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; MATTHYSSENS GE, 1975, MOL CELL BIOCHEM, V7, P119, DOI 10.1007/BF01792078; Metzger H, 1999, IMMUNOL LETT, V68, P53, DOI 10.1016/S0165-2478(99)00030-9; MINOGUCHI K, 1994, MOL IMMUNOL, V31, P519; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; Pribluda VS, 1997, J BIOL CHEM, V272, P11185; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RIVNAY B, 1982, BIOCHEMISTRY-US, V21, P6922, DOI 10.1021/bi00269a047; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; SIRAGANIAN RP, 1998, SIGNAL TRANSDUCTION, P115; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Stauffer TP, 1997, J CELL BIOL, V139, P1447, DOI 10.1083/jcb.139.6.1447; Torigoe C, 1997, P NATL ACAD SCI USA, V94, P1372, DOI 10.1073/pnas.94.4.1372; van't Hof W, 1999, J CELL BIOL, V145, P377, DOI 10.1083/jcb.145.2.377; Vonakis BM, 1997, J BIOL CHEM, V272, P24072, DOI 10.1074/jbc.272.38.24072; WILSON BS, 1995, J BIOL CHEM, V270, P4013, DOI 10.1074/jbc.270.8.4013; Wofsy C, 1999, P NATL ACAD SCI USA, V96, P8615, DOI 10.1073/pnas.96.15.8615; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; YAMASHITA T, UNPUB	38	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1041	1050		10.1074/jbc.M003397200	http://dx.doi.org/10.1074/jbc.M003397200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11010962	hybrid			2022-12-27	WOS:000166430900026
J	Hauck, CR; Hsia, DA; Schlaepfer, DD				Hauck, CR; Hsia, DA; Schlaepfer, DD			Focal adhesion kinase facilitates platelet-derived growth factor-BB-stimulated ERK2 activation required for chemotaxis migration of vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE SHP-2; C-TERMINAL DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; NEOINTIMA FORMATION; PROTEIN-KINASE; INTEGRIN; FAK; SRC; PHOSPHORYLATION; INHIBITION	The focal adhesion (FAK) non-receptor protein-tyrosine kinase (PTR) links both extracellular matrix/integrin and growth factor stimulation to intracellular signals promoting cell migration. Here we show that both transient and stable overexpression of the FAR C-terminal domain termed FRNK (FAK-related non-kinase) inhibits serum and platelet-derived growth factor (PDGF)HE-induced vascular smooth muscle cell (SMC) migration in wound healing and in vitro Boyden Chamber chemotaxis assays, respectively. Expression of FRNK, but not a point mutant of FRNK (FRNK L1034S), disrupted the formation of a complex containing both FAK and the activated PDGF-beta receptor and resulted in reduced tyrosine phosphorylation of endogenous FAK at the Tyr-397 binding site for Src family PTKs. As demonstrated using:FAK-deficient and FAR-reconstituted fibroblasts, FAK positively contributed to PDGF-BB-stimulated ERK2/MAP kinase activity, and in SMCs, ERR2/MAP kinase activity was required for PDGF-BB-stimulated chemotaxis, Stable expression of FRNK but not FRNK L1034S expression in SMCs lowered the extent and duration of stimulated ERK2/MAP kinase activation at low but not at high PDGF-BB concentrations. Importantly, stable expression of FRNK in SMCs did not affect SMC morphology or proliferation in culture. Because the increased migration of vascular SMCs in response to extracellular matrix proteins and growth factors contributes to neointima formation, our results show that FAR inhibition by FRNK expression may provide a novel approach to regulate abnormal vascular SMC migration in vivo.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Schlaepfer, DD (corresponding author), Scripps Res Inst, Dept Immunol, IMM-26,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [CA75240] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075240, R29CA075240] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andres V, 1998, INT J MOL MED, V2, P81; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cospedal R, 1999, CARDIOVASC RES, V41, P708, DOI 10.1016/S0008-6363(98)00232-6; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Gotwals PJ, 1996, J CLIN INVEST, V97, P2469, DOI 10.1172/JCI118693; Graf BM, 1997, J CARDIOVASC PHARM, V29, P1, DOI 10.1097/00005344-199701000-00001; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; HANKE H, 1990, CIRC RES, V67, P651, DOI 10.1161/01.RES.67.3.651; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lai JF, 2000, J BIOL CHEM, V275, P7474, DOI 10.1074/jbc.275.11.7474; Manes S, 1999, MOL CELL BIOL, V19, P3125; MATSUNO H, 1994, CIRCULATION, V90, P2203, DOI 10.1161/01.CIR.90.5.2203; Nolan K, 1999, MOL CELL BIOL, V19, P6120; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Qi JH, 1999, J BIOL CHEM, V274, P14455, DOI 10.1074/jbc.274.20.14455; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Rutherford C, 1997, ATHEROSCLEROSIS, V130, P45, DOI 10.1016/S0021-9150(96)06042-X; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Waltenberger J, 1999, CIRC RES, V85, P12; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zheng DQ, 1999, CANCER RES, V59, P1655	43	98	107	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41092	41099		10.1074/jbc.M005450200	http://dx.doi.org/10.1074/jbc.M005450200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10998418	hybrid, Green Published			2022-12-27	WOS:000166114600059
J	Leinweber, B; Parissenti, AM; Gallant, C; Gangopadhyay, SS; Kirwan-Rhude, A; Leavis, PC; Morgan, KG				Leinweber, B; Parissenti, AM; Gallant, C; Gangopadhyay, SS; Kirwan-Rhude, A; Leavis, PC; Morgan, KG			Regulation of protein kinase C by the cytoskeletal protein calponin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALPONIN; ACTIN-BINDING; SELECTIVE BINDING; MOLECULAR-CLONING; ACTIVATION; EPSILON; DOMAIN; IDENTIFICATION; PHOSPHOLIPIDS; REQUIREMENTS	Previous studies from this laboratory have shown that, upon agonist activation, calponin co-immunoprecipitates and co-localizes with protein kinase CE (PKC epsilon) in vascular smooth muscle cells. In the present study we demonstrate that calponin binds directly to the regulatory domain of PKC both in overlay assays and, under native conditions, by sedimentation with lipid vesicles. Calponin was found to bind to the Ca region of both PKC epsilon and PKC alpha with possible involvement of C1B. The C2 region of PKC epsilon binds to the calponin repeats with a requirement for the region between amino acids 160 and 182. We have also found that calponin can directly activate PKC autophosphorylation. By using anti-phospho-antibodies to residue Ser-660 of PKC beta II, we found that calponin, in a lipid-independent manner, increased auto-phosphorylation of PKCa, -epsilon, and -beta II severalfold compared with control conditions. Similarly, calponin was found to increase the amount of P-32-labeled phosphate incorporated into PKC from [gamma-P-32]ATP. We also observed that calponin addition strongly increased the incorporation of radiolabeled phosphate into an exogenous PKC peptide substrate, suggesting an activation of enzyme activity. Thus, these results raise the possibility that calponin may function in smooth muscle to regulate PKC activity by facilitating the phosphorylation of PRC.	Boston Biomed Res Inst, Watertown, MA 02472 USA; Northeastern Ontario Reg Canc Ctr, Sudbury, ON P3E 5J1, Canada; Tufts Univ, Grad Sch Biomed Sci, Dept Physiol, Boston, MA 02111 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Boston Biomedical Research Institute; Tufts University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Morgan, KG (corresponding author), Boston Biomed Res Inst, 64 Grove St, Watertown, MA 02472 USA.	morgan@bbri.org		Morgan, Kathleen/0000-0003-3300-3630	NHLBI NIH HHS [HL42293, HL31704, HL10026] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042293, R01HL031704] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE M, 1990, J BIOCHEM-TOKYO, V108, P835, DOI 10.1093/oxfordjournals.jbchem.a123289; Andrea JE, 1998, FEBS LETT, V429, P73, DOI 10.1016/S0014-5793(98)00567-5; Banuelos S, 1998, STRUCTURE, V6, P1419, DOI 10.1016/S0969-2126(98)00141-5; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BOGATCHEVA NV, 1995, FEBS LETT, V371, P123, DOI 10.1016/0014-5793(95)00868-A; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Dessy C, 1998, AM J PHYSIOL-CELL PH, V275, pC1081, DOI 10.1152/ajpcell.1998.275.4.C1081; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; FUJII T, 1995, J BIOCHEM-TOKYO, V117, P999, DOI 10.1093/oxfordjournals.jbchem.a124833; Gimona M, 1998, J CELL SCI, V111, P1813; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; Horowitz A, 1996, PHYSIOL REV, V76, P967, DOI 10.1152/physrev.1996.76.4.967; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Le YH, 1999, J PHYSIOL-LONDON, V517, P709, DOI 10.1111/j.1469-7793.1999.0709s.x; Leinweber BD, 1999, BIOCHEM J, V344, P117, DOI 10.1042/0264-6021:3440117; LEVENTHAL PS, 1993, J BIOL CHEM, V268, P13906; Masuda H, 1996, J BIOCHEM-TOKYO, V120, P415; Menice CB, 1997, J BIOL CHEM, V272, P25157, DOI 10.1074/jbc.272.40.25157; MEZGUELDI M, 1992, J BIOL CHEM, V267, P15943; Mino T, 1998, EUR J BIOCHEM, V251, P262, DOI 10.1046/j.1432-1327.1998.2510262.x; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; ORR JW, 1994, J BIOL CHEM, V269, P27715; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Parissenti AM, 1998, J BIOL CHEM, V273, P8940, DOI 10.1074/jbc.273.15.8940; Parissenti AM, 1996, J CELL PHYSIOL, V166, P609, DOI 10.1002/(SICI)1097-4652(199603)166:3<609::AID-JCP16>3.0.CO;2-1; PARKER CA, 1994, AM J PHYSIOL-CELL PH, V267, pC1262, DOI 10.1152/ajpcell.1994.267.5.C1262; Parker CA, 1998, J PHYSIOL-LONDON, V508, P187, DOI 10.1111/j.1469-7793.1998.187br.x; Prekeris R, 1998, J BIOL CHEM, V273, P26790, DOI 10.1074/jbc.273.41.26790; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; STAFFORD WF, 1995, J BIOL CHEM, V270, P10576, DOI 10.1074/jbc.270.18.10576; TAKAHASHI K, 1991, J BIOL CHEM, V266, P13284; WILLS FL, 1993, BIOCHEMISTRY-US, V32, P2321, DOI 10.1021/bi00060a025; WINDER SJ, 1993, CELL SIGNAL, V5, P677, DOI 10.1016/0898-6568(93)90029-L; Winder SJ, 1998, ACTA PHYSIOL SCAND, V164, P415, DOI 10.1111/j.1365-201X.1998.tb10697.x	42	55	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40329	40336		10.1074/jbc.M008257200	http://dx.doi.org/10.1074/jbc.M008257200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006297	hybrid			2022-12-27	WOS:000166039500073
J	Prakobphol, A; Xu, F; Hoang, VM; Larsson, T; Bergstrom, J; Johansson, I; Frangsmyr, L; Holmskov, U; Leffler, H; Nilsson, C; Boren, T; Wright, JR; Stromberg, N; Fisher, SJ				Prakobphol, A; Xu, F; Hoang, VM; Larsson, T; Bergstrom, J; Johansson, I; Frangsmyr, L; Holmskov, U; Leffler, H; Nilsson, C; Boren, T; Wright, JR; Stromberg, N; Fisher, SJ			Salivary agglutinin, which binds Streptococcus mutans and Helicobacter pylori, is the lung scavenger receptor cysteine-rich protein gp-340	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP ANTIGENS; MEDIATED ADHERENCE; ORAL STREPTOCOCCI; MONOCLONAL-ANTIBODIES; ARTIFICIAL SALIVAS; PROMOTES ADHESION; HUMAN-ENAMEL; MUCIN; GLYCOPROTEIN; HYDROXYAPATITE	Salivary agglutinin is a high molecular mass component of human saliva that binds Streptococcus mutans, an oral bacterium implicated in dental caries. To study its protein sequence, we isolated the agglutinin from human parotid saliva. After trypsin digestion, a portion was analyzed by matrix-assisted laser/desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS), which gave the molecular mass of 14 unique peptides. The remainder of the digest was subjected to high performance liquid chromatography, and the separated peptides were analyzed by MALDI-TOF/post-source decay; the spectra gave the sequences of five peptides. The molecular mass and peptide sequence information showed that salivary agglutinin peptides were identical to sequences in lung (lavage) gp-340, a member of the scavenger receptor cysteine-rich protein family. Immunoblotting with antibodies that specifically recognized either lung gp-340 or the agglutinin confirmed that the salivary agglutinin was gp-340. Immunoblotting with an antibody specific to the sialyl Le(X) carbohydrate epitope detected expression on the salivary but not the lung glycoprotein, possible evidence of different glycoforms. The salivary agglutinin also interacted with Helicobacter pylori, implicated in gastritis and peptic ulcer disease, Streptococcus agalactiae, implicated in neonatal meningitis, and several oral commensal streptococci. These results identify the salivary agglutinin as gp-340 and suggest it binds bacteria that are important determinants of either the oral ecology or systemic diseases.	Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA; Umea Univ, Dept Odontol Cardiol & Oral Microbiol, SE-90187 Umea, Sweden; Odense Univ, Med Biol Inst, Dept Med Microbiol, DK-5000 Odense C, Denmark; Univ Gothenburg, Dept Biochem Med, SE-41390 Gothenburg, Sweden; Lund Univ, Dept Mol Med, SE-22100 Lund, Sweden; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Umea University; University of Southern Denmark; University of Gothenburg; Lund University; Duke University	Fisher, SJ (corresponding author), Univ Calif San Francisco, Dept Stomatol, HSW 604, San Francisco, CA 94143 USA.	sfisher@cgl.ucsf.edu	Holmskov, Uffe/AAA-3056-2022; Abrams, William R/A-5782-2008; Leffler, Hakon/A-2416-2019	Holmskov, Uffe/0000-0002-2391-9445; Leffler, Hakon/0000-0003-4482-8945	NCRR NIH HHS [RR01614] Funding Source: Medline; NHLBI NIH HHS [HL51134] Funding Source: Medline; NIDCR NIH HHS [DE07244] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE007244, R37DE007244] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aguirre A, 1989, Dysphagia, V4, P95, DOI 10.1007/BF02407152; ALHASHIMI I, 1989, ARCH ORAL BIOL, V34, P289, DOI 10.1016/0003-9969(89)90070-8; AZEN EA, 1988, ADV HUM GENET, V17, P141; BENNICK A, 1983, ARCH ORAL BIOL, V28, P19, DOI 10.1016/0003-9969(83)90022-5; Blaser MJ, 1997, J CLIN INVEST, V100, P759, DOI 10.1172/JCI119588; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; BRADY LJ, 1992, INFECT IMMUN, V60, P1008, DOI 10.1128/IAI.60.3.1008-1017.1992; Bratt P, 1999, J DENT RES, V78, P1238, DOI 10.1177/00220345990780060701; Carlen A, 1996, ARCH ORAL BIOL, V41, P1133, DOI 10.1016/S0003-9969(96)00094-5; CARLEN A, 1995, J DENT RES, V74, P1040, DOI 10.1177/00220345950740040301; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Dunn BE, 1997, CLIN MICROBIOL REV, V10, P720, DOI 10.1128/CMR.10.4.720; EMILSON CG, 1989, ARCH ORAL BIOL, V34, P335, DOI 10.1016/0003-9969(89)90106-4; ERICSON T, 1983, EUR J BIOCHEM, V133, P255, DOI 10.1111/j.1432-1033.1983.tb07456.x; FISHER SJ, 1987, ARCH ORAL BIOL, V32, P509, DOI 10.1016/S0003-9969(87)80013-4; GANS RF, 1990, ARCH ORAL BIOL, V35, P487, DOI 10.1016/0003-9969(90)90077-N; GILLECECASTRO BL, 1991, J BIOL CHEM, V266, P17358; Groenink J, 1996, ANTON LEEUW INT J G, V70, P79, DOI 10.1007/BF00393572; HATTON MN, 1985, BIOCHEM J, V230, P817, DOI 10.1042/bj2300817; Holmskov U, 1999, P NATL ACAD SCI USA, V96, P10794, DOI 10.1073/pnas.96.19.10794; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; KISHIMOTO E, 1989, INFECT IMMUN, V57, P3702, DOI 10.1128/IAI.57.12.3702-3707.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMONT RJ, 1991, INFECT IMMUN, V59, P3446, DOI 10.1128/IAI.59.10.3446-3450.1991; LENANDERLUMIKARI M, 1992, CARIES RES, V26, P371, DOI 10.1159/000261471; LEVINE MJ, 1993, CRIT REV ORAL BIOL M, V4, P279, DOI 10.1177/10454411930040030401; LEVINE MJ, 1987, J DENT RES, V66, P693, DOI 10.1177/00220345870660S215; MAGNUSSON I, 1976, CARIES RES, V10, P113, DOI 10.1159/000260195; MANDEL ID, 1987, J DENT RES, V66, P623, DOI 10.1177/00220345870660S203; MARSHALL BJ, 1984, LANCET, V1, P1311; MELLERSH A, 1979, BRIT J VENER DIS, V55, P20; Miyabayashi H, 2000, HELICOBACTER, V5, P30, DOI 10.1046/j.1523-5378.2000.00004.x; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; MURRAY PA, 1992, INFECT IMMUN, V60, P31, DOI 10.1128/IAI.60.1.31-38.1992; Nagashunmugam T, 1998, J INFECT DIS, V178, P1635, DOI 10.1086/314511; OBENAUF SD, 1986, INFECT IMMUN, V51, P440, DOI 10.1128/IAI.51.2.440-444.1986; Oho T, 1998, INFECT IMMUN, V66, P115, DOI 10.1128/IAI.66.1.115-121.1998; Prakobphol A, 1998, BIOCHEMISTRY-US, V37, P4916, DOI 10.1021/bi972612a; Prakobphol A, 1999, BIOCHEMISTRY-US, V38, P6817, DOI 10.1021/bi990145m; PRAKOBPHOL A, 1993, CRIT REV ORAL BIOL M, V4, P325, DOI 10.1177/10454411930040031001; SCANNAPIECO FA, 1995, J DENT RES, V74, P1360, DOI 10.1177/00220345950740070701; Spahr H, 2000, J BIOL CHEM, V275, P1351, DOI 10.1074/jbc.275.2.1351; STENUDD CD, 1999, THESIS UMEA U UMEA S; Takano K., 1992, Okajimas Folia Anatomica Japonica, V69, P225; Tenovuo J, 1992, J Biol Buccale, V20, P85; Tino MJ, 1999, AM J RESP CELL MOL, V20, P759, DOI 10.1165/ajrcmb.20.4.3439; VANDERSPEK JC, 1989, AM J HUM GENET, V45, P381	48	186	191	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39860	39866		10.1074/jbc.M006928200	http://dx.doi.org/10.1074/jbc.M006928200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007786	hybrid			2022-12-27	WOS:000166039500012
J	Zhu, JH; Zhang, SZ; Jiang, JY; Chen, XB				Zhu, JH; Zhang, SZ; Jiang, JY; Chen, XB			Definition of the p53 functional domains necessary for inducing apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR-SUPPRESSOR P53; DNA-BINDING FUNCTION; CELL-CYCLE ARREST; C-TERMINAL DOMAIN; TRANSCRIPTIONAL ACTIVATION; PROTEOLYTIC CLEAVAGE; GROWTH SUPPRESSION; MUTANT P53; P53-MEDIATED APOPTOSIS	The p53 protein contains several functional domains necessary for inducing cell cycle arrest and apoptosis. The C-terminal basic domain within residues 364-393 and the proline-rich domain within residues 64-91 are required for apoptotic activity. In addition, activation domain 2 within residues 43-63 is necessary for apoptotic activity when the N-terminal activation domain 1 within residues 1-42 is deleted (Delta AD1) or mutated (AD1(-)). Here we have discovered that an activation domain 2 mutation at residues 53-54 (AD2(-)) abrogates the apoptotic activity but has no significant effect on cell cycle arrest. We have also found that p53-(Delta AD2), which lacks activation domain 2, is inert in inducing apoptosis. p53-(AD2(-)Delta BD), which is defective in activation domain 2 and lacks the C-terminal basic domain, p53-(Delta AD2 Delta BD), which lacks both activation domain 2 and the C-terminal basic domain, and p53-(Delta PRD Delta BD), which lacks both the proline-rich domain and the C-terminal basic domain, are also inert in inducing apoptosis. All four mutants are still capable of inducing cell cycle arrest, albeit to a lesser extent than wild-type p53. Interestingly, we have found that deletion of the N-terminal activation domain 1 alleviates the requirement of the C-terminal basic domain for apoptotic activity. Thus, we have generated a small but potent p53-(Delta AD1 Delta BD) molecule. Furthermore, we have determined that at least two of the three domains (activation domain 1, activation domain 2, and the proline-rich domain), are required for inducing cell cycle arrest. Taken together, our results suggest that activation domain 2 and the proline-rich domain form an activation domain for inducing pro-apoptotic genes or inhibiting antiapoptotic genes. The C-terminal basic domain is required for maintaining this activation domain competent for transactivation or transrepression.	Med Coll Georgia, Inst Mol Biol & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Biol & Genet, CB-2803, Augusta, GA 30912 USA.				NATIONAL CANCER INSTITUTE [R29CA076069, R01CA076069] Funding Source: NIH RePORTER; NCI NIH HHS [CA76069] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; Chen J, 1996, ONCOGENE, V13, P1395; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; CHEN YQ, 1995, CANCER RES, V55, P4536; Clayman GL, 1998, J CLIN ONCOL, V16, P2221, DOI 10.1200/JCO.1998.16.6.2221; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu L, 1999, MOL CELL BIOL, V19, P1202; Mee T, 1999, BRIT J CANCER, V81, P212, DOI 10.1038/sj.bjc.6690679; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Molinari M, 1996, ONCOGENE, V13, P2077; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Okorokov AL, 1997, ONCOL RES, V9, P267; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sekiguchi T, 1998, ONCOGENE, V16, P369, DOI 10.1038/sj.onc.1201539; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zhou XL, 1999, CANCER RES, V59, P843; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	65	95	100	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39927	39934		10.1074/jbc.M005676200	http://dx.doi.org/10.1074/jbc.M005676200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10982799	hybrid			2022-12-27	WOS:000166039500021
J	Lancaster, CRD; Bibikova, MV; Sabatino, P; Oesterhelt, D; Michel, H				Lancaster, CRD; Bibikova, MV; Sabatino, P; Oesterhelt, D; Michel, H			Structural basis of the drastically increased initial electron transfer rate in the reaction center from a Rhodopseudomonas viridis mutant described at 2.00-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION-CENTER; MEMBRANE-PROTEIN COMPLEX; CRYSTAL-STRUCTURES; CHARGE SEPARATION; PURPLE BACTERIA; MODEL; SPECTROSCOPY; MOLSCRIPT; REFINEMENT; QUINONE	It has previously been shown that replacement of the residue His L168 with Phe (HL168F) in the Rhodopseudomonas viridis reaction center (RC) leads to an unprecedented drastic acceleration of the initial electron transfer rate. Here we describe the determination of the x-ray crystal structure at 2.00-Angstrom resolution of the HL168F RC. The electron density maps confirm that a hydrogen bond from the protein to the special pair is removed by this mutation. Compared with the wild-type RC, the acceptor of this hydrogen bond, the ring I acetyl group of the "special pair" bacteriochlorophyll, D-L, is rotated, and its acetyl oxygen is found 1.1 Angstrom closer to the bacteriochlorophyll-Mg2+ Of the other special pair bacteriochlorophyll, D-M. The rotation of this acetyl group and the increased interaction between the D-L ring I acetyl oxygen and the D-M-Mg2+ provide the structural basis for the previously observed 80-mV decrease in the D+/D redox potential and the drastically increased rate of initial electron transfer to the accessory bacteriochlorophyll, B-A The high quality of the electron density maps also allowed a reliable discussion of the mode of binding of the triazine herbicide terbutryn at the binding site of the secondary quinone, Q(B).	Max Planck Inst Biophys, Abt Mol Membranbiol, D-60528 Frankfurt, Germany; Max Planck Inst Biochem, Abt Membranbiochem, D-82152 Martinsried, Germany	Max Planck Society; Max Planck Society	Lancaster, CRD (corresponding author), Max Planck Inst Biophys, Abt Mol Membranbiol, Heinrich Hoffmann Str 7, D-60528 Frankfurt, Germany.	Roy.Lancaster@mpibp-frankfurt.mpg.de	Lancaster, C. Roy/E-4313-2010	Lancaster, C. Roy D./0000-0002-2814-0051				Arlt T, 1996, J PHYS CHEM-US, V100, P12060, DOI 10.1021/jp960699o; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BIXON M, 1991, BIOCHIM BIOPHYS ACTA, V1056, P301, DOI 10.1016/S0005-2728(05)80062-3; BLANKENSHIP RE, 1995, ANOXYGENIC PHOTOSYNT; Bowyer J. R., 1991, Herbicides., P27; Breton J, 1998, PHOTOSYNTH RES, V55, P117; BRETON J, 1986, P NATL ACAD SCI USA, V83, P5121, DOI 10.1073/pnas.83.14.5121; BRUNGER AT, 1991, ANNU REV PHYS CHEM, V42, P197, DOI 10.1146/annurev.pc.42.100191.001213; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V726, P149, DOI 10.1016/0304-4173(83)90004-6; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x; DEISENHOFER J, 1995, J MOL BIOL, V246, P429, DOI 10.1006/jmbi.1994.0097; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; DRESSLER K, 1991, CHEM PHYS LETT, V183, P270, DOI 10.1016/0009-2614(91)80062-3; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; HEARST JE, 1986, PHOTOSYNTHESIS, V3, P382; Hiraishi A, 1997, INT J SYST BACTERIOL, V47, P217, DOI 10.1099/00207713-47-1-217; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; Hoff AJ, 1997, PHYS REP, V287, P1, DOI 10.1016/S0370-1573(97)00004-5; JEFFREY GA, 1991, HYDROGEN BONDING BIO, P372; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNAFF DB, 1993, PHOTOSYNTH RES, V35, P117, DOI 10.1007/BF00014743; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lancaster C. R. D., 1995, ANOXYGENIC PHOTOSYNT, P503; Lancaster CRD, 1999, J MOL BIOL, V286, P883, DOI 10.1006/jmbi.1998.2532; Lancaster CRD, 1997, STRUCTURE, V5, P1339, DOI 10.1016/S0969-2126(97)00285-2; Lancaster CRD, 1996, BIOPHYS J, V70, P2469, DOI 10.1016/S0006-3495(96)79820-X; Lancaster CRD, 1998, BBA-BIOENERGETICS, V1365, P143; MCPHERSON PH, 1990, BIOCHIM BIOPHYS ACTA, V1016, P289, DOI 10.1016/0005-2728(90)90071-B; MEYER E, 1992, PROTEIN SCI, V1, P1543, DOI 10.1002/pro.5560011203; Meyer TE, 1995, ANOXYGENIC PHOTOSYNT, P725; MICHEL H, 1985, EMBO J, V4, P1667, DOI 10.1002/j.1460-2075.1985.tb03835.x; MICHEL H, 1982, J MOL BIOL, V158, P567, DOI 10.1016/0022-2836(82)90216-9; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MICHEL H, 1986, ENCY PLANT PHYSL PHO, V19, P371; Michel-Beyerle M. E., 1996, REACTION CTR PHOTOSY; MITCHELL P, 1979, SCIENCE, V206, P1148, DOI 10.1126/science.388618; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parson William W., 1996, P125; Percival M. P., 1991, Herbicides., P1; SINNING I, 1989, BIOCHEMISTRY-US, V28, P5544, DOI 10.1021/bi00439a031; Sinning I, 1990, REACTION CTR PHOTOSY, P199; THORNBER JP, 1980, BIOCHIM BIOPHYS ACTA, V593, P60, DOI 10.1016/0005-2728(80)90008-0; TREBST A, 1986, Z NATURFORSCH C, V41, P240; TREBST A, 1987, Z NATURFORSCH C, V42, P742; WILLIAMS JC, 1992, BIOCHEMISTRY-US, V31, P11029, DOI 10.1021/bi00160a012; Woodbury NW, 1995, ANOXYGENIC PHOTOSYNT, P527, DOI [DOI 10.1007/0-306-47954-0_24, 10.1007/0-306-47954-0_24]; WRAIGHT CA, 1982, FUNCTIONS QUINONES E, P181; Zinth W, 1998, PHILOS T R SOC A, V356, P465, DOI 10.1098/rsta.1998.0176	55	59	64	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39364	39368		10.1074/jbc.M008225200	http://dx.doi.org/10.1074/jbc.M008225200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11005826	hybrid			2022-12-27	WOS:000165953100059
J	Marron, MB; Hughes, DP; Edge, MD; Forder, CL; Brindle, NPJ				Marron, MB; Hughes, DP; Edge, MD; Forder, CL; Brindle, NPJ			Evidence for heterotypic interaction between the receptor tyrosine kinases TIE-1 and TIE-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; VASCULAR ENDOTHELIAL-CELLS; MOLECULAR-CLONING; SURFACE-RECEPTOR; SOLUBLE TIE; PROTEIN; EXPRESSION; ANGIOPOIETIN-1; ANGIOGENESIS; SURVIVAL	The orphan receptor tyrosine kinase Tie-1 is expressed in endothelial cells and is essential for vascular development, Nothing is known about the signaling pathways utilized by this receptor. In this study we have used chimeric receptors composed of the TrkA ectodomain fused to the transmembrane and intracellular domains of Tie-1, or the related receptor Tie-2, to examine Tie-1 signaling capacity. In contrast to TrkA/Tie-2, the Tie-1 chimera was unable to phosphorylate cellular proteins or undergo autophosphorylation, Consistent with this Tie-1 exhibited negligible kinase activity, Co-immunoprecipitation analysis revealed Tie-1 was present in endothelial cells bound to Tie-2, Full-length Tie-1 and truncated receptor, formed by regulated endoproteolytic cleavage, were found to complex with Tie-2. Association was mediated by the intracellular domains of the receptors and did not require Tie-1 to be membrane-localized, Tie-1 bound to Tie-2 was not tyrosine-phosphorylated under basal conditions or following Tie-2 stimulation. This study provides the first evidence for the existence of a pre-formed complex of Tie-1 and Tie-2 in endothelial cells. The data suggest Tie-1 does not signal via ligand-induced kinase activation involving homo-oligomerization. The physical association between Tie-1 and Tie-2 is consistent with Tie-1 having a role in modulating Tie-2 signaling.	Univ Leicester, RKCSB, Dept Surg, Leicester LE2 7LX, Leics, England; AstraZeneca, Canc & Infect Biosci Dept, Macclesfield SK10 4TG, Cheshire, England	University of Leicester; AstraZeneca	Brindle, NPJ (corresponding author), Univ Leicester, RKCSB, Dept Surg, POB 65, Leicester LE2 7LX, Leics, England.	npjb1@leicester.ac.uk		Brindle, Nicholas/0000-0002-4221-677X				BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; DUMONT DJ, 1992, ONCOGENE, V7, P71; Glazebrook H, 1998, J VASC RES, V35, P143, DOI 10.1159/000025577; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HACK N, 1993, J BIOL CHEM, V268, P26441; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hayes AJ, 1999, MICROVASC RES, V58, P224, DOI 10.1006/mvre.1999.2179; HERBST R, 1991, J BIOL CHEM, V266, P19908; HUANG LW, 1995, ONCOGENE, V11, P2097; Huttelmaier S, 1999, FEBS LETT, V451, P68, DOI 10.1016/S0014-5793(99)00546-3; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; Katso RM, 1999, MOL CELL BIOL, V19, P6427; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kim I, 1999, FEBS LETT, V443, P353, DOI 10.1016/S0014-5793(99)00008-3; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MATTHEWS JA, 1985, ANAL BIOCHEM, V151, P205, DOI 10.1016/0003-2697(85)90073-9; McCarthy MJ, 1999, LAB INVEST, V79, P889; Mezquita J, 1999, BIOCHEM BIOPH RES CO, V260, P492, DOI 10.1006/bbrc.1999.0934; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Papapetropoulos A, 1999, LAB INVEST, V79, P213; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; Patan S, 1998, MICROVASC RES, V56, P1, DOI 10.1006/mvre.1998.2081; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; RUNTING AS, 1993, GROWTH FACTORS, V9, P99; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Sierke SL, 1997, BIOCHEM J, V322, P757, DOI 10.1042/bj3220757; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; Tallquist MD, 1999, ONCOGENE, V18, P7917, DOI 10.1038/sj.onc.1203216; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Yabkowitz R, 1999, BLOOD, V93, P1969, DOI 10.1182/blood.V93.6.1969.406k14_1969_1979; Yabkowitz R, 1997, BLOOD, V90, P706, DOI 10.1182/blood.V90.2.706.706_706_715; ZIEGLER SF, 1993, ONCOGENE, V8, P663	55	63	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39741	39746		10.1074/jbc.M007189200	http://dx.doi.org/10.1074/jbc.M007189200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995770	hybrid			2022-12-27	WOS:000165953100104
J	Nyborg, AC; Johnson, JL; Gunn, A; Watt, GD				Nyborg, AC; Johnson, JL; Gunn, A; Watt, GD			Evidence for a two-electron transfer using the all-ferrous Fe protein during nitrogenase catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII NITROGENASE; IRON PROTEIN; KLEBSIELLA-PNEUMONIAE; FE4S4 CLUSTER; COMPONENT; MOLYBDENUM; COMPLEX; STATE; HYDROLYSIS; MECHANISM	The nitrogenase catalyzed H-2 evolution and acetylene-reduction reactions using Ti(III) and dithionite (DT) as reductants were examined and compared under a variety of conditions. Ti(III) is known to make the all-ferrous Fe protein ([Fe4S4](0)) and lowers the amount of ATP hydrolyzed during nitrogenase catalysis by approximately a-fold. Here we further investigate this behavior and present results consistent with the Pe protein in the [Fe4S4](0) redox state transferring two electrons ([Fe4S4](2+)/[Fe4S4](0)) per MoFe protein interaction using Ti(III) but transferring only one electron ([Fe4S4](2+)/[Fe4S4](1+)) using DT, MoFe protein specific activity was measured as a function of Fe:MoFe protein ratio for both a one- and a two-electron transfer reaction, and nearly identical curves were obtained. However, Fe protein specific activity curves as a function of MoFe:Pe protein ratio showed two distinct reactivity patterns. With DT as reductant, typical MoFe inhibition curves were obtained for operation of the [Fe4S4](2+)/ [Fe4S4](1+) redox couple, but with Ti(III) as reductant the [Fe4S4](2+)/[Fe4S4](0) redox couple was functional and MoFe inhibition was not observed at high MoFe:Fe protein ratios. With Ti(III) as reductant, nitrogenase catalysis produced hyperbolic curves, yielding a V-max for the Fe protein specific activity of about 3200 nmol of H-2 min(-1) mg(-1) Fe protein, significantly higher than for reactions conducted with DT as reductant, Lag phase experiments (Hageman, R. V., and Burris, R. H. (1978) Proc. Natl. Acad. Sci. U. S. A. 75, 2699-2702) were carried out at MoFe:Fe protein ratios of 100 and 300 using both DT and Ti(III). A lag phase was observed for DT but, with Ti(III) product formation, began immediately and remained linear for over 30 min. Activity measurements using Av-Cp heterologous crosses were examined using both DT and Ti(III) as reductants to compare the reactivity of the [Fe4S4](2+)/[Fe4S4](1+) and [Fe4S4](2+)/ [Fe4S4](0) redox couples and both were inactive. The results are discussed in terms of the Fe protein transferring two electrons per MoFe protein encounter using the [Fe4S4,](2+)/[Fe4S4](0) redox couple with Ti(III) as reductant.	Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84604 USA; Brigham Young Univ, Undergrad Res Program, Provo, UT 84604 USA	Brigham Young University; Brigham Young University	Watt, GD (corresponding author), Brigham Young Univ, Dept Chem & Biochem, C-100 BNSN Bldg, Provo, UT 84604 USA.			Gunn, Alexander/0000-0002-1018-454X				Angove HC, 1998, J BIOL CHEM, V273, P26330, DOI 10.1074/jbc.273.41.26330; Angove HC, 1997, J AM CHEM SOC, V119, P8730, DOI 10.1021/ja9712837; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; DAESCH G, 1968, J BACTERIOL, V96, P346, DOI 10.1128/JB.96.2.346-351.1968; DALTON H, 1969, J GEN MICROBIOL, V56, P307, DOI 10.1099/00221287-56-3-307; DETROY RW, 1968, P NATL ACAD SCI USA, V61, P537, DOI 10.1073/pnas.61.2.537; EMERICH DW, 1976, P NATL ACAD SCI USA, V73, P4369, DOI 10.1073/pnas.73.12.4369; Erickson JA, 1999, BIOCHEMISTRY-US, V38, P14279, DOI 10.1021/bi991389+; Fiske CH, 1925, J BIOL CHEM, V66, P375; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HAGEMAN RV, 1980, BIOCHEMISTRY-US, V19, P2333, DOI 10.1021/bi00552a009; HAGEMAN RV, 1979, J BIOL CHEM, V254, P1189; Johnson JL, 2000, BBA-PROTEIN STRUCT M, V1543, P24, DOI 10.1016/S0167-4838(00)00195-3; Johnson JL, 2000, BBA-PROTEIN STRUCT M, V1543, P36, DOI 10.1016/S0167-4838(00)00196-5; Johnson JL, 1996, BIOCHEMISTRY-US, V35, P11336, DOI 10.1021/bi952581o; KIM J, 1994, BIOCHEMISTRY-US, V33, P389, DOI 10.1021/bi00168a001; Lanzilotta WN, 1996, BIOCHEMISTRY-US, V35, P7188, DOI 10.1021/bi9603985; MORTENSON LE, 1976, P 1 INT S NITR FIX, V1, P117; NYBORG AC, 2000, J INORG BIOCH; Orme-Johnson W. H., 1977, Recent developments in nitrogen fixation., P131; ORMEJOHNSON WH, 1977, IRON SULFUR PROTEINS, V3, P15; POSTGATE JR, 1971, CHEM BIOCH NITROGEN; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; SILVERST.R, 1970, BIOCHEMISTRY-US, V9, P3809, DOI 10.1021/bi00821a021; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; SORGER GJ, 1971, BIOCHEM J, V122, P305, DOI 10.1042/bj1220305; Thorneley R. N. F., 1985, MOLYBDENUM ENZYMES, P221; THORNELEY RNF, 1975, BIOCHIM BIOPHYS ACTA, V403, P269, DOI 10.1016/0005-2744(75)90057-1; THORNELEY RNF, 1984, BIOCHEM J, V224, P903, DOI 10.1042/bj2240903; WATT GD, 1994, J INORG BIOCHEM, V53, P281, DOI 10.1016/0162-0134(94)85115-8; WATT GD, 1986, BIOCHEMISTRY-US, V25, P8156, DOI 10.1021/bi00373a005; ZUMFT WG, 1975, BIOCHIM BIOPHYS ACTA, V416, P1, DOI 10.1016/0304-4173(75)90012-9	33	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39307	39312		10.1074/jbc.M007069200	http://dx.doi.org/10.1074/jbc.M007069200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11005818	hybrid			2022-12-27	WOS:000165953100051
J	Previs, SF; Withers, DJ; Ren, JM; White, MF; Shulman, GI				Previs, SF; Withers, DJ; Ren, JM; White, MF; Shulman, GI			Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR SUBSTRATE FAMILY; INSULIN-RESISTANCE; PHOSPHOTYROSINE PROTEIN; SIGNALING SYSTEM; MICE; MEMBER; GROWTH	To examine the impact of homozygous genetic disruption of insulin receptor substrate (IRS)-1 (IRS-1(-/-)) or IRS-S (IRS-2(-/-)) on basal and insulin-stimulated carbohydrate and lipid metabolism in vivo, we infused 18-h fasted mice (wild-type (WT), IRS-1(-/-), and IRS-2(-/-)) with [3-H-3]glucose and [H-2(5)]glycerol and assessed rates of glucose and glycerol turnover under basal (0-90 min) and hyperinsulinemic-euglycemic clamp (90-210 min; 5 mM glucose, and 5 milliunits of insulin kg(-1).min(-1)) conditions. Both IRS-1(-/-) and IRS-2(-/-) mice were insulin-resistant as reflected by markedly impaired insulin-stimulated whole-body glucose utilization compared with WT mice. Insulin resistance in the IRS-1(-/-) mice could be ascribed mainly to decreased insulin-stimulated peripheral glucose metabolism. In contrast, IRS-2(-/-) mice displayed multiple defects in insulin-mediated carbohydrate metabolism as reflected by (i) decreased peripheral glucose utilization, (ii) decreased suppression of endogenous glucose production, and (iii) decreased hepatic glycogen synthesis. Additionally, IRS-2(-/-) mice also showed marked insulin resistance in adipose tissue as reflected by reduced suppression of plasma free fatty acid concentrations and glycerol turnover during the hyperinsulinemic-euglycemic clamp. These data suggest important tissue-specific roles for IRS-1 and IRS-2 in mediating the effect of insulin on carbohydrate and Lipid metabolism in vivo in mice. IRS-1 appears to have its major role in muscle, whereas IRS-2 appears to impact on liver, muscle, and adipose tissue.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06536 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Joslin Diabet Ctr,Dept Biochem, Boston, MA 02215 USA	Howard Hughes Medical Institute; Yale University; Yale University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute	Shulman, GI (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 295 C Ave,POB 9812, New Haven, CT 06536 USA.		Withers, Dominic J/D-7671-2014; Shulman, Gerald I./P-7176-2019	Withers, Dominic J/0000-0002-8009-7521; Shulman, Gerald I./0000-0003-1529-5668	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK045735, R01DK040936] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK040936, R01 DK-40936, P30 DK-45735] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Bergman RN, 1997, RECENT PROG HORM RES, V52, P359; DeFronzo RA, 1997, DIABETES REV, V5, P177; Fantin VR, 2000, AM J PHYSIOL-ENDOC M, V278, pE127, DOI 10.1152/ajpendo.2000.278.1.E127; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Higaki Y, 1999, J BIOL CHEM, V274, P20791, DOI 10.1074/jbc.274.30.20791; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kim JK, 2000, J BIOL CHEM, V275, P8456, DOI 10.1074/jbc.275.12.8456; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Liu SCH, 1999, J BIOL CHEM, V274, P18093, DOI 10.1074/jbc.274.25.18093; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; Shen HQ, 1999, METABOLISM, V48, P965, DOI 10.1016/S0026-0495(99)90191-9; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; WALAAS O, 1950, J BIOL CHEM, V187, P769; WHITE MF, 1994, J BIOL CHEM, V269, P1; White MF, 1998, CURR TOP MICROBIOL, V228, P179; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074	24	215	227	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					38990	38994		10.1074/jbc.M006490200	http://dx.doi.org/10.1074/jbc.M006490200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995761	hybrid			2022-12-27	WOS:000165953100008
J	Zhang, W; Ou, JW; Inagaki, Y; Greenwel, P; Ramirez, F				Zhang, W; Ou, JW; Inagaki, Y; Greenwel, P; Ramirez, F			Synergistic cooperation between Sp1 and Smad3/Smad4 mediates transforming growth factor beta 1 stimulation of alpha 2(I)-collagen (COL1A2) transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR-1 PROMOTER; TGF-BETA; GENE-EXPRESSION; COLLAGEN GENE; SMAD PROTEINS; INDUCIBLE ELEMENTS; RESPONSIVE ELEMENT; DIRECT BINDING; C/EBP-BETA; RECEPTOR	Transforming growth factor-beta1 (TGF beta) is a strong activator of extracellular matrix accumulation. TG;FP stimulates the gene coding for human alpha2(I)-collagen (COL1A2) by inducing binding of an Sp1-containing complex to an upstream promoter element (TGF beta responsive element or TbRE) that contains a CAGA box. Here we report that the CAGA box of the TbRE is the binding site of the Smad3/Smad4 complex, and that the binding of the complex is required for TGF beta -induced COL1A2 up-regulation. Recombinant Smad3 and Smad4 bind in vitro to the CAGA box of COL1A2; TGF beta treatment of cultured fibroblasts induces Smad3/Smad4 binding to the TbRE; transient overexpression of Smad3 and Smad4 in fibroblasts transactivates TbRE-driven transcription; and COL1A2 gene up-regulation by TGF beta is abolished in cells stably transfected with plasmids that express dominant negative forms of Smad3 or Smad4. In Sp1-deficient Drosophila Schneider cells, there was cooperative synergy between Smad3/Smad4 and Sp1 at the TbRE site. The analysis also emphasized the requirement of both Sp1- and Smad-binding sites for optimal promoter transactivation. In cells stably transfected with a plasmid expressing a dominant negative form of Sp1, the synergy was shown to be promoter-specific and dependent on the binding of Sp1 to the TbRE. Interestingly, overexpression of dominant negative Sp1 was found to block the antagonistic signal of tumor necrosis factor-alpha on COL1A2 transcription, as well. These results provide the first linkage between the Smad3 and Smad4 proteins and TGF beta stimulation of type I collagen biosynthesis.	NYU, Mt Sinai Sch Med, Dept Biochem & Mol Biol, Brookdale Ctr, New York, NY 10029 USA; Natl Kanazawa Hosp, Dept Internal Med, Kanazawa, Ishikawa 9208650, Japan; Natl Kanazawa Hosp, Clin Res Inst, Kanazawa, Ishikawa 9208650, Japan	Icahn School of Medicine at Mount Sinai; New York University	Ramirez, F (corresponding author), NYU, Mt Sinai Sch Med, Dept Biochem & Mol Biol, Brookdale Ctr, 1 Gustave L Levy Pl, New York, NY 10029 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012196] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA12196] Funding Source: Medline; NIAMS NIH HHS [AR-386481] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Bitzer M, 2000, GENE DEV, V14, P187; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DIEGELMANN RF, 1988, COLLAGEN BIOCH BIOME, V2, P113; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; GREENWEL P, 1995, MOL CELL BIOL, V15, P6813; Greenwel P, 2000, MOL CELL BIOL, V20, P912, DOI 10.1128/MCB.20.3.912-918.2000; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hay E.D., 1991, CELL BIOL EXTRACELLU, P419; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; Johnson K, 1999, J BIOL CHEM, V274, P20709, DOI 10.1074/jbc.274.29.20709; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, GENE DEV, V14, P627; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; NEHLS MC, 1992, DNA CELL BIOL, V11, P443, DOI 10.1089/dna.1992.11.443; NIEDERREITHER K, 1992, J CELL BIOL, V119, P1361, DOI 10.1083/jcb.119.5.1361; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Raftery LA, 1999, DEV BIOL, V210, P251, DOI 10.1006/dbio.1999.9282; Sambrook J., 1983, MOL CLONING LAB MANU; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; VANDERREST M, 1991, FASEB J, V5, P1814; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; Yanagi Y, 1999, J BIOL CHEM, V274, P12971, DOI 10.1074/jbc.274.19.12971; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	47	195	201	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39237	39245		10.1074/jbc.M003339200	http://dx.doi.org/10.1074/jbc.M003339200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11007770	hybrid			2022-12-27	WOS:000165953100041
J	Salter, JP; Lim, KC; Hansell, E; Hsieh, I; McKerrow, JH				Salter, JP; Lim, KC; Hansell, E; Hsieh, I; McKerrow, JH			Schistosome invasion of human skin and degradation of dermal elastin are mediated by a single serine protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANSONI; CERCARIAE; PROTEINASE; PENETRATION; PARASITE; ENZYMES; TISSUE; LARVAE	Aquatic larvae (cercariae) of the trematode parasite Schistosoma mansoni rapidly penetrate human skin by degrading host proteins including elastin, Two serine proteases, one chymotrypsin-like and the second trypsin-like, have been proposed to be involved. To evaluate the relative roles of these two proteases in larval invasion, both were purified, identified by sequence, and then biochemically characterized. The trypsin-like activity was resolved into two distinct serine proteases 76% similar in predicted amino acid sequence, Southern blot analysis, genomic polymerase chain reaction, and immunolocalization demonstrated that the trypsin-like proteases are in fact not from the schistosome, but are released with larvae from the snail host Biomphalaria glabrata, Invasion inhibition assays using selective inhibitors confirmed that the chymotrypsin-like protease is the enzyme involved in skin penetration. Its ability to degrade skin elastin was confirmed, and the three sites of cleavage within elastin help define a new family of elastases.	Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Biomed Sci Grad Program, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	McKerrow, JH (corresponding author), Univ Calif San Francisco, Dept Pathol, 4150 Clement St,113-B, San Francisco, CA 94121 USA.	jmck@cgl.ucsf.edu						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; COHEN FE, 1991, BIOCHEMISTRY-US, V30, P11221, DOI 10.1021/bi00111a005; COHEN LM, 1980, J PARASITOL, V66, P362, DOI 10.2307/3280843; Dalton JP, 1997, PARASITOLOGY, V114, P105, DOI 10.1017/S003118209600830X; DRESDEN MH, 1972, BIOCHIM BIOPHYS ACTA, V289, P378, DOI 10.1016/0005-2744(72)90089-7; Fukuyama K, 1983, Curr Probl Dermatol, V11, P185; GAZZINEL.A, 1964, J PARASITOL, V50, P591, DOI 10.2307/3275632; GORDON RM, 1951, ANN TROP MED PARASIT, V45, P227, DOI 10.1080/00034983.1951.11685493; Haas W, 1997, J PARASITOL, V83, P1079, DOI 10.2307/3284366; LEWERT RM, 1956, J INFECT DIS, V99, P1, DOI 10.1093/infdis/99.1.1; Lim KC, 1999, AM J TROP MED HYG, V60, P487, DOI 10.4269/ajtmh.1999.60.487; MCKERROW JH, 1985, BIOCHEM J, V231, P47, DOI 10.1042/bj2310047; MCKERROW JH, 1985, J BIOL CHEM, V260, P3703; Mecham RP, 1997, J BIOL CHEM, V272, P18071, DOI 10.1074/jbc.272.29.18071; MISHKIN EM, 1986, J PARASITOL, V72, P885, DOI 10.2307/3281840; NEWPORT GR, 1988, J BIOL CHEM, V263, P13179; RAJU K, 1987, J BIOL CHEM, V262, P5755; RING CS, 1993, P NATL ACAD SCI USA, V90, P3583, DOI 10.1073/pnas.90.8.3583; Stirewalt M.A., 1974, Advances Parasit, V12, P115, DOI 10.1016/S0065-308X(08)60388-7; STIREWALT MA, 1974, EXP PARASITOL, V35, P1, DOI 10.1016/0014-4894(74)90002-2; STIREWALT MA, 1973, J PARASITOL, V59, P741, DOI 10.2307/3278879; STIREWALT MA, 1956, J PARASITOL, V42, P565, DOI 10.2307/3274873; TZENG S, 1983, J PARASITOL, V69, P992, DOI 10.2307/3281072	23	83	86	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38667	38673		10.1074/jbc.M006997200	http://dx.doi.org/10.1074/jbc.M006997200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10993899	hybrid			2022-12-27	WOS:000165739800072
J	Lin, CY; Huang, PH; Liao, WL; Cheng, HJ; Huang, CF; Kuo, JC; Patton, WA; Massenburg, D; Moss, J; Lee, FJS				Lin, CY; Huang, PH; Liao, WL; Cheng, HJ; Huang, CF; Kuo, JC; Patton, WA; Massenburg, D; Moss, J; Lee, FJS			ARL4, an ARF-like protein that is developmentally regulated and localized to nuclei and nucleoli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; SACCHAROMYCES-CEREVISIAE; CHOLERA-TOXIN; DIFFERENTIAL EXPRESSION; BINDING-PROTEINS; PHOSPHOLIPASE-D; CELLS; FAMILY; IDENTIFICATION; SEGMENTATION	ADP-ribosylation factors (ARFs) are highly conserved similar to 20-kDa guanine nucleotide-binding proteins that participate in both exocytic and endocytic vesicular transport pathways via mechanisms that are only partially understood. Although several ARF-like proteins (ARLs) are known, their biological functions remain unclear. To characterize its molecular properties, we cloned mouse and human ARL4 (mARL4 and hARL4) cDNA. The appearance of mouse ARL4 mRNA during embryonic development coincided temporally with the sequential formation of somites and the establishment of brain compartmentation. Using ARL4-specific antibody for immunofluorescence microscopy, we observed that endogenous mARL4 in cultured Sertoli and neuroblastoma cells was mainly concentrated in nuclei. When expressed in COS7 cells, ARL4-T34N mutant, predicted to exist with GDP bound, was concentrated in nucleoli. Yeast two-hybrid screening and in vitro protein-interaction assays showed that hARL4 interacted with importin-alpha through its C-terminal NLS region and that the interaction was not nucleotide-dependent. Like ARL2 and -3, recombinant hARL4 did not enhance cholera toxin-catalyzed auto-ADP-ribosylation. Its binding of guanosine 5'-O-(thiotriphosphate) was modified by phospholipid and detergent, and the N terminus of hARL4, like that of ARF, was myristoylated. Our findings suggest that ARL4, with its distinctive nuclear/nucleolar localization and pattern of developmental expression, may play a unique role(s) in neurogenesis and somitogenesis during embryonic development and in the early stages of spermatogenesis in adults.	Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Pathol, Taipei, Taiwan; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Taiwan University; National Taiwan University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Lee, FJS (corresponding author), 7 Chung Shan S Rd, Taipei, Taiwan.		Cheng, Hwai-Jong/AAY-5067-2021	Cheng, Hwai-Jong/0000-0003-0647-0567; HUANG, PEI-HSIN/0000-0002-2414-1487; LEE, FANG-JEN/0000-0002-2167-2426	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000638] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; CARSON DD, 1984, J BIOL CHEM, V259, P3117; CAVENAGH MM, 1994, J BIOL CHEM, V269, P18937; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; CONLON RA, 1995, DEVELOPMENT, V121, P1533; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DASCHER C, 1994, J BIOL CHEM, V269, P1437; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Durbin L, 1998, GENE DEV, V12, P3096, DOI 10.1101/gad.12.19.3096; Gant TM, 1997, ANNU REV CELL DEV BI, V13, P669, DOI 10.1146/annurev.cellbio.13.1.669; Gant TM, 1997, EUR J CELL BIOL, V74, P10; Garcia SN, 1999, CELL, V97, P825, DOI 10.1016/S0092-8674(00)80794-1; Harlow E., 1988, ANTIBODIES LAB MANUA; HAUN RS, 1993, J BIOL CHEM, V268, P7064; Heald R, 2000, TRENDS CELL BIOL, V10, P1, DOI 10.1016/S0962-8924(99)01691-8; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hong JX, 1998, J BIOL CHEM, V273, P15872, DOI 10.1074/jbc.273.25.15872; HONG JX, 1994, J BIOL CHEM, V269, P9743; Huang CF, 1999, J BIOL CHEM, V274, P3819, DOI 10.1074/jbc.274.6.3819; INO H, 1993, BRAIN RES, V614, P131, DOI 10.1016/0006-8993(93)91026-O; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; Jacobs S, 1998, BIOCHEM J, V335, P259, DOI 10.1042/bj3350259; Jacobs S, 1999, FEBS LETT, V456, P384, DOI 10.1016/S0014-5793(99)00759-0; LEE FJS, 1994, J BIOL CHEM, V269, P20931; Lee FJS, 1997, J BIOL CHEM, V272, P30998, DOI 10.1074/jbc.272.49.30998; Lowe SL, 1996, J CELL SCI, V109, P209; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; NORTHUP JK, 1983, J BIOL CHEM, V258, P1361; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Palmeirim I, 1997, CELL, V91, P639, DOI 10.1016/S0092-8674(00)80451-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHURMANN A, 1994, J BIOL CHEM, V269, P15683; Visintin R, 2000, CURR OPIN CELL BIOL, V12, P372, DOI 10.1016/S0955-0674(00)00102-2; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Yang CZ, 1998, J BIOL CHEM, V273, P4006, DOI 10.1074/jbc.273.7.4006; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21	42	41	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37815	37823		10.1074/jbc.M002470200	http://dx.doi.org/10.1074/jbc.M002470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10980193	hybrid			2022-12-27	WOS:000165618700069
J	Menshikova, EV; Cheong, EJ; Salama, G				Menshikova, EV; Cheong, EJ; Salama, G			Low N-ethylmaleimide concentrations activate ryanodine receptors by a reversible interaction, not an alkylation of critical thiols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; CARDIAC SARCOPLASMIC-RETICULUM; NITRIC-OXIDE PROTECTS; TRIGGER CA-2+ RELEASE; SKELETAL-MUSCLE; SINGLE-CHANNEL; INHIBITION; ATPASE; AG+	Previous studies proposed that N-ethylmaleimide (NEM) alkylates 3 classes of thiols on skeletal muscle ryanodine receptors (RyRs) producing 3 phases of channel modification, as function of time and concentration. NEM (5 mM) decreased, increased, and then decreased the open probability (P-o) of the channel by thiol alkylation, a reaction not reversed by reducing agents. We now show that low NEM concentrations (20-200 muM) elicit Ca2+ release from sarcoplasmic reticulum (SR) vesicles, but contrary to expectations, the effect was fully reversed by reducing agents or by washing SR vesicles, In bilayers, NEM (0.2 mM) increased P-o of RyRs within seconds when added to the cis (not trans) side, and dithiothreitol (DTT; 1 mM) decreased P-o in seconds. High (5 mM) NEM concentrations elicited SR Ca2+ release that was not reversed by DTT, as expected for an alkylation reaction. A non-sulfhydryl reagent structurally related to NEM, N-ethylsuccinimide (0.1-0.5 mM), also elicited SR Ca2+ release that was not reversed by DTT (1 mM). Other alkylating agents elicited SR Ca2+ release, which was fully (N-methylmaleimide) or partially (iodoacetic acid) reversed by DTT and inhibited by ruthenium red. Nitric oxide (NO) donors at concentrations that did not activate RyRs inhibited NEM-induced Ca2+ release, most likely by an interaction of NO with NEM rather than an inactivation of RyRs by NO. Thus, at low concentrations, NEM does not act as a selective thiol reagent and activates RyRs without alkylating critical thiols indicating that the multiple phases of ryanodine binding are unrelated to RyR activity or to NEM alkylation of RyRs,	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Salama, G (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Rm S314,Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15261 USA.				NHLBI NIH HHS [R01 HL57929, HL59614] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059614, R01HL057929] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMSON JJ, 1995, J BIOL CHEM, V270, P29644; Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; Aghdasi B, 1997, J BIOL CHEM, V272, P25462, DOI 10.1074/jbc.272.41.25462; BROCKLEHURST K, 1979, INT J BIOCHEM, V10, P259, DOI 10.1016/0020-711X(79)90088-0; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; Gorbunov NV, 1998, BIOCHEM BIOPH RES CO, V244, P647, DOI 10.1006/bbrc.1997.7951; Hart JDE, 2000, J MEMBRANE BIOL, V173, P227, DOI 10.1007/s002320001022; HASSELBACH W, 1972, MOL BIOENERGETICS MA, P149; HILKERT R, 1992, ARCH BIOCHEM BIOPHYS, V292, P1, DOI 10.1016/0003-9861(92)90043-V; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; Marengo JJ, 1998, BIOPHYS J, V74, P1263, DOI 10.1016/S0006-3495(98)77840-3; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; Menshikova EV, 1999, ANN NY ACAD SCI, V874, P371, DOI 10.1111/j.1749-6632.1999.tb09252.x; Meszaros LG, 1996, FEBS LETT, V380, P49, DOI 10.1016/0014-5793(96)00003-8; MOUTIN MJ, 1989, BIOCHIM BIOPHYS ACTA, V984, P289, DOI 10.1016/0005-2736(89)90295-2; MURPHY AJ, 1976, BIOCHEMISTRY-US, V15, P4492, DOI 10.1021/bi00665a025; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; PRABHU SD, 1990, ARCH BIOCHEM BIOPHYS, V277, P47, DOI 10.1016/0003-9861(90)90548-D; ROUSSEAU E, 1986, BIOPHYS J, V50, P1009, DOI 10.1016/S0006-3495(86)83543-3; SALAMA G, 1984, J BIOL CHEM, V259, P3363; SALAMA G, 1980, J BIOL CHEM, V255, P6525; Salama G, 2000, ANTIOXID REDOX SIGN, V2, P5, DOI 10.1089/ars.2000.2.1-5; Stoyanovsky D, 1997, CELL CALCIUM, V21, P19, DOI 10.1016/S0143-4160(97)90093-2; STOYANOVSKY DA, 1994, ARCH BIOCHEM BIOPHYS, V308, P214, DOI 10.1006/abbi.1994.1030; Suko J, 1999, BBA-MOL CELL RES, V1451, P271, DOI 10.1016/S0167-4889(99)00098-1; TRIMM JL, 1986, J BIOL CHEM, V261, P6092; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Zahradnikova A, 1997, CELL CALCIUM, V22, P447, DOI 10.1016/S0143-4160(97)90072-5; ZAIDI NF, 1989, J BIOL CHEM, V264, P21725; Zucchi R, 1997, PHARMACOL REV, V49, P1	30	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36775	36780		10.1074/jbc.C000367200	http://dx.doi.org/10.1074/jbc.C000367200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10998412	hybrid			2022-12-27	WOS:000165577700048
J	Singh, BB; Liu, XB; Ambudkar, IS				Singh, BB; Liu, XB; Ambudkar, IS			Expression of truncated transient receptor potential protein 1 alpha (Trp1 alpha) - Evidence that the Trp1 C terminus modulates store-operated Ca2+ entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; HTRP3 CHANNELS; CELLS; ACTIVATION	Transient receptor potential protein 1 (Trp1) has been proposed as a component of the store-operated Ca2+ entry (SOCE) channel. However, the exact mechanism by which Trp1 is regulated by store depletion is not known. Here, we examined the role of the Trpl C-terminal domain in SOCE by expressing hTrp1 alpha lacking amino acids 664-793 (Delta Trp1 alpha) or full-length hTrp1 alpha in the HSG (human submandibular gland) cell line. Both carbachol (CCh) and thapsigargin (Tg) activated sustained Ca2+ influx in control (nontransfected), Delta Trp1 alpha-, and Trp1 alpha -expressing cells. Sustained [Ca2+](i), following stimulation with either Tg or CCh in Delta Trp1 alpha -expressing cells, was about 1.5-2-fold higher than in Trp1 alpha -expressing cells and 4-fold higher than in control cells. Importantly, (i) basal Ca2+ influx and (ii) Tg- or CCh-stimulated internal Ca2+ release were similar in all the cells. A similar increase in Tg-stimulated Ca2+ influx was seen in cells expressing Delta 2Tr1 alpha, lacking the C-terminal domain amino acid 649-793, which includes the EWKFAR sequence. Further, both inositol 1,4,5-trisphosphate receptor-3 and caveolin-1 were immunoprecipitated with Delta Trp1 alpha and Trp1 alpha. In aggregate, these data suggest that (i) the EWKFAR sequence does not contribute significantly to the Trp1-associated increase in SOCE, and (ii) the Trpl C-terminal region, amino acids 664-793, is involved in the modulation of SOCE.	NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Ambudkar, IS (corresponding author), NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bldg 10,Rm 1N-113, Bethesda, MD 20892 USA.			Singh, Brij/0000-0003-0535-5997	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000438] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ambudkar IS, 2000, CRIT REV ORAL BIOL M, V11, P4, DOI 10.1177/10454411000110010301; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Liu XB, 1998, J BIOL CHEM, V273, P33295, DOI 10.1074/jbc.273.50.33295; Liu XB, 1998, AM J PHYSIOL-CELL PH, V275, pC571, DOI 10.1152/ajpcell.1998.275.2.C571; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; Wang WC, 1999, AM J PHYSIOL-CELL PH, V276, pC969, DOI 10.1152/ajpcell.1999.276.4.C969; WEI XY, 1994, J BIOL CHEM, V269, P1635; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Zhu X, 1998, NEWS PHYSIOL SCI, V13, P211; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	22	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36483	36486		10.1074/jbc.C000529200	http://dx.doi.org/10.1074/jbc.C000529200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10980191	hybrid			2022-12-27	WOS:000165577700002
J	Spiro, RG				Spiro, RG			Glucose residues as key determinants in the biosynthesis and quality control of glycoproteins with N-linked oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ALPHA-D-MANNOSIDASE; MOUSE LYMPHOMA-CELLS; RAT-LIVER GOLGI; ENDOPLASMIC-RETICULUM; PROCESSING ENZYME; ENDOMANNOSIDASE PATHWAY; MOLECULAR CHAPERONE; II-DEFICIENT; GLYCOSYLATION; CALNEXIN	Although glucose residues do not occur as constituents of mature N-linked oligosaccharides in eukaryotic cells, it has been appreciated for some time that they are integral components of the polymannose oligosaccharides of newly synthesized glycoproteins and their lipid-linked precursors (1). Indeed it has been shown that they play an essential role in the cotranslational. transfer of a preassembled triglucosylated oligosaccharide (Glc(3)Man(9)GlcNAc(2)) from a dolichyl pyrophosphoryl carrier to asparagine in Asn-X-Ser(Thr) sequences on the polypeptide chain (2, 3). Moreover, it has recently become apparent that the most internal of the three glucose residues, after being brought to a terminal position through the action of ER1-situated glucosidases, interacts with lectin-like chaperones to mediate proper folding and/or oligomerization during protein quality control (4, 5). From these observations it has become evident that the presence of transient glucose residues on the polymannose oligosaccharides provides ideal recognition signals for crucial biological events, which have implications for a number of disease states as well as for viral replication. A rather complicated enzymatic machinery occurs in eukaryotic cells to achieve glucose attachment (6) and removal (7, 8), and this has been studied effectively with the help of mutants and inhibitors. It is the purpose of this article to provide a succinct overview of this distinctive area of glycobiology.	Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Biol Chem, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Spiro, RG (corresponding author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.							ALONSO JM, 1991, BIOCHEM J, V278, P721, DOI 10.1042/bj2780721; BLOCK TM, 1994, P NATL ACAD SCI USA, V91, P2235, DOI 10.1073/pnas.91.6.2235; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Dairaku K, 1997, GLYCOBIOLOGY, V7, P579, DOI 10.1093/glycob/7.4.579; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; ESMON B, 1984, J BIOL CHEM, V259, P322; FEIZI T, 1990, Glycobiology, V1, P17, DOI 10.1093/glycob/1.1.17; Freeze HH, 1999, BBA-MOL BASIS DIS, V1455, P167, DOI 10.1016/S0925-4439(99)00072-1; FUJIMOTO K, 1991, J BIOL CHEM, V266, P3571; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HIRAIZUMI S, 1993, J BIOL CHEM, V268, P9927; KALZFULLER B, 1995, EUR J BIOCHEM, V231, P344, DOI 10.1111/j.1432-1033.1995.tb20706.x; Karaivanova VK, 2000, GLYCOBIOLOGY, V10, P727, DOI 10.1093/glycob/10.7.727; Karaivanova VK, 1998, GLYCOBIOLOGY, V8, P725, DOI 10.1093/glycob/8.7.725; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Korner C, 1998, P NATL ACAD SCI USA, V95, P13200, DOI 10.1073/pnas.95.22.13200; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1979, J BIOL CHEM, V254, P1649; Kuznetsov G, 1998, NEW ENGL J MED, V339, P1688, DOI 10.1056/NEJM199812033392307; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; MOORE SEH, 1992, J BIOL CHEM, V267, P8443; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; MOORE SEH, 1993, J BIOL CHEM, V268, P3809; MOORE SEH, 1994, J BIOL CHEM, V269, P12715; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; MURPHY LA, 1981, J BIOL CHEM, V256, P7487; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PARODI AJ, 1993, GLYCOBIOLOGY, V3, P193, DOI 10.1093/glycob/3.3.193; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; RAY MK, 1991, J BIOL CHEM, V266, P22818; REARICK JI, 1981, J BIOL CHEM, V256, P6255; REITMAN ML, 1982, J BIOL CHEM, V257, P357; ROBBINS PW, 1991, BIOCHEM SOC T, V19, P642, DOI 10.1042/bst0190642; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; SPIRO MJ, 1976, J BIOL CHEM, V251, P6400; Spiro MJ, 1997, J BIOL CHEM, V272, P29356, DOI 10.1074/jbc.272.46.29356; SPIRO MJ, 1991, J BIOL CHEM, V266, P5311; Spiro MJ, 2000, GLYCOBIOLOGY, V10, P521, DOI 10.1093/glycob/10.5.521; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; SPIRO RG, 2000, CARBOHYDRATES CHEM B, V3, P65; Suzuki T, 1998, J BIOL CHEM, V273, P10083, DOI 10.1074/jbc.273.17.10083; Suzuki T, 1997, P NATL ACAD SCI USA, V94, P6244, DOI 10.1073/pnas.94.12.6244; Suzuki T, 1998, J BIOL CHEM, V273, P21526, DOI 10.1074/jbc.273.34.21526; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; TURCO SJ, 1979, J BIOL CHEM, V254, P4560; TURCO SJ, 1982, J BIOL CHEM, V257, P8674; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Weng S, 1997, BIOCHEM J, V322, P655, DOI 10.1042/bj3220655; Weng SA, 1996, ARCH BIOCHEM BIOPHYS, V325, P113, DOI 10.1006/abbi.1996.0014; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yan Q, 1999, BIOCHEM BIOPH RES CO, V266, P684, DOI 10.1006/bbrc.1999.1886	58	72	76	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35657	35660		10.1074/jbc.R000022200	http://dx.doi.org/10.1074/jbc.R000022200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	11007802	hybrid			2022-12-27	WOS:000165382000001
J	Alkhalil, A; Achur, RN; Valiyaveettil, M; Ockenhouse, CF; Gowda, DC				Alkhalil, A; Achur, RN; Valiyaveettil, M; Ockenhouse, CF; Gowda, DC			Structural requirements for the adherence of Plasmodium falciparum-infected erythrocytes to chondroitin sulfate proteoglycans of human placenta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG OLIGOSACCHARIDE SEGMENT; HERPES-SIMPLEX-VIRUS; ANTIGENIC VARIATION; HEPARAN-SULFATE; ALCIAN BLUE; GROWTH-FACTOR; ADHESION; MALARIA; RECEPTOR; BINDING	Plasmodium falciparum infection during pregnancy results in the accumulation of infected red blood cells (IRBCs) in the placenta, leading to poor pregnancy outcome. In the preceding paper (Achur, R.N., Valiyaveettil, M., Alkhalil, A., Ockenhouse, C. F., and Gowda, D.C. (2000) J. Biol. Chem. 275, 40344-40356), we reported that unusually low sulfated chondroitin sulfate proteoglycans (CSPGs) in the intervillous spaces of the placenta mediate the IRBC adherence. In this study, we report the structural requirements for the adherence and the minimum chondroitin 4-sulfate (C4S) structural motif that supports IRBC adherence. Partially sulfated C4Ss with varying sulfate contents were prepared by solvolytic desulfation of a fully sulfated C4S. These and other nonmodified C4Ss, with different proportions of 4-, 6-, and nonsulfated disaccharide repeats, were analyzed for inhibition of IRBC adherence to the placental CSPG. C4Ss containing 30-50% 4-sulfated and 50-70% nonsulfated disaccharide repeats efficiently inhibited IRBC adherence; C6S had no inhibitory activity. Oligosaccharides of varying sizes were prepared by the partial depolymerization of C4Ss containing varying levels of 4-sulfation, and their ability to inhibit the IRBC adherence was studied. Oligosaccharides with six or more disaccharide repeats inhibited IRBC adherence to the same level as that of the intact C4Ss, indicating that a dodecasaccharide is the minimum structural motif required for optimal IRBC adherence. Of the C4S dodecasaccharides, only those with two or three sulfate groups per molecule showed maximum IRBC inhibition. These data define the structural requirements for the IRBC adherence to placental CSPGs with implications for the development of therapeutics for maternal malaria.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Walter Reed Army Inst Res, Dept Immunol, Silver Spring, MD 20910 USA	Georgetown University; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Gowda, DC (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	gowda@bc.georgetown.edu		Achur, Rajeshwara/0000-0001-9867-8917; Gowda, Channe/0000-0002-6860-5108	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045086, R21AI045086] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45086] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Achur RN, 2000, J BIOL CHEM, V275, P40344, DOI 10.1074/jbc.M006398200; BANFIELD BW, 1995, J VIROL, V69, P3290, DOI 10.1128/JVI.69.6.3290-3298.1995; Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Beeson JG, 1998, INFECT IMMUN, V66, P3397, DOI 10.1128/IAI.66.7.3397-3402.1998; BHAVANANDAN VP, 1992, GLYCOCONJUGATES COMP, P167; BIGGS BA, 1991, P NATL ACAD SCI USA, V88, P9171, DOI 10.1073/pnas.88.20.9171; BIGGS BA, 1992, J IMMUNOL, V149, P2047; BORST P, 1995, CELL, V82, P1, DOI 10.1016/0092-8674(95)90044-6; BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005; BRISSON JR, 1992, BIOCHEMISTRY-US, V31, P4996, DOI 10.1021/bi00136a012; Buffet PA, 1999, P NATL ACAD SCI USA, V96, P12743, DOI 10.1073/pnas.96.22.12743; Chaiyaroj SC, 1996, AM J TROP MED HYG, V55, P76, DOI 10.4269/ajtmh.1996.55.76; Chen JCR, 1996, J BIOL CHEM, V271, P11134, DOI 10.1074/jbc.271.19.11134; Cooke BM, 1996, BLOOD, V88, P4040, DOI 10.1182/blood.V88.10.4040.bloodjournal88104040; COWMAN MK, 1984, BIOCHEM J, V221, P707, DOI 10.1042/bj2210707; DISCHE Z, 1947, J BIOL CHEM, V167, P189; FINNE J, 1985, J BIOL CHEM, V260, P1265; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; Fried M, 1998, J MOL MED-JMM, V76, P162, DOI 10.1007/s001090050205; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Fried M, 1998, GLYCOBIOLOGY, V8, P1121; Gardner JP, 1996, P NATL ACAD SCI USA, V93, P3503, DOI 10.1073/pnas.93.8.3503; Gowda DC, 1999, BIOSCIENCE REP, V19, P261, DOI 10.1023/A:1020542206916; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Gysin J, 1997, MOL BIOCHEM PARASIT, V88, P267, DOI 10.1016/S0166-6851(97)00082-0; HATAE Y, 1975, ANAL BIOCHEM, V64, P30, DOI 10.1016/0003-2697(75)90400-5; HAYRINEN J, 1989, MOL IMMUNOL, V26, P523, DOI 10.1016/0161-5890(89)90003-5; HEROLD BC, 1995, VIROLOGY, V206, P1108, DOI 10.1006/viro.1995.1034; HOVINGH P, 1974, CARBOHYD RES, V37, P181, DOI 10.1016/S0008-6215(00)87073-1; JENSEN JB, 1978, AM J TROP MED HYG, V27, P1274, DOI 10.4269/ajtmh.1978.27.1274; Kishibe J, 2000, J BIOL CHEM, V275, P15321, DOI 10.1074/jbc.275.20.15321; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOLIAKOS GG, 1989, J BIOL CHEM, V264, P2313; KRUEGER RC, 1987, ANAL BIOCHEM, V167, P295, DOI 10.1016/0003-2697(87)90167-9; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MAGOWAN C, 1988, J EXP MED, V168, P1307, DOI 10.1084/jem.168.4.1307; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MATSUO M, 1993, CARBOHYD RES, V241, P209, DOI 10.1016/0008-6215(93)80107-P; MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0; NAGASAWA K, 1979, J BIOCHEM-TOKYO, V86, P1323, DOI 10.1093/oxfordjournals.jbchem.a132648; Najjam S, 1998, GLYCOBIOLOGY, V8, P509, DOI 10.1093/glycob/8.5.509; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; OCKENHOUSE CF, 1991, J INFECT DIS, V164, P163, DOI 10.1093/infdis/164.1.163; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; POOLE AR, 1986, BIOCHEM J, V236, P1; Pouvelle B, 1998, INFECT IMMUN, V66, P4950, DOI 10.1128/IAI.66.10.4950-4956.1998; Pouvelle B, 1997, MOL MED, V3, P508, DOI 10.1007/BF03401697; Reeder JC, 1999, P NATL ACAD SCI USA, V96, P5198, DOI 10.1073/pnas.96.9.5198; Robert C, 1995, RES IMMUNOL, V146, P383, DOI 10.1016/0923-2494(96)81042-X; Rogerson SJ, 1997, PARASITOL TODAY, V13, P70, DOI 10.1016/S0169-4758(96)10081-8; ROGERSON SJ, 1995, J EXP MED, V182, P15, DOI 10.1084/jem.182.1.15; Rostand KS, 1997, INFECT IMMUN, V65, P1; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; Steketee RW, 1996, AM J TROP MED HYG, V55, P2, DOI 10.4269/ajtmh.1996.55.2; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; VLODAVSKY I, 1993, BASEMENT MEMBRANES C, P327; Wadstrom T, 1999, J MED MICROBIOL, V48, P223, DOI 10.1099/00222615-48-3-223; WALL RS, 1988, ANAL BIOCHEM, V175, P298, DOI 10.1016/0003-2697(88)90392-2; WESSELS MR, 1989, J EXP MED, V169, P2121, DOI 10.1084/jem.169.6.2121	68	95	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40357	40364		10.1074/jbc.M006399200	http://dx.doi.org/10.1074/jbc.M006399200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11005815				2022-12-27	WOS:000166039500076
J	Christoffels, VM; Habets, PEMH; Das, AT; Clout, DEW; van Roon, MA; Moorman, AFM; Lamers, WH				Christoffels, VM; Habets, PEMH; Das, AT; Clout, DEW; van Roon, MA; Moorman, AFM; Lamers, WH			A single regulatory module of the carbamoylphosphate synthetase I gene executes its hepatic program of expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; ELEMENT-BINDING PROTEIN; RAT-LIVER ONTOGENESIS; TRANSGENIC MICE; GLUCOCORTICOID RECEPTOR; ORNITHINE CYCLE; MESSENGER-RNA; TRANSCRIPTION FACTORS; MULTIHORMONAL CONTROL	A 469-base pair (bp) upstream regulatory fragment (URF) and the proximal promoter of the carbamoylphosphate synthetase I (CPS) gene were analyzed for their role in the regulation of spatial, developmental, and hormone-induced expression in vivo. The URF is essential and sufficient for hepatocyte-specific expression, periportal localization, perinatal activation and induction by glucocorticoids, and cAMP in transgenic mice. Before birth, the transgene is silent but can be induced by cAMP and glucocorticoids, indicating that these compounds are responsible for the activation of expression at birth. A 102-bp glucocorticoid response unit within the URF, containing binding sites for HNF3, C/EBP, and the glucocorticoid receptor, is the main determinant of the hepatocyte-specific and hormone-controlled activity. Additional sequences are required for a productive interaction between this minimal response unit and the core CPS promoter. These results show that the 469-bp URF, and probably only the 102-bp glucocorticoid response unit, functions as a regulatory module, in that it autonomously executes a correct spatial, developmental and hormonal program of CPS expression in the liver.	Univ Amsterdam, Acad Med Ctr, Dept Anat & Embryol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Genetically Modofied Mice Facil, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Lamers, WH (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Anat & Embryol, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.		Lamers, Wouter H./D-2965-2012					ALBERTS B, 1994, MOL BIOL CELL, P756; Arnone MI, 1997, DEVELOPMENT, V124, P1851; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Christoffels VM, 1996, J BIOL CHEM, V271, P31243, DOI 10.1074/jbc.271.49.31243; CHRISTOFFELS VM, 1995, J BIOL CHEM, V270, P24932, DOI 10.1074/jbc.270.42.24932; Christoffels VM, 1998, MOL CELL BIOL, V18, P6305, DOI 10.1128/MCB.18.11.6305; Christoffels VM, 1999, HEPATOLOGY, V29, P1180, DOI 10.1002/hep.510290413; Chung JH, 1997, P NATL ACAD SCI USA, V94, P575, DOI 10.1073/pnas.94.2.575; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; Dingemanse MA, 1996, HEPATOLOGY, V24, P407; ESPINAS ML, 1995, MOL CELL BIOL, V15, P5346; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Franco D, 1997, DEV BIOL, V188, P17, DOI 10.1006/dbio.1997.8622; GEBHARDT R, 1992, PHARMACOL THERAPEUT, V53, P275, DOI 10.1016/0163-7258(92)90055-5; GOPING IS, 1994, J BIOL CHEM, V269, P3891; GOPING IS, 1995, NUCLEIC ACIDS RES, V23, P1717, DOI 10.1093/nar/23.10.1717; GOPING IS, 1992, GENE, V118, P283, DOI 10.1016/0378-1119(92)90201-Y; HOGAN B, 1994, MANIPULATING MOUSE E, P217; IMAI E, 1993, J BIOL CHEM, V268, P5353; Jungermann K, 1996, ANNU REV NUTR, V16, P179, DOI 10.1146/annurev.nu.16.070196.001143; JUNGERMANN K, 1995, HISTOCHEM CELL BIOL, V103, P81, DOI 10.1007/BF01454004; JUNGERMANN K, 1989, PHYSIOL REV, V69, P708, DOI 10.1152/physrev.1989.69.3.708; Kadonaga JT, 1999, CURR OPIN GENET DEV, V9, P129, DOI 10.1016/S0959-437X(99)80019-7; Kirchhamer CV, 1996, P NATL ACAD SCI USA, V93, P9322, DOI 10.1073/pnas.93.18.9322; KUO CF, 1990, DEVELOPMENT, V109, P473; LAGACE M, 1992, GENE, V118, P231, DOI 10.1016/0378-1119(92)90193-S; LAMERS WH, 1981, MECH AGEING DEV, V15, P93, DOI 10.1016/0047-6374(81)90010-5; LAMERS WH, 1981, MECH AGEING DEV, V15, P77, DOI 10.1016/0047-6374(81)90009-9; LAMERS WH, 1984, DEV BIOL, V105, P500, DOI 10.1016/0012-1606(84)90307-5; Legraverend C, 1996, MOL ENDOCRINOL, V10, P1507, DOI 10.1210/me.10.12.1507; LIEVENEMA H, 1995, J BIOL CHEM, V270, P28251; MCGRANE MM, 1992, TRENDS BIOCHEM SCI, V17, P40, DOI 10.1016/0968-0004(92)90426-A; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MEIJER AJ, 1990, PHYSIOL REV, V70, P701, DOI 10.1152/physrev.1990.70.3.701; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; MONTOLIU L, 1995, P NATL ACAD SCI USA, V92, P4244, DOI 10.1073/pnas.92.10.4244; MOORMAN AFM, 1993, HISTOCHEM J, V25, P251, DOI 10.1007/BF00159117; MOORMAN AFM, 1991, FEBS LETT, V288, P133, DOI 10.1016/0014-5793(91)81019-5; MOORMAN AFM, 1990, FEBS LETT, V276, P9, DOI 10.1016/0014-5793(90)80494-4; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V256, P343, DOI 10.1016/0003-9861(87)90455-3; MOYER ML, 1993, J BIOL CHEM, V268, P22933; NAGY P, 1994, J CELL BIOL, V126, P223, DOI 10.1083/jcb.126.1.223; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; PARK EA, 1993, J BIOL CHEM, V268, P613; RAMESH TM, 1995, MOL CELL BIOL, V15, P4947; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; ROBERTSON G, 1995, P NATL ACAD SCI USA, V92, P5371, DOI 10.1073/pnas.92.12.5371; Sambrook J., 2002, MOL CLONING LAB MANU; Sassi H, 1998, P NATL ACAD SCI USA, V95, P5621, DOI 10.1073/pnas.95.10.5621; SEITZ HJ, 1976, ENDOCRINOLOGY, V99, P1313, DOI 10.1210/endo-99-5-1313; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; Takiguchi M, 1995, BIOCHEM J, V312, P649, DOI 10.1042/bj3120649; VANDENHOFF MJB, 1993, NUCLEIC ACIDS RES, V21, P4987, DOI 10.1093/nar/21.21.4987; VANDENHOFF MJB, 1995, EUR J BIOCHEM, V228, P351; Wang YL, 1997, NAT BIOTECHNOL, V15, P239, DOI 10.1038/nbt0397-239; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yuh CH, 1998, SCIENCE, V279, P1896, DOI 10.1126/science.279.5358.1896; ZHANG HY, 1993, P NATL ACAD SCI USA, V90, P3880, DOI 10.1073/pnas.90.9.3880	60	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40020	40027		10.1074/jbc.M007001200	http://dx.doi.org/10.1074/jbc.M007001200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006287	hybrid			2022-12-27	WOS:000166039500032
J	Raya, A; Revert-Ros, F; Martinez-Martinez, P; Navarro, S; Rosello, E; Vieitas, B; Granero, F; Forteza, J; Saus, J				Raya, A; Revert-Ros, F; Martinez-Martinez, P; Navarro, S; Rosello, E; Vieitas, B; Granero, F; Forteza, J; Saus, J			Goodpasture antigen-binding protein, the kinase that phosphorylates the goodpasture antigen, is an alternatively spliced variant implicated in autoimmune pathogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; KERATINOCYTE APOPTOSIS; AUTOANTIGENS; GENE; EXPRESSION; MECHANISM; REGION	The non-collagenous C-terminal domain of the ag chain of collagen IV is the autoantigen in Goodpasture disease, an autoimmune disorder described only in humans. Specific N-terminal phosphorylation is a biological feature unique to the human domain when compared with other homologous domains lacking immunopathogenic potential. We have recently cloned from a HeLa-derived cDNA library a novel serine/threonine kinase (Goodpasture antigen-binding protein (GPBP)) that phosphorylates the N-terminal region of the human domain (Raya, A. Revert, F, Navarro, S. and Saus J, (1999) J. Biol. Chem. 274, 12642-12649). We show here that the pre-mRNA of GPBP is alternatively spliced in human tissues and that the most common transcript found encodes GPBP Delta 26, a molecular isoform devoid of a 26-residue serine-rich motif, Recombinantly expressed GPBP Delta 26 exhibits lower activity than GPBP, due at least in part to a reduced ability of GPBP Delta 26 to interact and to form very active high molecular weight aggregates. In human tissues, GPBP shows a more limited expression than GPBP Delta 26 but displays a remarkable preference for the small vessels and for histological structures targeted by natural autoimmune responses including alveolar and glomerular basement membranes, the two main targets in Goodpasture disease. GPBP expression is, in turn, up-regulated in the striated muscle of a Goodpasture patient and in other autoimmune conditions including cutaneous lupus erythematosus, pemphigoid, and lichen planus.	Inst Invest Citol, Fdn Valenciana Invest Biomed, Valencia 46010, Spain; Univ Valencia, Fac Med, Dept Patol, Valencia 46010, Spain; Hosp Peset Aleixandre, Serv Anat Patol, Valencia 46017, Spain; Hosp Clin Univ, Serv Anat Patol, Santiago De Compostela 15706, Spain	University of Valencia; Complexo Hospitalario Universitario de Santiago de Compostela	Saus, J (corresponding author), Inst Invest Citol, Fdn Valenciana Invest Biomed, C Amadeo Saboya 4, Valencia 46010, Spain.		Revert-Ros, Francisco/AAB-7055-2019; Raya, Angel/E-6205-2010	Raya, Angel/0000-0003-2189-9775; Martinez Martinez, Pilar/0000-0002-5990-3373; Saus, Juan/0000-0003-2082-1597; Revert-Ros, Francisco/0000-0002-6162-3370				Bayer KU, 1996, MOL CELL BIOL, V16, P29; BERNAL D, 1993, J BIOL CHEM, V268, P12090; Bolivar J, 1998, J BIOL CHEM, V273, P17122, DOI 10.1074/jbc.273.27.17122; CasciolaRosen L, 1997, LUPUS, V6, P175, DOI 10.1177/096120339700600213; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Casiano CA, 1996, J EXP MED, V184, P765, DOI 10.1084/jem.184.2.765; GOLAN TD, 1992, J CLIN INVEST, V90, P1067, DOI 10.1172/JCI115922; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Maruoka Y, 1997, BIOCHEM BIOPH RES CO, V238, P886, DOI 10.1006/bbrc.1997.7405; Naito Y, 1997, J BIOL CHEM, V272, P32704, DOI 10.1074/jbc.272.51.32704; Pablos JL, 1999, J PATHOL, V188, P63; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; PENADES JR, 1995, EUR J BIOCHEM, V229, P754, DOI 10.1111/j.1432-1033.1995.tb20524.x; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; QUINONES S, 1992, J BIOL CHEM, V267, P19780; Raya A, 1999, J BIOL CHEM, V274, P12642, DOI 10.1074/jbc.274.18.12642; REVERT F, 1995, J BIOL CHEM, V270, P13254, DOI 10.1074/jbc.270.22.13254; SAUS J, 1998, GOODPASTURES SYNDROM, V2, P1005; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; Utz PJ, 1998, ARTHRITIS RHEUM, V41, P1152, DOI 10.1002/1529-0131(199807)41:7<1152::AID-ART3>3.0.CO;2-L; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	24	63	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40392	40399		10.1074/jbc.M002769200	http://dx.doi.org/10.1074/jbc.M002769200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007769	hybrid			2022-12-27	WOS:000166039500081
J	Harris, D; Engelman, A				Harris, D; Engelman, A			Both the structure and DNA binding function of the barrier-to-autointegration factor contribute to reconstitution of HIV type 1 integration in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS PREINTEGRATION COMPLEXES; RETROVIRAL DNA; CELLULAR FACTOR; IN-VITRO; PROTEIN; DOMAIN; PURIFICATION	Retroviral integration is mediated by viral preintegration complexes (PICs), and human immunodeficiency virus type 1 (HIV-1) PICs treated with high salt lose their in vitro integration activity. Barrier-to-autointegration factor (EAF) is a host protein that efficiently restores PIC activity, but the mechanism(s) by which BAF participates in HIV-1 integration remains largely unknown. Here we developed a gel shift assay to study BAF DNA binding, and analyzed 14 mutant proteins containing substitutions of conserved residues for binding and PIC reconstitution activities, Although wild-type BAF efficiently bound double-stranded DNA, binding to single-stranded DNA, RNA, or an RNA/DNA hybrid was not detected, suggesting that BAF associates with retroviral cDNA relatively late during reverse transcription. Although some of the BAF mutant proteins efficiently bound DNA, others were defective for binding. Mutants that bound DNA efficiently reconstituted HIV-1 integration, even though in one case binding was just 0.2% of wild-type BAF, Although misfolded mutants did not reconstitute integration, a structurally intact DNA binding-defective mutant displayed partial activity at high BAF concentration. We therefore conclude that both BAF protein structure and its DNA binding activity play roles in reconstituting HIV-1 integration in vitro.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Engelman, A (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.				NIAID NIH HHS [AI39394] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI039394, R01AI039394] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brown P. O., 1997, P161; Cai M, 1998, NAT STRUCT BIOL, V5, P903, DOI 10.1038/2345; Chen HM, 1998, P NATL ACAD SCI USA, V95, P15270, DOI 10.1073/pnas.95.26.15270; Chen HM, 1999, J BIOL CHEM, V274, P17358, DOI 10.1074/jbc.274.24.17358; Craigie R., 1995, HIV, V2, P53; ENGELMAN A, 1995, J VIROL, V69, P5908, DOI 10.1128/JVI.69.9.5908-5911.1995; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Furukawa K, 1999, J CELL SCI, V112, P2485; HICKMAN AB, 1994, J BIOL CHEM, V269, P29279; LEE MS, 1994, P NATL ACAD SCI USA, V91, P9823, DOI 10.1073/pnas.91.21.9823; Lee MS, 1998, P NATL ACAD SCI USA, V95, P1528, DOI 10.1073/pnas.95.4.1528; Li L, 1998, J VIROL, V72, P2125, DOI 10.1128/JVI.72.3.2125-2131.1998; SMITH JS, 1993, J VIROL, V67, P4037, DOI 10.1128/JVI.67.7.4037-4049.1993; Telesnitsky A., 1997, P121; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; Wei SQ, 1998, P NATL ACAD SCI USA, V95, P10535, DOI 10.1073/pnas.95.18.10535; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; Wilson KL, 2000, TRENDS CELL BIOL, V10, P125, DOI 10.1016/S0962-8924(99)01708-0; YANG JT, 1986, METHOD ENZYMOL, V130, P208	19	56	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39671	39677		10.1074/jbc.M002626200	http://dx.doi.org/10.1074/jbc.M002626200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11005805	Green Published, hybrid			2022-12-27	WOS:000165953100095
J	Melhuish, TA; Wotton, D				Melhuish, TA; Wotton, D			The interaction of the carboxyl terminus-binding protein with the Smad corepressor TGIF is disrupted by a holoprosencephaly mutation in TGIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; TRANSCRIPTIONAL REPRESSOR; CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; BETA; HOX; HOMEODOMAIN; COMPLEXES; DOMAIN; PBX	The homeodomain protein TGIF represses transcription in part by recruiting histone deacetylases. TGIF binds directly to DNA to repress transcription or interacts with TGF-beta -activated Smads, thereby repressing genes normally activated by TGF-beta. Loss of function mutations in TGIF result in holoprosencephaly (HPE) in humans. One HPE mutation in TGIF results in a single amino acid substitution in a conserved PLDLS motif within the amino-terminal repression domain. We demonstrate that TGIF interacts with the corepressor carboxyl terminus-binding protein (CtBP) via this motif. CtBP, which was first identified by its ability to bind the adenovirus E1A protein, interacts both with gene-specific transcriptional repressors and with a subset of polycomb proteins, Efficient repression of TGF-beta -activated gene responses by TGIF is dependent on interaction with CtBP, and we show that TGIF is able to recruit CtBP to a TGF-beta -activated Smad complex. Disruption of the PLDLS motif in TGIF abolishes the interaction of CtBP with TGIF and compromises the ability of TGIF to repress transcription. Thus, at least one HPE mutation in TGIF appears to prevent CtBP-dependent transcriptional repression by TGIF, suggesting an important developmental role for the recruitment of CtBP by TGIF.	Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Wotton, D (corresponding author), Univ Virginia, Hosp West, Ctr Cell Signaling, HSC, Box 800577, Charlottesville, VA 22908 USA.	dw2p@virginia.edu		Wotton, David/0000-0002-4652-5350				Alkema MJ, 1997, J MOL BIOL, V273, P993, DOI 10.1006/jmbi.1997.1372; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Asahara H, 1999, MOL CELL BIOL, V19, P8219; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Bertolino E, 1995, J BIOL CHEM, V270, P31178, DOI 10.1074/jbc.270.52.31178; Bertolino E, 1996, DEV DYNAM, V205, P410, DOI 10.1002/(SICI)1097-0177(199604)205:4<410::AID-AJA5>3.0.CO;2-L; BIENZ L, 1995, BIOESSAYS, V17, P775, DOI 10.1002/bies.950170907; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P517; Gripp KW, 2000, NAT GENET, V25, P205, DOI 10.1038/76074; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Li C, 1998, MOL CELL BIOL, V18, P3771, DOI 10.1128/MCB.18.7.3771; Liu B, 1999, MOL CELL BIOL, V19, P424; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Ming JE, 1998, CLIN GENET, V53, P155; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Newberry EP, 1997, BIOCHEMISTRY-US, V36, P10451, DOI 10.1021/bi971008x; ORLANDO V, 1995, CURR OPIN GENET DEV, V5, P174, DOI 10.1016/0959-437X(95)80005-0; OVERHAUSER J, 1995, AM J HUM GENET, V57, P1080; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; RYAN AK, 1995, NUCLEIC ACIDS RES, V23, P3252, DOI 10.1093/nar/23.16.3252; Saurin AJ, 1998, J CELL BIOL, V142, P887, DOI 10.1083/jcb.142.4.887; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Shanmugam K, 1999, MOL CELL BIOL, V19, P7577; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wotton D, 1999, J BIOL CHEM, V274, P37105, DOI 10.1074/jbc.274.52.37105; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yang Y, 2000, J BIOL CHEM, V275, P20734, DOI 10.1074/jbc.M908382199; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	56	90	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39762	39766		10.1074/jbc.C000416200	http://dx.doi.org/10.1074/jbc.C000416200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995736	hybrid			2022-12-27	WOS:000165953100107
J	Otsuka, F; Yao, ZX; Lee, TH; Yamamoto, S; Erickson, GF; Shimasaki, S				Otsuka, F; Yao, ZX; Lee, TH; Yamamoto, S; Erickson, GF; Shimasaki, S			Bone morphogenetic protein-15 - Identification of target cells and biological functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT GRANULOSA-CELLS; FOLLICLE-STIMULATING-HORMONE; GROWTH FACTOR-BETA; INDUCED DIFFERENTIATION; AROMATASE-ACTIVITY; HOMOLOG GDF-9B; BOVINE ACTIVIN; ESTROUS-CYCLE; TGF-BETA; FOLLICULOGENESIS	In developing ovarian follicles, the regulation of cell proliferation and differentiation is tightly coordinated, Precisely how this coordination is achieved is unknown, but recent observations have suggested that molecules emitted by the oocyte are involved in the process. The newly discovered oocyte-specific growth factor, bone morphogenetic protein-15 (BMP-15), is one such molecule,At present, nothing is known about the target cells and biological functions of BMP-15. To fill this gap in our knowledge, recombinant BMP-15 and its antibody were produced and used to determine BMP-15 expression and bioactivity, BMP-15 mRNA and protein were shown to be co-expressed in oocytes throughout folliculogenesis, supporting the idea that BMP-15 is a physiological regulator of follicle cell proliferation and/or differentiation. To test this, we used primary cultures of rat granulosa cells (GCs), We found that BMP-15 is a potent stimulator of GC proliferation and importantly, the mitogenic effect was follicle-stimulating hormone (FSH)-independent. By contrast, BMP-15 alone had no effect on steroidogenesis. However, it produced a marked decrease in FSH-induced progesterone production, but had no effect on FSH stimulated estradiol production. This result indicates that BMP-15 is a selective modulator of FSH action. In summary, this study identifies GCs as the first target cells for BMP-15. Moreover, it identifies the stimulation of GC proliferation and the differential regulation of two crucial steroid hormones as the first biological functions of BMP-15, Significantly, BMP-15 is the first growth factor that can coordinate GC proliferation and differentiation in a way that reflects normal physiology.	Univ Calif San Diego, Sch Med, Dept Reprod Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Shimasaki, S (corresponding author), Univ Calif San Diego, Sch Med, Dept Reprod Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NICHD NIH HHS [U54HD12303] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD012303] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aaltonen J, 1999, J CLIN ENDOCR METAB, V84, P2744, DOI 10.1210/jc.84.8.2744; ADASHI EY, 1989, MOL CELL ENDOCRINOL, V61, P247, DOI 10.1016/0303-7207(89)90136-6; Carabatsos MJ, 1998, DEV BIOL, V204, P373, DOI 10.1006/dbio.1998.9087; Channing C P, 1970, Recent Prog Horm Res, V26, P589; DODSON WC, 1987, ENDOCRINOLOGY, V120, P512, DOI 10.1210/endo-120-2-512; Dong JW, 1996, NATURE, V383, P531, DOI 10.1038/383531a0; Dube JL, 1998, MOL ENDOCRINOL, V12, P1809, DOI 10.1210/me.12.12.1809; Elvin JA, 2000, MOL CELL ENDOCRINOL, V159, P1, DOI 10.1016/S0303-7207(99)00185-9; Eppig John J., 1997, Human Reproduction (Oxford), V12, P127; Erickson GF, 2000, TRENDS ENDOCRIN MET, V11, P193, DOI 10.1016/S1043-2760(00)00249-6; ERICKSON GF, 1978, ENDOCRINOLOGY, V102, P1275, DOI 10.1210/endo-102-4-1275; Galloway SM, 2000, NAT GENET, V25, P279, DOI 10.1038/77033; HUTCHINSON LA, 1987, BIOCHEM BIOPH RES CO, V146, P1405, DOI 10.1016/0006-291X(87)90806-0; INOUYE S, 1991, ENDOCRINOLOGY, V129, P815, DOI 10.1210/endo-129-2-815; Jaatinen R, 1999, MOL CELL ENDOCRINOL, V156, P189, DOI 10.1016/S0303-7207(99)00100-8; KNECHT M, 1987, ENDOCRINOLOGY, V120, P1243, DOI 10.1210/endo-120-4-1243; Laitinen M, 1998, MECH DEVELOP, V78, P135, DOI 10.1016/S0925-4773(98)00161-0; MIRO F, 1991, ENDOCRINOLOGY, V129, P3388, DOI 10.1210/endo-129-6-3388; NAKATANI A, 1991, ENDOCRINOLOGY, V129, P1521, DOI 10.1210/endo-129-3-1521; NAKATANI A, 1991, ENDOCRINOLOGY, V129, P603, DOI 10.1210/endo-129-2-603; NALBANDOV AV, 1970, S OOGENESIS, P513; Shimasaki S, 1999, P NATL ACAD SCI USA, V96, P7282, DOI 10.1073/pnas.96.13.7282; SMITH MS, 1975, ENDOCRINOLOGY, V96, P219, DOI 10.1210/endo-96-1-219; SUGINO H, 1988, BIOCHEM BIOPH RES CO, V153, P281, DOI 10.1016/S0006-291X(88)81219-1; Vitt UA, 2000, BIOL REPROD, V62, P370, DOI 10.1095/biolreprod62.2.370; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; XIAO S, 1990, MOL CELL ENDOCRINOL, V69, P1, DOI 10.1016/0303-7207(90)90082-J; YING SY, 1986, BIOCHEM BIOPH RES CO, V136, P969, DOI 10.1016/0006-291X(86)90427-4	28	325	356	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39523	39528		10.1074/jbc.M007428200	http://dx.doi.org/10.1074/jbc.M007428200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10998422	hybrid			2022-12-27	WOS:000165953100079
J	Suter, M; Reme, C; Grimm, C; Wenzel, A; Jaattela, M; Esser, P; Kociok, N; Leist, M; Richter, C				Suter, M; Reme, C; Grimm, C; Wenzel, A; Jaattela, M; Esser, P; Kociok, N; Leist, M; Richter, C			Age-related macular degeneration - The lipofuscin component N-retinyl-N-retinylidene ethanolamine detaches proapoptotic proteins from mitochondria and induces apoptosis in mammalian retinal pigment epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEAVER DAM EYE; NEURONAL APOPTOSIS; AUTOCRINE EXCITOTOXICITY; CYTOCHROME-C; CARDIOLIPINS; DISEASE; RELEASE; FLUOROPHORES; PATHOGENESIS; INHIBITION	10-20% of individuals over the age of 65 suffer hom age-related macular degeneration (ARID), the leading cause of severe visual impairment in humans living in developed countries, The pathogenesis of this complex disease is poorly understood, and no efficient therapy or prevention exists to date. A precondition for ARID appears to be the accumulation of the age pigment lipofuscin in lysosomes of retinal pigment epithelial (RPE) cells. In AMD, these cells seem to die by apoptosis with subsequent death of photoreceptor cells, and light may accelerate the disease process. Intracellular factors leading to cell death are not known. Here we show that the lipophilic cation N-retinyl-N-retinylidene ethanolamine (A2E), a lipofuscin component, induces apoptosis in RPE and other cells at concentrations found in human retina. Apoptosis is accompanied by the appearance of the proapoptotic proteins cytochrome c and apoptosis-inducing factor in the cytoplasm and the nucleus. Biochemical examinations show that A2E specifically targets cytochrome oxidase (COX). With both isolated mitochondria and purified COX, A2E inhibits oxygen consumption synergistically with light. Inhibition is reversed by the addition of cytochrome c or cardiolipin, a negatively charged phospholipid that facilitates the binding of cytochrome c to membranes, Succinate dehydrogenase activity is not altered by A2E, We suggest that A2E can act as a proapoptotic molecule via a mitochondria-related mechanism, possibly through site-specific targeting of this cation to COX Loss of RPE cell viability through inhibition of mitochondrial function might constitute a pivotal step toward the progressive degeneration of the central retina.	Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland; Univ Zurich Hosp, Dept Ophthalmol, Lab Retinal Cell Biol, CH-8091 Zurich, Switzerland; Danish Canc Soc, Apoptosis Lab, DK-2100 Copenhagen, Denmark; Univ Cologne, Eye Clin, D-50931 Cologne, Germany; Univ Constance, Fac Biol, Dept Mol Toxicol, D-78457 Constance, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University Zurich Hospital; Danish Cancer Society; University of Cologne; University of Konstanz	Richter, C (corresponding author), Swiss Fed Inst Technol, Inst Biochem, Univ Str 16, CH-8092 Zurich, Switzerland.	richter@bc.biol.ethz.ch	Jäättelä, Marja/AAT-7932-2021; Leist, Marcel/D-2133-2010	Jäättelä, Marja/0000-0001-5950-7111; Leist, Marcel/0000-0002-3778-8693; Grimm, Christian/0000-0001-9318-4352				ALDEZ IZ, 1977, J BIOENERG BIOMEMBR, V9, P237; Allikmets R, 1999, EUR J OPHTHALMOL, V9, P255, DOI 10.1177/112067219900900401; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Carmody RJ, 2000, CELL DEATH DIFFER, V7, P282, DOI 10.1038/sj.cdd.4400646; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cb.04.110188.001103; CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042; Cubeddu R, 1999, PHOTOCHEM PHOTOBIOL, V70, P172, DOI 10.1562/0031-8655(1999)070<0172:PSOAEP>2.3.CO;2; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Eldred GE, 1995, GERONTOLOGY, V41, P15; ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; Esser P, 1997, INVEST OPHTH VIS SCI, V38, P2852; FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583; Gorin MB, 1999, MOL VIS, V5, pU31; Hoch FL, 1998, J BIOENERG BIOMEMBR, V30, P511, DOI 10.1023/A:1020576315771; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737; Holz FG, 1999, OPHTHALMOLOGE, V96, P781, DOI 10.1007/s003470050496; ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KLEIN R, 1992, OPHTHALMOLOGY, V99, P933; Koshkin V, 2000, BIOCHEM J, V347, P687, DOI 10.1042/0264-6021:3470687; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Latta M, 2000, J EXP MED, V191, P1975, DOI 10.1084/jem.191.11.1975; LEIBOWITZ HM, 1989, SURF OPHTHALMOL S, V24, P335; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Leist M, 1997, EUR J NEUROSCI, V9, P1488, DOI 10.1111/j.1460-9568.1997.tb01503.x; Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514; Leist M, 1998, MOL PHARMACOL, V54, P789, DOI 10.1124/mol.54.5.789; MAFTAH A, 1994, MECH AGEING DEV, V77, P83, DOI 10.1016/0047-6374(94)90017-5; Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; Reinboth JJ, 1997, EXP EYE RES, V65, P639, DOI 10.1006/exer.1997.0367; Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4; Salamon Z, 1996, BIOPHYS J, V71, P858, DOI 10.1016/S0006-3495(96)79287-1; SCHLEGEL J, 1992, BIOCHEM J, V285, P65, DOI 10.1042/bj2850065; Schousboe A., 1989, DISSECTION TISSUE CU, P203; Silvestri G, 1997, MOL MED TODAY, V3, P84, DOI 10.1016/S1357-4310(96)10057-5; Single B, 1998, CELL DEATH DIFFER, V5, P1001, DOI 10.1038/sj.cdd.4400462; SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448; Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988; Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Volbracht C, 1999, MOL MED, V5, P477; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Xu G Z, 1996, Trans Am Ophthalmol Soc, V94, P411; YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700; YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392; Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401	56	240	252	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39625	39630		10.1074/jbc.M007049200	http://dx.doi.org/10.1074/jbc.M007049200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11006290	hybrid, Green Submitted			2022-12-27	WOS:000165953100089
J	Townson, JR; Graham, GJ; Landau, NR; Rasala, B; Nibbs, RJB				Townson, JR; Graham, GJ; Landau, NR; Rasala, B; Nibbs, RJB			Aminooxypentane addition to the chemokine macrophage inflammatory Protein-1 alpha P increases receptor affinities and HIV inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; GENETIC RESTRICTION; BETA-CHEMOKINES; RANTES; CCR5; POTENT; ANTAGONISTS; IDENTIFICATION; INDIVIDUALS; MIP-1-ALPHA	To enter its target cells, human immunodeficiency virus (HIV) must interact with CD4 and one of a family of chemokine receptors. CCR5 is widely used by the virus in this context, and its ligands can prevent HIV entry. Amino-terminal modified chemokine variants, in particular AOP-RANTES (aminooxypentane-linked regulated on activation normal T cell expressed and secreted), exhibit enhanced HIV entry inhibition. We have previously demonstrated that a non-allelic isoform of macrophage inflammatory protein (MIP)-l alpha termed MIP-1 alphaP, is the most active naturally occurring inhibitor of HIV entry known. Here we report the properties of a variant of MIP-l alphaP with an AOP group on the amino terminus. We show that, like RANTES, the addition of AOP to MIP-1 alphaP enhances its interactions with CCR1 and CCR5, allows more effective internalization of CCR5, and increases the ligand's potency as an inhibitor of HIV entry through CCR5. Importantly, AOP-MIP-l alphaP is about 10-fold more active than AOP-RANTES at inhibiting HIV entry, malting it the most effective chemokine-based inhibitor of HIV entry through CCR5 described to date. Surprisingly, the enhanced receptor interactions of AOP-MIP-1 alphaP do not translate into increased chemotaxis or coupling to calcium ion fluxes, suggesting that this protein should be viewed as a partial, rather than a full, agonist for CCR1 and CCR5.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Salk Inst Biol Studies, Infect Dis Lab, La Jolla, CA 92037 USA	Beatson Institute; Salk Institute	Nibbs, RJB (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	r.nibbs@beatson.gla.ac.uk	Graham, Gerard/D-1240-2009	Graham, Gerard/0000-0002-7801-204X; Nibbs, Robert/0000-0002-8150-0044	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043252] Funding Source: NIH RePORTER; NCI NIH HHS [CA7214] Funding Source: Medline; NIAID NIH HHS [AI43252] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Cairns JS, 1998, NAT MED, V4, P563, DOI 10.1038/nm0598-563; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Furci L, 1997, J EXP MED, V186, P455, DOI 10.1084/jem.186.3.455; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; Gong JH, 1997, J EXP MED, V186, P131, DOI 10.1084/jem.186.1.131; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; Graham GJ, 1992, GROWTH FACTORS, V7, P151, DOI 10.3109/08977199209046404; GRAHAM GJ, 1994, J BIOL CHEM, V269, P4974; GRAHAM GJ, 1993, CELL GROWTH DIFFER, V4, P137; Grone HJ, 1999, FASEB J, V13, P1371, DOI 10.1096/fasebj.13.11.1371; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; Jones SA, 1997, J BIOL CHEM, V272, P16166, DOI 10.1074/jbc.272.26.16166; Lalani AS, 1999, SCIENCE, V286, P1968, DOI 10.1126/science.286.5446.1968; Liu HL, 1999, P NATL ACAD SCI USA, V96, P4581, DOI 10.1073/pnas.96.8.4581; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; Martin MP, 1998, SCIENCE, V282, P1907, DOI 10.1126/science.282.5395.1907; MOSER B, 1993, J BIOL CHEM, V268, P7125; Nibbs RJB, 1999, J BIOL CHEM, V274, P17478, DOI 10.1074/jbc.274.25.17478; Nibbs RJB, 2000, J IMMUNOL, V164, P1488, DOI 10.4049/jimmunol.164.3.1488; Nibbs RJB, 1997, J BIOL CHEM, V272, P32078, DOI 10.1074/jbc.272.51.32078; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Panzer U, 1999, KIDNEY INT, V56, P2107, DOI 10.1046/j.1523-1755.1999.00767.x; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Price DA, 1998, CURR BIOL, V8, P355, DOI 10.1016/S0960-9822(98)70138-1; Proost P, 1998, J IMMUNOL, V160, P4034; Proost P, 1998, J BIOL CHEM, V273, P7222, DOI 10.1074/jbc.273.13.7222; Proudfoot AEI, 1999, J BIOL CHEM, V274, P32478, DOI 10.1074/jbc.274.45.32478; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; Signoret N, 1998, J CELL SCI, V111, P2819; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Teixeira MM, 1997, J CLIN INVEST, V100, P1657, DOI 10.1172/JCI119690; Torre VS, 2000, J VIROL, V74, P4868, DOI 10.1128/JVI.74.10.4868-4876.2000; Vila-Coro AJ, 1999, J IMMUNOL, V163, P3037; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yang OO, 1999, J VIROL, V73, P4582, DOI 10.1128/JVI.73.6.4582-4589.1999; Zagury D, 1998, P NATL ACAD SCI USA, V95, P3857, DOI 10.1073/pnas.95.7.3857; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	54	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39254	39261		10.1074/jbc.M006768200	http://dx.doi.org/10.1074/jbc.M006768200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11005816	hybrid			2022-12-27	WOS:000165953100043
J	Wang, XT; Martindale, JL; Holbrook, NJ				Wang, XT; Martindale, JL; Holbrook, NJ			Requirement for ERK activation in cisplatin-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL-REGULATED KINASE; PROGRAMMED CELL-DEATH; PROTEIN-KINASE; CYTOCHROME-C; OXIDATIVE STRESS; CANCER CELLS; INDUCED CYTOTOXICITY; MAMMALIAN-CELLS; FACTOR RECEPTOR	Cisplatin activates multiple signal transduction pathways involved in coordinating cellular responses to stress, Here we demonstrate a requirement for extracellular signal-regulated protein kinase (ERK), a member of the mitogen-activated protein kinase family in mediating cisplatin-induced apoptosis of human cervical carcinoma HeLa cells. Cisplatin treatment resulted in dose- and time- dependent activation of ERK, That elevated ERK activity contributed to cell death by cisplatin was supported by several observations: 1) PD98059 and U0126, chemical inhibitors of the MEK/ERK signaling pathway, prevented apoptosis; 2) pretreatment of cells with TPA, an activator of the ERK pathway, enhanced their sensitivity to cisplatin; 3) suramin, a growth factor receptor antagonist that greatly suppressed ERK activation, likewise inhibited cisplatin-induced apoptosis; and, finally, 4) HeLa cell variants selected for cisplatin resistance showed reduced activation of ERK following cisplatin treatment. Cisplatin-induced apoptosis was associated with cytochrome c release and subsequent caspase-3 activation, both of which could be prevented by treatment with the MEK inhibitors. However, the caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone protected HeLa cells against apoptosis without affecting ERK activation. Taken together, our findings suggest that ERK activation plays an active role in mediating cisplatin-induced apoptosis of HeLa cells and functions upstream of caspase activation to initiate the apoptotic signal.	NIA, Cell Stress & Aging Sect, Biol Chem Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Holbrook, NJ (corresponding author), NIA, Cell Stress & Aging Sect, Biol Chem Lab, NIH, Box 12,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Martindale, Jennifer Luethy/AAD-1963-2022	Martindale, Jennifer Luethy/0000-0002-3234-6861				Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; CHU G, 1990, P NATL ACAD SCI USA, V87, P3324, DOI 10.1073/pnas.87.9.3324; CHU G, 1994, J BIOL CHEM, V269, P787; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dixit M, 1997, J NATL CANCER I, V89, P365, DOI 10.1093/jnci/89.5.365; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fokstuen T, 1997, ANTICANCER RES, V17, P2347; Fulda S, 1997, CANCER RES, V57, P3823; Gao XS, 1995, ANTICANCER RES, V15, P1911; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hayakawa J, 1999, J BIOL CHEM, V274, P31648, DOI 10.1074/jbc.274.44.31648; HE H, 1997, CELL GROWTH DIFFER, V10, P307; Hocker M, 1998, J BIOL CHEM, V273, P23046, DOI 10.1074/jbc.273.36.23046; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; Kaneki M, 1999, MOL CELL BIOL, V19, P461; KRONING R, 1995, BRIT J CANCER, V72, P615, DOI 10.1038/bjc.1995.382; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Miyajima A, 1997, BRIT J CANCER, V76, P206, DOI 10.1038/bjc.1997.363; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Perez RP, 1998, EUR J CANCER, V34, P1535, DOI 10.1016/S0959-8049(98)00227-5; Persons DL, 1999, CLIN CANCER RES, V5, P1007; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Rao GN, 1996, ONCOGENE, V13, P713; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Sasada T, 1996, J CLIN INVEST, V97, P2268, DOI 10.1172/JCI118668; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sutherland CL, 1996, J IMMUNOL, V157, P3381; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TIMMERBOSSCHA H, 1992, BRIT J CANCER, V66, P227, DOI 10.1038/bjc.1992.249; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zanella CL, 1996, CANCER RES, V56, P5334; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhou H, 2000, J BIOL CHEM, V275, P22868, DOI 10.1074/jbc.M909273199; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	54	586	599	2	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39435	39443		10.1074/jbc.M004583200	http://dx.doi.org/10.1074/jbc.M004583200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993883	hybrid			2022-12-27	WOS:000165953100068
J	Davis, PJ; Shih, A; Lin, HY; Martino, LJ; Davis, FB				Davis, PJ; Shih, A; Lin, HY; Martino, LJ; Davis, FB			Thyroxine promotes association of mitogen-activated protein kinase and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation of TR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X RECEPTOR; CULTURED-CELLS; IN-VITRO; BINDING; ACID; DNA; TRANSCRIPTION; ANALOGS; COACTIVATORS; STIMULATION	Activated nongenomically by L-thyroxine (T-4), mitogen-activated protein kinase (MAPK) complexed in 10-20 min with endogenous nuclear thyroid hormone receptor (TR beta1 or TR) in nuclear fractions of 293T cells, resulting in serine phosphorylation of TR, Treatment of cells with the MAPK kinase inhibitor, PD 98059, prevented both T-4-induced nuclear MAPK-TR co-immunoprecipitation and serine phosphorylation of TR. T-4 treatment caused dissociation of TR and SMRT (silencing mediator of retinoid and thyroid hormone receptor), an effect also inhibited by PD 98059 and presumptively a result of association of nuclear MAPK with TR, Transfection into CV-1 cells of TR gene constructs in which one or both zinc fingers in the TR DNA-binding domain were replaced with those from the glucocorticoid receptor localized the site of TR phosphorylation by T-4-activated MAPK to a serine in the second zinc finger of the TR DNA-binding domain. In an in vitro cell- and hormone-free system, purified activated MAPK phosphorylated recombinant human TR beta1 (102-461). Thus, T-4 activates MAPK and causes MAPK-mediated serine phosphorylation of TR beta1 and dissociation of TR and the co-repressor SMRT.	Albany Med Coll, Dept Med, Albany, NY 12208 USA; Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Albany Med Coll, Samuel S Stratton Vet Affairs Med Ctr, Albany, NY 12208 USA; Albany Med Coll, Mol & Cellular Med Program, Albany, NY 12208 USA	Albany Medical College; Albany Medical College; Albany Medical College; Albany Medical College	Davis, PJ (corresponding author), Albany Med Coll, Dept Med, MC-16, Albany, NY 12208 USA.							BHAT MK, 1994, P NATL ACAD SCI USA, V91, P7927, DOI 10.1073/pnas.91.17.7927; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Ceresa BP, 1997, ENDOCRINOLOGY, V138, P4131, DOI 10.1210/en.138.10.4131; CHIN WW, 1997, CONT ENDOCRINOLOGY D, P17; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS FB, 1995, METABOLISM, V44, P865, DOI 10.1016/0026-0495(95)90238-4; DAVIS FB, 1993, J CLIN ENDOCR METAB, V77, P1427, DOI 10.1210/jc.77.5.1427; DAVIS PJ, 1982, LIFE SCI, V30, P675, DOI 10.1016/0024-3205(82)90283-1; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Han XB, 1999, ENDOCRINOLOGY, V140, P2241, DOI 10.1210/en.140.5.2241; JONES KE, 1994, ENDOCRINOLOGY, V134, P543, DOI 10.1210/en.134.2.543; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KATZ D, 1995, MOL CELL BIOL, V15, P2341; Krstic MD, 1997, MOL CELL BIOL, V17, P3947, DOI 10.1128/MCB.17.7.3947; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Leitman DC, 1996, J BIOL CHEM, V271, P21950, DOI 10.1074/jbc.271.36.21950; Lin HY, 1999, AM J PHYSIOL-CELL PH, V276, pC1014, DOI 10.1152/ajpcell.1999.276.5.C1014; Lin HY, 1997, AM J PHYSIOL-CELL PH, V273, pC1225, DOI 10.1152/ajpcell.1997.273.4.C1225; Lin HY, 1996, J CELL PHYSIOL, V167, P269, DOI 10.1002/(SICI)1097-4652(199605)167:2<269::AID-JCP10>3.0.CO;2-3; Lin HY, 1998, J IMMUNOL, V161, P843; Lin HY, 1999, BIOCHEM J, V338, P427, DOI 10.1042/0264-6021:3380427; LIN KH, 1992, P NATL ACAD SCI USA, V89, P7737, DOI 10.1073/pnas.89.16.7737; Nagaya T, 1996, BIOCHEM BIOPH RES CO, V222, P524, DOI 10.1006/bbrc.1996.0777; OPPENHEIMER JH, 1973, BIOCHEM BIOPH RES CO, V55, P544, DOI 10.1016/0006-291X(73)91177-7; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Safer JD, 1998, J BIOL CHEM, V273, P30175, DOI 10.1074/jbc.273.46.30175; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SCHUELER PA, 1990, MOL ENDOCRINOL, V4, P227, DOI 10.1210/mend-4-2-227; SELMI S, 1991, J BIOL CHEM, V266, P11589; SMITH TJ, 1992, BIOCHEM J, V284, P583, DOI 10.1042/bj2840583; SUGAWARA A, 1994, J BIOL CHEM, V269, P433; Tagami T, 1998, MOL ENDOCRINOL, V12, P1888, DOI 10.1210/me.12.12.1888; Ting YT, 1997, J BIOL CHEM, V272, P4129, DOI 10.1074/jbc.272.7.4129; Ting YT, 1997, THYROID, V7, P463, DOI 10.1089/thy.1997.7.463; Tzagarakis-Foster C, 1998, J BIOL CHEM, V273, P10926, DOI 10.1074/jbc.273.18.10926; WEINSTEIN SP, 1990, ENDOCRINOLOGY, V126, P1421, DOI 10.1210/endo-126-3-1421; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yamazaki T, 1997, CIRCULATION, V95, P1260; Yang XY, 1998, J BIOL CHEM, V273, P29879, DOI 10.1074/jbc.273.45.29879; YEN PM, 1992, J BIOL CHEM, V267, P23248; Zhu XG, 1998, J BIOL CHEM, V273, P27058, DOI 10.1074/jbc.273.42.27058	42	171	199	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38032	38039		10.1074/jbc.M002560200	http://dx.doi.org/10.1074/jbc.M002560200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982791	hybrid			2022-12-27	WOS:000165618700097
J	Sanders, MA; Basson, MD				Sanders, MA; Basson, MD			Collagen IV-dependent ERK activation in human Caco-2 intestinal epithelial cells requires focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEINS; INTEGRIN-MEDIATED ACTIVATION; IN-VITRO MODEL; TYROSINE PHOSPHORYLATION; ENTEROCYTIC DIFFERENTIATION; UROKINASE RECEPTOR; SIGNALING PATHWAYS; DOWN-REGULATION; GROWTH-FACTOR; MAP KINASE	Integrin-initiated extracellular signal-regulated kinase (ERK) activation by matrix adhesion may require focal adhesion kinase (FAK) or be FAK-independent via caveolin and Shc. This remains controversial for fibroblast and endothelial cell adhesion to fibronectin and is less understood for other matrix proteins and cells. We investigated Caco-2 intestinal epithelial cell ERK activation by collagen I and TV, laminin, and fibronectin. Collagens or laminin, but not fibronectin, stimulated tyrosine phosphorylation of FAK, paxillin, and p130(cas) and activated ERK1/2. Shc, tyrosine-phosphorylated by matrix adhesion in many cells, was not phosphorylated in Caco-2 cells in response to any matrix. Caveolin expression did not affect Caco-2 Shc phosphorylation in response to fibronectin. FAK, ERK, and p130(cas) tyrosine phosphorylation were activated after 10-min adhesion to collagen TV. FAK activity increased for 45 min after collagen TV adhesion and persisted for 2 h, while p130(cas) phosphorylation increased only slightly after 10 min. ERK activity peaked at 10 min, declined after 30 min, and returned to base line after 1 h. Transfection with FAK-related nonkinase, but not substrate domain deleted p130(cas), strongly inhibited ERK2 activation in response to collagen TV, indicating Caco-2 ERK activation is at least partly regulated by FAK.	Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA; Connecticut Vet Affairs Hlth Care SYst, W Haven, CT 06516 USA	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Basson, MD (corresponding author), Yale Univ, Sch Med, Dept Surg, 333 Cedar St,POB 208062, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047051] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29DK47051] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asthagiri AR, 1999, J BIOL CHEM, V274, P27119, DOI 10.1074/jbc.274.38.27119; Basson MD, 1998, CLIN EXP PHARMACOL P, V25, P280, DOI 10.1111/j.1440-1681.1998.t01-10-.x; Basson MD, 1996, EXP CELL RES, V225, P301, DOI 10.1006/excr.1996.0180; BASSON MD, 1992, J CLIN INVEST, V90, P15, DOI 10.1172/JCI115828; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; CHANTRET I, 1988, CANCER RES, V48, P1936; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; De Arcangelis A, 1996, J CELL BIOL, V133, P417, DOI 10.1083/jcb.133.2.417; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Field FJ, 1998, J LIPID RES, V39, P1938; FORSBERG E, 1994, EXP CELL RES, V213, P183, DOI 10.1006/excr.1994.1189; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Gibson PR, 1999, CARCINOGENESIS, V20, P539, DOI 10.1093/carcin/20.4.539; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Heath JP, 1996, CELL BIOL INT, V20, P139, DOI 10.1006/cbir.1996.0018; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; Levy P, 1998, J CELL PHYSIOL, V177, P618, DOI 10.1002/(SICI)1097-4652(199812)177:4<618::AID-JCP12>3.0.CO;2-R; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Lotz MM, 2000, AM J PATHOL, V156, P985, DOI 10.1016/S0002-9440(10)64966-8; Lotz MM, 1997, AM J PATHOL, V150, P747; MADRI JA, 1988, AM J PATHOL, V132, P18; Mirre C, 1996, AM J PHYSIOL-CELL PH, V271, pC887, DOI 10.1152/ajpcell.1996.271.3.C887; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; PETERSON MD, 1993, J CELL SCI, V105, P461; PETERSON MD, 1993, J CELL SCI, V105, P445; Podolsky DK, 1997, J GASTROENTEROL, V32, P122, DOI 10.1007/BF01213309; Pozzi M, 1998, J CELL BIOL, V142, P587; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; SIMONASSMANN P, 1995, EXPERIENTIA, V51, P883, DOI 10.1007/BF01921739; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; VACHON PH, 1995, AM J PHYSIOL-GASTR L, V268, pG857, DOI 10.1152/ajpgi.1995.268.5.G857; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; Vogel U, 1998, J CELL SCI, V111, P825; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Wilson AJ, 1997, CLIN SCI, V93, P97, DOI 10.1042/cs0930097; Wolpert S, 1996, AM J SURG, V171, P109, DOI 10.1016/S0002-9610(99)80083-X; Yu CF, 2000, AM J PHYSIOL-GASTR L, V278, pG952, DOI 10.1152/ajpgi.2000.278.6.G952; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	59	70	70	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38040	38047		10.1074/jbc.M003871200	http://dx.doi.org/10.1074/jbc.M003871200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10986280	hybrid			2022-12-27	WOS:000165618700098
J	Chau, KY; Chen, SM; Zack, DJ; Ono, SJ				Chau, KY; Chen, SM; Zack, DJ; Ono, SJ			Functional domains of the cone-rod homeobox (CRX) transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTORECEPTOR-SPECIFIC EXPRESSION; LEBER CONGENITAL AMAUROSIS; BINDING PROTEIN GENE; TRUNCATION MUTATIONS; HOMEODOMAIN PROTEIN; MAMMALIAN BRAIN; FACTOR NRL; OTX; DISSECTION; DYSTROPHY	The paired-like homeodomain transcription factor CRX (cone-rod homeobox) is involved in regulating photoreceptor gene expression and rod outer segment development. Mutations in CRX have been associated with several retinal degenerative diseases. These conditions range from Leber congenital amaurosis (a severe cone and rod degeneration of childhood onset) to adult onset cone-rod dystrophy and retinitis pigmentosa tan adult onset condition that primarily affects rods). The goal of this study is to better understand the molecular basis of CRX function and to provide insight into how mutations in CRX cause such a variety of clinical phenotypes. We performed deletion analysis in conjunction with DNA binding and transient transfection-based transactivation studies to identify the functional domains within CRX. DNA binding requires a complete homeodomain. Furthermore, truncated proteins that did not contain an intact homeodomain failed to demonstrate detectable expression in tissue culture upon transfection. Transactivation analysis indicated that both the OTX tail and the WSP domain are important for controlling positive regulatory activity of CRX interestingly, the mapped CRX transactivation domains were also critical when coexpressed with NRL, Specifically, the synergy between CRX and NRL was constant regardless of which CRX variant was used.	Harvard Univ, Sch Med, Schepens Eye Res Inst, Dept Ophthalmol, Boston, MA 02114 USA; Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA; Brigham & Womens Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Comm Immunol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute; Washington University (WUSTL); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Ono, SJ (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, Dept Ophthalmol, 20 Staniford St, Boston, MA 02114 USA.	sjono@vision.eri.harvard.edu	Chau, Kai-Yin (David)/C-2845-2011; Chau, David/P-8335-2019	Chau, David/0000-0002-5797-2922; Zack, Don/0000-0002-7966-1973	NATIONAL EYE INSTITUTE [R01EY009769, R01EY012543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049661] Funding Source: NIH RePORTER; NEI NIH HHS [EY09769, R01 EY012543] Funding Source: Medline; NIGMS NIH HHS [GM49661] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boatright J H, 1997, Mol Vis, V3, P15; Bobola N, 1999, MECH DEVELOP, V82, P165, DOI 10.1016/S0925-4773(98)00162-2; Chau KY, 2000, J NEUROSCI, V20, P7317; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Fei YJ, 1999, J BIOCHEM, V125, P1189, DOI 10.1093/oxfordjournals.jbchem.a022403; FINKELSTEIN R, 1994, TRENDS GENET, V10, P310, DOI 10.1016/0168-9525(94)90033-7; Fong SL, 1999, CURR EYE RES, V18, P283, DOI 10.1076/ceyr.18.4.283.5360; Freund CL, 1998, NAT GENET, V18, P311, DOI 10.1038/ng0498-311; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591; Hessabi B, 1999, EUR J BIOCHEM, V263, P170, DOI 10.1046/j.1432-1327.1999.00481.x; Hirth F, 1999, BIOESSAYS, V21, P677, DOI 10.1002/(SICI)1521-1878(199908)21:8<677::AID-BIES7>3.3.CO;2-#; Jacobson SG, 1998, INVEST OPHTH VIS SCI, V39, P2417; Kimura A, 2000, J BIOL CHEM, V275, P1152, DOI 10.1074/jbc.275.2.1152; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; Li XD, 1998, P NATL ACAD SCI USA, V95, P1876, DOI 10.1073/pnas.95.4.1876; Livesey FJ, 2000, CURR BIOL, V10, P301, DOI 10.1016/S0960-9822(00)00379-1; Mitton KP, 2000, J BIOL CHEM, V275, P29794, DOI 10.1074/jbc.M003658200; Morrow EM, 1998, TRENDS CELL BIOL, V8, P353, DOI 10.1016/S0962-8924(98)01341-5; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; Sakamoto K, 1999, NEUROSCI LETT, V261, P101, DOI 10.1016/S0304-3940(99)00008-7; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Silva E, 2000, INVEST OPHTH VIS SCI, V41, P2076; Simeone A, 1998, EMBO J, V17, P6790, DOI 10.1093/emboj/17.23.6790; Singh S, 1998, J BIOL CHEM, V273, P21531, DOI 10.1074/jbc.273.34.21531; Sohocki MM, 1998, AM J HUM GENET, V63, P1307, DOI 10.1086/302101; Swain PK, 1997, NEURON, V19, P1329, DOI 10.1016/S0896-6273(00)80423-7; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Swaroop A, 1999, HUM MOL GENET, V8, P299, DOI 10.1093/hmg/8.2.299; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Tang HK, 1998, J BIOL CHEM, V273, P7210, DOI 10.1074/jbc.273.13.7210; Yanagi Y, 2000, BIOCHEM BIOPH RES CO, V269, P410, DOI 10.1006/bbrc.2000.2304; Zhu XM, 2000, MOL CELL BIOL, V20, P5216, DOI 10.1128/MCB.20.14.5216-5226.2000; Zhu XM, 2000, BIOCHEM BIOPH RES CO, V270, P504, DOI 10.1006/bbrc.2000.2414	35	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37264	37270		10.1074/jbc.M002763200	http://dx.doi.org/10.1074/jbc.M002763200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10984472	hybrid			2022-12-27	WOS:000165577700111
J	Heaton, JH; Dlakic, WM; Dlakic, M; Gelehrter, TD				Heaton, JH; Dlakic, WM; Dlakic, M; Gelehrter, TD			Identification and cDNA cloning of a novel RNA-binding protein that interacts with the cyclic nucleotide-responsive sequence in the type-1 plasminogen activator inhibitor mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOMA-CELLS; A+U-RICH ELEMENTS; MESSENGER-RNA; 3'-UNTRANSLATED REGION; GENE-EXPRESSION; POSTTRANSCRIPTIONAL REGULATION; STABILITY COMPLEX; AUF1; DESTABILIZATION; INCREASES	Incubation of HTC rat hepatoma cells with 8-bromo-cAMP results in a 3-fold increase in the rate of degradation of type-1 plasminogen activator inhibitor (PAI-1) mRNA. We have reported previously that the 3'-most 134 nt of the PAI-1 mRNA is able to confer cyclic nucleotide regulation of message stability onto a heterologous transcript. R-EMSA and UV cross-linking experiments have shown that this 134 nt cyclic nucleotide-responsive sequence (CRS) binds HTC cell cytoplasmic proteins ranging in size from 38 to 76 kDa. Mutations in the A-rich region of the CRS both eliminate cyclic nucleotide regulation of mRNA decay and abolish RN-protein complex formation, suggesting that these RNA-binding proteins may be important regulators of mRNA stability. By sequential R-EMSA and SOS-PAGE we have purified a protein from HTC cell polysomes that binds to the PAI-1 CRS. N-terminal sequence analysis and a search of protein data bases revealed identity with two human sequences of unknown function. We have expressed one of these sequences in E. coli and confirmed that the recombinant protein interacts specifically with the PAI-1 CRS, Mutation of the A-rich portion of the PAI-1 CRS reduces binding by the recombinant PAI-1 RNA-binding protein. The amino acid sequence of this protein includes an RGG box and two arginine-rich regions, but does not include other recognizable RNA binding motifs, Detailed analyses of nucleic acid and protein data bases demonstrate that blocks of this sequence are highly conserved in a number of metazoans, including Arabidopsis, Drosophila, birds, and mammals. Thus, we have described a novel RNA-binding protein that identifies a family of proteins with a previously undefined sequence motif. Our results suggest that this protein, PAI-RBP1, may play a role in regulation of mRNA stability.	Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Heaton, JH (corresponding author), Univ Michigan, Sch Med, Dept Human Genet, 4909 Buhl Bldg,Box 0618,1241 E Catherine, Ann Arbor, MI 48109 USA.	heatonj@umich.edu	Dlakic, Mensur/S-2702-2019	Dlakic, Mensur/0000-0003-4315-1514	NATIONAL CANCER INSTITUTE [R01CA022729, R37CA022729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER; NCI NIH HHS [CA22729] Funding Source: Medline; NIDDK NIH HHS [5 P60 DK-20572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; Ausubel FM, 1988, MOL REPROD DEV; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Buzby JS, 1999, J BIOL CHEM, V274, P33973, DOI 10.1074/jbc.274.48.33973; Chkheidze AN, 1999, MOL CELL BIOL, V19, P4572; Cusack Stephen, 1999, Current Opinion in Structural Biology, V9, P66; DeMaria CT, 1997, J BIOL CHEM, V272, P27635, DOI 10.1074/jbc.272.44.27635; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Dieci G, 2000, PROTEIN EXPRES PURIF, V18, P346, DOI 10.1006/prep.2000.1203; Dodson RE, 1997, J BIOL CHEM, V272, P12249, DOI 10.1074/jbc.272.19.12249; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; HARGROVE JL, 1991, BIOESSAYS, V13, P667, DOI 10.1002/bies.950131209; HEATON JH, 1990, MOL ENDOCRINOL, V4, P171, DOI 10.1210/mend-4-1-171; HEATON JH, 1989, MOL ENDOCRINOL, V3, P349, DOI 10.1210/mend-3-2-349; HEATON JH, 1992, MOL ENDOCRINOL, V6, P53, DOI 10.1210/me.6.1.53; Heaton JH, 1998, J BIOL CHEM, V273, P14261, DOI 10.1074/jbc.273.23.14261; Henikoff JG, 2000, NUCLEIC ACIDS RES, V28, P228, DOI 10.1093/nar/28.1.228; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; KRUITHOF EKO, 1988, ENZYME, V40, P113, DOI 10.1159/000469153; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Makeyev AV, 1999, J BIOL CHEM, V274, P24849, DOI 10.1074/jbc.274.35.24849; Nelson LD, 2000, J BIOL CHEM, V275, P5573, DOI 10.1074/jbc.275.8.5573; Neuwald AF, 1997, NUCLEIC ACIDS RES, V25, P1665, DOI 10.1093/nar/25.9.1665; Paulding WR, 1999, J BIOL CHEM, V274, P2532, DOI 10.1074/jbc.274.4.2532; Rajagopalan LE, 1997, PROG NUCLEIC ACID RE, V56, P257, DOI 10.1016/S0079-6603(08)61007-7; Ramos A, 1997, CURR OPIN STRUC BIOL, V7, P317, DOI 10.1016/S0959-440X(97)80046-2; RANISH JA, 1991, J BIOL CHEM, V266, P19320; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; SYKES DE, 1992, DIFFERENTIATION, V50, P41, DOI 10.1111/j.1432-0436.1992.tb00484.x; Tillmann-Bogush M, 1999, J BIOL CHEM, V274, P1172, DOI 10.1074/jbc.274.2.1172; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; ZEHEB R, 1988, GENE, V73, P459, DOI 10.1016/0378-1119(88)90510-0; Zhang MC, 1999, MOL CELL BIOL, V19, P7314; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	46	94	100	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3341	3347		10.1074/jbc.M006538200	http://dx.doi.org/10.1074/jbc.M006538200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11001948	hybrid			2022-12-27	WOS:000166784900048
J	Bengtsson, E; Aspberg, A; Heinegard, D; Sommarin, Y; Spillmann, D				Bengtsson, E; Aspberg, A; Heinegard, D; Sommarin, Y; Spillmann, D			The amino-terminal part of PRELP binds to heparin and heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; COLLAGEN FIBRILLOGENESIS; PROTEOGLYCAN DECORIN; PROTEIN; CARTILAGE; GLYCOSAMINOGLYCAN; FIBROMODULIN; FAMILY; DIVERSITY; HOMOLOGY	PRELP (proline, arginine-rich end leucine-rich repeat protein) is an extracellular matrix leucine-rich repeat protein. The amino-terminal region of PRELP differs from that of other leucine-rich repeat proteins in containing a high number of proline and arginine residues. The clustered proline and basic residues are conserved in rat, bovine, and human PRELP, Although the function of PRELP is not yet known, the clustered arginine residues suggest a heparan sulfate/heparin-binding capacity, We show here that PRELP indeed binds heparin and heparan sulfate. Truncated PRELP without the amino-terminal region does not bind heparin. The dissociation constant for the interaction of PRELP with heparin was determined by an in solution binding assay and by surface plasmon resonance analysis to be in the range of 10-30 nM A 6-mer heparin oligosaccharide was the smallest size showing binding to PRELP, The binding increased with increasing length up to an 18-mer and depended on the degree of sulfation of heparin as well as heparan sulfate, Sulfate groups at all positions were shown to be of importance for the binding. Fibroblasts bind PRELP, and this interaction is inhibited with heparin, suggesting a function for PRELP as a linker between the matrix and cell surface proteoglycans.	Univ Lund, Dept Cell & Mol Biol, Sect Connect Tissue Biol, SE-22100 Lund, Sweden; Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden	Lund University; Uppsala University	Heinegard, D (corresponding author), Univ Lund, Dept Cell & Mol Biol, Sect Connect Tissue Biol, POB 94, SE-22100 Lund, Sweden.		Bengtsson, Eva/AAA-1968-2019	Aspberg, Anders/0000-0002-6588-6944; Bengtsson, Eva/0000-0001-7075-1772				ADAMS ME, 1992, ANAL BIOCHEM, V202, P89, DOI 10.1016/0003-2697(92)90211-O; ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; BENGTSSON E, 1995, J BIOL CHEM, V270, P25639, DOI 10.1074/jbc.270.43.25639; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; FISHER LW, 1989, J BIOL CHEM, V264, P4571; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEINEGARD D, 1986, J BIOL CHEM, V261, P3866; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Kohfeldt E, 1996, EUR J BIOCHEM, V238, P333, DOI 10.1111/j.1432-1033.1996.0333z.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Moses J, 1997, EUR J BIOCHEM, V248, P767, DOI 10.1111/j.1432-1033.1997.t01-1-00767.x; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; Petersen F, 1999, J BIOL CHEM, V274, P12376, DOI 10.1074/jbc.274.18.12376; POSCHL E, 1994, EMBO J, V13, P3741, DOI 10.1002/j.1460-2075.1994.tb06683.x; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; Roden L., 1972, METHODS ENZYMOLOGY, V28, P73; Schmid F. Z., 1997, PROTEIN STRUCTURE PR, P261; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; SOMMARIN Y, 1989, EXP CELL RES, V184, P181, DOI 10.1016/0014-4827(89)90376-5; Sommarin Y, 1998, J BIOL CHEM, V273, P16723, DOI 10.1074/jbc.273.27.16723; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	45	53	61	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40695	40702		10.1074/jbc.M007917200	http://dx.doi.org/10.1074/jbc.M007917200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007795	hybrid			2022-12-27	WOS:000166114600007
J	Cruz, JC; Chang, TY				Cruz, JC; Chang, TY			Fate of endogenously synthesized cholesterol in Niemann-Pick type C1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; SPHINGOLIPID-STORAGE DISEASES; COENZYME-A REDUCTASE; HAMSTER OVARY CELLS; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; N-BUTYLDEOXYNOJIRIMYCIN; INTRACELLULAR-TRANSPORT; FIBROBLASTS; PROTEIN	Mammalian cells obtain cholesterol via two pathways: endogenous synthesis in the endoplasmic reticulum and exogenous sources mainly through the low density lipoprotein (LDL) receptor pathway. We performed pulse-chase experiments to monitor the fate of endogenously synthesized cholesterol and showed that, after reaching the plasma membrane from the endoplasmic reticulum, the newly synthesized cholesterol eventually accumulates in an internal compartment in Niemann-Pick type C1 (NPC1) cells. Thus, the ultimate fate of endogenously synthesized cholesterol in NPC1 cells is the same as LDL-derived cholesterol. However, the time required for endogenous cholesterol to accumulate internally is much slower than LDL-derived cholesterol. Different pathways thus govern the post-plasma membrane trafficking of endogenous cholesterol and LDL-derived cholesterol to the internal compartment, Results using the inhibitor N-butyldeoxynojirimycin, which depletes cellular complex glycosphingolipids, demonstrates that the cholesterol trafficking defect in NPC1 cells is not caused by ganglioside accumulation. The ultimate cause of death in NPC disease is progressive neurological deterioration in the central nervous system, where the major source of cholesterol is derived from endogenous synthesis. Our current study provides a plausible link between defects in intracellular trafficking of endogenous cholesterol and the etiology of Niemann-Pick type C disease.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Chang, TY (corresponding author), Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA.			Chang, Ta-Yuan/0000-0002-3249-0468	NHLBI NIH HHS [HL36709] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036709, R37HL036709] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BYERS DM, 1992, BIOCHIM BIOPHYS ACTA, V1138, P20, DOI 10.1016/0925-4439(92)90146-E; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHANG CCY, 1986, BIOCHEMISTRY-US, V25, P1693, DOI 10.1021/bi00355a038; Chang CCY, 1998, J BIOL CHEM, V273, P35132, DOI 10.1074/jbc.273.52.35132; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CHANG TY, 1980, J BIOL CHEM, V255, P7787; Chen CS, 1999, LANCET, V354, P901, DOI 10.1016/S0140-6736(98)10034-X; CHIN J, 1981, J BIOL CHEM, V256, P6304; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; Gu JZ, 1997, P NATL ACAD SCI USA, V94, P7378, DOI 10.1073/pnas.94.14.7378; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; Henderson LP, 2000, J BIOL CHEM, V275, P20179, DOI 10.1074/jbc.M001793200; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; LANGE Y, 1994, J BIOL CHEM, V269, P3411; Lange Y, 1998, J BIOL CHEM, V273, P18915, DOI 10.1074/jbc.273.30.18915; LIMANEK JS, 1978, P NATL ACAD SCI USA, V75, P5452, DOI 10.1073/pnas.75.11.5452; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; Liu YJ, 2000, HUM MOL GENET, V9, P1087, DOI 10.1093/hmg/9.7.1087; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; Millard EE, 2000, J BIOL CHEM, V275, P38445, DOI 10.1074/jbc.M003180200; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Pentchev P. G., 1995, METABOLIC MOL BASIS; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Platt FM, 1997, SCIENCE, V276, P428, DOI 10.1126/science.276.5311.428; PLATT FM, 1994, J BIOL CHEM, V269, P8362; Platt FM, 1997, J BIOL CHEM, V272, P19365, DOI 10.1074/jbc.272.31.19365; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; SPILLANE DM, 1995, BBA-LIPID LIPID MET, V1254, P283, DOI 10.1016/0005-2760(94)00190-A; Turley SD, 1998, AM J PHYSIOL-ENDOC M, V274, pE1099, DOI 10.1152/ajpendo.1998.274.6.E1099; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; URBANI L, 1990, J BIOL CHEM, V265, P1919; Xie CL, 2000, J LIPID RES, V41, P1278; Yano T, 1996, P JPN ACAD B-PHYS, V72, P214, DOI 10.2183/pjab.72.214	42	79	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41309	41316		10.1074/jbc.M008272200	http://dx.doi.org/10.1074/jbc.M008272200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11013265	hybrid			2022-12-27	WOS:000166114600086
J	So, SP; Li, DW; Ruan, KH				So, SP; Li, DW; Ruan, KH			Identification of the substrate interaction site in the N-terminal membrane anchor segment of thromboxane A(2) synthase by determination of its substrate analog conformational changes using high resolution NMR technique	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; COHERENCE TRANSFER; SMOOTH-MUSCLE; SPECTROSCOPY; PROSTACYCLIN; TOPOLOGY; BIOSYNTHESIS; ASSIGNMENT; METABOLISM; PROTEINS	The present studies describe an investigation for the interaction of N-terminal membrane anchor domain of thromboxane A(2) synthase (TXAS) with its substrate analog in a membrane-bound environment using the two-dimensional NMR technique. TXAS and prostaglandin I-2 synthase (PGIS), respectively, convert the same substrate, prostaglandin H-2 (PGH(2)), to thromboxane A, and prostaglandin I-2, which have opposite biological functions. Our topology studies have indicated that the N-terminal region of TXAS has a longer N-terminal endoplasmic reticulum (ER) membrane anchor region compared with the same segment proposed for PGIS, The differences in their interaction with the ER membrane may have an important impact to facilitate their common substrate, PGH(2), across the membrane into their active sites from the luminal to the cytoplasmic side of the ER. To test this hypothesis, we first investigated the interaction of the TXAS N-terminal membrane anchor domain with its substrate analog. A synthetic peptide corresponding to the N-terminal membrane anchor domain (residues 135) of TXAS, which adopted a stable helical structure and exhibited a membrane anchor function in the membrane-bound environment, was used to interact with a stable PGH, analog, U44069, High resolution two-dimensional NMR experiments, NOESY and TOCSY, were performed to solve the solution structures of U44069 in a membrane-mimicking environment using dodecylphosphocholine micelles, Different U44069 conformations were clearly observed in the presence and absence of the TXAS N-terminal membrane anchor domain, Through combination of the two-dimensional NMR experiments, completed H-1 NMR assignments of U44069 were obtained, and the data were used to construct three-dimensional structures of U44069 in H2O and dodecylphosphocholine micelles, showing the detailed conformation change upon the interaction with the membrane anchor domain, The observation supported the presence of a substrate interaction site in the N-terminal region. The combination of the structural information of U44069 and U46619 was able to simulate a solution structure of the unstable TXAS and PGIS substrate, PGH(2).	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Vasc Biol Res Ctr, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Ruan, KH (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, 6431 Fannin St, Houston, TX 77030 USA.	kruan@imed2010.med.uth.tmc.edu			NHLBI NIH HHS [HL56712] Funding Source: Medline; NINDS NIH HHS [NS23327] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056712, R29HL056712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASUS VJ, 1989, METHOD ENZYMOL, V177, P132; BAX A, 1985, J MAGN RESON, V61, P306, DOI 10.1016/0022-2364(85)90085-X; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BUNTING S, 1976, PROSTAG OTH LIPID M, V12, P897, DOI 10.1016/0090-6980(76)90125-8; CHAZIN WJ, 1988, J MOL BIOL, V202, P603, DOI 10.1016/0022-2836(88)90290-2; ENGLANDER SW, 1987, BIOCHEMISTRY-US, V26, P5953, DOI 10.1021/bi00393a001; GRANSTROM E, 1982, PROSTAGLANDINS CARDI, P15; HECKER M, 1989, J BIOL CHEM, V264, P141; INGERMANWOJENSKI C, 1981, J CLIN INVEST, V67, P1292, DOI 10.1172/JCI110157; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Lin YZ, 1998, ARCH BIOCHEM BIOPHYS, V352, P78, DOI 10.1006/abbi.1998.0599; MAJERUS PW, 1983, J CLIN INVEST, V72, P1521, DOI 10.1172/JCI111110; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V22, P1970; MILLER DK, 1985, J BIOL CHEM, V260, P1006; MONCADA S, 1977, THROMB RES, V11, P323, DOI 10.1016/0049-3848(77)90185-2; MOORE WT, 1991, TECHNIQUES PROTEIN C, V2, P511; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; OTTO JC, 1994, J BIOL CHEM, V269, P19868; Peterson Julian A., 1995, P151; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; REN Y, 1995, ARCH BIOCHEM BIOPHYS, V323, P205, DOI 10.1006/abbi.1995.0027; RUAN KH, 1993, J BIOL CHEM, V268, P19483; Ruan KH, 1998, BIOCHEMISTRY-US, V37, P822, DOI 10.1021/bi971881y; RUAN KH, 1994, J BIOL CHEM, V269, P20938; RUAN KH, 1991, BIOCHEM J, V274, P849, DOI 10.1042/bj2740849; SMITH WL, 1986, ANNU REV PHYSIOL, V48, P251; SMITH WL, 1983, J BIOL CHEM, V258, P5922; Wang LH, 1996, J BIOL CHEM, V271, P19970, DOI 10.1074/jbc.271.33.19970; WEKSLER BB, 1978, J CLIN INVEST, V62, P923, DOI 10.1172/JCI109220; WUTHRICH K, 1986, NMR PROTEINS NUCL AC, P44	32	11	11	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40679	40685		10.1074/jbc.M005752200	http://dx.doi.org/10.1074/jbc.M005752200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11006279	hybrid			2022-12-27	WOS:000166114600005
J	Bettati, S; Benci, S; Campanini, B; Raboni, S; Chirico, G; Beretta, S; Schnackerz, KD; Hazlett, TL; Gratton, E; Mozzarelli, A				Bettati, S; Benci, S; Campanini, B; Raboni, S; Chirico, G; Beretta, S; Schnackerz, KD; Hazlett, TL; Gratton, E; Mozzarelli, A			Role of pyridoxal 5 '-phosphate in the structural stabilization of O-acetylserine sulfhydrylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM LT-2; TIME-RESOLVED FLUORESCENCE; ESCHERICHIA-COLI; ASPARTATE-AMINOTRANSFERASE; TRYPTOPHAN SYNTHASE; MULTIENZYME COMPLEX; GUANIDINE-HYDROCHLORIDE; 3-DIMENSIONAL STRUCTURE; CONFORMATIONAL-CHANGE; CYSTEINE SYNTHETASE	Proteins belonging to the superfamily of pyridoxal 5'-phosphate-dependent enzymes are currently classified into three functional groups and five distinct structural fold types. The variation within this enzyme group creates an ideal system to investigate the relationships among amino acid sequences, folding pathways, and enzymatic functions. The number of known three-dimensional structures of pyridoxal 5'-phosphate-dependent enzymes is rapidly increasing, but only for relatively few have the folding mechanisms been characterized in detail. The dimeric O-acetylserine sulfhydrylase from Salmonella typhimurium belongs to the beta -family and fold type II group. Here we report the guanidine hydrochloride-induced unfolding of the apo- and holoprotein, investigated using a variety of spectroscopic techniques. Data from absorption, fluorescence, circular dichroism, P-31 nuclear magnetic resonance, time-resolved fluorescence anisotropy, and photon correlation spectroscopy indicate that the O-acetylserine sulfhydrylase undergoes extensive disruption of native secondary and tertiary structure before monomerization. Also, we have observed that the holo-O-acetylserine sulfhydrylase exhibits a greater conformational stability than the apoenzyme form. The data are discussed in light of the fact that the role of the coenzyme in structural stabilization varies among the pyridoxal 5'-phosphate-dependent enzymes and does not seem to be linked to the particular enzyme fold type.	Univ Parma, Inst Biochem Sci, I-43100 Parma, Italy; Univ Parma, Inst Phys Sci, I-43100 Parma, Italy; Univ Parma, Natl Inst Phys Matter, I-43100 Parma, Italy; Univ Milan, Dept Phys, I-20133 Milan, Italy; Univ Birmingham, Sch Chem, Birmingham B15 2TT, W Midlands, England; Univ Illinois, Fluorescence Dynam Lab, Urbana, IL 61801 USA	University of Parma; University of Parma; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Parma; University of Milan; University of Birmingham; University of Illinois System; University of Illinois Urbana-Champaign	Mozzarelli, A (corresponding author), Univ Parma, Inst Biochem Sci, I-43100 Parma, Italy.	biochim@unipr.it	Bettati, Stefano/V-9975-2018; Campanini, Barbara/L-9723-2017; Mozzarelli, Andrea/C-3615-2014; RABONI, Samanta/P-7823-2018	Bettati, Stefano/0000-0001-6787-0594; Campanini, Barbara/0000-0003-0359-0627; Mozzarelli, Andrea/0000-0003-3762-0062; RABONI, Samanta/0000-0003-3068-3714; CHIRICO, Giuseppe/0000-0001-6578-6460	NCRR NIH HHS [RR03155] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; ARTIGUES A, 1994, J BIOL CHEM, V269, P21990; BALK H, 1981, BIOCHEMISTRY-US, V20, P6391, DOI 10.1021/bi00525a017; BECKER MA, 1969, J BIOL CHEM, V244, P2418; Beechem J. M., 1988, SPIE, V909, P70; Benci S, 1999, BBA-PROTEIN STRUCT M, V1429, P317, DOI 10.1016/S0167-4838(98)00229-5; Benci S, 1997, BIOCHEMISTRY-US, V36, P15419, DOI 10.1021/bi970464i; Benci S, 1999, J PHOTOCH PHOTOBIO B, V48, P17, DOI 10.1016/S1011-1344(99)00003-2; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burkhard P, 1999, J MOL BIOL, V291, P941, DOI 10.1006/jmbi.1999.3002; Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037; CAI K, 1995, J BIOL CHEM, V270, P19294, DOI 10.1074/jbc.270.33.19294; Chen CH, 1998, ARCH BIOCHEM BIOPHYS, V349, P175, DOI 10.1006/abbi.1997.0457; Chirico G, 1999, APPL OPTICS, V38, P2059, DOI 10.1364/AO.38.002059; Christen P, 1985, TRANSAMINASES; COOK PF, 1978, J BIOL CHEM, V253, P7874; COOK PF, 1977, ARCH BIOCHEM BIOPHYS, V178, P293, DOI 10.1016/0003-9861(77)90194-1; Cunningham EL, 1999, P NATL ACAD SCI USA, V96, P11008, DOI 10.1073/pnas.96.20.11008; DOMINICI P, 1993, BIOCHEM J, V295, P493, DOI 10.1042/bj2950493; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; HARA S, 1990, PROTEIN EXPRES PURIF, V1, P79; HAZLETT TL, 1993, BIOCHEMISTRY-US, V32, P13575, DOI 10.1021/bi00212a025; HEROLD M, 1992, FEBS LETT, V308, P26, DOI 10.1016/0014-5793(92)81042-K; HEROLD M, 1990, BIOCHEMISTRY-US, V29, P1907, DOI 10.1021/bi00459a035; Hindson VJ, 2000, J BIOL CHEM, V275, P461, DOI 10.1074/jbc.275.1.461; HYDE CC, 1988, J BIOL CHEM, V263, P17857; IVANOV VI, 1973, EUR J BIOCHEM, V40, P519, DOI 10.1111/j.1432-1033.1973.tb03222.x; JAENICKE R, 1991, EUR J BIOCHEM, V202, P715, DOI 10.1111/j.1432-1033.1991.tb16426.x; JAMESON RM, 1991, BIOPHYSICAL BIOCH AS, P105; KALLEN RG, 1985, TRANSAMINASES, P37; KAWAHARA K, 1966, J BIOL CHEM, V241, P3228; KREDICH NM, 1969, J BIOL CHEM, V244, P2428; KREDICH NM, 1966, J BIOL CHEM, V241, P4955; LAKOWICZ JR, 1983, TOPICS FLUORESCENCE, P241; LEISTLER B, 1992, EUR J BIOCHEM, V205, P603, DOI 10.1111/j.1432-1033.1992.tb16818.x; MCCLURE GD, 1994, BIOCHEMISTRY-US, V33, P1674, DOI 10.1021/bi00173a009; MEI G, 1992, BIOCHEMISTRY-US, V31, P7224, DOI 10.1021/bi00147a003; MIZOBATA T, 1995, J BIOCHEM, V117, P384, DOI 10.1093/jb/117.2.384; Mozzarelli A, 1998, J MOL BIOL, V283, P135, DOI 10.1006/jmbi.1998.2038; MUNRO I, 1979, P NATL ACAD SCI USA, V76, P56, DOI 10.1073/pnas.76.1.56; NEET KE, 1994, PROTEIN SCI, V3, P2167, DOI 10.1002/pro.5560031202; Nozaki Y, 1972, Methods Enzymol, V26, P43; Pace C N, 1986, Methods Enzymol, V131, P266; RAIBAUD O, 1973, J BIOL CHEM, V248, P3451; Rege VD, 1996, BIOCHEMISTRY-US, V35, P13485, DOI 10.1021/bi961517j; RELIMPIO A, 1981, J BIOL CHEM, V256, P4478; REMETA DP, 1995, PURE APPL CHEM, V67, P1859, DOI 10.1351/pac199567111859; REYES AM, 1993, J BIOL CHEM, V268, P22281; Schnackerz KD, 1995, ARCH BIOCHEM BIOPHYS, V324, P71, DOI 10.1006/abbi.1995.9927; SCHNACKERZ KD, 1995, BIOCHEMISTRY-US, V34, P12152, DOI 10.1021/bi00038a008; Schneider G, 2000, STRUCT FOLD DES, V8, pR1, DOI 10.1016/S0969-2126(00)00085-X; SEIFERT T, 1985, BIOCHEMISTRY-US, V24, P339, DOI 10.1021/bi00323a016; SKRZYNIA C, 1974, J BIOL CHEM, V249, P2325; Sohl JL, 1998, NATURE, V395, P817, DOI 10.1038/27470; Steiner R. F., 1991, TOPICS FLUORESCENCE, V2, P1, DOI DOI 10.1007/0-306-47058-6_; Strambini GB, 1996, BIOCHEMISTRY-US, V35, P8392, DOI 10.1021/bi952919e; TAI CH, 1993, BIOCHEMISTRY-US, V32, P6433, DOI 10.1021/bi00076a017; Tanford C., 1961, PHYS CHEM MACROMOLEC; TOYAMA H, 1991, J BIOCHEM-TOKYO, V110, P279, DOI 10.1093/oxfordjournals.jbchem.a123571; Venkatesha B, 1998, BBA-PROTEIN STRUCT M, V1384, P141, DOI 10.1016/S0167-4838(98)00013-2; WEBER G, 1977, J CHEM PHYS, V66, P4081, DOI 10.1063/1.434481; WEBER G, 1960, BIOCHEM J, V75, P335, DOI 10.1042/bj0750335; ZETINA CR, 1980, J BIOL CHEM, V255, P4381	65	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40244	40251		10.1074/jbc.M007015200	http://dx.doi.org/10.1074/jbc.M007015200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10995767	Green Published, hybrid			2022-12-27	WOS:000166039500062
J	Dhakshinamoorthy, S; Jaiswal, AK				Dhakshinamoorthy, S; Jaiswal, AK			Small Maf (MafG and MafK) proteins negatively regulate antioxidant response element-mediated expression and antioxidant induction of the NAD(P)H : quinone oxidoreductase1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; YA-SUBUNIT GENE; CONTROLLING INDUCIBLE EXPRESSION; TRANSCRIPTION FACTOR NRF2; OXIDATIVE STRESS; PHENOLIC ANTIOXIDANTS; DETOXIFYING ENZYMES; HEME OXYGENASE-1; C-FOS; FAMILY	The antioxidant response element (ARE) is known to regulate expression and induction of NQO1, GST Ya, and other detoxifying enzyme genes in response to antioxidants and xenobiotics. The nuclear transcription factor Nrf2 and Nrf1 bind to the ARE and positively regulate expression and induction of the NQO1 and GST Ya genes. In this study, we demonstrate that overexpression of small Maf (MafG and MafK) proteins negatively regulate ARE-mediated expression and tert-butyl hydroquinone induction of the NQO1 and GST Ya genes in transfected Hep-G2 cells. In similar experiments, overexpression of small Maf proteins also repressed Nrf2-mediated up-regulation of ARE-mediated NQO1 and GST Ya genes expression in Hep-G2 cells co-transfected with Nrf2 and small Maf proteins. Band and supershift assays with the NQO1 gene ARE and nuclear proteins demonstrate that small MafG and MafK bind to the ARE as Maf-Maf homodimers and Maf-Nrf2 heterodimers. Therefore, Maf-Maf homodimers and possibly Maf-Nrf2 heterodimers play a role in negative regulation of ARE-mediated transcription and antioxidant induction of NQO1 and other detoxifying enzyme genes. In contrast to Maf-Nrf2, the Maf-Nrf1 heterodimers failed to bind with the NQO1 gene ARE and did not demonstrate the repressive effect in transfection assays.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.	ajaiswal@bcm.tmc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047466, R01GM047466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CRESTEIL T, 1991, BIOCHEM PHARMACOL, V42, P1021, DOI 10.1016/0006-2952(91)90284-C; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; JAISWAL AK, 1994, J BIOL CHEM, V269, P14502; Jaiswal AK, 1999, INT CONGR SER, V1172, P103; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; Kwong M, 1999, J BIOL CHEM, V274, P37491, DOI 10.1074/jbc.274.52.37491; LI Y, 1992, J BIOL CHEM, V267, P15097; Liu SX, 1996, BIOCHEMISTRY-US, V35, P11517, DOI 10.1021/bi960572p; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; MONINOVA H, 1999, BIOCHEM BIOPH RES CO, V261, P661; Montano MM, 1998, J BIOL CHEM, V273, P25443, DOI 10.1074/jbc.273.39.25443; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; OESCH F, 1991, NATO ADV SCI I A-LIF, V202, P447; OKUDA A, 1990, EMBO J, V9, P1131, DOI 10.1002/j.1460-2075.1990.tb08219.x; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; Radjendirane Venugopal, 1997, P441; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SCHLAGER JJ, 1990, INT J CANCER, V45, P403, DOI 10.1002/ijc.2910450304; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2; TEPHLY TR, 1990, TRENDS PHARMACOL SCI, V11, P276, DOI 10.1016/0165-6147(90)90008-V; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; VASLIOU V, 1995, BIOCHEM PHARMACOL, V12, P2057; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wilkinson J, 1998, BIOCHEM BIOPH RES CO, V253, P855, DOI 10.1006/bbrc.1998.9804; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972	46	174	180	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40134	40141		10.1074/jbc.M003531200	http://dx.doi.org/10.1074/jbc.M003531200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11013233	hybrid			2022-12-27	WOS:000166039500047
J	Okuda, T; Mita, S; Yamauchi, S; Fukuta, N; Nakano, H; Sawada, T; Habuchi, O				Okuda, T; Mita, S; Yamauchi, S; Fukuta, N; Nakano, H; Sawada, T; Habuchi, O			Molecular cloning and characterization of GalNAc (4-sulfotransferase expressed in human pituitary gland	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; FIBROBLAST GROWTH-FACTOR; L-SELECTIN LIGAND; CHONDROITIN 6-SULFOTRANSFERASE; HEPARAN-SULFATE; GLYCOPROTEIN HORMONES; CARBONIC-ANHYDRASE; SIALYLATED OLIGOSACCHARIDES; STRUCTURAL ELUCIDATION	We have previously cloned chondroitin-4-sulfotransferase (C4ST) cDNA from mouse brain. In this paper, we report cloning and characterization of GalNAc 4-sulfotransferase (GalNAc4ST), which transfers sulfate to position 4 of the nonreducing terminal GalNAc residue. The obtained cDNA contains a single open reading frame that predicts a type II transmembrane protein composed of 424 amino acid residues. Identity of the amino acid sequence between GalNAc4ST and human C4ST was 30%. When the cDNA was transfected in COS-7 cells, sulfotransferase activity toward carbonic anhydrase VI was overexpressed but no sulfotransferase activity toward chondroitin or desulfated dermatan sulfate was increased over the control. Sulfation of carbonic anhydrase VI by the recombinant GalNAc4ST occurred at position 4 of the GalNAc residue of N-linked oligosaccharides. The recombinant GalNAc4ST transferred sulfate to position 4 of GalNAc residue of p-nitrophenyl GalNAc, indicating that this sulfotransferase transfers sulfate to position 4 at the nonreducing terminal GalNAc residue. Dot blot analysis showed that the message of GalNAc4ST was expressed strongly in the human pituitary, suggesting that the cloned GalNAc4ST may be involved in the synthesis of the nonreducing terminal GalNAc 4-sulfate residues found in the N-linked oligosaccharides of pituitary glycoprotein hormones.	Aichi Univ Educ, Dept Life Sci, Kariya, Aichi 4488542, Japan; Aichi Univ Educ, Dept Chem, Kariya, Aichi 4488542, Japan	Aichi University Education; Aichi University Education	Habuchi, O (corresponding author), Aichi Univ Educ, Dept Life Sci, Kariya, Aichi 4488542, Japan.		Nakano, Hirofumi/N-4588-2019; Okuda, Tetsuya/K-5305-2018	Nakano, Hirofumi/0000-0002-7632-8630; Okuda, Tetsuya/0000-0002-5262-8057				ARUFFO A, 1991, CURRENT PROTOCOL S43, V3; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brockhausen I, 1997, TRENDS GLYCOSCI GLYC, V9, P379, DOI 10.4052/tigg.9.379; DELFERT DM, 1985, ANAL BIOCHEM, V148, P303, DOI 10.1016/0003-2697(85)90233-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERNLEY RT, 1988, BIOCHEM J, V249, P201, DOI 10.1042/bj2490201; Fiete D, 1997, J BIOL CHEM, V272, P14629, DOI 10.1074/jbc.272.23.14629; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; Galustian C, 1997, BIOCHEM BIOPH RES CO, V240, P748, DOI 10.1006/bbrc.1997.7737; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; Habuchi O, 1996, GLYCOBIOLOGY, V6, P51, DOI 10.1093/glycob/6.1.51; HABUCHI O, 1980, BIOCHIM BIOPHYS ACTA, V616, P208, DOI 10.1016/0005-2744(80)90139-4; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; Habuchi O, 1997, GLYCOBIOLOGY, V7, P405, DOI 10.1093/glycob/7.3.405; HABUCHI O, 1995, J BIOL CHEM, V260, P13102; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; HOOPER LV, 1995, J BIOL CHEM, V270, P5985, DOI 10.1074/jbc.270.11.5985; HOOPER LV, 1995, J BIOL CHEM, V270, P16327, DOI 10.1074/jbc.270.27.16327; IMAI Y, 1993, NATURE, V361, P555; Kimura N, 1999, P NATL ACAD SCI USA, V96, P4530, DOI 10.1073/pnas.96.8.4530; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; Malet C, 1997, CARBOHYD RES, V303, P51, DOI 10.1016/S0008-6215(97)00142-0; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; NAGASAWA K, 1979, J BIOCHEM-TOKYO, V86, P1323, DOI 10.1093/oxfordjournals.jbchem.a132648; Nair SM, 1997, J NEUROCHEM, V68, P1286; Okuda T, 2000, J BIOCHEM, V128, P763, DOI 10.1093/oxfordjournals.jbchem.a022813; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; SKELTON TP, 1991, J BIOL CHEM, V266, P17142; SKELTON TP, 1992, J BIOL CHEM, V267, P12998; SUNDARAM V, 1986, AM J HUM GENET, V38, P125; Torii T, 2000, GLYCOBIOLOGY, V10, P203, DOI 10.1093/glycob/10.2.203; Tsuboi S, 1996, J BIOL CHEM, V271, P27213, DOI 10.1074/jbc.271.44.27213; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; Yamauchi S, 1999, J BIOL CHEM, V274, P2456, DOI 10.1074/jbc.274.4.2456; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975	51	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40605	40613		10.1074/jbc.M007983200	http://dx.doi.org/10.1074/jbc.M007983200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11001942	hybrid			2022-12-27	WOS:000166039500108
J	Robino, G; Parola, M; Marra, F; Caligiuri, A; De Franco, RMS; Zamara, E; Bellomo, G; Gentilini, P; Pinzani, M; Dianzani, MU				Robino, G; Parola, M; Marra, F; Caligiuri, A; De Franco, RMS; Zamara, E; Bellomo, G; Gentilini, P; Pinzani, M; Dianzani, MU			Interaction between 4-hydroxy-2,3-alkenals and the platelet-derived growth factor-beta receptor - Reduced tyrosine phosphorylation and downstream signaling in hepatic stellate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-STORING CELLS; NF-KAPPA-B; MONOCYTE CHEMOTACTIC PROTEIN-1; LIPID-PEROXIDATION; HUMAN LIVER; PHOSPHATIDYLINOSITOL 3-KINASE; FIBROBLAST PROLIFERATION; OXIDATIVE MODIFICATION; TRANSCRIPTION FACTOR; BINDING-ACTIVITY	Hepatic stellate cells (HSC) undergo activation toward myofibroblast-like cells during early stages of liver injury associated with fibrogenesis. Platelet-derived growth factor (PDGF), particularly its BE isoform, has been identified as the most potent mitogen for HSC. 4-Hydroxy-2,3-nonenal and related 4-hydroxy-2,3-alkenals (HAKs) have been suggested to modulate the process of HSC activation. In this study we investigated the relationship between HAKs and PDGF receptor activation in human HSC. By employing noncytotoxic concentrations (10(-6) M) of HAKs, we observed a significant inhibition of PDGF-BB-dependent DNA synthesis. HAKs inhibited relevant pathways of PDGF-BB-dependent mitogenic signaling, including autophosphorylation of PDGF receptor (PDGF-R) beta subunits and activation of phosphatidylinositol 3-kinase and extracellular regulated kinases 1/2. Inhibition of DNA synthesis was reversible, and recovery of PDGF-mediated mitogenic signaling occurred within 24-48 h and was associated with HAKs-induced up-regulation of PDGF-R beta gene expression. 4-Hydroxy-2,3-nonena1, used as a model HAK, inhibited the intrinsic tyrosine kinase activity associated with the PDGF-R beta subunit, whereas binding of PDGF to its receptor was unaffected. This study identifies a novel regulatory mechanism of reactive aldehydes on PDGF receptor signaling and biologic actions, which may be relevant in several pathophysiological conditions, including liver fibrosis.	Univ Turin, Dipartimento Med & Oncol Sperimentale, I-10125 Turin, Italy; Univ Florence, Dipartimento Med Interna, I-50134 Florence, Italy; Univ A Avogadro, Dipartimento Sci Med, I-28100 Novara, Italy	University of Turin; University of Florence; University of Eastern Piedmont Amedeo Avogadro	Parola, M (corresponding author), Univ Turin, Dipartimento Med & Oncol Sperimentale, Corso Raffaello 30, I-10125 Turin, Italy.	parola@medfarm.unito.it	Marra, Fabio/K-7263-2016	Marra, Fabio/0000-0001-8629-0878; Parola, Maurizio/0000-0001-7720-5141				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Baroni GS, 1998, HEPATOLOGY, V27, P720; Blanc EM, 1997, J NEUROCHEM, V69, P570; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; CASINI A, 1993, GASTROENTEROLOGY, V105, P245, DOI 10.1016/0016-5085(93)90033-9; Casini A, 1997, HEPATOLOGY, V25, P361; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CRAWFORD D, 1988, ONCOGENE, V3, P27; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dianzani MU, 1998, FREE RADICAL RES, V28, P553, DOI 10.3109/10715769809065811; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; GAY S, 1989, J INVEST DERMATOL, V92, P301, DOI 10.1111/1523-1747.ep12276895; GESUALDO L, 1994, J CLIN INVEST, V94, P50, DOI 10.1172/JCI117348; GESUALDO L, 1991, LAB INVEST, V65, P160; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KS, 1995, J CLIN INVEST, V96, P2461, DOI 10.1172/JCI118304; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; MARRA F, 1993, J CLIN INVEST, V92, P1674, DOI 10.1172/JCI116753; Marra F, 1999, J INVEST MED, V47, P66; MARRA F, 1995, FEBS LETT, V376, P141, DOI 10.1016/0014-5793(95)01261-0; Marra F, 1997, GASTROENTEROLOGY, V112, P1297, DOI 10.1016/S0016-5085(97)70144-6; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; NAGAOKA I, 1990, J CLIN INVEST, V85, P2023, DOI 10.1172/JCI114669; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PARADISI L, 1985, CHEM-BIOL INTERACT, V53, P209, DOI 10.1016/S0009-2797(85)80097-1; PAROLA M, 1993, BIOCHEM BIOPH RES CO, V194, P1044, DOI 10.1006/bbrc.1993.1927; Parola M, 1998, J CLIN INVEST, V102, P1942, DOI 10.1172/JCI1413; Parola M, 1999, ANTIOXID REDOX SIGN, V1, P255, DOI 10.1089/ars.1999.1.3-255; PINZANI M, 1995, HEPATOLOGY, V21, P232, DOI 10.1002/hep.1840210136; PINZANI M, 1989, J CLIN INVEST, V84, P1786, DOI 10.1172/JCI114363; Pinzani M, 1998, LIVER, V18, P2; Pinzani M, 1996, AM J PATHOL, V148, P785; Poli G, 1997, FREE RADICAL BIO MED, V22, P287, DOI 10.1016/S0891-5849(96)00327-9; REUTERDAHL C, 1991, LAB INVEST, V64, P321; Rigacci S, 1997, BIOCHEM J, V324, P791, DOI 10.1042/bj3240791; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSSI MA, 1991, BIOCHEM PHARMACOL, V39, P1715; Sandirasegarane L, 2000, AM J PHYSIOL-CELL PH, V279, pC225, DOI 10.1152/ajpcell.2000.279.1.C225; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHIBANUMA M, 1988, ONCOGENE, V3, P17; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SILVER BJ, 1989, P NATL ACAD SCI USA, V86, P1056, DOI 10.1073/pnas.86.3.1056; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; UCHIDA K, 1994, BIOCHEMISTRY-US, V33, P12487, DOI 10.1021/bi00207a016; UCHIDA K, 1994, METHOD ENZYMOL, V233, P371; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Whalen R, 1999, HEPATOLOGY, V30, P927, DOI 10.1002/hep.510300404; Wilmer WA, 1997, J BIOL CHEM, V272, P10877	61	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40561	40567		10.1074/jbc.M007694200	http://dx.doi.org/10.1074/jbc.M007694200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007794	hybrid			2022-12-27	WOS:000166039500102
J	Sinal, CJ; Miyata, M; Tohkin, M; Nagata, K; Bend, JR; Gonzalez, FJ				Sinal, CJ; Miyata, M; Tohkin, M; Nagata, K; Bend, JR; Gonzalez, FJ			Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID EPOXYGENASE; NA-K-ATPASE; EPOXYEICOSATRIENOIC ACIDS; HYPERTENSIVE RATS; LIVER; METABOLITES; EICOSANOIDS; MICE; BIOSYNTHESIS; INHIBITORS	Renal microsomal cytochrome P-450 monooxygenase-dependent metabolism of arachidonic acid generates a series of regioisomeric epoxyeicosatrienoic acids that can be further metabolized by soluble epoxide hydrolase to the corresponding dihydroxyeicosatrienoic acids. Evidence exists that these metabolites affect renal function and, in particular, blood pressure regulation. To examine this possibility, blood pressure and renal arachidonic acid metabolism were examined in mice with a targeted disruption of the soluble epoxide hydrolase gene. Systolic blood pressure of male soluble epoxide hydrolase-null mice was lower compared with wild-type mice in both the absence and presence of dietary salt loading. Both female soluble epoxide hydrolase-null and wild-type female mice also had significantly lower systolic blood pressure than male wild-type mice. Renal formation of epoxyeicosatrienoic and dihydroxyeicosatrienoic acids was markedly lower for soluble epoxide hydrolase-null versus wild-type mice of both sexes. Although disruption of soluble epoxide hydrolase in female mice had minimal effects on blood pressure, deletion of this gene feminized male mice by lowering systolic blood pressure and altering arachidonic acid metabolism. These data provide the first direct evidence for a role for soluble epoxide hydrolase in blood pressure regulation and identify this enzyme as a novel and attractive target for therapeutic intervention in hypertension.	NCI, Lab Metab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6A 5C1, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Western University (University of Western Ontario)	Gonzalez, FJ (corresponding author), NCI, Lab Metab, Div Basic Sci, NIH, Bldg 37,Rm 3E24, Bethesda, MD 20892 USA.			Sinal, Christopher/0000-0001-8301-3349	NATIONAL CANCER INSTITUTE [Z01BC005562, ZIABC005562] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Argiriadi MA, 1999, P NATL ACAD SCI USA, V96, P10637, DOI 10.1073/pnas.96.19.10637; BORHAN B, 1995, ANAL BIOCHEM, V231, P188, DOI 10.1006/abio.1995.1520; Campbell WB, 2000, TRENDS PHARMACOL SCI, V21, P125, DOI 10.1016/S0165-6147(00)01472-3; Capdevila JH, 2000, J LIPID RES, V41, P163; CAPDEVILA JH, 1992, J BIOL CHEM, V267, P21720; CARROLL MA, 1993, J BIOL CHEM, V268, P12260; Carroll MA, 1997, ADV EXP MED BIOL, V407, P255; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; GILL SS, 1979, BIOCHEM BIOPH RES CO, V89, P965, DOI 10.1016/0006-291X(79)91872-2; Grant DF, 1996, BIOCHEM PHARMACOL, V51, P503, DOI 10.1016/0006-2952(95)02227-9; GRANT DF, 1993, J BIOL CHEM, V268, P17628; HASEGAWA LS, 1982, BIOCHEM PHARMACOL, V31, P1979, DOI 10.1016/0006-2952(82)90408-7; HIRT DL, 1989, J CLIN INVEST, V84, P1805, DOI 10.1172/JCI114365; HU SL, 1993, EUR J PHARMACOL, V230, P215, DOI 10.1016/0014-2999(93)90805-R; Imig JD, 1996, J AM SOC NEPHROL, V7, P2364; Imig JD, 1999, METH MOL B, V120, P173; INOUE N, 1995, BIOL PHARM BULL, V18, P536; KATOH T, 1991, AM J PHYSIOL, V261, pF578, DOI 10.1152/ajprenal.1991.261.4.F578; KNICKLE LC, 1994, MOL PHARMACOL, V45, P1273; LOURY DN, 1985, BIOCHEM PHARMACOL, V34, P1827, DOI 10.1016/0006-2952(85)90656-2; MA YH, 1994, AM J PHYSIOL, V267, pR579, DOI 10.1152/ajpregu.1994.267.2.R579; MAKITA K, 1994, J CLIN INVEST, V94, P2414, DOI 10.1172/JCI117608; Messer-Letienne I, 1999, AM J HYPERTENS, V12, P398; Miyata M, 1999, J BIOL CHEM, V274, P23963, DOI 10.1074/jbc.274.34.23963; Morisseau C, 1999, P NATL ACAD SCI USA, V96, P8849, DOI 10.1073/pnas.96.16.8849; O'Banion MK, 1999, CRIT REV NEUROBIOL, V13, P45, DOI 10.1615/CritRevNeurobiol.v13.i1.30; Ominato M, 1996, J MEMBRANE BIOL, V152, P235, DOI 10.1007/s002329900101; PINOT F, 1995, BIOCHEM PHARMACOL, V50, P501, DOI 10.1016/0006-2952(95)00167-X; RAPP JP, 1982, HYPERTENSION, V4, P753, DOI 10.1161/01.HYP.4.6.753; ROMERO MF, 1991, ADV PROSTAG THROMB L, V21, P205; ROMERO MF, 1991, RENAL PHYSIOL BIOCH, V14, P199; SAKAIRI Y, 1995, AM J PHYSIOL-RENAL, V268, pF931, DOI 10.1152/ajprenal.1995.268.5.F931; SATOH T, 1993, J CLIN INVEST, V91, P409, DOI 10.1172/JCI116215; SCHLADT L, 1987, BIOCHEM PHARMACOL, V36, P345, DOI 10.1016/0006-2952(87)90292-9; SCHLONDORFF D, 1987, AM J PHYSIOL, V253, pF464, DOI 10.1152/ajprenal.1987.253.3.F464; Seeds MC, 1999, CLIN REV ALLERG IMMU, V17, P5, DOI 10.1007/BF02737594; Seidegard J, 1997, ENVIRON HEALTH PERSP, V105, P791, DOI 10.2307/3433285; Spokas EG, 1999, METH MOL B, V120, P213; Stec DE, 1996, HYPERTENSION, V27, P1329, DOI 10.1161/01.HYP.27.6.1329; Yu ZG, 2000, MOL PHARMACOL, V57, P1011; Zeldin DC, 1996, ARCH BIOCHEM BIOPHYS, V330, P87, DOI 10.1006/abbi.1996.0229; ZELDIN DC, 1993, J BIOL CHEM, V268, P6402	42	285	303	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40504	40510		10.1074/jbc.M008106200	http://dx.doi.org/10.1074/jbc.M008106200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11001943	hybrid			2022-12-27	WOS:000166039500095
J	Withers, DA; Hakomori, S				Withers, DA; Hakomori, S			Human alpha(1,3)-fucosyltransferase IV (FUTIV) gene expression is regulated by Elk-1 in the U937 cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; SIALYL-LEWIS-X; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; DOMAIN TRANSCRIPTION FACTORS; MESSENGER-RNA EXPRESSION; FUCOSYL-TRANSFERASE GENE; HUMAN COLORECTAL-CANCER; TERNARY COMPLEX FACTORS; MOLECULAR-CLONING; E-SELECTIN	The alpha1,3-fucosyltransferase IV (FucTIV) encoded by its gene (FUTIV) is responsible for synthesis of Le(x) (Gal beta4[Fuc alpha3]GlcNAc beta 3Gal beta1,R), which causes compaction in the morula stage of the preimplantation mouse embryo, as well as alpha1,3-fucosylation at multiple internal GlcNAc of unbranched poly-N-acetyllactosamine, termed "myeloglycan," the physiological epitope of E-selectin. Since myeloglycan-type structure is also expressed in various types of human cancer and may mediate E-selectin-dependent metastasis, expression of FUTIV is oncodevelopmentally regulated. The mechanisms controlling FUTIV expression remain to be clarified. In this report, we further characterize FUTIV gene structure and define a non-TATA box-dependent transcriptional start region just upstream from the translational start. FUTIV promoter/reporter fusion constructs defined a "full-length" promoter and highly active fragments in the macrophage-derived U937 and myeloid HL60 cell lines. One highly active fragment contains a consensus binding site for the Ets-l transcription factor (Withers, D. A. and Hakomori, S. (1997) Glycoconj. J. 14, 764). Gel shift analysis shows specific binding to this site in nuclear extracts from U937 cells. Mutation of the Ets consensus site significantly reduces FUTIV promoter activity in both cell lines. Gel supershift and dominant negative cotransfection experiments identified the Ets family member Elk-l as one component binding and regulating the FUTIV promoter in U937 cells. The significance of FUTIV regulation by Elk-l is discussed.	Pacific NW Res Inst, Div Biomembrane Res, Seattle, WA 98122 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Withers, DA (corresponding author), Pacific NW Res Inst, Div Biomembrane Res, 720 Broadway, Seattle, WA 98122 USA.				NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER; NCI NIH HHS [CA42505] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akamatsu S, 1996, GLYCOCONJUGATE J, V13, P1021, DOI 10.1007/BF01053198; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; Boubelik M, 1998, GLYCOBIOLOGY, V8, P139, DOI 10.1093/glycob/8.2.139; Boubelik M, 1996, BIOCHEM BIOPH RES CO, V224, P283, DOI 10.1006/bbrc.1996.1022; Buckhaults P, 1997, J BIOL CHEM, V272, P19575, DOI 10.1074/jbc.272.31.19575; CAMERON HS, 1995, J BIOL CHEM, V270, P20112, DOI 10.1074/jbc.270.34.20112; Charron M, 1999, MOL CELL BIOL, V19, P5823; CHILDS RA, 1983, BIOCHEM J, V215, P491, DOI 10.1042/bj2150491; Clarke JL, 1996, J BIOL CHEM, V271, P10317, DOI 10.1074/jbc.271.17.10317; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Cullen P, 1997, ARTERIOSCL THROM VAS, V17, P1591, DOI 10.1161/01.ATV.17.8.1591; DENT CL, 1993, TRANSCRIPTION FACTOR, P1; DRABER P, 1987, P NATL ACAD SCI USA, V84, P5798, DOI 10.1073/pnas.84.16.5798; EGGENS I, 1989, J BIOL CHEM, V264, P9476; EGGENS I, 1989, BIOCHEM BIOPH RES CO, V158, P913, DOI 10.1016/0006-291X(89)92809-X; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; FUKUSHI Y, 1984, J BIOL CHEM, V259, P511; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; Grabenhorst E, 1998, J BIOL CHEM, V273, P30985, DOI 10.1074/jbc.273.47.30985; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Hakomori S, 1996, CANCER RES, V56, P5309; Handa K, 1997, BIOCHEMISTRY-US, V36, P12412, DOI 10.1021/bi971181t; Handa K, 1998, BIOCHEM BIOPH RES CO, V243, P199, DOI 10.1006/bbrc.1998.8080; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOLMES EH, 1995, J BIOL CHEM, V270, P8145, DOI 10.1074/jbc.270.14.8145; Ito H, 1997, INT J CANCER, V71, P556, DOI 10.1002/(SICI)1097-0215(19970516)71:4<556::AID-IJC9>3.3.CO;2-J; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Kaneko M, 1999, FEBS LETT, V452, P237, DOI 10.1016/S0014-5793(99)00640-7; Kang R, 1996, J BIOL CHEM, V271, P26706, DOI 10.1074/jbc.271.43.26706; Ko JH, 1999, J BIOL CHEM, V274, P22941, DOI 10.1074/jbc.274.33.22941; KOJIMA N, 1994, GLYCOCONJUGATE J, V11, P238, DOI 10.1007/BF00731224; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; Kudo T, 1998, LAB INVEST, V78, P797; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; LeMarer N, 1997, GLYCOBIOLOGY, V7, P357; Lo SK, 1997, BLOOD, V89, P307, DOI 10.1182/blood.V89.1.307.307_307_314; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MCCURLEY RS, 1995, GENOMICS, V26, P142, DOI 10.1016/0888-7543(95)80094-3; MIYAKE M, 1988, CANCER RES, V48, P7150; MOLLICONE R, 1992, CARBOHYD RES, V228, P265, DOI 10.1016/S0008-6215(00)90564-0; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; Niemela R, 1998, J BIOL CHEM, V273, P4021, DOI 10.1074/jbc.273.7.4021; Ogawa J, 1996, CANCER RES, V56, P325; Ozawa M, 1996, J BIOCHEM-TOKYO, V119, P302; Petretti T, 1999, BBA-GEN SUBJECTS, V1428, P209, DOI 10.1016/S0304-4165(99)00080-X; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; ROBINSON NE, 1994, GLYCOBIOLOGY, V4, P317, DOI 10.1093/glycob/4.3.317; Sambrook J., 2002, MOL CLONING LAB MANU; SASAKI K, 1994, J BIOL CHEM, V269, P14730; Schug J., 1997, CBILTR19971001V00 U; Shore P, 1996, MOL CELL BIOL, V16, P3338; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P770, DOI 10.1021/bi952461g; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; TURNER H, 1997, J EXP MED, V185, P45; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; Weissensteiner T, 1996, BIOTECHNIQUES, V21, P1102; WERNERT N, 1994, CANCER RES, V54, P5683; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Withers D. A., 1997, Glycoconjugate Journal, V14, P764; YAGO K, 1993, CANCER RES, V53, P5559; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Zhang W, 2000, BIOCHEM J, V347, P511, DOI 10.1042/0264-6021:3470511	79	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40588	40593		10.1074/jbc.M007262200	http://dx.doi.org/10.1074/jbc.M007262200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006292	hybrid			2022-12-27	WOS:000166039500105
J	Cohen, H; Azriel, A; Cohen, T; Meraro, D; Hashmueli, S; Bech-Otschir, D; Kraft, R; Dubiel, W; Levi, BZ				Cohen, H; Azriel, A; Cohen, T; Meraro, D; Hashmueli, S; Bech-Otschir, D; Kraft, R; Dubiel, W; Levi, BZ			Interaction between interferon consensus sequence-binding protein and COP9/signalosome subunit CSN2 (Trip15) - A possible link between interferon regulatory factor signaling and the COP9/signalosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; GP91(PHOX) EXPRESSION; POSITIVE FEEDBACK; HORMONE-RECEPTOR; COP9 SIGNALOSOME; MAMMALIAN-CELLS; FACTOR FAMILY; DNA-BINDING; FACTOR-I; COMPLEX	Interferon consensus sequence-binding protein (ICSBP) is a member of the interferon regulatory factors (IRF) that has a pivotal role in mediating resistance to pathogenic infections in mice and in promoting the differentiation of myeloid cells. ICSBP exerts some of its transcriptional activities via association with other factors that enable its binding to a variety of promoters containing DNA composite elements. These interactions are mediated through a specific COOH-terminal domain termed IAD (IRF association domain). To gain a broader insight of the capacity of ICSBP to interact with other factors, yeast two-hybrid screens were performed using ICSBP-IAD as a bait against a B-cell cDNA library. Trip15 was identified as a specific interacting factor with ICSBP in yeast cells, which was also confirmed by in vitro glutathione S-transferase pull-down assays and by coimmunoprecipitation studies in COS7 cells. Trip15 was recently identified as a component of the COP9/signalosome (CSN) complex composed of eight evolutionary conserved subunits and thus termed CSN2. This complex has a role in cell-signaling processes, which is manifested by its associated novel kinase activity and by the involvement of its subunits in regulating multiple cell-signaling pathways and cell-cycle progression. We show that in vitro association of ICSBP with the CSN leads to phosphorylation of ICSBP at a unique serine residue within its IAD. The phosphorylated residue is essential for efficient association with IRF-1 and thus for the repressor activity of ICSBP exerted on IRF-1. This suggests that the CSN has a role in integrating incoming signals that affect the transcriptional activity of ICSBP.	Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel; Humboldt Univ, Med Fac Charit 233, Inst Biochem, D-10117 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Technion Israel Institute of Technology; Humboldt University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Levi, BZ (corresponding author), Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel.	fobenzi@techunix.technion.ac.il		Dubiel, Wolfgang/0000-0002-3393-0701				Bartel P. L., 1993, CELLULAR INTERACTION, P153; BOVOLENTA C, 1994, P NATL ACAD SCI USA, V91, P5046, DOI 10.1073/pnas.91.11.5046; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Dressel U, 1999, MOL CELL BIOL, V19, P3383; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Fehr T, 1997, J EXP MED, V185, P921, DOI 10.1084/jem.185.5.921; Giese NA, 1997, J EXP MED, V186, P1535, DOI 10.1084/jem.186.9.1535; Goubeaud A, 1996, MECH DEVELOP, V57, P59, DOI 10.1016/0925-4773(96)00532-1; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; Hein J, 2000, INFECT IMMUN, V68, P1408, DOI 10.1128/IAI.68.3.1408-1417.2000; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Kantakamalakul W, 1999, J IMMUNOL, V162, P7417; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Mahalingam S, 1998, P NATL ACAD SCI USA, V95, P3419, DOI 10.1073/pnas.95.7.3419; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Meraro D, 1999, J IMMUNOL, V163, P6468; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Nagulapalli S, 1998, MOL CELL BIOL, V18, P4639, DOI 10.1128/MCB.18.8.4639; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Ortiz MA, 1999, P NATL ACAD SCI USA, V96, P2740, DOI 10.1073/pnas.96.6.2740; Osterlund MT, 1999, TRENDS CELL BIOL, V9, P113, DOI 10.1016/S0962-8924(99)01499-3; Perkel JM, 1998, J IMMUNOL, V160, P241; POLITIS AD, 1994, J IMMUNOL, V152, P2270; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Schaefer L, 1999, GENOMICS, V56, P310, DOI 10.1006/geno.1998.5728; SchartonKersten T, 1997, J EXP MED, V186, P1523, DOI 10.1084/jem.186.9.1523; Schmidt M, 1998, BLOOD, V91, P22, DOI 10.1182/blood.V91.1.22.22_22_29; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; SHARF R, 1995, J BIOL CHEM, V270, P13063, DOI 10.1074/jbc.270.22.13063; Sharf R, 1997, J BIOL CHEM, V272, P9785; Spain BH, 1996, MOL CELL BIOL, V16, P6698; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; Wei N, 1998, PHOTOCHEM PHOTOBIOL, V68, P237; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; WEISZ A, 1992, J BIOL CHEM, V267, P25589; WEISZ A, 1994, INT IMMUNOL, V6, P1125; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	51	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39081	39089		10.1074/jbc.M004900200	http://dx.doi.org/10.1074/jbc.M004900200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10991940	hybrid			2022-12-27	WOS:000165953100020
J	Carroll, JS; Prall, OWJ; Musgrove, EA; Sutherland, RL				Carroll, JS; Prall, OWJ; Musgrove, EA; Sutherland, RL			A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITORS; MAMMARY-CARCINOMA CELLS; CDK INHIBITORS; D1 EXPRESSION; GROWTH-FACTOR; S-PHASE; ANTIESTROGEN; PHOSPHORYLATION; PROGRESSION; ACTIVATION	Estrogen antagonists inhibit cell cycle progression in estrogen-responsive cells, but the molecular mechanisms are not fully defined. Antiestrogen-mediated G(0)/G(1) arrest is associated with decreased cyclin D1 gene expression, inactivation of cyclin D1-cyclin dependent kinase (Cdk) 4 complexes, and decreased phosphorylation of the retinoblastoma protein (pRb). We now show that treatment of MCF-7 breast cancer cells with the pure estrogen antagonist ICI 182780 results in inhibition of cyclin E-Cdk2 activity prior to a decrease in the G(1) to S phase transition. This decrease was dependent on p21(WAF1/Cip1) since treatment with antisense oligonucleotides to p21 attenuated the effect, Recruitment of p21 to cyclin E-Cdk2 complexes was in turn dependent on decreased cyclin D1 expression since it was apparent following treatment with antisense cyclin D1 oligonucleotides, To define where within the G(0) to S phase continuum antiestrogen-treated cells arrested, we assessed the relative abundance and phosphorylation state of pocket protein-E2F complexes. While both pRb and p107 levels were significantly decreased, p130 was increased 4-fold and was accompanied by the formation of p130.E2F4 complexes and the accumulation of hyperphophorylated E2F4, putative markers of cellular quiescence. Thus, ICI 182780 inhibits both cyclin D1-Cdk4 and cyclin E-Cdk2 activity, resulting in the arrest of MCF-7 cells in a state with characteristics of quiescence (G(0)), as opposed to G(1) arrest.	St Vincents Hosp, Canc Res Program, Garvan Inst Med Res, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney	Sutherland, RL (corresponding author), St Vincents Hosp, Canc Res Program, Garvan Inst Med Res, 384 Victoria St, Sydney, NSW 2010, Australia.		Sutherland, Robert L/A-8378-2008	Carroll, Jason/0000-0003-3643-0080				Altucci L, 1996, ONCOGENE, V12, P2315; Barboule N, 1997, ONCOGENE, V15, P2867, DOI 10.1038/sj.onc.1201469; Baserga R, 1985, BIOL CELL REPROD; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Clarke M, 1998, LANCET, V351, P1451; DEFRIEND DJ, 1994, CANCER RES, V54, P408; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harlow E., 1988, ANTIBODIES LAB MANUA; Harper JW, 1998, GENE DEV, V12, P285, DOI 10.1101/gad.12.3.285; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; KATZENELLENBOGEN BS, 1991, J NATL CANCER I, V83, P1434, DOI 10.1093/jnci/83.20.1434; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; Liu JB, 2000, ONCOGENE, V19, P661, DOI 10.1038/sj.onc.1203373; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MacGregor JI, 1998, PHARMACOL REV, V50, P151; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mayol X, 1997, Prog Cell Cycle Res, V3, P157; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Mori A, 1999, ONCOGENE, V18, P6209, DOI 10.1038/sj.onc.1203044; MUSGROVE EA, 1989, CANCER RES, V49, P2398; MUSGROVE EA, 1993, EUR J CANCER, V29A, P2273, DOI 10.1016/0959-8049(93)90221-Z; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OSBORNE CK, 1995, J NATL CANCER I, V87, P746, DOI 10.1093/jnci/87.10.746; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN RC, 1995, OXFORD TXB ONCOL, P629; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; SUTHERLAND RL, 1983, CANCER RES, V43, P3998; Swarbrick A, 2000, MOL CELL BIOL, V20, P2581, DOI 10.1128/MCB.20.7.2581-2591.2000; TAYLOR IW, 1983, CANCER RES, V43, P4007; Thomas NSB, 1998, J BIOL CHEM, V273, P23659, DOI 10.1074/jbc.273.37.23659; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; van der Sman J, 1999, J BIOL CHEM, V274, P12009, DOI 10.1074/jbc.274.17.12009; WAKELING AE, 1991, CANCER RES, V51, P3867; WAKELING AE, 1989, J MOL ENDOCRINOL, V2, P225, DOI 10.1677/jme.0.0020225; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804	56	121	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38221	38229		10.1074/jbc.M004424200	http://dx.doi.org/10.1074/jbc.M004424200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10991938	hybrid			2022-12-27	WOS:000165739800014
J	Chu, GX; Lester, JW; Young, KB; Luo, WS; Zhai, J; Kranias, EG				Chu, GX; Lester, JW; Young, KB; Luo, WS; Zhai, J; Kranias, EG			A single site (Ser(16)) phosphorylation in phospholamban is sufficient in mediating its maximal cardiac responses to beta-agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-DEPENDENT PHOSPHORYLATION; RETICULUM CALCIUM-TRANSPORT; SARCOPLASMIC-RETICULUM; PROTEIN-KINASE; ADRENERGIC STIMULATION; INTACT HEART; MYOCARDIAL-CONTRACTILITY; IN-VIVO; MECHANISMS; THR(17)	Phospholamban (PLB) can be phosphorylated at Ser(16) by cyclic AMP-dependent protein kinase and at Thr(17) by Ca2+-calmodulin-dependent protein kinase during beta -agonist stimulation. A previous study indicated that mutation of S16A in PLB resulted in lack of Thr(17) phosphorylation and attenuation of the beta -agonist stimulatory effects in perfused mouse hearts. To further delineate the functional interplay between dual-site PLB phosphorylation, we generated transgenic mice expressing the T17A mutant PLB in the cardiac compartment of the null background. Lines expressing similar levels of T17A mutant, S16A mutant, or wild-type PLB in the null background mere characterized in parallel. Cardiac myocyte basal mechanics and Ca2+ kinetics were similar among the three groups. Isoproterenol stimulation was associated with phosphorylation of both Ser(16) and Thr(17) in wild-type PLB and Ser(16) phosphorylation in T17A mutant PLB, whereas there was no detectable phosphorylation of S16A mutant PLB. Phosphorylation of Ser(16) alone in T17A mutant PLB resulted in responses of the mechanical and Ca2+ kinetic parameters to isoproterenol similar to those in wild-type myocytes, which exhibited dual-site PLB phosphorylation. However, those parameters were significantly attenuated in the S16A mutant myocytes. Thus, Ser(16) in PLB can be phosphorylated independently of Thr(17) in vivo, and phosphorylation of Ser(16) is sufficient for mediating the maximal cardiac responses to beta -adrenergic stimulation.	Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Kranias, EG (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, 231 Bethesda Ave, Cincinnati, OH 45267 USA.				NCRR NIH HHS [P40RR12358] Funding Source: Medline; NHLBI NIH HHS [HL26057, HL52318] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR012358] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026057, P50HL052318, R37HL026057] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASSANI RA, 1995, AM J PHYSIOL-HEART C, V268, pH703, DOI 10.1152/ajpheart.1995.268.2.H703; Calaghan SC, 1998, PFLUG ARCH EUR J PHY, V436, P948, DOI 10.1007/s004240050728; Chu GX, 1997, CIRC RES, V81, P485, DOI 10.1161/01.RES.81.4.485; Chu GX, 1998, J BIOL CHEM, V273, P33674, DOI 10.1074/jbc.273.50.33674; COLYER J, 1991, J BIOL CHEM, V266, P17486; Colyer J, 1998, ANN NY ACAD SCI, V853, P79, DOI 10.1111/j.1749-6632.1998.tb08258.x; DAVIS BA, 1983, J BIOL CHEM, V258, P3587; Hagemann D, 2000, J BIOL CHEM, V275, P22532, DOI 10.1074/jbc.C000253200; HOIT BD, 1995, CIRC RES, V77, P632, DOI 10.1161/01.RES.77.3.632; Hulme JT, 1997, PFLUG ARCH EUR J PHY, V434, P475, DOI 10.1007/s004240050423; Hussain M, 1997, AM J PHYSIOL-HEART C, V273, pH695, DOI 10.1152/ajpheart.1997.273.2.H695; Jackson WA, 1996, BIOCHEM J, V316, P201, DOI 10.1042/bj3160201; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; Kimura Y, 1996, J BIOL CHEM, V271, P21726, DOI 10.1074/jbc.271.36.21726; Kiss E, 1997, AM J PHYSIOL-HEART C, V272, pH785, DOI 10.1152/ajpheart.1997.272.2.H785; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; Kranias E.G., 1998, AM J PHYSIOL, V274, P1335; KRANIAS EG, 1985, BIOCHIM BIOPHYS ACTA, V844, P193, DOI 10.1016/0167-4889(85)90090-4; Kuschel M, 1999, AM J PHYSIOL-HEART C, V276, pH1625, DOI 10.1152/ajpheart.1999.276.5.H1625; LEPEUCH CJ, 1979, BIOCHEMISTRY-US, V18, P5150, DOI 10.1021/bi00590a019; LINDEMANN JP, 1985, J BIOL CHEM, V260, P4516; Luo WS, 1996, CIRC RES, V78, P839, DOI 10.1161/01.RES.78.5.839; Luo WS, 1998, J BIOL CHEM, V273, P4734, DOI 10.1074/jbc.273.8.4734; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MacLennan DH, 1998, ANN NY ACAD SCI, V853, P31, DOI 10.1111/j.1749-6632.1998.tb08254.x; MATTIAZZI A, 1994, AM J PHYSIOL, V267, pH812, DOI 10.1152/ajpheart.1994.267.2.H812; MOVSESIAN MA, 1984, J BIOL CHEM, V259, P8029; MundinaWeilenmann C, 1996, J BIOL CHEM, V271, P33561, DOI 10.1074/jbc.271.52.33561; NAPOLITANO R, 1992, J MOL CELL CARDIOL, V24, P387, DOI 10.1016/0022-2828(92)93193-N; RAEYMAEKERS L, 1988, BIOCHEM J, V252, P269, DOI 10.1042/bj2520269; Santana LF, 1997, J PHYSIOL-LONDON, V503, P21, DOI 10.1111/j.1469-7793.1997.021bi.x; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; TADA M, 1983, J MOL CELL CARDIOL, V15, P335, DOI 10.1016/0022-2828(83)91345-7; TALOSI L, 1993, AM J PHYSIOL, V264, pH791; Vittone L, 1998, J BIOL CHEM, V273, P9804, DOI 10.1074/jbc.273.16.9804; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; Wolska BM, 1996, AM J PHYSIOL-CELL PH, V271, pC391, DOI 10.1152/ajpcell.1996.271.1.C391	37	125	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38938	38943		10.1074/jbc.M004079200	http://dx.doi.org/10.1074/jbc.M004079200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10988285	hybrid			2022-12-27	WOS:000165739800108
J	Barnett, ME; Zolkiewska, A; Zolkiewski, M				Barnett, ME; Zolkiewska, A; Zolkiewski, M			Structure and activity of ClpB from Escherichia coli - Role of the amino- and carboxyl-terminal domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE SYSTEM; PROTEIN; MECHANISM; PROTEASES; HSP104; FAMILY; ASSAY; DNAK; GRPE	ClpB is a member of a protein-disaggregating multi-chaperone system in Escherichia coli, The mechanism of protein-folding reactions mediated by ClpB is currently unknown, and the functional role of different sequence regions in ClpB is under discussion. We have expressed and purified the full-length ClpB and three truncated variants with the N-terminal, C terminal, and a double N- and C-terminal deletion. We studied the protein concentration-dependent and ATP-induced oligomerization of ClpB, casein-induced activation of ClpB ATPase, and ClpB-assisted reactivation of denatured firefly luciferase, We found that both the N- and C-terminal truncation of ClpB strongly inhibited its chaperone activity. The reasons for such inhibition were different, however, for the N- and C-terminal truncation. Deletion of the C-terminal domain inhibited the self-association of ClpB, which led to decreased affinity for ATP and to decreased ATPase and chaperone activity of the C terminally truncated variants. In contrast, deletion of the N-terminal domain did not inhibit the self-association of ClpB and its basal ATPase activity but decreased the ability of casein to activate ClpB ATPase, These results indicate that the N-terminal region of ClpB may contain a functionally significant protein-binding site, whereas the main role of the C-terminal region is to support oligomerization of ClpB.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Barnett, ME (corresponding author), Kansas State Univ, Dept Biochem, 104 Willard Hall, Manhattan, KS 66506 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058626] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58626, R01 GM058626, R01 GM058626-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; Kessel M, 1996, FEBS LETT, V398, P274, DOI 10.1016/S0014-5793(96)01261-6; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; Maurizi MR, 1998, BIOCHEMISTRY-US, V37, P7778, DOI 10.1021/bi973093e; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; PARK SK, 1993, J BIOL CHEM, V268, P20170; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Stafford WF, 1994, MODERN ANAL ULTRACEN, P119; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WOO KM, 1992, J BIOL CHEM, V267, P20429; WYMAN J, 1990, BINDING LINKAGE FUNC, P206; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083; Zolkiewski M, 1999, PROTEIN SCI, V8, P1899, DOI 10.1110/ps.8.9.1899	23	94	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37565	37571		10.1074/jbc.M005211200	http://dx.doi.org/10.1074/jbc.M005211200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982797	Green Accepted, hybrid			2022-12-27	WOS:000165618700037
J	Cunha, RA; Almeida, T; Ribeiro, JA				Cunha, RA; Almeida, T; Ribeiro, JA			Modification by arachidonic acid of extracellular adenosine metabolism and neuromodulatory action in the rat hippocampus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBER NERVE-ENDINGS; CULTURED CHROMAFFIN CELLS; LONG-TERM POTENTIATION; GLUTAMATE RELEASE; FATTY-ACIDS; ACETYLCHOLINE-RELEASE; SYNAPTIC-TRANSMISSION; ECTO-NUCLEOTIDASES; SERUM-ALBUMIN; BRAIN	Adenosine and arachidonate (AA) fulfil opposite modulatory roles, arachidonate facilitating and adenosine inhibiting cellular responses. To understand if there is an inter-play between these two neuromodulatory systems, we investigated the effect of AA on extracellular adenosine metabolism in hippocampal nerve terminals. AA (30 muM) facilitated by 67% adenosine evoked release and by 45% ATP evoked release. These effects were not significantly modified upon blockade of lipooxygenase or cyclooxygenase and were attenuated (52-61%) by the protein kinase C inhibitor, chelerythrine (6 muM). The ecto-5'-nucleotidase inhibitor, alpha,beta -methylene ADP (100 muM), caused a larger inhibition (54%) of adenosine release in the presence of AA (30 muM) compared with control (37% inhibition) indicating that the AA-induced extracellular adenosine accumulation is mostly originated from an increased release and extracellular catabolism of ATP. This AA-induced extracellular adenosine accumulation is further potentiated by an AA-induced decrease (48%) of adenosine transporters capacity. AA (30 muM) increased by 36-42% the tonic inhibition by endogenous extracellular adenosine of adenosine A(1) receptors in the modulation of acetylcholine release and of CA1 hippocampal synaptic transmission in hippocampal slices. These results indicate that AA increases tonic adenosine modulation as a possible feedback loop to limit AA facilitation of neuronal excitability.	Univ Lisbon, Fac Med, Neurosci Lab, P-1649028 Lisbon, Portugal; Univ Lisbon, Fac Sci, Dept Chem & Biochem, P-1649028 Lisbon, Portugal	Universidade de Lisboa; Universidade de Lisboa	Cunha, RA (corresponding author), Univ Lisbon, Fac Med, Neurosci Lab, Av Prof Egas Moniz, P-1649028 Lisbon, Portugal.	racunha@neurociencias.pt	Cunha, Rodrigo A/E-7475-2015	Cunha, Rodrigo A/0000-0003-2550-6422; Ribeiro, Joaquim/0000-0002-9330-3507				ADESUYI SA, 1985, J NEUROCHEM, V45, P770, DOI 10.1111/j.1471-4159.1985.tb04059.x; Almeida T, 1999, BRAIN RES, V826, P104, DOI 10.1016/S0006-8993(99)01267-6; Ambrosio AF, 1997, EUR J PHARMACOL, V340, P301, DOI 10.1016/S0014-2999(97)01451-9; ANDERSON WW, 1997, NEUR ABST, V23, P665; BAZAN NG, 1989, ANN NY ACAD SCI, V559, P1; BIRKLE DL, 1987, J NEUROCHEM, V48, P1768, DOI 10.1111/j.1471-4159.1987.tb05735.x; BRADFORD PG, 1983, J NEUROCHEM, V41, P1684, DOI 10.1111/j.1471-4159.1983.tb00881.x; Breukel AIM, 1997, BRAIN RES, V773, P90, DOI 10.1016/S0006-8993(97)00918-9; CHAN PH, 1983, J NEUROCHEM, V41, P1550, DOI 10.1111/j.1471-4159.1983.tb00863.x; Chen WC, 1998, GLIA, V22, P360, DOI 10.1002/(SICI)1098-1136(199804)22:4<360::AID-GLIA5>3.0.CO;2-7; CLEMENTS MP, 1991, NEUROSCIENCE, V45, P379, DOI 10.1016/0306-4522(91)90235-G; Collins DR, 1995, EUR J PHARMACOL, V294, P147, DOI 10.1016/0014-2999(95)00523-4; Cunha RA, 2001, NEUROCHEM INT, V38, P107, DOI 10.1016/S0197-0186(00)00034-6; Cunha RA, 1998, J NEUROSCI, V18, P1987; Cunha RA, 1996, J NEUROCHEM, V67, P2180; CUNHA RA, 1992, J NEUROCHEM, V59, P657, DOI 10.1111/j.1471-4159.1992.tb09420.x; CUNHA RA, 1994, J NEUROCHEM, V63, P207; Cunha RA, 1999, EUR J NEUROSCI, V11, P2171, DOI 10.1046/j.1460-9568.1999.00661.x; DAMRON DS, 1993, NEUROCHEM RES, V18, P1231, DOI 10.1007/BF00975040; DELICADO EG, 1991, BIOCHEM J, V279, P651, DOI 10.1042/bj2790651; deMendonca A, 1996, LIFE SCI, V60, P245, DOI 10.1016/S0024-3205(96)00544-9; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DOMANSKAJANIK K, 1993, NEUROREPORT, V4, P451, DOI 10.1097/00001756-199304000-00029; DRAGUNOW M, 1988, PROG NEUROBIOL, V31, P85, DOI 10.1016/0301-0082(88)90028-7; DUMAN RS, 1986, J NEUROCHEM, V47, P800; DUNWIDDIE TV, 1990, BRAIN RES, V527, P76, DOI 10.1016/0006-8993(90)91062-L; FREDHOLM BB, 1994, J NEUROCHEM, V62, P563; Fredholm BB, 1997, INT REV NEUROBIOL, V40, P259; FREEMAN EJ, 1990, NEUROCHEM RES, V15, P743, DOI 10.1007/BF00973656; FREEMAN EJ, 1991, J NEUROCHEM, V56, P1079, DOI 10.1111/j.1471-4159.1991.tb02032.x; Gonzalez L, 1997, NEUROCHEM RES, V22, P189, DOI 10.1023/A:1027319708321; GU JG, 1993, J NEUROCHEM, V60, P2232, DOI 10.1111/j.1471-4159.1993.tb03509.x; HENKE DC, 1984, ANAL BIOCHEM, V140, P87, DOI 10.1016/0003-2697(84)90137-4; JAMES S, 1993, J NEUROCHEM, V60, P219, DOI 10.1111/j.1471-4159.1993.tb05841.x; KENAKIN TP, 1987, PHARM ANAL DRUG RECE; Kitakaze M, 1997, BIOCHEM BIOPH RES CO, V239, P171, DOI 10.1006/bbrc.1997.7445; KOIDE T, 1986, J NEUROCHEM, V46, P235, DOI 10.1111/j.1471-4159.1986.tb12952.x; KRAGHHANSEN U, 1981, PHARMACOL REV, V33, P17; LINDGREN JA, 1984, P NATL ACAD SCI-BIOL, V81, P6212, DOI 10.1073/pnas.81.19.6212; LUPICA CR, 1990, J PHARMACOL EXP THER, V252, P1134; LYNCH MA, 1990, J NEUROCHEM, V55, P215, DOI 10.1111/j.1471-4159.1990.tb08841.x; LYNCH MA, 1991, BIOCHEM SOC T, V19, P391, DOI 10.1042/bst0190391; Masino SA, 1999, J NEUROSCI, V19, P1932; MITCHELL JB, 1993, J NEUROSCI, V13, P3439; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; Pankratov Y, 1998, EUR J NEUROSCI, V10, P3898, DOI 10.1046/j.1460-9568.1998.00419.x; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; PIOMELLI D, 1989, P NATL ACAD SCI USA, V86, P8550, DOI 10.1073/pnas.86.21.8550; REHNCRONA S, 1982, J NEUROCHEM, V38, P84, DOI 10.1111/j.1471-4159.1982.tb10857.x; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; SAMPLES DR, 1989, AM J PHYSIOL, V257, pC1166; SEN RP, 1993, J NEUROCHEM, V60, P613, DOI 10.1111/j.1471-4159.1993.tb03192.x; SHEARMAN MS, 1991, FEBS LETT, V279, P261, DOI 10.1016/0014-5793(91)80163-W; SPECTOR T, 1978, ANAL BIOCHEM, V86, P142, DOI 10.1016/0003-2697(78)90327-5; VERNON LP, 1992, PHARMACOL THERAPEUT, V54, P269, DOI 10.1016/0163-7258(92)90003-I; VOLTERRA A, 1992, ADV EXP MED BIOL, V318, P147; Wieraszko A, 1996, ACTA NEUROBIOL EXP, V56, P637; Wildman SS, 1997, BRIT J PHARMACOL, V120, P221, DOI 10.1038/sj.bjp.0700903; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; Zimmermann H, 1996, PROG NEUROBIOL, V49, P589, DOI 10.1016/0301-0082(96)00026-3	60	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37572	37581		10.1074/jbc.M003011200	http://dx.doi.org/10.1074/jbc.M003011200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978314	hybrid			2022-12-27	WOS:000165618700038
J	Poyet, JL; Srinivasula, SM; Lin, JH; Fernandes-Alnemri, T; Yamaoka, S; Tsichlis, PN; Alnemri, ES				Poyet, JL; Srinivasula, SM; Lin, JH; Fernandes-Alnemri, T; Yamaoka, S; Tsichlis, PN; Alnemri, ES			Activation of the I kappa B kinases by RIP via IKK gamma/NEMO-mediated oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-RECEPTOR; SIGNALING COMPLEX; CONTAINS 2; ALPHA; PROTEIN; PHOSPHORYLATION; TNF; BETA; APOPTOSIS; PATHWAY	To understand the mechanism of activation of the I kappaB kinase (IKK) complex in the tumor necrosis factor (TNF) receptor 1 pathway, we examined the possibility that oligomerization of the IKK complex triggered by ligand-induced trimerization of the TNF receptor 1 complex is responsible for activation of the IKKs. Gel filtration analysis of the IKK complex revealed that TNF alpha stimulation induces a large increase in the size of this complex, suggesting oligomerization. Substitution of the C-terminal region of IKK gamma, which interacts with RIP, with a truncated DR4 lacking its cytoplasmic death domain, produced a molecule that could induce IKK and NF-kappaB activation in cells in response to TRAIL. Enforced oligomerization of the N terminus of IKK gamma or truncated IKK alpha or IKK beta lacking their serine-cluster domains can also induce IKK and NF-kappaB activation. These data suggest that IKK gamma functions as a signaling adaptor between the upstream regulators such as RIP and the IKKs and that oligomerization of the IKK complex by upstream regulators is a critical step in activation of this complex.	Thomas Jefferson Univ, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Tokyo Med & Dent Univ, Sch Med, Dept Microbiol, Bunkyo Ku, Tokyo 1138519, Japan	Jefferson University; Jefferson University; Tokyo Medical & Dental University (TMDU)	Alnemri, ES (corresponding author), Thomas Jefferson Univ, Ctr Apoptosis Res, Philadelphia, PA 19107 USA.		Poyet, Jean-Luc/G-7114-2017	Poyet, Jean-Luc/0000-0002-3747-255X	NCI NIH HHS [CA38047, CA78890, CA85421] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078890, R01CA038047, R01CA085421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Burke JR, 1998, J BIOL CHEM, V273, P12041, DOI 10.1074/jbc.273.20.12041; Cha SS, 1999, IMMUNITY, V11, P253, DOI 10.1016/S1074-7613(00)80100-4; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Chin AID, 1999, MOL CELL BIOL, V19, P6665; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hymowitz SG, 2000, BIOCHEMISTRY-US, V39, P633, DOI 10.1021/bi992242l; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Ozes ON, 1999, NATURE, V401, P82; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; SPENCER DM, 1993, SCIENCE, V262, P119; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; WIRTH T, 1988, EMBO J, V7, P3109, DOI 10.1002/j.1460-2075.1988.tb03177.x; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	52	142	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37966	37977		10.1074/jbc.M006643200	http://dx.doi.org/10.1074/jbc.M006643200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10980203	hybrid			2022-12-27	WOS:000165618700089
J	Ueoka, C; Kaneda, N; Okazaki, I; Nadanaka, S; Muramatsu, T; Sugahara, K				Ueoka, C; Kaneda, N; Okazaki, I; Nadanaka, S; Muramatsu, T; Sugahara, K			Neuronal cell adhesion, mediated by the heparin-binding neuroregulatory factor midkine, is specifically inhibited by chondroitin sulfate E - Structural and functional implications of the over-sulfated chondroitin sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-ASSOCIATED MOLECULE; CENTRAL-NERVOUS-SYSTEM; HIGH-AFFINITY BINDING; NEURITE OUTGROWTH; HB-GAM; DERMATAN SULFATE; ZETA/RPTP-BETA; RAT-BRAIN; 6B4 PROTEOGLYCAN/PHOSPHACAN	The heparin-binding neurotrophic factor midkine (MK) has been proposed to mediate neuronal cell adhesion and neurite outgrowth promotion by interacting with cell-surface heparan sulfate. We have observed that over-sulfated chondroitin sulfate (CS) D and CS-E show neurite outgrowth-promoting activity in embryonic day (E) 18 rat hippocampal neurons (Nadanaka, S., Clement, A., Masayama, K., Faissner, A., and Sugahara, K. (1998) J. Biol. Chem. 273, 3296-3307). In the present study, various CS isoforms were examined for their ability to inhibit the MK-mediated cell. adhesion of cortical neuronal cells in comparison with heparin from porcine intestine and heparan sulfate from bovine kidney. E17-18 rat cortical neuronal cells were cultured on plates coated with recombinant MK in a grid pattern. The cells attached to and extended their neurites along the MK substratum. Cell adhesion was inhibited by squid cartilage over-sulfated CS-E as well as by heparin, but not by heparan sulfate or other CS isoforms. Direct interactions of MH with various glycosaminoglycans were then evaluated using surface plasmon resonance, showing that CS-E bound MK as strongly as heparin, followed by other over-sulfated CS isoforms, CS-H and CS K. Furthermore, E18 rat brain extracts showed an E disaccharide unit, GlcUA beta1-3GalNAc(4,6-O-disulfate). These findings indicate that CS chains containing the E unit as well as heparin-like glycosaminoglycans may be involved in the expression and/or modulation of the multiple neuroregulatory functions of MK such as neuronal adhesion and migration and promotion of neurite outgrowth.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Meijo Univ, Fac Pharm, Dept Analyt Neurobiol, Nagoya, Aichi 4688503, Japan; Nagoya Univ, Sch Med, Dept Biochem, Nagoya, Aichi 4660065, Japan; Biacore Kabushiki Kaisha, Minato Ku, Tokyo 1050011, Japan	Kobe Pharmaceutical University; Meijo University; Nagoya University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan.							ANNO K, 1971, BIOCHIM BIOPHYS ACTA, V237, P173, DOI 10.1016/0304-4165(71)90046-8; BARNEA G, 1994, J BIOL CHEM, V269, P14349; BRITTIS PA, 1992, SCIENCE, V255, P733, DOI 10.1126/science.1738848; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Engel M, 1996, J COMP NEUROL, V366, P34; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FERNAUDESPINOSA I, 1994, J CELL SCI, V107, P1437; Garwood J, 1999, J NEUROSCI, V19, P3888; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; Horiba M, 2000, J CLIN INVEST, V105, P489, DOI 10.1172/JCI7208; IWANE M, 1987, BIOCHEM BIOPH RES CO, V146, P470, DOI 10.1016/0006-291X(87)90553-5; Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; Kaneda N, 1996, J BIOCHEM-TOKYO, V119, P1150; Kaneda N, 1996, BIOCHEM BIOPH RES CO, V220, P108, DOI 10.1006/bbrc.1996.0365; KARLSSON R, 1995, ANAL BIOCHEM, V228, P274, DOI 10.1006/abio.1995.1350; KATOHSEMBA R, 1995, EUR J NEUROSCI, V7, P613, DOI 10.1111/j.1460-9568.1995.tb00665.x; Kinnunen T, 1996, J BIOL CHEM, V271, P2243, DOI 10.1074/jbc.271.4.2243; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; Kinoshita A, 1997, J BIOL CHEM, V272, P19656, DOI 10.1074/jbc.272.32.19656; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; KINOSHITA A, 1998, ABSTR 19 INT CARB S; KINOSHITA A, 1997, SEIKAGAKU, V69, P794; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; KOJIMA S, 1995, J BIOL CHEM, V270, P9590, DOI 10.1074/jbc.270.16.9590; Kojima T, 1996, J BIOL CHEM, V271, P5914, DOI 10.1074/jbc.271.10.5914; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LAFONT F, 1992, DEVELOPMENT, V114, P17; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; LEVY JB, 1993, J BIOL CHEM, V268, P10573; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; Lindahl U., 1989, HEPARIN, P159; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; MAEDA N, 1995, NEUROSCIENCE, V67, P23, DOI 10.1016/0306-4522(94)00069-H; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MATSUMOTO K, 1994, DEV BRAIN RES, V79, P229, DOI 10.1016/0165-3806(94)90127-9; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; Milev P, 1998, J BIOL CHEM, V273, P6998, DOI 10.1074/jbc.273.12.6998; Munakata H, 1999, GLYCOBIOLOGY, V9, P1023, DOI 10.1093/glycob/9.10.1023; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; MURAMATSU H, 1994, BIOCHEM BIOPH RES CO, V203, P1131, DOI 10.1006/bbrc.1994.2300; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; OOHIRA A, 1988, J BIOL CHEM, V263, P10240; OOHIRA A, 1991, J NEUROSCI, V11, P822; RAUCH U, 1991, J BIOL CHEM, V266, P14785; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; SAIGO K, 1970, J NEUROCHEM, V17, P633, DOI 10.1111/j.1471-4159.1970.tb00543.x; SENO N, 1982, CARBOHYD RES, V103, P190; SNOW DM, 1990, DEV BIOL, V138, P359, DOI 10.1016/0012-1606(90)90203-U; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; SNOW DM, 1991, DEVELOPMENT, V113, P1473; Snyder SE, 1996, MOL BRAIN RES, V40, P79; STALLCUP WB, 1981, DEV BIOL, V83, P154, DOI 10.1016/S0012-1606(81)80018-8; STREIT A, 1993, J CELL BIOL, V120, P799, DOI 10.1083/jcb.120.3.799; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; SUZUKI S, 1968, J BIOL CHEM, V243, P1543; Ueoka C, 1999, GLYCOCONJUGATE J, V16, P291, DOI 10.1023/A:1007022229813; UEOKA C, 1997, ABSTR 4 BIA S JAP OS, P62; WATANABE E, 1995, J BIOL CHEM, V270, P26876, DOI 10.1074/jbc.270.45.26876; YAMADA H, 1994, J BIOL CHEM, V269, P10119; Yamada S, 1998, EUR J BIOCHEM, V258, P775, DOI 10.1046/j.1432-1327.1998.2580775.x; Yamane Y, 1998, J BIOL CHEM, V273, P7375, DOI 10.1074/jbc.273.13.7375; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; Zou K, 2000, EUR J BIOCHEM, V267, P4046, DOI 10.1046/j.1432-1327.2000.01440.x	71	130	130	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37407	37413		10.1074/jbc.M002538200	http://dx.doi.org/10.1074/jbc.M002538200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978312	hybrid			2022-12-27	WOS:000165618700015
J	Bertolotto, C; Maulon, L; Filippa, N; Baier, G; Auberger, P				Bertolotto, C; Maulon, L; Filippa, N; Baier, G; Auberger, P			Protein kinase C theta and epsilon promote T-cell survival by a rsk-dependent phosphorylation and inactivation of BAD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED APOPTOSIS; SIGNALING PATHWAY; DEATH; SUPPRESSION; ACTIVATION; INHIBITION; CLEAVAGE; RAS	Both MAPK and protein kinase C (PKC) signaling pathways promote cell survival and protect against cell death. Here, we show that 12-O-tetradecanoylphorbol-13-acetate (TPA) prevents Fas-induced apoptosis in T lymphocytes. The effect of TPA was specifically abolished by the PKC inhibitor GF109203X and by dominant negative PKC theta, PKC is an element of, and PKC alpha, suggesting that novel and conventional PKC isoforms mediate phorbol ester action. Moreover, TPA stimulated phosphorylation of BAD at serine 112, an effect abrogated by GF109203X but not by the MEK inhibitor PD98059. Expression of constitutively active PKC increased the phosphorylation of BAD at serine 112 but not at serine 136. Additionally, Fas-mediated cell death was enhanced by overexpression of a catalytically inactive form of p90Rsk (Rsk2-KN). Finally, Rsk2-KN abolished the protective effect of constitutively active PKC and totally blocked phosphorylation of BAD on serine 112. Thus, novel PKC theta and PKC is an element of rescue T lymphocytes from Fas-mediated apoptosis via a p90Rsk-dependent phosphorylation and inactivation of BAD.	Equipe Labelisee Ligue, INSERM, U526, F-06107 Nice 2, France; INSERM, U145, F-06107 Nice 2, France; Univ Innsbruck, Inst Med Biol & Human Genet, A-6020 Innsbruck, Austria	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Innsbruck	Auberger, P (corresponding author), Equipe Labelisee Ligue, INSERM, U526, IFR 50,28 Ave Valombrose, F-06107 Nice 2, France.	auberger@unice.fr	AUBERGER, Patrick/G-1491-2013; Bertolotto-Ballotti, Corine/O-2155-2016; Bertolotto, Corine/AAF-6634-2021; Baier, Gottfried/E-8755-2012	AUBERGER, Patrick/0000-0002-2481-8275; Bertolotto, Corine/0000-0001-6971-7753; Baier, Gottfried/0000-0002-2085-8325				BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Bertolotto C, 2000, J BIOL CHEM, V275, P12941, DOI 10.1074/jbc.275.17.12941; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Chen CY, 1999, J BIOL CHEM, V274, P15320, DOI 10.1074/jbc.274.22.15320; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Datta SR, 1998, HORM SIGNALING, V1, P257; DEL PL, 1997, SCIENCE, V278, P687; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; JARVIS WD, 1994, CANCER RES, V54, P1707; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; MARQUARDT B, 1994, ONCOGENE, V9, P3213; Mayne GC, 1998, J BIOL CHEM, V273, P24115, DOI 10.1074/jbc.273.37.24115; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Savickiene J, 1999, CELL DEATH DIFFER, V6, P698, DOI 10.1038/sj.cdd.4400541; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Soh JW, 1999, MOL CELL BIOL, V19, P1313; SOZERI O, 1992, ONCOGENE, V7, P2259; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	30	125	131	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37246	37250		10.1074/jbc.M007732200	http://dx.doi.org/10.1074/jbc.M007732200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10976111	hybrid			2022-12-27	WOS:000165577700108
J	Wang, CZ; Yano, H; Nagashima, K; Seino, S				Wang, CZ; Yano, H; Nagashima, K; Seino, S			The Na+-driven Cl-/HCO3- exchanger - Cloning, tissue distribution, and functional characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH; CYTOPLASMIC PH; GLUCOSE; TRANSPORT; EXPRESSION; CELLS; CL	The Na+-driven Cl-/HCO3- exchanger is an important regulator of intracellular pH in various cells, but its molecular basis has not been determined. We show here the primary structure, tissue distribution, and functional characterization of (N) under bara(+)-driven (c) under bar hloride/(b) under bar icarbonate exchanger (designated NCBE) cloned from the insulin-secreting cell line MING cDNA library. The NCBE protein consists of 1088 amino acids having 74, 72, and 55% amino acid identity to the human skeletal muscle, rat smooth muscle, and human kidney sodium bicarbonate cotransporter, respectively. The protein has 10 putative membrane-spanning regions. NCBE mRNA is expressed at high levels in the brain and the mouse insulinoma cell line MIN6 and at low levels in the pituitary, testis, kidney, and ileum. Functional analyses of the NCBE protein expressed in Xenopus laevis oocytes and HEK293 cells demonstrate that it transports extracellular Na+ and HCO3- into cells in exchange for intracellular Cl- and H+, thus raising the intracellular pH. Thus, we conclude that NCBE is a Na+-driven Cl-/HCO3- exchanger that regulates intracellular pH in native cells.	Chiba Univ, Grad Sch Med, Dept Mol Med, Chuo Ku, Chiba 2608670, Japan	Chiba University	Yano, H (corresponding author), Chiba Univ, Grad Sch Med, Dept Mol Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	hyano@molmed.m.chiba-u.ac.jp						ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; ARKHAMMAR P, 1986, BIOSCIENCE REP, V6, P355, DOI 10.1007/BF01116422; BEST L, 1988, J MOL ENDOCRINOL, V1, P33, DOI 10.1677/jme.0.0010033; Boron WF, 1997, J EXP BIOL, V200, P263; Burnham CE, 1997, J BIOL CHEM, V272, P19111, DOI 10.1074/jbc.272.31.19111; BUSA WB, 1986, CURR TOP MEMBR TRANS, V26, P291; BUSA WB, 1984, AM J PHYSIOL, V246, pR409, DOI 10.1152/ajpregu.1984.246.4.R409; CHOL I, 2000, NATURE, V405, P571; DELEERS M, 1985, HORM METAB RES, V17, P391, DOI 10.1055/s-2007-1013555; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; INAGAKI N, 1994, P NATL ACAD SCI USA, V91, P2679, DOI 10.1073/pnas.91.7.2679; ISHIBASHI K, 1993, AM J PHYSIOL, V264, pF251, DOI 10.1152/ajprenal.1993.264.2.F251; Ishibashi K, 1998, BIOCHEM BIOPH RES CO, V246, P535, DOI 10.1006/bbrc.1998.8658; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; LINDSTROM P, 1984, BIOCHEM J, V218, P887, DOI 10.1042/bj2180887; PACE CS, 1983, J MEMBRANE BIOL, V73, P39, DOI 10.1007/BF01870339; Pushkin A, 1999, J BIOL CHEM, V274, P16569, DOI 10.1074/jbc.274.23.16569; Romero MF, 1999, ANNU REV PHYSIOL, V61, P699, DOI 10.1146/annurev.physiol.61.1.699; Romero MF, 2000, J BIOL CHEM, V275, P24552, DOI 10.1074/jbc.M003476200; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; RUSSELL JM, 1976, NATURE, V264, P73, DOI 10.1038/264073a0; SCHWIENING CJ, 1994, J PHYSIOL-LONDON, V475, P59, DOI 10.1113/jphysiol.1994.sp020049; SHEPHERD RM, 1995, J BIOL CHEM, V270, P7915, DOI 10.1074/jbc.270.14.7915; SHRODE LD, 1994, GLIA, V12, P196, DOI 10.1002/glia.440120305; Strazzabosco M, 1997, HEPATOLOGY, V25, P976, DOI 10.1002/hep.510250431; Sun B, 1999, AM J PHYSIOL-HEART C, V277, pH28, DOI 10.1152/ajpheart.1999.277.1.H28; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TOBEY NA, 1993, GASTROENTEROLOGY, V104, P185, DOI 10.1016/0016-5085(93)90851-3; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wang CZ, 1996, BIOCHEM BIOPH RES CO, V220, P196, DOI 10.1006/bbrc.1996.0380; Zeng Y, 1996, DEV BIOL, V173, P510, DOI 10.1006/dbio.1996.0044	33	118	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35486	35490		10.1074/jbc.C000456200	http://dx.doi.org/10.1074/jbc.C000456200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10993873	hybrid			2022-12-27	WOS:000165422800086
J	Ferrington, DA; Sun, HY; Murray, KK; Costa, J; Williams, TD; Bigelow, DJ; Squier, TC				Ferrington, DA; Sun, HY; Murray, KK; Costa, J; Williams, TD; Bigelow, DJ; Squier, TC			Selective degradation of oxidized calmodulin by the 20 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; MEMBRANE CA-ATPASE; SEQUENCE-INDEPENDENT RECOGNITION; SECONDARY STRUCTURE; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; METHIONINE OXIDATION; ANTIGEN PRESENTATION; MODIFIED HEMOGLOBIN; 26S PROTEASOME	We have investigated the mechanisms that target oxidized calmodulin for degradation by the proteasome, After methionine oxidation within calmodulin, rates of degradation by the 20 S proteasome are substantially enhanced. Mass spectrometry was used to identify the time course of the proteolytic fragments released from the proteasome. Oxidized calmodulin is initially degraded into large proteolytic fragments that are released from the proteasome and subsequently degraded into small peptides that vary in size from 6 to 12 amino acids. To investigate the molecular determinants that result in the selective degradation of oxidized calmodulin, we used circular dichroism and fluorescence spectroscopy to assess oxidant-induced structural changes. There is a linear correlation between decreases in secondary structure and the rate of degradation. Calcium binding or the repair of oxidized calmodulin by methionine sulfoxide reductase induces comparable changes in alpha -helical content and rates of degradation. In contrast, alterations in the surface hydrophobicity of oxidized calmodulin do not alter the rate of degradation by the proteasome, indicating that changes in surface hydrophobicity do not necessarily lead to enhanced proteolytic susceptibility. These results suggest that decreases in secondary structure expose proteolytically sensitive sites in oxidized calmodulin that are cleaved by the proteasome in a nonprocessive manner.	Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA; Univ Kansas, Mass Spectrometry Lab, Lawrence, KS 66045 USA; Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA; Univ Kansas, Mass Spectrometry Lab, Lawrence, KS 66045 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Kansas; University of Kansas; University of Kansas	Ferrington, DA (corresponding author), Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA.	ferri013@tc.umn.edu		Ferrington, Deborah/0000-0003-2561-7464	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR006294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG012993, R01AG017996] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR0 6294] Funding Source: Medline; NIA NIH HHS [AG17996, AG12993] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; Conconi M, 1996, ARCH BIOCHEM BIOPHYS, V331, P232, DOI 10.1006/abbi.1996.0303; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DADO GP, 1993, J AM CHEM SOC, V115, P12609, DOI 10.1021/ja00079a060; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; Ferrington DA, 1997, BIOCHEM BIOPH RES CO, V237, P163, DOI 10.1006/bbrc.1997.7105; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; Gao J, 1998, BIOPHYS J, V74, P1115, DOI 10.1016/S0006-3495(98)77830-0; Gao J, 1998, BIOCHEMISTRY-US, V37, P9536, DOI 10.1021/bi9803877; GarciaEcheverria C, 1996, BIOORG MED CHEM LETT, V6, P229, DOI 10.1016/0960-894X(96)00009-1; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; GIULIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329, DOI 10.1006/abbi.1994.1245; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; Grune T, 1997, BIOFACTORS, V6, P165, DOI 10.1002/biof.5520060210; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Holzhutter HG, 1999, J MOL BIOL, V286, P1251, DOI 10.1006/jmbi.1998.2530; Huhmer AFR, 1996, CHEM RES TOXICOL, V9, P484, DOI 10.1021/tx950152l; JENNISSEN HP, 1995, EUR J BIOCHEM, V231, P1; Kisselev AF, 1998, J BIOL CHEM, V273, P1982, DOI 10.1074/jbc.273.4.1982; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laub M, 1998, EUR J BIOCHEM, V255, P422, DOI 10.1046/j.1432-1327.1998.2550422.x; LEVINE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2120, DOI 10.1073/pnas.78.4.2120; Majetschak M, 1998, EUR J BIOCHEM, V255, P482, DOI 10.1046/j.1432-1327.1998.2550482.x; Michaelis ML, 1996, LIFE SCI, V59, P405, DOI 10.1016/0024-3205(96)00319-0; Moskovitz J, 1996, P NATL ACAD SCI USA, V93, P2095, DOI 10.1073/pnas.93.5.2095; MYKLES DL, 1991, ARCH BIOCHEM BIOPHYS, V288, P543, DOI 10.1016/0003-9861(91)90233-9; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Niedermann G, 1996, P NATL ACAD SCI USA, V93, P8572, DOI 10.1073/pnas.93.16.8572; Nussbaum AK, 1998, P NATL ACAD SCI USA, V95, P12504, DOI 10.1073/pnas.95.21.12504; ONEIL KT, 1989, J BIOL CHEM, V264, P14571; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; POTTER SM, 1993, PROTEIN SCI, V2, P1648, DOI 10.1002/pro.5560021011; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; RIVETT AJ, 1994, METHOD ENZYMOL, V244, P331; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; Schenck HL, 1996, J AM CHEM SOC, V118, P12487, DOI 10.1021/ja962026p; Sharov VS, 1999, FEBS LETT, V455, P247, DOI 10.1016/S0014-5793(99)00888-1; Squier TC, 2000, FRONT BIOSCI-LANDMRK, V5, pD504, DOI 10.2741/Squier; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STRASBURG GM, 1988, J BIOL CHEM, V263, P542; Sun HY, 1999, BIOCHEMISTRY-US, V38, P105, DOI 10.1021/bi981295k; Szymanska G, 1998, J BIOL CHEM, V273, P28516, DOI 10.1074/jbc.273.43.28516; Tarcsa E, 2000, J BIOL CHEM, V275, P20295, DOI 10.1074/jbc.M001555200; TAYLOR JE, 1994, BIOCHEM SOC T, V22, P949, DOI 10.1042/bst0220949; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wang R, 1999, BIOCHEMISTRY-US, V38, P14573, DOI 10.1021/bi990826h; Yao YH, 1996, BIOCHEMISTRY-US, V35, P2767, DOI 10.1021/bi951712i; Yin D, 2000, CHEM RES TOXICOL, V13, P103, DOI 10.1021/tx990142a; YU B, 1991, J BIOL CHEM, V266, P17396	61	101	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					937	943		10.1074/jbc.M005356200	http://dx.doi.org/10.1074/jbc.M005356200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11010965	hybrid			2022-12-27	WOS:000166430900012
J	Landrieu, I; Odaert, B; Wieruszeski, JM; Drobecq, H; Rousselot-Pailley, P; Inze, D; Lippens, G				Landrieu, I; Odaert, B; Wieruszeski, JM; Drobecq, H; Rousselot-Pailley, P; Inze, D; Lippens, G			p13(SUC1) and the WW domain of PIN1 bind to the same phosphothreonine-proline epitope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL-PROLYL ISOMERASE; XENOPUS SUC1/CKS PROTEIN; CYCLE-REGULATORY PROTEIN; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; PHOSPHORYLATION; RECOGNITION; SUBSTRATE; INTERACTS; COMPLEX	The WW domain of the human PIN1 and p13SUC1, a subunit of the cyclin-dependent kinase complex, were previously shown to be involved in the regulation of the cyclin-dependent kinase complex activity at the entry into mitosis, by an unresolved molecular mechanism. We report here experimental evidence for the direct interaction of p13(SUC1) With a model CDC25 peptide, dependent on the phosphorylation state of its threonine, Chemical shift perturbation of backbone H-1(N), N-15, and C-13 alpha, resonances during MMR titration experiments allows accurate identification of the binding site, primarily localized around the anion-binding site, occupied in the crystal structure of the homologous p9(CKSHs2) by a sulfate molecule. The epitope recognized by p13(SUC1) includes the proline at position +1 of the phosphothreonine, as was shown by the decrease in affinity for a mutated CDC25 phosphopeptide, containing an alanine/ proline substitution. No direct interaction between the PIN1 WW domain or its catalytic proline cis/transisomerase domain and p13(SUC1) was detected, but our study showed that in vitro the WW domain of the human PIN1 antagonizes the binding of the p13(SUC1) to the CDC25 phosphopeptide, by binding to the same phosphoepitope. We thus propose that the full cyclin-dependent kinase complex stimulates the phosphorylation of CDC25 through binding of its p13(SUC1) module to the phosphoepitope of the substrate and that the reported WW antagonism of p13(SUC1)-stimulated CDC25 phosphorylation is caused by competitive binding of both protein modules to the same phosphoepitope.	Inst Pasteur, Inst Biol Lille, CNRS UMR 8525, F-59019 Lille, France; Fac Univ Sci Agron Gembloux, Unite Microbiol, B-5030 Gembloux, Belgium; State Univ Ghent VIB, Dept Plant Genet, Genet Lab, B-9000 Ghent, Belgium	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; University of Liege; Flanders Institute for Biotechnology (VIB); Ghent University	Landrieu, I (corresponding author), Inst Pasteur, Inst Biol Lille, CNRS UMR 8525, F-59019 Lille, France.	isabelle.landrieu@pasteur-lille.fr; guy.lippens@pasteur-lille.fr	Rousselot-Pailley, Pierre/E-4151-2015; Inzé, Dirk/AAW-6381-2021; Landrieu, Isabelle/AAF-8495-2019	Inzé, Dirk/0000-0002-3217-8407; Landrieu, Isabelle/0000-0002-4883-2637; Lippens, Guy/0000-0002-8236-0901; Drobecq, Herve/0000-0002-4081-1575				ARVAI AS, 1995, J MOL BIOL, V249, P835, DOI 10.1006/jmbi.1995.0341; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; Egan EA, 1998, MOL CELL BIOL, V18, P3659, DOI 10.1128/MCB.18.7.3659; ENDICOTT JA, 1995, EMBO J, V14, P1004, DOI 10.1002/j.1460-2075.1995.tb07081.x; Landrieu I, 2000, J BIOL CHEM, V275, P10577, DOI 10.1074/jbc.275.14.10577; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Morris MC, 1998, BIOCHEMISTRY-US, V37, P14257, DOI 10.1021/bi980913u; Morris MC, 2000, J BIOL CHEM, V275, P28849, DOI 10.1074/jbc.M002942200; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; PARGE HE, 1993, SCIENCE, V262, P387, DOI 10.1126/science.8211159; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; Patra D, 1999, J BIOL CHEM, V274, P36839, DOI 10.1074/jbc.274.52.36839; Patra D, 1998, GENE DEV, V12, P2549, DOI 10.1101/gad.12.16.2549; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Rippmann JF, 2000, CELL GROWTH DIFFER, V11, P409; Rousseau F, 1998, J MOL BIOL, V284, P503, DOI 10.1006/jmbi.1998.2173; Sambrook J., 1989, MOL CLONING LAB MANU; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Sudakin V, 1997, J BIOL CHEM, V272, P18051, DOI 10.1074/jbc.272.29.18051; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Watson MH, 1996, J MOL BIOL, V261, P646, DOI 10.1006/jmbi.1996.0490; Winkler KE, 2000, SCIENCE, V287, P1644, DOI 10.1126/science.287.5458.1644; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Zarrinpar A, 2000, NAT STRUCT BIOL, V7, P611, DOI 10.1038/77891	34	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1434	1438		10.1074/jbc.M006420200	http://dx.doi.org/10.1074/jbc.M006420200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11013245	hybrid			2022-12-27	WOS:000166430900077
J	Sakthivel, R; Zhang, JC; Strickland, DK; Gafvels, M; McCrae, KR				Sakthivel, R; Zhang, JC; Strickland, DK; Gafvels, M; McCrae, KR			Regulation of the ligand binding activity of the human very low density lipoprotein receptor by protein kinase C-dependent phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; APOLIPOPROTEIN-E RECEPTOR; TISSUE-SPECIFIC EXPRESSION; PROMOTING PHORBOL ESTERS; IN-SITU HYBRIDIZATION; MESSENGER-RNA LEVELS; VLDL RECEPTOR; ENDOTHELIAL-CELLS; LDL RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR	The very low density lipoprotein receptor (VLDL-R) binds and internalizes several ligands, including very low density lipoprotein (VLDL), urokinase-type plasminogen activator:plasminogen activator inhibitor type 1 complexes, lipoprotein lipase, and the 39-kDa receptor-associated protein that copurifies with the low density lipoprotein receptor-related protein/alpha (2)-macraglobulin receptor. Although several agonists regulate VLDL-R mRNA and/or protein expression, post-transcriptional regulation of receptor activity has not been described. Here, we report that the ligand binding activity of the VLDL-R in THP-1 monocytic cells, endothelial cells, smooth muscle cells, and VLDL-R transfected HEK 293 cells is diminished after treatment with phorbol 12-myristate 13-acetate. This response was blacked by inhibitors of protein kinase C (PK-C), including a specific inhibitor of the PK-C PII isoform, and was associated with phosphorylation of serine residues in the cytoplasmic domain of the receptor. Culture of endothelial cells in the presence of high glucose concentrations, which stimulate diacylglycerol synthesis and PK-C PII activation, also induced a PK-C-dependent loss of VLDL-R ligand binding activity. Taken together, these studies demonstrate that the ligand binding activity of the VLDL-R is regulated by PK-C-dependent phosphorylation and that hyperglycemia may diminish VLDL-R activity.	Case Western Reserve Univ, Sch Med, Dept Med, Div Hematol Oncol, Cleveland, OH 44106 USA; Amer Red Cross, Holland Labs, Rockville, MD 20855 USA; Huddinge Univ Hosp, Karolinska Inst, Ctr Nutr & Toxicol, S-14186 Huddinge, Sweden	Case Western Reserve University; American Red Cross; Karolinska Institutet	McCrae, KR (corresponding author), Case Western Reserve Univ, Sch Med, Dept Med, Div Hematol Oncol, BRB 329,10900 Euclid Ave, Cleveland, OH 44106 USA.				NHLBI NIH HHS [HL50787, HL50827] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050827] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ando M, 1997, KIDNEY INT, V51, P785, DOI 10.1038/ki.1997.110; Argraves KM, 1997, J CLIN INVEST, V100, P2170, DOI 10.1172/JCI119753; ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; BINGHAM EW, 1976, BIOCHIM BIOPHYS ACTA, V429, P448, DOI 10.1016/0005-2744(76)90293-X; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; BROWN KD, 1984, BIOCHEM BIOPH RES CO, V123, P377, DOI 10.1016/0006-291X(84)90424-8; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; Bu GJ, 1998, J BIOL CHEM, V273, P13359, DOI 10.1074/jbc.273.21.13359; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHRIST G, 1993, BLOOD, V81, P1277; DEISHER TA, 1993, FEBS LETT, V331, P285, DOI 10.1016/0014-5793(93)80354-W; FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453; GAFVELS ME, 1994, ENDOCRINOLOGY, V135, P387, DOI 10.1210/en.135.1.387; GAFVELS ME, 1993, SOMAT CELL MOLEC GEN, V19, P557, DOI 10.1007/BF01233382; GRUNBERGER G, 1982, AM J PHYSIOL, V246, pE319; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1994, FUNCTIONS LDL RECEPT, P14; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; ISHIBASHI T, 1994, ARTERIOSCLER THROMB, V14, P1534, DOI 10.1161/01.ATV.14.10.1534; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; IWASHITA S, 1984, J BIOL CHEM, V259, P2559; JACOBS S, 1983, P NATL ACAD SCI-BIOL, V80, P6211, DOI 10.1073/pnas.80.20.6211; Jingami Hisato, 1995, Current Opinion in Lipidology, V6, P104, DOI 10.1097/00041433-199504000-00008; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; Kibbey RG, 1998, J CELL BIOL, V142, P59, DOI 10.1083/jcb.142.1.59; King GL, 1996, DIABETS, V45, P105; KISHIMOTO A, 1987, J BIOL CHEM, V262, P9367; KISHIMOTO A, 1987, J BIOL CHEM, V262, P1344; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kobayashi K, 1996, J BIOL CHEM, V271, P6852, DOI 10.1074/jbc.271.12.6852; Kohno M, 1997, ATHEROSCLEROSIS, V133, P45, DOI 10.1016/S0021-9150(97)00112-3; Kozarsky KF, 1996, NAT GENET, V13, P54, DOI 10.1038/ng0596-54; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE LS, 1978, SCIENCE, V202, P313, DOI 10.1126/science.308698; LEE TS, 1989, P NATL ACAD SCI USA, V86, P5141, DOI 10.1073/pnas.86.13.5141; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; MAGNUSON DK, 1989, SURGERY, V106, P216; Magrane J, 1998, J LIPID RES, V39, P2172; Martensen PM, 1997, EUR J BIOCHEM, V248, P583, DOI 10.1111/j.1432-1033.1997.00583.x; MASUZAKI H, 1994, FEBS LETT, V347, P211, DOI 10.1016/0014-5793(94)00546-X; MCCAFFREY PG, 1984, J BIOL CHEM, V259, P2502; MCCRAE KR, 1991, BRIT J HAEMATOL, V79, P595, DOI 10.1111/j.1365-2141.1991.tb08087.x; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MEHTA K, 1986, CANCER RES, V46, P1388; Multhaupt HAB, 1996, AM J PATHOL, V148, P1985; Nakamura J, 1999, DIABETES, V48, P2090, DOI 10.2337/diabetes.48.10.2090; Nakazato K, 1996, AM J PATHOL, V149, P1831; Niemeier A, 1996, J LIPID RES, V37, P1733; Nimpf J, 1998, ATHEROSCLEROSIS, V141, P191, DOI 10.1016/S0021-9150(98)00172-5; OKA K, 1994, EUR J BIOCHEM, V224, P975, DOI 10.1111/j.1432-1033.1994.00975.x; OKA K, 1994, GENOMICS, V20, P298, DOI 10.1006/geno.1994.1171; Park JY, 2000, DIABETES, V49, P1239, DOI 10.2337/diabetes.49.7.1239; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; RUDLING M, 1992, J LIPID RES, V33, P493; RUSSELL DW, 1983, P NATL ACAD SCI-BIOL, V80, P7501, DOI 10.1073/pnas.80.24.7501; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SAKTHIVEL R, 1998, VASCULAR BIOL 9 0415, P32; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SIMONSEN ACW, 1994, FEBS LETT, V354, P279, DOI 10.1016/0014-5793(94)01138-9; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; SUZUKI J, 1995, BIOCHEM BIOPH RES CO, V206, P835, DOI 10.1006/bbrc.1995.1119; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; Takahashi S, 1996, FEBS LETT, V386, P197, DOI 10.1016/0014-5793(96)00439-5; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; Warshawsky I, 1996, J BIOL CHEM, V271, P25873, DOI 10.1074/jbc.271.42.25873; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1999, J MOL MED-JMM, V77, P306, DOI 10.1007/s001090050356; WITTMAACK FM, 1995, ENDOCRINOLOGY, V136, P340, DOI 10.1210/en.136.1.340; WRANN M, 1980, SCIENCE, V210, P1363, DOI 10.1126/science.6254158; Wyne KL, 1996, ARTERIOSCL THROM VAS, V16, P407, DOI 10.1161/01.ATV.16.3.407; XIA P, 1994, DIABETES, V43, P1122, DOI 10.2337/diabetes.43.9.1122; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; YAMAMOTO T, 1993, TRENDS CARDIOVAS MED, V3, P144, DOI 10.1016/1050-1738(93)90015-X; Yan SF, 2000, J BIOL CHEM, V275, P11921, DOI 10.1074/jbc.275.16.11921; Yanase K, 1997, J CLIN INVEST, V100, P25, DOI 10.1172/JCI119517	93	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					555	562		10.1074/jbc.M003953200	http://dx.doi.org/10.1074/jbc.M003953200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11010963	hybrid			2022-12-27	WOS:000166280700075
J	Galvez, T; Prezeau, L; Milioti, G; Franek, M; Joly, C; Froestl, W; Bettler, B; Bertrand, HO; Blahos, J; Pin, JP				Galvez, T; Prezeau, L; Milioti, G; Franek, M; Joly, C; Froestl, W; Bettler, B; Bertrand, HO; Blahos, J; Pin, JP			Mapping the agonist-binding site of GABA(B) type 1 subunit sheds light on the activation process of GABA(B) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; PUTATIVE PHEROMONE RECEPTORS; CALCIUM-SENSING RECEPTOR; AMINO-TERMINAL DOMAIN; LIGAND-BINDING; MGLUR4 SUBTYPE; PROTEIN; IDENTIFICATION; EXPRESSION; CLONING	The gamma -amino-n-butyric acid type B (GABA(B)) receptor is composed of two subunits, GABA(B)1 and GABA(B)2, belonging to the family 3 heptahelix receptors. These proteins possess two domains, a seven transmembrane core and an extracellular domain containing the agonist binding site. This binding domain is likely to fold like bacterial periplasmic binding proteins that are constituted of two lobes that close upon ligand binding. Here, using molecular modeling and site-directed mutagenesis, we have identified residues in the GABA(B)1 subunit that are critical for agonist binding and activation of the heteromeric receptor. Our data suggest that two residues (Ser(246) and Asp(471)) located within lobe I form H bonds and a salt bridge with carboxylic and amino groups of GABA, respectively, demonstrating the pivotal role of lobe I in agonist binding. Interestingly, our data also suggest that a residue within lobe II (Tyr(366)) interacts with the agonists in a closed form model of the binding domain, and its mutation into Ala converts the agonist baclofen into an antagonist. These data demonstrate the pivotal role played by the GABA(B)1 subunit in the activation of the heteromeric GABA(B) receptor and are-consistent with the idea that a closed state of the binding domain of family 3 receptors is required for their activation.	CNRS, UPR9023, CCIPE, F-34094 Montpellier 5, France; Charles Univ, Lab Mol Physiol, Med Sch 3, Prague 2, Czech Republic; Acad Sci Czech Republ, Prague 2, Czech Republic; Novartis Pharma AG, TA Nervous Syst, CH-4002 Basel, Switzerland; Mol Simulat Inc, F-91893 Orsay, France	Centre National de la Recherche Scientifique (CNRS); Charles University Prague; Czech Academy of Sciences; Novartis	Galvez, T (corresponding author), CNRS, UPR9023, CCIPE, 141 Rue Cardonille, F-34094 Montpellier 5, France.		Pin, Jean-Philippe/Y-6668-2019; bettler, bernhard/AAO-8018-2020; Blahos, Jaroslav/G-4397-2014; Blahos, Jaroslav/G-8325-2017	Pin, Jean-Philippe/0000-0002-1423-345X; galvez, thierry/0000-0003-2800-3732; Bettler, Bernhard/0000-0003-0842-8207; Blahos, Jaroslav/0000-0003-3355-1469; Blahos, Jaroslav/0000-0001-9803-0061				Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Bai M, 1999, P NATL ACAD SCI USA, V96, P2834, DOI 10.1073/pnas.96.6.2834; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Costantino G, 1996, J MED CHEM, V39, P3998, DOI 10.1021/jm9601718; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Franek M, 1999, NEUROPHARMACOLOGY, V38, P1657, DOI 10.1016/S0028-3908(99)00135-5; FROESTL W, 1995, J MED CHEM, V38, P3297, DOI 10.1021/jm00017a015; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Galvez T, 2000, MOL PHARMACOL, V57, P419, DOI 10.1124/mol.57.3.419; Gomeza J, 1996, MOL PHARMACOL, V50, P923; Hampson DR, 1999, J BIOL CHEM, V274, P33488, DOI 10.1074/jbc.274.47.33488; Han GM, 1999, J BIOL CHEM, V274, P10008, DOI 10.1074/jbc.274.15.10008; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; Isomoto S, 1998, BIOCHEM BIOPH RES CO, V253, P10, DOI 10.1006/bbrc.1998.9706; Jensen AA, 2000, EUR J PHARMACOL, V397, P247, DOI 10.1016/S0014-2999(00)00283-1; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kaupmann K., 1997, WO 97/46675, Patent No. 9746675; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Malitschek B, 1999, MOL PHARMACOL, V56, P448, DOI 10.1124/mol.56.2.448; Malitschek B, 1998, MOL CELL NEUROSCI, V12, P56, DOI 10.1006/mcne.1998.0698; Martin SC, 1999, MOL CELL NEUROSCI, V13, P180, DOI 10.1006/mcne.1999.0741; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; O'Hara BP, 2000, PROTEIN ENG, V13, P129, DOI 10.1093/protein/13.2.129; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; PEARL L, 1994, EMBO J, V13, P5810, DOI 10.1002/j.1460-2075.1994.tb06924.x; Pfaff T, 1999, EUR J NEUROSCI, V11, P2874, DOI 10.1046/j.1460-9568.1999.00704.x; Pin JP, 1999, EUR J PHARMACOL, V375, P277, DOI 10.1016/S0014-2999(99)00258-7; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Speca DJ, 1999, NEURON, V23, P487, DOI 10.1016/S0896-6273(00)80802-8; Sullivan R, 2000, J PHARMACOL EXP THER, V293, P460; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; YAO NH, 1994, BIOCHEMISTRY-US, V33, P4769, DOI 10.1021/bi00182a004	45	108	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41166	41174		10.1074/jbc.M007848200	http://dx.doi.org/10.1074/jbc.M007848200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10986293	hybrid			2022-12-27	WOS:000166114600069
J	Hahn-Dantona, EA; Aimes, RT; Quigley, JP				Hahn-Dantona, EA; Aimes, RT; Quigley, JP			The isolation, characterization, and molecular cloning of a 75-kDa gelatinase B-like enzyme, a member of the matrix metalloproteinase (MMP) family - An avian enzyme that is MMP-9-like in its cell expression pattern but diverges from mammalian gelatinase B in sequence and biochemical properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEPWISE ACTIVATION MECHANISMS; HUMAN FIBROBLAST COLLAGENASE; CHICKEN-EMBRYO FIBROBLASTS; C-TERMINAL DOMAIN; TISSUE INHIBITOR; IV COLLAGENASE; PROGELATINASE-A; 4-AMINOPHENYLMERCURIC ACETATE; POLYACRYLAMIDE GELS; 72-KDA GELATINASE	We have isolated a novel 75-kDa gelatinase from a chicken macrophage cell line, HD11. Biochemical and immunological characterization of the purified enzyme demonstrated that it is distinct from the chicken 72-kDa gelatinase A (MMP-2). The enzyme is capable of specific gelatin binding and rapid gelatin cleavage. Incubation with an organomercurial compound (p-aminophenylmercuric acetate) induces proteolytic processing and activation of this enzyme, and the resultant gelatinolytic activity is sensitive to both zinc chelators and tissue inhibitors of metalloproteinases. A full-length cDNA for the enzyme has been cloned, and sequence analysis demonstrated that the enzyme possesses the characteristic multidomain structure of an MMP gelatinase including a cysteine switch prodomain, three fibronectin type II repeats, a catalytic zinc binding region, and a hemopexin-like domain, The 75-kDa gelatinase is produced by phorbol ester-treated chicken bone marrow cells, monocytes, and polymorphonuclear leukocytes, cell types that characteristically produce the 92-kDa mammalian gelatinase B (MMP-9). The absence of a 90-110-kDa gelatinase in these cell types indicates that the 75-kDa gelatinase is likely the avian counterpart of gelatinase B, However, the protein is only 59% identical to human gelatinase B, whereas all previously cloned chicken MMP homologues are 75-90% identical to their human counterparts. In addition, the new 75-kDa chicken gelatinase lacks the type V collagen domain that is found in all mammalian gelatinase Bs, Furthermore, the secreted enzyme appears structurally distinct from known gelatinase Bs and the activated enzyme can cleave fibronectin, which is not a substrate for mammalian gelatinase B, Thus the results of this study indicate that a second MMP gelatinase exists in chickens, and although it is MIMP-9/gelatinase B-like in its overall domain structure and expression pattern, it appears to be biochemically divergent from mammalian gelatinase B.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA	Scripps Research Institute; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Quigley, JP (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines RD,VB1, La Jolla, CA 92037 USA.	jquigley@scripps.edu			NCI NIH HHS [CA55852] Funding Source: Medline; PHS HHS [H60769S] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055852] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams DO., 1992, INFLAMMATION BASIC P, P637; Aimes RT, 1998, J CELL PHYSIOL, V174, P342, DOI 10.1002/(SICI)1097-4652(199803)174:3<342::AID-JCP8>3.3.CO;2-K; AMES RT, 1994, BIOCHEM J, V300, P729, DOI 10.1042/bj3000729; Andreasen CB, 1999, AVIAN DIS, V43, P656, DOI 10.2307/1592734; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; BEBBINGTON CR, 1992, BIO-TECHNOL, V10, P169, DOI 10.1038/nbt0292-169; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BROWN PD, 1993, KIDNEY INT, V43, P163, DOI 10.1038/ki.1993.27; CHEN JM, 1991, J BIOL CHEM, V266, P5113; FRIDMAN R, 1995, CANCER RES, V55, P2548; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Hahn-Dantona E, 1999, ANN NY ACAD SCI, V878, P372, DOI 10.1111/j.1749-6632.1999.tb07696.x; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; Hua J, 1996, CANCER RES, V56, P5279; HUARTE J, 1987, GENE DEV, V1, P1201, DOI 10.1101/gad.1.10.1201; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; Lei HQ, 1999, BIOL REPROD, V60, P183, DOI 10.1095/biolreprod60.1.183; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Mazo IB, 1999, J LEUKOCYTE BIOL, V66, P25, DOI 10.1002/jlb.66.1.25; Miyazaki K, 1996, P NATL ACAD SCI USA, V93, P6819, DOI 10.1073/pnas.93.13.6819; MOLL UM, 1990, CANCER RES, V50, P6162; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; MURPHY G, 1994, J BIOL CHEM, V269, P6632; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1992, J BIOL CHEM, V267, P9612; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; Nagase H, 1992, Matrix Suppl, V1, P237; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NAGASE H, 1991, BIOMED BIOCHIM ACTA, V50, P749; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; Owen CA, 1999, J LEUKOCYTE BIOL, V65, P137, DOI 10.1002/jlb.65.2.137; Park HI, 2000, J BIOL CHEM, V275, P20540, DOI 10.1074/jbc.M002349200; POURMOTABBED T, 1994, ANN NY ACAD SCI, V732, P372, DOI 10.1111/j.1749-6632.1994.tb24757.x; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; Sato T, 1999, ANN NY ACAD SCI, V878, P713, DOI 10.1111/j.1749-6632.1999.tb07770.x; Solari F, 1996, J CELL SCI, V109, P1203; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; Steffensen B, 1998, J BIOL CHEM, V273, P20622, DOI 10.1074/jbc.273.32.20622; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Suzuki K, 1998, BIOL CHEM, V379, P185, DOI 10.1515/bchm.1998.379.2.185; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANFURTH R, 1992, INFLAMMATION BASIC P, P325; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOESSNER JF, 1994, ANN NY ACAD SCI, V732, P11; Yang MZ, 1996, J BIOL CHEM, V271, P25548, DOI 10.1074/jbc.271.41.25548	58	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40827	40838		10.1074/jbc.M006234200	http://dx.doi.org/10.1074/jbc.M006234200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11010969	hybrid			2022-12-27	WOS:000166114600024
J	Nyitrai, M; Hild, G; Hartvig, N; Belagyi, J; Somogyi, B				Nyitrai, M; Hild, G; Hartvig, N; Belagyi, J; Somogyi, B			Conformational and dynamic differences between actin filaments polymerized from ATP- or ADP-actin monomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE ENERGY-TRANSFER; NUCLEOTIDE-BINDING-SITES; RABBIT SKELETAL-MUSCLE; F-ACTIN; TRANSFER SPECTROSCOPY; RADIAL COORDINATE; DIVALENT-CATIONS; PHALLOIDIN; FLEXIBILITY; MYOSIN	Conformational and dynamic properties of actin filaments polymerized from ATP- or ADP-actin monomers were compared by using fluorescence spectroscopic methods. The fluorescence intensity of LAEDANS attached to the Cys(374) residue of actin was smaller in filaments from ADP-actin than in filaments from ATP-actin monomers, which reflected a nucleotide-induced conformational difference in subdomain 1 of the monomer. Radial coordinate calculations revealed that this conformational difference did not modify the distance of Cys(374) from the longitudinal filament axis. Temperature-dependent fluorescence resonance energy transfer measurements between donor and acceptor molecules on Cys(374) Of neighboring actin protomers revealed that the inter-monomer flexibility of filaments assembled from ADP-actin monomers were substantially greater than the one of filaments from ATP-actin monomers, Flexibility was reduced by phalloidin in both types of filaments.	Univ Pecs, Res Grp Fluorescence Spect, Off Acad Res Grp Attached Univ & Other Inst, H-7601 Pecs, Hungary; Univ Pecs, Dept Biophys, Fac Med, H-7601 Pecs, Hungary; Univ Pecs, Cent Res Lab, Fac Med, H-7601 Pecs, Hungary	University of Pecs; University of Pecs; University of Pecs	Somogyi, B (corresponding author), Univ Pecs, Res Grp Fluorescence Spect, Off Acad Res Grp Attached Univ & Other Inst, POB 99, H-7601 Pecs, Hungary.			Nyitrai, Miklos/0000-0002-6229-4337				BARDEN JA, 1987, EUR J BIOCHEM, V162, P583, DOI 10.1111/j.1432-1033.1987.tb10679.x; BAY Z, 1963, P NATL ACAD SCI USA, V50, P1071, DOI 10.1073/pnas.50.6.1071; BURLACU S, 1992, AM J PHYSIOL, V262, P569; Carlier M F, 1990, Adv Biophys, V26, P51, DOI 10.1016/0065-227X(90)90007-G; Carlier MF, 1991, CURR OPIN CELL BIOL, V3, P12, DOI 10.1016/0955-0674(91)90160-Z; CARLIER MF, 1987, BIOCHEM BIOPH RES CO, V143, P1069, DOI 10.1016/0006-291X(87)90361-5; CARLIER MF, 1988, J BIOL CHEM, V263, P817; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CARLIER MF, 1986, BIOCHEMISTRY-US, V25, P7789, DOI 10.1021/bi00372a001; DANCKER P, 1975, BIOCHIM BIOPHYS ACTA, V400, P407, DOI 10.1016/0005-2795(75)90196-8; DREWES G, 1991, J BIOL CHEM, V266, P5508; ELZINGA M, 1973, P NATL ACAD SCI USA, V70, P2687, DOI 10.1073/pnas.70.9.2687; FAULSTICH H, 1988, J MUSCLE RES CELL M, V9, P370, DOI 10.1007/BF01774064; FAULSTICH H, 1993, FEBS LETT, V318, P218, DOI 10.1016/0014-5793(93)80515-V; Feuer G., 1948, HUNGARICA ACTA PHYSIOL, V1, P150; FRIEDEN C, 1980, J BIOL CHEM, V255, P8991; Gaszner B, 1999, BIOCHEMISTRY-US, V38, P12885, DOI 10.1021/bi990748y; GENNIS RB, 1972, BIOCHEMISTRY-US, V11, P2509, DOI 10.1021/bi00763a020; Hild G, 1998, BIOPHYS J, V75, P3015, DOI 10.1016/S0006-3495(98)77742-2; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; ISAMBERT H, 1995, J BIOL CHEM, V270, P11437, DOI 10.1074/jbc.270.19.11437; Ishiwata S, 1997, BIOPHYS J, V73, P895, DOI 10.1016/S0006-3495(97)78122-0; JANMEY PA, 1990, NATURE, V347, P95, DOI 10.1038/347095a0; KASPRZAK AA, 1988, BIOCHEMISTRY-US, V27, P4512, DOI 10.1021/bi00412a044; KAWAMURA M, 1972, J BIOCHEM-TOKYO, V72, P179, DOI 10.1093/oxfordjournals.jbchem.a129884; KOUYAMA T, 1985, BIOPHYS J, V47, P43, DOI 10.1016/S0006-3495(85)83875-3; MIKI M, 1986, BIOCHIM BIOPHYS ACTA, V871, P137, DOI 10.1016/0167-4838(86)90166-4; MIKI M, 1986, BIOCHEM INT, V12, P725; MIKI M, 1986, BIOCHIM BIOPHYS ACTA, V872, P76, DOI 10.1016/0167-4838(86)90149-4; MIKI M, 1987, EUR J BIOCHEM, V165, P125, DOI 10.1111/j.1432-1033.1987.tb11202.x; MIKI M, 1987, EUR J BIOCHEM, V168, P339, DOI 10.1111/j.1432-1033.1987.tb13425.x; Moens PDJ, 1997, BIOCHEMISTRY-US, V36, P7353, DOI 10.1021/bi962588l; MOENS PDJ, 1994, BIOCHEMISTRY-US, V33, P13102, DOI 10.1021/bi00248a020; NEWMAN J, 1993, BIOPHYS J, V64, P1559, DOI 10.1016/S0006-3495(93)81525-X; NUNNALLY MH, 1981, J BIOL CHEM, V256, P2083; Nyitrai M, 1999, J BIOL CHEM, V274, P12996, DOI 10.1074/jbc.274.19.12996; ORLOVA A, 1995, J MOL BIOL, V245, P582, DOI 10.1006/jmbi.1994.0048; ORLOVA A, 1993, J MOL BIOL, V232, P334, DOI 10.1006/jmbi.1993.1393; ORLOVA A, 1992, J MOL BIOL, V227, P1043, DOI 10.1016/0022-2836(92)90520-T; POLLARD TD, 1992, J BIOL CHEM, V267, P20339; POLLARD TD, 1984, FEBS LETT, V170, P94, DOI 10.1016/0014-5793(84)81376-9; Rebello CA, 1998, BIOCHEMISTRY-US, V37, P14529, DOI 10.1021/bi981240i; RICKARD JE, 1988, J MOL BIOL, V201, P675, DOI 10.1016/0022-2836(88)90466-4; SELVE N, 1986, J MOL BIOL, V187, P627, DOI 10.1016/0022-2836(86)90341-4; SOMOGYI B, 1984, BIOCHEMISTRY-US, V23, P3403, DOI 10.1021/bi00310a004; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Steinmetz MO, 1997, J CELL BIOL, V138, P559, DOI 10.1083/jcb.138.3.559; STRZELECKAGOLASZEWSKA H, 1993, EUR J BIOCHEM, V211, P731, DOI 10.1111/j.1432-1033.1993.tb17603.x; TAKASHI R, 1979, BIOCHEMISTRY-US, V18, P5164, DOI 10.1021/bi00590a021; TAYLOR DL, 1981, J CELL BIOL, V89, P362, DOI 10.1083/jcb.89.2.362; WEGNER A, 1970, J MOL BIOL, V109, P139; YIN HL, 1980, J BIOL CHEM, V255, P9494	53	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41143	41149		10.1074/jbc.M004146200	http://dx.doi.org/10.1074/jbc.M004146200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11005806	hybrid			2022-12-27	WOS:000166114600066
J	Borsu, L; Presse, F; Nahon, JL				Borsu, L; Presse, F; Nahon, JL			The AROM gene, spliced mRNAs encoding new DNA/RNA-binding proteins are transcribed from the opposite strand of the melanin-concentrating hormone gene in mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; TISSUE-SPECIFIC EXPRESSION; FIBROBLAST GROWTH-FACTOR; RNA-RECOGNITION; ANTISENSE RNA; RAT-BRAIN; SEQUENCE; DNA; PEPTIDE; CELLS	Melanin-concentrating hormone (MCH) mRNA expression is induced by nerve growth factor and lithium in PC12 cells, whereas three large MCH RNA species are found in untreated cells. In this study, we investigated the structures, regulations of expression, and putative functions of these transcripts. Northern blot, rapid amplification of cDNA ends-polymerase chain reaction, reverse transcriptase-polymerase chain reaction, and sequencing experiments demonstrated that they are antisense RNAs complementary to the MCH gene. Two classes of antisense RNAs could be discriminated as follows: 1) non-coding unspliced RNAs that overlap mainly the coding part of the MCH gene; 2) spliced variant mRNAs complementary to the 3'-flanking end of the MCH gene and that encode putative proteins containing DNA/RNA binding domains. We named this new transcriptional unit AROM for antisense-RNA-overlapping-MCH gene. Spliced variant AROM mRNAs are expressed in a broad range of rat organs. Western blot and immunohistochemistry experiments revealed several proteins with cytoplasmic but also nuclear localization in PC12 cells. Time course studies during nerve growth factor and lithium treatment of PC12 cells indicated a reciprocal regulation of the MCH and AROM gene transcripts, reflected also at the level of AROM proteins. The major translational product is a 64-kDa protein (AROM-p64). Recombinant AROM-p64 displayed high binding to single-stranded DNA and poly(A) homopolymers suggesting that this protein could play a role in mRNA maturation/metabolism.	Inst Pharmacol Mol & Cellulaire, CNRS UPR 411, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Nahon, JL (corresponding author), Inst Pharmacol Mol & Cellulaire, CNRS UPR 411, 660 Route Lucioles Sophia Antipolis, F-06560 Valbonne, France.		PRESSE, Francoise/O-8508-2016; NAHON, Jean-Louis/O-7977-2016	NAHON, Jean-Louis/0000-0001-9572-7779				ARMSTRONG BC, 1992, CELL GROWTH DIFFER, V3, P385; BAKER BI, 1994, TRENDS ENDOCRIN MET, V5, P120, DOI 10.1016/1043-2760(94)90093-0; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; BRESSON JL, 1989, NEUROSCI LETT, V102, P39, DOI 10.1016/0304-3940(89)90304-2; BRETON C, 1993, MOL BRAIN RES, V18, P297, DOI 10.1016/0169-328X(93)90093-5; BRETON C, 1993, MOL CELL NEUROSCI, V4, P271, DOI 10.1006/mcne.1993.1035; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; HENIKOFF S, 1986, CELL, V44, P33, DOI 10.1016/0092-8674(86)90482-4; HERVIEU G, 1995, NEUROENDOCRINOLOGY, V61, P348, DOI 10.1159/000126857; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P10; KAWAUCHI H, 1983, NATURE, V305, P321, DOI 10.1038/305321a0; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; Knee R, 1997, P NATL ACAD SCI USA, V94, P4943, DOI 10.1073/pnas.94.10.4943; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Krystal G. W., 1992, Gene regulation: biology of antisense RNA and DNA., P11; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Miller CL, 1998, BRAIN RES, V803, P86, DOI 10.1016/S0006-8993(98)00626-X; MUNROE SH, 1991, J BIOL CHEM, V266, P22083; NAHON JL, 1989, ENDOCRINOLOGY, V125, P2056, DOI 10.1210/endo-125-4-2056; NAHON JL, 1994, CRIT REV NEUROBIOL, V8, P221; Presse F, 1997, MOL BRAIN RES, V52, P270, DOI 10.1016/S0169-328X(97)00273-8; Presse F, 1996, NEUROSCIENCE, V71, P735, DOI 10.1016/0306-4522(95)00481-5; PRESSE F, 1991, HORIZONS ENDOCRINOLO, V2, P241; PRESSE F, 1997, MCH SEIZURES NEUROMO, P31; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Rossi M, 1997, ENDOCRINOLOGY, V138, P351, DOI 10.1210/en.138.1.351; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; SKOFITSCH G, 1985, BRAIN RES BULL, V15, P635, DOI 10.1016/0361-9230(85)90213-8; Soret J, 1998, MOL CELL BIOL, V18, P4924, DOI 10.1128/MCB.18.8.4924; THOMPSON RC, 1990, DNA CELL BIOL, V9, P637, DOI 10.1089/dna.1990.9.637; Tommasi S, 1999, J BIOL CHEM, V274, P27829, DOI 10.1074/jbc.274.39.27829; Toumaniantz G, 1996, ENDOCRINOLOGY, V137, P4518, DOI 10.1210/en.137.10.4518; VAUGHAN JM, 1989, ENDOCRINOLOGY, V125, P1660, DOI 10.1210/endo-125-3-1660; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; Viale A, 1998, MOL BIOL EVOL, V15, P196, DOI 10.1093/oxfordjournals.molbev.a025915; Zhang G, 1998, J BACTERIOL, V180, P377, DOI 10.1128/JB.180.2.377-387.1998	47	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40576	40587		10.1074/jbc.M006524200	http://dx.doi.org/10.1074/jbc.M006524200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006283	hybrid			2022-12-27	WOS:000166039500104
J	Iglesias, T; Cabrera-Poch, N; Mitchell, MP; Naven, TJP; Rozengurt, E; Schiavo, G				Iglesias, T; Cabrera-Poch, N; Mitchell, MP; Naven, TJP; Rozengurt, E; Schiavo, G			Identification and cloning of Kidins220, a novel neuronal substrate of protein kinase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; C-MU; PHORBOL ESTER; D PKD; CELLS; ACTIVATION; DIACYLGLYCEROL; COMPLEX; ASSOCIATION; CORTACTIN	Protein kinase D (PKD) is a serine/threonine kinase regulated by diacylglycerol signaling pathways with unique domain composition and enzymatic properties, still awaiting identification of its specific substrate(s). Here we have isolated, cloned, and characterized a novel protein from PC12 cells, termed Kidins220 (kinase D-interacting substrate of 220 kDa), as the first identified PKD physiological substrate. Kidins220 contains 11 ankyrin repeats and four transmembrane domains within the N-terminal region. We have shown that Kidins220 is an integral membrane protein selectively expressed in brain and neuroendocrine cells, where it concentrates at the tip of neurites. In PC12 cells, PKD coimmunoprecipitates and phosphorylates endogenous Kidins220. This phosphorylation is increased after stimulating PKD activity in vivo by phorbol-12,13-dibutyrate treatment. A constitutively active PKD mutant (PKD-S744E/S748E) phosphorylates recombinant Kidins220-VSVG in vitro in the absence of phorbol-12,13-dibutyrate. Conversely, Kidins220-VSVG phosphorylation is abolished when a dominant negative mutant of PHD (PKD-D733A) is used. Moreover, a peptide within the Kidins220 sequence, containing serine 919 in a consensus motif for PHD-specific phosphorylation, behaved as the best peptide substrate to date. Substitution of serine 919 to alanine abrogated peptide phosphorylation. Furthermore, by generating an antibody recognizing Kidins220 phosphorylated on serine 919, we show that phorbol ester treatment causes the specific phosphorylation of this residue in PC12 cells in vivo. Our results provide the first physiological substrate for PKD and indicate that Kidins220 is phosphorylated by PKD at serine 919 in vivo.	Imperial Canc Res Fund, Mol Neuropathobiol Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Cell Biol Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Computat Genome Anal Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Prot Sequencing Lab, London WC2A 3PX, England; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Cancer Research UK; Cancer Research UK; Cancer Research UK; The Genome Analysis Centre (TGAC); Cancer Research UK; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Iglesias, T (corresponding author), Imperial Canc Res Fund, Mol Neuropathobiol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	tiglesias@iib.uam.es	Vacas, Teresa Iglesias/ABF-8663-2020	Vacas, Teresa Iglesias/0000-0002-4326-9005; Schiavo, Giampietro/0000-0002-4319-8745				Abedi H, 1998, FEBS LETT, V427, P209, DOI 10.1016/S0014-5793(98)00427-X; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Burgoyne RD, 1998, BIOESSAYS, V20, P328, DOI 10.1002/(SICI)1521-1878(199804)20:4<328::AID-BIES9>3.0.CO;2-L; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; EXTON JH, 1990, J BIOL CHEM, V265, P1; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, FEBS LETT, V437, P19, DOI 10.1016/S0014-5793(98)01189-2; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Johannes FJ, 1999, FEBS LETT, V461, P68, DOI 10.1016/S0014-5793(99)01424-6; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Nagase T, 1999, DNA Res, V6, P337, DOI 10.1093/dnares/6.5.337; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Paolucci L, 1999, CANCER RES, V59, P572; Rozengurt E, 1995, MUTAT RES-FUND MOL M, V333, P153, DOI 10.1016/0027-5107(95)00141-7; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 1999, ELECTROPHORESIS, V20, P382, DOI 10.1002/(SICI)1522-2683(19990201)20:2<382::AID-ELPS382>3.0.CO;2-N; Wooten MW, 1997, J NEUROSCI RES, V49, P393, DOI 10.1002/(SICI)1097-4547(19970815)49:4<393::AID-JNR1>3.0.CO;2-3; Yaffe MB, 1999, NATURE, V402, P30; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	44	125	130	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40048	40056		10.1074/jbc.M005261200	http://dx.doi.org/10.1074/jbc.M005261200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10998417	hybrid			2022-12-27	WOS:000166039500036
J	Lin, M; Napoli, JL				Lin, M; Napoli, JL			cDNA cloning and expression of a human aldehyde dehydrogenase (ALDH) active with 9-cis-retinal and identification of a rat ortholog, ALDH12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-BINDING-PROTEINS; ESCHERICHIA-COLI; ACID RECEPTORS; RETINALDEHYDE; BIOSYNTHESIS; OXIDATION; 9-CIS; RECOGNITION; MECHANISMS; METABOLISM	This report describes the isolation of a heretofore uncharacterized aldehyde dehydrogenase (ALDH) with retinal dehydrogenase activity from rat kidney and the cloning and expression of a cDNA that encodes its human ortholog, the previously unknown ALDH12. The human ALDH12 cDNA predicts a 487-residue protein with the 23 invariant amino acids, four conserved regions, cofactor binding motif (G(209)XGX(3)G), and active site cysteine residue (Cys(287)) that typify members of the ALDH superfamily. ALDH12 seems at least as efficient (V-m/K-m) in converting 9-cis-retinal into the retinoid X receptor ligand 9-cis-retinoic acid as two previously identified ALDHs with 9-cis-retinal dehydrogenase activity, rat retinal dehydrogenase (RALDH) 1 and RALDH2. ALDH12, however, has similar to 40-fold higher activity with 9-cis- retinal than with all-trans-retinal, whereas RALDH1 and RALDH2 have equivalent and similar to4-fold less efficiencies for 9-cis-retinal versus all-trans-retinal, respectively. Therefore, ALDH12 is the first known ALDH to show a preference for 9-cis-retinal relative to all-trans-retinal. Evidence consistent with the possibility that ALDH12 could function in a pathway of 9-cis-retinoic acid biosynthesis in vivo includes biosynthesis of 9-cis-retinoic acid from 9-cis-retinol in cells co-transfected with cDNAs encoding ALDH12 and the 9-cis-retinoUandrogen dehydrogenase, cis-retinoid/androgen dehydrogenase type 1. Intense ALDH12 mRNA expression in adult and fetal liver and kidney, two organs that reportedly have relatively high concentrations of 9-cis-retinol, reinforces this notion.	Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Napoli, JL (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, 119 Morgan Hall,MC 3104, Berkeley, CA 94720 USA.	jna@uclink4.berkeley.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013566] Funding Source: NIH RePORTER; NIA NIH HHS [AG13566] Funding Source: Medline; NIDDK NIH HHS [DK47839] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABEDINIA M, 1990, EXP EYE RES, V51, P419, DOI 10.1016/0014-4835(90)90154-M; Bhat PV, 1995, GENE, V166, P303, DOI 10.1016/0378-1119(96)81752-5; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHANDLER LA, 1987, J FOOD SCI, V52, P669, DOI 10.1111/j.1365-2621.1987.tb06700.x; DOCKHAM PA, 1992, BIOCHEM PHARMACOL, V43, P2453, DOI 10.1016/0006-2952(92)90326-E; ELAKAWI Z, 1994, BIOCHEMISTRY-US, V33, P1938, DOI 10.1021/bi00173a042; Glass CK, 1997, BIOCHEM SOC T, V25, P602, DOI 10.1042/bst0250602; Graham C, 1996, J BIOL CHEM, V271, P15623, DOI 10.1074/jbc.271.26.15623; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; LABRECQUE J, 1995, BIOCHEM J, V305, P681, DOI 10.1042/bj3050681; Lamb AL, 1999, BIOCHEMISTRY-US, V38, P6003, DOI 10.1021/bi9900471; Lamb AL, 1998, ACTA CRYSTALLOGR D, V54, P639, DOI 10.1107/S0907444997014121; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Maden M, 1998, SUB CELL BIOCHEM, V30, P81; Morriss-Kay GM, 1999, INT REV CYTOL, V188, P73; NAGAO A, 1994, FASEB J, V8, P968, DOI 10.1096/fasebj.8.12.8088462; Napoli JL, 1997, SEMIN CELL DEV BIOL, V8, P403, DOI 10.1006/scdb.1997.0164; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; NAPOLI JL, 2000, IN PRESS MOL CELL EN; Paik J, 2000, BIOCHEMISTRY-US, V39, P8073, DOI 10.1021/bi992152g; Penzes P, 1997, GENE, V191, P167, DOI 10.1016/S0378-1119(97)00054-1; Penzes P, 1997, BBA-PROTEIN STRUCT M, V1342, P175, DOI 10.1016/S0167-4838(97)00102-7; PEREIRA F, 1991, BIOCHEM BIOPH RES CO, V175, P831, DOI 10.1016/0006-291X(91)91640-X; POSCH KC, 1992, J BIOL CHEM, V267, P19676; Vasiliou V, 1999, PHARMACOGENETICS, V9, P421, DOI 10.1097/00008571-199910000-00004; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; YOSHIDA A, 1993, ADV EXP MED BIOL, V328, P37; Yoshida A, 1998, EUR J BIOCHEM, V251, P549, DOI 10.1046/j.1432-1327.1998.2510549.x; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x	31	45	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40106	40112		10.1074/jbc.M008027200	http://dx.doi.org/10.1074/jbc.M008027200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007799	hybrid			2022-12-27	WOS:000166039500043
J	Ali, S; Ali, S				Ali, S; Ali, S			Recruitment of the protein-tyrosine phosphatase SHP-2 to the C-terminal tyrosine of the prolactin receptor and to the adaptor protein Gab2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; GRB2 BINDING-SITE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; DOCKING PROTEIN; ACTIVATION; KINASE; PHOSPHORYLATION; ASSOCIATION	The protein-tyrosine phosphatase SHP-2 modulates signaling events through receptor tyrosine kinases and cytokine receptors including the receptor for prolactin (PRLR). Here we investigated mechanisms of SHP-2 recruitment within the PRLR signaling complex. Using SHP-2 and PRLR immunoprecipitation studies in 293 cells and in the mouse mammary epithelial cell line HC11, we found that SHP-2 co-immunoprecipitates with the PRLR and that the C-terminal tyrosine of the PRLR plays a regulatory role in both the tyrosine phosphorylation and the recruitment of SHP-2. Our results further indicate that SHP-2 association to the PRLR occurs via the C-terminal SH2 domain of the phosphatase. In addition, we determined that the newly identified adaptor protein Gab2, but not Gab1, is specifically tyrosine phosphorylated and is able to recruit SHP-2 and phosphatidyinositol 3-kinase in response to PRLR activation. Together, these studies suggest the presence of dual recruitment sites for SHP-2; the first is to the C-terminal tyrosine of the PRLR and the second is to the adaptor protein Gab2.	McGill Univ, Royal Victoria Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Dept Med, Div Hematol, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital	Ali, S (corresponding author), McGill Univ, Royal Victoria Hosp, Mol Oncol Grp, H5-81,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	Suhad.Ali@muhc.mcgill.ca						ALI S, 1992, MOL ENDOCRINOL, V6, P1242, DOI 10.1210/me.6.8.1242; Ali S, 1998, J BIOL CHEM, V273, P7709, DOI 10.1074/jbc.273.13.7709; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Bazenet CE, 1996, MOL CELL BIOL, V16, P6926; Berchtold S, 1998, MOL ENDOCRINOL, V12, P556, DOI 10.1210/me.12.4.556; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Gadina M, 1998, J IMMUNOL, V160, P4657; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kim H, 1999, MOL CELL BIOL, V19, P5326; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LEBRUN JJ, 1995, J BIOL CHEM, V270, P10664, DOI 10.1074/jbc.270.18.10664; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Liu L, 1997, J BIOL CHEM, V272, P10998; Maegawa H, 1999, J BIOL CHEM, V274, P30236, DOI 10.1074/jbc.274.42.30236; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; Merlo GR, 1996, EUR J CELL BIOL, V70, P97; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Okuda K, 1997, BLOOD, V90, P4759, DOI 10.1182/blood.V90.12.4759.4759_4759_4766; Pezet A, 1997, J BIOL CHEM, V272, P25043, DOI 10.1074/jbc.272.40.25043; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Rocchi S, 1998, MOL ENDOCRINOL, V12, P914, DOI 10.1210/me.12.7.914; Ronnstrand L, 1999, ONCOGENE, V18, P3696, DOI 10.1038/sj.onc.1202705; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Sorensen P, 1997, BIOCHEM BIOPH RES CO, V241, P710, DOI 10.1006/bbrc.1997.7879; Stofega MR, 1998, J BIOL CHEM, V273, P7112, DOI 10.1074/jbc.273.12.7112; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	31	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39073	39080		10.1074/jbc.M007478200	http://dx.doi.org/10.1074/jbc.M007478200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10991949	hybrid			2022-12-27	WOS:000165953100019
J	Baron, V; Schwartz, M				Baron, V; Schwartz, M			Cell adhesion regulates ubiquitin-mediated degradation of the platelet-derived growth factor receptor beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; TRANSFORMED PHENOTYPE; C-CBL; FIBRONECTIN; PDGF; PHOSPHORYLATION; PROTEASOME; ATTACHMENT; ACTIVATION	Cross-talk between integrin-mediated adhesion and growth factors has been described in many recent studies; however, the underlying mechanisms remain incompletely understood. We report here that detachment of cells from the extracellular matrix induced a decrease in both the autophosphorylation and protein levels of the platelet-derived growth factor receptor beta (PDGF-R beta), which was completely reversed upon replating cells on fibronectin. The effect occurred in all cells examined but to a greater extent in primary fibroblasts compared with established cell lines. Decreased PDGF-R levels in suspended cells correlated with ubiquitination of the PDGF-R and was blocked by treatment with inhibitors of the proteasome pathway. Unlike PDGF-induced down-regulation, detachment-induced degradation did not require receptor autophosphorylation, internalization, or tyrosine kinase activity. me conclude that cell detachment results in cellular desensitization to PDGF that is mediated by degradation of the PDGF-R via a novel ubiquitin-dependent pathway.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schwartz, M (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			schwartz, martin/0000-0002-2071-1243	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL48728] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; HELDIN CH, 1982, J BIOL CHEM, V257, P4216; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hirsch C, 2000, TRENDS CELL BIOL, V10, P268, DOI 10.1016/S0962-8924(00)01768-2; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; Leng J, 1999, J BIOL CHEM, V274, P37855, DOI 10.1074/jbc.274.53.37855; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lin TH, 1997, J BIOL CHEM, V272, P8849; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; SYMINGTON BE, 1990, CELL REGUL, V1, P637, DOI 10.1091/mbc.1.9.637; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707	38	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39318	39323		10.1074/jbc.M003618200	http://dx.doi.org/10.1074/jbc.M003618200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11007771	hybrid			2022-12-27	WOS:000165953100053
J	Fanayan, S; Firth, SM; Butt, AJ; Baxter, RC				Fanayan, S; Firth, SM; Butt, AJ; Baxter, RC			Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF-beta) and the type II TGF-beta receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SKIN FIBROBLASTS; EPITHELIAL-CELLS; CELLULAR GROWTH; CARCINOMA CELLS; RETINOIC ACID; SMAD PROTEINS; MAD PROTEINS; MCF-7 CELLS; EXPRESSION; RESISTANCE	This study explores the relationship between anti-proliferative signaling by transforming growth factor-p (TGF-beta) and insulin-like growth factor-binding protein-3 (IGFBP-3) in human breast cancer cells. In MCF-7 cells, the expression of recombinant IGFBP-3 inhibited proliferation and sensitized the cells to further inhibition by TGF-beta1. To investigate the mechanism, we used T47D cells that lack type II TGF-P receptor (TGF-beta RII) and are insensitive to TGF-beta1. After introducing the TGF-beta RII by transfection, the basal proliferation rate was significantly decreased. Exogenous TGF-beta1 caused no further growth inhibition, but immunoneutralization of endogenous TGF-PI restored the proliferation rate almost to the control level. The addition of IGFBP-3 did not inhibit the proliferation of control cells but caused dose-dependent inhibition in TGF-beta RII-expressing cells when exogenous TGF-beta1 was also present. Similarly, receptor-expressing cells showed dose-dependent sensitivity to exogenous TGF-beta 1only in the presence of exogenous IGFBP-3. This indicates that in these cells, antiproliferative signaling by exogenous IGFBP-3 requires both the TGF-beta RII and exogenous TGF-beta1. To investigate this synergism, the phosphorylation of TGF-beta signaling intermediates, Smad2 and Smad3, was measured. Phosphorylation of each Smad was stimulated by TGF-beta1 and, independently, by IGFBP-3 with the two agents together showing a cumulative effect. These data suggest that IGFBP-3 inhibitory signaling requires an active TGF-beta signaling pathway and implicate Smad2 and Smad3 in IGFBP-3 signal transduction.	Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Baxter, RC (corresponding author), Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.	robaxter@med.usyd.edu.au	Baxter, Robert C/F-3927-2012; Fanayan, Susan/H-1137-2011	Baxter, Robert C/0000-0001-5061-2142; Fanayan, Susan/0000-0003-4369-6987; Butt, Alison/0000-0002-6216-5105				ARTEAGA CL, 1988, CANCER RES, V48, P3898; ATTISAN L, 1990, ANN REV CELL BIOL, V6, P597; Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BAXTER RC, 1994, HORM RES, V42, P140, DOI 10.1159/000184186; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1988, J BIOL CHEM, V263, P17225; CHEN JC, 1994, J CELL PHYSIOL, V158, P69, DOI 10.1002/jcp.1041580110; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; Colston KW, 1998, J MOL ENDOCRINOL, V20, P157, DOI 10.1677/jme.0.0200157; DALY RJ, 1990, J CELL BIOCHEM, V43, P199, DOI 10.1002/jcb.240430302; deJonge RR, 1997, ONCOL RES, V9, P89; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; Firth SM, 1998, BIOCHEM BIOPH RES CO, V246, P325, DOI 10.1006/bbrc.1998.8615; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; Grimes RW, 1996, BREAST CANCER RES TR, V39, P187, DOI 10.1007/BF01806185; Gucev ZS, 1996, CANCER RES, V56, P1545; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HODGKINSON S, 1995, J ENDOCRINOL, V145, pR1, DOI 10.1677/joe.0.145R001; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Jakowlew SB, 1997, ANTICANCER RES, V17, P1849; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Kim IY, 1996, CANCER RES, V56, P44; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; Ko Y, 1998, J CELL PHYSIOL, V176, P424, DOI 10.1002/(SICI)1097-4652(199808)176:2<424::AID-JCP21>3.3.CO;2-N; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Leal SM, 1999, J BIOL CHEM, V274, P6711, DOI 10.1074/jbc.274.10.6711; Martin JL, 1999, J BIOL CHEM, V274, P16407, DOI 10.1074/jbc.274.23.16407; MARTIN JL, 1990, ENDOCRINOLOGY, V127, P781, DOI 10.1210/endo-127-2-781; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; MARTIN JL, 1995, ENDOCRINOLOGY, V136, P1219, DOI 10.1210/en.136.3.1219; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MURPHY LC, 1989, MOL ENDOCRINOL, V3, P611, DOI 10.1210/mend-3-4-611; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; OH Y, 1993, J BIOL CHEM, V268, P26045; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; OH YM, 1993, J BIOL CHEM, V268, P14964; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PIRCHER R, 1986, BIOCHEM BIOPH RES CO, V136, P30, DOI 10.1016/0006-291X(86)90872-7; PIRCHER R, 1984, CANCER RES, V44, P5538; Pouliot F, 1999, INT J CANCER, V81, P98, DOI 10.1002/(SICI)1097-0215(19990331)81:1<98::AID-IJC17>3.0.CO;2-9; PRATT SE, 1993, CANCER RES, V53, P5193; PRATT SE, 1994, BIOCHEM BIOPH RES CO, V198, P292, DOI 10.1006/bbrc.1994.1041; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; ROBERTS AB, 1988, RECENT PROG HORM RES, V44, P157; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; Salahifar H, 2000, ENDOCRINOLOGY, V141, P3104, DOI 10.1210/en.141.9.3104; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TUCKER RF, 1984, P NATL ACAD SCI-BIOL, V81, P6757, DOI 10.1073/pnas.81.21.6757; VALVERIUS EM, 1989, CANCER RES, V49, P6269; Wakefield L M, 1992, Cancer Treat Res, V61, P97; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WOOD WI, 1988, MOL ENDOCRINOL, V2, P1176, DOI 10.1210/mend-2-12-1176; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521	65	108	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39146	39151		10.1074/jbc.M006964200	http://dx.doi.org/10.1074/jbc.M006964200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993898	hybrid			2022-12-27	WOS:000165953100029
J	Ogier-Denis, E; Pattingre, S; El Benna, J; Codogno, P				Ogier-Denis, E; Pattingre, S; El Benna, J; Codogno, P			Erk1/2-dependent phosphorylation of G alpha-interacting protein stimulates its GTPase accelerating activity and autophagy in human colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; RGS PROTEINS; ACTIVATING PROTEINS; KINASE ACTIVATION; HT-29 CELLS; GAIP; FAMILY; SUBUNITS; SEQUESTRATION; PROTEOLYSIS	G alpha -interacting protein (GAIP) is a regulator of G protein signaling (RGS) that accelerates the rate of GTP hydrolysis by the alpha -subunit of the trimeric G(i3) protein. Both proteins are part of a signaling pathway that controls lysosomal-autophagic catabolism in human colon cancer HT-29 cells. Here we show that GAIP is phosphorylated by an extracellular signal-regulated (Erk1/2) MAP kinase-dependent pathway sensitive to amino acids, MEK1/2 (PD098059), and protein kinase C (GF109203X) inhibitors. An in vitro phosphorylation assay demonstrates that Erk2-dependent phosphorylation of GAIP stimulates its GTPase-activating protein activity toward the G alpha (i3) protein (k = 0.187 +/- 0.001 s(-1), EC50 = 1.12 +/- 0.10 muM) when compared with unphosphorylated recombinant GAIP (k = 0.145 +/- 0.003 s(-1), EC50 = 3.16 +/- 0.12 muM) or to GAIP phosphorylated by other Ser/Thr protein kinases (protein kinase C, casein kinase II). This stimulation and the phosphorylation of GAIP by Erk2 were abrogated when serine at position 151 in the RGS domain was substituted by an alanine residue using site-directed mutagenesis. Furthermore, the lysosomal-autophagic pathway was not stimulated in S151A-GAIP mutant-expressing cells when compared with wild-type GAIP-expressing cells. These results demonstrate that the GTPase-activating protein activity of GAIP is stimulated by Erk2 phosphorylation. They also suggested that Erk1/2 and GAIP are engaged in the signaling control of a major catabolic pathway in intestinal derived cells.	INSERM, U504, F-94807 Villejuif, France; Fac Med Xavier Bichat, INSERM, U479, F-75018 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Codogno, P (corresponding author), INSERM, U504, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.		Codogno, Patrice/G-1384-2013; Ogier-Denis, Eric/E-5030-2016	Codogno, Patrice/0000-0002-5492-3180; Ogier-Denis, Eric/0000-0002-0057-7593; Pattingre, Sophie/0000-0001-6284-6050				Andre F, 1999, GASTROENTEROLOGY, V116, P64, DOI 10.1016/S0016-5085(99)70230-1; Arshavsky VY, 1998, NEURON, V20, P11, DOI 10.1016/S0896-6273(00)80430-4; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BIOMMAART EFC, 1995, J BIOL CHEM, V270, P2320; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; BOYLE DM, 1988, J STEROID BIOCHEM, V30, P239, DOI 10.1016/0022-4731(88)90099-4; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; de Alba E, 1999, J MOL BIOL, V291, P927, DOI 10.1006/jmbi.1999.2989; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; De Vries L, 1998, MOL BIOL CELL, V9, P1123, DOI 10.1091/mbc.9.5.1123; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Fischer T, 2000, P NATL ACAD SCI USA, V97, P4040, DOI 10.1073/pnas.97.8.4040; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; Haussinger D, 1999, GASTROENTEROLOGY, V116, P921, DOI 10.1016/S0016-5085(99)70076-4; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; Kreegipuu A, 1998, FEBS LETT, V430, P45, DOI 10.1016/S0014-5793(98)00503-1; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; Mortimore G E, 1996, Subcell Biochem, V27, P93; OgierDenis E, 1997, J BIOL CHEM, V272, P24599, DOI 10.1074/jbc.272.39.24599; OgierDenis E, 1996, J BIOL CHEM, V271, P28593, DOI 10.1074/jbc.271.45.28593; OGIERDENIS E, 1995, J BIOL CHEM, V270, P13, DOI 10.1074/jbc.270.1.13; Petiot A, 1999, BIOCHEM J, V337, P289, DOI 10.1042/0264-6021:3370289; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wylie F, 1999, AM J PHYSIOL-CELL PH, V276, pC497, DOI 10.1152/ajpcell.1999.276.2.C497; Zheng B, 1999, TRENDS BIOCHEM SCI, V24, P411, DOI 10.1016/S0968-0004(99)01474-7	38	246	253	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39090	39095		10.1074/jbc.M006198200	http://dx.doi.org/10.1074/jbc.M006198200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993892	hybrid			2022-12-27	WOS:000165953100021
J	Hassan, H; Reis, CA; Bennett, EP; Mirgorodskaya, E; Roepstorff, P; Hollingsworth, MA; Burchell, J; Taylor-Papadimitriou, J; Clausen, H				Hassan, H; Reis, CA; Bennett, EP; Mirgorodskaya, E; Roepstorff, P; Hollingsworth, MA; Burchell, J; Taylor-Papadimitriou, J; Clausen, H			The lectin domain of UDP-N-acetyl-D-galactosamine : polypeptide N-acetylgalactosaminyltransferase-T4 directs its glycopeptide specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-GALACTOSAMINE; O-LINKED GLYCOSYLATION; MUC1 TANDEM REPEAT; CDNA CLONING; GALNAC-TRANSFERASES; CANCER-CELLS; HT-29 CELLS; ACETYLGALACTOSAMINYLTRANSFERASE; PEPTIDE; EXPRESSION	The initiation step of mucin-type O-glycosylation is controlled by a large family of homologous UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferases (GalNAc-transferases), Differences in kinetic properties, substrate specificities, and expression patterns of these isoenzymes provide for differential regulation of O-glycan attachment sites and density, Recently, it has emerged that some GalNAc-transferase isoforms in, vitro selectively function with partially GalNAc O-glycosylated acceptor peptides rather than with the corresponding unglycosylated peptides, O-Glycan attachment to selected sites, most notably two sites in the MUC1 tandem repeat, is entirely dependent on the glycosylation-dependent function of GalNAc-T4. Here we present data that a putative lectin domain found in the C terminus of GalNAc-T4 functions as a GalNAc lectin and confers its glycopeptide specificity. A single amino acid substitution in the lectin domain of a secreted form of GalNAc-T4 selectively blocked GalNAc-glycopeptide activity, while the general activity to peptides exerted by this enzyme was unaffected. Furthermore, the GalNAc-glycopeptide activity of wild-type secreted GalNAc-T4 was selectively inhibited by free GalNAc, while the activity with peptides was unaffected.	Fac Hlth Sci, Sch Dent, DK-2200 Copenhagen, Denmark; Univ Porto, Inst Mol Pathol & Immunol, P-4200 Oporto, Portugal; Odense Univ, Dept Biochem & Mol Biol, Univ So Denmark, DK-5230 Odense, Denmark; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Imperial Canc Res Fund, London WC2A 3PX, England	Universidade do Porto; University of Southern Denmark; University of Nebraska System; University of Nebraska Medical Center; Cancer Research UK	Clausen, H (corresponding author), Fac Hlth Sci, Sch Dent, DK-2200 Copenhagen, Denmark.		Bennett, Eric/AAG-6120-2020; clausen, henrik/AAD-8016-2021; Burchell, Joy/G-4560-2012; REIS, Celso A/B-9969-2008	Bennett, Eric/0000-0002-4976-0647; REIS, Celso A/0000-0002-0286-6639; Burchell, Joy/0000-0003-0413-3823; Clausen, Henrik/0000-0002-0915-5055	NATIONAL CANCER INSTITUTE [R01CA066234] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1CA66234] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; BAECKSTROM D, 1991, J BIOL CHEM, V266, P21537; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; Bennett EP, 1999, J BIOL CHEM, V274, P25362, DOI 10.1074/jbc.274.36.25362; Bennett EP, 1999, FEBS LETT, V460, P226, DOI 10.1016/S0014-5793(99)01268-5; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Buschiazzo A, 2000, EMBO J, V19, P16, DOI 10.1093/emboj/19.1.16; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; Day PJ, 1996, BIOCHEMISTRY-US, V35, P11098, DOI 10.1021/bi960880n; Elhammer AP, 1999, GLYCOCONJUGATE J, V16, P171, DOI 10.1023/A:1026465232149; FARQUHAR MG, 1997, GOLGI APPARATUS, P63; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; GENDLER SJ, 1991, AM REV RESPIR DIS, V144, P42; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; Hagen FK, 1997, J BIOL CHEM, V272, P13843, DOI 10.1074/jbc.272.21.13843; Hanisch FG, 1999, J BIOL CHEM, V274, P9946, DOI 10.1074/jbc.274.15.9946; HASSAN H, 2000, OLIGOSACCHARIDES CHE, P273; Hazes B, 1996, PROTEIN SCI, V5, P1490, DOI 10.1002/pro.5560050805; Hennebicq-Reig S, 1998, BIOCHEM J, V334, P283, DOI 10.1042/bj3340283; HOMA FL, 1993, J BIOL CHEM, V268, P12609; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; Imberty A, 1997, PROTEIN ENG, V10, P1353, DOI 10.1093/protein/10.12.1353; KUAN SF, 1989, J BIOL CHEM, V264, P19271; Lugemwa FN, 1996, J BIOL CHEM, V271, P19159, DOI 10.1074/jbc.271.32.19159; Mirgorodskaya E, 1999, ANAL BIOCHEM, V269, P54, DOI 10.1006/abio.1998.3089; Monlauzeur L, 1998, J BIOL CHEM, V273, P30263, DOI 10.1074/jbc.273.46.30263; Muller S, 1997, J BIOL CHEM, V272, P24780, DOI 10.1074/jbc.272.40.24780; Muller S, 1999, J BIOL CHEM, V274, P18165, DOI 10.1074/jbc.274.26.18165; NISHIMORI I, 1994, CANCER RES, V54, P3738; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; Rottger S, 1998, J CELL SCI, V111, P45; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; Taylor-Papadimitriou J, 1999, BBA-MOL BASIS DIS, V1455, P301, DOI 10.1016/S0925-4439(99)00055-1; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; Ten Hagen KG, 1999, J BIOL CHEM, V274, P27867; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; White KE, 2000, GENE, V246, P347, DOI 10.1016/S0378-1119(00)00050-0; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; Zanetta JP, 2000, GLYCOBIOLOGY, V10, P565, DOI 10.1093/glycob/10.6.565	42	132	160	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38197	38205		10.1074/jbc.M005783200	http://dx.doi.org/10.1074/jbc.M005783200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10984485	hybrid			2022-12-27	WOS:000165739800011
J	Fuller, W; Cuthbert, AW				Fuller, W; Cuthbert, AW			Post-translational disruption of the Delta F508 cystic fibrosis transmembrane conductance regulator (CFTR)-molecular chaperone complex with geldanamycin stabilizes Delta F508 CFTR in the rabbit reticulocyte lysate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONE; ANTITUMOR AGENT; HERBIMYCIN-A; IN-VITRO; DEGRADATION; PROTEIN; HSP90; RECEPTOR	The Delta F508 mutation of cystic fibrosis transmembrane conductance regulator (CFTR) is a trafficking mutant, which is retained and degraded in the endoplasmic reticulum by the ubiquitin-proteasome pathway. The mutant protein fails to reach a completely folded conformation that is no longer a substrate for ubiquitination ("stable B"). Wild type protein reaches this state with 25% efficiency. In this study the rabbit reticulocyte lysate with added microsomal membranes has been used to reproduce the post-translational events in the folding of wild type and Delta F508 CFTR. In this system wild type CFTR does not reach the stable B form if the post-translational temperature is 37 degreesC, whereas at 30 degreesC the behavior of both wild type and mutant proteins mimics that observed in the cell. Geldanamycin stabilizes Delta F508 CFTR with respect to ubiquitination only when added post-translationally. The interaction of wild type and mutant CFTR with the molecular chaperones heat shock cognate 70 (hsc70) and heat shock protein 90 (hsp90) has been assessed. Release of wild type protein from hsc70 coincides with the cessation of ubiquitination and formation of stable B. Geldanamycin immediately prevents the binding of hsp90 to Delta F508 CFTR, and after a delay releases it from hsc70. Release of mutant protein from hsc70 also coincides with the formation of stable B Delta F508 CFTR.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England	University of Cambridge	Cuthbert, AW (corresponding author), Addenbrookes Hosp, Dept Med, Level 5,Box 157,Hills Rd, Cambridge CB2 2QQ, England.			Fuller, William/0000-0002-5883-4433				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; Bercovich B, 1997, J BIOL CHEM, V272, P9002; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Gilmore R, 1998, J BIOL CHEM, V273, P15227, DOI 10.1074/jbc.273.24.15227; GROSS M, 1980, MOL CELL BIOCHEM, V31, P25, DOI 10.1007/BF00817888; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; Hartson SD, 1996, BIOCHEMISTRY-US, V35, P13451, DOI 10.1021/bi961332c; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; Imamura T, 1998, J BIOL CHEM, V273, P11183, DOI 10.1074/jbc.273.18.11183; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Jiang CW, 1998, AM J PHYSIOL-CELL PH, V275, pC171, DOI 10.1152/ajpcell.1998.275.1.C171; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; MURAKAMI Y, 1994, BIOCHEM J, V301, P57, DOI 10.1042/bj3010057; PIND S, 1994, J BIOL CHEM, V269, P12784; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sato S, 1998, J BIOL CHEM, V273, P7189, DOI 10.1074/jbc.273.13.7189; Sawa T, 1996, BIOCHEM BIOPH RES CO, V218, P449, DOI 10.1006/bbrc.1996.0080; Scheibel T, 1998, BIOCHEM PHARMACOL, V56, P675, DOI 10.1016/S0006-2952(98)00120-8; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; SUPKO JG, 1995, CANCER CHEMOTH PHARM, V36, P305, DOI 10.1007/BF00689048; UEHARA Y, 1989, CANCER RES, V49, P780; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WHITESELL L, 1992, CANCER RES, V52, P1721; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480	43	48	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37462	37468		10.1074/jbc.M006278200	http://dx.doi.org/10.1074/jbc.M006278200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982807	hybrid			2022-12-27	WOS:000165618700023
J	Hughes, AL; Gollapudi, L; Sladek, TL; Neet, KE				Hughes, AL; Gollapudi, L; Sladek, TL; Neet, KE			Mediation of nerve growth factor-driven cell cycle arrest in PC12 cells by p53 simultaneous - Differentiation and proliferation subsequent to p53 functional inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; CDK INHIBITOR P21(WAF1/CIP1); NEURONAL DIFFERENTIATION; NUCLEAR-LOCALIZATION; TYROSINE PHOSPHORYLATION; PHEOCHROMOCYTOMA CELLS; NITRIC-OXIDE; PROTEIN; GENE; NGF	Upon stimulation with nerve growth factor (NGF), PC12 cells extend neurites and cease to proliferate by influencing cell cycle proteins. Previous studies have shown that neuritogenesis and a block at the G(1)/S checkpoint correlate with the nuclear translocation of and an increase in the p53 tumor suppressor protein. This study was designed to determine if p53 plays a direct role in mediating NGF-driven G(1) arrest. A retroviral vector that overexpresses a temperature-sensitive p53 mutant protein (p53ts) was used to extinguish the function of endogenous p53 in PC12 cells in a dominant-negative manner at the nonpermissive temperature. NGF treatment led to transactivation of a p53 response element in a luciferase reporter construct in PC12 cells, whereas this response to NGF was absent in PC12(p53ts) cells at the nonpermissive temperature. With p53 functionally inactivated, NGF failed to activate growth arrest, as measured by bromodeoxyuridine incorporation, and also failed to induce p21/WAF1 expression, as measured by Western blotting. Since neurite outgrowth proceeded unharmed, 50% of the cells simultaneously demonstrated neurite morphology and were in S phase. Both PC12 cells expressing SV40 T antigen and PC12 cells treated with p53 antisense oligonucleotides continued through the cell cycle, confirming the dependence of the NGF growth arrest signal on a p53 pathway. Activation of Ras in a dexamethasone-inducible PC12 cell line (GSRas1) also caused p53 nuclear translocation and growth arrest, Therefore, wild-type p53 is indispensable in mediating the NGF antiproliferative signal through the Ras/MAPK pathway that regulates the cell cycle of PC12 cells.	Finch Univ Hlth Sci Chicago Med Sch, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA; Finch Univ Hlth Sci Chicago Med Sch, Dept Microbiol & Immunol, N Chicago, IL 60064 USA	Chicago Medical School; Chicago Medical School	Neet, KE (corresponding author), Finch Univ Hlth Sci Chicago Med Sch, Dept Biol Chem, 3333 Green Bay Rd, N Chicago, IL 60064 USA.				NINDS NIH HHS [NS24380] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024380] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; BELL JC, 1986, MOL CELL BIOL, V6, P617, DOI 10.1128/MCB.6.2.617; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; Billon N, 1996, ONCOGENE, V13, P2047; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHEN J, 1990, CELL GROWTH DIFFER, V1, P79; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DAVIES AM, 1994, NEUROSCI LETT, V182, P112, DOI 10.1016/0304-3940(94)90219-4; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erhardt JA, 1998, ONCOGENE, V16, P443, DOI 10.1038/sj.onc.1201577; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; FUKUI Y, 1987, METHOD CELL BIOL, V28, P347; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; Gollapudi L, 1997, J NEUROSCI RES, V49, P461, DOI 10.1002/(SICI)1097-4547(19970815)49:4<461::AID-JNR7>3.3.CO;2-6; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; GUNNING PW, 1981, J NEUROSCI, V1, P368; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSANG M, 1987, EMBO J, V6, P1197, DOI 10.1002/j.1460-2075.1987.tb02354.x; IGNATIUS MJ, 1985, J NEUROSCI, V5, P343; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; Knippschild U, 1996, ONCOGENE, V12, P1755; LEROUX I, 1993, P NATL ACAD SCI USA, V90, P9120, DOI 10.1073/pnas.90.19.9120; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LUO Y, 1992, J BIOL CHEM, V267, P12275; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; Poluha W, 1997, J BIOL CHEM, V272, P24002, DOI 10.1074/jbc.272.38.24002; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SLADEK TL, 1992, J VIROL, V66, P1059, DOI 10.1128/JVI.66.2.1059-1065.1992; Sladek TL, 1996, CELL PROLIFERAT, V29, P579, DOI 10.1111/j.1365-2184.1996.tb00973.x; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Troy CM, 1996, J NEUROSCI, V16, P253; TSUJI K, 1994, MOL CARCINOGEN, V9, P167, DOI 10.1002/mc.2940090308; TSUKADA T, 1993, ONCOGENE, V8, P3313; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; Urdiales JL, 1998, J NEUROSCI, V18, P6767; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WOODRUFF NR, 1986, BIOCHEMISTRY-US, V25, P7967, DOI 10.1021/bi00372a027; Yan GZ, 1997, J NEUROSCI, V17, P6122; YAN GZ, 1995, J NEUROSCI, V15, P6200; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	65	57	59	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37829	37837		10.1074/jbc.M003146200	http://dx.doi.org/10.1074/jbc.M003146200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978315	hybrid			2022-12-27	WOS:000165618700071
J	Peiro, S; Comella, JX; Enrich, C; Martin-Zanca, D; Rocamora, N				Peiro, S; Comella, JX; Enrich, C; Martin-Zanca, D; Rocamora, N			PC12 cells have caveolae that contain TrkA - Caveolae-disrupting drugs inhibit nerve growth factor-induced, but not epidermal growth factor-induced, MAPK phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; IN-VIVO; MEDIATED TRANSPORT; MEMBRANE DOMAINS; PLASMA-MEMBRANE; GENE FAMILY; CHOLESTEROL; PROTEIN; TYROSINE; KINASE	Nerve growth factor (NGF) induces survival and differentiation of the neural crest-derived PC12 cell line. Caveolae are cholesterol-enriched, caveolin-containing plasma membrane microdomains involved in vesicular transport and signal transduction. Here we demonstrate the presence of caveolae in PC12 cells and their involvement in NGF signaling. Our results showed the expression of caveolin-1 by Western blot and confocal immuno-microscopy. The presence of plasma membrane caveolae was directly shown by rapid-freeze deep-etching electron microscopy. Moreover, combined deep-etching and immunogold techniques revealed the presence of the NGF receptor TrkA in the caveolae of PC12 cells. These data together with the cofractionation of Shc, Ras, caveolin, and TrkA in the caveolae fraction supported a role for these plasma membrane microdomains in NGF signaling. To approach this hypothesis, caveolae were disrupted by treatment of PC12 cells with cholesterol binding drugs. Either filipin or cyclodextrin treatment increased basal levels of MAPK phosphorylation. in contrast, pretreatment of PC12 cells with these drugs inhibited the NGF- but not the epidermal growth factor-induced MAPK phosphorylation without affecting the TrkA autophosphorylation. Taken together, our results demonstrate the presence of caveolae in PC12 cells, which contain the high affinity NGF receptor TrkA, and the specific involvement of these cholesterol-enriched plasma membrane microdomains in the propagation of the NGF-induced signal.	Inst Catala Oncol, Lab Biol Mol, Barcelona 08907, Spain; Univ Barcelona, Fac Med, IDIBAPS, Inst Invest Biomed August Pi & Sunyer,Dept Biol C, Barcelona 08036, Spain; Univ Lleida, Fac Med, Dept Ciencias Med Basiques, Grp Neurobiol Mol, Lleida 25198, Spain; Univ Salamanca, CSIC, Inst Microbiol Bioquim, Salamanca 37007, Spain	Catalan Institute of Oncology; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Universitat de Lleida; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Rocamora, N (corresponding author), Inst Catala Oncol, Lab Biol Mol, Avda Gran Via S-N,Km 2-7, Barcelona 08907, Spain.	rocamora@ico.scs.es	Comella, Joan/GQA-4279-2022; Comella, Joan X/D-7333-2012	Comella, Joan X/0000-0002-6218-0786; Enrich, Carlos/0000-0003-0382-2993				ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Baorto DM, 1997, NATURE, V389, P636, DOI 10.1038/39376; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Barrett GL, 1996, J NEUROSCI RES, V45, P117, DOI 10.1002/(SICI)1097-4547(19960715)45:2<117::AID-JNR4>3.0.CO;2-D; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; Cameron PL, 1997, J NEUROSCI, V17, P9520; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; Chao M, 1998, BRAIN RES REV, V26, P295, DOI 10.1016/S0165-0173(97)00036-2; CLARY DO, 1994, MOL BIOL CELL, V5, P549, DOI 10.1091/mbc.5.5.549; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; ESCAIG J, 1982, J MICROSC-OXFORD, V126, P221, DOI 10.1111/j.1365-2818.1982.tb00379.x; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grimes ML, 1997, P NATL ACAD SCI USA, V94, P9909, DOI 10.1073/pnas.94.18.9909; Grimes ML, 1996, J NEUROSCI, V16, P7950; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Monier S, 1996, FEBS LETT, V388, P143, DOI 10.1016/0014-5793(96)00519-4; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Oh P, 1999, J BIOL CHEM, V274, P23144, DOI 10.1074/jbc.274.33.23144; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PALADE GE, 1953, J APPL PHYS, V24, P1424; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; QUINTANA C, 1994, MICRON, V25, P63, DOI 10.1016/0968-4328(94)90056-6; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Taglialatela G, 1997, J NEUROSCI RES, V47, P155; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Waugh MG, 1999, BIOCHEM J, V337, P591, DOI 10.1042/0264-6021:3370591; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962	52	82	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37846	37852		10.1074/jbc.M000487200	http://dx.doi.org/10.1074/jbc.M000487200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982788	hybrid			2022-12-27	WOS:000165618700073
J	Yang, TX; Park, JM; Arend, L; Huang, YN; Topaloglu, R; Pasumarthy, A; Praetorius, H; Spring, K; Briggs, JP; Schnermann, J				Yang, TX; Park, JM; Arend, L; Huang, YN; Topaloglu, R; Pasumarthy, A; Praetorius, H; Spring, K; Briggs, JP; Schnermann, J			Low chloride stimulation of prostaglandin E-2 release and cyclooxygenase-2 expression in a mouse macula densa cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; THICK ASCENDING LIMB; CYTOSOLIC PHOSPHOLIPASE A(2); ACTIVATED PROTEIN-KINASE; MESSENGER-RNA; RAT-KIDNEY; RENIN SECRETION; PHOSPHORYLATION; COTRANSPORTER; LOCALIZATION	Reducing luminal NaCl concentration in the macula densa region of the nephron stimulates renin secretion, and this response is blocked by a specific inhibitor of cyclooxygenase-2 (COX-2) (Traynor, T. R., Smart, A., Briggs, J. P., and Schnermann, J. (1999) Am. J. Physiol. Renal Physiol, 277, F706-710), To study whether low NaCl activates COX-2 activity or expression we clonally derived a macula densa cell line (MMDD1 cells) from SV-40 transgenic mice using fluorescence-activated cell sorting of renal tubular cells labeled with segment-specific fluorescent lectins, MMDD1 cells express COX-2, bNOS, NKCC2, and ROMK, but not Tamm-Horsfall protein, and showed rapid Rb-86(+) uptake that was inhibited by a reduction in NaCl concentration and by bumetanide or furosemide. Isosmotic exposure of MMDD1 cells to low NaCl (60 mM) caused a prompt and time-dependent stimulation of prostaglandin E-2 (PGE(2)) release that was prevented by the COX-2 specific inhibitor NS-398 (10 muM). Reducing NaCl to 60 and 6 mM for 16 h increased COX-2 expression in a chloride-dependent fashion. Low NaCl phosphorylated p38 kinase within 30 min and ERK1/2 kinases within 15 min without changing total MAP kinase levels. Low NaCl-stimulated PGE(2) release and COX-2 expression was inhibited by SE 203580 and PD 98059 (10 muM), inhibitors of p38 and ERK kinase pathways. We conclude that low chloride stimulates PGE(2) release and COX-2 expression in MMDD1 cells through activation of MAP kinases.	NIDDK, NIH, Bethesda, MD 20892 USA; NHLBI, NIH, Bethesda, MD 20892 USA; Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA; Univ Rochester, Dept Pathol & Lab Med, Rochester, NY 14642 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Michigan System; University of Michigan; University of Rochester	Schnermann, J (corresponding author), NIDDK, NIH, Bldg 10,Rm 4D51,10 Ctr Dr,MSC 1370, Bethesda, MD 20892 USA.	jurgens@intra.niddk.nih.gov	TOPALOGLU, Rezan/I-9095-2013; Briggs, Josephine P/B-9394-2009; Arend, Lois/ABE-2002-2020	Briggs, Josephine P/0000-0003-0798-1190; Arend, Lois/0000-0001-5434-7630; Topaloglu, Rezan/0000-0002-6423-0927; Praetorius, Helle/0000-0002-0970-5061	NIDDK NIH HHS [DK37448, DK39255, DK40042] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040042, P50DK039255, Z01DK043407, R01DK037448] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atherfold PA, 1999, MOL IMMUNOL, V36, P543, DOI 10.1016/S0161-5890(99)00076-0; Bell PD, 1997, CLIN EXP PHARMACOL P, V24, P541, DOI 10.1111/j.1440-1681.1997.tb01243.x; Borsch-Haubold AG, 1999, EUR J BIOCHEM, V265, P195, DOI 10.1046/j.1432-1327.1999.00722.x; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Ecelbarger CA, 1996, AM J PHYSIOL-RENAL, V271, pF619, DOI 10.1152/ajprenal.1996.271.3.F619; ECELBARGER CA, 2001, IN PRESS J AM SOC NE; FOWLER BC, 1995, KIDNEY INT, V47, P746, DOI 10.1038/ki.1995.114; FRANCISCO LL, 1982, AM J PHYSIOL, V243, pF537, DOI 10.1152/ajprenal.1982.243.6.F537; Gillen CM, 1999, AM J PHYSIOL-CELL PH, V276, pC328, DOI 10.1152/ajpcell.1999.276.2.C328; GREENBERG SG, 1993, AM J PHYSIOL, V265, pF578, DOI 10.1152/ajprenal.1993.265.4.F578; GREGER R, 1985, PHYSIOL REV, V65, P760, DOI 10.1152/physrev.1985.65.3.760; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; Hartner A, 1998, HYPERTENSION, V31, P201, DOI 10.1161/01.HYP.31.1.201; Hiller G, 1999, CELL SIGNAL, V11, P863, DOI 10.1016/S0898-6568(99)00058-3; Jensen BL, 1996, AM J PHYSIOL-RENAL, V271, pF659, DOI 10.1152/ajprenal.1996.271.3.F659; KIZER NL, 1995, AM J PHYSIOL-RENAL, V268, pF347, DOI 10.1152/ajprenal.1995.268.2.F347; Lapointe JY, 1998, KIDNEY INT, V54, pS58, DOI 10.1046/j.1523-1755.1998.06712.x; Lee SA, 2000, MOL BRAIN RES, V75, P16, DOI 10.1016/S0169-328X(99)00280-6; LORENZ JN, 1991, AM J PHYSIOL, V260, pF486, DOI 10.1152/ajprenal.1991.260.4.F486; Marais R, 1996, CANCER SURV, V27, P101; MUNDEL P, 1992, KIDNEY INT, V42, P1017, DOI 10.1038/ki.1992.382; Naidu PS, 1999, AM J PHYSIOL-HEART C, V277, pH1061, DOI 10.1152/ajpheart.1999.277.3.H1061; Nielsen S, 1998, AM J PHYSIOL-RENAL, V275, pF885, DOI 10.1152/ajprenal.1998.275.6.F885; Oberbaumer I, 1998, BIOL CHEM, V379, P913; OKUDA T, 1989, J CLIN INVEST, V84, P1866, DOI 10.1172/JCI114373; Parfenova H, 1999, AM J PHYSIOL-CELL PH, V277, pC728, DOI 10.1152/ajpcell.1999.277.4.C728; Parfenova H, 1998, AM J PHYSIOL-CELL PH, V274, pC72, DOI 10.1152/ajpcell.1998.274.1.C72; Peti-Peterdi J, 1999, AM J PHYSIOL-RENAL, V277, pF472, DOI 10.1152/ajprenal.1999.277.3.F472; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; RIELLE JC, 1987, ANAT RECORD, V218, P243, DOI 10.1002/ar.1092180304; SCHNERMANN J, 1976, PFLUG ARCH EUR J PHY, V362, P229, DOI 10.1007/BF00581175; SCHNERMANN J, 1982, KIDNEY INT, pS82; SCHULTE BA, 1983, AM J ANAT, V168, P345, DOI 10.1002/aja.1001680308; Singh I, 1996, AM J PHYSIOL-RENAL, V270, pF1027, DOI 10.1152/ajprenal.1996.270.6.F1027; SKOTT O, 1987, SCIENCE, V237, P1618, DOI 10.1126/science.3306925; STOOS BA, 1991, KIDNEY INT, V39, P1168, DOI 10.1038/ki.1991.148; Traynor TR, 1999, AM J PHYSIOL-RENAL, V277, pF706, DOI 10.1152/ajprenal.1999.277.5.F706; VANDER AJ, 1967, PHYSIOL REV, V47, P359, DOI 10.1152/physrev.1967.47.3.359; Wang J.-L., 1999, Journal of the American Society of Nephrology, V10, p464A; Wang JL, 1999, HYPERTENSION, V34, P96, DOI 10.1161/01.HYP.34.1.96; WILCOX CS, 1992, P NATL ACAD SCI USA, V89, P11993, DOI 10.1073/pnas.89.24.11993; Xia P, 1998, BIOPHYS J, V74, P3302, DOI 10.1016/S0006-3495(98)78037-3; Xu JZ, 1997, AM J PHYSIOL-RENAL, V273, pF739, DOI 10.1152/ajprenal.1997.273.5.F739; Yang TX, 2000, J BIOL CHEM, V275, P23281, DOI 10.1074/jbc.M910237199; Yang TX, 1999, AM J PHYSIOL-RENAL, V277, pF1, DOI 10.1152/ajprenal.1999.277.1.F1; Yang TX, 1998, AM J PHYSIOL-RENAL, V274, pF481, DOI 10.1152/ajprenal.1998.274.3.F481	46	125	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37922	37929		10.1074/jbc.M006218200	http://dx.doi.org/10.1074/jbc.M006218200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982805	hybrid			2022-12-27	WOS:000165618700083
J	Gu, XJ; Kozarsky, K; Krieger, M				Gu, XJ; Kozarsky, K; Krieger, M			Scavenger receptor class B, type I-mediated [H-3]cholesterol efflux to high and low density lipoproteins is dependent on lipoprotein binding to the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SR-BI; CELLULAR CHOLESTEROL; TANGIER-DISEASE; SURFACE-RECEPTOR; SELECTIVE UPTAKE; HDL; IDENTIFICATION; EXPRESSION; REMOVAL; PATHWAY	The murine scavenger receptor class B, type I (mSR-BI) is a receptor for high density lipoprotein (HDL), low density lipoprotein (LDL), and acetylated LDL (AcLDL). It mediates selective uptake of lipoprotein lipid and stimulates efflux of [H-3]cholesterol to lipoproteins. SR-BI-mediated [H-3]cholesterol efflux was proposed to be independent of ligand binding. In this study, using anti-mSR-BI antibody KKB-1 and two mSR-BI mutants with altered ligand binding properties, we demonstrated that SR-BI-mediated [H-3]cholesterol efflux to lipoproteins was correlated with ligand binding and lipid uptake activities of the receptor. The KKB-1 antibody, which blocked lipoprotein binding without substantially altering the cholesterol oxidase-accessible cellular [H-3]cholesterol, also blocked [H-3]cholesterol efflux to HDL and LDL. One of the SR-BI mutants, which has a double substitution of arginines for glutamines at positions 402 and 418 (Q402R/Q418R), exhibited a high level of LDL binding and lipid uptake from LDL, but lost most of the corresponding HDL receptor activity. This mutant could mediate efficient [H-3]cholesterol efflux to LDL, but not to HDL. Another mutant, M158R, with an arginine in place of methionine at position 158, exhibited reduced HDL and LDL receptor activities, but apparently normal AcLDL receptor activity. This mutant could mediate efficient [H-3]cholesterol efflux to AcLDL, but not to HDL or LDL. These results suggest that SR-BI-stimulated [H-3]cholesterol efflux to lipoproteins critically depends on ligand binding to this receptor and raise the possibility that the mechanisms of selective lipid uptake and [H-3]cholesterol efflux may be intimately related.	MIT, Dept Biol, Cambridge, MA 02139 USA; Smith Kline Beecham Pharmaceut, Dept Cardiovasc Pharmacol, King Of Prussia, PA 19406 USA	Massachusetts Institute of Technology (MIT)	Krieger, M (corresponding author), MIT, Dept Biol, Rm 68-483,77 Mass Ave, Cambridge, MA 02139 USA.		Krieger, Marco/AAE-8611-2020		NHLBI NIH HHS [HL41484, HL52212] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052212, P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; Chernomordik LV, 1999, MOL MEMBR BIOL, V16, P33; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; Gillotte KL, 1998, J LIPID RES, V39, P1918; GLOMSET JA, 1968, J LIPID RES, V9, P155; Gu XJ, 2000, J BIOL CHEM, V275, P9120, DOI 10.1074/jbc.275.13.9120; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Hauser H, 1998, BIOCHEMISTRY-US, V37, P17843, DOI 10.1021/bi982404y; Hirano K, 1999, CIRC RES, V85, P108; Huszar D, 2000, ARTERIOSCL THROM VAS, V20, P1068, DOI 10.1161/01.ATV.20.4.1068; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Monck JR, 1996, CURR OPIN CELL BIOL, V8, P524, DOI 10.1016/S0955-0674(96)80031-7; Oram J F, 1986, Methods Enzymol, V129, P645; Oram JF, 1996, J LIPID RES, V37, P2473; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Rothblat G H, 1986, Methods Enzymol, V129, P628; Rothblat GH, 1999, J LIPID RES, V40, P781; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SCHOUTEN D, 1990, ARTERIOSCLEROSIS, V10, P1127, DOI 10.1161/01.ATV.10.6.1127; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; von Eckardstein A, 1998, ATHEROSCLEROSIS, V137, pS7, DOI 10.1016/S0021-9150(97)00311-0; Williams DL, 1999, CURR OPIN LIPIDOL, V10, P329, DOI 10.1097/00041433-199908000-00007	45	166	171	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29993	30001		10.1074/jbc.275.39.29993	http://dx.doi.org/10.1074/jbc.275.39.29993			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	11001950	hybrid			2022-12-27	WOS:000089577900012
J	Shih, SC; Mullen, A; Abrams, K; Mukhopadhyay, D; Claffey, KP				Shih, SC; Mullen, A; Abrams, K; Mukhopadhyay, D; Claffey, KP			Role of protein kinase C isoforms in phorbol ester-induced vascular endothelial growth factor expression in human glioblastoma cells. (vol 274, pg 15407, 1999)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Correction																		Shih SC, 1999, J BIOL CHEM, V274, P15407, DOI 10.1074/jbc.274.22.15407	1	2	2	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29178	29178						1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10979985				2022-12-27	WOS:000089330700110
J	Atkins, A; Wyborn, NR; Wallace, AJ; Stillman, TJ; Black, LK; Fielding, AB; Hisakado, M; Artymiuk, PJ; Green, J				Atkins, A; Wyborn, NR; Wallace, AJ; Stillman, TJ; Black, LK; Fielding, AB; Hisakado, M; Artymiuk, PJ; Green, J			Structure-function relationships of a novel bacterial toxin, hemolysin E - The role of alpha(G)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FUSION PROTEINS; PORE; EXPRESSION; MEMBRANE; BINDING; SLYA; CLYA	The novel pore-forming toxin hemolysin E (HlyE, ClyA,or SheA) consists of a long four-helix bundle with a subdomain (beta tongue) that interacts with target membranes at one pole and an additional helix (alpha (G)) that, with the four long helices, forms a five-helix bundle (tail domain) at the other pole. Random amino acid substitutions that-impair hemolytic activity were clustered mostly, but clot exclusively, within the tail domain, specifically-amino acids within, adjacent to, or interacting with cud. Deletion of amino acids downstream of alpha (G) did not affect activity, but deletions encompassing alpha (G) yielded insoluble and inactive proteins. In the periplasm Cys-285 (alpha (G)) is linked to Cys-87 (alpha (B)) of the four-helix bundle via an intramolecular disulfide, Oxidized HlyE did not form spontaneously in vitro but could be generated by addition of Cu(II) or mimicked by treatment with Hg(II) salts to yield inactive proteins, Such treatments did not affect binding to target membranes:nor assembly into non-covalently linked octameric complexes once associated with a membrane. However, gel filtration analyses suggested that immobilizing alpha (G) inhibits oligomerization in solution. Thus once associated with a membrane, immobilizing alpha (G) inhibits HlyE activity at a late stage of pore formation, whereas in solution it prevents aggregation and consequent inactivation.	Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Green, J (corresponding author), Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.			Fielding, Andrew/0000-0002-3170-9966				Duche D, 1999, J MOL BIOL, V285, P1965, DOI 10.1006/jmbi.1998.2423; EBERSPACHER B, 1989, INFECT IMMUN, V57, P983; Green J, 1997, MICROBIOL-SGM, V143, P3785, DOI 10.1099/00221287-143-12-3785; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Kerr ID, 1996, PROTEIN ENG, V9, P161, DOI 10.1093/protein/9.2.161; Ludwig A, 1995, MOL GEN GENET, V249, P474, DOI 10.1007/BF00290573; Ludwig A, 1999, MOL MICROBIOL, V31, P557, DOI 10.1046/j.1365-2958.1999.01196.x; MARSH P, 1986, NUCLEIC ACIDS RES, V14, P3603, DOI 10.1093/nar/14.8.3603; Oscarsson J, 1999, MOL MICROBIOL, V32, P1226, DOI 10.1046/j.1365-2958.1999.01435.x; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; Ralph ET, 1998, P NATL ACAD SCI USA, V95, P10449, DOI 10.1073/pnas.95.18.10449; ROWE GE, 1994, METHOD ENZYMOL, V235, P657; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Wallace AJ, 2000, CELL, V100, P265, DOI 10.1016/S0092-8674(00)81564-0; Zitzer A, 1999, J BIOL CHEM, V274, P1375, DOI 10.1074/jbc.274.3.1375; Zitzer A, 1997, EUR J BIOCHEM, V247, P209, DOI 10.1111/j.1432-1033.1997.00209.x	16	40	55	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41150	41155		10.1074/jbc.M005420200	http://dx.doi.org/10.1074/jbc.M005420200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11006277	hybrid			2022-12-27	WOS:000166114600067
J	Bond, M; Murphy, G; Bennett, MR; Amour, A; Knauper, V; Newby, AC; Baker, AH				Bond, M; Murphy, G; Bennett, MR; Amour, A; Knauper, V; Newby, AC; Baker, AH			Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus - Metalloproteinase inhibition is associated with proapoptotic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-POTENTIATING ACTIVITY; SMOOTH-MUSCLE-CELLS; SORSBYS-FUNDUS-DYSTROPHY; 72 KDA PROGELATINASE; MELANOMA-CELLS; IV COLLAGENASE; GELATINASE-A; IN-VITRO; TIMP-3; EXPRESSION	The tissue inhibitors of metalloproteinases (TIMPs) are a family of four secreted inhibitors of matrix metalloproteinases (MIMPs). Recently, additional functions have been attributed to the TIMPs, including cell growth and inhibition of angiogenesis. In particular, we demonstrated that TIMP-3 overexpression using gene transfer induces apoptosis in a variety of cell types and can inhibit vascular neointima formation in vivo. However, little is know about the mechanisms underlying TIMP-3-mediated apoptosis. Here, using both purified recombinant proteins and novel adenoviral vectors we demonstrate that the prodeath domain of TIMP-3 is located within the N-terminal three loops of TIMP-3. Although both wild type and N-terminal TIMP-3 proteins promoted apoptosis, a T-2/T-3 chimera, in which the N-terminal three loops of TIMP-3 are replaced by those of TIMP-2, failed to induce cell death. Furthermore, a point mutation at residue 1 of TIMP-3 totally abolished MMP-inhibitory activity of TIMP-3 and also failed to promote apoptosis. This study demonstrates, using multiple apoptosis assays, that the predeath function of TIMP-3 is located within the N-terminal three loops and the presence of functional metalloproteinase-inhibitory activity is associated with the induction of apoptosis.	Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol BS2 8HW, Avon, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; Univ Glasgow, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland	Bristol Royal Infirmary; University of Bristol; University of East Anglia; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Glasgow	Bond, M (corresponding author), Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Level 7, Bristol BS2 8HW, Avon, England.	Mark.bond@bris.ac.uk	Baker, Andy/AAO-5250-2021; Bond, Mark/AAG-9293-2019	Baker, Andy/0000-0003-1441-5576; Bennett, Martin/0000-0002-2565-1825; Knauper, Vera/0000-0002-3965-9924; Bond, Mark/0000-0003-2788-278X				Ahonen M, 1998, CANCER RES, V58, P2310; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; Baker AH, 1996, MATRIX BIOL, V15, P383, DOI 10.1016/S0945-053X(96)90158-4; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Bendeck MP, 1996, CIRC RES, V78, P38, DOI 10.1161/01.RES.78.1.38; BENNETT MR, 1994, J CLIN INVEST, V93, P820, DOI 10.1172/JCI117036; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846; Caterina NCM, 1997, J BIOL CHEM, V272, P32141, DOI 10.1074/jbc.272.51.32141; CHESLER L, 1995, BLOOD, V86, P4506, DOI 10.1182/blood.V86.12.4506.bloodjournal86124506; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; Fabunmi RP, 1996, BIOCHEM J, V315, P335, DOI 10.1042/bj3150335; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; George SJ, 2000, CIRCULATION, V101, P296, DOI 10.1161/01.CIR.101.3.296; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778; LECO KJ, 1994, J BIOL CHEM, V269, P9352; NGUYEN Q, 1994, BIOCHEMISTRY-US, V33, P2089, DOI 10.1021/bi00174a015; NICKLIN S, 1999, VASCULAR DIS MOL BIO, V1, P271; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; SOUTHGATE KM, 1992, BIOCHEM J, V288, P93, DOI 10.1042/bj2880093; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; Valente P, 1998, INT J CANCER, V75, P246, DOI 10.1002/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; YANG TT, 1992, P NATL ACAD SCI USA, V89, P10676, DOI 10.1073/pnas.89.22.10676; YU W, 2000, IN PRESS J BIOL CHEM	41	98	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41358	41363		10.1074/jbc.M007929200	http://dx.doi.org/10.1074/jbc.M007929200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007798	hybrid			2022-12-27	WOS:000166114600092
J	Long, XM; Griffith, LC				Long, XM; Griffith, LC			Identification and characterization of a SUMO-1 conjugation system that modifies neuronal calcium/calmodulin-dependent protein kinase II in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; GTPASE-ACTIVATING PROTEIN; NUCLEAR-PORE COMPLEX; COVALENT MODIFICATION; HUMAN HOMOLOG; CENTROMERE PROTEIN; ESCHERICHIA-COLI; ENZYME; GENE; YEAST	Drosophila Uba2 and Ubc9 SUMO-1 conjugation enzyme homologs (DmUba2 and DmUbc9) were isolated as calcium/calmodulin-dependent kinase II (CaMKII) interacting proteins by yeast two-hybrid screening of an adult head cDNA library. We found that at least one isoform of Drosophila neuronal CaMXII is conjugated to DmSUMO-1 in vivo. The interactions observed in the two-hybrid screen may therefore reflect catalytic events. To understand the role of SUMO conjugation in the brain, we undertook a characterization of the system. The other required components of the system, Drosophila Aos1 and SUMO-1 (DmAos1 and DmSUMO-1), were identified in expressed sequence tag data base searches. Purified recombinant DmUbaB/DmAos1 dimer can activate DmSUMO-1 in vitro and transfer DmSUMO-1 to recombinant DmUbc9. DmSUMO-1 conjugation occurs in all developmental stages of Drosophila and in the adult central nervous system. Overexpression of a putative dominant negative DmUba2(C175S) mutant protein in the Drosophila central nervous system resulted in an increase in overall DmSUMO-1 conjugates and a base-sensitive p120 species, which is likely to be DmUba2(C175S) linked to endogenous DmSUMO-1 through an oxygen ester bond. Overexpression of DmUba2(wt) protein in vivo also led to increased levels of DmSUMO-1 conjugates. High level overexpression of either DmUba2(wt) or DmUba2(C175S) in the Drosophila central nervous system caused pupal and earlier stage lethality. Expression in the developing eye led to a rough eye phenotype with retinal degeneration. These results suggest that normal SUMO conjugation is essential in the differentiated nervous system and reveal a potential novel mechanism that regulates neuronal calcium/calmodulin-dependent protein kinase II function.	Brandeis Univ, Dept Biol, Biochem Grad Program, Waltham, MA 02254 USA; Brandeis Univ, Volen Ctr Complex Syst, Waltham, MA 02254 USA	Brandeis University; Brandeis University	Griffith, LC (corresponding author), Brandeis Univ, Dept Biol, Biochem Grad Program, MS008,415 South St, Waltham, MA 02254 USA.		Long, Samuel/AAR-8118-2021	Long, Samuel/0000-0001-7559-3232; Griffith, Leslie/0000-0003-3164-9876	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054408] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM054408, GM54408] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhaskar V, 2000, J BIOL CHEM, V275, P4033, DOI 10.1074/jbc.275.6.4033; Boddy MN, 1996, ONCOGENE, V13, P971; BRAND AH, 1993, DEVELOPMENT, V118, P401; Choudhury BK, 1997, BIOCHEM BIOPH RES CO, V234, P788, DOI 10.1006/bbrc.1997.6709; delOlmo M, 1997, MOL GEN GENET, V255, P209, DOI 10.1007/s004380050491; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; DEV IK, 1988, P NATL ACAD SCI USA, V85, P1472, DOI 10.1073/pnas.85.5.1472; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; Epps JL, 1998, CURR BIOL, V8, P1277, DOI 10.1016/S0960-9822(07)00538-6; GRIFFITH LC, 1993, J NEUROCHEM, V61, P1534, DOI 10.1111/j.1471-4159.1993.tb13650.x; Griffith Leslie C., 1997, Invertebrate Neuroscience, V3, P93, DOI 10.1007/BF02480364; Haas AL, 1997, FASEB J, V11, P1053, DOI 10.1096/fasebj.11.13.9367340; Haas AL, 1997, FASEB J, V11, P1257; Hay BA, 1997, P NATL ACAD SCI USA, V94, P5195, DOI 10.1073/pnas.94.10.5195; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Joanisse DR, 1998, BIOCHEM BIOPH RES CO, V244, P102, DOI 10.1006/bbrc.1998.8214; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kevil CG, 1997, BIOCHEM BIOPH RES CO, V238, P277, DOI 10.1006/bbrc.1997.7284; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Lapenta V, 1997, GENOMICS, V40, P362, DOI 10.1006/geno.1996.4556; Lee GW, 1998, J BIOL CHEM, V273, P6503, DOI 10.1074/jbc.273.11.6503; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mannen H, 1996, BIOCHEM BIOPH RES CO, V222, P178, DOI 10.1006/bbrc.1996.0717; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Merrill C, 1999, SCIENCE, V283, P1742, DOI 10.1126/science.283.5408.1742; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; OGILVIE JW, 1964, BIOCHEMISTRY-US, V3, P754, DOI 10.1021/bi00894a003; Okura T, 1996, J IMMUNOL, V157, P4277; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Sambrook J., 2002, MOL CLONING LAB MANU; Schopperle WM, 1998, NEURON, V20, P565, DOI 10.1016/S0896-6273(00)80995-2; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; Yasugi T, 1996, NUCLEIC ACIDS RES, V24, P2005, DOI 10.1093/nar/24.11.2005	50	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40765	40776		10.1074/jbc.M003949200	http://dx.doi.org/10.1074/jbc.M003949200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10995744	hybrid			2022-12-27	WOS:000166114600016
J	Tokunaga, F; Brostrom, C; Koide, T; Arvan, P				Tokunaga, F; Brostrom, C; Koide, T; Arvan, P			Endoplasmic reticulum (ER)-associated degradation of misfolded N-linked glycoproteins is suppressed upon inhibition of ER mannosidase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TCR-ALPHA PROTEINS; MOLECULAR CHAPERONES; SECRETORY PATHWAY; RAT-LIVER; SACCHAROMYCES-CEREVISIAE; CARBOXYPEPTIDASE YSCY; PROTEASOME PATHWAY; CONGENITAL GOITER; STORAGE DISEASES; QUALITY-CONTROL	To examine the role of early carbohydrate recognition/trimming reactions in targeting endoplasmic reticulum (ER)-retained, misfolded glycoproteins for ER-associated degradation (ERAD), we have stably expressed the cog thyroglobulin (Tg) mutant cDNA in Chinese hamster ovary cells. We found that inhibitors of ER mannosidase I (but not other glycosidases) acutely suppressed Cog Tg degradation and also perturbed the ERAD process for Tg reduced with dithiothreitol as well as for gamma -carboxylation-deficient protein C expressed in warfarin-treated baby hamster kidney cells. Kifunensine inhibition of ER mannosidase I also suppressed ERAD in castanospermine-treated cells; thus, suppression of ERAD does not require lectin-like binding of ER chaperones calnexin and calreticulin to monoglucosylated oligosaccharides. Notably, the undegraded protein fraction remained completely microsome-associated. In pulse-chase studies, kifunensine-sensitive degradation was still inhibitable even 1 h after Tg synthesis. Intriguingly, chronic treatment with kifunensine caused a 3-fold accumulation of Cog Tg in Chinese hamster ovary cells and did not lead to significant induction of the ER unfolded protein response. We hypothesize that, in a manner not requiring lectin-like activity of calnexin/ calreticulin, the recognition or processing of a specific branched N-linked mannose structure enhances the efficiency of glycoprotein retrotranslocation from the ER lumen.	Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol biol, Div Endocrinol, Bronx, NY 10461 USA; Univ Med & Dent New Jersey, Dept Pharmacol, Piscataway, NJ 08854 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Div Endocrinol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; Yeshiva University; Albert Einstein College of Medicine	Arvan, P (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol biol, Div Endocrinol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Tokunaga, Fuminori/0000-0003-3626-9119	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040344, R29DK040344] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40344] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; de Virgilio M, 1999, MOL BIOL CELL, V10, P4059, DOI 10.1091/mbc.10.12.4059; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; Keller SH, 1998, J BIOL CHEM, V273, P17064, DOI 10.1074/jbc.273.27.17064; KIM PS, 1991, J BIOL CHEM, V266, P12412; Kim PS, 1996, J CELL BIOL, V133, P517, DOI 10.1083/jcb.133.3.517; Kim PS, 1998, P NATL ACAD SCI USA, V95, P9909, DOI 10.1073/pnas.95.17.9909; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; Knop M, 1996, YEAST, V12, P1229, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1229::AID-YEA15>3.0.CO;2-H; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; LODISH HF, 1993, J BIOL CHEM, V268, P20598; Marcus NY, 2000, J BIOL CHEM, V275, P1987, DOI 10.1074/jbc.275.3.1987; MCCLURE DB, 1992, J BIOL CHEM, V267, P19710; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Parodi AJ, 1999, BBA-GEN SUBJECTS, V1426, P287, DOI 10.1016/S0304-4165(98)00130-5; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Plemper RK, 1999, FEBS LETT, V443, P241, DOI 10.1016/S0014-5793(98)01724-4; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; ROMAGNOLI P, 1995, J EXP MED, V182, P2027, DOI 10.1084/jem.182.6.2027; Romisch K, 1997, P NATL ACAD SCI USA, V94, P6730, DOI 10.1073/pnas.94.13.6730; Schubert U, 1998, J VIROL, V72, P2280, DOI 10.1128/JVI.72.3.2280-2288.1998; Selby M, 1999, J IMMUNOL, V162, P669; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; SU K, 1993, J BIOL CHEM, V268, P14301; Suzuki T, 1998, J BIOL CHEM, V273, P10083, DOI 10.1074/jbc.273.17.10083; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; TOKUNAGA F, 1995, BIOCHEMISTRY-US, V34, P1163, DOI 10.1021/bi00004a009; Tokunaga F, 2000, THROMB RES, V99, P511, DOI 10.1016/S0049-3848(00)00258-9; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; VanLeeuwen JEM, 1997, J BIOL CHEM, V272, P4179, DOI 10.1074/jbc.272.7.4179; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Weng S, 1997, BIOCHEM J, V322, P655, DOI 10.1042/bj3220655; Weng S, 1996, GLYCOBIOLOGY, V6, P861, DOI 10.1093/glycob/6.8.861; WENG SA, 1993, J BIOL CHEM, V268, P25656; White AL, 1999, J LIPID RES, V40, P275; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	68	105	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40757	40764		10.1074/jbc.M001073200	http://dx.doi.org/10.1074/jbc.M001073200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10984471	hybrid			2022-12-27	WOS:000166114600015
J	Zakhary, DR; Fink, MA; Ruehr, ML; Bond, M				Zakhary, DR; Fink, MA; Ruehr, ML; Bond, M			Selectivity and regulation of A-kinase anchoring proteins in the heart - The role of autophosphorylation of the type II regulatory subunit of cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPONIN-I; MOLECULAR CHARACTERIZATION; SARCOPLASMIC-RETICULUM; CALCIUM CHANNELS; PHOSPHORYLATION; BINDING; MODULATION; MEMBRANE; BETA; RII	Downstream regulation of the cAMP-dependent protein kinase (PKA) pathway is mediated by anchoring proteins (AKAPs) that sequester PKA to specific subcellular locations through binding to PKA regulatory subunits (RI or RII). The RII-binding domain of all AKAPs forms an amphipathic alpha -helix with similar secondary structure. However, the importance of sequence differences in the RII-binding domains of different AKAPs is unknown, and mechanisms that regulate AKAP-PKA affinity are not clearly defined. Using surface plasmon resonance (SPR) spectroscopy, we measured real-time kinetics of RII interaction with various AKAPs, Baseline equilibrium binding constants (K-d) for RII binding to Ht31, mAKAP, and AKAP15/18 were 10 nM, 119 nM, and 6.6 muM, respectively, PKA stimulation of intact Chinese hamster ovary cells increased RII alpha binding to AKAP100/mAKAP and AKAP15/18 by similar to7- and 82-fold, respectively. These results suggest that differences in primary sequence of the RII-binding domain may be responsible for the selective affinity of RII for different AKAPs. Furthermore, RII autophosphorylation may provide additional localized regulation of kinase anchoring. In cardiac myocytes, disruption of RII-AKAP interaction decreased PKA phosphorylation of the PKA substrate, myosin-binding protein C. Thus, these mechanisms may be involved in adding additional specificity in intracellular signaling in diverse cell types and under conditions of cAMP/PKA activation.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Bond, M (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, NB50, Cleveland, OH 44195 USA.			Russell, Mary A/0000-0001-5677-8194; Zakhary, Daniel/0000-0002-5328-6757	NHLBI NIH HHS [HL56256, F32HL10236] Funding Source: Medline; NIA NIH HHS [AG16613] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010236, R01HL056256] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016613] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Angelo R, 1998, J BIOL CHEM, V273, P14633, DOI 10.1074/jbc.273.23.14633; Angelo RG, 2000, J BIOL CHEM, V275, P4351, DOI 10.1074/jbc.275.6.4351; Bodor GS, 1997, CIRCULATION, V96, P1495, DOI 10.1161/01.CIR.96.5.1495; Burton KA, 1997, P NATL ACAD SCI USA, V94, P11067, DOI 10.1073/pnas.94.20.11067; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; Davare MA, 1999, J BIOL CHEM, V274, P30280, DOI 10.1074/jbc.274.42.30280; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Dong F, 1998, J BIOL CHEM, V273, P6533, DOI 10.1074/jbc.273.11.6533; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Fraser IDC, 1999, NEURON, V23, P423, DOI 10.1016/S0896-6273(00)80795-3; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; GARVEY JL, 1988, BIOCHEM J, V249, P709, DOI 10.1042/bj2490709; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; Hausken ZE, 1996, J BIOL CHEM, V271, P29016, DOI 10.1074/jbc.271.46.29016; Herberg FW, 2000, J MOL BIOL, V298, P329, DOI 10.1006/jmbi.2000.3662; HITT M, 1995, METH MOL G, V7, P13; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; JIN JP, 1995, J BIOL CHEM, V270, P6908; Kapiloff MS, 1999, J CELL SCI, V112, P2725; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; MCCARTNEY S, 1995, J BIOL CHEM, V270, P9327, DOI 10.1074/jbc.270.16.9327; McConnell BK, 1997, AM J PHYSIOL-HEART C, V273, pH1440, DOI 10.1152/ajpheart.1997.273.3.H1440; Miki E, 1998, J BIOL CHEM, V273, P34384, DOI 10.1074/jbc.273.51.34384; Miki K, 1999, J BIOL CHEM, V274, P29057, DOI 10.1074/jbc.274.41.29057; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; Purcell IF, 2000, BIOPHYS J, V78, p226A; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; Ruehr ML, 1999, J BIOL CHEM, V274, P33092, DOI 10.1074/jbc.274.46.33092; Russell MA, 2000, BIOPHYS J, V78, p432A; Scott JD, 1997, SOC GEN PHY, V52, P227; SOLARO RJ, 1976, NATURE, V262, P615, DOI 10.1038/262615a0; TADA M, 1983, J MOL CELL CARDIOL, V15, P335, DOI 10.1016/0022-2828(83)91345-7; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TSIEN RW, 1986, J MOL CELL CARDIOL, V18, P691, DOI 10.1016/S0022-2828(86)80941-5; Yang JC, 1998, J CELL BIOL, V142, P511, DOI 10.1083/jcb.142.2.511; YOSHIDA A, 1992, J BIOCHEM-TOKYO, V111, P186, DOI 10.1093/oxfordjournals.jbchem.a123735; Zakhary DR, 2000, CIRCULATION, V101, P1459, DOI 10.1161/01.CIR.101.12.1459; Zakhary DR, 1999, CIRCULATION, V99, P505, DOI 10.1161/01.CIR.99.4.505	43	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41389	41395		10.1074/jbc.M004212200	http://dx.doi.org/10.1074/jbc.M004212200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10993882	hybrid			2022-12-27	WOS:000166114600096
J	Howe, DL; Duewel, HS; Woodard, RW				Howe, DL; Duewel, HS; Woodard, RW			Histidine 268 in 3-deoxy-D-arabino-heptulosonic acid 7-phosphate synthase plays the same role as histidine 202 in 3-deoxy-D-manno-octulosonic acid 8-phosphate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; CHEMICAL MODIFICATION; DIETHYL PYROCARBONATE; ESSENTIAL CYSTEINES; ACTIVE-SITE; SYNTHETASE; PURIFICATION; RESIDUE; STEREOCHEMISTRY	The enzyme 3-deoxy-D-arabino-heptulosonate 7-phosphate (DAH 7-P) synthase (Phe) is inactivated by diethyl pyrocarbonate (DEPC). The inactivation is first order with respect to enzyme and DEPC concentrations with a pseudo-second order rate constant of inactivation by DEPC of 4.9 +/- 0.8 M-1 s(-1) at pH 6.8 and 4 degreesC. The dependence of inactivation on pH and the spectral features of enzyme modified at specific pH values imply that both histidine and cysteine residues are modified, which is confirmed by site-directed mutagenesis. Analysis of the chemical modification data indicates that one histidine is essential for activity. DAH 7-P synthase (Phe) is protected against DEPC inactivation by phosphoenolpyruvate, whereas D-erythrose 4-phosphate offers only minimal protection. The conserved residues H-172, H-207, H-268, and H-304 were individually mutated to glycine. The H304G and H207G mutants retain some level of activity, whereas the H268G and H172G mutants are virtually inactive. A comparison of the circular dichroism spectra of wild-type enzyme and the various mutants demonstrates that H-172 may play a structural role. Comparison of the UV spectra of the H268G and wildtype enzymes saturated with Cu2+ indicates that the metal-binding site of the H268G mutant resembles that of the wild-type enzyme. The residue H-268 may play a catalytic role based on the site-directed mutagenesis and spectroscopic studies. Cysteine 61 appears to influence the pK(a) of H-268 in the wild-type enzyme. The pK(a), of H-268 increases from 6.0 to 7.0 following mutation of C-61 to glycine.	Univ Michigan, Coll Pharm, Dept Med Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Woodard, RW (corresponding author), Univ Michigan, Coll Pharm, Dept Med Chem, 428 Church St, Ann Arbor, MI 48109 USA.			Woodard, Ronald/0000-0002-7472-3653				AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; BAASOV T, 1989, J BACTERIOL, V170, P5500; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN Y, 1974, BIOCHEMISTRY-US, V13, P205, DOI 10.1021/bi00698a030; DELEO AB, 1968, BIOCHEM BIOPH RES CO, V32, P873, DOI 10.1016/0006-291X(68)90322-7; DELEO AB, 1973, J BIOL CHEM, V248, P2344; DOTSON GD, 1993, BIOCHEMISTRY-US, V32, P12392, DOI 10.1021/bi00097a017; DOY CH, 1967, BIOCHEM BIOPH RES CO, V26, P187, DOI 10.1016/0006-291X(67)90232-X; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; GOMI T, 1983, BIOCHEMISTRY-US, V22, P137, DOI 10.1021/bi00270a020; Haslam E., 1993, SHIKIMIC ACID METABO; HEDSTROM L, 1988, BIOCHEM BIOPH RES CO, V157, P816, DOI 10.1016/S0006-291X(88)80322-X; HORIIKE K, 1979, J BIOL CHEM, V254, P6638; HUISMAN OC, 1974, J BIOL CHEM, V249, P6842; HUYNH QK, 1987, ARCH BIOCHEM BIOPHYS, V258, P233, DOI 10.1016/0003-9861(87)90340-7; KOHEN A, 1993, BIOORG MED CHEM LETT, V3, P1577, DOI 10.1016/S0960-894X(00)80021-9; LEVIN DH, 1959, J BIOL CHEM, V234, P2532; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; NAGANO H, 1970, ARCH BIOCHEM BIOPHYS, V138, P58, DOI 10.1016/0003-9861(70)90284-5; ONDERKA DK, 1969, BIOCHEM BIOPH RES CO, V35, P801, DOI 10.1016/0006-291X(69)90694-9; ONDERKA DK, 1969, J AM CHEM SOC, V91, P5894, DOI 10.1021/ja01049a046; Park OK, 1999, J BACTERIOL, V181, P1636, DOI 10.1128/JB.181.5.1636-1642.1999; Radaev S, 2000, J BIOL CHEM, V275, P9476, DOI 10.1074/jbc.275.13.9476; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAY PH, 1983, ACS SYM SER, V231, P141; RAY PH, 1980, J BACTERIOL, V141, P635, DOI 10.1128/JB.141.2.635-644.1980; Salleh HM, 1996, BIOCHEMISTRY-US, V35, P8942, DOI 10.1021/bi952373w; SALUJA AK, 1980, BIOCHEM BIOPH RES CO, V94, P1091, DOI 10.1016/0006-291X(80)90531-8; SCHONER R, 1976, J BIOL CHEM, V251, P5440; Sheflyan GY, 1999, BIOCHEMISTRY-US, V38, P14320, DOI 10.1021/bi9829884; Sheflyan GY, 1998, J AM CHEM SOC, V120, P11027, DOI 10.1021/ja9816281; Shumilin IA, 1999, STRUCTURE, V7, P865, DOI 10.1016/S0969-2126(99)80109-9; SIMPSON RJ, 1976, EUR J BIOCHEM, V70, P501, DOI 10.1111/j.1432-1033.1976.tb11041.x; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; SRINIVASAN PR, 1959, J BIOL CHEM, V234, P716; STAUB M, 1969, BIOCHIM BIOPHYS ACTA, V178, P588, DOI 10.1016/0005-2744(69)90227-7; STEPHENS CM, 1992, J BIOL CHEM, V267, P5762; STEPHENS CM, 1991, J BIOL CHEM, V266, P20810; Subramaniam PS, 1998, J BACTERIOL, V180, P119, DOI 10.1128/JB.180.1.119-127.1998; SUGIMOTO S, 1980, J BIOCHEM-TOKYO, V87, P881, DOI 10.1093/oxfordjournals.jbchem.a132818; Sundaram AK, 1998, FEBS LETT, V441, P195, DOI 10.1016/S0014-5793(98)01545-2; TAKEUCHI M, 1986, J BIOCHEM-TOKYO, V99, P1571, DOI 10.1093/oxfordjournals.jbchem.a135630; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; WEINER MP, 1994, PCR METH APPL, V4, pS131	45	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40258	40265		10.1074/jbc.M003585200	http://dx.doi.org/10.1074/jbc.M003585200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10988284	hybrid			2022-12-27	WOS:000166039500064
J	Kugel, JF; Goodrich, JA				Kugel, JF; Goodrich, JA			A kinetic model for the early steps of RNA synthesis by human RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENERAL TRANSCRIPTION FACTORS; PROMOTER ESCAPE; ELONGATION COMPLEXES; MINIMAL SET; INITIATION; ATP; TFIIH; DNA; IDENTIFICATION; INVITRO	Eukaryotic mRNA synthesis is a highly regulated process involving numerous proteins acting in concert with RNA polymerase II to set levels of transcription from individual promoters. The transcription reaction consists of multiple steps beginning with preinitiation complex formation and ending in the production of a full-length primary transcript. We used pre-steady-state approaches to study the steps of human mRNA transcription at the adenovirus major late promoter in a minimal in vitro transcription system. These kinetic studies revealed an early transition in RNA polymerase II transcription, termed escape commitment, that occurs after initiation and prior to promoter escape. Escape commitment is rapid and is characterized by sensitivity to competitor DNA. Upon completion of escape commitment, ternary complexes are resistant to challenge by competitor DNA and slowly proceed forward through promoter escape. Escape commitment is stimulated by transcription factors TFIIE and TFIIH. We measured forward and reverse rate constants for discrete steps in transcription and present a kinetic model for the mechanism of RNA polymerase II transcription that describes five distinct steps (preinitiation complex formation, initiation, escape commitment, promoter escape, and transcript elongation) and clearly shows promoter escape is rate-limiting in this system.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Goodrich, JA (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.							BORUKHOV S, 1993, J BIOL CHEM, V268, P23477; Bradsher J, 2000, J BIOL CHEM, V275, P2532, DOI 10.1074/jbc.275.4.2532; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAI H, 1987, J BIOL CHEM, V262, P298; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Dvir A, 1996, J BIOL CHEM, V271, P23352, DOI 10.1074/jbc.271.38.23352; Dvir A, 1997, J BIOL CHEM, V272, P28175, DOI 10.1074/jbc.272.45.28175; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Fiedler U, 2000, BIOESSAYS, V22, P316, DOI 10.1002/(SICI)1521-1878(200004)22:4<316::AID-BIES2>3.0.CO;2-B; FLORES O, 1992, J BIOL CHEM, V267, P2786; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; Jiang Y, 1996, MOL CELL BIOL, V16, P1614; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; Kugel JF, 1998, P NATL ACAD SCI USA, V95, P9232, DOI 10.1073/pnas.95.16.9232; Kumar KP, 1998, P NATL ACAD SCI USA, V95, P9767, DOI 10.1073/pnas.95.17.9767; LUSE DS, 1987, J BIOL CHEM, V262, P14990; LUSE DS, 1987, J BIOL CHEM, V262, P289; Moreland RJ, 1999, J BIOL CHEM, V274, P22127, DOI 10.1074/jbc.274.32.22127; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; REINBERG D, 1987, J BIOL CHEM, V262, P3322; Reines D, 1999, CURR OPIN CELL BIOL, V11, P342, DOI 10.1016/S0955-0674(99)80047-7; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; Yan M, 1997, EMBO J, V16, P7457, DOI 10.1093/emboj/16.24.7457; Yan M, 1999, J BIOL CHEM, V274, P34819, DOI 10.1074/jbc.274.49.34819; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	37	31	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40483	40491		10.1074/jbc.M006401200	http://dx.doi.org/10.1074/jbc.M006401200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10982810	hybrid			2022-12-27	WOS:000166039500092
J	Yan, BX; Smith, JW				Yan, BX; Smith, JW			A redox site involved in integrin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; GLYCOPROTEIN IIB-IIIA; NITRIC-OXIDE; PLATELET-AGGREGATION; BETA(3) SUBUNIT; NITROSATIVE STRESS; FIBRINOGEN BINDING; RELAXING FACTOR; SERUM-ALBUMIN; GPIIB-IIIA	Integrin adhesion receptors contain an on/off switch that regulates ligand binding affinity and cell adhesion. The switch from "off" to "on" is commonly referred to as integrin activation. The objective of this study was to gain insight into the nature of the on/off switch in platelet integrin alpha (IIb)beta (3). Here, we show that a select group of the cysteines, located within the extracellular cysteine-rich domain of the beta subunit, remain unpaired. These unpaired cysteine residues exhibit the properties of a redox site involved in integrin activation. Alterations to the redox site prevent the inter-conversion between resting and active integrin. Altogether, the study establishes integrin as a direct target for redox modulation, revealing an unappreciated link between cell adhesion and redox biology.	Burnham Inst, Ctr Canc Res, Program Cell Adhes, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Smith, JW (corresponding author), Burnham Inst, Ctr Canc Res, Program Cell Adhes, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jsmith@burnham.org			NATIONAL CANCER INSTITUTE [R01CA069306, P30CA030199] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058925] Funding Source: NIH RePORTER; NCI NIH HHS [CA69306, CA30199] Funding Source: Medline; NHLBI NIH HHS [HL58925] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEER J, 1989, J BIOL CHEM, V264, P17564; BEER JH, 1992, BLOOD, V79, P117; Burgess JK, 2000, J BIOL CHEM, V275, P9758, DOI 10.1074/jbc.275.13.9758; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CHEN YP, 1994, J BIOL CHEM, V269, P18307; COLLER BS, 1995, THROMB HAEMOSTASIS, V74, P302; COTTRELL JS, 1994, PEPTIDE RES, V7, P115; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Edwards BS, 1998, J LEUKOCYTE BIOL, V63, P190, DOI 10.1002/jlb.63.2.190; EDWARDS BS, 1995, BLOOD, V86, P2288, DOI 10.1182/blood.V86.6.2288.bloodjournal8662288; Essex DW, 1999, BRIT J HAEMATOL, V104, P448, DOI 10.1046/j.1365-2141.1999.01197.x; ESSEX DW, 1995, BLOOD, V86, P2168, DOI 10.1182/blood.V86.6.2168.bloodjournal8662168; FITZGERALD LA, 1985, ANAL BIOCHEM, V151, P169, DOI 10.1016/0003-2697(85)90067-3; Fox-Robichaud A, 1998, J CLIN INVEST, V101, P2497, DOI 10.1172/JCI2736; Freedman JE, 1998, CIRCULATION, V98, P1481, DOI 10.1161/01.CIR.98.15.1481; Freedman JE, 1999, CIRC RES, V84, P1416; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; JANG YS, 1994, J AM COLL CARDIOL, V24, P1591, DOI 10.1016/0735-1097(94)90162-7; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Kashiwagi H, 1999, BLOOD, V93, P2559, DOI 10.1182/blood.V93.8.2559.408k12_2559_2568; KEANEY JF, 1993, J CLIN INVEST, V91, P1582, DOI 10.1172/JCI116364; Kim WK, 1999, NEURON, V24, P461, DOI 10.1016/S0896-6273(00)80859-4; KOUNS WC, 1992, J BIOL CHEM, V267, P18844; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Landry F, 2000, ANAL BIOCHEM, V279, P1, DOI 10.1006/abio.1999.4468; Loftus JC, 1997, J CLIN INVEST, V100, pS77; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; Martin-Bermudo MD, 1998, J CELL BIOL, V141, P1073, DOI 10.1083/jcb.141.4.1073; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MENDELSOHN ME, 1990, J BIOL CHEM, V265, P19028; Ni HY, 1998, J BIOL CHEM, V273, P7981, DOI 10.1074/jbc.273.14.7981; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Pappin D J, 1997, Methods Mol Biol, V64, P165; PEERSCHKE EI, 1995, THROMB HAEMOSTASIS, V73, P862; PELLETIER AJ, 1995, J BIOL CHEM, V270, P18133, DOI 10.1074/jbc.270.30.18133; Pelletier AJ, 1996, J BIOL CHEM, V271, P1364, DOI 10.1074/jbc.271.3.1364; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; Shattil SJ, 1997, J CLIN INVEST, V100, pS91; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; SIMON DI, 1993, ARTERIOSCLER THROMB, V13, P791, DOI 10.1161/01.ATV.13.6.791; SMITH JW, 1990, J BIOL CHEM, V265, P11008; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; *SYNPH INV, 2000, LANCET, V355, P337; TIMMONS S, 1989, METHOD ENZYMOL, V169, P11; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; WIPPLER J, 1994, J BIOL CHEM, V269, P8754; Yan B, 2000, J BIOL CHEM, V275, P7249, DOI 10.1074/jbc.275.10.7249; YAN B, 1992, CHIN BIOCH J, V8, P755; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; ZUCKER MB, 1984, THROMB HAEMOSTASIS, V51, P119	62	135	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39964	39972		10.1074/jbc.M007041200	http://dx.doi.org/10.1074/jbc.M007041200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10993900	hybrid			2022-12-27	WOS:000166039500025
J	Lenk, U; Sommer, T				Lenk, U; Sommer, T			Ubiquitin-mediated proteolysis of a short lived regulatory protein depends on its cellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME PATHWAY; ENDOPLASMIC-RETICULUM; NUCLEAR TRANSPORT; DEGRADATION; YEAST; EXPORT; REPRESSOR; LOCATION; SIGNAL; IDENTIFICATION	In this study we demonstrate that the Deg1 degradation signal of the transcriptional repressor Mat alpha2 confers compartment-specific turnover to a reporter protein. Rapid degradation of a Deg1-containing fusion protein is observed only when the reporter is efficiently imported into the nucleus, In contrast, a reporter that is constantly exported from the nucleus exhibits an extended half-life. Furthermore, nuclear import functions are crucial for both Deg1-induced degradation as well as for the turnover of the endogenous Mat alpha2 protein. The conjugation of ubiquitin to a Deg1 containing reporter protein is abrogated in mutants affected in nuclear import. Obviously, the Deg1 signal initiates rapid proteolysis within the nucleoplasm, whereas in the cytosol it mediates turnover via a slower pathway. In both pathways the ubiquitin-conjugating enzymes Ubc6p/Ubc7p play a pivotal role. These observations imply that both the cellular targeting of a substrate and the compartment-specific activity of components of the ubiquitin-proteasome system define the half-life of naturally short-lived proteins.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Sommer, T (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.							Ausubel F.M, 1989, CURRENT PROTOCALS MO; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; Davarinos NA, 1999, J BIOL CHEM, V274, P28708, DOI 10.1074/jbc.274.40.28708; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Enenkel C, 1998, EMBO J, V17, P6144, DOI 10.1093/emboj/17.21.6144; Gorner M, 1999, BIOL CHEM, V380, P147; HALL MN, 1990, P NATL ACAD SCI USA, V87, P6954, DOI 10.1073/pnas.87.18.6954; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; Johnson PR, 1998, CELL, V94, P217, DOI 10.1016/S0092-8674(00)81421-X; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; NEHRBASS U, 1993, EUR J CELL BIOL, V62, P1; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	33	44	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39403	39410		10.1074/jbc.M006949200	http://dx.doi.org/10.1074/jbc.M006949200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10991948	hybrid			2022-12-27	WOS:000165953100064
J	Ryu, S; Kawabe, T; Nada, S; Yamaguchi, A				Ryu, S; Kawabe, T; Nada, S; Yamaguchi, A			Identification of basic residues involved in drug export function of human multidrug resistance-associated protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC ANION-TRANSPORTER; DUBIN-JOHNSON-SYNDROME; HUMAN P-GLYCOPROTEIN; KIDNEY MDCK CELLS; SUBSTRATE-SPECIFICITY; BINDING-SITE; TRANSMEMBRANE DOMAIN; LABELING SITES; CMOAT MRP2; GENE	Multidrurg resistance-associated protein 2 (MRPS)/canalicular multispecific organic anion transporter (cMOAT) is involved in the ATP-dependent export of organic anions across the bile canalicular membrane. To identify functional amino acid residues that play essential roles in the substrate transport, each of 13 basic residues around transmembrane regions (TMs) 6-17 were replaced with alanine. Wild type and mutant proteins were expressed in COS-7 cells, and the transport activity was measured as the excretion of glutathione-methylfluorescein. Four mutants, K324A (TM6), K483A (TM9), R1210A (TM16), and R1257A (TM17), showed decreased transport activity, and another mutant, K578A (TM11), showed decreased protein expression. These five mutants were normally delivered to the cell surface similar to the other fully active mutants and wild type MRP2. The importance of TM6, TM16, and TM17 in the transport function of MRP2 is consistent with the previous observation indicating the importance of the corresponding TMI, TM11, and TM12 on P-glycoprotein (Loo, T. W, and Clarke, D. M. (1999) J. Biol. Chem. 274, 35388-35392). Another observation that MRP2 inhibitor, cyclosporine A, failed to inhibit R1230A specifically, indicated the existence of its binding site within TM16.	Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, Ibaraki, Osaka 5670047, Japan; Osaka Univ, Fac Pharmaceut Sci, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Osaka 5670047, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Yamaguchi, A (corresponding author), Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, 8-1 Mihogaoka, Ibaraki, Osaka 5670047, Japan.	akihito@sanken.osaka-u.ac.jp						Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; Buchler M, 1996, J BIOL CHEM, V271, P15091; Chen ZS, 1999, MOL PHARMACOL, V56, P1219, DOI 10.1124/mol.56.6.1219; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; ELFERINK RPJO, 1994, PHARMACOL THERAPEUT, V64, P77, DOI 10.1016/0163-7258(94)90034-5; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; Evers R, 1998, J CLIN INVEST, V101, P1310, DOI 10.1172/JCI119886; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; Ito K, 1998, J BIOL CHEM, V273, P1684, DOI 10.1074/jbc.273.3.1684; KAJIJI S, 1993, BIOCHEMISTRY-US, V32, P4185, DOI 10.1021/bi00067a005; Keppler D, 1996, Prog Liver Dis, V14, P55; Keppler D, 1997, FASEB J, V11, P509, DOI 10.1096/fasebj.11.7.9212074; Kinoshita S, 1998, PHARMACEUT RES, V15, P1851, DOI 10.1023/A:1011953906065; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Kool M, 1997, CANCER RES, V57, P3537; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1993, J BIOL CHEM, V268, P19965; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; Muller M, 1996, J HEPATOL, V24, P100; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Roelofsen H, 1998, J CELL SCI, V111, P1137; Smit JW, 1998, BRIT J PHARMACOL, V123, P361, DOI 10.1038/sj.bjp.0701606; Taguchi Y, 1997, BIOCHEMISTRY-US, V36, P8883, DOI 10.1021/bi970553v; Toh S, 1999, AM J HUM GENET, V64, P739, DOI 10.1086/302292; Wada M, 1998, HUM MOL GENET, V7, P203, DOI 10.1093/hmg/7.2.203; Yamazaki M, 1996, PHARMACEUT RES, V13, P497, DOI 10.1023/A:1016077517241; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441; Zheleznova EE, 2000, TRENDS BIOCHEM SCI, V25, P39, DOI 10.1016/S0968-0004(99)01514-5	39	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39617	39624		10.1074/jbc.M005149200	http://dx.doi.org/10.1074/jbc.M005149200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10978330	hybrid			2022-12-27	WOS:000165953100088
J	Bommakanti, RK; Vinayak, S; Simonds, WF				Bommakanti, RK; Vinayak, S; Simonds, WF			Dual regulation of Akt/protein kinase B by heterotrimeric G protein subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	American-Society-of-Biochemistry-and-Molecular-Biology Annual Meeting	MAY 15-20, 1998	WASHINGTON, D.C.	Amer Soc Biochem & Molec Biol			BETA-GAMMA-SUBUNITS; ACTIVATED PHOSPHATIDYLINOSITOL 3-KINASE; GLYCOGEN-SYNTHASE KINASE-3; PLECKSTRIN HOMOLOGY DOMAIN; FACTOR-I RECEPTOR; COUPLED RECEPTORS; PHOSPHOINOSITIDE 3-KINASE-GAMMA; MOLECULAR-CLONING; AKT PROTOONCOGENE; INSULIN	While positive regulation of c-Akt (also known as protein kinase B) by receptor tyrosine kinases is well documented, compounds acting through G protein-coupled receptors can also activate Akt and its downstream targets. We therefore explored the role of G protein subunits in the regulation of Akt in cultured mammalian cells,In HEK-293 and COS-7 cells transiently transfected with beta (2)-adrenergic or m2 muscarinic receptors, respectively, treatment with agonist-induced phosphorylation of Akt at serine 473 as evidenced by phosphoserine-specific immunoblots. This effect was blocked by the phosphatidylinositol-3-OH kinase inhibitor LY294002 and wild-type G alpha (il), and was not duplicated by co-transfection of the constitutively active G alpha (s)-Q227L or G alpha (i)-Q204L mutant, Co-transfection of G beta (1), G beta (2) but not G beta (5) together with G gamma (2) activated the kinase when assayed in vitro following immunoprecipitation of the epitope-tagged enzyme. In contrast, constitutively activated G protein subunits representing the four G alpha subfamilies were found unable to activate Akt in either cell line. The latter results are in disagreement with a report by Murga et al. (Murga, C., Laguinge, L., Wetzker, R., Cuadrado, A., and Gutkind, J. S. (1998) J, Biol. Chem. 273, 19080-19085) that described activation of Akt in response to mutationally activated G alpha (q) and G alpha (i) transfection in COS cells. To the contrary, in our experiments G alpha (q)-Q209L inhibited Akt activation resulting from beta gamma or mutationally activated H-Ras co-transfection in these cells. In HEK-293 cells G alpha (q)-Q209L transfection inhibited insulin-like growth factor-1 activation of epitope-tagged Akt. In m1 muscarinic receptor transfected HEK-293 cells, carbachol inhibited insulin-like growth factor-1 stimulated phosphorylation at Ser(473) of endogenous Akt in an atropine-reversible fashion. me conclude that G proteins can regulate Akt by two distinct and potentially opposing mechanisms: activation by G beta gamma heterodimers in a phosphatidylinositol-3-OH kinase-dependent fashion, and inhibition mediated by G alpha (q). This work identifies Akt as a novel point of convergence between disparate signaling pathways.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Simonds, WF (corresponding author), NIDDK, Metab Dis Branch, NIH, Bldg 10,Rm 8C-101,10 Ctr Dr,MSC 1752, Bethesda, MD 20892 USA.	wfs@helix.nih.gov						Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Barthel A, 1998, BIOCHEM BIOPH RES CO, V243, P509, DOI 10.1006/bbrc.1998.8134; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; LEE CH, 1995, J BIOL CHEM, V270, P8779, DOI 10.1074/jbc.270.15.8779; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Lindorfer MA, 1998, J BIOL CHEM, V273, P34429, DOI 10.1074/jbc.273.51.34429; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P2505, DOI 10.1074/jbc.273.5.2505; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Maier U, 2000, J BIOL CHEM, V275, P13746, DOI 10.1074/jbc.275.18.13746; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; MURAKAMI T, 1992, BIOCHEMISTRY-US, V31, P2905, DOI 10.1021/bi00126a009; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Okada T, 1996, BIOCHEM J, V317, P475, DOI 10.1042/bj3170475; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; Rubio I, 1997, BIOCHEM J, V326, P891, DOI 10.1042/bj3260891; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; YAMAMOTO K, 1992, J BIOL CHEM, V267, P11337; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575; Zheng WH, 2000, J BIOL CHEM, V275, P13377, DOI 10.1074/jbc.275.18.13377; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	59	81	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38870	38876		10.1074/jbc.M007403200	http://dx.doi.org/10.1074/jbc.M007403200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	381AH	10986289	hybrid			2022-12-27	WOS:000165739800099
J	Ding, HF; Lin, YL; McGill, G; Juo, P; Zhu, H; Blenis, J; Yuan, JY; Fisher, DE				Ding, HF; Lin, YL; McGill, G; Juo, P; Zhu, H; Blenis, J; Yuan, JY; Fisher, DE			Essential role for caspase-8 in transcription-independent apoptosis triggered by p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; CELL-CYCLE ARREST; CYTOCHROME-C; DEATH DOMAIN; P53-DEPENDENT APOPTOSIS; CD95 FAS/APO-1; RECEPTOR/LIGAND SYSTEM; CANCER-THERAPY; ACTIVATION; PROTEIN	p53's dual regulation of arrest versus apoptosis may underlie tumor-selective effects of anti-cancer therapy. p53's apoptotic effect has been suggested to involve both transcription-dependent and -independent mechanisms. It is shown here that caspase-8 is activated early in cells undergoing p53-mediated apoptosis and in S100 cell-free extracts that recapitulate transcription-independent apoptosis, Depletion or inactivation of caspase-8 either in cells or cell-free extracts completely prevents this transcription-independent apoptosis and significantly attenuates overall death induced by wildtype p53. Importantly, caspase-8 activation appears to be independent of FADD, and caspase-8 is found in a novel 600-kDa complex following p53 activation. These findings highlight the roles of both transcription-dependent and -independent apoptosis by p53 and identify an essential role for caspase-8 in the transcription-independent pathway.	Dana Farber Canc Inst, Div Pediat Hematol Oncol, Dept Pediat Hematol Oncol, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Fisher, DE (corresponding author), Dana Farber Canc Inst, Div Pediat Hematol Oncol, Dept Pediat Hematol Oncol, D630,44 Binney St, Boston, MA 02115 USA.	david_fisher@dfci.harvard.edu	Juo, Peter/CJY-3695-2022	Juo, Peter/0000-0002-3039-2266; Zhu, Hong/0000-0002-2575-4031; Ding, Han-Fei/0000-0001-5702-3439	NATIONAL CANCER INSTITUTE [R01CA069531] Funding Source: NIH RePORTER; NCI NIH HHS [CA69531] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bissonnette N, 1997, BIOCHEM CELL BIOL, V75, P351, DOI 10.1139/bcb-75-4-351; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chandler JM, 1997, BIOCHEM J, V322, P19, DOI 10.1042/bj3220019; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; Gao CF, 1999, JPN J CANCER RES, V90, P180, DOI 10.1111/j.1349-7006.1999.tb00731.x; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HARDENBERG PH, 1998, INT J RADIAT ONCOL, V43, P601; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hengartner M, 1998, SCIENCE, V281, P1298, DOI 10.1126/science.281.5381.1298; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; Kim AL, 1999, J BIOL CHEM, V274, P34924, DOI 10.1074/jbc.274.49.34924; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rakkar ANS, 1999, CELL DEATH DIFFER, V6, P326, DOI 10.1038/sj.cdd.4400498; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	76	119	125	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38905	38911		10.1074/jbc.M004714200	http://dx.doi.org/10.1074/jbc.M004714200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10988287	Green Published, hybrid			2022-12-27	WOS:000165739800104
J	Rodriguez, JA; Henderson, BR				Rodriguez, JA; Henderson, BR			Identification of a functional nuclear export sequence in BRCA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN-CANCER CELLS; SUBCELLULAR-LOCALIZATION; BREAST-CANCER; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; IMPORTIN-BETA; IN-VIVO; SIGNAL; PROTEIN; CRM1	Germ-line mutations in the tumor suppressor gene Brca1 confer increased susceptibility to breast and ovarian cancers. BRCA1 is a 1863-amino acid protein with roles in transcriptional regulation and the cellular responses to DNA damage. Given its function in these nuclear processes, the subcellular localization of BRCA1 is an important issue and has been the object of recent controversy. BRCA1 contains two nuclear localization signals and is most frequently detected in the cell nucleus by immunofluorescence microscopy. In this study, we show that BRCA1 is a nuclear-cytoplasmic shuttling protein, capable of both entering and exiting the nucleus. We identified a functional Rev-type nuclear export sequence ((81)QLVEELLKIICAFQLDTGL) near the amino terminus of BRCA1 that facilitates export via the CRM1/exportin pathway. Mutational inactivation of this nuclear export sequence, or treatment of cells with the CRM1-specific export inhibitor leptomycin B, induced nuclear accumulation of ectopic full-length BRCA1. Moreover, overexpression of the CRM1 export receptor resulted in decreased nuclear localization of endogenous BRCA1. The unexpected ability of BRCA1 to shuttle between nucleus and cytoplasm may have implications for the regulation and function of this tumor suppressor.	Univ Sydney, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia	University of Sydney; Westmead Institute for Medical Research	Henderson, BR (corresponding author), Univ Sydney, Westmead Millennium Inst, Westmead Inst Canc Res, POB 412,Darcy Rd, Westmead, NSW 2145, Australia.		Rodriguez, Jose Antonio/AAA-1125-2019	Rodriguez, Jose Antonio/0000-0002-2823-3733				Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen YM, 1996, SCIENCE, V272, P125, DOI 10.1126/science.272.5258.125; Chen YM, 1996, CANCER RES, V56, P3168; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; FISHER U, 1995, CELL, V82, P475; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Taylor J, 1998, INT J CANCER, V79, P334, DOI 10.1002/(SICI)1097-0215(19980821)79:4<334::AID-IJC5>3.0.CO;2-W; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	40	124	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38589	38596		10.1074/jbc.M003851200	http://dx.doi.org/10.1074/jbc.M003851200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10991937	hybrid			2022-12-27	WOS:000165739800061
J	Busby, WH; Nam, TJ; Moralez, A; Smith, C; Jennings, M; Clemmons, DR				Busby, WH; Nam, TJ; Moralez, A; Smith, C; Jennings, M; Clemmons, DR			The complement component C1s is the protease that accounts for cleavage of insulin-like growth factor-binding protein-5 in fibroblast medium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGF BINDING; SERINE-PROTEASE; CELLS; IDENTIFICATION; PROTEOLYSIS; MECHANISMS; THROMBIN; TISSUE	Cultured fibroblasts secrete an 88-kDa serine protease that cleaves insulin-like growth factor binding protein-5 (IGFBP-5). Because IGFBP-5 has been shown to regulate IGF-I actions, understanding the chemical identity and regulation of this protease is important for understanding how IGF-I stimulates anabolic functions. The protease was purified from human fibroblast-conditioned medium by hydrophobic interaction, lectin affinity, and heparin Sepharose affinity chromatography followed by SDS polyacrylamide gel electrophoresis. An 88-kDa band was excised and digested with lysyl-endopeptidase. Sequencing of the high pressure liquid chromatography-purified peptides yielded the complement components C1r and C1s. To confirm that C1r/C1s accounted for the proteolytic activity in the medium, immunoaffinity chromatography was performed. Most of the protease activity adhered to the column, and the eluant was fully active in cleaving IGFBP-5. SDS-polyacrylamide gel electrophoresis with silver staining showed two bands, and IGFBP-5 zymography showed a single 88-kDa band. Amino acid sequencing confirmed that the 88-kDa band contained only Clr and Cls. Clr in the fibroblast medium underwent autoactivation, and the activated form cleaved Cls. Cls purified from the conditioned medium cleaved C-4, a naturally occurring substrate. The purified protease cleaved IGFBP-5 but had no activity against IGFBP-1 through -4. C1 inhibitor, a protein known to inhibit activated Cls, was shown to inhibit the cleavage of IGFBP-5 by the protease in the conditioned medium. In summary, human fibroblasts secrete Clr and Cls that actively cleave IGFBP-5. The findings define a mechanism for cleaving IGFBP-5 in the culture medium, thus allowing release of IGF-I to cell surface receptors.	Univ N Carolina, Div Endocrinol, Sch Med, Dept Med, Chapel Hill, NC 27599 USA; Monsanto Inc, Dept Prot Chem, Chesterfield, MO 63198 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Monsanto	Clemmons, DR (corresponding author), Univ N Carolina, Div Endocrinol, Sch Med, Dept Med, CB 7170,6111 Thurston Bowles, Chapel Hill, NC 27599 USA.	endo@med.unc.edu			NIA NIH HHS [AGO23331] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1991, INSULIN LIKE GROWTH; ARLAUD G, 1983, METHOD ENZYMOL, V223, P61; Bang Peter, 1995, Progress in Growth Factor Research, V6, P285, DOI 10.1016/0955-2235(96)00007-5; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BINOUX M, 1994, INT CONGR SER, V1056, P217; Booth BA, 1996, AM J PHYSIOL-ENDOC M, V271, pE465, DOI 10.1152/ajpendo.1996.271.3.E465; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CAMBELL PG, 1992, ENDOCRINOLOGY, V130, P1401; DAVIES AE, 1983, METHOD ENZYMOL, V223, P97; ERIKSSON H, 1990, BIOCHIM BIOPHYS ACTA, V1037, P2109; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; Imai Y, 1997, J CLIN INVEST, V100, P2596, DOI 10.1172/JCI119803; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KATZ Y, 1995, J CLIN ENDOCR METAB, V80, P2027, DOI 10.1210/jc.80.7.2027; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang CH, 1996, AM J PHYSIOL-ENDOC M, V270, pE430, DOI 10.1152/ajpendo.1996.270.3.E430; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; LOVELL AB, 1990, IMMUNOL METHODS, V129, P55; MOFFAT GJ, 1989, CLIN EXP IMMUNOL, V78, P54; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; Nam TJ, 1996, ENDOCRINOLOGY, V137, P5530, DOI 10.1210/en.137.12.5530; Nam TJ, 2000, ENDOCRINOLOGY, V141, P1100, DOI 10.1210/en.141.3.1100; NAM TJ, 1994, ENDOCRINOLOGY, V135, P1385, DOI 10.1210/en.135.4.1385; NISSEN MH, 1990, EUR J BIOCHEM, V189, P423, DOI 10.1111/j.1432-1033.1990.tb15505.x; Parker A, 1996, J BIOL CHEM, V271, P13523, DOI 10.1074/jbc.271.23.13523; RADLEY K, 1996, IMMUNOLOGY, V88, P648; Sakai H, 1998, GENE, V209, P87, DOI 10.1016/S0378-1119(98)00015-8; SAKIYAMA H, 1991, J IMMUNOL, V146, P183; SAKIYAWA H, 1994, CELL TISSUE RES, V227, P239; SCHASTEIN CS, 1997, MOL IMMUNOL, P17; VANAGRECHI K, 1990, FEBS LETT, V268, P206; Zheng B, 1998, ENDOCRINOLOGY, V139, P1708, DOI 10.1210/endo.139.4.5945; ZICCARDI RJ, 1976, J IMMUNOL, V116, P504	36	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37638	37644		10.1074/jbc.M006107200	http://dx.doi.org/10.1074/jbc.M006107200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982804	hybrid			2022-12-27	WOS:000165618700046
J	Petrulis, JR; Hord, NG; Perdew, GH				Petrulis, JR; Hord, NG; Perdew, GH			Subcellular localization of the aryl hydrocarbon receptor is modulated by the immunophilin homolog hepatitis B virus X-associated protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; HEPA 1C1C7 CELLS; AH RECEPTOR; DIOXIN RECEPTOR; CORE COMPLEX; NUCLEAR; LIGAND; ROLES	The hepatitis B virus X-associated protein 2 (XAP2) is an immunophilin homolog and core component of the aryl hydrocarbon receptor (AhR). Immunophilins are components of many steroid receptor complexes, serving a largely unknown function, Transiently expressed AhR.YFP (yellow fluorescent protein) localized to the nuclei of COS-l and NIH-3T3 cells. Go-expression of AhR YFP with XAP2 restored cytoplasmic localization, which was reversed by 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment (TCDD), The effect of XAP2 on AhR localization was specific involving a nuclear localization signal-mediated pathway. Examination of the ratio of AhR to XAP2 in the AhR complex revealed that similar to 25% of transiently expressed AhR was associated with XAP2, in contrast with similar to 100% when the AhR and XAP2 were coexpressed. Strikingly, TCDD did not influence these ratios, suggesting that ligand binding initiates nuclear translocation prior to complex dissociation. Analysis of endogenous AhR in Hepa-l cells revealed that similar to 40% of the AhR complex was associated with XAP2, predicting observed AhR localization to cytoplasm and nuclei. This study reveals a novel functional role for the immunophilin-like component of a soluble receptor complex and provides new insight into the mechanism of AhR-mediated signal transduction, demonstrating the existence of two structurally distinct and possibly functionally unique forms of the AhR.	Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Perdew, GH (corresponding author), Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA.	ghp2@psu.edu			NIEHS NIH HHS [ES04869] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES004869, R01ES004869] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTT BD, 1995, DEV DYNAM, V204, P133, DOI 10.1002/aja.1002040204; ARMISTEAD DM, 1993, ANNU REP MED CHEM, V28, P207; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chen HS, 1997, ARCH BIOCHEM BIOPHYS, V348, P190, DOI 10.1006/abbi.1997.0398; Denison MS, 1998, TARG ORG T, P3; Dogra SC, 1998, CLIN EXP PHARMACOL P, V25, P1, DOI 10.1111/j.1440-1681.1998.tb02135.x; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fukunaga BN, 1996, J BIOL CHEM, V271, P3743; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Heid SE, 2000, MOL PHARMACOL, V57, P82; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; Lees MJ, 1999, MOL CELL BIOL, V19, P5811; Ma Q, 1997, J BIOL CHEM, V272, P8878; Meyer BK, 2000, CELL STRESS CHAPERON, V5, P243, DOI 10.1379/1466-1268(2000)005<0243:AHARLA>2.0.CO;2; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; PERDEW GH, 1995, HYBRIDOMA, V14, P279, DOI 10.1089/hyb.1995.14.279; PERDEW GH, 1993, EXP CELL RES, V209, P350, DOI 10.1006/excr.1993.1320; PERDEW GH, 1991, ARCH BIOCHEM BIOPHYS, V291, P284, DOI 10.1016/0003-9861(91)90136-7; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Sabatini DM, 1997, MOL NEUROBIOL, V15, P223, DOI 10.1007/BF02740635; Singh SS, 1996, ARCH BIOCHEM BIOPHYS, V329, P47, DOI 10.1006/abbi.1996.0190; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174	28	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37448	37453		10.1074/jbc.M006873200	http://dx.doi.org/10.1074/jbc.M006873200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10986286	hybrid			2022-12-27	WOS:000165618700021
